Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Abortion, Spontaneous
miR-520 promotes DNA-damage-induced trophoblast cell apoptosis by targeting PARP1 in recurrent spontaneous abortion (RSA).
Acidosis
Activation of poly(ADP-ribose) polymerase in severe hemorrhagic shock and resuscitation.
Acidosis
Augmentation of poly(ADP-ribose) polymerase-dependent neuronal cell death by acidosis.
Acidosis
Inhibitory effects of glibenclamide and pertussis toxin on the attenuation of ischemia-induced myocardial acidosis following ischemic preconditioning in dogs.
Acquired Immunodeficiency Syndrome
Damage and repair of DNA in HIV encephalitis.
Acquired Immunodeficiency Syndrome
Pharmacologic disruption of base excision repair sensitizes mismatch repair-deficient and -proficient colon cancer cells to methylating agents.
Acute Kidney Injury
5-aminoisoquinoline improves renal function and fibrosis during recovery phase of cisplatin-induced acute kidney injury in rats.
Acute Kidney Injury
Effect of poly(ADP-ribose) polymerase inhibition on outer medullary hypoxic damage.
Acute Kidney Injury
Inhibition of PARP overactivation protects acute kidney injury of septic shock.
Acute Kidney Injury
Inhibition of Poly(ADP-Ribose) Polymerase Attenuates Acute Kidney Injury in Sodium Taurocholate-Induced Acute Pancreatitis in Rats.
Acute Kidney Injury
Inhibition of poly(ADP-ribose) polymerase attenuates ischemic renal injury in rats.
Acute Kidney Injury
Inhibition of Poly-(ADP-Ribose) Polymerase Protects the Kidney in a Canine Model of Endotoxic Shock.
Acute Kidney Injury
Poly (ADP-ribose) polymerase as a potential target for the treatment of acute renal injury caused by lipopolysaccharide.
Acute Kidney Injury
Poly(ADP-ribose) polymerase 1 activation links ischemic acute kidney injury to interstitial fibrosis.
Acute Kidney Injury
Poly(ADP-ribose) polymerase-1 gene ablation protects mice from ischemic renal injury.
Acute Kidney Injury
Poly(ADP-ribose) polymerase-mediated cell injury in acute renal failure.
Acute Kidney Injury
Regulation of necrotic cell death: p53, PARP1 and cyclophilin D-overlapping pathways of regulated necrosis?
Acute Kidney Injury
Role of poly (ADP-ribose) polymerase-1 and cytokines in acute renal injury in elderly Chinese patients with diabetes mellitus.
Acute Kidney Injury
Role of the poly(ADP-ribose)polymerase activity in vancomycin-induced renal injury.
Acute Lung Injury
Administration of poly(ADP-ribose) polymerase inhibitor into bronchial artery attenuates pulmonary pathophysiology after smoke inhalation and burn in an ovine model.
Acute Lung Injury
Inflammatory and transcriptional roles of poly (ADP-ribose) polymerase in ventilator-induced lung injury.
Acute Lung Injury
Inhibition of poly (ADP-ribose) polymerase attenuates acute lung injury in an ovine model of sepsis.
Acute Lung Injury
Murine strain differences in acute lung injury and activation of poly(ADP-ribose) polymerase by in vitro exposure of lung slices to bleomycin.
Acute Lung Injury
Neutrophil transfer of miR-223 to lung epithelial cells dampens acute lung injury in mice.
Acute Lung Injury
PARP inhibitor, olaparib ameliorates acute lung and kidney injury upon intratracheal administration of LPS in mice.
Acute Lung Injury
PARP-1 inhibitor, DPQ, attenuates LPS-induced acute lung injury through inhibiting NF-?B-mediated inflammatory response.
Acute Lung Injury
Pharmacological inhibition of poly (ADP-ribose) polymerase by olaparib, prevents acute lung injury associated cognitive deficits potentially through suppression of inflammatory response.
Acute Lung Injury
Poly(ADP-ribose) Polymerase Inhibition in Acute Lung Injury: A Re-emerging Concept.
Acute Lung Injury
Role of PARP on iNOS pathway during endotoxin-induced acute lung injury.
Acute Lung Injury
The molecular mechanism of acute lung injury caused by Pseudomonas aeruginosa: from bacterial pathogenesis to host response.
Acute Lung Injury
The role of poly(ADP-ribose) polymerase-1 inhibitor in carrageenan-induced lung inflammation in mice.
Adenocarcinoma
A Preclinical Trial and Molecularly Annotated Patient Cohort Identify Predictive Biomarkers in Homologous Recombination-deficient Pancreatic Cancer.
Adenocarcinoma
Adenosine diphosphate ribosyl transferase and x-ray repair cross-complementing 1 polymorphisms in gastric cardia cancer.
Adenocarcinoma
Annonaceous acetogenin mimic AA005 induces cancer cell death via apoptosis inducing factor through a caspase-3-independent mechanism.
Adenocarcinoma
Antiproliferative and apoptotic activities of tosylcyclonovobiocic acids as potent heat shock protein 90 inhibitors in human cancer cells.
Adenocarcinoma
Antiproliferative and Proapoptotic Activities of Marine Sponge Hyrtios erectus Extract on Breast Carcinoma Cell Line (MCF-7).
Adenocarcinoma
BRCA2 secondary mutation-mediated resistance to platinum and PARP inhibitor-based therapy in pancreatic cancer.
Adenocarcinoma
Correlation between PARP-1 Val762Ala polymorphism and the risk of lung cancer in a Chinese population.
Adenocarcinoma
Cyclin-dependent protein kinase 2 activity is required for mitochondrial translocation of Bax and disruption of mitochondrial transmembrane potential during etoposide-induced apoptosis.
Adenocarcinoma
Development of novel synthesized phthalazinone-based PARP-1 inhibitors with apoptosis inducing mechanism in lung cancer.
Adenocarcinoma
DNA Damage Repair Alterations are Frequent in Prostatic Adenocarcinomas with Focal Pleomorphic Giant Cell Features.
Adenocarcinoma
Dysregulation of PARP1 is involved in development of Barrett's esophagus.
Adenocarcinoma
Evaluation of apoptosis induction using PARP cleavage on gastric adenocarcinoma and fibroblast cell lines by different strains of Helicobacter pylori.
Adenocarcinoma
Expression of poly-ADP-ribose polymerase (PARP) in endometrial adenocarcinoma: Prognostic potential.
Adenocarcinoma
High nuclear poly-(ADP-ribose)-polymerase expression is prognostic of improved survival in pancreatic cancer.
Adenocarcinoma
HuR posttranscriptionally regulates WEE1: implications for the DNA damage response in pancreatic cancer cells.
Adenocarcinoma
Hypomethylation of ETS transcription factor binding sites and upregulation of PARP1 expression in endometrial cancer.
Adenocarcinoma
Increased in vitro and in vivo sensitivity of BRCA2-associated pancreatic cancer to the poly(ADP-ribose) polymerase-1/2 inhibitor BMN 673.
Adenocarcinoma
Metformin and epothilone A treatment up regulate pro-apoptotic PARP-1, Casp-3 and H2AX genes and decrease of AKT kinase level to control cell death of human hepatocellular carcinoma and ovary adenocarcinoma cells.
Adenocarcinoma
Pan-Cancer Analysis of PARP1 Alterations as Biomarkers in the Prediction of Immunotherapeutic Effects and the Association of Its Expression Levels and Immunotherapy Signatures.
Adenocarcinoma
Pancreatic acinar cell carcinoma is associated with BRCA2 germline mutations: a case report and literature review.
Adenocarcinoma
Pancreatic mucinous cystadenocarcinoma in a patient harbouring BRCA1 germline mutation effectively treated with olaparib: A case report.
Adenocarcinoma
PARP Inhibition Suppresses GR-MYCN-CDK5-RB1-E2F1 Signaling and Neuroendocrine Differentiation in Castration-Resistant Prostate Cancer.
Adenocarcinoma
Parp-1 deficiency implicated in colon and liver tumorigenesis induced by azoxymethane.
Adenocarcinoma
PARP-1 regulates epithelial-mesenchymal transition (EMT) in prostate tumorigenesis.
Adenocarcinoma
Poly (ADP-Ribose) Polymerase 1 Protein Expression in Normal Pancreas and Pancreatic Adenocarcinoma.
Adenocarcinoma
Protein and phosphoprotein levels in glioma and adenocarcinoma cell lines grown in normoxia and hypoxia in monolayer and three-dimensional cultures.
Adenocarcinoma
PTEN deficiency in endometrioid endometrial adenocarcinomas predicts sensitivity to PARP inhibitors.
Adenocarcinoma
Rapid Progression of Metastatic Pancreatic Adenocarcinoma During Platinum-Based Therapy in a Patient Harboring a Pathogenic BRCA2 Germline Variant.
Adenocarcinoma
Sanguinarine-induced apoptosis is associated with an early and severe cellular glutathione depletion.
Adenocarcinoma
Talazoparib monotherapy in metastatic castration-resistant prostate cancer with DNA repair alterations (TALAPRO-1): an open-label, phase 2 trial.
Adenocarcinoma
Targeted PARP Inhibition Combined with FGFR1 Blockade is Synthetically Lethal to Malignant Cells in Patients with Pancreatic Cancer.
Adenocarcinoma
The BET inhibitor JQ1 attenuates double-strand break repair and sensitizes models of pancreatic ductal adenocarcinoma to PARP inhibitors.
Adenocarcinoma
The role of PARP inhibitors in germline BRCA-associated pancreatic ductal adenocarcinoma.
Adenocarcinoma
Treatment Options for Germline BRCA-Mutated Metastatic Pancreatic Adenocarcinoma.
Adenocarcinoma
Upregulation of Poly (ADP-Ribose) Polymerase-1 (PARP1) in Triple-Negative Breast Cancer and Other Primary Human Tumor Types.
Adenocarcinoma
ZM336372 induces apoptosis associated with phosphorylation of GSK-3beta in pancreatic adenocarcinoma cell lines.
Adenocarcinoma of Lung
ATM deficiency is associated with sensitivity to PARP1 and ATR inhibitors in lung adenocarcinoma.
Adenocarcinoma of Lung
Bax is essential for Drp1-mediated mitochondrial fission but not for mitochondrial outer membrane permeabilization caused by photodynamic therapy.
Adenocarcinoma of Lung
Compromised CDK1 activity sensitizes BRCA-proficient cancers to PARP inhibition.
Adenocarcinoma of Lung
Diagnostic and therapeutic ER?, HER2, BRCA biomakers in the histological subtypes of lung adenocarcinoma according to the IASLC/ATS/ERS classification.
Adenocarcinoma of Lung
Dual role of poly(ADP-ribose) glycohydrolase in the regulation of cell death in oxidatively stressed A549 cells.
Adenocarcinoma of Lung
Erucin, a new promising cancer chemopreventive agent from rocket salads, shows anti-proliferative activity on human lung carcinoma A549 cells.
Adenocarcinoma of Lung
Loss of tumor suppressor inositol polyphosphate 4-phosphatase type B impairs DNA double-strand break repair by destabilization of DNA tethering protein Rad50.
Adenocarcinoma of Lung
Pan-Cancer Analysis of PARP1 Alterations as Biomarkers in the Prediction of Immunotherapeutic Effects and the Association of Its Expression Levels and Immunotherapy Signatures.
Adenocarcinoma of Lung
PARP1 enhances lung adenocarcinoma metastasis by novel mechanisms independent of DNA repair.
Adenocarcinoma of Lung
Poly (ADP-ribose) polymerase-1 Binding Protein Facilitates Lung Adenocarcinoma Cell Proliferation and Correlates with Poor Prognosis.
Adenocarcinoma of Lung
Reduced tumor burden through increased oxidative stress in lung adenocarcinoma cells of PARP-1 and PARP-2 knockout mice.
Adenocarcinoma of Lung
Response to olaparib in metastatic lung adenocarcinoma with germline BRCA2 mutation: a case report.
Adenocarcinoma of Lung
Stenoparib, an Inhibitor of Cellular Poly(ADP-Ribose) Polymerase, Blocks Replication of the SARS-CoV-2 and HCoV-NL63 Human Coronaviruses In Vitro.
Adenocarcinoma of Lung
Targeting MALAT1 induces DNA damage and sensitize non-small cell lung cancer cells to cisplatin by repressing BRCA1.
Adenocarcinoma of Lung
The Joint Effect of hOGG1, APE1, and ADPRT Polymorphisms and Cooking Oil Fumes on the Risk of Lung Adenocarcinoma in Chinese Non-Smoking Females.
Adenoma
Abnormal dopamine sensitivity in some human prolactinomas.
Adenoma
Effect of prostaglandin F2 alpha on human parathyroid adenomas: evidence for uncoupling of parathyroid hormone secretion and cAMP accumulation.
Adenoma
Effects of cumene hydroperoxide on adenosine diphosphate ribosyl transferase in mononuclear leukocytes of patients with adenomatous polyps in the colon.
Adenoma
Fish fatty acids alter markers of apoptosis in colorectal adenoma and adenocarcinoma cell lines but fish consumption has no impact on apoptosis-induction ex vivo.
Adenoma
Genetic variation in base excision repair genes and the prevalence of advanced colorectal adenoma.
Adenoma
Overexpression of poly(ADP-ribose) polymerase-1 (PARP-1) in the early stage of colorectal carcinogenesis.
Adenoma
Parp-1 deficiency implicated in colon and liver tumorigenesis induced by azoxymethane.
Adenoma
PARP-1 expression is increased in colon adenoma and carcinoma and correlates with OGG1.
Adenoma
Pertussis toxin inhibits somatostatin-induced K+ conductance in human pituitary tumor cells.
Adenoma
Poly(ADP-ribose) polymerase-1 is a component of the oncogenic T-cell factor-4/beta-catenin complex.
Adenoma
Some changes of receptor and postreceptor signal transduction regulated by somatostatin in pituitary hGH-secreting adenomas.
Adenoma
Suppression of familial adenomatous polyposis by CP-31398, a TP53 modulator, in APCmin/+ mice.
Adenomatous Polyposis Coli
Absence of stimulation of poly(ADP-ribose) polymerase activity in patients predisposed to colon cancer.
Adenomatous Polyposis Coli
Glial reactions and degeneration of myelinated processes in spinal cord gray matter in chronic experimental autoimmune encephalomyelitis.
Adenomatous Polyposis Coli
Olaparib enhances curcumin-mediated apoptosis in oral cancer cells by inducing PARP trapping through modulation of BER and chromatin assembly.
Adenomatous Polyposis Coli
Poly(ADP-ribose) polymerase-1 is a component of the oncogenic T-cell factor-4/beta-catenin complex.
Adenoviridae Infections
An enzyme-linked-immunosorbent assay method for detection of immunoglobulins to pertussis toxin.
Adrenal Cortex Neoplasms
Bitter Melon (Momordica charantia) Extract Suppresses Adrenocortical Cancer Cell Proliferation Through Modulation of the Apoptotic Pathway, Steroidogenesis, and Insulin-Like Growth Factor Type 1 Receptor/RAC-? Serine/Threonine-Protein Kinase Signaling.
Adrenal Insufficiency
Poly(ADP-ribose) polymerase inhibition suppresses inflammation and promotes recovery from adrenal injury in a rat model of acute necrotizing pancreatitis.
Adrenocortical Carcinoma
Pan-Cancer Analysis of PARP1 Alterations as Biomarkers in the Prediction of Immunotherapeutic Effects and the Association of Its Expression Levels and Immunotherapy Signatures.
Albuminuria
Tempol reduces podocyte apoptosis via PARP signaling pathway in experimental diabetes mellitus.
Albuminuria
Theobromine increases NAD?/Sirt-1 activity and protects the kidney under diabetic conditions.
Alveolar Bone Loss
Role of poly(ADP-ribose) polymerase activation in the pathogenesis of periodontitis in diabetes.
Alzheimer Disease
Activation of PARP by oxidative stress induced by ?-amyloid: implications for Alzheimer's disease.
Alzheimer Disease
Alzheimer's disease related peptides affected cholinergic receptor mediated poly(ADP-ribose) polymerase activity in the hippocampus.
Alzheimer Disease
Beta-amyloid activates PARP causing astrocytic metabolic failure and neuronal death.
Alzheimer Disease
Bioenergetic Impairment in Animal and Cellular Models of Alzheimer's Disease: PARP-1 Inhibition Rescues Metabolic Dysfunctions.
Alzheimer Disease
Cancer Imprints an Increased PARP-1 and p53-Dependent Resistance to Oxidative Stress on Lymphocytes of Patients That Later Develop Alzheimer's Disease.
Alzheimer Disease
Correction: Parp mutations protect from mitochondrial toxicity in Alzheimer's disease.
Alzheimer Disease
Efficacy and safety of NAD+ ADP-ribosyltransferase 1 agonist versus Donepezil in elderly Chinese patients with Alzheimer disease: A novel target for effective therapy.
Alzheimer Disease
Evaluation of the poly(ADP-ribose) polymerase-1 gene variants in Alzheimer's disease.
Alzheimer Disease
Evidence for Decreased Nucleolar PARP-1 as an Early Marker of Cognitive Impairment.
Alzheimer Disease
In silico identification of AChE and PARP-1 dual-targeted inhibitors of Alzheimer's disease.
Alzheimer Disease
Increased poly(ADP-ribosyl)ation of nuclear proteins in Alzheimer's disease.
Alzheimer Disease
Inhibition of poly(ADP-ribose) polymerase-1 alters expression of mitochondria-related genes in PC12 cells: relevance to mitochondrial homeostasis in neurodegenerative disorders.
Alzheimer Disease
Interaction between poly(ADP-ribose) polymerase 1 and interleukin 1A genes is associated with Alzheimer's disease risk.
Alzheimer Disease
Neurotoxic mechanisms by Alzheimer's disease-linked N141I mutant presenilin 2.
Alzheimer Disease
Neurotoxic mechanisms triggered by Alzheimer's disease-linked mutant M146L presenilin 1: involvement of NO synthase via a novel pertussis toxin target.
Alzheimer Disease
Nicotinamide treatment reduces the levels of oxidative stress, apoptosis, and PARP-1 activity in A?(1-42)-induced rat model of Alzheimer's disease.
Alzheimer Disease
Nucleolar PARP-1 Expression Is Decreased in Alzheimer's Disease: Consequences for Epigenetic Regulation of rDNA and Cognition.
Alzheimer Disease
Papers of note in Science Translational Medicine 9 (392).
Alzheimer Disease
Parp mutations protect from mitochondrial toxicity in Alzheimer's disease.
Alzheimer Disease
PARP1 gene variation and microglial activity on [(11)C]PBR28 PET in older adults at risk for Alzheimer's disease.
Alzheimer Disease
Poly (ADP-ribose) polymerase-1 as a promising drug target for neurodegenerative diseases.
Alzheimer Disease
Poly(ADP-ribose) polymerase inhibitors: new pharmacological functions and potential clinical implications.
Alzheimer Disease
Poly(ADP-ribose) Polymerase-1 in Amyloid Beta Toxicity and Alzheimer's Disease.
Alzheimer Disease
PolyADP-ribosylation is involved in neurotrophic activity.
Alzheimer Disease
Synthesis, preliminarily biological evaluation and molecular docking study of new Olaparib analogues as multifunctional PARP-1 and cholinesterase inhibitors.
Alzheimer Disease
The Polyphenol Oleuropein Aglycone Modulates the PARP1-SIRT1 Interplay: An In Vitro and In Vivo Study.
Alzheimer Disease
The role of poly(ADP-ribose) polymerase-1 in CNS disease.
Alzheimer Disease
Transient OGG1, APE1, PARP1 and Pol? expression in an Alzheimer's disease mouse model.
Alzheimer Disease
Variants of Base Excision Repair Genes MUTYH , PARP1 and XRCC1 in Alzheimer's Disease Risk.
Amnesia
Differential prevention of morphine amnesia by antisense oligodeoxynucleotides directed against various Gi-protein alpha subunits.
Amnesia
Effect of pertussis toxin on baclofen- and diphenhydramine-induced amnesia.
Amnesia
Inhibition of PARP-1 participates in the mechanisms of propofol-induced amnesia in mice and human.
Amyotrophic Lateral Sclerosis
Fused in Sarcoma (FUS) in DNA Repair: Tango with Poly(ADP-ribose) Polymerase 1 and Compartmentalisation of Damaged DNA.
Amyotrophic Lateral Sclerosis
Low levels of selenium compounds are selectively toxic for a human neuron cell line through ROS/RNS increase and apoptotic process activation.
Amyotrophic Lateral Sclerosis
PARP expression is increased in astrocytes but decreased in motor neurons in the spinal cord of sporadic ALS patients.
Amyotrophic Lateral Sclerosis
Poly (ADP-ribose) polymerase-1 as a promising drug target for neurodegenerative diseases.
Amyotrophic Lateral Sclerosis
Reactive astrocytes express PARP in the central nervous system of SOD(G93A) transgenic mice.
Anaphylaxis
Adjuvant effect of pertussis toxin on the production of anti-ovalbumin IgE in mice and lack of direct correlation between PCA and ELISA.
Anaphylaxis
Anaphylaxis and mortality induced by treatment of mice with anti-VLA-4 antibody and pertussis toxin.
Anaphylaxis
Anaphylaxis to a self-peptide in the absence of mast cells or histamine.
Anaphylaxis
Asiasari radix inhibits immunoglobulin E production on experimental models in vitro and in vivo.
Anaphylaxis
Basophil activation through ASGM1 stimulation triggers PAF release and anaphylaxis-like shock in mice.
Anaphylaxis
Disodium cromoglycate inhibits production of immunoglobulin E.
Anaphylaxis
Inhibition of immunoglobulin E production by Poncirus trifoliata fruit extract.
Anaphylaxis
Inhibitory effect on immunoglobulin E production in vivo and in vitro by Siegesbeckia glabrescens.
Anaphylaxis
Murine responses to immunization with pertussis toxin and bovine serum albumin: I. Mortality observed after bovine albumin challenge is due to an anaphylactic reaction.
Anaphylaxis
Pertussis toxin enhanced IgG1 and IgE responses to primary tetanus immunization are mediated by interleukin-4 and persist during secondary responses to tetanus alone.
Anaphylaxis
Suppression of passive cutaneous anaphylaxis by pertussis toxin, an islet-activating protein, as a result of inhibition of histamine release from mast cells.
Anemia
Efficacy and safety of PARP inhibitors in the treatment of advanced ovarian cancer: An updated systematic review and meta-analysis of randomized controlled trials.
Anemia
Erythropoietin-driven signalling and cell migration mediated by polyADP-ribosylation.
Anemia
Haematologic toxicities with PARP inhibitors in cancer patients: an up-to-date meta-analysis of 29 randomized controlled trials.
Anemia
PARP inhibitors in ovarian cancer: Clinical evidence for informed treatment decisions.
Anemia
PARP-2 sustains erythropoiesis in mice by limiting replicative stress in erythroid progenitors.
Anemia
Risk of severe hematologic toxicities in cancer patients treated with PARP inhibitors: a meta-analysis of randomized controlled trials.
Anemia
Therapeutic options following second-line platinum-based chemotherapy in patients with recurrent ovarian cancer: Comparison of active surveillance and maintenance treatment.
Anemia
[Analysis of PARP inhibitors induced anemia in advanced and relapsed epithelial ovarian cancer].
Anemia
[Interstitial Pneumonia Caused by Olaparib during Treatment of Breast Cancer-A Case Report].
Aneurysm
Clinical perspectives of PARP inhibitors.
Aneurysm
Pharmacological inhibition of poly(ADP-ribose) polymerase in cardiovascular disorders: future directions.
Angina, Unstable
Activation and overexpression of PARP-1 in circulating mononuclear cells promote TNF-alpha and IL-6 expression in patients with unstable angina.
Angioedema
Angioedema as a predominant symptom of Bordetella pertussis infection.
Angiomyolipoma
Human TSC-associated renal angiomyolipoma cells are hypersensitive to ER stress.
Anthrax
cAMP imaging of cells treated with pertussis toxin, cholera toxin, and anthrax edema toxin.
Anthrax
Caspase- and p53-dependent apoptosis in breast carcinoma cells induced by a synthetic selenadiazole derivative.
Anthrax
Monoclonal antibodies and toxins--a perspective on function and isotype.
Antiphospholipid Syndrome
Poly(ADP-ribose) polymerase alleles in French Caucasians are associated neither with lupus nor with primary antiphospholipid syndrome. GRAID Research Group. Group for Research on Auto-Immune Disorders.
Aortic Aneurysm, Abdominal
PARP-1 (Poly[ADP-Ribose] Polymerase 1) Inhibition Protects From Ang II (Angiotensin II)-Induced Abdominal Aortic Aneurysm in Mice.
Aortic Valve Stenosis
Increased transcript level of poly(ADP-ribose) polymerase (PARP-1) in human tricuspid compared with bicuspid aortic valves correlates with the stenosis severity.
Apnea
Effect of pertussis toxin treatment on the putative adenosine A3 receptor-mediated hypotensive response in the rat.
Apnea
The role of A3 adenosine receptors in central regulation of arterial blood pressure.
Arrhythmias, Cardiac
E3 Ubiquitin ligase NEDD4 family?regulatory network in cardiovascular disease.
Arrhythmias, Cardiac
Gi alpha 1-mediated cardiac electrophysiological remodeling and arrhythmia in hypertrophic cardiomyopathy.
Arthritis
Essential role of neutrophils in anti-type II collagen antibody and lipopolysaccharide-induced arthritis.
Arthritis
GPI 6150, a poly (ADP-ribose) polymerase inhibitor, exhibits an anti-inflammatory effect in rat models of inflammation.
Arthritis
Inhibition of poly(ADP-ribose) polymerase activity is insufficient to induce tetraploidy.
Arthritis
Modulation of inflammatory arthritis by inhibition of poly(ADP ribose) polymerase.
Arthritis
Multifaceted Role of PARP-1 in DNA Repair and Inflammation: Pathological and Therapeutic Implications in Cancer and Non-Cancer Diseases.
Arthritis
Partial protection against collagen antibody-induced arthritis in PARP-1 deficient mice.
Arthritis
Poly(ADP-ribose) polymerase (PARP) polymorphisms associated with nephritis and arthritis in systemic lupus erythematosus.
Arthritis
Poly(ADP-ribose) polymerase inhibitors.
Arthritis
Poly(ADP-ribose) polymerase-1 inhibitor modulates T regulatory and IL-17 cells in the prevention of adjuvant induced arthritis in mice model.
Arthritis
Poly(ADP-Ribose) Polymerases in Host-Pathogen Interactions, Inflammation, and Immunity.
Arthritis
Protection against peroxynitrite-induced fibroblast injury and arthritis development by inhibition of poly(ADP-ribose) synthase.
Arthritis
Structure and function of poly(ADP-ribose) polymerase-1: role in oxidative stress-related pathologies.
Arthritis
Therapeutic Effect of a Poly(ADP-Ribose) Polymerase-1 Inhibitor on Experimental Arthritis by Downregulating Inflammation and Th1 Response.
Arthritis, Experimental
Synergistic effects of thalidomide and poly (ADP-ribose) polymerase inhibition on type II collagen-induced arthritis in mice.
Arthritis, Experimental
Therapeutic Effect of a Poly(ADP-Ribose) Polymerase-1 Inhibitor on Experimental Arthritis by Downregulating Inflammation and Th1 Response.
Arthritis, Rheumatoid
A poly(ADP-ribose) polymerase haplotype spanning the promoter region confers susceptibility to rheumatoid arthritis.
Arthritis, Rheumatoid
Beyond dna repair,the immunological role of parp-1 and its siblings.
Arthritis, Rheumatoid
Lack of association between Poly(ADP-ribose) polymerase (PARP) polymorphisms and rheumatoid arthritis in a Korean population.
Arthritis, Rheumatoid
PARP inhibitors: New partners in the therapy of cancer and inflammatory diseases.
Arthritis, Rheumatoid
Partial protection against collagen antibody-induced arthritis in PARP-1 deficient mice.
Arthritis, Rheumatoid
Poly(ADP-ribose) polymerase inhibition reduces tumor necrosis factor-induced inflammatory response in rheumatoid synovial fibroblasts.
Arthritis, Rheumatoid
Poly(ADP-ribosyl)ation in relation to cancer and autoimmune disease.
Arthritis, Rheumatoid
The Rheumatoid Arthritis Risk Variant CCR6DNP Regulates CCR6 via PARP-1.
Arthritis, Rheumatoid
The Role of Poly(ADP-ribose) Polymerase-1 in Rheumatoid Arthritis.
Arthritis, Rheumatoid
The Val762Ala polymorphism in the poly(ADP-ribose) polymerase-1 gene is not associated with susceptibility in Turkish rheumatoid arthritis patients.
Arthritis, Rheumatoid
Therapeutic Effect of a Poly(ADP-Ribose) Polymerase-1 Inhibitor on Experimental Arthritis by Downregulating Inflammation and Th1 Response.
Asbestosis
Poly(ADP-ribosyl)ation in asthma and other lung diseases.
Asthma
Asthma and poly(ADP-ribose) polymerase inhibition: a new therapeutic approach.
Asthma
Asthmatic bronchial epithelium is more susceptible to oxidant-induced apoptosis.
Asthma
Effects of poly(ADP-ribose) polymerase inhibition on inflammatory cell migration in a murine model of asthma.
Asthma
Gene knockout or pharmacological inhibition of poly(ADP-ribose) polymerase-1 prevents lung inflammation in a murine model of asthma.
Asthma
Genomic Instability in Chronic Airway Inflammatory Diseases.
Asthma
Increased poly(ADP-ribose) polymerase (PARP)-1 expression and activity are associated with inflammation but not goblet cell metaplasia in murine models of allergen-induced airway inflammation.
Asthma
Inhibition of poly(ADP-ribose) polymerase prevents allergen-induced asthma-like reaction in sensitized Guinea pigs.
Asthma
Investigation of poly (ADP-ribose) polymerase-1 genetic variants as a possible risk for allergic rhinitis.
Asthma
Minocycline blocks asthma-associated inflammation in part by interfering with the T cell receptor-nuclear factor ?B-GATA-3-IL-4 axis without a prominent effect on poly(ADP-ribose) polymerase.
Asthma
Multifaceted Role of PARP-1 in DNA Repair and Inflammation: Pathological and Therapeutic Implications in Cancer and Non-Cancer Diseases.
Asthma
PARP inhibition by olaparib alleviates chronic asthma-associated remodeling features via modulating inflammasome signaling in mice.
Asthma
PARP inhibition by olaparib or gene knockout blocks asthma-like manifestation in mice by modulating CD4(+) T cell function.
Asthma
PARP inhibition treatment in a nonconventional experimental mouse model of chronic asthma.
Asthma
PARP inhibitor, olaparib ameliorates acute lung and kidney injury upon intratracheal administration of LPS in mice.
Asthma
PARP is activated in human asthma and its inhibition by olaparib blocks house dust mite-induced disease in mice.
Asthma
PARP-1 deficiency blocks IL-5 expression through calpain-dependent degradation of STAT-6 in a murine asthma model.
Asthma
PARP-1 inhibition ameliorates elastase induced lung inflammation and emphysema in mice.
Asthma
PARP-1 Is Critical for Recruitment of Dendritic Cells to the Lung in a Mouse Model of Asthma but Dispensable for Their Differentiation and Function.
Asthma
PARP-1: a new player in the asthma field?
Asthma
Poly(ADP-Ribose)Polymerase-1 in Lung Inflammatory Disorders: A Review.
Asthma
Poly(ADP-ribosyl)ation in asthma and other lung diseases.
Asthma
Silencing of poly(ADP-ribose) polymerase-1 suppresses hyperstretch-induced expression of inflammatory cytokines in vitro.
Asthma
The Ala allele at Val762Ala polymorphism in poly(ADP-ribose) polymerase-1 (PARP-1) gene is associated with a decreased risk of asthma in a Turkish population.
Asthma
The pertussis hypothesis: Bordetella pertussis colonization in the etiology of asthma and diseases of allergic sensitization.
Asthma
The Role of Poly(ADP-ribose) Polymerase-1 in Rheumatoid Arthritis.
Asthma
[Involvement of G proteins between receptors and KCa channels in the regulation of airway tone by the autonomic nervous system]
Astrocytoma
Comparative status of activated ERK1/2 and PARP cleavage in human gliomas.
Astrocytoma
Guanine nucleotide-sensitive, high affinity binding of carbachol to muscarinic cholinergic receptors of 1321N1 astrocytoma cells is insensitive to pertussis toxin.
Astrocytoma
Inhibition of Mer and Axl Receptor Tyrosine Kinases in Astrocytoma Cells Leads to Increased Apoptosis and Improved Chemosensitivity.
Astrocytoma
PARP1 expression and its correlation with survival is tumour molecular subtype dependent in glioblastoma.
Astrocytoma
PARP1 expression in pediatric central nervous system tumors.
Astrocytoma
Pertussis toxin does not inhibit muscarinic-receptor-mediated phosphoinositide hydrolysis or calcium mobilization.
Astrocytoma
The G12 coupled thrombin receptor stimulates mitogenesis through the Shc SH2 domain.
Astrocytoma
Tumor treating fields combined with a poly (adenosine diphosphate-ribose) polymerase inhibitor during radiotherapy for rapidly progressing IDH-wildtype diffuse astrocytoma: a case report.
Astrocytoma
[Functional characteristics of nucleotide-receptors in human neutrophils]
Asymptomatic Infections
Cell-mediated immune responses to antigens of Bordetella pertussis and protection against pertussis in school children.
Asymptomatic Infections
Widespread silent transmission of pertussis in families: antibody correlates of infection and symptomatology.
Ataxia
Acute ethanol-induced adenosine diphosphate ribosylation regulates the functional activity of rat striatal pertussis toxin-sensitive g proteins.
Ataxia
Cerebellar CB(1) receptor mediation of Delta(9)-THC-induced motor incoordination and its potentiation by ethanol and modulation by the cerebellar adenosinergic A(1) receptor in the mouse.
Ataxia
Interactions of intracerebroventricular pertussis toxin treatment with the ataxic and hypothermic effects of ethanol.
Ataxia
Involvement of kappa-opioids in the mouse cerebellar adenosinergic modulation of ethanol-induced motor incoordination.
Ataxia
Modulation of ethanol-induced motor incoordination by mouse striatal A(1) adenosinergic receptor.
Ataxia
Mouse cerebellar adenosinergic modulation of ethanol-induced motor incoordination: possible involvement of cAMP.
Ataxia
p53 Activation by nitric oxide involves down-regulation of Mdm2.
Ataxia
The PARP inhibitor PJ34 causes a PARP1-independent, p21 dependent mitotic arrest.
Ataxia
The promise of DNA damage response inhibitors for the treatment of glioblastoma.
Ataxia
XRCC1 mutation is associated with PARP1 hyperactivation and cerebellar ataxia.
Ataxia Telangiectasia
53BP1 depletion causes PARP inhibitor resistance in ATM-deficient breast cancer cells.
Ataxia Telangiectasia
A P53-Independent DNA Damage Response Suppresses Oncogenic Proliferation and Genome Instability.
Ataxia Telangiectasia
Analyzing the Opportunities to Target DNA Double-Strand Breaks Repair and Replicative Stress Responses to Improve Therapeutic Index of Colorectal Cancer.
Ataxia Telangiectasia
ATM-Deficient Cancers Provide New Opportunities for Precision Oncology.
Ataxia Telangiectasia
ATR Inhibition Potentiates PARP Inhibitor Cytotoxicity in High Risk Neuroblastoma Cell Lines by Multiple Mechanisms.
Ataxia Telangiectasia
Biomarker-Guided Development of DNA Repair Inhibitors.
Ataxia Telangiectasia
Ceralasertib-Mediated ATR Inhibition Combined With Olaparib in Advanced Cancers Harboring DNA Damage Response and Repair Alterations (Olaparib Combinations).
Ataxia Telangiectasia
Defining and targeting wild-type BRCA high-grade serous ovarian cancer: DNA repair and cell cycle checkpoints.
Ataxia Telangiectasia
Down-expression of poly(ADP-ribose) polymerase in p53-regulated pancreatic cancer cells.
Ataxia Telangiectasia
Enhanced cytotoxicity of PARP inhibition in mantle cell lymphoma harbouring mutations in both ATM and p53.
Ataxia Telangiectasia
Epigenetic inactivation of BCL6B, a novel functional tumour suppressor for gastric cancer, is associated with poor survival of gastric cancer.
Ataxia Telangiectasia
Histone deacetylase 2 is involved in DNA damage-mediated cell death of human osteosarcoma cells through stimulation of the ATM/p53 pathway.
Ataxia Telangiectasia
Identification of proteins in the hamster DNA end-binding complex.
Ataxia Telangiectasia
Implications for breast cancer treatment from increased autotaxin production in adipose tissue after radiotherapy.
Ataxia Telangiectasia
Inhibition of poly(ADP-ribose) polymerase (PARP) and ataxia telangiectasia mutated (ATM) on the chemosensitivity of mantle cell lymphoma to agents that induce DNA strand breaks.
Ataxia Telangiectasia
Interactions Between Ataxia Telangiectasia Mutated Kinase Inhibition, Poly(ADP-ribose) Polymerase-1 Inhibition and BRCA1 Status in Breast Cancer Cells.
Ataxia Telangiectasia
Introductory review: involvement of ADP-ribosylation in cellular recovery from some forms of DNA damage.
Ataxia Telangiectasia
Is there a role for base excision repair in estrogen/estrogen receptor-driven breast cancers?
Ataxia Telangiectasia
Loss of NEIL3 DNA glycosylase markedly increases replication associated double strand breaks and enhances sensitivity to ATR inhibitor in glioblastoma cells.
Ataxia Telangiectasia
Low ATM protein expression and depletion of p53 correlates with olaparib sensitivity in gastric cancer cell lines.
Ataxia Telangiectasia
Mitochondrial protein ATPase family, AAA domain containing 3A correlates with radioresistance in glioblastoma.
Ataxia Telangiectasia
Monitoring and signaling of radiation-induced damage in mammalian cells.
Ataxia Telangiectasia
Novel and emerging drugs for rarer chronic lymphoid leukaemias.
Ataxia Telangiectasia
PARP1-dependent recruitment of KDM4D histone demethylase to DNA damage sites promotes double-strand break repair.
Ataxia Telangiectasia
PARP10 deficiency manifests by severe developmental delay and DNA repair defect.
Ataxia Telangiectasia
Poly (ADP-ribose) polymerase-1 inhibition decreases proliferation through G2/M arrest in esophageal squamous cell carcinoma.
Ataxia Telangiectasia
Poly(ADP-ribose) polymerase activity is not affected in ataxia telangiectasia cells and knockout mice.
Ataxia Telangiectasia
Predictive and Prognostic Value of DNA Damage Response Associated Kinases in Solid Tumors.
Ataxia Telangiectasia
Radiosensitizing Potential of Curcumin in Different Cancer Models.
Ataxia Telangiectasia
Randomized, Double-Blind Phase II Trial With Prospective Classification by ATM Protein Level to Evaluate the Efficacy and Tolerability of Olaparib Plus Paclitaxel in Patients With Recurrent or Metastatic Gastric Cancer.
Ataxia Telangiectasia
Replication Stress: An Achilles' Heel of Glioma Cancer Stem-like Cells.
Ataxia Telangiectasia
Role of autophagy in chemoresistance: regulation of the ATM-mediated DNA-damage signaling pathway through activation of DNA-PKcs and PARP-1.
Ataxia Telangiectasia
S-phase checkpoints regulate Apo2 ligand/TRAIL and CPT-11-induced apoptosis of prostate cancer cells.
Ataxia Telangiectasia
Shelterin-Mediated Telomere Protection.
Ataxia Telangiectasia
Targeted cancer therapies based on the inhibition of DNA strand break repair.
Ataxia Telangiectasia
Targeting DNA Damage Repair for Immune Checkpoint Inhibition: Mechanisms and Potential Clinical Applications.
Ataxia Telangiectasia
Targeting poly(ADP-ribose) polymerase and the c-Myb-regulated DNA damage response pathway in castration-resistant prostate cancer.
Ataxia Telangiectasia
The DNA damage response (DDR) is induced by the C9orf72 repeat expansion in amyotrophic lateral sclerosis.
Ataxia Telangiectasia
The DNA damage sensors ataxia-telangiectasia mutated kinase and checkpoint kinase 2 are required for hepatitis C virus RNA replication.
Ataxia Telangiectasia
The Herpesvirus Nuclear Egress Complex Component, UL31, Can Be Recruited to Sites of DNA Damage Through Poly-ADP Ribose Binding.
Ataxia Telangiectasia
The inhibition of poly(ADP-ribose) polymerase enhances growth rates of ataxia telangiectasia cells.
Ataxia Telangiectasia
The promise of DNA damage response inhibitors for the treatment of glioblastoma.
Ataxia Telangiectasia
Thyroid hormones derivatives reduce proliferation and induce cell death and DNA damage in ovarian cancer.
Atherosclerosis
Activation of poly(ADP-ribose) polymerase contributes to the endothelial dysfunction associated with hypertension and aging.
Atherosclerosis
Acyl-CoA-binding domain containing 3 modulates NAD+ metabolism through activating poly(ADP-ribose) polymerase 1.
Atherosclerosis
Differential effects of PARP inhibition on vascular cell survival and ACAT-1 expression favouring atherosclerotic plaque stability.
Atherosclerosis
E3 Ubiquitin ligase NEDD4 family?regulatory network in cardiovascular disease.
Atherosclerosis
G protein beta3 subunit 825T allele and enhanced coronary vasoconstriction on alpha(2)-adrenoceptor activation.
Atherosclerosis
Low shear stress induced HMGB1 translocation and release via PECAM-1/PARP-1 pathway to induce inflammation response.
Atherosclerosis
Multifaceted Role of PARP-1 in DNA Repair and Inflammation: Pathological and Therapeutic Implications in Cancer and Non-Cancer Diseases.
Atherosclerosis
Opposing roles of PARP-1 in MMP-9 and TIMP-2 expression and mast cell degranulation in dyslipidemic dilated cardiomyopathy.
Atherosclerosis
PARP inhibition in atherosclerosis and its effects on dendritic cells, T cells and auto-antibody levels.
Atherosclerosis
PARP-1 Involvement in Autophagy and Their Roles in Apoptosis of Vascular Smooth Muscle Cells under Oxidative Stress.
Atherosclerosis
PARP-1 Represses LXR-mediated ABCA1 Expression and Cholesterol Efflux in Macrophages.
Atherosclerosis
PARP1 is required for adhesion molecule expression in atherogenesis.
Atherosclerosis
PARPs in lipid metabolism and related diseases.
Atherosclerosis
Phenotypic Switching of Atherosclerotic Smooth Muscle Cells is Regulated by Activated PARP1-Dependent TET1 Expression.
Atherosclerosis
PJ34, a PARP1 inhibitor, promotes endothelial repair in a rabbit model of high fat diet-induced atherosclerosis.
Atherosclerosis
Poly (ADP-Ribose) Polymerase 1 Mediated Arginase II Activation Is Responsible for Oxidized LDL-Induced Endothelial Dysfunction.
Atherosclerosis
Poly (ADP-Ribose) Polymerase Inhibition Attenuates Atherosclerotic Plaque Development in ApoE-/- Mice with Hyperhomocysteinemia.
Atherosclerosis
Poly(ADP-ribose) Polymerase (PARP) and PARP Inhibitors: Mechanisms of Action and Role in Cardiovascular Disorders.
Atherosclerosis
Poly(ADP-ribose) Polymerase 1 (PARP1) in Atherosclerosis: From Molecular Mechanisms to Therapeutic Implications.
Atherosclerosis
Poly(ADP-ribose) polymerase 1 deficiency increases nitric oxide production and attenuates aortic atherogenesis through downregulation of arginase II.
Atherosclerosis
Poly(ADP-ribose) polymerase 1 inhibition protects against low shear stress induced inflammation.
Atherosclerosis
Poly(ADP-ribose) polymerase 1 inhibition protects human aortic endothelial cells against LPS-induced inflammation response.
Atherosclerosis
Poly(ADP-ribose) polymerase inhibition improves endothelial dysfunction induced by reactive oxidant hydrogen peroxide in vitro.
Atherosclerosis
Poly(ADP-ribose) polymerase inhibition reduces atherosclerotic plaque size and promotes factors of plaque stability in apolipoprotein E-deficient mice: effects on macrophage recruitment, nuclear factor-kappaB nuclear translocation, and foam cell death.
Atherosclerosis
Role of oxidative-nitrosative stress and downstream pathways in various forms of cardiomyopathy and heart failure.
Atherosclerosis
Role of poly(ADP-ribose) polymerase 1 (PARP-1) in cardiovascular diseases: the therapeutic potential of PARP inhibitors.
Atherosclerosis
The Role of Poly(ADP-ribose) Polymerase-1 in Rheumatoid Arthritis.
Atherosclerosis
Thieno[2,3-c]isoquinolin-5-one, a potent poly(ADP-ribose) polymerase inhibitor, promotes atherosclerotic plaque regression in high-fat diet-fed apolipoprotein E-deficient mice: effects on inflammatory markers and lipid content.
Atrial Fibrillation
DNA damage-induced PARP1 activation confers cardiomyocyte dysfunction through NAD+ depletion in experimental atrial fibrillation.
Atrial Fibrillation
[The epidemiological characteristics and adherence to hypoglycemic agents of ischemic stroke patients with diabetes].
Autoimmune Diseases
Analysis of experimental autoimmune encephalomyelitis induced in F344 rats by pertussis toxin administration.
Autoimmune Diseases
Apoptosis in leukemia cells is accompanied by alterations in the levels and localization of nucleolin.
Autoimmune Diseases
Autoantibodies to Poly(ADP-Ribose) Polymerase in Centenarians: A Reappraisal of Grabar's Hypothesis.
Autoimmune Diseases
Dissociating the enhancing and inhibitory effects of pertussis toxin on autoimmune disease.
Autoimmune Diseases
Genetic analysis of the influence of pertussis toxin on experimental allergic encephalomyelitis susceptibility: an environmental agent can override genetic checkpoints.
Autoimmune Diseases
Histamine H2 receptor signaling x environment interactions determine susceptibility to experimental allergic encephalomyelitis.
Autoimmune Diseases
Immunomodulation of murine experimental autoimmune encephalomyelitis by pertussis toxin: the protective activity, but not the disease-enhancing activity, can be attributed to the nontoxic B-oligomer.
Autoimmune Diseases
Locus controlling Bordetella pertussis-induced histamine sensitization (Bphs), an autoimmune disease-susceptibility gene, maps distal to T-cell receptor beta-chain gene on mouse chromosome 6.
Autoimmune Diseases
Lymphocyte proliferation induced by pertussis toxin utilizes a pathway parallel to transforming growth factor-beta-sensitive growth.
Autoimmune Diseases
Paradoxical effect of pertussis toxin on the delayed hypersensitivity response to autoantigens in mice.
Autoimmune Diseases
PARP activity and NAD concentration in PMC from patients affected by systemic sclerosis and lupus erythematosus.
Autoimmune Diseases
Pertussis toxin alters the innate and the adaptive immune responses in a pertussis-dependent model of autoimmunity.
Autoimmune Diseases
Pertussis toxin enhances Th1 responses by stimulation of dendritic cells.
Autoimmune Diseases
Pertussis toxin inhibits induction of tissue-specific autoimmune disease by disrupting G protein-coupled signals.
Autoimmune Diseases
Pertussis toxin potentiates Th1 and Th2 responses to co-injected antigen: adjuvant action is associated with enhanced regulatory cytokine production and expression of the co-stimulatory molecules B7-1, B7-2 and CD28.
Autoimmune Diseases
Pertussis toxin reduces the number of splenic Foxp3+ regulatory T cells.
Autoimmune Diseases
Pertussis toxin-induced hyperacute autoimmune encephalomyelitis in Lewis rats is correlated with increased expression of inducible nitric oxide synthase and tumor necrosis factor alpha.
Autoimmune Diseases
Pertussis toxin-induced lymphocytosis is associated with alterations in thymocyte subpopulations.
Autoimmune Diseases
Pharmacological targeting of IDO-mediated tolerance for treating autoimmune disease.
Autoimmune Diseases
Poly (ADP-Ribose) Polymerase-1 (PARP-1) as Immune Regulator.
Autoimmune Diseases
Poly(ADP-ribosyl)ation in relation to cancer and autoimmune disease.
Autoimmune Diseases
Poly(ADP-ribosyl)ation of FOXP3 Protein Mediated by PARP-1 Protein Regulates the Function of Regulatory T Cells.
Autoimmune Diseases
Protection against autoimmune disease by bacterial agents. II. PPD and pertussis toxin as proteins active in protecting mice against experimental autoimmune encephalomyelitis.
Autoimmune Diseases
Repetitive pertussis toxin promotes development of regulatory T cells and prevents central nervous system autoimmune disease.
Autoimmune Diseases
Roles of poly(ADP-ribose) polymerase activation in the pathogenesis of diabetes mellitus and its complications.
Autoimmune Diseases
The Role of PARP-1 in Host-Pathogen Interaction and Cellular Stress Responses.
Autoimmune Diseases
Transcriptional reprogramming and resistance to colonic mucosal injury in Poly(ADP-ribose) polymerase 1 (PARP1)-deficient mice.
Azoospermia
An ADP-ribosyltransferase 3 (ART3) variant is associated with reduced sperm counts in Czech males: case/control association study replicating results from the Japanese population.
Azoospermia
Association of polymorphisms in ART3 gene with male infertility in the Chinese population.
Bacterial Infections
Host poly(ADP-ribose) polymerases (PARPs) in acute and chronic bacterial infections.
Bacterial Infections
Monocyte Trafficking to Hepatic Sites of Bacterial Infection Is Chemokine Independent and Directed by Focal Intercellular Adhesion Molecule-1 Expression.
Barrett Esophagus
Dysregulation of PARP1 is involved in development of Barrett's esophagus.
Barrett Esophagus
MicroRNA 223 is upregulated in the multistep progression of Barrett's esophagus and modulates sensitivity to chemotherapy by targeting PARP1.
Bicuspid Aortic Valve Disease
Increased transcript level of poly(ADP-ribose) polymerase (PARP-1) in human tricuspid compared with bicuspid aortic valves correlates with the stenosis severity.
Biliary Tract Neoplasms
Biliary tract cancer and genomic alterations in homologous recombinant deficiency: exploiting synthetic lethality with PARP inhibitors.
Biliary Tract Neoplasms
Inhibition of WEE1 Potentiates Sensitivity to PARP Inhibitor in Biliary Tract Cancer.
Biliary Tract Neoplasms
Investigational PARP inhibitors for the treatment of biliary tract cancer: spotlight on preclinical and clinical studies.
Biliary Tract Neoplasms
PARP Inhibitors in Biliary Tract Cancer: A New Kid on the Block?
Blister
Activation of poly [ADP-Ribose] polymerase in endothelial cells and keratinocytes: role in an in vitro model of sulfur mustard-mediated vesication.
Blister
Cell surface antigens of Bordetella pertussis.
Blister
Involvement of small GTPases Rho and Rac in the invasion of rat ascites hepatoma cells.
Blister
Neolignans from Nectandra megapotamica (Lauraceae) Display in vitro Cytotoxic Activity and Induce Apoptosis in Leukemia Cells.
Blister
PARP determines the mode of cell death in skin fibroblasts, but not keratinocytes, exposed to sulfur mustard.
Blister
Putative role of proteolysis and inflammatory response in the toxicity of nerve and blister chemical warfare agents: implications for multi-threat medical countermeasures.
Blister
The SC-35 Splicing Factor Interacts with RNA Pol II and A-Type Lamin Depletion Weakens This Interaction.
Blister
Two phases of pseudopod protrusion in tumor cells revealed by a micropipette.
Bloom Syndrome
Design, Synthesis, and Evaluation of New Quinazolinone Derivatives that Inhibit Bloom Syndrome Protein (BLM) Helicase, Trigger DNA Damage at the Telomere Region, and Synergize with PARP Inhibitors.
Bloom Syndrome
Identification of proteins in the hamster DNA end-binding complex.
Bone Diseases
NAMPT/PBEF1 enzymatic activity is indispensable for myeloma cell growth and osteoclast activity.
Bone Neoplasms
Spinal RhoA/Rho Kinase Signaling Pathway may Participate in the Development of Bone Cancer Pain.
Bone Resorption
Effects of pertussis toxin on resorption of 19-day-old fetal rat long bones.
Bone Resorption
Inhibitory action of pertussis toxin on parathyroid hormone and prostaglandin E2-stimulated bone resorption in cultured neonatal mouse calvaria.
Bone Resorption
Pertussis toxin inhibits hormonal stimulation of bone resorption in fetal rat limb bones.
Bone Resorption
Rho-A is critical for osteoclast podosome organization, motility, and bone resorption.
Bone Resorption
Role of the activation of the nuclear enzyme poly(ADP-ribose) polymerase in the pathogenesis of periodontitis.
Bone Resorption
Stimulation of a Gs-like G protein in the osteoclast inhibits bone resorption but enhances tartrate-resistant acid phosphatase secretion.
Bone Resorption
The small GTP-binding protein, rho p21, is involved in bone resorption by regulating cytoskeletal organization in osteoclasts.
Bordetella Infections
Bordetella adenylate cyclase is a virulence associated factor and an immunoprotective antigen.
Bordetella Infections
Polymorphism in the pertussis toxin promoter region affecting the DNA-based diagnosis of Bordetella infection.
Bordetella Infections
Western blot analysis of antibody responses of young infants to pertussis infection.
Bradycardia
Altered sinus nodal and atrioventricular nodal function in freely moving mice overexpressing the A1 adenosine receptor.
Bradycardia
Differentiation of muscarinic receptors mediating negative chronotropic and vasoconstrictor responses to acetylcholine in isolated rat hearts.
Bradycardia
Effect of pertussis toxin treatment on the putative adenosine A3 receptor-mediated hypotensive response in the rat.
Bradycardia
Enhanced negative chronotropy by inhibitory receptors in transgenic heart overexpressing beta(2)-adrenoceptors.
Bradycardia
Mechanism of the cardiovascular effects of GABAB receptor activation in the nucleus tractus solitarii of the rat.
Bradycardia
Preconditioning against infarction in the rat heart does not involve a pertussis toxin sensitive G protein.
Brain Death
Activation and modulation of cardiac poly-adenosine diphosphate ribose polymerase activity in a rat model of brain death.
Brain Diseases
Apoptosis and microglial activation in influenza encephalopathy.
Brain Diseases
Bordetella Dermonecrotic Toxin Is a Neurotropic Virulence Factor That Uses CaV3.1 as the Cell Surface Receptor.
Brain Diseases
Metalloproteinases control brain inflammation induced by pertussis toxin in mice overexpressing the chemokine CCL2 in the central nervous system.
Brain Diseases
Murine model for pertussis vaccine encephalopathy: role of the major histocompatibility complex; antibody to albumin and to Bordetella pertussis and pertussis toxin.
Brain Diseases
PARP inhibition delays progression of mitochondrial encephalopathy in mice.
Brain Diseases
Pertussis encephalopathy with high cerebrospinal fluid antibody titers to pertussis toxin and filamentous hemagglutinin.
Brain Diseases
Pertussis toxin is required for pertussis vaccine encephalopathy.
Brain Diseases
Pertussis toxin-induced reversible encephalopathy dependent on monocyte chemoattractant protein-1 overexpression in mice.
Brain Diseases
Poly(ADP-ribosyl)ation enhancement in brain cell nuclei is associated with diabetic neuropathy.
Brain Edema
Contribution of poly(ADP-ribose) polymerase to postischemic blood-brain barrier damage in rats.
Brain Edema
Poly(ADP-ribose) polymerase activation and brain edema formation by hemoglobin after intracerebral hemorrhage in rats.
Brain Edema
Poly(ADP-ribose) polymerase during reperfusion after transient forebrain ischemia: its role in brain edema and cell death.
Brain Infarction
Neuronal death in brain infarcts in man.
Brain Infarction
Poly(ADP-ribose) polymerase as a key player in excitotoxicity and post-ischemic brain damage.
Brain Injuries
A novel and potent poly(ADP-ribose) polymerase-1 inhibitor, FR247304 (5-chloro-2-[3-(4-phenyl-3,6-dihydro-1(2H)-pyridinyl)propyl]-4(3H)-quinazolinone), attenuates neuronal damage in in vitro and in vivo models of cerebral ischemia.
Brain Injuries
A novel PARP inhibitor L-2286 in a rat model of impact acceleration head injury: An immunohistochemical and behavioral study.
Brain Injuries
Acute Meningitis.
Brain Injuries
At the scene of ischemic brain injury: is PARP a perp?
Brain Injuries
Biphasic changes in the levels of poly(ADP-ribose) polymerase-1 and caspase 3 in the immature brain following hypoxia-ischemia.
Brain Injuries
Contribution of poly(ADP-ribose) polymerase to postischemic blood-brain barrier damage in rats.
Brain Injuries
Direct phosphorylation and regulation of poly(ADP-ribose) polymerase-1 by extracellular signal-regulated kinases 1/2.
Brain Injuries
Drug-induced hypothermia begun 5 minutes after injury with a poly(adenosine 5'-diphosphate-ribose) polymerase inhibitor reduces hypoxic brain injury in rat pups.
Brain Injuries
Effect of 3-Aminobenzamide on the Ultrastructure of Astrocytes and Microvessels After Focal Cerebral Ischemia in Rats.
Brain Injuries
Effects of Poly(ADP-Ribose) Polymerase-1 Inhibition in a Neonatal Rodent Model of Hypoxic-Ischemic Injury.
Brain Injuries
Effects of transient global ischemia and kainate on poly(ADP-ribose) polymerase (PARP) gene expression and proteolytic cleavage in gerbil and rat brains.
Brain Injuries
Enhanced poly(ADP-ribose) polymerase-1 activation contributes to recombinant tissue plasminogen activator-induced aggravation of ischemic brain injury in vivo.
Brain Injuries
Hyperglycemia potentiates a shift from apoptosis to RIP1-dependent necroptosis.
Brain Injuries
Influence of PARP-1 polymorphisms in patients after traumatic brain injury.
Brain Injuries
Inhibition of neuronal nitric oxide synthase-mediated activation of poly(ADP-ribose) polymerase in traumatic brain injury: neuroprotection by 3-aminobenzamide.
Brain Injuries
Interaction between inducible nitric oxide synthase and poly(ADP-ribose) polymerase in focal ischemic brain injury.
Brain Injuries
Ischemic brain injury is mediated by the activation of poly(ADP-ribose)polymerase.
Brain Injuries
Local administration of the poly(ADP-ribose) polymerase inhibitor INO-1001 prevents NAD+ depletion and improves water maze performance after traumatic brain injury in mice.
Brain Injuries
Microglial activation induced by the alarmin S100B is regulated by poly(ADP-ribose) polymerase-1.
Brain Injuries
NAD+ and NADH in ischemic brain injury.
Brain Injuries
NAD+ Metabolism and NAD+-Dependent Enzymes: Promising Therapeutic Targets for Neurological Diseases.
Brain Injuries
Neuroprotective effects of a novel Poly (ADP-Ribose) Polymerase-1 inhibitor, JPI-289, in hypoxic rat cortical neurons.
Brain Injuries
Neuroprotective effects of KCL-440, a new poly(ADP-ribose) polymerase inhibitor, in the rat middle cerebral artery occlusion model.
Brain Injuries
Nicotinamide mononucleotide administration after sever hypoglycemia improves neuronal survival and cognitive function in rats.
Brain Injuries
Oxidative Stress and NAD(+) in Ischemic Brain Injury: Current Advances and Future Perspectives.
Brain Injuries
Oxidative stress in bacterial meningitis.
Brain Injuries
PARP inhibition attenuates early brain injury through NF-?B/MMP-9 pathway in a rat model of subarachnoid hemorrhage.
Brain Injuries
PARP-1 gene disruption in mice preferentially protects males from perinatal brain injury.
Brain Injuries
Poly(ADP-ribose) polymerase is not involved in the neuroprotection exerted by azithromycin against ischemic stroke in mice.
Brain Injuries
Poly(ADP-ribose) polymerase-1 and its clinical applications in brain injury.
Brain Injuries
Poly(ADP-ribosyl)ation and stroke.
Brain Injuries
Postnatal Age Influences Hypoglycemia-induced Poly(ADP-ribose) Polymerase-1 Activation in the Brain Regions of Rats.
Brain Injuries
Protective effects of PJ34, a novel, potent inhibitor of poly(ADP-ribose) polymerase (PARP) in in vitro and in vivo models of stroke.
Brain Injuries
Roles of NAD (+) , PARP-1, and Sirtuins in Cell Death, Ischemic Brain Injury, and Synchrotron Radiation X-Ray-Induced Tissue Injury.
Brain Injuries
Sex differences in the response to activation of the poly (ADP-ribose) polymerase pathway after experimental stroke.
Brain Injuries
Temporal patterns of poly(ADP-ribose) polymerase activation in the cortex following experimental brain injury in the rat.
Brain Injuries
[Involvement of caspase on apoptosis in ischemia-induced neuronal cell death: usefulness of caspase inhibitors for stroke therapy]
Brain Injuries, Traumatic
A dual role for poly-ADP-ribosylation in spatial memory acquisition after traumatic brain injury in mice involving NAD+ depletion and ribosylation of 14-3-3gamma.
Brain Injuries, Traumatic
Acyl-CoA-binding domain containing 3 modulates NAD+ metabolism through activating poly(ADP-ribose) polymerase 1.
Brain Injuries, Traumatic
Alternative mechanisms of inhibiting activity of poly (ADP-ribose) polymerase-1.
Brain Injuries, Traumatic
Beneficial effects of PJ34 and INO-1001, two novel water-soluble poly(ADP-ribose) polymerase inhibitors, on the consequences of traumatic brain injury in rat.
Brain Injuries, Traumatic
Effect of 3-Aminobenzamide on the Ultrastructure of Astrocytes and Microvessels After Focal Cerebral Ischemia in Rats.
Brain Injuries, Traumatic
Effect of Acute Poly(ADP-Ribose) Polymerase Inhibition by 3-AB on Blood-Brain Barrier Permeability and Edema Formation After Focal Traumatic Brain Injury in Rats.
Brain Injuries, Traumatic
Identification of poly-ADP-ribosylated mitochondrial proteins after traumatic brain injury.
Brain Injuries, Traumatic
Increased expression and activation of poly(ADP-ribose) polymerase (PARP) contribute to retinal ganglion cell death following rat optic nerve transection.
Brain Injuries, Traumatic
Influence of PARP-1 polymorphisms in patients after traumatic brain injury.
Brain Injuries, Traumatic
Inhibition of neuronal nitric oxide synthase-mediated activation of poly(ADP-ribose) polymerase in traumatic brain injury: neuroprotection by 3-aminobenzamide.
Brain Injuries, Traumatic
Inhibition of poly(ADP-ribose) polymerase activity is insufficient to induce tetraploidy.
Brain Injuries, Traumatic
Local administration of the poly(ADP-ribose) polymerase inhibitor INO-1001 prevents NAD+ depletion and improves water maze performance after traumatic brain injury in mice.
Brain Injuries, Traumatic
Microglial activation induced by brain trauma is suppressed by post-injury treatment with a PARP inhibitor.
Brain Injuries, Traumatic
PARP inhibition improves the effectiveness of neural stem cell transplantation in experimental brain trauma.
Brain Injuries, Traumatic
PARP-1 Inhibition Attenuates Neuronal Loss, Microglia Activation and Neurological Deficits after Traumatic Brain Injury.
Brain Injuries, Traumatic
PARP1 might enhance the therapeutic effect of tetrahydroxystilbene glucoside in traumatic brain injury via inhibition of Ras/JNK signalling pathway.
Brain Injuries, Traumatic
Pharmacologic inhibition of poly(ADP-ribose) polymerase is neuroprotective following traumatic brain injury in rats.
Brain Injuries, Traumatic
Poly(ADP ribose) polymerase cleavage precedes neuronal death in the hippocampus and cerebellum following injury to the developing rat forebrain.
Brain Injuries, Traumatic
Poly(ADP-Ribose)Polymerase 1 (PARP-1) Activation and Ca(2+) Permeable ?-Amino-3-Hydroxy-5-Methyl-4-Isoxazolepropionic Acid (AMPA) Channels in Post-Ischemic Brain Damage: New Therapeutic Opportunities?
Brain Injuries, Traumatic
Protective actions of PJ34, a poly(ADP-ribose)polymerase inhibitor, on the blood-brain barrier after traumatic brain injury in mice.
Brain Injuries, Traumatic
Protective effects of PARP inhibitor, PJ34, is related to down-regulation of calpain and NF-?B in a mouse model of TBI.
Brain Injuries, Traumatic
Protective functions of PJ34, a PARP inhibitor, is related to down-regulation of calpain and NF-?B in a mouse model of TBI.
Brain Injuries, Traumatic
Reduction of cognitive and motor deficits after traumatic brain injury in mice deficient in poly(ADP-ribose) polymerase.
Brain Injuries, Traumatic
The expression pattern of ADP-ribosyltransferase 3 in rat traumatic brain injury.
Brain Injuries, Traumatic
Traumatic brain injury in mice deficient in poly-ADP(ribose) polymerase: a preliminary report.
Brain Injuries, Traumatic
[Neuronal death: potential role of the nuclear enzyme, poly (ADP-ribose) polymerase]
Brain Ischemia
3-Aminobenzamide reduces brain infarction and neutrophil infiltration after transient focal cerebral ischemia in mice.
Brain Ischemia
A newly synthesized poly(ADP-ribose) polymerase inhibitor, DR2313 [2-methyl-3,5,7,8-tetrahydrothiopyrano[4,3-d]-pyrimidine-4-one]: pharmacological profiles, neuroprotective effects, and therapeutic time window in cerebral ischemia in rats.
Brain Ischemia
A novel and potent poly(ADP-ribose) polymerase-1 inhibitor, FR247304 (5-chloro-2-[3-(4-phenyl-3,6-dihydro-1(2H)-pyridinyl)propyl]-4(3H)-quinazolinone), attenuates neuronal damage in in vitro and in vivo models of cerebral ischemia.
Brain Ischemia
Another "string to the bow" of PJ34, a potent poly(ADP-Ribose)polymerase inhibitor: an antiplatelet effect through P2Y12 antagonism?
Brain Ischemia
Anti-inflammatory effects of PJ34, a poly(ADP-ribose) polymerase inhibitor, in transient focal cerebral ischemia in mice.
Brain Ischemia
Apoptosis-inducing factor triggered by poly(ADP-Ribose) polymerase and bid mediates neuronal cell death after oxygen-glucose deprivation and focal cerebral ischemia.
Brain Ischemia
Augmentation of poly(ADP-ribose) polymerase-dependent neuronal cell death by acidosis.
Brain Ischemia
Cellular NAD replenishment confers marked neuroprotection against ischemic cell death: role of enhanced DNA repair.
Brain Ischemia
Combined therapy with PJ34, a poly(ADP-ribose)polymerase inhibitor, reduces tissue plasminogen activator-induced hemorrhagic transformations in cerebral ischemia in mice.
Brain Ischemia
Comet assay as a novel approach for studying DNA damage in focal cerebral ischemia: differential effects of NMDA receptor antagonists and poly(ADP-ribose) polymerase inhibitors.
Brain Ischemia
Contributions of poly(ADP-ribose) polymerase-1 and -2 to nuclear translocation of apoptosis-inducing factor and injury from focal cerebral ischemia.
Brain Ischemia
Different doses of dexmedetomidine reduce plasma cytokine production, brain oxidative injury, PARP and caspase expression levels but increase liver oxidative toxicity in cerebral ischemia-induced rats.
Brain Ischemia
Differential PARP Cleavage: An Indication of Heterogeneous Forms of Cell Death and Involvement of Multiple Proteases in the Infarct of Focal Cerebral Ischemia in Rat.
Brain Ischemia
Effect of 3-aminobenzamide, PARP inhibitor, on matrix metalloproteinase-9 level in plasma and brain of ischemic stroke model.
Brain Ischemia
Enhanced poly(ADP-ribose) polymerase-1 activation contributes to recombinant tissue plasminogen activator-induced aggravation of ischemic brain injury in vivo.
Brain Ischemia
Enhanced poly(ADP-ribosyl)ation after focal ischemia in rat brain.
Brain Ischemia
Epigallocatechin gallate alleviates neuronal cell damage against focal cerebral ischemia in rats.
Brain Ischemia
Ginsenoside Rd blocks AIF mitochondrio-nuclear translocation and NF-?B nuclear accumulation by inhibiting poly(ADP-ribose) polymerase-1 after focal cerebral ischemia in rats.
Brain Ischemia
Improved Reperfusion and Vasculoprotection by the Poly(ADP-Ribose)Polymerase Inhibitor PJ34 After Stroke and Thrombolysis in Mice.
Brain Ischemia
Inhibition of poly (ADP-ribose) polymerase and caspase-3, but not caspase-1, prevents apoptosis and improves spatial memory of rats with twice-repeated cerebral ischemia.
Brain Ischemia
Inhibition of poly(ADP-ribose) polymerase: reduction of ischemic injury and attenuation of N-methyl-D-aspartate-induced neurotransmitter dysregulation.
Brain Ischemia
Interaction between inducible nitric oxide synthase and poly(ADP-ribose) polymerase in focal ischemic brain injury.
Brain Ischemia
Ischemia of rat brain decreases pertussis toxin-catalyzed [32P]ADP ribosylation of GTP-binding proteins (Gi1 and G0) in membranes.
Brain Ischemia
Ischemic nitric oxide and poly (ADP-ribose) polymerase-1 in cerebral ischemia: male toxicity, female protection.
Brain Ischemia
Mitochondrial impairment induced by poly(ADP-ribose) polymerase-1 activation in cortical neurons after oxygen and glucose deprivation.
Brain Ischemia
Natural Inhibitors of Poly(ADP-ribose) Polymerase-1.
Brain Ischemia
Neuropilin-1 modulates vascular endothelial growth factor-induced poly(ADP-ribose)-polymerase leading to reduced cerebrovascular apoptosis.
Brain Ischemia
Neuroprotection by the PARP inhibitor PJ34 modulates cerebral and circulating RAGE levels in rats exposed to focal brain ischemia.
Brain Ischemia
Neuroprotective effects of a novel water-soluble poly(ADP-ribose) polymerase-1 inhibitor, MP-124, in in vitro and in vivo models of cerebral ischemia.
Brain Ischemia
Neuroprotective effects of NU1025, a PARP inhibitor in cerebral ischemia are mediated through reduction in NAD depletion and DNA fragmentation.
Brain Ischemia
Neuroprotective effects of poly (ADP-ribose) polymerase inhibitors in transient focal cerebral ischemia of rats.
Brain Ischemia
Neuroprotective Properties of Picroside II in a Rat Model of Focal Cerebral Ischemia.
Brain Ischemia
NMDA but not non-NMDA excitotoxicity is mediated by Poly(ADP-ribose) polymerase.
Brain Ischemia
Novel isoquinolinone-derived inhibitors of poly(ADP-ribose) polymerase-1: pharmacological characterization and neuroprotective effects in an in vitro model of cerebral ischemia.
Brain Ischemia
Oxidative Stress and NAD(+) in Ischemic Brain Injury: Current Advances and Future Perspectives.
Brain Ischemia
Oxidative stress in brain ischemia.
Brain Ischemia
PARP-1 cleavage fragments: signatures of cell-death proteases in neurodegeneration.
Brain Ischemia
Pathophysiologic role of oxidative stress-induced poly(ADP-ribose) polymerase-1 activation: focus on cell death and transcriptional regulation.
Brain Ischemia
Pertussis Toxin Ameliorates Microglial Activation Associated With Ischemic Stroke.
Brain Ischemia
Poly (ADP-ribose) polymerase-1 initiated neuronal cell death pathway--do androgens matter?
Brain Ischemia
Poly(ADP-ribose) polymerase gene disruption renders mice resistant to cerebral ischemia.
Brain Ischemia
Poly(ADP-ribose) polymerase inhibition protect neurons and the white matter and regulates the translocation of apoptosis-inducing factor in stroke.
Brain Ischemia
Poly(ADP-ribose) polymerase inhibitors activate the p53 signaling pathway in neural stem/progenitor cells.
Brain Ischemia
Poly(ADP-ribose) polymerase inhibitors attenuate necrotic but not apoptotic neuronal death in experimental models of cerebral ischemia.
Brain Ischemia
Poly(ADP-Ribose)-Polymerase-Catalyzed Hydrolysis of NAD(+): QM/MM Simulation of the Enzyme Reaction.
Brain Ischemia
Poly(ADP-ribose)polymerase 1 (PARP-1) and postischemic brain damage.
Brain Ischemia
Poly(ADP-ribosyl)ation and stroke.
Brain Ischemia
Post-treatment with an inhibitor of poly(ADP-ribose) polymerase attenuates cerebral damage in focal ischemia.
Brain Ischemia
Protection of the brain following cerebral ischemia through the attenuation of PARP-1-induced neurovascular unit damage in rats.
Brain Ischemia
Protective effects of PJ34, a novel, potent inhibitor of poly(ADP-ribose) polymerase (PARP) in in vitro and in vivo models of stroke.
Brain Ischemia
Reduction of hemorrhagic transformation by PJ34, a poly(ADP-ribose)polymerase inhibitor, after permanent focal cerebral ischemia in mice.
Brain Ischemia
Role of continuous high thoracic epidural anesthesia in hippocampal apoptosis after global cerebral ischemia in rats.
Brain Ischemia
Role of superoxide in poly(ADP-ribose) polymerase upregulation after transient cerebral ischemia.
Brain Ischemia
Sex differences in the response to activation of the poly (ADP-ribose) polymerase pathway after experimental stroke.
Brain Ischemia
SPATIAL AND FUNCTIONAL RELATIONSHIP BETWEEN POLY(ADP-RIBOSE) POLYMERASE-1 AND POLY(ADP-RIBOSE) GLYCOHYDROLASE IN THE BRAIN.
Brain Ischemia
The effect of reperfusion on neuroprotection using an inhibitor of poly(ADP-ribose) polymerase.
Brain Ischemia
The neuroprotective effect of cerebral poly(ADP-ribose)polymerase inhibition in a rat model of global ischemia.
Brain Ischemia
Towards new neuroprotective agents: design and synthesis of 4H-thieno[2,3-c] isoquinolin-5-one derivatives as potent PARP-1 inhibitors.
Brain Ischemia
[Neuronal death: potential role of the nuclear enzyme, poly (ADP-ribose) polymerase]
Brain Neoplasms
A BRCA1 deficient-like signature is enriched in breast cancer brain metastases and predicts DNA damage-induced poly (ADP-ribose) polymerase inhibitor sensitivity.
Brain Neoplasms
A phase I trial of veliparib (ABT-888) and temozolomide in children with recurrent CNS tumors: a Pediatric Brain Tumor Consortium report
Brain Neoplasms
Association Between PARP1 Single Nucleotide Polymorphism and Brain Tumors.
Brain Neoplasms
Brain distribution and efficacy as chemosensitizer of an oral formulation of PARP-1 inhibitor GPI 15427 in experimental models of CNS tumors.
Brain Neoplasms
Breast cancer brain metastases show increased levels of genomic aberration-based homologous recombination deficiency scores relative to their corresponding primary tumors.
Brain Neoplasms
Chemopotentiation by PARP inhibitors in cancer therapy.
Brain Neoplasms
DNA strand break-sensing molecule poly(ADP-Ribose) polymerase cooperates with p53 in telomere function, chromosome stability, and tumor suppression.
Brain Neoplasms
Niraparib as Maintenance Therapy in Germline ATM-mutated and Somatic BRCA2-mutated Ovarian Cancer with Brain Metastases: A Case Report and Literature Review.
Brain Neoplasms
Non-invasive PET Imaging of PARP1 Expression in Glioblastoma Models.
Brain Neoplasms
Null mutation of DNA strand break-binding molecule poly(ADP-ribose) polymerase causes medulloblastomas in p53(-/-) mice.
Brain Neoplasms
Pamiparib is a potent and selective PARP inhibitor with unique potential for the treatment of brain tumor.
Brain Neoplasms
PARP inhibition sensitizes childhood high grade glioma, medulloblastoma and ependymoma to radiation.
Brain Neoplasms
Preclinical and first-in-human-brain-cancer applications of [18F]poly (ADP-ribose) polymerase inhibitor PET/MR.
Brain Neoplasms
Rad51 Degradation: Role in Oncolytic Virus-Poly(ADP-Ribose) Polymerase Inhibitor Combination Therapy in Glioblastoma.
Brain Neoplasms
Successful treatment of a patient with brain metastases from endometrial cancer using Niraparib: a case report.
Brain Neoplasms
Synthetic lethal genetic interactions between Rad54 and PARP-1 in mouse development and oncogenesis.
Brain Neoplasms
Targeted Therapies for Breast Cancer Brain Metastases.
Brain Neoplasms
Targeted Therapy for Brain Tumours: Role of PARP Inhibitors.
Brain Neoplasms
The potential role and application of PARP inhibitors in cancer treatment.
Brain Neoplasms
Transferrin Modified GSH Sensitive Hyaluronic Acid Derivative Micelle to Deliver HSP90 Inhibitors to Enhance the Therapeutic Efficacy of Brain Cancers.
Brain Neoplasms
Type 5 phosphodiesterase regulates glioblastoma multiforme aggressiveness and clinical outcome.
Brain Neoplasms
Whole-body hyperthermia and ADPRT inhibition in experimental treatment of brain tumors.
Breast Diseases
Poly(ADP-ribose) polymerase in human breast cancer: a case-control analysis.
Breast Neoplasms
2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD) induces oxidative stress, DNA strand breaks, and poly(ADP-ribose) polymerase-1 activation in human breast carcinoma cell lines.
Breast Neoplasms
2,3,7,8-Tetrachlorodibenzo-p-dioxin modulates the induction of DNA strand breaks and poly(ADP-ribose) polymerase-1 activation by 17beta-estradiol in human breast carcinoma cells through alteration of CYP1A1 and CYP1B1 expression.
Breast Neoplasms
2,3,7,8-Tetrachlorodibenzo-p-dioxin poly(ADP-ribose) polymerase (TiPARP, ARTD14) is a mono-ADP-ribosyltransferase and repressor of aryl hydrocarbon receptor transactivation.
Breast Neoplasms
3-Aminobenzamide delays rejoining of DNA strand breaks in gamma-irradiated lymphocytes from patients with breast cancer and not cervical cancer.
Breast Neoplasms
4-(4-Chloro-2-methylphenoxy)-N-hydroxybutanamide (CMH) targets mRNA of the c-FLIP variants and induces apoptosis in MCF-7 human breast cancer cells.
Breast Neoplasms
4-Hydroxybenzoic acid (4-HBA) enhances the sensitivity of human breast cancer cells to adriamycin as a specific HDAC6 inhibitor by promoting HIPK2/p53 pathway.
Breast Neoplasms
4-[3-(4-cyclopropanecarbonylpiperazine-1-carbonyl)-4-fluorobenzyl]-2H-phthalazin-1-one: a novel bioavailable inhibitor of poly(ADP-ribose) polymerase-1.
Breast Neoplasms
53BP1 depletion causes PARP inhibitor resistance in ATM-deficient breast cancer cells.
Breast Neoplasms
?-hydroxyundec-9-enoic acid induces apoptosis by ROS mediated JNK and p38 phosphorylation in breast cancer cell lines.
Breast Neoplasms
?-hydroxyundec-9-enoic acid induction of breast cancer cells apoptosis through generation of mitochondrial ROS and phosphorylation of AMPK.
Breast Neoplasms
?-Mangostin Induces Apoptosis and Inhibits Metastasis of Breast Cancer Cells via Regulating RXR?-AKT Signaling Pathway.
Breast Neoplasms
A BRCA1 deficient-like signature is enriched in breast cancer brain metastases and predicts DNA damage-induced poly (ADP-ribose) polymerase inhibitor sensitivity.
Breast Neoplasms
A Comparative Study of the Anticancer Activity and PARP-1 Inhibiting Effect of Benzofuran-Pyrazole Scaffold and Its Nano-Sized Particles in Human Breast Cancer Cells.
Breast Neoplasms
A conserved NAD(+) binding pocket that regulates protein-protein interactions during aging.
Breast Neoplasms
A DNA Repair BRCA1 Estrogen Receptor and Targeted Therapy in Breast Cancer.
Breast Neoplasms
A high-throughput RNA interference screen for DNA repair determinants of PARP inhibitor sensitivity.
Breast Neoplasms
A marker of homologous recombination predicts pathological complete response to neoadjuvant chemotherapy in primary breast cancer.
Breast Neoplasms
A nano-liposome formulation of the PARP inhibitor Talazoparib enhances treatment efficacy and modulates immune cell populations in mammary tumors of BRCA-deficient mice.
Breast Neoplasms
A novel crosstalk between BRCA1 and poly (ADP-ribose) polymerase 1 in breast cancer.
Breast Neoplasms
A Phase 1 trial of the poly(ADP-ribose) polymerase inhibitor olaparib (AZD2281) in combination with the anti-angiogenic cediranib (AZD2171) in recurrent epithelial ovarian or triple-negative breast cancer.
Breast Neoplasms
A phase I dose-finding, pharmacokinetics and genotyping study of olaparib and lurbinectedin in patients with advanced solid tumors.
Breast Neoplasms
A phase I followed by a randomized phase II trial of two cycles carboplatin-olaparib followed by olaparib monotherapy versus capecitabine in BRCA1- or BRCA2-mutated HER2-negative advanced breast cancer as first line treatment (REVIVAL): study protocol for a randomized controlled trial.
Breast Neoplasms
A Population of Heterogeneous Breast Cancer Patient-Derived Xenografts Demonstrate Broad Activity of PARP Inhibitor in BRCA1/2 Wild-Type Tumors.
Breast Neoplasms
A Population Pharmacokinetic Meta-Analysis of Veliparib, a PARP Inhibitor, Across Phase 1/2/3 Trials in Cancer Patients.
Breast Neoplasms
A population-based study of the Arg399Gln polymorphism in X-ray repair cross- complementing group 1 (XRCC1) and risk of pancreatic adenocarcinoma.
Breast Neoplasms
A randomized Phase II study of veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in BRCA1/2 metastatic breast cancer: design and rationale.
Breast Neoplasms
A real or apparent decrease in glomerular filtration rate in patients using olaparib?
Breast Neoplasms
A review of current progress in triple-negative breast cancer therapy.
Breast Neoplasms
A review of triple-negative breast cancer.
Breast Neoplasms
A Review on Poly (ADP-ribose) Polymerase (PARP) Inhibitors and Synthetic Methodologies.
Breast Neoplasms
A selective eradication of human nonhereditary breast cancer cells by phenanthridine-derived polyADP-ribose polymerase inhibitors.
Breast Neoplasms
A systematic review of international guidelines and recommendations for the genetic screening, diagnosis, genetic counseling, and treatment of BRCA-mutated breast cancer.
Breast Neoplasms
ABC4 Consensus: First Latin American Meeting-Assessment, Comments, and Application of Its Recommendations.
Breast Neoplasms
ABCB1 Attenuates the Brain Penetration of the PARP Inhibitor AZD2461.
Breast Neoplasms
ABT-888 and quinacrine induced apoptosis in metastatic breast cancer stem cells by inhibiting base excision repair via adenomatous polyposis coli.
Breast Neoplasms
Actionable co-alterations in breast tumors with pathogenic mutations in the homologous recombination DNA damage repair pathway.
Breast Neoplasms
Activation of caspase-3 and c-Jun NH2-terminal kinase-1 signaling pathways in tamoxifen-induced apoptosis of human breast cancer cells.
Breast Neoplasms
Activation of choline kinase by extracellular Ca2+ is Ca(2+)-sensing receptor, Galpha12 and Rho-dependent in breast cancer cells.
Breast Neoplasms
Activation of HIF-1? by ?-Opioid Receptors Induces COX-2 Expression in Breast Cancer Cells and Leads to Paracrine Activation of Vascular Endothelial Cells.
Breast Neoplasms
Adenovirus-mediated p53 and ING4 gene co?transfer elicits synergistic antitumor effects through enhancement of p53 acetylation in breast cancer.
Breast Neoplasms
Adjuvant PARP Inhibitors in Patients With High-Risk Early-Stage HER2-Negative Breast Cancer and Germline BRCA Mutations: ASCO Hereditary Breast Cancer Guideline Rapid Recommendation Update.
Breast Neoplasms
Adoptive cell therapy of triple negative breast cancer with redirected cytokine-induced killer cells.
Breast Neoplasms
ADP ribose polymerase inhibitors for treating non-small cell lung cancer: new additions to the pharmacotherapeutic armamentarium.
Breast Neoplasms
Advances in PARP inhibitors for the treatment of breast cancer.
Breast Neoplasms
Advances in the use of PARP inhibitor therapy for breast cancer.
Breast Neoplasms
Advances in the use of PARP inhibitors for BRCA1/2-associated breast cancer: talazoparib.
Breast Neoplasms
Airborne particulate collected from central Taiwan induces DNA strand breaks, Poly(ADP-ribose) polymerase-1 activation, and estrogen-disrupting activity in human breast carcinoma cell lines.
Breast Neoplasms
Amplification of the Mutation-Carrying BRCA2 Allele Promotes RAD51 Loading and PARP Inhibitor Resistance in the Absence of Reversion Mutations.
Breast Neoplasms
An HTS-compatible HTRF assay measuring the glycohydrolase activity of human PARG.
Breast Neoplasms
An Overview of PARP Inhibitors for the Treatment of Breast Cancer.
Breast Neoplasms
An update on PARP inhibitors--moving to the adjuvant setting.
Breast Neoplasms
Analysis of genetic variants of the poly(ADP-ribose) polymerase-1 gene in breast cancer in French patients.
Breast Neoplasms
Analysis of molecular markers as predictive factors of lymph node involvement in breast carcinoma.
Breast Neoplasms
Androgen receptor inhibitor enhances the anti-tumor effect of PARP inhibitor in breast cancer cells by modulating DNA damage response.
Breast Neoplasms
Anti-miR-203 Upregulates SOCS3 Expression in Breast Cancer Cells and Enhances Cisplatin Chemosensitivity.
Breast Neoplasms
Anticancer activities of an anthocyanin-rich extract from black rice against breast cancer cells in vitro and in vivo.
Breast Neoplasms
Anticancer activity of RAPTA-EA1 in triple-negative BRCA1 proficient breast cancer cells: single and combined treatment with the PARP inhibitor olaparib.
Breast Neoplasms
Antiproliferative and Proapoptotic Activities of Marine Sponge Hyrtios erectus Extract on Breast Carcinoma Cell Line (MCF-7).
Breast Neoplasms
Antitumor and anticancer stem cell activity of a poly ADP-ribose polymerase inhibitor olaparib in breast cancer cells.
Breast Neoplasms
Apigenin Inhibits Growth of Breast Cancer Cells: The Role of ER? and HER2/neu.
Breast Neoplasms
Application and reflection of genomic scar assays in evaluating the efficacy of platinum salts and PARP inhibitors in cancer therapy.
Breast Neoplasms
ART3 regulates triple-negative breast cancer cell function via activation of Akt and ERK pathways.
Breast Neoplasms
Assessment of Global DNA Double-Strand End Resection using BrdU-DNA Labeling coupled with Cell Cycle Discrimination Imaging.
Breast Neoplasms
Association between PARP-1 V762A polymorphism and breast cancer susceptibility in Saudi population.
Breast Neoplasms
Association of PARP1 rs4653734, rs907187 and rs1136410 variants with breast cancer risk among Iranian women.
Breast Neoplasms
ATM-depletion in breast cancer cells confers sensitivity to PARP inhibition.
Breast Neoplasms
Augmentation of the antitumor effects of PARP inhibitors in triple-negative breast cancer via degradation by hydrophobic tagging modulation.
Breast Neoplasms
Autocrine WNT signaling contributes to breast cancer cell proliferation via the canonical WNT pathway and EGFR transactivation.
Breast Neoplasms
Autoimmune response to PARP and BRCA1/BRCA2 in cancer.
Breast Neoplasms
Basal activity of a PARP1-NuA4 complex varies dramatically across cancer cell lines.
Breast Neoplasms
BCL2 Suppresses PARP1 Function and Nonapoptotic Cell Death.
Breast Neoplasms
Biological and clinical significance of PARP1 protein expression in breast cancer.
Breast Neoplasms
BiPar Sciences presents interim phase 2 results for PARP inhibitor BSI-201 at San Antonio Breast Cancer Symposium.
Breast Neoplasms
Bisphosphonates induce apoptosis in human breast cancer cell lines.
Breast Neoplasms
Bitter melon (Momordica charantia) extract inhibits breast cancer cell proliferation by modulating cell cycle regulatory genes and promotes apoptosis.
Breast Neoplasms
Blockade of MUC1 expression by glycerol guaiacolate inhibits proliferation of human breast cancer cells.
Breast Neoplasms
Blocking c-Met and EGFR reverses acquired resistance of PARP inhibitors in triple-negative breast cancer.
Breast Neoplasms
Blocking c-Met-mediated PARP1 phosphorylation enhances anti-tumor effects of PARP inhibitors.
Breast Neoplasms
Blocking Fra-1 sensitizes triple-negative breast cancer to PARP inhibitor.
Breast Neoplasms
BMN 673 (talazoparib): A potent PARP inhibitor for triple negative breast cancer with different genetic profile.
Breast Neoplasms
Both BRCA1-wild type and -mutant triple-negative breast cancers show sensitivity to the NAE inhibitor MLN4924 which is enhanced upon MLN4924 and cisplatin combination treatment.
Breast Neoplasms
BRCA mutation testing in determining breast cancer therapy.
Breast Neoplasms
BRCA1 and PARP1 mRNA expression during progression from normal breast to ductal carcinoma in situ and invasive breast cancer: a laser microdissection study.
Breast Neoplasms
BRCA1 promoter hypermethylation, 53BP1 protein expression and PARP-1 activity as biomarkers of DNA repair deficit in breast cancer.
Breast Neoplasms
BRCA1 promoter methylation in breast cancer patients is associated with response to olaparib/eribulin combination therapy.
Breast Neoplasms
BRCA1-methylated sporadic breast cancers are BRCA-like in showing a basal phenotype and absence of ER expression.
Breast Neoplasms
BRCA1/2 testing: therapeutic implications for breast cancer management.
Breast Neoplasms
BRCA2-Deficient CAPAN-1 Cells are Extremely Sensitive to the Inhibition of Poly (ADP-Ribose) Polymerase: An Issue of Potency.
Breast Neoplasms
BRCA2-Deficient Sarcomatoid Mammary Tumors Exhibit Multidrug Resistance.
Breast Neoplasms
BRCAness: a deeper insight into basal-like breast tumors.
Breast Neoplasms
Breast cancer brain metastases show increased levels of genomic aberration-based homologous recombination deficiency scores relative to their corresponding primary tumors.
Breast Neoplasms
Breast Cancer Resistance Protein (BCRP/ABCG2) and P-glycoprotein (P-GP/ABCB1) Restrict Oral Availability and Brain Accumulation of the PARP Inhibitor Rucaparib (AG-014699).
Breast Neoplasms
Breast cancer under age 40: a different approach.
Breast Neoplasms
Breast cancer.
Breast Neoplasms
BreastDefend enhances effect of tamoxifen in estrogen receptor-positive human breast cancer in vitro and in vivo.
Breast Neoplasms
BTH-8, a novel poly (ADP-ribose) polymerase-1 (PARP-1) inhibitor, causes DNA double-strand breaks and exhibits anticancer activities in vitro and in vivo.
Breast Neoplasms
Bufadienolide compounds sensitize human breast cancer cells to TRAIL-induced apoptosis via inhibition of STAT3/Mcl-1 pathway.
Breast Neoplasms
Calmodulin-like protein 3 is an estrogen receptor alpha coregulator for gene expression and drug response in a SNP, estrogen, and SERM-dependent fashion.
Breast Neoplasms
Capsaicin causes cell-cycle arrest and apoptosis in ER-positive and -negative breast cancer cells by modulating the EGFR/HER-2 pathway.
Breast Neoplasms
Caspase- and p53-dependent apoptosis in breast carcinoma cells induced by a synthetic selenadiazole derivative.
Breast Neoplasms
Catalase Abrogates ?-Lapachone-Induced PARP1 Hyperactivation-Directed Programmed Necrosis in NQO1-Positive Breast Cancers.
Breast Neoplasms
Cationic liposome codelivering PI3K pathway regulator improves the response of BRCA1-deficient breast cancer cells to PARP1 inhibition.
Breast Neoplasms
Caught in the act: binding of Ku and PARP to MARs reveals novel aspects of their functional interaction.
Breast Neoplasms
CDK2-dependent activation of PARP-1 is required for hormonal gene regulation in breast cancer cells.
Breast Neoplasms
Cdk5 promotes DNA replication stress checkpoint activation through RPA-32 phosphorylation, and impacts on metastasis free survival in breast cancer patients.
Breast Neoplasms
Cell-cycle progression and response of germ cell tumors to cisplatin in vitro.
Breast Neoplasms
Chemical characterization and biological activity data for a novel indirubin derivative, LDD-1819.
Breast Neoplasms
Chromosome 13 poly(ADP-ribose) polymerase polymorphisms and lung cancer risk.
Breast Neoplasms
Clinical potential of novel therapeutic targets in breast cancer: CDK4/6, Src, JAK/STAT, PARP, HDAC, and PI3K/AKT/mTOR pathways.
Breast Neoplasms
Clinical practice guidelines for BRCA1 and BRCA2 genetic testing.
Breast Neoplasms
Clinical trial data and emerging immunotherapeutic strategies: hormone receptor-positive, HER2- negative breast cancer.
Breast Neoplasms
Co-enzyme Q10, riboflavin and niacin supplementation on alteration of DNA repair enzyme and DNA methylation in breast cancer patients undergoing tamoxifen therapy.
Breast Neoplasms
Co-targeting of the PI3K pathway improves the response of BRCA1 deficient breast cancer cells to PARP1 inhibition.
Breast Neoplasms
Co-treatment with BEZ235 Enhances Sensitivity of BRCA1-negative Breast Cancer Cells to Olaparib.
Breast Neoplasms
Combination treatment using DDX3 and PARP inhibitors induces synthetic lethality in BRCA1-proficient breast cancer.
Breast Neoplasms
Combined inhibition of PI3K and PARP is effective in the treatment of ovarian cancer cells with wild-type PIK3CA genes.
Breast Neoplasms
Combining a PI3K inhibitor with a PARP inhibitor provides an effective therapy for a mouse model of BRCA1-related breast cancer.
Breast Neoplasms
Combining poly(ADP-ribose) polymerase inhibitors and immune checkpoint inhibitors in breast cancer: rationale and preliminary clinical results.
Breast Neoplasms
Comparative antiproliferative effects of iniparib and olaparib on a panel of triple-negative and non-triple-negative breast cancer cell lines.
Breast Neoplasms
Comparative efficacy, safety, and acceptability of single-agent poly (ADP-ribose) polymerase (PARP) inhibitors in BRCA-mutated HER2-negative metastatic or advanced breast cancer: a network meta-analysis.
Breast Neoplasms
Coordinated signals from PARP-1 and PARP-2 are required to establish a proper T cell immune response to breast tumors in mice.
Breast Neoplasms
Cordycepin blocks lung injury-associated inflammation and promotes BRCA1-deficient breast cancer cell killing by effectively inhibiting PARP.
Breast Neoplasms
Cordyceps militaris Induces Immunogenic Cell Death and Enhances Antitumor Immunogenic Response in Breast Cancer.
Breast Neoplasms
Correction to: Molecular targeted drugs resistance impairs double?strand break repair and sensitizes ER?positive breast cancer to PARP inhibitors.
Breast Neoplasms
Correction: Association between PARP-1 V762A Polymorphism and Breast Cancer Susceptibility in Saudi Population.
Breast Neoplasms
Correction: HP1? is a biomarker for breast cancer prognosis and PARP inhibitor therapy.
Breast Neoplasms
Correlation between PARP-1 immunoreactivity and cytomorphological features of parthanatos, a specific cellular death in breast cancer cells.
Breast Neoplasms
Corrigendum to "Gold nanoparticle conjugated Rad6 inhibitor induces cell death in triple negative breast cancer cells by inducing mitochondrial dysfunction and PARP-1 hyperactivation: Synthesis and characterization" [Nanomedicine 12 (3) (2016), 745-757].
Breast Neoplasms
Cost-Effectiveness Analysis of Olaparib Maintenance Treatment for Germline BRCA-Mutated Metastatic Pancreatic Cancer.
Breast Neoplasms
CRISPR/Cas9-mediated mutagenesis to validate the synergy between PARP1 inhibition and chemotherapy in BRCA1-mutated breast cancer cells.
Breast Neoplasms
Crosstalk of DNA double-strand break repair pathways in poly(ADP-ribose) polymerase inhibitor treatment of breast cancer susceptibility gene 1/2-mutated cancer.
Breast Neoplasms
Crystal structure-based discovery of a novel synthesized PARP1 inhibitor (OL-1) with apoptosis-inducing mechanisms in triple-negative breast cancer.
Breast Neoplasms
CUDC-907 enhances TRAIL-induced apoptosis through upregulation of DR5 in breast cancer cells.
Breast Neoplasms
Curcumin enhances poly(ADP-ribose) polymerase inhibitor sensitivity to chemotherapy in breast cancer cells.
Breast Neoplasms
Current and Future Directions for PARP Inhibition.
Breast Neoplasms
Current status and future prospects of PARP inhibitor clinical trials in ovarian cancer.
Breast Neoplasms
Cyclin A2 regulates homologous recombination DNA repair and sensitivity to DNA damaging agents and poly(ADP-ribose) polymerase (PARP) inhibitors in human breast cancer cells.
Breast Neoplasms
Cytoplasmic poly(adenosine diphosphate-ribose) polymerase expression is predictive and prognostic in patients with breast cancer treated with neoadjuvant chemotherapy.
Breast Neoplasms
d-3-Deoxy-dioctanoylphosphatidylinositol induces cytotoxicity in human MCF-7 breast cancer cells via a mechanism that involves downregulation of the D-type cyclin-retinoblastoma pathway.
Breast Neoplasms
Dancing with the DNA damage response: next-generation anti-cancer therapeutic strategies.
Breast Neoplasms
Data on the effects of anti-cancer drug of resveratrol in breast cancer cells, MDA-MB-231 cells.
Breast Neoplasms
Decreased DNA repair gene XRCC1 expression is associated with radiotherapy-induced acute side effects in breast cancer patients.
Breast Neoplasms
Decreased expression of the translation factor eIF3e induces senescence in breast cancer cells via suppression of PARP1 and activation of mTORC1.
Breast Neoplasms
Deep exploration of PARP inhibitors in breast cancer: monotherapy and combination therapy.
Breast Neoplasms
Defective repair of oxidative dna damage in triple-negative breast cancer confers sensitivity to inhibition of poly(ADP-ribose) polymerase.
Breast Neoplasms
Deficiency in the Repair of DNA Damage by Homologous Recombination and Sensitivity to Poly(ADP-Ribose) Polymerase Inhibition.
Breast Neoplasms
Deoxyrhapontigenin, a Natural Stilbene Derivative Isolated From Rheum undulatum L. Induces Endoplasmic Reticulum Stress-Mediated Apoptosis in Human Breast Cancer Cells.
Breast Neoplasms
Design and synthesis of some barbituric and 1,3-dimethylbarbituric acid derivatives: A non-classical scaffold for potential PARP1 inhibitors.
Breast Neoplasms
Design, synthesis, and biological evaluation of quinazolin-4(3H)-one derivatives co-targeting poly(ADP-ribose) polymerase-1 and bromodomain containing protein 4 for breast cancer therapy.
Breast Neoplasms
Detection of heterogeneity of apoptotic fragments of poly (ADP-ribose) polymerase in MDA-MB-468 breast cancer cells: two-dimensional gel analysis.
Breast Neoplasms
Detection of PARP-1 activity based on hyperbranched-poly (ADP-ribose) polymers responsive current in artificial nanochannels.
Breast Neoplasms
Development and evaluation of poly adenosine 5'-diphosphate-ribose polymerase 1 immobilization-based receptor chromatography.
Breast Neoplasms
Development of 'synthetic lethal' strategies to target BRCA1-deficient breast cancer.
Breast Neoplasms
Development of PARP inhibitors in gynecological malignancies.
Breast Neoplasms
Development of poly(ADP-ribose) polymerase inhibitors in the treatment of BRCA-mutated breast cancer.
Breast Neoplasms
Development of the PARP inhibitor talazoparib for the treatment of advanced BRCA1 and BRCA2 mutated breast cancer.
Breast Neoplasms
Differences in Expression of Key DNA Damage Repair Genes after Epigenetic-Induced BRCAness Dictate Synthetic Lethality with PARP1 Inhibition.
Breast Neoplasms
Differential inhibition of fatty acid transport in tissue-isolated steroid receptor negative human breast cancer xenografts perfused in situ with isomers of conjugated linoleic acid.
Breast Neoplasms
Differential Potential of Pharmacological PARP Inhibitors for Inhibiting Cell Proliferation and Inducing Apoptosis in Human Breast Cancer Cells.
Breast Neoplasms
Differential regulation of breast cancer bone metastasis by PARP1 and PARP2.
Breast Neoplasms
Discovery of 1-substituted benzyl-quinazoline-2,4(1H,3H)-dione derivatives as novel poly(ADP-ribose)polymerase-1 inhibitors.
Breast Neoplasms
Discovery of novel functionalized 1,2,4-triazoles as PARP-1 inhibitors in breast cancer: Design, synthesis and antitumor activity evaluation.
Breast Neoplasms
Discovery of novel PARP/PI3K dual inhibitors with high efficiency against BRCA-proficient triple negative breast cancer.
Breast Neoplasms
Discovery of potent 2,4-difluoro-linker poly(ADP-ribose) polymerase 1 inhibitors with enhanced water solubility and in vivo anticancer efficacy.
Breast Neoplasms
Discovery, mechanism and metabolism studies of 2,3-difluorophenyl-linker-containing PARP1 inhibitors with enhanced in vivo efficacy for cancer therapy.
Breast Neoplasms
Disparity in the induction of glutathione depletion, ROS formation, poly(ADP-ribose) polymerase-1 activation, and apoptosis by quinonoid derivatives of naphthalene in human cultured cells.
Breast Neoplasms
Dissecting the molecular determinants of clinical PARP1 inhibitor selectivity for tankyrase1.
Breast Neoplasms
Diverse BRCA1 and BRCA2 Reversion Mutations in Circulating Cell-Free DNA of Therapy-Resistant Breast or Ovarian Cancer.
Breast Neoplasms
DNA damage repair in breast cancer and its therapeutic implications.
Breast Neoplasms
DNA Damage Repair Inhibitor for Breast Cancer Treatment.
Breast Neoplasms
DNA damage response and breast cancer development: Possible therapeutic applications of ATR, ATM, PARP, BRCA1 inhibition.
Breast Neoplasms
DNA methyltransferase inhibitors induce a BRCAness phenotype that sensitizes NSCLC to PARP inhibitor and ionizing radiation.
Breast Neoplasms
Doubling down on the PI3K-AKT-mTOR pathway enhances the antitumor efficacy of PARP inhibitor in triple negative breast cancer model beyond BRCA-ness.
Breast Neoplasms
Down-regulation of PARP1 by miR-891b sensitizes human breast cancer cells to alkylating chemotherapeutic drugs.
Breast Neoplasms
Downregulation of APE1 potentiates breast cancer cells to olaparib by inhibiting PARP-1 expression.
Breast Neoplasms
Downregulation of miR-221-3p and upregulation of its target gene PARP1 are prognostic biomarkers for triple negative breast cancer patients and associated with poor prognosis.
Breast Neoplasms
Dramatic response to PARP inhibition in a PALB2-mutated breast cancer: moving beyond BRCA.
Breast Neoplasms
Drug repurposing screen identifies lestaurtinib amplifies the ability of the poly (ADP-ribose) polymerase 1 inhibitor AG14361 to kill breast cancer associated gene-1 mutant and wild type breast cancer cells.
Breast Neoplasms
Drug Targeting of Genomic Instability in Multiple Myeloma.
Breast Neoplasms
Dual PARP and RAD51 Inhibitory Drug Conjugates Show Synergistic and Selective Effects on Breast Cancer Cells.
Breast Neoplasms
Durvalumab with olaparib and paclitaxel for high-risk HER2-negative stage II/III breast cancer: Results from the adaptively randomized I-SPY2 trial.
Breast Neoplasms
Effect of adriamycin on BRCA1 and PARP-1 expression in MCF-7 breast cancer cells.
Breast Neoplasms
Effect of Food on the Pharmacokinetics of Olaparib after Oral Dosing of the Capsule Formulation in Patients with Advanced Solid Tumors.
Breast Neoplasms
Effect of Oncoxin Oral Solution in HER2-Overexpressing Breast Cancer.
Breast Neoplasms
Effect of poly(ADP-ribose)polymerase and DNA topoisomerase I inhibitors on the p53/p63-dependent survival of carcinoma cells.
Breast Neoplasms
Effects of germline and somatic events in candidate BRCA-like genes on breast-tumor signatures.
Breast Neoplasms
Effects of passive smoking on breast cancer risk in pre/post-menopausal women as modified by polymorphisms of PARP1 and ESR1.
Breast Neoplasms
Effects of pertussis toxin on adenylate cyclase responses to prostaglandin E2 and calcitonin in human breast cancer cells.
Breast Neoplasms
Efficacy and mechanism of the combination of PARP and CDK4/6 inhibitors in the treatment of triple-negative breast cancer.
Breast Neoplasms
Efficacy and pharmacodynamics of niraparib in BRCA-mutant and wild-type intracranial triple-negative breast cancer murine models.
Breast Neoplasms
Efficacy and safety of PARP inhibitors in patients with BRCA-mutated advanced breast cancer: A meta-analysis and systematic review.
Breast Neoplasms
Efficacy of PARP inhibition combined with EZH2 inhibition depends on BRCA mutation status and microenvironment in breast cancer.
Breast Neoplasms
Efficacy of the PARP Inhibitor Veliparib with Carboplatin or as a Single Agent in Patients with Germline BRCA1- or BRCA2-Associated Metastatic Breast Cancer.
Breast Neoplasms
Elevated expression of erbB3 confers paclitaxel resistance in erbB2-overexpressing breast cancer cells via upregulation of Survivin.
Breast Neoplasms
Emerging PARP inhibitors for treating breast cancer.
Breast Neoplasms
Emerging therapeutic modalities of PARP inhibitors in breast cancer.
Breast Neoplasms
Enhancement of chemotherapeutically-induced apoptosis in vivo by biochemical modulation of poly (ADP-ribose) polymerase.
Breast Neoplasms
Enhancing radiosensitivity: targeting the DNA repair pathways.
Breast Neoplasms
Enhancing the Cytotoxic Effects of PARP Inhibitors with DNA Demethylating Agents - A Potential Therapy for Cancer.
Breast Neoplasms
Epidermal Growth Factor Receptor activation promotes ADA3 acetylation through the AKT-p300 pathway.
Breast Neoplasms
Epigenetic bivalent marking is permissive to the synergy of HDAC and PARP inhibitors on TXNIP expression in breast cancer cells.
Breast Neoplasms
Erratum to "Doubling Down on the PI3K-AKTmTOR Pathway Enhances the Antitumor Efficacy of PARP Inhibitor in Triple Negative Breast Cancer Model beyond BRCA-ness" [Neoplasia 16 (2014) 43-72].
Breast Neoplasms
Erratum to: 53BP1 depletion causes PARP inhibitor resistance in ATM-deficient breast cancer cells.
Breast Neoplasms
Erythropoietin-driven signalling and cell migration mediated by polyADP-ribosylation.
Breast Neoplasms
Estrogen enhances the cytotoxicity of PARP inhibitors on breast cancer cells through stimulating nitric oxide production.
Breast Neoplasms
Evaluation of efficacy and safety of PARP inhibitors in breast cancer: A systematic review and meta-analysis.
Breast Neoplasms
Evaluation of the pharmacodynamics and pharmacokinetics of the PARP inhibitor olaparib: a Phase I multicentre trial in patients scheduled for elective breast cancer surgery.
Breast Neoplasms
Evidence of a novel antiapoptotic factor: role of inhibitor of differentiation or DNA binding (Id-1) in anticancer drug-induced apoptosis.
Breast Neoplasms
Evidence to date: talazoparib in the treatment of breast cancer.
Breast Neoplasms
Exploiting DNA repair defects in breast cancer: from chemotherapy to immunotherapy.
Breast Neoplasms
Expression of base excision repair key factors and miR17 in familial and sporadic breast cancer.
Breast Neoplasms
Expression of DNA Damage Response Molecules PARP1, ?H2AX, BRCA1, and BRCA2 Predicts Poor Survival of Breast Carcinoma Patients.
Breast Neoplasms
Expression of DNA Damage Response Proteins and Associations with Clinicopathologic Characteristics in Chinese Familial Breast Cancer Patients with BRCA1/2 Mutations.
Breast Neoplasms
EZH2 contributes to the response to PARP inhibitors through its PARP-mediated poly-ADP ribosylation in breast cancer.
Breast Neoplasms
Ferulic acid in combination with PARP inhibitor sensitizes breast cancer cells as chemotherapeutic strategy.
Breast Neoplasms
First PARP Inhibitor Ok'd for Breast Cancer.
Breast Neoplasms
Frame-shift mediated reduction of gain-of-function p53 R273H and deletion of the R273H C-terminus in breast cancer cells result in replication-stress sensitivity.
Breast Neoplasms
Function and mechanism of combined PARP-1 and BRCA genes in regulating the radiosensitivity of breast cancer cells.
Breast Neoplasms
Functional Ex Vivo Assay to Select Homologous Recombination-Deficient Breast Tumors for PARP Inhibitor Treatment.
Breast Neoplasms
Functional profiling of nucleotide Excision repair in breast cancer.
Breast Neoplasms
G-protein-mediated epidermal growth factor signal transduction in a human breast cancer cell line. Evidence for two intracellular pathways distinguishable by pertussis toxin.
Breast Neoplasms
Gain-of-Function Mutant p53 R273H Interacts with Replicating DNA and PARP1 in Breast Cancer.
Breast Neoplasms
Galectin-3: a novel antiapoptotic molecule with a functional BH1 (NWGR) domain of Bcl-2 family.
Breast Neoplasms
Gallic acid and curcumin induce cytotoxicity and apoptosis in human breast cancer cell MDA-MB-231.
Breast Neoplasms
GALNT6 Promotes Tumorigenicity and Metastasis of Breast Cancer Cell via ?-catenin/MUC1-C Signaling Pathway.
Breast Neoplasms
Gamma-tocotrienol induced apoptosis is associated with unfolded protein response in human breast cancer cells.
Breast Neoplasms
gammaH2AX and cleaved PARP-1 as apoptotic markers in irradiated breast cancer BT474 cellular spheroids.
Breast Neoplasms
Ganetespib overcomes resistance to PARP inhibitors in breast cancer by targeting core proteins in the DNA repair machinery.
Breast Neoplasms
GATA3 cooperates with PARP1 to regulate CCND1 transcription through modulating histone H1 incorporation.
Breast Neoplasms
Gene 33 inhibits apoptosis of breast cancer cells and increases poly(ADP-ribose) polymerase expression.
Breast Neoplasms
Gene expression and pathologic response to neoadjuvant chemotherapy in breast cancer.
Breast Neoplasms
Genetic and epigenetic heterogeneity of epithelial ovarian cancer and the clinical implications for molecular targeted therapy.
Breast Neoplasms
Genetic polymorphisms in base-excision repair pathway genes and risk of breast cancer.
Breast Neoplasms
Genetic polymorphisms of multiple DNA repair pathways impact age at diagnosis and TP53 mutations in breast cancer.
Breast Neoplasms
Genetic sequence variations and ADPRT haplotype analysis in French Canadian families with high risk of breast cancer.
Breast Neoplasms
Genome-wide analysis of gynecologic cancer: The Cancer Genome Atlas in ovarian and endometrial cancer.
Breast Neoplasms
Genomic Correlates of DNA Damage in Breast Cancer Subtypes.
Breast Neoplasms
Genomic landscape of metastatic breast cancer identifies preferentially dysregulated pathways and targets.
Breast Neoplasms
Germline mutations in the PALB2 gene are population specific and occur with low frequencies in familial breast cancer.
Breast Neoplasms
Global analysis of transcriptional regulation by poly(ADP-ribose) polymerase-1 and poly(ADP-ribose) glycohydrolase in MCF-7 human breast cancer cells.
Breast Neoplasms
Gold nanoparticle conjugated Rad6 inhibitor induces cell death in triple negative breast cancer cells by inducing mitochondrial dysfunction and PARP-1 hyperactivation: Synthesis and characterization.
Breast Neoplasms
Haploinsufficiency of Parp1 accelerates Brca1-associated centrosome amplification, telomere shortening, genetic instability, apoptosis, and embryonic lethality.
Breast Neoplasms
HDAC inhibitor SNDX-275 enhances efficacy of trastuzumab in erbB2-overexpressing breast cancer cells and exhibits potential to overcome trastuzumab resistance.
Breast Neoplasms
Hepatocyte growth factor/scatter factor blocks the mitochondrial pathway of apoptosis signaling in breast cancer cells.
Breast Neoplasms
HER2 Overexpression Renders Human Breast Cancers Sensitive to PARP Inhibition Independently of Any Defect in Homologous Recombination DNA Repair.
Breast Neoplasms
Heterogeneous drug penetrance of veliparib and carboplatin measured in triple negative breast tumors.
Breast Neoplasms
High BRCA2 Gene Expression is Associated with Aggressive and Highly Proliferative Breast Cancer.
Breast Neoplasms
High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs.
Breast Neoplasms
Higher cytoplasmic and nuclear poly(ADP-ribose) polymerase expression in familial than in sporadic breast cancer.
Breast Neoplasms
Highlights of the Chemotherapy Foundation Symposium XXVII: therapeutic options for breast cancer.
Breast Neoplasms
Histone deacetylase inhibitor treatment induces 'BRCAness' and synergistic lethality with PARP inhibitor and cisplatin against human triple negative breast cancer cells.
Breast Neoplasms
Homologous recombination deficiency in breast cancer: Implications for risk, cancer development, and therapy.
Breast Neoplasms
Homologous recombination DNA repair deficiency and PARP inhibition activity in primary triple negative breast cancer.
Breast Neoplasms
HP1? Is a Biomarker for Breast Cancer Prognosis and PARP Inhibitor Therapy.
Breast Neoplasms
HRDetect is a predictor of BRCA1 and BRCA2 deficiency based on mutational signatures.
Breast Neoplasms
Identification of a novel truncating mutation in PALB2 gene by a multigene sequencing panel for mutational screening of breast cancer risk-associated and related genes.
Breast Neoplasms
Identification of BRCA2 Cis Double Heterozygous Breast Cancer Cases Using Whole Exome Sequencing: Phenotypic Expression and Impact on Personalized Oncology.
Breast Neoplasms
Identifying new piperazine-based PARP1 inhibitors using text mining and integrated molecular modeling approaches.
Breast Neoplasms
Immuno-related polymorphisms and cervical cancer risk: The IARC multicentric case-control study.
Breast Neoplasms
In silico investigation of PARP-1 catalytic domains in holo and apo states for the design of high-affinity PARP-1 inhibitors.
Breast Neoplasms
In vitro assessment of the role of DpC in the treatment of head and neck squamous cell carcinoma.
Breast Neoplasms
In vitro cytotoxic effect of PARP inhibitor alone and in combination with nab?paclitaxel on triple?negative and luminal A breast cancer cells.
Breast Neoplasms
In vivo visualization of PARP inhibitor pharmacodynamics.
Breast Neoplasms
Inactivation of the prolyl isomerase Pin1 sensitizes BRCA1-proficient breast cancer to PARP inhibition.
Breast Neoplasms
Increased Expression of FosB through Reactive Oxygen Species Accumulation Functions as Pro-Apoptotic Protein in Piperlongumine Treated MCF7 Breast Cancer Cells.
Breast Neoplasms
Increased oxidative stress mediates the antitumor effect of PARP inhibition in ovarian cancer.
Breast Neoplasms
Indirect treatment comparison of olaparib and talazoparib in germline BRCA-mutated HER2-negative metastatic breast cancer.
Breast Neoplasms
Induction of cell growth arrest and apoptotic cell death in human breast cancer MCF-7 cells by the COX-1 inhibitor FR122047.
Breast Neoplasms
Induction of cytotoxicity, aldehydic DNA lesions, and poly(ADP-ribose) polymerase-1 activation by catechol derivatives of pentachlorophenol in calf thymus DNA and in human breast cancer cells.
Breast Neoplasms
Induction of ROS formation, poly(ADP-ribose) polymerase-1 activation, and cell death by PCB126 and PCB153 in human T47D and MDA-MB-231 breast cancer cells.
Breast Neoplasms
Inhibition of DNA Repair Pathways and Induction of ROS Are Potential Mechanisms of Action of the Small Molecule Inhibitor BOLD-100 in Breast Cancer.
Breast Neoplasms
Inhibition of mTOR downregulates expression of DNA repair proteins and is highly efficient against BRCA2-mutated breast cancer in combination to PARP inhibition.
Breast Neoplasms
Inhibition of poly(ADP)-ribose polymerase as a therapeutic strategy for breast cancer.
Breast Neoplasms
Inhibition of Poly(ADP-Ribose) Polymerase by Nucleic Acid Metabolite 7-Methylguanine.
Breast Neoplasms
Inhibition of Rad51 sensitizes breast cancer cells with wild-type PTEN to olaparib.
Breast Neoplasms
Inhibition of SYK kinase does not confer a pro-proliferative or pro-invasive phenotype in breast epithelium or breast cancer cells.
Breast Neoplasms
Inhibition of TACC3 by a small molecule inhibitor in breast cancer.
Breast Neoplasms
Inhibitors targeting CDK4/6, PARP and PI3K in breast cancer: a review.
Breast Neoplasms
INO-1001, a novel inhibitor of poly(ADP-ribose) polymerase, enhances tumor response to doxorubicin.
Breast Neoplasms
Integrated proteomic, transcriptomic, and biological network analysis of breast carcinoma reveals molecular features of tumorigenesis and clinical relapse.
Breast Neoplasms
Integrating PARP inhibitors into the management of breast cancer: where are we?
Breast Neoplasms
Integrating poly(ADP-ribose) polymerase (PARP) inhibitors in the treatment of early breast cancer.
Breast Neoplasms
Interaction of BARD1 and HP1 is required for BRCA1 retention at sites of DNA damage.
Breast Neoplasms
Interactions Between Ataxia Telangiectasia Mutated Kinase Inhibition, Poly(ADP-ribose) Polymerase-1 Inhibition and BRCA1 Status in Breast Cancer Cells.
Breast Neoplasms
Interleukin 4 inhibits growth and induces apoptosis in human breast cancer cells.
Breast Neoplasms
Ionizing radiation-induced NF-kappaB activation requires PARP-1 function to confer radioresistance.
Breast Neoplasms
Is there a role for base excision repair in estrogen/estrogen receptor-driven breast cancers?
Breast Neoplasms
Is there an epigenetic component underlying the resistance of triple-negative breast cancers to parp inhibitors?
Breast Neoplasms
Isoalantolactone induces apoptosis in human breast cancer cells via ROS-mediated mitochondrial pathway and downregulation of SIRT1.
Breast Neoplasms
Isodeoxyelephantopin, a Sesquiterpene Lactone Induces ROS Generation, Suppresses NF-?B Activation, Modulates LncRNA Expression and Exhibit Activities Against Breast Cancer.
Breast Neoplasms
JMJD1C demethylates MDC1 to regulate the RNF8 and BRCA1-mediated chromatin response to DNA breaks.
Breast Neoplasms
KIFC1 is a novel potential therapeutic target for breast cancer.
Breast Neoplasms
Knockdown delta-5-desaturase in breast cancer cells that overexpress COX-2 results in inhibition of growth, migration and invasion via a dihomo-?-linolenic acid peroxidation dependent mechanism.
Breast Neoplasms
Knowledge and attitude of hereditary breast cancer among Japanese university female students.
Breast Neoplasms
Kub5-Hera
RPRD1B
Deficiency Promotes "BRCAness" and Vulnerability to PARP Inhibition in BRCA-proficient Breast Cancers.
Breast Neoplasms
Let-7 Status Is Crucial for PARP1 Expression in HER2-Overexpressing Breast Tumors.
Breast Neoplasms
Limitations of Systemic Oncological Therapy in Breast Cancer Patients with Chronic Kidney Disease.
Breast Neoplasms
Long non-coding RNA H19 regulates proliferation and doxorubicin resistance in MCF-7 cells by targeting PARP1.
Breast Neoplasms
Long-term treatment with the PARP inhibitor niraparib does not increase the mutation load in cell line models and tumour xenografts.
Breast Neoplasms
Loss of CtIP disturbs homologous recombination repair and sensitizes breast cancer cells to PARP inhibitors.
Breast Neoplasms
Low E2F2 activity is associated with high genomic instability and PARPi resistance.
Breast Neoplasms
LSD1 Overexpression Is Associated with Poor Prognosis in Basal-Like Breast Cancer, and Sensitivity to PARP Inhibition.
Breast Neoplasms
Lysyl oxidase propeptide sensitizes pancreatic and breast cancer cells to doxorubicin-induced apoptosis.
Breast Neoplasms
MAPK4 silencing together with a PARP1 inhibitor as a combination therapy in triple?negative breast cancer cells.
Breast Neoplasms
Mechanisms of PARP inhibitor sensitivity and resistance.
Breast Neoplasms
Medical Management of newly diagnosed breast cancer in a BRCA1/2 mutation carrier.
Breast Neoplasms
Metabolic Stability Assessment of New PARP Inhibitor Talazoparib Using Validated LC-MS/MS Methodology: In silico Metabolic Vulnerability and Toxicity Studies.
Breast Neoplasms
Metabotropic glutamate receptor-1: a potential therapeutic target for the treatment of breast cancer.
Breast Neoplasms
Metal-Based Inhibition of Poly(ADP-ribose) Polymerase - The Guardian Angel of DNA.
Breast Neoplasms
Metformin inhibits breast cancer cell growth, colony formation and induces cell cycle arrest in vitro.
Breast Neoplasms
Methoxyphenylcipro induces antitumor activity in human cancer cells.
Breast Neoplasms
Methylseleninic acid potentiates multiple types of cancer cells to ABT-737-induced apoptosis by targeting Mcl-1 and Bad.
Breast Neoplasms
MGMT Inhibition Restores ER? Functional Sensitivity to Anti-Estrogen Therapy.
Breast Neoplasms
MicroRNAs and DNA-Damaging Drugs in Breast Cancer: Strength in Numbers.
Breast Neoplasms
miR-151-5p, targeting chromatin remodeler SMARCA5, as a marker for the BRCAness phenotype.
Breast Neoplasms
miR-182-mediated downregulation of BRCA1 impacts DNA repair and sensitivity to PARP inhibitors.
Breast Neoplasms
Modulation of the poly (ADP-ribose) polymerase inhibitor response and DNA recombination in breast cancer cells by drugs affecting endogenous wild-type p53.
Breast Neoplasms
Molecular targeted drugs resistance impairs double-strand break repair and sensitizes ER-positive breast cancer to PARP inhibitors.
Breast Neoplasms
Molecular Testing in Breast Cancer.
Breast Neoplasms
More breast cancer patients could benefit from PARP inhibitors.
Breast Neoplasms
Moving beyond PARP Inhibition: Current State and Future Perspectives in Breast Cancer.
Breast Neoplasms
Mutant p53 mediates survival of breast cancer cells.
Breast Neoplasms
Network Meta-Analysis on the Effects of DNA Damage Response-Related Gene Mutations on Overall Survival of Breast Cancer Based on TCGA Database.
Breast Neoplasms
Network Pharmacology-Based Validation of Caveolin-1 as a Key Mediator of Ai Du Qing Inhibition of Drug Resistance in Breast Cancer.
Breast Neoplasms
New insight into the significance of KLF4 PARylation in genome stability, carcinogenesis, and therapy.
Breast Neoplasms
Next-generation sequencing-based BRCA testing on cytological specimens from ovarian cancer ascites reveals high concordance with tumour tissue analysis.
Breast Neoplasms
NHERF1 together with PARP1 and BRCA1 expression as a new potential biomarker to stratify breast cancer patients.
Breast Neoplasms
Nicotinamide sensitizes human breast cancer cells to the cytotoxic effects of radiation and cisplatin.
Breast Neoplasms
Nicotinamide, a Poly [ADP-Ribose] Polymerase 1 (PARP-1) Inhibitor, as an Adjunctive Therapy for the Treatment of Alzheimer's Disease.
Breast Neoplasms
Niraparib (MK-4827), a novel poly(ADP-Ribose) polymerase inhibitor, radiosensitizes human lung and breast cancer cells.
Breast Neoplasms
Niraparib for the treatment of ovarian cancer.
Breast Neoplasms
Non-NAD-Like poly(ADP-Ribose) Polymerase-1 Inhibitors effectively Eliminate Cancer in vivo.
Breast Neoplasms
Non-small cell lung cancer cells with deficiencies in homologous recombination genes are sensitive to PARP inhibitors.
Breast Neoplasms
Nonpeptidic and potent small-molecule inhibitors of cIAP-1/2 and XIAP proteins.
Breast Neoplasms
Novel allosteric PARP1 inhibitors for the treatment of BRCA-deficient leukemia.
Breast Neoplasms
Novel Poly(ADP-ribose) Polymerase-1 Inhibitor DDHCB Inhibits Proliferation of BRCA Mutant Breast Cancer Cell In Vitro and In Vivo through a Synthetic Lethal Mechanism.
Breast Neoplasms
Novel splice-switching oligonucleotide promotes BRCA1 aberrant splicing and susceptibility to PARP inhibitor action.
Breast Neoplasms
Novel synthetic triterpenoid methyl 25-hydroxy-3-oxoolean-12-en-28-oate induces apoptosis through JNK and p38 MAPK pathways in human breast adenocarcinoma MCF-7 cells.
Breast Neoplasms
Novel treatment strategies in triple-negative breast cancer: specific role of poly(adenosine diphosphate-ribose) polymerase inhibition.
Breast Neoplasms
Nuclear PARP-1 protein overexpression is associated with poor overall survival in early breast cancer.
Breast Neoplasms
Nuclear PARP1 expression and its prognostic significance in breast cancer patients.
Breast Neoplasms
Nuclear translocation of the receptor tyrosine kinase c-MET reduces the treatment efficacies of olaparib and gemcitabine in pancreatic ductal adenocarcinoma cells.
Breast Neoplasms
Nuclear-cytoplasmic PARP-1 expression as an unfavorable prognostic marker in lymph node?negative early breast cancer: 15-year follow-up.
Breast Neoplasms
Nutlin-3a suppresses poly (ADP-ribose) polymerase 1 by mechanisms different from conventional PARP1 suppressors in a human breast cancer cell line.
Breast Neoplasms
Olaparib and ?-specific PI3K inhibitor alpelisib for patients with epithelial ovarian cancer: a dose-escalation and dose-expansion phase 1b trial.
Breast Neoplasms
Olaparib for the treatment of breast cancer.
Breast Neoplasms
Olaparib in germline-mutated metastatic breast cancer: implications of the OlympiAD trial.
Breast Neoplasms
Olaparib Keeps Hereditary Breast Tumors in Check.
Breast Neoplasms
Olaparib monotherapy as primary treatment in unselected triple negative breast cancer.
Breast Neoplasms
Olaparib Suppresses MDSC Recruitment via SDF1?/CXCR4 Axis to Improve the Anti-tumor Efficacy of CAR-T Cells on Breast Cancer in Mice.
Breast Neoplasms
Olaparib tablets for the treatment of germ line BRCA-mutated metastatic breast cancer.
Breast Neoplasms
Olaparib: A Novel Therapy for Metastatic Breast Cancer in Patients With a BRCA1/2 Mutation.
Breast Neoplasms
ON-III inhibits erbB-2 tyrosine kinase receptor signal pathway and triggers apoptosis through induction of Bim in breast cancer cells.
Breast Neoplasms
Optimizing the management of HER2-negative metastatic breast cancer in the era of PARP inhibitors-proceedings from breast cancer expert group meeting.
Breast Neoplasms
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial.
Breast Neoplasms
Overexpression of PARP is an independent prognostic marker for poor survival in Middle Eastern breast cancer and its inhibition can be enhanced with embelin co-treatment.
Breast Neoplasms
Oxidative stress, DNA repair, and cancer susceptibility.
Breast Neoplasms
p110? and p110? isoforms of PI3K are involved in protection against H2O2 induced oxidative stress in cancer cells.
Breast Neoplasms
p38? mitogen-activated protein kinase contributes to oncogenic properties maintenance and resistance to poly (ADP-ribose)-polymerase-1 inhibition in breast cancer.
Breast Neoplasms
p63 involvement in poly(ADP-ribose) polymerase 1 signaling of topoisomerase I-dependent DNA damage in carcinoma cells.
Breast Neoplasms
Pan-cancer analysis reveals synergistic effects of CDK4/6i and PARPi combination treatment in RB-proficient and RB-deficient breast cancer cells.
Breast Neoplasms
PARP (Poly ADP-Ribose Polymerase) inhibitors for locally advanced or metastatic breast cancer.
Breast Neoplasms
PARP and PARG inhibitors in cancer treatment.
Breast Neoplasms
PARP inhibition in breast cancer.
Breast Neoplasms
PARP Inhibition in Cancer: An Update on Clinical Development.
Breast Neoplasms
PARP inhibition in homologous-recombination-deficient early-stage breast cancer.
Breast Neoplasms
PARP inhibition potentiates the cytotoxic activity of C-1305, a selective inhibitor of topoisomerase II, in human BRCA1-positive breast cancer cells.
Breast Neoplasms
PARP inhibition sensitizes p53-deficient breast cancer cells to doxorubicin-induced apoptosis.
Breast Neoplasms
PARP inhibitor and platinum agent in triple negative breast cancer: utilizing innovative trial design to bring together something "new" and something "old".
Breast Neoplasms
PARP inhibitor development for systemic cancer targeting.
Breast Neoplasms
PARP Inhibitor in Platinum-Resistant Ovarian Cancer: Single-Center Real-World Experience.
Breast Neoplasms
PARP inhibitor olaparib has a potential to increase the effectiveness of electrochemotherapy in BRCA1 mutated breast cancer in mice.
Breast Neoplasms
PARP inhibitor reduces proliferation and increases apoptosis in breast cancer cells.
Breast Neoplasms
PARP inhibitor resistance: the underlying mechanisms and clinical implications.
Breast Neoplasms
PARP inhibitor treatment in ovarian and breast cancer.
Breast Neoplasms
PARP inhibitors and more.
Breast Neoplasms
PARP inhibitors and the treatment of breast cancer: beyond BRCA1/2?
Breast Neoplasms
PARP inhibitors and their evolving role in breast cancer.
Breast Neoplasms
PARP Inhibitors as a Therapeutic Agent for Homologous Recombination Deficiency in Breast Cancers.
Breast Neoplasms
PARP inhibitors combined with ionizing radiation induce different effects in melanoma cells and healthy fibroblasts.
Breast Neoplasms
PARP Inhibitors for the Treatment and Prevention of Breast Cancer.
Breast Neoplasms
PARP inhibitors in BRCA1/BRCA2 germline mutation carriers with ovarian and breast cancer.
Breast Neoplasms
PARP Inhibitors in Breast Cancer.
Breast Neoplasms
PARP inhibitors in breast cancer: BRCA and beyond.
Breast Neoplasms
PARP inhibitors in breast cancer: Bringing synthetic lethality to the bedside.
Breast Neoplasms
PARP Inhibitors in Breast Cancer: Why, How, and When?
Breast Neoplasms
PARP inhibitors in cancer therapy: promise, progress, and puzzles.
Breast Neoplasms
PARP inhibitors in cancer therapy: two modes of attack on the cancer cell widening the clinical applications.
Breast Neoplasms
PARP inhibitors in older patients with ovarian and breast cancer: Young International Society of Geriatric Oncology review paper.
Breast Neoplasms
PARP inhibitors in the management of breast cancer: current data and future prospects.
Breast Neoplasms
PARP Inhibitors in the Treatment of Early Breast Cancer: The Step Beyond?
Breast Neoplasms
PARP Inhibitors in Triple-Negative Breast Cancer Including Those With BRCA Mutations.
Breast Neoplasms
PARP inhibitors stumble in breast cancer.
Breast Neoplasms
PARP inhibitors--current status and the walk towards early breast cancer.
Breast Neoplasms
PARP inhibitor treatment of advanced breast cancer beyond the BRCA-mutated type: a meta-analysis.
Breast Neoplasms
PARP regulates TGF-beta receptor type II expression in estrogen receptor-positive breast cancer cell lines.
Breast Neoplasms
PARP-1 expression in breast cancer including BRCA1-associated, triple negative and basal-like tumors: possible implications for PARP-1 inhibitor therapy.
Breast Neoplasms
PARP-1 inhibitors: a novel genetically specific agents for cancer therapy.
Breast Neoplasms
PARP-1 inhibitors: are they the long-sought genetically specific drugs for BRCA1/2-associated breast cancers?
Breast Neoplasms
PARP-1 Regulates Estrogen-Dependent Gene Expression in Estrogen Receptor ?-Positive Breast Cancer Cells.
Breast Neoplasms
PARP1 and phospho-p65 protein expression is increased in human HER2-positive breast cancers.
Breast Neoplasms
PARP1 and PRC2 double deficiency promotes BRCA-proficient breast cancer growth by modification of the tumor microenvironment.
Breast Neoplasms
PARP1 Co-Regulates EP300-BRG1-Dependent Transcription of Genes Involved in Breast Cancer Cell Proliferation and DNA Repair.
Breast Neoplasms
PARP1 Inhibition Radiosensitizes Models of Inflammatory Breast Cancer to Ionizing Radiation.
Breast Neoplasms
PARP1 Inhibitors: antitumor drug design.
Breast Neoplasms
PARP1 Trapping by PARP Inhibitors Drives Cytotoxicity in Both Cancer Cells and Healthy Bone Marrow.
Breast Neoplasms
PARP3 controls TGF? and ROS driven epithelial-to-mesenchymal transition and stemness by stimulating a TG2-Snail-E-cadherin axis.
Breast Neoplasms
PARP3 inhibitors ME0328 and olaparib potentiate vinorelbine sensitization in breast cancer cell lines.
Breast Neoplasms
PARP3, a new therapeutic target to alter Rictor/mTORC2 signaling and tumor progression in BRCA1-associated cancers.
Breast Neoplasms
Period-2: a tumor suppressor gene in breast cancer.
Breast Neoplasms
Perspectives on PARP inhibitors as pharmacotherapeutic strategies for breast cancer.
Breast Neoplasms
Pharmacokinetic Effects and Safety of Olaparib Administered with Endocrine Therapy: A Phase I Study in Patients with Advanced Solid Tumours.
Breast Neoplasms
Pharmacokinetics and clinical response to single agent rucaparib in a dialysis dependent patient with BRCA associated breast and recurrent ovarian cancer.
Breast Neoplasms
Pharmacologic characterization of fluzoparib, a novel poly(ADP-ribose) polymerase inhibitor undergoing clinical trials.
Breast Neoplasms
Phase 2 multicentre trial investigating intermittent and continuous dosing schedules of the poly(ADP-ribose) polymerase inhibitor rucaparib in germline BRCA mutation carriers with advanced ovarian and breast cancer.
Breast Neoplasms
Phase I and pharmacokinetic study of veliparib, a PARP inhibitor, and pegylated liposomal doxorubicin (PLD) in recurrent gynecologic cancer and triple negative breast cancer with long-term follow-up.
Breast Neoplasms
Phase I Study of Veliparib (ABT-888) Combined with Cisplatin and Vinorelbine in Advanced Triple-Negative Breast Cancer and/or BRCA Mutation-Associated Breast Cancer.
Breast Neoplasms
Phosphoglycerate mutase 1 regulates dNTP pool and promotes homologous recombination repair in cancer cells.
Breast Neoplasms
PI3K inhibition impairs BRCA1/2 expression and sensitizes BRCA proficient triple negative breast cancer to PARP inhibition.
Breast Neoplasms
Poly (ADP-ribose) polymerase (PARP): rationale, preclinical and clinical evidences of its inhibition as breast cancer treatment.
Breast Neoplasms
Poly (ADP-ribose) polymerase inhibition enhances trastuzumab antitumour activity in HER2 overexpressing breast cancer.
Breast Neoplasms
Poly (ADP-ribose) Polymerase Inhibition in Patients with Breast Cancer and BRCA 1 and 2 Mutations.
Breast Neoplasms
Poly (ADP-Ribose) Polymerase Inhibitors: Talazoparib in Ovarian Cancer and Beyond.
Breast Neoplasms
Poly (ADP-ribose) polymerase-1 Inhibition: Preclinical and Clinical Development of Synthetic Lethality.
Breast Neoplasms
Poly (ADP-ribose) polymerases inhibitor, Zj6413, as a potential therapeutic agent against breast cancer.
Breast Neoplasms
Poly(ADP-ribose) polymerase 1 (PARP1) overexpression in human breast cancer stem cells and resistance to olaparib.
Breast Neoplasms
Poly(ADP-ribose) polymerase 1 modulates the lethality of CHK1 inhibitors in mammary tumors.
Breast Neoplasms
Poly(ADP-ribose) polymerase and Ku autoantigen form a complex and synergistically bind to matrix attachment sequences.
Breast Neoplasms
Poly(ADP-ribose) polymerase as a novel regulator of 17?-estradiol-induced cell growth through a control of the estrogen receptor/IGF-1 receptor/PDZK1 axis.
Breast Neoplasms
Poly(ADP-ribose) polymerase gene expression status and genomic instability in human breast cancer.
Breast Neoplasms
Poly(ADP-ribose) polymerase in human breast cancer: a case-control analysis.
Breast Neoplasms
Poly(ADP-Ribose) polymerase inhibition: "Targeted" therapy for triple-negative breast cancer.
Breast Neoplasms
Poly(ADP-ribose) polymerase inhibition: a new direction for BRCA and triple-negative breast cancer?
Breast Neoplasms
Poly(ADP-ribose) polymerase inhibitor induces accelerated senescence in irradiated breast cancer cells and tumors.
Breast Neoplasms
Poly(ADP-ribose) polymerase inhibitors in triple-negative breast cancer.
Breast Neoplasms
Poly(ADP-ribose) polymerase-1 mRNA expression in human breast cancer: a meta-analysis.
Breast Neoplasms
Poly(ADP-ribose) polymerase-1 plays a role in suppressing mammary tumourigenesis in mice.
Breast Neoplasms
Poly(ADP-ribose) polymerase-1 promotes recruitment of meiotic recombination-11 to chromatin and DNA double-strand break repair in Ku70-deficient breast cancer cells.
Breast Neoplasms
Poly-(ADP-ribose) polymerase inhibitors: paradigm shift in the first-line treatment of newly diagnosed advanced ovarian cancer.
Breast Neoplasms
Poly-ADP-Ribosylation of Estrogen Receptor-Alpha by PARP1 Mediates Antiestrogen Resistance in Human Breast Cancer Cells.
Breast Neoplasms
Polyclonal BRCA2 mutations following carboplatin treatment confer resistance to the PARP inhibitor rucaparib in a patient with mCRPC: a case report.
Breast Neoplasms
Polygenic model of DNA repair genetic polymorphisms in human breast cancer risk.
Breast Neoplasms
Polymorphisms in poly (ADP-ribose) polymerase-1 (PARP1) promoter and 3' untranslated region and their association with PARP1 expression in breast cancer patients.
Breast Neoplasms
Polymorphisms of ADPRT Val762Ala and XRCC1 Arg399Glu and risk of breast cancer in Chinese women: a case control analysis.
Breast Neoplasms
PPAR?-inactive ?2-troglitazone independently triggers ER stress and apoptosis in breast cancer cells.
Breast Neoplasms
Prognostic and clinicopathological value of poly (adenosine diphosphate-ribose) polymerase expression in breast cancer: A meta-analysis.
Breast Neoplasms
Prolonged response to treatment based on cell-free DNA analysis and molecular profiling in three patients with metastatic cancer: a case series.
Breast Neoplasms
Prosopis juliflora (Sw.), DC induces apoptosis and cell cycle arrest in triple negative breast cancer cells: in vitro and in vivo investigations.
Breast Neoplasms
Prospect for Application of PARP Inhibitor in Patients with HER2 Negative Breast Cancer.
Breast Neoplasms
Proteasome ubiquitin receptor PSMD4 is an amplification target in breast cancer and may predict sensitivity to PARPi.
Breast Neoplasms
Proteome-wide analysis of mutant p53 targets in breast cancer identifies new levels of gain-of-function that influence PARP, PCNA, and MCM4.
Breast Neoplasms
PTK6 regulates growth and survival of endocrine therapy-resistant ER+ breast cancer cells.
Breast Neoplasms
Pyrosequencing analysis of BRCA1 methylation level in breast cancer cells.
Breast Neoplasms
RAC1 GTPase promotes the survival of breast cancer cells in response to hyper-fractionated radiation treatment.
Breast Neoplasms
RAD51 foci as a functional biomarker of homologous recombination repair and PARP inhibitor resistance in germline BRCA-mutated breast cancer.
Breast Neoplasms
Rad51 inhibition sensitizes breast cancer stem cells to PARP inhibitor in triple-negative breast cancer.
Breast Neoplasms
RAD51 Mediates Resistance of Cancer Stem Cells to PARP Inhibition in Triple-Negative Breast Cancer.
Breast Neoplasms
Radiosensitization with combined use of olaparib and PI-103 in triple-negative breast cancer.
Breast Neoplasms
Randomised phase II trial of olaparib, chemotherapy or olaparib and cediranib in patients with platinum-resistant ovarian cancer (OCTOVA): a study protocol.
Breast Neoplasms
Rapamycin sensitizes cancer cells to growth inhibition by the PARP inhibitor olaparib.
Breast Neoplasms
Rapid activation of epithelial-mesenchymal transition drives PARP inhibitor resistance in Brca2-mutant mammary tumours.
Breast Neoplasms
Rapid Progression of Metastatic Pancreatic Adenocarcinoma During Platinum-Based Therapy in a Patient Harboring a Pathogenic BRCA2 Germline Variant.
Breast Neoplasms
Rare mutations in XRCC2 increase the risk of breast cancer.
Breast Neoplasms
RBR-type E3 ubiquitin ligase RNF144A targets PARP1 for ubiquitin-dependent degradation and regulates PARP inhibitor sensitivity in breast cancer cells.
Breast Neoplasms
Recent Advances in Enhancing the Therapeutic Index of PARP Inhibitors in Breast Cancer.
Breast Neoplasms
Recent developments in treatment stratification for metastatic breast cancer.
Breast Neoplasms
Reduced PAK1 activity sensitizes FA/BRCA-proficient breast cancer cells to PARP inhibition.
Breast Neoplasms
Relevance of poly (ADP-ribose) polymerase inhibitors in prostate cancer.
Breast Neoplasms
Response of Breast Cancer Cells to PARP Inhibitors Is Independent of BRCA Status.
Breast Neoplasms
Response of subtype-specific human breast cancer-derived cells to poly(ADP-ribose) polymerase and checkpoint kinase 1 inhibition.
Breast Neoplasms
Response to Olaparib in a Patient with Germline BRCA2 Mutation and Breast Cancer Leptomeningeal Carcinomatosis.
Breast Neoplasms
Response to olaparib in metastatic castration-resistant prostate cancer with germline BRCA2 mutation: a case report.
Breast Neoplasms
Resurrection of PARP Inhibitors in Breast Cancer.
Breast Neoplasms
Resveratrol enhances the efficacy of sorafenib mediated apoptosis in human breast cancer MCF7 cells through ROS, cell cycle inhibition, caspase 3 and PARP cleavage.
Breast Neoplasms
Resveratrol-induced apoptosis in human breast cancer cells is mediated primarily through the caspase-3-dependent pathway.
Breast Neoplasms
Resveratrol-induced growth inhibition in MDA-MB-231 breast cancer cells is associated with mitogen-activated protein kinase signaling and protein translation.
Breast Neoplasms
Reversion and non-reversion mechanisms of resistance to PARP inhibitor or platinum chemotherapy in BRCA1/2-mutant metastatic breast cancer.
Breast Neoplasms
RING domain-deficient BRCA1 promotes PARP inhibitor and platinum resistance.
Breast Neoplasms
Role of autophagy in chemoresistance: regulation of the ATM-mediated DNA-damage signaling pathway through activation of DNA-PKcs and PARP-1.
Breast Neoplasms
Role of BRCA Mutations in Cancer Treatment with Poly(ADP-ribose) Polymerase (PARP) Inhibitors.
Breast Neoplasms
Role of Poly (ADP-Ribose) Polymerase inhibitors beyond BReast CAncer Gene-mutated ovarian tumours: definition of homologous recombination deficiency?
Breast Neoplasms
Selective anticancer effects and protection from chemotherapy by the botanical compound LCS101: Implications for cancer treatment.
Breast Neoplasms
Selective resistance to the PARP inhibitor olaparib in a mouse model for BRCA1-deficient metaplastic breast cancer.
Breast Neoplasms
Selenocystine induces caspase-independent apoptosis in MCF-7 human breast carcinoma cells with involvement of p53 phosphorylation and reactive oxygen species generation.
Breast Neoplasms
Selinexor, a selective inhibitor of nuclear export, enhances the anti-tumor activity of olaparib in triple negative breast cancer regardless of BRCA1 mutation status.
Breast Neoplasms
Sensitivity and acquired resistance of BRCA1;p53-deficient mouse mammary tumors to the topoisomerase I inhibitor topotecan.
Breast Neoplasms
Sequences and combinations of multifaceted therapy in advanced prostate cancer.
Breast Neoplasms
Shieldin complex promotes DNA end-joining and counters homologous recombination in BRCA1-null cells.
Breast Neoplasms
Should Tumor Infiltrating Lymphocytes, Androgen Receptor, and FOXA1 Expression Predict the Clinical Outcome in Triple Negative Breast Cancer Patients?
Breast Neoplasms
Sigma-2 ligands and PARP inhibitors synergistically trigger cell death in breast cancer cells.
Breast Neoplasms
Simple prediction model for homologous recombination deficiency in breast cancers in adolescents and young adults.
Breast Neoplasms
Single-agent PARP inhibitors for the treatment of patients with BRCA-mutated HER2-negative metastatic breast cancer: a systematic review and meta-analysis.
Breast Neoplasms
Somatic mutations in the BRCA1 gene in Chinese women with sporadic breast cancer.
Breast Neoplasms
Somatostatin receptor targeted liposomes with Diacerein inhibit IL-6 for breast cancer therapy.
Breast Neoplasms
Stabilization of mutant BRCA1 protein confers PARP inhibitor and platinum resistance.
Breast Neoplasms
Structure-Guided Design and In-Cell Target Profiling of a Cell-Active Target Engagement Probe for PARP Inhibitors.
Breast Neoplasms
Stumbling blocks on the path to personalized medicine in breast cancer: the case of PARP inhibitors for BRCA1/2-associated cancers.
Breast Neoplasms
Sulforaphane induces cell type-specific apoptosis in human breast cancer cell lines.
Breast Neoplasms
Suppression of survival in human SKBR3 breast carcinoma in response to metal-chelator complexes is preferential for copper-dithiocarbamate.
Breast Neoplasms
Survival benefits of PARP inhibitors in advanced breast cancer: a mirage?
Breast Neoplasms
Sustained Cytotoxicity of Wogonin on Breast Cancer Cells by Encapsulation in Solid Lipid Nanoparticles.
Breast Neoplasms
Synergistic Effect of Bazedoxifene and PARP Inhibitor in the Treatment of Ovarian Cancer Regardless of BRCA Mutation.
Breast Neoplasms
Synergistic Effect of Trabectedin and Olaparib Combination Regimen in Breast Cancer Cell Lines.
Breast Neoplasms
Synergy of theophylline reduces necrotic effect of berberine, induces cell cycle arrest and PARP, HMGB1, Bcl-2 family mediated apoptosis in MDA-MB-231 breast cancer cells.
Breast Neoplasms
Synthesis of a novel fluorescent berberine derivative convenient for its subcellular localization study.
Breast Neoplasms
Synthesis of Some Benzimidazole-derived Molecules and Their Effects on PARP-1 Activity and MDA-MB-231, MDA-MB-436, MDA-MB-468 Breast Cancer Cell Viability.
Breast Neoplasms
Synthesis, biological evaluation and molecular docking studies of novel 1,2,3-triazole-quinazolines as antiproliferative agents displaying ERK inhibitory activity.
Breast Neoplasms
Synthesis, chemical characterization, PARP inhibition, DNA binding and cellular uptake of novel ruthenium(II)-arene complexes bearing benzamide derivatives in human breast cancer cells.
Breast Neoplasms
Synthesis, cytotoxic evaluation and molecular docking study of novel quinazoline derivatives as PARP-1 inhibitors.
Breast Neoplasms
Synthetic lethal interactions between EGFR and PARP inhibition in human triple negative breast cancer cells.
Breast Neoplasms
Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors.
Breast Neoplasms
Synthetic lethal therapies for cancer: what's next after PARP inhibitors?
Breast Neoplasms
Synthetic Lethality of PARP Inhibitors in Combination with MYC Blockade Is Independent of BRCA Status in Triple-Negative Breast Cancer.
Breast Neoplasms
Systematic comparison of ligand-based and structure-based virtual screening methods on poly (ADP-ribose) polymerase-1 inhibitors.
Breast Neoplasms
Systems biology approaches based discovery of a small molecule inhibitor targeting both c-Met/PARP-1 and inducing cell death in breast cancer.
Breast Neoplasms
Tamoxifen enhances the cytotoxic effects of nelfinavir in breast cancer cells.
Breast Neoplasms
Tanshinone IIA Induces Mitochondria Dependent Apoptosis in Prostate Cancer Cells in Association with an Inhibition of Phosphoinositide 3-Kinase/AKT Pathway.
Breast Neoplasms
Targeted radiosensitization with PARP1 inhibition: optimization of therapy and identification of biomarkers of response in breast cancer.
Breast Neoplasms
Targeted Therapies for Breast Cancer Brain Metastases.
Breast Neoplasms
Targeted Therapies for Triple-Negative Breast Cancer.
Breast Neoplasms
Targeted therapy in breast cancer: what's new?
Breast Neoplasms
Targeted therapy of metastatic breast cancer.
Breast Neoplasms
Targeting BRCA1 localization to augment breast tumor sensitivity to poly(ADP-ribose) polymerase inhibition.
Breast Neoplasms
Targeting DNA repair in breast cancer.
Breast Neoplasms
Targeting DNA repair in breast cancer: A clinical and translational update.
Breast Neoplasms
Targeting PARP1 in XRCC1 deficient sporadic invasive breast cancer or pre-invasive ductal carcinoma in situ induces synthetic lethality and chemoprevention.
Breast Neoplasms
TBCRC 048: Phase II Study of Olaparib for Metastatic Breast Cancer and Mutations in Homologous Recombination-Related Genes.
Breast Neoplasms
TCDD-Inducible Poly-ADP-Ribose Polymerase (TIPARP), A Novel Therapeutic Target Of Breast Cancer.
Breast Neoplasms
TGF? induces "BRCAness" and sensitivity to PARP inhibition in breast cancer by regulating DNA-repair genes.
Breast Neoplasms
The C Allele of a Synonymous SNP (rs1805414, Ala284Ala) in PARP1 is a Risk Factor for Susceptibility to Breast Cancer in Saudi Patients.
Breast Neoplasms
The CDK1 inhibitor RO3306 improves the response of BRCA-pro?cient breast cancer cells to PARP inhibition.
Breast Neoplasms
The cyclin-dependent kinase inhibitor SNS-032 induces apoptosis in breast cancer cells via depletion of Mcl-1 and X-linked inhibitor of apoptosis protein and displays antitumor activity in vivo.
Breast Neoplasms
The diagnostic value of DNA repair gene in breast cancer metastasis.
Breast Neoplasms
The emerging potential of poly(ADP-ribose) polymerase inhibitors in the treatment of breast cancer.
Breast Neoplasms
The evolution of poly(ADP-ribose) polymerase inhibitors in the treatment of breast cancer.
Breast Neoplasms
The expression of gene transcripts of telomere-associated genes in human breast cancer: correlation with clinico-pathological parameters and clinical outcome.
Breast Neoplasms
The F-Box Domain-Dependent Activity of EMI1 Regulates PARPi Sensitivity in Triple-Negative Breast Cancers.
Breast Neoplasms
The implications of BRCA loss of heterozygosity (LOH) and deficient mismatch repair gene (dMMR) expression in the breast cancer of a patient with both inherited breast and ovarian cancer syndrome (BRCA2) and Lynch syndrome (MLH1).
Breast Neoplasms
The Inhibition and Treatment of Breast Cancer with Poly (ADP-ribose) Polymerase (PARP-1) Inhibitors.
Breast Neoplasms
The nuclear expression of poly (ADP-ribose) polymerase-1 (PARP1) in invasive primary breast tumors is associated with chemotherapy sensitivity.
Breast Neoplasms
The OlympiAD trial: who won the gold?
Breast Neoplasms
The PARP Enzyme Family and the Hallmarks of Cancer Part 1. Cell Intrinsic Hallmarks.
Breast Neoplasms
The PARP inhibitor AZD2281 (Olaparib) induces autophagy/mitophagy in BRCA1 and BRCA2 mutant breast cancer cells.
Breast Neoplasms
The Poly (ADP-Ribose) Polymerase Inhibitor Veliparib and Radiation Cause Significant Cell Line Dependent Metabolic Changes in Breast Cancer Cells.
Breast Neoplasms
The potential of PARP inhibitors in genetic breast and ovarian cancers.
Breast Neoplasms
The Prognostic and Predictive Significance of PARP-1 in Locally Advanced Breast Cancer of Egyptian Patients Receiving Neoadjuvant Chemotherapy.
Breast Neoplasms
The promise of combining inhibition of PI3K and PARP as cancer therapy.
Breast Neoplasms
The Real Impact of Target Therapy in Breast Cancer Patients: Between Hope and Reality.
Breast Neoplasms
The role of Kif4A in doxorubicin-induced apoptosis in breast cancer cells.
Breast Neoplasms
The role of microRNA-binding site polymorphisms in DNA repair genes as risk factors for bladder cancer and breast cancer and their impact on radiotherapy outcomes.
Breast Neoplasms
The role of novel poly (ADP-ribose) inhibitors in the treatment of locally advanced and metastatic Her-2/neu negative breast cancer with inherited germline BRCA1/2 mutations. A review of the literature.
Breast Neoplasms
The role of PARP inhibition in triple-negative breast cancer: Unraveling the wide spectrum of synthetic lethality.
Breast Neoplasms
The Role of PARPs in Inflammation-and Metabolic-Related Diseases: Molecular Mechanisms and Beyond.
Breast Neoplasms
The synthetic ?-nitrostyrene derivative CYT-Rx20 induces breast cancer cell death and autophagy via ROS-mediated MEK/ERK pathway.
Breast Neoplasms
The triple-negative subtype: new ideas for the poorest prognosis breast cancer.
Breast Neoplasms
The tumor invasion inhibitor dihydromotuporamine C activates RHO, remodels stress fibers and focal adhesions, and stimulates sodium-proton exchange.
Breast Neoplasms
The ups and downs of Poly(ADP-ribose) Polymerase-1 inhibitors in cancer therapy-Current progress and future direction.
Breast Neoplasms
Therapeutic innovations in breast cancer.
Breast Neoplasms
Therapeutic potential of PARP inhibitors for metastatic breast cancer.
Breast Neoplasms
Therapeutic Potential of PARP Inhibitors in the Treatment of Metastatic Castration-Resistant Prostate Cancer.
Breast Neoplasms
TNFR2 promotes Adriamycin resistance in breast cancer cells by repairing DNA damage.
Breast Neoplasms
Tocotrienols promote apoptosis in human breast cancer cells by inducing poly(ADP-ribose) polymerase cleavage and inhibiting nuclear factor kappa-B activity.
Breast Neoplasms
Tosylcyclonovobiocic acids promote cleavage of the hsp90-associated cochaperone p23.
Breast Neoplasms
Transcriptional dysregulation of base excision repair proteins in breast cancer.
Breast Neoplasms
Transcriptional Regulation of CCL2 by PARP1 Is a Driver for Invasiveness in Breast Cancer.
Breast Neoplasms
Translational highlights in breast cancer research and treatment: recent developments with clinical impact.
Breast Neoplasms
Trastuzumab resistant HER2+ breast cancer cells retain sensitivity to poly (ADP-ribose) polymerase (PARP) inhibition.
Breast Neoplasms
Treating breast cancer in the 21st century: emerging biological therapies.
Breast Neoplasms
Triple negative breast cancer: Emerging therapeutic modalities and novel combination therapies.
Breast Neoplasms
Triple-negative breast cancer and Poly(ADP-ribose) polymerase inhibitors.
Breast Neoplasms
Triptolide sensitizes human breast cancer cells to tumor necrosis factor???induced apoptosis by inhibiting activation of the nuclear factor??B pathway.
Breast Neoplasms
Tumor-suppressive effect of adenovirus-mediated inhibitor of growth 4 gene transfer in breast carcinoma cells in vitro and in vivo.
Breast Neoplasms
Ubiquitin ligase RNF8 suppresses Notch signaling to regulate mammary development and tumorigenesis.
Breast Neoplasms
Update Breast Cancer 2020 Part 2 - Advanced Breast Cancer: New Treatments and Implementation of Therapies with Companion Diagnostics.
Breast Neoplasms
Update on PARP Inhibitors in Breast Cancer.
Breast Neoplasms
Using multiple targeted therapies in oncology: considerations for use, and progress to date in breast cancer.
Breast Neoplasms
VEGI, a new member of the TNF family activates nuclear factor-kappa B and c-Jun N-terminal kinase and modulates cell growth.
Breast Neoplasms
Veliparib in ovarian cancer: a new synthetically lethal therapeutic approach.
Breast Neoplasms
Verrucarin A alters cell-cycle regulatory proteins and induces apoptosis through reactive oxygen species-dependent p38MAPK activation in the human breast cancer cell line MCF-7.
Breast Neoplasms
Where Do We Stand on the Integration of PARP Inhibitors for the Treatment of Breast Cancer?
Breast Neoplasms
Wise Management of Ovarian Cancer: On the Cutting Edge.
Breast Neoplasms
Withanolide C Inhibits Proliferation of Breast Cancer Cells via Oxidative Stress-Mediated Apoptosis and DNA Damage.
Breast Neoplasms
XRCC1 and ADPRT polymorphisms associated with survival in breast cancer cases treated with chemotherapy.
Breast Neoplasms
XRCC1 deficient triple negative breast cancers are sensitive to ATR, ATM and Wee1 inhibitor either alone or in combination with olaparib.
Breast Neoplasms
Zebrafish Xenografts Unveil Sensitivity to Olaparib beyond BRCA Status.
Breast Neoplasms
[(18)F]FluorThanatrace uptake as a marker of PARP1 expression and activity in breast cancer.
Breast Neoplasms
[18F]-SuPAR: A Radiofluorinated Probe for Noninvasive Imaging of DNA Damage-Dependent Poly(ADP-ribose) Polymerase Activity.
Breast Neoplasms
[Breakthrough breast cancer treatment--PARP inhibitor, BRCA, and triple negative breast cancer]
Breast Neoplasms
[Effects of Olaparib, a PARP-1 Inhibitor, on Triple Negative Breast Cancer Cells with a BRCA1 Mutation].
Breast Neoplasms
[From poly(ADP-ribose) discovery to PARP inhibitors in cancer therapy].
Breast Neoplasms
[Hereditary Breast and Ovarian Cancer Syndrome].
Breast Neoplasms
[Hereditary breast carcinomas pathologist's perspective].
Breast Neoplasms
[Learning from My Experience: Outpatient Care for Cancer Multigene Genomic Testing].
Breast Neoplasms
[New advances in targeted therapy for breast cancer].
Breast Neoplasms
[New targeted therapies in breast cancer].
Breast Neoplasms
[Olaparib potentiates the antitumor effect of Taxol on 4T1 breast cancer].
Breast Neoplasms
[On the prospects of using the DNA repair inhibitors in radiotherapy of tumors].
Breast Neoplasms
[PARP inhibitors and breast cancer: update and perspectives].
Breast Neoplasms
[PARP inhibitors in breast cancer: Current clinical development and perspectives].
Breast Neoplasms
[PARP inhibitors--theoretical basis and clinical application].
Breast Neoplasms
[The Role of Preoperative Chemotherapy Depending on Breast Cancer Subtype].
Bronchiolitis
Fulminant pertussis: a multi-center study with new insights into the clinico-pathological mechanisms.
Burkitt Lymphoma
Biological Effects of MC2050, a Quinazoline-Based PARP-1 Inhibitor, in Human Neuroblastoma and EBV-Positive Burkitt's Lymphoma Cells.
Burkitt Lymphoma
Chromosome 13 poly(ADP-ribose) polymerase polymorphisms and lung cancer risk.
Burkitt Lymphoma
IGH/MYC Translocation Associates with BRCA2 Deficiency and Synthetic Lethality to PARP1 Inhibitors.
Burkitt Lymphoma
PARP1 Is Overexpressed in Hematological Malignant Cell Lines: A Framework for Experimental Oncology.
Burkitt Lymphoma
Poly(ADP-ribose) polymerase 1 is necessary for coactivating hypoxia-inducible factor-1-dependent gene expression by Epstein-Barr virus latent membrane protein 1.
Burkitt Lymphoma
Prolongation of the p53 response to DNA strand breaks in cells depleted of PARP by antisense RNA expression.
Burkitt Lymphoma
Synthesis and serotonin transporter activity of 1,3-bis(aryl)-2-nitro-1-propenes as a new class of anticancer agents.
Burkitt Lymphoma
The antidepressants maprotiline and fluoxetine induce Type II autophagic cell death in drug-resistant Burkitt's lymphoma.
Calcinosis
Calcinosis in Systemic Sclerosis: Updates in Pathophysiology, Evaluation, and Treatment.
Carcinogenesis
Advanced small cell lung cancer (SCLC): new challenges and new expectations.
Carcinogenesis
Analysis of genetic variants of the poly(ADP-ribose) polymerase-1 gene in breast cancer in French patients.
Carcinogenesis
Analyzing structure-function relationships of artificial and cancer-associated PARP1 variants by reconstituting TALEN-generated HeLa PARP1 knock-out cells.
Carcinogenesis
Asbestos exposure affects poly(ADP-ribose) polymerase-1 activity: role in asbestos-induced carcinogenesis.
Carcinogenesis
Association between PARP-1 V762A polymorphism and cancer susceptibility: a meta-analysis.
Carcinogenesis
Association of PARP1-specific polymorphisms and haplotypes with non-small cell lung cancer subtypes.
Carcinogenesis
Beyond DNA Repair: Additional Functions of PARP-1 in Cancer.
Carcinogenesis
Chemopreventive effect of hesperidin, a citrus bioflavonoid in two stage skin carcinogenesis in Swiss albino mice.
Carcinogenesis
Common and unique genetic interactions of the poly(ADP-ribose) polymerases PARP1 and PARP2 with DNA double-strand break repair pathways.
Carcinogenesis
Crosstalk between PARP-1 and NF-kappaB modulates the promotion of skin neoplasia.
Carcinogenesis
Cyclooxygenase-2 inhibitor nimesulide blocks ultraviolet B-induced photocarcinogenesis in SKH-1 hairless mice.
Carcinogenesis
Cytoplasmic PARP-1 promotes pancreatic cancer tumorigenesis and resistance.
Carcinogenesis
Defective control of mitotic and post-mitotic checkpoints in poly(ADP-ribose) polymerase-1(-/-) fibroblasts after mitotic spindle disruption.
Carcinogenesis
Deficiency in Poly(ADP-ribose) Polymerase-1 (PARP-1) Accelerates Aging and Spontaneous Carcinogenesis in Mice.
Carcinogenesis
DNA double-strand break repair pathway choice - from basic biology to clinical exploitation.
Carcinogenesis
DNA strand break-sensing molecule poly(ADP-Ribose) polymerase cooperates with p53 in telomere function, chromosome stability, and tumor suppression.
Carcinogenesis
Effect of APE1 T2197G (Asp148Glu) polymorphism on APE1, XRCC1, PARP1 and OGG1 expression in patients with colorectal cancer.
Carcinogenesis
Enhancement of DEN initiation of liver carcinogenesis by inhibitors of NAD+ ADP ribosyl transferase in rats.
Carcinogenesis
Ex vivo study of MAPK profiles correlated with parameters of apoptosis during cervical carcinogenesis.
Carcinogenesis
Expression of BAG-1 and PARP-1 in Precursor Lesions and Invasive Cervical Cancer Associated with Human Papillomavirus (HPV).
Carcinogenesis
Expression of the Gene Encoding Poly(ADP-ribose) Polymerase-1 Is Modulated by Fibronectin during Corneal Wound Healing.
Carcinogenesis
Functional Characterization of Long Noncoding RNA Lnc_bc060912 in Human Lung Carcinoma Cells.
Carcinogenesis
Functions of poly(ADP-ribose) polymerase (PARP) in DNA repair, genomic integrity and cell death.
Carcinogenesis
Genetic alteration of poly(ADP-ribose) polymerase-1 in human germ cell tumors.
Carcinogenesis
Genetic interaction between PARP and DNA-PK in V(D)J recombination and tumorigenesis.
Carcinogenesis
Glycolytic rate and lymphomagenesis depend on PARP14, an ADP ribosyltransferase of the B aggressive lymphoma (BAL) family.
Carcinogenesis
H2AX a promising biomarker for lung cancer: a review.
Carcinogenesis
Identification and Characterization of MortaparibPlus-A Novel Triazole Derivative That Targets Mortalin-p53 Interaction and Inhibits Cancer-Cell Proliferation by Wild-Type p53-Dependent and -Independent Mechanisms.
Carcinogenesis
Impact of telomerase ablation on organismal viability, aging, and tumorigenesis in mice lacking the DNA repair proteins PARP-1, Ku86, or DNA-PKcs.
Carcinogenesis
Increased susceptibility of poly(ADP-ribose) polymerase-1 knockout mice to nitrosamine carcinogenicity.
Carcinogenesis
Inhibition of methylazoxymethanol acetate initiation of colon carcinogenesis in rats by treatment with the poly(ADP-ribose)polymerase inhibitor 3-aminobenzamide.
Carcinogenesis
Inhibition of poly adenosine diphosphate-ribose polymerase decreases hepatocellular carcinoma growth by modulation of tumor-related gene expression.
Carcinogenesis
Inhibition of poly(ADP-ribose) polymerase 1 protects against acute myeloid leukemia by suppressing the myeloproliferative leukemia virus oncogene.
Carcinogenesis
Inhibition of poly(ADP-ribose) polymerase activity accelerates T-cell lymphomagenesis in p53 deficient mice.
Carcinogenesis
Inhibition of poly(ADP-ribose) polymerase modulates tumor-related gene expression, including hypoxia-inducible factor-1 activation, during skin carcinogenesis.
Carcinogenesis
Interaction among susceptibility genotypes of PARP1 SNPs in thyroid carcinoma.
Carcinogenesis
Involvement of poly(ADP-ribose) polymerase in trophoblastic cell differentiation during tumorigenesis.
Carcinogenesis
Knockdown of PARP-1 Inhibits Proliferation and ERK Signals, Increasing Drug Sensitivity in Osteosarcoma U2OS Cells.
Carcinogenesis
Loss of PIDD limits NF-?B activation and cytokine production but not cell survival or transformation after DNA damage.
Carcinogenesis
Loss of poly(ADP-ribose) polymerase-1 causes increased tumour latency in p53-deficient mice.
Carcinogenesis
Mechanism of early biphasic activation of poly(ADP-ribose) polymerase-1 in response to ultraviolet B radiation.
Carcinogenesis
Modulation of brain tumor risk by genetic SNPs in PARP1gene: Hospital based case control study.
Carcinogenesis
Modulation of farnesoid X receptor results in post-translational modification of poly (ADP-ribose) polymerase 1 in the liver.
Carcinogenesis
Modulation of transcription by PARP-1: consequences in carcinogenesis and inflammation.
Carcinogenesis
Molecular/Genetic therapies in ovarian cancer: future opportunities and challenges.
Carcinogenesis
New insight into the significance of KLF4 PARylation in genome stability, carcinogenesis, and therapy.
Carcinogenesis
Nicotinamide Phosphoribosyltransferase in Malignancy: A Review.
Carcinogenesis
Non-NAD-like PARP-1 inhibitors in prostate cancer treatment.
Carcinogenesis
Overexpression of dominant negative PARP interferes with tumor formation of HeLa cells in nude mice: evidence for increased tumor cell apoptosis in vivo.
Carcinogenesis
Overexpression of poly(ADP-ribose) polymerase-1 (PARP-1) in the early stage of colorectal carcinogenesis.
Carcinogenesis
PARP inhibitors for BRCA1/2-mutated and sporadic ovarian cancer: current practice and future directions.
Carcinogenesis
PARP-1 activity in normal and cancerous human endometrium and its relationship with quantity of abasic sites (AP).
Carcinogenesis
Parp-1 deficiency does not enhance liver carcinogenesis induced by 2-amino-3-methylimidazo[4,5-f]quinoline in mice.
Carcinogenesis
Parp-1 deficiency does not increase the frequency of tumors in the oral cavity and esophagus of ICR/129Sv mice by 4-nitroquinoline 1-oxide, a carcinogen producing bulky adducts.
Carcinogenesis
Parp-1 deficiency implicated in colon and liver tumorigenesis induced by azoxymethane.
Carcinogenesis
Parp-1 deficiency in ES cells promotes invasive and metastatic lesions accompanying induction of trophoblast giant cells during tumorigenesis in uterine environment.
Carcinogenesis
Parp-1 genetic ablation in Ela-myc mice unveils novel roles for Parp-1 in pancreatic cancer.
Carcinogenesis
PARP-1 protects against colorectal tumor induction, but promotes inflammation-driven colorectal tumor progression.
Carcinogenesis
PARP-1 regulates epithelial-mesenchymal transition (EMT) in prostate tumorigenesis.
Carcinogenesis
PARP-1 serves as a novel molecular marker for hepatocellular carcinoma in a Southern Chinese Zhuang population.
Carcinogenesis
PARP-1 Val762Ala polymorphism and risk of cancer: a meta-analysis based on 39 case-control studies.
Carcinogenesis
PARP-1-dependent 3-nitrotyrosine protein modification after DNA damage.
Carcinogenesis
PARP1 and DNA-PKcs synergize to suppress p53 mutation and telomere fusions during T-lineage lymphomagenesis.
Carcinogenesis
PARP1 enhances lung adenocarcinoma metastasis by novel mechanisms independent of DNA repair.
Carcinogenesis
PARP1 Gene Polymorphisms and the Prognosis of Esophageal Cancer Patients from Cixian High-Incidence Region in Northern China.
Carcinogenesis
PARP1 Is Up-Regulated in Non-small Cell Lung Cancer Tissues in the Presence of the Cyanobacterial Toxin Microcystin.
Carcinogenesis
PARP1 rs1136410 (A/G) polymorphism is associated with early age of onset of gallbladder cancer.
Carcinogenesis
PARP10 promotes cellular proliferation and tumorigenesis by alleviating replication stress.
Carcinogenesis
PARP14 promotes the proliferation and gemcitabine chemoresistance of pancreatic cancer cells through activation of NF-?B pathway.
Carcinogenesis
PARP3 interacts with FoxM1 to confer glioblastoma cell radioresistance.
Carcinogenesis
Poly(ADP-ribose) polymerase gene on chromosome 1q: early role in differentiation linked replication; gene on human chromosome 13q: marker of carcinogenesis.
Carcinogenesis
Poly(ADP-ribose) polymerase-1 inhibition by arsenite promotes the survival of cells with unrepaired DNA lesions induced by UV exposure.
Carcinogenesis
Poly(ADP-ribose) polymerase-1 is a component of the oncogenic T-cell factor-4/beta-catenin complex.
Carcinogenesis
Poly(ADP-ribose) polymerase-1 plays a role in suppressing mammary tumourigenesis in mice.
Carcinogenesis
Poly(ADP-ribose) polymerase: a guardian angel protecting the genome and suppressing tumorigenesis.
Carcinogenesis
Poly(ADP-ribose)polymerase-1 (PARP-1) in carcinogenesis: potential role of PARP inhibitors in cancer treatment.
Carcinogenesis
Poly(ADP-ribosyl)ation and aging.
Carcinogenesis
PolyADP-ribosylation and cancer.
Carcinogenesis
Possible role of poly(ADP-ribose) polymerase on the early stage of liver carcinogenesis by diethylnitrosamine in rats.
Carcinogenesis
RecQ helicases and PARP1 team up in maintaining genome integrity.
Carcinogenesis
Regulation of the poly(ADP-ribose) polymerase-1 gene expression by the transcription factors Sp1 and Sp3 is under the influence of cell density in primary cultured cells.
Carcinogenesis
Sulfur and nitrogen mustards induce characteristic poly(ADP-ribosyl)ation responses in HaCaT keratinocytes with distinctive cellular consequences.
Carcinogenesis
Synthetic lethal genetic interactions between Rad54 and PARP-1 in mouse development and oncogenesis.
Carcinogenesis
Synthetic viability by BRCA2 and PARP1/ARTD1 deficiencies.
Carcinogenesis
Tannins elevate the level of poly(ADP-ribose) in HeLa cell extracts.
Carcinogenesis
Targeting PARP-1 with metronomic therapy modulates MDSC suppressive function and enhances anti-PD-1 immunotherapy in colon cancer.
Carcinogenesis
The beneficial effects of dietary restriction: reduced oxidative damage and enhanced apoptosis.
Carcinogenesis
The emerging role of poly(ADP-ribose) polymerase-1 in longevity.
Carcinogenesis
The Histone Methyltransferase SMYD2 Methylates PARP1 and Promotes Poly(ADP-ribosyl)ation Activity in Cancer Cells.
Carcinogenesis
The neem limonoids azadirachtin and nimbolide inhibit cell proliferation and induce apoptosis in an animal model of oral oncogenesis.
Carcinogenesis
The Significance of Targeting Poly (ADP-Ribose) Polymerase-1 in Pancreatic Cancer for Providing a New Therapeutic Paradigm.
Carcinogenesis
The transcription factor GATA3 is required for homologous recombination repair by regulating CtIP expression.
Carcinogenesis
Therapeutic Targeting of Poly(ADP-Ribose) Polymerase-1 (PARP1) in Cancer: Current Developments, Therapeutic Strategies, and Future Opportunities.
Carcinogenesis
TiPARP forms nuclear condensates to degrade HIF-1? and suppress tumorigenesis.
Carcinogenesis
Transcript response of soft coral (Scleronephthya gracillimum) on exposure to polycyclic aromatic hydrocarbons.
Carcinogenesis
Two DNA repair gene polymorphisms on the risk of gastrointestinal cancers: a meta-analysis.
Carcinogenesis
Upregulation of Poly (ADP-Ribose) Polymerase-1 (PARP1) in Triple-Negative Breast Cancer and Other Primary Human Tumor Types.
Carcinogenesis
Vulnerabilities of PTEN-TP53-deficient prostate cancers to compound PARP-PI3K inhibition.
Carcinogenesis
[Diethylnitrosamine-induced carcinogenesis in PARP-1(-/-) and PARP-1(+/+) mice]
Carcinogenesis
[DNA damage in human peripheral blood lymphocyte caused by nickel and cadmium]
Carcinogenesis
[Features of carcinogenesis and aging in knockout male mice PARP-1]
Carcinogenesis
[Poly(ADP-ribosa)polymerase--the relationships with life span and carcinogenesis]
Carcinoid Tumor
MG-132 Inhibits Carcinoid Growth and Alters the Neuroendocrine Phenotype.
Carcinoid Tumor
The PARP inhibitor ABT-888 potentiates dacarbazine-induced cell death in carcinoids.
Carcinoma
A phase I trial adding poly(ADP-ribose) polymerase inhibitor veliparib to induction carboplatin-paclitaxel in patients with head and neck squamous cell carcinoma: Alliance A091101.
Carcinoma
A Phase I-II Study of the Oral Poly(ADP-ribose) Polymerase Inhibitor Rucaparib in Patients with Germline BRCA1/2-mutated Ovarian Carcinoma or Other Solid Tumors.
Carcinoma
A profile on the FoundationFocus CDxBRCA tests.
Carcinoma
Acquired RAD51C Promoter Methylation Loss Causes PARP Inhibitor Resistance in High-Grade Serous Ovarian Carcinoma.
Carcinoma
Activity of CEP-9722, a poly (ADP-ribose) polymerase inhibitor, in urothelial carcinoma correlates inversely with homologous recombination repair response to DNA damage.
Carcinoma
Anti-Cancer Effect of Quercetin in Xenograft Models with EBV-Associated Human Gastric Carcinoma.
Carcinoma
Antimicrobial cyclic decapeptides with anticancer activity.
Carcinoma
Antitumor activity and safety of the PARP inhibitor rucaparib in patients with high-grade ovarian carcinoma and a germline or somatic BRCA1 or BRCA2 mutation: Integrated analysis of data from Study 10 and ARIEL2.
Carcinoma
Antitumor efficacy of PARP inhibitors in homologous recombination deficient carcinomas.
Carcinoma
Assessment of apoptosis by immunohistochemistry to active caspase-3, active caspase-7, or cleaved PARP in monolayer cells and spheroid and subcutaneous xenografts of human carcinoma.
Carcinoma
Association of Poly (ADP-Ribose) Polymerase 1 Variants with Oral Squamous Cell Carcinoma Susceptibility in a South Indian Population.
Carcinoma
ATARI trial: ATR inhibitor in combination with olaparib in gynecological cancers with ARID1A loss or no loss (ENGOT/GYN1/NCRI).
Carcinoma
Aurora A kinase regulates non-homologous end-joining and poly(ADP-ribose) polymerase function in ovarian carcinoma cells.
Carcinoma
Autophagy suppression enhances DNA damage and cell death upon treatment with PARP inhibitor Niraparib in laryngeal squamous cell carcinoma.
Carcinoma
Bax is essential for Drp1-mediated mitochondrial fission but not for mitochondrial outer membrane permeabilization caused by photodynamic therapy.
Carcinoma
BRCA Methylation Testing Identifies a Subset of Ovarian Carcinomas without Germline Variants That Can Benefit from PARP Inhibitor.
Carcinoma
BRCA Reversion Mutations in Circulating Tumor DNA Predict Primary and Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma.
Carcinoma
BRCA1 intronic Alu elements drive gene rearrangements and PARP inhibitor resistance.
Carcinoma
BRCA1 RING function is essential for tumor suppression but dispensable for therapy resistance.
Carcinoma
Breast cancer signatures for invasiveness and prognosis defined by deep sequencing of microRNA.
Carcinoma
c-Abl Is an Upstream Regulator of Acid Sphingomyelinase in Apoptosis Induced by Inhibition of Integrins ?v?3 and ?v?5.
Carcinoma
c-Abl-independent p73 stabilization during gemcitabine- or 4'-thio-{beta}-D-arabinofuranosylcytosine-induced apoptosis in wild-type and p53-null colorectal cancer cells.
Carcinoma
Candidate Markers of Olaparib Response from Genomic Data Analyses of Human Cancer Cell Lines.
Carcinoma
Cellular and biochemical antileukemic mechanisms of the meroterpenoid Oncocalyxone A.
Carcinoma
Chemopotentiation of temozolomide, irinotecan, and cisplatin activity by CEP-6800, a poly(ADP-ribose) polymerase inhibitor.
Carcinoma
Cisplatin benefit is predicted by immunohistochemical analysis of DNA repair proteins in squamous cell carcinoma but not adenocarcinoma: theranostic modeling by NSCLC constituent histological subclasses.
Carcinoma
Clinical Impact of Somatic Variants in Homologous Recombination Repair-Related Genes in Ovarian High-Grade Serous Carcinoma.
Carcinoma
Combination therapy in advanced urothelial cancer: the role of PARP, HER-2 and mTOR inhibitors.
Carcinoma
Combined EGFR1 and PARP1 Inhibition Enhances the Effect of Radiation in Head and Neck Squamous Cell Carcinoma Models.
Carcinoma
Comparative evaluation of antiproliferative, antiangiogenic and apoptosis inducing potential of black tea polyphenols in the hamster buccal pouch carcinogenesis model.
Carcinoma
Correction to: Low expression of TRAF3IP2-AS1 promotes progression of NONO-TFE3 translocation renal cell carcinoma by stimulating N6-methyladenosine of PARP1 mRNA and downregulating PTEN.
Carcinoma
Cytoplasmic EBP50 and elevated PARP1 are unfavorable prognostic factors in ovarian clear cell carcinoma.
Carcinoma
Deletions of BRCA1/2 and p53 R248W gain-of-function mutation suggest impaired homologous recombination repair in fragile histidine triad-negative sebaceous gland carcinomas.
Carcinoma
Design, synthesis, and anticancer evaluation of long-chain alkoxylated mono-carbonyl analogues of curcumin.
Carcinoma
Development of Olaparib for BRCA-Deficient Recurrent Epithelial Ovarian Cancer.
Carcinoma
Development of poly ADP-ribose polymerase-1 inhibitor with anti-cervical carcinoma activity.
Carcinoma
Differential radiosensitization by the poly(ADP-ribose) transferase inhibitor 3-aminobenzamide in human tumor cells of varying radiosensitivity.
Carcinoma
Discovery and Structure-Activity Relationships of Modified Salicylanilides as Cell Permeable Inhibitors of Poly(ADP-ribose) Glycohydrolase (PARG).
Carcinoma
DNA strand break-sensing molecule poly(ADP-Ribose) polymerase cooperates with p53 in telomere function, chromosome stability, and tumor suppression.
Carcinoma
Dual disruption of DNA repair and telomere maintenance for the treatment of head and neck cancer.
Carcinoma
Effect of a poly(ADP-ribose) polymerase-1 inhibitor against esophageal squamous cell carcinoma cell lines.
Carcinoma
Effect of cisplatin on metastatic castration-resistant prostate cancer with BRCA2 mutation: A case report.
Carcinoma
Effect of PARP Inhibitors as Maintenance Treatment on Restricted Mean Survival Time in Platinum-Sensitive Recurrent Ovarian Cancer: A Systematic Review and Meta-analysis.
Carcinoma
Effect of Poly (ADP-ribose) Polymerase-1 Inhibition on the Proliferation of Murine Colon Carcinoma CT26 Cells.
Carcinoma
Effects of pertussis toxin on signal transductions via P2-purinergic receptors in A-431 human epidermoidal carcinoma cells.
Carcinoma
Efficacy and safety of rucaparib in previously treated, locally advanced or metastatic urothelial carcinoma from a phase 2, open-label trial (ATLAS).
Carcinoma
Epigenetic Treatment of Urothelial Carcinoma Cells Sensitizes to Cisplatin Chemotherapy and PARP Inhibitor Treatment.
Carcinoma
ESMO recommendations on predictive biomarker testing for homologous recombination deficiency and PARP inhibitor benefit in ovarian cancer.
Carcinoma
Evidence for the efficacy of Iniparib, a PARP-1 inhibitor, in BRCA2-associated pancreatic cancer.
Carcinoma
Evidence of a novel antiapoptotic factor: role of inhibitor of differentiation or DNA binding (Id-1) in anticancer drug-induced apoptosis.
Carcinoma
Exosome component 1 cleaves single-stranded DNA and sensitizes human kidney renal clear cell carcinoma cells to poly(ADP-ribose) polymerase inhibitor.
Carcinoma
Expression of BAG-1 and PARP-1 in Precursor Lesions and Invasive Cervical Cancer Associated with Human Papillomavirus (HPV).
Carcinoma
Expression of MRE11 complex (MRE11, RAD50, NBS1) and hRap1 and its relation with telomere regulation, telomerase activity in human gastric carcinomas.
Carcinoma
Expression of telomeric repeat binding factor 1 and 2 and TRF1-interacting nuclear protein 2 in human gastric carcinomas.
Carcinoma
Fast dose fractionation using ultra-short laser accelerated proton pulses can increase cancer cell mortality, which relies on functional PARP1 protein.
Carcinoma
Flavone inhibition of tumor growth via apoptosis in vitro and in vivo.
Carcinoma
Fluorescence-guided resection of tumors in mouse models of oral cancer.
Carcinoma
Genetic polymorphisms in DNA base-excision repair genes ADPRT, XRCC1, and APE1 and the risk of squamous cell carcinoma of the head and neck.
Carcinoma
Genomic profiling in ovarian cancer retreated with platinum based chemotherapy presented homologous recombination deficiency and copy number imbalances of CCNE1 and RB1 genes.
Carcinoma
Heterogeneous nuclear ribonucleoprotein U-like 1 and Poly (ADP-ribose) polymerase 1 are downregulated in renal cell carcinoma and connected with the prognosis.
Carcinoma
Histone methyltransferases EHMT1 and EHMT2 (GLP/G9A) maintain PARP inhibitor resistance in high-grade serous ovarian carcinoma.
Carcinoma
Identification of miRNA modulators to PARP inhibitor response.
Carcinoma
Identification of potent nontoxic poly(ADP-Ribose) polymerase-1 inhibitors: chemopotentiation and pharmacological studies.
Carcinoma
Imidazoquinolinone, imidazopyridine, and isoquinolindione derivatives as novel and potent inhibitors of the poly(ADP-ribose) polymerase (PARP): a comparison with standard PARP inhibitors.
Carcinoma
Immunohistochemistry expression of targeted therapies biomarkers in ovarian clear cell and endometrioid carcinomas (type I) and endometriosis.
Carcinoma
In vivo anti-tumor activity of the PARP inhibitor niraparib in homologous recombination deficient and proficient ovarian carcinoma.
Carcinoma
Increased cytotoxicity of an unusual DNA topoisomerase II inhibitor compound C-1305 toward HeLa cells with downregulated PARP-1 activity results from re-activation of the p53 pathway and modulation of mitotic checkpoints.
Carcinoma
Increased oxidative stress mediates the antitumor effect of PARP inhibition in ovarian cancer.
Carcinoma
Influence of MLH1 on colon cancer sensitivity to poly(ADP-ribose) polymerase inhibitor combined with irinotecan.
Carcinoma
Influence of pertussis toxin on superficial bladder carcinoma in rats.
Carcinoma
Inhibition of arginine ADP-ribosyltransferase 1 reduces the expression of poly(ADP-ribose) polymerase-1 in colon carcinoma.
Carcinoma
Inhibition of poly(ADP-ribose) polymerase prevents irinotecan-induced intestinal damage and enhances irinotecan/temozolomide efficacy against colon carcinoma.
Carcinoma
Inhibition of poly(ADP-ribose) polymerase-1 by olaparib (AZD2281) increases the radiosensitivity of a lung tumor xenograft.
Carcinoma
Intrinsic presence of poly (ADP-ribose) is significantly increased in malignant prostate compared to benign prostate cell lines.
Carcinoma
Lack of MRE11-RAD50-NBS1 (MRN) complex detection occurs frequently in low-grade epithelial ovarian cancer.
Carcinoma
Levels of superoxide dismutases, glutathione, and poly(ADP-ribose) polymerase in radioresistant human KB carcinoma cell line.
Carcinoma
Linifanib (ABT-869), enhances cytotoxicity with poly (ADP-ribose) polymerase inhibitor, veliparib (ABT-888), in head and neck carcinoma cells.
Carcinoma
Loss of PPP2R2A inhibits homologous recombination DNA repair and predicts tumor sensitivity to PARP inhibition.
Carcinoma
Low expression of TRAF3IP2-AS1 promotes progression of NONO-TFE3 translocation renal cell carcinoma by stimulating N6-methyladenosine of PARP1 mRNA and downregulating PTEN.
Carcinoma
Mainstreaming germline BRCA1/2 testing in non-mucinous epithelial ovarian cancer in the North West of England.
Carcinoma
Male rats fed methyl- and folate-deficient diets with or without niacin develop hepatic carcinomas associated with decreased tissue NAD concentrations and altered poly(ADP-ribose) polymerase activity.
Carcinoma
MAPK4 deletion enhances radiation effects and triggers synergistic lethality with simultaneous PARP1 inhibition in cervical cancer.
Carcinoma
MBP-1 mediated apoptosis involves cytochrome c release from mitochondria.
Carcinoma
Methylation of all BRCA1 copies predicts response to the PARP inhibitor rucaparib in ovarian carcinoma.
Carcinoma
Mitochondrial DNA depletion reduces PARP-1 levels and promotes progression of the neoplastic phenotype in prostate carcinoma.
Carcinoma
Mitochondrial DNA depletion sensitizes cancer cells to PARP inhibitors by translational and post-translational repression of BRCA2.
Carcinoma
Molecular and clinical determinants of response and resistance to rucaparib for recurrent ovarian cancer treatment in ARIEL2 (Parts 1 and 2).
Carcinoma
Multifaceted Impact of MicroRNA 493-5p on Genome-Stabilizing Pathways Induces Platinum and PARP Inhibitor Resistance in BRCA2-Mutated Carcinomas.
Carcinoma
New insights on the pathogenesis of ovarian carcinoma: molecular basis and clinical implications.
Carcinoma
Novel BRCA1 and BRCA2 Tumor Test as Basis for Treatment Decisions and Referral for Genetic Counselling of Patients with Ovarian Carcinomas.
Carcinoma
Optical Imaging of PARP1 in Response to Radiation in Oral Squamous Cell Carcinoma.
Carcinoma
Ovarian Serous Carcinoma With a Novel HSP90AB1 Mutation in a Patient With Synchronous Primary Fallopian Tube Serous Carcinoma.
Carcinoma
Overexpression of BCL2 blocks TNF-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in human lung cancer cells.
Carcinoma
Overexpression of chromatin assembly factor-1 p60, poly(ADP-ribose) polymerase 1 and nestin predicts metastasizing behaviour of oral cancer.
Carcinoma
p63 involvement in poly(ADP-ribose) polymerase 1 signaling of topoisomerase I-dependent DNA damage in carcinoma cells.
Carcinoma
Pan-Cancer Analysis of PARP1 Alterations as Biomarkers in the Prediction of Immunotherapeutic Effects and the Association of Its Expression Levels and Immunotherapy Signatures.
Carcinoma
Pancreatic acinar cell carcinoma is associated with BRCA2 germline mutations: a case report and literature review.
Carcinoma
PARG regulates the proliferation and differentiation of DCs and T cells via PARP/NF??B in tumour metastases of colon carcinoma.
Carcinoma
PARP and CHK inhibitors interact to cause DNA damage and cell death in mammary carcinoma cells.
Carcinoma
PARP inhibition enhances radiotherapy of SMAD4 deficient human head and neck squamous cell carcinomas in experimental models.
Carcinoma
PARP inhibitor olaparib sensitizes esophageal carcinoma cells to fractionated proton irradiation.
Carcinoma
PARP inhibitors and radiation potentiate liver cell death in vitro. Do hepatocellular carcinomas have an achilles' heel?
Carcinoma
PARP Inhibitors for Recurrent Ovarian Carcinoma: Current Treatment Options and Future Perspectives.
Carcinoma
PARP inhibitors: A new era of targeted therapy.
Carcinoma
PARP-1 cooperates with Ptc1 to suppress medulloblastoma and basal cell carcinoma.
Carcinoma
Parp-1 deficiency does not increase the frequency of tumors in the oral cavity and esophagus of ICR/129Sv mice by 4-nitroquinoline 1-oxide, a carcinogen producing bulky adducts.
Carcinoma
PARP-1 expression in breast cancer including BRCA1-associated, triple negative and basal-like tumors: possible implications for PARP-1 inhibitor therapy.
Carcinoma
PARP-1 expression is increased in colon adenoma and carcinoma and correlates with OGG1.
Carcinoma
PARP-1 induces EMT in non-small cell lung carcinoma cells via modulating the transcription factors Smad4, p65 and ZEB1.
Carcinoma
PARP-1 Val762Ala polymorphism is associated with reduced risk of non-Hodgkin lymphoma in Korean males.
Carcinoma
PARP-1 Val762Ala polymorphism is associated with risk of cervical carcinoma.
Carcinoma
PARP1 and CASP3 gene expression in a patient with multiple head and neck squamous cell carcinoma and Parkinson disease.
Carcinoma
PARP1 Gene Polymorphisms and the Prognosis of Esophageal Cancer Patients from Cixian High-Incidence Region in Northern China.
Carcinoma
PARP1 in Carcinomas and PARP1 Inhibitors as Antineoplastic Drugs.
Carcinoma
PARP1 rs1136410 C/C genotype associated with an increased risk of esophageal cancer in smokers.
Carcinoma
Pharmacological Inhibition of Poly(ADP-ribose) Polymerase (PARP) Activity in PARP-1 Silenced Tumour Cells Increases Chemosensitivity to Temozolomide and to a N3-Adenine Selective Methylating Agent.
Carcinoma
Pharmacological inhibition of poly(ADP-ribose) polymerase (PARP) activity in PARP-1 silenced tumour cells increases chemosensitivity to temozolomide and to a N3-adenine selective methylating agent.
Carcinoma
PK11195, an isoquinoline carboxamide ligand of the mitochondrial benzodiazepine receptor, increased drug uptake and facilitated drug-induced apoptosis in human multidrug-resistant leukemia cells in vitro.
Carcinoma
Platinum and PARP Inhibitor Resistance Due to Overexpression of MicroRNA-622 in BRCA1-Mutant Ovarian Cancer.
Carcinoma
Poly (ADP-Ribose) Polymerase Inhibitor, ABT888, Improved Cisplatin Effect in Human Oral Cell Carcinoma.
Carcinoma
Poly (ADP-ribose) polymerase-1 inhibition decreases proliferation through G2/M arrest in esophageal squamous cell carcinoma.
Carcinoma
Poly ADP-ribose polymerase-1 as a potential therapeutic target in Merkel cell carcinoma.
Carcinoma
Poly(adenosine diphosphate-ribose) polymerase expression in BRCA-proficient ovarian high-grade serous carcinoma; association with patient survival.
Carcinoma
Poly(adenosine diphosphate-ribose) polymerase expression in serous ovarian carcinoma: correlation with p53, MIB-1, and outcome.
Carcinoma
Poly(ADP-ribose) polymerase (PARP) and DNA-fragmentation factor (DFF45): expression and correlation in normal, hyperplastic and neoplastic endometrial tissues.
Carcinoma
Poly(ADP-ribose) polymerase (PARP) inhibitors as treatment versus maintenance in ovarian carcinoma.
Carcinoma
Poly(ADP-ribose) polymerase 1 modulates the lethality of CHK1 inhibitors in carcinoma cells.
Carcinoma
Poly(ADP-ribose) polymerase 1 modulates the lethality of CHK1 inhibitors in mammary tumors.
Carcinoma
Poly(ADP-ribose) polymerase activity in proliferating and quiescent murine mammary carcinoma cells.
Carcinoma
Poly(ADP-ribose) polymerase inhibition down-regulates expression of metastasis-related genes in CT26 colon carcinoma cells.
Carcinoma
Poly(ADP-ribose) polymerase signaling of topoisomerase 1-dependent DNA damage in carcinoma cells.
Carcinoma
Poly(ADP-ribose) polymerase turnover alterations do not contribute to PARP overexpression in Ewing's sarcoma cells.
Carcinoma
Poly(ADP-ribose) polymerase, a major determinant of early cell response to ionizing radiation.
Carcinoma
Poly(ADP-ribose) polymerase-1 plays a role in suppressing mammary tumourigenesis in mice.
Carcinoma
Poly(ADP-ribose) polymerase-1, a novel partner of progesterone receptors in endometrial cancer and its precursors.
Carcinoma
Poly-ADP-ribosyl-polymerase inhibitor resistance mechanisms and their therapeutic implications.
Carcinoma
Preclinical evaluation of the PARP inhibitor BMN-673 for the treatment of ovarian clear cell cancer.
Carcinoma
Prevalence of germline pathogenic BRCA1/2 variants in sequential epithelial ovarian cancer cases.
Carcinoma
Prevalence of hereditary breast and ovarian cancer (HBOC) predisposition gene mutations among 882 HBOC high-risk Chinese individuals.
Carcinoma
Prevention of oxidant-induced cell death in Caco-2 colon carcinoma cells after inhibition of poly(ADP-ribose) polymerase and Ca2+ chelation: involvement of a common mechanism.
Carcinoma
Prolonged response to treatment based on cell-free DNA analysis and molecular profiling in three patients with metastatic cancer: a case series.
Carcinoma
Promising anti- cervical carcinoma and inflammatory agent, Resveratrol targets poly (ADP-ribose) polymerase 1 (PARP-1) induced premature ovarian failure with a potent enzymatic modulatory activity.
Carcinoma
Radiation-inducible Immunotherapy for Cancer: Senescent Tumor Cells as a Cancer Vaccine.
Carcinoma
Radiosensitization by the PARP inhibitor olaparib in BRCA1-proficient and deficient high-grade serous ovarian carcinomas.
Carcinoma
Radiosensitization of head and neck squamous cell carcinoma lines by DNA-PK inhibitors is more effective than PARP-1 inhibition and is enhanced by SLFN11 and hypoxia.
Carcinoma
Radiosensitizing Potential of Curcumin in Different Cancer Models.
Carcinoma
Ras(V12) induces Survivin/AuroraB pathway conferring tumor cell apoptosis resistance.
Carcinoma
Reversion of malignant phenotype by 5-iodo-6-amino-1,2-benzopyrone a non-covalently binding ligand of poly(ADP-ribose) polymerase.
Carcinoma
RIG-I enhanced interferon independent apoptosis upon Junin virus infection.
Carcinoma
Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial.
Carcinoma
Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial.
Carcinoma
Sam68 reduces cisplatin-induced apoptosis in tongue carcinoma.
Carcinoma
Secondary Somatic Mutations Restoring RAD51C and RAD51D Associated with Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma.
Carcinoma
Silencing of CHFR Sensitizes Gastric Carcinoma to PARP Inhibitor Treatment.
Carcinoma
Silibinin causes cell cycle arrest and apoptosis in human bladder transitional cell carcinoma cells by regulating CDKI-CDK-cyclin cascade, and caspase 3 and PARP cleavages.
Carcinoma
Sodium salicylate induces apoptosis in HCT116 colorectal cancer cells through activation of p38MAPK.
Carcinoma
Spatiotemporal activation of caspase-dependent and -independent pathways in staurosporine-induced apoptosis of p53wt and p53mt human cervical carcinoma cells.
Carcinoma
Synergetic Effects of PARP Inhibitor AZD2281 and Cisplatin in Oral Squamous Cell Carcinoma in Vitro and in Vivo.
Carcinoma
Synergistic Anti-Tumour Effect of Syk Inhibitor and Olaparib in Squamous Cell Carcinoma: Roles of Syk in EGFR Signalling and PARP1 Activation.
Carcinoma
Synergistic effect of arginine-specific ADP-ribosyltransferase 1 and poly(ADP-ribose) polymerase-1 on apoptosis induced by cisplatin in CT26 cells.
Carcinoma
Systemic treatment for hereditary cancers: a 2012 update.
Carcinoma
Tankyrase-1 mRNA expression in bladder cancer and paired urine sediment: preliminary experience.
Carcinoma
Tanshinone IIA Facilitates TRAIL Sensitization by Up-regulating DR5 through the ROS-JNK-CHOP Signaling Axis in Human Ovarian Carcinoma Cell Lines.
Carcinoma
Targeted blockade of HSP90 impairs DNA-damage response proteins and increases the sensitivity of ovarian carcinoma cells to PARP inhibition.
Carcinoma
The antipsychotic agent flupentixol is a new PI3K inhibitor and potential anticancer drug for lung cancer.
Carcinoma
The CHK1 inhibitor SRA737 synergizes with PARP1 inhibitors to kill carcinoma cells.
Carcinoma
The DEAD/DEAH Box Helicase, DDX11, Is Essential for the Survival of Advanced Clear Cell Renal Cell Carcinoma and Is a Determinant of PARP Inhibitor Sensitivity.
Carcinoma
The Emerging Role of Poly (ADP-Ribose) Polymerase Inhibitors as Effective Therapeutic Agents in Renal Cell Carcinoma.
Carcinoma
The JNK, ERK and p53 pathways play distinct roles in apoptosis mediated by the antitumor agents vinblastine, doxorubicin, and etoposide.
Carcinoma
The La antigen is over-expressed in lung cancer and is a selective dead cancer cell target for radioimmunotherapy using the La-specific antibody APOMAB®.
Carcinoma
The Prognostic Value of BRCA1 and PARP Expression in Epithelial Ovarian Carcinoma: Immunohistochemical Detection.
Carcinoma
The RECAP Test Rapidly and Reliably Identifies Homologous Recombination-Deficient Ovarian Carcinomas.
Carcinoma
The Role of PARP Inhibitors in the Treatment of Ovarian Carcinomas.
Carcinoma
The TLR7/8/9 antagonist IMO-8503 inhibits cancer-induced cachexia.
Carcinoma
Triptolide induces s phase arrest and apoptosis in gallbladder cancer cells.
Carcinoma
Tumor growth inhibition by olaparib in BRCA2 germline-mutated patient-derived ovarian cancer tissue xenografts.
Carcinoma
Validation of the use of a fluorescent PARP1 inhibitor for the detection of oral, oropharyngeal and oesophageal epithelial cancers.
Carcinoma
Valproate augments Niraparib killing of tumor cells.
Carcinoma
Xanthorrhizol Induces Apoptosis Through ROS-Mediated MAPK Activation in Human Oral Squamous Cell Carcinoma Cells and Inhibits DMBA-Induced Oral Carcinogenesis in Hamsters.
Carcinoma
[BRCA1 and BRCA2 - pathologists starting kit].
Carcinoma
[Hereditary breast and ovarian cancers].
Carcinoma
[Il ruolo di niraparib nel trattamento del carcinoma ovarico: attualità e prospettive.]
Carcinoma
[Inhibitory effect of 5-aminoisoquinolinone on PARP activity in colon carcinoma cell line HT-29]
Carcinoma
[Oncopathological aspects of BRCA1 and BRCA2 genes inactivation in tumors of ovary, fallopian tube and pelvic peritoneum].
Carcinoma
[The effect of tanshinone ?A potentiates the effects of Cisplatin in Fadu cells in vitro through downregulation of survivin].
Carcinoma, Acinar Cell
Pancreatic acinar cell carcinoma is associated with BRCA2 germline mutations: a case report and literature review.
Carcinoma, Adenoid Cystic
Prolonged response to treatment based on cell-free DNA analysis and molecular profiling in three patients with metastatic cancer: a case series.
Carcinoma, Basal Cell
PARP-1 cooperates with Ptc1 to suppress medulloblastoma and basal cell carcinoma.
Carcinoma, Ductal
BRCA1 and PARP1 mRNA expression during progression from normal breast to ductal carcinoma in situ and invasive breast cancer: a laser microdissection study.
Carcinoma, Ductal
Nuclear PARP-1 protein overexpression is associated with poor overall survival in early breast cancer.
Carcinoma, Ductal
Targeting PARP1 in XRCC1 deficient sporadic invasive breast cancer or pre-invasive ductal carcinoma in situ induces synthetic lethality and chemoprevention.
Carcinoma, Ductal
Upregulation of Poly (ADP-Ribose) Polymerase-1 (PARP1) in Triple-Negative Breast Cancer and Other Primary Human Tumor Types.
Carcinoma, Ehrlich Tumor
NAD[S], an NAD analogue with reduced susceptibility to phosphodiesterase. Chemical synthesis and enzymic properties.
Carcinoma, Ehrlich Tumor
Poly(ADP-ribose) polymerase from Ehrlich ascites tumor cells. Properties of the purified polymerase.
Carcinoma, Ehrlich Tumor
Purification of poly(ADP-ribose) polymerase from Ehrlich ascites tumor cells by chromatography on DNA-agarose.
Carcinoma, Embryonal
PARP expression in germ cell tumours.
Carcinoma, Embryonal
Reduced proficiency in homologous recombination underlies the high sensitivity of embryonal carcinoma testicular germ cell tumors to Cisplatin and poly (adp-ribose) polymerase inhibition.
Carcinoma, Endometrioid
Immunohistochemistry expression of targeted therapies biomarkers in ovarian clear cell and endometrioid carcinomas (type I) and endometriosis.
Carcinoma, Endometrioid
Poly(ADP-ribose) polymerase (PARP) and DNA-fragmentation factor (DFF45): expression and correlation in normal, hyperplastic and neoplastic endometrial tissues.
Carcinoma, Hepatocellular
2,3,7,8-Tetrachlorodibenzo-p-dioxin poly(ADP-ribose) polymerase (TiPARP, ARTD14) is a mono-ADP-ribosyltransferase and repressor of aryl hydrocarbon receptor transactivation.
Carcinoma, Hepatocellular
6,(5H)-phenanthridinone protects against carbon tetrachloride-induced cytotoxicity in human HepG2 cells.
Carcinoma, Hepatocellular
Arsenite-loaded nanoparticles inhibit PARP-1 to overcome multidrug resistance in hepatocellular carcinoma cells.
Carcinoma, Hepatocellular
Autophagy suppresses radiation damage by activating PARP-1 and attenuating reactive oxygen species in hepatoma cells.
Carcinoma, Hepatocellular
Chemopreventive action of Lygodium flexuosum extract in human hepatoma PLC/PRF/5 and Hep 3B cells.
Carcinoma, Hepatocellular
Cloning and expression of cDNA for human poly(ADP-ribose) polymerase.
Carcinoma, Hepatocellular
Combining Chemical Genetics with Proximity-Dependent Labeling Reveals Cellular Targets of Poly(ADP-ribose) Polymerase 14 (PARP14).
Carcinoma, Hepatocellular
Conjugated linoleic acid isomers and trans fatty acids inhibit fatty acid transport in hepatoma 7288CTC and inguinal fat pads in Buffalo rats.
Carcinoma, Hepatocellular
Dual roles of ULK1 (unc-51 like autophagy activating kinase 1) in cytoprotection against lipotoxicity.
Carcinoma, Hepatocellular
EGFR and c-MET Cooperate to Enhance Resistance to PARP Inhibitors in Hepatocellular Carcinoma.
Carcinoma, Hepatocellular
Enhancement of cell permeabilization apoptosis-inducing activity of selenium nanoparticles by ATP surface decoration.
Carcinoma, Hepatocellular
EP1 Prostanoid Receptor Coupling to Gi/o Upregulates the Expression of Hypoxia-Inducible Factor-1{alpha} Through Activation of a Phosphoinositide-3 Kinase Signaling Pathway.
Carcinoma, Hepatocellular
Expression of poly(ADP-ribose) polymerase in human hepatocellular carcinoma and analysis of biopsy specimens obtained under sonographic guidance.
Carcinoma, Hepatocellular
Global proteomic profiling in multistep hepatocarcinogenesis and identification of PARP1 as a novel molecular marker in hepatocellular carcinoma.
Carcinoma, Hepatocellular
Hepatoma cell-intrinsic TLR9 activation induces immune escape through PD-L1 upregulation in hepatocellular carcinoma.
Carcinoma, Hepatocellular
Human alcohol dehydrogenase 1 is an acceptor protein for polyADP-ribosylation.
Carcinoma, Hepatocellular
Identification of poly(ADP-ribose) polymerase-1 as a cell cycle regulator through modulating Sp1 mediated transcription in human hepatoma cells.
Carcinoma, Hepatocellular
Induction of apoptosis in normal cultured rat hepatocytes and in Hep3B, a human hepatoma cell line.
Carcinoma, Hepatocellular
Inhibited effects of veliparib combined doxorubicin for BEL-7404 proliferation of human liver cancer cell line.
Carcinoma, Hepatocellular
Inhibition of Poly(ADP-Ribose) Polymerase Increased Lipid Accumulation Through SREBP1 Modulation.
Carcinoma, Hepatocellular
Inhibitors of PARP-1 exert inhibitory effects on the biological characteristics of hepatocellular carcinoma cells in vitro.
Carcinoma, Hepatocellular
Interaction of hepatitis B virus X protein with PARP1 results in inhibition of DNA repair in hepatocellular carcinoma.
Carcinoma, Hepatocellular
Isolation of 4,4'-bond secalonic acid D from the marine-derived fungus Penicillium oxalicum with inhibitory property against hepatocellular carcinoma.
Carcinoma, Hepatocellular
Macrophage mediated anti-proliferation effects of Anthodia camphorata non-polysaccharide based extracts on human hepatoma cells.
Carcinoma, Hepatocellular
Mechanism for the antitumor and anticachectic effects of n-3 fatty acids.
Carcinoma, Hepatocellular
Metabonomics applied in exploring the antitumour mechanism of physapubenolide on hepatocellular carcinoma cells by targeting glycolysis through the Akt-p53 pathway.
Carcinoma, Hepatocellular
Metformin and epothilone A treatment up regulate pro-apoptotic PARP-1, Casp-3 and H2AX genes and decrease of AKT kinase level to control cell death of human hepatocellular carcinoma and ovary adenocarcinoma cells.
Carcinoma, Hepatocellular
MicroRNA-31-5p regulates chemosensitivity by preventing the nuclear location of PARP1 in hepatocellular carcinoma.
Carcinoma, Hepatocellular
MK5 is degraded in response to doxorubicin and negatively regulates doxorubicin-induced apoptosis in hepatocellular carcinoma cells.
Carcinoma, Hepatocellular
Momordin Ic induces HepG2 cell apoptosis through MAPK and PI3K/Akt-mediated mitochondrial pathways.
Carcinoma, Hepatocellular
New guaiane-type sesquiterpenoid dimers from Artemisia atrovirens and their antihepatoma activity.
Carcinoma, Hepatocellular
NF90 regulates PARP1 mRNA stability in hepatocellular carcinoma.
Carcinoma, Hepatocellular
No associations of polymorphisms in ADPRT with hepatitis B virus clearance and hepatocellular carcinoma occurrence in a Korean population.
Carcinoma, Hepatocellular
Pan-Cancer Analysis of PARP1 Alterations as Biomarkers in the Prediction of Immunotherapeutic Effects and the Association of Its Expression Levels and Immunotherapy Signatures.
Carcinoma, Hepatocellular
PARP inhibition and the radiosensitizing effects of the PARP inhibitor ABT-888 in in vitro hepatocellular carcinoma models.
Carcinoma, Hepatocellular
PARP inhibitor Olaparib overcomes Sorafenib resistance through reshaping the pluripotent transcriptome in hepatocellular carcinoma.
Carcinoma, Hepatocellular
PARP inhibitors and radiation potentiate liver cell death in vitro. Do hepatocellular carcinomas have an achilles' heel?
Carcinoma, Hepatocellular
PARP-1 inhibitor sensitizes arsenic trioxide in hepatocellular carcinoma cells via abrogation of G2/M checkpoint and suppression of DNA damage repair.
Carcinoma, Hepatocellular
PARP-1 promotes tumor recurrence after warm ischemic liver graft transplantation via neutrophil recruitment and polarization.
Carcinoma, Hepatocellular
PARP-1 serves as a novel molecular marker for hepatocellular carcinoma in a Southern Chinese Zhuang population.
Carcinoma, Hepatocellular
PARP10 suppresses tumor metastasis through regulation of Aurora A activity.
Carcinoma, Hepatocellular
PARP14 promotes the Warburg effect in hepatocellular carcinoma by inhibiting JNK1-dependent PKM2 phosphorylation and activation.
Carcinoma, Hepatocellular
Pertussis Toxin, an Inhibitor of G(?i) PCR, Inhibits Bile Acid- and Cytokine-Induced Apoptosis in Primary Rat Hepatocytes.
Carcinoma, Hepatocellular
Pinus kesiya Royle ex Gordon induces apoptotic cell death in hepatocellular carcinoma HepG2 cell via intrinsic pathway by PARP and Topoisomerase I suppression.
Carcinoma, Hepatocellular
PJ34, an inhibitor of PARP-1, suppresses cell growth and enhances the suppressive effects of cisplatin in liver cancer cells.
Carcinoma, Hepatocellular
PLK1/NF-?B feedforward circuit antagonizes the mono-ADP-ribosyltransferase activity of PARP10 and facilitates HCC progression.
Carcinoma, Hepatocellular
Poly (ADP-ribose) polymerase inhibition synergizes with the NF-?B inhibitor DHMEQ to kill hepatocellular carcinoma cells.
Carcinoma, Hepatocellular
Poly(ADP-ribose) synthase is the major endogenous nonhistone acceptor for poly(ADP-ribose) in alkylated rat hepatoma cells.
Carcinoma, Hepatocellular
Potentiation of the antitumor effects of both selective cyclooxygenase-1 and cyclooxygenase-2 inhibitors in human hepatic cancer cells by inhibition of the MEK/ERK pathway.
Carcinoma, Hepatocellular
Protective effect of the poly(ADP-ribose) polymerase inhibitor PJ34 on mitochondrial depolarization-mediated cell death in hepatocellular carcinoma cells involves attenuation of c-Jun N-terminal kinase-2 and protein kinase B/Akt activation.
Carcinoma, Hepatocellular
Radiosensitizing Potential of Curcumin in Different Cancer Models.
Carcinoma, Hepatocellular
Rational combination therapy for hepatocellular carcinoma with PARP1 and DNA-PK inhibitors.
Carcinoma, Hepatocellular
Retraction Note: MicroRNA-31-5p regulates chemosensitivity by preventing the nuclear location of PARP1 in hepatocellular carcinoma.
Carcinoma, Hepatocellular
SQSTM1/p62 activates NFE2L2/NRF2 via ULK1-mediated autophagic KEAP1 degradation and protects mouse liver from lipotoxicity.
Carcinoma, Hepatocellular
Targeting PARP and autophagy evoked synergistic lethality in hepatocellular carcinoma.
Carcinoma, Hepatocellular
The assessment of an in-vitro model for evaluating the role of PARP in ethanol-mediated hepatotoxicity.
Carcinoma, Hepatocellular
The long noncoding RNA lncPARP1 contributes to progression of hepatocellular carcinoma through up-regulation of PARP1.
Carcinoma, Hepatocellular
Toxic bile salts induce rodent hepatocyte apoptosis via direct activation of Fas.
Carcinoma, Hepatocellular
Update on hepatocellular carcinoma breakthroughs: Poly(ADP-ribose) polymerase inhibitors as a promising therapeutic strategy.
Carcinoma, Hepatocellular
[Role of proteins in Fas-mediated apoptosis in tumor cells and lymphocytes co-cultured in vitro]
Carcinoma, Intraductal, Noninfiltrating
BRCA1 and PARP1 mRNA expression during progression from normal breast to ductal carcinoma in situ and invasive breast cancer: a laser microdissection study.
Carcinoma, Intraductal, Noninfiltrating
Nuclear PARP-1 protein overexpression is associated with poor overall survival in early breast cancer.
Carcinoma, Intraductal, Noninfiltrating
Targeting PARP1 in XRCC1 deficient sporadic invasive breast cancer or pre-invasive ductal carcinoma in situ induces synthetic lethality and chemoprevention.
Carcinoma, Lewis Lung
The TLR7/8/9 antagonist IMO-8503 inhibits cancer-induced cachexia.
Carcinoma, Merkel Cell
Poly ADP-ribose polymerase-1 as a potential therapeutic target in Merkel cell carcinoma.
Carcinoma, Neuroendocrine
Evaluation of PARP and PDL-1 as potential therapeutic targets for women with high-grade neuroendocrine carcinomas of the cervix.
Carcinoma, Neuroendocrine
Treatment of neuroendocrine carcinoma of the cervix with a PARP inhibitor based on next generation sequencing.
Carcinoma, Non-Small-Cell Lung
?-Hydroxyundec-9-enoic acid induces apoptosis through ROS-mediated endoplasmic reticulum stress in non-small cell lung cancer cells.
Carcinoma, Non-Small-Cell Lung
A Small Compound KJ-28d Enhances the Sensitivity of Non-Small Cell Lung Cancer to Radio- and Chemotherapy.
Carcinoma, Non-Small-Cell Lung
An analysis of the gene interaction networks identifying the role of PARP1 in metastasis of non-small cell lung cancer.
Carcinoma, Non-Small-Cell Lung
APR-246 (PRIMA-1(MET)) strongly synergizes with AZD2281 (olaparib) induced PARP inhibition to induce apoptosis in non-small cell lung cancer cell lines.
Carcinoma, Non-Small-Cell Lung
Association of T2285C polymorphism in PARP1 gene coding region with its expression, activity and NSCLC risk along with prognosis.
Carcinoma, Non-Small-Cell Lung
Chemopotentiation of temozolomide, irinotecan, and cisplatin activity by CEP-6800, a poly(ADP-ribose) polymerase inhibitor.
Carcinoma, Non-Small-Cell Lung
Expression of ERCC1, MSH2 and PARP1 in non-small cell lung cancer and prognostic value in patients treated with platinum-based chemotherapy.
Carcinoma, Non-Small-Cell Lung
Fluzoparib increases radiation sensitivity of non-small cell lung cancer (NSCLC) cells without BRCA1/2 mutation, a novel PARP1 inhibitor undergoing clinical trials.
Carcinoma, Non-Small-Cell Lung
Functional Polymorphisms of Base Excision Repair Genes XRCC1 and APEX1 Predict Risk of Radiation Pneumonitis in Patients with Non-Small Cell Lung Cancer Treated with Definitive Radiation Therapy.
Carcinoma, Non-Small-Cell Lung
Hypoxia Potentiates the Radiation-Sensitizing Effect of Olaparib in Human Non-Small Cell Lung Cancer Xenografts by Contextual Synthetic Lethality.
Carcinoma, Non-Small-Cell Lung
Identification of amentoflavone as a potent highly selective PARP-1 inhibitor and its potentiation on carboplatin in human non-small cell lung cancer.
Carcinoma, Non-Small-Cell Lung
Identification of compound CA-5f as a novel late-stage autophagy inhibitor with potent anti-tumor effect against non-small cell lung cancer.
Carcinoma, Non-Small-Cell Lung
Inhibition of ELF3 confers synthetic lethality of PARP inhibitor in non-small cell lung cancer.
Carcinoma, Non-Small-Cell Lung
Inhibition of poly(ADP-ribose) polymerase-1 by olaparib (AZD2281) increases the radiosensitivity of a lung tumor xenograft.
Carcinoma, Non-Small-Cell Lung
JASPER: Phase 2 trial of first-line niraparib plus pembrolizumab in patients with advanced non-small cell lung cancer.
Carcinoma, Non-Small-Cell Lung
Negative prognostic value of high levels of intracellular poly(ADP-ribose) in non-small cell lung cancer.
Carcinoma, Non-Small-Cell Lung
New Approaches of PARP-1 Inhibitors in Human Lung Cancer Cells and Cancer Stem-Like Cells by Some Selected Anthraquinone-Derived Small Molecules.
Carcinoma, Non-Small-Cell Lung
Non-small cell lung cancer cells with deficiencies in homologous recombination genes are sensitive to PARP inhibitors.
Carcinoma, Non-Small-Cell Lung
Overexpression of BCL2 blocks TNF-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in human lung cancer cells.
Carcinoma, Non-Small-Cell Lung
PARP inhibition enhances tumor cell-intrinsic immunity in ERCC1-deficient non-small cell lung cancer.
Carcinoma, Non-Small-Cell Lung
PARP inhibition induces BAX/BAK-independent synthetic lethality of BRCA1-deficient non-small cell lung cancer.
Carcinoma, Non-Small-Cell Lung
PARP inhibition selectively increases sensitivity to cisplatin in ERCC1-low non-small cell lung cancer cells.
Carcinoma, Non-Small-Cell Lung
PARP inhibitor activates the intrinsic pathway of apoptosis in primary lung cancer cells.
Carcinoma, Non-Small-Cell Lung
PARP inhibitor niraparib as a radiosensitizer promotes antitumor immunity of radiotherapy in EGFR-mutated non-small cell lung cancer.
Carcinoma, Non-Small-Cell Lung
PARP-1 induces EMT in non-small cell lung carcinoma cells via modulating the transcription factors Smad4, p65 and ZEB1.
Carcinoma, Non-Small-Cell Lung
PARP1 Is Up-Regulated in Non-small Cell Lung Cancer Tissues in the Presence of the Cyanobacterial Toxin Microcystin.
Carcinoma, Non-Small-Cell Lung
Pelargonium quercetorum Agnew induces apoptosis without PARP or cytokeratin 18 cleavage in non-small cell lung cancer cell lines.
Carcinoma, Non-Small-Cell Lung
Phase I and Pharmacologic Study of Olaparib in Combination with High-dose Radiotherapy with and without Concurrent Cisplatin for Non-Small Cell Lung Cancer.
Carcinoma, Non-Small-Cell Lung
Poly (ADP-ribose) polymerase 3 (PARP3), a potential repressor of telomerase activity.
Carcinoma, Non-Small-Cell Lung
Poly(ADP-ribose) Polymerase Inhibitors Sensitize Cancer Cells to Death Receptor-mediated Apoptosis by Enhancing Death Receptor Expression.
Carcinoma, Non-Small-Cell Lung
Radiosensitizing Potential of Curcumin in Different Cancer Models.
Carcinoma, Non-Small-Cell Lung
Radiosynthesis of 3 H- and 14 C-labeled Veliparib.
Carcinoma, Non-Small-Cell Lung
Rapamycin sensitizes cancer cells to growth inhibition by the PARP inhibitor olaparib.
Carcinoma, Non-Small-Cell Lung
Reduction of metastatic potential by inhibiting EGFR/Akt/p38/ERK signaling pathway and epithelial-mesenchymal transition after carbon ion exposure is potentiated by PARP-1 inhibition in non-small-cell lung cancer.
Carcinoma, Non-Small-Cell Lung
Replication-dependent ?-H2AX formation is involved in docetaxel-induced apoptosis in NSCLC A549 cells.
Carcinoma, Non-Small-Cell Lung
Smoking History Predicts Sensitivity to PARP Inhibitor Veliparib in Patients with Advanced Non-Small Cell Lung Cancer: Methodological Issues.
Carcinoma, Non-Small-Cell Lung
Smoking History Predicts Sensitivity to PARP Inhibitor Veliparib in Patients with Advanced Non-Small Cell Lung Cancer.
Carcinoma, Non-Small-Cell Lung
Synergistic effect of fenretinide and curcumin for treatment of non-small cell lung cancer.
Carcinoma, Non-Small-Cell Lung
Synergistic effects of type I PRMT and PARP inhibitors against non-small cell lung cancer cells.
Carcinoma, Non-Small-Cell Lung
Synergistic interaction between cisplatin and PARP inhibitors in non-small cell lung cancer.
Carcinoma, Non-Small-Cell Lung
Synergy between the NAMPT inhibitor GMX1777(8) and pemetrexed in non-small cell lung cancer cells is mediated by PARP activation and enhanced NAD consumption.
Carcinoma, Non-Small-Cell Lung
Tankyrase 1 polymorphism associated with an increased risk in developing non-small cell lung cancer in a Chinese population: a proof-of-principle study.
Carcinoma, Non-Small-Cell Lung
Tankyrase 2 (TNKS2) polymorphism associated with risk in developing non-small cell lung cancer in a Chinese population.
Carcinoma, Non-Small-Cell Lung
Triptolide suppresses the in vitro and in vivo growth of lung cancer cells by targeting hyaluronan-CD44/RHAMM signaling.
Carcinoma, Non-Small-Cell Lung
WITHDRAWN: An analysis of the gene interaction networks identifying the role of PARP1 in metastasis of non-small cell lung cancer.
Carcinoma, Ovarian Epithelial
A functional polymorphism in the poly(ADP-ribose) polymerase-1 gene is associated with platinum-based chemotherapeutic response and prognosis in epithelial ovarian cancer patients.
Carcinoma, Ovarian Epithelial
A phase I study of the PARP inhibitor niraparib in combination with bevacizumab in platinum-sensitive epithelial ovarian cancer: NSGO AVANOVA1/ENGOT-OV24.
Carcinoma, Ovarian Epithelial
A profile on the FoundationFocus CDxBRCA tests.
Carcinoma, Ovarian Epithelial
A Unique Subset of Epithelial Ovarian Cancers with Platinum Sensitivity and PARP Inhibitor Resistance.
Carcinoma, Ovarian Epithelial
Adenovirus-mediated thymidine kinase gene therapy induces apoptosis in human epithelial ovarian cancer cells and damages PARP-1.
Carcinoma, Ovarian Epithelial
Advances in the Treatment of Ovarian Cancer Using PARP Inhibitors and the Underlying Mechanism of Resistance.
Carcinoma, Ovarian Epithelial
ALDH1A1 contributes to PARP inhibitor resistance via enhancing DNA repair in BRCA2-/- ovarian cancer cells.
Carcinoma, Ovarian Epithelial
Assessment of PARP protein expression in epithelial ovarian cancer by ELISA pharmacodynamic assay and immunohistochemistry.
Carcinoma, Ovarian Epithelial
Association of expression of p53, livin, ERCC1, BRCA1 and PARP1 in epithelial ovarian cancer tissue with drug resistance and prognosis.
Carcinoma, Ovarian Epithelial
BET Bromodomain Inhibition Synergizes with PARP Inhibitor in Epithelial Ovarian Cancer.
Carcinoma, Ovarian Epithelial
BET, SRC, and BCL2 family inhibitors are synergistic drug combinations with PARP inhibitors in ovarian cancer.
Carcinoma, Ovarian Epithelial
BMS-536924 sensitizes human epithelial ovarian cancer cells to the PARP inhibitor, 3-aminobenzamide.
Carcinoma, Ovarian Epithelial
BRCA1 Expression by Immunohistochemistry and Prognosis in Ovarian Cancer: A Systematic Review and Meta-Analysis.
Carcinoma, Ovarian Epithelial
Circulating HOXA9-methylated tumour DNA: A novel biomarker of response to poly (ADP-ribose) polymerase inhibition in BRCA-mutated epithelial ovarian cancer.
Carcinoma, Ovarian Epithelial
Clinicopathological features of homologous recombination-deficient epithelial ovarian cancers: sensitivity to PARP inhibitors, platinum, and survival.
Carcinoma, Ovarian Epithelial
Combination of triapine, olaparib, and cediranib suppresses progression of BRCA-wild type and PARP inhibitor-resistant epithelial ovarian cancer.
Carcinoma, Ovarian Epithelial
Cumulative defects in DNA repair pathways drive the PARP inhibitor response in high-grade serous epithelial ovarian cancer cell lines.
Carcinoma, Ovarian Epithelial
Development of a 3D functional assay and identification of biomarkers, predictive for response of high-grade serous ovarian cancer (HGSOC) patients to poly-ADP ribose polymerase inhibitors (PARPis): targeted therapy.
Carcinoma, Ovarian Epithelial
DUETTE: a phase II randomized, multicenter study to investigate the efficacy and tolerability of a second maintenance treatment in patients with platinum-sensitive relapsed epithelial ovarian cancer, who have previously received poly(ADP-ribose) polymerase (PARP) inhibitor maintenance treatment.
Carcinoma, Ovarian Epithelial
Enhanced Efficacy of Combined Therapy with Checkpoint Kinase 1 Inhibitor and Rucaparib Via Regulation of Rad-51 Expression in BRCA Wild-Type Epithelial Ovarian Cancer Cells.
Carcinoma, Ovarian Epithelial
Evaluation of the Efficacy and Safety of PARP Inhibitors in Advanced-Stage Epithelial Ovarian Cancer.
Carcinoma, Ovarian Epithelial
Expression of poly (adenosine diphosphate-ribose) polymerase and p53 in epithelial ovarian cancer and their role in prognosis and disease outcome.
Carcinoma, Ovarian Epithelial
Germline whole exome sequencing and large-scale replication identifies FANCM as a likely high grade serous ovarian cancer susceptibility gene.
Carcinoma, Ovarian Epithelial
N6-Methylation of Adenosine of FZD10 mRNA Contributes to PARP Inhibitor Resistance.
Carcinoma, Ovarian Epithelial
Olaparib and ?-specific PI3K inhibitor alpelisib for patients with epithelial ovarian cancer: a dose-escalation and dose-expansion phase 1b trial.
Carcinoma, Ovarian Epithelial
Olaparib maintenance for first-line treatment of ovarian cancer: will SOLO1 reset the standard of care?
Carcinoma, Ovarian Epithelial
Overcoming Platinum and PARP-Inhibitor Resistance in Ovarian Cancer.
Carcinoma, Ovarian Epithelial
Overcoming resistance to PARP inhibitor in epithelial ovarian cancer, are we ready?
Carcinoma, Ovarian Epithelial
PARP inhibition in epithelial ovarian cancer: high hopes undergo a reality check.
Carcinoma, Ovarian Epithelial
PARP Inhibition Increases the Reliance on ATR/CHK1 Checkpoint Signaling Leading to Synthetic Lethality-An Alternative Treatment Strategy for Epithelial Ovarian Cancer Cells Independent from HR Effectiveness.
Carcinoma, Ovarian Epithelial
PARP inhibitors alone and in combination with other biological agents in homologous recombination deficient epithelial ovarian cancer: From the basic research to the clinic.
Carcinoma, Ovarian Epithelial
PARP inhibitors and epithelial ovarian cancer: an approach to targeted chemotherapy and personalised medicine.
Carcinoma, Ovarian Epithelial
PARP inhibitors and epithelial ovarian cancer: Molecular mechanisms, clinical development and future prospective.
Carcinoma, Ovarian Epithelial
PARP Inhibitors for Ovarian Cancer: Current Indications, Future Combinations, and Novel Assets in Development to Target DNA Damage Repair.
Carcinoma, Ovarian Epithelial
PARP inhibitors in epithelial ovarian cancer.
Carcinoma, Ovarian Epithelial
PARP Inhibitors in Epithelial Ovarian Cancer: State of Art and Perspectives of Clinical Research.
Carcinoma, Ovarian Epithelial
PARP-1 may be involved in angiogenesis in epithelial ovarian cancer.
Carcinoma, Ovarian Epithelial
PARP1 blockade is synthetically lethal in XRCC1 deficient sporadic epithelial ovarian cancers.
Carcinoma, Ovarian Epithelial
Pharmacological ascorbate induces 'BRCAness' and enhances the effects of Poly(ADP-Ribose) polymerase inhibitors against BRCA1/2 wild-type ovarian cancer.
Carcinoma, Ovarian Epithelial
Plectin-targeted liposomes enhance the therapeutic efficacy of a PARP inhibitor in the treatment of ovarian cancer.
Carcinoma, Ovarian Epithelial
Poly (adenosine diphosphate [ADP]-ribose) polymerase (PARP) inhibitors as maintenance therapy in women with newly diagnosed ovarian cancer: a systematic review and meta-analysis.
Carcinoma, Ovarian Epithelial
Poly (ADP-ribose) polymerase (PARP) as target for the treatment of epithelial ovarian cancer: what to know.
Carcinoma, Ovarian Epithelial
Poly (ADP-ribose) polymerase inhibitors in the management of ovarian cancer.
Carcinoma, Ovarian Epithelial
Poly (ADP-ribose) polymerase inhibitors: on the horizon of tailored and personalized therapies for epithelial ovarian cancer.
Carcinoma, Ovarian Epithelial
Poly (ADP-ribose) polymerase inhibitors: recent advances and future development.
Carcinoma, Ovarian Epithelial
Poly(ADP-ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer.
Carcinoma, Ovarian Epithelial
Predictive value of ATP7b, BRCA1, BRCA2, PARP1, UIMC1 (RAP80), HOXA9, DAXX, TXN (TRX1), THBS1 (TSP1) and PRR13 (TXR1) genes in patients with epithelial ovarian cancer who received platinum-taxane first-line therapy.
Carcinoma, Ovarian Epithelial
Rationale for combination PARP inhibitor and antiangiogenic treatment in advanced epithelial ovarian cancer: A review.
Carcinoma, Ovarian Epithelial
Secondary Somatic Mutations Restoring RAD51C and RAD51D Associated with Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma.
Carcinoma, Ovarian Epithelial
Targeted therapy of ovarian cancer including immune check point inhibitor.
Carcinoma, Ovarian Epithelial
Targeting homologous repair deficiency in breast and ovarian cancers: Biological pathways, preclinical and clinical data.
Carcinoma, Ovarian Epithelial
The circuitous path of PARP inhibitor development in epithelial ovarian cancer.
Carcinoma, Ovarian Epithelial
The Emerging Role of PARP Inhibitors in the Treatment of Epithelial Ovarian Cancer.
Carcinoma, Ovarian Epithelial
The Prognostic and Predictive Role of Somatic BRCA Mutations in Ovarian Cancer: Results from a Multicenter Cohort Study.
Carcinoma, Ovarian Epithelial
The Prognostic Relevance of Poly (ADP-Ribose) Polymerase Expression in Ovarian Cancer Tissue of Wild Type and BRCA-Mutation Carrier Patients.
Carcinoma, Ovarian Epithelial
The Prognostic Value of BRCA1 and PARP Expression in Epithelial Ovarian Carcinoma: Immunohistochemical Detection.
Carcinoma, Ovarian Epithelial
The Prognostic Value of PARP Expression in High-Grade Epithelial Ovarian Cancer.
Carcinoma, Ovarian Epithelial
The RECAP Test Rapidly and Reliably Identifies Homologous Recombination-Deficient Ovarian Carcinomas.
Carcinoma, Ovarian Epithelial
Tolerance and toxicity of the PARP inhibitor olaparib in older women with epithelial ovarian cancer.
Carcinoma, Ovarian Epithelial
Treatment of recurrent ovarian cancer.
Carcinoma, Ovarian Epithelial
Triapine Disrupts CtIP-Mediated Homologous Recombination Repair and Sensitizes Ovarian Cancer Cells to PARP and Topoisomerase Inhibitors.
Carcinoma, Ovarian Epithelial
Tumor BRCA Test for Patients with Epithelial Ovarian Cancer: The Role of Molecular Pathology in the Era of PARP Inhibitor Therapy.
Carcinoma, Ovarian Epithelial
Universal tumor DNA BRCA1/2 testing of ovarian cancer: prescreening PARPi treatment and genetic predisposition.
Carcinoma, Ovarian Epithelial
Update in the use and evaluation of poly (ADP-ribose) polymerase inhibitors in epithelial ovarian cancer: current and pending clinical research.
Carcinoma, Ovarian Epithelial
Using PARP Inhibitors in the Treatment of Patients With Ovarian Cancer.
Carcinoma, Ovarian Epithelial
[Maintenance therapy in patients with advanced epithelial ovarian cancer-impact of anti-angiogenic molecular targeted agents in progress].
Carcinoma, Renal Cell
Characterization of MVP and VPARP assembly into vault ribonucleoprotein complexes.
Carcinoma, Renal Cell
Correction to: Low expression of TRAF3IP2-AS1 promotes progression of NONO-TFE3 translocation renal cell carcinoma by stimulating N6-methyladenosine of PARP1 mRNA and downregulating PTEN.
Carcinoma, Renal Cell
Heterogeneous nuclear ribonucleoprotein U-like 1 and Poly (ADP-ribose) polymerase 1 are downregulated in renal cell carcinoma and connected with the prognosis.
Carcinoma, Renal Cell
Low expression of TRAF3IP2-AS1 promotes progression of NONO-TFE3 translocation renal cell carcinoma by stimulating N6-methyladenosine of PARP1 mRNA and downregulating PTEN.
Carcinoma, Renal Cell
Radiosensitizing Potential of Curcumin in Different Cancer Models.
Carcinoma, Renal Cell
Sunitinib induces genomic instability of renal carcinoma cells through affecting the interaction of LC3-II and PARP-1.
Carcinoma, Renal Cell
The DEAD/DEAH Box Helicase, DDX11, Is Essential for the Survival of Advanced Clear Cell Renal Cell Carcinoma and Is a Determinant of PARP Inhibitor Sensitivity.
Carcinoma, Renal Cell
The Emerging Role of Poly (ADP-Ribose) Polymerase Inhibitors as Effective Therapeutic Agents in Renal Cell Carcinoma.
Carcinoma, Squamous Cell
A phase I trial adding poly(ADP-ribose) polymerase inhibitor veliparib to induction carboplatin-paclitaxel in patients with head and neck squamous cell carcinoma: Alliance A091101.
Carcinoma, Squamous Cell
Berberine inhibits growth, induces G1 arrest and apoptosis in human epidermoid carcinoma A431 cells by regulating Cdki-Cdk-cyclin cascade, disruption of mitochondrial membrane potential and cleavage of caspase 3 and PARP.
Carcinoma, Squamous Cell
Cisplatin benefit is predicted by immunohistochemical analysis of DNA repair proteins in squamous cell carcinoma but not adenocarcinoma: theranostic modeling by NSCLC constituent histological subclasses.
Carcinoma, Squamous Cell
Combined EGFR1 and PARP1 Inhibition Enhances the Effect of Radiation in Head and Neck Squamous Cell Carcinoma Models.
Carcinoma, Squamous Cell
Combining PARP and DNA-PK Inhibitors With Irradiation Inhibits HPV-Negative Head and Neck Cancer Squamous Carcinoma Growth.
Carcinoma, Squamous Cell
Discovery and Structure-Activity Relationships of Modified Salicylanilides as Cell Permeable Inhibitors of Poly(ADP-ribose) Glycohydrolase (PARG).
Carcinoma, Squamous Cell
Dual disruption of DNA repair and telomere maintenance for the treatment of head and neck cancer.
Carcinoma, Squamous Cell
Effect of poly(ADP-ribose)polymerase and DNA topoisomerase I inhibitors on the p53/p63-dependent survival of carcinoma cells.
Carcinoma, Squamous Cell
Expression of BAG-1 and PARP-1 in Precursor Lesions and Invasive Cervical Cancer Associated with Human Papillomavirus (HPV).
Carcinoma, Squamous Cell
Genetic polymorphisms in DNA base-excision repair genes ADPRT, XRCC1, and APE1 and the risk of squamous cell carcinoma of the head and neck.
Carcinoma, Squamous Cell
Pan-Cancer Analysis of PARP1 Alterations as Biomarkers in the Prediction of Immunotherapeutic Effects and the Association of Its Expression Levels and Immunotherapy Signatures.
Carcinoma, Squamous Cell
PARP inhibition enhances radiotherapy of SMAD4 deficient human head and neck squamous cell carcinomas in experimental models.
Carcinoma, Squamous Cell
PARP inhibitors: A new era of targeted therapy.
Carcinoma, Squamous Cell
Parp-1 deficiency does not increase the frequency of tumors in the oral cavity and esophagus of ICR/129Sv mice by 4-nitroquinoline 1-oxide, a carcinogen producing bulky adducts.
Carcinoma, Squamous Cell
PARP-1 Val762Ala polymorphism is associated with risk of cervical carcinoma.
Carcinoma, Squamous Cell
PARP1 and CASP3 gene expression in a patient with multiple head and neck squamous cell carcinoma and Parkinson disease.
Carcinoma, Squamous Cell
Radiosensitization of head and neck squamous cell carcinoma lines by DNA-PK inhibitors is more effective than PARP-1 inhibition and is enhanced by SLFN11 and hypoxia.
Carcinoma, Squamous Cell
Radiosensitizing Potential of Curcumin in Different Cancer Models.
Carcinoma, Squamous Cell
Sam68 reduces cisplatin-induced apoptosis in tongue carcinoma.
Carcinoma, Squamous Cell
Synergistic Anti-Tumour Effect of Syk Inhibitor and Olaparib in Squamous Cell Carcinoma: Roles of Syk in EGFR Signalling and PARP1 Activation.
Carcinoma, Squamous Cell
The epidermal growth factor receptor is coupled to a pertussis toxin-sensitive guanine nucleotide regulatory protein in rat hepatocytes.
Carcinoma, Squamous Cell
[The effect of tanshinone ?A potentiates the effects of Cisplatin in Fadu cells in vitro through downregulation of survivin].
Carcinoma, Transitional Cell
Influence of pertussis toxin on superficial bladder carcinoma in rats.
Carcinoma, Transitional Cell
Silibinin causes cell cycle arrest and apoptosis in human bladder transitional cell carcinoma cells by regulating CDKI-CDK-cyclin cascade, and caspase 3 and PARP cleavages.
Carcinoma, Transitional Cell
Tankyrase-1 mRNA expression in bladder cancer and paired urine sediment: preliminary experience.
Cardiomegaly
Activation of poly(ADP-ribose) polymerase contributes to the endothelial dysfunction associated with hypertension and aging.
Cardiomegaly
AG-690/11026014, a novel PARP-1 inhibitor, protects cardiomyocytes from AngII-induced hypertrophy.
Cardiomegaly
E3 Ubiquitin ligase NEDD4 family?regulatory network in cardiovascular disease.
Cardiomegaly
Effect of L-2286, a poly(ADP-ribose)polymerase inhibitor and enalapril on myocardial remodeling and heart failure.
Cardiomegaly
Increased expression of poly(ADP-ribose) polymerase-1 contributes to caspase-independent myocyte cell death during heart failure.
Cardiomegaly
Multifarious molecular signaling cascades of cardiac hypertrophy: can the muddy waters be cleared?
Cardiomegaly
Myocardial Gi alpha-protein levels in patients with hypertensive cardiac hypertrophy, ischemic heart disease and cardiogenic shock.
Cardiomegaly
Opposing roles of PARP-1 in MMP-9 and TIMP-2 expression and mast cell degranulation in dyslipidemic dilated cardiomyopathy.
Cardiomegaly
PARP inhibition prevents postinfarction myocardial remodeling and heart failure via the protein kinase C/glycogen synthase kinase-3beta pathway.
Cardiomegaly
PARP mediates structural alterations in diabetic cardiomyopathy.
Cardiomegaly
PARP-2 knockdown protects cardiomyocytes from hypertrophy via activation of SIRT1.
Cardiomegaly
PARP1 interacts with HMGB1 and promotes its nuclear export in pathological myocardial hypertrophy.
Cardiomegaly
PARP1 interacts with STAT3 and retains active phosphorylated-STAT3 in nucleus during pathological myocardial hypertrophy.
Cardiomegaly
Poly(ADP-ribose) polymerase-1-deficient mice are protected from angiotensin II-induced cardiac hypertrophy.
Cardiomegaly
Possible role of poly(ADP-ribose) polymerase in pathological and physiological cardiac hypertrophy.
Cardiomegaly
Salvianolic acid B protects cardiomyocytes from angiotensin II-induced hypertrophy via inhibition of PARP-1.
Cardiomegaly
SIRT3 inhibits cardiac hypertrophy by regulating PARP-1 activity.
Cardiomegaly
The orphan receptor NOR1 participates in isoproterenol-induced cardiac hypertrophy by regulating PARP-1.
Cardiomegaly
The piRNA CHAPIR regulates cardiac hypertrophy by controlling METTL3-dependent N6-methyladenosine methylation of Parp10 mRNA.
Cardiomegaly
The poly(ADP-ribosyl)ation of BRD4 mediated by PARP1 promoted pathological cardiac hypertrophy.
Cardiomegaly
The poly(ADP-ribosyl)ation of FoxO3 mediated by PARP1 participates in isoproterenol-induced cardiac hypertrophy.
Cardiomegaly
Transcriptome-Wide Analysis Identifies Novel Associations With Blood Pressure.
Cardiomegaly
[The role of G protein, protein kinase C and Na(+)-H+ exchanger in endothelin-1-induced cardiomyocyte hypertrophic responses]
Cardiomyopathies
A novel compound DT-010 protects against doxorubicin-induced cardiotoxicity in zebrafish and H9c2 cells by inhibiting reactive oxygen species-mediated apoptotic and autophagic pathways.
Cardiomyopathies
Cardioprotective effects of poly(ADP-ribose) polymerase inhibition.
Cardiomyopathies
CircTLK1 modulates sepsis-induced cardiomyocyte apoptosis via enhancing PARP1/HMGB1 axis-mediated mitochondrial DNA damage by sponging miR-17-5p.
Cardiomyopathies
Disruption of Nrf2 Synergizes with High Glucose to Cause Heightened Myocardial Oxidative Stress and Severe Cardiomyopathy in Diabetic Mice.
Cardiomyopathies
Myocardial postischemic injury is reduced by polyADPripose polymerase-1 gene disruption.
Cardiomyopathies
PARP-1 inhibition protects the diabetic heart through activation of SIRT1-PGC-1? axis.
Cardiomyopathies
Quantification of Gi alpha-proteins in the failing and nonfailing human myocardium.
Cardiomyopathies
Regulation of kinase cascade activation and heat shock protein expression by poly(ADP-ribose) polymerase inhibition in doxorubicin-induced heart failure.
Cardiomyopathies
Role of poly(ADP-ribose) polymerase 1 (PARP-1) in cardiovascular diseases: the therapeutic potential of PARP inhibitors.
Cardiomyopathies
Roles of poly(ADP-ribose) polymerase activation in the pathogenesis of diabetes mellitus and its complications.
Cardiomyopathies
The pathogenesis of diabetic complications: the role of DNA injury and poly(ADP-ribose) polymerase activation in peroxynitrite-mediated cytotoxicity.
Cardiomyopathies
Trypanosoma cruzi Induces the PARP1/AP-1 Pathway for Upregulation of Metalloproteinases and Transforming Growth Factor ? in Macrophages: Role in Cardiac Fibroblast Differentiation and Fibrosis in Chagas Disease.
Cardiomyopathy, Dilated
Coupling of adenosine receptors to a pertussis toxin-sensitive G protein in the human heart.
Cardiomyopathy, Dilated
Immunodetectable levels of the inhibitory guanine nucleotide-binding regulatory proteins in failing human heart: discordance with measurements of adenylate cyclase activity and levels of pertussis toxin substrate.
Cardiomyopathy, Dilated
Increase of Gi alpha in human hearts with dilated but not ischemic cardiomyopathy.
Cardiomyopathy, Dilated
Opposing roles of PARP-1 in MMP-9 and TIMP-2 expression and mast cell degranulation in dyslipidemic dilated cardiomyopathy.
Cardiomyopathy, Dilated
Quantification of Gi alpha-proteins in the failing and nonfailing human myocardium.
Cardiotoxicity
Activation of poly(ADP-ribose) polymerase contributes to development of doxorubicin-induced heart failure.
Cardiotoxicity
E3 Ubiquitin ligase NEDD4 family?regulatory network in cardiovascular disease.
Cardiotoxicity
Hesperidin promotes lysosomal biogenesis in chronically ethanol-induced cardiotoxicity in rats: A proposed mechanisms of protection.
Cardiotoxicity
Influence of PARP-1 inhibition in the cardiotoxicity of the topoisomerase 2 inhibitors doxorubicin and mitoxantrone.
Cardiotoxicity
sFRP1 has a biphasic effect on doxorubicin-induced cardiotoxicity in a cellular location-dependent manner in NRCMs and Rats.
Cardiotoxicity
The clinically active PARP inhibitor AG014699 ameliorates cardiotoxicity but does not enhance the efficacy of doxorubicin, despite improving tumor perfusion and radiation response in mice.
Cardiovascular Diseases
In vitro effect of the potent poly(ADP-ribose) polymerase (PARP) inhibitor INO-1001 alone and in combination with aspirin, eptifibatide, tirofiban, enoxaparin or alteplase on haemostatic parameters.
Cardiovascular Diseases
Mitochondrial-to-nuclear translocation of apoptosis-inducing factor in cardiac myocytes during oxidant stress: potential role of poly(ADP-ribose) polymerase-1.
Cardiovascular Diseases
NAD+ and cardiovascular diseases.
Cardiovascular Diseases
Novel modulators of poly(ADP-ribose) polymerase.
Cardiovascular Diseases
PARP inhibitors: New partners in the therapy of cancer and inflammatory diseases.
Cardiovascular Diseases
PARP1 interacts with STAT3 and retains active phosphorylated-STAT3 in nucleus during pathological myocardial hypertrophy.
Cardiovascular Diseases
PARP1 promote autophagy in cardiomyocytes via modulating FoxO3a transcription.
Cardiovascular Diseases
PCB-induced endothelial cell dysfunction: role of poly(ADP-ribose) polymerase.
Cardiovascular Diseases
Pharmacological inhibition of poly(ADP-ribose) polymerase in cardiovascular disorders: future directions.
Cardiovascular Diseases
Poly(ADP-ribose) polymerase as a drug target for cardiovascular disease and cancer: an update.
Cardiovascular Diseases
Poly(ADP-ribose) polymerase inhibition improves endothelial dysfunction induced by reactive oxidant hydrogen peroxide in vitro.
Cardiovascular Diseases
Poly(ADP-ribose) polymerase inhibition reduces atherosclerotic plaque size and promotes factors of plaque stability in apolipoprotein E-deficient mice: effects on macrophage recruitment, nuclear factor-kappaB nuclear translocation, and foam cell death.
Cardiovascular Diseases
Poly(ADP-Ribose) polymerase promotes cardiac remodeling, contractile failure, and translocation of apoptosis-inducing factor in a murine experimental model of aortic banding and heart failure.
Cardiovascular Diseases
Restoration of the endothelial function in the aortic rings of apolipoprotein E deficient mice by pharmacological inhibition of the nuclear enzyme poly(ADP-ribose) polymerase.
Cardiovascular Diseases
Role of poly(ADP-ribose) polymerase 1 (PARP-1) in cardiovascular diseases: the therapeutic potential of PARP inhibitors.
Cardiovascular Diseases
Sp1 Targeted PARP1 Inhibition Protects Cardiomyocytes From Myocardial Ischemia-Reperfusion Injury via Downregulation of Autophagy.
Cardiovascular Diseases
The Role of PARPs in Inflammation-and Metabolic-Related Diseases: Molecular Mechanisms and Beyond.
caspase-3 deficiency
Deficiency of caspase-3 in MCF7 cells blocks Bax-mediated nuclear fragmentation but not cell death.
Catalepsy
Cholera toxin antagonizes morphine-induced catalepsy through a cyclic AMP-independent mechanism.
Cataract
Aldose reductase inhibitor fidarestat counteracts diabetes-associated cataract formation, retinal oxidative-nitrosative stress, glial activation, and apoptosis.
Cataract
Associations of PARP-1 variant rs1136410 with PARP activities, oxidative DNA damage, and the risk of age-related cataract in a Chinese Han population: A two-stage case-control analysis.
Cataract
Biochemical Evidence Indicates the Preventive Effect of Resveratrol and Nicotinamide in the Treatment of STZ-induced Diabetic Cataract.
Cataract
PARP-1 inhibition influences the oxidative stress response of the human lens.
Cataract
Poly(ADP-ribose)polymerase inhibition counteracts cataract formation and early retinal changes in streptozotocin-diabetic rats.
Central Nervous System Diseases
Multiple roles for poly(ADP-ribose)polymerase-1 in neurological disease.
Central Nervous System Diseases
PARP-DNA trapping ability of PARP inhibitors jeopardizes astrocyte viability: Implications for CNS disease therapeutics.
Central Nervous System Diseases
Targeting poly(ADP-ribose)polymerase1 in neurological diseases: A promising trove for new pharmacological interventions to enter clinical translation.
Central Nervous System Diseases
The role of poly(ADP-ribose) polymerase-1 in CNS disease.
Central Nervous System Neoplasms
PARP1 expression in pediatric central nervous system tumors.
Cerebellar Ataxia
XRCC1 mutation is associated with PARP1 hyperactivation and cerebellar ataxia.
Cerebral Hemorrhage
Poly(ADP-ribose) polymerase activation and brain edema formation by hemoglobin after intracerebral hemorrhage in rats.
Cerebral Infarction
Baicalein attenuates caspase-independent cells death via inhibiting PARP-1 activation and AIF nuclear translocation in cerebral ischemia/reperfusion rats.
Cerebral Infarction
Evaluation of the poly(ADP-ribose) polymerase gene in human stroke.
Cerebral Infarction
MP-124, a novel poly(ADP-ribose) polymerase-1 (PARP-1) inhibitor, ameliorates ischemic brain damage in a non-human primate model.
Cerebral Infarction
Neuroprotective effects of KCL-440, a new poly(ADP-ribose) polymerase inhibitor, in the rat middle cerebral artery occlusion model.
Cerebral Infarction
Protection of the brain following cerebral ischemia through the attenuation of PARP-1-induced neurovascular unit damage in rats.
Cerebral Infarction
Reversible induction of PARP1 degradation by p53-inducible cis-imidazoline compounds.
Cerebral Infarction
[Effect of acupuncture on neurological function, cerebral infarction volume, thrombolysis time window and cerebral cell apoptosis signaling pathway in cerebral infarction rats].
Cerebrovascular Disorders
Neuropilin-1 modulates vascular endothelial growth factor-induced poly(ADP-ribose)-polymerase leading to reduced cerebrovascular apoptosis.
Cerebrovascular Disorders
Poly(ADP-ribose) polymerase gene disruption renders mice resistant to cerebral ischemia.
Cervical Intraepithelial Neoplasia
Poly(ADP-Ribose) Polymerase in Cervical Cancer Pathogenesis: Mechanism and Potential Role for PARP Inhibitors.
Chagas Cardiomyopathy
Evidence that myocardial pertussis toxin substrates are uniquely altered in acute murine Chagas' disease in a manner unrelated to myocardial dysfunction.
Chagas Disease
Evidence that myocardial pertussis toxin substrates are uniquely altered in acute murine Chagas' disease in a manner unrelated to myocardial dysfunction.
Chagas Disease
Inhibition of poly(ADP-ribose) polymerase interferes with Trypanosoma cruzi infection and proliferation of the parasite.
Chagas Disease
PARP1 depletion improves mitochondrial and heart function in Chagas disease: Effects on POLG dependent mtDNA maintenance.
Chagas Disease
Trypanosoma cruzi Induces the PARP1/AP-1 Pathway for Upregulation of Metalloproteinases and Transforming Growth Factor ? in Macrophages: Role in Cardiac Fibroblast Differentiation and Fibrosis in Chagas Disease.
Chickenpox
Immunity against vaccine-preventable diseases in Finnish pediatric healthcare workers in 2015.
Chickenpox
Immunity to vaccine-preventable diseases among paediatric healthcare workers in Denmark, 2019.
Chickenpox
Waning vaccine immunity and vaccination responses in children treated for acute lymphoblastic leukemia: A Canadian Immunization Research Network Study.
Cholangiocarcinoma
Binding of tumour necrosis factor-alpha (TNF-alpha) to TNF-RI induces caspase(s)-dependent apoptosis in human cholangiocarcinoma cell lines.
Cholangiocarcinoma
Case Report: BAP1 Mutation and RAD21 Amplification as Predictive Biomarkers to PARP Inhibitor in Metastatic Intrahepatic Cholangiocarcinoma.
Cholangiocarcinoma
Guggulsterone inhibits human cholangiocarcinoma Sk-ChA-1 and Mz-ChA-1 cell growth by inducing caspase-dependent apoptosis and downregulation of survivin and Bcl-2 expression.
Cholangiocarcinoma
Non-canonical Hedgehog signaling contributes to chemotaxis in cholangiocarcinoma.
Cholangiocarcinoma
PARP inhibitor olaparib sensitizes cholangiocarcinoma cells to radiation.
Cholangiocarcinoma
Targeting therapeutic vulnerabilities with PARP inhibition and radiation in IDH-mutant gliomas and cholangiocarcinomas.
Cholangiocarcinoma
The combination of BET and PARP inhibitors is synergistic in models of cholangiocarcinoma.
Cholangiocarcinoma
XIAP Antagonist Embelin Inhibited Proliferation of Cholangiocarcinoma Cells.
Cholera
1,25(OH)2-vitamin D-3 stimulates phospholipase A2 activity via a guanine nucleotide-binding protein in chick myoblasts.
Cholera
24,25-(OH)2D3 regulates protein kinase C through two distinct phospholipid-dependent mechanisms.
Cholera
3H-naloxone benzoylhydrazone binding in MOR-1-transfected Chinese hamster ovary cells: evidence for G-protein-dependent antagonist binding.
Cholera
5-HT1A receptor-mediated activation of G-protein-gated inwardly rectifying K+ current in rat periaqueductal gray neurons.
Cholera
5-Hydroxytryptamine receptor-mediated phosphoinositide hydrolysis in canine cultured tracheal smooth muscle cells.
Cholera
A cholera toxin-sensitive G-protein stimulates exocytosis in sea urchin eggs.
Cholera
A cholera toxin-sensitive guanyl nucleotide binding protein mediates the movement of pituitary luteinizing hormone into a releasable pool: loss of this event is associated with the onset of homologous desensitization to gonadotropin-releasing hormone.
Cholera
A comparative study of endothelin- and platelet-activating-factor-mediated signal transduction and prostaglandin synthesis in rat Kupffer cells.
Cholera
A comparative study of the role of adenylate cyclase in the release of adrenocorticotropin from the ovine and rat anterior pituitary.
Cholera
A developmental role for the heterotrimeric G protein Go alpha in a migratory population of embryonic neurons.
Cholera
A guanine nucleotide-binding protein mediates 1,25-dihydroxy-vitamin D-3-dependent rapid stimulation of Ca2+ uptake in skeletal muscle.
Cholera
A membrane-delimited pathway of G-protein regulation of the guard-cell inward K+ channel.
Cholera
A novel approach to detect toxin-catalyzed ADP-ribosylation in intact cells: its use to study the action of Pasteurella multocida toxin.
Cholera
A novel cholera toxin-sensitive G-protein (Gc) regulating receptor-mediated phosphoinositide signalling in human pituitary clonal cells.
Cholera
A novel G protein alpha subunit containing atypical guanine nucleotide-binding domains is differentially expressed in a molluscan nervous system.
Cholera
A novel G protein alpha subunit in embryo of the ascidian, Halocynthia roretzi.
Cholera
A novel guanine nucleotide-binding protein coupled to the alpha 1-adrenergic receptor. II. Purification, characterization, and reconstitution.
Cholera
A novel role for testicular descent; temperature-dependent induction of pertussis toxin-sensitive Gi protein function in postnatal rat Leydig cells.
Cholera
A pertussis/cholera toxin sensitive G-protein may mediate vasopressin-induced inositol phosphate formation in smooth muscle cell.
Cholera
A subtype of kappa-opioid receptor mediates inhibition of high-affinity GTPase inherent in Gi1 in guinea pig cerebellar membranes.
Cholera
AB5 ADP-ribosylating toxins: comparative anatomy and physiology.
Cholera
Abnormal dopamine sensitivity in some human prolactinomas.
Cholera
Activation of 5-HT(7) receptor in rat glomerulosa cells is associated with an increase in adenylyl cyclase activity and calcium influx through T-type calcium channels.
Cholera
Activation of a keratinocyte phospholipase A2 by bradykinin and 4 beta-phorbol 12-myristate 13-acetate. Evidence for a receptor-GTP-binding protein versus a protein-kinase-C mediated mechanism.
Cholera
Activation of A(3) adenosine receptor induces calcium entry and chloride secretion in A(6) cells.
Cholera
Activation of adenylate cyclase in rat fat cells promotes an increase in GTP content which controls the enzyme activity.
Cholera
Activation of cell membrane potassium conductance by mercury in cultured renal epithelioid (MDCK) cells.
Cholera
Activation of dense human tonsilar B cells. Induction of c-myc gene expression via two distinct signal transduction pathways.
Cholera
Activation of endothelial cell phospholipase D by sphingosine and sphingosine-1-phosphate.
Cholera
Activation of endothelial nitric oxide synthase by proanthocyanidin-rich fraction from Croton celtidifolius (Euphorbiaceae): involvement of extracellular calcium influx in rat thoracic aorta.
Cholera
Activation of Galpha (i) and subsequent uncoupling of receptor-Galpha(i) signaling by Pasteurella multocida toxin.
Cholera
Activation of muscarinic m5 receptors inhibits recombinant KCNQ2/KCNQ3 K+ channels expressed in HEK293T cells.
Cholera
Activation of particulate guanylate cyclase by adrenomedullin in cultured SV-40 transformed cat iris sphincter smooth muscle (SV-CISM-2) cells.
Cholera
Activation of phospholipase C via adenosine receptors provides synergistic signals for secretion in antigen-stimulated RBL-2H3 cells. Evidence for a novel adenosine receptor.
Cholera
Activation of PKCbeta(II) and PKCtheta is essential for LDL-induced cell proliferation of human aortic smooth muscle cells via Gi-mediated Erk1/2 activation and Egr-1 upregulation.
Cholera
Activation of the cloned human kappa opioid receptor by agonists enhances [35S]GTPgammaS binding to membranes: determination of potencies and efficacies of ligands.
Cholera
Activation of the superoxide-generating NADPH oxidase of macrophages by sodium dodecyl sulfate in a soluble cell-free system: evidence for involvement of a G protein.
Cholera
Additive induction of Egr-1 (zif/268) mRNA expression in neuroblastoma x glioma hybrid NG108-15 cells via cholinergic muscarinic, alpha 2-adrenergic, and bradykinin receptors.
Cholera
Adenine nucleotides directly stimulate pertussis toxin.
Cholera
Adenosine diphosphate ribosylation of G proteins by pertussis and cholera toxin in isolated membranes. Different requirements for and effects of guanine nucleotides and Mg2+.
Cholera
Adenosine inhibits the renal plasma-membrane (Ca2+ + Mg2+)-ATPase through a pathway sensitive to cholera toxin and sphingosine.
Cholera
Adenosine release and uptake in cerebellar granule neurons both occur via an equilibrative nucleoside carrier that is modulated by G proteins.
Cholera
Adenylate cyclase activity of v-ras-k transformed rat epithelial thyroid cells.
Cholera
Adenylate cyclase system in fetal rat keratinizing epidermal cells (FRSK cells) and SV40-transformed human keratinocytes.
Cholera
Adenylyl cyclase and G-proteins in Phytomonas.
Cholera
Adenylyl cyclase is involved in desensitization and recovery of ATP-stimulated Cl- secretion in MDCK cells.
Cholera
Adipocyte plasma membranes contain two Gi subtypes but are devoid of Go.
Cholera
Adjuvant action of cholera toxin and pertussis toxin in the induction of IgA antibody response to orally administered antigen.
Cholera
ADP-ribosylation and early transcription regulation by bacteriophage T4.
Cholera
ADP-ribosylation of bovine S-antigen by cholera toxin.
Cholera
ADP-ribosylation of membrane proteins by bacterial toxins in the presence of NAD glycohydrolase.
Cholera
ADP-ribosylation of transducin by pertussis toxin blocks the light-stimulated hydrolysis of GTP and cGMP in retinal photoreceptors.
Cholera
ADP-ribosyltransferase-specific modification of human neutrophil peptide-1.
Cholera
Age-dependent changes in transmembrane signalling: identification of G proteins in human lymphocytes and polymorphonuclear leukocytes.
Cholera
Age-related and testicular regression-induced changes in adenosine 3',5'-monophosphate responses in cultured hamster Sertoli cells.
Cholera
Age-related changes in beta-adrenergic neuroeffector systems in the human heart.
Cholera
Age-related changes in G proteins in rat aorta.
Cholera
Agonist-dependent, cholera toxin-catalyzed ADP-ribosylation of pertussis toxin-sensitive G-proteins following transfection of the human alpha 2-C10 adrenergic receptor into rat 1 fibroblasts. Evidence for the direct interaction of a single receptor with two pertussis toxin-sensitive G-proteins, Gi2 and Gi3.
Cholera
Albumin endocytosis is regulated by heterotrimeric GTP-binding protein G alpha i-3 in opossum kidney cells.
Cholera
Alterations in G-proteins in congestive heart failure in cardiomyopathic (UM-X7.1) hamsters.
Cholera
Alterations of G protein function in cardiac tissues from streptozotocin-induced chronic diabetic rats.
Cholera
Altered expression of inhibitory guanine nucleotide regulatory proteins (Gi alpha) in spontaneously hypertensive rats.
Cholera
Altered responses to modulators of guanine nucleotide binding protein activity in endotoxin tolerance.
Cholera
An arginine residue is the site of receptor-stimulated, cholera toxin-catalysed ADP-ribosylation of pertussis toxin-sensitive G-proteins.
Cholera
An autocrine motility factor secreted by the Dunning R-3327 rat prostatic adenocarcinoma cell subtype AT2.1.
Cholera
An examination of the relationship between mu-opioid antinociceptive efficacy and G-protein coupling using pertussis and cholera toxins.
Cholera
Anaphylatoxins C5a and C3a induce nuclear factor kappaB activation in human peripheral blood monocytes.
Cholera
Angiotensin II-mediated activation of L-type calcium channels involves phosphatidylinositol hydrolysis-independent activation of protein kinase C in rat portal vein myocytes.
Cholera
Anti-Inflammatory Effect of Geniposide on Regulating the Functions of Rheumatoid Arthritis Synovial Fibroblasts via Inhibiting Sphingosine-1-Phosphate Receptors1/3 Coupling G?i/G?s Conversion.
Cholera
Antibodies to the ras gene product inhibit adenylate cyclase and accelerate progesterone-induced cell division in Xenopus laevis oocytes.
Cholera
Antilipolytic effects of insulin and adenylate cyclase inhibitors on isolated human fat cells.
Cholera
Antisense oligodeoxynucleotides to GS protein alpha-subunit sequence accelerate differentiation of fibroblasts to adipocytes.
Cholera
Association of a solubilized prostaglandin E2 receptor from renal medulla with a pertussis toxin-reactive guanine nucleotide regulatory protein.
Cholera
Astrocytes possess prostaglandin F2 alpha receptors coupled to phospholipase C.
Cholera
Atrial natriuretic factor effects on cyclic nucleotides in a human renal cell line.
Cholera
Attenuation of changes in G(i)-proteins and adenylyl cyclase in heart failure by an ACE inhibitor, imidapril.
Cholera
Autoregulation of acute progesterone and adenosine 3',5'-monophosphate responses to follicle-stimulating hormone (FSH) in porcine granulosa cells: effects of FSH, cholera toxin, forskolin, and pertussis toxin.
Cholera
B- and T-cell responses to the mycobacterium surface antigen PstS-1 in the respiratory tract and adjacent tissues. Role of adjuvants and routes of immunization.
Cholera
Bacteria and their toxins tamed for immunotherapy.
Cholera
Bacterial toxins affect early events of T lymphocyte activation.
Cholera
Bacterial type AB? enterotoxins--structure, function and mechanism of action.
Cholera
Beta(2)-Adrenergic activation increases glycogen synthesis in L6 skeletal muscle cells through a signalling pathway independent of cyclic AMP.
Cholera
beta-adrenergic modulation of maxi-K channels in vascular smooth muscle via Gi through a membrane-delimited pathway.
Cholera
Beta-adrenoceptor mediated signal transduction in congestive heart failure in cardiomyopathic (UM-X7.1) hamsters.
Cholera
Bilateral ureteral obstruction alters levels of the G-protein subunits G alpha s and G alpha q/11.
Cholera
Biochemical demonstration of mu-opioid receptor association with Gsalpha: enhancement following morphine exposure.
Cholera
Biosynthesis of paf-acether in cultured-mouse mast cells: the role of calcium and G proteins.
Cholera
Biphasic effect of cAMP-elevating agents on ICAM-1 expression stimulated by retinoic acid and interferon gamma.
Cholera
Biphasic modulation of voltage-dependent currents of retinal cones by cannabinoid CB1 receptor agonist WIN 55212-2.
Cholera
Blockade of morphine analgesia by both pertussis and cholera toxins in the periaqueductal gray and locus coeruleus.
Cholera
Blockage of amyloid beta peptide-induced cytosolic free calcium by fullerenol-1, carboxylate C60 in PC12 cells.
Cholera
Blood mononuclear cell production of TNF-alpha and IL-8: engagement of different signal transduction pathways including the p42 MAP kinase pathway.
Cholera
Bone Gla protein messenger ribonucleic acid is regulated by both 1,25-dihydroxyvitamin D3 and 3',5'-cyclic adenosine monophosphate in rat osteosarcoma cells.
Cholera
Botulinum C2 toxin ADP-ribosylates actin.
Cholera
Bovine pituitary, kidney, uterine and mammary gland extracts contain bovine mammary epithelium growth factors that synergise with IGF-I and fetal calf serum: indication for involvement of GTP-binding proteins.
Cholera
Bradykinin B2 receptor-mediated proliferation via activation of the Ras/Raf/MEK/MAPK pathway in rat vascular smooth muscle cells.
Cholera
Bradykinin modulates the electrophysiology of cultured rat sensory neurons through a pertussis toxin-insensitive G protein.
Cholera
Bradykinin-induced phosphoinositide hydrolysis and Ca2+ mobilization in canine cultured tracheal epithelial cells.
Cholera
C5a stimulus-secretion coupling in rat basophilic leukaemia (RBL-2H3) cells transfected with the human C5a receptor is mediated by pertussis and cholera toxin-sensitive G proteins.
Cholera
Ca2+-stimulated catecholamine release from alpha-toxin-permeabilized PC12 cells: biochemical evidence for exocytosis and its modulation by protein kinase C and G proteins.
Cholera
Calcium entry stimulated by swelling of Madin-Darby canine kidney cells.
Cholera
Calcium mobilization and protease-activated receptor cleavage after thrombin stimulation in motor neurons.
Cholera
Calcium- and G-protein-dependent activation of arachidonic acid release by concanavalin-A-stimulated mouse macrophages.
Cholera
cAMP antagonizes ERK-dependent antiapoptotic action of insulin.
Cholera
cAMP imaging of cells treated with pertussis toxin, cholera toxin, and anthrax edema toxin.
Cholera
cAMP modulates transepithelial resistance response of LLC-PK1 renal epithelia to tumor necrosis factor.
Cholera
cAMP-dependent inhibition is dominant in regulating superoxide production in the bone-resorbing osteoclasts.
Cholera
cAMP-independent dilation of coronary arterioles to adenosine : role of nitric oxide, G proteins, and K(ATP) channels.
Cholera
Cannabidiol, a novel inverse agonist for GPR12.
Cholera
Carbohydrate moiety of follitropin receptor is not required for high affinity hormone-binding or for functional coupling between receptor and guanine nucleotide-binding protein in bovine calf testis membranes.
Cholera
CD3/T-cell receptor coupling to a pertussis and cholera toxin-insensitive G-protein.
Cholera
Cell-surface expression, progestin binding, and rapid nongenomic signaling of zebrafish membrane progestin receptors alpha and beta in transfected cells.
Cholera
Cellular Basis for Bimatoprost Effects on Human Conventional Outflow.
Cholera
Cellular mechanisms of melatonin action.
Cholera
Changes in cAMP formation in mononuclear leukocytes of heart and renal transplant recipients.
Cholera
Changes in inositol 1,4,5-trisphosphate mass in agonist-stimulated human neutrophils.
Cholera
Characterization of a streptococcal antitumor glycoprotein (SAGP).
Cholera
Characterization of adenosine receptors in brush-border membranes from pig kidney.
Cholera
Characterization of botulinum C3-catalyzed ADP-ribosylation of rho proteins and identification of mammalian C3-like ADP-ribosyltransferase.
Cholera
Characterization of bradykinin receptors in canine cultured corneal epithelial cells: pharmacological and functional studies.
Cholera
Characterization of G-proteins in rat glomeruli.
Cholera
Characterization of heterotrimeric G-proteins in adult Acanthocheilonema viteae.
Cholera
Characterization of influenza A virus activation of the human neutrophil.
Cholera
Characterization of nitric oxide-stimulated ADP-ribosylation of various proteins from the mouse macrophage cell line ANA-1 using sodium nitroprusside and the novel nitric oxide-donating compound diethylamine dinitric oxide.
Cholera
Characterization of phosphatidylinositol-specific phospholipase C (PI-PLC) from Lilium daviddi pollen.
Cholera
Characterization of the G protein involved in the muscarinic stimulation of adenylyl cyclase of rat olfactory bulb.
Cholera
Characterization of the membrane-associated GTPase activity: effects of chemotactic factors and toxins.
Cholera
Characterization of the plasma membrane bound GTPase from rabbit neutrophils. I. Evidence for an Ni-like protein coupled to the formyl peptide, C5a, and leukotriene B4 chemotaxis receptors.
Cholera
Characterization of vasopressin-mediated GSH efflux from Hep G2 cells: significance of protein kinase C.
Cholera
Chemotactic peptide receptor-supported ADP-ribosylation of a pertussis toxin substrate GTP-binding protein by cholera toxin in neutrophil-type HL-60 cells.
Cholera
Chicken liver contains a large quantity of a G-protein-linked neurotensin receptor.
Cholera
Chloride channels in cultured human skeletal muscle are regulated by G proteins.
Cholera
Cholera and pertussis exotoxins protect mice against the lethal Schwartzman reaction and antagonize the effects of lipopolysaccharide on second messenger systems.
Cholera
Cholera and pertussis toxins amplify prostacyclin synthesis in aortic smooth muscle cells.
Cholera
Cholera toxin accentuates the antagonism by acetylcholine of higenamine-induced positive chronotropy is isolated right atria of mice.
Cholera
Cholera toxin ADP-ribosylates the receptor-coupled form of pertussis toxin-sensitive G-proteins.
Cholera
Cholera toxin and dibutyryl cyclic adenosine 3',5'-monophosphate sensitize gonadotropin-releasing hormone-stimulated inositol phosphate production to inhibition in protein kinase-C (PKC)-depleted cells: evidence for cross-talk between a cholera toxin-sensitive G-protein and PKC.
Cholera
Cholera toxin and pertussis toxin on opioid- and alpha 2-mediated supraspinal analgesia in mice.
Cholera
Cholera toxin and pertussis toxin provoke differential effects on luteinizing hormone release, inositol phosphate production, and gonadotropin-releasing hormone (GnRH) receptor binding in the gonadotrope: evidence for multiple guanyl nucleotide binding proteins in GnRH action.
Cholera
Cholera toxin and pertussis toxin regulate the Fc receptor-mediated phagocytic response of human neutrophils in a manner analogous to regulation by monoclonal antibody 1C2.
Cholera
Cholera toxin and pertussis toxin stimulate prostaglandin E2 synthesis in a murine macrophage cell line.
Cholera
Cholera toxin and pertussis toxin substrates and endogenous ADP-ribosyltransferase activity in Drosophila melanogaster.
Cholera
Cholera toxin antagonizes morphine-induced catalepsy through a cyclic AMP-independent mechanism.
Cholera
Cholera toxin blocks glucagon-mediated inhibition of the liver plasma membrane (Ca2+-Mg2+)-ATPase.
Cholera
Cholera toxin but not pertussis toxin inhibits angiotensin II-enhanced contractions in the rat portal vein.
Cholera
Cholera toxin can ADP-ribosylate Gs as well as Gi in ACTH-unresponsive human adrenocortical cancer.
Cholera
Cholera toxin directly stimulates pregnenolone generation with increasing Ca2+ efflux in bovine adrenocortical mitochondria.
Cholera
Cholinergic-induced [3H] noradrenaline release in rat brain cortical slices is mediated via a pertussis toxin sensitive GTP binding protein and involves activation of protein kinase C.
Cholera
Chronic ethanol promotes the neuronal differentiation of NG108-15 cells independently of toxin-sensitive G-proteins.
Cholera
Cloning and characterization of a cDNA coding for the alpha-subunit of a stimulatory G protein from Schistosoma mansoni.
Cholera
Cloning and characterization of a G protein alpha-subunit-encoding gene from the basidiomycete, Coprinus congregatus.
Cholera
Coexistence of CD14-dependent and independent pathways for stimulation of human monocytes by gram-positive bacteria.
Cholera
Collagen type IV stimulates an increase in intracellular Ca2+ in pancreatic acinar cells via activation of phospholipase C.
Cholera
Common features of the NAD-binding and catalytic site of ADP-ribosylating toxins.
Cholera
Computer modelling of the NAD binding site of ADP-ribosylating toxins: active-site structure and mechanism of NAD binding.
Cholera
Concanavalin A stimulation of O2 consumption in electropermeabilized neutrophils via a pertussis toxin-insensitive G protein.
Cholera
Conditional activation of cAMP signal transduction by protein kinase C. The effect of phorbol esters on adenylyl cyclase in permeabilized and intact cells.
Cholera
Contribution of ligand structure to activation of alpha 2-adrenergic receptor subtype coupling to Gs.
Cholera
Could dual G-protein coupling explain [D-Met2]FMRFamide's mixed action in vivo?
Cholera
Coupling factor 6 enhances the spontaneous microaggregation of platelets by decreasing cytosolic cAMP irrespective of antiplatelet therapy.
Cholera
Coupling of bradykinin receptors to phospholipase C in cultured fibroblasts is mediated by a G-protein.
Cholera
Coupling of gonadotropin-releasing hormone receptor to Gi protein in human reproductive tract tumors.
Cholera
Cross-linking of G-proteins to the prolactin receptor in rat NB2 lymphoma cells.
Cholera
Cyclic AMP can partially restore platelet-derived growth factor-stimulated prostaglandin E2 biosynthesis, and calcium mobilization in EJ-ras-transformed NIH-3T3 cells.
Cholera
Cyclic AMP-dependent regulation of the number of [3H]batrachotoxinin benzoate binding sites on rat cardiac myocytes.
Cholera
Cyclic guanosine monophosphate analogs do not reverse bacterial toxin modulation of lactogen-stimulated NB2 cell mitogenesis.
Cholera
Cytoplasmic pH change induced by leukotriene B4 in human neutrophils.
Cholera
Cytoskeletal alterations as a parameter for assessment of toxicity.
Cholera
D2L, D2S, and D3 dopamine receptors stably transfected into NG108-15 cells couple to a voltage-dependent potassium current via distinct G protein mechanisms.
Cholera
Decreased potency of glucagon on transformed-induced MDCK cells does not reflect an alteration of adenylate cyclase components.
Cholera
Deduced amino acid sequence of bovine retinal Go alpha: similarities to other guanine nucleotide-binding proteins.
Cholera
DeoxyNAD and deoxyADP-ribosylation of proteins.
Cholera
Desensitization to parathyroid hormone in renal cells from aged rats is associated with alterations in G-protein activity.
Cholera
Detection of arginine-ADP-ribosylated protein using recombinant ADP-ribosylarginine hydrolase.
Cholera
Detection of G proteins in purified bovine brain myelin.
Cholera
Developmental changes in the levels of substrates for cholera toxin-catalyzed and pertussis toxin-catalyzed ADP-ribosylation in rat cardiac cell membranes.
Cholera
Dexamethasone effects on beta-adrenergic receptors and adenylate cyclase regulatory proteins Gs and Gi in ROS 17/2.8 cells.
Cholera
Different domains in the third intracellular loop of the GLP-1 receptor are responsible for Galpha(s) and Galpha(i)/Galpha(o) activation.
Cholera
Different endothelin receptor subtypes are involved in phospholipid signalling in the proximal tubule of rat kidney.
Cholera
Different G proteins are involved in the biphasic response of clonal rat pituitary cells to thyrotropin-releasing hormone.
Cholera
Different stimulatory opioid effects on intracellular Ca(2+) in SH-SY5Y cells.
Cholera
Differential alterations in cardiac adrenergic signaling in chronic hypoxia or norepinephrine infusion.
Cholera
Differential alterations in left and right ventricular G-proteins in congestive heart failure due to myocardial infarction.
Cholera
Differential cholera-toxin- and pertussis-toxin-catalysed ADP-ribosylation of G-proteins coupled to formyl-peptide and leukotriene B4 receptors.
Cholera
Differential effects of bacterial toxins on mitogenic actions of sodium fluoride and those of aluminum fluoride in human TE85 osteosarcoma cells.
Cholera
Differential effects of cholera toxin and pertussis toxin on the c-fos and c-jun mRNA expression in rat C6 glioma cells.
Cholera
Differential effects of fluoride and a non-hydrolysable GTP analogue on adenylate cyclase and G-proteins in Ceratitis capitata neural tissue.
Cholera
Differential involvement of hippocampal G-protein subtypes in the memory process of rats.
Cholera
Differential modulatory effects of cholera toxin and pertussis toxin on pain behavior induced by TNF-alpha, interleukin-1beta and interferon-gamma injected intrathecally.
Cholera
Differential modulatory roles of cholera toxin and pertussis toxin in the regulation of pain responses induced by excitatory amino acids administered intrathecally in mice.
Cholera
Differential roles of spinal cholera toxin- and pertussis toxin-sensitive G proteins in nociceptive responses caused by formalin, capsaicin, and substance P in mice.
Cholera
Differentiation of renal Na(+)-K(+)-ATPase in control and streptozotocin-induced diabetic mice by G-protein acting toxins and phorbol esters.
Cholera
Direct coupling of opioid receptors to both stimulatory and inhibitory guanine nucleotide-binding proteins in F-11 neuroblastoma-sensory neuron hybrid cells.
Cholera
Dissection of lymphocyte function-associated antigen 1-dependent adhesion and signal transduction in human natural killer cells shown by the use of cholera or pertussis toxin.
Cholera
Distinct mechanisms for Ca2+ entry induced by OKT3 and Ca2+ depletion in Jurkat T cells.
Cholera
Does interleukin 2 stimulus-response coupling result in generation of intracellular second messengers?
Cholera
Dopamine D3 receptor-mediated inhibition of Na+/H+ exchanger activity in normotensive and spontaneously hypertensive rat proximal tubular epithelial cells.
Cholera
Dopamine-induced synaptic depression in the parabrachial nucleus is independent of CTX- and PTX-sensitive G-proteins, PKA and PLC signalling pathways.
Cholera
Dopaminergic receptors linked to adenylate cyclase in human cerebromicrovascular endothelium.
Cholera
Dual role of GTP-binding proteins in the control of endothelial prostacyclin.
Cholera
Effect of adenylate cyclase stimulation on meiotic resumption and cyclic AMP content of zona-free and cumulus-enclosed bovine oocytes in vitro.
Cholera
Effect of cholera toxin and pertussis toxin on opioid tolerance and dependence in the guinea-pig myenteric plexus.
Cholera
Effect of cholera toxin and pertussis toxin on prostaglandin H synthase-2, prostaglandin E2, and matrix metalloproteinase production by human monocytes.
Cholera
Effect of cholera toxin and pertussis toxin on the growth of A431 cells: kinetics of cyclic AMP and inositol trisphosphate in toxin-treated cells.
Cholera
Effect of heat shock, [Ca2+]i, and cAMP on inositol trisphosphate in human epidermoid A-431 cells.
Cholera
Effect of in vivo injection of cholera and pertussis toxin on glucose transport in rat skeletal muscle.
Cholera
Effect of light on phosphatidate phosphohydrolase activity of retina rod outer segments: the role of transducin.
Cholera
Effect of nonhydrolyzable guanosine phosphate on IgE-mediated activation of phospholipase C and histamine release from rodent mast cells.
Cholera
EFFECT OF PEPTIDOGLYCANE OF STAPHYLOCOCCUS AUREUS CELL WALL ON THE MECHANISM OF REGULATION OF CONTRACTILE ACTIVITY OF RAT MYOMETRIUM BY ADENYLATE CYCLASE SYSTEM.
Cholera
Effect of pertussis and cholera toxins administered supraspinally on CA3 hippocampal neuronal cell death and the blood glucose level induced by kainic acid in mice.
Cholera
Effect of prenylcysteine analogues on chemoattractant receptor-mediated G protein activation.
Cholera
Effect of site-directed mutagenic alterations on ADP-ribosyltransferase activity of the A subunit of Escherichia coli heat-labile enterotoxin.
Cholera
Effect of sodium fluoride on the generation of lipoxygenase products from human polymorphonuclear granulocytes, mononuclear cells and platelets--indication for the involvement of G proteins.
Cholera
Effects of angiotensin II and angiotensin III on airway epithelial short-circuit current: involvement of pertussis toxin-sensitive G protein.
Cholera
Effects of calcium on light-activated GTP-binding proteins in squid photoreceptor membranes.
Cholera
Effects of cholera and pertussis toxins on prolactin stimulation of lactose synthesis and ornithine decarboxylase activity in mouse mammary gland explants.
Cholera
Effects of chronic receptor blockade on excitation-contraction coupling in rat aortic rings.
Cholera
Effects of cyclosporine A on cyclic AMP generation and GTP-binding proteins in isolated islets.
Cholera
Effects of fluoride and cholera and pertussis toxins on sensory transduction in the carotid body.
Cholera
Effects of follicle stimulating hormone, cholera toxin, pertussis toxin and forskolin on adenosine cyclic 3',5'-monophosphate output by granulosa cells from Booroola ewes with or without the F gene.
Cholera
Effects of G protein and cGMP on phytochrome-mediated amaranthin synthesis inAmaranthus caudatus seedlings.
Cholera
Effects of insulin on inositol phosphate production in cultured rat hepatocytes.
Cholera
Effects of insulin, pertussis toxin and cholera toxin on protein synthesis and diacylglycerol production in 3T3 fibroblasts: evidence for a G-protein mediated activation of phospholipase C in the insulin signal mechanism.
Cholera
Effects of litter removal on the lipolytic response and the regulatory components of the adenylate cyclase in adipocytes isolated from lactating rats.
Cholera
Effects of nicotine on the immune response. II. Chronic nicotine treatment induces T cell anergy.
Cholera
Effects of Pasteurella haemolytica A1 culture supernatant on mechanisms controlling bovine alveolar macrophage oxygen radical production.
Cholera
Effects of pertussis and cholera toxin on the interferon-gamma stimulated immunocytochemical staining of ICAM-1 and inositol phosphate formation in a human renal carcinoma cell line.
Cholera
Effects of pertussis and cholera toxins on alpha-adrenoceptor function in rat tail artery: differences in hypertension.
Cholera
Effects of protein kinase C activation on cyclic AMP and testosterone production of rat Leydig cells in vitro.
Cholera
Effects of Ro 5-4864 and PK 11195 in rat duodenum and vas deferens.
Cholera
Effects of S-nitroso-cysteine on proteins that regulate exocytosis in PC12 cells: inhibitory effects on translocation of synaptophysin and ADP-ribosylation of GTP-binding proteins.
Cholera
Effects of spinally and supraspinally injected 3-isobutyl-1-methylxanthine, cholera toxin, and pertussis toxin on cold water swimming stress-induced antinociception in the mouse.
Cholera
Effects of spinally and supraspinally injected 3-isobutyl-1-methylxanthine, cholera toxin, and pertussis toxin on immobilization stress-induced antinociception in the mouse.
Cholera
Effects of tiazofurin on guanine nucleotide binding regulatory proteins in HL-60 cells.
Cholera
EGF inhibits secretagogue-induced cAMP production and amylase secretion by Gi proteins in pancreatic acini.
Cholera
Endogenous ADP-ribosylation of Gs subunit and autonomous regulation of adenylate cyclase.
Cholera
Endogenous prostaglandin E2 and insulin-like growth factor 1 can modulate the levels of parathyroid hormone receptor in human osteoarthritic osteoblasts.
Cholera
Endothelin 1 stimulates beta1Pix-dependent activation of Cdc42 through the G(salpha) pathway.
Cholera
Endothelin receptor subtypes are coupled to adenylate cyclase via different guanyl nucleotide-binding proteins in vasculature.
Cholera
Endothelin stimulates platelet-activating factor synthesis by cultured rat Kupffer cells.
Cholera
Endothelin- and sarafotoxin-induced phosphoinositide hydrolysis in cultured canine tracheal smooth muscle cells.
Cholera
Endothelin-1 and insulin activate the steady-state voltage dependent R-type Ca2+ channel in aortic smooth muscle cells via a pertussis toxin and cholera toxin sensitive G-protein.
Cholera
Endothelin-1 receptors on cultured rat articular chondrocytes: regulation by age, growth factors, and cytokines, and effect on cAMP production.
Cholera
Endothelin-evoked Release of Arachidonic Acid from Mouse Astrocytes in Primary Culture.
Cholera
Endotoxin-mediated synthesis of nitric oxide is dependent on Gq protein signal transduction.
Cholera
Endotoxins in cholera and pertussis toxins interfere with in vivo responses to these agents in the albino rabbit eye.
Cholera
Enhanced expression of inhibitory guanine nucleotide regulatory protein in spontaneously hypertensive rats. Relationship to adenylate cyclase inhibition.
Cholera
Enhanced negative inotropic effect of an adenosine A1-receptor agonist in rat left atria in hypothyroidism.
Cholera
Enhancement in beta-adrenergic responsiveness of adenylate cyclase in rat liver during regeneration after carbon tetrachloride administration.
Cholera
Enhancement of parathyroid hormone-responsive renal cortical adenylate cyclase activity by a cytosol protein activator from rat reticulocytes.
Cholera
Entamoeba invadens contains the components of a classical adrenergic signaling system.
Cholera
Epidermal growth factor activation of rat parotid gland adenylate cyclase and mediation by a GTP-binding regulatory protein.
Cholera
Epoxyeicosatrienoic acid stimulates ADP-ribosylation of a 52 kDa protein in rat liver cytosol.
Cholera
Estrogen uncouples beta-adrenergic receptor from the stimulatory guanine nucleotide-binding protein in female rat hypothalamus.
Cholera
ET-1 stimulates pulmonary arterial smooth muscle cell proliferation via induction of reactive oxygen species.
Cholera
Evaluation of activation of G proteins in response to thyroid stimulating hormone in thyroid gland cells from euthyroid and hyperthyroid cats.
Cholera
Evidence for expression of a Ras-like and a stage specific GTP binding homologous protein by Plasmodium falciparum.
Cholera
Evidence for G-Protein Regulation of Inward K+ Channel Current in Guard Cells of Fava Bean.
Cholera
Evidence for guanosine triphosphate--binding proteins in Trypanosoma cruzi.
Cholera
Evidence for the implication of phosphoinositol signal transduction in mu-opioid inhibition of DNA synthesis.
Cholera
Evidence for the involvement of a pertussis toxin-insensitive G-protein in egg activation of the frog, Xenopus laevis.
Cholera
Evidence for tight coupling of Gi protein-mediated lysophosphatidic acid receptor to stimulated cytokine production in ovarian cancer cell.
Cholera
Evidence for two different stimulatory adenylate cyclase coupling mechanisms in rat renal papilla.
Cholera
Evidence that activation of a common G-protein by receptors for leukotriene B4 and N-formylmethionyl-leucyl-phenylalanine in HL-60 cells occurs by different mechanisms.
Cholera
Evidence that Arg-295, Glu-378, and Glu-380 are active-site residues of the ADP-ribosyltransferase activity of iota toxin.
Cholera
Evidence that the action of calcitonin on rat osteoclasts is mediated by two G proteins acting via separate post-receptor pathways.
Cholera
Evidence that the appressorial development in barley powdery mildew is controlled by MAP kinase activity in conjunction with the cAMP pathway.
Cholera
Evidence that thyrotropin-releasing hormone-induced increases in GTPase activity and phosphoinositide metabolism in GH3 cells are mediated by a guanine nucleotide-binding protein other than Gs or Gi.
Cholera
Evidence that v-Src-induced phospholipase D activity is mediated by a G protein.
Cholera
Expression of Bordetella pertussis Antigens Fused to Different Vectors and Their Effectiveness as Vaccines.
Cholera
Extracellular ATP elevates cytoplasmatic free Ca2+ in HeLa cells by the interaction with a 5'-nucleotide receptor.
Cholera
Extracellular matrix proteins are potent agonists of human smooth muscle cell migration.
Cholera
Facilitative actions of the protein kinase-C effector system on hormonally stimulated adenosine 3',5'-monophosphate production by swine luteal cells.
Cholera
Fluoride activation of neutrophils: similarities to formylmethionyl-leucyl-phenylalanine.
Cholera
Fluoride produces endothelium-dependent relaxation and endothelium-independent contraction in coronary artery.
Cholera
FMS*Calciumfluor increases alkaline phosphatase expression during osteogenesis in vitro of tibia-derived rat osteoblasts by activation of G alpha 0/G alpha i proteins.
Cholera
Follicle-stimulating hormone receptor-mediated uptake of 45Ca2+ by cultured rat Sertoli cells does not require activation of cholera toxin- or pertussis toxin-sensitive guanine nucleotide binding proteins or adenylate cyclase.
Cholera
Functional and molecular characterization of CCK receptors in the rat pancreatic acinar cell line AR 4-2J.
Cholera
Functional and molecular characterization of VIP receptor--effector system in rat developing immunocompetent cells: G protein involvement.
Cholera
Functional characterization of the Na(+)-H+ exchanger in rat mast cells: crosstalks between different kinase pathways.
Cholera
Functional compartments in rat mast cells for cAMP and calcium on histamine release.
Cholera
Functional interactions between colony-stimulating factors and the insulin family hormones for human myeloid leukemic cells.
Cholera
Functional maturation of human T lymphocytes is accompanied by changes in the G-protein pattern.
Cholera
Functional modification by cholera-toxin-catalyzed ADP-ribosylation of a guanine-nucleotide-binding regulatory protein serving as the substrate of pertussis toxin.
Cholera
Functional reconstitution of detergent-solubilized bovine calf testis luteinizing hormone/chorionic gonadotropin receptor into phospholipid vesicles.
Cholera
Functional specialization of fibronectin-binding beta 1-integrins in T lymphocyte migration.
Cholera
Further Elucidation of a Pertussis Toxin-Sensitive Transmembrane Signaling Mechanism Involved in Central alpha(2)-Adrenoceptor Activation in the Rat.
Cholera
G protein activation inhibits amiloride-blockable highly selective sodium channels in A6 cells.
Cholera
G protein coupling of antigen receptor-stimulated polyphosphoinositide hydrolysis in B cells.
Cholera
G protein coupling of CGS 21680 binding sites in the rat hippocampus and cortex is different from that of adenosine A1 and striatal A2A receptors.
Cholera
G protein coupling to M1 and M3 muscarinic receptors in sublingual glands.
Cholera
G protein function in the ischaemic myocardium.
Cholera
G protein in stimulation of PI hydrolysis by CCK in isolated rat pancreatic acinar cells.
Cholera
G proteins in aortic endothelial cells and bradykinin-induced formation of nitric oxide.
Cholera
G proteins in Aplysia: biochemical characterization and regional and subcellular distribution.
Cholera
G proteins regulate calcium channels in the luminal membranes of the rabbit nephron.
Cholera
G proteins subserve relaxations mediated by adenosine receptors in human coronary artery.
Cholera
G-protein activation decreases isoflurane inhibition of N-type Ba2+ currents.
Cholera
G-protein activators induce a potassium conductance in murine macrophages.
Cholera
G-protein from Medicago sativa: functional association to photoreceptors.
Cholera
G-protein involvement in muscarinic receptor-stimulation of inositol phosphates in longitudinal smooth muscle from the small intestine of the guinea-pig.
Cholera
G-protein mediation of cannabinoid-induced phospholipase activation.
Cholera
G-protein regulation of an L-type calcium channel current in canine jejunal circular smooth muscle.
Cholera
G-protein-dependency of orexin/hypocretin receptor signalling in recombinant Chinese hamster ovary cells.
Cholera
G-protein-mediated regulation of the insulin-responsive glucose transporter in isolated cardiac myocytes.
Cholera
G-proteins and egg activation.
Cholera
G-proteins coupled to phosphoinositide hydrolysis in the cochlear and vestibular sensory epithelia of the rat are insensitive to cholera and pertussis toxins.
Cholera
G-proteins modulate amiloride-sensitive sodium channels.
Cholera
G-proteins modulate prolactin- and interleukin-2-stimulated mitogenesis in rat Nb2 lymphoma cells.
Cholera
G?14 subunit-mediated inhibition of voltage-gated Ca2+ and K+ channels via neurokinin-1 receptors in rat celiac-superior mesenteric ganglion neurons.
Cholera
G?s proteins activate p72(Syk) and p60-c-Src tyrosine kinases to mediate sickle red blood cell adhesion to endothelium via LW-?v?3 and CD44-CD44 interactions.
Cholera
Galectin-3 stimulates uptake of extracellular Ca2+ in human Jurkat T-cells.
Cholera
Gastrin stimulation of histamine synthesis in enterochromaffin-like cells from rabbit fundic mucosa.
Cholera
Gbetagamma dimers released in response to thyrotropin activate phosphoinositide 3-kinase and regulate gene expression in thyroid cells.
Cholera
Generation of inositol phosphates in bitter taste transduction.
Cholera
Genes coding for proteins in central nervous system myelin.
Cholera
Gi protein-mediated translocation of serine/threonine phosphatase to the plasma membrane and apoptosis of ovarian cancer cell in response to gonadotropin-releasing hormone antagonist cetrorelix.
Cholera
Gialpha3 protein-coupled dopamine D3 receptor-mediated inhibition of renal NHE3 activity in SHR proximal tubular cells is a PLC-PKC-mediated event.
Cholera
Gonadotropin-releasing hormone (GnRH)-receptor coupling to inositol phosphate and prolactin production in GH3 cells stably transfected with rat GnRH receptor complementary deoxyribonucleic acid.
Cholera
Granulocyte-macrophage colony stimulating factor activates proteoglycan, type II collagen, and cAMP production by rat articular chondrocytes through specific binding sites.
Cholera
Growth factors, signaling pathways, and the regulation of proliferation and differentiation in BC3H1 muscle cells. I. A pertussis toxin-sensitive pathway is involved.
Cholera
GTP-binding protein couples with metabotropic glutamate receptor in bovine retinal on-bipolar cell.
Cholera
GTP-binding protein G alpha Z: its down-regulation by dexamethasone and its credentials as a mediator of antigen-induced responses in RBL-2H3 cells.
Cholera
GTP-binding proteins and adenylate cyclase activity in v-Ki-ras transformed NIH/3T3 fibroblast cells.
Cholera
GTP-binding proteins associated with serotonin-activated adenylate cyclase in Fasciola hepatica.
Cholera
GTP-binding proteins in luminal and basolateral membranes from pars convoluta and pars recta of rabbit kidney proximal tubule.
Cholera
Guanine nucleotide binding protein involvement in early steps of phytochrome-regulated gene expression.
Cholera
Guanine nucleotide binding proteins and the regulation of cyclic AMP synthesis in NS20Y neuroblastoma cells: role of D1 dopamine and muscarinic receptors.
Cholera
Guanine nucleotide binding proteins mediate the chemotactic signal of transforming growth factor-beta 1 in rat IL-2 activated natural killer cells.
Cholera
Guanine nucleotide-binding protein regulation of microsomal phospholipase D activity of canine cerebral cortex.
Cholera
Guanine nucleotide-binding proteins involved in transmembrane signaling.
Cholera
Guanine nucleotides induce Ca2+-independent insulin secretion from permeabilized RINm5F cells.
Cholera
Guanine-induced inhibition of renal Na(+)-ATPase activity: Evidence for the involvement of the Gi protein-coupled receptor.
Cholera
Guanosine triphosphate can directly regulate cortisol production by activating Ca(2+)-messenger systems in bovine adrenal fasciculata cells.
Cholera
Gz, a guanine nucleotide-binding protein with unique biochemical properties.
Cholera
Heat shock increases cytosolic free Ca2+ concentration via Na(+)-Ca2+ exchange in human epidermoid A 431 cells.
Cholera
Heterologous regulations of cAMP responses in pregnant rat myometrium. Evolution from a stimulatory to an inhibitory prostaglandin E2 and prostacyclin effect.
Cholera
Heterotrimeric G-protein candidates for Ge in the ACTH secretory pathway.
Cholera
Histamine H1 receptors in C6 glial cells are coupled to calcium-dependent potassium channels via release of calcium from internal stores.
Cholera
HIV-1 Tat protein mimicry of chemokines.
Cholera
Homotypic lysosome fusion in macrophages: analysis using an in vitro assay.
Cholera
Hormonal regulation of rat renal proximal tubule brush-border membrane ionic permeability.
Cholera
HSP-72 synthesis is promoted by increase in [Ca2+]i or activation of G proteins but not pHi or cAMP.
Cholera
Human glycolipid transfer protein (GLTP) expression modulates cell shape.
Cholera
Human leukocyte elastase induces keratinocyte proliferation by epidermal growth factor receptor activation.
Cholera
Human pancreatic tumor growth hormone (GH) - releasing factor and cyclic adenosine 3',5'- monophosphate evoke GH release from anterior pituitary cells: the effects of pertussis toxin, cholera toxin, forskolin, and cycloheximide.
Cholera
Hyperosmolar solution effects in guinea pig airways. III. Studies on the identity of epithelium-derived relaxing factor in isolated perfused trachea using pharmacological agents.
Cholera
Idazoxan down-regulates beta-adrenoceptors on C6 glioma cells in vitro.
Cholera
Identification and purification from bovine brain of a guanine-nucleotide-binding protein distinct from Gs, Gi and Go.
Cholera
Identification of a botulinum C3-like enzyme in bovine brain that catalyzes ADP-ribosylation of GTP-binding proteins.
Cholera
Identification of a region in the S1 subunit of pertussis toxin that is required for enzymatic activity and that contributes to the formation of a neutralizing antigenic determinant.
Cholera
Identification of a second putative receptor of platelet-activating factor from human polymorphonuclear leukocytes.
Cholera
Identification of CCR8 as the specific receptor for the human beta-chemokine I-309: cloning and molecular characterization of murine CCR8 as the receptor for TCA-3.
Cholera
Identification of G-proteins in rat parotid gland plasma membranes and granule membranes: presence of distinct components in granule membranes.
Cholera
Identification of heterotrimeric and low molecular weight GTP-binding proteins in rabbit skeletal muscle longitudinal sarcoplasmic reticulum.
Cholera
Identification of Novel Competing ?(2)AR Phospho-Extracellular Signal Regulated Kinase 1/2 Signaling Pathways in Human Trabecular Meshwork Cells.
Cholera
Identification of novel phytocannabinoids from Ganoderma by label-free dynamic mass redistribution assay.
Cholera
Identification of the pertussis and cholera toxin substrates in normal and N-ras transformed NIH3T3 fibroblasts and an assessment of their involvement in bombesin-stimulation of inositol phospholipid metabolism.
Cholera
IL-8 induces the locomotion of human IL-2-activated natural killer cells. Involvement of a guanine nucleotide binding (Go) protein.
Cholera
Immunochemical detection of GTP-binding protein in cephalopod photoreceptors by anti-peptide antibodies.
Cholera
Impaired G-proteins and cyclic nucleotide phosphodiesterase activity in T-lymphocytes from patients with sarcoidosis.
Cholera
Importance of CCL2-CCR2A/2B signaling for monocyte migration into spheroids of breast cancer-derived fibroblasts.
Cholera
In vitro effects of 17 beta-oestradiol on the sensitivity of receptors coupled to adenylate cyclase on striatal neurons in primary culture.
Cholera
In vivo evidence that lithium inactivates Gi modulation of adenylate cyclase in brain.
Cholera
Increase in Gs and cyclic AMP generation in HIT cells. Evidence that the 45-kDa alpha-subunit of Gs has greater functional activity than the 52-kDa alpha-subunit.
Cholera
Increased intracellular cyclic adenosine monophosphate inhibits T lymphocyte-mediated cytolysis by two distinct mechanisms.
Cholera
Induction of promiscuous G protein coupling of the follicle-stimulating hormone (FSH) receptor: a novel mechanism for transducing pleiotropic actions of FSH isoforms.
Cholera
Influence of bacterial toxins and forskolin upon vasopressin-induced inositol phosphate accumulation in WRK 1 cells.
Cholera
Influence of pertussis toxin on parathyroid hormone stimulated cyclic AMP production and phosphate transport in opossum kidney cells.
Cholera
Inhibition and activation of interleukin 2 synthesis by direct modification of guanosine triphosphate-binding proteins.
Cholera
Inhibition of hormonally induced inositol trisphosphate production in Transfected GH4 sup>C1 cells: A novel role for the D5 subtype of the dopamine receptor.
Cholera
Inhibition of protein phosphatase 2A (PP2A) mimics suckling-induced sensitization of mammotropes: involvement of a pertussis toxin (PTX) sensitive G-protein and the adenylate cyclase (AC).
Cholera
Inhibition of renal Na+-ATPase activity by inosine is mediated by A1 receptor-induced inhibition of the cAMP signaling pathway.
Cholera
Inhibition of swine microglial cell phagocytosis of Cryptococcus neoformans by femtomolar concentrations of morphine.
Cholera
Inhibition of thyrotropin-stimulated adenosine 3',5'-monophosphate formation in rat thyroid cells by an adenosine analog. Evidence that the inhibition is mediated by the putative inhibitory guanine nucleotide regulatory protein.
Cholera
Inhibitors of ADP-ribosylating bacterial toxins based on oxacarbenium ion character at their transition states.
Cholera
Inositol phosphate formation and chloride current responses induced by acetylcholine and serotonin through GTP-binding proteins in Xenopus oocyte after injection of rat brain messenger RNA.
Cholera
Insulin activates GTP binding to a 40 kDa protein in fat cells.
Cholera
Insulin stimulates a novel GTPase activity in human platelets.
Cholera
Insulin stimulation of cyclic AMP phosphodiesterase is independent from the G-protein pathways involved in adenylate cyclase regulation.
Cholera
Insulin-like growth factors enhance phagocytosis by human neutrophils in vitro.
Cholera
Insulinotropic toxins as molecular probes for analysis of glucagon-likepeptide-1 receptor-mediated signal transduction in pancreatic beta-cells.
Cholera
Interactions of alpha-melanotropin and agouti on B16 melanoma cells: evidence for inverse agonism of agouti.
Cholera
Interleukin (IL)-8-induced in vitro human lymphocyte migration is inhibited by cholera and pertussis toxins and inhibitors of protein kinase C.
Cholera
Interleukin-1 beta inhibition of insulin release in rat pancreatic islets: possible involvement of G-proteins in the signal transduction pathway.
Cholera
Interleukin-1 signal transduction. Increased GTP binding and hydrolysis in membranes of a murine thymoma line (EL4).
Cholera
Interleukin-1beta-induced inhibition of hair growth in vitro is mediated by cyclic AMP.
Cholera
Intracellular coupling of prostaglandin inhibition of acid secretion in isolated rabbit gastric parietal cells.
Cholera
Intracellular regulation of enzyme secretion from rat osteoclasts and evidence for a functional role in bone resorption.
Cholera
Involvement of a GTP-binding protein in stimulating action of angiotensin II on calcium channels in vascular smooth muscle cells.
Cholera
Involvement of a guanine-nucleotide-binding component in membrane IgM-stimulated phosphoinositide breakdown.
Cholera
Involvement of an inhibitory G-protein in the signal transduction pathway of maturation-inducing hormone (17 alpha,20 beta-dihydroxy-4-pregnen-3-one) action in rainbow trout (Oncorhynchus mykiss) oocytes.
Cholera
Involvement of G proteins in the effect of insulin-like growth factor I on gonadotropin-induced rat granulosa cell differentiation.
Cholera
Involvement of heterotrimeric G proteins in phagocytosis and recycling from the phagosomal compartment.
Cholera
Involvement of Rho and p38 MAPK in endothelin-1-induced expression of PGHS-2 mRNA in osteoblast-like cells.
Cholera
Involvement of signal transducing GTP-binding proteins in renal artery alpha 1-adrenoceptor mediated smooth muscle contraction.
Cholera
Involvement of signaling pathways in bovine sperm motility, and effect of ergot alkaloids.
Cholera
Ionomycin induces prostaglandin E2 formation in murine osteoblastic MC3T3-E1 cells via mechanisms independent of its ionophoric nature.
Cholera
Islet-activating protein impairs alpha 2-adrenoceptor-mediated inhibitory regulation of human platelet adenylate cyclase.
Cholera
Isolation and mode of action of rabbit corticostatic (antiadrenocorticotropin) peptides.
Cholera
Isoproterenol enhances a calcium-independent potassium current in mouse anterior pituitary tumor cells.
Cholera
K-ras transformation greatly increases the toxin-dependent ADP-ribosylation of GTP binding proteins in thyroid cells. Involvement of an inhibitor of the ADP-ribosylation reaction.
Cholera
Kainate receptors coupled to G(i)/G(o) proteins in the rat hippocampus.
Cholera
L-channel modulation by alpha-1 adrenoceptor activation in neonatal rat ventricular cells: intracellular mechanisms.
Cholera
Label-free detection and identification of protein ligands captured by receptors in a polymerized planar lipid bilayer using MALDI-TOF MS.
Cholera
Ligand binding and functional characterization of muscarinic acetylcholine receptors on the TE671/RD human cell line.
Cholera
Ligand-induced formation of the leukotriene B4 receptor-G protein complex of human polymorphonuclear leukocytes.
Cholera
Light activation of phosphatidylethanolamine N-methyltransferase in rod outer segments and its modulation by association states of transducin.
Cholera
Light activation of phospholipase A2 in rod outer segments of bovine retina and its modulation by GTP-binding proteins.
Cholera
Light-dependent GTP-binding proteins in squid photoreceptors.
Cholera
Lithium administration modulates platelet Gi in humans.
Cholera
Localization of several G-protein subunits to the apical and basolateral membranes of cortical tubular cells from the rat kidney.
Cholera
Low-density lipoprotein (LDL) binds to a G-protein coupled receptor in human platelets. Evidence that the proaggregatory effect induced by LDL is modulated by down-regulation of binding sites and desensitization of its mediated signaling.
Cholera
Luteinizing hormone secretion is enhanced by pertussis toxin, cholera toxin, and forskolin. Evidence for the involvement of the cyclic AMP-generating system.
Cholera
Luteinizing hormone/choriogonadotropin-dependent, cholera toxin-catalyzed adenosine 5'-diphosphate (ADP)-ribosylation of the long and short forms of Gs alpha and pertussis toxin-catalyzed ADP-ribosylation of Gi alpha*.
Cholera
Lysophosphatidic acid augments fibroblast-mediated contraction of released collagen gels.
Cholera
M2 muscarinic receptor-mediated inhibition of the Ca2+ current in rat magnocellular cholinergic basal forebrain neurones.
Cholera
mADP-RTs: versatile virulence factors from bacterial pathogens of plants and mammals.
Cholera
Mast cell activation by pedicellarial toxin of sea urchin, Toxopneustes pileolus.
Cholera
Mastoparan, a wasp venom peptide, stimulates release of prolactin from cultured rat anterior pituitary cells.
Cholera
Mastoparan-induced apoptosis of cultured cerebellar granule neurons is initiated by calcium release from intracellular stores.
Cholera
Mechanism involved in the mobilization of neutrophil calcium by 5-hydroxyeicosatetraenoate.
Cholera
Mechanism of action of GTP in the induction of Ca2+ release from hepatic microsomes.
Cholera
Mechanism of endothelial nitric oxide-dependent vasorelaxation induced by wine polyphenols in rat thoracic aorta.
Cholera
Mechanism of macrophage injury following traumatic hemorrhagic shock: through PTX-sensitive G-protein-mediated signal transduction pathway.
Cholera
Mechanism(s) of activation of secretory phospholipase A(2)s in mouse keratinocytes.
Cholera
Mechanisms of bradykinin-mediated Ca(2+) signalling in canine cultured corneal epithelial cells.
Cholera
Mechanisms of nonopsonic phagocytosis of Pseudomonas aeruginosa.
Cholera
Melanocortin receptor-mediated mobilization of intracellular free calcium in HEK293 cells.
Cholera
Melatonin receptors in benign prostate epithelial cells: evidence for the involvement of cholera and pertussis toxins-sensitive G proteins in their signal transduction pathways.
Cholera
Membrane-bound form of ADP-ribosyl cyclase in rat cortical astrocytes in culture.
Cholera
Metallothionein mediates leukocyte chemotaxis.
Cholera
Mg(++)-induced endothelial cell migration: substratum selectivity and receptor-involvement.
Cholera
Microsomal and cytosolic fractions of guinea pig hepatocytes contain 100-kilodalton GTP-binding proteins reactive with antisera against alpha subunits of stimulatory and inhibitory heterotrimeric GTP-binding proteins.
Cholera
Minimally modified low density lipoprotein-induced inflammatory responses in endothelial cells are mediated by cyclic adenosine monophosphate.
Cholera
Mitigation of beta 1- and/or beta 2-adrenoceptor function in human heart failure.
Cholera
Mitoxantrone induces nonimmunological histamine release from rat mast cells.
Cholera
Modification of biological responses to interleukin-1 by agents that perturb signal transduction pathways.
Cholera
Modification of the amounts of G proteins and of the activity of adenylyl cyclase in human benign thyroid tumours.
Cholera
Modification of the function of pertussis toxin substrate GTP-binding protein by cholera toxin-catalyzed ADP-ribosylation.
Cholera
Modulation by 1,25(OH)2-vitamin D3 of the adenylyl cyclase/cyclic AMP pathway in rat and chick myoblasts.
Cholera
Modulation of brain Na+ channels by a G-protein-coupled pathway.
Cholera
Modulation of Ca(2+)-channel currents by protein kinase C in adult rat sympathetic neurons.
Cholera
Modulation of Ca2+ currents by various G protein-coupled receptors in sympathetic neurons of male rat pelvic ganglia.
Cholera
Modulation of CD4 Th cell differentiation by ganglioside GD1a in vitro.
Cholera
Modulation of meiotic arrest in mouse oocytes by guanyl nucleotides and modifiers of G-proteins.
Cholera
Modulation of prolactin-stimulated Nb2 lymphoma cell mitogenesis by cholera toxin and pertussis toxin.
Cholera
Modulation of protein kinase C by adenosine: involvement of adenosine A1 receptor-pertussis toxin sensitive nucleotide binding protein system.
Cholera
Modulation of sperm acrosomal exocytosis by guanyl nucleotides and G-protein-modifier agents.
Cholera
Modulation of tumor necrosis factor-alpha cytotoxicity in L929 cells by bacterial toxins, hydrocortisone and inhibitors of arachidonic acid metabolism.
Cholera
Molecular characterization of a G protein alpha-subunit-encoding gene from Mucor circinelloides.
Cholera
Molecular model of the G protein alpha subunit based on the crystal structure of the HRAS protein.
Cholera
Mono(adenosine diphosphate ribosyl) transferase in Xenopus tissues. Direct demonstration by a zymographic localization in sodium dodecyl sulfate--polyacrylamide gels.
Cholera
Monoclonal antibodies against the enzymatic subunit of both pertussis and cholera toxins.
Cholera
Morphine stimulates phagocytosis of Mycobacterium tuberculosis by human microglial cells: involvement of a G protein-coupled opiate receptor.
Cholera
Mucosal immunization with a genetically engineered pertussis toxin S1 fragment-cholera toxin subunit B chimeric protein.
Cholera
Mucosal vaccination approach against mosquito-borne Japanese encephalitis virus.
Cholera
Multiple effects of phorbol ester on secretory activity in rabbit gastric glands and parietal cells.
Cholera
Multiple isoforms of ADP-ribosylated G-like proteins from mammalian thyroid membranes.
Cholera
Multiple signaling pathways of histamine H2 receptors. Identification of an H2 receptor-dependent Ca2+ mobilization pathway in human HL-60 promyelocytic leukemia cells.
Cholera
Multiple trimeric G-proteins on the trans-Golgi network exert stimulatory and inhibitory effects on secretory vesicle formation.
Cholera
Multiplicative interaction between intrathecally and intracerebroventricularly administered morphine for antinociception in the mouse: effects of spinally and supraspinally injected 3-isobutyl-1-methylxanthine, cholera toxin, and pertussis toxin.
Cholera
Muscarine modulation by a G-protein alpha-subunit of delayed rectifier K+ current in rat ventromedial hypothalamic neurones.
Cholera
Muscarinic receptor activation modulates Ca2+ channels in rat intracardiac neurons via a PTX- and voltage-sensitive pathway.
Cholera
Muscarinic receptor subclassification and G-proteins: significance for lithium action in affective disorders and for the treatment of the extrapyramidal side effects of neuroleptics.
Cholera
Muscarinic receptor-linked elevation of cAMP in SH-SY5Y neuroblastoma cells is mediated by Ca2+ and protein kinase C.
Cholera
Muscarinic receptor-mediated dual regulation of ADP-ribosyl cyclase in NG108-15 neuronal cell membranes.
Cholera
Muscarinic receptor-mediated hydrolysis of phosphatidylinositols in human neuroblastoma (SH-SY5Y) cells is sensitive to pertussis toxin.
Cholera
Myelin basic protein binds GTP at a single site in the N-terminus.
Cholera
Myeloid cell proliferation stimulated by Steel factor is pertussis toxin sensitive and enhanced by cholera toxin.
Cholera
NADP+ enhances cholera and pertussis toxin-catalyzed ADP-ribosylation of membrane proteins.
Cholera
Neuropeptide FF receptors couple to a cholera toxin-sensitive G-protein in rat dorsal raphe neurones.
Cholera
Neurotensin modulates the electrical activity of frog pituitary melanotropes via activation of a G-protein-coupled receptor pharmacologically related to both the NTS1 and nts2 receptors of mammals.
Cholera
Neutrophil activation by surface bound IgG: pertussis toxin insensitive activation.
Cholera
Neutrophil thrombospondin receptors are linked to GTP-binding proteins.
Cholera
Nod factors activate both heterotrimeric and monomeric G-proteins in Vigna unguiculata (L.) Walp.
Cholera
Nongenomic aldosterone effects: the cell membrane as a specific target of mineralocorticoid action.
Cholera
Nonpeptidic antagonists of ETA and ETB receptors reverse the ET-1-induced sustained increase of cytosolic and nuclear calcium in human aortic vascular smooth muscle cells.
Cholera
Nootropic drug modulation of neuronal nicotinic acetylcholine receptors in rat cortical neurons.
Cholera
Noradrenaline release enhanced by cholera toxin and pertussis toxin in rat cerebral cortical slices.
Cholera
Noradrenergic potentiation of cerebellar Purkinje cell responses to GABA: cyclic AMP as intracellular intermediary.
Cholera
Novel mechanism for non-genomic action of 17 beta-oestradiol on kainate-induced currents in isolated rat CA1 hippocampal neurones.
Cholera
Novel molecular biology approaches to acellular vaccines.
Cholera
Nuclear membrane R-type calcium channels mediate cytosolic ET-1-induced increase of nuclear calcium in human vascular smooth muscle cells.
Cholera
Occurrence and biochemical characterization of GTP-binding proteins in Candida albicans.
Cholera
On the mechanism of action of dexamethasone in a rat mast cell line (RBL-2H3 cells). Evidence for altered coupling of receptors and G-proteins.
Cholera
Ontogenesis of alpha 2-adrenoceptor coupling with GTP-binding proteins in the rat telencephalon.
Cholera
Oocyte adenylyl cyclase contains Ni, yet the guanine nucleotide-dependent inhibition by progesterone is not sensitive to pertussis toxin.
Cholera
Opioid peptides promote cholera-toxin-catalysed ADP-ribosylation of the inhibitory guanine-nucleotide-binding protein (Gi) in membranes of neuroblastoma x glioma hybrid cells.
Cholera
Opioids mobilize calcium from inositol 1,4,5-trisphosphate-sensitive stores in NG108-15 cells.
Cholera
Opposing influences of dexamethasone and retinoic acid on adenylate cyclase activity in ROS 17/2.8 cells.
Cholera
Opposite coupling of prostaglandin E receptor EP3C with Gs and G(o). Stimulation of Gs and inhibition of G(o).
Cholera
OxLDL induces mitogen-activated protein kinase activation mediated via PI3-kinase/Akt in vascular smooth muscle cells.
Cholera
OxLDL upregulates CXCR2 expression in monocytes via scavenger receptors and activation of p38 mitogen-activated protein kinase.
Cholera
P2-purinoceptor-stimulated phosphoinositide turnover in chick myotubes. Calcium mobilization and the role of guanyl nucleotide-binding proteins.
Cholera
PAF effects on transmembrane signaling pathways in rat Kupffer cells.
Cholera
Pancreatic glucagon-like peptide-1 receptor couples to multiple G proteins and activates mitogen-activated protein kinase pathways in Chinese hamster ovary cells.
Cholera
Parathyroid hormone/adenylate cyclase coupling in vascular smooth muscle cells.
Cholera
PARPs and PAR as novel pharmacological targets for the treatment of stress granule-associated disorders.
Cholera
Participation of pertussis toxin-sensitive GTP-binding regulatory proteins in the suppression of baroreceptor reflex by neurotensin in the rat.
Cholera
Peptide mapping studies of the pertussis toxin substrate in human neutrophils, platelets and erythrocytes.
Cholera
Peptidergic modulation of G-protein coupled cyclic-AMP accumulation in the rat caudate nucleus.
Cholera
Pertussis and cholera toxin ADP-ribosylation in Dictyostelium discoideum membranes.
Cholera
Pertussis but not cholera toxin inhibits the stimulated increase in actin association with the cytoskeleton in rabbit neutrophils: role of the "G proteins" in stimulus-response coupling.
Cholera
Pertussis toxin actions on the pituitary-derived 235-1 clone: effects of PGE1, cholera toxin, and forskolin on cyclic AMP metabolism and prolactin release.
Cholera
Pertussis toxin B-subunit-induced Ca2(+)-fluxes in Jurkat human lymphoma cells: the action of long-term pre-treatment with cholera and pertussis holotoxins.
Cholera
Pertussis toxin inhibits intracellular pH changes in human neutrophils stimulated by N-formyl-methionyl-leucyl-phenylalanine.
Cholera
Pertussis toxin pretreatment abolishes the inhibitory effect of riluzole and carbachol on D-[3H]aspartate release from cultured cerebellar granule cells.
Cholera
Pertussis toxin substrate is a guanosine 5'-[beta-thio]diphosphate-, N-ethylmaleimide-, Mg2+- and temperature-sensitive GTP-binding protein.
Cholera
Pertussis toxin treatment blocks the inhibition of somatostatin and increases the stimulation by forskolin of cyclic AMP accumulation and adrenocorticotropin secretion from mouse anterior pituitary tumor cells.
Cholera
Pertussis toxin-mediated ADP-ribosylation of rabbit luteal Gi uncouples enkephalin inhibition of adenylyl cyclase.
Cholera
Pertussis toxin-sensitive G protein modulates the ability of histamine to stimulate cAMP production in the chick pineal gland.
Cholera
Pertussis toxin-sensitive G proteins mediate carbachol-induced REM sleep and respiratory depression.
Cholera
Pertussis toxin-sensitive Galphai protein and ERK-dependent pathways mediate ultrasound promotion of osteogenic transcription in human osteoblasts.
Cholera
Pertussis toxin-sensitive GTP-binding proteins regulate activation-induced apoptotic cell death of human natural killer cells.
Cholera
Pertussis-toxin insensitive enkephalin inhibition of adenylyl cyclase in lacrimal acinar cells.
Cholera
PGE2 increases the tetrodotoxin-resistant Nav1.9 sodium current in mouse DRG neurons via G-proteins.
Cholera
Phosphatidic acid and lysophosphatidic acid induce haptotactic migration of human monocytes.
Cholera
Phosphoinositide metabolism in a polyoma-BK-virus-transformed pancreatic islet cell line: evidence for constitutively activated phospholipase C.
Cholera
Photosensitivity of the isolated pigment epithelium and arachidonic acid metabolism: preliminary results.
Cholera
Physical and functional association of follitropin receptors with cholera toxin-sensitive guanine nucleotide-binding protein.
Cholera
Platelet activating factor activates MAPK and increases in intracellular calcium via independent pathways in B lymphocytes.
Cholera
Platelet activating factor stimulates a receptor-coupled membrane GTPase in guinea pig eosinophils.
Cholera
Platelet cytosolic 44-kDa protein is a substrate of cholera toxin-induced ADP-ribosylation and is not recognized by antisera against the alpha subunit of the stimulatory guanine nucleotide-binding regulatory protein.
Cholera
Platelet-activating factor (PAF) induces a contraction of isolated smooth muscle cells from guinea pig ileum: intracellular pathway involved.
Cholera
Platelet-activating factor (PAF) stimulates phosphatidylinositol hydrolysis in human peripheral blood mononuclear leukocytes.
Cholera
Platelet-activating factor induces NF-kappa B activation through a G protein-coupled pathway.
Cholera
Platelet-activating factor stimulates transcription of the heparin-binding epidermal growth factor-like growth factor in monocytes. Correlation with an increased kappa B binding activity.
Cholera
Pneumocystis carinii infection alters GTP-binding proteins in the lung.
Cholera
Possible involvement of GTP-binding proteins in 1 alpha,25-dihydroxyvitamin D3 induction of tissue transglutaminase in mouse peritoneal macrophages.
Cholera
Post-receptor defect accounts for phosphorylase hypersensitivity in cultured diabetic cardiomyocytes.
Cholera
Potentiation by cholera toxin of bradykinin-induced inositol phosphate production in the osteoblast-like cell line MC3T3-E1.
Cholera
Potentiation by higenamine of the aconitine-induced positive chronotropic effect in isolated right atria of mice: the effects of cholera toxin, forskolin and pertussis toxin.
Cholera
Potentiation of the glycine-activated Cl- current by ethanol in cultured mouse spinal neurons.
Cholera
Preferential involvement of Go and Gz proteins in mediating rat natural killer cell lysis of allogeneic and tumor target cells.
Cholera
Pregnancy enhances G protein activation and nitric oxide release from uterine arteries.
Cholera
Presynaptic inhibition by concanavalin A: are alpha-latrotoxin receptors involved in action potential-dependent transmitter release?
Cholera
Pretreatment with cholera or pertussis toxin differentially modulates morphine- and beta-endorphin-induced antinociception in the mouse formalin test.
Cholera
Priming effects of granulocyte-macrophage colony-stimulating factor are coupled to cholera toxin-sensitive guanine nucleotide binding protein in human T lymphocytes.
Cholera
Probable occurrence of toxin-susceptible G proteins in the nematode Caenorhabditis elegans.
Cholera
Properties of 1-methyladenine receptors in starfish oocyte membranes: involvement of pertussis toxin-sensitive GTP-binding protein in the receptor-mediated signal transduction.
Cholera
Properties of a novel GTP-binding protein which is associated with soluble phosphoinositides-specific phospholipase C.
Cholera
Properties of muscarinic-stimulated adenylate cyclase activity in rat olfactory bulb.
Cholera
Propionic acid-induced calcium mobilization in human neutrophils.
Cholera
Prostaglandin E(2) inhibits calcium current in two sub-populations of acutely isolated mouse trigeminal sensory neurons.
Cholera
Prostaglandin E2 can bimodally inhibit and stimulate the epididymal adipocyte adenylyl cyclase activity.
Cholera
Prostaglandin E2 contracts vascular smooth muscle and inhibits potassium currents in vascular smooth muscle cells of rat tail artery.
Cholera
Prostaglandin F(2alpha) receptor-dependent regulation of prostaglandin transport.
Cholera
Protein intake affects levels of G-protein subunits G alpha i2, G alpha i3, and G beta in rat glomerular membranes.
Cholera
Protein kinase C potentiates isoproterenol-mediated cyclic AMP production without modifying the homologous desensitization process in J774 cells.
Cholera
Protein kinase C regulation of the adenylyl cyclase system in rat prostatic epithelium.
Cholera
Protein tyrosine kinase involvement in the production of superoxide anion by neutrophils exposed to Aroclor 1242, a mixture of polychlorinated biphenyls.
Cholera
Purification of a histamine H3 receptor negatively coupled to phosphoinositide turnover in the human gastric cell line HGT1.
Cholera
Purine metabolites suppress proliferation of human NK cells through a lineage-specific purine receptor.
Cholera
Quartz crystal microbalance investigation of the interaction of bacterial toxins with ganglioside containing solid supported membranes.
Cholera
Rapid high mass resolution mass spectrometry using matrix-assisted ionization.
Cholera
Rapid membrane responses to dihydrotestosterone are sex dependent in growth plate chondrocytes.
Cholera
Receptors and transduction pathways for monocyte chemotactic protein-2 and monocyte chemotactic protein-3. Similarities and differences with MCP-1.
Cholera
Reduced hormone-stimulated adenylate cyclase activity in NIH-3T3 cells expressing the EJ human bladder ras oncogene.
Cholera
Regional characterization of G-protein subunits in glomeruli, cortices and medullas of the rat kidney.
Cholera
Regulation by GTP of a Ca(2+)-activated K+ channel in the apical membrane of rabbit cortical collecting duct cells.
Cholera
Regulation of bradykinin receptor level by cholera toxin, pertussis toxin and forskolin in cultured human fibroblasts.
Cholera
Regulation of bradykinin-induced Ins(1,4,5)P3 formation by protein kinase C in human fibroblasts.
Cholera
Regulation of cytosolic calcium by cAMP and cGMP in freshly isolated smooth muscle cells from bovine trachea.
Cholera
Regulation of follicle-stimulating hormone binding to receptors on bovine calf testis membranes by cholera toxin-sensitive guanine nucleotide binding protein.
Cholera
Regulation of G proteins by adenosine receptor agonist in coronary artery.
Cholera
Regulation of G(q/11)alpha by the gonadotropin-releasing hormone receptor.
Cholera
Regulation of kinesin expression and type IV collagenase secretion in invasive human prostate PC-3 tumor sublines.
Cholera
Regulation of lens cyclic nucleotide metabolism by Ca2+ plus calmodulin.
Cholera
Regulation of melanoma cell adhesion stabilization to fibronectin.
Cholera
Regulation of mouse placental lactogen secretion by G proteins before midpregnancy.
Cholera
Regulation of renal cortical Na-HCO3 cotransporter. II. Role of G proteins.
Cholera
Regulation of superoxide anion generation in bovine alveolar macrophages by bacterial lipopolysaccharide, serum proteins, and modulators of signal transduction.
Cholera
Regulation of the CHAPS-solubilized muscarinic receptors by an inhibitory GTP binding protein (Gi) in the brain of neonatal and adult rats.
Cholera
Regulation of the mannose 6-phosphate/IGF II receptor expression at the cell surface by mannose 6-phosphate, insulin like growth factors and epidermal growth factor.
Cholera
Regulation of thrombin-induced endothelial cell activation by bacterial toxins.
Cholera
Regulatory factors that determine growth and phenotype of normal human melanocytes.
Cholera
Relationship between the self-incompatibility and cAMP level in Lilium longiflorum.
Cholera
Release of guanosine triphosphate binding protein alpha subunits from mouse myocardial membranes: basic properties and their alterations in acute murine Chagas disease.
Cholera
Requirements for Langerhans' cell depletion following in vitro exposure of murine skin to ultraviolet-B.
Cholera
Resistance of the insulinotropic action of alpha-D-glucose and beta-L-glucose pentaacetates to cholera and pertussis toxins.
Cholera
Role of a pertussis toxin sensitive G-protein in mediating the effects of phorbol esters on receptor activated cyclic AMP accumulation in Jurkat cells.
Cholera
Role of a pertussis toxin substrate in the control of lectin-induced cap formation in human neutrophils.
Cholera
Role of a protein regulating guanine nucleotide binding in phosphoinositide breakdown and calcium mobilization by bradykinin in neuroblastoma X glioma hybrid NG108-15 cells: effects of pertussis toxin and cholera toxin on receptor-mediated signal transduction.
Cholera
Role of G-proteins in ciliary process adenylyl cyclase responses of the albino rabbit eye.
Cholera
Role of guanine nucleotide regulatory proteins and inositol phosphates in the hormone induced mobilization of hepatocyte calcium.
Cholera
Role of protein kinase C in transforming growth factor-beta 1 induction of carcinoembryonic antigen in human colon carcinoma cells.
Cholera
Sarafotoxin-induced calcium mobilization in cultured dog tracheal smooth muscle cells.
Cholera
Second-messenger regulation of receptor association with clathrin-coated pits: a novel and selective mechanism in the control of CD4 endocytosis.
Cholera
Secretoneurin and chemoattractant receptor interactions.
Cholera
Selective activation of a chimeric Gi1/Gs G protein alpha subunit by the human IP prostanoid receptor: analysis using agonist stimulation of high affinity GTPase activity and [35S]guanosine-5'-O-(3-thio)triphosphate binding.
Cholera
Selective loss of pertussis toxin-sensitive G-proteins from the plasma membrane after antibody-induced internalization of T-cell surface molecules.
Cholera
Selective modulation by guanine nucleotides of the high affinity subset of plasma membrane receptors for leukotriene B4 on human polymorphonuclear leukocytes.
Cholera
Sequence and structural links between distant ADP-ribosyltransferase families.
Cholera
Sequence of the alpha subunit of photoreceptor G protein: homologies between transducin, ras, and elongation factors.
Cholera
Serotonin receptor-mediated activation of adenylate cyclase in the neuroblastoma NCB.20: a novel 5-hydroxytryptamine receptor.
Cholera
Serum amyloid A induces calcium mobilization and chemotaxis of human monocytes by activating a pertussis toxin-sensitive signaling pathway.
Cholera
Signal transduction alterations in GH(1)2C1 rat pituitary tumour cells following treatment with 5-azacytidine.
Cholera
Signal transduction in Coprinus congregatus: evidence for the involvement of G proteins in blue light photomorphogenesis.
Cholera
Signal transduction modulation by lithium: cell culture, cerebral microdialysis and human studies.
Cholera
Signal transduction of a tissue interaction during embryonic heart development.
Cholera
Signal transduction via the B cell antigen receptor: involvement of a G protein and regulation of signaling.
Cholera
Simultaneous coupling of alpha 2-adrenergic receptors to two G-proteins with opposing effects. Subtype-selective coupling of alpha 2C10, alpha 2C4, and alpha 2C2 adrenergic receptors to Gi and Gs.
Cholera
Single-cell analysis of macrophage chemotactic protein-1-regulated cytosolic Ca2+ increase in human adherent monocytes.
Cholera
Site-specific mutagenesis of the catalytic subunit of cholera toxin: substituting lysine for arginine 7 causes loss of activity.
Cholera
Solubilization from rat pancreatic plasma membranes of a cholecystokinin (CCK) agonist-receptor complex interacting with guanine nucleotide regulatory proteins coexisting in the same macromolecular system.
Cholera
Solubilization of the vasopressin receptor from rat liver plasma membranes. Evidence for a receptor X GTP-binding protein complex.
Cholera
Somatocrinin stimulates adenylate cyclase-Ns regulatory subunit in a GH3 cell-line: comparison with VIP.
Cholera
Somatostatin acts through G-proteins on dopaminergic adenylate cyclase in the caudate-putamen of the rat.
Cholera
Somatostatin inhibits bombesin-stimulated Gi-protein via its own receptor in rabbit colonic smooth muscle cells.
Cholera
Somatostatin inhibits cAMP-mediated cholinergic transmission in the myenteric plexus.
Cholera
Somatostatin modulation of adenosine receptor coupled G-protein subunits in the caudate nucleus of the rat.
Cholera
Spermatozoa contain a guanine nucleotide-binding protein ADP-ribosylated by pertussis toxin.
Cholera
Stimulation of beta(3)-adrenoceptors causes phosphorylation of p38 mitogen-activated protein kinase via a stimulatory G protein-dependent pathway in 3T3-L1 adipocytes.
Cholera
Stimulation of cyclic adenosine 3',5'-monophosphate production enhances hypothalamic luteinizing hormone-releasing hormone release without increasing prostaglandin E2 synthesis: studies in prepubertal female rats.
Cholera
Stimulation of DNA synthesis in Jurkat cells by synergistic action between adenine and guanine nucleotides.
Cholera
Stimulation of generation of inositol phosphates by carbamoylcholine and its inhibition by phorbol esters and iodide in dog thyroid cells.
Cholera
Stimulation of glycogenolysis by three locust adipokinetic hormones involves Gs and cAMP.
Cholera
Stimulation of high-affinity GTPase activity and cholera toxin-catalysed [32P]ADP-ribosylation of Gi by lysophosphatidic acid (LPA) in wild-type and alpha 2C10 adrenoceptor-transfected Rat 1 fibroblasts.
Cholera
Stimulation of luteinizing hormone (LH) release and phospholipid breakdown by guanosine triphosphate in permeabilized pituitary gonadotropes: antagonist action suggests association of a G protein and gonadotropin-releasing hormone receptor.
Cholera
Stimulation of luteinizing hormone release by sodium fluoride is independent of protein kinase-C activity and unaffected by desensitization to gonadotropin-releasing hormone.
Cholera
Stimulation of mitogen-activated protein kinase by gonadotropin-releasing hormone in human granulosa-luteal cells.
Cholera
Stimulation of mitogen-activated protein kinase by thyrotropin in primary cultured human thyroid follicles.
Cholera
Stimulation of mono-ADP ribosylation in rat liver plasma membranes after long-term alcohol intake.
Cholera
Stimulatory and inhibitory guanine-nucleotide-binding regulatory protein involvement in stimulation of arachidonic-acid release by N-formyl-methionyl-leucyl-phenylalanine and platelet-activating factor from guinea-pig alveolar macrophages. Differential receptor/G-protein interaction assessed by pertussis and cholera toxins.
Cholera
Stimulatory effect of guanine nucleotides on prostaglandin E1 binding to murine renal outer medulla.
Cholera
Streptococcal glycoprotein-induced tumour cell growth inhibition involves the modulation of a pertussis toxin-sensitive G protein.
Cholera
Stromal Cell-Derived Factor 1 Increases Tetrodotoxin-Resistant Sodium Currents Nav1.8 and Nav1.9 in Rat Dorsal Root Ganglion Neurons via Different Mechanisms.
Cholera
Structural and functional relationships of guanosine triphosphate binding proteins.
Cholera
Structural characterization of pertussis toxin A subunit.
Cholera
Structural evidence for the evolution of pyrogenic toxin superantigens.
Cholera
Structure-activity relationship of adrenomedullin, a novel vasodilatory peptide, in cultured rat vascular smooth muscle cells.
Cholera
Study of the activation mechanism of adriamycin on rat mast cells.
Cholera
Study of the phorbol ester effect on Alzheimer amyloid precursor processing: sequence requirements and involvement of a cholera toxin sensitive protein.
Cholera
Subcellular distribution and membrane association of human neutrophil substrates for ADP-ribosylation by pertussis toxin and cholera toxin.
Cholera
Substance P stimulation of polyphosphoinositide hydrolysis in rat anterior pituitary membranes involves a GTP-dependent mechanism.
Cholera
Subtype-specific coupling with ADP-ribosyl cyclase of metabotropic glutamate receptors in retina, cervical superior ganglion and NG108-15 cells.
Cholera
Subtypes of Guanine-Nucleotide-Binding Regulatory Proteins at the Locus coeruleus Involved in Fentanyl-Induced Muscular Rigidity in the Rat.
Cholera
Subunit S1 of pertussis toxin: mapping of the regions essential for ADP-ribosyltransferase activity.
Cholera
Suramin has adjuvant properties and promotes expansion of antigen-specific Th1 and Th2 cells in vivo.
Cholera
Sustained activation of phospholipase D via adenosine A3 receptors is associated with enhancement of antigen- and Ca(2+)-ionophore-induced secretion in a rat mast cell line.
Cholera
T cell activation via the T cell receptor: a comparison between WT31 (defining alpha/beta TcR)-induced and anti-CD3-induced activation of human T lymphocytes.
Cholera
Terminal serotonin autoreceptor function in the rat hippocampus is not modified by pertussis and cholera toxins.
Cholera
The adenylyl cyclase-cyclic AMP system modulates morphological and functional development of hypothalamic beta-endorphin neurons in culture.
Cholera
The antineoplastic drug vinorelbine activates non-immunological histamine release from rat mast cells.
Cholera
The bombesin receptor is coupled to a guanine nucleotide-binding protein which is insensitive to pertussis and cholera toxins.
Cholera
The central cannabinoid receptor (CB1) mediates inhibition of nitric oxide production by rat microglial cells.
Cholera
The cloned human 5-HT1E receptor couples to inhibition and activation of adenylyl cyclase via two distinct pathways in transfected BS-C-1 cells.
Cholera
The comparative analysis of proenkephalin mRNA expression induced by cholera toxin and pertussis toxin in primary cultured rat cortical astrocytes.
Cholera
The effect of cholera toxin on the inhibition of vasopressin-stimulated inositol phospholipid hydrolysis is a cyclic AMP-mediated event at the level of receptor binding.
Cholera
The effect of PGF2 alpha on parathyroid hormone-stimulated cyclic AMP production in mouse osteoblastic cell, MC3T3E1.
Cholera
The effect of vasoactive intestinal polypeptide (VIP) on forskolin stimulated adenylate cyclase in the caudate-putamen of the rat.
Cholera
The effects of cholera toxin, pertussis toxin, sodium fluoride and alpha-interferon on prostaglandin production by the guinea-pig endometrium.
Cholera
The effects of endothelins on the secretion of prolactin, luteinizing hormone, and follicle-stimulating hormone are mediated by different guanine nucleotide-binding proteins.
Cholera
The effects of extracellular calcium and epinephrine on cytosolic-free calcium in single rat adipocytes.
Cholera
The effects of pertussis toxin and cholera toxin on mitogen-induced interleukin-2 production: evidence for G protein involvement in signal transduction.
Cholera
The effects of phorbol 12-myristate 13-acetate, cholera toxin, prostaglandin E2 and norepinephrine on inducible nitric oxide synthase activation induced by lipopolysaccharide in C6 cells.
Cholera
The GTP-binding regulatory proteins, Gs and G(i), are altered in erythrocyte membranes of patients with ischemic heart disease resulting from coronary atherosclerosis.
Cholera
The heterotrimeric GTP-binding protein, GS, modulates the Cl- conductance of rat parotid acinar secretory granules.
Cholera
The inhibition of high-voltage-activated calcium current by activation of MrgC11 involves phospholipase C-dependent mechanisms.
Cholera
The lymphoma transmembrane glycoprotein GP85 (CD44) is a novel guanine nucleotide-binding protein which regulates GP85 (CD44)-ankyrin interaction.
Cholera
The P2Y purinoceptor in rat brain microvascular endothelial cells couple to inhibition of adenylate cyclase.
Cholera
The regulation of adenylate cyclase in liver membranes of lean and obese mice.
Cholera
The role of G proteins in thromospondin-1-induced vascular smooth muscle cell migration.
Cholera
The role of G-proteins in the activation of human leukocytes by particulate stimuli to produce reactive oxygen metabolites.
Cholera
The role of G-proteins in the mitogenesis of rat lactogen-dependent and lactogen-independent Nb2 lymphoma cells.
Cholera
The role of protein kinases A and C pathways in the regulation of mitogen-activated protein kinase activation in response to gonadotropin-releasing hormone receptor activation.
Cholera
The signaling pathway in photoresponses that may be mediated by visual pigments in erythrophores of Nile tilapia.
Cholera
The stimulatory and inhibitory effects of dopamine on prolactin secretion involve different G-proteins.
Cholera
The thyrotropin receptor is not involved in the activation of p42/p44 mitogen-activated protein kinases by thyrotropin preparations in Chinese hamster ovary cells expressing the human thyrotropin receptor.
Cholera
The uterotonic action of the aqueous extract of Bridelia atroviridis in the rat.
Cholera
Theileria parva sporozoite entry into bovine lymphocytes involves both parasite and host cell signal transduction processes.
Cholera
Thrombin, unlike vasopressin, appears to stimulate two distinct guanine nucleotide regulatory proteins in human platelets.
Cholera
Thrombospondin promotes chemotaxis and haptotaxis of human peripheral blood monocytes.
Cholera
Thromboxane A2 agonist modulation of excitatory synaptic transmission in the rat hippocampal slice.
Cholera
Thromboxane A2 mediates the stimulation of inositol 1,4,5-trisphosphate production and intracellular calcium mobilization by bradykinin in neonatal rat ventricular cardiomyocytes.
Cholera
Thyrotropin effect on the availability of Ni regulatory protein in FRTL-5 rat thyroid cells to ADP-ribosylation by pertussis toxin.
Cholera
Thyrotropin-releasing hormone activates a Ca2+-dependent polyphosphoinositide phosphodiesterase in permeable GH3 cells. GTP gamma S potentiation by a cholera and pertussis toxin-insensitive mechanism.
Cholera
Thyrotropin-releasing hormone and gonadotropin-releasing hormone receptors activate phospholipase C by coupling to the guanosine triphosphate-binding proteins Gq and G11.
Cholera
Thyrotropin-releasing hormone stimulation of polyphosphoinositide hydrolysis in GH3 cell membranes is GTP dependent but insensitive to cholera or pertussis toxin.
Cholera
TLR2 transmodulates monocyte adhesion and transmigration via Rac1- and PI3K-mediated inside-out signaling in response to Porphyromonas gingivalis fimbriae.
Cholera
TNF-alpha stimulates increased plasma membrane guanine nucleotide binding protein activity in polymorphonuclear leukocytes.
Cholera
Toxins-useful biochemical tools for leukocyte research.
Cholera
Transcriptional regulation of Na/K-ATPase by corticosteroids, glycyrrhetinic acid and second messenger pathways in rat kidney epithelial cells.
Cholera
Transforming growth factor-beta1 regulation of growth zone chondrocytes is mediated by multiple interacting pathways.
Cholera
Treatment of intact striatal neurones with cholera toxin or 8-bromoadenosine 3',5'-(cyclic)phosphate decreases the ability of pertussis toxin to ADP-ribosylate the alpha-subunits of inhibitory and other guanine-nucleotide-binding regulatory proteins, Gi and Go. Evidence for two distinct mechanisms.
Cholera
Trimeric G proteins regulate the cytosol-induced redistribution of Golgi enzymes into the endoplasmic reticulum.
Cholera
Trypanosoma cruzi: infection of cultured human endothelial cells alters inositol phosphate synthesis.
Cholera
Tumor necrosis factor alpha 'primes' the platelet-activating factor-induced superoxide production by human neutrophils: possible involvement of G proteins.
Cholera
Tumor necrosis factor alpha modulates parathyroid hormone action in UMR-106-01 osteoblastic cells.
Cholera
Two different G-proteins mediate neuropeptide Y and bradykinin-stimulated phospholipid breakdown in cultured rat sensory neurons.
Cholera
Two distinct light regulated G-proteins in octopus photoreceptors.
Cholera
Two distinct pathways of platelet-activating factor-induced hydrolysis of phosphoinositides in primary cultures of rat Kupffer cells.
Cholera
TXA2 agonists inhibit high-voltage-activated calcium channels in rat hippocampal CA1 neurons.
Cholera
Vanadate changes Ca2+ influx pathway properties in human red blood cells.
Cholera
Variations in guanine-binding proteins (Gs, Gi) in cultured bovine adrenal cells. Consequences on the effects of phorbol ester and angiotensin II on adrenocorticotropin-induced and cholera-toxin-induced cAMP production.
Cholera
Vascular insulin/insulin-like growth factor-1 resistance in female obese Zucker rats.
Cholera
Vasoactive intestinal polypeptide modulates GABAA receptor function through activation of cyclic AMP.
Cholera
Vasopressin and amastatin induce V(1)-receptor-mediated suppression of excitatory transmission in the rat parabrachial nucleus.
Cholera
Vasopressin resistance in chronic renal failure. Evidence for the role of decreased V2 receptor mRNA.
Cholera
Voltage-dependent calcium channels and Gi regulatory protein mediate the human sperm acrosomal exocytosis induced by N-acetylglucosaminyl/mannosyl neoglycoproteins.
Cholera
Wnt-5a and G-protein signaling are required for collagen-induced DDR1 receptor activation and normal mammary cell adhesion.
Cholera
[Abnormalities in the beta-adrenergic receptor-adenylate cyclase system in the ventricular myocardium of spontaneously hypertensive rats]
Cholera
[Effect of bacterial toxins on the mitogen-induced increase of the Ca2+ concentration in the cytoplasm of rat thymocytes. The role of N proteins]
Cholera
[Identification and purification of GTP-binding regulatory proteins from plasma membranes of swine heart]
Cholera
[Involvement of G proteins between receptors and KCa channels in the regulation of airway tone by the autonomic nervous system]
Cholera
[Isoproterenol, denopamine, and atenolol-induced alterations in beta-adrenergic receptor-adenylate cyclase system of rat myocardium]
Cholera
[Role of a guanine nucleotide regulatory protein in exocrine pancreatic secretion--effects of cholera toxin and pertussis toxin on cholecystokinin action]
Cholera
[The effect of G protein regulator on pollen germination and [Ca2+]i variation in Pyrus serotina Rehd. pollen.]
Cholera
[The role of different subtypes of G protein in the secretory function of macrophages stimulated by activated complement following severe burn injury]
Chondrosarcoma
BL-038, a Benzofuran Derivative, Induces Cell Apoptosis in Human Chondrosarcoma Cells through Reactive Oxygen Species/Mitochondrial Dysfunction and the Caspases Dependent Pathway.
Chondrosarcoma
Current questions in bone sarcomas.
Chondrosarcoma
Inhibition of PARP Sensitizes Chondrosarcoma Cell Lines to Chemo- and Radiotherapy Irrespective of the IDH1 or IDH2 Mutation Status.
Chondrosarcoma
Recombinant human PDCD5 sensitizes chondrosarcomas to cisplatin chemotherapy in vitro and in vivo.
Chondrosarcoma
Sensitization of chondrosarcoma cells with PARP inhibitor and high-LET radiation.
Chondrosarcoma
Vacuolar Protein Sorting 4B (VPS4B) Regulates Apoptosis of Chondrocytes via p38 Mitogen-Activated Protein Kinases (MAPK) in Osteoarthritis.
Chordoma
Blockage of Stat3 With CDDO-Me Inhibits Tumor Cell Growth in Chordoma.
Chordoma
Combination of PARP inhibitor and temozolomide to suppress chordoma progression.
Chordoma
Defective homologous recombination DNA repair as therapeutic target in advanced chordoma.
Chordoma
Histone deacetylase inhibitors as potential therapeutic approaches for chordoma: An immunohistochemical and functional analysis.
Chordoma
Identification of therapeutic targets in chordoma through comprehensive genomic and transcriptomic analyses.
Chordoma
PARP1 is a novel independent prognostic factor for the poor prognosis of chordoma.
Choriocarcinoma
Overexpression of NANOG in gestational trophoblastic diseases: effect on apoptosis, cell invasion, and clinical outcome.
Choriocarcinoma
PARP expression in germ cell tumours.
Ciliopathies
Analysis from the perspective of cilia: the protective effect of PARP inhibitors on visual function during light-induced damage.
Cleft Palate
Alteration of DNA Damage Response Causes Cleft Palate.
Cockayne Syndrome
Cockayne syndrome group A and B proteins converge on transcription-linked resolution of non-B DNA.
Cockayne Syndrome
Cooperation of the Cockayne syndrome group B protein and poly(ADP-ribose) polymerase 1 in the response to oxidative stress.
Cockayne Syndrome
Hypermutation of immunoglobulin genes in memory B cells of DNA repair-deficient mice.
Cockayne Syndrome
Linking DNA damage, NAD(+)/SIRT1, and aging.
Cockayne Syndrome
PARP and CSB modulate the processing of transcription-mediated DNA strand breaks.
Cockayne Syndrome
PARP10 deficiency manifests by severe developmental delay and DNA repair defect.
Cockayne Syndrome
Poly(ADP-ribose) polymerase 1 (PARP1) promotes oxidative stress-induced association of Cockayne syndrome group B protein with chromatin.
Cockayne Syndrome
Poly(ADP-ribosyl)ation accelerates DNA repair in a pathway dependent on Cockayne syndrome B protein.
Coinfection
Activation of caspases in pig kidney cells infected with wild-type and CrmA/SPI-2 mutants of cowpox and rabbitpox viruses.
Coinfection
C-terminal deletion mutant p21(WAF1/CIP1) enhances E2F-1-mediated apoptosis in colon adenocarcinoma cells.
Coinfection
Lethal infection by Bordetella pertussis mutants in the infant mouse model.
Colitis
5-Aminoisoquinolinone reduces colon injury by experimental colitis.
Colitis
Activator protein-1 signalling pathway and apoptosis are modulated by poly(ADP-ribose) polymerase-1 in experimental colitis.
Colitis
Attenuation of the progression of adjuvant-induced arthritis by 3-aminobenzamide treatment.
Colitis
Beyond dna repair,the immunological role of parp-1 and its siblings.
Colitis
Effects of 3-aminobenzamide, an inhibitor of poly (ADP-ribose) polymerase, in a mouse model of acute pancreatitis induced by cerulein.
Colitis
GPI 6150, a PARP inhibitor, reduces the colon injury caused by dinitrobenzene sulfonic acid in the rat.
Colitis
Inhibition of poly(ADP-ribose) polymerase attenuates inflammation in a model of chronic colitis.
Colitis
Inhibitors of poly (ADP-ribose) polymerase modulate signal transduction pathways in colitis.
Colitis
PARP inhibition reduces acute colonic inflammation in rats.
Colitis
Poly(ADP-ribose) polymerase and the therapeutic effects of its inhibitors.
Colitis
Poly(ADP-ribose) polymerase inhibitors.
Colitis
Poly(ADP-ribose) polymerase inhibitors: new pharmacological functions and potential clinical implications.
Colitis
Poly(ADP-ribose) polymerase is a regulator of chemokine production: relevance for the pathogenesis of shock and inflammation.
Colitis
Poly(ADP-ribose) polymerase-1 (PARP-1) and its therapeutic implications.
Colitis
Poly(ADP-ribose) polymerase-1 inhibitor ameliorates dextran sulfate sodium-induced colitis in mice by regulating the balance of Th17/Treg cells and inhibiting the NF-?B signaling pathway.
Colitis
Structure and function of poly(ADP-ribose) polymerase-1: role in oxidative stress-related pathologies.
Colitis
The Peri-appendiceal Red Patch in Ulcerative Colitis: Review of the University of Chicago Experience.
Colitis
Transcriptional reprogramming and resistance to colonic mucosal injury in Poly(ADP-ribose) polymerase 1 (PARP1)-deficient mice.
Colitis
Treatment with PARP-1 inhibitors, GPI 15427 or GPI 16539, ameliorates intestinal damage in rat models of colitis and shock.
Colitis
Upregulation of Salmonella-induced IL-6 production in Caco-2 cells by PJ-34, PARP-1 inhibitor: involvement of PI3K, p38 MAPK, ERK, JNK, and NF-kappaB.
Colitis, Ulcerative
DNA Repair Protein Expression and Oxidative/Nitrosative Stress in Ulcerative Colitis and Sporadic Colorectal Cancer.
Colitis, Ulcerative
PARP inhibition reduces acute colonic inflammation in rats.
Colonic Neoplasms
2'-Hydroxycinnamaldehyde induces apoptosis through HSF1-mediated BAG3 expression.
Colonic Neoplasms
8-Oxo-7,8-dihydroguanine and uric acid as efficient predictors of survival in colon cancer patients.
Colonic Neoplasms
?-Lapachone Inhibits Lung Metastasis of Colorectal Cancer by Inducing Apoptosis of CT26 Cells.
Colonic Neoplasms
Absence of stimulation of poly(ADP-ribose) polymerase activity in patients predisposed to colon cancer.
Colonic Neoplasms
Acetylcholinesterase expression mediated by c-Jun-NH2-terminal kinase pathway during anticancer drug-induced apoptosis.
Colonic Neoplasms
Acriflavine enhances radiosensitivity of colon cancer cells through endoplasmic reticulum stress-mediated apoptosis.
Colonic Neoplasms
Adenosine induces apoptosis through TNFR1/RIPK1/P38 axis in colon cancer cells.
Colonic Neoplasms
Anticancer effect of fermented Insampaedok-san in human colon cancer cells: a pilot study.
Colonic Neoplasms
Apigenin induces apoptosis by suppressing Bcl-xl and Mcl-1 simultaneously via signal transducer and activator of transcription 3 signaling in colon cancer.
Colonic Neoplasms
Benzo[b]tryptanthrin inhibits MDR1, topoisomerase activity, and reverses adriamycin resistance in breast cancer cells.
Colonic Neoplasms
Bufalin induces autophagy-mediated cell death in human colon cancer cells through reactive oxygen species generation and JNK activation.
Colonic Neoplasms
Capsaicin Mediates Cell Cycle Arrest and Apoptosis in Human Colon Cancer Cells via Stabilizing and Activating p53.
Colonic Neoplasms
CD44-shRNA recombinant adenovirus inhibits cell proliferation, invasion, and migration, and promotes apoptosis in HCT116 colon cancer cells.
Colonic Neoplasms
Checkpoint signaling, base excision repair, and PARP promote survival of colon cancer cells treated with 5-fluorodeoxyuridine but not 5-fluorouracil.
Colonic Neoplasms
Chemical characterization and biological activity data for a novel indirubin derivative, LDD-1819.
Colonic Neoplasms
Colloidal mesoporous silica nanoparticles enhance the biological activity of resveratrol.
Colonic Neoplasms
Common fragile sites in colon cancer cell lines: role of mismatch repair, RAD51 and poly(ADP-ribose) polymerase-1.
Colonic Neoplasms
Correction: Targeting PARP-1 with metronomic therapy modulates MDSC suppressive function and enhances anti-PD-1- immunotherapy in colon cancer.
Colonic Neoplasms
Cytotoxic effects of Echinacea purpurea flower extracts and cichoric acid on human colon cancer cells through induction of apoptosis.
Colonic Neoplasms
Detection of poly(ADP-ribose) polymerase cleavage in response to treatment with topoisomerase I inhibitors: a potential surrogate end point to assess treatment effectiveness.
Colonic Neoplasms
Dihydroartemisinin increases apoptosis of colon cancer cells through targeting Janus kinase 2/signal transducer and activator of transcription 3 signaling.
Colonic Neoplasms
Dimeric 3,5-bis(benzylidene)-4-piperidones: A novel cluster of tumour-selective cytotoxins possessing multidrug-resistant properties.
Colonic Neoplasms
DNA repair single-nucleotide polymorphisms in colorectal cancer and their role as modifiers of the effect of cigarette smoking and alcohol in the Singapore Chinese Health Study.
Colonic Neoplasms
Downregulation of NIT2 inhibits colon cancer cell proliferation and induces cell cycle arrest through the caspase-3 and PARP pathways.
Colonic Neoplasms
Epigallocatechin-3-Gallate Induces Apoptosis as a TRAIL Sensitizer via Activation of Caspase 8 and Death Receptor 5 in Human Colon Cancer Cells.
Colonic Neoplasms
ERCC1, PARP-1, and AQP1 as predictive biomarkers in colon cancer patients receiving adjuvant chemotherapy.
Colonic Neoplasms
Expression of an Oncogenic BARD1 Splice Variant Impairs Homologous Recombination and Predicts Response to PARP-1 Inhibitor Therapy in Colon Cancer.
Colonic Neoplasms
Fish fatty acids alter markers of apoptosis in colorectal adenoma and adenocarcinoma cell lines but fish consumption has no impact on apoptosis-induction ex vivo.
Colonic Neoplasms
Frondoside A Enhances the Anti-Cancer Effects of Oxaliplatin and 5-Fluorouracil on Colon Cancer Cells.
Colonic Neoplasms
Functional characterization of peroxisome proliferator-activated receptor-?/? expression in colon cancer.
Colonic Neoplasms
Human colon cancer HT-29 cell death responses to doxorubicin and Morus Alba leaves flavonoid extract.
Colonic Neoplasms
Identification of PARP-1 in cancer stem cells of gastrointestinal cancers: A preliminary study.
Colonic Neoplasms
Ilimaquinone induces death receptor expression and sensitizes human colon cancer cells to TRAIL-induced apoptosis through activation of ROS-ERK/p38 MAPK-CHOP signaling pathways.
Colonic Neoplasms
Induction of apoptosis in colon cancer cells by cyclooxygenase-2 inhibitor NS398 through a cytochrome c-dependent pathway.
Colonic Neoplasms
Influence of MLH1 on colon cancer sensitivity to poly(ADP-ribose) polymerase inhibitor combined with irinotecan.
Colonic Neoplasms
Inhibition of arginine ADP-ribosyltransferase 1 reduces the expression of poly(ADP-ribose) polymerase-1 in colon carcinoma.
Colonic Neoplasms
Inhibition of poly(ADP-ribose) polymerase prevents irinotecan-induced intestinal damage and enhances irinotecan/temozolomide efficacy against colon carcinoma.
Colonic Neoplasms
Ipatasertib sensitizes colon cancer cells to TRAIL-induced apoptosis through ROS-mediated caspase activation.
Colonic Neoplasms
Mechanism of colon cancer cell apoptosis mediated by pyropheophorbide-a methylester photosensitization.
Colonic Neoplasms
Melatonin potentiates the antiproliferative and pro-apoptotic effects of ursolic acid in colon cancer cells by modulating multiple signaling pathways.
Colonic Neoplasms
Methylseleninic acid potentiates multiple types of cancer cells to ABT-737-induced apoptosis by targeting Mcl-1 and Bad.
Colonic Neoplasms
MSH3 expression does not influence the sensitivity of colon cancer HCT116 cell line to oxaliplatin and poly(ADP-ribose) polymerase (PARP) inhibitor as monotherapy or in combination.
Colonic Neoplasms
Novel TOPK inhibitor HI-TOPK-032 effectively suppresses colon cancer growth.
Colonic Neoplasms
Pan-Cancer Analysis of PARP1 Alterations as Biomarkers in the Prediction of Immunotherapeutic Effects and the Association of Its Expression Levels and Immunotherapy Signatures.
Colonic Neoplasms
PARP-1 expression is increased in colon adenoma and carcinoma and correlates with OGG1.
Colonic Neoplasms
Patulin induces colorectal cancer cells apoptosis through EGR-1 dependent ATF3 up-regulation.
Colonic Neoplasms
Periostin induces chemoresistance in colon cancer cells through activation of the PI3K/Akt/survivin pathway.
Colonic Neoplasms
Photodynamic therapy with the phthalocyanine photosensitizer Pc 4 of SW480 human colon cancer xenografts in athymic mice.
Colonic Neoplasms
Polyunsaturated fatty acids, DNA repair single nucleotide polymorphisms and colorectal cancer in the Singapore Chinese Health Study.
Colonic Neoplasms
Prodigiosin-induced apoptosis in human colon cancer cells.
Colonic Neoplasms
Sclareol induces apoptosis in human HCT116 colon cancer cells in vitro and suppression of HCT116 tumor growth in immunodeficient mice.
Colonic Neoplasms
SHP2-Mediated Inhibition of DNA Repair Contributes to cGAS-STING Activation and Chemotherapeutic Sensitivity in Colon Cancer.
Colonic Neoplasms
Simultaneous inhibition of ATR and PARP sensitizes colon cancer cell lines to irinotecan.
Colonic Neoplasms
Targeting PARP-1 with metronomic therapy modulates MDSC suppressive function and enhances anti-PD-1 immunotherapy in colon cancer.
Colonic Neoplasms
Terpenes from essential oils and hydrolate of Teucrium alopecurus triggered apoptotic events dependent on caspases activation and PARP cleavage in human colon cancer cells through decreased protein expressions.
Colonic Neoplasms
The PARP inhibitor ABT-888 synergizes irinotecan treatment of colon cancer cell lines.
Colonic Neoplasms
The pro-apoptotic effect of quercetin in cancer cell lines requires ER?-dependent signals.
Colonic Neoplasms
The steroidal Na+/K+ ATPase inhibitor 3-[(R)-3-pyrrolidinyl]oxime derivative (3-R-POD) induces potent pro-apoptotic responses in colonic tumor cells.
Colonic Neoplasms
The use of olaparib (AZD2281) potentiates SN-38 cytotoxicity in colon cancer cells by indirect inhibition of Rad51-mediated repair of DNA double-strand breaks.
Colonic Neoplasms
TRAIL and docosahexaenoic acid cooperate to induce HT-29 colon cancer cell death.
Colonic Neoplasms
Transgelin interacts with PARP1 in human colon cancer cells.
Colonic Neoplasms
Tumor necrosis factor-alpha induces apoptosis associated with poly(ADP-ribose) polymerase cleavage in HT-29 colon cancer cells.
Colonic Neoplasms
Two new Loci for body-weight regulation identified in a joint analysis of genome-wide association studies for early-onset extreme obesity in French and german study groups.
Colonic Neoplasms
Ursolic acid simultaneously targets multiple signaling pathways to suppress proliferation and induce apoptosis in colon cancer cells.
Colonic Neoplasms
Vitexin-2-O-xyloside, raphasatin and (-)-epigallocatechin-3-gallate synergistically affect cell growth and apoptosis of colon cancer cells.
Colorectal Neoplasms
A novel small molecule inhibits STAT3 phosphorylation and DNA binding activity and exhibits potent growth suppressive activity in human cancer cells.
Colorectal Neoplasms
A phase 2 study of the PARP inhibitor veliparib plus temozolomide in patients with heavily pretreated metastatic colorectal cancer.
Colorectal Neoplasms
A Subset of Colorectal Cancers with Cross-Sensitivity to Olaparib and Oxaliplatin.
Colorectal Neoplasms
Alkannin-Induced Oxidative DNA Damage Synergizes With PARP Inhibition to Cause Cancer-Specific Cytotoxicity.
Colorectal Neoplasms
Analyzing structure-function relationships of artificial and cancer-associated PARP1 variants by reconstituting TALEN-generated HeLa PARP1 knock-out cells.
Colorectal Neoplasms
ASO Author Reflections: ATMIN Altering the WNT Signaling Pathway via PARP1 in MSI-High Colorectal Cancer.
Colorectal Neoplasms
ATM-Deficient Colorectal Cancer Cells Are Sensitive to the PARP Inhibitor Olaparib.
Colorectal Neoplasms
ATMIN Suppresses Metastasis by Altering the WNT-Signaling Pathway via PARP1 in MSI-High Colorectal Cancer.
Colorectal Neoplasms
BRD4 Inhibitor AZD5153 Suppresses the Proliferation of Colorectal Cancer Cells and Sensitizes the Anticancer Effect of PARP Inhibitor.
Colorectal Neoplasms
Chromosome 13 poly(ADP-ribose) polymerase polymorphisms and lung cancer risk.
Colorectal Neoplasms
Colorectal cancers differ in respect of PARP-1 protein expression.
Colorectal Neoplasms
Combination Therapy with Radiation and PARP Inhibition Enhances Responsiveness to Anti-PD-1 Therapy in Colorectal Tumor Models.
Colorectal Neoplasms
Combined olaparib and oxaliplatin inhibits tumor proliferation and induces G2/M arrest and ?-H2AX foci formation in colorectal cancer.
Colorectal Neoplasms
Control of replication stress and mitosis in colorectal cancer stem cells through the interplay of PARP1, MRE11 and RAD51.
Colorectal Neoplasms
Discovery of Novel Spiroindoline Derivatives as Selective Tankyrase Inhibitors.
Colorectal Neoplasms
DNA Repair Protein Expression and Oxidative/Nitrosative Stress in Ulcerative Colitis and Sporadic Colorectal Cancer.
Colorectal Neoplasms
DNA repair single-nucleotide polymorphisms in colorectal cancer and their role as modifiers of the effect of cigarette smoking and alcohol in the Singapore Chinese Health Study.
Colorectal Neoplasms
Dual inhibition of VEGF and PARP suppresses KRAS-mutant colorectal cancer.
Colorectal Neoplasms
Effect of acidic environment and p53 on apoptosis induction by hyperthermia.
Colorectal Neoplasms
Effect of APE1 T2197G (Asp148Glu) polymorphism on APE1, XRCC1, PARP1 and OGG1 expression in patients with colorectal cancer.
Colorectal Neoplasms
Expression and Single Nucleotide Polymorphism of Poly (ADPRibose) Polymerase-1 in Gastrointestinal Tumours: Clinical Involvement.
Colorectal Neoplasms
From PARP1 to TNKS2 Inhibition: A Structure-Based Approach.
Colorectal Neoplasms
Glycogen synthase kinase 3? inhibition synergizes with PARP inhibitors through the induction of homologous recombination deficiency in colorectal cancer.
Colorectal Neoplasms
HOXD8 exerts a tumor-suppressing role in colorectal cancer as an apoptotic inducer.
Colorectal Neoplasms
Identification of anticancer drugs to radiosensitise BRAF-wild-type and mutant colorectal cancer.
Colorectal Neoplasms
Inhibition of poly(ADP-ribose) polymerase prevents irinotecan-induced intestinal damage and enhances irinotecan/temozolomide efficacy against colon carcinoma.
Colorectal Neoplasms
Interaction of tankyrase and peroxiredoxin II is indispensable for the survival of colorectal cancer cells.
Colorectal Neoplasms
In Vitro and In Vivo Enhancement of Chemoradiation Using the Oral PARP Inhibitor ABT-888 in Colorectal Cancer Cells.
Colorectal Neoplasms
Luteolin induces apoptosis in BE colorectal cancer cells by downregulating calpain, UHRF1, and DNMT1 expressions.
Colorectal Neoplasms
MACROD2 deletions cause impaired PARP1 activity and chromosome instability in colorectal cancer.
Colorectal Neoplasms
MACROD2 Haploinsufficiency Impairs Catalytic Activity of PARP1 and Promotes Chromosome Instability and Growth of Intestinal Tumors.
Colorectal Neoplasms
Molecular correlates of sensitivity to PARP inhibition beyond homologous recombination deficiency in pre-clinical models of colorectal cancer point to wild-type TP53 activity.
Colorectal Neoplasms
MRE11 Deficiency Increases Sensitivity to Poly(ADP-ribose) Polymerase Inhibition in Microsatellite Unstable Colorectal Cancers.
Colorectal Neoplasms
MSH3 Mediates Sensitization of Colorectal Cancer Cells to Cisplatin, Oxaliplatin, and a Poly(ADP-ribose) Polymerase Inhibitor.
Colorectal Neoplasms
New structural analogues of curcumin exhibit potent growth suppressive activity in human colorectal carcinoma cells.
Colorectal Neoplasms
Nogo-B (Reticulon-4B) functions as a negative regulator of the apoptotic pathway through the interaction with c-FLIP in colorectal cancer cells.
Colorectal Neoplasms
Novel derivative of aminobenzenesulfonamide (3c) induces apoptosis in colorectal cancer cells through ROS generation and inhibits cell migration.
Colorectal Neoplasms
Novel mutations of the PARP-1 gene associated with colorectal cancer in the Saudi population.
Colorectal Neoplasms
Overexpression of poly(ADP-ribose) polymerase-1 (PARP-1) in the early stage of colorectal carcinogenesis.
Colorectal Neoplasms
p53 Enhances Artemisia annua L. Polyphenols-Induced Cell Death Through Upregulation of p53-Dependent Targets and Cleavage of PARP1 and Lamin A/C in HCT116 Colorectal Cancer Cells.
Colorectal Neoplasms
PARP-1 protects against colorectal tumor induction, but promotes inflammation-driven colorectal tumor progression.
Colorectal Neoplasms
PARP-Targeted Auger Therapy in p53 Mutant Colon Cancer Xenograft Mouse Models.
Colorectal Neoplasms
PARP6, a mono(ADP-ribosyl) transferase and a negative regulator of cell proliferation, is involved in colorectal cancer development.
Colorectal Neoplasms
Poly (ADP-ribose) polymerase inhibitor LT-626: Sensitivity correlates with MRE11 mutations and synergizes with platinums and irinotecan in colorectal cancer cells.
Colorectal Neoplasms
Poly(ADP-ribose) polymerase inhibition down-regulates expression of metastasis-related genes in CT26 colon carcinoma cells.
Colorectal Neoplasms
Poly(ADP-Ribose) Polymerase Inhibition Sensitizes Colorectal Cancer-Initiating Cells to Chemotherapy.
Colorectal Neoplasms
Poly(ADP-ribose) polymerase-1 is a component of the oncogenic T-cell factor-4/beta-catenin complex.
Colorectal Neoplasms
Polymorphisms in genes of APE1, PARP1, and XRCC1: risk and prognosis of colorectal cancer in a Northeast Chinese population.
Colorectal Neoplasms
Post-Transcriptional Regulation of PARP7 Protein Stability Is Controlled by Androgen Signaling.
Colorectal Neoplasms
Quantitative Proteomics Identifies DNA Repair as a Novel Biological Function for Hepatocyte Nuclear Factor 4? in Colorectal Cancer Cells.
Colorectal Neoplasms
Radiosensitization of HT-29 cells and xenografts by the nitric oxide donor DETANONOate.
Colorectal Neoplasms
Reactive Oxygen Species and p53 Mediated Activation of p38 and Caspases is Critically Involved in Kaempferol Induced Apoptosis in Colorectal Cancer Cells.
Colorectal Neoplasms
Sensitization of colorectal cancer to irinotecan therapy by PARP inhibitor rucaparib.
Colorectal Neoplasms
Sildenafil inhibits the growth of human colorectal cancer in vitro and in vivo.
Colorectal Neoplasms
Temozolomide: Mechanisms of Action, Repair and Resistance.
Colorectal Neoplasms
The depletion of securin enhances butein-induced apoptosis and tumor inhibition in human colorectal cancer.
Colorectal Neoplasms
The Effect of Poly(ADP-ribose) Polymerase-1 Gene 3'Untranslated Region Polymorphism in Colorectal Cancer Risk among Saudi Cohort.
Colorectal Neoplasms
The synthetic lethal killing of RAD54B-deficient colorectal cancer cells by PARP1 inhibition is enhanced with SOD1 inhibition.
Colorectal Neoplasms
Treatment with the PARP inhibitor, niraparib, sensitizes colorectal cancer cell lines to irinotecan regardless of MSI/MSS status.
Colorectal Neoplasms
Two DNA repair gene polymorphisms on the risk of gastrointestinal cancers: a meta-analysis.
Colorectal Neoplasms
Ursolic Acid Induces Apoptosis in Colorectal Cancer Cells Partially via Upregulation of MicroRNA-4500 and Inhibition of JAK2/STAT3 Phosphorylation.
Colorectal Neoplasms
XRCC2 promotes colorectal cancer cell growth, regulates cell cycle progression, and apoptosis.
Colorectal Neoplasms
XRCC2 rs3218536 polymorphism decreases the sensitivity of colorectal cancer cells to poly(ADP-ribose) polymerase 1 inhibitor.
Colorectal Neoplasms
[Inhibitory effect of 5-aminoisoquinolinone on PARP activity in colon carcinoma cell line HT-29]
Colorectal Neoplasms
[PARP10 Influences the Proliferation of Colorectal Carcinoma Cells, a Preliminary Study].
Colorectal Neoplasms, Hereditary Nonpolyposis
Temozolomide: Mechanisms of Action, Repair and Resistance.
Colorectal Neoplasms, Hereditary Nonpolyposis
The Importance of Distinguishing Sporadic Cancers from Those Related to Cancer Predisposing Germline Mutations.
Colorectal Neoplasms, Hereditary Nonpolyposis
[Molecular Targeted Therapies for Hereditary Cancer Syndrome].
Communicable Diseases
Pertussis toxin: transition state analysis for ADP-ribosylation of G-protein peptide alphai3C20.
Congenital Abnormalities
Association of sperm morphology and the sperm deformity index (SDI) with poly (ADP-ribose) polymerase (PARP) cleavage inhibition.
Congenital Abnormalities
Calcium Alleviates Fluoride-Induced Bone Damage by Inhibiting Endoplasmic Reticulum Stress and Mitochondrial Dysfunction.
Contracture
Effect of pertussis toxin on normorphine-dependence and on acute inhibitory effects of normorphine and clonidine in guinea-pig isolated ileum.
Contracture
Effects of cannabinoids on tension induced by acetylcholine and choline in slow skeletal muscle fibers of the frog.
Coronary Artery Disease
DNA Damage, an Innocent Bystander in Atrial Fibrillation and Other Cardiovascular Diseases?
Coronary Artery Disease
Poly(ADP-ribose) Polymerase (PARP) and PARP Inhibitors: Mechanisms of Action and Role in Cardiovascular Disorders.
Coronary Artery Disease
Poly(ADP-Ribose) Polymerase Activity and Coronary Artery Disease in Type 2 Diabetes Mellitus: An Observational and Bidirectional Mendelian Randomization Study.
Coronary Artery Disease
Relationship between NADPH oxidase p22phox C242T, PARP-1 Val762Ala polymorphisms, angiographically verified coronary artery disease and myocardial infarction in South Indian patients with type 2 diabetes mellitus.
Coronary Occlusion
Poly(ADP-ribose) Polymerase (PARP) and PARP Inhibitors: Mechanisms of Action and Role in Cardiovascular Disorders.
Coronavirus Infections
Coronavirus infection and PARP expression dysregulate the NAD metabolome: An actionable component of innate immunity.
Coronavirus Infections
Reactive oxygen species as an initiator of toxic innate immune responses in retort to SARS-CoV-2 in an ageing population, consider N-acetylcysteine as early therapeutic intervention.
Cough
Antibody responses to individual Bordetella pertussis fimbrial antigens Fim2 or Fim3 following immunisation with five component acellular pertussis vaccine or disease.
Cough
Comparative efficacy of acellular pertussis vaccines: an analysis of recent trials.
Cough
Determination of pertactin IgG antibodies for the diagnosis of pertussis.
Cough
Measures to control an outbreak of pertussis in a neonatal intermediate care nursery after exposure to a healthcare worker.
Cough
Parents as source of pertussis transmission in hospitalized young infants.
Cough
Poly(ADP-ribose) polymerase inhibition with HYDAMTIQ reduces allergen-induced asthma-like reaction, bronchial hyper-reactivity and airway remodelling.
Cough
Prevalence and incidence of adult pertussis in an urban population.
Cough
Responses to Bordetella pertussis mutant strains and to vaccination in the coughing rat model of pertussis.
Cough
[Humoral reaction to Bordetella pertussis antigens: pertussis toxin, filamentous hemagglutinin and lipopolysaccharide in children with clinical symptoms of whooping cough. II. Occurence and level of B. pertussis antigens in children with suspected whooping cough]
COVID-19
Chemotherapy directly followed by poly(ADP-ribose) polymerase inhibition as an alternative to surgery in patients with BRCA-mutated ovarian cancer: a potential management strategy in the era of coronavirus disease 2019.
COVID-19
Coronavirus and PARP expression dysregulate the NAD Metabolome: a potentially actionable component of innate immunity.
COVID-19
Covid-19 pathogenesis in prostatic cancer and TMPRSS2-ERG regulatory genetic pathway.
COVID-19
Immunotherapy of COVID-19 with poly (ADP-ribose) polymerase inhibitors: starting with nicotinamide.
COVID-19
Role of Poly(ADP-ribose) Polymerase (PARP1) in Viral Infection and its Implication in SARS-CoV-2 Pathogenesis.
COVID-19
The potential association between PARP14 and SARS-CoV-2 infection (COVID-19).
COVID-19
Thirty-day suicidal thoughts and behaviours in the Spanish adult general population during the first wave of the Spain COVID-19 pandemic.
Cowpox
Activation of a CrmA-insensitive, p35-sensitive pathway in ionizing radiation-induced apoptosis.
Cowpox
IL-3 withdrawal activates a CrmA-insensitive poly(ADP-ribose) polymerase cleavage enzyme in factor-dependent myeloid progenitor cells.
Craniocerebral Trauma
A novel PARP inhibitor L-2286 in a rat model of impact acceleration head injury: An immunohistochemical and behavioral study.
Craniocerebral Trauma
Development of a high-throughput screening-amenable assay for human poly(ADP-ribose) polymerase inhibitors.
Craniocerebral Trauma
Poly(adenosine diphosphate-ribose) polymerase expression in human traumatic brain injury.
Crohn Disease
Distinct production of autoantibodies to nuclear components in ulcerative colitis and in Crohn's disease.
Crohn Disease
Role of microRNA-223 in the regulation of poly(ADP-ribose) polymerase in pediatric patients with Crohn's disease.
Cryptorchidism
Heat stress reduces poly(ADPR)polymerase expression in rat testis.
Cryptorchidism
Over expression of LDOC1 and PARP1, two pro-apoptotic genes, in a patient with cryptorchidism and DiGeorge anomaly.
Cystadenoma
Rapamycin-resistant PARP1 overexpression is a potential therapeutic target in lymphangioleiomyomatosis (LAM).
Cystadenoma, Serous
Poly(adenosine diphosphate-ribose) polymerase expression in serous ovarian carcinoma: correlation with p53, MIB-1, and outcome.
Cystic Fibrosis
Children with cystic fibrosis produce an immune response against exoenzyme S, a type III cytotoxin of Pseudomonas aeruginosa.
Cystic Fibrosis
Distinct fates of monocytes and T cells directly activated by Pseudomonas aeruginosa exoenzyme S.
Cystic Fibrosis
G-protein regulation of outwardly rectified epithelial chloride channels incorporated into planar bilayer membranes.
Cystic Fibrosis
Pseudomonas aeruginosa exoenzyme S induces transcriptional expression of proinflammatory cytokines and chemokines.
Cystic Fibrosis
Role of exoenzyme S in chronic Pseudomonas aeruginosa lung infections.
Cystic Fibrosis
The role of protein kinase C in alpha-adrenergic regulation of NaCl(K) cotransport in human airway epithelial cells.
Cystic Fibrosis
TRIM44 links the UPS to SQSTM1/p62-dependent aggrephagy and removing misfolded proteins.
Cystitis
Pathophysiological aspects of cyclophosphamide and ifosfamide induced hemorrhagic cystitis; implication of reactive oxygen and nitrogen species as well as PARP activation.
Cystitis
Protein nitration, PARP activation and NAD+ depletion may play a critical role in the pathogenesis of cyclophosphamide-induced hemorrhagic cystitis in the rat.
Cysts
In vitro formation and expansion of cysts derived from human renal cortex epithelial cells.
Cysts
Inhibiting heat shock protein 90 (HSP90) limits the formation of liver cysts induced by conditional deletion of Pkd1 in mice.
cytidine deaminase deficiency
Cytidine deaminase deficiency impairs sister chromatid disjunction by decreasing PARP-1 activity.
cytidine deaminase deficiency
Pyrimidine Pool Disequilibrium Induced by a Cytidine Deaminase Deficiency Inhibits PARP-1 Activity, Leading to the Under Replication of DNA.
Dehydration
Effects of long-term dehydration on oxidative stress, apoptotic markers and neuropeptides in the gastric mucosa of the dromedary camel.
Dehydration
Photo-Protective Mechanisms and the Role of Poly (ADP-Ribose) Polymerase Activity in a Facultative CAM Plant Exposed to Long-Term Water Deprivation.
Dehydration
Physiological, biochemical and molecular responses to water stress and rehydration in Mediterranean adapted tomato landraces.
Dementia
Caspase gene expression in the brain as a function of the clinical progression of Alzheimer disease.
Demyelinating Diseases
A humanized model for multiple sclerosis using HLA-DR2 and a human T-cell receptor.
Demyelinating Diseases
A new EAE model of brain demyelination induced by intracerebroventricular pertussis toxin.
Demyelinating Diseases
A new lipophilic amino alcohol, chemically similar to compound FTY720, attenuates the pathogenesis of experimental autoimmune encephalomyelitis by PI3K/Akt pathway inhibition.
Demyelinating Diseases
Activation of microglial poly(ADP-ribose)-polymerase-1 by cholesterol breakdown products during neuroinflammation: a link between demyelination and neuronal damage.
Demyelinating Diseases
Chronic mechanical hypersensitivity in experimental autoimmune encephalomyelitis is regulated by disease severity and neuroinflammation.
Demyelinating Diseases
IL-6 induces regionally selective spinal cord injury in patients with the neuroinflammatory disorder transverse myelitis.
Demyelinating Diseases
Inhibiting poly(ADP-ribose) polymerase: a potential therapy against oligodendrocyte death.
Demyelinating Diseases
P0 protein peptide 180-199 together with pertussis toxin induces experimental autoimmune neuritis in resistant C57BL/6 mice.
Demyelinating Diseases
PARP-1 deletion promotes subventricular zone neural stem cells toward a glial fate.
Demyelinating Diseases
PARP-1 inhibition prevents CNS migration of dendritic cells during EAE, suppressing the encephalitogenic response and relapse severity.
Dermatitis
High-content screening identifies inhibitors of oxidative stress-induced parthanatos: cytoprotective and anti-inflammatory effects of ciclopirox.
Dermatitis
Structure and function of poly(ADP-ribose) polymerase-1: role in oxidative stress-related pathologies.
Dermatitis, Allergic Contact
Nitric oxide-peroxynitrite-poly(ADP-ribose) polymerase pathway in the skin.
Dermatitis, Contact
Engagement of CD47 inhibits the contact hypersensitivity response via the suppression of motility and B7 expression by Langerhans cells.
Dermatitis, Contact
Genetic ablation of PARP-1 protects against oxazolone-induced contact hypersensitivity by modulating oxidative stress.
Dermatitis, Contact
Nitric oxide-peroxynitrite-poly(ADP-ribose) polymerase pathway in the skin.
Dermatitis, Contact
Peroxynitrite production, DNA breakage, and poly(ADP-ribose) polymerase activation in a mouse model of oxazolone-induced contact hypersensitivity.
Dermatitis, Contact
Poly(ADP-ribose) polymerase mediates inflammation in a mouse model of contact hypersensitivity.
Dermatitis, Phototoxic
Crosstalk between oxidative stress-induced apoptotic and autophagic signaling pathways in Zn(II) phthalocyanine photodynamic therapy of melanoma.
Dermatitis, Phototoxic
The PARP inhibitor PJ-34 sensitizes cells to UVA-induced phototoxicity by a PARP independent mechanism.
Diabetes Complications
Aldose reductase inhibition counteracts oxidative-nitrosative stress and poly(ADP-ribose) polymerase activation in tissue sites for diabetes complications.
Diabetes Complications
Diabetes, microvascular complications, and cardiovascular complications: what is it about glucose?
Diabetes Complications
Diabetes-induced overexpression of endothelin-1 and endothelin receptors in the rat renal cortex is mediated via poly(ADP-ribose) polymerase activation.
Diabetes Complications
Does diabetes mellitus target motor neurons?
Diabetes Complications
Increased sorbitol pathway activity generates oxidative stress in tissue sites for diabetic complications.
Diabetes Complications
Marrow-Derived Cells Regulate the Development of Early Diabetic Retinopathy and Tactile Allodynia in Mice.
Diabetes Complications
Oxidative stress-induced, poly(ADP-ribose) polymerase-dependent upregulation of ET-1 expression in chronic diabetic complications.
Diabetes Complications
Oxidative-Nitrosative Stress and Poly(ADP-Ribose) Polymerase (PARP) Activation in Experimental Diabetic Neuropathy: The Relation Is Revisited.
Diabetes Complications
PARP activation and the alteration of vasoactive factors and extracellular matrix protein in retina and kidney in diabetes.
Diabetes Complications
PARP inhibition ameliorates nephropathy in an animal model of type 2 diabetes: focus on oxidative stress, inflammation, and fibrosis.
Diabetes Complications
PARP inhibition or gene deficiency counteracts intraepidermal nerve fiber loss and neuropathic pain in advanced diabetic neuropathy.
Diabetes Complications
PARP mediates structural alterations in diabetic cardiomyopathy.
Diabetes Complications
Poly(ADP-Ribose) Polymerase Inhibition Alleviates Experimental Diabetic Sensory Neuropathy.
Diabetes Complications
Poly(ADP-ribose) polymerase inhibition improves endothelial dysfunction induced by reactive oxidant hydrogen peroxide in vitro.
Diabetes Complications
Poly(ADP-ribose) polymerase is involved in the development of diabetic cystopathy via regulation of nuclear factor kappa B.
Diabetes Complications
Poly(ADP-ribose)polymerase inhibition counteracts renal hypertrophy and multiple manifestations of peripheral neuropathy in diabetic Akita mice.
Diabetes Complications
Role of nitrosative stress and peroxynitrite in the pathogenesis of diabetic complications. Emerging new therapeutical strategies.
Diabetes Complications
Role of poly(ADP-ribose) polymerase-1 activation in the pathogenesis of diabetic complications: endothelial dysfunction, as a common underlying theme.
Diabetes Complications
Roles of poly(ADP-ribose) polymerase activation in the pathogenesis of diabetes mellitus and its complications.
Diabetes Complications
The pathogenesis of diabetic complications: the role of DNA injury and poly(ADP-ribose) polymerase activation in peroxynitrite-mediated cytotoxicity.
Diabetes Insipidus, Nephrogenic
Effect of pertussis toxin on water metabolism in the rat.
Diabetes Mellitus
Adenosine thiamine triphosphate (AThTP) inhibits poly(ADP-ribose) polymerase-1 (PARP-1) activity.
Diabetes Mellitus
Diabetes-induced cerebrovascular dysfunction: role of poly(ADP-ribose) polymerase.
Diabetes Mellitus
Effects of Trans-Resveratrol on hyperglycemia-induced abnormal spermatogenesis, DNA damage and alterations in poly (ADP-ribose) polymerase signaling in rat testis.
Diabetes Mellitus
Nitrative stress and poly(ADP-ribose) polymerase activation in healthy and gestational diabetic pregnancies.
Diabetes Mellitus
PARP as a Drug Target for the Therapy of Diabetic Cardiovascular Dysfunction.
Diabetes Mellitus
PARP1 deficiency protects against hyperglycemia-induced neointimal hyperplasia by upregulating TFPI2 activity in diabetic mice.
Diabetes Mellitus
Poly(ADP-ribose) polymerase 1 inhibition improves coronary arteriole function in type 2 diabetes mellitus.
Diabetes Mellitus
Poly(ADP-Ribose) Polymerase Activity and Coronary Artery Disease in Type 2 Diabetes Mellitus: An Observational and Bidirectional Mendelian Randomization Study.
Diabetes Mellitus
Poly(ADP-ribose) polymerase as a drug target for cardiovascular disease and cancer: an update.
Diabetes Mellitus
Poly(ADP-ribose) polymerase contributes to the development of myocardial infarction in diabetic rats and regulates the nuclear translocation of apoptosis-inducing factor.
Diabetes Mellitus
Poly(ADP-ribose) polymerase: the nuclear target in signal transduction and its role in brain ischemia-reperfusion injury.
Diabetes Mellitus
Quantification of PARP Activity in Human Tissues: Ex Vivo Assays in Blood Cells and Immunohistochemistry in Human Biopsies.
Diabetes Mellitus
Rapid 'glycaemic swings' induce nitrosative stress, activate poly(ADP-ribose) polymerase and impair endothelial function in a rat model of diabetes mellitus.
Diabetes Mellitus
Relationship between NADPH oxidase p22phox C242T, PARP-1 Val762Ala polymorphisms, angiographically verified coronary artery disease and myocardial infarction in South Indian patients with type 2 diabetes mellitus.
Diabetes Mellitus
Role of poly (ADP-ribose) polymerase-1 and cytokines in acute renal injury in elderly Chinese patients with diabetes mellitus.
Diabetes Mellitus
Roles of poly(ADP-ribose) polymerase activation in the pathogenesis of diabetes mellitus and its complications.
Diabetes Mellitus
Tempol reduces podocyte apoptosis via PARP signaling pathway in experimental diabetes mellitus.
Diabetes Mellitus
The parp-1 and bax genes as potential targets for treatment of the heart functioning impairments induced by type 1 diabetes mellitus.
Diabetes Mellitus
Theobromine increases NAD?/Sirt-1 activity and protects the kidney under diabetic conditions.
Diabetes Mellitus, Experimental
Tempol reduces podocyte apoptosis via PARP signaling pathway in experimental diabetes mellitus.
Diabetes Mellitus, Type 1
A dinucleotide repeat polymorphism at the poly(ADP-ribose) polymerase gene is not associated with predisposition to type 1 diabetes in French Caucasians.
Diabetes Mellitus, Type 1
A peroxynitrite decomposition catalyst counteracts sensory neuropathy in streptozotocin-diabetic mice.
Diabetes Mellitus, Type 1
Contribution of type 1 diabetes to rat liver dysfunction and cellular damage via activation of NOS, PARP, IkappaBalpha/NF-kappaB, MAPKs, and mitochondria-dependent pathways: Prophylactic role of arjunolic acid.
Diabetes Mellitus, Type 1
Diabetes-induced cerebrovascular dysfunction: role of poly(ADP-ribose) polymerase.
Diabetes Mellitus, Type 1
Effects of Trans-Resveratrol on hyperglycemia-induced abnormal spermatogenesis, DNA damage and alterations in poly (ADP-ribose) polymerase signaling in rat testis.
Diabetes Mellitus, Type 1
Enhanced G protein activation in IDDM patients with diabetic nephropathy.
Diabetes Mellitus, Type 1
Mice lacking the poly(ADP-ribose) polymerase gene are resistant to pancreatic beta-cell destruction and diabetes development induced by streptozocin.
Diabetes Mellitus, Type 1
Poly (ADP-ribose) polymerase inhibition prevents spontaneous and recurrent autoimmune diabetes in NOD mice by inducing apoptosis of islet-infiltrating leukocytes.
Diabetes Mellitus, Type 1
Poly(Adenosine 5'-Diphosphate-Ribose) Polymerase Inhibition Counteracts Multiple Manifestations of Experimental Type 1 Diabetic Nephropathy.
Diabetes Mellitus, Type 1
Poly(ADP-ribose) polymerase (PARP) inhibition counteracts multiple manifestations of kidney disease in long-term streptozotocin-diabetic rat model.
Diabetes Mellitus, Type 1
The parp-1 and bax genes as potential targets for treatment of the heart functioning impairments induced by type 1 diabetes mellitus.
Diabetes Mellitus, Type 1
Unexpected sensitivity of nonobese diabetic mice with a disrupted poly(ADP-Ribose) polymerase-1 gene to streptozotocin-induced and spontaneous diabetes.
Diabetes Mellitus, Type 2
Enhanced NF?B Activity Impairs Vascular Function through PARP-1, SP-1 and COX2-Dependent Mechanisms in Type 2 Diabetes.
Diabetes Mellitus, Type 2
PARP inhibition ameliorates nephropathy in an animal model of type 2 diabetes: focus on oxidative stress, inflammation, and fibrosis.
Diabetes Mellitus, Type 2
Poly (ADP-ribose) polymerase-1-inhibiting flavonoids attenuate cytokine release in blood from male patients with chronic obstructive pulmonary disease or type 2 diabetes.
Diabetes Mellitus, Type 2
Poly(ADP-ribose) polymerase 1 inhibition improves coronary arteriole function in type 2 diabetes mellitus.
Diabetes Mellitus, Type 2
Poly(ADP-Ribose) Polymerase Activity and Coronary Artery Disease in Type 2 Diabetes Mellitus: An Observational and Bidirectional Mendelian Randomization Study.
Diabetes Mellitus, Type 2
Poly(ADP-ribose) polymerase inhibitors ameliorate nephropathy of type 2 diabetic Leprdb/db mice.
Diabetes Mellitus, Type 2
Poly(ADP-Ribose) polymerase is activated in subjects at risk of developing type 2 diabetes and is associated with impaired vascular reactivity.
Diabetes Mellitus, Type 2
Poly(ADP-ribose)polymerase activity is reduced in circulating mononuclear cells from type 2 diabetic patients.
Diabetes Mellitus, Type 2
Relationship between NADPH oxidase p22phox C242T, PARP-1 Val762Ala polymorphisms, angiographically verified coronary artery disease and myocardial infarction in South Indian patients with type 2 diabetes mellitus.
Diabetes Mellitus, Type 2
The relationship between obstructive sleep apnea and intra-epidermal nerve fiber density, PARP activation and foot ulceration in patients with type 2 diabetes.
Diabetes Mellitus, Type 2
The role of impaired insulin/IGF action in primary diabetic encephalopathy.
Diabetes, Gestational
[The severity of gestational diabetes mellitus affects microvascular dysfunction measured three years after pregnancy that may be related to increased oxidative stress].
Diabetic Cardiomyopathies
Beneficial effects of a novel ultrapotent poly(ADP-ribose) polymerase inhibitor in murine models of heart failure.
Diabetic Cardiomyopathies
Metallothionein alleviates cardiac dysfunction in streptozotocin-induced diabetes: role of Ca2+ cycling proteins, NADPH oxidase, poly(ADP-Ribose) polymerase and myosin heavy chain isozyme.
Diabetic Cardiomyopathies
PARP mediates structural alterations in diabetic cardiomyopathy.
Diabetic Cardiomyopathies
PARP-1 inhibition protects the diabetic heart through activation of SIRT1-PGC-1? axis.
Diabetic Cardiomyopathies
Poly(ADP-ribose) polymerase 1 inhibition protects cardiomyocytes from inflammation and apoptosis in diabetic cardiomyopathy.
Diabetic Cardiomyopathies
Xanthine oxidase inhibitor allopurinol attenuates the development of diabetic cardiomyopathy.
Diabetic Nephropathies
Diabetes-induced overexpression of endothelin-1 and endothelin receptors in the rat renal cortex is mediated via poly(ADP-ribose) polymerase activation.
Diabetic Nephropathies
Gallotannin ameliorates the development of streptozotocin-induced diabetic nephropathy by preventing the activation of PARP.
Diabetic Nephropathies
PARP inhibition ameliorates nephropathy in an animal model of type 2 diabetes: focus on oxidative stress, inflammation, and fibrosis.
Diabetic Nephropathies
PARP-1 and SIRT-1 are Interacted in Diabetic Nephropathy by Activating AMPK/PGC-1? Signaling Pathway.
Diabetic Nephropathies
Poly(ADP-ribose) polymerase (PARP) inhibition counteracts multiple manifestations of kidney disease in long-term streptozotocin-diabetic rat model.
Diabetic Nephropathies
Poly(ADP-ribose) polymerase inhibitors ameliorate nephropathy of type 2 diabetic Leprdb/db mice.
Diabetic Nephropathies
Poly(ADP-ribose) polymerase-1 (PARP-1) gene deficiency alleviates diabetic kidney disease.
Diabetic Nephropathies
Psoralea corylifolia L. Seed Extract Attenuates Diabetic Nephropathy by Inhibiting Renal Fibrosis and Apoptosis in Streptozotocin-Induced Diabetic Mice.
Diabetic Nephropathies
Role for poly(ADP-ribose) polymerase activation in diabetic nephropathy, neuropathy and retinopathy.
Diabetic Nephropathies
Role of nitrosative stress and peroxynitrite in the pathogenesis of diabetic complications. Emerging new therapeutical strategies.
Diabetic Nephropathies
Saxagliptin protects against diabetic nephropathy by inhibiting caspase 3/PARP-1-dependent nephrocyte apoptosis.
Diabetic Neuropathies
Biomarkers in diabetic neuropathy.
Diabetic Neuropathies
Bone marrow expression of poly(ADP-ribose) polymerase underlies diabetic neuropathy via hematopoietic-neuronal cell fusion.
Diabetic Neuropathies
Concurrent targeting of nitrosative stress-PARP pathway corrects functional, behavioral and biochemical deficits in experimental diabetic neuropathy.
Diabetic Neuropathies
Effects of poly(ADP-ribose) polymerase inhibition on dysfunction of non-adrenergic non-cholinergic neurotransmission in gastric fundus in diabetic rats.
Diabetic Neuropathies
Emerging drugs for diabetic neuropathy.
Diabetic Neuropathies
Evaluation of orally active poly(ADP-ribose) polymerase inhibitor in streptozotocin-diabetic rat model of early peripheral neuropathy.
Diabetic Neuropathies
Functional and biochemical evidence indicating beneficial effect of Melatonin and Nicotinamide alone and in combination in experimental diabetic neuropathy.
Diabetic Neuropathies
Leu54Phe and Val762Ala polymorphisms in the poly(ADP-ribose)polymerase-1 gene are associated with diabetic polyneuropathy in Russian type 1 diabetic patients.
Diabetic Neuropathies
Lipoic Acid Decreases the Expression of Poly ADP-Ribose Polymerase and Inhibits Apoptosis in Diabetic Rats.
Diabetic Neuropathies
Low-dose poly(ADP-ribose) polymerase inhibitor-containing combination therapies reverse early peripheral diabetic neuropathy.
Diabetic Neuropathies
Molecular mechanism of diabetic neuropathy and its pharmacotherapeutic targets.
Diabetic Neuropathies
New Therapeutic and Biomarker Discovery for Peripheral Diabetic Neuropathy: PARP Inhibitor, Nitrotyrosine, and Tumor Necrosis Factor-{alpha}
Diabetic Neuropathies
Oxidative-Nitrosative Stress and Poly(ADP-Ribose) Polymerase (PARP) Activation in Experimental Diabetic Neuropathy: The Relation Is Revisited.
Diabetic Neuropathies
PARP inhibition or gene deficiency counteracts intraepidermal nerve fiber loss and neuropathic pain in advanced diabetic neuropathy.
Diabetic Neuropathies
Poly(ADP-Ribose) Polymerase Inhibition Alleviates Experimental Diabetic Sensory Neuropathy.
Diabetic Neuropathies
Poly(ADP-ribose) polymerase inhibition as a novel therapeutic approach against intraepidermal nerve fiber loss and neuropathic pain associated with advanced diabetic neuropathy: a commentary on "PARP Inhibition or gene deficiency counteracts intraepidermal nerve fiber loss and neuropathic pain in advanced diabetic neuropathy".
Diabetic Neuropathies
Protective effects of 4-amino1,8-napthalimide, a poly (ADP-ribose) polymerase inhibitor in experimental diabetic neuropathy.
Diabetic Neuropathies
Role of poly(ADP-ribose) polymerase activation in diabetic neuropathy.
Diabetic Neuropathies
Treatment with Actovegin® Improves Sensory Nerve Function and Pathology in Streptozotocin-Diabetic Rats via Mechanisms Involving Inhibition of PARP Activation.
Diabetic Retinopathy
Aldose Reductase / Polyol Inhibitors For Diabetic Retinopathy.
Diabetic Retinopathy
Effect of the regimen of Gaoshan Hongjingtian on the mechanism of poly (ADP-ribose) polymerase regulation of nuclear factor kappa B in the experimental diabetic retinopathy.
Diabetic Retinopathy
Identification of low micromolar dual inhibitors for aldose reductase (ALR2) and poly (ADP-ribose) polymerase (PARP-1) using structure based design approach.
Diabetic Retinopathy
PARP activation and the alteration of vasoactive factors and extracellular matrix protein in retina and kidney in diabetes.
Diabetic Retinopathy
Poly(ADP-ribose) polymerase inhibitors counteract diabetes- and hypoxia-induced retinal vascular endothelial growth factor overexpression.
Diabetic Retinopathy
Poly(ADP-ribose) polymerase is involved in the development of diabetic retinopathy via regulation of nuclear factor-kappaB.
Diabetic Retinopathy
Role of nitric oxide, superoxide, peroxynitrite and PARP in diabetic retinopathy.
Diabetic Retinopathy
Role of PARP-1 as a novel transcriptional regulator of MMP-9 in diabetic retinopathy.
Diabetic Retinopathy
The Poly(ADP-Ribose)Polymerase-1 Inhibitor 1,5-Isoquinolinediol Attenuate Diabetes-Induced NADPH Oxidase-Derived Oxidative Stress in Retina.
Diffuse Intrinsic Pontine Glioma
Targeting Mutant PPM1D Sensitizes Diffuse Intrinsic Pontine Glioma Cells to the PARP Inhibitor Olaparib.
DiGeorge Syndrome
Over expression of LDOC1 and PARP1, two pro-apoptotic genes, in a patient with cryptorchidism and DiGeorge anomaly.
Diphtheria
A Belgian Serosurveillance/Seroprevalence Study of Diphtheria, Tetanus and Pertussis Using a Luminex xMAP Technology-Based Pentaplex.
Diphtheria
A chimeric toxin to study the role of the 21 kDa GTP binding protein rho in the control of actin microfilament assembly.
Diphtheria
A fully liquid DTaP-IPV-Hep B-PRP-T hexavalent vaccine for primary and booster vaccination of healthy Mexican children.
Diphtheria
A modified vaccine reduces the rate of large injection site reactions to the preschool booster dose of diphtheria-tetanus-acellular pertussis vaccine: results of a randomized, controlled trial.
Diphtheria
A randomized controlled trial of two acellular pertussis-diphtheria-tetanus vaccines in primary immunization in Ghana: antibody responses and adverse reactions.
Diphtheria
Acellular pertussis vaccine given by accelerated schedule: response of preterm infants.
Diphtheria
Adequate tetanus but poor diphtheria and pertussis response to a Tdap booster in adolescents with juvenile systemic lupus erythematosus.
Diphtheria
Adverse effects and sero-responses to an acellular pertussis/diphtheria/tetanus vaccine when combined with Haemophilus influenzae type b vaccine in an accelerated schedule.
Diphtheria
Adverse reactions of a pertussis toxoid vaccine in a double-blind placebo-controlled trial.
Diphtheria
Antibody persistence 2 and 3 years after booster vaccination of adolescents with recombinant acellular pertussis monovalent aPgen or combined TdaPgen vaccines.
Diphtheria
Antibody response to diphtheria-tetanus-pertussis immunization in preterm infants who receive dexamethasone for chronic lung disease.
Diphtheria
Antibody responses of healthy infants to concurrent administration of a bivalent haemophilus influenzae type b-hepatitis B vaccine with diphtheria-tetanus-pertussis, polio and measles-mumps-rubella vaccines.
Diphtheria
Antibody responses to Bordetella pertussis and other childhood vaccines in infants born to mothers who received pertussis vaccine in pregnancy- a prospective, observational cohort study from the UK.
Diphtheria
Assessment of Intracellular Auto-Modification Levels of ARTD10 Using Mono-ADP-Ribose-Specific Macrodomains 2 and 3 of Murine Artd8.
Diphtheria
Association of Routine Infant Vaccinations With Antibody Levels Among Preterm Infants.
Diphtheria
Bacterial toxins inhibiting or activating small GTP-binding proteins.
Diphtheria
Botulinum C2 toxin ADP-ribosylates actin.
Diphtheria
Chemical probes to study ADP-ribosylation: synthesis and biochemical evaluation of inhibitors of the human ADP-ribosyltransferase ARTD3/PARP3.
Diphtheria
Clinical reactions and immunogenicity of the BIKEN acellular diphtheria and tetanus toxoids and pertussis vaccine in 4- through 6-year-old US children.
Diphtheria
Cloning, nucleotide sequence, and hybridization studies of the type IIb heat-labile enterotoxin gene of Escherichia coli.
Diphtheria
Common features of the NAD-binding and catalytic site of ADP-ribosylating toxins.
Diphtheria
Comparative safety and immunogenicity of an acellular versus whole-cell pertussis component of diphtheria-tetanus-pertussis vaccines in Senegalese infants.
Diphtheria
Comparative study of a whole-cell pertussis vaccine and a recombinant acellular pertussis vaccine. The Italian Multicenter Group for the Study of Recombinant Acellular Pertussis Vaccine.
Diphtheria
Comparison of 13 acellular pertussis vaccines: overview and serologic response.
Diphtheria
Comparison of a fifth dose of a five-component acellular or a whole cell pertussis vaccine in children four to six years of age.
Diphtheria
Comparison of the safety and immunogenicity of acellular (BIKEN) and whole-cell pertussis vaccines in 15- to 20-month-old children.
Diphtheria
Computer modelling of the NAD binding site of ADP-ribosylating toxins: active-site structure and mechanism of NAD binding.
Diphtheria
Conservation of a common motif in enzymes catalyzing ADP-ribose transfer. Identification of domains in mammalian transferases.
Diphtheria
Construction of a diphtheria toxin A fragment-C180 peptide fusion protein which elicits a neutralizing antibody response against diphtheria toxin and pertussis toxin.
Diphtheria
Crystal structure of the catalytic domain of Pseudomonas exotoxin A complexed with a nicotinamide adenine dinucleotide analog: implications for the activation process and for ADP ribosylation.
Diphtheria
Decline of serologic immunity to diphtheria, tetanus and pertussis with age suggested a full life vaccination in mainland China.
Diphtheria
Detection of arginine-ADP-ribosylated protein using recombinant ADP-ribosylarginine hydrolase.
Diphtheria
Development and validation of a multiplex immunoassay for the simultaneous determination of serum antibodies to Bordetella pertussis, diphtheria and tetanus.
Diphtheria
Development and Validation of Magnetic Bead Pentaplex Immunoassay for Simultaneous Quantification of murine serum IgG antibodies to Acellular Pertussis, Diphtheria and Tetanus Antigens used in combination vaccines.
Diphtheria
Diphtheria, tetanus and pertussis antibodies in 10-year-old children before and after a booster dose of three toxoids: implications for the timing of a booster dose.
Diphtheria
Effect of combination with an acellular pertussis, diphtheria, tetanus vaccine on antibody response to Hib vaccine (PRP-T).
Diphtheria
Effect of local massage on vaccination: DTP and DTPa.
Diphtheria
Effect of priming with diphtheria and tetanus toxoids combined with whole-cell pertussis vaccine or with acellular pertussis vaccine on the safety and immunogenicity of a booster dose of an acellular pertussis vaccine containing a genetically inactivated pertussis toxin in fifteen- to twenty-one-month-old children. Italian Multicenter Group for the Study of Recombinant Acellular Pertussis Vaccine.
Diphtheria
Enhanced post-licensure safety surveillance of a new recombinant acellular pertussis vaccine licensed as a monovalent (aP, Pertagen®) and tetanus, reduced-dose diphtheria combination (TdaP, Boostagen®) vaccine for immunization of adolescents and adults in Thailand.
Diphtheria
Evaluation of a guinea pig model to assess interference in the immunogenicity of different components of a combination vaccine comprising diphtheria, tetanus and acellular pertussis (DTaP) vaccine and haemophilus influenzae type b capsular polysaccharide conjugate vaccine.
Diphtheria
Experience with monocomponent acellular pertussis combination vaccines for infants, children, adolescents and adults-A review of safety, immunogenicity, efficacy and effectiveness studies and 15 years of field experience.
Diphtheria
Expression and purification of a trivalent pertussis toxin-diphtheria toxin-tetanus toxin fusion protein in Escherichia coli.
Diphtheria
Extensive swelling after booster doses of acellular pertussis-tetanus-diphtheria vaccines.
Diphtheria
Fast, antigen-saving multiplex immunoassay to determine levels and avidity of mouse serum antibodies to pertussis, diphtheria, and tetanus antigens.
Diphtheria
Generation of plant-derived recombinant DTP subunit vaccine.
Diphtheria
Genetic Variation in the Magnitude and Longevity of the IgG Subclass Response to a Diphtheria-Tetanus-Acellular Pertussis (DTaP) Vaccine in Mice.
Diphtheria
Genome-Wide Association Mapping of the Antibody Response to Diphtheria, Tetanus and Acellular Pertussis Vaccine in Mice.
Diphtheria
Humoral immunity of dTap-IPV vaccine (REPEVAX(®)) administered one month after dT-IPV vaccine (REVAXIS(®)) in adults with unknown vaccination history.
Diphtheria
Identification of amino acid residues essential for the enzymatic activities of pertussis toxin.
Diphtheria
Identification of peptides that mimic the pertussis toxin binding site on bovine fetuin.
Diphtheria
Immune response to a Tdap booster in vertically HIV-infected adolescents.
Diphtheria
Immunity against vaccine-preventable diseases in Finnish pediatric healthcare workers in 2015.
Diphtheria
Immunity to vaccine-preventable diseases among paediatric healthcare workers in Denmark, 2019.
Diphtheria
Immunogenicity and reactogenicity of a single dose of a diphtheria--tetanus--acellular pertussis component vaccine (DTaP) compared to a diphtheria--tetanus toxoid (Td) and a diphtheria toxoid vaccine (d) in adults.
Diphtheria
Immunogenicity and reactogenicity of the component acellular pertussis vaccine produced by a combination of column purified pertussis toxin and filamentous haemagglutinin.
Diphtheria
Immunogenicity and safety after booster vaccination of diphtheria, tetanus, and acellular pertussis in young adults: an open randomized controlled trial in Japan.
Diphtheria
Immunogenicity and Safety of Monovalent Acellular Pertussis Vaccine at Birth: A Randomized Clinical Trial.
Diphtheria
Immunogenicity of a combined DTPa-HB vaccine co-administered with Haemophilus influenzae type B conjugate vaccine (PRP-T) for primary and booster vaccinations.
Diphtheria
Immunogenicity of combined diphtheria, tetanus, and pertussis vaccine given at 2, 3, and 4 months versus 3, 5, and 9 months of age.
Diphtheria
Immunogenicity of primary DPT vaccination.
Diphtheria
Immunogenicity study of a combined diphtheria, tetanus, acellular pertussis, inactivated poliomyelitis vaccine used to reconstitute a freeze-dried Haemophilus influenzae type b vaccine (DTaP-IPV//PRP-T) administered simultaneously with a hepatitis B vaccine at two, three and four months of life.
Diphtheria
Influence of maternal vaccination against diphtheria, tetanus, and pertussis on the avidity of infant antibody responses to a pertussis containing vaccine in Belgium.
Diphtheria
Inhibitors of ADP-ribosylating bacterial toxins based on oxacarbenium ion character at their transition states.
Diphtheria
Interchangeability of meningococcal group C conjugate vaccines with different carrier proteins in the United Kingdom infant immunisation schedule.
Diphtheria
Local reactions and IgE antibodies to pertussis toxin after acellular diphtheria-tetanus-pertussis immunization.
Diphtheria
mADP-RTs: versatile virulence factors from bacterial pathogens of plants and mammals.
Diphtheria
Measuring immunoglobulin g antibodies to tetanus toxin, diphtheria toxin, and pertussis toxin with single-antigen enzyme-linked immunosorbent assays and a bead-based multiplex assay.
Diphtheria
Novel bacterial ADP-ribosylating toxins: structure and function.
Diphtheria
On technological and immunological benefits of multivalent single-injection microsphere vaccines.
Diphtheria
Optimization of rPDT fusion protein expression by Escherichia coli in pilot scale fermentation: a statistical experimental design approach.
Diphtheria
PARP inhibitors: polypharmacology versus selective inhibition.
Diphtheria
PARP-1 and gene regulation: Progress and puzzles.
Diphtheria
Persistence of antibody after accelerated immunisation with diphtheria/tetanus/pertussis vaccine.
Diphtheria
Pertussis toxin-induced alterations of murine hepatic drug metabolism following administration of diphtheria and tetanus toxoids and pertussis vaccine adsorbed.
Diphtheria
Pertussis toxin-sensitive GTP-binding proteins regulate activation-induced apoptotic cell death of human natural killer cells.
Diphtheria
Pertussis vaccination during pregnancy in Belgium: Follow-up of infants until 1 month after the fourth infant pertussis vaccination at 15 months of age.
Diphtheria
Pertussis vaccination during pregnancy in Belgium: Results of a prospective controlled cohort study.
Diphtheria
Pertussis vaccination during pregnancy in Vietnam: Results of a randomized controlled trial Pertussis vaccination during pregnancy.
Diphtheria
Phosphorylation, desensitization and internalization of human alpha1B-adrenoceptors induced by insulin-like growth factor-I.
Diphtheria
Poor immune responses to a birth dose of diphtheria, tetanus, and acellular pertussis vaccine.
Diphtheria
Production of exoenzyme S by clinical isolates of Pseudomonas aeruginosa.
Diphtheria
Protective immunogenicity of synthetic peptides selected from the amino acid sequence of Bordetella pertussis toxin subunit S1.
Diphtheria
Protective immunogenicity of two synthetic peptides selected from the amino acid sequence of Bordetella pertussis toxin subunit S1.
Diphtheria
Pseudomonas aeruginosa exoenzyme S: an adenosine diphosphate ribosyltransferase distinct from toxin A.
Diphtheria
Quantitative determination of bioactive proteins in diphtheria tetanus acellular pertussis (DTaP) vaccine by liquid chromatography tandem mass spectrometry.
Diphtheria
Reactogenicity and immunogenicity of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine (Tdap) in pregnant and nonpregnant women.
Diphtheria
Regulation of the actin cytoskeleton by thrombin in human endothelial cells: role of Rho proteins in endothelial barrier function.
Diphtheria
Safety and immunogenicity of a combined pentavalent diphtheria, tetanus, acellular pertussis, inactivated poliovirus and Haemophilus influenzae type b-tetanus conjugate vaccine in infants, compared with a whole cell pertussis pentavalent vaccine.
Diphtheria
Safety and immunogenicity of Biken acellular pertussis vaccine in combination with diphtheria and tetanus toxoid as a fifth dose at four to six years of age. Munich Vaccine Study Group.
Diphtheria
Safety and immunogenicity of heptavalent pneumococcal CRM197 conjugate vaccine in infants and toddlers.
Diphtheria
Safety and immunogenicity of six acellular pertussis vaccines and one whole-cell pertussis vaccine given as a fifth dose in four- to six-year-old children.
Diphtheria
Sequence and structural links between distant ADP-ribosyltransferase families.
Diphtheria
Seroepidemiology of diphtheria and pertussis in Beijing, China: A cross-sectional study.
Diphtheria
Seroepidemiology of diphtheria and pertussis in Chongqing, China: serology-based evidence of Bordetella pertussis infection.
Diphtheria
Seroprevalence and placental transportation of maternal antibodies specific for Neisseria meningitidis serogroup C, Haemophilus influenzae type B, diphtheria, tetanus, and pertussis.
Diphtheria
Seroprevalence of antibodies against diphtheria, tetanus, and pertussis among healthy Thai adolescents.
Diphtheria
Seroprevalence of antibodies for pertussis and diphtheria among people leaving or entering China: a cross-sectional study.
Diphtheria
Seroprevalence of antibodies to pertussis and diphtheria among healthy adults in China.
Diphtheria
Serum antibodies to diphtheria-tetanus-pertussis vaccine components in Argentine children.
Diphtheria
Serum antibodies to the components of diphtheria-tetanus-pertussis vaccine in Polish children related to vaccination status.
Diphtheria
Spotlight on Tdap? vaccine (Covaxis®) as a single-booster immunization for the prevention of tetanus, diphtheria, and pertussis: in children (aged ?4 years), adolescents, and adults.
Diphtheria
Standardization of acellular pertussis vaccine by assay of serum neutralizing antibodies to pertussis toxin (antitoxin): analogy with diphtheria toxoid.
Diphtheria
Structural Basis for Lack of ADP-Ribosyltransferase Activity in Poly(ADP-Ribose) Polymerase-13/Zinc Finger Antiviral Protein.
Diphtheria
Structure-function analysis of water-soluble inhibitors of the catalytic domain of exotoxin A from Pseudomonas aeruginosa.
Diphtheria
Tdap booster to adolescents with juvenile idiopathic arthritis on and off anti-TNF agents is safe and immunogenic.
Diphtheria
Tdap(5) vaccine (covaxis®): a review of its use as a single-booster immunization for the prevention of tetanus, diphtheria, and pertussis in children (aged ?4 years), adolescents, and adults.
Diphtheria
The diphtheria and pertussis components of diphtheria-tetanus toxoids-pertussis vaccine should be genetically inactivated mutant toxins.
Diphtheria
The Effect of Maternal Pertussis Immunization on Infant Vaccine Responses to a Booster Pertussis-Containing Vaccine in Vietnam.
Diphtheria
The PARP Enzyme Family and the Hallmarks of Cancer Part 1. Cell Intrinsic Hallmarks.
Diphtheria
The quantitative analysis of the mechanism involved in pertussis toxin-mediated cell clustering and its implications in the in vitro quality control of diphtheria tetanus and whole cell pertussis vaccines.
Diphtheria
Use of biotinylated NAD to label and purify ADP-ribosylated proteins.
Diphtheria
Vaccines, emerging viruses, and how to avoid disaster.
Diphtheria
[Induction of protective immunity for Bordetella pertussis by nasal inoculation of pertussis vaccine in mice]
Diphtheria
[Seroepidemiological Studies on Pertussis, Diphtheria and Tetanus among Nursing Students Enrolled between 1994 and 2011 in the Kitakyushu District].
Diphtheria
[The risk of pertussis and diphtheria infections among pediatric healthcare workers in Japan]
DNA Repair-Deficiency Disorders
A high-fat diet and NAD(+) activate Sirt1 to rescue premature aging in cockayne syndrome.
DNA Repair-Deficiency Disorders
Combinatorial Therapy of High Dose Vitamin C and PARP Inhibitors in DNA Repair Deficiency: A Series of 8 Patients.
DNA Repair-Deficiency Disorders
Combined Inhibition of STAT3 and DNA Repair in Palbociclib-Resistant ER-Positive Breast Cancer.
DNA Repair-Deficiency Disorders
Hereditary cancer syndromes: utilizing DNA repair deficiency as therapeutic target.
DNA Repair-Deficiency Disorders
Homologous recombination DNA repair deficiency and PARP inhibition activity in primary triple negative breast cancer.
DNA Repair-Deficiency Disorders
Inhibition of mTOR downregulates expression of DNA repair proteins and is highly efficient against BRCA2-mutated breast cancer in combination to PARP inhibition.
DNA Repair-Deficiency Disorders
Mitochondrial protein ATPase family, AAA domain containing 3A correlates with radioresistance in glioblastoma.
DNA Repair-Deficiency Disorders
PARP inhibition: A promising therapeutic target in ovarian cancer.
DNA Repair-Deficiency Disorders
Predictive biomarkers for cancer therapy with PARP inhibitors.
DNA Repair-Deficiency Disorders
Supraphysiological androgens suppress prostate cancer growth through androgen receptor-mediated DNA damage.
DNA Repair-Deficiency Disorders
The BET inhibitor JQ1 attenuates double-strand break repair and sensitizes models of pancreatic ductal adenocarcinoma to PARP inhibitors.
DNA Repair-Deficiency Disorders
The Landscape and Therapeutic Implications of Molecular Profiles in Epithelial Ovarian Cancer.
DNA Repair-Deficiency Disorders
Trastuzumab resistant HER2+ breast cancer cells retain sensitivity to poly (ADP-ribose) polymerase (PARP) inhibition.
DNA Repair-Deficiency Disorders
Utility of Homologous Recombination Deficiency Biomarkers Across Cancer Types.
dna-3-methyladenine glycosylase ii deficiency
Alkyladenine DNA glycosylase deficiency uncouples alkylation-induced strand break generation from PARP-1 activation and glycolysis inhibition.
Down Syndrome
Differential expression of PARP1 mRNA in leucocytes of patients with down's syndrome.
Down Syndrome
The role of poly(ADP-ribose)polymerase in the induction of sister chromatid exchanges and micronuclei by mitomycin C in Down's syndrome cells as compared to euploid cells.
Drug-Related Side Effects and Adverse Reactions
Identification of different side effects between PARP inhibitors and their polypharmacological multi-target rationale.
Dyslexia
The complex of TFII-I, PARP1, and SFPQ proteins regulates the DYX1C1 gene implicated in neuronal migration and dyslexia.
Dyslipidemias
Protective effects of PARP-1 knockout on dyslipidemia-induced autonomic and vascular dysfunction in ApoE mice: effects on eNOS and oxidative stress.
Dyslipidemias
[Gender-specific factors of ischemic stroke among atrial fibrillation patients].
Ectropion
The Curcumin Analogs 2-Pyridyl Cyclohexanone Induce Apoptosis via Inhibition of the JAK2-STAT3 Pathway in Human Esophageal Squamous Cell Carcinoma Cells.
Ehrlichiosis
Specific processing of poly(ADP-ribose) polymerase, accompanied by activation of caspase-3 and elevation/reduction of ceramide/hydrogen peroxide levels, during induction of apoptosis in host HL-60 cells infected by the human granulocytic ehrlichiosis (HGE) agent.
Encephalitis
Damage and repair of DNA in HIV encephalitis.
Encephalitis
Estrogen treatment following severe burn injury reduces brain inflammation and apoptotic signaling.
Encephalitis
Metalloproteinases control brain inflammation induced by pertussis toxin in mice overexpressing the chemokine CCL2 in the central nervous system.
Encephalitis
The role of poly(ADP-ribose) polymerase-1 in CNS disease.
Encephalomyelitis
Amifostine ameliorates induction of experimental autoimmune encephalomyelitis: Effect on reactive oxygen species/NLRP3 pathway.
Encephalomyelitis
Analysis of experimental autoimmune encephalomyelitis induced in F344 rats by pertussis toxin administration.
Encephalomyelitis
Attenuation of the progression of adjuvant-induced arthritis by 3-aminobenzamide treatment.
Encephalomyelitis
Beyond dna repair,the immunological role of parp-1 and its siblings.
Encephalomyelitis
Centrally administered pertussis toxin inhibits microglia migration to the spinal cord and prevents dissemination of disease in an EAE mouse model.
Encephalomyelitis
Crawling phagocytes recruited in the brain vasculature after pertussis toxin exposure through IL6, ICAM1, and ITG?M.
Encephalomyelitis
Defective CD4T cell priming and resistance to experimental autoimmune encephalomyelitis in TNF-deficient mice due to innate immune hypo-responsiveness.
Encephalomyelitis
Delineation of the minimal encephalitogenic epitope within the immunodominant region of myelin oligodendrocyte glycoprotein: diverse V beta gene usage by T cells recognizing the core epitope encephalitogenic for T cell receptor V beta b and T cell receptor V beta a H-2b mice.
Encephalomyelitis
Differential roles of Fas ligand in spontaneous and actively induced autoimmune encephalomyelitis.
Encephalomyelitis
Diversified serum IgG response involving non-myelin CNS proteins during experimental autoimmune encephalomyelitis.
Encephalomyelitis
Elevated axonal membrane permeability and its correlation with motor deficits in an animal model of multiple sclerosis.
Encephalomyelitis
Experimental Autoimmune Encephalomyelitis Develops in CC Chemokine Receptor 7-deficient Mice with Altered T-cell Responses.
Encephalomyelitis
Immunomodulation By Subchronic Low Dose 2,3,7,8-Tetrachlorodibenzo-p-Dioxin in Experimental Autoimmune Encephalomyelitis in the Absence of Pertussis Toxin.
Encephalomyelitis
Immunomodulation of murine experimental autoimmune encephalomyelitis by pertussis toxin: the protective activity, but not the disease-enhancing activity, can be attributed to the nontoxic B-oligomer.
Encephalomyelitis
Induction of Autoimmunity by Expansion of Autoreactive CD4+CD62Llow Cells In Vivo.
Encephalomyelitis
Inhibitors of poly(ADP-ribose) polymerase-1 suppress transcriptional activation in lymphocytes and ameliorate autoimmune encephalomyelitis in rats.
Encephalomyelitis
Kinetics of IL-17- and interferon-gamma-producing PLPp-specific CD4 T cells in EAE induced by coinjection of PLPp/IFA with pertussis toxin in SJL mice.
Encephalomyelitis
Long-term suppression of EAE relapses by pharmacological impairment of epitope spreading.
Encephalomyelitis
Native, but not genetically inactivated, pertussis toxin protects mice against experimental allergic encephalomyelitis.
Encephalomyelitis
Neuroinflammation and B-Cell Phenotypes in Cervical and Lumbosacral Regions of the Spinal Cord in Experimental Autoimmune Encephalomyelitis in the Absence of Pertussis Toxin.
Encephalomyelitis
Neuroprotective Effects of 6-Shogaol and Its Metabolite, 6-Paradol, in a Mouse Model of Multiple Sclerosis.
Encephalomyelitis
Paradoxical effect of pertussis toxin on the delayed hypersensitivity response to autoantigens in mice.
Encephalomyelitis
PARP-1 deficiency increases the severity of disease in a mouse model of multiple sclerosis.
Encephalomyelitis
PARP-1 inhibition prevents CNS migration of dendritic cells during EAE, suppressing the encephalitogenic response and relapse severity.
Encephalomyelitis
Pertussis toxin attenuates experimental autoimmune encephalomyelitis by upregulating neuronal vascular endothelial growth factor.
Encephalomyelitis
Pertussis Toxin Inhibits Encephalitogenic T-Cell Infiltration and Promotes a B-Cell-Driven Disease during Th17-EAE.
Encephalomyelitis
Pertussis toxin inhibits induction of tissue-specific autoimmune disease by disrupting G protein-coupled signals.
Encephalomyelitis
Pertussis toxin modulates microglia and T cell profile to protect experimental autoimmune encephalomyelitis.
Encephalomyelitis
Pertussis toxin modulates the immune response to neuroantigens injected in incomplete Freund's adjuvant: induction of Th1 cells and experimental autoimmune encephalomyelitis in the presence of high frequencies of Th2 cells.
Encephalomyelitis
Pertussis toxin promotes relapsing-remitting experimental autoimmune encephalomyelitis in Lewis rats.
Encephalomyelitis
Pertussis toxin reduces the number of splenic Foxp3+ regulatory T cells.
Encephalomyelitis
Pertussis toxin-induced hyperacute autoimmune encephalomyelitis in Lewis rats is correlated with increased expression of inducible nitric oxide synthase and tumor necrosis factor alpha.
Encephalomyelitis
Poly(ADP-ribose) polymerase 2 contributes to neuroinflammation and neurological dysfunction in mouse experimental autoimmune encephalomyelitis.
Encephalomyelitis
Protection against autoimmune disease by bacterial agents. II. PPD and pertussis toxin as proteins active in protecting mice against experimental autoimmune encephalomyelitis.
Encephalomyelitis
Protective effects of pharmacological therapies in animal models of multiple sclerosis: a review of studies 2014-2019.
Encephalomyelitis
Rapid depletion of peripheral antigen-specific T cells in TCR-transgenic mice after oral administration of myelin basic protein.
Encephalomyelitis
Regulation of experimental autoimmune encephalomyelitis by CD4+, CD25+ and CD8+ T cells: analysis using depleting antibodies.
Encephalomyelitis
Repetitive pertussis toxin promotes development of regulatory T cells and prevents central nervous system autoimmune disease.
Encephalomyelitis
Special AT-rich sequence binding protein 1 is required for maintenance of T cell receptor responsiveness and development of experimental autoimmune encephalomyelitis.
Encephalomyelitis
The potential role of subclinical Bordetella Pertussis colonization in the etiology of multiple sclerosis.
Encephalomyelitis
The regulatory effect of liuwei dihuang pills on cytokines in mice with experimental autoimmune encephalomyelitis.
Encephalomyelitis
TLR4 contributes to disease-inducing mechanisms resulting in central nervous system autoimmune disease.
Encephalomyelitis
Vascular and immunopathological role of Asymmetric Dimethylarginine (ADMA) in Experimental Autoimmune Encephalomyelitis.
Encephalomyelitis, Autoimmune, Experimental
Amifostine ameliorates induction of experimental autoimmune encephalomyelitis: Effect on reactive oxygen species/NLRP3 pathway.
Encephalomyelitis, Autoimmune, Experimental
Analysis of experimental autoimmune encephalomyelitis induced in F344 rats by pertussis toxin administration.
Encephalomyelitis, Autoimmune, Experimental
Attenuation of the progression of adjuvant-induced arthritis by 3-aminobenzamide treatment.
Encephalomyelitis, Autoimmune, Experimental
Beyond dna repair,the immunological role of parp-1 and its siblings.
Encephalomyelitis, Autoimmune, Experimental
Centrally administered pertussis toxin inhibits microglia migration to the spinal cord and prevents dissemination of disease in an EAE mouse model.
Encephalomyelitis, Autoimmune, Experimental
Crawling phagocytes recruited in the brain vasculature after pertussis toxin exposure through IL6, ICAM1, and ITG?M.
Encephalomyelitis, Autoimmune, Experimental
Defective CD4T cell priming and resistance to experimental autoimmune encephalomyelitis in TNF-deficient mice due to innate immune hypo-responsiveness.
Encephalomyelitis, Autoimmune, Experimental
Delineation of the minimal encephalitogenic epitope within the immunodominant region of myelin oligodendrocyte glycoprotein: diverse V beta gene usage by T cells recognizing the core epitope encephalitogenic for T cell receptor V beta b and T cell receptor V beta a H-2b mice.
Encephalomyelitis, Autoimmune, Experimental
Diversified serum IgG response involving non-myelin CNS proteins during experimental autoimmune encephalomyelitis.
Encephalomyelitis, Autoimmune, Experimental
Elevated axonal membrane permeability and its correlation with motor deficits in an animal model of multiple sclerosis.
Encephalomyelitis, Autoimmune, Experimental
Experimental Autoimmune Encephalomyelitis Develops in CC Chemokine Receptor 7-deficient Mice with Altered T-cell Responses.
Encephalomyelitis, Autoimmune, Experimental
Genetic analysis of the influence of pertussis toxin on experimental allergic encephalomyelitis susceptibility: an environmental agent can override genetic checkpoints.
Encephalomyelitis, Autoimmune, Experimental
Immunomodulation By Subchronic Low Dose 2,3,7,8-Tetrachlorodibenzo-p-Dioxin in Experimental Autoimmune Encephalomyelitis in the Absence of Pertussis Toxin.
Encephalomyelitis, Autoimmune, Experimental
Immunomodulation of murine experimental autoimmune encephalomyelitis by pertussis toxin: the protective activity, but not the disease-enhancing activity, can be attributed to the nontoxic B-oligomer.
Encephalomyelitis, Autoimmune, Experimental
Induction of Autoimmunity by Expansion of Autoreactive CD4+CD62Llow Cells In Vivo.
Encephalomyelitis, Autoimmune, Experimental
Inhibition by CTLA4Ig of experimental allergic encephalomyelitis.
Encephalomyelitis, Autoimmune, Experimental
Inhibitors of poly(ADP-ribose) polymerase-1 suppress transcriptional activation in lymphocytes and ameliorate autoimmune encephalomyelitis in rats.
Encephalomyelitis, Autoimmune, Experimental
Kinetics of IL-17- and interferon-gamma-producing PLPp-specific CD4 T cells in EAE induced by coinjection of PLPp/IFA with pertussis toxin in SJL mice.
Encephalomyelitis, Autoimmune, Experimental
Long-term suppression of EAE relapses by pharmacological impairment of epitope spreading.
Encephalomyelitis, Autoimmune, Experimental
Native, but not genetically inactivated, pertussis toxin protects mice against experimental allergic encephalomyelitis.
Encephalomyelitis, Autoimmune, Experimental
Neuroinflammation and B-Cell Phenotypes in Cervical and Lumbosacral Regions of the Spinal Cord in Experimental Autoimmune Encephalomyelitis in the Absence of Pertussis Toxin.
Encephalomyelitis, Autoimmune, Experimental
Neuroprotective Effects of 6-Shogaol and Its Metabolite, 6-Paradol, in a Mouse Model of Multiple Sclerosis.
Encephalomyelitis, Autoimmune, Experimental
Paradoxical effect of pertussis toxin on the delayed hypersensitivity response to autoantigens in mice.
Encephalomyelitis, Autoimmune, Experimental
PARP-1 deficiency increases the severity of disease in a mouse model of multiple sclerosis.
Encephalomyelitis, Autoimmune, Experimental
PARP-1 inhibition prevents CNS migration of dendritic cells during EAE, suppressing the encephalitogenic response and relapse severity.
Encephalomyelitis, Autoimmune, Experimental
PD-L1 is increased in the spinal cord and infiltrating lymphocytes in experimental allergic encephalomyelitis.
Encephalomyelitis, Autoimmune, Experimental
Pertussis toxin attenuates experimental autoimmune encephalomyelitis by upregulating neuronal vascular endothelial growth factor.
Encephalomyelitis, Autoimmune, Experimental
Pertussis toxin induces angiogenesis in brain microvascular endothelial cells.
Encephalomyelitis, Autoimmune, Experimental
Pertussis Toxin Inhibits Encephalitogenic T-Cell Infiltration and Promotes a B-Cell-Driven Disease during Th17-EAE.
Encephalomyelitis, Autoimmune, Experimental
Pertussis toxin inhibits induction of tissue-specific autoimmune disease by disrupting G protein-coupled signals.
Encephalomyelitis, Autoimmune, Experimental
Pertussis toxin modulates microglia and T cell profile to protect experimental autoimmune encephalomyelitis.
Encephalomyelitis, Autoimmune, Experimental
Pertussis toxin modulates the immune response to neuroantigens injected in incomplete Freund's adjuvant: induction of Th1 cells and experimental autoimmune encephalomyelitis in the presence of high frequencies of Th2 cells.
Encephalomyelitis, Autoimmune, Experimental
Pertussis toxin promotes relapsing-remitting experimental autoimmune encephalomyelitis in Lewis rats.
Encephalomyelitis, Autoimmune, Experimental
Pertussis toxin reduces the number of splenic Foxp3+ regulatory T cells.
Encephalomyelitis, Autoimmune, Experimental
Pertussis toxin-induced hyperacute autoimmune encephalomyelitis in Lewis rats is correlated with increased expression of inducible nitric oxide synthase and tumor necrosis factor alpha.
Encephalomyelitis, Autoimmune, Experimental
Poly(ADP-ribose) polymerase 2 contributes to neuroinflammation and neurological dysfunction in mouse experimental autoimmune encephalomyelitis.
Encephalomyelitis, Autoimmune, Experimental
Poly(ADP-ribose) polymerase inhibitors.
Encephalomyelitis, Autoimmune, Experimental
Poly(ADP-ribose) polymerase-1 activation in a primate model of multiple sclerosis.
Encephalomyelitis, Autoimmune, Experimental
Protection against autoimmune disease by bacterial agents. II. PPD and pertussis toxin as proteins active in protecting mice against experimental autoimmune encephalomyelitis.
Encephalomyelitis, Autoimmune, Experimental
Protective effects of pharmacological therapies in animal models of multiple sclerosis: a review of studies 2014-2019.
Encephalomyelitis, Autoimmune, Experimental
Rapid depletion of peripheral antigen-specific T cells in TCR-transgenic mice after oral administration of myelin basic protein.
Encephalomyelitis, Autoimmune, Experimental
Regulation of experimental autoimmune encephalomyelitis by CD4+, CD25+ and CD8+ T cells: analysis using depleting antibodies.
Encephalomyelitis, Autoimmune, Experimental
Repetitive pertussis toxin promotes development of regulatory T cells and prevents central nervous system autoimmune disease.
Encephalomyelitis, Autoimmune, Experimental
Special AT-rich sequence binding protein 1 is required for maintenance of T cell receptor responsiveness and development of experimental autoimmune encephalomyelitis.
Encephalomyelitis, Autoimmune, Experimental
The potential role of subclinical Bordetella Pertussis colonization in the etiology of multiple sclerosis.
Encephalomyelitis, Autoimmune, Experimental
The regulatory effect of liuwei dihuang pills on cytokines in mice with experimental autoimmune encephalomyelitis.
Encephalomyelitis, Autoimmune, Experimental
The therapeutic effects of PJ34 [N-(6-oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide.HCl], a selective inhibitor of poly(ADP-ribose) polymerase, in experimental allergic encephalomyelitis are associated with immunomodulation.
Encephalomyelitis, Autoimmune, Experimental
The third signal in T cell-mediated autoimmune disease?
Encephalomyelitis, Autoimmune, Experimental
TLR4 contributes to disease-inducing mechanisms resulting in central nervous system autoimmune disease.
Encephalomyelitis, Autoimmune, Experimental
Transgenic mice that express a myelin basic protein-specific T cell receptor develop spontaneous autoimmunity.
Encephalomyelitis, Autoimmune, Experimental
Vascular and immunopathological role of Asymmetric Dimethylarginine (ADMA) in Experimental Autoimmune Encephalomyelitis.
Encephalomyelitis, Venezuelan Equine
Interferon-stimulated poly(ADP-Ribose) polymerases are potent inhibitors of cellular translation and virus replication.
Endodermal Sinus Tumor
PARP expression in germ cell tumours.
Endometrial Hyperplasia
Autophagy in the physiological endometrium and cancer.
Endometrial Hyperplasia
Poly(ADP-ribose) polymerase-1, a novel partner of progesterone receptors in endometrial cancer and its precursors.
Endometrial Neoplasms
An olaparib window-of-opportunity trial in patients with early-stage endometrial carcinoma: POLEN study.
Endometrial Neoplasms
Anti-tumor activity of olaparib, a poly (ADP-ribose) polymerase (PARP) inhibitor, in cultured endometrial carcinoma cells.
Endometrial Neoplasms
Autophagy in the physiological endometrium and cancer.
Endometrial Neoplasms
Current Systemic Treatment Landscape of Advanced Gynecologic Malignancies.
Endometrial Neoplasms
Durable response in a woman with recurrent low-grade endometrioid endometrial cancer and a germline BRCA2 mutation treated with a PARP inhibitor.
Endometrial Neoplasms
Effect of MRE11 loss on PARP-inhibitor sensitivity in endometrial cancer in vitro.
Endometrial Neoplasms
Evaluation of the management of PARP inhibitor toxicities in ovarian and endometrial cancer within a multi-institution health-system.
Endometrial Neoplasms
Expression of DNA repair proteins in endometrial cancer predicts disease outcome.
Endometrial Neoplasms
Expression of poly-ADP-ribose polymerase (PARP) in endometrial adenocarcinoma: Prognostic potential.
Endometrial Neoplasms
Histone deacetylase inhibitors induce apoptosis in both Type I and Type II endometrial cancer cells.
Endometrial Neoplasms
Hypomethylation of ETS transcription factor binding sites and upregulation of PARP1 expression in endometrial cancer.
Endometrial Neoplasms
Inhibition of PI3K-AKT-mTOR pathway sensitizes endometrial cancer cell lines to PARP inhibitors.
Endometrial Neoplasms
Low levels of circulating estrogen sensitize PTEN-null endometrial tumors to PARP inhibition in vivo.
Endometrial Neoplasms
MLH1 enhances the sensitivity of human endometrial carcinoma cells to cisplatin by activating the MLH1/c-Abl apoptosis signaling pathway.
Endometrial Neoplasms
Moving From Mutation to Actionability.
Endometrial Neoplasms
Pan-Cancer Analysis of PARP1 Alterations as Biomarkers in the Prediction of Immunotherapeutic Effects and the Association of Its Expression Levels and Immunotherapy Signatures.
Endometrial Neoplasms
PARP and PD-1/PD-L1 checkpoint inhibition in recurrent or metastatic endometrial cancer.
Endometrial Neoplasms
PARP inhibition sensitizes endometrial cancer cells to paclitaxel-induced apoptosis.
Endometrial Neoplasms
PARP inhibitors and immunotherapy in ovarian and endometrial cancers.
Endometrial Neoplasms
PARP inhibitors in BRCA gene-mutated ovarian cancer and beyond.
Endometrial Neoplasms
PARP Inhibitors in Endometrial Cancer: Current Status and Perspectives.
Endometrial Neoplasms
Poly(ADP-ribose) polymerase (PARP) and DNA-fragmentation factor (DFF45): expression and correlation in normal, hyperplastic and neoplastic endometrial tissues.
Endometrial Neoplasms
Poly(ADP-ribose) polymerase-1, a novel partner of progesterone receptors in endometrial cancer and its precursors.
Endometrial Neoplasms
PTEN deficiency in endometrioid endometrial adenocarcinomas predicts sensitivity to PARP inhibitors.
Endometrial Neoplasms
PTEN deficiency sensitizes endometrioid endometrial cancer to compound PARP-PI3K inhibition but not PARP inhibition as monotherapy.
Endometrial Neoplasms
Research progress of PARP inhibitor monotherapy and combination therapy for endometrial cancer.
Endometrial Neoplasms
Successful treatment of a patient with brain metastases from endometrial cancer using Niraparib: a case report.
Endometrial Neoplasms
The SGK1 inhibitor SI113 induces autophagy, apoptosis, and endoplasmic reticulum stress in endometrial cancer cells.
Endometrial Neoplasms
TRAF4 knockdown triggers synergistic lethality with simultaneous PARP1 inhibition in endometrial cancer.
Endometrial Neoplasms
[Influence of pertussis toxin on GPER-mediated activation of phosphatidylinositol 3-kinase/protein kinase B signaling induced by 17?-estradiol in endometrial carcinoma cells].
Endometriosis
Immunohistochemistry expression of targeted therapies biomarkers in ovarian clear cell and endometrioid carcinomas (type I) and endometriosis.
Endotoxemia
Heterotrimeric G?(i) proteins are regulated by lipopolysaccharide and are anti-inflammatory in endotoxemia and polymicrobial sepsis.
Endotoxemia
Nicotinamide increases systemic vascular resistance in ovine endotoxemia.
Endotoxemia
Role of lipopolysaccharide and cecal ligation and puncture on blood coagulation and inflammation in sensitive and resistant mice models.
Endotoxemia
Role of PARP on iNOS pathway during endotoxin-induced acute lung injury.
Endotoxemia
Systemic and hepatosplanchnic hemodynamic and metabolic effects of the PARP inhibitor PJ34 during hyperdynamic porcine endotoxemia.
Enterocolitis, Necrotizing
Poly(ADP-Ribose) Polymerase-1: A Novel Therapeutic Target in Necrotizing Enterocolitis.
Eosinophilia
PARP is activated in human asthma and its inhibition by olaparib blocks house dust mite-induced disease in mice.
Eosinophilia
PARP-1 deficiency blocks IL-5 expression through calpain-dependent degradation of STAT-6 in a murine asthma model.
Eosinophilia
Post-allergen challenge inhibition of poly(ADP-ribose) polymerase harbors therapeutic potential for treatment of allergic airway inflammation.
Eosinophilia
Reciprocal regulation of iNOS and PARP-1 during allergen-induced eosinophilia.
Eosinophilic Esophagitis
Correlation of increased PARP14 and CCL26 expression in biopsies from children with eosinophilic esophagitis.
Ependymoma
Elevated CXorf67 Expression in PFA Ependymomas Suppresses DNA Repair and Sensitizes to PARP Inhibitors.
Ependymoma
PARP inhibition sensitizes childhood high grade glioma, medulloblastoma and ependymoma to radiation.
Epilepsy
Amygdaloid kindling elicits persistent changes in pertussis toxin-catalyzed ADP-ribosylation.
Epilepsy
Cellular NAD depletion and decline of SIRT1 activity play critical roles in PARP-1-mediated acute epileptic neuronal death in vitro.
Epilepsy
Poly(ADP-ribose) polymerase inhibition protects epileptic hippocampal neurons from apoptosis via suppressing Akt-mediated apoptosis-inducing factor translocation in vitro.
Epilepsy
TRPM2 ion channel is involved in the aggravation of cognitive impairment and down regulation of epilepsy threshold in pentylenetetrazole-induced kindling mice.
Epilepsy, Absence
Pertussis toxin decreases absence seizures and GABA(B) receptor binding in thalamus of a genetically prone rat (GAERS).
Epstein-Barr Virus Infections
Generation of human monoclonal antibodies that confer protection against pertussis toxin.
Erectile Dysfunction
Poly(Adenosine diphosphate-ribose) polymerase inhibition preserves erectile function in rats after cavernous nerve injury.
Erectile Dysfunction
Poly(ADP-ribose) polymerase inhibition reverses nitrergic neurovascular dysfunctions in penile erectile tissue from streptozotocin-diabetic mice.
Erythema
Increase in intradermal vascular permeability caused by pertussis toxin from Bordetella pertussis.
Erythema
Nitric oxide-peroxynitrite-poly(ADP-ribose) polymerase pathway in the skin.
Esophageal Neoplasms
Involvement of homologous recombination in the synergism between cisplatin and poly(ADP-ribose) polymerase inhibition.
Esophageal Neoplasms
PARP inhibitor olaparib sensitizes esophageal carcinoma cells to fractionated proton irradiation.
Esophageal Neoplasms
PARP1 Gene Polymorphisms and the Prognosis of Esophageal Cancer Patients from Cixian High-Incidence Region in Northern China.
Esophageal Neoplasms
PARP1 rs1136410 C/C genotype associated with an increased risk of esophageal cancer in smokers.
Esophageal Neoplasms
Single?cell intratumoral stemness analysis reveals the involvement of cell cycle and DNA damage repair in two different types of esophageal cancer.
Esophageal Neoplasms
The Synthetic ?-Nitrostyrene Derivative CYT-Rx20 Inhibits Esophageal Tumor Growth and Metastasis via PI3K/AKT and STAT3 Pathways.
Esophageal Squamous Cell Carcinoma
Effect of a poly(ADP-ribose) polymerase-1 inhibitor against esophageal squamous cell carcinoma cell lines.
Esophageal Squamous Cell Carcinoma
PARP1 Gene Polymorphisms and the Prognosis of Esophageal Cancer Patients from Cixian High-Incidence Region in Northern China.
Esophageal Squamous Cell Carcinoma
PARP1 rs1136410 C/C genotype associated with an increased risk of esophageal cancer in smokers.
Esophageal Squamous Cell Carcinoma
Poly (ADP-ribose) polymerase-1 inhibition decreases proliferation through G2/M arrest in esophageal squamous cell carcinoma.
Essential Hypertension
Enhanced G protein activation in IDDM patients with diabetic nephropathy.
Essential Hypertension
Selectively enhanced cellular signaling by Gi proteins in essential hypertension. G alpha i2, G alpha i3, G beta 1, and G beta 2 are not mutated.
Exanthema
Association of apoptosis-related microsatellite polymorphisms on chromosome 1q in Taiwanese systemic lupus erythematosus patients.
Eye Abnormalities
Anterior uveitis in murine relapsing experimental autoimmune encephalomyelitis (EAE), a mouse model of multiple sclerosis (MS).
Fallopian Tube Neoplasms
Niraparib for the Treatment of Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer.
Fanconi Anemia
A phase 1 study of the PARP inhibitor veliparib in combination with temozolomide in acute myeloid leukemia.
Fanconi Anemia
Acquisition of relative interstrand crosslinker resistance and PARP inhibitor sensitivity in Fanconi anemia head and neck cancers.
Fanconi Anemia
Differential and common DNA repair pathways for topoisomerase I- and II-targeted drugs in a genetic DT40 repair cell screen panel.
Fanconi Anemia
DNA helicases FANCM and DDX11 are determinants of PARP inhibitor sensitivity.
Fanconi Anemia
DNA Repair Deficient Chinese Hamster Ovary Cells Exhibiting Differential Sensitivity to Charged Particle Radiation under Aerobic and Hypoxic Conditions.
Fanconi Anemia
HSF2BP negatively regulates homologous recombination in DNA interstrand crosslink repair.
Fanconi Anemia
No abnormalities in the NAD+ ADP-ribosyltransferase (polymerizing) gene of transformed cells from a Fanconi's anemia patient.
Fanconi Anemia
Rare mutations in XRCC2 increase the risk of breast cancer.
Fanconi Anemia
Reduced PAK1 activity sensitizes FA/BRCA-proficient breast cancer cells to PARP inhibition.
Fanconi Anemia
The cellular control enzyme polyADP ribosyl transferase is eliminated in cultured Fanconi anemia fibroblasts at confluency.
Fanconi Anemia
The Fanconi anemia cell line HSC536N is not sensitive to interferon-gamma and does not cleave PARP in response to FAS-mediated cell killing.
Fatty Liver
2,3,7,8-Tetrachlorodibenzo-p-Dioxin (TCDD)-Inducible Poly-ADP-Ribose Polymerase (TIPARP/PARP7) Catalytic Mutant Mice (TiparpH532A) Exhibit Increased Sensitivity to TCDD-Induced Hepatotoxicity and Lethality.
Fatty Liver
Hepatocyte-Specific Deletion of TIPARP, a Negative Regulator of the Aryl Hydrocarbon Receptor, Is Sufficient to Increase Sensitivity to Dioxin-Induced Wasting Syndrome.
Fatty Liver
Loss of the Mono-ADP-ribosyltransferase, Tiparp, Increases Sensitivity to Dioxin-induced Steatohepatitis and Lethality.
Fatty Liver
Metabolic roles of poly(ADP-ribose) polymerases.
Fatty Liver
Oval cells compensate for damage and replicative senescence of mature hepatocytes in mice with fatty liver disease.
Fatty Liver
PARP inhibition protects against alcoholic and non-alcoholic steatohepatitis.
Fatty Liver
PARP1-mediated PPAR? poly(ADP-ribosyl)ation suppresses fatty acid oxidation in non-alcoholic fatty liver disease.
Fatty Liver
PARPs in lipid metabolism and related diseases.
Fatty Liver
Pertussis toxin induces fatty liver, hyperlipemia and ketosis in hamsters.
Fatty Liver
Steatohepatitis: PARP inhibition protective against alcoholic steatohepatitis and NASH.
Fatty Liver, Alcoholic
PARP inhibition protects against alcoholic and non-alcoholic steatohepatitis.
Fatty Liver, Alcoholic
Poly(ADP-Ribose) Polymerase Inhibitor PJ34 Attenuated Hepatic Triglyceride Accumulation in Alcoholic Fatty Liver Disease in Mice.
Fatty Liver, Alcoholic
Steatohepatitis: PARP inhibition protective against alcoholic steatohepatitis and NASH.
Fetal Alcohol Spectrum Disorders
Nicotinamide Inhibits Ethanol-Induced Caspase-3 and PARP-1 Over-activation and Subsequent Neurodegeneration in the Developing Mouse Cerebellum.
Fibroma
PARP-1 expression as a prognostic factor in Desmoid-type fibromatosis.
Fibromatosis, Aggressive
PARP-1 expression as a prognostic factor in Desmoid-type fibromatosis.
Fibrosarcoma
HMGA2 as a functional antagonist of PARP1 inhibitors in tumor cells.
Fibrosarcoma
Response of DNA repair enzymes in murine fibrosarcoma, lymphosarcoma and ascites cells following gamma irradiation.
Fibrosarcoma
Role of JNK-1 regulation in the protection of contact-inhibited fibroblasts from oxidative stress.
Friedreich Ataxia
Frataxin Deficiency Promotes Excess Microglial DNA Damage and Inflammation that Is Rescued by PJ34.
Frontotemporal Lobar Degeneration
Fused in Sarcoma (FUS) in DNA Repair: Tango with Poly(ADP-ribose) Polymerase 1 and Compartmentalisation of Damaged DNA.
Gallbladder Neoplasms
PARP1 rs1136410 (A/G) polymorphism is associated with early age of onset of gallbladder cancer.
Gallbladder Neoplasms
Triptolide induces s phase arrest and apoptosis in gallbladder cancer cells.
Ganglion Cysts
A G Protein Mediates the Inhibition of the Voltage-Dependent Potassium M Current by Muscarine, LHRH, Substance P and UTP in Bullfrog Sympathetic Neurons.
Ganglion Cysts
Poly(ADP-ribose) polymerase inhibition improves corneal epithelial innervation and wound healing in diabetic rats.
Gastrointestinal Diseases
Expression and Single Nucleotide Polymorphism of Poly (ADPRibose) Polymerase-1 in Gastrointestinal Tumours: Clinical Involvement.
Gastrointestinal Diseases
Safety profile of poly (ADP-ribose) polymerase (PARP) inhibitors in cancer: a network meta-analysis of randomized controlled trials.
Gastrointestinal Neoplasms
Expression and Single Nucleotide Polymorphism of Poly (ADPRibose) Polymerase-1 in Gastrointestinal Tumours: Clinical Involvement.
Gastrointestinal Neoplasms
Identification of PARP-1 in cancer stem cells of gastrointestinal cancers: A preliminary study.
Gastrointestinal Neoplasms
Therapeutic Potential of PARP Inhibitors in the Treatment of Gastrointestinal Cancers.
Genetic Diseases, Inborn
The function of poly (ADP-ribosylation) in DNA breakage and rejoining.
Giant Cell Tumors
Bisphosphonates may reduce recurrence in giant cell tumor by inducing apoptosis.
Glioblastoma
A constitutively active form of neurokinin 1 receptor and neurokinin 1 receptor-mediated apoptosis in glioblastomas.
Glioblastoma
A New Pathway Promotes Adaptation of Human Glioblastoma Cells to Glucose Starvation.
Glioblastoma
A novel small molecule inhibits STAT3 phosphorylation and DNA binding activity and exhibits potent growth suppressive activity in human cancer cells.
Glioblastoma
A novel small molecule, LLL12, inhibits STAT3 phosphorylation and activities and exhibits potent growth-suppressive activity in human cancer cells.
Glioblastoma
A randomized phase I/II study of ABT-888 in combination with temozolomide in recurrent temozolomide resistant glioblastoma: an NRG oncology RTOG group study.
Glioblastoma
A randomized phase II trial of veliparib, radiotherapy and temozolomide in patients with unmethylated MGMT glioblastoma: the VERTU study.
Glioblastoma
ABCB1 Attenuates the Brain Penetration of the PARP Inhibitor AZD2461.
Glioblastoma
ABCB1, ABCG2 and PTEN determine the response of glioblastoma to temozolomide and ABT-888 therapy.
Glioblastoma
An 18F-Labeled Poly(ADP-ribose) Polymerase Positron Emission Tomography Imaging Agent.
Glioblastoma
Associations between polymorphisms in DNA repair genes and glioblastoma.
Glioblastoma
BKM120 sensitizes glioblastoma to the PARP inhibitor rucaparib by suppressing homologous recombination repair.
Glioblastoma
BRCAness as a Biomarker of Susceptibility to PARP Inhibitors in Glioblastoma Multiforme.
Glioblastoma
Cannabidiol inhibits human glioma by induction of lethal mitophagy through activating TRPV4.
Glioblastoma
Caspase-dependent signaling underlies glioblastoma cell death in response to the fungal metabolite, fusarochromanone.
Glioblastoma
Celastrol targets proteostasis and acts synergistically with a heat-shock protein 90 inhibitor to kill human glioblastoma cells.
Glioblastoma
Cellular and biochemical antileukemic mechanisms of the meroterpenoid Oncocalyxone A.
Glioblastoma
Chemopotentiation of temozolomide, irinotecan, and cisplatin activity by CEP-6800, a poly(ADP-ribose) polymerase inhibitor.
Glioblastoma
Combining PARP inhibitors with radiation therapy for the treatment of glioblastoma: Is PTEN predictive of response?
Glioblastoma
Comparative status of activated ERK1/2 and PARP cleavage in human gliomas.
Glioblastoma
Deubiquitinating enzyme 4 facilitates chemoresistance in glioblastoma by inhibiting P53 activity.
Glioblastoma
Discordant in vitro and in vivo chemopotentiating effects of the PARP inhibitor veliparib in temozolomide-sensitive versus -resistant glioblastoma multiforme xenografts.
Glioblastoma
Discovery of a perinecrotic 60 kDa MDM2 isoform within glioma spheroids and glioblastoma biopsy material.
Glioblastoma
Discriminating radiation injury from recurrent tumor with [18F]PARPi and amino acid PET in mouse models.
Glioblastoma
Dual Inhibition of Bcl-2/Bcl-xL and XPO1 is synthetically lethal in glioblastoma model systems.
Glioblastoma
Dual-Modality Optical/PET Imaging of PARP1 in Glioblastoma.
Glioblastoma
Effect of p53 activity on the sensitivity of human glioblastoma cells to PARP-1 inhibitor in combination with topoisomerase I inhibitor or radiation.
Glioblastoma
Effective sensitization of temozolomide by ABT-888 is lost with development of temozolomide resistance in glioblastoma xenograft lines.
Glioblastoma
Efficacy of PARP Inhibitor Rucaparib in Orthotopic Glioblastoma Xenografts Is Limited by Ineffective Drug Penetration into the Central Nervous System.
Glioblastoma
EGFR Amplification Induces Increased DNA Damage Response and Renders Selective Sensitivity to Talazoparib (PARP Inhibitor) in Glioblastoma.
Glioblastoma
Enhanced efficacy of combined HDAC and PARP targeting in glioblastoma.
Glioblastoma
Eradication of LIG4-deficient glioblastoma cells by the combination of PARP inhibitor and alkylating agent.
Glioblastoma
Evaluation of poly (ADP-ribose) polymerase inhibitor ABT-888 combined with radiotherapy and temozolomide in glioblastoma.
Glioblastoma
Exploitation of a novel phenothiazine derivative for its anti-cancer activities in malignant glioblastoma.
Glioblastoma
Expression of poly(ADP-ribose) polymerase and distribution of poly(ADP-ribosyl)ation in glioblastoma and in a glioma multicellular tumour spheroid model.
Glioblastoma
Functional Biological Activity of Sorafenib as a Tumor-Treating Field Sensitizer for Glioblastoma Therapy.
Glioblastoma
Glioblastoma Cells Containing Mutations in the Cohesin Component STAG2 Are Sensitive to PARP Inhibition.
Glioblastoma
Glioblastoma multiforme: overview of current treatment and future perspectives.
Glioblastoma
Heat Shock Factor 1 Depletion Sensitizes A172 Glioblastoma Cells to Temozolomide via Suppression of Cancer Stem Cell-Like Properties.
Glioblastoma
Impact of PARP-1 and DNA-PK expression on survival in patients with glioblastoma multiforme.
Glioblastoma
In vitro and in vivo radiosensitization of glioblastoma cells by the poly (ADP-ribose) polymerase inhibitor E7016.
Glioblastoma
Inhibition of glioma growth by flavokawain B is mediated through endoplasmic reticulum stress induced autophagy.
Glioblastoma
Interleukin-4 Enhances PARP-Dependent DNA Repair Activity In Vitro.
Glioblastoma
Intratumor administration of interleukin 13 receptor-targeted cytotoxin induces apoptotic cell death in human malignant glioma tumor xenografts.
Glioblastoma
Investigation of U-251 cell death triggered by flavonoid luteolin: towards a better understanding on its anticancer property against glioblastomas.
Glioblastoma
LLL-3 inhibits STAT3 activity, suppresses glioblastoma cell growth and prolongs survival in a mouse glioblastoma model.
Glioblastoma
Luteolin Decreases Epidermal Growth Factor Receptor-Mediated Cell Proliferation and Induces Apoptosis in Glioblastoma Cell Lines.
Glioblastoma
MEG-3-mediated Wnt/?-catenin signaling pathway controls the inhibition of tunicamycin-mediated viability in glioblastoma.
Glioblastoma
Myc targeted CDK18 promotes ATR and homologous recombination to mediate PARP inhibitor resistance in glioblastoma.
Glioblastoma
Non-invasive PET Imaging of PARP1 Expression in Glioblastoma Models.
Glioblastoma
Overcoming Resistance of Glioblastoma to Conventional Cytotoxic Therapies by the Addition of PARP Inhibitors.
Glioblastoma
Pan-Cancer Analysis of PARP1 Alterations as Biomarkers in the Prediction of Immunotherapeutic Effects and the Association of Its Expression Levels and Immunotherapy Signatures.
Glioblastoma
PARP inhibition restores extrinsic apoptotic sensitivity in glioblastoma.
Glioblastoma
PARP inhibitor cyanine dye conjugate with enhanced cytotoxic and antiproliferative activity in patient derived glioblastoma cell lines.
Glioblastoma
PARP Inhibitors for Sensitization of Alkylation Chemotherapy in Glioblastoma: Impact of Blood-Brain Barrier and Molecular Heterogeneity.
Glioblastoma
PARP mediated PARylation of MGMT is critical to promote repair of temozolomide-induced O6-methylguanine DNA damage in glioblastoma.
Glioblastoma
PARP Targeted Alpha-Particle Therapy Enhances Response to PD-1 Immune-Checkpoint Blockade in a Syngeneic Mouse Model of Glioblastoma.
Glioblastoma
PARP-1 inhibitors DPQ and PJ-34 negatively modulate proinflammatory commitment of human glioblastoma cells.
Glioblastoma
PARP-1 protein expression in glioblastoma multiforme.
Glioblastoma
PARP1 expression and its correlation with survival is tumour molecular subtype dependent in glioblastoma.
Glioblastoma
PARP1-Targeted Radiotherapy in Mouse Models of Glioblastoma.
Glioblastoma
PARP3 interacts with FoxM1 to confer glioblastoma cell radioresistance.
Glioblastoma
PARPi-FL--a fluorescent PARP1 inhibitor for glioblastoma imaging.
Glioblastoma
Pharmacokinetics, safety and tolerability of olaparib and temozolomide for recurrent glioblastoma: results of the phase I OPARATIC trial.
Glioblastoma
Pharmacological inhibition of poly(ADP-ribose) polymerase-1 modulates resistance of human glioblastoma stem cells to temozolomide.
Glioblastoma
Poly (ADP-ribose) polymerase 1 protein expression in normal and neoplastic prostatic tissue.
Glioblastoma
Poly (ADP-Ribose) Polymerase 1 Protein Expression in Normal Pancreas and Pancreatic Adenocarcinoma.
Glioblastoma
Poly(ADP-ribose) polymerase inhibitor increases growth inhibition and reduces G(2)/M cell accumulation induced by temozolomide in malignant glioma cells.
Glioblastoma
Poly(ADP-ribosyl)ation is required for p53-dependent signal transduction induced by radiation.
Glioblastoma
Poly(ADPR)polymerase-1 signalling of the DNA damage induced by DNA topoisomerase I poison in D54(p53wt) and U251(p53mut) glioblastoma cell lines.
Glioblastoma
Polyphenolic Compounds of Crataegus Berry, Leaf, and Flower Extracts Affect Viability and Invasive Potential of Human Glioblastoma Cells.
Glioblastoma
Protein kinase C-eta regulates resistance to UV- and gamma-irradiation-induced apoptosis in glioblastoma cells by preventing caspase-9 activation.
Glioblastoma
PTEN loss compromises homologous recombination repair in astrocytes: implications for glioblastoma therapy with temozolomide or poly(ADP-ribose) polymerase inhibitors.
Glioblastoma
Quercetin Increases the Efficacy of Glioblastoma Treatment Compared to Standard Chemoradiotherapy by the Suppression of PI-3-Kinase-Akt Pathway.
Glioblastoma
Rad51 Degradation: Role in Oncolytic Virus-Poly(ADP-Ribose) Polymerase Inhibitor Combination Therapy in Glioblastoma.
Glioblastoma
Radioiodinated PARP1 tracers for glioblastoma imaging.
Glioblastoma
Radiosensitization Effect of Talazoparib, a Parp Inhibitor, on Glioblastoma Stem Cells Exposed to Low and High Linear Energy Transfer Radiation.
Glioblastoma
Radiosensitizing Potential of Curcumin in Different Cancer Models.
Glioblastoma
Rationale for PARP inhibitors in combination therapy with camptothecins or temozolomide based on PARP trapping versus catalytic inhibition.
Glioblastoma
RECQ1 Promotes Stress Resistance and DNA Replication Progression Through PARP1 Signaling Pathway in Glioblastoma.
Glioblastoma
Restoration of Temozolomide Sensitivity by PARP Inhibitors in Mismatch Repair Deficient Glioblastoma is Independent of Base Excision Repair.
Glioblastoma
Restricted Delivery of Talazoparib Across the Blood-Brain Barrier Limits the Sensitizing Effects of PARP Inhibition on Temozolomide Therapy in Glioblastoma.
Glioblastoma
SB365 induces apoptosis and suppresses proliferation of glioblastoma cells.
Glioblastoma
Selective small molecule PARG inhibitor causes replication fork stalling and cancer cell death.
Glioblastoma
Silibinin Induced Human Glioblastoma Cell Apoptosis Concomitant with Autophagy through Simultaneous Inhibition of mTOR and YAP.
Glioblastoma
Sustained inhibition of PARP-1 activity delays glioblastoma recurrence by enhancing radiation-induced senescence.
Glioblastoma
Synthesis and Evaluation of a Radioiodinated Tracer with Specificity for Poly(ADP-ribose) Polymerase-1 (PARP-1) in Vivo.
Glioblastoma
Synthetic chenodeoxycholic acid derivatives inhibit glioblastoma multiform tumor growth in vitro and in vivo.
Glioblastoma
Systemic administration of GPI 15427, a novel poly(ADP-ribose) polymerase-1 inhibitor, increases the antitumor activity of temozolomide against intracranial melanoma, glioma, lymphoma.
Glioblastoma
Targeting EGFR induced oxidative stress by PARP1 inhibition in glioblastoma therapy.
Glioblastoma
Temozolomide: Mechanisms of Action, Repair and Resistance.
Glioblastoma
The Combination PARP Inhibitor Olaparib With Temozolomide in an Experimental Glioblastoma Model.
Glioblastoma
The effect of iodine-131 beta-particles in combination with A-966492 and Topotecan on radio-sensitization of glioblastoma: An in-vitro study.
Glioblastoma
Treatment of Pediatric Glioblastoma with Combination Olaparib and Temozolomide Demonstrates 2-Year Durable Response.
Glioblastoma
Tumor treating fields combined with a poly (adenosine diphosphate-ribose) polymerase inhibitor during radiotherapy for rapidly progressing IDH-wildtype diffuse astrocytoma: a case report.
Glioblastoma
Urokinase plasminogen activator receptor and/or matrix metalloproteinase-9 inhibition induces apoptosis signaling through lipid rafts in glioblastoma xenograft cells.
Glioblastoma
Verbascoside Inhibits Glioblastoma Cell Proliferation, Migration and Invasion While Promoting Apoptosis Through Upregulation of Protein Tyrosine Phosphatase SHP-1 and Inhibition of STAT3 Phosphorylation.
Glioblastoma
VRK1 Depletion Facilitates the Synthetic Lethality of Temozolomide and Olaparib in Glioblastoma Cells.
Glioma
2'-Hydroxy C16-Ceramide Induces Apoptosis-Associated Proteomic Changes in C6 Glioma Cells.
Glioma
2-Hydroxyglutarate produced by neomorphic IDH mutations suppresses homologous recombination and induces PARP inhibitor sensitivity.
Glioma
5-Benzylglycinyl-amiloride kills proliferating and nonproliferating malignant glioma cells through caspase-independent necroptosis mediated by apoptosis-inducing factor.
Glioma
A novel selenadiazole derivative induces apoptosis in human glioma cells by dephosphorylation of AKT.
Glioma
A therapeutic update on PARP inhibitors: implications in the treatment of glioma.
Glioma
ABCB1 Attenuates the Brain Penetration of the PARP Inhibitor AZD2461.
Glioma
Activation of a K+ conductance by bradykinin and by inositol-1,4,5-trisphosphate in rat glioma cells: involvement of intracellular and extracellular Ca2+.
Glioma
Adjuvant immunotherapy of C6 glioma in rats with pertussis toxin.
Glioma
ADP and, indirectly, ATP are potent inhibitors of cAMP production in intact isoproterenol-stimulated C6 glioma cells.
Glioma
AG490 influences UCN-01-induced cytotoxicity in Glioma cells in a p53-dependent fashion, correlating with effects on BAX cleavage and BAD phosphorylation.
Glioma
Agonist-induced down-regulation of muscarinic cholinergic and alpha 2-adrenergic receptors after inactivation of Ni by pertussis toxin.
Glioma
Antitumor Efficacy of PKI-587, a Highly Potent Dual PI3K/mTOR Kinase Inhibitor.
Glioma
Assays for G-protein-coupled receptor signaling using RGS-insensitive Galpha subunits.
Glioma
Association and interactions between DNA repair gene polymorphisms and adult glioma.
Glioma
Association between DNA repair gene polymorphisms and risk of glioma: A systematic review and meta-analysis.
Glioma
Association between PARP-1 V762A polymorphism and cancer susceptibility: a meta-analysis.
Glioma
Association Between PARP1 Single Nucleotide Polymorphism and Brain Tumors.
Glioma
ATRX/EZH2 complex epigenetically regulates FADD/PARP1 axis, contributing to TMZ resistance in glioma.
Glioma
Betulinic acid derivative B10 inhibits glioma cell proliferation through suppression of SIRT1, acetylation of FOXO3a and upregulation of Bim/PUMA.
Glioma
Cannabidiol inhibits human glioma by induction of lethal mitophagy through activating TRPV4.
Glioma
Capitalizing on ATRX loss in glioma via PARP inhibition: Comment on "Loss of ATRX confers DNA repair defects and PARP inhibitor sensitivity" by Garbarino et al.
Glioma
Celastrol enhances TRAIL-induced apoptosis in human glioblastoma via the death receptor pathway.
Glioma
Chronic exposure to pertussis toxin alters muscarinic receptor-mediated regulation of cyclic AMP metabolism in neuroblastoma x glioma NG108-15 hybrid cells.
Glioma
Combination of measles virus virotherapy and radiation therapy has synergistic activity in the treatment of glioblastoma multiforme.
Glioma
Combinations of PARP Inhibitors with Temozolomide Drive PARP1 Trapping and Apoptosis in Ewing's Sarcoma.
Glioma
Comparative status of activated ERK1/2 and PARP cleavage in human gliomas.
Glioma
Concomitant treatment with pertussis toxin plus temozolomide increases the survival of rats bearing intracerebral RG2 glioma.
Glioma
Contribution of caspase-independent pathway to apoptosis in malignant glioma induced by carbon ion beams.
Glioma
Deoxypodophyllotoxin triggers parthanatos in glioma cells via induction of excessive ROS.
Glioma
Differential effects of cholera toxin and pertussis toxin on the c-fos and c-jun mRNA expression in rat C6 glioma cells.
Glioma
Differential PARP cleavage: an indication for existence of multiple forms of cell death in human gliomas.
Glioma
Doxorubicin-mediated apoptosis in glioma cells requires NFAT3.
Glioma
Effect of chronic D-Ala,2 D-Leu5-enkephalin or pertussis toxin treatment on the high-affinity state of delta opioid receptor in neuroblastoma x glioma NG108-15 hybrid cells.
Glioma
Effect of pertussis toxin treatment on the down-regulation of opiate receptors in neuroblastoma X glioma NG108-15 hybrid cells.
Glioma
EGFR Amplification Induces Increased DNA Damage Response and Renders Selective Sensitivity to Talazoparib (PARP Inhibitor) in Glioblastoma.
Glioma
Electro-hyperthermia inhibits glioma tumorigenicity through the induction of E2F1-mediated apoptosis.
Glioma
Endogenous regulator of g protein signaling proteins reduce {mu}-opioid receptor desensitization and down-regulation and adenylyl cyclase tolerance in C6 cells.
Glioma
Endogenous regulators of G protein signaling differentially modulate full and partial mu-opioid agonists at adenylyl cyclase as predicted by a collision coupling model.
Glioma
Endothelin-elicited stimulation of phospholipase C is mediated by guanine nucleotide binding protein(s).
Glioma
Endothelin-induced activation of phosphoinositide turnover, calcium mobilization, and transmitter release in cultured neurons and neurally related cell types.
Glioma
Enhanced radiosensitization of human glioma cells by combining inhibition of poly(ADP-ribose) polymerase with inhibition of heat shock protein 90.
Glioma
Expression of poly(ADP-ribose) polymerase and distribution of poly(ADP-ribosyl)ation in glioblastoma and in a glioma multicellular tumour spheroid model.
Glioma
Fucoxanthin induces apoptosis in human glioma cells by triggering ROS-mediated oxidative damage and regulating MAPKs and PI3K/AKT pathways.
Glioma
Genetic advances in glioma: susceptibility genes and networks.
Glioma
Glioma risk associates with polymorphisms of DNA repair genes, XRCC1 and PARP1.
Glioma
Guanine nucleotide regulation of the pertussis and cholera toxin substrates of rat glioma C6 BU1 cells.
Glioma
Guanine nucleotide-sensitive, high affinity binding of carbachol to muscarinic cholinergic receptors of 1321N1 astrocytoma cells is insensitive to pertussis toxin.
Glioma
H2O2-induced cell death in human glioma cells: role of lipid peroxidation and PARP activation.
Glioma
Idazoxan down-regulates beta-adrenoceptors on C6 glioma cells in vitro.
Glioma
Identification of a 116 kDa protein able to bind 1,3-bis(2-chloroethyl)-1-nitrosourea-damaged DNA as poly(ADP-ribose) polymerase.
Glioma
Identification of a P2Y-purinergic receptor that inhibits adenylyl cyclase.
Glioma
Impact of four lncRNA polymorphisms (rs2151280, rs7763881, rs1136410, and rs3787016) on glioma risk and prognosis: A case-control study.
Glioma
Incidence and prognostic value of multiple gene promoter methylations in gliomas.
Glioma
Induction of apoptosis in glioma cells requires cell-to-cell contact with human umbilical cord blood stem cells.
Glioma
Inhibition of PARP Sensitizes Chondrosarcoma Cell Lines to Chemo- and Radiotherapy Irrespective of the IDH1 or IDH2 Mutation Status.
Glioma
Involvement of poly(ADP-ribose) polymerase-1 in Chinese patients with glioma: a potential target for effective patient care.
Glioma
JNK Activation Contributes to Oxidative Stress-Induced Parthanatos in Glioma Cells via Increase of Intracellular ROS Production.
Glioma
Large-conductance K+ channel openers induce death of human glioma cells.
Glioma
Linarin suppresses glioma through inhibition of NF-?B/p65 and up-regulating p53 expression in vitro and in vivo.
Glioma
Lysophosphatidylserine stimulates chemotactic migration in U87 human glioma cells.
Glioma
Molecular mechanisms for the activation of Ca2+-permeable nonselective cation channels by endothelin-1 in C6 glioma cells.
Glioma
mTOR, S6 and AKT expression in relation to proliferation and apoptosis/autophagy in glioma.
Glioma
Muscarinic cholinergic receptor-induced enhancement of PGE1-stimulated cAMP accumulation in neuroblastoma X glioma cells: prevention by pertussis toxin.
Glioma
N-methylpurine DNA glycosylase and DNA polymerase {beta} modulate BER inhibitor potentiation of glioma cells to temozolomide.
Glioma
NADPH treatment decreases C6 glioma cell survival by increasing oxidative stress.
Glioma
Noscapine induces apoptosis in human glioma cells by an apoptosis-inducing factor-dependent pathway.
Glioma
NPM1 histone chaperone is upregulated in glioblastoma to promote cell survival and maintain nucleolar shape.
Glioma
Oncoprotein Bmi-1 renders apoptotic resistance to glioma cells through activation of the IKK-nuclear factor-kappaB Pathway.
Glioma
Opioid peptides promote cholera-toxin-catalysed ADP-ribosylation of the inhibitory guanine-nucleotide-binding protein (Gi) in membranes of neuroblastoma x glioma hybrid cells.
Glioma
Oroxyloside inhibits human glioma progression by suppressing proliferation, metastasis and inducing apoptosis related pathways.
Glioma
Oxidative stress and PARP activation mediate the NADH-induced decrease in glioma cell survival.
Glioma
Oxidative stress induces apoptosis in C6 glioma cells: involvement of mitogen-activated protein kinases and nuclear factor kappa B.
Glioma
Pan-Cancer Analysis of PARP1 Alterations as Biomarkers in the Prediction of Immunotherapeutic Effects and the Association of Its Expression Levels and Immunotherapy Signatures.
Glioma
PARP inhibition sensitizes childhood high grade glioma, medulloblastoma and ependymoma to radiation.
Glioma
PARP targeting counteracts gliomagenesis through induction of mitotic catastrophe and aggravation of deficiency in homologous recombination in PTEN-mutant glioma.
Glioma
PARP-1, PARP-2, and the cellular response to low doses of ionizing radiation.
Glioma
PARP1 expression and its correlation with survival is tumour molecular subtype dependent in glioblastoma.
Glioma
PARP1 expression in pediatric central nervous system tumors.
Glioma
Pediatric high-grade glioma: identification of poly(ADP-ribose) polymerase as a potential therapeutic target.
Glioma
Pertussis toxin decreases opiate receptor binding and adenylate inhibition in a neuroblastoma x glioma hybrid cell line.
Glioma
Pertussis Toxin Is a Robust and Selective Inhibitor of High Grade Glioma Cell Migration and Invasion.
Glioma
Pertussis toxin treatment prevents 5-HT(5a) receptor-mediated inhibition of cyclic AMP accumulation in rat C6 glioma cells.
Glioma
Poly(ADP-ribose) polymerase inhibitor increases growth inhibition and reduces G(2)/M cell accumulation induced by temozolomide in malignant glioma cells.
Glioma
Poly(ADP-ribose) polymerase-1 inhibition reverses temozolomide resistance in a DNA mismatch repair-deficient malignant glioma xenograft.
Glioma
Poly(ADP-ribose) polymerase-independent potentiation of nitrosourea cytotoxicity by 3-aminobenzamide in human malignant glioma cells.
Glioma
Polymorphisms in DNA Repair Gene and Susceptibility to Glioma: A Systematic Review and Meta-Analysis Based on 33 Studies with 15 SNPs in 9 Genes.
Glioma
Pre-clinical and clinical evaluation of PARP inhibitors as tumour-specific radiosensitisers.
Glioma
Pre-treatment or Post-treatment of Human Glioma Cells With BIX01294, the Inhibitor of Histone Methyltransferase G9a, Sensitizes Cells to Temozolomide.
Glioma
Protein and phosphoprotein levels in glioma and adenocarcinoma cell lines grown in normoxia and hypoxia in monolayer and three-dimensional cultures.
Glioma
Relationship between genetically determined telomere length and glioma risk.
Glioma
Replication-dependent radiosensitization of human glioma cells by inhibition of poly(ADP-Ribose) polymerase: mechanisms and therapeutic potential.
Glioma
Restoration of Temozolomide Sensitivity by PARP Inhibitors in Mismatch Repair Deficient Glioblastoma is Independent of Base Excision Repair.
Glioma
Rhaponticum carthamoides transformed root extract inhibits human glioma cells viability, induces double strand DNA damage, H2A.X phosphorylation, and PARP1 cleavage.
Glioma
Rho/ROCK pathway as a target of tumor therapy.
Glioma
Role of a protein regulating guanine nucleotide binding in phosphoinositide breakdown and calcium mobilization by bradykinin in neuroblastoma X glioma hybrid NG108-15 cells: effects of pertussis toxin and cholera toxin on receptor-mediated signal transduction.
Glioma
Selenocysteine induces apoptosis in human glioma cells: evidence for TrxR1-targeted inhibition and signaling crosstalk.
Glioma
Specific uncoupling by islet-activating protein, pertussis toxin, of negative signal transduction via alpha-adrenergic, cholinergic, and opiate receptors in neuroblastoma x glioma hybrid cells.
Glioma
Synergism in cytosolic Ca2+ mobilization between bradykinin and agonists for pertussis toxin-sensitive G-protein-coupled receptors in NG 108-15 cells.
Glioma
Synthetic Lethality of PARP Inhibition and Ionizing Radiation is p53-dependent.
Glioma
Systemic administration of GPI 15427, a novel poly(ADP-ribose) polymerase-1 inhibitor, increases the antitumor activity of temozolomide against intracranial melanoma, glioma, lymphoma.
Glioma
Targeting Mutant PPM1D Sensitizes Diffuse Intrinsic Pontine Glioma Cells to the PARP Inhibitor Olaparib.
Glioma
Targeting therapeutic vulnerabilities with PARP inhibition and radiation in IDH-mutant gliomas and cholangiocarcinomas.
Glioma
TCH1036, a indeno[1,2-c]quinoline derivative, potentially inhibited the growth of human brain malignant glioma (GBM) 8401 cells via suppression of the expression of Suv39h1 and PARP.
Glioma
Telomerase subunits expression variation between biopsy samples and cell lines derived from malignant glioma.
Glioma
Tetrandrine and caffeine modulated cell cycle and increased glioma cell death via caspase-dependent and caspase-independent apoptosis pathways.
Glioma
The CHAC1-inhibited Notch3 pathway is involved in temozolomide-induced glioma cytotoxicity.
Glioma
The effects of phorbol 12-myristate 13-acetate, cholera toxin, prostaglandin E2 and norepinephrine on inducible nitric oxide synthase activation induced by lipopolysaccharide in C6 cells.
Glioma
The GTP-binding regulatory proteins of neuroblastoma x glioma, NG108-15, and glioma, C6, cells. Immunochemical evidence of a pertussis toxin substrate that is neither Ni nor No.
Glioma
The presumed atypical chemokine receptor CXCR7 signals through G(i/o) proteins in primary rodent astrocytes and human glioma cells.
Glioma
The Selective Acetamidine-Based iNOS Inhibitor CM544 Reduces Glioma Cell Proliferation by Enhancing PARP-1 Cleavage In Vitro.
Glioma
The transcription factor Forkhead box P3 (FoxP3) is expressed in glioma cells and associated with increased apoptosis.
Glioma
Treatment of Pediatric Glioblastoma with Combination Olaparib and Temozolomide Demonstrates 2-Year Durable Response.
Glioma
Whole-body hyperthermia and ADPRT inhibition in experimental treatment of brain tumors.
Glioma
Whole-genome profiling of pediatric diffuse intrinsic pontine gliomas highlights platelet-derived growth factor receptor alpha and poly (ADP-ribose) polymerase as potential therapeutic targets.
Glioma
[PARP inhibitors and radiotherapy: rational and prospects for a clinical use].
Glioma
[Toxic effects of Vitamin C combined with temozolomide on glioma cells and its mechanism].
Gliosarcoma
Cellular regulation of poly(ADP) ribosylation of proteins. I. Comparison of hepatocytes, cultured cells and liver nuclei and the influence of varying concentrations of NAD.
Glomerulonephritis
Experimental autoimmune vasculitis: an animal model of anti-neutrophil cytoplasmic autoantibody-associated systemic vasculitis.
Glomerulonephritis
Poly(ADP-ribose) polymerase-1 regulates the progression of autoimmune nephritis in males by inducing necrotic cell death and modulating inflammation.
Glomerulonephritis, IGA
Defective activation of the MAPK/ERK pathway, leading to PARP1 and DNMT1 dysregulation, is a common defect in IgA nephropathy and Henoch-Schönlein purpura.
Glucose Intolerance
Poly(ADP-ribose) polymerase gene disruption conferred mice resistant to streptozotocin-induced diabetes.
Graft vs Host Disease
Adoptive cell therapy of triple negative breast cancer with redirected cytokine-induced killer cells.
Graft vs Host Disease
Reduced PARP1 as a Serum Biomarker for Graft Rejection in Kidney Transplantation.
Graves Disease
Association of PARP-1, NF-?B, NF-?BIA and IL-6, IL-1? and TNF-? with Graves Disease and Graves Ophthalmopathy.
Graves Disease
Poly (ADP-Ribose) Polymerase-1 (PARP-1) in Chinese patients with Graves Disease and Graves Ophthalmopathy.
Graves Ophthalmopathy
Association of PARP-1, NF-?B, NF-?BIA and IL-6, IL-1? and TNF-? with Graves Disease and Graves Ophthalmopathy.
Graves Ophthalmopathy
Poly (ADP-Ribose) Polymerase-1 (PARP-1) in Chinese patients with Graves Disease and Graves Ophthalmopathy.
Growth Hormone-Secreting Pituitary Adenoma
Phorbol ester and phospholipase C-induced growth hormone secretion from pituitary somatotroph adenoma cells in culture: effects of somatostatin, bromocriptine, and pertussis toxin.
Haemophilus Infections
Effect of pertussis toxin on susceptibility of infant rats to Haemophilus influenzae type b.
Head and Neck Neoplasms
Acquisition of relative interstrand crosslinker resistance and PARP inhibitor sensitivity in Fanconi anemia head and neck cancers.
Head and Neck Neoplasms
Cetuximab augments cytotoxicity with poly (adp-ribose) polymerase inhibition in head and neck cancer.
Head and Neck Neoplasms
Combining PARP and DNA-PK Inhibitors With Irradiation Inhibits HPV-Negative Head and Neck Cancer Squamous Carcinoma Growth.
Head and Neck Neoplasms
Efficacy of poly (ADP-ribose) polymerase inhibitor olaparib against head and neck cancer cells: Predictions of drug sensitivity based on PAR-p53-NF-?B interactions.
Head and Neck Neoplasms
Final Report of a Phase I Trial of Olaparib with Cetuximab and Radiation for Heavy Smoker Patients with Locally Advanced Head and Neck Cancer.
Head and Neck Neoplasms
Head and neck cancer radiosensitization by the novel poly(ADP-ribose) polymerase inhibitor GPI-15427.
Head and Neck Neoplasms
PARP inhibitors in head and neck cancer: Molecular mechanisms, preclinical and clinical data.
Head and Neck Neoplasms
Photodynamic therapy (PDT) resistance by PARP1 regulation on PDT-induced apoptosis with autophagy in head and neck cancer cells.
Head and Neck Neoplasms
Poly (ADP-ribose) polymerase inhibitor efficacy in head and neck cancer.
Head and Neck Neoplasms
Synergistic inhibition of head and neck tumor growth by green tea (-)-epigallocatechin-3-gallate and EGFR tyrosine kinase inhibitor.
Head and Neck Neoplasms
The poly(ADP-Ribose) polymerase inhibitor ABT-888 reduces radiation-induced nuclear EGFR and augments head and neck tumor response to radiotherapy.
Heart Arrest
Inhibition of poly(adp-ribose) polymerase reduces cardiomyocytic apoptosis after global cardiac arrest under cardiopulmonary bypass.
Heart Arrest
INO-1001 a novel poly(ADP-ribose) polymerase (PARP) inhibitor improves cardiac and pulmonary function after crystalloid cardioplegia and extracorporal circulation.
Heart Arrest
Mesenteric injury after cardiopulmonary bypass: role of poly(adenosine 5'-diphosphate-ribose) polymerase.
Heart Arrest
Neuronal accumulation of poly(ADP-ribose) after brain ischaemia.
Heart Arrest
Poly(ADP-ribose) polymerase inhibitor PJ-34 reduces mesenteric vascular injury induced by experimental cardiopulmonary bypass with cardiac arrest.
Heart Arrest
Role of poly(ADP-ribose) polymerase activation in the pathogenesis of cardiopulmonary dysfunction in a canine model of cardiopulmonary bypass.
Heart Diseases
1,25(OH)2 D3 improves cardiac dysfunction, hypertrophy and fibrosis through PARP1/SIRT1/mTOR related mechanisms in Type 1 diabetes.
Heart Diseases
Association study of hsa_circ_0001946, hsa-miR-7-5p and PARP1 in coronary atherosclerotic heart disease.
Heart Diseases
Comment on: Association study of hsa_circ_0001946, hsa-miR-7-5p and PARP1 in coronary atherosclerotic heart disease.
Heart Diseases
In vitro effect of the potent poly(ADP-ribose) polymerase (PARP) inhibitor INO-1001 alone and in combination with aspirin, eptifibatide, tirofiban, enoxaparin or alteplase on haemostatic parameters.
Heart Diseases
PARP1 induces cardiac fibrosis by mediating mTOR activity.
Heart Diseases
Salvage of nicotinamide adenine dinucleotide plays a critical role in the bioenergetic recovery of post-hypoxic cardiomyocytes.
Heart Diseases
[Research progress of poly (ADP-ribose) polymerase-1 in cardiac diseases.]
Heart Failure
Activation of poly(ADP-ribose) polymerase contributes to development of doxorubicin-induced heart failure.
Heart Failure
Activation of the poly(ADP-ribose) polymerase pathway in human heart failure.
Heart Failure
Additional use of immunostaining for active caspase 3 and cleaved actin and PARP fragments to detect apoptosis in patients with chronic heart failure.
Heart Failure
AG-690/11026014, a novel PARP-1 inhibitor, protects cardiomyocytes from AngII-induced hypertrophy.
Heart Failure
Beneficial effects of a novel ultrapotent poly(ADP-ribose) polymerase inhibitor in murine models of heart failure.
Heart Failure
Cardioprotective effects of poly(ADP-ribose) polymerase inhibition.
Heart Failure
Desensitization of cardiac beta-adrenoceptor signaling with heart failure produced by myocardial infarction in the rat. Evidence for the role of Gi but not Gs or phosphorylating proteins.
Heart Failure
DNA Damage, an Innocent Bystander in Atrial Fibrillation and Other Cardiovascular Diseases?
Heart Failure
E3 Ubiquitin ligase NEDD4 family?regulatory network in cardiovascular disease.
Heart Failure
Effect of L-2286, a poly(ADP-ribose)polymerase inhibitor and enalapril on myocardial remodeling and heart failure.
Heart Failure
Fulminant pertussis: a multi-center study with new insights into the clinico-pathological mechanisms.
Heart Failure
G?i)- and G?i3-specific regulation of voltage-dependent L-type calcium channels in cardiomyocytes.
Heart Failure
Immobilization Stress With ?2-Adrenergic Stimulation Induces Regional and Transient Reduction of Cardiac Contraction Through Gi Coupling in Rats.
Heart Failure
Increased expression of poly(ADP-ribose) polymerase-1 contributes to caspase-independent myocyte cell death during heart failure.
Heart Failure
Interplay of oxidative, nitrosative/nitrative stress, inflammation, cell death and autophagy in diabetic cardiomyopathy.
Heart Failure
Mitochondrial protective effects of PARP-inhibition in hypertension-induced myocardial remodeling and in stressed cardiomyocytes.
Heart Failure
Myocardial cell death and regeneration during progression of cardiac hypertrophy to heart failure.
Heart Failure
Nicotinamide adenine dinucleotide homeostasis and signalling in heart disease: Pathophysiological implications and therapeutic potential.
Heart Failure
Nitrosative stress and pharmacological modulation of heart failure.
Heart Failure
Oxidative Stress-Related Parthanatos of Circulating Mononuclear Leukocytes in Heart Failure.
Heart Failure
PARP inhibition and postinfarction myocardial remodeling.
Heart Failure
PARP inhibition delays transition of hypertensive cardiopathy to heart failure in spontaneously hypertensive rats.
Heart Failure
PARP inhibition prevents postinfarction myocardial remodeling and heart failure via the protein kinase C/glycogen synthase kinase-3beta pathway.
Heart Failure
PARP-1 inhibition attenuates cardiac fibrosis induced by myocardial infarction through regulating autophagy.
Heart Failure
PARP-2 knockdown protects cardiomyocytes from hypertrophy via activation of SIRT1.
Heart Failure
PARP-inhibitor treatment prevents hypertension induced cardiac remodeling by favorable modulation of heat shock proteins, Akt-1/GSK-3? and several PKC isoforms.
Heart Failure
Pertussis toxin treatment of whole blood. A novel approach to assess G protein function in congestive heart failure.
Heart Failure
Pharmacologic inhibition of poly(adenosine diphosphate-ribose) polymerase may represent a novel therapeutic approach in chronic heart failure.
Heart Failure
Poly(ADP-ribose) Polymerase (PARP) and PARP Inhibitors: Mechanisms of Action and Role in Cardiovascular Disorders.
Heart Failure
Poly(ADP-ribose) polymerase as a drug target for cardiovascular disease and cancer: an update.
Heart Failure
Poly(ADP-Ribose) polymerase promotes cardiac remodeling, contractile failure, and translocation of apoptosis-inducing factor in a murine experimental model of aortic banding and heart failure.
Heart Failure
Poly(ADP-ribose) polymerase regulates myocardial calcium handling in doxorubicin-induced heart failure.
Heart Failure
Poly(ADP-ribose) polymerase-1-deficient mice are protected from angiotensin II-induced cardiac hypertrophy.
Heart Failure
Poly(ADP-ribose) polymerase-1-dependent cardiac myocyte cell death during heart failure is mediated by NAD+ depletion and reduced Sir2alpha deacetylase activity.
Heart Failure
Protective effect of lncRNA CRNDE on myocardial cell apoptosis in heart failure by regulating HMGB1 cytoplasm translocation through PARP-1.
Heart Failure
Regulation of kinase cascade activation and heat shock protein expression by poly(ADP-ribose) polymerase inhibition in doxorubicin-induced heart failure.
Heart Failure
Revealing the synergistic mechanism of Shenfu Decoction for anti-heart failure through network pharmacology strategy.
Heart Failure
Role of altered G-protein expression in the regulation of myocardial adenylate cyclase activity and force of contraction in spontaneous hypertensive cardiomyopathy in rats.
Heart Failure
Role of oxidative-nitrosative stress and downstream pathways in various forms of cardiomyopathy and heart failure.
Heart Failure
Role of poly(ADP-ribose) polymerase 1 (PARP-1) in cardiovascular diseases: the therapeutic potential of PARP inhibitors.
Heart Failure
Selective targeting of ubiquitination and degradation of PARP1 by E3 ubiquitin ligase WWP2 regulates isoproterenol-induced cardiac remodeling.
Heart Failure
The effect of pertussis toxin on beta-adrenoceptor responses in isolated cardiac myocytes from noradrenaline-treated guinea-pigs and patients with cardiac failure.
Heart Failure
The Promise of Proteomics for the Study of ADP-Ribosylation.
Heart Valve Diseases
E3 Ubiquitin ligase NEDD4 family?regulatory network in cardiovascular disease.
Hemangiosarcoma
PARP inhibition in UV-associated angiosarcoma preclinical models.
Hematologic Neoplasms
Combined treatment with temozolomide and poly(ADP-ribose) polymerase inhibitor enhances survival of mice bearing hematologic malignancy at the central nervous system site.
Hematologic Neoplasms
Poly (ADP-ribose) polymerase inhibitors selectively induce cytotoxicity in TCF3-HLF-positive leukemic cells.
Hematologic Neoplasms
Population Pharmacokinetic Modeling of Veliparib (ABT-888) in Patients with Non-Hematologic Malignancies.
Hematologic Neoplasms
The Use of PARP Inhibitors in Cancer Therapy: Use as Adjuvant with Chemotherapy or Radiotherapy, Use as a Single Agent in Susceptible Patients, and Techniques Used to Identify Susceptible Patients.
Hematologic Neoplasms
The Use of PARP Inhibitors in Cancer Therapy: Use as Adjuvant with Chemotherapy or Radiotherapy; Use as a Single Agent in Susceptible Patients; Techniques Used to Identify Susceptible Patients.
Hemoglobinuria
Neutrophil activation in response to immune complex-bearing endothelial cells depends on the functional cooperation of Fc gamma RII (CD32) and Fc gamma RIII (CD16).
Hemoglobinuria, Paroxysmal
Neutrophil activation in response to immune complex-bearing endothelial cells depends on the functional cooperation of Fc gamma RII (CD32) and Fc gamma RIII (CD16).
Hemorrhagic Septicemia, Viral
Molecular characterization and expressional analysis of two poly (ADP-ribose) polymerase (PARP) domain-containing Gig2 isoforms in rockfish (Sebastes schlegelii) and their antiviral activity against viral hemorrhagic septicemia virus.
Hepatitis
Influence of diet free of NAD-precursors on acetaminophen hepatotoxicity in mice.
Hepatitis
Murine Coronavirus Infection Activates the Aryl Hydrocarbon Receptor in an Indoleamine 2,3-Dioxygenase-Independent Manner, Contributing to Cytokine Modulation and Proviral TCDD-Inducible-PARP Expression.
Hepatitis
PARP2 deficiency affects invariant-NKT-cell maturation and protects mice from Concanavalin A-induced liver injury.
Hepatitis
Poly (ADP-ribose) polymerase-1 is a key mediator of liver inflammation and fibrosis.
Hepatitis
Repurposing of Clinically Approved Poly-(Adp-Ribose) Polymerase Inhibitors For The Therapy of Sepsis.
Hepatitis
TRAIL induces necroptosis involving RIPK1/RIPK3-dependent PARP-1 activation.
Hepatitis A
Concomitant use of VAQTA® with PedvaxHIB® and Infanrix® in 12 to 17 month old children.
Hepatitis A
Immunity against vaccine-preventable diseases in Finnish pediatric healthcare workers in 2015.
Hepatitis B
A fully liquid DTaP-IPV-Hep B-PRP-T hexavalent vaccine for primary and booster vaccination of healthy Mexican children.
Hepatitis B
A Randomized, Controlled Study of DTaP-IPV-HB-PRP-T, a Fully Liquid Hexavalent Vaccine, Administered in a 3-, 5- and 11- to 12-month Schedule.
Hepatitis B
Antibody responses of healthy infants to concurrent administration of a bivalent haemophilus influenzae type b-hepatitis B vaccine with diphtheria-tetanus-pertussis, polio and measles-mumps-rubella vaccines.
Hepatitis B
Immunity against vaccine-preventable diseases in Finnish pediatric healthcare workers in 2015.
Hepatitis B
Immunogenicity of a combined DTPa-HB vaccine co-administered with Haemophilus influenzae type B conjugate vaccine (PRP-T) for primary and booster vaccinations.
Hepatitis B
Immunogenicity study of a combined diphtheria, tetanus, acellular pertussis, inactivated poliomyelitis vaccine used to reconstitute a freeze-dried Haemophilus influenzae type b vaccine (DTaP-IPV//PRP-T) administered simultaneously with a hepatitis B vaccine at two, three and four months of life.
Hepatitis B
Interaction of hepatitis B virus X protein with PARP1 results in inhibition of DNA repair in hepatocellular carcinoma.
Hepatitis B
No associations of polymorphisms in ADPRT with hepatitis B virus clearance and hepatocellular carcinoma occurrence in a Korean population.
Hepatitis B
Novel poly (ADP-ribose) polymerase 1 binding motif in hepatitis B virus core promoter impairs DNA damage repair.
Hepatitis B
PARP-1 serves as a novel molecular marker for hepatocellular carcinoma in a Southern Chinese Zhuang population.
Hepatitis B
Reduced ADP-ribosylation by PARP1 natural polymorphism V762A and by PARP1 inhibitors enhance Hepatitis B virus replication.
Hepatitis C
Hepatitis C virus induces oxidative stress and DNA damage by regulating DNAPKCs, ATM, ATR and PARP mediated signaling and guards cell from cancerous condition by upregulating RB, P53 and downregulating VEGF.
Hepatoblastoma
PARP1 activation increases expression of modified tumor suppressors and pathways underlying development of aggressive hepatoblastoma.
Hepatoblastoma
Wnt/?-catenin signaling as a useful therapeutic target in hepatoblastoma.
Hereditary Breast and Ovarian Cancer Syndrome
Hereditary pancreatic cancer.
Hereditary Breast and Ovarian Cancer Syndrome
[Molecular Targeted Therapies for Hereditary Cancer Syndrome].
Heredodegenerative Disorders, Nervous System
XRCC1 protein; Form and function.
Herpes Simplex
ADP-ribosyltransferase PARP11 modulates the interferon antiviral response by mono-ADP-ribosylating the ubiquitin E3 ligase ?-TrCP.
Herpes Simplex
Herpes simplex virus 1 infection activates poly(ADP-ribose) polymerase and triggers the degradation of poly(ADP-ribose) glycohydrolase.
Herpes Simplex
Herpes simplex virus requires poly(ADP-ribose) polymerase activity for efficient replication and induces extracellular signal-related kinase-dependent phosphorylation and ICP0-dependent nuclear localization of tankyrase 1.
Herpes Simplex
Inhibition of poly(ADP-ribose)polymerase stimulates extrachromosomal homologous recombination in mouse Ltk-fibroblasts.
Herpes Zoster
A guanine nucleotide-binding regulatory protein in human sperm mediates acrosomal exocytosis induced by the human zona pellucida.
Herpes Zoster
Calcium influx into mouse spermatozoa activated by solubilized mouse zona pellucida, monitored with the calcium fluorescent indicator, fluo-3. Inhibition of the influx by three inhibitors of the zona pellucida induced acrosome reaction: tyrphostin A48, pertussis toxin, and 3-quinuclidinyl benzilate.
Herpes Zoster
Characterization of the biologic activities of a recombinant human zona pellucida protein 3 expressed in human ovarian teratocarcinoma (PA-1) cells.
Herpes Zoster
Differential sensitivity of progesterone- and zona pellucida-induced acrosome reactions to pertussis toxin.
Herpes Zoster
Evidence for the role of heterotrimeric guanine nucleotide-binding regulatory proteins in the regulation of the mouse sperm adenylyl cyclase by the egg's zona pellucida.
Herpes Zoster
Immunity against vaccine-preventable diseases in Finnish pediatric healthcare workers in 2015.
Herpes Zoster
Immunity to vaccine-preventable diseases among paediatric healthcare workers in Denmark, 2019.
Herpes Zoster
Inhibition of G protein in human sperm and its influence on acrosome reaction and zona pellucida binding.
Histiocytic Sarcoma
[Role of proteins in Fas-mediated apoptosis in tumor cells and lymphocytes co-cultured in vitro]
histone acetyltransferase deficiency
Acetylation limits 53BP1 association with damaged chromatin to promote homologous recombination.
HIV Infections
A major human immunodeficiency virus type 1-initiated killing pathway distinct from apoptosis.
HIV Infections
Immunotherapy of COVID-19 with poly (ADP-ribose) polymerase inhibitors: starting with nicotinamide.
HIV Infections
Inhibition of intra- and extra-cellular Tat function and HIV expression by pertussis toxin B-oligomer.
HIV Infections
Minireview, The oxidative stress-induced niacin sink (OSINS) model for HIV pathogenesis.
HIV Infections
Pertussis toxin B-oligomer inhibits HIV infection and replication in hu-PBL-SCID mice.
HIV Infections
The dual action of poly(ADP-ribose) polymerase -1 (PARP-1) inhibition in HIV-1 infection: HIV-1 LTR inhibition and diminution in Rho GTPase activity.
Huntington Disease
Discovery of bioactive small-molecule inhibitor of poly adp-ribose polymerase: implications for energy-deficient cells.
Huntington Disease
Modulation of Inflammasome and Pyroptosis by Olaparib, a PARP-1 Inhibitor, in the R6/2 Mouse Model of Huntington's Disease.
Huntington Disease
PARP-1 Inhibition Is Neuroprotective in the R6/2 Mouse Model of Huntington's Disease.
Huntington Disease
Selective Sparing of Striatal Interneurons after Poly (ADP-Ribose) Polymerase 1 Inhibition in the R6/2 Mouse Model of Huntington's Disease.
Hyperalgesia
Activation of G(i) induces mechanical hyperalgesia poststress or inflammation.
Hyperalgesia
Chronic morphine administration and in vivo pertussis toxin treatment induce hyperalgesia and enhance 3H-nitrendipine binding.
Hyperalgesia
Concurrent targeting of nitrosative stress-PARP pathway corrects functional, behavioral and biochemical deficits in experimental diabetic neuropathy.
Hyperalgesia
Histamine H4 receptor agonist-induced relief from painful peripheral neuropathy is mediated by inhibition of spinal neuroinflammation and oxidative stress.
Hyperalgesia
Intracerebroventricular treatment of mice with pertussis toxin induces hyperalgesia and enhances 3H-nitrendipine binding to synaptic membranes: similarity with morphine tolerance.
Hyperalgesia
Intrathecal pertussis toxin induces thermal hyperalgesia: involvement of excitatory and inhibitory amino acids.
Hyperalgesia
Intrathecal pertussis toxin produces hyperalgesia and allodynia in mice.
Hyperalgesia
Kappa- and delta-opioids block sympathetically dependent hyperalgesia.
Hyperalgesia
Marrow-Derived Cells Regulate the Development of Early Diabetic Retinopathy and Tactile Allodynia in Mice.
Hyperalgesia
Mediation of serotonin hyperalgesia by the cAMP second messenger system.
Hyperalgesia
Mu-opioid agonist enhancement of prostaglandin-induced hyperalgesia in the rat: a G-protein beta gamma subunit-mediated effect?
Hyperalgesia
N-Methyl-d-aspartate receptor antagonist d-AP5 prevents pertussis toxin-induced alterations in rat spinal cords by inhibiting increase in concentrations of spinal CSF excitatory amino acids and downregulation of glutamate transporters.
Hyperalgesia
PARP inhibition or gene deficiency counteracts intraepidermal nerve fiber loss and neuropathic pain in advanced diabetic neuropathy.
Hyperalgesia
PARP inhibitors attenuate chemotherapy-induced painful neuropathy.
Hyperalgesia
PARP-1-regulated TNF-? expression in the dorsal root ganglia and spinal dorsal horn contributes to the pathogenesis of neuropathic pain in rats.
Hyperalgesia
Peripheral nociceptive effects of alpha 2-adrenergic receptor agonists in the rat.
Hyperalgesia
Pharmacologic reversal of pertussis toxin-induced thermal allodynia in mice.
Hyperalgesia
Poly(ADP-ribose)polymerase inhibition counteracts renal hypertrophy and multiple manifestations of peripheral neuropathy in diabetic Akita mice.
Hyperalgesia
Protein kinase C inhibitor chelerythrine attenuates the morphine-induced excitatory amino acid release and reduction of the antinociceptive effect of morphine in rats injected intrathecally with pertussis toxin.
Hyperalgesia
Reversal of ongoing thermal hyperalgesia in mice by a recombinant herpesvirus that encodes human preproenkephalin.
Hyperalgesia
Reversal of pertussis toxin-induced thermal allodynia by muscarinic cholinergic agonists in mice.
Hyperalgesia
RhoA/Rho kinase pathway contributes to the pathogenesis of thermal hyperalgesia in diabetic mice.
Hyperalgesia
Some new insights into the effects of opioids in phasic and tonic nociceptive tests.
Hyperalgesia
Ultra-low dose naloxone restores the antinociceptive effect of morphine in pertussis toxin-treated rats and prevents glutamate transporter downregulation by suppressing the p38 mitogen-activated protein kinase signaling pathway.
Hyperalgesia
Ultra-low-dose naloxone restores the antinociceptive effect of morphine and suppresses spinal neuroinflammation in PTX-treated rats.
Hypercholesterolemia
Loss of endothelial pertussis toxin-sensitive G protein function in atherosclerotic porcine coronary arteries.
Hyperglycemia
Amelioration of diabetes-induced neurobehavioral and neurochemical changes by melatonin and nicotinamide: implication of oxidative stress-PARP pathway.
Hyperglycemia
Antioxidant therapy in diabetic complications: what is new?
Hyperglycemia
Augmentation of poly(ADP-ribose) polymerase-dependent neuronal cell death by acidosis.
Hyperglycemia
Cardiovascular Protective Effect of Metformin and Telmisartan: Reduction of PARP1 Activity via the AMPK-PARP1 Cascade.
Hyperglycemia
Comparative study of peripheral neuropathy and nerve regeneration in NOD and ICR diabetic mice.
Hyperglycemia
Contribution of type 1 diabetes to rat liver dysfunction and cellular damage via activation of NOS, PARP, IkappaBalpha/NF-kappaB, MAPKs, and mitochondria-dependent pathways: Prophylactic role of arjunolic acid.
Hyperglycemia
Diabetic endothelial dysfunction: the role of poly(ADP-ribose) polymerase activation.
Hyperglycemia
Effect of D-glucose feeding on mortality induced by sepsis.
Hyperglycemia
Hyperglycemia accentuates and ketonemia attenuates hypoglycemia-induced neuronal injury in the developing rat brain.
Hyperglycemia
Mangiferin Enhanced Autophagy via Inhibiting mTORC1 Pathway to Prevent High Glucose-Induced Cardiomyocyte Injury.
Hyperglycemia
Molecular targets of diabetic vascular complications and potential new drugs.
Hyperglycemia
PARP inhibition ameliorates nephropathy in an animal model of type 2 diabetes: focus on oxidative stress, inflammation, and fibrosis.
Hyperglycemia
Parp inhibition prevents ten eleven translocase enzyme activation and hyperglycemia induced DNA demethylation.
Hyperglycemia
PARP-1 inhibition alleviates diabetic cardiac complications in experimental animals.
Hyperglycemia
Poly(ADP-ribose) polymerase 1 inhibition protects cardiomyocytes from inflammation and apoptosis in diabetic cardiomyopathy.
Hyperglycemia
Poly(ADP-ribose) polymerase is involved in the development of diabetic retinopathy via regulation of nuclear factor-kappaB.
Hyperglycemia
Poly(ADP-ribose)polymerase activity is reduced in circulating mononuclear cells from type 2 diabetic patients.
Hyperglycemia
Poly(ADP-ribose)polymerase inhibition counteracts renal hypertrophy and multiple manifestations of peripheral neuropathy in diabetic Akita mice.
Hyperglycemia
Poly-ADP-ribose polymerase inhibition enhances ischemic and diabetic wound healing by promoting angiogenesis.
Hyperglycemia
Propolis ethanol extract abrogates hyperglycemia, lipotoxicity, and lowered hepatic poly (ADP-ribose) polymerase protein level in male albino rats.
Hyperglycemia
Recurrent hypoinsulinemic hyperglycemia in neonatal rats increases PARP-1 and NF-?B expression and leads to microglial activation in the cerebral cortex.
Hyperglycemia
Sirtuin 1-mediated cellular metabolic memory of high glucose via the LKB1/AMPK/ROS pathway and therapeutic effects of metformin.
Hyperglycemia
The activation of ?2-adrenergic receptor in the spinal cord lowers sepsis-induced mortality.
Hyperglycemia
The role of poly(ADP-ribose) polymerase activation in the development of myocardial and endothelial dysfunction in diabetes.
Hyperglycemia
Treatment with insulin inhibits poly(ADP-ribose)polymerase activation in a rat model of endotoxemia.
Hyperhomocysteinemia
Melatonin inhibits neural apoptosis induced by homocysteine in hippocampus of rats via inhibition of cytochrome c translocation and caspase-3 activation and by regulating pro- and anti-apoptotic protein levels.
Hyperhomocysteinemia
Poly (ADP-Ribose) Polymerase Inhibition Attenuates Atherosclerotic Plaque Development in ApoE-/- Mice with Hyperhomocysteinemia.
Hyperhomocysteinemia
Poly (ADP-ribose) polymerase inhibition improves endothelial dysfunction induced by hyperhomocysteinemia in rats.
Hyperinsulinism
Acute stress-induced hyperinsulinemia in the pertussis toxin-treated rat: possible role of humoral beta-cell-tropic factors.
Hyperinsulinism
Severe reactions associated with diphtheria-tetanus-pertussis vaccine: detailed study of children with seizures, hypotonic-hyporesponsive episodes, high fevers, and persistent crying.
Hyperinsulinism
The quantitative analysis of the mechanism involved in pertussis toxin-mediated cell clustering and its implications in the in vitro quality control of diphtheria tetanus and whole cell pertussis vaccines.
Hyperkinesis
Neuropeptide Y and sigma ligand (JO 1784) act through a Gi protein to block the psychological stress and corticotropin-releasing factor-induced colonic motor activation in rats.
Hyperlipidemias
PARPs in lipid metabolism and related diseases.
Hyperlipidemias
Pertussis toxin induces fatty liver, hyperlipemia and ketosis in hamsters.
Hyperlipidemias
Poly (ADP-Ribose) Polymerase Inhibition Attenuates Atherosclerotic Plaque Development in ApoE-/- Mice with Hyperhomocysteinemia.
Hypersensitivity
53BP1 inhibits homologous recombination in Brca1-deficient cells by blocking resection of DNA breaks.
Hypersensitivity
A novel role for the mono-ADP-ribosyltransferase PARP14/ARTD8 in promoting homologous recombination and protecting against replication stress.
Hypersensitivity
A Short BRCA2-Derived Cell-Penetrating Peptide Targets RAD51 Function and Confers Hypersensitivity toward PARP Inhibition.
Hypersensitivity
Advanced Oxidative Protein Products Cause Pain Hypersensitivity in Rats by Inducing Dorsal Root Ganglion Neurons Apoptosis via NADPH Oxidase 4/c-Jun N-terminal Kinase Pathways.
Hypersensitivity
Analysis of PARP inhibitor toxicity by multidimensional fluorescence microscopy reveals mechanisms of sensitivity and resistance.
Hypersensitivity
Analysis of the role of Bphs/Hrh1 in the genetic control of responsiveness to pertussis toxin.
Hypersensitivity
APTO-253 Is a New Addition to the Repertoire of Drugs that Can Exploit DNA BRCA1/2 Deficiency.
Hypersensitivity
Ataxia Telangiectasia Mutated (ATM) Is Dispensable for Endonuclease I-SceI-induced Homologous Recombination in Mouse Embryonic Stem Cells.
Hypersensitivity
Attenuation of the progression of adjuvant-induced arthritis by 3-aminobenzamide treatment.
Hypersensitivity
Base excision repair defects invoke hypersensitivity to PARP inhibition.
Hypersensitivity
Base excision repair is efficient in cells lacking poly(ADP-ribose) polymerase 1.
Hypersensitivity
Beyond dna repair,the immunological role of parp-1 and its siblings.
Hypersensitivity
Break of unresponsiveness of delayed-type hypersensitivity to sheep red blood cells by pertussis toxin.
Hypersensitivity
Combinations of PARP Inhibitors with Temozolomide Drive PARP1 Trapping and Apoptosis in Ewing's Sarcoma.
Hypersensitivity
CTCF facilitates DNA double-strand break repair by enhancing homologous recombination repair.
Hypersensitivity
Decapping protein EDC4 regulates DNA repair and phenocopies BRCA1.
Hypersensitivity
Decreased PARP-1 levels accelerate embryonic lethality but attenuate neuronal apoptosis in DNA polymerase beta-deficient mice.
Hypersensitivity
Delayed-type hypersensitivity responses in mice treated with pertussis toxin and betamethasone.
Hypersensitivity
DNA repair and cell cycle checkpoint defects in a mouse model of 'BRCAness' are partially rescued by 53BP1 deletion.
Hypersensitivity
Effects of pertussis toxin (PT) on T-cell populations sensitized for delayed-type hypersensitivity in mice.
Hypersensitivity
Effects of pertussis toxin on delayed-type hypersensitivity responses and on the activity of suppressor T cells on the responses.
Hypersensitivity
Elevated APOBEC3B expression drives a kataegic-like mutation signature and replication stress-related therapeutic vulnerabilities in p53-defective cells.
Hypersensitivity
Enhancement of histamine-induced vascular leakage by pertussis toxin in SJL/J mice but not BALB/c mice.
Hypersensitivity
Human CHD1 is required for early DNA-damage signaling and is uniquely regulated by its N terminus.
Hypersensitivity
Hypersensitivity of BRCA2 deficient cells to rosemary extract explained by weak PARP inhibitory activity.
Hypersensitivity
Hypersensitivity to clinically useful alkylating agents and radiation in poly(ADP-ribose) polymerase-deficient cell lines.
Hypersensitivity
IGH/MYC Translocation Associates with BRCA2 Deficiency and Synthetic Lethality to PARP1 Inhibitors.
Hypersensitivity
Impact of carboplatin hypersensitivity and desensitization on patients with recurrent ovarian cancer.
Hypersensitivity
Increased PARP-1 Association with DNA in Alkylation Damaged, PARP-Inhibited Mouse Fibroblasts.
Hypersensitivity
Inhibiting Mitochondrial DNA Ligase III? Activates Caspase 1-Dependent Apoptosis in Cancer Cells.
Hypersensitivity
Intrinsic ATR signaling shapes DNA end resection and suppresses toxic DNA-PKcs signaling.
Hypersensitivity
LC8/DYNLL1 is a 53BP1 effector and regulates checkpoint activation.
Hypersensitivity
Loss of the p12 subunit of DNA polymerase delta leads to a defect in HR and sensitization to PARP inhibitors.
Hypersensitivity
Mechanism by which pertussis toxin breaks unresponsiveness of delayed-type hypersensitivity to sheep red blood cells in mice.
Hypersensitivity
Microsatellite instability induced mutations in DNA repair genes Ctip and MRE11 confer hypersensitivity to poly (ADP-ribose) polymerase (PARP) inhibitors in myeloidmalignancies.
Hypersensitivity
Modulation of hypersensitivity to oxidative DNA damage in ATM defective cells induced by potassium bromate by inhibition of the Poly (ADP-ribose) polymerase (PARP).
Hypersensitivity
Parp1 activation in mouse embryonic fibroblasts promotes Pol beta-dependent cellular hypersensitivity to alkylation damage.
Hypersensitivity
PARP3 affects the relative contribution of homologous recombination and nonhomologous end-joining pathways.
Hypersensitivity
Pertussis adjuvant prolongs intestinal hypersensitivity.
Hypersensitivity
Pertussis toxin potentiates Th1 and Th2 responses to co-injected antigen: adjuvant action is associated with enhanced regulatory cytokine production and expression of the co-stimulatory molecules B7-1, B7-2 and CD28.
Hypersensitivity
Pertussis toxin stimulates hypersensitivity and enhances nerve-mediated antigen uptake in rat intestine.
Hypersensitivity
Poly (ADP-Ribose) Polymerase Inhibitor Hypersensitivity in Aggressive Myeloproliferative Neoplasms.
Hypersensitivity
Poly(ADP-ribose) polymerase inhibitors: new pharmacological functions and potential clinical implications.
Hypersensitivity
Poly(ADP-ribose) polymerase-1 inhibitor treatment regresses autochthonous Brca2/p53-mutant mammary tumors in vivo and delays tumor relapse in combination with carboplatin.
Hypersensitivity
Poly(ADP-ribose) polymerases: homology, structural domains and functions. Novel therapeutical applications.
Hypersensitivity
RAD18 and poly(ADP-ribose) polymerase independently suppress the access of nonhomologous end joining to double-strand breaks and facilitate homologous recombination-mediated repair.
Hypersensitivity
Sensitivity to poly(ADP-ribose) polymerase (PARP) inhibition identifies ubiquitin-specific peptidase 11 (USP11) as a regulator of DNA double-strand break repair.
Hypersensitivity
Synaptonemal complex protein SYCP3 impairs mitotic recombination by interfering with BRCA2.
Hypersensitivity
Targeting poly(ADP-ribose) polymerase activity for cancer therapy.
Hypersensitivity
The ADP-ribosyltransferase PARP10/ARTD10 interacts with Proliferating Cell Nuclear Antigen (PCNA) and is required for DNA damage tolerance.
Hypersensitivity
The Ewing Family of Tumors Relies on BCL-2 and BCL-XL to Escape PARP Inhibitor Toxicity.
Hypersensitivity
The PARP-1 inhibitor Olaparib suppresses BRCA1 protein levels, increases apoptosis and causes radiation hypersensitivity in BRCA1
Hypersensitivity
The role of BRCA1 in homologous recombination repair in response to replication stress: significance in tumorigenesis and cancer therapy.
Hypersensitivity
The USP1/UAF1 complex promotes double-strand break repair through homologous recombination.
Hypersensitivity
Use of type I and type IV hypersensitivity responses to define the immunopharmacological profile of drugs.
Hypersensitivity
USP-11 as a predictive and prognostic factor following neoadjuvant therapy in women with breast cancer.
Hypersensitivity
Wnt signaling inhibition confers induced synthetic lethality to PARP inhibitors.
Hypersensitivity
[PARP inhibitors and radiotherapy: rational and prospects for a clinical use].
Hypersensitivity, Delayed
Paradoxical effect of pertussis toxin on the delayed hypersensitivity response to autoantigens in mice.
Hypertension
Activation of poly(ADP-ribose) polymerase contributes to the endothelial dysfunction associated with hypertension and aging.
Hypertension
Angiotensin II-mediated endothelial dysfunction: role of poly(ADP-ribose) polymerase activation.
Hypertension
Cardiovascular Protective Effect of Metformin and Telmisartan: Reduction of PARP1 Activity via the AMPK-PARP1 Cascade.
Hypertension
Contribution of poly(ADP-ribose) polymerase to endothelial dysfunction and hypertension in a rat model of pre-eclampsia.
Hypertension
E3 Ubiquitin ligase NEDD4 family?regulatory network in cardiovascular disease.
Hypertension
Effects of quinapril, losartan and hydralazine on cardiac hypertrophy and beta-adrenergic neuroeffector mechanisms in transgenic (mREN2)27 rats.
Hypertension
Impaired 3',5'-cyclic adenosine monophosphate-mediated signaling in immediate early responsive gene X-1-deficient vascular smooth muscle cells.
Hypertension
Inactivation of enhanced expression of G(i) proteins by pertussis toxin attenuates the development of high blood pressure in spontaneously hypertensive rats.
Hypertension
Influence of pertussis toxin pretreatment on the development of L-NAME-induced hypertension.
Hypertension
Inhibition of PARP prevents angiotensin II-induced aortic fibrosis in rats.
Hypertension
iNOS induction and PARP-1 activation in human atherosclerotic lesions: an immunohistochemical and ultrastructural approach.
Hypertension
Knockdown of Inhibitory Guanine Nucleotide Binding Protein Gi?-2 by Antisense Oligodeoxynucleotides Attenuates the Development of Hypertension and Tachycardia in Spontaneously Hypertensive Rats.
Hypertension
MicroRNAs Modulate Oxidative Stress in Hypertension through PARP-1 Regulation.
Hypertension
PARP-inhibitor treatment prevents hypertension induced cardiac remodeling by favorable modulation of heat shock proteins, Akt-1/GSK-3? and several PKC isoforms.
Hypertension
PCB-induced endothelial cell dysfunction: role of poly(ADP-ribose) polymerase.
Hypertension
Pertussis toxin-sensitive G-proteins and regulation of blood pressure in the spontaneously hypertensive rat.
Hypertension
Role of nifedipine-sensitive sympathetic vasoconstriction in maintenance of high blood pressure in spontaneously hypertensive rats: effect of Gi-protein inactivation by pertussis toxin.
Hypertension
Role of oxidative-nitrosative stress and downstream pathways in various forms of cardiomyopathy and heart failure.
Hypertension
Therapeutic options following second-line platinum-based chemotherapy in patients with recurrent ovarian cancer: Comparison of active surveillance and maintenance treatment.
Hypertension
[Gender-specific factors of ischemic stroke among atrial fibrillation patients].
Hypertension, Pulmonary
Caffeine to prevent respiratory failure and improve outcome in infant pertussis.
Hypertension, Pulmonary
E3 Ubiquitin ligase NEDD4 family?regulatory network in cardiovascular disease.
Hypertension, Pulmonary
Effects of calcium channel antagonists and pertussis toxin on noradrenaline-induced contractions in pulmonary artery from pulmonary hypertensive rats.
Hypertension, Pulmonary
MicroRNAs and PARP: co-conspirators with ROS in pulmonary hypertension. Focus on "miR-223 reverses experimental pulmonary arterial hypertension".
Hypertension, Pulmonary
Pertussis toxin promotes pulmonary hypertension in an infant mouse model of Bordetella pertussis infection.
Hypertension, Pulmonary
Poly (ADP-ribose) polymerase-1: An emerging target in right ventricle dysfunction associated with pulmonary hypertension.
Hyperthyroidism
Pertussis toxin effects on adenylate cyclase activity, cyclic AMP accumulation and lipolysis in adipocytes from hypothyroid, euthyroid and hyperthyroid rats.
Hyperthyroidism
Poly(ADP-ribose) polymerase is affected early by thyroid state during liver regeneration in rats.
Hyperthyroidism
Poly(ADP-ribosyl)ation of proteins and germ cell development in hyperthyroid rat testes.
Hyperthyroidism
Tissue- and subunit-specific regulation of G-protein expression by hypo- and hyperthyroidism.
Hypertrophy, Right Ventricular
Poly (ADP-ribose) polymerase-1: An emerging target in right ventricle dysfunction associated with pulmonary hypertension.
Hypoglycemia
Hypoglycemic neuronal death and cognitive impairment are prevented by poly(ADP-ribose) polymerase inhibitors administered after hypoglycemia.
Hypoglycemia
Infection of newborn piglets with Bordetella pertussis: a new model for pertussis.
Hypoglycemia
Postnatal Age Influences Hypoglycemia-induced Poly(ADP-ribose) Polymerase-1 Activation in the Brain Regions of Rats.
Hypoglycemia
Prevention of acute/severe hypoglycemia-induced neuron death by lactate administration.
Hypoglycemia
Pyruvate administered after severe hypoglycemia reduces neuronal death and cognitive impairment.
Hypoglycemia
Pyruvate administration reduces recurrent/moderate hypoglycemia-induced cortical neuron death in diabetic rats.
Hypoglycemia
Severe reactions associated with diphtheria-tetanus-pertussis vaccine: detailed study of children with seizures, hypotonic-hyporesponsive episodes, high fevers, and persistent crying.
Hypoglycemia
Signaling pathways involved in thrombin-induced cell protection.
Hypoglycemia
The quantitative analysis of the mechanism involved in pertussis toxin-mediated cell clustering and its implications in the in vitro quality control of diphtheria tetanus and whole cell pertussis vaccines.
Hypoglycemia
Zinc release contributes to hypoglycemia-induced neuronal death.
Hypotension
Activation and modulation of cardiac poly-adenosine diphosphate ribose polymerase activity in a rat model of brain death.
Hypotension
Inhibition of Nitro-Oxidative Stress Attenuates Pulmonary and Systemic Injury Induced by High-Tidal Volume Mechanical Ventilation.
Hypotension
Mechanism of the cardiovascular effects of GABAB receptor activation in the nucleus tractus solitarii of the rat.
Hypotension
The neuroprotective effect of cerebral poly(ADP-ribose)polymerase inhibition in a rat model of global ischemia.
Hypotension
Vascular beta-adrenoceptor blocking activity of endotoxin and pertussis toxin from Bordetella pertussis in rats.
Hypothyroidism
Tissue- and subunit-specific regulation of G-protein expression by hypo- and hyperthyroidism.
Idiopathic Pulmonary Fibrosis
Effects of PARP-1 Deficiency and Histamine H4 Receptor Inhibition in an Inflammatory Model of Lung Fibrosis in Mice.
Idiopathic Pulmonary Fibrosis
Regulation of myofibroblast differentiation by poly(ADP-ribose) polymerase 1.
Immune Complex Diseases
[THE EFFECT OF OF POLY(ADP-RIBOSE) POLYMERASE INHIBITOR 4-HYDROXY-QUINAZOLINE ON DEATH OF IMMUNE CELLS UNDER IMMUNE COMPLEX-MEDIATED INJURY IN MICE].
Immune System Diseases
A key role for poly(ADP-ribose) polymerase-1 activity during human dendritic cell maturation.
Infarction, Middle Cerebral Artery
Delayed PARP-1 Inhibition Alleviates Post-stroke Inflammation in Male Versus Female Mice: Differences and Similarities.
Infarction, Middle Cerebral Artery
Enhanced poly(ADP-ribosyl)ation after focal ischemia in rat brain.
Infarction, Middle Cerebral Artery
Influence of electroacupuncture on the mRNA of heat shock protein 70 and 90 in brain after cerebral ischemia/reperfusion of rats.
Infarction, Middle Cerebral Artery
Long-term neuroprotective effect of inhibiting poly(ADP-ribose) polymerase in rats with middle cerebral artery occlusion using a behavioral assessment.
Infarction, Middle Cerebral Artery
MP-124, a novel poly(ADP-ribose) polymerase-1 (PARP-1) inhibitor, ameliorates ischemic brain damage in a non-human primate model.
Infarction, Middle Cerebral Artery
Neuroprotective effect of 4-amino-1,8-napthalimide, a poly(ADP ribose) polymerase inhibitor in middle cerebral artery occlusion-induced focal cerebral ischemia in rat.
Infarction, Middle Cerebral Artery
Neuroprotective effect of combination of poly (ADP-ribose) polymerase inhibitor and antioxidant in middle cerebral artery occlusion induced focal ischemia in rats.
Infarction, Middle Cerebral Artery
Neuroprotective effects of KCL-440, a new poly(ADP-ribose) polymerase inhibitor, in the rat middle cerebral artery occlusion model.
Infarction, Middle Cerebral Artery
Neuroprotective effects of NU1025, a PARP inhibitor in cerebral ischemia are mediated through reduction in NAD depletion and DNA fragmentation.
Infarction, Middle Cerebral Artery
Novel insight into circular RNA HECTD1 in astrocyte activation via autophagy by targeting MIR142-TIPARP: implications for cerebral ischemic stroke.
Infarction, Middle Cerebral Artery
Pertussis toxin reduces calcium influx to protect ischemic stroke in a middle cerebral artery occlusion model.
Infarction, Middle Cerebral Artery
Poly(ADP-ribose) polymerase as a key player in excitotoxicity and post-ischemic brain damage.
Infarction, Middle Cerebral Artery
Poly(ADP-ribose) polymerase gene disruption renders mice resistant to cerebral ischemia.
Infarction, Middle Cerebral Artery
Poly(ADP-ribose) polymerase inhibition by cilostazol is implicated in the neuroprotective effect against focal cerebral ischemic infarct in rat.
Infarction, Middle Cerebral Artery
Poly(ADP-Ribose)Polymerase 1 (PARP-1) Activation and Ca(2+) Permeable ?-Amino-3-Hydroxy-5-Methyl-4-Isoxazolepropionic Acid (AMPA) Channels in Post-Ischemic Brain Damage: New Therapeutic Opportunities?
Infarction, Middle Cerebral Artery
Sex differences in minocycline-induced neuroprotection after experimental stroke.
Infarction, Middle Cerebral Artery
Sex differences in the effects of PARP inhibition on microglial phenotypes following neonatal stroke.
Infarction, Middle Cerebral Artery
Tumor necrosis factor-like weak inducer of apoptosis and fibroblast growth factor-inducible 14 mediate cerebral ischemia-induced poly(ADP-ribose) polymerase-1 activation and neuronal death.
Infections
Acellular pertussis vaccine in children with perinatal human immunodeficiency virus-type 1 infection.
Infections
Activation of caspase-3 and cleavage of Rb are associated with p16-mediated apoptosis in human non-small cell lung cancer cells.
Infections
Activation of caspases in pig kidney cells infected with wild-type and CrmA/SPI-2 mutants of cowpox and rabbitpox viruses.
Infections
Activation of cell signaling pathways is dependant on the biotype of bovine viral diarrhea viruses type 2.
Infections
Activation of the abundant nuclear factor poly(ADP-ribose) polymerase-1 by Helicobacter pylori.
Infections
Acute exacerbation of idiopathic pulmonary fibrosis induced by pertussis: the first case report.
Infections
Adenovirus-Mediated Gene Transfer of FKHRL1 Triple Mutant Efficiently Induces Apoptosis in Melanoma Cells.
Infections
Adenylate cyclase toxin is critical for colonization and pertussis toxin is critical for lethal infection by Bordetella pertussis in infant mice.
Infections
ADP-ribosyl-binding and hydrolase activities of the alphavirus nsP3 macrodomain are critical for initiation of virus replication.
Infections
ADP-ribosylation by exoenzyme T of Pseudomonas aeruginosa induces an irreversible effect on the host cell cytoskeleton in vivo.
Infections
Age-specific long-term course of IgG antibodies to pertussis toxin after symptomatic infection with Bordetella pertussis.
Infections
An Interaction with PARP-1 and Inhibition of Parylation Contribute to Attenuation of DNA Damage Signaling by the Adenovirus E4orf4 Protein.
Infections
Analogous IgG subclass response to pertussis toxin in vaccinated children, healthy or affected by whooping cough.
Infections
Antibodies recognizing protective pertussis toxin epitopes are preferentially elicited by natural infection versus acellular immunization.
Infections
Antibody responses to pertussis toxin display different kinetics after clinical Bordetella pertussis infection than after vaccination with an acellular pertussis vaccine.
Infections
Apoptosis induced by adenovirus-mediated p14ARF expression in U2OS osteosarcoma cells is associated with increased Fas expression.
Infections
Apoptosis induction in BEFV-infected Vero and MDBK cells through Src-dependent JNK activation regulates caspase-3 and mitochondria pathways.
Infections
Apoptosis of human retina and retinal pigment cells induced by human cytomegalovirus infection.
Infections
Apoptosis-inducing factor contributes to epithelial cell apoptosis induced by enteropathogenic Escherichia coli.
Infections
Assessment of IgA anti-PT and IgG anti-ACT reflex testing to improve Bordetella pertussis serodiagnosis in recently vaccinated subjects.
Infections
Assessment of Poly(ADP-ribose) Polymerase1 (PARP1) expression and activity in cells purified from blood and milk of dairy cattle.
Infections
Bax is activated during rotavirus-induced apoptosis through the mitochondrial pathway.
Infections
Biochemical Variations in Cytolytic Activity of Ortho- and Paramyxoviruses in Human Lung Tumor Cell Culture.
Infections
Blockade of tumor growth due to matrix metalloproteinase-9 inhibition is mediated by sequential activation of beta1-integrin, ERK, and NF-kappaB.
Infections
Bordetella pertussis and Bordetella parapertussis: two immunologically distinct species.
Infections
Bordetella pertussis infection exacerbates influenza virus infection through pertussis toxin-mediated suppression of innate immunity.
Infections
Bordetella pertussis infection in mice: correlation of specific antibodies against two antigens, pertussis toxin, and filamentous hemagglutinin with mouse protectivity in an intracerebral or aerosol challenge system.
Infections
Bordetella pertussis infection of human respiratory epithelial cells up-regulates intercellular adhesion molecule-1 expression: role of filamentous hemagglutinin and pertussis toxin.
Infections
Bordetella Pertussis Toxin does not induce the release of pro-inflammatory cytokines in human whole blood.
Infections
Bordetella Pertussis virulence factors in the continuing evolution of whooping cough vaccines for improved performance.
Infections
Caspase activation and specific cleavage of substrates after coxsackievirus B3-induced cytopathic effect in HeLa cells.
Infections
Caspase-mediated cleavage of adenovirus early region 1A proteins.
Infections
Caspase-mediated cleavage of the feline calicivirus capsid protein.
Infections
Cell-mediated immune responses to antigens of Bordetella pertussis and protection against pertussis in school children.
Infections
Characterization of a key neutralizing epitope on pertussis toxin recognized by monoclonal antibody 1B7.
Infections
Characterization of individual human antibodies binding pertussis toxin stimulated by acellular immunization.
Infections
Characterization of murine lung inflammation after infection with parental Bordetella pertussis and mutants deficient in adhesins or toxins.
Infections
Chick embryo, a model to study the lethal activity of pertussis toxin, infectivity of Bordetella pertussis, and their neutralization by immune sera.
Infections
Chlamydia pneumoniae alters mildly oxidized low-density lipoprotein-induced cell death in human endothelial cells, leading to necrosis rather than apoptosis.
Infections
Chromatin remodeling factor encoded by ini1 induces G1 arrest and apoptosis in ini1-deficient cells.
Infections
Clustered cases of Bordetella pertussis infection cause high levels of IgG antibodies against pertussis toxin in adolescents in Gaobeidian city, China.
Infections
Combined effects of adenovirus-mediated wild-type p53 transduction, temozolomide and poly (ADP-ribose) polymerase inhibitor in mismatch repair deficient and non-proliferating tumor cells.
Infections
Comparative analysis of key immune protection factors in H9N2 avian influenza viruses infected and immunized specific pathogen-free chicken.
Infections
Comparison of polymerase chain reaction, culture, and western immunoblot serology for diagnosis of Bordetella pertussis infection.
Infections
Conflicting effects of poly(ADP-ribose) polymerase inhibitor on cell-mediated and virion-mediated HTLV-1 infection.
Infections
Constitutive inositol phosphate formation in cytomegalovirus-infected human fibroblasts is due to expression of the chemokine receptor homologue pUS28.
Infections
Construction of Bordetella pertussis strains that overproduce genetically inactivated pertussis toxin.
Infections
Contribution of exoenzyme S to the virulence of Pseudomonas aeruginosa.
Infections
Contribution of the B oligomer to the protective activity of genetically attenuated pertussis toxin.
Infections
Coronavirus infection and PARP expression dysregulate the NAD metabolome: An actionable component of innate immunity.
Infections
Coxiella burnetii induces apoptosis during early stage infection via a caspase-independent pathway in human monocytic THP-1 cells.
Infections
Crimean-Congo haemorrhagic fever replication interplays with regulation mechanisms of apoptosis.
Infections
Delayed role of tumor necrosis factor- alpha in overcoming the effects of pertussis toxin.
Infections
Determination of serum neutralizing antibodies reveals important difference in quality of antibodies against pertussis toxin in children after infection.
Infections
Differences in avidity of IgG antibodies to pertussis toxin after acellular pertussis booster vaccination and natural infection.
Infections
Differences in epitope-specific antibodies to pertussis toxin after infection and acellular vaccinations.
Infections
DNA damage sensors ATM, ATR, DNA-PKcs, and PARP-1 are dispensable for human immunodeficiency virus type 1 integration.
Infections
DNA vaccine encoding pertussis toxin S1 subunit induces protection against Bordetella pertussis in mice.
Infections
Effect of pertussis toxin on susceptibility of infant rats to Haemophilus influenzae type b.
Infections
Efficacy of pertussis components in an acellular vaccine, as assessed in a murine model of respiratory infection and a murine intracerebral challenge model.
Infections
Efficient retroviral infection of mammalian cells is blocked by inhibition of poly(ADP-ribose) polymerase activity.
Infections
Elucidation of linear epitopes of pertussis toxin using overlapping synthetic decapeptides: identification of a human B-cell determinant in the S1 subunit indicative of acute infections.
Infections
Epithelial anion transporter pendrin contributes to inflammatory lung pathology in mouse models of Bordetella pertussis infection.
Infections
Epitope specificity of three anti-pertussis toxin monoclonal antibodies with dissimilar effects in assays of toxin neutralizing activity.
Infections
Estimated and reported incidence of pertussis in Estonian adults: A seroepidemiological study.
Infections
Evaluation of an immunoglobulin G enzyme-linked immunosorbent assay for pertussis toxin and filamentous hemagglutinin in diagnosis of pertussis in Senegal.
Infections
Evaluation of inactivated Bordetella pertussis as a delivery system for the immunization of mice with Pneumococcal Surface Antigen A.
Infections
Evaluation of serology and nasopharyngeal cultures for diagnosis of pertussis in a vaccine efficacy trial.
Infections
Evidence that myocardial pertussis toxin substrates are uniquely altered in acute murine Chagas' disease in a manner unrelated to myocardial dysfunction.
Infections
Examining the Role of Actin-Plasma Membrane Association in Pseudomonas aeruginosa Infection and Type III Secretion Translocation in Migratory T24 Epithelial Cells.
Infections
ExoU expression by Pseudomonas aeruginosa correlates with acute cytotoxicity and epithelial injury.
Infections
Expression of cytotoxicity-associated genes in Marek's disease virus-infected chickens.
Infections
Flavonol morin targets host ACE2, IMP-?, PARP-1 and viral proteins of SARS-CoV-2, SARS-CoV and MERS-CoV critical for infection and survival: a computational analysis.
Infections
Functional dissection of an IFN-alpha/beta receptor 1 promoter variant that confers higher risk to chronic hepatitis B virus infection.
Infections
Gene transfer of constitutively active caspase-3 induces apoptosis in a human hepatoma cell line.
Infections
Genetic and pharmacological inhibition of poly(ADP-ribose) polymerase-1 interferes in the chlamydial life cycle.
Infections
Genetic approaches to study Pseudomonas aeruginosa protein antigens.
Infections
Genital antibody responses in mice after intranasal infection with an attenuated candidate vector strain of Bordetella pertussis.
Infections
Hepatitis C virus induced a novel apoptosis-like death of pancreatic beta cells through a caspase 3-dependent pathway.
Infections
Herpes simplex virus 1 infection activates poly(ADP-ribose) polymerase and triggers the degradation of poly(ADP-ribose) glycohydrolase.
Infections
High PARP-1 expression is associated with tumor invasion and poor prognosis in gastric cancer.
Infections
Hippocampal poly(ADP-Ribose) polymerase 1 and caspase 3 activation in neonatal bornavirus infection.
Infections
Histamine release from basophils in childhood: age dependency and inhibition by pertussis infection and pertussis toxin.
Infections
HIV-1 coreceptor activity of CCR5 and its inhibition by chemokines: independence from G protein signaling and importance of coreceptor downmodulation.
Infections
Host relieves lnc-IRAK3-3-sequestered miR-891b to attenuate apoptosis in Enterovirus 71 infection.
Infections
Human cytomegalovirus UL38 protein blocks apoptosis.
Infections
Human immunodeficiency virus-1 infection requires pertussis toxin sensitive G-protein-coupled signalling and mediates cAMP downregulation.
Infections
Human serum antibody responses to Bordetella pertussis infection and pertussis vaccination.
Infections
Identification of Salmonella typhi promoters activated by invasion of eukaryotic cells.
Infections
IL-1R signaling is required to overcome the effects of pertussis toxin and for efficient infection or vaccination induced immunity against Bordetella pertussis.
Infections
Immunologic and epidemiologic experience of vaccination with a monocomponent pertussis toxoid vaccine.
Infections
Impact of a pertussis booster vaccination program in adolescents and adults on the epidemiology of pertussis in Austria.
Infections
Impaired formation of the second messenger cAMP in mononuclear blood cells of children with pertussis.
Infections
In Vivo Blockade of Murine ARTC2.2 During Cell Preparation Preserves the Vitality and Function of Liver Tissue-Resident Memory T Cells.
Infections
Incidence of pertussis infection in healthcare workers.
Infections
Increase in de novo HBV DNA integrations in response to oxidative DNA damage or inhibition of poly(ADP-ribosyl)ation.
Infections
Increased population prevalence of low pertussis toxin antibody levels in young children preceding a record pertussis epidemic in Australia.
Infections
Induction of apoptosis and cleavage of poly(ADP-ribose) polymerase by cytopathic bovine viral diarrhea virus infection.
Infections
Induction of apoptosis in p16INK4A mutant cell lines by adenovirus-mediated overexpression of p16INK4A protein.
Infections
Inhibition of host cell apoptosis by Toxoplasma gondii is accompanied by reduced activation of the caspase cascade and alterations of poly(ADP-ribose) polymerase expression.
Infections
Inhibition of ICE-like proteases inhibits apoptosis and increases virus production during adenovirus infection.
Infections
Inhibition of PARP1 Dampens Pseudorabies Virus Infection through DNA Damage-Induced Antiviral Innate Immunity.
Infections
Inhibition of poly(ADP-ribose) polymerase interferes with Trypanosoma cruzi infection and proliferation of the parasite.
Infections
Inhibition of Poly(ADP-ribose)polymerase impairs Epstein Barr Virus lytic cycle progression.
Infections
Inhibitors of ADP-ribosylating bacterial toxins based on oxacarbenium ion character at their transition states.
Infections
Insulin-like growth factor binding protein-3 inhibits the growth of non-small cell lung cancer.
Infections
Interaction of Sindbis virus non-structural protein 3 with poly(ADP-ribose) polymerase 1 in neuronal cells.
Infections
Interferon-gamma levels in serum and bronchoalveolar lavage fluid of mice infected with Bordetella pertussis.
Infections
Involvement of PI 3 kinase/Akt-dependent Bad phosphorylation in Toxoplasma gondii-mediated inhibition of host cell apoptosis.
Infections
Is rheumatoid arthritis a consequence of natural selection for enhanced tuberculosis resistance?
Infections
Isolation and characterization of transposon-induced mutants of Pseudomonas aeruginosa deficient in production of exoenzyme S.
Infections
Kinetics of the IgG antibody response to pertussis toxin after infection with B. pertussis.
Infections
Lethal infection by Bordetella pertussis mutants in the infant mouse model.
Infections
Loss of dendritic cell migration and impaired resistance to Leishmania donovani infection in mice deficient in CCL19 and CCL21.
Infections
Loss of multi-epitope specificity in memory CD4(+) T cell responses to B. Pertussis with age.
Infections
Mechanism of pertussis toxin B oligomer-mediated protection against Bordetella pertussis respiratory infection.
Infections
Metallothioneins/PARP-1/IL-6 interplay on natural killer cell activity in elderly: parallelism with nonagenarians and old infected humans. Effect of zinc supply.
Infections
Mitochondrial damage elicits a TCDD-inducible poly(ADP-ribose) polymerase-mediated antiviral response.
Infections
MMP-2 siRNA induced Fas/CD95-mediated extrinsic II apoptotic pathway in the A549 lung adenocarcinoma cell line.
Infections
Modeling rates of infection with transient maternal antibodies and waning active immunity: application to Bordetella pertussis in Sweden.
Infections
Modulating poly (ADP-ribose) polymerase activity: potential for the prevention and therapy of pathogenic situations involving DNA damage and oxidative stress.
Infections
Modulation of Bordetella pertussis infection with monoclonal antibodies to pertussis toxin.
Infections
Monoclonal antibody against pertussis toxin: effect on toxin activity and pertussis infections.
Infections
Murine Coronavirus Infection Activates the Aryl Hydrocarbon Receptor in an Indoleamine 2,3-Dioxygenase-Independent Manner, Contributing to Cytokine Modulation and Proviral TCDD-Inducible-PARP Expression.
Infections
Neutralizing antibodies to pertussis toxin in whooping cough.
Infections
New Insights into the Significance of PARP-1 Activation: Flow Cytometric Detection of Poly(ADP-Ribose) as a Marker of Bovine Intramammary Infection.
Infections
Nitric oxide-peroxynitrite-poly(ADP-ribose) polymerase pathway in the skin.
Infections
No associations of polymorphisms in ADPRT with hepatitis B virus clearance and hepatocellular carcinoma occurrence in a Korean population.
Infections
NSm protein of Rift Valley fever virus suppresses virus-induced apoptosis.
Infections
Nuclear Translocation of NF-{kappa}B Precedes Apoptotic Poly(ADP-ribose) Polymerase Cleavage during Productive HSV-1 Replication in Corneal Epithelial Cells.
Infections
Parenteral immunization of mice with a genetically inactivated pertussis toxin DNA vaccine induces cell-mediated immunity and protection.
Infections
Parents of ataxia-telangiectasia patients display a distinct cellular immune phenotype mimicking ATM mutated patients.
Infections
PARP inhibitor olaparib increases the oncolytic activity of dl922-947 in in vitro and in vivo model of anaplastic thyroid carcinoma.
Infections
PARP-1 controls NK cell recruitment to the site of viral infection.
Infections
PARP-1 Val762Ala polymorphism, CagA(+) H. pylori infection and risk for gastric cancer in Han Chinese population.
Infections
PARP1 Enhances Influenza A Virus Propagation by Facilitating Degradation of Host Type I Interferon Receptor.
Infections
PARP1 interacts with STAT3 and retains active phosphorylated-STAT3 in nucleus during pathological myocardial hypertrophy.
Infections
PARP1 Polymorphisms Increase the Risk of Gastric Cancer in a Chinese Population.
Infections
PARP1: A potential biomarker for gastric cancer.
Infections
Parthanatos-associated proteins are stimulated intraocularly during development of experimental murine cytomegalovirus retinitis in mice with retrovirus-induced immunosuppression.
Infections
Pertussis Leukocytosis: Mechanisms, Clinical Relevance and Treatment.
Infections
Pertussis seroepidemiology in women and their infants in Sarlahi District, Nepal.
Infections
Pertussis toxin and adenylate cyclase toxin provide a one-two punch for establishment of Bordetella pertussis infection of the respiratory tract.
Infections
Pertussis toxin and extracytoplasmic adenylate cyclase as virulence factors of Bordetella pertussis.
Infections
Pertussis toxin and its binding unit inhibit HIV-1 infection of human cervical tissue and macrophages involving a CD14 pathway.
Infections
Pertussis toxin exacerbates and prolongs airway inflammatory responses during Bordetella pertussis infection.
Infections
Pertussis toxin IgA testing over-diagnoses recent pertussis infection.
Infections
Pertussis toxin inhibits early chemokine production to delay neutrophil recruitment in response to Bordetella pertussis respiratory tract infection in mice.
Infections
Pertussis toxin permeabilization enhances the traversal of Escherichia coli K1, macrophages, and monocytes in a cerebral endothelial barrier model in vitro.
Infections
Pertussis toxin plays an early role in respiratory tract colonization by Bordetella pertussis.
Infections
Pertussis toxin promotes pulmonary hypertension in an infant mouse model of Bordetella pertussis infection.
Infections
Pertussis toxin sensitization alters the pathogenesis of subsequent respiratory syncytial virus infection.
Infections
Pertussis toxin stimulates IL-17 production in response to Bordetella pertussis infection in mice.
Infections
Pertussis toxin targets airway macrophages to promote Bordetella pertussis infection of the respiratory tract.
Infections
Phenotypic comparison of Pseudomonas aeruginosa strains isolated from a variety of clinical sites.
Infections
Phosphoprotein Gene Contributes to the Enhanced Apoptosis Induced by Wild-Type Rabies Virus GD-SH-01 In Vitro.
Infections
Poly (ADP-ribose) polymerase-1 silences retroviruses independently of viral DNA integration or heterochromatin formation.
Infections
Poly(ADP-ribose) polymerase 1 is not strictly required for infection of murine cells by retroviruses.
Infections
Poly(ADP-ribose) polymerase 1 promotes transcriptional repression of integrated retroviruses.
Infections
Poly(ADP-ribose) polymerase activity in various U937 cell subclones with different susceptibility to HIV-1 infection: its dramatic decrease following persistent virus infection.
Infections
Poly(ADP-ribose) polymerase-1 is required for efficient HIV-1 integration.
Infections
Poly(ADP-ribose)polymerase activity is reduced in circulating mononuclear cells from type 2 diabetic patients.
Infections
Poly(ADP-ribose)polymerase inhibition - where now?
Infections
Poly-ADP Ribosyl Polymerase 1 (PARP1) Regulates Influenza A Virus Polymerase.
Infections
Polymorphism in the pertussis toxin promoter region affecting the DNA-based diagnosis of Bordetella infection.
Infections
Porcine parvovirus infection activates mitochondria-mediated apoptotic signaling pathway by inducing ROS accumulation.
Infections
Porcine reproductive and respiratory syndrome virus infection induces endoplasmic reticulum stress, facilitates virus replication, and contributes to autophagy and apoptosis.
Infections
Potent antitumor efficacy of XAF1 delivered by conditionally replicative adenovirus vector via caspase-independent apoptosis.
Infections
Prevalence, diagnosis, and disease course of pertussis in adults with acute cough: a prospective, observational study in primary care.
Infections
Production of exoenzyme S during Pseudomonas aeruginosa infections of burned mice.
Infections
Production of extracellular virulence factors by Pseudomonas aeruginosa isolates obtained from tracheal, urinary tract, and wound infections.
Infections
Prognostic Performance of Peripheral Blood Biomarkers in Identifying Seropositive Individuals at Risk of Developing Clinically Symptomatic Chagas Cardiomyopathy.
Infections
Proliferative responses and gamma interferon and tumor necrosis factor production by lymphocytes isolated from tracheobroncheal lymph nodes and spleen of mice aerosol infected with Bordetella pertussis.
Infections
Pseudomonas aeruginosa exoenzyme S stimulates murine lymphocyte proliferation in vitro.
Infections
Pseudomonas aeruginosa strains obtained from patients with tracheal, urinary tract and wound infection: variations in virulence factors and virulence genes.
Infections
Rac1, RhoA, and Cdc42 participate in HeLa cell invasion by group B streptococcus.
Infections
Recombinant oncolytic Newcastle disease virus displays antitumor activities in anaplastic thyroid cancer cells.
Infections
Repurposing of antiparasitic niclosamide to inhibit respiratory syncytial virus (RSV) replication.
Infections
Respiratory syncytial virus inhibits apoptosis and induces NF-kappa B activity through a phosphatidylinositol 3-kinase-dependent pathway.
Infections
RGS2 overexpression or G(i) inhibition rescues the impaired PKA signaling and slow AP firing of cultured adult rabbit pacemaker cells.
Infections
RIG-I enhanced interferon independent apoptosis upon Junin virus infection.
Infections
Role of ADP-ribosyltransferase activity of pertussis toxin in toxin-adhesin redundancy with filamentous hemagglutinin during Bordetella pertussis infection.
Infections
Role of exoenzyme S in chronic Pseudomonas aeruginosa lung infections.
Infections
Role of Major Toxin Virulence Factors in Pertussis Infection and Disease Pathogenesis.
Infections
Role of neutrophils in response to Bordetella pertussis infection in mice.
Infections
Role of pertussis toxin in causing symptoms of Bordetella parapertussis infection.
Infections
Role of Pseudomonas aeruginosa extracellular enzymes in lung disease.
Infections
Role of the adrenal medulla in stress-induced hyperinsulinaemia in normal mice and in mice infected with Bordetella pertussis or treated with pertussis toxin.
Infections
Schistosoma mansoni eggs induce Wnt/?-catenin signaling and activate the protooncogene c-Jun in human and hamster colon.
Infections
Selenium Plays a Protective Role in Staphylococcus aureus-Induced Endometritis in the Uterine Tissue of Rats.
Infections
Sero-epidemiology of Bordetella pertussis in England and Wales.
Infections
Seroepidemiology of diphtheria and pertussis in Chongqing, China: serology-based evidence of Bordetella pertussis infection.
Infections
Seroepidemiology of whooping cough in the Czech Republic: estimates of incidence of infection in adults.
Infections
Seroprevalence of Bordetella pertussis infection during pregnancy measured by IgG antibodies against pertussis toxin.
Infections
Seroprevalence of IgG antibodies to pertussis toxin in children and adolescents in Estonia.
Infections
Seroprevalence of pertussis in The Netherlands: evidence for increased circulation of Bordetella pertussis.
Infections
Serotonin and melatonin, neurohormones for homeostasis, as novel inhibitors of infections by the intracellular parasite chlamydia.
Infections
Serum antibody response to B. pertussis Tn5 mutants, purified PT and FHA in two different mouse strains and passive protection in the murine intranasal infection model.
Infections
Serum IgG, IgA, and IgM responses to pertussis toxin, filamentous hemagglutinin, and agglutinogens 2 and 3 after infection with Bordetella pertussis and immunization with whole-cell pertussis vaccine.
Infections
Severe acute respiratory syndrome coronavirus triggers apoptosis via protein kinase R but is resistant to its antiviral activity.
Infections
Simian virus 40 infection triggers a balanced network that includes apoptotic, survival, and stress pathways.
Infections
Specificity and sensitivity of high levels of immunoglobulin G antibodies against pertussis toxin in a single serum sample for diagnosis of infection with Bordetella pertussis.
Infections
Stabilization of Nrf2 by tBHQ confers protection against oxidative stress-induced cell death in human neural stem cells.
Infections
Stimulus-response coupling in monocytes infected with Leishmania. Attenuation of calcium transients is related to defective agonist-induced accumulation of inositol phosphates.
Infections
Structural relationship between the S1 and S4 subunits of pertussis toxin.
Infections
Structure-activity relationships for inhibitors of Pseudomonas aeruginosa exoenzyme S ADP-ribosyltransferase activity.
Infections
Subclass compositions of immunoglobulin G to pertussis toxin in patients with whooping cough, in healthy individuals, and in recipients of a pertussis toxoid vaccine.
Infections
Suppression of serum antibody responses by pertussis toxin after respiratory tract colonization by Bordetella pertussis and identification of an immunodominant lipoprotein.
Infections
Temporal changes in chromatin, intracellular calcium, and poly(ADP-ribose) polymerase during Sindbis virus-induced apoptosis of neuroblastoma cells.
Infections
The diphtheria and pertussis components of diphtheria-tetanus toxoids-pertussis vaccine should be genetically inactivated mutant toxins.
Infections
The dual action of poly(ADP-ribose) polymerase -1 (PARP-1) inhibition in HIV-1 infection: HIV-1 LTR inhibition and diminution in Rho GTPase activity.
Infections
The effect of investigator compliance (observer bias) on calculated efficacy in a pertussis vaccine trial.
Infections
The efficacy of a whole cell pertussis vaccine and fimbriae against Bordetella pertussis and Bordetella parapertussis infections in a respiratory mouse model.
Infections
The efficiency of R5 HIV-1 infection is determined by CD4 T-cell surface CCR5 density through G alpha i-protein signalling.
Infections
The growth of arthralgic Ross River virus is restricted in human monocytic cells.
Infections
The incidence of Bordetella pertussis infections estimated in the population from a combination of serological surveys.
Infections
The JAK/STAT3 signaling pathway mediates inhibition of host cell apoptosis by Chlamydia psittaci infection.
Infections
The role of exoenzyme S in infections with Pseudomonas aeruginosa.
Infections
The Role of ExoS in Dissemination of Pseudomonas aeruginosa during Pneumonia.
Infections
The seroepidemiology of Bordetella pertussis in Israel--Estimate of incidence of infection.
Infections
The seroepidemiology of Bordetella pertussis infection in Western Europe.
Infections
The seroepidemiology of pertussis in NSW: fluctuating immunity profiles related to changes in vaccination schedules.
Infections
Toxoplasma gondii triggers Gi-dependent PI 3-kinase signaling required for inhibition of host cell apoptosis.
Infections
TRAIL enhances apoptosis of human hepatocellular carcinoma cells sensitized by hepatitis C virus infection: therapeutic implications.
Infections
Transient inhibition of poly(ADP-ribose) polymerase expression and activity by Toxoplasma gondii is dispensable for parasite-mediated blockade of host cell apoptosis and intracellular parasite replication.
Infections
Trends in Hospital Admissions for Pertussis Infection: A Nationwide Retrospective Observational Study in Italy, 2002-2016.
Infections
Trypanosoma cruzi Induces the PARP1/AP-1 Pathway for Upregulation of Metalloproteinases and Transforming Growth Factor ? in Macrophages: Role in Cardiac Fibroblast Differentiation and Fibrosis in Chagas Disease.
Infections
Tula hantavirus infection of Vero E6 cells induces apoptosis involving caspase 8 activation.
Infections
Tumor suppressor in lung cancer-1 (TSLC1) mediated by dual-regulated oncolytic adenovirus exerts specific antitumor actions in a mouse model.
Infections
Tumor suppressor XAF1 induces apoptosis, inhibits angiogenesis and inhibits tumor growth in hepatocellular carcinoma.
Infections
Two-Component Cluster Analysis of a Large Serodiagnostic Database for Specificity of Increases of IgG Antibodies against Pertussis Toxin in Paired Serum Samples and of Absolute Values in Single Serum Samples.
Infections
U20 Is Responsible for Human Herpesvirus 6B Inhibition of TNF Receptor-Dependent Signaling and Apoptosis.
Infections
Use of chemokine receptors by poxviruses.
Infections
Use of transposon mutants to assess the role of exoenzyme S in chronic pulmonary disease due to Pseudomonas aeruginosa.
Infections
Viral macrodomains: a structural and evolutionary assessment of the pharmacological potential.
Infections
Western blot analysis of antibody responses of young infants to pertussis infection.
Infections
Widespread silent transmission of pertussis in families: antibody correlates of infection and symptomatology.
Infections
[A field survey carried out on the confirmation of a pertussis case in a village of Kirikkale Province, Turkey]
Infections
[Humoral reaction to Bordetella pertussis antigens: pertussis toxin, filamentous hemagglutinin and lipopolysaccharide in children with clinical symptoms of whooping cough. I. Antibody level for B pertussis antigens in children without respiratory tract infection symptoms]
Infections
[Preliminary results in the use of a new composite prosthesis in incisional hernia repair]
Infections
[Progress of nicotinamide in preventing infection and sepsis].
Infections
[Synergistic Effect of NF-?B Signaling Pathway Inhibitor and Oncolytic ?Measles Virus Vaccine Strain against Lung Cancer and Underlying Mechanisms].
Infections
[The frequency of detection of IgA, IgG and IgM antibodies to pertussis toxin in patients with respiratory tract infections in Poland]
Infertility
Disruption of Poly(ADP-Ribose) Homeostasis Affects Spermiogenesis and Sperm Chromatin Integrity in Mice.
Infertility
Doxorubicin-induced testicular damage is related to PARP-1 signaling molecules in mice.
Infertility, Male
Association of common SNP rs1136410 in PARP1 gene with the susceptibility to male infertility with oligospermia.
Infertility, Male
Role of poly(ADP-ribose) polymerases in male reproduction.
Infertility, Male
Spermatid Head Elongation with Normal Nuclear Shaping Requires ADP-Ribosyltransferase PARP11 (ARTD11) in Mice.
Inflammatory Bowel Diseases
Activator protein-1 signalling pathway and apoptosis are modulated by poly(ADP-ribose) polymerase-1 in experimental colitis.
Inflammatory Bowel Diseases
GPI 6150, a PARP inhibitor, reduces the colon injury caused by dinitrobenzene sulfonic acid in the rat.
Inflammatory Bowel Diseases
Inhibitors of poly (ADP-ribose) polymerase modulate signal transduction pathways in colitis.
Inflammatory Breast Neoplasms
PARP1 Inhibition Radiosensitizes Models of Inflammatory Breast Cancer to Ionizing Radiation.
Influenza in Birds
Biochemical Variations in Cytolytic Activity of Ortho- and Paramyxoviruses in Human Lung Tumor Cell Culture.
Influenza in Birds
Poly-ADP Ribosyl Polymerase 1 (PARP1) Regulates Influenza A Virus Polymerase.
Influenza, Human
ADP-ribosyltransferase PARP11 modulates the interferon antiviral response by mono-ADP-ribosylating the ubiquitin E3 ligase ?-TrCP.
Influenza, Human
Apoptosis and microglial activation in influenza encephalopathy.
Influenza, Human
Battle between influenza A virus and a newly identified antiviral activity of the PARP-containing ZAPL protein.
Influenza, Human
Bordetella pertussis infection exacerbates influenza virus infection through pertussis toxin-mediated suppression of innate immunity.
Influenza, Human
Enhancing effects of pertussis toxin B oligomer on the immunogenicity of influenza vaccine administered intranasally.
Influenza, Human
PARP1 Enhances Influenza A Virus Propagation by Facilitating Degradation of Host Type I Interferon Receptor.
Influenza, Human
Poly-ADP Ribosyl Polymerase 1 (PARP1) Regulates Influenza A Virus Polymerase.
Influenza, Human
Safety and immunogenicity of heptavalent pneumococcal CRM197 conjugate vaccine in infants and toddlers.
Influenza, Human
The Short Form of the Zinc Finger Antiviral Protein Inhibits Influenza A Virus Protein Expression and Is Antagonized by the Virus-Encoded NS1.
Insulin Resistance
Effect of NAD on PARP-mediated insulin sensitivity in oleic acid treated hepatocytes.
Insulin Resistance
Lysophosphatidylcholine as an effector of fatty acid-induced insulin resistance.
Insulin Resistance
Oxidative Stress in Young Zucker Rats with Impaired Glucose Tolerance is Diminished by Acarbose.
Insulin Resistance
Palmitate activation by fatty acid transport protein 4 as a model system for hepatocellular apoptosis and steatosis.
Insulin Resistance
PARP inhibition ameliorates nephropathy in an animal model of type 2 diabetes: focus on oxidative stress, inflammation, and fibrosis.
Insulin Resistance
PARP-1 DEFICIENCY EXACERBATES DIET-INDUCED OBESITY IN MICE.
Insulinoma
Effects of alpha 2-adrenergic agonism, imidazolines, and G-protein on insulin secretion in beta cells.
Insulinoma
Increased susceptibility to streptozotocin-induced beta-cell apoptosis and delayed autoimmune diabetes in alkylpurine-DNA-N-glycosylase-deficient mice.
Insulinoma
Liquiritigenin prevents palmitate-induced beta-cell apoptosis via estrogen receptor-mediated AKT activation.
Insulinoma
Poly(ADP-ribose) polymerase facilitates the repair of N-methylpurines in mitochondrial DNA.
Insulinoma
Regulation of ATP-sensitive K+ channels in insulinoma cells: activation by somatostatin and protein kinase C and the role of cAMP.
Insulinoma
Role of JNK activation in pancreatic beta-cell death by streptozotocin.
Insulinoma
Somatostatin activates glibenclamide-sensitive and ATP-regulated K+ channels in insulinoma cells via a G-protein.
Intervertebral Disc Degeneration
Tension induces intervertebral disc degeneration via endoplasmic reticulum stress-mediated autophagy.
Intestinal Polyposis
Poly(ADP-ribose) polymerase-1 is a component of the oncogenic T-cell factor-4/beta-catenin complex.
Iron Overload
Antiapoptotic effects of cannabidiol in an experimental model of cognitive decline induced by brain iron overload.
Iron Overload
Effects of intracellular iron overload on cell death and identification of potent cell death inhibitors.
Ischemic Attack, Transient
Effect of transient focal ischemia of mouse brain on energy state and NAD levels: no evidence that NAD depletion plays a major role in secondary disturbances of energy metabolism.
Ischemic Attack, Transient
Ischemic brain injury is mediated by the activation of poly(ADP-ribose)polymerase.
Ischemic Attack, Transient
Role of superoxide in poly(ADP-ribose) polymerase upregulation after transient cerebral ischemia.
Ischemic Stroke
Anti-inflammatory mechanism of taurine against ischemic stroke is related to down-regulation of PARP and NF-?B.
Ischemic Stroke
Baicalein attenuates caspase-independent cells death via inhibiting PARP-1 activation and AIF nuclear translocation in cerebral ischemia/reperfusion rats.
Ischemic Stroke
Chromosomal damage and micronucleus induction by MP-124, a novel poly(ADP-ribose) polymerase-1 (PARP-1) inhibitor: Evidence for a non-DNA-reactive mode of action.
Ischemic Stroke
Climbing STAIRs towards clinical trials with a novel PARP-1 inhibitor for the treatment of ischemic stroke.
Ischemic Stroke
Combined therapy with PJ34, a poly(ADP-ribose)polymerase inhibitor, reduces tissue plasminogen activator-induced hemorrhagic transformations in cerebral ischemia in mice.
Ischemic Stroke
Delayed PARP-1 Inhibition Alleviates Post-stroke Inflammation in Male Versus Female Mice: Differences and Similarities.
Ischemic Stroke
Early Treatment with Poly(ADP-Ribose) Polymerase-1 Inhibitor (JPI-289) Reduces Infarct Volume and Improves Long-Term Behavior in an Animal Model of Ischemic Stroke.
Ischemic Stroke
Effect of 3-aminobenzamide, PARP inhibitor, on matrix metalloproteinase-9 level in plasma and brain of ischemic stroke model.
Ischemic Stroke
Emerging role of PARP-1 and PARthanatos in ischemic stroke.
Ischemic Stroke
Endonuclease G does not play an obligatory role in poly(ADP-ribose) polymerase-dependent cell death after transient focal cerebral ischemia.
Ischemic Stroke
First-in-Human Evaluation of the Safety, Tolerability, and Pharmacokinetics of a Neuroprotective Poly (ADP-ribose) Polymerase-1 Inhibitor, JPI-289, in Healthy Volunteers.
Ischemic Stroke
Ginsenoside Rd blocks AIF mitochondrio-nuclear translocation and NF-?B nuclear accumulation by inhibiting poly(ADP-ribose) polymerase-1 after focal cerebral ischemia in rats.
Ischemic Stroke
Interaction between inducible nitric oxide synthase and poly(ADP-ribose) polymerase in focal ischemic brain injury.
Ischemic Stroke
MP-124, a novel poly(ADP-ribose) polymerase-1 (PARP-1) inhibitor, ameliorates ischemic brain damage in a non-human primate model.
Ischemic Stroke
Neuroprotective effects of a novel Poly (ADP-Ribose) Polymerase-1 inhibitor, JPI-289, in hypoxic rat cortical neurons.
Ischemic Stroke
Neuroprotective effects of ONO-1924H, an inhibitor of poly ADP-ribose polymerase (PARP), on cytotoxicity of PC12 cells and ischemic cerebral damage.
Ischemic Stroke
Nicotinamide prevents NAD+ depletion and protects neurons against excitotoxicity and cerebral ischemia: NAD+ consumption by SIRT1 may endanger energetically compromised neurons.
Ischemic Stroke
Novel insight into circular RNA HECTD1 in astrocyte activation via autophagy by targeting MIR142-TIPARP: implications for cerebral ischemic stroke.
Ischemic Stroke
Pertussis Toxin Ameliorates Microglial Activation Associated With Ischemic Stroke.
Ischemic Stroke
Pertussis toxin reduces calcium influx to protect ischemic stroke in a middle cerebral artery occlusion model.
Ischemic Stroke
Pertussis toxin-induced inflammatory response exacerbates intracerebral haemorrhage and ischaemic stroke in mice.
Ischemic Stroke
Poly(ADP-ribose) polymerase is not involved in the neuroprotection exerted by azithromycin against ischemic stroke in mice.
Ischemic Stroke
Polymorphism of PARP-1 indicates an increased risk and a worse initial severity of ischemic stroke.
Ischemic Stroke
Post-treatment with an inhibitor of poly(ADP-ribose) polymerase attenuates cerebral damage in focal ischemia.
Ischemic Stroke
Regulatory T cells increase after treatment with poly (ADP-ribose) polymerase-1 inhibitor in ischemic stroke patients.
Ischemic Stroke
Repurposing of Clinically Approved Poly-(Adp-Ribose) Polymerase Inhibitors For The Therapy of Sepsis.
Ischemic Stroke
The early immunological response to acute ischemic stroke: Differential gene expression in subpopulations of mononuclear cells.
Ischemic Stroke
The effect of PARP inhibitor on ischaemic cell death, its related inflammation and survival signals.
Ischemic Stroke
[Gender-specific factors of ischemic stroke among atrial fibrillation patients].
Ischemic Stroke
[The epidemiological characteristics and adherence to hypoglycemic agents of ischemic stroke patients with diabetes].
Joint Instability
Genotype-phenotype relationship in a child with 2.3 Mb de novo interstitial 12p13.33-p13.32 deletion.
Keloid
A Selenium-Enriched Ziyang Green Tea Polysaccharide Induces Bax-Dependent Mitochondrial Apoptosis and Inhibits TGF-?1-Stimulated Collagen Expression in Human Keloid Fibroblasts via NG2 Inactivation.
Keloid
PARP1 Inhibition as a Novel Therapeutic Target for Keloid Disease.
Ketosis
Pertussis toxin induces fatty liver, hyperlipemia and ketosis in hamsters.
Kidney Diseases
Poly(ADP-ribose) polymerase (PARP) inhibition counteracts multiple manifestations of kidney disease in long-term streptozotocin-diabetic rat model.
Kidney Failure, Chronic
Accumulation of plasma N-methyl-2-pyridone-5-carboxamide in patients with chronic renal failure.
Kidney Failure, Chronic
Accumulation of poly(ADP-ribose) polymerase inhibitors in children with chronic renal failure.
Kidney Failure, Chronic
PARP inhibition ameliorates nephropathy in an animal model of type 2 diabetes: focus on oxidative stress, inflammation, and fibrosis.
Kidney Failure, Chronic
Poly(ADP-ribose) polymerase 1 accelerates vascular calcification by upregulating Runx2.
Kidney Neoplasms
Development of flexible-heteroarotinoids for kidney cancer.
Kidney Neoplasms
Folliculin deficient renal cancer cells exhibit BRCA1 A complex expression impairment and sensitivity to PARP1 inhibitor olaparib.
Kidney Neoplasms
Glutaminase and poly(ADP-ribose) polymerase inhibitors suppress pyrimidine synthesis and VHL-deficient renal cancers.
Kidney Neoplasms
Histone-dependent PARP-1 inhibitors: A novel therapeutic modality for the treatment of prostate and renal cancers.
Kidney Neoplasms
Long noncoding RNA PVT1 inhibits renal cancer cell apoptosis by up-regulating Mcl-1.
Kidney Neoplasms
MIR494 reduces renal cancer cell survival coinciding with increased lipid droplets and mitochondrial changes.
Kidney Neoplasms
Penta-O-galloyl-?-D-glucose attenuates cisplatin-induced nephrotoxicity via reactive oxygen species reduction in renal epithelial cells and enhances antitumor activity in Caki-2 renal cancer cells.
Labyrinth Diseases
High dose combination pertussis toxin induces autoimmune inner ear disease in Sprague-Dawley rats.
Laryngeal Neoplasms
Reduced poly(ADP-ribosyl)ation in lymphocytes of laryngeal cancer patients: results of a case-control study.
Laryngeal Neoplasms
[Apoptosis mechanism of taxol combined with resveratrol on human laryngeal carcinoma Hep-2 cells].
Leg Ulcer
Redox Profiling Reveals Clear Differences between Molecular Patterns of Wound Fluids from Acute and Chronic Wounds.
Leiomyoma
Enhanced polyadenosine diphosphate-ribosylation in gonadotropin-releasing hormone agonist-treated uterine leiomyoma.
Leiomyoma
Progesterone receptor modulator CDB-2914 down-regulates proliferative cell nuclear antigen and Bcl-2 protein expression and up-regulates caspase-3 and poly(adenosine 5'-diphosphate-ribose) polymerase expression in cultured human uterine leiomyoma cells.
Leiomyoma
Selective progesterone receptor modulator asoprisnil induces endoplasmic reticulum stress in cultured human uterine leiomyoma cells.
Leiomyosarcoma
Genomic Landscape of Uterine Sarcomas Defined Through Prospective Clinical Sequencing.
Leiomyosarcoma
Homologous recombination repair deficiency as a therapeutic target in sarcoma.
Leiomyosarcoma
Novel approaches to treatment of leiomyosarcomas.
Leishmaniasis
Activation of PI3K/Akt signaling has a dominant negative effect on IL-12 production by macrophages infected with Leishmania amazonensis promastigotes.
Leprosy
Effect of inhibitor of poly (ADP-ribose) polymerase in blood lymphocyte cultures of untreated leprosy patients.
Leukemia
A novel synthesized 3', 5'-diprenylated chalcone mediates the proliferation of human leukemia cells by regulating apoptosis and autophagy pathways.
Leukemia
A Phase I study of topotecan, carboplatin and the PARP inhibitor veliparib in acute leukemias, aggressive myeloproliferative neoplasms and chronic myelomonocytic leukemia.
Leukemia
A Regulatory Role for RUNX1, RUNX3 in the Maintenance of Genomic Integrity.
Leukemia
A112, a tamibarotene dimethylaminoethyl ester, may inhibit human leukemia cell growth more potently than tamibarotene.
Leukemia
Activation of caspases and poly (ADP-ribose) polymerase cleavage to induce apoptosis in leukemia HL-60 cells by Inula racemosa.
Leukemia
ALCAPs induce mitochondrial apoptosis and activate DNA damage response by generating ROS and inhibiting topoisomerase I enzyme activity in K562 leukemia cell line.
Leukemia
Anticancer activity of a synthetic peptide derived from harmoniasin, an antibacterial peptide from the ladybug Harmonia axyridis.
Leukemia
Apoptosis and perturbation of cell cycle progression in an acidic environment after hyperthermia.
Leukemia
Apoptosis in leukemia cells is accompanied by alterations in the levels and localization of nucleolin.
Leukemia
Apoptotic Effect of Galbanic Acid via Activation of Caspases and Inhibition of Mcl-1 in H460 Non-Small Lung Carcinoma Cells.
Leukemia
Apoptotic resistance to ionizing radiation in pediatric B-precursor acute lymphoblastic leukemia frequently involves increased NF-kappaB survival pathway signaling.
Leukemia
Augmentation of tumor necrosis factor-alpha-induced monocytic differentiation of a myelomonocytic leukemia (WEHI-3B JCS) by pertussis toxin.
Leukemia
Auraptene Induces Apoptosis via Myeloid Cell Leukemia 1-Mediated Activation of Caspases in PC3 and DU145 Prostate Cancer Cells.
Leukemia
beta-Lapachone (LAPA) Decreases Cell Viability and Telomerase Activity in Leukemia Cells: Suppression of Telomerase Activity by LAPA.
Leukemia
Biochemical pathways of apoptosis: nicotinamide adenine dinucleotide-deficient cells are resistant to tumor necrosis factor or ultraviolet light activation of the 24-kD apoptotic protease and DNA fragmentation.
Leukemia
BRCA1 deficiency and synthetic lethality in leukemias; not only gene mutation matters.
Leukemia
Breaking chemoresistance and radioresistance with [213Bi]anti-CD45 antibodies in leukemia cells.
Leukemia
c-MYC Generates Repair Errors via Increased Transcription of Alternative-NHEJ Factors, LIG3 and PARP1, in Tyrosine Kinase-Activated Leukemias.
Leukemia
Celastrol and an EGCG pro-drug exhibit potent chemosensitizing activity in human leukemia cells.
Leukemia
Cellular and biochemical antileukemic mechanisms of the meroterpenoid Oncocalyxone A.
Leukemia
Characterization of antibodies specific for the caspase cleavage site on poly(ADP-ribose) polymerase: specific detection of apoptotic fragments and mapping of the necrotic fragments of poly(ADP-ribose) polymerase.
Leukemia
Characterization of increased K+ permeability associated with the stimulation of receptors for immunoglobulin E on rat basophilic leukemia cells.
Leukemia
Cladribine in combination with entinostat synergistically elicits anti-proliferative/anti-survival effects on multiple myeloma cells.
Leukemia
Combination of a hypomethylating agent and inhibitors of PARP and HDAC traps PARP1 and DNMT1 to chromatin, acetylates DNA repair proteins, down-regulates NuRD and induces apoptosis in human leukemia and lymphoma cells.
Leukemia
Combination treatment with arsenic trioxide and phytosphingosine enhances apoptotic cell death in arsenic trioxide-resistant cancer cells.
Leukemia
Combinatorial Effects of PARP Inhibitor PJ34 and Histone Deacetylase Inhibitor Vorinostat on Leukemia Cell Lines.
Leukemia
Curcumin Induces Apoptosis in Pre-B Acute Lymphoblastic Leukemia Cell Lines Via PARP-1 Cleavage.
Leukemia
Cytotoxic components from the leaves of Erythrophleum fordii induce human acute leukemia cell apoptosis through caspase 3 activation and PARP cleavage.
Leukemia
Cytotoxic synergy between the multikinase inhibitor sorafenib and the proteasome inhibitor bortezomib in vitro: induction of apoptosis through Akt and c-Jun NH2-terminal kinase pathways.
Leukemia
Cytotoxicity of Gymnopilus purpureosquamulosus extracts on hematologic malignant cells through activation of the SAPK/JNK signaling pathway.
Leukemia
Dietary flavonoids as proteasome inhibitors and apoptosis inducers in human leukemia cells.
Leukemia
Differential responses of proliferative and non-proliferative leukemia cells to oxidative stress.
Leukemia
Down-modulation of poly(ADP-ribose) polymerase-1 (PARP-1) in human TUR leukemia cells restores transcriptional responsiveness for differentiation and cell cycle arrest.
Leukemia
Downregulation of cyclooxygenase-2 expression and activation of caspase-3 are involved in peroxisome proliferator-activated receptor-gamma agonists induced apoptosis in human monocyte leukemia cells in vitro.
Leukemia
Effect of Notch and PARP Pathways' Inhibition in Leukemic Cells.
Leukemia
Eltrombopag modulates reactive oxygen species and decreases acute myeloid leukemia cell survival.
Leukemia
Epicochalasines?A and B: Two Bioactive Merocytochalasans Bearing Caged Epicoccine Dimer Units from Aspergillus flavipes.
Leukemia
Eupatorin-induced cell death in human leukemia cells is dependent on caspases and activates the mitogen-activated protein kinase pathway.
Leukemia
Gene expression and mutation-guided synthetic lethality eradicates proliferating and quiescent leukemia cells.
Leukemia
Histamine receptor-dependent and/or -independent activation of guanine nucleotide-binding proteins by histamine and 2-substituted histamine derivatives in human leukemia (HL-60) and human erythroleukemia (HEL) cells.
Leukemia
Histone deacetylase inhibitors decrease NHEJ both by acetylation of repair factors and trapping of PARP1 at DNA double-strand breaks in chromatin.
Leukemia
Hyperisampsins H-M, Cytotoxic Polycyclic Polyprenylated Acylphloroglucinols from Hypericum sampsonii.
Leukemia
Induction of G2/M phase arrest and apoptosis of human leukemia cells by potent antitumor triazoloacridinone C-1305.
Leukemia
Inhibition of PARP Sensitizes Chondrosarcoma Cell Lines to Chemo- and Radiotherapy Irrespective of the IDH1 or IDH2 Mutation Status.
Leukemia
Inhibition of poly(ADP-ribose) polymerase 1 protects against acute myeloid leukemia by suppressing the myeloproliferative leukemia virus oncogene.
Leukemia
Inhibition of proteasome activity by various fruits and vegetables is associated with cancer cell death.
Leukemia
Inhibition of the mutated c-KIT kinase in AML1-ETO-positive leukemia cells restores sensitivity to PARP inhibitor.
Leukemia
Inhibitors of poly(ADP-ribose) polymerase block nitric oxide-induced apoptosis but not differentiation in human leukemia HL-60 cells.
Leukemia
Interactive effects of histone deacetylase inhibitors and TRAIL on apoptosis in human leukemia cells: involvement of both death receptor and mitochondrial pathways.
Leukemia
Loperamide, an antidiarrheal agent, induces apoptosis and DNA damage in leukemia cells.
Leukemia
Lupane-type triterpenoids from Microtropis fokienensis and Perrottetia arisanensis and the apoptotic effect of 28-hydroxy-3-oxo-lup-20(29)-en-30-al.
Leukemia
Methadone, commonly used as maintenance medication for outpatient treatment of opioid dependence, kills leukemia cells and overcomes chemoresistance.
Leukemia
Methylene chloride fraction of Scutellaria barbata induces apoptosis in human U937 leukemia cells via the mitochondrial signaling pathway.
Leukemia
MiR-181a enhances drug sensitivity of mixed lineage leukemia-rearranged acute myeloid leukemia by increasing poly(ADP-ribose) polymerase1 acetylation.
Leukemia
MLL-AF9 leukemias are sensitive to PARP1 inhibitors combined with cytotoxic drugs.
Leukemia
Modeling and targeting of erythroleukemia by hematopoietic genome editing.
Leukemia
Non-NAD-like PARP1 inhibitor enhanced synthetic lethal effect of NAD-like PARP inhibitors against BRCA1-deficient leukemia.
Leukemia
Novel allosteric PARP1 inhibitors for the treatment of BRCA-deficient leukemia.
Leukemia
Novel deazaflavin tyrosyl-DNA phosphodiesterase 2 (TDP2) inhibitors.
Leukemia
Oleanolic Acid Induces Apoptosis in Human Leukemia Cells through Caspase Activation and Poly(ADP-ribose) Polymerase Cleavage.
Leukemia
Overexpression of poly(ADP-ribose) polymerase promotes cell cycle arrest and inhibits neutrophilic differentiation of NB4 acute promyelocytic leukemia cells.
Leukemia
Paclitaxel induces apoptosis in leukemia cells through a JNK activation-dependent pathway.
Leukemia
PARP goes the weasel! Emerging role of PARP inhibitors in acute leukemias.
Leukemia
PARP inhibitor re?sensitizes Adriamycin resistant leukemia cells through DNA damage and apoptosis.
Leukemia
PARP Inhibitors as Therapeutic Options for Tyrosine Kinase-dependent Leukemia: A Review.
Leukemia
PARP Inhibitors Suppress AML1-ETO- and PML-RAR?-Positive Leukemia.
Leukemia
PARP-1 (Poly[ADP-Ribose] Polymerase 1) Inhibition Protects From Ang II (Angiotensin II)-Induced Abdominal Aortic Aneurysm in Mice.
Leukemia
Peroxynitrite-induced apoptosis involves activation of multiple caspases in HL-60 cells.
Leukemia
Pertussis toxin inhibits activation-induced cell death of human thymocytes, pre-B leukemia cells and monocytes.
Leukemia
Pertussis toxin inhibits differentiation induced by retinoic acid in a human promyelocytic leukemia cell line HL-60.
Leukemia
Pertussis toxin inhibits phospholipase C activation and Ca2+ mobilization by sphingosylphosphorylcholine and galactosylsphingosine in HL60 leukemia cells. Implications of GTP-binding protein-coupled receptors for lysosphingolipids.
Leukemia
Pertussis toxin selectively interferes with the responses of the HL-60 human promyelocytic cell line to dimethylsulfoxide.
Leukemia
Poly (ADP-ribose) polymerase inhibitors selectively induce cytotoxicity in TCF3-HLF-positive leukemic cells.
Leukemia
Poly(ADP-ribose) polymerase 1 promotes transcriptional repression of integrated retroviruses.
Leukemia
Poly(ADP-ribose) polymerase inhibitor ABT-888 potentiates the cytotoxic activity of temozolomide in leukemia cells: influence of mismatch repair status and O6-methylguanine-DNA methyltransferase activity.
Leukemia
Poly(ADP-Ribose) Polymerase Inhibitors for Arsenic Trioxide-Resistant Acute Promyelocytic Leukemia: Synergistic In Vitro Antitumor Effects with Hypomethylating Agents or High-Dose Vitamin C.
Leukemia
Purging effect of dibutyl phthalate on leukemia cells involves fas independent activation of caspase-3/CPP32 protease.
Leukemia
Pyrrolo[1,2-b][1,2,5]benzothiadiazepines (PBTDs) exert their anti-proliferative activity by interfering with Akt-mTOR signaling and bax:bcl-2 ratio modulation in cells from chronic myeloid leukemic patients.
Leukemia
Quercetin induces FasL-related apoptosis, in part, through promotion of histone H3 acetylation in human leukemia HL-60 cells.
Leukemia
Quercetin-induced apoptosis of HL-60 cells by reducing PI3K/Akt.
Leukemia
Resistance-modifying agents. 5. Synthesis and biological properties of quinazolinone inhibitors of the DNA repair enzyme poly(ADP-ribose) polymerase (PARP).
Leukemia
Restoration of TET2 Function Blocks Aberrant Self-Renewal and Leukemia Progression.
Leukemia
Seed Oil of Brucea javanica Induces Apoptotic Death of Acute Myeloid Leukemia Cells via Both the Death Receptors and the Mitochondrial-Related Pathways.
Leukemia
Selective targeting of JAK/STAT signaling is potentiated by Bcl-xL blockade in IL-2-dependent adult T-cell leukemia.
Leukemia
Selenite-induced p53 Ser-15 phosphorylation and caspase-mediated apoptosis in LNCaP human prostate cancer cells.
Leukemia
Sequence-specific binding of poly(ADP-ribose) polymerase-1 to the human T cell leukemia virus type-I tax responsive element.
Leukemia
Stratification of pediatric ALL by in vitro cellular responses to DNA double-strand breaks provides insight into the molecular mechanisms underlying clinical response.
Leukemia
Synergistic anticancer action of reversibly and irreversibly acting ligands of poly (ADP-ribose) polymerase.
Leukemia
Synergistic property of cordycepin in cultivated Cordyceps militaris-mediated apoptosis in human leukemia cells.
Leukemia
Synthesis, biological evaluation and docking studies of 4-amino substituted 1H-pyrazolo[3,4-d]pyrimidines.
Leukemia
Synthetic lethal targeting of oncogenic transcription factors in acute leukemia by PARP inhibitors.
Leukemia
Tanshinone IIA Induces Autophagic Cell Death via Activation of AMPK and ERK and Inhibition of mTOR and p70 S6K in KBM-5 Leukemia Cells.
Leukemia
TET2 and DNMT3A Mutations Exert Divergent Effects on DNA Repair and Sensitivity of Leukemia Cells to PARP Inhibitors.
Leukemia
The combination of the PARP inhibitor rucaparib and 5FU is an effective strategy for treating acute leukemias.
Leukemia
The human formyl peptide receptor as model system for constitutively active G-protein-coupled receptors.
Leukemia
The interleukin 1beta-converting enzyme inhibitor CrmA prevents Apo1/Fas- but not glucocorticoid-induced poly(ADP-ribose) polymerase cleavage and apoptosis in lymphoblastic leukemia cells.
Leukemia
The mechanism of tumor cell clearance by rituximab in vivo in patients with B-cell chronic lymphocytic leukemia: evidence of caspase activation and apoptosis induction.
Leukemia
The Natural Antiangiogenic Compound AD0157 Induces Caspase-Dependent Apoptosis in Human Myeloid Leukemia Cells.
Leukemia
To PARP or not to PARP?-Toward sensitizing acute myeloid leukemia stem cells to immunotherapy.
Leukemia
Tyrosine kinase inhibitor-induced defects in DNA repair sensitize FLT3(ITD)-positive leukemia cells to PARP1 inhibitors.
Leukemia
WK175, a novel antitumor agent, decreases the intracellular nicotinamide adenine dinucleotide concentration and induces the apoptotic cascade in human leukemia cells.
Leukemia
Zephycandidine A, the First Naturally Occurring Imidazo[1,2-f]phenanthridine Alkaloid from Zephyranthes candida, Exhibits Significant Anti-tumor and Anti-acetylcholinesterase Activities.
Leukemia
Zinc is a potent inhibitor of the apoptotic protease, caspase-3. A novel target for zinc in the inhibition of apoptosis.
Leukemia
[Gene Expression Profile of Apoptosis in Leukemia Cells Induced by Hsp90 Selective inhibitor 17-AAG].
Leukemia, Erythroblastic, Acute
A novel synthesized 3', 5'-diprenylated chalcone mediates the proliferation of human leukemia cells by regulating apoptosis and autophagy pathways.
Leukemia, Erythroblastic, Acute
Berberis libanotica extract targets NF-?B/COX-2, PI3K/Akt and mitochondrial/caspase signalling to induce human erythroleukemia cell apoptosis.
Leukemia, Erythroblastic, Acute
Induction of erythroid differentiation of murine erythroleukemia cells by nicotinamide and related compounds.
Leukemia, Erythroblastic, Acute
Mitosis may be an obligatory route to terminal differentiation in the Friend erythroleukemia cell.
Leukemia, Hairy Cell
Cladribine in combination with entinostat synergistically elicits anti-proliferative/anti-survival effects on multiple myeloma cells.
Leukemia, Lymphocytic, Chronic, B-Cell
A subset of chronic lymphocytic leukemia patients display reduced levels of PARP1 expression coupled with a defective irradiation-induced apoptosis.
Leukemia, Lymphocytic, Chronic, B-Cell
Combretastatin-A4 prodrug induces mitotic catastrophe in chronic lymphocytic leukemia cell line independent of caspase activation and poly(ADP-ribose) polymerase cleavage.
Leukemia, Lymphocytic, Chronic, B-Cell
Poly(ADP-ribose) polymerase can bind melphalan damaged DNA.
Leukemia, Lymphocytic, Chronic, B-Cell
Poly(ADP-ribose) polymerase inhibitor CEP-8983 synergizes with bendamustine in chronic lymphocytic leukemia cells in vitro.
Leukemia, Lymphocytic, Chronic, B-Cell
Role of nicotinamide adenine dinucleotide and adenosine triphosphate in glucocorticoid-induced cytotoxicity in susceptible lymphoid cells.
Leukemia, Lymphocytic, Chronic, B-Cell
Two mouse models reveal an actionable PARP1 dependence in aggressive chronic lymphocytic leukemia.
Leukemia, Monocytic, Acute
PARP-1 (Poly[ADP-Ribose] Polymerase 1) Inhibition Protects From Ang II (Angiotensin II)-Induced Abdominal Aortic Aneurysm in Mice.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Apoptotic effects of some tetrahydronaphthalene derivatives on K562 human chronic myelogenous leukemia cell line.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
c-MYC Generates Repair Errors via Increased Transcription of Alternative-NHEJ Factors, LIG3 and PARP1, in Tyrosine Kinase-Activated Leukemias.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Hyaluronic Acid Inhibitor 4-Methylumbelliferone Activates the Intrinsic Apoptosis Pathway in K562 Chronic Myelogenous Leukemia Cells.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
PARP1 inhibitor eliminated imatinib-refractory chronic myeloid leukemia cells in bone marrow microenvironment conditions.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Poly(ADP-ribose) polymerase 1 promotes tumor cell survival by coactivating hypoxia-inducible factor-1-dependent gene expression.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Pyrrolo[1,2-b][1,2,5]benzothiadiazepines (PBTDs) exert their anti-proliferative activity by interfering with Akt-mTOR signaling and bax:bcl-2 ratio modulation in cells from chronic myeloid leukemic patients.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Targeting autophagy potentiates the anti-tumor effect of PARP inhibitor in pediatric chronic myeloid leukemia.
Leukemia, Myeloid
Antinflammatory and anticancer effects of terpenes from oily fractions of Teucruim alopecurus, blocker of I?B? kinase, through downregulation of NF-?B activation, potentiation of apoptosis and suppression of NF-?B-regulated gene expression.
Leukemia, Myeloid
Antiproliferation effects of ponicidin on human myeloid leukemia cells in vitro.
Leukemia, Myeloid
Gi and Gq/11 proteins are involved in dissemination of myeloid leukemia cells to the liver and spleen, whereas bone marrow colonization involves Gq/11 but not Gi.
Leukemia, Myeloid
PARP1 Is Overexpressed in Hematological Malignant Cell Lines: A Framework for Experimental Oncology.
Leukemia, Myeloid
PK11195, an isoquinoline carboxamide ligand of the mitochondrial benzodiazepine receptor, increased drug uptake and facilitated drug-induced apoptosis in human multidrug-resistant leukemia cells in vitro.
Leukemia, Myeloid
Poly(ADP-ribose) polymerase inhibitor-associated myelodysplastic syndrome/acute myeloid leukemia: a pharmacovigilance analysis of the FAERS database.
Leukemia, Myeloid
Poly(ADP-ribose) Polymerase Inhibitors Sensitize Cancer Cells to Death Receptor-mediated Apoptosis by Enhancing Death Receptor Expression.
Leukemia, Myeloid
TET2 Function in Hematopoietic Malignancies, Immune Regulation, and DNA Repair.
Leukemia, Myeloid
[Apoptosis of myeloid leukemia cell line HL60 induced by Bortezomib, a proteasome inhibitor]
Leukemia, Myeloid, Acute
A phase 1 study of the PARP inhibitor veliparib in combination with temozolomide in acute myeloid leukemia.
Leukemia, Myeloid, Acute
BRCA1, PARP1 and ?H2AX in acute myeloid leukemia: Role as biomarkers of response to the PARP inhibitor olaparib.
Leukemia, Myeloid, Acute
Different regulation of PARP1, PARP2, PARP3 and TRPM2 genes expression in acute myeloid leukemia cells.
Leukemia, Myeloid, Acute
Enhancing the Cytotoxic Effects of PARP Inhibitors with DNA Demethylating Agents - A Potential Therapy for Cancer.
Leukemia, Myeloid, Acute
High PARP-1 expression predicts poor survival in acute myeloid leukemia and PARP-1 inhibitor and SAHA-bendamustine hybrid inhibitor combination treatment synergistically enhances anti-tumor effects.
Leukemia, Myeloid, Acute
Inhibition of poly(ADP-ribose) polymerase 1 protects against acute myeloid leukemia by suppressing the myeloproliferative leukemia virus oncogene.
Leukemia, Myeloid, Acute
Inhibitors of poly ADP-ribose polymerase (PARP) induce apoptosis of myeloid leukemic cells: potential for therapy of myeloid leukemia and myelodysplastic syndromes.
Leukemia, Myeloid, Acute
NF?B and Poly (ADP-ribose) Polymerase 1 Form a Positive Feedback Loop that Regulates DNA Repair in Acute Myeloid Leukemia Cells.
Leukemia, Myeloid, Acute
Olaparib for the treatment of epithelial ovarian cancer.
Leukemia, Myeloid, Acute
Omics Technologies to Decipher Regulatory Networks in Granulocytic Cell Differentiation.
Leukemia, Myeloid, Acute
PARP goes the weasel! Emerging role of PARP inhibitors in acute leukemias.
Leukemia, Myeloid, Acute
PARP Inhibitors Suppress AML1-ETO- and PML-RAR?-Positive Leukemia.
Leukemia, Myeloid, Acute
PARP-1 Overexpression as an Independent Prognostic Factor in Adult Non-M3 Acute Myeloid Leukemia.
Leukemia, Myeloid, Acute
PARP-inhibitor-induced synthetic lethality for acute myeloid leukemia treatment.
Leukemia, Myeloid, Acute
Partnering with PARP inhibitors in acute myeloid leukemia with FLT3-ITD.
Leukemia, Myeloid, Acute
Poly (ADP-ribose) polymerase-1 (PARP1) as a therapeutic target in acute myeloid leukemia and myelodysplastic syndrome.
Leukemia, Myeloid, Acute
PRMT5 Regulates DNA Repair by Controlling the Alternative Splicing of Histone-Modifying Enzymes.
Leukemia, Myeloid, Acute
Regulation of the nuclear proteasome activity in myelomonocytic human leukemia cells after adriamycin treatment.
Leukemia, Myeloid, Acute
Synergistic Cytotoxic Effect of Busulfan and the PARP Inhibitor Veliparib in Myeloproliferative Neoplasms.
Leukemia, Myeloid, Acute
The Association between PARP1 and LIG3 Expression Levels and Chromosomal Translocations in Acute Myeloid Leukemia Patients.
Leukemia, Myeloid, Acute
The poly (ADP ribose) polymerase inhibitor niraparib: Management of toxicities.
Leukemia, Myeloid, Acute
The poly(ADP-ribose) polymerase inhibitor olaparib induces up-regulation of death receptors in primary acute myeloid leukemia blasts by NF-?B activation.
Leukemia, Myeloid, Acute
The vascular targeting agent combretastatin-A4 and a novel cis-Restricted {beta}-Lactam Analogue, CA-432, induce apoptosis in human chronic myeloid leukemia cells and ex vivo patient samples including those displaying multidrug resistance.
Leukemia, Myeloid, Acute
To PARP or not to PARP?-Toward sensitizing acute myeloid leukemia stem cells to immunotherapy.
Leukemia, Myelomonocytic, Chronic
A Phase I study of topotecan, carboplatin and the PARP inhibitor veliparib in acute leukemias, aggressive myeloproliferative neoplasms and chronic myelomonocytic leukemia.
Leukemia, Promyelocytic, Acute
Overexpression of poly(ADP-ribose) polymerase promotes cell cycle arrest and inhibits neutrophilic differentiation of NB4 acute promyelocytic leukemia cells.
Leukemia, Promyelocytic, Acute
Poly(ADP-Ribose) Polymerase Inhibitors for Arsenic Trioxide-Resistant Acute Promyelocytic Leukemia: Synergistic In Vitro Antitumor Effects with Hypomethylating Agents or High-Dose Vitamin C.
Leukemia, T-Cell
Fermented wheat germ extract inhibits glycolysis/pentose cycle enzymes and induces apoptosis through poly(ADP-ribose) polymerase activation in Jurkat T-cell leukemia tumor cells.
Leukemia, T-Cell
Identification of poly(ADP-ribose) polymerase as a transcriptional coactivator of the human T-cell leukemia virus type 1 Tax protein.
Leukemia, T-Cell
Sequence-specific binding of poly(ADP-ribose) polymerase-1 to the human T cell leukemia virus type-I tax responsive element.
Leukemia-Lymphoma, Adult T-Cell
Small PARP inhibitor PJ-34 induces cell cycle arrest and apoptosis of adult T-cell leukemia cells.
Leukocytosis
A cocktail of humanized anti-pertussis toxin antibodies limits disease in murine and baboon models of whooping cough.
Leukocytosis
Analysis of the role of Bphs/Hrh1 in the genetic control of responsiveness to pertussis toxin.
Leukocytosis
Collaborative study on test systems to assess toxicity of whole cell pertussis vaccine.
Leukocytosis
Effect of pertussis toxin on susceptibility of infant rats to Haemophilus influenzae type b.
Leukocytosis
Immune response to the B oligomer of pertussis toxin.
Leukocytosis
Neutralization of pertussis toxin by a single antibody prevents clinical pertussis in neonatal baboons.
Leukocytosis
Pertussis Leukocytosis: Mechanisms, Clinical Relevance and Treatment.
Leukocytosis
Pertussis toxin treatment in vivo reduces surface expression of the adhesion integrin leukocyte function antigen-1 (LFA-1).
Leukocytosis
Severe reactions associated with diphtheria-tetanus-pertussis vaccine: detailed study of children with seizures, hypotonic-hyporesponsive episodes, high fevers, and persistent crying.
Leukocytosis
The prevention of severe pertussis and pertussis deaths in young infants.
Leukocytosis
The quantitative analysis of the mechanism involved in pertussis toxin-mediated cell clustering and its implications in the in vitro quality control of diphtheria tetanus and whole cell pertussis vaccines.
Leukoencephalopathies
Neuroprotective potential of erythropoietin and its derivative carbamylated erythropoietin in periventricular leukomalacia.
Leukoencephalopathies
PARP-1 deregulation in multiple sclerosis.
Leukoencephalopathy, Progressive Multifocal
PARP-1 deregulation in multiple sclerosis.
Leukopenia
Pertussis toxin induces bronchopulmonary hyperresponsiveness in guinea-pigs while antagonizing the effects of formyl-L-methionyl-L-leucyl-L-phenylalanine.
Leukoplakia
Recurrent genomic alterations in sequential progressive leukoplakia and oral cancer: drivers of oral tumorigenesis?
Leukostasis
Fulminant pertussis: a multi-center study with new insights into the clinico-pathological mechanisms.
Leukostasis
Peroxynitrite decomposition catalyst, FP15, and poly(ADP-ribose) polymerase inhibitor, PJ34, inhibit leukocyte entrapment in the retinal microcirculation of diabetic rats.
Lewy Body Disease
The expression of PARP, NF-kappa B and parvalbumin is increased in Parkinson disease.
Li-Fraumeni Syndrome
DNA strand break-sensing molecule poly(ADP-Ribose) polymerase cooperates with p53 in telomere function, chromosome stability, and tumor suppression.
Lipid Metabolism Disorders
Inhibition of Poly(ADP-Ribose) Polymerase Increased Lipid Accumulation Through SREBP1 Modulation.
Liposarcoma
Activity of trabectedin and the PARP inhibitor rucaparib in soft-tissue sarcomas.
Liposarcoma
Growth inhibitory effect of quercetin on SW 872 human liposarcoma cells.
Liver Cirrhosis
Baicalin Ameliorates Experimental Liver Cholestasis in Mice by Modulation of Oxidative Stress, Inflammation, and NRF2 Transcription Factor.
Liver Cirrhosis
Poly (ADP-ribose) polymerase-1 is a key mediator of liver inflammation and fibrosis.
Liver Cirrhosis
Puerarin protects against CCl4-induced liver fibrosis in mice: possible role of PARP-1 inhibition.
Liver Diseases
Contribution of type 1 diabetes to rat liver dysfunction and cellular damage via activation of NOS, PARP, IkappaBalpha/NF-kappaB, MAPKs, and mitochondria-dependent pathways: Prophylactic role of arjunolic acid.
Liver Diseases
Metabolic roles of poly(ADP-ribose) polymerases.
Liver Diseases
Oval cells compensate for damage and replicative senescence of mature hepatocytes in mice with fatty liver disease.
Liver Diseases
PARP inhibition protects against alcoholic and non-alcoholic steatohepatitis.
Liver Diseases
PARPs in lipid metabolism and related diseases.
Liver Diseases
Poly (ADP?ribose) polymerase? and cytochrome c?mediated apoptosis induces hepatocyte injury in a rat model of hyperammonia?induced hepatic failure.
Liver Diseases
Poly(ADP-Ribose) Polymerase Inhibitor PJ34 Attenuated Hepatic Triglyceride Accumulation in Alcoholic Fatty Liver Disease in Mice.
Liver Diseases
SQSTM1/p62 activates NFE2L2/NRF2 via ULK1-mediated autophagic KEAP1 degradation and protects mouse liver from lipotoxicity.
Liver Diseases
The impact of the phytotherapeutic agent quercetin on expression of genes and activity of signaling pathways.
Liver Diseases, Alcoholic
PARP inhibition protects against alcoholic and non-alcoholic steatohepatitis.
Liver Failure
Cytosolic phospholipase A(2)? protects against Fas- but not LPS-induced liver injury.
Liver Neoplasms
A novel small molecule inhibits STAT3 phosphorylation and DNA binding activity and exhibits potent growth suppressive activity in human cancer cells.
Liver Neoplasms
Anticancer effect of xanthohumol induces growth inhibition and apoptosis of human liver cancer through NF-?B/p53-apoptosis signaling pathway.
Liver Neoplasms
Autoimmune response to PARP and BRCA1/BRCA2 in cancer.
Liver Neoplasms
Chromatin remodeler ALC1 prevents replication-fork collapse by slowing fork progression.
Liver Neoplasms
Cinchonine activates endoplasmic reticulum stress-induced apoptosis in human liver cancer cells.
Liver Neoplasms
Combination PARP and HDAC inhibition as a therapeutic strategy targeting liver cancer stem cells?
Liver Neoplasms
Comparison of the Phytochemical Properties, Antioxidant Activity and Cytotoxic Effect on HepG2 Cells in Mongolian and Taiwanese Rhubarb Species.
Liver Neoplasms
Direct measurement of protein-protein interactions by FLIM-FRET at UV laser-induced DNA damage sites in living cells.
Liver Neoplasms
Disulfiram combined with copper induces immunosuppression via PD-L1 stabilization in hepatocellular carcinoma.
Liver Neoplasms
Expression of cluster of differentiation-95 and relevant signaling molecules in liver cancer.
Liver Neoplasms
Inhibited effects of veliparib combined doxorubicin for BEL-7404 proliferation of human liver cancer cell line.
Liver Neoplasms
Inhibition of poly (ADP-ribose) polymerase-1 enhances doxorubicin activity against liver cancer cells.
Liver Neoplasms
Interference of Mucin 1 inhibits the growth of liver cancer cells by inducing mitochondria-mediated and death receptor-mediated cell apoptosis.
Liver Neoplasms
Male rats fed methyl- and folate-deficient diets with or without niacin develop hepatic carcinomas associated with decreased tissue NAD concentrations and altered poly(ADP-ribose) polymerase activity.
Liver Neoplasms
PARP inhibition and the radiosensitizing effects of the PARP inhibitor ABT-888 in in vitro hepatocellular carcinoma models.
Liver Neoplasms
PJ34, an inhibitor of PARP-1, suppresses cell growth and enhances the suppressive effects of cisplatin in liver cancer cells.
Liver Neoplasms
Repressing of NHERF1 inhibits liver cancer progression by promoting the production of ROS.
Liver Neoplasms
Synergistic effect of arginine-specific ADP-ribosyltransferase 1 and poly(ADP-ribose) polymerase-1 on apoptosis induced by cisplatin in CT26 cells.
Liver Neoplasms
Synergistic role of Ku80 and poly(ADP-ribose) polymerase in suppressing chromosomal aberrations and liver cancer formation.
Liver Neoplasms
Synergistic suppressive effect of PARP-1 inhibitor PJ34 and HDAC inhibitor SAHA on proliferation of liver cancer cells.
Liver Neoplasms
The chromatin remodeler ALC1 underlies resistance to PARP inhibitor treatment.
Liver Neoplasms
Veliparib overcomes multidrug resistance in liver cancer cells.
Liver Neoplasms
[Overexpression of protein phosphatase 2 regulatory subunit B''? gene effect on proliferation and invasion of hepatoma cells].
Long QT Syndrome
PARP inhibitor-induced torsades de pointes in long QT syndrome: a case report.
Lung Diseases
Poly(ADP-ribosyl)ation in asthma and other lung diseases.
Lung Diseases
Ubiquitin-Specific Protease 14 (USP14) Aggravates Inflammatory Response and Apoptosis of Lung Epithelial Cells in Pneumonia by Modulating Poly (ADP-Ribose) Polymerase-1 (PARP-1).
Lung Diseases
Use of transposon mutants to assess the role of exoenzyme S in chronic pulmonary disease due to Pseudomonas aeruginosa.
Lung Diseases, Interstitial
[Interstitial Pneumonia Caused by Olaparib during Treatment of Breast Cancer-A Case Report].
Lung Injury
Adrenomedullin in inflammatory process associated with experimental pulmonary fibrosis.
Lung Injury
Alteration of pulmonary structure by Pseudomonas aeruginosa exoenzyme S.
Lung Injury
Effects of 5-aminoisoquinolinone, a water-soluble, potent inhibitor of the activity of poly (ADP-ribose) polymerase, in a rodent model of lung injury.
Lung Injury
Excitotoxicity in the lung: N-methyl-D-aspartate-induced, nitric oxide-dependent, pulmonary edema is attenuated by vasoactive intestinal peptide and by inhibitors of poly(ADP-ribose) polymerase.
Lung Injury
Immunotherapy of COVID-19 with poly (ADP-ribose) polymerase inhibitors: starting with nicotinamide.
Lung Injury
Inhibition of poly(ADP-ribose) polymerase attenuates lung tissue damage after hind limb ischemia-reperfusion in rats.
Lung Injury
Inhibition of poly(ADP-ribose) polymerase attenuates the severity of acute pancreatitis and associated lung injury.
Lung Injury
Inhibitors of poly(ADP-ribose) polymerase modulate signal transduction pathways and the development of bleomycin-induced lung injury.
Lung Injury
INO-1001 a novel poly(ADP-ribose) polymerase (PARP) inhibitor improves cardiac and pulmonary function after crystalloid cardioplegia and extracorporal circulation.
Lung Injury
Pharmacological inhibition of poly (ADP-ribose) polymerase by olaparib ameliorates influenza-virus-induced pneumonia in mice.
Lung Injury
Poly(ADP-ribose) polymerase-1 (PARP-1) controls lung cell proliferation and repair after hyperoxia-induced lung damage.
Lung Injury
Poly-ADP-ribose polymerase inhibition provides protection against lung injury in a rat paraquat toxicity model.
Lung Injury
Preexposure to hyperoxia causes increased lung injury and epithelial apoptosis in mice ventilated with high tidal volumes.
Lung Injury
Prolonged poly(ADP-ribose) polymerase-1 activity regulates JP-8-induced sustained cytokine expression in alveolar macrophages.
Lung Injury
Protective effect of orally administered carnosine on bleomycin-induced lung injury.
Lung Injury
Protective effect of polyphenols in an inflammatory process associated with experimental pulmonary fibrosis in mice.
Lung Injury
Pulmonary and renal protection: targeting PARP to ventilator-induced lung and kidney injury?
Lung Injury
Renal hypoperfusion and impaired endothelium-dependent vasodilation in an animal model of VILI: the role of the peroxynitrite-PARP pathway.
Lung Injury
Role of PARP on iNOS pathway during endotoxin-induced acute lung injury.
Lung Injury
Role of poly(ADP-ribose) polymerase activation in the pathogenesis of cardiopulmonary dysfunction in a canine model of cardiopulmonary bypass.
Lung Injury
Therapeutic treatment with poly(ADP-ribose) polymerase inhibitors attenuates the severity of acute pancreatitis and associated liver and lung injury.
Lung Injury
Treatment with 3-aminobenzamide during ex vivo lung perfusion of damaged rat lungs reduces graft injury and dysfunction after transplantation.
Lung Injury
[Acute poisoning by chemical warfare agent: sulfur mustard]
Lung Neoplasms
?-Hydroxyundec-9-enoic acid induces apoptosis through ROS-mediated endoplasmic reticulum stress in non-small cell lung cancer cells.
Lung Neoplasms
A Dose-finding Study Followed by a Phase II Randomized, Placebo-controlled Trial of Chemoradiotherapy With or Without Veliparib in Stage III Non-small-cell Lung Cancer: SWOG 1206 (8811).
Lung Neoplasms
A genetic snapshot of small cell lung cancer.
Lung Neoplasms
A Phase I Dose-Escalation Study of Veliparib Combined with Carboplatin and Etoposide in Patients with Extensive-Stage Small Cell Lung Cancer and Other Solid Tumors.
Lung Neoplasms
A randomized Phase II study of veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in BRCA1/2 metastatic breast cancer: design and rationale.
Lung Neoplasms
A Small Compound KJ-28d Enhances the Sensitivity of Non-Small Cell Lung Cancer to Radio- and Chemotherapy.
Lung Neoplasms
A subset of lung cancer cases shows robust signs of homologous recombination deficiency associated genomic mutational signatures.
Lung Neoplasms
Acquired Resistance of EGFR-Mutated Lung Cancer to Tyrosine Kinase Inhibitor Treatment Promotes PARP Inhibitor Sensitivity.
Lung Neoplasms
Activation of the p38 pathway by a novel monoketone curcumin analog, EF24, suggests a potential combination strategy.
Lung Neoplasms
Activation of the PI3K/mTOR Pathway following PARP Inhibition in Small Cell Lung Cancer.
Lung Neoplasms
Adenosine diphosphate ribosyl transferase responses to a standardized dose of hydrogen peroxide in the mononuclear leukocytes of patients with a diagnosis of cancer.
Lung Neoplasms
Albanol B from Mulberries Exerts Anti-Cancer Effect through Mitochondria ROS Production in Lung Cancer Cells and Suppresses In Vivo Tumor Growth.
Lung Neoplasms
Altered expression profile of apoptosis-related molecules correlated with clinicopathological factors in non-small-cell lung cancer.
Lung Neoplasms
An analysis of the gene interaction networks identifying the role of PARP1 in metastasis of non-small cell lung cancer.
Lung Neoplasms
Anticarcinogenic effects of halofuginone on lung-derived cancer cells.
Lung Neoplasms
Antitumor effect of BPR-DC-2, a novel synthetic cyclic cyanoguanidine derivative, involving the inhibition of MDR-1 expression and down-regulation of p-AKT and PARP-1 in lung cancer.
Lung Neoplasms
APR-246 (PRIMA-1(MET)) strongly synergizes with AZD2281 (olaparib) induced PARP inhibition to induce apoptosis in non-small cell lung cancer cell lines.
Lung Neoplasms
Association of PARP1-specific polymorphisms and haplotypes with non-small cell lung cancer subtypes.
Lung Neoplasms
Association of T2285C polymorphism in PARP1 gene coding region with its expression, activity and NSCLC risk along with prognosis.
Lung Neoplasms
Autoimmune response to PARP and BRCA1/BRCA2 in cancer.
Lung Neoplasms
Base excision repair genes and risk of lung cancer among San Francisco Bay Area Latinos and African-Americans.
Lung Neoplasms
BCL2 Suppresses PARP1 Function and Nonapoptotic Cell Death.
Lung Neoplasms
Beetroot red (betanin) inhibits vinyl carbamate- and benzo(a)pyrene-induced lung tumorigenesis through apoptosis.
Lung Neoplasms
Biological evaluation of 2-arylidene-4, 7-dimethyl indan-1-one (FXY-1): a novel Akt inhibitor with potent activity in lung cancer.
Lung Neoplasms
Blocking c-Met-mediated PARP1 phosphorylation enhances anti-tumor effects of PARP inhibitors.
Lung Neoplasms
Cepharanthine induces apoptosis through reactive oxygen species and mitochondrial dysfunction in human non-small-cell lung cancer cells.
Lung Neoplasms
Characterization of a sulfated galactoglucan from Antrodia cinnamomea and its anticancer mechanism via TGF?/FAK/Slug axis suppression.
Lung Neoplasms
Chromosome 13 poly(ADP-ribose) polymerase polymorphisms and lung cancer risk.
Lung Neoplasms
Clinical significance of NQO1 polymorphism and expression of p53, SOD2, PARP1 in limited-stage small cell lung cancer.
Lung Neoplasms
Combination Olaparib and Temozolomide in Relapsed Small-Cell Lung Cancer.
Lung Neoplasms
Correction to: The dual HDAC-PI3K inhibitor CUDC-907 displays single-agent activity and synergizes with PARP inhibitor olaparib in small cell lung cancer.
Lung Neoplasms
Correlation between PARP-1 Val762Ala polymorphism and the risk of lung cancer in a Chinese population.
Lung Neoplasms
CXCR1/2 antagonism with CXCL8/Interleukin-8 analogue CXCL8(3-72)K11R/G31P restricts lung cancer growth by inhibiting tumor cell proliferation and suppressing angiogenesis.
Lung Neoplasms
Development of novel synthesized phthalazinone-based PARP-1 inhibitors with apoptosis inducing mechanism in lung cancer.
Lung Neoplasms
DNA methyltransferase inhibition enhances apoptosis induced by histone deacetylase inhibitors.
Lung Neoplasms
Downregulation of PARP1 transcription by CDK4/6 inhibitors sensitizes human lung cancer cells to anticancer drug-induced death by impairing OGG1-dependent base excision repair.
Lung Neoplasms
Drug Targeting of Genomic Instability in Multiple Myeloma.
Lung Neoplasms
Dynamic variations in epithelial-to-mesenchymal transition (EMT), ATM, and SLFN11 govern response to PARP inhibitors and cisplatin in small cell lung cancer.
Lung Neoplasms
EGFR-Activating Mutations Correlate with a Fanconi Anemia-like Cellular Phenotype That Includes PARP Inhibitor Sensitivity.
Lung Neoplasms
Ethnic differences in poly(ADP-ribose) polymerase pseudogene genotype distribution and association with lung cancer risk.
Lung Neoplasms
Expression of ERCC1, MSH2 and PARP1 in non-small cell lung cancer and prognostic value in patients treated with platinum-based chemotherapy.
Lung Neoplasms
FLLL12 induces apoptosis in lung cancer cells through a p53/p73-independent but death receptor 5-dependent pathway.
Lung Neoplasms
Fluzoparib increases radiation sensitivity of non-small cell lung cancer (NSCLC) cells without BRCA1/2 mutation, a novel PARP1 inhibitor undergoing clinical trials.
Lung Neoplasms
Folic acid (FA)-conjugated mesoporous silica nanoparticles combined with MRP-1 siRNA improves the suppressive effects of myricetin on non-small cell lung cancer (NSCLC).
Lung Neoplasms
Fucoidan upregulates TLR4/CHOP-mediated caspase-3 and PARP activation to enhance cisplatin-induced cytotoxicity in human lung cancer cells.
Lung Neoplasms
Functional Polymorphisms of Base Excision Repair Genes XRCC1 and APEX1 Predict Risk of Radiation Pneumonitis in Patients with Non-Small Cell Lung Cancer Treated with Definitive Radiation Therapy.
Lung Neoplasms
H2AX a promising biomarker for lung cancer: a review.
Lung Neoplasms
Hypoxia Potentiates the Radiation-Sensitizing Effect of Olaparib in Human Non-Small Cell Lung Cancer Xenografts by Contextual Synthetic Lethality.
Lung Neoplasms
Identification of amentoflavone as a potent highly selective PARP-1 inhibitor and its potentiation on carboplatin in human non-small cell lung cancer.
Lung Neoplasms
Identification of compound CA-5f as a novel late-stage autophagy inhibitor with potent anti-tumor effect against non-small cell lung cancer.
Lung Neoplasms
Identifying new piperazine-based PARP1 inhibitors using text mining and integrated molecular modeling approaches.
Lung Neoplasms
Improved radiosynthesis of 123I-MAPi, an auger theranostic agent.
Lung Neoplasms
Inhibition of ELF3 confers synthetic lethality of PARP inhibitor in non-small cell lung cancer.
Lung Neoplasms
Inhibition of poly(ADP-ribose) polymerase (PARP) induces apoptosis in lung cancer cell lines.
Lung Neoplasms
Inhibition of poly(ADP-ribose) polymerase enhances cell death and improves tumor growth delay in irradiated lung cancer models.
Lung Neoplasms
Inhibition of STAT3 signaling induces apoptosis and suppresses growth of lung cancer: good and bad.
Lung Neoplasms
JASPER: Phase 2 trial of first-line niraparib plus pembrolizumab in patients with advanced non-small cell lung cancer.
Lung Neoplasms
Kinesin light chain-4 depletion induces apoptosis of radioresistant cancer cells by mitochondrial dysfunction via calcium ion influx.
Lung Neoplasms
MicroRNA-224 is implicated in lung cancer pathogenesis through targeting caspase-3 and caspase-7.
Lung Neoplasms
Miltirone-induced apoptosis in cisplatin-resistant lung cancer cells through upregulation of p53 signaling pathways.
Lung Neoplasms
MiR-205 and miR-218 expression is associated with carboplatin chemoresistance and regulation of apoptosis via Mcl-1 and Survivin in lung cancer cells.
Lung Neoplasms
MiR-335 regulates the chemo-radioresistance of small cell lung cancer cells by targeting PARP-1.
Lung Neoplasms
MiR-7-5p-mediated downregulation of PARP1 impacts DNA homologous recombination repair and resistance to doxorubicin in small cell lung cancer.
Lung Neoplasms
Molecular mechanism of Antrodia cinnamomea sulfated polysaccharide on the suppression of lung cancer cell growth and migration via induction of transforming growth factor ? receptor degradation.
Lung Neoplasms
MSH2/BRCA1 expression as a DNA-repair signature predicting survival in early-stage lung cancer patients from the IFCT-0002 Phase 3 Trial.
Lung Neoplasms
Nanoemulsion-Based Delivery of Fluorescent PARP Inhibitors in Mouse Models of Small Cell Lung Cancer.
Lung Neoplasms
Nanopharmaceutical Approach for Enhanced Anti-cancer Activity of Betulinic Acid in Lung-cancer Treatment via Activation of PARP: Interaction with DNA as a Target: -Anti-cancer Potential of Nano-betulinic Acid in Lung Cancer.
Lung Neoplasms
Negative prognostic value of high levels of intracellular poly(ADP-ribose) in non-small cell lung cancer.
Lung Neoplasms
New Approaches of PARP-1 Inhibitors in Human Lung Cancer Cells and Cancer Stem-Like Cells by Some Selected Anthraquinone-Derived Small Molecules.
Lung Neoplasms
No association between haplotypes of three variants (codon 81, 284, and 762) in poly(ADP-ribose) polymerase gene and risk of primary lung cancer.
Lung Neoplasms
Non-small and small cell lung carcinoma cell lines exhibit cell type-specific sensitivity to edelfosine-induced cell death and different cell line-specific responses to edelfosine treatment.
Lung Neoplasms
Non-small cell lung cancer cells with deficiencies in homologous recombination genes are sensitive to PARP inhibitors.
Lung Neoplasms
Novel targeted strategies to overcome resistance in small-cell lung cancer: focus on PARP inhibitors and rovalpituzumab tesirine.
Lung Neoplasms
NSCLC Mutated Isoforms of CCDC6 Affect the Intracellular Distribution of the Wild Type Protein Promoting Cisplatinum Resistance and PARP Inhibitors Sensitivity in Lung Cancer Cells.
Lung Neoplasms
Oncolytic newcastle disease virus triggers cell death of lung cancer spheroids and is enhanced by pharmacological inhibition of autophagy.
Lung Neoplasms
P-glycoprotein-independent apoptosis induction by a novel synthetic compound, MMPT [5-[(4-methylphenyl)methylene]-2-(phenylamino)-4(5H)-thiazolone].
Lung Neoplasms
PARP inhibition enhances tumor cell-intrinsic immunity in ERCC1-deficient non-small cell lung cancer.
Lung Neoplasms
PARP inhibition induces BAX/BAK-independent synthetic lethality of BRCA1-deficient non-small cell lung cancer.
Lung Neoplasms
PARP inhibition selectively increases sensitivity to cisplatin in ERCC1-low non-small cell lung cancer cells.
Lung Neoplasms
PARP Inhibition Suppresses Growth of EGFR-Mutant Cancers by Targeting Nuclear PKM2.
Lung Neoplasms
PARP inhibitor activates the intrinsic pathway of apoptosis in primary lung cancer cells.
Lung Neoplasms
PARP Inhibitor Activity Correlates with SLFN11 Expression and Demonstrates Synergy with Temozolomide in Small Cell Lung Cancer.
Lung Neoplasms
PARP inhibitor niraparib as a radiosensitizer promotes antitumor immunity of radiotherapy in EGFR-mutated non-small cell lung cancer.
Lung Neoplasms
PARP inhibitors for small cell lung cancer and their potential for integration into current treatment approaches.
Lung Neoplasms
PARP inhibitors in lung cancer.
Lung Neoplasms
PARP Inhibitors in Small-Cell Lung Cancer: Rational Combinations to Improve Responses.
Lung Neoplasms
PARP inhibitors synergize with gemcitabine by potentiating DNA damage in non-small-cell lung cancer.
Lung Neoplasms
PARP inhibitors: an interesting pathway also for Non-Small Cell Lung Cancer?
Lung Neoplasms
PARP Inhibitors: Extending Benefit Beyond BRCA Mutant Cancers.
Lung Neoplasms
PARP-1 induces EMT in non-small cell lung carcinoma cells via modulating the transcription factors Smad4, p65 and ZEB1.
Lung Neoplasms
PARP-1 rs3219073 polymorphism may contribute to susceptibility to lung cancer.
Lung Neoplasms
PARP1 enhances lung adenocarcinoma metastasis by novel mechanisms independent of DNA repair.
Lung Neoplasms
PARP1 impact on DNA repair of platinum adducts: Preclinical and clinical read-outs.
Lung Neoplasms
PARP1 Inhibitors: antitumor drug design.
Lung Neoplasms
PARP1 Is Up-Regulated in Non-small Cell Lung Cancer Tissues in the Presence of the Cyanobacterial Toxin Microcystin.
Lung Neoplasms
Participation of poly(ADP-ribose) polymerase in the drug sensitivity in human lung cancer cell lines.
Lung Neoplasms
Pelargonium quercetorum Agnew induces apoptosis without PARP or cytokeratin 18 cleavage in non-small cell lung cancer cell lines.
Lung Neoplasms
Phase I and Pharmacologic Study of Olaparib in Combination with High-dose Radiotherapy with and without Concurrent Cisplatin for Non-Small Cell Lung Cancer.
Lung Neoplasms
Phosphorylation of the Cytoskeletal Protein CAP1 Regulates Non-Small Cell Lung Cancer Survival and Proliferation by GSK3?.
Lung Neoplasms
Photoluminescent And Self-Assembled Hyaluronic Acid-Zinc Oxide-Ginsenoside Rh2 Nanoparticles And Their Potential Caspase-9 Apoptotic Mechanism Towards Cancer Cell Lines.
Lung Neoplasms
Phoyunnanin E Induces Apoptosis of Non-small Cell Lung Cancer Cells via p53 Activation and Down-regulation of Survivin.
Lung Neoplasms
Poly (ADP-ribose) polymerase 3 (PARP3), a potential repressor of telomerase activity.
Lung Neoplasms
Poly(ADP-ribose) Polymerase Inhibitors Sensitize Cancer Cells to Death Receptor-mediated Apoptosis by Enhancing Death Receptor Expression.
Lung Neoplasms
Poly(ADP-ribose) polymerase-1 regulates vimentin expression in lung cancer cells.
Lung Neoplasms
Polymorphisms in DNA base excision repair genes ADPRT and XRCC1 and risk of lung cancer.
Lung Neoplasms
Preliminary evaluation of a novel 18F-labeled PARP-1 ligand for PET imaging of PARP-1 expression in prostate cancer.
Lung Neoplasms
Proteomic markers of DNA repair and PI3K pathway activation predict response to the PARP inhibitor BMN 673 in small cell lung cancer.
Lung Neoplasms
Proteomic Profiling Identifies Dysregulated Pathways in Small Cell Lung Cancer and Novel Therapeutic Targets Including PARP1.
Lung Neoplasms
Purpurin, a anthraquinone induces ROS-mediated A549 lung cancer cell apoptosis via inhibition of PI3K/AKT and proliferation.
Lung Neoplasms
Putative tumor suppressor Lats2 induces apoptosis through downregulation of Bcl-2 and Bcl-x(L).
Lung Neoplasms
Radiosensitizing Potential of Curcumin in Different Cancer Models.
Lung Neoplasms
Radiosynthesis of 3 H- and 14 C-labeled Veliparib.
Lung Neoplasms
Randomized, Double-Blind, Phase II Study of Temozolomide in Combination With Either Veliparib or Placebo in Patients With Relapsed-Sensitive or Refractory Small-Cell Lung Cancer.
Lung Neoplasms
Rapamycin sensitizes cancer cells to growth inhibition by the PARP inhibitor olaparib.
Lung Neoplasms
Reduction of metastatic potential by inhibiting EGFR/Akt/p38/ERK signaling pathway and epithelial-mesenchymal transition after carbon ion exposure is potentiated by PARP-1 inhibition in non-small-cell lung cancer.
Lung Neoplasms
Replication-dependent ?-H2AX formation is involved in docetaxel-induced apoptosis in NSCLC A549 cells.
Lung Neoplasms
Retraction Note to: Correlation between PARP-1 Val762Ala polymorphism and the risk of lung cancer in a Chinese population.
Lung Neoplasms
Revealing biomarkers associated with PARP inhibitors based on genetic interactions in cancer genome.
Lung Neoplasms
Silencing tankyrase and telomerase promotes A549 human lung adenocarcinoma cell apoptosis and inhibits proliferation.
Lung Neoplasms
Smoking History Predicts Sensitivity to PARP Inhibitor Veliparib in Patients with Advanced Non-Small Cell Lung Cancer: Methodological Issues.
Lung Neoplasms
Smoking History Predicts Sensitivity to PARP Inhibitor Veliparib in Patients with Advanced Non-Small Cell Lung Cancer.
Lung Neoplasms
Stimulatory heterotrimeric G protein augments gamma ray-induced apoptosis by up-regulation of Bak expression via CREB and AP-1 in H1299 human lung cancer cells.
Lung Neoplasms
Suppression of NF-?B signaling and P-glycoprotein function by gambogic acid synergistically potentiates adriamycin -induced apoptosis in lung cancer.
Lung Neoplasms
Synergistic anticancer action of reversibly and irreversibly acting ligands of poly (ADP-ribose) polymerase.
Lung Neoplasms
Synergistic effect of fenretinide and curcumin for treatment of non-small cell lung cancer.
Lung Neoplasms
Synergistic Effect of Olaparib with Combination of Cisplatin on PTEN-Deficient Lung Cancer Cells.
Lung Neoplasms
Synergistic effects of type I PRMT and PARP inhibitors against non-small cell lung cancer cells.
Lung Neoplasms
Synergistic interaction between cisplatin and PARP inhibitors in non-small cell lung cancer.
Lung Neoplasms
Synergy between the NAMPT inhibitor GMX1777(8) and pemetrexed in non-small cell lung cancer cells is mediated by PARP activation and enhanced NAD consumption.
Lung Neoplasms
Tankyrase 1 polymorphism associated with an increased risk in developing non-small cell lung cancer in a Chinese population: a proof-of-principle study.
Lung Neoplasms
Tankyrase 2 (TNKS2) polymorphism associated with risk in developing non-small cell lung cancer in a Chinese population.
Lung Neoplasms
Target engagement imaging of PARP inhibitors in small-cell lung cancer.
Lung Neoplasms
Temozolomide plus PARP Inhibition in Small-Cell Lung Cancer: Could Patient-Derived Xenografts Accelerate Discovery of Biomarker Candidates?
Lung Neoplasms
Tetrandrine suppresses lung cancer growth and induces apoptosis, potentially via the VEGF/HIF-1?/ICAM-1 signaling pathway.
Lung Neoplasms
The Combination of the PARP Inhibitor Olaparib and the WEE1 Inhibitor AZD1775 as a New Therapeutic Option for Small Cell Lung Cancer.
Lung Neoplasms
The dual HDAC-PI3K inhibitor CUDC-907 displays single-agent activity and synergizes with PARP inhibitor olaparib in small cell lung cancer.
Lung Neoplasms
The MYC Paralog-PARP1 Axis as a Potential Therapeutic Target in MYC Paralog-Activated Small Cell Lung Cancer.
Lung Neoplasms
The non-canonical target PARP16 contributes to polypharmacology of the PARP inhibitor talazoparib and its synergy with WEE1 inhibitors.
Lung Neoplasms
Triptolide suppresses the in vitro and in vivo growth of lung cancer cells by targeting hyaluronan-CD44/RHAMM signaling.
Lung Neoplasms
Tumor suppressor in lung cancer-1 (TSLC1) mediated by dual-regulated oncolytic adenovirus exerts specific antitumor actions in a mouse model.
Lung Neoplasms
Uncovering synthetic lethal interactions for therapeutic targets and predictive markers in lung adenocarcinoma.
Lung Neoplasms
Unveiling the mechanistic roles of chlorine substituted phthalazinone-based compounds containing chlorophenyl moiety towards the differential inhibition of poly (ADP-ribose) polymerase-1 in the treatment of lung cancer.
Lung Neoplasms
Veliparib in Combination with Carboplatin and Etoposide in Patients with Treatment-Naïve Extensive-Stage Small Cell Lung Cancer: A Phase 2 Randomized Study.
Lung Neoplasms
Voies de réparation de l'ADN et cancers bronchiques non à petites cellules : perspectives cliniques.
Lung Neoplasms
WITHDRAWN: An analysis of the gene interaction networks identifying the role of PARP1 in metastasis of non-small cell lung cancer.
Lung Neoplasms
XPO1 inhibition synergizes with PARP1 inhibition in small cell lung cancer by targeting nuclear transport of FOXO3a.
Lung Neoplasms
XRN2 interactome reveals its synthetic lethal relationship with PARP1 inhibition.
Lung Neoplasms
[Distribution of poly(ADP-ribose) polymerase pseudogene polymorphism and association with susceptibility to lung cancer in Chinese people]
Lupus Erythematosus, Systemic
Altered autoantigen structure in Sjögren's syndrome: implications for the pathogenesis of autoimmune tissue damage.
Lupus Erythematosus, Systemic
Association of poly(ADP-ribose) polymerase 1 and a novel candidate locus, LOC127086, with systemic lupus erythematosus.
Lupus Erythematosus, Systemic
Autoantibodies reacting with poly(ADP-ribose) and with a zinc-finger functional domain of poly(ADP-ribose) polymerase involved in the recognition of damaged DNA.
Lupus Erythematosus, Systemic
Constitutive abnormal expression of RasGRP-1 isoforms and low expression of PARP-1 in patients with systemic lupus erythematosus.
Lupus Erythematosus, Systemic
Identification of autoantibody against poly (ADP-ribose) polymerase (PARP) fragment as a serological marker in systemic lupus erythematosus.
Lupus Erythematosus, Systemic
MiR-199-3p promotes ERK-mediated IL-10 production by targeting poly (ADP-ribose) Polymerase-1 in patients with systemic lupus erythematosus.
Lupus Erythematosus, Systemic
PARP activity and NAD concentration in PMC from patients affected by systemic sclerosis and lupus erythematosus.
Lupus Erythematosus, Systemic
PARP alleles within the linked chromosomal region are associated with systemic lupus erythematosus.
Lupus Erythematosus, Systemic
Poly(ADP-ribose) polymerase (PARP) polymorphisms associated with nephritis and arthritis in systemic lupus erythematosus.
Lupus Erythematosus, Systemic
Poly(ADP-ribose) polymerase activity in systemic lupus erythematosis and systemic sclerosis.
Lupus Erythematosus, Systemic
Poly(ADP-ribose) polymerase alleles in French Caucasians are associated neither with lupus nor with primary antiphospholipid syndrome. GRAID Research Group. Group for Research on Auto-Immune Disorders.
Lupus Erythematosus, Systemic
Poly(ADP-ribose) polymerase polymorphisms are not a genetic risk factor for systemic lupus erythematosus in German Caucasians.
Lymphangioleiomyomatosis
Rapamycin-resistant PARP1 overexpression is a potential therapeutic target in lymphangioleiomyomatosis (LAM).
Lymphatic Metastasis
Analysis of molecular markers as predictive factors of lymph node involvement in breast carcinoma.
Lymphatic Metastasis
Down-regulation of Notch receptor signaling pathway induces caspase-dependent and caspase-independent apoptosis in lung squamous cell carcinoma cells.
Lymphatic Metastasis
ERCC1, PARP-1, and AQP1 as predictive biomarkers in colon cancer patients receiving adjuvant chemotherapy.
Lymphatic Metastasis
High PARP-1 expression is associated with tumor invasion and poor prognosis in gastric cancer.
Lymphatic Metastasis
Lymph Node Metastasis of Gastric Cancer Is Associated with the Interaction Between Poly (ADP-Ribose) Polymerase 1 and Matrix Metallopeptidase 2.
Lymphatic Metastasis
PARP-1 may be involved in angiogenesis in epithelial ovarian cancer.
Lymphocytosis
A novel bivalent acellular pertussis vaccine based on the 69 kDa protein and FHA.
Lymphocytosis
Antitoxin in human pertussis immune globulins.
Lymphocytosis
Bacterial toxins affect early events of T lymphocyte activation.
Lymphocytosis
Caffeine to prevent respiratory failure and improve outcome in infant pertussis.
Lymphocytosis
Clinical reactions and immunogenicity of the BIKEN acellular diphtheria and tetanus toxoids and pertussis vaccine in 4- through 6-year-old US children.
Lymphocytosis
Effects of dexamethasone and indomethacin on the vascular beta 2-adrenolytic action of pertussis toxin in rats; a prostaglandin-mediated phenomenon.
Lymphocytosis
Infection of newborn piglets with Bordetella pertussis: a new model for pertussis.
Lymphocytosis
Inhibition of lymphocyte circulation in mice by pertussis toxin.
Lymphocytosis
Marked increase in L-selectin-negative T cells in neonatal pertussis. The lymphocytosis explained?
Lymphocytosis
Molecular mechanisms of lymphocyte extravasation. III. The loss of lymphocyte extravasation potential induced by pertussis toxin is not mediated via the activation of protein kinase C.
Lymphocytosis
Pertussis toxin induces lymphocytosis in rhesus macaques.
Lymphocytosis
Pertussis toxin treatment in vivo reduces surface expression of the adhesion integrin leukocyte function antigen-1 (LFA-1).
Lymphocytosis
Reovirus transport--studies using lymphocytosis promoting factor.
Lymphocytosis
Severe reactions associated with diphtheria-tetanus-pertussis vaccine: detailed study of children with seizures, hypotonic-hyporesponsive episodes, high fevers, and persistent crying.
Lymphocytosis
Studies on the lymphocytosis induced by pertussis toxin.
Lymphocytosis
The lymphocytosis promoting action of pertussis toxin can be mimicked in vitro. Holotoxin but not the B subunit inhibits invasion of human T lymphoma cells through fibroblast monolayers.
Lymphocytosis
The lymphocytosis-promoting agent pertussis toxin affects virus burden and lymphocyte distribution in the SIV-infected rhesus macaque.
Lymphocytosis
The prevention of severe pertussis and pertussis deaths in young infants.
Lymphoma
3,5,7-Substituted Pyrazolo[4,3- d]pyrimidine Inhibitors of Cyclin-Dependent Kinases and Their Evaluation in Lymphoma Models.
Lymphoma
A multi-centre phase I trial of the PARP inhibitor olaparib in patients with relapsed chronic lymphocytic leukaemia, T-prolymphocytic leukaemia or mantle cell lymphoma.
Lymphoma
A polysaccharide from the fruiting bodies of Agaricus blazei Murill induces caspase-dependent apoptosis in human leukemia HL-60 cells.
Lymphoma
A role of intracellular mono-ADP-ribosylation in cancer biology.
Lymphoma
Amplification of cyclic AMP generation reveals agonistic effects of certain beta-adrenergic antagonists.
Lymphoma
An hour after immunization peritoneal B-1 cells are activated to migrate to lymphoid organs where within 1 day they produce IgM antibodies that initiate elicitation of contact sensitivity.
Lymphoma
Antrodia salmonea induces apoptosis and enhances cytoprotective autophagy in colon cancer cells.
Lymphoma
Antrodia salmonea-induced oxidative stress abrogates HER-2 signaling cascade and enhanced apoptosis in ovarian carcinoma cells.
Lymphoma
Apoptolidin, a selective cytotoxic agent, is an inhibitor of F0F1-ATPase.
Lymphoma
Apoptosis in the absence of cytochrome c accumulation in the cytosol.
Lymphoma
Assessment of diarrhea as side effect of oral targeted antineoplastic agents in clinical practice.
Lymphoma
ATM deficiency sensitizes mantle cell lymphoma cells to poly(ADP-ribose) polymerase-1 inhibitors.
Lymphoma
B-aggressive lymphoma family proteins have unique domains that modulate transcription and exhibit poly(ADP-ribose) polymerase activity.
Lymphoma
Characterization of the human FLICE-inhibitory protein locus and comparison of the anti-apoptotic activity of four different flip isoforms.
Lymphoma
Chk2 deficiency in Myc overexpressing lymphoma cells elicits a synergistic lethal response in combination with PARP inhibition.
Lymphoma
Chlorophyllin e6?mediated photodynamic therapy inhibits proliferation and induces apoptosis in human bladder cancer cells.
Lymphoma
Combination of a hypomethylating agent and inhibitors of PARP and HDAC traps PARP1 and DNMT1 to chromatin, acetylates DNA repair proteins, down-regulates NuRD and induces apoptosis in human leukemia and lymphoma cells.
Lymphoma
Combined loss of p21(waf1/cip1) and p27(kip1) enhances tumorigenesis in mice.
Lymphoma
Correlation of poly(ADP-ribose)polymerase and p53 expression levels in high-grade lymphomas.
Lymphoma
Curcumin sensitizes lymphoma cells to DNA damage agents through regulating Rad51-dependent homologous recombination.
Lymphoma
Cytotoxicity of Gymnopilus purpureosquamulosus extracts on hematologic malignant cells through activation of the SAPK/JNK signaling pathway.
Lymphoma
Dimethyl sulfoxide activates tumor necrosis factor?-p53 mediated apoptosis and down regulates d-fructose-6-phosphate-2-kinase and lactate dehydrogenase-5 in Dalton's lymphoma in vivo.
Lymphoma
Dual effects of pertussis toxin on in vitro invasive behavior of metastatic lymphoma variants.
Lymphoma
Effect of 6(5H)-phenanthridinone, an inhibitor of poly(ADP-ribose) polymerase, on cultured tumor cells.
Lymphoma
Effect of Shuangdan Mingmu capsule, a Chinese herbal formula, on oxidative stress-induced apoptosis of pericytes through PARP/GAPDH pathway.
Lymphoma
Enhanced cytotoxicity of PARP inhibition in mantle cell lymphoma harbouring mutations in both ATM and p53.
Lymphoma
FADD expression and caspase activation in B-cell lymphomas resistant to Fas-mediated apoptosis.
Lymphoma
Gi and Gq/11 proteins are involved in dissemination of myeloid leukemia cells to the liver and spleen, whereas bone marrow colonization involves Gq/11 but not Gi.
Lymphoma
Glycolytic rate and lymphomagenesis depend on PARP14, an ADP ribosyltransferase of the B aggressive lymphoma (BAL) family.
Lymphoma
Granzyme B leakage-induced apoptosis is a crucial mechanism of cell death in nasal-type NK/T-cell lymphoma.
Lymphoma
HMG-CoA reductase inhibitors induce apoptosis of lymphoma cells by promoting ROS generation and regulating Akt, Erk and p38 signals via suppression of mevalonate pathway.
Lymphoma
Immunohistochemical detection of poly(ADP-ribose) polymerase inhibition by ABT-888 in patients with refractory solid tumors and lymphomas.
Lymphoma
Inhibition of cytochrome P450 2J2 by tanshinone IIA induces apoptotic cell death in hepatocellular carcinoma HepG2 cells.
Lymphoma
Inhibition of lymphoma invasion and liver metastasis formation by pertussis toxin.
Lymphoma
Inhibition of poly(ADP-ribose) polymerase (PARP) and ataxia telangiectasia mutated (ATM) on the chemosensitivity of mantle cell lymphoma to agents that induce DNA strand breaks.
Lymphoma
Inhibitors of poly(ADP-ribose) polymerase increase antibody class switching.
Lymphoma
Interactions between a lymphoma membrane-associated guanosine 5'-triphosphate-binding protein and the cytoskeleton during receptor patching and capping.
Lymphoma
Leukemic non-nodal mantle cell lymphomas have a distinct phenotype and are associated with deletion of PARP1 and 13q14.
Lymphoma
Ligation of CD40 potentiates Fas-mediated activation of the cysteine protease CPP32, cleavage of its death substrate PARP, and apoptosis in Ramos-Burkitt lymphoma B cells.
Lymphoma
Ligation of CD40 rescues Ramos-Burkitt lymphoma B cells from calcium ionophore- and antigen receptor-triggered apoptosis by inhibiting activation of the cysteine protease CPP32/Yama and cleavage of its substrate PARP.
Lymphoma
Linarin sensitizes tumor necrosis factor-related apoptosis (TRAIL)-induced ligand-triggered apoptosis in human glioma cells and in xenograft nude mice.
Lymphoma
Low ATM protein expression and depletion of p53 correlates with olaparib sensitivity in gastric cancer cell lines.
Lymphoma
Mechanism of pertussis toxin action on the adenylate cyclase system. Inhibition of the turn-on reaction of the inhibitory regulatory site.
Lymphoma
Modulation of prolactin-stimulated Nb2 lymphoma cell mitogenesis by cholera toxin and pertussis toxin.
Lymphoma
Modulation of pyridyl cyanoguanidine (CHS 828) induced cytotoxicity by 3-aminobenzamide in U-937 GTB cells.
Lymphoma
Modulation of the antiproliferative activity of anticancer drugs in hematopoietic tumor cell lines by the poly(ADP-ribose) polymerase inhibitor 6(5H)-phenanthridinone.
Lymphoma
Motexafin gadolinium induces mitochondrially-mediated caspase-dependent apoptosis.
Lymphoma
Novel deazaflavin tyrosyl-DNA phosphodiesterase 2 (TDP2) inhibitors.
Lymphoma
Novel targeted therapeutics: inhibitors of MDM2, ALK and PARP.
Lymphoma
PARP activation promotes nuclear AID accumulation in lymphoma cells.
Lymphoma
PARP1 and DNA-PKcs synergize to suppress p53 mutation and telomere fusions during T-lineage lymphomagenesis.
Lymphoma
PARP1 expression in mantle cell lymphoma: the utility of PARP1 immunohistochemistry and its relationship with markers of DNA damage.
Lymphoma
PARP1-TDP1 coupling for the repair of topoisomerase I-induced DNA damage.
Lymphoma
PARP9 is overexpressed in human breast cancer and promotes cancer cell migration.
Lymphoma
Pertussis toxin B-subunit-induced Ca2(+)-fluxes in Jurkat human lymphoma cells: the action of long-term pre-treatment with cholera and pertussis holotoxins.
Lymphoma
Pertussis toxin catalyzes the ADP-ribosylation of two distinct peptides, 40 and 41 kDa, in rat fat cell membranes.
Lymphoma
Pertussis toxin inhibition of B cell and macrophage responses to bacterial lipopolysaccharide.
Lymphoma
Phase I Study of PARP Inhibitor ABT-888 in Combination with Topotecan in Adults with Refractory Solid Tumors and Lymphomas.
Lymphoma
Poly(ADP-ribose) polymerase inhibitors combined with external beam and radioimmunotherapy to treat aggressive lymphoma.
Lymphoma
Quercetin-3-O-(2?-galloyl)-?-L-rhamnopyranoside attenuates cholesterol oxidation product-induced apoptosis by suppressing NF-?B-mediated cell death process in differentiated PC12 cells.
Lymphoma
Rationale for PARP inhibitors in combination therapy with camptothecins or temozolomide based on PARP trapping versus catalytic inhibition.
Lymphoma
Resveratrol inhibits proliferation and migration through SIRT1 mediated post?translational modification of PI3K/AKT signaling in hepatocellular carcinoma cells.
Lymphoma
Robust immunoglobulin class switch recombination and end joining in Parp9-deficient mice.
Lymphoma
Role of nicotinamide adenine dinucleotide and adenosine triphosphate in glucocorticoid-induced cytotoxicity in susceptible lymphoid cells.
Lymphoma
Systemic administration of GPI 15427, a novel poly(ADP-ribose) polymerase-1 inhibitor, increases the antitumor activity of temozolomide against intracranial melanoma, glioma, lymphoma.
Lymphoma
The chemokine receptor CXCR4 is required for outgrowth of colon carcinoma micrometastases.
Lymphoma
The Effects of 5,6,7,8,3',4'-Hexamethoxyflavone on Apoptosis of Cultured Human Choriocarcinoma Trophoblast Cells.
Lymphoma
The effects of benzamide ADP-ribosyl transferase inhibitors on cell survival and DNA strand-break repair in irradiated mammalian cells.
Lymphoma
The In Vitro and In Vivo Anticancer Properties of Chalcone Flavokawain B through Induction of ROS-Mediated Apoptotic and Autophagic Cell Death in Human Melanoma Cells.
Lymphoma
The lymphocytosis promoting action of pertussis toxin can be mimicked in vitro. Holotoxin but not the B subunit inhibits invasion of human T lymphoma cells through fibroblast monolayers.
Lymphoma
The PARP inhibitor olaparib enhances the cytotoxicity of combined gemcitabine, busulfan and melphalan in lymphoma cells.
Lymphoma
Triptonide acts as a novel potent anti-lymphoma agent with low toxicity mainly through inhibition of proto-oncogene Lyn transcription and suppression of Lyn signal pathway.
Lymphoma, B-Cell
3,5-Diethoxy-3'-Hydroxyresveratrol (DEHR) Ameliorates Liver Fibrosis via Caveolin-1 Activation in Hepatic Stellate Cells and in a Mouse Model of Bile Duct Ligation Injury.
Lymphoma, B-Cell
A diphenyl diselenide-supplemented diet and swimming exercise promote neuroprotection, reduced cell apoptosis and glial cell activation in the hypothalamus of old rats.
Lymphoma, B-Cell
Analysis and Identification of Active Compounds from Gami-Soyosan Toxic to MCF-7 Human Breast Adenocarcinoma Cells.
Lymphoma, B-Cell
Anti-cancer effects of 2-oxoquinoline derivatives on the HCT116 and LoVo human colon cancer cell lines.
Lymphoma, B-Cell
Anti-Cancer Properties of Theaflavins.
Lymphoma, B-Cell
Anti-proliferative and apoptosis inducing effect of nimbolide by altering molecules involved in apoptosis and IGF signalling via PI3K/Akt in prostate cancer (PC-3) cell line.
Lymphoma, B-Cell
Anticancer effects of eleven triterpenoids derived from Antrodia camphorata.
Lymphoma, B-Cell
Anticancer effects of oleanolic acid on human melanoma cells.
Lymphoma, B-Cell
Apigenin induces apoptosis via extrinsic pathway, inducing p53 and inhibiting STAT3 and NF?B signaling in HER2-overexpressing breast cancer cells.
Lymphoma, B-Cell
Apoptosis in B-cell lymphomas and reactive lymphoid tissues always involves activation of caspase 3 as determined by a new in situ detection method.
Lymphoma, B-Cell
Apoptosis in human compressive myelopathy due to metastatic neoplasia.
Lymphoma, B-Cell
Apoptotic effect of lambertianic acid through AMPK/FOXM1 signaling in MDA-MB231 breast cancer cells.
Lymphoma, B-Cell
BCL2 Suppresses PARP1 Function and Nonapoptotic Cell Death.
Lymphoma, B-Cell
Cadmium Activates Reactive Oxygen Species-dependent AKT/mTOR and Mitochondrial Apoptotic Pathways in Neuronal Cells.
Lymphoma, B-Cell
Cadmium-induced apoptosis in neuronal cells is mediated by Fas/FasL-mediated mitochondrial apoptotic signaling pathway.
Lymphoma, B-Cell
CCT020312 Inhibits Triple-Negative Breast Cancer Through PERK Pathway-Mediated G1 Phase Cell Cycle Arrest and Apoptosis.
Lymphoma, B-Cell
Celastrol induces the apoptosis of breast cancer cells and inhibits their invasion via downregulation of MMP-9.
Lymphoma, B-Cell
Characterization and anti-tumor activity of saponin-rich fractions of South Korean sea cucumbers (Apostichopus japonicus).
Lymphoma, B-Cell
Chelerythrine chloride induces apoptosis in renal cancer HEK-293 and SW-839 cell lines.
Lymphoma, B-Cell
Chromosome 13 poly(ADP-ribose) polymerase polymorphisms and lung cancer risk.
Lymphoma, B-Cell
Clinical case report of patients with osteosarcoma and anticancer benefit of calycosin against human osteosarcoma cells.
Lymphoma, B-Cell
Coix lacryma-jobi var. ma-yuen Stapf sprout extract induces cell cycle arrest and apoptosis in human cervical carcinoma cells.
Lymphoma, B-Cell
Dehydroxyhispolon Methyl Ether, A Hispolon Derivative, Inhibits WNT/?-Catenin Signaling to Elicit Human Colorectal Carcinoma Cell Apoptosis.
Lymphoma, B-Cell
Distinct roles for PARP-1 and PARP-2 in c-Myc-driven B-cell lymphoma in mice.
Lymphoma, B-Cell
Down-expression of poly(ADP-ribose) polymerase in p53-regulated pancreatic cancer cells.
Lymphoma, B-Cell
Effect of Shuangdan Mingmu capsule, a Chinese herbal formula, on oxidative stress-induced apoptosis of pericytes through PARP/GAPDH pathway.
Lymphoma, B-Cell
Enhanced Susceptibility to 5-Fluorouracil in Human Colon Cancer Cells by Silencing of GRP78.
Lymphoma, B-Cell
Eugenol protects the transplanted heart against ischemia/reperfusion injury in rats by inhibiting the inflammatory response and apoptosis.
Lymphoma, B-Cell
EX527, a Sirt-1 inhibitor, induces apoptosis in glioma via activating the p53 signaling pathway.
Lymphoma, B-Cell
Flavonoids isolated from Citrus platymamma induced G2/M cell cycle arrest and apoptosis in A549 human lung cancer cells.
Lymphoma, B-Cell
Galbanic acid potentiates TRAIL induced apoptosis in resistant non-small cell lung cancer cells via inhibition of MDR1 and activation of caspases and DR5.
Lymphoma, B-Cell
Inhibition of Proliferation in U937 Cells Treated by Blue Light Irradiation and Combined Blue Light Irradiation/Drug.
Lymphoma, B-Cell
Inhibitors of poly(ADP-ribose) polymerase increase antibody class switching.
Lymphoma, B-Cell
Inhibitory effects of nodakenin on inflammation and cell death in lipopolysaccharide-induced liver injury mice.
Lymphoma, B-Cell
Inulin Induces Dendritic Cells Apoptosis through the Caspase-Dependent Pathway and Mitochondrial Dysfunction.
Lymphoma, B-Cell
Knockdown of stromal interaction molecule 1 inhibits proliferation of colorectal cancer cells by inducing apoptosis.
Lymphoma, B-Cell
Korean Red Ginseng Extract Enhances the Anticancer Effects of Sorafenib through Abrogation of CREB and c-Jun Activation in Renal Cell Carcinoma.
Lymphoma, B-Cell
Miltirone-induced apoptosis in cisplatin-resistant lung cancer cells through upregulation of p53 signaling pathways.
Lymphoma, B-Cell
miR-30d inhibits cell biological progression of Ewing's sarcoma by suppressing the MEK/ERK and PI3K/Akt pathways
Lymphoma, B-Cell
Naphthazarin suppresses cell proliferation and induces apoptosis in human colorectal cancer cells via the B-cell lymphoma 2/B-cell associated X protein signaling pathway.
Lymphoma, B-Cell
Neuroprotective and antioxidant activities of bamboo salt soy sauce against H2O2-induced oxidative stress in rat cortical neurons.
Lymphoma, B-Cell
Non-esterified Fatty Acid Induce Dairy Cow Hepatocytes Apoptosis via the Mitochondria-Mediated ROS-JNK/ERK Signaling Pathway.
Lymphoma, B-Cell
Novel proapoptotic agent SM-1 enhances the inhibitory effect of 5-fluorouracil on colorectal cancer cells in vitro and in vivo.
Lymphoma, B-Cell
Palmitic Acid-Induced Podocyte Apoptosis via the Reactive Oxygen Species-Dependent Mitochondrial Pathway.
Lymphoma, B-Cell
Pipoxolan Exhibits Antitumor Activity Toward Oral Squamous Cell Carcinoma Through Reactive Oxygen Species-mediated Apoptosis.
Lymphoma, B-Cell
Polychlorinated biphenyl quinone induces mitochondrial-mediated and caspase-dependent apoptosis in HepG2 cells.
Lymphoma, B-Cell
Protective effect of hypoxylonol C and 4,5,4',5'-tetrahydroxy-1,1'-binaphthyl isolated from Annulohypoxylon annulatum against streptozotocin-induced damage in INS-1 cells.
Lymphoma, B-Cell
Quercetin-3-O-(2?-galloyl)-?-L-rhamnopyranoside attenuates cholesterol oxidation product-induced apoptosis by suppressing NF-?B-mediated cell death process in differentiated PC12 cells.
Lymphoma, B-Cell
Radiosensitizing Potential of Curcumin in Different Cancer Models.
Lymphoma, B-Cell
Research Progress on PARP14 as a Drug Target.
Lymphoma, B-Cell
Role of Exogenous Hsp72 on Liver Dysfunction during Sepsis.
Lymphoma, B-Cell
Serum-free corneal organ culture medium (SFM) but not conventional minimal essential organ culture medium (MEM) protects human corneal endothelial cells from apoptotic and necrotic cell death.
Lymphoma, B-Cell
Silencing LDHA inhibits proliferation, induces apoptosis and increases chemosensitivity to temozolomide in glioma cells.
Lymphoma, B-Cell
Target prioritization of novel substituted 5-aryl-2-oxo-/thioxo-2,3-dihydro-1H-benzo[6,7]chromeno[2,3-d]pyrimidine-4,6,11(5H)-triones as anticancer agents using in-silico approach.
Lymphoma, B-Cell
The Effects of 5,6,7,8,3',4'-Hexamethoxyflavone on Apoptosis of Cultured Human Choriocarcinoma Trophoblast Cells.
Lymphoma, B-Cell
The PARP inhibitor veliparib can be safely added to bendamustine and rituximab and has preliminary evidence of activity in B-cell lymphoma.
Lymphoma, B-Cell
The role of mitogen-activated protein kinase in cadmium-induced primary rat cerebral cortical neurons apoptosis via a mitochondrial apoptotic pathway.
Lymphoma, B-Cell
Toona sinensis extracts induced cell cycle arrest and apoptosis in the human lung large cell carcinoma.
Lymphoma, B-Cell
Transferrin-conjugated liposomes loaded with carnosic acid inhibit liver cancer growth by inducing mitochondria-mediated apoptosis.
Lymphoma, B-Cell
Triptolide induces DNA breaks, activates caspase-3-dependent apoptosis and sensitizes B-cell lymphoma to poly(ADP-ribose) polymerase 1 and phosphoinositide 3-kinase inhibitors.
Lymphoma, Large B-Cell, Diffuse
BCL2 Suppresses PARP1 Function and Nonapoptotic Cell Death.
Lymphoma, Large B-Cell, Diffuse
Lysosomotropic cationic drugs induce cytostatic and cytotoxic effects: Role of liposolubility and autophagic flux and antagonism by cholesterol ablation.
Lymphoma, Large B-Cell, Diffuse
Mechanisms of JP-8 jet fuel toxicity. I. Induction of apoptosis in rat lung epithelial cells.
Lymphoma, Large B-Cell, Diffuse
Research Progress on PARP14 as a Drug Target.
Lymphoma, Mantle-Cell
A multi-centre phase I trial of the PARP inhibitor olaparib in patients with relapsed chronic lymphocytic leukaemia, T-prolymphocytic leukaemia or mantle cell lymphoma.
Lymphoma, Mantle-Cell
ATM deficiency sensitizes mantle cell lymphoma cells to poly(ADP-ribose) polymerase-1 inhibitors.
Lymphoma, Mantle-Cell
Enhanced cytotoxicity of PARP inhibition in mantle cell lymphoma harbouring mutations in both ATM and p53.
Lymphoma, Mantle-Cell
Inhibition of poly(ADP-ribose) polymerase (PARP) and ataxia telangiectasia mutated (ATM) on the chemosensitivity of mantle cell lymphoma to agents that induce DNA strand breaks.
Lymphoma, Mantle-Cell
Linarin sensitizes tumor necrosis factor-related apoptosis (TRAIL)-induced ligand-triggered apoptosis in human glioma cells and in xenograft nude mice.
Lymphoma, Mantle-Cell
Low ATM protein expression and depletion of p53 correlates with olaparib sensitivity in gastric cancer cell lines.
Lymphoma, Mantle-Cell
PARP1 expression in mantle cell lymphoma: the utility of PARP1 immunohistochemistry and its relationship with markers of DNA damage.
Lymphoma, Non-Hodgkin
Correlation of poly(ADP-ribose)polymerase and p53 expression levels in high-grade lymphomas.
Lymphoma, Non-Hodgkin
PARP-1 protein expression in glioblastoma multiforme.
Lymphoma, Non-Hodgkin
PARP-1 Val762Ala polymorphism is associated with reduced risk of non-Hodgkin lymphoma in Korean males.
Lymphoma, Non-Hodgkin
Poly(ADP-ribose) polymerase inhibitors combined with external beam and radioimmunotherapy to treat aggressive lymphoma.
Lymphoma, Non-Hodgkin
Response of DNA repair enzymes in murine fibrosarcoma, lymphosarcoma and ascites cells following gamma irradiation.
Lymphoma, Non-Hodgkin
Upregulation of Poly (ADP-Ribose) Polymerase-1 (PARP1) in Triple-Negative Breast Cancer and Other Primary Human Tumor Types.
Lymphoma, T-Cell
Molecular cloning of a functional murine arginine-specific mono-ADP-ribosyltransferase and its expression in lymphoid cells.
Lymphoma, T-Cell, Cutaneous
The synergistic proapoptotic effect of PARP-1 and HDAC inhibition in cutaneous T-cell lymphoma is mediated via Blimp-1.
Lymphopenia
Coordinated signals from the DNA repair enzymes PARP-1 and PARP-2 promotes B-cell development and function.
Macular Degeneration
Protective effects of PARP1-inhibitory compound in dry age-related macular degeneration.
Malaria
The pathophysiology of falciparum malaria.
Mastitis
Assessment of Poly(ADP-ribose) Polymerase1 (PARP1) expression and activity in cells purified from blood and milk of dairy cattle.
Mastitis
New Insights into the Significance of PARP-1 Activation: Flow Cytometric Detection of Poly(ADP-Ribose) as a Marker of Bovine Intramammary Infection.
Mastocytoma
Characterization of cytosolic pertussis toxin-sensitive GTP-binding protein in mastocytoma P-815 cells.
Mastocytoma
Trichostatin A induces apoptosis of p815 mastocytoma cells in histone acetylation- and mitochondria-dependent fashion.
Mastocytosis
Kit inhibitor APcK110 induces apoptosis and inhibits proliferation of acute myeloid leukemia cells.
Measles
Antibody responses of healthy infants to concurrent administration of a bivalent haemophilus influenzae type b-hepatitis B vaccine with diphtheria-tetanus-pertussis, polio and measles-mumps-rubella vaccines.
Measles
Immunity to vaccine-preventable diseases among paediatric healthcare workers in Denmark, 2019.
Medulloblastoma
A combination of PARP and CHK1 inhibitors efficiently antagonizes MYCN-driven tumors.
Medulloblastoma
Carbon ion radiotherapy eradicates medulloblastomas with chromothripsis in an orthotopic Li-Fraumeni patient-derived mouse model.
Medulloblastoma
Central nervous system penetration and enhancement of temozolomide activity in childhood medulloblastoma models by poly(ADP-ribose) polymerase inhibitor AG-014699.
Medulloblastoma
Cleaved caspase-3, caspase-7 and poly (ADP-ribose) polymerase are complementarily but differentially expressed in human medulloblastomas.
Medulloblastoma
Expression of Gli1 and PARP1 in medulloblastoma: an immunohistochemical study of 65 cases.
Medulloblastoma
Medulloblastoma in mice lacking p53 and PARP: all roads lead to Gli.
Medulloblastoma
Null mutation of DNA strand break-binding molecule poly(ADP-ribose) polymerase causes medulloblastomas in p53(-/-) mice.
Medulloblastoma
PARP inhibition sensitizes childhood high grade glioma, medulloblastoma and ependymoma to radiation.
Medulloblastoma
PARP-1 cooperates with Ptc1 to suppress medulloblastoma and basal cell carcinoma.
Medulloblastoma
PARP1 expression in pediatric central nervous system tumors.
Medulloblastoma
Synthetic lethal genetic interactions between Rad54 and PARP-1 in mouse development and oncogenesis.
Medulloblastoma
Veliparib Is an Effective Radiosensitizing Agent in a Preclinical Model of Medulloblastoma.
Melanoma
17-Aminogeldanamycin selectively diminishes IRE1?-XBP1s pathway activity and cooperatively induces apoptosis with MEK1/2 and BRAFV600E inhibitors in melanoma cells of different genetic subtypes.
Melanoma
4'-Bromo-resveratrol, a dual Sirtuin-1 and Sirtuin-3 inhibitor, inhibits melanoma cell growth through mitochondrial metabolic reprogramming.
Melanoma
4-Thiazolidinone derivative Les-3833 effectively inhibits viability of human melanoma cells through activating apoptotic mechanisms.
Melanoma
A common intronic variant of PARP1 confers melanoma risk and mediates melanocyte growth via regulation of MITF.
Melanoma
A dermatan sulfate-functionalized biomimetic nanocarrier for melanoma targeted chemotherapy.
Melanoma
A phase II study of the potent PARP inhibitor, Rucaparib (PF-01367338, AG014699), with temozolomide in patients with metastatic melanoma demonstrating evidence of chemopotentiation.
Melanoma
A role for poly(ADP-ribose) polymerase in the transcriptional regulation of the melanoma growth stimulatory activity (CXCL1) gene expression.
Melanoma
A375 melanoma cells are sensitized to cisplatin-induced toxicity by a synthetic nitro-flavone derivative 2-(4-Nitrophenyl)-4H-chromen-4-one through inhibition of PARP1.
Melanoma
Activating the Wnt/?-Catenin Pathway for the Treatment of Melanoma--Application of LY2090314, a Novel Selective Inhibitor of Glycogen Synthase Kinase-3.
Melanoma
Activation of p21-activated kinase 1 is required for lysophosphatidic acid-induced focal adhesion kinase phosphorylation and cell motility in human melanoma A2058 cells.
Melanoma
Altered Expression of the Poly(ADP-Ribosyl)ation Enzymes in Uveal Melanoma and Regulation of PARG Gene Expression by the Transcription Factor ERM.
Melanoma
An amyloid-like C-terminal domain of thrombospondin-1 displays CD47 agonist activity requiring both VVM motifs.
Melanoma
Anti-proliferative and proapoptotic effects of (-)-epigallocatechin-3-gallate on human melanoma: possible implications for the chemoprevention of melanoma.
Melanoma
Apigenin Attenuates Melanoma Cell Migration by Inducing Anoikis through Integrin and Focal Adhesion Kinase Inhibition.
Melanoma
Apoptotic Effect of Astragalin in Melanoma Skin Cancers via Activation of Caspases and Inhibition of Sry-related HMg-Box Gene 10.
Melanoma
Approach to the Triple Negative Breast Cancer in New Drugs Area.
Melanoma
Arachidonic acid stimulates cell adhesion through a novel p38 MAPK-RhoA signaling pathway that involves heat shock protein 27.
Melanoma
Attenuation of genotoxicity under adhesion-restrictive conditions through modulation of p53, gamma H2AX and nuclear DNA organization.
Melanoma
Blockade of BAFF Receptor BR3 on T Cells Enhances Their Activation and Cytotoxicity.
Melanoma
Brain distribution and efficacy as chemosensitizer of an oral formulation of PARP-1 inhibitor GPI 15427 in experimental models of CNS tumors.
Melanoma
BRIT-1 expression and its relationship with PARP-1 and CAF-1/p60 in cutaneous melanoma.
Melanoma
c-Myc is able to sensitize human melanoma cells to diverse apoptotic triggers.
Melanoma
Cepharanthine exerts antitumor activity on choroidal melanoma by reactive oxygen species production and c-Jun N-terminal kinase activation.
Melanoma
Characterization of human melanoma cell lines according to their migratory properties in vitro.
Melanoma
Co-targeting HGF/cMET Signaling with MEK Inhibitors in Metastatic Uveal Melanoma.
Melanoma
Combination of PDT and inhibitor treatment affects melanoma cells and spares keratinocytes.
Melanoma
Combinations of PARP Inhibitors with Temozolomide Drive PARP1 Trapping and Apoptosis in Ewing's Sarcoma.
Melanoma
Cyclosporine A and its non-immunosuppressive derivative NIM811 induce apoptosis of malignant melanoma cells in in vitro and in vivo studies.
Melanoma
Deficiency of C-C chemokine receptor 5 suppresses tumor development via inactivation of NF-?B and upregulation of IL-1Ra in melanoma model.
Melanoma
Dibutyltin(IV) and Tributyltin(IV) Derivatives of meso-Tetra(4-sulfonatophenyl)porphine Inhibit the Growth and the Migration of Human Melanoma Cells.
Melanoma
Differential regulation of CXC ligand 1 transcription in melanoma cell lines by poly(ADP-ribose) polymerase-1.
Melanoma
Dimethylfumarate inhibits melanoma cell proliferation via p21 and p53 induction and bcl-2 and cyclin B1 downregulation.
Melanoma
Effect of ABT-888 on the apoptosis, motility and invasiveness of BRAFi-resistant melanoma cells.
Melanoma
eIF4E Is an Adverse Prognostic Marker of Melanoma Patient Survival by Increasing Melanoma Cell Invasion.
Melanoma
Encorafenib (LGX818), a potent BRAF inhibitor, induces senescence accompanied by autophagy in BRAFV600E melanoma cells.
Melanoma
Endothelin receptor B inhibition triggers apoptosis and enhances angiogenesis in melanomas.
Melanoma
Enhanced anti-melanoma efficacy of interferon ?-2b via overexpression of ING4 by enhanced Fas/FasL-mediated apoptosis.
Melanoma
Evaluation of anti-melanoma activities of (1S,2E,4R,6E,8R,11S,12R)-8,12-epoxy-2,6-cembradiene-4,11-diol, (1S,2E,4R,6E,8S,11R,12S)-8,11-epoxy-4,12-epoxy-2,6-cembradiene and (1S,4R,13S)-cembra-2E,7E,11E-trien-4,13-diol from the Red Sea soft coral Sarcophyton glaucum.
Melanoma
Evaluation of the anti-melanoma activities of sarcophine, (+)-7alpha,8beta-dihydroxydeepoxysarcophine and sarcophytolide from the Red Sea soft coral Sarcophyton glaucum.
Melanoma
Exoenzyme C3 transferase lowers actin cytoskeleton dynamics, genomic stability and survival of malignant melanoma cells under UV-light stress.
Melanoma
Fatty acid synthase inhibitors cerulenin and C75 retard growth and induce caspase-dependent apoptosis in human melanoma A-375 cells.
Melanoma
G-protein involvement in matrix-mediated motility and invasion of high and low experimental metastatic B16 melanoma clones.
Melanoma
Genetic variants in PARP1 (rs3219090) and IRF4 (rs12203592) genes associated with melanoma susceptibility in a Spanish population.
Melanoma
Genetic variants of the ADPRT, XRCC1 and APE1 genes and risk of cutaneous melanoma.
Melanoma
Genetic variation in DNA repair pathway genes and melanoma risk.
Melanoma
Hazelnut (Corylus avellana L.) Shells Extract: Phenolic Composition, Antioxidant Effect and Cytotoxic Activity on Human Cancer Cell Lines.
Melanoma
HDAC-inhibitor (S)-8 disrupts HDAC6-PP1 complex prompting A375 melanoma cell growth arrest and apoptosis.
Melanoma
Human melanoma cells selected for resistance to apoptosis by prolonged exposure to tumor necrosis factor-related apoptosis-inducing ligand are more vulnerable to necrotic cell death induced by Cisplatin.
Melanoma
Iciartin, a novel FASN inhibitor, exerts anti-melanoma activities through IGF-1R/STAT3 signaling.
Melanoma
Identification, purification, and partial sequence analysis of autotaxin, a novel motility-stimulating protein.
Melanoma
Identifying new piperazine-based PARP1 inhibitors using text mining and integrated molecular modeling approaches.
Melanoma
Influence of onconase in the therapeutic potential of PARP inhibitors in A375 malignant melanoma cells.
Melanoma
Inherited genetic variants associated with occurrence of multiple primary melanoma.
Melanoma
Inherited variation in the PARP1 gene and survival from melanoma.
Melanoma
Inhibition of AURKB, regulated by pseudogene MTND4P12, confers synthetic lethality to PARP inhibition in skin cutaneous melanoma.
Melanoma
Inhibition of melanoma growth and metastasis by ATF2-derived peptides.
Melanoma
Inhibition of PARP activity by PJ-34 leads to growth impairment and cell death associated with aberrant mitotic pattern and nucleolar actin accumulation in M14 melanoma cell line.
Melanoma
Inhibition of Poly(ADP-Ribose) Polymerase Enhances the Effect of Chemotherapy in an Animal Model of Regional Therapy for the Treatment of Advanced Extremity Malignant Melanoma.
Melanoma
Inhibition of SOX4 induces melanoma cell apoptosis via downregulation of NF-?B p65 signaling.
Melanoma
Inhibition of telomerase increases resistance of melanoma cells to temozolomide, but not to temozolomide combined with poly (adp-ribose) polymerase inhibitor.
Melanoma
Isolation, structure elucidation, total synthesis, and evaluation of new natural and synthetic ceramides on human SK-MEL-1 melanoma cells.
Melanoma
Lauroside B, a megastigmane glycoside from Laurus nobilis (bay laurel) leaves, induces apoptosis in human melanoma cell lines by inhibiting NF-?B activation.
Melanoma
Loss of function of vascular smooth muscle cells by nitric oxide-dependent and -independent interactions with tumorigenic cells.
Melanoma
Melanoma cells replicate through chemotherapy by reducing levels of key homologous recombination protein RAD51 and increasing expression of translesion synthesis DNA polymerase ?.
Melanoma
Metabolic utilization of exogenous pyruvate by mutant p53(R175H) human melanoma cells promotes survival under glucose depletion.
Melanoma
Methoxyphenylcipro induces antitumor activity in human cancer cells.
Melanoma
MITF suppression improves the sensitivity of melanoma cells to a BRAF inhibitor.
Melanoma
Mitochondrial transmembrane potential in spontaneous and camptothecin-induced apoptosis of melanotic and amelanotic melanoma cells.
Melanoma
MLS-2384, a new 6-bromoindirubin derivative with dual JAK/Src kinase inhibitory activity, suppresses growth of diverse cancer cells.
Melanoma
Molecular, Biological and Structural Features of VL CDR-1 Rb44 Peptide, Which Targets the Microtubule Network in Melanoma Cells.
Melanoma
Murine melanoma cell differentiation and melanogenesis induced by poly(ADP-ribose) polymerase inhibitors.
Melanoma
Mutation clearance and complete radiologic resolution of immunotherapy relapsed metastatic melanoma after treatment with nivolumab and olaparib in a patient with homologous recombinant deficiency: any role for PARP inhibitors and checkpoint blockade?
Melanoma
Nitroprusside induces melanoma ferroptosis with serum supplementation and prolongs survival under serum depletion or hypoxia.
Melanoma
Onconase Restores Cytotoxicity in Dabrafenib-Resistant A375 Human Melanoma Cells and Affects Cell Migration, Invasion and Colony Formation Capability.
Melanoma
Overexpression of HSP70 prevents ultraviolet B-induced apoptosis of a human melanoma cell line.
Melanoma
Pan-Cancer Analysis of PARP1 Alterations as Biomarkers in the Prediction of Immunotherapeutic Effects and the Association of Its Expression Levels and Immunotherapy Signatures.
Melanoma
PARP activity in peripheral blood lymphocytes as a predictive biomarker for PARP inhibition in tumor tissues - A population pharmacokinetic/pharmacodynamic analysis of rucaparib.
Melanoma
PARP Inhibition Increases the Response to Chemotherapy in Uveal Melanoma.
Melanoma
PARP Inhibitor PJ34 Protects Mitochondria and Induces DNA-Damage Mediated Apoptosis in Combination With Cisplatin or Temozolomide in B16F10 Melanoma Cells.
Melanoma
PARP inhibitors combined with ionizing radiation induce different effects in melanoma cells and healthy fibroblasts.
Melanoma
PARP Inhibitors Talazoparib and Niraparib Sensitize Melanoma Cells to Ionizing Radiation.
Melanoma
PARP-1 regulates metastatic melanoma through modulation of vimentin-induced malignant transformation.
Melanoma
PARP1 as a Marker of an Aggressive Clinical Phenotype in Cutaneous Melanoma-A Clinical and an In Vitro Study.
Melanoma
PARP1 inhibitor olaparib (Lynparza) exerts synthetic lethal effect against ligase 4-deficient melanomas.
Melanoma
PARP1 Inhibitors: antitumor drug design.
Melanoma
PARP1 polymorphisms play opposing roles in melanoma occurrence and survival.
Melanoma
Pertussis toxin inhibits stimulated motility independently of the adenylate cyclase pathway in human melanoma cells.
Melanoma
Pharmacological Inhibition of Poly(ADP-ribose) Polymerase (PARP) Activity in PARP-1 Silenced Tumour Cells Increases Chemosensitivity to Temozolomide and to a N3-Adenine Selective Methylating Agent.
Melanoma
Pharmacological inhibition of poly(ADP-ribose) polymerase (PARP) activity in PARP-1 silenced tumour cells increases chemosensitivity to temozolomide and to a N3-adenine selective methylating agent.
Melanoma
Poly(adenosine diphosphate-ribose) polymerase 1 expression in malignant melanomas from photoexposed areas of the head and neck region.
Melanoma
Poly(Adenosine Diphosphate-Ribose) Polymerase-1 Expression in Cutaneous Malignant Melanomas as a New Molecular Marker of Aggressive Tumor.
Melanoma
Poly(ADP-ribose) in the skin and in melanomas.
Melanoma
Polymorphisms in base excision DNA repair genes and association with melanoma risk in a pilot study on Central-South Italian population.
Melanoma
Prenylation Inhibition-Induced Cell Death in Melanoma: Reduced Sensitivity in BRAF Mutant/PTEN Wild-Type Melanoma Cells.
Melanoma
Prevalence of Homologous Recombination Pathway Gene Mutations in Melanoma: Rationale for a New Targeted Therapeutic Approach.
Melanoma
Radiation-inducible Immunotherapy for Cancer: Senescent Tumor Cells as a Cancer Vaccine.
Melanoma
Radiosynthesis of 3 H- and 14 C-labeled Veliparib.
Melanoma
Rare germline copy number variations and disease susceptibility in familial melanoma.
Melanoma
RIN1 exhibits oncogenic property to suppress apoptosis and its aberrant accumulation associates with poor prognosis in melanoma.
Melanoma
Sasanquasaponin ??? from Schima crenata Korth induces autophagy through Akt/mTOR/p70S6K pathway and promotes apoptosis in human melanoma A375 cells.
Melanoma
Selective modulation by PARP-1 of HIF-1?-recruitment to chromatin during hypoxia is required for tumor adaptation to hypoxic conditions.
Melanoma
Stable depletion of poly (ADP-ribose) polymerase-1 reduces in vivo melanoma growth and increases chemosensitivity.
Melanoma
Survivin, a member of the inhibitor of apoptosis family, is induced by photodynamic therapy and is a target for improving treatment response.
Melanoma
Synergistic apoptosis-inducing effects on A375 human melanoma cells of natural borneol and curcumin.
Melanoma
Systemic administration of GPI 15427, a novel poly(ADP-ribose) polymerase-1 inhibitor, increases the antitumor activity of temozolomide against intracranial melanoma, glioma, lymphoma.
Melanoma
Tanshinone I and simvastatin inhibit melanoma tumour cell growth by regulating poly (ADP ribose) polymerase 1 expression.
Melanoma
Targeted silencing of the ADP-ribosyltransferase 3 gene inhibits the migration ability of melanoma cells.
Melanoma
Temozolomide pharmacodynamics in patients with metastatic melanoma: dna damage and activity of repair enzymes O6-alkylguanine alkyltransferase and poly(ADP-ribose) polymerase-1.
Melanoma
Temozolomide- and fotemustine-induced apoptosis in human malignant melanoma cells: response related to MGMT, MMR, DSBs, and p53.
Melanoma
The 1q42.1 Risk Allele Promotes Melanoma via PARP1 Upregulation.
Melanoma
The activity of caspases in spontaneous and camptothecin-induced death of melanotic and amelanotic melanoma cell.
Melanoma
The Antitumor Activity of Antrodia camphorata in Melanoma Cells: Modulation of Wnt/?-Catenin Signaling Pathways.
Melanoma
The gallium complex KP46 exerts strong activity against primary explanted melanoma cells and induces apoptosis in melanoma cell lines.
Melanoma
The melanoma specific 9.2.27PE immunotoxin efficiently kills melanoma cells in vitro.
Melanoma
The Prognostic Values of PARP-1 Expression in Uveal Melanoma.
Melanoma
The role of G-protein in matrix-mediated motility of highly and poorly invasive melanoma cells.
Melanoma
The toxicity of nitrofuran compounds on melanoma and neuroblastoma cells is enhanced by Olaparib and ameliorated by melanin pigment.
Melanoma
Topical 2'-Hydroxyflavanone for Cutaneous Melanoma.
Melanoma
Tumor apoptosis induced by ruthenium(II)-ketoconazole is enhanced in nonsusceptible carcinoma by monoclonal antibody to EGF receptor.
Melanoma
Type IV collagen stimulates an increase in intracellular calcium. Potential role in tumor cell motility.
Melanoma
Up-Regulation of PARP1 Expression Significantly Correlated with Poor Survival in Mucosal Melanomas.
Melanoma
Xeroderma Pigmentosum Group A Promotes Autophagy to Facilitate Cisplatin Resistance in Melanoma Cells through the Activation of PARP1.
Melanoma, Experimental
Sphingosine 1-phosphate triggers apoptotic signal for B16 melanoma cells via ERK and caspase activation.
Memory Disorders
Kaempferol protects against cadmium chloride-induced hippocampal damage and memory deficits by activation of silent information regulator 1 and inhibition of poly (ADP-Ribose) polymerase-1.
Memory Disorders
TRPM2 ion channel is involved in the aggravation of cognitive impairment and down regulation of epilepsy threshold in pentylenetetrazole-induced kindling mice.
Meniere Disease
Poly(ADP-ribose) polymerase-1 (PARP-1) longer alleles spanning the promoter region may confer protection to bilateral Meniere's disease.
Meningioma
Expression of a functional endothelin (ETA) receptor in human meningiomas.
Meningioma
Poly(ADP-ribose) polymerase-1 (PARP1) and p53 labelling index correlates with tumour grade in meningiomas.
Meningitis
SNPs in DNA repair genes associated to meningitis and host immune response.
Meningitis, Bacterial
A putative role for homocysteine in the pathophysiology of acute bacterial meningitis in children.
Meningitis, Bacterial
Advances in adjuvant therapy against acute bacterial meningitis.
Meningitis, Bacterial
Meningitis-associated central nervous system complications are mediated by the activation of poly(ADP-ribose) polymerase.
Meningitis, Pneumococcal
Meningitis-associated central nervous system complications are mediated by the activation of poly(ADP-ribose) polymerase.
Meningococcal Infections
Polymorphisms in PARP, IL1B, IL4, IL10, C1INH, DEFB1 and DEFA4 in meningococcal disease in three populations.
Mesothelioma
Analysis of CCDC6 as a novel biomarker for the clinical use of PARP1 inhibitors in malignant pleural mesothelioma.
Mesothelioma
BAP1-Altered Malignant Pleural Mesothelioma: Outcomes With Chemotherapy, Immune Check-Point Inhibitors and Poly(ADP-Ribose) Polymerase Inhibitors.
Mesothelioma
Blockage of epithelial to mesenchymal transition and upregulation of let 7b are critically involved in ursolic acid induced apoptosis in malignant mesothelioma cell.
Mesothelioma
Downregulation of Sp1 is involved in honokiol-induced cell cycle arrest and apoptosis in human malignant pleural mesothelioma cells.
Mesothelioma
Evaluation of gene expression levels in the diagnosis of lung adenocarcinoma and malignant pleural mesothelioma.
Mesothelioma
Hesperidin Induces Apoptosis by Inhibiting Sp1 and Its Regulatory Protein in MSTO-211H Cells.
Mesothelioma
Initial evaluation of Cu-64 labeled PARPi-DOTA PET imaging in mice with mesothelioma.
Mesothelioma
PARP1 inhibition affects pleural mesothelioma cell viability and uncouples AKT/mTOR axis via SIRT1.
Mesothelioma
Reduced cell viability and apoptosis induction in human thyroid carcinoma and mesothelioma cells exposed to cidofovir.
Mesothelioma
Rucaparib in patients with BAP1-deficient or BRCA1-deficient mesothelioma (MiST1): an open-label, single-arm, phase 2a clinical trial.
Mesothelioma
Sensitivity of Mesothelioma Cells to PARP Inhibitors Is Not Dependent on BAP1 but Is Enhanced by Temozolomide in Cells With High-Schlafen 11 and Low-O6-methylguanine-DNA Methyltransferase Expression.
Mesothelioma
Synthetic lethality in malignant pleural mesothelioma with PARP1 inhibition.
Mesothelioma
Taurolidine and oxidative stress: a rationale for local treatment of mesothelioma.
Mesothelioma
Unsymmetric Cisplatin-Based Pt(IV) Conjugates Containing a PARP-1 Inhibitor Pharmacophore Tested on Malignant Pleural Mesothelioma Cell Lines.
Mesothelioma, Malignant
Analysis of CCDC6 as a novel biomarker for the clinical use of PARP1 inhibitors in malignant pleural mesothelioma.
Mesothelioma, Malignant
Analysis of mutations of PARP1, RNF213, PAX8, KMT2C, MTRR in malignant mesothelioma of testicular tunica vaginalis testis.
Mesothelioma, Malignant
Anticarcinogenic effects of halofuginone on lung-derived cancer cells.
Mesothelioma, Malignant
BAP1-Altered Malignant Pleural Mesothelioma: Outcomes With Chemotherapy, Immune Check-Point Inhibitors and Poly(ADP-Ribose) Polymerase Inhibitors.
Mesothelioma, Malignant
Evaluation of gene expression levels in the diagnosis of lung adenocarcinoma and malignant pleural mesothelioma.
Mesothelioma, Malignant
Synthetic lethality in malignant pleural mesothelioma with PARP1 inhibition.
Mesothelioma, Malignant
Unsymmetric Cisplatin-Based Pt(IV) Conjugates Containing a PARP-1 Inhibitor Pharmacophore Tested on Malignant Pleural Mesothelioma Cell Lines.
Metabolic Diseases
Antagonistic crosstalk between SIRT1, PARP-1, and -2 in the regulation of chronic inflammation associated with aging and metabolic diseases.
Metabolic Diseases
Biology of Poly(ADP-Ribose) Polymerases: The Factotums of Cell Maintenance.
Metabolic Diseases
Inhibition of Poly(ADP-Ribose) Polymerase Increased Lipid Accumulation Through SREBP1 Modulation.
Metabolic Diseases
Metabolic roles of poly(ADP-ribose) polymerases.
Metabolic Diseases
Oxidative-Nitrative Stress and Poly (ADP-Ribose) Polymerase Activation 3 Years after Pregnancy.
Metabolic Diseases
PARP-1 Inhibition Increases Mitochondrial Metabolism through SIRT1 Activation.
Metabolic Diseases
Poly(ADP-ribose) polymerases in aging - friend or foe?
Metabolic Diseases
The NAD(+) precursor nicotinamide riboside enhances oxidative metabolism and protects against high-fat diet-induced obesity.
Metabolic Syndrome
Functions of NQO1 in Cellular Protection and CoQ10 Metabolism and its Potential Role as a Redox Sensitive Molecular Switch.
Microcephaly
Genotype-phenotype relationship in a child with 2.3 Mb de novo interstitial 12p13.33-p13.32 deletion.
Mitochondrial Diseases
Insights into the functional aspects of poly(ADP-ribose) polymerase-1 (PARP-1) in mitochondrial homeostasis in Dictyostelium discoideum.
Mitochondrial Diseases
Pharmacological NAD-Boosting Strategies Improve Mitochondrial Homeostasis in Human Complex I-Mutant Fibroblasts.
Monoclonal Gammopathy of Undetermined Significance
Altered mRNA expression of telomere-associated genes in monoclonal gammopathy of undetermined significance and multiple myeloma.
Monoclonal Gammopathy of Undetermined Significance
Targeting the MALAT1/PARP1/LIG3 complex induces DNA damage and apoptosis in multiple myeloma.
Mouth Neoplasms
Anticancer effects of eleven triterpenoids derived from Antrodia camphorata.
Mouth Neoplasms
Apoptosis induced by caffeic acid phenethyl ester in human oral cancer cell lines: Involvement of Puma and Bax activation.
Mouth Neoplasms
Detection and delineation of oral cancer with a PARP1 targeted optical imaging agent.
Mouth Neoplasms
Fluorescence-guided resection of tumors in mouse models of oral cancer.
Mouth Neoplasms
In Vitro Assessment of the Anticancer Potential of Evodiamine in Human Oral Cancer Cell Lines.
Mouth Neoplasms
Kaempferol and quercetin, components of Ginkgo biloba extract (EGb 761), induce caspase-3-dependent apoptosis in oral cavity cancer cells.
Mouth Neoplasms
Licochalcone A induces apoptosis in KB human oral cancer cells via a caspase-dependent FasL signaling pathway.
Mouth Neoplasms
Mechanism of sappanchalcone-induced growth inhibition and apoptosis in human oral cancer cells.
Mouth Neoplasms
Methanol Extract of Usnea barbata Induces Cell Killing, Apoptosis, and DNA Damage against Oral Cancer Cells through Oxidative Stress.
Mouth Neoplasms
MicroRNA-205 suppresses the oral carcinoma oncogenic activity via down-regulation of Axin-2 in KB human oral cancer cell.
Mouth Neoplasms
Norcantharidin-induced apoptosis in oral cancer cells is associated with an increase of proapoptotic to antiapoptotic protein ratio.
Mouth Neoplasms
Olaparib enhances curcumin-mediated apoptosis in oral cancer cells by inducing PARP trapping through modulation of BER and chromatin assembly.
Mouth Neoplasms
Optical Imaging of PARP1 in Response to Radiation in Oral Squamous Cell Carcinoma.
Mouth Neoplasms
Oridonin induces apoptosis in oral squamous cell carcinoma probably through the generation of reactive oxygen species and the p38/JNK MAPK pathway.
Mouth Neoplasms
Overexpression of chromatin assembly factor-1 p60, poly(ADP-ribose) polymerase 1 and nestin predicts metastasizing behaviour of oral cancer.
Mouth Neoplasms
PARP inhibitor Olaparib Enhances the Apoptotic Potentiality of Curcumin by Increasing the DNA Damage in Oral Cancer Cells through Inhibition of BER Cascade.
Mouth Neoplasms
PARP inhibitor Veliparib (ABT-888) enhances the anti-angiogenic potentiality of Curcumin through deregulation of NECTIN-4 in oral cancer: Role of nitric oxide (NO).
Mouth Neoplasms
Poly (ADP-Ribose) Polymerase Inhibitor, ABT888, Improved Cisplatin Effect in Human Oral Cell Carcinoma.
Mouth Neoplasms
Polyphyllin G induces apoptosis and autophagy cell death in human oral cancer cells.
Mouth Neoplasms
Preventive measures in oral cancer: An overview.
Mouth Neoplasms
Synergetic Effects of PARP Inhibitor AZD2281 and Cisplatin in Oral Squamous Cell Carcinoma in Vitro and in Vivo.
Mouth Neoplasms
Tetrandrine induces apoptosis Via caspase-8, -9, and -3 and poly (ADP ribose) polymerase dependent pathways and autophagy through beclin-1/ LC3-I, II signaling pathways in human oral cancer HSC-3 cells.
Mouth Neoplasms
The Apoptotic Effect of the Hexane Extract of Rheum undulatum L. in Oral Cancer Cells through the Down-regulation of Specificity Protein 1 and Survivin.
MPTP Poisoning
A novel in vivo post-translational modification of p53 by PARP-1 in MPTP-induced parkinsonism.
MPTP Poisoning
Poly(ADP-ribose) polymerase activation mediates 1-methyl-4-phenyl-1, 2,3,6-tetrahydropyridine (MPTP)-induced parkinsonism.
MPTP Poisoning
SPATIAL AND FUNCTIONAL RELATIONSHIP BETWEEN POLY(ADP-RIBOSE) POLYMERASE-1 AND POLY(ADP-RIBOSE) GLYCOHYDROLASE IN THE BRAIN.
Mucositis
Efficacy of professionally-administered plaque removal with or without adjunctive measures for the treatment of peri-implant mucositis. A systematic review and meta-analysis.
Multiple Endocrine Neoplasia
[Molecular Targeted Therapies for Hereditary Cancer Syndrome].
Multiple Endocrine Neoplasia Type 2a
[Molecular Targeted Therapies for Hereditary Cancer Syndrome].
Multiple Myeloma
A Cyclin-Dependent Kinase Inhibitor, Dinaciclib, Impairs Homologous Recombination and Sensitizes Multiple Myeloma Cells to PARP Inhibition.
Multiple Myeloma
A novel small molecule inhibits STAT3 phosphorylation and DNA binding activity and exhibits potent growth suppressive activity in human cancer cells.
Multiple Myeloma
Altered mRNA expression of telomere-associated genes in monoclonal gammopathy of undetermined significance and multiple myeloma.
Multiple Myeloma
Bortezomib-induced "BRCAness" sensitizes multiple myeloma cells to PARP inhibitors.
Multiple Myeloma
Cladribine in combination with entinostat synergistically elicits anti-proliferative/anti-survival effects on multiple myeloma cells.
Multiple Myeloma
Combining Chemical Genetics with Proximity-Dependent Labeling Reveals Cellular Targets of Poly(ADP-ribose) Polymerase 14 (PARP14).
Multiple Myeloma
Cytotoxicity of Gymnopilus purpureosquamulosus extracts on hematologic malignant cells through activation of the SAPK/JNK signaling pathway.
Multiple Myeloma
Decursin and Doxorubicin Are in Synergy for the Induction of Apoptosis via STAT3 and/or mTOR Pathways in Human Multiple Myeloma Cells.
Multiple Myeloma
Inhibition of Pim-2 kinase by LT-171-861 promotes DNA damage and exhibits enhanced lethal effects with PARP inhibitor in multiple myeloma.
Multiple Myeloma
Loss of heterozygosity as a marker of homologous repair deficiency in multiple myeloma: a role for PARP inhibition?
Multiple Myeloma
PJ34, a poly(ADP-ribose) polymerase (PARP) inhibitor, reverses melphalan-resistance and inhibits repair of DNA double-strand breaks by targeting the FA/BRCA pathway in multidrug resistant multiple myeloma cell line RPMI8226/R.
Multiple Myeloma
Poly(ADP-ribose) polymerase family member 14 (PARP14) is a novel effector of the JNK2-dependent pro-survival signal in multiple myeloma.
Multiple Myeloma
Proteasomal degradation of topoisomerase I is preceded by c-Jun NH2-terminal kinase activation, Fas up-regulation, and poly(ADP-ribose) polymerase cleavage in SN38-mediated cytotoxicity against multiple myeloma.
Multiple Myeloma
Research Progress on PARP14 as a Drug Target.
Multiple Myeloma
Targeting poly (ADP-ribose) polymerase partially contributes to bufalin-induced cell death in multiple myeloma cells.
Multiple Myeloma
TRIM44 links the UPS to SQSTM1/p62-dependent aggrephagy and removing misfolded proteins.
Multiple Myeloma
[Effect of PARP1 inhibitor PJ34 on multi-drug resistance in human multiple myeloma cell line and its relationship with FA/BRCA pathway].
Multiple Sclerosis
Centrally administered pertussis toxin inhibits microglia migration to the spinal cord and prevents dissemination of disease in an EAE mouse model.
Multiple Sclerosis
Inhibiting poly(ADP-ribose) polymerase: a potential therapy against oligodendrocyte death.
Multiple Sclerosis
Neuroinflammation and B-Cell Phenotypes in Cervical and Lumbosacral Regions of the Spinal Cord in Experimental Autoimmune Encephalomyelitis in the Absence of Pertussis Toxin.
Multiple Sclerosis
PARP-1 deficiency increases the severity of disease in a mouse model of multiple sclerosis.
Multiple Sclerosis
PARP-1 deregulation in multiple sclerosis.
Multiple Sclerosis
Pertussis toxin attenuates experimental autoimmune encephalomyelitis by upregulating neuronal vascular endothelial growth factor.
Multiple Sclerosis
Pertussis toxin induces angiogenesis in brain microvascular endothelial cells.
Multiple Sclerosis
Pertussis toxin modulates microglia and T cell profile to protect experimental autoimmune encephalomyelitis.
Multiple Sclerosis
Poly(ADP-ribose) polymerase-1 activation in a primate model of multiple sclerosis.
Multiple Sclerosis
The potential role of subclinical Bordetella Pertussis colonization in the etiology of multiple sclerosis.
Multiple Sclerosis
The regulatory effect of liuwei dihuang pills on cytokines in mice with experimental autoimmune encephalomyelitis.
Multiple Sclerosis
Vascular and immunopathological role of Asymmetric Dimethylarginine (ADMA) in Experimental Autoimmune Encephalomyelitis.
Mumps
Antibody responses of healthy infants to concurrent administration of a bivalent haemophilus influenzae type b-hepatitis B vaccine with diphtheria-tetanus-pertussis, polio and measles-mumps-rubella vaccines.
Mumps
Immunity to vaccine-preventable diseases among paediatric healthcare workers in Denmark, 2019.
Murine Acquired Immunodeficiency Syndrome
Parthanatos-associated proteins are stimulated intraocularly during development of experimental murine cytomegalovirus retinitis in mice with retrovirus-induced immunosuppression.
Muscle Hypotonia
Genotype-phenotype relationship in a child with 2.3 Mb de novo interstitial 12p13.33-p13.32 deletion.
Muscular Atrophy
Absence of Caspase-3 Protects Against Denervation Induced Skeletal Muscle Atrophy.
Muscular Atrophy
Neer Award 2016: reduced muscle degeneration and decreased fatty infiltration after rotator cuff tear in a poly(ADP-ribose) polymerase 1 (PARP-1) knock-out mouse model.
Muscular Diseases
Repurposing of Clinically Approved Poly-(Adp-Ribose) Polymerase Inhibitors For The Therapy of Sepsis.
Muscular Dystrophies
Telomere shortening is associated to TRF1 and PARP1 overexpression in Duchenne muscular dystrophy.
Muscular Dystrophy, Duchenne
Telomere shortening is associated to TRF1 and PARP1 overexpression in Duchenne muscular dystrophy.
Mycosis Fungoides
Therapeutic and prognostic significance of PARP-1 in advanced mycosis fungoides and Sezary syndrome.
Myelitis
Effects of a metalloporphyrinic peroxynitrite decomposition catalyst, ww-85, in a mouse model of spinal cord injury.
Myelitis
IL-6 induces regionally selective spinal cord injury in patients with the neuroinflammatory disorder transverse myelitis.
Myelitis
Inhibition of tyrosine kinase-mediated cellular signalling by Tyrphostins AG126 and AG556 modulates secondary damage in experimental spinal cord trauma.
Myelitis
Inhibitors of poly(ADP-ribose) polymerase modulate signal transduction pathways and secondary damage in experimental spinal cord trauma.
Myelodysplastic Syndromes
Bone marrow PARP1 mRNA levels predict response to treatment with 5-azacytidine in patients with myelodysplastic syndrome.
Myelodysplastic Syndromes
Can synthetic lethality approach be used with DNA repair genes for primary and secondary MDS?
Myelodysplastic Syndromes
Cytotoxicity and Differentiating Effect of the Poly(ADP-Ribose) Polymerase Inhibitor Olaparib in Myelodysplastic Syndromes.
Myelodysplastic Syndromes
Inhibitors of poly ADP-ribose polymerase (PARP) induce apoptosis of myeloid leukemic cells: potential for therapy of myeloid leukemia and myelodysplastic syndromes.
Myelodysplastic Syndromes
Microsatellite instability induced mutations in DNA repair genes Ctip and MRE11 confer hypersensitivity to poly (ADP-ribose) polymerase (PARP) inhibitors in myeloidmalignancies.
Myelodysplastic Syndromes
Myelodysplastic syndrome and acute myeloid leukaemia in patients treated with PARP inhibitors: a safety meta-analysis of randomised controlled trials and a retrospective study of the WHO pharmacovigilance database.
Myelodysplastic Syndromes
PARP inhibitors-understanding the risk of myelodysplastic syndrome and acute myeloid leukaemia.
Myelodysplastic Syndromes
PARP1 V762A polymorphism affects the prognosis of myelodysplastic syndromes.
Myelodysplastic Syndromes
Poly (ADP-ribose) polymerase 1 mRNA levels strongly correlate with the prognosis of myelodysplastic syndromes.
Myelodysplastic Syndromes
Poly (ADP-ribose) polymerase-1 (PARP1) as a therapeutic target in acute myeloid leukemia and myelodysplastic syndrome.
Myelodysplastic Syndromes
The poly (ADP ribose) polymerase inhibitor niraparib: Management of toxicities.
Myocardial Infarction
A novel and orally active poly(ADP-ribose) polymerase inhibitor, KR-33889 [2-[methoxycarbonyl(4-methoxyphenyl) methylsulfanyl]-1H-benzimidazole-4-carboxylic acid amide], attenuates injury in in vitro model of cell death and in vivo model of cardiac ischemia.
Myocardial Infarction
A randomized, placebo-controlled trial to evaluate the tolerability, safety, pharmacokinetics, and pharmacodynamics of a potent inhibitor of poly(ADP-ribose) polymerase (INO-1001) in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention: results of the TIMI 37 trial.
Myocardial Infarction
Activation of poly(ADP-ribose) polymerase by myocardial ischemia and coronary reperfusion in human circulating leukocytes.
Myocardial Infarction
Activation of poly(ADP-ribose) polymerase in circulating leukocytes during myocardial infarction.
Myocardial Infarction
Acute myocardial infarction induced increases in plasma tumor necrosis factor-alpha and interleukin-10 are associated with the activation of poly(ADP-ribose) polymerase of circulating mononuclear cell.
Myocardial Infarction
E3 Ubiquitin ligase NEDD4 family?regulatory network in cardiovascular disease.
Myocardial Infarction
Effects of 3-aminobenzamide on expressions of poly (ADP ribose) polymerase and apoptosis inducing factor in cardiomyocytes of rats with acute myocardial infarction.
Myocardial Infarction
Imidazoquinolinone, imidazopyridine, and isoquinolindione derivatives as novel and potent inhibitors of the poly(ADP-ribose) polymerase (PARP): a comparison with standard PARP inhibitors.
Myocardial Infarction
Increased Poly (ADP-ribosyl)ation in Peripheral Leukocytes and the Reperfused Myocardium Tissue of Rats with Ischemia/Reperfusion Injury: Prevention by 3-Aminobenzamide Treatment.
Myocardial Infarction
Inhibition of the activity of poly (ADP-ribose) polymerase reduces heart ischaemia/reperfusion injury via suppressing JNK-mediated AIF translocation.
Myocardial Infarction
Inhibition of the activity of Poly(ADP-Ribose) Polymerase reduces heart ischemia/reperfusion injury via suppressing JNK mediated AIF translocation.
Myocardial Infarction
Inotropic responses to human gene 2 (B29) relaxin in a rat model of myocardial infarction (MI): effect of pertussis toxin.
Myocardial Infarction
Isoflurane preconditions myocardium against infarction via activation of inhibitory guanine nucleotide binding proteins.
Myocardial Infarction
Local Administration of the Poly ADP-Ribose Polymerase (PARP) Inhibitor, PJ34 During Hindlimb Ischemia Modulates Skeletal Muscle Reperfusion Injury.
Myocardial Infarction
MicroRNA-577 inhibits cardiomyocyte apoptosis induced by myocardial infarction via targeting PARP1.
Myocardial Infarction
MicroRNA-760-mediated low expression of DUSP1 impedes the protective effect of NaHS on myocardial ischemia-reperfusion injury.
Myocardial Infarction
Minocycline improves cardiac function after myocardial infarction in rats by inhibiting activation of PARP-1.
Myocardial Infarction
Myocardial postischemic injury is reduced by polyADPripose polymerase-1 gene disruption.
Myocardial Infarction
Natural Inhibitors of Poly(ADP-ribose) Polymerase-1.
Myocardial Infarction
PARP inhibition prevents postinfarction myocardial remodeling and heart failure via the protein kinase C/glycogen synthase kinase-3beta pathway.
Myocardial Infarction
PARP-1 inhibition attenuates cardiac fibrosis induced by myocardial infarction through regulating autophagy.
Myocardial Infarction
Poly (ADP-ribose) polymerase, nitric oxide and cell death.
Myocardial Infarction
Poly (ADP-Ribose) Polymerase-1 (PARP-1) as Immune Regulator.
Myocardial Infarction
Poly(ADP-ribose) Polymerase (PARP) and PARP Inhibitors: Mechanisms of Action and Role in Cardiovascular Disorders.
Myocardial Infarction
Poly(ADP-ribose) polymerase as a drug target for cardiovascular disease and cancer: an update.
Myocardial Infarction
Poly(ADP-ribose) polymerase contributes to the development of myocardial infarction in diabetic rats and regulates the nuclear translocation of apoptosis-inducing factor.
Myocardial Infarction
Poly(ADP-ribose) polymerase inhibitors: new pharmacological functions and potential clinical implications.
Myocardial Infarction
Poly(ADP-ribose) polymerases: homology, structural domains and functions. Novel therapeutical applications.
Myocardial Infarction
Potential clinical applications of poly(ADP-ribose) polymerase (PARP) inhibitors.
Myocardial Infarction
Pretreatment of therapeutic cells with poly(ADP-ribose) polymerase inhibitor enhances their efficacy in an in vitro model of cell-based therapy in myocardial infarct.
Myocardial Infarction
Protective effect of diethylcarbamazine inhibits NF-?B activation in isoproterenol-induced acute myocardial infarction rat model through the PARP pathway.
Myocardial Infarction
Relationship between NADPH oxidase p22phox C242T, PARP-1 Val762Ala polymorphisms, angiographically verified coronary artery disease and myocardial infarction in South Indian patients with type 2 diabetes mellitus.
Myocardial Infarction
Reversible induction of PARP1 degradation by p53-inducible cis-imidazoline compounds.
Myocardial Infarction
Rho-kinase signaling pathway promotes the expression of PARP to accelerate cardiomyocyte apoptosis in ischemia/reperfusion.
Myocardial Infarction
Role of oxidative-nitrosative stress and downstream pathways in various forms of cardiomyopathy and heart failure.
Myocardial Infarction
Specific protein 1 inhibitor mithramycin A protects cardiomyocytes from myocardial infarction via interacting with PARP.
Myocardial Infarction
Suppression of poly (ADP-ribose) polymerase activation by 3-aminobenzamide in a rat model of myocardial infarction: long-term morphological and functional consequences.
Myocardial Infarction
The functional role of poly(ADP-ribose)polymerase 1 as novel coactivator of NF-kappaB in inflammatory disorders.
Myocardial Infarction
The role of Akt and mitogen-activated protein kinase systems in the protective effect of poly(ADP-ribose) polymerase inhibition in Langendorff perfused and in isoproterenol-damaged rat hearts.
Myocardial Infarction
[Poly(ADP-ribose) polymerases-1 inhibitor MRL-45696 alleviates DNA damage after myocardial ischemia-reperfusion in diabetic rats].
Myocardial Ischemia
A novel and orally active poly(ADP-ribose) polymerase inhibitor, KR-33889 [2-[methoxycarbonyl(4-methoxyphenyl) methylsulfanyl]-1H-benzimidazole-4-carboxylic acid amide], attenuates injury in in vitro model of cell death and in vivo model of cardiac ischemia.
Myocardial Ischemia
Absence of poly(ADP-ribose)polymerase-1 alters nuclear factor-kappa B activation and gene expression of apoptosis regulators after reperfusion injury.
Myocardial Ischemia
Activation of poly(ADP-ribose) polymerase by myocardial ischemia and coronary reperfusion in human circulating leukocytes.
Myocardial Ischemia
Development of a high-throughput screening-amenable assay for human poly(ADP-ribose) polymerase inhibitors.
Myocardial Ischemia
Development of a miniaturized assay for the high-throughput screening program for poly(ADP-ribose) polymerase-1.
Myocardial Ischemia
Differential regulation of activator protein-1 and heat shock factor-1 in myocardial ischemia and reperfusion injury: role of poly(ADP-ribose) polymerase-1.
Myocardial Ischemia
In vitro effect of the potent poly(ADP-ribose) polymerase (PARP) inhibitor INO-1001 alone and in combination with aspirin, eptifibatide, tirofiban, enoxaparin or alteplase on haemostatic parameters.
Myocardial Ischemia
Inhibition of poly(ADP-ribose) polymerase activity is insufficient to induce tetraploidy.
Myocardial Ischemia
Inhibitors of poly (ADP-ribose) polymerase ameliorate myocardial reperfusion injury by modulation of activator protein-1 and neutrophil infiltration.
Myocardial Ischemia
Myocardial postischemic injury is reduced by polyADPripose polymerase-1 gene disruption.
Myocardial Ischemia
PARP1 promote autophagy in cardiomyocytes via modulating FoxO3a transcription.
Myocardial Ischemia
Poly(ADP-ribose) polymerase inhibitors.
Myocardial Ischemia
Prevalent role of Akt and ERK activation in cardioprotective effect of Ca(2+) channel- and beta-adrenergic receptor blockers.
Myocardial Ischemia
Suppression of poly (ADP-ribose) polymerase activation by 3-aminobenzamide in a rat model of myocardial infarction: long-term morphological and functional consequences.
Myocardial Ischemia
Therapeutic injection of PARP inhibitor INO-1001 preserves cardiac function in porcine myocardial ischemia and reperfusion without reducing infarct size.
Myocardial Ischemia
Vasodilator signals from the ischemic myocardium are transduced to the coronary vascular wall by pertussis toxin-sensitive G proteins: a new experimental method for the analysis of the interaction between the myocardium and coronary vessels.
Myocardial Reperfusion Injury
Absence of poly(ADP-ribose)polymerase-1 alters nuclear factor-kappa B activation and gene expression of apoptosis regulators after reperfusion injury.
Myocardial Reperfusion Injury
Activation of poly(ADP-ribose) polymerase in circulating leukocytes during myocardial infarction.
Myocardial Reperfusion Injury
Beneficial effects of a novel ultrapotent poly(ADP-ribose) polymerase inhibitor in murine models of heart failure.
Myocardial Reperfusion Injury
Beneficial effects of poly (ADP-ribose) polymerase inhibition against the reperfusion injury in heart transplantation.
Myocardial Reperfusion Injury
Differential regulation of activator protein-1 and heat shock factor-1 in myocardial ischemia and reperfusion injury: role of poly(ADP-ribose) polymerase-1.
Myocardial Reperfusion Injury
Inhibitors of poly (ADP-ribose) polymerase ameliorate myocardial reperfusion injury by modulation of activator protein-1 and neutrophil infiltration.
Myocardial Reperfusion Injury
Pharmacologic inhibition of poly(adenosine diphosphate-ribose) polymerase may represent a novel therapeutic approach in chronic heart failure.
Myocardial Reperfusion Injury
Role of nitrosative stress and poly(ADP-ribose) polymerase activation in myocardial reperfusion injury.
Myocardial Reperfusion Injury
Suppression of poly (ADP-ribose) polymerase activation by 3-aminobenzamide in a rat model of myocardial infarction: long-term morphological and functional consequences.
Myositis
Interleukin-37 (IL-37) Suppresses Pertussis Toxin-Induced Inflammatory Myopathy in a Rat Model.
Myxoma
Poxvirus infection rapidly activates tyrosine kinase signal transduction.
nad+ adp-ribosyltransferase deficiency
A possible role for telomerase RNA and telomere length in global mitotic recombination.
nad+ adp-ribosyltransferase deficiency
Analysis of genetic variants of the poly(ADP-ribose) polymerase-1 gene in breast cancer in French patients.
nad+ adp-ribosyltransferase deficiency
B Cell-Intrinsic and -Extrinsic Regulation of Antibody Responses by PARP14, an Intracellular (ADP-Ribosyl)Transferase.
nad+ adp-ribosyltransferase deficiency
Changes in poly(ADP-ribose) level modulate the kinetics of DNA strand break rejoining.
nad+ adp-ribosyltransferase deficiency
Chromosomal aberrations in PARP(-/-) mice: genome stabilization in immortalized cells by reintroduction of poly(ADP-ribose) polymerase cDNA.
nad+ adp-ribosyltransferase deficiency
CRISPR/Cas9-mediated mutagenesis to validate the synergy between PARP1 inhibition and chemotherapy in BRCA1-mutated breast cancer cells.
nad+ adp-ribosyltransferase deficiency
Cytokine-mediated ?-cell damage in PARP-1-deficient islets.
nad+ adp-ribosyltransferase deficiency
Dietary flavones and flavonoles are inhibitors of poly(ADP-ribose)polymerase-1 in pulmonary epithelial cells.
nad+ adp-ribosyltransferase deficiency
Differential susceptibility of normal and PARP knock-out mouse fibroblasts to proteasome inhibitors.
nad+ adp-ribosyltransferase deficiency
DNA strand break-sensing molecule poly(ADP-Ribose) polymerase cooperates with p53 in telomere function, chromosome stability, and tumor suppression.
nad+ adp-ribosyltransferase deficiency
Effect of PARP-1 deficiency on DNA damage and repair in human bronchial epithelial cells exposed to Benzo(a)pyrene.
nad+ adp-ribosyltransferase deficiency
Effects of PARP-1 Deficiency and Histamine H4 Receptor Inhibition in an Inflammatory Model of Lung Fibrosis in Mice.
nad+ adp-ribosyltransferase deficiency
Effects of PARP-1 deficiency on airway inflammatory cell recruitment in response to LPS or TNF: differential effects on CXCR2 ligands and Duffy antigen receptor for chemokines.
nad+ adp-ribosyltransferase deficiency
Effects of PARP-1 deficiency on Th1 and Th2 cell differentiation.
nad+ adp-ribosyltransferase deficiency
Erratum to: PARP10 deficiency manifests by severe developmental delay and DNA repair defect.
nad+ adp-ribosyltransferase deficiency
Genetic alteration of poly(ADP-ribose) polymerase-1 in human germ cell tumors.
nad+ adp-ribosyltransferase deficiency
Glycolytic rate and lymphomagenesis depend on PARP14, an ADP ribosyltransferase of the B aggressive lymphoma (BAL) family.
nad+ adp-ribosyltransferase deficiency
Increased Foxp3+ regulatory T cells in poly(ADP-Ribose) polymerase-1 deficiency.
nad+ adp-ribosyltransferase deficiency
Inhibition of poly(ADP-ribose) polymerase activity is insufficient to induce tetraploidy.
nad+ adp-ribosyltransferase deficiency
Investigation of the relative biological effectiveness and uniform isobiological killing effects of irradiation with a clinical carbon SOBP beam on DNA repair deficient CHO cells.
nad+ adp-ribosyltransferase deficiency
Loss of PARP-1 attenuates diabetic arteriosclerotic calcification via Stat1/Runx2 axis.
nad+ adp-ribosyltransferase deficiency
Loss of poly(ADP-ribose) polymerase 1 attenuates renal fibrosis and inflammation during unilateral ureteral obstruction.
nad+ adp-ribosyltransferase deficiency
Misregulation of gene expression in primary fibroblasts lacking poly(ADP-ribose) polymerase.
nad+ adp-ribosyltransferase deficiency
Modulation of Poly(ADP-Ribose) Polymerase-1 (PARP-1)-Mediated Oxidative Cell Injury by Ring Finger Protein 146 (RNF146) in Cardiac Myocytes.
nad+ adp-ribosyltransferase deficiency
Mutagenic effects of poly (ADP-ribose) polymerase-1 deficiency in transgenic mice.
nad+ adp-ribosyltransferase deficiency
Normal telomere length and chromosomal end capping in poly(ADP-ribose) polymerase-deficient mice and primary cells despite increased chromosomal instability.
nad+ adp-ribosyltransferase deficiency
Opposing roles of PARP-1 in MMP-9 and TIMP-2 expression and mast cell degranulation in dyslipidemic dilated cardiomyopathy.
nad+ adp-ribosyltransferase deficiency
Parg deficiency confers radio-sensitization through enhanced cell death in mouse ES cells exposed to various forms of ionizing radiation.
nad+ adp-ribosyltransferase deficiency
PARP-1 deficiency blocks IL-5 expression through calpain-dependent degradation of STAT-6 in a murine asthma model.
nad+ adp-ribosyltransferase deficiency
Parp-1 deficiency causes an increase of deletion mutations and insertions/rearrangements in vivo after treatment with an alkylating agent.
nad+ adp-ribosyltransferase deficiency
Parp-1 deficiency does not enhance liver carcinogenesis induced by 2-amino-3-methylimidazo[4,5-f]quinoline in mice.
nad+ adp-ribosyltransferase deficiency
Parp-1 deficiency does not increase the frequency of tumors in the oral cavity and esophagus of ICR/129Sv mice by 4-nitroquinoline 1-oxide, a carcinogen producing bulky adducts.
nad+ adp-ribosyltransferase deficiency
PARP-1 DEFICIENCY EXACERBATES DIET-INDUCED OBESITY IN MICE.
nad+ adp-ribosyltransferase deficiency
Parp-1 deficiency implicated in colon and liver tumorigenesis induced by azoxymethane.
nad+ adp-ribosyltransferase deficiency
Parp-1 deficiency in ES cells promotes invasive and metastatic lesions accompanying induction of trophoblast giant cells during tumorigenesis in uterine environment.
nad+ adp-ribosyltransferase deficiency
PARP-1 deficiency increases the severity of disease in a mouse model of multiple sclerosis.
nad+ adp-ribosyltransferase deficiency
PARP-1 involves in UVB-induced inflammatory response in keratinocytes and skin injury via regulation of ROS-dependent EGFR transactivation and p38 signaling.
nad+ adp-ribosyltransferase deficiency
Parp1 deficiency confers defects in chromatin surveillance and remodeling during reprogramming by nuclear transfer.
nad+ adp-ribosyltransferase deficiency
PARP1 deficiency protects against hyperglycemia-induced neointimal hyperplasia by upregulating TFPI2 activity in diabetic mice.
nad+ adp-ribosyltransferase deficiency
PARP1 Deficiency Reduces Tumour Growth by Decreasing E2F1 Hyperactivation: A Novel Mechanism in the Treatment of Cancer.
nad+ adp-ribosyltransferase deficiency
PARP1 Is a TRF2-associated poly(ADP-ribose)polymerase and protects eroded telomeres.
nad+ adp-ribosyltransferase deficiency
PARP1 poly(ADP-ribosyl)ates Sox2 to control Sox2 protein levels and FGF4 expression during embryonic stem cell differentiation.
nad+ adp-ribosyltransferase deficiency
PARP10 deficiency manifests by severe developmental delay and DNA repair defect.
nad+ adp-ribosyltransferase deficiency
PARP9 and PARP14 cross-regulate macrophage activation via STAT1 ADP-ribosylation.
nad+ adp-ribosyltransferase deficiency
Partial protection against collagen antibody-induced arthritis in PARP-1 deficient mice.
nad+ adp-ribosyltransferase deficiency
Poly (ADP-Ribose) Polymerase-1 (PARP-1) as Immune Regulator.
nad+ adp-ribosyltransferase deficiency
Poly (ADP-Ribose) Polymerase-1 (PARP1) Deficiency and Pharmacological Inhibition by Pirenzepine Protects From Cisplatin-Induced Ototoxicity Without Affecting Antitumor Efficacy.
nad+ adp-ribosyltransferase deficiency
Poly (ADP-ribose) polymerase-1 deficiency does not affect ethylnitrosourea mutagenicity in liver and testis of lacZ transgenic mice.
nad+ adp-ribosyltransferase deficiency
Poly(ADP-ribose) polymerase 1 accelerates vascular calcification by upregulating Runx2.
nad+ adp-ribosyltransferase deficiency
Poly(ADP-ribose) polymerase 1 activation is required for cisplatin nephrotoxicity.
nad+ adp-ribosyltransferase deficiency
Poly(ADP-ribose) polymerase 1 deficiency increases nitric oxide production and attenuates aortic atherogenesis through downregulation of arginase II.
nad+ adp-ribosyltransferase deficiency
Poly(ADP-ribose) polymerase impairs early and long-term experimental stroke recovery.
nad+ adp-ribosyltransferase deficiency
Poly(ADP-ribose) polymerase suppression protects rheumatoid synovial fibroblasts from Fas-induced apoptosis.
nad+ adp-ribosyltransferase deficiency
Poly(ADP-ribose) polymerase-1 is a determining factor in Crm1-mediated nuclear export and retention of p65 NF-kappa B upon TLR4 stimulation.
nad+ adp-ribosyltransferase deficiency
Poly(ADP-ribose) polymerase-1 modulates interferon-gamma-inducible protein (IP)-10 expression in murine embryonic fibroblasts by stabilizing IP-10 mRNA.
nad+ adp-ribosyltransferase deficiency
Poly(ADP-ribose) polymerase-1 plays a role in suppressing mammary tumourigenesis in mice.
nad+ adp-ribosyltransferase deficiency
Poly(ADP-ribose) polymerase-1 regulates the stability of the wild-type p53 protein.
nad+ adp-ribosyltransferase deficiency
Poly(ADP-ribosyl)ation of Methyl CpG Binding Domain Protein 2 Regulates Chromatin Structure.
nad+ adp-ribosyltransferase deficiency
Reduced stability of regularly spliced but not alternatively spliced p53 protein in PARP-deficient mouse fibroblasts.
nad+ adp-ribosyltransferase deficiency
Role of Parp-1 in suppressing spontaneous deletion mutation in the liver and brain of mice at adolescence and advanced age.
nad+ adp-ribosyltransferase deficiency
Role of poly(ADP-ribosyl)ation in a 'two-hit' model of hypoxia and oxidative stress in human A549 epithelial cells in vitro.
nad+ adp-ribosyltransferase deficiency
Role of the activation of the nuclear enzyme poly(ADP-ribose) polymerase in the pathogenesis of periodontitis.
nad+ adp-ribosyltransferase deficiency
Spontaneous Development of Dental Dysplasia in Aged Parp-1 Knockout Mice.
nad+ adp-ribosyltransferase deficiency
Syncytiotrophoblastic giant cells in teratocarcinoma-like tumors derived from Parp-disrupted mouse embryonic stem cells.
nad+ adp-ribosyltransferase deficiency
Synthetic viability by BRCA2 and PARP1/ARTD1 deficiencies.
nad+ adp-ribosyltransferase deficiency
The BRCT domain of PARP-1 is required for immunoglobulin gene conversion.
nad+ adp-ribosyltransferase deficiency
Transcriptional regulation by poly(ADP-ribose) polymerase-1 during T cell activation.
nad+ adp-ribosyltransferase deficiency
Transcriptional reprogramming and resistance to colonic mucosal injury in Poly(ADP-ribose) polymerase 1 (PARP1)-deficient mice.
Nasal Polyps
Intralesional bleomycin A5 injection for the treatment of nasal polyps through inducing apoptosis.
Nasopharyngeal Carcinoma
CHM-1 Suppresses Formation of Cell Surface-associated GRP78-p85? Complexes, Inhibiting PI3K-AKT Signaling and Inducing Apoptosis of Human Nasopharyngeal Carcinoma Cells.
Nasopharyngeal Carcinoma
Evidence of a novel antiapoptotic factor: role of inhibitor of differentiation or DNA binding (Id-1) in anticancer drug-induced apoptosis.
Nasopharyngeal Carcinoma
Loss of NFBD1/MDC1 disrupts homologous recombination repair and sensitizes nasopharyngeal carcinoma cells to PARP inhibitors.
Nasopharyngeal Carcinoma
PARP-1 promotes autophagy via the AMPK/mTOR pathway in CNE-2 human nasopharyngeal carcinoma cells following ionizing radiation, while inhibition of autophagy contributes to the radiation sensitization of CNE-2 cells.
Nasopharyngeal Carcinoma
Poly(ADP-ribose) polymerase 1 is overexpressed in nasopharyngeal carcinoma and its inhibition enhances radiotherapy.
Nasopharyngeal Carcinoma
Poly(ADP-ribose) polymerase-1 regulates the mechanism of irradiation-induced CNE-2 human nasopharyngeal carcinoma cell autophagy and inhibition of autophagy contributes to the radiation sensitization of CNE-2 cells.
Nasopharyngeal Carcinoma
Protein expression and intracellular localization of prostate apoptosis response-4 (Par-4) are associated with apoptosis induction in nasopharyngeal carcinoma cell lines.
Nasopharyngeal Carcinoma
Radiosensitizing Potential of Curcumin in Different Cancer Models.
Nasopharyngeal Carcinoma
Tanshinone IIA inhibits proliferation and induces apoptosis of human nasopharyngeal carcinoma cells via p53-cyclin B1/CDC2.
Nasopharyngeal Carcinoma
[Expression and Implication of Base Excision Repair Genes in Human Nasopharyngeal Carcinoma and Non-tumor Nasopharyngeal Tissues.]
Neoplasm Metastasis
5-Fluorouracil induced Fas upregulation associated with apoptosis in liver metastases of colorectal cancer patients.
Neoplasm Metastasis
A chromatin localization screen reveals poly (ADP ribose)-regulated recruitment of the repressive polycomb and NuRD complexes to sites of DNA damage.
Neoplasm Metastasis
Advancements in PARP1 Targeted Nuclear Imaging and Theranostic Probes.
Neoplasm Metastasis
An analysis of the gene interaction networks identifying the role of PARP1 in metastasis of non-small cell lung cancer.
Neoplasm Metastasis
Analysis of molecular markers as predictive factors of lymph node involvement in breast carcinoma.
Neoplasm Metastasis
Apigenin Attenuates Melanoma Cell Migration by Inducing Anoikis through Integrin and Focal Adhesion Kinase Inhibition.
Neoplasm Metastasis
ATMIN Suppresses Metastasis by Altering the WNT-Signaling Pathway via PARP1 in MSI-High Colorectal Cancer.
Neoplasm Metastasis
Cdk5 promotes DNA replication stress checkpoint activation through RPA-32 phosphorylation, and impacts on metastasis free survival in breast cancer patients.
Neoplasm Metastasis
Combination therapy with dacarbazine and statins improved the survival rate in mice with metastatic melanoma.
Neoplasm Metastasis
Deciphering the Insights of Poly(ADP-Ribosylation) in Tumor Progression.
Neoplasm Metastasis
Differential regulation of breast cancer bone metastasis by PARP1 and PARP2.
Neoplasm Metastasis
DNA damage response genes and the development of cancer metastasis.
Neoplasm Metastasis
Down-regulation of Notch receptor signaling pathway induces caspase-dependent and caspase-independent apoptosis in lung squamous cell carcinoma cells.
Neoplasm Metastasis
ERCC1, PARP-1, and AQP1 as predictive biomarkers in colon cancer patients receiving adjuvant chemotherapy.
Neoplasm Metastasis
Expression of PARP-1 and its active polymer PAR in prostate cancer and benign prostatic hyperplasia in Chinese patients.
Neoplasm Metastasis
Garcinol Inhibits Cell Proliferation and Promotes Apoptosis in Pancreatic Adenocarcinoma Cells.
Neoplasm Metastasis
Genomic profiling in locally advanced and inflammatory breast cancer and its link to DCE-MRI and overall survival.
Neoplasm Metastasis
High PARP-1 expression is associated with tumor invasion and poor prognosis in gastric cancer.
Neoplasm Metastasis
Identification of PARP-1 in cancer stem cells of gastrointestinal cancers: A preliminary study.
Neoplasm Metastasis
Individual and Combined Expression of DNA Damage Response Molecules PARP1, ?H2AX, BRCA1, and BRCA2 Predict Shorter Survival of Soft Tissue Sarcoma Patients.
Neoplasm Metastasis
Inhibition of lymphoma invasion and liver metastasis formation by pertussis toxin.
Neoplasm Metastasis
Integration of Comprehensive Genomic Analysis and Functional Screening of Affected Molecular Pathways to Inform Cancer Therapy.
Neoplasm Metastasis
Lymph Node Metastasis of Gastric Cancer Is Associated with the Interaction Between Poly (ADP-Ribose) Polymerase 1 and Matrix Metallopeptidase 2.
Neoplasm Metastasis
Mortaparib, a novel dual inhibitor of mortalin and PARP1, is a potential drug candidate for ovarian and cervical cancers.
Neoplasm Metastasis
PARG regulates the proliferation and differentiation of DCs and T cells via PARP/NF??B in tumour metastases of colon carcinoma.
Neoplasm Metastasis
PARP Inhibitor Olaparib Use in a BRCA1-Positive Patient With Metastatic Triple-Negative Breast Cancer, Without the Initial Use of Platinum-Based Chemotherapy, Showing Significant Rapid Near Resolution of Large Liver Metastasis While Patient Experienced Gout-Like Symptoms.
Neoplasm Metastasis
PARP-1 induces EMT in non-small cell lung carcinoma cells via modulating the transcription factors Smad4, p65 and ZEB1.
Neoplasm Metastasis
PARP-1 inhibition as a targeted strategy to treat Ewing's sarcoma.
Neoplasm Metastasis
PARP-1 inhibitor modulate ?-catenin signaling to enhance cisplatin sensitivity in cancer cervix.
Neoplasm Metastasis
PARP-1 serves as a novel molecular marker for hepatocellular carcinoma in a Southern Chinese Zhuang population.
Neoplasm Metastasis
PARP1 as a Marker of an Aggressive Clinical Phenotype in Cutaneous Melanoma-A Clinical and an In Vitro Study.
Neoplasm Metastasis
PARP1 enhances lung adenocarcinoma metastasis by novel mechanisms independent of DNA repair.
Neoplasm Metastasis
PARP1 in Carcinomas and PARP1 Inhibitors as Antineoplastic Drugs.
Neoplasm Metastasis
PARP10 suppresses tumor metastasis through regulation of Aurora A activity.
Neoplasm Metastasis
PARP3 inhibitors ME0328 and olaparib potentiate vinorelbine sensitization in breast cancer cell lines.
Neoplasm Metastasis
Pertussis toxin inhibition of T-cell hybridoma invasion is reversed by manganese-induced activation of LFA-1.
Neoplasm Metastasis
Poly(ADP-Ribose) Polymerase Inhibition Sensitizes Colorectal Cancer-Initiating Cells to Chemotherapy.
Neoplasm Metastasis
Poly(ADP-ribose)polymerase inhibition decreases angiogenesis.
Neoplasm Metastasis
Reduction of metastatic potential by inhibiting EGFR/Akt/p38/ERK signaling pathway and epithelial-mesenchymal transition after carbon ion exposure is potentiated by PARP-1 inhibition in non-small-cell lung cancer.
Neoplasm Metastasis
Response to Olaparib in a Patient with Germline BRCA2 Mutation and Breast Cancer Leptomeningeal Carcinomatosis.
Neoplasm Metastasis
RNF114 suppresses metastasis through regulation of PARP10 in cervical cancer cells.
Neoplasm Metastasis
Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial.
Neoplasm Metastasis
SOX2 inhibits cell proliferation and metastasis, promotes apoptotic by downregulating CCND1 and PARP in gastric cancer.
Neoplasm Metastasis
Targeting Gi/o protein-coupled receptor signaling blocks HER2-induced breast cancer development and enhances HER2-targeted therapy.
Neoplasm Metastasis
The chemokine receptor CXCR4 is required for outgrowth of colon carcinoma micrometastases.
Neoplasm Metastasis
The diagnostic value of DNA repair gene in breast cancer metastasis.
Neoplasm Metastasis
The expression of gene transcripts of telomere-associated genes in human breast cancer: correlation with clinico-pathological parameters and clinical outcome.
Neoplasm Metastasis
The PARP Enzyme Family and the Hallmarks of Cancer Part 1. Cell Intrinsic Hallmarks.
Neoplasm Metastasis
The relationship between motility factor receptor internalization and the lung colonization capacity of murine melanoma cells.
Neoplasm Metastasis
Topical 2'-Hydroxyflavanone for Cutaneous Melanoma.
Neoplasm Metastasis
Transgelin interacts with PARP1 in human colon cancer cells.
Neoplasm Metastasis
Uncovering synthetic lethal interactions for therapeutic targets and predictive markers in lung adenocarcinoma.
Neoplasm Metastasis
WITHDRAWN: An analysis of the gene interaction networks identifying the role of PARP1 in metastasis of non-small cell lung cancer.
Neoplasm Metastasis
[Mechanism of the activation of extracellular signal-regulated kinase (ERK) in prostate cancer cell lines with different metastatic potential]
Neoplasm Micrometastasis
The chemokine receptor CXCR4 is required for outgrowth of colon carcinoma micrometastases.
Neoplasm, Residual
Major clinical research advances in gynecologic cancer in 2019.
Neoplasm, Residual
PARP inhibitor Olaparib overcomes Sorafenib resistance through reshaping the pluripotent transcriptome in hepatocellular carcinoma.
Neoplasm, Residual
Treatment of triple-negative breast cancer using anti-EGFR-directed radioimmunotherapy combined with radiosensitizing chemotherapy and PARP inhibitor.
Neoplasms
"Lazarus Response" to Olaparib in a Virtually Chemonaive Breast Cancer Patient Carrying Gross BRCA2 Gene Deletion.
Neoplasms
'PARP'ing fibrosis: repurposing poly (ADP ribose) polymerase (PARP) inhibitors.
Neoplasms
(-)-Epigallocatechin Gallate (EGCG) Enhances the Sensitivity of Colorectal Cancer Cells to 5-FU by Inhibiting GRP78/NF-?B/miR-155-5p/MDR1 Pathway.
Neoplasms
1,3-Bis(3,5-dichlorophenyl) urea compound 'COH-SR4' inhibits proliferation and activates apoptosis in melanoma.
Neoplasms
15-Lipoxygenase-1 induced by interleukin-4 mediates apoptosis in oral cavity cancer cells.
Neoplasms
17?-androstenediol-mediated oncophagy of tumor cells by different mechanisms is determined by the target tumor.
Neoplasms
18?-Glycyrrhetinic acid potentiates Hsp90 inhibition-induced apoptosis in human epithelial ovarian carcinoma cells via activation of death receptor and mitochondrial pathway.
Neoplasms
2-Hydroxyglutarate produced by neomorphic IDH mutations suppresses homologous recombination and induces PARP inhibitor sensitivity.
Neoplasms
2-[4-(7-chloro-2-quinoxalinyloxy)phenoxy]-propionic acid (XK469) inhibition of topoisomerase IIbeta is not sufficient for therapeutic response in human Waldenstrom's macroglobulinemia xenograft model.
Neoplasms
2-[5-Selenocyanato-pentyl]-6-amino-benzo[de]isoquinoline-1,3-dione inhibits angiogenesis, induces p53 dependent mitochondrial apoptosis and enhances therapeutic efficacy of cyclophosphamide.
Neoplasms
2D and 3D similarity landscape analysis identifies PARP as a novel off-target for the drug Vatalanib.
Neoplasms
3,3'-Diindolylmethane enhances chemosensitivity of multiple chemotherapeutic agents in pancreatic cancer.
Neoplasms
3-Aminobenzamide delays rejoining of DNA strand breaks in gamma-irradiated lymphocytes from patients with breast cancer and not cervical cancer.
Neoplasms
4-[3-(4-cyclopropanecarbonylpiperazine-1-carbonyl)-4-fluorobenzyl]-2H-phthalazin-1-one: a novel bioavailable inhibitor of poly(ADP-ribose) polymerase-1.
Neoplasms
5-Fluorouracil induced Fas upregulation associated with apoptosis in liver metastases of colorectal cancer patients.
Neoplasms
5-Substituted 3-isopropyl-7-[4-(2-pyridyl)benzyl]amino-1(2)H-pyrazolo[4,3-d]pyrimidines with anti-proliferative activity as potent and selective inhibitors of cyclin-dependent kinases.
Neoplasms
53BP1 as a potential predictor of response in PARP inhibitor-treated homologous recombination-deficient ovarian cancer.
Neoplasms
53BP1 depletion causes PARP inhibitor resistance in ATM-deficient breast cancer cells.
Neoplasms
53BP1-RIF1-shieldin counteracts DSB resection through CST- and Pol?-dependent fill-in.
Neoplasms
53BP1: a DSB escort.
Neoplasms
6-thioguanine selectively kills BRCA2-defective tumors and overcomes PARP inhibitor resistance.
Neoplasms
?-Catenin, a Wnt/?-catenin modulator, reveals inducible mutagenesis promoting cancer cell survival adaptation and metabolic reprogramming.
Neoplasms
?-Mangostin inhibits DMBA/TPA-induced skin cancer through inhibiting inflammation and promoting autophagy and apoptosis by regulating PI3K/Akt/mTOR signaling pathway in mice.
Neoplasms
?-Tocotrienol-induced autophagy in malignant mammary cancer cells.
Neoplasms
A cationic cholesterol based nanocarrier for the delivery of p53-EGFP-C3 plasmid to cancer cells.
Neoplasms
A combination of PARP and CHK1 inhibitors efficiently antagonizes MYCN-driven tumors.
Neoplasms
A comparative pharmacokinetic study of PARP inhibitors demonstrates favorable properties for niraparib efficacy in preclinical tumor models.
Neoplasms
A comprehensive look of poly(ADP-ribose) polymerase inhibition strategies and future directions for cancer therapy.
Neoplasms
A conserved NAD(+) binding pocket that regulates protein-protein interactions during aging.
Neoplasms
A critical evaluation of methods to interpret drug combinations.
Neoplasms
A Data Integration Workflow to Identify Drug Combinations Targeting Synthetic Lethal Interactions.
Neoplasms
A decade of clinical development of PARP inhibitors in perspective.
Neoplasms
A deletion linked to a poly(ADP-ribose) polymerase gene on chromosome 13q33-qter occurs frequently in the normal black population as well as in multiple tumor DNA.
Neoplasms
A dermatan sulfate-functionalized biomimetic nanocarrier for melanoma targeted chemotherapy.
Neoplasms
A duplicated region is responsible for the poly(ADP-ribose) polymerase polymorphism, on chromosome 13, associated with a predisposition to cancer.
Neoplasms
A first-in-class Polymerase Theta Inhibitor selectively targets Homologous-Recombination-Deficient Tumors.
Neoplasms
A GEMA of a personalized medicine strategy.
Neoplasms
A general framework for quantifying the effects of DNA repair inhibitors on radiation sensitivity as a function of dose.
Neoplasms
A high-throughput chemical screen with FDA approved drugs reveals that the antihypertensive drug Spironolactone impairs cancer cell survival by inhibiting homology directed repair.
Neoplasms
A high-throughput RNA interference screen for DNA repair determinants of PARP inhibitor sensitivity.
Neoplasms
A Homogeneous Polysaccharide from Fructus Schisandra chinensis (Turz.) Baill Induces Mitochondrial Apoptosis through the Hsp90/AKT Signalling Pathway in HepG2 Cells.
Neoplasms
A label-free PFP-based photoelectrochemical biosensor for highly sensitive detection of PARP-1 activity.
Neoplasms
A macrohistone variant links dynamic chromatin compaction to BRCA1-dependent genome maintenance.
Neoplasms
A marker of homologous recombination predicts pathological complete response to neoadjuvant chemotherapy in primary breast cancer.
Neoplasms
A meta-analysis of reversion mutations in BRCA genes identifies signatures of DNA end-joining repair mechanisms driving therapy resistance.
Neoplasms
A nano-liposome formulation of the PARP inhibitor Talazoparib enhances treatment efficacy and modulates immune cell populations in mammary tumors of BRCA-deficient mice.
Neoplasms
A new ADP-ribosyltransferase in human serum: significance in cancer.
Neoplasms
A New Nanobody-Based Biosensor to Study Endogenous PARP1 In Vitro and in Live Human Cells.
Neoplasms
A new underlying mechanism for the neuroprotective effect of bosutinib: Reverting toxicity-induced PARylation in SIN1-mediated neurotoxicity.
Neoplasms
A novel diterpene suppresses CWR22Rv1 tumor growth in vivo through antiproliferation and proapoptosis.
Neoplasms
A novel L-fucose-binding lectin from Fenneropenaeus indicus induced cytotoxicity in breast cancer cells.
Neoplasms
A Novel Mechanism to Induce BRCAness in Cancer Cells.
Neoplasms
A novel PI3K inhibitor displays potent preclinical activity against an androgen-independent and PTEN-deficient prostate cancer model established from the cell line PC3.
Neoplasms
A novel poly(ADP-ribose) polymerase inhibitor, ABT-888, radiosensitizes malignant human cell lines under hypoxia.
Neoplasms
A novel sLRP6E1E2 inhibits canonical Wnt signaling, epithelial-to-mesenchymal transition, and induces mitochondria-dependent apoptosis in lung cancer.
Neoplasms
A novel small molecule, LLL12, inhibits STAT3 phosphorylation and activities and exhibits potent growth-suppressive activity in human cancer cells.
Neoplasms
A novel synthetic derivative of the natural product berbamine inhibits cell viability and induces apoptosis of human osteosarcoma cells, associated with activation of JNK/AP-1 signaling.
Neoplasms
A novel tankyrase inhibitor, MSC2504877, enhances the effects of clinical CDK4/6 inhibitors.
Neoplasms
A Novel Use for Olaparib for Treatment of Metastatic Castration-Recurrent Prostate Cancer.
Neoplasms
A novel yeast cell-based screen identifies flavone as a tankyrase inhibitor.
Neoplasms
A novelly synthesized phenanthroline derivative is a promising DNA-damaging anticancer agent inhibiting G1/S checkpoint transition and inducing cell apoptosis in cancer cells.
Neoplasms
A P53-Independent DNA Damage Response Suppresses Oncogenic Proliferation and Genome Instability.
Neoplasms
A peptide with three hyaluronan binding motifs inhibits tumor growth and induces apoptosis.
Neoplasms
A PET imaging agent for evaluating PARP-1 expression in ovarian cancer.
Neoplasms
A phase 1 study of PARP-inhibitor ABT-767 in advanced solid tumors with BRCA1/2 mutations and high-grade serous ovarian, fallopian tube, or primary peritoneal cancer.
Neoplasms
A Phase I Clinical Trial of the Poly(ADP-ribose) Polymerase Inhibitor Veliparib and Weekly Topotecan in Patients with Solid Tumors.
Neoplasms
A Phase I Combination Study of Olaparib with Cisplatin and Gemcitabine in Adults with Solid Tumors.
Neoplasms
A Phase I Dose-Escalation Study of Veliparib Combined with Carboplatin and Etoposide in Patients with Extensive-Stage Small Cell Lung Cancer and Other Solid Tumors.
Neoplasms
A phase I study of intravenous and oral rucaparib in combination with chemotherapy in patients with advanced solid tumours.
Neoplasms
A phase I study of the PD-L1 inhibitor, durvalumab, in combination with a PARP inhibitor, olaparib, and a VEGFR1-3 inhibitor, cediranib, in recurrent women's cancers with biomarker analyses.
Neoplasms
A phase I study of the safety and tolerability of olaparib (AZD2281, KU0059436) and dacarbazine in patients with advanced solid tumours.
Neoplasms
A Phase I study of topotecan, carboplatin and the PARP inhibitor veliparib in acute leukemias, aggressive myeloproliferative neoplasms and chronic myelomonocytic leukemia.
Neoplasms
A Phase I study of veliparib (ABT-888) in combination with low-dose fractionated whole abdominal radiation therapy in patients with advanced solid malignancies and peritoneal carcinomatosis.
Neoplasms
A Phase I Study of Veliparib in Combination with Metronomic Cyclophosphamide in Adults with Refractory Solid Tumors and Lymphomas.
Neoplasms
A Phase I, dose-finding and pharmacokinetic study of olaparib (AZD2281) in Japanese patients with advanced solid tumors*,.
Neoplasms
A Phase I-II Study of the Oral Poly(ADP-ribose) Polymerase Inhibitor Rucaparib in Patients with Germline BRCA1/2-mutated Ovarian Carcinoma or Other Solid Tumors.
Neoplasms
A phase II clinical trial of 6-mercaptopurine (6MP) and methotrexate in patients with BRCA defective tumours: a study protocol.
Neoplasms
A phase II evaluation of the potent, highly selective PARP inhibitor veliparib in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who carry a germline BRCA1 or BRCA2 mutation - An NRG Oncology/Gynecologic Oncology Group study.
Neoplasms
A phenanthrene derived PARP inhibitor is an extra-centrosomes de-clustering agent exclusively eradicating human cancer cells.
Neoplasms
A polysaccharide from Trametes robiniophila inhibits human osteosarcoma xenograft tumor growth in vivo.
Neoplasms
A Population of Heterogeneous Breast Cancer Patient-Derived Xenografts Demonstrate Broad Activity of PARP Inhibitor in BRCA1/2 Wild-Type Tumors.
Neoplasms
A Population Pharmacokinetic Meta-Analysis of Veliparib, a PARP Inhibitor, Across Phase 1/2/3 Trials in Cancer Patients.
Neoplasms
A potent and selective PARP14 inhibitor decreases protumor macrophage gene expression and elicits inflammatory responses in tumor explants.
Neoplasms
A potential synthetic lethal strategy with PARP inhibitors: perspective on 'Inactivation of the tumor suppressor p53 by long noncoding RNA RMRP'.
Neoplasms
A profile on the FoundationFocus CDxBRCA tests.
Neoplasms
A Prospective Phase II Single-arm Study of Niraparib Plus Dostarlimab in Patients With Advanced Non-small-cell Lung Cancer and/or Malignant Pleural Mesothelioma, Positive for PD-L1 Expression and Germline or Somatic Mutations in the DNA Repair Genes: Rationale and Study Design.
Neoplasms
A Quantitative Assay Reveals Ligand Specificity of the DNA Scaffold Repair Protein XRCC1 and Efficient Disassembly of Complexes of XRCC1 and the Poly(ADP-ribose) Polymerase 1 by Poly(ADP-ribose) Glycohydrolase.
Neoplasms
A RAD51 assay feasible in routine tumor samples calls PARP inhibitor response beyond BRCA mutation.
Neoplasms
A Radiotracer Strategy to Quantify PARP-1 Expression In Vivo Provides a Biomarker That Can Enable Patient Selection for PARP Inhibitor Therapy.
Neoplasms
A randomized Phase II study of veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in BRCA1/2 metastatic breast cancer: design and rationale.
Neoplasms
A review of PARP inhibitors: from bench to bedside.
Neoplasms
A Review on DNA Repair Inhibition by PARP Inhibitors in Cancer Therapy.
Neoplasms
A review on PARP1 inhibitors: Pharmacophore modeling, virtual and biological screening studies to identify novel PARP1 inhibitors.
Neoplasms
A Review on Poly (ADP-ribose) Polymerase (PARP) Inhibitors and Synthetic Methodologies.
Neoplasms
A role of intracellular mono-ADP-ribosylation in cancer biology.
Neoplasms
A Selenium Containing Inhibitor for the Treatment of Hepatocellular Cancer.
Neoplasms
A Short BRCA2-Derived Cell-Penetrating Peptide Targets RAD51 Function and Confers Hypersensitivity toward PARP Inhibition.
Neoplasms
A single nucleotide variant of human PARP1 determines response to PARP inhibitors.
Neoplasms
A small molecule Focal Adhesion Kinase (FAK) inhibitor, targeting Y397 site: 1-(2-Hydroxyethyl) -3, 5, 7-triaza-1-azoniatricyclo [3.3.1.13,7]decane; bromide effectively inhibits FAK autophosphorylation activity and decreases cancer cell viability, clonogenicity and tumor growth in vivo.
Neoplasms
A Small-Molecule Protein-Protein Interaction Inhibitor of PARP1 That Targets Its BRCT Domain.
Neoplasms
A snapshot of chemoresistance to PARP inhibitors.
Neoplasms
A Subset of Colorectal Cancers with Cross-Sensitivity to Olaparib and Oxaliplatin.
Neoplasms
A subset of lung cancer cases shows robust signs of homologous recombination deficiency associated genomic mutational signatures.
Neoplasms
A subset of PARP inhibitors induces lethal telomere fusion in ALT-dependent tumor cells.
Neoplasms
A synthetic lethal siRNA screen identifying genes mediating sensitivity to a PARP inhibitor.
Neoplasms
A therapeutic update on PARP inhibitors: implications in the treatment of glioma.
Neoplasms
A transcriptomic model for homologous recombination deficiency in prostate cancer.
Neoplasms
A triazole-conjugated benzoxazone induces reactive oxygen species and promotes autophagic apoptosis in human lung cancer cells.
Neoplasms
A Very Long-Acting PARP Inhibitor Suppresses Cancer Cell Growth in DNA Repair-Deficient Tumor Models.
Neoplasms
A-kinase anchor protein 4 (AKAP4) a promising therapeutic target of colorectal cancer.
Neoplasms
A375 melanoma cells are sensitized to cisplatin-induced toxicity by a synthetic nitro-flavone derivative 2-(4-Nitrophenyl)-4H-chromen-4-one through inhibition of PARP1.
Neoplasms
ABBV-176, a PRLR antibody drug conjugate with a potent DNA-damaging PBD cytotoxin and enhanced activity with PARP inhibition.
Neoplasms
Aberrant morphology, proliferation, and apoptosis of B-cell chronic lymphocytic leukemia cells.
Neoplasms
Absence of Specific Cell Killing of the BRCA2-Deficient Human Cancer Cell Line CAPAN1 by Poly(ADP-ribose) Polymerase Inhibition.
Neoplasms
ABT-263 induces G1/G0-phase arrest, apoptosis and autophagy in human esophageal cancer cells in vitro.
Neoplasms
ABT-888 and quinacrine induced apoptosis in metastatic breast cancer stem cells by inhibiting base excision repair via adenomatous polyposis coli.
Neoplasms
ABT-888 confers broad in vivo activity in combination with temozolomide in diverse tumors.
Neoplasms
ABT-888, an orally active poly(ADP-ribose) polymerase inhibitor that potentiates DNA-damaging agents in preclinical tumor models.
Neoplasms
Acetylation blocks DNA damage-induced chromatin ADP-ribosylation.
Neoplasms
Achyranthoside H methyl ester, a novel oleanolic acid saponin derivative from Achyranthes fauriei roots, induces apoptosis in human breast cancer MCF-7 and MDA-MB-453 cells via a caspase activation pathway.
Neoplasms
Acquired multiple secondary BRCA2 mutations upon PARPi resistance in a metastatic pancreatic cancer patient harboring a BRCA2 germline mutation.
Neoplasms
Acquired Resistance of EGFR-Mutated Lung Cancer to Tyrosine Kinase Inhibitor Treatment Promotes PARP Inhibitor Sensitivity.
Neoplasms
Acquired resistance of phosphatase and tensin homolog-deficient cells to poly(ADP-ribose) polymerase inhibitor and Ara-C mediated by 53BP1 loss and SAMHD1 overexpression.
Neoplasms
Acquired Resistance to Combination Treatment with Temozolomide and ABT-888 Is Mediated by Both Base Excision Repair and Homologous Recombination DNA Repair Pathways.
Neoplasms
Activating the Wnt/?-Catenin Pathway for the Treatment of Melanoma--Application of LY2090314, a Novel Selective Inhibitor of Glycogen Synthase Kinase-3.
Neoplasms
Activation of a CrmA-insensitive, p35-sensitive pathway in ionizing radiation-induced apoptosis.
Neoplasms
Activation of caspase-3-like enzymes in non-apoptotic T cells.
Neoplasms
Activation of Nur77 by selected 1,1-Bis(3'-indolyl)-1-(p-substituted phenyl)methanes induces apoptosis through nuclear pathways.
Neoplasms
Activation of PARP-1 by snoRNAs Controls Ribosome Biogenesis and Cell Growth via the RNA Helicase DDX21.
Neoplasms
Activation of poly(adenosine diphosphate-ribose) polymerase in mouse tumors treated by photodynamic therapy.
Neoplasms
Activation of Poly(ADP-Ribose) Polymerase-1 Delays Wound Healing by Regulating Keratinocyte Migration and Production of Inflammatory Mediators.
Neoplasms
Activation of proline metabolism maintains ATP levels during cocaine-induced polyADP-ribosylation.
Neoplasms
Activation of the formyl peptide receptor by the HIV-derived peptide T-20 suppresses interleukin-12 p70 production by human monocytes.
Neoplasms
Activation of the PI3K/mTOR Pathway following PARP Inhibition in Small Cell Lung Cancer.
Neoplasms
Acute myocardial infarction induced increases in plasma tumor necrosis factor-alpha and interleukin-10 are associated with the activation of poly(ADP-ribose) polymerase of circulating mononuclear cell.
Neoplasms
Acyl-CoA-binding domain containing 3 modulates NAD+ metabolism through activating poly(ADP-ribose) polymerase 1.
Neoplasms
Additive activation of hepatic NF-kappaB by ethanol and hepatitis B protein X (HBX) or HCV core protein: involvement of TNF-alpha receptor 1-independent and -dependent mechanisms.
Neoplasms
Adenosine diphosphate ribosyl transferase responses to a standardized dose of hydrogen peroxide in the mononuclear leukocytes of patients with a diagnosis of cancer.
Neoplasms
Adenoviral-mediated transfer of the TNF-related apoptosis-inducing ligand/Apo-2 ligand gene induces tumor cell apoptosis.
Neoplasms
Adenovirus-mediated p53 and ING4 gene co?transfer elicits synergistic antitumor effects through enhancement of p53 acetylation in breast cancer.
Neoplasms
Adjunctive Chinese herbal medicine therapy for nasopharyngeal carcinoma: Clinical evidence and experimental validation.
Neoplasms
Adjuvant immunotherapy of C6 glioma in rats with pertussis toxin.
Neoplasms
Adoptive transfer of tumor-primed, in vitro-activated, CD4+ T effector cells (TEs) combined with CD8+ TEs provides intratumoral TE proliferation and synergistic antitumor response.
Neoplasms
ADP-Ribosylation Levels and Patterns Correlate with Gene Expression and Clinical Outcomes in Ovarian Cancers.
Neoplasms
ADP-ribosylation of the G protein Rho inhibits integrin regulation of tumor cell growth.
Neoplasms
ADP-ribosylation of the GTP-binding protein RhoA blocks cytoplasmic division in human myelomonocytic cells.
Neoplasms
ADP-ribosylation of wild-type p53 in vitro: binding of p53 protein to specific p53 consensus sequence prevents its modification.
Neoplasms
ADP-ribosylation: from molecular mechanisms to human disease.
Neoplasms
Advanced epithelial ovarian cancer: from standard chemotherapy to promising molecular pathway targets--where are we now?
Neoplasms
Advancements in PARP1 Targeted Nuclear Imaging and Theranostic Probes.
Neoplasms
Advances and perspectives of PARP inhibitors.
Neoplasms
Advances in PARP inhibitors for the treatment of breast cancer.
Neoplasms
Advances in the use of PARP inhibitor therapy for breast cancer.
Neoplasms
Advances in the use of PARP inhibitors for BRCA1/2-associated breast cancer: talazoparib.
Neoplasms
Advances in using PARP inhibitors to treat cancer.
Neoplasms
Advantage of a baculovirus expression system for protein-protein interaction studies. Involvement of posttranslational phosphorylation in the interaction between wt p53 protein and poly(ADP-ribose) polymerase-1.
Neoplasms
Aloe-emodin (AE) nanoparticles suppresses proliferation and induces apoptosis in human lung squamous carcinoma via ROS generation in vitro and in vivo.
Neoplasms
Altered Expression of the Poly(ADP-Ribosyl)ation Enzymes in Uveal Melanoma and Regulation of PARG Gene Expression by the Transcription Factor ERM.
Neoplasms
Altering Nitrogen Heterocycles of AZD2461 Affords High Affinity Poly(ADP-ribose) Polymerase-1 Inhibitors with Decreased P-Glycoprotein Interactions.
Neoplasms
Alternate therapeutic pathways for PARP inhibitors and potential mechanisms of resistance.
Neoplasms
Alternative mechanisms of inhibiting activity of poly (ADP-ribose) polymerase-1.
Neoplasms
Alternative Non-Homologous End-Joining: Error-Prone DNA Repair as Cancer's Achilles' Heel.
Neoplasms
Amblyomin-X induces ER stress, mitochondrial dysfunction, and caspase activation in human melanoma and pancreatic tumor cell.
Neoplasms
AMPK/mTOR-mediated inhibition of survivin partly contributes to metformin-induced apoptosis in human gastric cancer cell.
Neoplasms
Amplifying the Noise: Oncometabolites Mask an Epigenetic Signal of DNA Damage.
Neoplasms
AMXI-5001, a novel dual parp1/2 and microtubule polymerization inhibitor for the treatment of human cancers.
Neoplasms
An 18F-Labeled Poly(ADP-ribose) Polymerase Positron Emission Tomography Imaging Agent.
Neoplasms
An Algorithm Combining Patient Performance Status, Second Hit Analysis, PROVEAN and Dann Prediction Tools Could Foretell Sensitization to PARP Inhibitors in Digestive, Skin, Ovarian and Breast Cancers.
Neoplasms
An Analysis of Patients with DNA Repair Pathway Mutations Treated with a PARP Inhibitor.
Neoplasms
An assessment of poly (ADP-ribose) polymerase-1 role in normal and cancer cells.
Neoplasms
An atypical BRCT-BRCT interaction with the XRCC1 scaffold protein compacts human DNA Ligase III? within a flexible DNA repair complex.
Neoplasms
An emerging entity: pancreatic adenocarcinoma associated with a known BRCA mutation: clinical descriptors, treatment implications, and future directions.
Neoplasms
An enzyme-linked immunosorbent poly(ADP-ribose) polymerase biomarker assay for clinical trials of PARP inhibitors.
Neoplasms
An Epstein-Barr virus positive natural killer lymphoma xenograft derived for drug testing.
Neoplasms
An evaluation of olaparib for the treatment of pancreatic cancer.
Neoplasms
An ex vivo assay of XRT-induced Rad51 foci formation predicts response to PARP-inhibition in ovarian cancer.
Neoplasms
An Interaction with PARP-1 and Inhibition of Parylation Contribute to Attenuation of DNA Damage Signaling by the Adenovirus E4orf4 Protein.
Neoplasms
An NQO1 substrate with potent antitumor activity that selectively kills by PARP1-induced programmed necrosis.
Neoplasms
An olaparib window-of-opportunity trial in patients with early-stage endometrial carcinoma: POLEN study.
Neoplasms
An open-label, dose-escalation study to evaluate the safety and pharmacokinetics of CEP-9722 (a PARP-1 and PARP-2 inhibitor) in combination with gemcitabine and cisplatin in patients with advanced solid tumors.
Neoplasms
An oriental herbal cocktail, ka-mi-kae-kyuk-tang, exerts anti-cancer activities by targeting angiogenesis, apoptosis and metastasis.
Neoplasms
An update on PARP inhibitors for the treatment of cancer.
Neoplasms
An update on PARP inhibitors--moving to the adjuvant setting.
Neoplasms
An Update on Poly(ADP-ribose)polymerase-1 (PARP-1) Inhibitors: Opportunities and Challenges in Cancer Therapy.
Neoplasms
Analysis of DNA Damage Response Gene Alterations and Tumor Mutational Burden Across 17,486 Tubular Gastrointestinal Carcinomas: Implications for Therapy.
Neoplasms
Analysis of genetic variants of the poly(ADP-ribose) polymerase-1 gene in breast cancer in French patients.
Neoplasms
Analysis of molecular markers as predictive factors of lymph node involvement in breast carcinoma.
Neoplasms
Analysis of mutation status and homologous recombination deficiency in tumors of patients with germline BRCA1 or BRCA2 mutations and metastatic breast cancer: OlympiAD.
Neoplasms
Analysis of poly(ADP-ribose) polymerase-1 (PARP1) gene alteration in human germ cell tumor cell lines.
Neoplasms
Analysis of poly(ADP-ribose) polymerase-1 by enzyme-initiated auto-PARylation-controlled aggregation of hemin-graphene nanocomposites.
Neoplasms
Analysis Suggests Wider Use for PARP Inhibitors.
Neoplasms
Androgen receptor inhibitor-induced "BRCAness" and PARP inhibition are synthetically lethal for castration-resistant prostate cancer.
Neoplasms
Anti-androgen receptor signaling and prostate cancer inhibitory effects of sucrose- and benzophenone-compounds.
Neoplasms
Anti-angiogenesis for cancer: Current status and prospects.
Neoplasms
Anti-cancer action of 4-iodo-3-nitrobenzamide in combination with buthionine sulfoximine: inactivation of poly(ADP-ribose) polymerase and tumor glycolysis and the appearance of a poly(ADP-ribose) polymerase protease.
Neoplasms
Anti-inflammatory effects of PJ34, a poly(ADP-ribose) polymerase inhibitor, in transient focal cerebral ischemia in mice.
Neoplasms
Anti-tumor activity and the mechanism of SIP-S: A sulfated polysaccharide with anti-metastatic effect.
Neoplasms
Anti-tumor activity of olaparib, a poly (ADP-ribose) polymerase (PARP) inhibitor, in cultured endometrial carcinoma cells.
Neoplasms
Anti-tumor effect of ?-glucan from Lentinus edodes and the underlying mechanism.
Neoplasms
Antiangiogenic and proapoptotic effects of dietary restriction on experimental mouse and human brain tumors.
Neoplasms
Anticancer Activity of BIM-46174, a New Inhibitor of the Heterotrimeric G{alpha}/G{beta}{gamma} Protein Complex.
Neoplasms
Anticancer activity of HS-527, a novel inhibitor targeting PI3-kinase in human pancreatic cancer cells.
Neoplasms
Anticancer activity of tetrandrine by inducing pro-death apoptosis and autophagy in human gastric cancer cells.
Neoplasms
Anticancer agents based on vulnerable components in a signalling pathway.
Neoplasms
Anticancer bioactive peptides suppress human colorectal tumor cell growth and induce apoptosis via modulating the PARP-p53-Mcl-1 signaling pathway.
Neoplasms
Anticancer chemosensitization and radiosensitization by the novel poly(ADP-ribose) polymerase-1 inhibitor AG14361.
Neoplasms
Anticancer Effect of Mountain Ginseng on Human Breast Cancer: Comparison with Farm-Cultivated Ginseng.
Neoplasms
Anticancer mechanism of equol in 7,12-dimethylbenz(a)anthracene-treated animals.
Neoplasms
Antiinvasive effect of xanthohumol, a prenylated chalcone present in hops (Humulus lupulus L.) and beer.
Neoplasms
Antimyeloma activity of two novel N-substituted and tetraflourinated thalidomide analogs.
Neoplasms
Antitumor Ability of KT2 Peptide Derived from Leukocyte Peptide of Crocodile Against Human HCT116 Colon Cancer Xenografts.
Neoplasms
Antitumor activity of noscapine in human non-small cell lung cancer xenograft model.
Neoplasms
Antitumor activity of RT2 peptide derived from crocodile leukocyte peptide on human colon cancer xenografts in nude mice.
Neoplasms
Antitumor Effects and the Compatibility Mechanisms of Herb Pair Scleromitrion diffusum (Willd.) R. J. Wang-Sculellaria barbata D. Don.
Neoplasms
Antitumor Efficacy of PKI-587, a Highly Potent Dual PI3K/mTOR Kinase Inhibitor.
Neoplasms
Antitumor efficacy profile of PKI-402, a dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor.
Neoplasms
Antitumor triptycene bisquinones: a novel synthetic class of dual inhibitors of DNA topoisomerase I and II activities.
Neoplasms
APOMAB, a La-specific monoclonal antibody, detects the apoptotic tumor response to life-prolonging and DNA-damaging chemotherapy.
Neoplasms
Apoptosis induced by ID6105, a new anthracycline (11-hydroxyaclacinomycin X, Hyrubicin), and its anti-tumor effects on experimental tumor models.
Neoplasms
Apoptosis induced by t10,c12-conjugated linoleic acid is mediated by an atypical endoplasmic reticulum stress response.
Neoplasms
Apoptosis induction in lung and prostate cancer cells through silver nanoparticles synthesized from Pinus roxburghii bioactive fraction.
Neoplasms
Apoptosis induction in prostate cancer cells and xenografts by combined treatment with Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand and CPT-11.
Neoplasms
Apoptosis induction of oroxylin A in human cervical cancer HeLa cell line in vitro and in vivo.
Neoplasms
Apoptosis signal-regulating kinase 1-thioredoxin complex dissociation by capsaicin causes pancreatic tumor growth suppression by inducing apoptosis.
Neoplasms
Apoptosis-related gene and protein expression in human lymphoma xenografts (Raji) after low dose rate radiation using 67Cu-2IT-BAT-Lym-1 radioimmunotherapy.
Neoplasms
Apoptotic and anti-angiogenic effects of Pulsatilla koreana extract on hepatocellular carcinoma.
Neoplasms
Apoptotic and antiproliferative effects of Stigmast-5-en-3-ol from Dendronephthya gigantea on human leukemia HL-60 and human breast cancer MCF-7 cells.
Neoplasms
Apoptotic and genotoxic effects of a methyl sulfonate ester that selectively generates N3-methyladenine and poly(ADP-ribose) polymerase inhibitors in normal peripheral blood lymphocytes.
Neoplasms
Apoptotic and Immunosuppressive Effects of Turmeric Paste on 7, 12 Di Methyl Benz (a) Anthracene Induced Skin Tumor Model of Wistar Rat.
Neoplasms
Apoptotic resistance to ionizing radiation in pediatric B-precursor acute lymphoblastic leukemia frequently involves increased NF-kappaB survival pathway signaling.
Neoplasms
Application and reflection of genomic scar assays in evaluating the efficacy of platinum salts and PARP inhibitors in cancer therapy.
Neoplasms
Approaches for Identifying Novel Targets in Precision Medicine: Lessons from DNA Repair.
Neoplasms
Aqueous extract of Taxus chinensis var. mairei regulates the Hippo-YAP pathway and promotes apoptosis of non-small cell lung cancer via ATF3 in vivo and in vitro.
Neoplasms
Arenobufagin, a natural bufadienolide from toad venom, induces apoptosis and autophagy in human hepatocellular carcinoma cells through inhibition of PI3K/Akt/mTOR pathway.
Neoplasms
ARID1A Deficiency Impairs the DNA Damage Checkpoint and Sensitizes Cells to PARP Inhibitors.
Neoplasms
Arsenite induced poly(ADP-ribosyl)ation of tumor suppressor P53 in human skin keratinocytes as a possible mechanism for carcinogenesis associated with arsenic exposure.
Neoplasms
Artocarpus altilis (Parkinson) Fosberg Extracts and Geranyl Dihydrochalcone Inhibit STAT3 Activity in Prostate Cancer DU145 Cells.
Neoplasms
Asiatic acid induces colon cancer cell growth inhibition and apoptosis through mitochondrial death cascade.
Neoplasms
Aspirin enhances tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in hormone-refractory prostate cancer cells through survivin down-regulation.
Neoplasms
ASPM promotes homologous recombination-mediated DNA repair by safeguarding BRCA1 stability.
Neoplasms
Assessment of PARP protein expression in epithelial ovarian cancer by ELISA pharmacodynamic assay and immunohistochemistry.
Neoplasms
Assessment of PARP-1 Distribution in Tissues of Cynomolgus Monkeys.
Neoplasms
Assessment of the in vitro cytochrome P450 (CYP) inhibition potential of ZYTP1, a novel poly (ADP-ribose) polymerase inhibitor.
Neoplasms
Assessment of the Inhibitory Effects of Ficin-hydrolyzed Gelatin Derived from Squid (Uroteuthis duvauceli) on Breast Cancer Cell Lines and Animal Model.
Neoplasms
Association between PARP-1 V762A polymorphism and cancer susceptibility: a meta-analysis.
Neoplasms
Association between the PARP1 Val762Ala polymorphism and cancer risk: evidence from 43 studies.
Neoplasms
Association of PARP-1, NF-?B, NF-?BIA and IL-6, IL-1? and TNF-? with Graves Disease and Graves Ophthalmopathy.
Neoplasms
Association of PARP1-specific polymorphisms and haplotypes with non-small cell lung cancer subtypes.
Neoplasms
Association of Poly (ADP-Ribose) Polymerase 1 Variants with Oral Squamous Cell Carcinoma Susceptibility in a South Indian Population.
Neoplasms
Association of T2285C polymorphism in PARP1 gene coding region with its expression, activity and NSCLC risk along with prognosis.
Neoplasms
ATARI trial: ATR inhibitor in combination with olaparib in gynecological cancers with ARID1A loss or no loss (ENGOT/GYN1/NCRI).
Neoplasms
ATM deficiency is associated with sensitivity to PARP1 and ATR inhibitors in lung adenocarcinoma.
Neoplasms
ATM deficiency promotes progression of CRPC by enhancing Warburg effect.
Neoplasms
ATM deficiency sensitizes mantle cell lymphoma cells to poly(ADP-ribose) polymerase-1 inhibitors.
Neoplasms
ATM Dysfunction in Pancreatic Adenocarcinoma and Associated Therapeutic Implications.
Neoplasms
ATM in DNA repair in cancer.
Neoplasms
ATM Loss Confers Greater Sensitivity to ATR Inhibition than PARP Inhibition in Prostate Cancer.
Neoplasms
ATM-Deficient Cancers Provide New Opportunities for Precision Oncology.
Neoplasms
ATM-Dependent Recruitment of BRD7 is required for Transcriptional Repression and DNA Repair at DNA Breaks Flanking Transcriptional Active Regions.
Neoplasms
ATM-depletion in breast cancer cells confers sensitivity to PARP inhibition.
Neoplasms
ATMIN Suppresses Metastasis by Altering the WNT-Signaling Pathway via PARP1 in MSI-High Colorectal Cancer.
Neoplasms
ATR addiction in multiple myeloma: synthetic lethal approaches exploiting established therapies.
Neoplasms
ATR inhibition amplifies antitumor effects of olaparib in biliary tract cancer.
Neoplasms
ATR inhibition disrupts rewired homologous recombination and fork protection pathways in PARP inhibitor-resistant BRCA-deficient cancer cells.
Neoplasms
ATR-mediated proteome remodeling is a major determinant of homologous recombination capacity in cancer cells.
Neoplasms
Attenuation of SRC Kinase Activity Augments PARP Inhibitor-mediated Synthetic Lethality in BRCA2-altered Prostate Tumors.
Neoplasms
Augmentation of tumor necrosis factor-alpha-induced monocytic differentiation of a myelomonocytic leukemia (WEHI-3B JCS) by pertussis toxin.
Neoplasms
Auriculasin-induced ROS causes prostate cancer cell death via induction of apoptosis.
Neoplasms
Aurora A kinase regulates non-homologous end-joining and poly(ADP-ribose) polymerase function in ovarian carcinoma cells.
Neoplasms
Aurora-A expressing tumour cells are deficient for homology-directed DNA double strand-break repair and sensitive to PARP inhibition.
Neoplasms
Autocrine motility factor is a growth factor.
Neoplasms
Autoimmune response to PARP and BRCA1/BRCA2 in cancer.
Neoplasms
Autophagy in the physiological endometrium and cancer.
Neoplasms
Autophagy suppression enhances DNA damage and cell death upon treatment with PARP inhibitor Niraparib in laryngeal squamous cell carcinoma.
Neoplasms
Avasimibe exerts anticancer effects on human glioblastoma cells via inducing cell apoptosis and cell cycle arrest.
Neoplasms
Avicularin reversed multidrug-resistance in human gastric cancer through enhancing Bax and BOK expressions.
Neoplasms
Avoid the trap: Targeting PARP1 beyond human malignancy.
Neoplasms
AXL Inhibition Suppresses the DNA Damage Response and Sensitizes Cells to PARP Inhibition in Multiple Cancers.
Neoplasms
Azoxystrobin Induces Apoptosis of Human Esophageal Squamous Cell Carcinoma KYSE-150 Cells through Triggering of the Mitochondrial Pathway.
Neoplasms
B-lymphoblastic leukemia/lymphoma: overexpression of nuclear DNA repair protein PARP-1 correlates with antiapoptotic protein Bcl-2 and complex chromosomal abnormalities.
Neoplasms
Baicalein attenuates proteasome inhibition-induced apoptosis by suppressing the activation of the mitochondrial pathway and the caspase-8- and Bid-dependent pathways.
Neoplasms
Baicalin is a major component of PC-SPES which inhibits the proliferation of human cancer cells via apoptosis and cell cycle arrest.
Neoplasms
BAP1-Altered Malignant Pleural Mesothelioma: Outcomes With Chemotherapy, Immune Check-Point Inhibitors and Poly(ADP-Ribose) Polymerase Inhibitors.
Neoplasms
BAP1: Not just a BRCA1-associated protein.
Neoplasms
BARD1 homozygous deletion, a possible alternative to BRCA1 mutation in basal breast cancer.
Neoplasms
Base excision repair imbalance in colorectal cancer has prognostic value and modulates response to chemotherapy.
Neoplasms
Base excision repair pathway: PARP1 genotypes as modulators of therapy response in cervical cancer patients.
Neoplasms
Base excision repair, the redox environment and therapeutic implications.
Neoplasms
Baseline sister chromatid exchange in human cell lines with different levels of poly(ADP-ribose) polymerase.
Neoplasms
BAX Redistribution Induces Apoptosis Resistance and Selective Stress Sensitivity in Human HCC.
Neoplasms
Bcl-2 overexpression blocks activation of the death protease CPP32/Yama/apopain.
Neoplasms
Bcl-2/Bcl-xL Inhibition Increases the Efficacy of Mek Inhibition Alone and in Combination with PI3 Kinase Inhibition in Lung and Pancreatic Tumor Models.
Neoplasms
Beet root juice protects against doxorubicin toxicity in cardiomyocytes while enhancing apoptosis in breast cancer cells.
Neoplasms
Berberine induces caspase-independent cell death in colon tumor cells through activation of apoptosis-inducing factor.
Neoplasms
Berberine induces oxidative DNA damage and impairs homologous recombination repair in ovarian cancer cells to confer increased sensitivity to PARP inhibition.
Neoplasms
BET Bromodomain Inhibition Synergizes with PARP Inhibitor in Epithelial Ovarian Cancer.
Neoplasms
Beyond Breast and Ovarian Cancers: PARP Inhibitors for BRCA Mutation-Associated and BRCA-Like Solid Tumors.
Neoplasms
Beyond DNA Repair: Additional Functions of PARP-1 in Cancer.
Neoplasms
Bezielle selectively targets mitochondria of cancer cells to inhibit glycolysis and OXPHOS.
Neoplasms
Biasing human epidermal growth factor receptor 4 (HER4) tyrosine kinase signaling with antibodies: Induction of cell death by antibody-dependent HER4 intracellular domain trafficking.
Neoplasms
Biliary tract cancer and genomic alterations in homologous recombinant deficiency: exploiting synthetic lethality with PARP inhibitors.
Neoplasms
Bioinformatic Analysis of the Nicotinamide Binding Site in Poly(ADP-Ribose) Polymerase Family Proteins.
Neoplasms
Biological and clinical significance of PARP1 protein expression in breast cancer.
Neoplasms
Biological characterization of bovine mammary epithelial cell lines immortalized by HPV16 E6/E7 and SV40T.
Neoplasms
Biology of Poly(ADP-Ribose) Polymerases: The Factotums of Cell Maintenance.
Neoplasms
Biomarker-driven and molecularly targeted therapies for pancreatic adenocarcinoma.
Neoplasms
Biomarker-Guided Development of DNA Repair Inhibitors.
Neoplasms
Biomarkers for Homologous Recombination Deficiency in Cancer.
Neoplasms
Biomarkers of drug resistance in ovarian cancer - an update.
Neoplasms
Biomarkers predicting clinical benefit: fact or fiction?
Neoplasms
Biosynthesized composites of Au-Ag nanoparticles using Trapa peel extract induced ROS-mediated p53 independent apoptosis in cancer cells.
Neoplasms
Biphasic reduction of histone H3 phosphorylation in response to N-nitroso compounds induced DNA damage.
Neoplasms
Bisphosphonates may reduce recurrence in giant cell tumor by inducing apoptosis.
Neoplasms
Bivalent smac mimetics with a diazabicyclic core as highly potent antagonists of XIAP and cIAP1/2 and novel anticancer agents.
Neoplasms
BKM120 sensitizes BRCA-proficient triple negative breast cancer cells to olaparib through regulating FOXM1 and Exo1 expression.
Neoplasms
BKM120 sensitizes glioblastoma to the PARP inhibitor rucaparib by suppressing homologous recombination repair.
Neoplasms
Black Tea: Phytochemicals, Cancer Chemoprevention and Clinical Studies.
Neoplasms
Blockade of the MEK/ERK signalling cascade by AS703026, a novel selective MEK1/2 inhibitor, induces pleiotropic anti-myeloma activity in vitro and in vivo.
Neoplasms
Blocking c-Met-mediated PARP1 phosphorylation enhances anti-tumor effects of PARP inhibitors.
Neoplasms
Blocking of CDCP1 cleavage in vivo prevents Akt-dependent survival and inhibits metastatic colonization through PARP1-mediated apoptosis of cancer cells.
Neoplasms
Bone marrow PARP1 mRNA levels predict response to treatment with 5-azacytidine in patients with myelodysplastic syndrome.
Neoplasms
Bortezomib-enhanced radiosensitization through the suppression of radiation-induced nuclear factor-?B activity in human oral cancer cells.
Neoplasms
Brain distribution and efficacy as chemosensitizer of an oral formulation of PARP-1 inhibitor GPI 15427 in experimental models of CNS tumors.
Neoplasms
Brain Metastases from Ovarian Cancer: Current Evidence in Diagnosis, Treatment, and Prognosis.
Neoplasms
BRCA 1/2-Mutation Related and Sporadic Breast and Ovarian Cancers: More Alike than Different.
Neoplasms
BRCA Gene Mutations and Poly(ADP-Ribose) Polymerase Inhibitors in Triple-Negative Breast Cancer.
Neoplasms
BRCA in breast cancer: from risk assessment to therapeutic prediction.
Neoplasms
BRCA in Gastrointestinal Cancers: Current Treatments and Future Perspectives.
Neoplasms
BRCA mutations and gastrointestinal cancers: When to expect the unexpected?
Neoplasms
BRCA Reversion Mutations in Circulating Tumor DNA Predict Primary and Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma.
Neoplasms
BRCA-deficient mouse mammary tumor organoids to study cancer-drug resistance.
Neoplasms
BRCA1 alterations with additional defects in DNA damage response genes may confer chemoresistance to BRCA-like breast cancers treated with neoadjuvant chemotherapy.
Neoplasms
BRCA1 and BARD1 colocalize mainly in the cytoplasm of breast cancer tumors, and their isoforms show differential expression.
Neoplasms
BRCA1 and BRCA2 tumor suppressors protect against endogenous acetaldehyde toxicity.
Neoplasms
BRCA1 deficiency and synthetic lethality in leukemias; not only gene mutation matters.
Neoplasms
BRCA1 deficiency is a recurrent event in early-onset triple-negative breast cancer: a comprehensive analysis of germline mutations and somatic promoter methylation.
Neoplasms
BRCA1 Mutation-Specific Responses to 53BP1 Loss-Induced Homologous Recombination and PARP Inhibitor Resistance.
Neoplasms
BRCA1 Mutations in Cancer: Coordinating Deficiencies in Homologous Recombination with Tumorigenesis.
Neoplasms
BRCA1 promoter hypermethylation, 53BP1 protein expression and PARP-1 activity as biomarkers of DNA repair deficit in breast cancer.
Neoplasms
BRCA1 Promoter Methylation Is Linked to Defective Homologous Recombination Repair and Elevated miR-155 to Disrupt Myeloid Differentiation in Myeloid Malignancies.
Neoplasms
BRCA1 RING function is essential for tumor suppression but dispensable for therapy resistance.
Neoplasms
BRCA1, PARP1 and ?H2AX in acute myeloid leukemia: Role as biomarkers of response to the PARP inhibitor olaparib.
Neoplasms
BRCA1- and BRCA2-related mutations: therapeutic implications in ovarian cancer.
Neoplasms
BRCA1185delAG tumors may acquire therapy resistance through expression of RING-less BRCA1.
Neoplasms
BRCA2 abrogation triggers innate immune responses potentiated by treatment with PARP inhibitors.
Neoplasms
BRCA2 Deletion Induces Alternative Lengthening of Telomeres in Telomerase Positive Colon Cancer Cells.
Neoplasms
BRCA2 secondary mutation-mediated resistance to platinum and PARP inhibitor-based therapy in pancreatic cancer.
Neoplasms
BRCA2-Deficient CAPAN-1 Cells are Extremely Sensitive to the Inhibition of Poly (ADP-Ribose) Polymerase: An Issue of Potency.
Neoplasms
BRCA2-Deficient Sarcomatoid Mammary Tumors Exhibit Multidrug Resistance.
Neoplasms
BRCAness and Prognosis in Triple-Negative Breast Cancer Patients Treated with Neoadjuvant Chemotherapy.
Neoplasms
BRCAness and prostate cancer: diagnostic and therapeutic considerations.
Neoplasms
BRCAness: finding the Achilles heel in ovarian cancer.
Neoplasms
BRD4 Inhibitor AZD5153 Suppresses the Proliferation of Colorectal Cancer Cells and Sensitizes the Anticancer Effect of PARP Inhibitor.
Neoplasms
Breast cancer brain metastases show increased levels of genomic aberration-based homologous recombination deficiency scores relative to their corresponding primary tumors.
Neoplasms
Breast cancer in BRCA mutation carriers: medical treatment.
Neoplasms
Breast Cancer in BRCA1/2 Mutation Carriers - Do We Treat It Differently? Focus on Systemic Therapy for BRCA1/2 Associated Breast Cancer.
Neoplasms
Breast Cancer Predisposition Genes and Synthetic Lethality.
Neoplasms
Breviscapine (BVP) inhibits prostate cancer progression through damaging DNA by minichromosome maintenance protein-7 (MCM-7) modulation.
Neoplasms
Bridging of DNA breaks activates PARP2-HPF1 to modify chromatin.
Neoplasms
Bufalin induces autophagy-mediated cell death in human colon cancer cells through reactive oxygen species generation and JNK activation.
Neoplasms
c-MYC Suppresses BIN1 to Release Poly(ADP-Ribose) Polymerase 1: A Mechanism by Which Cancer Cells Acquire Cisplatin Resistance.
Neoplasms
Cadmium and cancer.
Neoplasms
Calcium channel blocker verapamil accelerates gambogic acid-induced cytotoxicity via enhancing proteasome inhibition and ROS generation.
Neoplasms
Calcium-dependent modulation of poly(ADP-ribose) polymerase-1 alters cellular metabolism and DNA repair.
Neoplasms
Can integrative biomarker approaches improve prediction of platinum and PARP inhibitor response in ovarian cancer?
Neoplasms
Can Poly (ADP-Ribose) Polymerase Inhibitors Palliate Paclitaxel-Induced Peripheral Neuropathy in Patients With Cancer?
Neoplasms
Cancer biomarkers for targeted therapy.
Neoplasms
Cancer during pregnancy alters the activity of rat placenta and enhances the expression of cleaved PARP, cytochrome-c and caspase 3.
Neoplasms
Cancer Imprints an Increased PARP-1 and p53-Dependent Resistance to Oxidative Stress on Lymphocytes of Patients That Later Develop Alzheimer's Disease.
Neoplasms
Candidate biomarkers of PARP inhibitor sensitivity in ovarian cancer beyond the BRCA genes.
Neoplasms
Candidate synthetic lethality partners to PARP inhibitors in the treatment of ovarian clear cell cancer.
Neoplasms
Cannabidiol inhibits human glioma by induction of lethal mitophagy through activating TRPV4.
Neoplasms
Capitalizing on Cancer Replication Stress by Preventing PAR Chain Turnover: A New Type of Synthetic Lethality.
Neoplasms
Capsaicin causes cell-cycle arrest and apoptosis in ER-positive and -negative breast cancer cells by modulating the EGFR/HER-2 pathway.
Neoplasms
Cardiac glycoside cerberin exerts anticancer activity through PI3K/AKT/mTOR signal transduction inhibition.
Neoplasms
Cardiomyocyte death in patients with end-stage heart failure before and after support with a left ventricular assist device: low incidence of apoptosis despite ubiquitous mediators.
Neoplasms
Casein kinase 2 inhibition attenuates cholesterol oxidation product-induced apoptosis by suppressing the activation of the mitochondrial pathway and the caspase-8- and bid-dependent pathways.
Neoplasms
Caspase-3 is required for alpha-fodrin cleavage but dispensable for cleavage of other death substrates in apoptosis.
Neoplasms
Caspase-independent cell death by arsenic trioxide in human cervical cancer cells: reactive oxygen species-mediated poly(ADP-ribose) polymerase-1 activation signals apoptosis-inducing factor release from mitochondria.
Neoplasms
Castalagin and vescalagin purified from leaves of Syzygium samarangense (Blume) Merrill & L.M. Perry: Dual inhibitory activity against PARP1 and DNA topoisomerase II.
Neoplasms
Casticin induces DNA damage and inhibits DNA repair-associated protein expression in B16F10 mouse melanoma cancer cells.
Neoplasms
Catalase Abrogates ?-Lapachone-Induced PARP1 Hyperactivation-Directed Programmed Necrosis in NQO1-Positive Breast Cancers.
Neoplasms
Cationic liposome codelivering PI3K pathway regulator improves the response of BRCA1-deficient breast cancer cells to PARP1 inhibition.
Neoplasms
Causing DNA damage and stopping DNA repair - Vitamin D supplementation with Poly(ADP-ribose) polymerase 1 (PARP1) inhibitors may cause selective cell death of cancer cells: A novel therapeutic paradigm utilizing elevated copper levels within the tumour.
Neoplasms
CBP-Mediated FOXO-1 Acetylation Inhibits Pancreatic Tumor Growth by Targeting SirT.
Neoplasms
CCDC6: the identity of a protein known to be partner in fusion.
Neoplasms
CCNE1 Is a Putative Therapeutic Target for ARID1A-Mutated Ovarian Clear Cell Carcinoma.
Neoplasms
CD40- and HLA-DR-mediated cell death pathways share a lot of similarities but differ in their use of ADP-ribosyltransferase activities.
Neoplasms
CDK1 promotes nascent DNA synthesis and induces resistance of cancer cells to DNA-damaging therapeutic agents.
Neoplasms
CDK12 Inhibition Reverses De Novo and Acquired PARP Inhibitor Resistance in BRCA Wild-Type and Mutated Models of Triple-Negative Breast Cancer.
Neoplasms
CDK12 regulates DNA repair genes by suppressing intronic polyadenylation.
Neoplasms
Cediranib suppresses homology-directed DNA repair through down-regulation of BRCA1/2 and RAD51.
Neoplasms
Celastrol induces the apoptosis of breast cancer cells and inhibits their invasion via downregulation of MMP-9.
Neoplasms
Celebrating the 80th anniversary of hormone ablation for prostate cancer.
Neoplasms
Cell Cycle Resolved Measurements of Poly(ADP-Ribose) Formation and DNA Damage Signaling by Quantitative Image-Based Cytometry.
Neoplasms
Cell death associated with abnormal mitosis observed by confocal imaging in live cancer cells.
Neoplasms
Cell death in cancer in the era of precision medicine.
Neoplasms
Cell death protection by 3-aminobenzamide: impairment of cytoskeleton function in human NK cell-mediated killing.
Neoplasms
Cell-autonomous inflammation of BRCA1-deficient ovarian cancers drives both tumor-intrinsic immunoreactivity and immune resistance via STING.
Neoplasms
Central and carboxy-terminal regions of human p53 protein are essential for interaction and complex formation with PARP-1.
Neoplasms
Cepharanthine combined with 5-fluorouracil inhibits the growth of p53-mutant human colorectal cancer cells.
Neoplasms
Ceralasertib-Mediated ATR Inhibition Combined With Olaparib in Advanced Cancers Harboring DNA Damage Response and Repair Alterations (Olaparib Combinations).
Neoplasms
Ceramide 1-phosphate regulates cell migration and invasion of human pancreatic cancer cells.
Neoplasms
Cetuximab augments cytotoxicity with poly (adp-ribose) polymerase inhibition in head and neck cancer.
Neoplasms
Characterisation of Deubiquitylating Enzymes in the Cellular Response to High-LET Ionizing Radiation and Complex DNA Damage.
Neoplasms
Characterization and anti-tumor activity of saponin-rich fractions of South Korean sea cucumbers (Apostichopus japonicus).
Neoplasms
Characterization of human chorionic gonadotropin as a novel angiogenic factor.
Neoplasms
Characterization of transcriptomic signature of primary prostate cancer analogous to prostatic small cell neuroendocrine carcinoma.
Neoplasms
Characterization, Detection, and Treatment Approaches for Homologous Recombination Deficiency in Cancer.
Neoplasms
Chemopotentiation by PARP inhibitors in cancer therapy.
Neoplasms
Chemoprevention of hormone receptor-negative breast cancer: new approaches needed.
Neoplasms
Chemopreventive effect of kava on 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone plus benzo[a]pyrene-induced lung tumorigenesis in A/J mice.
Neoplasms
Chemosensitivity profiling of osteosarcoma tumour cell lines identifies a model of BRCAness.
Neoplasms
Chemotherapy for Patients with BRCA1 and BRCA2-Mutated Ovarian Cancer: Same or Different?
Neoplasms
Chemotherapy reduces PARP1 in cancers of the ovary: implications for future clinical trials involving PARP inhibitors.
Neoplasms
Chemotherapy-induced p53-dependent and -independent DNA damage responses are enhanced by poly(ADP-ribose) polymerase (PARP) inhibition in BRCA-proficient cancer cells.
Neoplasms
CHFR regulates the mitotic checkpoint by targeting PARP-1 for ubiquitination and degradation.
Neoplasms
CHIR-258: a potent inhibitor of FLT3 kinase in experimental tumor xenograft models of human acute myelogenous leukemia.
Neoplasms
Chitosan-Dextran sulfate coated doxorubicin loaded PLGA-PVA-nanoparticles caused apoptosis in doxorubicin resistance breast cancer cells through induction of DNA damage.
Neoplasms
CHK2 Inhibition Provides a Strategy to Suppress Hematologic Toxicity from PARP Inhibitors.
Neoplasms
Chlorambucil targets BRCA1/2-deficient tumours and counteracts PARP inhibitor resistance.
Neoplasms
Chromatin (dis)organization and cancer: BUR-binding proteins as biomarkers for cancer.
Neoplasms
Chromatin to Clinic: The Molecular Rationale for PARP1 Inhibitor Function.
Neoplasms
Circulating HOXA9-methylated tumour DNA: A novel biomarker of response to poly (ADP-ribose) polymerase inhibition in BRCA-mutated epithelial ovarian cancer.
Neoplasms
cis-[RuCl(BzCN) (bipy) (dppe)]PF6 induces anti-angiogenesis and apoptosis by a mechanism of caspase-dependent involving DNA damage, PARP activation, and Tp53 induction in Ehrlich tumor cells.
Neoplasms
Cisplatin induces primary necrosis through poly(ADP-ribose) polymerase 1 activation in kidney proximal tubular cells.
Neoplasms
Cisplatin Resistance and Redox-Metabolic Vulnerability: A Second Alteration.
Neoplasms
Cisplatin resistance associated with PARP hyperactivation.
Neoplasms
Cisplatin resistance coupled to enhanced sensitivity to metabolic interventions.
Neoplasms
Class I histone deacetylase inhibitors inhibit the retention of BRCA1 and 53BP1 at the site of DNA damage.
Neoplasms
ClC-3/SGK1 regulatory axis enhances the olaparib-induced antitumor effect in human stomach adenocarcinoma.
Neoplasms
Cleavage of caspases-1, -3, -6, -8 and -9 substrates by proteases in skeletal muscles from mice undergoing cancer cachexia.
Neoplasms
Cleavage of Poly(ADP-ribose) polymerase measured in situ in individual cells: relationship to DNA fragmentation and cell cycle position during apoptosis.
Neoplasms
Cleavage of poly(ADP-ribose) transferase during p53-independent apoptosis in rat liver after treatment with N-nitrosomorpholine and cyproterone acetate.
Neoplasms
Cleaved caspase-3, caspase-7 and poly (ADP-ribose) polymerase are complementarily but differentially expressed in human medulloblastomas.
Neoplasms
Clinical Application of Poly(ADP-Ribose) Polymerase Inhibitors in High-Grade Serous Ovarian Cancer.
Neoplasms
Clinical Development of PARP Inhibitors in Treating Metastatic Castration-Resistant Prostate Cancer.
Neoplasms
Clinical factors of response in patients with advanced ovarian cancer participating in early phase clinical trials.
Neoplasms
Clinical management of hereditary breast cancer syndromes.
Neoplasms
Clinical perspectives of PARP inhibitors.
Neoplasms
Clinical Pharmacokinetics and Mass Balance of Veliparib in Combination with Temozolomide in Subjects with Nonhematologic Malignancies.
Neoplasms
Clinical poly(ADP-ribose) polymerase inhibitors for the treatment of cancer.
Neoplasms
Clinical practice guidelines for BRCA1 and BRCA2 genetic testing.
Neoplasms
Clinical Significance of Tumor Infiltrating Lymphocytes in Association with Hormone Receptor Expression Patterns in Epithelial Ovarian Cancer.
Neoplasms
Clinical Stratification of High-Grade Ovarian Serous Carcinoma Using a Panel of Six Biomarkers.
Neoplasms
Clinical trials and future potential of targeted therapy for ovarian cancer.
Neoplasms
Clinical Trials of Poly(ADP-Ribose) Polymerase Inhibitors for Cancer Therapy: A Review.
Neoplasms
Clinical use and mechanisms of resistance for PARP inhibitors in homologous recombination-deficient cancers.
Neoplasms
Clitocine targets Mcl-1 to induce drug-resistant human cancer cell apoptosis in vitro and tumor growth inhibition in vivo.
Neoplasms
Cloricromene, a coumarine derivative, reduced the development of periodontitis in rats.
Neoplasms
Co-regulated expression of dbl and poly(ADP-ribose) polymerase in Ewing's sarcoma cells and dbl-transformed NIH3T3 fibroblasts.
Neoplasms
Co-targeting poly(ADP-ribose) polymerase (PARP) and histone deacetylase (HDAC) in triple-negative breast cancer: Higher synergism in BRCA mutated cells.
Neoplasms
Colorectal cancers differ in respect of PARP-1 protein expression.
Neoplasms
Combination effects of poly(ADP-ribose) polymerase inhibitors and DNA-damaging agents in ovarian tumor cell lines--with special reference to cisplatin.
Neoplasms
Combination of a hypomethylating agent and inhibitors of PARP and HDAC traps PARP1 and DNMT1 to chromatin, acetylates DNA repair proteins, down-regulates NuRD and induces apoptosis in human leukemia and lymphoma cells.
Neoplasms
Combination of erlotinib and a PARP inhibitor inhibits growth of A2780 tumor xenografts due to increased autophagy.
Neoplasms
Combination of photoactive hypericin and Manumycin A exerts multiple anticancer effects on oxaliplatin-resistant colorectal cells.
Neoplasms
Combination Olaparib and Temozolomide in Relapsed Small-Cell Lung Cancer.
Neoplasms
Combination Platinum-based and DNA Damage Response-targeting Cancer Therapy: Evolution and Future Directions.
Neoplasms
Combination therapy in advanced urothelial cancer: the role of PARP, HER-2 and mTOR inhibitors.
Neoplasms
Combination Therapy With Charged Particles and Molecular Targeting: A Promising Avenue to Overcome Radioresistance.
Neoplasms
Combination therapy with dacarbazine and statins improved the survival rate in mice with metastatic melanoma.
Neoplasms
Combination Therapy with Radiation and PARP Inhibition Enhances Responsiveness to Anti-PD-1 Therapy in Colorectal Tumor Models.
Neoplasms
Combination treatment using DDX3 and PARP inhibitors induces synthetic lethality in BRCA1-proficient breast cancer.
Neoplasms
Combination treatment with auranofin and nutlin-3a induces synergistic cytotoxicity in breast cancer cells.
Neoplasms
Combinations of PARP Inhibitors with Temozolomide Drive PARP1 Trapping and Apoptosis in Ewing's Sarcoma.
Neoplasms
Combinations of PARP, hedgehog and HDAC inhibitors with standard drugs.
Neoplasms
Combinatorial Efficacy of Olaparib with Radiation and ATR Inhibitor Requires PARP1 Protein in Homologous Recombination-Proficient Pancreatic Cancer.
Neoplasms
Combinatorial therapy of immune checkpoint and cancer pathways provides a novel perspective on ovarian cancer treatment.
Neoplasms
Combined Effect of Hsp90 Inhibitor Geldanamycin and Parthenolide via Reactive Oxygen Species-Mediated Apoptotic Process on Epithelial Ovarian Cancer Cells.
Neoplasms
Combined effects of adenovirus-mediated wild-type p53 transduction, temozolomide and poly (ADP-ribose) polymerase inhibitor in mismatch repair deficient and non-proliferating tumor cells.
Neoplasms
Combined inhibition of PI3K and PARP is effective in the treatment of ovarian cancer cells with wild-type PIK3CA genes.
Neoplasms
Combined PARP and ATR inhibition potentiates genome instability and cell death in ATM-deficient cancer cells.
Neoplasms
Combined PARP Inhibition and Immune Checkpoint Therapy in Solid Tumors.
Neoplasms
Combined poly-ADP ribose polymerase and ataxia-telangiectasia mutated/Rad3-related inhibition targets ataxia-telangiectasia mutated-deficient lung cancer cells.
Neoplasms
Combined Strategies with Poly (ADP-Ribose) Polymerase (PARP) Inhibitors for the Treatment of Ovarian Cancer: A Literature Review.
Neoplasms
Combined TP53 and RB1 Loss Promotes Prostate Cancer Resistance to a Spectrum of Therapeutics and Confers Vulnerability to Replication Stress.
Neoplasms
Combined Treatment Modalities for High-Energy Proton Irradiation: Exploiting Specific DNA Repair Dependencies.
Neoplasms
Combined treatment with auranofin and trametinib induces synergistic apoptosis in breast cancer cells.
Neoplasms
Combined treatment with PI3K inhibitor BKM120 and PARP inhibitor olaparib is effective in inhibiting the gastric cancer cells with ARID1A deficiency.
Neoplasms
Combined treatment with temozolomide and poly(ADP-ribose) polymerase inhibitor enhances survival of mice bearing hematologic malignancy at the central nervous system site.
Neoplasms
Combined tumor sequencing and case/control analyses of RAD51C in breast cancer.
Neoplasms
Combining 53BP1 with BRCA1 as a biomarker to predict the sensitivity of poly(ADP-ribose) polymerase (PARP) inhibitors.
Neoplasms
Combining PARP Inhibition with Platinum, Ruthenium or Gold Complexes for Cancer Therapy.
Neoplasms
Combining PARP inhibition, radiation, and immunotherapy: A possible strategy to improve the treatment of cancer?
Neoplasms
Combining poly(ADP-ribose) polymerase 1 (PARP-1) inhibition and radiation in Ewings sarcoma results in lethal DNA damage.
Neoplasms
Combining poly(ADP-ribose) polymerase inhibitors and immune checkpoint inhibitors in breast cancer: rationale and preliminary clinical results.
Neoplasms
Comparative antiproliferative effects of iniparib and olaparib on a panel of triple-negative and non-triple-negative breast cancer cell lines.
Neoplasms
Comparative Assessment of Diagnostic Homologous Recombination Deficiency-Associated Mutational Signatures in Ovarian Cancer.
Neoplasms
Comparative inhibitory profile and distribution of bacterial PARPs, using Clostridioides difficile CD160 PARP as a model.
Neoplasms
Comparative oncogenomics identifies combinations of driver genes and drug targets in BRCA1-mutated breast cancer.
Neoplasms
Comparative safety and tolerability of approved PARP inhibitors in cancer: A systematic review and network meta-analysis.
Neoplasms
Comparative status of activated ERK1/2 and PARP cleavage in human gliomas.
Neoplasms
Comparing mutation frequencies for homologous recombination genes in uterine serous and high-grade serous ovarian carcinomas: A case for homologous recombination deficiency testing in uterine serous carcinoma.
Neoplasms
Complementary genetic screens identify the E3 ubiquitin ligase CBLC, as a modifier of PARP inhibitor sensitivity.
Neoplasms
Complete pathological response to olaparib and bevacizumab in advanced cervical cancer following chemoradiation in a BRCA1 mutation carrier: a case report.
Neoplasms
Compound 21 and Telmisartan combination mitigates type 2 diabetic nephropathy through amelioration of caspase mediated apoptosis.
Neoplasms
Compromised CDK1 activity sensitizes BRCA-proficient cancers to PARP inhibition.
Neoplasms
Computational analysis of data from a genome-wide screening identifies new PARP1 functional interactors as potential therapeutic targets.
Neoplasms
Computational investigation of FDA approved drugs as selective PARP-1 inhibitors by targeting BRCT domain for cancer therapy.
Neoplasms
Concordance of ATM (Ataxia Telangiectasia Mutated) Immunohistochemistry between Biopsy or Metastatic Tumor Samples and Primary Tumors in Gastric Cancer Patients.
Neoplasms
Consumer Beware: A Systematic Assessment of Potential Bias in the Lay Electronic Media to Examine the Portrayal of "PARP" Inhibitors for Cancer Treatment.
Neoplasms
Contemporary prognostic indicators for prostate cancer incorporating International Society of Urological Pathology recommendations.
Neoplasms
Contextual synthetic lethality of cancer cell kill based on the tumor microenvironment.
Neoplasms
Contrasting roles of H3K4me3 and H3K9me3 in regulation of apoptosis and gemcitabine resistance in human pancreatic cancer cells.
Neoplasms
Contributions of PARP-1 rs1136410 C>T polymorphism to the development of cancer.
Neoplasms
Converting cancer mutations into therapeutic opportunities.
Neoplasms
Coordinated signals from PARP-1 and PARP-2 are required to establish a proper T cell immune response to breast tumors in mice.
Neoplasms
Coordinated signals from the DNA repair enzymes PARP-1 and PARP-2 promotes B-cell development and function.
Neoplasms
Coordination of DNA mismatch repair and base excision repair processing of chemotherapy and radiation damage for targeting resistant cancers.
Neoplasms
Copper-Mediated Radiosynthesis of [18F]Rucaparib.
Neoplasms
Cordycepin blocks lung injury-associated inflammation and promotes BRCA1-deficient breast cancer cell killing by effectively inhibiting PARP.
Neoplasms
Correction: Overcoming Resistance of Cancer Cells to PARP-1 Inhibitors with Three Different Drug Combinations.
Neoplasms
Correction: PARP-1 inhibitor modulate ?-catenin signaling to enhance cisplatin sensitivity in cancer cervix.
Neoplasms
Correction: Synergistic Activity of PARP Inhibition by Talazoparib (BMN 673) with Temozolomide in Pediatric Cancer Models in the Pediatric Preclinical Testing Program.
Neoplasms
Coupling of gonadotropin-releasing hormone receptor to Gi protein in human reproductive tract tumors.
Neoplasms
Coxiella burnetii inhibits apoptosis in human THP-1 cells and monkey primary alveolar macrophages.
Neoplasms
CP-31398 restores mutant p53 tumor suppressor function and inhibits UVB-induced skin carcinogenesis in mice.
Neoplasms
CRISPR screens identify genomic ribonucleotides as a source of PARP-trapping lesions.
Neoplasms
CRISPR Screens in Synthetic Lethality and Combinatorial Therapies for Cancer.
Neoplasms
CRISPR/Cas9-mediated mutagenesis to validate the synergy between PARP1 inhibition and chemotherapy in BRCA1-mutated breast cancer cells.
Neoplasms
CRISPR/Cas9-mediated Trp53 and Brca2 knockout to generate improved murine models of ovarian high grade serous carcinoma.
Neoplasms
Critical role for BRCA1 expression as a marker of chemosensitivity response and prognosis.
Neoplasms
Critical role of the automodification of poly(ADP-ribose) polymerase-1 in nuclear factor-kappaB-dependent gene expression in primary cultured mouse glial cells.
Neoplasms
Crossroads of telomere biology and anticancer drug discovery.
Neoplasms
Crosstalk between PARP-1 and NF-kappaB modulates the promotion of skin neoplasia.
Neoplasms
Crosstalk of DNA double-strand break repair pathways in poly(ADP-ribose) polymerase inhibitor treatment of breast cancer susceptibility gene 1/2-mutated cancer.
Neoplasms
Crystal structure of the catalytic domain of human PARP2 in complex with PARP inhibitor ABT-888.
Neoplasms
Crystal structure of the catalytic fragment of murine poly(ADP-ribose) polymerase-2.
Neoplasms
CTLA-4 Blockade Synergizes Therapeutically with PARP Inhibition in BRCA1-Deficient Ovarian Cancer.
Neoplasms
Cucurbitacins as inducers of cell death and a rich source of potential anticancer compounds.
Neoplasms
CUDC-907 enhances TRAIL-induced apoptosis through upregulation of DR5 in breast cancer cells.
Neoplasms
Cultured networks of excitatory projection neurons and inhibitory interneurons for studying human cortical neurotoxicity.
Neoplasms
Curcumin Combined with Oxaliplatin Effectively Suppress Colorectal Carcinoma in vivo Through Inducing Apoptosis.
Neoplasms
Curcumin enhances poly(ADP-ribose) polymerase inhibitor sensitivity to chemotherapy in breast cancer cells.
Neoplasms
Curcumin inhibits PhIP induced cytotoxicity in breast epithelial cells through multiple molecular targets.
Neoplasms
Curcumin Nicotinate Selectively Induces Cancer Cell Apoptosis and Cycle Arrest through a P53-Mediated Mechanism.
Neoplasms
Curcumin suppresses multiple DNA damage response pathways and has potency as a sensitizer to PARP inhibitor.
Neoplasms
Curcumin targets the AKT-mTOR pathway for uterine leiomyosarcoma tumor growth suppression.
Neoplasms
Current and Future Directions for PARP Inhibition.
Neoplasms
Current and future landscape of poly (ADP-ribose) polymerase inhibition resistance.
Neoplasms
Current development of clinical inhibitors of poly(ADP-ribose) polymerase in oncology.
Neoplasms
Current status and future prospects of PARP inhibitor clinical trials in ovarian cancer.
Neoplasms
Current Strategies and Novel Therapeutic Approaches for Metastatic Urothelial Carcinoma.
Neoplasms
Current Systemic Treatment Landscape of Advanced Gynecologic Malignancies.
Neoplasms
Current treatment landscape and emerging therapies for pancreatic cancer.
Neoplasms
Current Treatment Options in Triple Negative Breast Cancer.
Neoplasms
CX-5461 is a DNA G-quadruplex stabilizer with selective lethality in BRCA1/2 deficient tumours.
Neoplasms
CX-5461 sensitises DNA damage repair proficient castrate-resistant prostate cancer to PARP inhibition.
Neoplasms
Cyclic hypoxia does not alter RAD51 expression or PARP inhibitor cell kill in tumor cells.
Neoplasms
Cyclin A2 regulates homologous recombination DNA repair and sensitivity to DNA damaging agents and poly(ADP-ribose) polymerase (PARP) inhibitors in human breast cancer cells.
Neoplasms
Cyclin D1 silencing impairs DNA double strand break repair, sensitizes BRCA1 wildtype ovarian cancer cells to olaparib.
Neoplasms
Cycloart-24-ene-26-ol-3-one, a New Cycloartane Isolated from Leaves of Aglaia exima Triggers Tumour Necrosis Factor-Receptor 1-Mediated Caspase-Dependent Apoptosis in Colon Cancer Cell Line.
Neoplasms
Cyclophosphamide induces caspase 9-dependent apoptosis in 9L tumor cells.
Neoplasms
Cytoplasmic ADP-ribosylation levels correlate with markers of patient outcome in distinct human cancers.
Neoplasms
Cytoplasmic EBP50 and elevated PARP1 are unfavorable prognostic factors in ovarian clear cell carcinoma.
Neoplasms
Cytotoxic and antioxidant activity of 4-methylthio-3-butenyl isothiocyanate from Raphanus sativus L. (Kaiware Daikon) sprouts.
Neoplasms
Cytotoxic and apoptotic effects of heat killed Mycobacterium indicus pranii (MIP) on various human cancer cell lines.
Neoplasms
Cytotoxic and targeted therapy for BRCA1/2-driven cancers.
Neoplasms
Cytotoxic and targeted therapy for hereditary cancers.
Neoplasms
Cytotoxic gold compounds: synthesis, biological characterization and investigation of their inhibition properties of the zinc finger protein PARP-1.
Neoplasms
Cytotoxic synergy between the multikinase inhibitor sorafenib and the proteasome inhibitor bortezomib in vitro: induction of apoptosis through Akt and c-Jun NH2-terminal kinase pathways.
Neoplasms
Cytotoxicity and bioavailability studies on a decoction of Oldenlandia diffusa and its fractions separated by HPLC.
Neoplasms
Cytotoxicity and Differentiating Effect of the Poly(ADP-Ribose) Polymerase Inhibitor Olaparib in Myelodysplastic Syndromes.
Neoplasms
Cytotoxicity and genotoxicity induced in vitro by solvent-extractable organic matter of size-segregated urban particulate matter.
Neoplasms
Cytotoxicity and Pro-Apoptotic, Antioxidant and Anti-Inflammatory Activities of Geopropolis Produced by the Stingless Bee Melipona fasciculata Smith.
Neoplasms
Cytotoxicity of lapachol, ?-lapachone and related synthetic 1,4-naphthoquinones against oesophageal cancer cells.
Neoplasms
Daphnane Diterpenoids from Daphne genkwa Inhibit PI3K/Akt/mTOR Signaling and Induce Cell Cycle Arrest and Apoptosis in Human Colon Cancer Cells.
Neoplasms
DAXX, as a Tumor Suppressor, Impacts DNA Damage Repair and Sensitizes BRCA-Proficient TNBC Cells to PARP Inhibitors.
Neoplasms
Decapping protein EDC4 regulates DNA repair and phenocopies BRCA1.
Neoplasms
Deciphering the Insights of Poly(ADP-Ribosylation) in Tumor Progression.
Neoplasms
Decreased expression of the translation factor eIF3e induces senescence in breast cancer cells via suppression of PARP1 and activation of mTORC1.
Neoplasms
Defective ALC1 nucleosome remodeling confers PARPi sensitization and synthetic lethality with HRD.
Neoplasms
Defective DNA repair mechanisms in prostate cancer: impact of olaparib.
Neoplasms
Defective homologous recombination in human cancers.
Neoplasms
Defects in HR repair behind the human diseases: FA and HBOC.
Neoplasms
Deficiency in the Repair of DNA Damage by Homologous Recombination and Sensitivity to Poly(ADP-Ribose) Polymerase Inhibition.
Neoplasms
Defining and targeting wild-type BRCA high-grade serous ovarian cancer: DNA repair and cell cycle checkpoints.
Neoplasms
Degradation of 5hmC-marked stalled replication forks by APE1 causes genomic instability.
Neoplasms
Delayed role of tumor necrosis factor- alpha in overcoming the effects of pertussis toxin.
Neoplasms
Deleterious somatic variants in 473 consecutive individuals with ovarian cancer: results of the observational AGO-TR1 study (NCT02222883).
Neoplasms
Delving into PARP inhibition from bench to bedside and back.
Neoplasms
Deoxypodophyllotoxin triggers parthanatos in glioma cells via induction of excessive ROS.
Neoplasms
Dependence of trans-ADP-ribosylation and nuclear glycolysis on the Arg 34-ATP complex of Zn2+ finger I of poly-ADP-ribose polymerase-1.
Neoplasms
Design and Synthesis of DNA-Interactive ?-Carboline-Oxindole Hybrids as Cytotoxic and Apoptosis-Inducing Agents.
Neoplasms
Design, synthesis and anticancer activities of novel dual poly(ADP-ribose) polymerase-1/histone deacetylase-1 inhibitors.
Neoplasms
Design, synthesis and antitumor evaluation of new 1,8-naphthalimide derivatives targeting nuclear DNA.
Neoplasms
Design, synthesis and biological activity of novel molecules designed to target PARP and DNA.
Neoplasms
Design, synthesis and biological evaluation of 4-amidobenzimidazole acridine derivatives as dual PARP and Topo inhibitors for cancer therapy.
Neoplasms
Design, synthesis and biological evaluation of cinnamic acyl shikonin derivatives.
Neoplasms
Design, synthesis and biological evaluation of erythrina derivatives bearing a 1,2,3-triazole moiety as PARP-1 inhibitors.
Neoplasms
Design, synthesis and biological evaluation of methylenehydrazine-1-carboxamide derivatives with (5-((4-(pyridin-3-yl)pyrimidin-2-yl)amino)-1H-indole scaffold: Novel potential CDK9 inhibitors.
Neoplasms
Design, synthesis and biological evaluation of novel 5-fluoro-1H-benzimidazole-4-carboxamide derivatives as potent PARP-1 inhibitors.
Neoplasms
Detection and delineation of oral cancer with a PARP1 targeted optical imaging agent.
Neoplasms
Detection and Delineation of Oral Cancer With a PARP1-Targeted Optical Imaging Agent.
Neoplasms
Detection of Molecular Signatures of Homologous Recombination Deficiency in Bladder Cancer.
Neoplasms
Determination of in vitro absorption in Caco-2 monolayers of anticancer Ru(II)-based complexes acting as dual human topoisomerase and PARP inhibitors.
Neoplasms
Determination of the absolute oral bioavailability of niraparib by simultaneous administration of a
Neoplasms
Development and validation of a high-performance liquid chromatography method for the quantitation of intracellular PARP inhibitor Olaparib in cancer cells.
Neoplasms
Development and validation of high-throughput screening assays for poly(ADP-ribose) polymerase-2 inhibitors.
Neoplasms
Development of 'synthetic lethal' strategies to target BRCA1-deficient breast cancer.
Neoplasms
Development of a Cationic Amphiphilic Helical Peptidomimetic (B18L) As A Novel Anti-Cancer Drug Lead.
Neoplasms
Development of a functional assay for homologous recombination status in primary cultures of epithelial ovarian tumor and correlation with sensitivity to poly(ADP-ribose) polymerase inhibitors.
Neoplasms
Development of a high-throughput screening-amenable assay for human poly(ADP-ribose) polymerase inhibitors.
Neoplasms
Development of breast tumors in CHEK2, NBN/NBS1 and BLM mutation carriers does not commonly involve somatic inactivation of the wild-type allele.
Neoplasms
Development of PARP and Immune-Checkpoint Inhibitor Combinations.
Neoplasms
Development of PARP inhibitor combinations for castration resistant prostate cancer unselected for homologous recombination repair mutations.
Neoplasms
Development of PARP inhibitors in gynecological malignancies.
Neoplasms
Development of PARP inhibitors in oncology.
Neoplasms
Development of poly(ADP-ribose) polymerase inhibitors in the treatment of BRCA-mutated breast cancer.
Neoplasms
Development of substituted 6-[4-fluoro-3-(piperazin-1-ylcarbonyl)benzyl]-4,5-dimethylpyridazin-3(2H)-ones as potent poly(ADP-ribose) polymerase-1 (PARP-1) inhibitors active in BRCA deficient cells.
Neoplasms
Diet-induced obesity exacerbates auditory degeneration via hypoxia, inflammation, and apoptosis signaling pathways in CD/1 mice.
Neoplasms
Dietary fish oil deactivates a growth-promoting signaling pathway in hepatoma 7288CTC in Buffalo rats.
Neoplasms
Differences in the cellular response and signaling pathways of cisplatin and BBR3464 ([[trans-PtCl(NH3)(2)]2mu-(trans-Pt(NH3)(2)(H2N(CH2)(6)-NH2)2)]4+) influenced by copper homeostasis.
Neoplasms
Different Array CGH profiles within hereditary breast cancer tumors associated to BRCA1 expression and overall survival.
Neoplasms
Different T cell memory in preadolescents after whole-cell or acellular pertussis vaccination.
Neoplasms
Differential effects of PARP inhibition on vascular cell survival and ACAT-1 expression favouring atherosclerotic plaque stability.
Neoplasms
Differential effects of poly(ADP-ribose) polymerase inhibition on DNA break repair in human cells are revealed with Epstein-Barr virus.
Neoplasms
Differential expression of Ia by murine keratinocytes and gut epithelium in response to recombinant gamma-interferon.
Neoplasms
Differential immunomodulatory effect of PARP inhibition in BRCA1 deficient and competent tumor cells.
Neoplasms
Differential induction of apoptosis and MAP kinase signaling by mitochondrial toxicants in drug-sensitive compared to drug-resistant B-lineage lymphoid cell lines.
Neoplasms
Differential radiosensitization by the poly(ADP-ribose) transferase inhibitor 3-aminobenzamide in human tumor cells of varying radiosensitivity.
Neoplasms
Differential regulation of breast cancer bone metastasis by PARP1 and PARP2.
Neoplasms
Differential therapeutic effects of PARP and ATR inhibition combined with radiotherapy in the treatment of subcutaneous versus orthotopic lung tumour models.
Neoplasms
Differentiation-Associated Downregulation of Poly(ADP-Ribose) Polymerase-1 Expression in Myoblasts Serves to Increase Their Resistance to Oxidative Stress.
Neoplasms
Dihomo-?-linolenic acid inhibits growth of xenograft tumors in mice bearing human pancreatic cancer cells (BxPC-3) transfected with delta-5-desaturase shRNA.
Neoplasms
Dioscin attenuates hepatic ischemia-reperfusion injury in rats through inhibition of oxidative-nitrative stress, inflammation and apoptosis.
Neoplasms
Direct current electrical fields induce apoptosis in oral mucosa cancer cells by NADPH oxidase-derived reactive oxygen species.
Neoplasms
Directed therapy of subtypes of triple-negative breast cancer.
Neoplasms
Discovery and SAR of 2-(1-propylpiperidin-4-yl)-1H-benzimidazole-4-carboxamide: A potent inhibitor of poly(ADP-ribose) polymerase (PARP) for the treatment of cancer.
Neoplasms
Discovery and SAR of orally efficacious tetrahydropyridopyridazinone PARP inhibitors for the treatment of cancer.
Neoplasms
Discovery and SAR of substituted 3-oxoisoindoline-4-carboxamides as potent inhibitors of poly(ADP-ribose) polymerase (PARP) for the treatment of cancer.
Neoplasms
Discovery and SAR study of 2-(1-propylpiperidin-4-yl)-3H-imidazo[4,5-c]pyridine-7-carboxamide: A potent inhibitor of poly(ADP-ribose) polymerase-1 (PARP-1) for the treatment of cancer.
Neoplasms
Discovery and Structure-Activity Relationships of Modified Salicylanilides as Cell Permeable Inhibitors of Poly(ADP-ribose) Glycohydrolase (PARG).
Neoplasms
Discovery of 2-(1-(3-(4-Chloroxyphenyl)-3-oxo- propyl)pyrrolidine-3-yl)-1H-benzo[d]imidazole-4-carboxamide: A Potent Poly(ADP-ribose) Polymerase (PARP) Inhibitor for Treatment of Cancer.
Neoplasms
Discovery of 2-[1-(4,4-Difluorocyclohexyl)piperidin-4-yl]-6-fluoro-3-oxo-2,3-dihydro-1H-isoindole-4-carboxamide (NMS-P118): A Potent, Orally Available, and Highly Selective PARP-1 Inhibitor for Cancer Therapy.
Neoplasms
Discovery of 2-{4-[(3S)-Piperidin-3-yl]phenyl}-2H-indazole-7-carboxamide (MK-4827): A Novel Oral Poly(ADP-ribose)polymerase (PARP) Inhibitor Efficacious in BRCA-1 and -2 Mutant Tumors.
Neoplasms
Discovery of a novel DNA polymerase inhibitor and characterization of its antiproliferative properties.
Neoplasms
Discovery of MTR-106 as a highly potent G-quadruplex stabilizer for treating BRCA-deficient cancers.
Neoplasms
Discovery of naphthacemycins as a novel class of PARP1 inhibitors.
Neoplasms
Discovery of New H2S Releasing Phosphordithioates and 2,3-Dihydro-2-phenyl-2-sulfanylenebenzo[d][1,3,2]oxazaphospholes with Improved Antiproliferative Activity.
Neoplasms
Discovery of novel and potent PARP/PI3K dual inhibitors for the treatment of cancer.
Neoplasms
Discovery of Novel Apigenin-Piperazine Hybrids as Potent and Selective Poly (ADP-Ribose) Polymerase-1 (PARP-1) Inhibitors for the Treatment of Cancer.
Neoplasms
Discovery of Novel Bromophenol-Thiosemicarbazone Hybrids as Potent Selective Inhibitors of Poly(ADP-ribose) Polymerase-1 (PARP-1) for Use in Cancer.
Neoplasms
Discovery of Novel Dual Poly(ADP-ribose)polymerase and Phosphoinositide 3-Kinase Inhibitors as a Promising Strategy for Cancer Therapy.
Neoplasms
Discovery of Pamiparib (BGB-290), a Potent and Selective Poly (ADP-ribose) Polymerase (PARP) Inhibitor in Clinical Development.
Neoplasms
Discovery of potent 2,4-difluoro-linker poly(ADP-ribose) polymerase 1 inhibitors with enhanced water solubility and in vivo anticancer efficacy.
Neoplasms
Discovery of SK-575 as a Highly Potent and Efficacious Proteolysis-Targeting Chimera Degrader of PARP1 for Treating Cancers.
Neoplasms
Discovery of Stereospecific PARP-1 Inhibitor Isoindolinone NMS-P515.
Neoplasms
Discovery of the PARP (poly ADP-ribose polymerase) inhibitor 2-(1-(4,4-difluorocyclohexyl)piperidin-4-yl)-1H-benzo[d]imidazole-4-carboxamide for the treatment of cancer.
Neoplasms
Discovery of the Poly(ADP-ribose) polymerase (PARP) inhibitor 2-[(R)-2-methylpyrrolidin-2-yl]-1H-benzimidazole-4-carboxamide (ABT-888) for the treatment of cancer.
Neoplasms
Discovery, mechanism and metabolism studies of 2,3-difluorophenyl-linker-containing PARP1 inhibitors with enhanced in vivo efficacy for cancer therapy.
Neoplasms
Discriminating radiation injury from recurrent tumor with [18F]PARPi and amino acid PET in mouse models.
Neoplasms
Discussion of PARP inhibitors in cancer therapy.
Neoplasms
DISPOSITION AND DRUG-DRUG INTERACTION POTENTIAL OF VELIPARIB (ABT-888), A NOVEL AND POTENT INHIBITOR OF POLY(ADP-RIBOSE) POLYMERASE.
Neoplasms
Disrupting Na(+),HCO3(-)-cotransporter NBCn1 (Slc4a7) delays murine breast cancer development.
Neoplasms
Dissecting the molecular determinants of clinical PARP1 inhibitor selectivity for tankyrase1.
Neoplasms
Distinct roles for PARP-1 and PARP-2 in c-Myc-driven B-cell lymphoma in mice.
Neoplasms
Disulfide Cleavage in a Dimeric Epipolythiodioxopiperazine Natural Product Diminishes Its Apoptosis-Inducing Effect but Enhances Autophagy in Tumor Cells.
Neoplasms
Disulfiram combined with copper induces immunosuppression via PD-L1 stabilization in hepatocellular carcinoma.
Neoplasms
DNA Damage Repair Alterations are Frequent in Prostatic Adenocarcinomas with Focal Pleomorphic Giant Cell Features.
Neoplasms
DNA Damage Repair and the Emerging Role of Poly(ADP-ribose) Polymerase Inhibition in Cancer Therapeutics.
Neoplasms
DNA damage repair functions and targeted treatment in breast cancer.
Neoplasms
DNA damage response as a therapeutic target in gynecological cancers.
Neoplasms
DNA damage response genes and the development of cancer metastasis.
Neoplasms
DNA damage response markers are differentially expressed in BRCA-mutated breast cancers.
Neoplasms
DNA damage signalling barrier, oxidative stress and treatment-relevant DNA repair factor alterations during progression of human prostate cancer.
Neoplasms
DNA double strand break repair defect and sensitivity to poly ADP-ribose polymerase (PARP) inhibition in human papillomavirus 16-positive head and neck squamous cell carcinoma.
Neoplasms
DNA Glycosylases Involved in Base Excision Repair May Be Associated with Cancer Risk in BRCA1 and BRCA2 Mutation Carriers.
Neoplasms
DNA helicases FANCM and DDX11 are determinants of PARP inhibitor sensitivity.
Neoplasms
DNA methyltransferase inhibitors induce a BRCAness phenotype that sensitizes NSCLC to PARP inhibitor and ionizing radiation.
Neoplasms
DNA repair deficiency as a therapeutic target in cancer.
Neoplasms
DNA Repair Deficiency in Breast Cancer: Opportunities for Immunotherapy.
Neoplasms
DNA Repair Deficiency Is Common in Advanced Prostate Cancer: New Therapeutic Opportunities.
Neoplasms
DNA repair factors and telomere-chromosome integrity in mammalian cells.
Neoplasms
DNA Repair Gene Alterations and PARP Inhibitor Response in Patients With Metastatic Castration-Resistant Prostate Cancer.
Neoplasms
DNA repair genes are selectively mutated in diffuse large B cell lymphomas.
Neoplasms
DNA repair genes polymorphisms and genetic susceptibility to Philadelphia-negative myeloproliferative neoplasms in a Portuguese population: The role of base excision repair genes polymorphisms.
Neoplasms
DNA Repair in Prostate Cancer: Biology and Clinical Implications.
Neoplasms
DNA repair proteins as therapeutic targets in ovarian cancer.
Neoplasms
DNA repair signature is associated with anthracycline response in triple negative breast cancer patients.
Neoplasms
DNA repair single-nucleotide polymorphisms in colorectal cancer and their role as modifiers of the effect of cigarette smoking and alcohol in the Singapore Chinese Health Study.
Neoplasms
DNA replication stress and emerging prospects for PARG inhibitors in ovarian cancer therapy.
Neoplasms
DNA strand break-sensing molecule poly(ADP-Ribose) polymerase cooperates with p53 in telomere function, chromosome stability, and tumor suppression.
Neoplasms
DNA-binding properties of poly(ADP-ribose) polymerase: a target for anticancer therapy.
Neoplasms
DNA-Damaging Anticancer Drugs - a Perspective for DNA Repair-Oriented Therapy.
Neoplasms
DNA-ligase IV and DNA-protein kinase play a critical role in deficient caspases activation in apoptosis-resistant cancer cells by using doxorubicin.
Neoplasms
DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer.
Neoplasms
DNA2-An Important Player in DNA Damage Response or Just Another DNA Maintenance Protein?
Neoplasms
Does the Poly (ADP-Ribose) Polymerase Inhibitor Veliparib Merit Further Study for Cancer-Associated Weight Loss? Observations and Conclusions from Sixty Prospectively Treated Patients.
Neoplasms
Dose-dependent inhibition of tobacco smoke carcinogen-induced lung tumorigenesis in A/J mice by indole-3-carbinol.
Neoplasms
Dose-dependent study of effects of 532-nm continuous wave laser on rat skin: A mechanistic insight.
Neoplasms
Double-barreled gun: Combination of PARP inhibitor with conventional chemotherapy.
Neoplasms
Down-regulated expression of OPCML predicts an unfavorable prognosis and promotes disease progression in human gastric cancer.
Neoplasms
Down-regulation of inhibitor of apoptosis proteins by deguelin selectively induces apoptosis in breast cancer cells.
Neoplasms
Down-regulation of tyrosine aminotransferase at a frequently deleted region 16q22 contributes to the pathogenesis of hepatocellular carcinoma.
Neoplasms
Downregulation of GSDMD attenuates tumor proliferation via the intrinsic mitochondrial apoptotic pathway and inhibition of EGFR/Akt signaling and predicts a good prognosis in non?small cell lung cancer.
Neoplasms
Downregulation of PARP1 transcription by CDK4/6 inhibitors sensitizes human lung cancer cells to anticancer drug-induced death by impairing OGG1-dependent base excision repair.
Neoplasms
Doxorubicin enhances Snail/LSD1-mediated PTEN suppression in a PARP1-dependent manner.
Neoplasms
Doxorubicin-mediated apoptosis in glioma cells requires NFAT3.
Neoplasms
Drug conjugation to hyaluronan widens therapeutic indications for ovarian cancer.
Neoplasms
Drug Driven Synthetic Lethality: bypassing tumor cell genetics with a combination of Dbait and PARP inhibitors.
Neoplasms
Drug repurposing screen identifies lestaurtinib amplifies the ability of the poly (ADP-ribose) polymerase 1 inhibitor AG14361 to kill breast cancer associated gene-1 mutant and wild type breast cancer cells.
Neoplasms
Drug repurposing studies of PARP inhibitors as a new therapy for inherited retinal degeneration.
Neoplasms
Drug Target Strategies in Breast Cancer Treatment: Recent Developments.
Neoplasms
Drug-induced xenogenization of tumors: A possible role in the immune control of malignant cell growth in the brain?
Neoplasms
Drugging the Cancers Addicted to DNA Repair.
Neoplasms
Drugging topoisomerases: lessons and challenges.
Neoplasms
Drugs interfering with apoptosis in breast cancer.
Neoplasms
Dual Inhibition of PARP and the Intra-S/G2 Cell Cycle Checkpoints Results in Highly Effective Radiosensitization of HPV-Positive HNSCC Cells.
Neoplasms
Dual roles of PARP-1 promote cancer growth and progression.
Neoplasms
Dual Targeting of ERBB2/ERBB3 for the Treatment of SLC3A2-NRG1-Mediated Lung Cancer.
Neoplasms
Dual-Modality Optical/PET Imaging of PARP1 in Glioblastoma.
Neoplasms
Echinacoside Induces Apoptosis in Human SW480 Colorectal Cancer Cells by Induction of Oxidative DNA Damages.
Neoplasms
Editorial: Inhibiting PARP as a Strategic Target in Cancer.
Neoplasms
Effect of 6(5H)-phenanthridinone, an inhibitor of poly(ADP-ribose) polymerase, on cultured tumor cells.
Neoplasms
Effect of a poly(ADP-ribose) polymerase-1 inhibitor against esophageal squamous cell carcinoma cell lines.
Neoplasms
Effect of APE1 T2197G (Asp148Glu) polymorphism on APE1, XRCC1, PARP1 and OGG1 expression in patients with colorectal cancer.
Neoplasms
Effect of curcumin on irradiated and estrogen-transformed human breast cell lines.
Neoplasms
Effect of hyperthermia and chemotherapeutic agents on TRAIL-induced cell death in human colon cancer cells.
Neoplasms
Effect of mitochondrially targeted carboxy proxyl nitroxide on Akt-mediated survival in Daudi cells: Significance of a dual mode of action.
Neoplasms
Effect of MRE11 loss on PARP-inhibitor sensitivity in endometrial cancer in vitro.
Neoplasms
Effect of niraparib on cardiac repolarization in patients with platinum-sensitive, recurrent epithelial ovarian, fallopian tube, and primary peritoneal cancer.
Neoplasms
Effect of poly(ADP-ribose)polymerase and DNA topoisomerase I inhibitors on the p53/p63-dependent survival of carcinoma cells.
Neoplasms
Effectiveness and safety of poly (ADP-ribose) polymerase inhibitors in cancer therapy: A systematic review and meta-analysis.
Neoplasms
Effects of cardiotoxin III on NF-kappaB function, proliferation, and apoptosis in human breast MCF-7 cancer cells.
Neoplasms
Effects of Combined Treatment with Ionizing Radiation and the PARP Inhibitor Olaparib in BRCA Mutant and Wild Type Patient-Derived Pancreatic Cancer Xenografts.
Neoplasms
Effects of long-term dehydration on oxidative stress, apoptotic markers and neuropeptides in the gastric mucosa of the dromedary camel.
Neoplasms
Effects of novel inhibitors of poly(ADP-ribose) polymerase-1 and the DNA-dependent protein kinase on enzyme activities and DNA repair.
Neoplasms
Effects of PARP inhibition on drug and Fas-induced apoptosis in leukaemic cells.
Neoplasms
Effects of poly (ADP-ribose) polymerase-1 (PARP-1) inhibition on sulfur mustard-induced cutaneous injuries in vitro and in vivo.
Neoplasms
Effects of poly(ADP-ribose) polymerase inhibition on cell death and chromosome damage induced by VP16 and bleomycin.
Neoplasms
Effects of veliparib on microglial activation and functional outcomes following traumatic brain injury in the rat and pig.
Neoplasms
Effects on apoptosis and cell cycle arrest contribute to the antitumor responses of interleukin-27 mediated by retrovirus in human pancreatic carcinoma cells.
Neoplasms
Efficacy and safety of anti-PD-1-based therapy in combination with PARP inhibitors for patients with advanced solid tumors in a real-world setting.
Neoplasms
Efficacy of PARP inhibition combined with EZH2 inhibition depends on BRCA mutation status and microenvironment in breast cancer.
Neoplasms
Efficacy of PARP Inhibition in Metastatic Castration-resistant Prostate Cancer is Very Different with Non-BRCA DNA Repair Alterations: Reconstructing Prespecified Endpoints for Cohort B from the Phase 3 PROfound Trial of Olaparib.
Neoplasms
Efficacy of the Combination of a PARP Inhibitor and UVC on Cancer Cells as Imaged by Focus Formation by the DNA Repair-related Protein 53BP1 Linked to Green Fluorescent Protein.
Neoplasms
Efficient deletion of normal Brca2-deficient intestinal epithelium by poly(ADP-ribose) polymerase inhibition models potential prophylactic therapy.
Neoplasms
EGFR Amplification Induces Increased DNA Damage Response and Renders Selective Sensitivity to Talazoparib (PARP Inhibitor) in Glioblastoma.
Neoplasms
EGFR and c-MET Cooperate to Enhance Resistance to PARP Inhibitors in Hepatocellular Carcinoma.
Neoplasms
EGFR Mutations Compromise Hypoxia-Associated Radiation Resistance through Impaired Replication Fork-Associated DNA Damage Repair.
Neoplasms
Elevated CXorf67 Expression in PFA Ependymomas Suppresses DNA Repair and Sensitizes to PARP Inhibitors.
Neoplasms
Elevated poly-(ADP-ribose)-polymerase activity sensitizes retinoblastoma-deficient cells to DNA damage-induced necrosis.
Neoplasms
Eliminating hypoxic tumor cells improves response to PARP inhibitors in homologous recombination-deficient cancer models.
Neoplasms
Ellagic acid inhibits human pancreatic cancer growth in Balb c nude mice.
Neoplasms
Embelin Suppresses Growth of Human Pancreatic Cancer Xenografts, and Pancreatic Cancer Cells Isolated from KrasG12D Mice by Inhibiting Akt and Sonic Hedgehog Pathways.
Neoplasms
Embracing synthetic lethality of novel anticancer therapies.
Neoplasms
Emerging drugs for the treatment of ovarian cancer: a focused review of PARP inhibitors.
Neoplasms
Endoplasmic reticulum stress mediates withaferin A-induced apoptosis in human renal carcinoma cells.
Neoplasms
Endotoxin tolerance impairs a pertussis-toxin-sensitive G-protein regulating tumour necrosis factor release by macrophages from tumour-bearing rats.
Neoplasms
Endpoint of cancer treatment: targeted therapies.
Neoplasms
Enhanced anti-tumor activity of a new curcumin-related compound against melanoma and neuroblastoma cells.
Neoplasms
Enhanced cytotoxicity of PARP inhibition in mantle cell lymphoma harbouring mutations in both ATM and p53.
Neoplasms
Enhanced Efficacy of Combined Therapy with Checkpoint Kinase 1 Inhibitor and Rucaparib Via Regulation of Rad-51 Expression in BRCA Wild-Type Epithelial Ovarian Cancer Cells.
Neoplasms
Enhanced killing of cancer cells by poly(ADP-ribose) polymerase inhibitors and topoisomerase I inhibitors reflects poisoning of both enzymes.
Neoplasms
Enhanced poly ADP-ribosylation in human leukemia lymphocytes and ovarian cancers.
Neoplasms
Enhanced polyadenosine diphosphate-ribosylation in gonadotropin-releasing hormone agonist-treated uterine leiomyoma.
Neoplasms
Enhanced suppression of proliferation and migration in highly-metastatic lung cancer cells by combination of valproic acid and coumarin-3-carboxylic acid and its molecular mechanisms of action.
Neoplasms
Enhancement of Cytotoxicity and Inhibition of Angiogenesis in Oral Cancer Stem Cells by a Hybrid Nanoparticle of Bioactive Quinacrine and Silver: Implication of Base Excision Repair Cascade.
Neoplasms
Enhancement of Synthetic Lethality via Combinations of ABT-888, a PARP Inhibitor, and Carboplatin In Vitro and In Vivo Using BRCA1 and BRCA2 Isogenic Models.
Neoplasms
Enhancing the anti-tumour activity of 177Lu-DOTA-octreotate radionuclide therapy in somatostatin receptor-2 expressing tumour models by targeting PARP.
Neoplasms
Enhancing the Cytotoxic Effects of PARP Inhibitors with DNA Demethylating Agents - A Potential Therapy for Cancer.
Neoplasms
Enhancing tumor-targeting monoclonal antibodies therapy by PARP inhibitors.
Neoplasms
Enzyme-mediated depletion of serum l-Met abrogates prostate cancer growth via multiple mechanisms without evidence of systemic toxicity.
Neoplasms
Epigallocatechin gallate (EGCG) suppresses growth and tumorigenicity in breast cancer cells by downregulation of miR-25.
Neoplasms
Epigenetic activation of HORMAD1 in basal-like breast cancer: role in Rucaparib sensitivity.
Neoplasms
Epigenetic inactivation of BCL6B, a novel functional tumour suppressor for gastric cancer, is associated with poor survival of gastric cancer.
Neoplasms
Epistasis in genomic and survival data of cancer patients.
Neoplasms
Epstein-Barr Virus Infection and Altered Control of Apoptotic Pathways in Posttransplant Lymphoproliferative Disorders.
Neoplasms
Epstein-Barr Virus Oncoprotein LMP1 Mediates Epigenetic Changes in Host Gene Expression through PARP1.
Neoplasms
ER maleate is a novel anticancer agent in oral cancer: Implications for cancer therapy.
Neoplasms
ERCC1, PARP-1, and AQP1 as predictive biomarkers in colon cancer patients receiving adjuvant chemotherapy.
Neoplasms
ERCC1-XPF deficiency is a predictor of olaparib induced synthetic lethality and platinum sensitivity in epithelial ovarian cancers.
Neoplasms
Erratum for the Perspective: "Laying a trap to kill cancer cells: PARP inhibitors and their mechanisms of action" by Y. Pommier, M. J. O'Connor, J. de Bono.
Neoplasms
Erythropoietin-driven signalling and cell migration mediated by polyADP-ribosylation.
Neoplasms
Escin, a pentacyclic triterpene, chemosensitizes human tumor cells through inhibition of nuclear factor-kappaB signaling pathway.
Neoplasms
Establishment and Characterization of a Brca1-/-, p53-/- Mouse Mammary Tumor Cell Line.
Neoplasms
Estradiol and progesterone regulate proliferation and apoptosis in colon cancer.
Neoplasms
Estrogen enhances the cytotoxicity of PARP inhibitors on breast cancer cells through stimulating nitric oxide production.
Neoplasms
Ethanol Extract of Securidaca longipedunculata Induces Apoptosis in Brain Tumor (U87) Cells.
Neoplasms
Ethyl pyruvate administration inhibits hepatic tumor growth.
Neoplasms
Evaluating and comparing immunostaining and computational methods for spatial profiling of drug response in patient-derived explants.
Neoplasms
Evaluation of a Low-Toxicity PARP Inhibitor as a Neuroprotective Agent for Parkinson's Disease.
Neoplasms
Evaluation of absorption, distribution, metabolism, and excretion of [14C]-rucaparib, a poly(ADP-ribose) polymerase inhibitor, in patients with advanced solid tumors.
Neoplasms
Evaluation of anti-tumorigenic activity of BP3B against colon cancer with patient-derived tumor xenograft model.
Neoplasms
Evaluation of candidate biomarkers to predict cancer cell sensitivity or resistance to PARP-1 inhibitor treatment.
Neoplasms
Evaluation of Drug-Drug Interactions of Rucaparib and CYP1A2, CYP2C9, CYP2C19, CYP3A, and P-gp Substrates in Patients With an Advanced Solid Tumor.
Neoplasms
Evaluation of PARP and PDL-1 as potential therapeutic targets for women with high-grade neuroendocrine carcinomas of the cervix.
Neoplasms
Evaluation of poly (ADP-ribose) polymerase inhibitor ABT-888 combined with radiotherapy and temozolomide in glioblastoma.
Neoplasms
Evaluation of tankyrase inhibition in whole cells.
Neoplasms
Evaluation of the methods to identify patients who may benefit from PARP inhibitor use.
Neoplasms
Evaluation of the pharmacodynamics and pharmacokinetics of the PARP inhibitor olaparib: a Phase I multicentre trial in patients scheduled for elective breast cancer surgery.
Neoplasms
Evidence for tight coupling of Gi protein-mediated lysophosphatidic acid receptor to stimulated cytokine production in ovarian cancer cell.
Neoplasms
Evidence of a novel antiapoptotic factor: role of inhibitor of differentiation or DNA binding (Id-1) in anticancer drug-induced apoptosis.
Neoplasms
Evidence of securin-mediated resistance to gefitinib-induced apoptosis in human cancer cells.
Neoplasms
Evolution of pre-existing versus acquired resistance to platinum drugs and PARP inhibitors in BRCA-associated cancers.
Neoplasms
Evolutionary dynamics of cancer multidrug resistance in response to olaparib and photodynamic therapy.
Neoplasms
EWS-FLI1 increases transcription to cause R-loops and block BRCA1 repair in Ewing sarcoma.
Neoplasms
Ex vivo treatment of prostate tumor tissue recapitulates in vivo therapy response.
Neoplasms
Examination of Diazaspiro Cores as Piperazine Bioisosteres in the Olaparib Framework Shows Reduced DNA Damage and Cytotoxicity.
Neoplasms
Exceptional Response to Olaparib in a Patient With Recurrent Ovarian Cancer and an Entire BRCA1 Germline Gene Deletion.
Neoplasms
Exogenous fatty acid binding protein 4 promotes human prostate cancer cell progression.
Neoplasms
Exosome component 1 cleaves single-stranded DNA and sensitizes human kidney renal clear cell carcinoma cells to poly(ADP-ribose) polymerase inhibitor.
Neoplasms
Experiencia con el uso de olaparib en pacientes con cáncer de ovario.
Neoplasms
Exploiting Defective DNA Repair in IDH-Mutant Cancers.
Neoplasms
Exploiting interconnected synthetic lethal interactions between PARP inhibition and cancer cell reversible senescence.
Neoplasms
Exploiting the Achilles heel of cancer: the therapeutic potential of poly(ADP-ribose) polymerase inhibitors in BRCA2-defective cancer.
Neoplasms
Exploring and comparing adverse events between PARP inhibitors.
Neoplasms
Exploring the effect of PARP-1 flexibility in docking studies.
Neoplasms
Expression and Single Nucleotide Polymorphism of Poly (ADPRibose) Polymerase-1 in Gastrointestinal Tumours: Clinical Involvement.
Neoplasms
Expression of DNA Damage Response Molecules PARP1, ?H2AX, BRCA1, and BRCA2 Predicts Poor Survival of Breast Carcinoma Patients.
Neoplasms
Expression of DNA Damage Response Proteins and Associations with Clinicopathologic Characteristics in Chinese Familial Breast Cancer Patients with BRCA1/2 Mutations.
Neoplasms
Expression of DNA damage response proteins in cervical cancer patients treated with radical chemoradiotherapy.
Neoplasms
Expression of human poly (ADP-ribose) polymerase 1 in Saccharomyces cerevisiae: Effect on survival, homologous recombination and identification of genes involved in intracellular localization.
Neoplasms
Expression of nuclear matrix proteins binding matrix attachment regions in prostate cancer. PARP-1: New player in tumor progression.
Neoplasms
Expression of PARP-1 and its active polymer PAR in prostate cancer and benign prostatic hyperplasia in Chinese patients.
Neoplasms
Expression of poly (adenosine diphosphate-ribose) polymerase and p53 in epithelial ovarian cancer and their role in prognosis and disease outcome.
Neoplasms
Expression of poly(ADP-ribose) polymerase and distribution of poly(ADP-ribosyl)ation in glioblastoma and in a glioma multicellular tumour spheroid model.
Neoplasms
Expression of poly(ADP-ribose) polymerase in human hepatocellular carcinoma and analysis of biopsy specimens obtained under sonographic guidance.
Neoplasms
Expression of potential biomarkers associated with homologous recombination repair in patients with ovarian or triple-negative breast cancer.
Neoplasms
Expression profiles of vault components MVP, TEP1 and vPARP and their correlation to other multidrug resistance proteins in ovarian cancer.
Neoplasms
Extent of radiosensitization by the PARP inhibitor olaparib depends on its dose, the radiation dose and the integrity of the homologous recombination pathway of tumor cells.
Neoplasms
Extract of Solanum muricatum (Pepino/CSG) inhibits tumor growth by inducing apoptosis.
Neoplasms
EZH2 contributes to the response to PARP inhibitors through its PARP-mediated poly-ADP ribosylation in breast cancer.
Neoplasms
F-Box Protein-Mediated Resistance to PARP Inhibitor Therapy.
Neoplasms
Failure of Iniparib to Inhibit Poly(ADP-Ribose) Polymerase In Vitro.
Neoplasms
Failure of poly(ADP-ribose) polymerase cleavage by caspases leads to induction of necrosis and enhanced apoptosis.
Neoplasms
FAM35A associates with REV7 and modulates DNA damage responses of normal and BRCA1-defective cells.
Neoplasms
Fast dose fractionation using ultra-short laser accelerated proton pulses can increase cancer cell mortality, which relies on functional PARP1 protein.
Neoplasms
FDA Approval Summary: Niraparib for the Maintenance Treatment of Patients with Recurrent Ovarian Cancer in Response to Platinum-Based Chemotherapy.
Neoplasms
Fermented wheat germ extract inhibits glycolysis/pentose cycle enzymes and induces apoptosis through poly(ADP-ribose) polymerase activation in Jurkat T-cell leukemia tumor cells.
Neoplasms
First-line PARP inhibitors in ovarian cancer: summary of an ESMO Open - Cancer Horizons round-table discussion.
Neoplasms
Flavanonol taxifolin attenuates proteasome inhibition-induced apoptosis in differentiated PC12 cells by suppressing cell death process.
Neoplasms
Fluzoparib increases radiation sensitivity of non-small cell lung cancer (NSCLC) cells without BRCA1/2 mutation, a novel PARP1 inhibitor undergoing clinical trials.
Neoplasms
Folic Acid Receptor-Mediated Targeting Enhances the Cytotoxicity, Efficacy, and Selectivity of Withania somnifera Leaf Extract: In vitro and in vivo Evidence.
Neoplasms
Folliculin deficient renal cancer cells exhibit BRCA1 A complex expression impairment and sensitivity to PARP1 inhibitor olaparib.
Neoplasms
FOXK1 Participates in DNA Damage Response by Controlling 53BP1 Function.
Neoplasms
Fragile gene product, Fhit, in oxidative and replicative stress responses.
Neoplasms
Free energy calculation provides insight into the action mechanism of selective PARP-1 inhibitor.
Neoplasms
Frequency and prognostic value of mutations associated with the homologous recombination DNA repair pathway in a large pan cancer cohort.
Neoplasms
Frequent occurrence of abnormal E-cadherin/beta-catenin protein expression in advanced gallbladder cancers and its association with decreased apoptosis.
Neoplasms
From polypharmacology to target specificity: the case of PARP inhibitors.
Neoplasms
Function and Regulation of the Mono-ADP-Ribosyltransferase ARTD10.
Neoplasms
Functional and mutational landscapes of BRCA1 for homology-directed repair and therapy resistance.
Neoplasms
Functional Characterization of Long Noncoding RNA Lnc_bc060912 in Human Lung Carcinoma Cells.
Neoplasms
Functional Characterization of PALB2 Variants of Uncertain Significance: Toward Cancer Risk and Therapy Response Prediction.
Neoplasms
Functional consequences of a rare missense BARD1 c.403G>A germline mutation identified in a triple-negative breast cancer patient.
Neoplasms
Functional Ex Vivo Assay Reveals Homologous Recombination Deficiency in Breast Cancer Beyond BRCA Gene Defects.
Neoplasms
Functional Ex Vivo Assay to Select Homologous Recombination-Deficient Breast Tumors for PARP Inhibitor Treatment.
Neoplasms
Functional genomic analysis of drug sensitivity pathways to guide adjuvant strategies in breast cancer.
Neoplasms
Functional overexpression of human poly(ADP-ribose) polymerase in transfected rat tumor cells.
Neoplasms
Functional Radiogenetic Profiling Implicates ERCC6L2 in Non-homologous End Joining.
Neoplasms
Further Analyses Highlight Benefits of PARP Inhibitors As Frontline Maintenance in Ovarian Cancer.
Neoplasms
Fuzheng Qingjie Granules Inhibit Growth of Hepatoma Cells via Inducing Mitochondria-Mediated Apoptosis and Enhancing Immune Function.
Neoplasms
Fuzuloparib: First Approval.
Neoplasms
Gain-of-Function Mutant p53 R273H Interacts with Replicating DNA and PARP1 in Breast Cancer.
Neoplasms
Galangin Inhibits Gastric Cancer Growth Through Enhancing STAT3 Mediated ROS Production.
Neoplasms
Gamma ray-induced in vitro cell migration via EGFR/ERK/Akt/p38 activation is prevented by olaparib pretreatment.
Neoplasms
Ganetespib overcomes resistance to PARP inhibitors in breast cancer by targeting core proteins in the DNA repair machinery.
Neoplasms
Garcinol Inhibits Cell Proliferation and Promotes Apoptosis in Pancreatic Adenocarcinoma Cells.
Neoplasms
Gastrointestinal events with PARP inhibitors in cancer patients: A meta-analysis of phase II/III randomized controlled trials.
Neoplasms
Gemcitabine impacts differentially on bladder and kidney cancer cells: distinct modulations in the expression patterns of apoptosis-related microRNAs and BCL2 family genes.
Neoplasms
Gene Panel Tumor Testing in Ovarian Cancer Patients Significantly Increases the Yield of Clinically Actionable Germline Variants beyond BRCA1/BRCA2.
Neoplasms
Generation of Dose-Response Curves and Improved IC50s for PARP Inhibitor Nanoformulations.
Neoplasms
Genetic alteration of poly(ADP-ribose) polymerase-1 in human germ cell tumors.
Neoplasms
Genetic Association of PARP15 Polymorphisms with Clinical Outcome of Acute Myeloid Leukemia in a Korean Population.
Neoplasms
Genetic cooperation between the Werner syndrome protein and poly(ADP-ribose) polymerase-1 in preventing chromatid breaks, complex chromosomal rearrangements, and cancer in mice.
Neoplasms
Genetic diagnosis of familial breast cancer using clonal sequencing.
Neoplasms
Genetic Dissection of PARylation in the Filamentous Fungus Neurospora crassa.
Neoplasms
Genetic polymorphisms in DNA base-excision repair genes ADPRT, XRCC1, and APE1 and the risk of squamous cell carcinoma of the head and neck.
Neoplasms
Genetic sequence variations and ADPRT haplotype analysis in French Canadian families with high risk of breast cancer.
Neoplasms
Genetics of triple-negative breast cancer: Implications for patient care.
Neoplasms
Genistein inhibits radiation-induced activation of NF-kappaB in prostate cancer cells promoting apoptosis and G2/M cell cycle arrest.
Neoplasms
Genome-scale CRISPR knockout screen identifies TIGAR as a modifier of PARP inhibitor sensitivity.
Neoplasms
Genome-wide analysis of gynecologic cancer: The Cancer Genome Atlas in ovarian and endometrial cancer.
Neoplasms
Genome-wide and high-density CRISPR-Cas9 screens identify point mutations in PARP1 causing PARP inhibitor resistance.
Neoplasms
Genome-wide CRISPR screens reveal cyclin C as synthetic survival target of BRCA2.
Neoplasms
Genomic alterations and abnormal expression of APE2 in multiple cancers.
Neoplasms
Genomic Characterization of High-Grade Serous Ovarian Cancer: Dissecting Its Molecular Heterogeneity as a Road Towards Effective Therapeutic Strategies.
Neoplasms
Genomic Features of Metastatic Testicular Sex Cord Stromal Tumors.
Neoplasms
Genomic hallmarks of homologous recombination deficiency in invasive breast carcinomas.
Neoplasms
Genomic instability in breast and ovarian cancers: translation into clinical predictive biomarkers.
Neoplasms
Genomic instability in pancreatic adenocarcinoma: a new step towards precision medicine and novel therapeutic approaches.
Neoplasms
Genomic landscape of metastatic breast cancer identifies preferentially dysregulated pathways and targets.
Neoplasms
Genomic Profiling and Potentially Targetable Alterations in Pancreatic Ductal Adenocarcinoma.
Neoplasms
Genomic profiling in locally advanced and inflammatory breast cancer and its link to DCE-MRI and overall survival.
Neoplasms
Genomic scars as biomarkers of homologous recombination deficiency and drug response in breast and ovarian cancers.
Neoplasms
Genomic Testing in Patients with Metastatic Castration-resistant Prostate Cancer: A Pragmatic Guide for Clinicians.
Neoplasms
Genomic, Transcriptomic, and Functional Alterations in DNA Damage Response Pathways as Putative Biomarkers of Chemotherapy Response in Ovarian Cancer.
Neoplasms
Gentian violet induces wtp53 transactivation in cancer cells.
Neoplasms
Geranylgeranyl transferase inhibition stimulates anti-melanoma immune response through MHC Class I and costimulatory molecule expression.
Neoplasms
Germline Missense Variants in BRCA1: New Trends and Challenges for Clinical Annotation.
Neoplasms
Germline mutations in Black patients with ovarian, fallopian tube and primary peritoneal carcinomas.
Neoplasms
Germline mutations in RAD51D confer susceptibility to ovarian cancer.
Neoplasms
Germline mutations in the PALB2 gene are population specific and occur with low frequencies in familial breast cancer.
Neoplasms
Glioblastoma Cells Containing Mutations in the Cohesin Component STAG2 Are Sensitive to PARP Inhibition.
Neoplasms
Glucuronorhamnoxylan from Capsosiphon fulvescens inhibits the growth of HT-29 human colon cancer cells in vitro and in vivo via induction of apoptotic cell death.
Neoplasms
Glutathione-Depleting Pro-Oxidant as a Selective Anticancer Therapeutic Agent.
Neoplasms
Glycerol enhances CDDP-induced growth inhibition of thyroid anaplastic carcinoma tumor carrying mutated p53 gene.
Neoplasms
Glycogen synthase kinase 3? inhibition synergizes with PARP inhibitors through the induction of homologous recombination deficiency in colorectal cancer.
Neoplasms
Gonadotropin-mediated chemoresistance: Delineation of molecular pathways and targets.
Neoplasms
Gonadotropin-releasing hormone activates a rapid Ca2+-independent phosphodiester hydrolysis of polyphosphoinositides in pituitary gonadotrophs.
Neoplasms
Gramine inhibits angiogenesis and induces apoptosis via modulation of TGF-? signalling in 7,12 dimethylbenz[a]anthracene (DMBA) induced hamster buccal pouch carcinoma.
Neoplasms
Granulocyte-macrophage colony stimulating factor activates proteoglycan, type II collagen, and cAMP production by rat articular chondrocytes through specific binding sites.
Neoplasms
Grape seed extract inhibits in vitro and in vivo growth of human colorectal carcinoma cells.
Neoplasms
Growth inhibitory and apoptosis-inducing effects of xanthohumol, a prenylated chalone present in hops, in human prostate cancer cells.
Neoplasms
GSK2801, a BAZ2/BRD9 Bromodomain Inhibitor, Synergizes with BET Inhibitors to Induce Apoptosis in Triple-Negative Breast Cancer.
Neoplasms
Guanylate cyclase activator YC-1 potentiates apoptotic effect of licochalcone A on human epithelial ovarian carcinoma cells via activation of death receptor and mitochondrial pathways.
Neoplasms
Gynaecological cancer: PARP inhibition - moving beyond BRCA-mutated disease.
Neoplasms
Gynecologic Cancers: Emerging Novel Strategies for Targeting DNA Repair Deficiency.
Neoplasms
H2AX a promising biomarker for lung cancer: a review.
Neoplasms
Haematologic toxicities with PARP inhibitors in cancer patients: an up-to-date meta-analysis of 29 randomized controlled trials.
Neoplasms
Haploinsufficiency of Parp1 accelerates Brca1-associated centrosome amplification, telomere shortening, genetic instability, apoptosis, and embryonic lethality.
Neoplasms
Harnessing DNA Double-Strand Break Repair for Cancer Treatment.
Neoplasms
HARP?111-136 enhances radiation-induced apoptosis of U87MG glioblastoma by induction of the proapoptotic protein CHOP.
Neoplasms
Heat Shock Factor 1 Depletion Sensitizes A172 Glioblastoma Cells to Temozolomide via Suppression of Cancer Stem Cell-Like Properties.
Neoplasms
Heat shock protein inhibitors increase the efficacy of measles virotherapy.
Neoplasms
Hedgehog/GLI1 Transcriptionally Regulates FANCD2 in Ovarian Tumor Cells: Its Inhibition Induces HR-Deficiency and Synergistic Lethality with PARP Inhibition.
Neoplasms
HELB Is a Feedback Inhibitor of DNA End Resection.
Neoplasms
Helicobacter pylori activation of PARP-1: Usurping a versatile regulator of host cellular health.
Neoplasms
HER2 Overexpression Renders Human Breast Cancers Sensitive to PARP Inhibition Independently of Any Defect in Homologous Recombination DNA Repair.
Neoplasms
Hereditary breast cancer: new genetic developments, new therapeutic avenues.
Neoplasms
Hereditary breast cancer: pathobiology, clinical translation, and potential for targeted cancer therapeutics.
Neoplasms
Hereditary Prostate Cancer: Genes Related, Target Therapy and Prevention.
Neoplasms
Hexane fraction of adlay (Coix lachryma-jobi L.) testa ethanolic extract inhibits human uterine sarcoma cancer cells growth and chemosensitizes human uterine sarcoma cells to doxorubicin.
Neoplasms
HGS-ETR1, a fully human TRAIL-receptor 1 monoclonal antibody, induces cell death in multiple tumour types in vitro and in vivo.
Neoplasms
High BRCA2 Gene Expression is Associated with Aggressive and Highly Proliferative Breast Cancer.
Neoplasms
High energy shock waves and 5-aminolevulinic for sonodynamic therapy: effects in a syngeneic model of colon cancer.
Neoplasms
High frequency of pathogenic germline variants within homologous recombination repair in patients with advanced cancer.
Neoplasms
High incidence of protein-truncating TP53 mutations in BRCA1-related breast cancer.
Neoplasms
High level of apoptosis and low AKT activation in mass screening as opposed to standard neuroblastoma.
Neoplasms
High PARP-1 expression is associated with tumor invasion and poor prognosis in gastric cancer.
Neoplasms
High PARP-1 expression predicts poor survival in acute myeloid leukemia and PARP-1 inhibitor and SAHA-bendamustine hybrid inhibitor combination treatment synergistically enhances anti-tumor effects.
Neoplasms
High poly(adenosine diphosphate-ribose) polymerase expression and poor survival in advanced-stage serous ovarian cancer.
Neoplasms
High resolution melting profiles (HRMPs) obtained by magnetic induction cycler (MIC) have been used to monitor the BRCA2 status highlighted by next generation tumor sequencing (NGTS): a combined approach in a diagnostic environment.
Neoplasms
High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs.
Neoplasms
High specificity and efficiency electrochemical detection of poly(ADP-ribose) polymerase-1 activity based on versatile peptide-templated copper nanoparticles and detection array.
Neoplasms
High-Throughput Colorimetric Assay for Identifying PARP-1 Inhibitors Using a Large Small-Molecule Collection.
Neoplasms
Histone deacetylase inhibition of cardiac autophagy in rats on a high?fat diet with low?dose streptozotocin-induced type 2 diabetes mellitus.
Neoplasms
Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), enhances anti-tumor effects of the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib in triple-negative breast cancer cells.
Neoplasms
Histone gammaH2AX and poly(ADP-ribose) as clinical pharmacodynamic biomarkers.
Neoplasms
Histone H2AX is a critical factor for cellular protection against DNA alkylating agents.
Neoplasms
Histone Parylation factor 1 contributes to the inhibition of PARP1 by cancer drugs.
Neoplasms
Histone-dependent PARP-1 inhibitors: A novel therapeutic modality for the treatment of prostate and renal cancers.
Neoplasms
HMGA2 as a functional antagonist of PARP1 inhibitors in tumor cells.
Neoplasms
hMOB2 deficiency impairs homologous recombination-mediated DNA repair and sensitises cancer cells to PARP inhibitors.
Neoplasms
Homologous recombination deficiency and ovarian cancer.
Neoplasms
Homologous recombination in cancer development, treatment and development of drug resistance.
Neoplasms
Homologous Recombination Repair Deficiency and Implications for Tumor Immunogenicity.
Neoplasms
Homologous Recombination Repair Truncations Predict Hypermutation in Microsatellite Stable Colorectal and Endometrial Tumors.
Neoplasms
Homologous Recombination-Mediated DNA Repair and Implications for Clinical Treatment of Repair Defective Cancers.
Neoplasms
Homology-Directed Repair and the Role of BRCA1, BRCA2, and Related Proteins in Genome Integrity and Cancer.
Neoplasms
Honokiol-induced apoptosis and autophagy in glioblastoma multiforme cells.
Neoplasms
HORMAD1 is a negative prognostic indicator in lung adenocarcinoma and specifies resistance to oxidative and genotoxic stress.
Neoplasms
Host poly(ADP-ribose) polymerases (PARPs) in acute and chronic bacterial infections.
Neoplasms
How and when to refer patients for oncogenetic counseling in the era of PARP inhibitors.
Neoplasms
How to kill tumor cells with inhibitors of poly(ADP-ribosyl)ation.
Neoplasms
HPMA copolymer-bound doxorubicin induces apoptosis in human ovarian carcinoma cells by a Fas-independent pathway.
Neoplasms
HPW-RX40 restores anoikis sensitivity of human breast cancer cells by inhibiting integrin/FAK signaling.
Neoplasms
HRDetect is a predictor of BRCA1 and BRCA2 deficiency based on mutational signatures.
Neoplasms
Human Mass Balance and Metabolite Profiling of [14 C]-Pamiparib, a Poly (ADP-Ribose) Polymerase Inhibitor, in Patients With Advanced Cancer.
Neoplasms
Human MCF10A mammary epithelial cells undergo apoptosis following actin depolymerization that is independent of attachment and rescued by Bcl-2.
Neoplasms
Human pancreatic tumor growth hormone (GH) - releasing factor and cyclic adenosine 3',5'- monophosphate evoke GH release from anterior pituitary cells: the effects of pertussis toxin, cholera toxin, forskolin, and cycloheximide.
Neoplasms
Human V?2V?2 T cells limit breast cancer growth by modulating cell survival-, apoptosis-related molecules and microenvironment in tumors.
Neoplasms
HuR-targeted small molecule inhibitor exhibits cytotoxicity towards human lung cancer cells.
Neoplasms
Hydrogen peroxide-induced injury of cells and its prevention by inhibitors of poly(ADP-ribose) polymerase.
Neoplasms
Hyper-active non-homologous end joining selects for synthetic lethality resistant and pathological Fanconi anemia hematopoietic stem and progenitor cells.
Neoplasms
Hypericin induced death receptor-mediated apoptosis in photoactivated tumor cells.
Neoplasms
Identification and analysis of the active phytochemicals from the anti-cancer botanical extract Bezielle.
Neoplasms
Identification and Characterization of MortaparibPlus-A Novel Triazole Derivative That Targets Mortalin-p53 Interaction and Inhibits Cancer-Cell Proliferation by Wild-Type p53-Dependent and -Independent Mechanisms.
Neoplasms
Identification and mechanism of action analysis of the new PARP-1 inhibitor 2?-hydroxygenkwanol A.
Neoplasms
Identification and preclinical characterization of a novel and potent poly (ADP-ribose) polymerase (PARP) inhibitor ZYTP1.
Neoplasms
Identification and quantification of DNA repair protein poly(ADP ribose) polymerase 1 (PARP1) in human tissues and cultured cells by liquid chromatography/isotope-dilution tandem mass spectrometry.
Neoplasms
Identification and SAR of novel pyrrolo[1,2-a]pyrazin-1(2H)-one derivatives as inhibitors of poly(ADP-ribose) polymerase-1 (PARP-1).
Neoplasms
Identification by array comparative genomic hybridization of a new amplicon on chromosome 17q highly recurrent in BRCA1 mutated triple negative breast cancer.
Neoplasms
Identification of a new tamoxifen-xanthene hybrid as pro-apoptotic anticancer agent.
Neoplasms
Identification of a rearrangement in the 5' upstream region of the poly(ADP-ribose) polymerase pseudogene on chromosome 13 in Ewing's sarcoma cells.
Neoplasms
Identification of aminoethyl pyrrolo dihydroisoquinolinones as novel poly(ADP-ribose) polymerase-1 inhibitors.
Neoplasms
Identification of an antitumor effect of demethylzeylasteral on human gastric cancer cells.
Neoplasms
Identification of biomarkers complementary to homologous recombination deficiency for improving the clinical outcome of ovarian serous cystadenocarcinoma.
Neoplasms
Identification of BRCA1-like triple-negative breast cancers by quantitative multiplex-ligation-dependent probe amplification (MLPA) analysis of BRCA1-associated chromosomal regions: a validation study.
Neoplasms
Identification of Novel Biomarkers of Homologous Recombination Defect in DNA Repair to Predict Sensitivity of Prostate Cancer Cells to PARP-Inhibitors.
Neoplasms
Identification of Novel Interaction Partners of Ets-1: Focus on DNA Repair.
Neoplasms
Identification of PARP-1 in cancer stem cells of gastrointestinal cancers: A preliminary study.
Neoplasms
Identification of PARP-1, Histone H1 and SIRT-1 as New Regulators of Breast Cancer-Related Aromatase Promoter I.3/II.
Neoplasms
Identification of PARP14 inhibitors using novel methods for detecting auto-ribosylation.
Neoplasms
Identification of poly(ADP-ribose) polymerase-1 as the OXPHOS-generated ATP sensor of nuclei of animal cells.
Neoplasms
Identification of probe-quality degraders for Poly(ADP-ribose) polymerase-1 (PARP-1).
Neoplasms
Identification of several high-risk HPV inhibitors and drug targets with a novel high-throughput screening assay.
Neoplasms
Identification of Somatically Acquired BRCA1/2 Mutations by cfDNA Analysis in Patients with Metastatic Breast Cancer.
Neoplasms
Identifying and Overcoming Mechanisms of PARP Inhibitor Resistance in Homologous Recombination Repair-Deficient and Repair-Proficient High Grade Serous Ovarian Cancer Cells.
Neoplasms
Identifying new piperazine-based PARP1 inhibitors using text mining and integrated molecular modeling approaches.
Neoplasms
Identifying patients eligible for PARP inhibitor treatment: from NGS-based tests to 3D functional assays.
Neoplasms
Ifosfamide-loaded poly (lactic-co-glycolic acid) PLGA-dextran polymeric nanoparticles to improve the antitumor efficacy in Osteosarcoma.
Neoplasms
IGH/MYC Translocation Associates with BRCA2 Deficiency and Synthetic Lethality to PARP1 Inhibitors.
Neoplasms
IL-24 Inhibits Lung Cancer Growth by Suppressing GLI1 and Inducing DNA Damage.
Neoplasms
Imatinib modulates pro-inflammatory microenvironment with angiostatic effects in experimental lung carcinogenesis.
Neoplasms
Immune Checkpoint and Poly(ADP-Ribose) Polymerase Inhibition for Recurrent Platinum-Resistant Ovarian and Metastatic Triple-Negative Breast Cancers.
Neoplasms
Immune System and DNA Repair Defects in Ovarian Cancer: Implications for Locoregional Approaches.
Neoplasms
Immunochemical analysis of poly(ADP-ribosyl)ation in HaCaT keratinocytes induced by the mono-alkylating agent 2-chloroethyl ethyl sulfide (CEES): Impact of experimental conditions.
Neoplasms
Immunohistochemical detection of poly(ADP-ribose) polymerase inhibition by ABT-888 in patients with refractory solid tumors and lymphomas.
Neoplasms
Immunomodulatory Roles of PARP-1 and PARP-2: Impact on PARP-Centered Cancer Therapies.
Neoplasms
Immunophenotypic predictive profiling of BRCA1-associated breast cancer.
Neoplasms
Immunotherapy for breast cancer using EpCAM aptamer tumor-targeted gene knockdown.
Neoplasms
Immunotherapy in ovarian, endometrial and cervical cancer: State of the art and future perspectives.
Neoplasms
Immunotherapy of COVID-19 with poly (ADP-ribose) polymerase inhibitors: starting with nicotinamide.
Neoplasms
Impact of mutations in homologous recombination repair genes on treatment outcomes for metastatic castration resistant prostate cancer.
Neoplasms
Impact of PARP-1 and DNA-PK expression on survival in patients with glioblastoma multiforme.
Neoplasms
Impact of Polypharmacy for Chronic Ailments in Colon Cancer Patients: A Review Focused on Drug Repurposing.
Neoplasms
Impact of telomerase ablation on organismal viability, aging, and tumorigenesis in mice lacking the DNA repair proteins PARP-1, Ku86, or DNA-PKcs.
Neoplasms
Impaired DNA damage response - An Achilles' heel sensitizing cancer to chemotherapy and radiotherapy.
Neoplasms
Imprecise Medicine: BRCA2 Variants of Uncertain Significance (VUS), the Challenges and Benefits to Integrate a Functional Assay Workflow with Clinical Decision Rules.
Neoplasms
Improved prediction of PARP inhibitor response and identification of synergizing agents through use of a novel gene expression signature generation algorithm.
Neoplasms
Improved Therapeutic Window in BRCA-mutant Tumors with Antibody-linked Pyrrolobenzodiazepine Dimers with and without PARP Inhibition.
Neoplasms
Improved tumor-suppressive effect of OZ-001 combined with cisplatin mediated by mTOR/p70S6K and STAT3 inactivation in A549 human lung cancer cells.
Neoplasms
In silico discovery of novel flavonoids as poly ADP ribose polymerase (PARP) inhibitors.
Neoplasms
In Silico Investigation of Potential PARP-1 Inhibitors from Traditional Chinese Medicine.
Neoplasms
In Silico Screening Identifies a Novel Potential PARP1 Inhibitor Targeting Synthetic Lethality in Cancer Treatment.
Neoplasms
In vitro and in vivo radiosensitization of glioblastoma cells by the poly (ADP-ribose) polymerase inhibitor E7016.
Neoplasms
In vitro effects of poly(ADP-ribose) polymerase inhibitors on the production of tumor necrosis factor-? by interferon- ? - and lipopolysaccharide-stimulated peripheral blood mononuclear cells of horses.
Neoplasms
In Vitro Long-Term Proliferation Assays to Study Antiproliferative Effects of PARP Inhibitors on Cancer Cells.
Neoplasms
In vivo and in vitro antitumor effects of platycodin d, a saponin purified from platycodi radix on the h520 lung cancer cell.
Neoplasms
In vivo imaging of specific drug-target binding at subcellular resolution.
Neoplasms
In Vivo therapeutic potential of mesenchymal stem cell-derived extracellular vesicles with optical imaging reporter in tumor mice model.
Neoplasms
In vivo visualization of PARP inhibitor pharmacodynamics.
Neoplasms
Inactivation of hypoxia-induced YAP by statins overcomes hypoxic resistance tosorafenib in hepatocellular carcinoma cells.
Neoplasms
Inactivation of mirk/dyrk1b kinase targets quiescent pancreatic cancer cells.
Neoplasms
Inactivation of the prolyl isomerase Pin1 sensitizes BRCA1-proficient breast cancer to PARP inhibition.
Neoplasms
Inactivation of the tumor suppressor p53 by long noncoding RNA RMRP.
Neoplasms
Increased cell-surface receptor expression on U-937 cells induced by 1-O-octadecyl-2-O-methyl-sn-glycero-3-phosphocholine.
Neoplasms
Increased cytotoxicity of an unusual DNA topoisomerase II inhibitor compound C-1305 toward HeLa cells with downregulated PARP-1 activity results from re-activation of the p53 pathway and modulation of mitotic checkpoints.
Neoplasms
Increased Occurrence of Caspase-Dependent Apoptosis in Unfavorable Neuroblastomas.
Neoplasms
Increased PARP Activity and DNA Damage in NSCLC Patients: The Influence of COPD.
Neoplasms
Increased PARP1-DNA binding due to autoPARylation inhibition of PARP1 on DNA rather than PARP1-DNA trapping is correlated with PARP1 inhibitor's cytotoxicity.
Neoplasms
Increased susceptibility of vault poly(ADP-ribose) polymerase-deficient mice to carcinogen-induced tumorigenesis.
Neoplasms
Indicators of homologous recombination deficiency in breast cancer and association with response to neoadjuvant chemotherapy.
Neoplasms
Individual and Combined Expression of DNA Damage Response Molecules PARP1, ?H2AX, BRCA1, and BRCA2 Predict Shorter Survival of Soft Tissue Sarcoma Patients.
Neoplasms
Indole-3-Carbinol (I3C) enhances the sensitivity of murine breast adenocarcinoma cells to doxorubicin (DOX) through inhibition of NF-??, blocking angiogenesis and regulation of mitochondrial apoptotic pathway.
Neoplasms
Indoleamine 2,3-dioxygenase mediates immune-independent human tumor cell resistance to olaparib, gamma radiation, and cisplatin.
Neoplasms
Inducing Synthetic Lethality using PARP Inhibitors.
Neoplasms
Induction of adenosine A1 receptor expression by pertussis toxin via an adenosine 5'-diphosphate ribosylation-independent pathway.
Neoplasms
Induction of apoptosis and down-regulation of Bcl-XL in cancer cells by a novel small molecule, 2[[3-(2,3-dichlorophenoxy)propyl]amino]ethanol.
Neoplasms
Induction of Apoptosis and Reduction of Endogenous Glutathione Level by the Ethyl-Acetate Soluble Fraction of the Methanol Extract of the Roots of Potentilla fulgens in Cancer Cells.
Neoplasms
Induction of Bax protein and degradation of lamin A during p53-dependent apoptosis induced by chemotherapeutic agents in human cancer cell lines.
Neoplasms
Induction of BRCAness in Triple-Negative Breast Cancer by a CDK12/13 Inhibitor Improves Chemotherapy.
Neoplasms
Induction of CD4(+) and CD8(+) Bordetella pertussis toxin subunit S1 specific T cells by immunization with synthetic peptides.
Neoplasms
Induction of endonuclease-mediated apoptosis in tumor cells by C-nitroso-substituted ligands of poly(ADP-ribose) polymerase.
Neoplasms
Induction of necrosis in human liver tumor cells by ?-phellandrene.
Neoplasms
Induction of non-small cell lung carcinoma apoptosis using soluble RGD-TRAIL by targeting the integrin receptor of tumor cells.
Neoplasms
Induction of poly(ADP-ribose) polymerase-1 cleavage by antitumor triptycene bisquinones in wild-type and daunorubicin-resistant HL-60 cell lines.
Neoplasms
Influence of MLH1 on colon cancer sensitivity to poly(ADP-ribose) polymerase inhibitor combined with irinotecan.
Neoplasms
Inherited gynaecological cancers.
Neoplasms
Inherited variation in the PARP1 gene and survival from melanoma.
Neoplasms
Inhibited effects of veliparib combined doxorubicin for BEL-7404 proliferation of human liver cancer cell line.
Neoplasms
Inhibiteurs de la PARP : des avancées significatives dans le traitement des cancers.
Neoplasms
Inhibiting Mitochondrial DNA Ligase III? Activates Caspase 1-Dependent Apoptosis in Cancer Cells.
Neoplasms
Inhibiting systemic autophagy during interleukin 2 immunotherapy promotes long-term tumor regression.
Neoplasms
Inhibiting the MCM8-9 complex selectively sensitizes cancer cells to cisplatin and olaparib.
Neoplasms
Inhibition of BUB1 Kinase by BAY 1816032 Sensitizes Tumor Cells toward Taxanes, ATR, and PARP Inhibitors In Vitro and In Vivo.
Neoplasms
Inhibition of c-MET increases the antitumour activity of PARP inhibitors in gastric cancer models.
Neoplasms
Inhibition of cell growth and potentiation of tumor necrosis factor-? (TNF-?)-induced apoptosis by a phenanthroindolizidine alkaloid antofine in human colon cancer cells.
Neoplasms
Inhibition of gastric tumor growth by a novel Hsp90 inhibitor.
Neoplasms
Inhibition of HIV-1 infectivity by zinc-ejecting aromatic C-nitroso compounds.
Neoplasms
Inhibition of MEK suppresses hepatocellular carcinoma growth through independent MYC and BIM regulation.
Neoplasms
Inhibition of methylazoxymethanol acetate initiation of colon carcinogenesis in rats by treatment with the poly(ADP-ribose)polymerase inhibitor 3-aminobenzamide.
Neoplasms
Inhibition of neuroblastoma xenograft growth by Hsp90 inhibitors.
Neoplasms
Inhibition of PARP activity by PJ-34 leads to growth impairment and cell death associated with aberrant mitotic pattern and nucleolar actin accumulation in M14 melanoma cell line.
Neoplasms
Inhibition of Parp1 by BMN673 Effectively Sensitizes Cells to Radiotherapy by Upsetting the Balance of Repair Pathways Processing DNA Double-Strand Breaks.
Neoplasms
Inhibition of phosphotidylinositol-3 kinase pathway by a novel naphthol derivative of betulinic acid induces cell cycle arrest and apoptosis in cancer cells of different origin.
Neoplasms
Inhibition of Pim-2 kinase by LT-171-861 promotes DNA damage and exhibits enhanced lethal effects with PARP inhibitor in multiple myeloma.
Neoplasms
Inhibition of poly (ADP-ribose) polymerase-1 enhances doxorubicin activity against liver cancer cells.
Neoplasms
Inhibition of poly (ADP-Ribose) polymerase-1 in telomerase deficient mouse embryonic fibroblasts increases arsenite-induced genome instability.
Neoplasms
Inhibition of poly adenosine diphosphate-ribose polymerase decreases hepatocellular carcinoma growth by modulation of tumor-related gene expression.
Neoplasms
Inhibition of poly(ADP-RIBOSE) polymerase (PARP) by nitric oxide and reactive nitrogen oxide species.
Neoplasms
Inhibition of poly(ADP-ribose) polymerase (PARP) induces apoptosis in lung cancer cell lines.
Neoplasms
Inhibition of poly(ADP-ribose) polymerase 1 protects against acute myeloid leukemia by suppressing the myeloproliferative leukemia virus oncogene.
Neoplasms
Inhibition of poly(ADP-ribose) polymerase attenuates inflammation in a model of chronic colitis.
Neoplasms
Inhibition of poly(ADP-ribose) polymerase down-regulates BRCA1 and RAD51 in a pathway mediated by E2F4 and p130.
Neoplasms
Inhibition of poly(ADP-ribose) polymerase enhances cell death and improves tumor growth delay in irradiated lung cancer models.
Neoplasms
Inhibition of Poly(ADP-Ribose) Polymerase Enhances Radiochemosensitivity in Cancers Proficient in DNA Double-Strand Break Repair.
Neoplasms
Inhibition of Poly(ADP-Ribose) Polymerase Enhances the Effect of Chemotherapy in an Animal Model of Regional Therapy for the Treatment of Advanced Extremity Malignant Melanoma.
Neoplasms
Inhibition of poly(ADP-ribose) polymerase in cancer.
Neoplasms
Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers.
Neoplasms
Inhibition of poly(ADP-ribose) polymerase modulates tumor-related gene expression, including hypoxia-inducible factor-1 activation, during skin carcinogenesis.
Neoplasms
Inhibition of poly(ADP-ribose) polymerase prevents allergen-induced asthma-like reaction in sensitized Guinea pigs.
Neoplasms
Inhibition of poly(ADP-ribose) polymerase prevents irinotecan-induced intestinal damage and enhances irinotecan/temozolomide efficacy against colon carcinoma.
Neoplasms
Inhibition of poly(ADP-ribose) polymerase-1 by olaparib (AZD2281) increases the radiosensitivity of a lung tumor xenograft.
Neoplasms
Inhibition of poly(ADP-ribose) polymerase-1 enhances temozolomide and topotecan activity against childhood neuroblastoma.
Neoplasms
Inhibition of poly(ADP-ribose) polymerase-1 or poly(ADP?ribose) glycohydrolase individually, but not in combination, leads to improved chemotherapeutic efficacy in HeLa cells.
Neoplasms
Inhibition of poly(ADP-ribosyl)ation in cancer: old and new paradigms revisited.
Neoplasms
Inhibition of Stat3 Activity by YC-1 Enhances Chemo-Sensitivity in Hepatocellular Carcinoma.
Neoplasms
Inhibition of T cell homing by down-regulation of CD62L and the induction of a Th-2 response as a method to prevent acute allograft rejection in mice.
Neoplasms
Inhibition of telomerase increases resistance of melanoma cells to temozolomide, but not to temozolomide combined with poly (adp-ribose) polymerase inhibitor.
Neoplasms
Inhibition of tyrosine-kinase-mediated cellular signaling by tyrphostins AG 126 and AG556 modulates murine experimental acute pancreatitis.
Neoplasms
Inhibition of WEE1 Potentiates Sensitivity to PARP Inhibitor in Biliary Tract Cancer.
Neoplasms
Inhibitor and NAD+ binding to poly(ADP-ribose) polymerase as derived from crystal structures and homology modeling.
Neoplasms
Inhibitor of apoptosis protein Livin promotes tumor progression and chemoradioresistance in human anaplastic thyroid cancer.
Neoplasms
Inhibitory Effects of Different Forms of Tocopherols, Tocopherol Phosphates, and Tocopherol Quinones on Growth of Colon Cancer Cells.
Neoplasms
Inhibitory effects of resveratrol and pterostilbene on human colon cancer cells: a side-by-side comparison.
Neoplasms
Iniparib nonselectively modifies cysteine-containing proteins in tumor cells and is not a Bona Fide PARP inhibitor.
Neoplasms
Iniparib, a PARP1 inhibitor for the potential treatment of cancer, including triple-negative breast cancer.
Neoplasms
Innovative Strategies: Targeting Subtypes in Metastatic Breast Cancer.
Neoplasms
INO-1001, a novel inhibitor of poly(ADP-ribose) polymerase, enhances tumor response to doxorubicin.
Neoplasms
Inotodiol inhibits cells migration and invasion and induces apoptosis via p53-dependent pathway in HeLa cells.
Neoplasms
INPP4B overexpression enhances the antitumor efficacy of PARP inhibitor AG014699 in MDA-MB-231 triple-negative breast cancer cells.
Neoplasms
Insights into PARP Inhibitors' Selectivity Using Fluorescence Polarization and Surface Plasmon Resonance Binding Assays.
Neoplasms
Insights into the binding of PARP inhibitors to the catalytic domain of human tankyrase-2.
Neoplasms
Insulin regulates cleavage of procaspase-9 via binding of X chromosome-linked inhibitor of apoptosis protein in HT-29 cells.
Neoplasms
Insulin-like growth factor binding protein-3 induces early apoptosis in malignant prostate cancer cells and inhibits tumor formation in vivo.
Neoplasms
Integrated Genomic, Epigenomic, and Expression Analyses of Ovarian Cancer Cell Lines.
Neoplasms
Integrated stress response is critical for gemcitabine resistance in pancreatic ductal adenocarcinoma.
Neoplasms
Integrated support vector machine and pharmacophore based virtual screening driven identification of thiophene carboxamide scaffold containing compound as potential PARP1 inhibitor.
Neoplasms
Integrating PARP Inhibitors Into Advanced Prostate Cancer Therapeutics.
Neoplasms
Integrating PARP inhibitors into the management of breast cancer: where are we?
Neoplasms
Integrin-independent support of cancer drug resistance by tetraspanin CD151.
Neoplasms
Interaction between N-cadherin and decoy receptor-2 regulates apoptosis in head and neck cancer.
Neoplasms
Interaction of BARD1 and HP1 is required for BRCA1 retention at sites of DNA damage.
Neoplasms
Interaction of germline variants in a family with a history of early-onset clear cell renal cell carcinoma.
Neoplasms
Interactive effects of pertussis toxin and the phorbol ester tumour promotor, phorbol dibutyrate, on T-lymphocyte mitogenesis and the expression of phenotypic determinants.
Neoplasms
Interfaces between cellular responses to DNA damage and cancer immunotherapy.
Neoplasms
Intestinal secretory factor released by macrophages stimulated with Clostridium difficile toxin A: role of interleukin 1beta.
Neoplasms
Intracellular elevations of free calcium induced by activation of histamine H1 receptors in interphase and mitotic HeLa cells: hormone signal transduction is altered during mitosis.
Neoplasms
Intracellular trafficking and surface expression of SS-A (Ro), SS-B (La), poly(ADP-ribose) polymerase and alpha-fodrin autoantigens during apoptosis in human salivary gland cells induced by tumour necrosis factor-alpha.
Neoplasms
Intratumor administration of interleukin 13 receptor-targeted cytotoxin induces apoptotic cell death in human malignant glioma tumor xenografts.
Neoplasms
Intravesical therapy with pertussis toxin before radical cystectomy in patients with bladder cancer: a Phase I study.
Neoplasms
Investigating isoquinoline derivatives for inhibition of inhibitor of apoptosis proteins for ovarian cancer treatment.
Neoplasms
Investigating the allosteric reverse signalling of PARP inhibitors with microsecond molecular dynamic simulations and fluorescence anisotropy.
Neoplasms
Investigating the Mechanistic Inhibitory Discrepancies of Novel Halogen and Alkyl Di-Substituted Oxadiazole-Based Dibenzo-Azepine-Dione Derivatives on Poly (ADP-Ribose) Polymerase-1.
Neoplasms
Investigation of U-251 cell death triggered by flavonoid luteolin: towards a better understanding on its anticancer property against glioblastomas.
Neoplasms
Investigational CHK1 inhibitors in early phase clinical trials for the treatment of cancer.
Neoplasms
Investigational PARP inhibitors for the treatment of biliary tract cancer: spotlight on preclinical and clinical studies.
Neoplasms
Involvement of homologous recombination in the synergism between cisplatin and poly(ADP-ribose) polymerase inhibition.
Neoplasms
Involvement of poly(ADP-ribose) polymerase in trophoblastic cell differentiation during tumorigenesis.
Neoplasms
Iodinated benzimidazole PARP radiotracer for evaluating PARP1/2 expression in vitro and in vivo.
Neoplasms
Irigenin sensitizes TRAIL-induced apoptosis via enhancing pro-apoptotic molecules in gastric cancer cells.
Neoplasms
Is there a role for base excision repair in estrogen/estrogen receptor-driven breast cancers?
Neoplasms
Is there an epigenetic component underlying the resistance of triple-negative breast cancers to parp inhibitors?
Neoplasms
Isolation of 4,4'-bond secalonic acid D from the marine-derived fungus Penicillium oxalicum with inhibitory property against hepatocellular carcinoma.
Neoplasms
Isolation, Characterization and Anticancer Potential of Cytotoxic Triterpenes from Betula utilis Bark.
Neoplasms
ITCH-dependent proteasomal degradation of c-FLIP induced by the anti-HER3 antibody 9F7-F11 promotes DR5/caspase 8-mediated apoptosis of tumor cells.
Neoplasms
JF-305, a pancreatic cancer cell line is highly sensitive to the PARP inhibitor olaparib.
Neoplasms
Kaempferol Protects Against Hydrogen Peroxide-Induced Retinal Pigment Epithelium Cell Inflammation and Apoptosis by Activation of SIRT1 and Inhibition of PARP1.
Neoplasms
Kaiware Daikon (Raphanus sativus L.) extract: a naturally multipotent chemopreventive agent.
Neoplasms
KCP10043F Represses the Proliferation of Human Non-Small Cell Lung Cancer Cells by Caspase-Mediated Apoptosis via STAT3 Inactivation.
Neoplasms
KIFC1 is a novel potential therapeutic target for breast cancer.
Neoplasms
Kinetic and static analysis of poly-(adenosine diphosphate-ribose) polymerase-1 (PARP-1) targeted 18F-FluorThanatrace (18F-FTT) PET images of ovarian cancer.
Neoplasms
KML001, a telomere-targeting drug, sensitizes glioblastoma cells to temozolomide chemotherapy and radiotherapy through DNA damage and apoptosis.
Neoplasms
Kub5-Hera
RPRD1B
Deficiency Promotes "BRCAness" and Vulnerability to PARP Inhibition in BRCA-proficient Breast Cancers.
Neoplasms
Labeling Substrate Proteins of Poly(ADP-ribose) Polymerases with Clickable NAD Analog.
Neoplasms
Lactate dehydrogenase inhibition affects homologous recombination repair independently of cell metabolic asset; implications for anticancer treatment.
Neoplasms
Landmark trials in the medical oncology management of metastatic breast cancer.
Neoplasms
Laying a trap to kill cancer cells: PARP inhibitors and their mechanisms of action.
Neoplasms
Lead Discovery of Dual G-Quadruplex Stabilizers and Poly(ADP-ribose) Polymerases (PARPs) Inhibitors: A New Avenue in Anticancer Treatment.
Neoplasms
Leveraging an NQO1 Bioactivatable Drug for Tumor-Selective Use of Poly(ADP-ribose) Polymerase Inhibitors.
Neoplasms
Liensinine inhibited gastric cancer cell growth through ROS generation and the PI3K/AKT pathway.
Neoplasms
Linifanib (ABT-869), enhances cytotoxicity with poly (ADP-ribose) polymerase inhibitor, veliparib (ABT-888), in head and neck carcinoma cells.
Neoplasms
Liquid chromatography-tandem mass spectrometry assay for the quantification of niraparib and its metabolite M1 in human plasma and urine.
Neoplasms
LKB1 is a DNA damage response protein that regulates cellular sensitivity to PARP inhibitors.
Neoplasms
LMO2 Confers Synthetic Lethality to PARP Inhibition in DLBCL.
Neoplasms
LncRNA-SLC6A9-5:2: A potent sensitizer in 131I-resistant papillary thyroid carcinoma with PARP-1 induction.
Neoplasms
LOH analysis of genes around D4S2964 identifies ARD1B as a prognostic predictor of hepatocellular carcinoma.
Neoplasms
Long-term treatment with the PARP inhibitor niraparib does not increase the mutation load in cell line models and tumour xenografts.
Neoplasms
Longitudinal analysis of a secondary BRCA2 mutation using digital droplet PCR.
Neoplasms
Loss of 53BP1 causes PARP inhibitor resistance in Brca1-mutated mouse mammary tumors.
Neoplasms
Loss of androgen receptor in aging and oxidative stress through Myb protooncoprotein-regulated reciprocal chromatin dynamics of p53 and poly(ADP-ribose) polymerase PARP-1.
Neoplasms
Loss of ARID1A in Tumor Cells Renders Selective Vulnerability to Combined Ionizing Radiation and PARP Inhibitor Therapy.
Neoplasms
Loss of ATRX confers DNA repair defects and PARP inhibitor sensitivity.
Neoplasms
Loss of CHD1 causes DNA repair defects and enhances prostate cancer therapeutic responsiveness.
Neoplasms
Loss of CtIP disturbs homologous recombination repair and sensitizes breast cancer cells to PARP inhibitors.
Neoplasms
Loss of DNA Damage Response in Neuroblastoma and Utility of a PARP Inhibitor.
Neoplasms
Loss of E2F7 confers resistance to poly-ADP-ribose polymerase (PARP) inhibitors in BRCA2-deficient cells.
Neoplasms
Loss of heterozygosity as a marker of homologous repair deficiency in multiple myeloma: a role for PARP inhibition?
Neoplasms
Loss of INPP4B causes a DNA repair defect through loss of BRCA1, ATM and ATR and can be targeted with PARP inhibitor treatment.
Neoplasms
Loss of MIEF1/MiD51 confers susceptibility to BAX-mediated cell death and PINK1-PRKN-dependent mitophagy.
Neoplasms
Loss of NEIL3 DNA glycosylase markedly increases replication associated double strand breaks and enhances sensitivity to ATR inhibitor in glioblastoma cells.
Neoplasms
Loss of NFBD1/MDC1 disrupts homologous recombination repair and sensitizes nasopharyngeal carcinoma cells to PARP inhibitors.
Neoplasms
Loss of poly(ADP-ribose) polymerase-1 causes increased tumour latency in p53-deficient mice.
Neoplasms
Loss of PPP2R2A inhibits homologous recombination DNA repair and predicts tumor sensitivity to PARP inhibition.
Neoplasms
Loss of the p12 subunit of DNA polymerase delta leads to a defect in HR and sensitization to PARP inhibitors.
Neoplasms
Loss of the SWI/SNF-ATPase subunit members SMARCF1 (ARID1A), SMARCA2 (BRM), SMARCA4 (BRG1) and SMARCB1 (INI1) in oesophageal adenocarcinoma.
Neoplasms
Low ATM protein expression and depletion of p53 correlates with olaparib sensitivity in gastric cancer cell lines.
Neoplasms
Low energy proton beam induces tumor cell apoptosis through reactive oxygen species and activation of caspases.
Neoplasms
Low levels of circulating estrogen sensitize PTEN-null endometrial tumors to PARP inhibition in vivo.
Neoplasms
Low-dose naltrexone inhibits colorectal cancer progression and promotes apoptosis by increasing M1-type macrophages and activating the Bax/Bcl-2/caspase-3/PARP pathway.
Neoplasms
LRF maintains genome integrity by regulating the non-homologous end joining pathway of DNA repair.
Neoplasms
LRRK2 inhibition potentiates PARP inhibitor cytotoxicity through inhibiting homologous recombination-mediated DNA double strand break repair.
Neoplasms
Lupus susceptibility genes on human chromosome 1.
Neoplasms
Lycopene metabolite, apo-10'-lycopenoic acid, inhibits diethylnitrosamine-initiated, high fat diet-promoted hepatic inflammation and tumorigenesis in mice.
Neoplasms
Lymph Node Metastasis of Gastric Cancer Is Associated with the Interaction Between Poly (ADP-Ribose) Polymerase 1 and Matrix Metallopeptidase 2.
Neoplasms
Lysophosphatidic acid induces focal adhesion assembly through Rho/Rho-associated kinase pathway in human ovarian cancer cells.
Neoplasms
M1 and M2 macrophages derived from THP-1 cells differentially modulate the response of cancer cells to etoposide.
Neoplasms
m5C modification of mRNA serves a DNA damage code to promote homologous recombination.
Neoplasms
MACROD2 Haploinsufficiency Impairs Catalytic Activity of PARP1 and Promotes Chromosome Instability and Growth of Intestinal Tumors.
Neoplasms
Magnitude of benefit of the addition of poly ADP-ribose polymerase (PARP) inhibitors to therapy for malignant tumor: A meta-analysis.
Neoplasms
Major clinical research advances in gynecologic cancer in 2018.
Neoplasms
Management of early breast cancer in patients bearing germline BRCA mutations.
Neoplasms
MAPK4 deletion enhances radiation effects and triggers synergistic lethality with simultaneous PARP1 inhibition in cervical cancer.
Neoplasms
Matrix screen identifies synergistic combination of PARP inhibitors and nicotinamide phosphoribosyltransferase (NAMPT) inhibitors in Ewing sarcoma.
Neoplasms
MCM4 Is a Novel Biomarker Associated With Genomic Instability, BRCAness Phenotype, and Therapeutic Potentials in Soft-Tissue Sarcoma.
Neoplasms
mda-7/IL-24 induces apoptosis in human GBC-SD gallbladder carcinoma cells via mitochondrial apoptotic pathway.
Neoplasms
MDA-7/IL-24 regulates the miRNA processing enzyme DICER through downregulation of MITF.
Neoplasms
Mechanism and current progress of Poly ADP-ribose polymerase (PARP) inhibitors in the treatment of ovarian cancer.
Neoplasms
Mechanism of Action and Clinical Efficacy of CDK4/6 Inhibitors in BRCA-Mutated, Estrogen Receptor-Positive Breast Cancers: Case Report and Literature Review.
Neoplasms
Mechanisms of acquired resistance of BRCA1/2-driven tumors to platinum compounds and PARP inhibitors.
Neoplasms
Mechanisms of naringenin-induced apoptotic cascade in cancer cells: involvement of estrogen receptor alpha and beta signalling.
Neoplasms
Mechanisms of PARP inhibitor resistance in cancer and insights into the DNA damage response.
Neoplasms
Mechanisms of PARP inhibitor resistance in ovarian cancer.
Neoplasms
Mechanisms of PARP inhibitor sensitivity and resistance.
Neoplasms
Mechanisms of Therapy Resistance in Patient-Derived Xenograft Models of BRCA1-Deficient Breast Cancer.
Neoplasms
Mechanistic Dissection of PARP1 Trapping and the Impact on In Vivo Tolerability and Efficacy of PARP Inhibitors.
Neoplasms
Mediation of cell death by poly(ADP-ribose) polymerase-1.
Neoplasms
Medical Management of newly diagnosed breast cancer in a BRCA1/2 mutation carrier.
Neoplasms
Medicinal chemistry approaches of poly ADP-Ribose polymerase 1 (PARP1) inhibitors as anticancer agents - A recent update.
Neoplasms
MEK Inhibition Remodels the Immune Landscape of Mutant KRAS Tumors to Overcome Resistance to PARP and Immune Checkpoint Inhibitors.
Neoplasms
Melanoma cells replicate through chemotherapy by reducing levels of key homologous recombination protein RAD51 and increasing expression of translesion synthesis DNA polymerase ?.
Neoplasms
Melatonin inhibition of cancer growth in vivo involves suppression of tumor fatty acid metabolism via melatonin receptor-mediated signal transduction events.
Neoplasms
Mertensene, a Halogenated Monoterpene, Induces G2/M Cell Cycle Arrest and Caspase Dependent Apoptosis of Human Colon Adenocarcinoma HT29 Cell Line through the Modulation of ERK-1/-2, AKT and NF-?B Signaling.
Neoplasms
Metabolic roles of poly(ADP-ribose) polymerases.
Neoplasms
Metastatic Castration-Resistant Prostate Cancer with Neuroendocrine Transformation and BRCA 1 Germ-Line Mutation: A Case Report and Literature Review.
Neoplasms
Metastatic Thymoma Harboring a Deleterious BRCA2 Mutation Derives Durable Clinical Benefit from Olaparib.
Neoplasms
Metformin reverses PARP inhibitors-induced epithelial-mesenchymal transition and PD-L1 upregulation in triple-negative breast cancer.
Neoplasms
METH-Induced Neurotoxicity Is Alleviated by Lactulose Pretreatment Through Suppressing Oxidative Stress and Neuroinflammation in Rat Striatum.
Neoplasms
Methylation of the hMLH1, p16, and MDR1 genes in colorectal carcinoma: associations with clinicopathological features.
Neoplasms
Methylation of tumor suppressor genes is related with copy number aberrations in breast cancer.
Neoplasms
MGMT Expression Predicts PARP-Mediated Resistance to Temozolomide.
Neoplasms
MicroRNA216b mediated downregulation of HSP27/STAT3/AKT signaling is critically involved in lambertianic acid induced apoptosis in human cervical cancers.
Neoplasms
MicroRNAs and DNA-Damaging Drugs in Breast Cancer: Strength in Numbers.
Neoplasms
Microsatellite instability induced mutations in DNA repair genes Ctip and MRE11 confer hypersensitivity to poly (ADP-ribose) polymerase (PARP) inhibitors in myeloidmalignancies.
Neoplasms
Midkine silencing enhances the anti-prostate cancer stem cell activity of the flavone apigenin: cooperation on signaling pathways regulated by ERK, p38, PTEN, PARP, and NF-?B.
Neoplasms
MIF is a 3' flap nuclease that facilitates DNA replication and promotes tumor growth.
Neoplasms
Mild hyperthermia inhibits homologous recombination, induces BRCA2 degradation, and sensitizes cancer cells to poly (ADP-ribose) polymerase-1 inhibition.
Neoplasms
Minor grove binding ligands disrupt PARP-1 activation pathways.
Neoplasms
MiR-124 acts as a tumor suppressor by inhibiting the expression of sphingosine kinase 1 and its downstream signaling in head and neck squamous cell carcinoma.
Neoplasms
miR-151-5p, targeting chromatin remodeler SMARCA5, as a marker for the BRCAness phenotype.
Neoplasms
miR-182-mediated downregulation of BRCA1 impacts DNA repair and sensitivity to PARP inhibitors.
Neoplasms
miR-223 reverses experimental pulmonary arterial hypertension.
Neoplasms
miR-7-5p overexpression suppresses cell proliferation and promotes apoptosis through inhibiting the ability of DNA damage repair of PARP-1 and BRCA1 in TK6 cells exposed to hydroquinone.
Neoplasms
MiRNA and LncRNA as Potential Biomarkers in Triple-Negative Breast Cancer: A Review.
Neoplasms
MiRNA-200C expression in Fanconi anemia pathway functionally deficient lung cancers.
Neoplasms
Misregulation of gene expression in primary fibroblasts lacking poly(ADP-ribose) polymerase.
Neoplasms
Mitigating effect of biotin against irradiation-induced cerebral cortical and hippocampal damage in the rat brain tissue.
Neoplasms
Mitochondria and chronic effects of cancer therapeutics: The clinical implications.
Neoplasms
Mitochondria-targeted betulinic and ursolic acid derivatives: synthesis and anticancer activity.
Neoplasms
Mitochondrial DNA depletion sensitizes cancer cells to PARP inhibitors by translational and post-translational repression of BRCA2.
Neoplasms
Mitochondrial dysfunction in cancer chemoresistance.
Neoplasms
Mitochondrial Protection by PARP Inhibition.
Neoplasms
MK-4827, a PARP-1/-2 inhibitor, strongly enhances response of human lung and breast cancer xenografts to radiation.
Neoplasms
MLN4924 suppresses the BRCA1 complex and synergizes with PARP inhibition in NSCLC cells.
Neoplasms
MLS-2384, a new 6-bromoindirubin derivative with dual JAK/Src kinase inhibitory activity, suppresses growth of diverse cancer cells.
Neoplasms
Modeling of the Enzyme-Substrate Complexes of Human Poly(ADP-Ribose) Polymerase 1.
Neoplasms
Modeling pharmacodynamic response to the poly(ADP-Ribose) polymerase inhibitor ABT-888 in human peripheral blood mononuclear cells.
Neoplasms
Modeling Therapy Resistance in BRCA1/2-Mutant Cancers.
Neoplasms
Modulating poly (ADP-ribose) polymerase activity: potential for the prevention and therapy of pathogenic situations involving DNA damage and oxidative stress.
Neoplasms
Modulation of brain tumor risk by genetic SNPs in PARP1gene: Hospital based case control study.
Neoplasms
Modulation of cytokine-induced cardiac myocyte apoptosis by nitric oxide, Bak, and Bcl-x.
Neoplasms
Modulation of the antiproliferative activity of anticancer drugs in hematopoietic tumor cell lines by the poly(ADP-ribose) polymerase inhibitor 6(5H)-phenanthridinone.
Neoplasms
Modulation of the cancer susceptibility measure, adenosine diphosphate ribosyl transferase (ADPRT), by differences in low-dose n-3 and n-6 fatty acids.
Neoplasms
Modulation of the poly (ADP-ribose) polymerase inhibitor response and DNA recombination in breast cancer cells by drugs affecting endogenous wild-type p53.
Neoplasms
Modulation of transcription by PARP-1: consequences in carcinogenesis and inflammation.
Neoplasms
Molecular correlates of sensitivity to PARP inhibition beyond homologous recombination deficiency in pre-clinical models of colorectal cancer point to wild-type TP53 activity.
Neoplasms
Molecular hybrids: A five-year survey on structures of multiple targeted hybrids of protein kinase inhibitors for cancer therapy.
Neoplasms
Molecular mechanisms of cholangiocarcinoma cell inhibition by medicinal plants.
Neoplasms
Molecular mechanisms underlying mifepristone's agonistic action on ovarian cancer progression.
Neoplasms
Molecular Modeling Studies on Benzimidazole Carboxamide Derivatives as PARP-1 Inhibitors Using 3D-QSAR and Docking.
Neoplasms
Molecular natural history of breast cancer: Leveraging transcriptomics to predict breast cancer progression and aggressiveness.
Neoplasms
Molecular pathways: exploiting tumor-specific molecular defects in DNA repair pathways for precision cancer therapy.
Neoplasms
Molecular pathways: how can BRCA-mutated tumors become resistant to PARP inhibitors?
Neoplasms
Molecular Pathways: Targeting DNA Repair Pathway Defects Enriched in Metastasis.
Neoplasms
Molecular Pathways: Targeting ETS Gene Fusions in Cancer.
Neoplasms
Molecular Pathways: Targeting PARP in Cancer Treatment.
Neoplasms
Molecular pathways: understanding the role of Rad52 in homologous recombination for therapeutic advancement.
Neoplasms
Molecular stratification of triple-negative breast cancers.
Neoplasms
Molecular Testing Identifies Determinants of Exceptional Response and Guides Precision Therapy in a Patient with Lethal, Treatment-emergent Neuroendocrine Prostate Cancer.
Neoplasms
Molecular Testing in Breast Cancer.
Neoplasms
Molecular-targeted therapy toward precision medicine for gastrointestinal caner: Current progress and challenges.
Neoplasms
Monitoring and signaling of radiation-induced damage in mammalian cells.
Neoplasms
Morin Hydrate Reverses Cisplatin Resistance by Impairing PARP1/HMGB1-Dependent Autophagy in Hepatocellular Carcinoma.
Neoplasms
Mortalin (GRP75/HSPA9) Promotes Survival and Proliferation of Thyroid Carcinoma Cells.
Neoplasms
Mortaparib, a novel dual inhibitor of mortalin and PARP1, is a potential drug candidate for ovarian and cervical cancers.
Neoplasms
Mouse models for BRCA1 associated tumorigenesis: from fundamental insights to preclinical utility.
Neoplasms
Movement of Poly-ADP Ribose (PARP) Inhibition into Frontline Treatment of Ovarian Cancer.
Neoplasms
Moving beyond PARP Inhibition in ATM-Deficient Prostate Cancer.
Neoplasms
Moving beyond PARP Inhibition: Current State and Future Perspectives in Breast Cancer.
Neoplasms
Moving From Mutation to Actionability.
Neoplasms
Moving From Poly (ADP-Ribose) Polymerase Inhibition to Targeting DNA Repair and DNA Damage Response in Cancer Therapy.
Neoplasms
Moving toward personalized medicine: treatment-focused genetic testing of women newly diagnosed with ovarian cancer.
Neoplasms
Mre11-dependent degradation of stalled DNA replication forks is prevented by BRCA2 and PARP1.
Neoplasms
MTA2 sensitizes gastric cancer cells to PARP inhibition by induction of DNA replication stress.
Neoplasms
mTOR Inhibitors Suppress Homologous Recombination Repair and Synergize with PARP Inhibitors via Regulating SUV39H1 in BRCA-Proficient Triple-Negative Breast Cancer.
Neoplasms
mTOR, S6 and AKT expression in relation to proliferation and apoptosis/autophagy in glioma.
Neoplasms
Multi gene panel testing for hereditary breast cancer - is it ready to be used?
Neoplasms
Multifaceted Role of PARP-1 in DNA Repair and Inflammation: Pathological and Therapeutic Implications in Cancer and Non-Cancer Diseases.
Neoplasms
Multifarious molecular signaling cascades of cardiac hypertrophy: can the muddy waters be cleared?
Neoplasms
Mutant p53L194F Harboring Luminal-A Breast Cancer Cells Are Refractory to Apoptosis and Cell Cycle Arrest in Response to MortaparibPlus, a Multimodal Small Molecule Inhibitor.
Neoplasms
Mutation analysis of BRCA1, BRCA2, PALB2 and BRD7 in a hospital-based series of German patients with triple-negative breast cancer.
Neoplasms
Mutational Profile of Aggressive, Localised Prostate Cancer from African Caribbean Men Versus European Ancestry Men.
Neoplasms
Mutations of BRCA2 in canine mammary tumors and their targeting potential in clinical therapy.
Neoplasms
MUTYH, an adenine DNA glycosylase, mediates p53 tumor suppression via PARP-dependent cell death.
Neoplasms
MYC status as a determinant of synergistic response to Olaparib and Palbociclib in ovarian cancer.
Neoplasms
Myc targeted CDK18 promotes ATR and homologous recombination to mediate PARP inhibitor resistance in glioblastoma.
Neoplasms
MYCN expression induces replication stress and sensitivity to PARP inhibition in neuroblastoma.
Neoplasms
Myelodysplastic syndrome and acute myeloid leukaemia in patients treated with PARP inhibitors: a safety meta-analysis of randomised controlled trials and a retrospective study of the WHO pharmacovigilance database.
Neoplasms
Myocardial cell death and regeneration during progression of cardiac hypertrophy to heart failure.
Neoplasms
NAD+ depletion by type I interferon signaling sensitizes pancreatic cancer cells to NAMPT inhibition.
Neoplasms
NADP+ is an endogenous PARP inhibitor in DNA damage response and tumor suppression.
Neoplasms
NAD[S], an NAD analogue with reduced susceptibility to phosphodiesterase. Chemical synthesis and enzymic properties.
Neoplasms
Nanoformulation of Olaparib Amplifies PARP Inhibition and Sensitizes PTEN/TP53-Deficient Prostate Cancer to Radiation.
Neoplasms
Nanoformulation of Talazoparib Delays Tumor Progression and Ascites Formation in a Late Stage Cancer Model.
Neoplasms
Nanomedicine-based paclitaxel induced apoptotic signaling pathways in A562 leukemia cancer cells.
Neoplasms
Nanoparticle Formulations of Poly (ADP-ribose) Polymerase Inhibitors for Cancer Therapy.
Neoplasms
Nanoparticle-mediated delivery of siRNA targeting Parp1 extends survival of mice bearing tumors derived from Brca1-deficient ovarian cancer cells.
Neoplasms
Natural and glucosyl flavonoids inhibit poly(ADP-ribose) polymerase activity and induce synthetic lethality in BRCA mutant cells.
Neoplasms
Natural product ?-thujaplicin inhibits homologous recombination repair and sensitizes cancer cells to radiation therapy.
Neoplasms
NEAT1 Knockdown Suppresses the Cisplatin Resistance in Ovarian Cancer by Regulating miR-770-5p/PARP1 Axis.
Neoplasms
Neoadjuvant degarelix with or without apalutamide followed by radical prostatectomy for intermediate and high-risk prostate cancer: ARNEO, a randomized, double blind, placebo-controlled trial.
Neoplasms
Neoadjuvant olaparib targets hypoxia to improve radioresponse in a homologous recombination-proficient breast cancer model.
Neoplasms
Neuroglobin, a pro-survival player in estrogen receptor ?-positive cancer cells.
Neoplasms
New (E)-1-alkyl-1H-benzo[d]imidazol-2-yl)methylene)indolin-2-ones: Synthesis, in vitro cytotoxicity evaluation and apoptosis inducing studies.
Neoplasms
New Approaches of PARP-1 Inhibitors in Human Lung Cancer Cells and Cancer Stem-Like Cells by Some Selected Anthraquinone-Derived Small Molecules.
Neoplasms
New chalcone derivative exhibits antiproliferative potential by inducing G2/M cell cycle arrest, mitochondrial-mediated apoptosis and modulation of MAPK signalling pathway.
Neoplasms
New combinatorial strategies to improve the PARP inhibitors efficacy in the urothelial bladder Cancer treatment.
Neoplasms
New insight into the significance of KLF4 PARylation in genome stability, carcinogenesis, and therapy.
Neoplasms
New Insights Into DNA Helicases as Druggable Targets for Cancer Therapy.
Neoplasms
New PARP targets for cancer therapy.
Neoplasms
New Perspectives for Resistance to PARP Inhibitors in Triple-Negative Breast Cancer.
Neoplasms
New Targeted Agents in Gynecologic Cancers: Synthetic Lethality, Homologous Recombination Deficiency, and PARP Inhibitors.
Neoplasms
New Therapeutic and Biomarker Discovery for Peripheral Diabetic Neuropathy: PARP Inhibitor, Nitrotyrosine, and Tumor Necrosis Factor-{alpha}
Neoplasms
New therapeutic perspectives in CCDC6 deficient lung cancer cells.
Neoplasms
New Therapeutic Strategies for Triple-Negative Breast Cancer.
Neoplasms
Next-generation sequencing-based BRCA testing on cytological specimens from ovarian cancer ascites reveals high concordance with tumour tissue analysis.
Neoplasms
NF-?B mediates radio-sensitization by the PARP-1 inhibitor, AG-014699.
Neoplasms
NF-kB signaling mediates acquired resistance after PARP inhibition.
Neoplasms
NF90 regulates PARP1 mRNA stability in hepatocellular carcinoma.
Neoplasms
NF?B and Poly (ADP-ribose) Polymerase 1 Form a Positive Feedback Loop that Regulates DNA Repair in Acute Myeloid Leukemia Cells.
Neoplasms
NF?B Down-regulation and PARP Cleavage by Novel 3-?-Butyryloxy-?-boswellic Acid Results in Cancer Cell Specific Apoptosis and in vivo Tumor Regression.
Neoplasms
Nickel(II) affects poly(ADP-ribose) polymerase-mediated DNA repair in normal and cancer cells.
Neoplasms
Nicotinamide abrogates acute lung injury caused by ischaemia/reperfusion.
Neoplasms
Nicotinamide N-Methyltransferase in Acquisition of Stem Cell Properties and Therapy Resistance in Cancer.
Neoplasms
Niraparib (MK-4827), a novel poly(ADP-Ribose) polymerase inhibitor, radiosensitizes human lung and breast cancer cells.
Neoplasms
Niraparib activates interferon signaling and potentiates anti-PD-1 antibody efficacy in tumor models.
Neoplasms
Niraparib as Maintenance Therapy in Germline ATM-mutated and Somatic BRCA2-mutated Ovarian Cancer with Brain Metastases: A Case Report and Literature Review.
Neoplasms
Niraparib for the Treatment of Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer.
Neoplasms
Niraparib Suppresses Cholangiocarcinoma Tumor Growth by Inducing Oxidative and Replication Stress.
Neoplasms
Niraparib: A Poly(ADP-ribose) Polymerase (PARP) Inhibitor for the Treatment of Tumors with Defective Homologous Recombination.
Neoplasms
Niraparib: A Review in Ovarian Cancer.
Neoplasms
Niraparib: First Global Approval.
Neoplasms
Nitric oxide induced poly(ADP-ribose) polymerase cleavage in RAW 264.7 macrophage apoptosis is blocked by Bcl-2.
Neoplasms
Nitric oxide-donor/PARP-inhibitor combination: A new approach for sensitization to ionizing radiation.
Neoplasms
Nitric Oxide: Genomic Instability And Synthetic Lethality.
Neoplasms
No associations of polymorphisms in ADPRT with hepatitis B virus clearance and hepatocellular carcinoma occurrence in a Korean population.
Neoplasms
No evidence for PALB2 methylation in high-grade serous ovarian cancer.
Neoplasms
Non-canonical Activation of the DNA Sensing Adaptor STING by ATM and IFI16 Mediates NF-?B Signaling after Nuclear DNA Damage.
Neoplasms
Non-NAD-Like poly(ADP-Ribose) Polymerase-1 Inhibitors effectively Eliminate Cancer in vivo.
Neoplasms
Non-small cell lung cancer cells with deficiencies in homologous recombination genes are sensitive to PARP inhibitors.
Neoplasms
Non-thermal plasma-induced apoptosis is modulated by ATR- and PARP1-mediated DNA damage responses and circadian clock.
Neoplasms
Notch/HES1-mediated PARP1 activation: a cell type-specific mechanism for tumor suppression.
Neoplasms
Novel ?-Carboline/Hydroxamic Acid Hybrids Targeting Both Histone Deacetylase and DNA Display High Anticancer Activity via Regulation of the p53 Signaling Pathway.
Neoplasms
Novel allosteric PARP1 inhibitors for the treatment of BRCA-deficient leukemia.
Neoplasms
Novel Azaquinolones as PARP1 Inhibitors for Treating Cancer.
Neoplasms
Novel BRCA1 and BRCA2 Tumor Test as Basis for Treatment Decisions and Referral for Genetic Counselling of Patients with Ovarian Carcinomas.
Neoplasms
Novel Caffeic Acid Phenethyl Ester-Mortalin Antibody Nanoparticles Offer Enhanced Selective Cytotoxicity to Cancer Cells.
Neoplasms
Novel Compound 1, 3-bis (3, 5-dichlorophenyl) urea Inhibits Lung Cancer Progression.
Neoplasms
Novel DNA targeted therapies for head and neck cancers: clinical potential and biomarkers.
Neoplasms
Novel ent-Kaurane Diterpenoid from Rubus corchorifolius L. f. Inhibits Human Colon Cancer Cell Growth via Inducing Cell Cycle Arrest and Apoptosis.
Neoplasms
Novel insights into PARPs in gene expression: regulation of RNA metabolism.
Neoplasms
Novel PARP1/2 inhibitor mefuparib hydrochloride elicits potent in vitro and in vivo anticancer activity, characteristic of high tissue distribution.
Neoplasms
Novel poly (ADP-ribose) polymerase inhibitor, AZD2281, enhances radiosensitivity of both normoxic and hypoxic esophageal squamous cancer cells.
Neoplasms
Novel Poly(ADP-ribose) Polymerase-1 Inhibitor DDHCB Inhibits Proliferation of BRCA Mutant Breast Cancer Cell In Vitro and In Vivo through a Synthetic Lethal Mechanism.
Neoplasms
Novel poly(ADP-ribose) polymerase-1 inhibitor, AG14361, restores sensitivity to temozolomide in mismatch repair-deficient cells.
Neoplasms
Novel poly-ADP-ribose polymerase inhibitor combination strategies in ovarian cancer.
Neoplasms
Novel roles of 1?,25(OH)2D3 on DNA repair provide new strategies for breast cancer treatment.
Neoplasms
Novel splice-switching oligonucleotide promotes BRCA1 aberrant splicing and susceptibility to PARP inhibitor action.
Neoplasms
Novel Therapeutics for Ovarian Cancer: The 11th Biennial Rivkin Center Ovarian Cancer Research Symposium.
Neoplasms
Novel treatment strategies in triple-negative breast cancer: specific role of poly(adenosine diphosphate-ribose) polymerase inhibition.
Neoplasms
Novel tricyclic poly(ADP-ribose) polymerase-1 inhibitors with potent anticancer chemopotentiating activity: design, synthesis, and X-ray cocrystal structure.
Neoplasms
NQO1-dependent, tumor-selective radiosensitization of non-small cell lung cancers.
Neoplasms
NSC348884, a nucleophosmin inhibitor disrupts oligomer formation and induces apoptosis in human cancer cells.
Neoplasms
Nuclear Export Inhibitor KPT-8602 Synergizes with PARP Inhibitors in Escalating Apoptosis in Castration Resistant Cancer Cells.
Neoplasms
Nuclear PARP-1 protein overexpression is associated with poor overall survival in early breast cancer.
Neoplasms
Nutlin-3a suppresses poly (ADP-ribose) polymerase 1 by mechanisms different from conventional PARP1 suppressors in a human breast cancer cell line.
Neoplasms
NVP-LDE-225 (Erismodegib) inhibits epithelial-mesenchymal transition and human prostate cancer stem cell growth in NOD/SCID IL2R? null mice by regulating Bmi-1 and microRNA-128.
Neoplasms
Oct-4 expression maintained cancer stem-like properties in lung cancer-derived CD133-positive cells.
Neoplasms
Oct4 confers stemness and radioresistance to head and neck squamous cell carcinoma by regulating the homologous recombination factors PSMC3IP and RAD54L.
Neoplasms
Olaparib , PARP1 inhibitor in ovarian cancer.
Neoplasms
Olaparib and temozolomide in desmoplastic small round cell tumors: a promising combination in vitro and in vivo.
Neoplasms
Olaparib as maintenance treatment for patients with platinum-sensitive relapsed ovarian cancer.
Neoplasms
Olaparib effective in four advanced cancers.
Neoplasms
Olaparib for metastatic breast cancer in a patient with a germline PALB2 variant.
Neoplasms
Olaparib for the treatment of ovarian cancer.
Neoplasms
Olaparib hydroxamic acid derivatives as dual PARP and HDAC inhibitors for cancer therapy.
Neoplasms
Olaparib in germline-mutated metastatic breast cancer: implications of the OlympiAD trial.
Neoplasms
Olaparib in the management of ovarian cancer.
Neoplasms
Olaparib increases the therapeutic index of hemithoracic irradiation compared with hemithoracic irradiation alone in a mouse lung cancer model.
Neoplasms
Olaparib Inhibits Tumor Growth of Hepatoblastoma in Patient-Derived Xenograft Models.
Neoplasms
Olaparib Keeps Hereditary Breast Tumors in Check.
Neoplasms
Olaparib modulates DNA repair efficiency, sensitizes cervical cancer cells to cisplatin and exhibits anti-metastatic property.
Neoplasms
Olaparib shows promise in multiple tumor types.
Neoplasms
Olaparib significantly delays photoreceptor loss in a model for hereditary retinal degeneration.
Neoplasms
Olaparib Synergizes the Anticancer Activity of Daunorubicin via Interaction with AKR1C3.
Neoplasms
Olaparib tablet formulation: effect of food on the pharmacokinetics after oral dosing in patients with advanced solid tumours.
Neoplasms
Olaparib Tablet: A Review in Ovarian Cancer Maintenance Therapy.
Neoplasms
Olaparib Targets Some Advanced Prostate Cancers.
Neoplasms
Olaparib-Based Photoaffinity Probes for PARP-1 Detection in Living Cells.
Neoplasms
Olaparib: A tale of two dosage forms.
Neoplasms
Olaparib: an oral PARP-1 and PARP-2 inhibitor with promising activity in ovarian cancer.
Neoplasms
Olaparib: first global approval.
Neoplasms
Oleanolic acid and its synthetic derivatives for the prevention and therapy of cancer: Preclinical and clinical evidence.
Neoplasms
Oleanolic Acid Induces Apoptosis in Human Leukemia Cells through Caspase Activation and Poly(ADP-ribose) Polymerase Cleavage.
Neoplasms
Oncogenic miR-181a/b affect the DNA damage response in aggressive breast cancer.
Neoplasms
ONS-donor ligand based Pt(II) complexes display extremely high anticancer potency through autophagic cell death pathway.
Neoplasms
Opening a Door to PARP Inhibitor-Induced Lethality in HR-Proficient Human Tumor Cells.
Neoplasms
Optimize radiochemotherapy in pancreatic cancer: PARP inhibitors a new therapeutic opportunity.
Neoplasms
Optimizing PARP inhibition through combined epigenetic and immunotherapy.
Neoplasms
Oral administration of benzyl-isothiocyanate inhibits solid tumor growth and lung metastasis of 4T1 murine mammary carcinoma cells in BALB/c mice.
Neoplasms
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial.
Neoplasms
Oral treatment of the TRAMP mice with doxazosin suppresses prostate tumor growth and metastasis.
Neoplasms
OSU-A9 induced-reactive oxygen species cause cytotoxicity in duodenal and gastric cancer cells by decreasing phosphorylated nuclear pyruvate kinase M2 protein levels.
Neoplasms
Ovarian cancer cells, not normal cells, are damaged by Mirk/Dyrk1B kinase inhibition.
Neoplasms
Ovarian cancer stem cells: ready for prime time?
Neoplasms
Ovarian Cancer Translational Activity of the Multicenter Italian Trial in Ovarian Cancer (MITO) Group: Lessons Learned in 10 Years of Experience.
Neoplasms
Ovarian cancer treatment in mutation carriers/brcaness.
Neoplasms
Ovarian cancer.
Neoplasms
Overcoming PARPi resistance: Preclinical and clinical evidence in ovarian cancer.
Neoplasms
Overcoming Platinum and PARP-Inhibitor Resistance in Ovarian Cancer.
Neoplasms
Overcoming Resistance of Cancer Cells to PARP-1 Inhibitors with Three Different Drug Combinations.
Neoplasms
Overcoming Resistance of Glioblastoma to Conventional Cytotoxic Therapies by the Addition of PARP Inhibitors.
Neoplasms
Overcoming Treatment Toxicity through Sequential Therapy.
Neoplasms
Overexpression of dominant negative PARP interferes with tumor formation of HeLa cells in nude mice: evidence for increased tumor cell apoptosis in vivo.
Neoplasms
Overexpression of IRS-4 Correlates with Procaspase 3 Levels in Tumoural Tissue of Patients with Colorectal Cancer.
Neoplasms
Overexpression of MEKK3 confers resistance to apoptosis through activation of NFkappaB.
Neoplasms
Overexpression of PARP is an independent prognostic marker for poor survival in Middle Eastern breast cancer and its inhibition can be enhanced with embelin co-treatment.
Neoplasms
Overexpression of poly(ADP-ribose) polymerase-1 (PARP-1) in the early stage of colorectal carcinogenesis.
Neoplasms
Oxidative stress, DNA repair, and cancer susceptibility.
Neoplasms
p53 Activation by nitric oxide involves down-regulation of Mdm2.
Neoplasms
p53 Enhances Artemisia annua L. Polyphenols-Induced Cell Death Through Upregulation of p53-Dependent Targets and Cleavage of PARP1 and Lamin A/C in HCT116 Colorectal Cancer Cells.
Neoplasms
p53 induces formation of NEAT1 lncRNA-containing paraspeckles that modulate replication stress response and chemosensitivity.
Neoplasms
p66ShcA potentiates the cytotoxic response of triple-negative breast cancers to PARP inhibitors.
Neoplasms
Paclitaxel induces apoptosis in leukemia cells through a JNK activation-dependent pathway.
Neoplasms
PALB2 chromatin recruitment restores homologous recombination in BRCA1-deficient cells depleted of 53BP1.
Neoplasms
Pamiparib in combination with tislelizumab in patients with advanced solid tumours: results from the dose-escalation stage of a multicentre, open-label, phase 1a/b trial.
Neoplasms
Pamiparib is a potent and selective PARP inhibitor with unique potential for the treatment of brain tumor.
Neoplasms
Pamiparib: First Approval.
Neoplasms
Pan-Cancer Analysis of BRCA1 and BRCA2 Genomic Alterations and Their Association With Genomic Instability as Measured by Genome-Wide Loss of Heterozygosity.
Neoplasms
Pan-cancer analysis of genomic scar signatures associated with homologous recombination deficiency suggests novel indications for existing cancer drugs.
Neoplasms
Pan-Cancer Analysis of PARP1 Alterations as Biomarkers in the Prediction of Immunotherapeutic Effects and the Association of Its Expression Levels and Immunotherapy Signatures.
Neoplasms
Pan-cancer analysis reveals synergistic effects of CDK4/6i and PARPi combination treatment in RB-proficient and RB-deficient breast cancer cells.
Neoplasms
Panobinostat sensitizes cyclin E high, homologous recombination-proficient ovarian cancer to olaparib.
Neoplasms
Papers of note in Science Translational Medicine 9 (392).
Neoplasms
Parasporin-2 from a New Bacillus thuringiensis 4R2 Strain Induces Caspases Activation and Apoptosis in Human Cancer Cells.
Neoplasms
Parent-Metabolite Pharmacokinetic Modeling and Pharmacodynamics of Veliparib (ABT-888), a PARP Inhibitor, in Patients With BRCA 1/2-Mutated Cancer or PARP-Sensitive Tumor Types.
Neoplasms
PARG deficiency is neither synthetic lethal with BRCA1 nor PTEN deficiency.
Neoplasms
PARG inhibitors and functional PARG inhibition models.
Neoplasms
PARG Inhibitors and Functional PARG Inhibition Models.
Neoplasms
PARG regulates the proliferation and differentiation of DCs and T cells via PARP/NF??B in tumour metastases of colon carcinoma.
Neoplasms
PARP (Poly ADP-Ribose Polymerase) inhibitors for locally advanced or metastatic breast cancer.
Neoplasms
PARP activity and inhibition in fetal and adult oligodendrocyte precursor cells: Effect on cell survival and differentiation.
Neoplasms
PARP activity in peripheral blood lymphocytes as a predictive biomarker for PARP inhibition in tumor tissues - A population pharmacokinetic/pharmacodynamic analysis of rucaparib.
Neoplasms
PARP and CHK inhibitors interact to cause DNA damage and cell death in mammary carcinoma cells.
Neoplasms
PARP and other prospective targets for poisoning cancer cell metabolism.
Neoplasms
PARP and PARG inhibitors in cancer treatment.
Neoplasms
PARP and PARG Inhibitors-New Therapeutic Targets in Cancer Treatment.
Neoplasms
PARP and PD-1/PD-L1 checkpoint inhibition in recurrent or metastatic endometrial cancer.
Neoplasms
PARP cleavage and perturbance in mitochondrial membrane potential by 3-?-propionyloxy-?-boswellic acid results in cancer cell death and tumor regression in murine models.
Neoplasms
PARP expression in germ cell tumours.
Neoplasms
PARP inhibition and gynecologic malignancies: A review of current literature and on-going trials.
Neoplasms
PARP inhibition and immune modulation: scientific rationale and perspectives for the treatment of gynecologic cancers.
Neoplasms
PARP inhibition and the radiosensitizing effects of the PARP inhibitor ABT-888 in in vitro hepatocellular carcinoma models.
Neoplasms
PARP Inhibition as a Prototype for Synthetic Lethal Screens.
Neoplasms
PARP inhibition as frontline therapy in ovarian cancer.
Neoplasms
PARP inhibition by olaparib or gene knockout blocks asthma-like manifestation in mice by modulating CD4(+) T cell function.
Neoplasms
PARP inhibition causes premature loss of cohesion in cancer cells.
Neoplasms
PARP Inhibition Combined With Thoracic Irradiation Exacerbates Esophageal and Skin Toxicity in C57BL6 Mice.
Neoplasms
PARP Inhibition Elicits STING-Dependent Antitumor Immunity in Brca1-Deficient Ovarian Cancer.
Neoplasms
PARP inhibition enhances tumor cell-intrinsic immunity in ERCC1-deficient non-small cell lung cancer.
Neoplasms
PARP Inhibition in Cancer: An Update on Clinical Development.
Neoplasms
PARP inhibition in epithelial ovarian cancer: high hopes undergo a reality check.
Neoplasms
PARP inhibition in the ovarian cancer patient: Current approvals and future directions.
Neoplasms
PARP inhibition in UV-associated angiosarcoma preclinical models.
Neoplasms
PARP Inhibition Increases the Reliance on ATR/CHK1 Checkpoint Signaling Leading to Synthetic Lethality-An Alternative Treatment Strategy for Epithelial Ovarian Cancer Cells Independent from HR Effectiveness.
Neoplasms
PARP Inhibition Increases the Response to Chemotherapy in Uveal Melanoma.
Neoplasms
PARP inhibition induces BAX/BAK-independent synthetic lethality of BRCA1-deficient non-small cell lung cancer.
Neoplasms
PARP inhibition potentiates the cytotoxic activity of C-1305, a selective inhibitor of topoisomerase II, in human BRCA1-positive breast cancer cells.
Neoplasms
PARP inhibition protects against alcoholic and non-alcoholic steatohepatitis.
Neoplasms
PARP inhibition protects mitochondria and reduces ROS production via PARP-1-ATF4-MKP-1-MAPK retrograde pathway.
Neoplasms
PARP inhibition selectively increases sensitivity to cisplatin in ERCC1-low non-small cell lung cancer cells.
Neoplasms
PARP inhibition sensitizes childhood high grade glioma, medulloblastoma and ependymoma to radiation.
Neoplasms
PARP inhibition sensitizes endometrial cancer cells to paclitaxel-induced apoptosis.
Neoplasms
PARP inhibition sensitizes to low dose-rate radiation TMPRSS2-ERG fusion gene-expressing and PTEN-deficient prostate cancer cells.
Neoplasms
PARP Inhibition Suppresses Growth of EGFR-Mutant Cancers by Targeting Nuclear PKM2.
Neoplasms
PARP inhibition: A promising therapeutic target in ovarian cancer.
Neoplasms
PARP inhibition: targeting the Achilles' heel of DNA repair to treat germline and sporadic ovarian cancers.
Neoplasms
PARP inhibitor (PARPi) monotherapy treatment in non-BRCA and/or non-serous gynaecological cancers.
Neoplasms
PARP inhibitor ABT-888 affects response of MDA-MB-231 cells to doxorubicin treatment, targeting Snail expression.
Neoplasms
PARP inhibitor and chemotherapy combination trials for the treatment of advanced malignancies: does a development pathway forward exist?
Neoplasms
PARP inhibitor associated treatment related myeloid neoplasms: What was a "Rare" complication may be less so.
Neoplasms
PARP inhibitor attenuated colony formation can be restored by MAP kinase inhibitors in different irradiated cancer cell lines.
Neoplasms
PARP inhibitor combination therapy.
Neoplasms
PARP inhibitor development for systemic cancer targeting.
Neoplasms
PARP Inhibitor Drugs In The Treatment Of Breast, Ovarian, Prostate And Pancreatic Cancers: An Update of Clinical Trials.
Neoplasms
PARP Inhibitor Efficacy Depends on CD8+ T-cell Recruitment via Intratumoral STING Pathway Activation in BRCA-Deficient Models of Triple-Negative Breast Cancer.
Neoplasms
PARP inhibitor increases chemosensitivity by upregulating miR-664b-5p in BRCA1-mutated triple-negative breast cancer.
Neoplasms
PARP inhibitor olaparib increases the oncolytic activity of dl922-947 in in vitro and in vivo model of anaplastic thyroid carcinoma.
Neoplasms
PARP inhibitor olaparib sensitizes cholangiocarcinoma cells to radiation.
Neoplasms
PARP Inhibitor PJ34 Protects Mitochondria and Induces DNA-Damage Mediated Apoptosis in Combination With Cisplatin or Temozolomide in B16F10 Melanoma Cells.
Neoplasms
PARP Inhibitor PJ34 Suppresses Osteogenic Differentiation in Mouse Mesenchymal Stem Cells by Modulating BMP-2 Signaling Pathway.
Neoplasms
PARP inhibitor resistance and TP53 mutations in patients treated with olaparib for BRCA-mutated cancer: Four case reports.
Neoplasms
PARP Inhibitor Resistance Mechanisms and Implications for Post-Progression Combination Therapies.
Neoplasms
PARP Inhibitor Resistance: A Tug-of-War in BRCA-Mutated Cells.
Neoplasms
PARP inhibitor resistance: the underlying mechanisms and clinical implications.
Neoplasms
PARP inhibitor rucaparib induces changes in NAD levels in cells and liver tissues as assessed by MRS.
Neoplasms
PARP inhibitor tilts cell death from necrosis to apoptosis in cancer cells.
Neoplasms
PARP inhibitor upregulates PD-L1 expression and enhances cancer-associated immunosuppression.
Neoplasms
PARP inhibitors affect growth, survival and radiation susceptibility of human alveolar and embryonal rhabdomyosarcoma cell lines.
Neoplasms
PARP inhibitors and cancer therapy - early results and potential applications.
Neoplasms
PARP inhibitors and immunotherapy in ovarian and endometrial cancers.
Neoplasms
PARP inhibitors and more.
Neoplasms
PARP inhibitors and newly second primary malignancies in cancer patients: a systematic review and safety meta-analysis of placebo randomized controlled trials.
Neoplasms
PARP Inhibitors and Prostate Cancer: To Infinity and Beyond BRCA.
Neoplasms
PARP inhibitors and radiation potentiate liver cell death in vitro. Do hepatocellular carcinomas have an achilles' heel?
Neoplasms
PARP Inhibitors and the Evolving Landscape of Ovarian Cancer Management: A Review.
Neoplasms
PARP inhibitors and the treatment of breast cancer: beyond BRCA1/2?
Neoplasms
PARP Inhibitors as a Therapeutic Agent for Homologous Recombination Deficiency in Breast Cancers.
Neoplasms
PARP inhibitors as antitumor agents: a patent update (2013-2015).
Neoplasms
PARP inhibitors as potential therapeutic agents for various cancers: focus on niraparib and its first global approval for maintenance therapy of gynecologic cancers.
Neoplasms
PARP Inhibitors as Therapeutics: Beyond Modulation of PARylation.
Neoplasms
PARP inhibitors blaze a trail in difficult-to-treat cancers.
Neoplasms
PARP inhibitors combined with ionizing radiation induce different effects in melanoma cells and healthy fibroblasts.
Neoplasms
PARP inhibitors enhance replication stress and cause mitotic catastrophe in MYCN-dependent neuroblastoma.
Neoplasms
PARP inhibitors for BRCA wild type ovarian cancer; gene alterations, homologous recombination deficiency and combination therapy.
Neoplasms
PARP Inhibitors for BRCA1/2 mutation-associated and BRCA-like malignancies.
Neoplasms
PARP inhibitors for BRCA1/2-mutated and sporadic ovarian cancer: current practice and future directions.
Neoplasms
PARP inhibitors for cancer therapy.
Neoplasms
PARP Inhibitors for Cancer Therapy.
Neoplasms
PARP Inhibitors for Ovarian Cancer: Current Indications, Future Combinations, and Novel Assets in Development to Target DNA Damage Repair.
Neoplasms
PARP Inhibitors for Recurrent Ovarian Carcinoma: Current Treatment Options and Future Perspectives.
Neoplasms
PARP Inhibitors for Sensitization of Alkylation Chemotherapy in Glioblastoma: Impact of Blood-Brain Barrier and Molecular Heterogeneity.
Neoplasms
PARP Inhibitors for the Treatment and Prevention of Breast Cancer.
Neoplasms
Parp Inhibitors for the Treatment of Ovarian Cancer.
Neoplasms
PARP Inhibitors in Biliary Tract Cancer: A New Kid on the Block?
Neoplasms
PARP inhibitors in BRCA gene-mutated ovarian cancer and beyond.
Neoplasms
PARP inhibitors in BRCA1-/BRCA2-associated and triple-negative breast cancers.
Neoplasms
PARP inhibitors in BRCA1/BRCA2 germline mutation carriers with ovarian and breast cancer.
Neoplasms
PARP inhibitors in breast cancer: BRCA and beyond.
Neoplasms
PARP inhibitors in breast cancer: Bringing synthetic lethality to the bedside.
Neoplasms
PARP Inhibitors in Cancer Diagnosis and Therapy.
Neoplasms
PARP inhibitors in cancer therapy: an update.
Neoplasms
PARP Inhibitors in Cancer Therapy: Magic Bullets but Moving Targets.
Neoplasms
PARP inhibitors in cancer therapy: promise, progress, and puzzles.
Neoplasms
PARP inhibitors in cancer therapy: two modes of attack on the cancer cell widening the clinical applications.
Neoplasms
PARP inhibitors in cancer: moving beyond BRCA.
Neoplasms
PARP Inhibitors in Clinical Use Induce Genomic Instability in Normal Human Cells.
Neoplasms
PARP Inhibitors in Endometrial Cancer: Current Status and Perspectives.
Neoplasms
PARP Inhibitors in Epithelial Ovarian Cancer: State of Art and Perspectives of Clinical Research.
Neoplasms
PARP inhibitors in gastric cancer: beacon of hope.
Neoplasms
PARP Inhibitors in Gynecologic Cancers: What Is the Next Big Development?
Neoplasms
PARP inhibitors in head and neck cancer: Molecular mechanisms, preclinical and clinical data.
Neoplasms
PARP inhibitors in oncology: a new synthetic lethal approach to cancer therapy.
Neoplasms
PARP inhibitors in ovarian and other cancers.
Neoplasms
PARP Inhibitors in Ovarian Cancer: A Trailblazing and Transformative Journey.
Neoplasms
PARP inhibitors in ovarian cancer: An overview of the practice-changing trials.
Neoplasms
PARP inhibitors in ovarian cancer: Current status and future promise.
Neoplasms
PARP inhibitors in ovarian cancer: evidence for maintenance and treatment strategies.
Neoplasms
PARP inhibitors in ovarian cancer: evidence, experience and clinical potential.
Neoplasms
PARP inhibitors in ovarian cancer: Sensitivity prediction and resistance mechanisms.
Neoplasms
PARP Inhibitors in Ovarian Cancer: The Route to "Ithaca".
Neoplasms
PARP Inhibitors in Pancreatic Cancer: From Phase I to Plenary Session.
Neoplasms
PARP inhibitors in pancreatic cancer: molecular mechanisms and clinical applications.
Neoplasms
PARP Inhibitors in Prostate and Urothelial Cancers.
Neoplasms
PARP Inhibitors in Prostate CancerThe Preclinical Rationale and Current Clinical Development.
Neoplasms
PARP Inhibitors in Reproductive System Cancers: Current Use and Developments.
Neoplasms
PARP inhibitors in the management of breast cancer: current data and future prospects.
Neoplasms
PARP Inhibitors in the Management of Ovarian Cancer: ASCO Guideline.
Neoplasms
PARP Inhibitors in Triple-Negative Breast Cancer Including Those With BRCA Mutations.
Neoplasms
PARP inhibitors promote stromal fibroblast activation by enhancing CCL5 autocrine signaling in ovarian cancer.
Neoplasms
PARP Inhibitors Refocus for Rebound.
Neoplasms
PARP inhibitors synergize with gemcitabine by potentiating DNA damage in non-small-cell lung cancer.
Neoplasms
PARP Inhibitors Talazoparib and Niraparib Sensitize Melanoma Cells to Ionizing Radiation.
Neoplasms
PARP inhibitors--current status and the walk towards early breast cancer.
Neoplasms
PARP inhibitors.
Neoplasms
PARP inhibitors: A new era of targeted therapy.
Neoplasms
PARP inhibitors: a tsunami of indications in different malignancies.
Neoplasms
PARP inhibitors: an interesting pathway also for Non-Small Cell Lung Cancer?
Neoplasms
PARP Inhibitors: Clinical Relevance, Mechanisms of Action and Tumor Resistance.
Neoplasms
PARP inhibitors: Clinical utility and possibilities of overcoming resistance.
Neoplasms
PARP Inhibitors: Extending Benefit Beyond BRCA Mutant Cancers.
Neoplasms
PARP inhibitors: its role in treatment of cancer.
Neoplasms
PARP Inhibitors: Mechanism of Action and Their Potential Role in the Prevention and Treatment of Cancer.
Neoplasms
PARP inhibitors: New partners in the therapy of cancer and inflammatory diseases.
Neoplasms
PARP inhibitors: New tools to protect from inflammation.
Neoplasms
PARP inhibitors: polypharmacology versus selective inhibition.
Neoplasms
PARP inhibitors: review of mechanisms of action and BRCA1/2 mutation targeting.
Neoplasms
PARP inhibitors: shifting the paradigm in the treatment of pancreatic cancer.
Neoplasms
PARP inhibitors: Synthetic lethality in the clinic.
Neoplasms
PARP Inhibitors: The Cornerstone of DNA Repair-Targeted Therapies.
Neoplasms
PARP is important for genomic stability but dispensable in apoptosis.
Neoplasms
PARP Power: A Structural Perspective on PARP1, PARP2, and PARP3 in DNA Damage Repair and Nucleosome Remodelling.
Neoplasms
PARP Targeted Alpha-Particle Therapy Enhances Response to PD-1 Immune-Checkpoint Blockade in a Syngeneic Mouse Model of Glioblastoma.
Neoplasms
PARP targeting counteracts gliomagenesis through induction of mitotic catastrophe and aggravation of deficiency in homologous recombination in PTEN-mutant glioma.
Neoplasms
PARP Theranostic Auger Emitters Are Cytotoxic in BRCA Mutant Ovarian Cancer and Viable Tumors from Ovarian Cancer Patients Enable Ex-Vivo Screening of Tumor Response.
Neoplasms
PARP-1 and Ku compete for repair of DNA double strand breaks by distinct NHEJ pathways.
Neoplasms
PARP-1 and PARP-2: New players in tumour development.
Neoplasms
PARP-1 cooperates with Ptc1 to suppress medulloblastoma and basal cell carcinoma.
Neoplasms
Parp-1 deficiency does not increase the frequency of tumors in the oral cavity and esophagus of ICR/129Sv mice by 4-nitroquinoline 1-oxide, a carcinogen producing bulky adducts.
Neoplasms
Parp-1 deficiency implicated in colon and liver tumorigenesis induced by azoxymethane.
Neoplasms
Parp-1 deficiency in ES cells promotes invasive and metastatic lesions accompanying induction of trophoblast giant cells during tumorigenesis in uterine environment.
Neoplasms
PARP-1 depletion in combination with carbon ion exposure significantly reduces MMPs activity and overall increases TIMPs expression in cultured HeLa cells.
Neoplasms
PARP-1 expression as a prognostic factor in Desmoid-type fibromatosis.
Neoplasms
PARP-1 expression in breast cancer including BRCA1-associated, triple negative and basal-like tumors: possible implications for PARP-1 inhibitor therapy.
Neoplasms
PARP-1 expression in CD34+ leukemic cells in childhood acute lymphoblastic leukemia: relation to response to initial therapy and other prognostic factors.
Neoplasms
PARP-1 expression is increased in colon adenoma and carcinoma and correlates with OGG1.
Neoplasms
Parp-1 genetic ablation in Ela-myc mice unveils novel roles for Parp-1 in pancreatic cancer.
Neoplasms
PARP-1 induces EMT in non-small cell lung carcinoma cells via modulating the transcription factors Smad4, p65 and ZEB1.
Neoplasms
PARP-1 inhibition as a targeted strategy to treat Ewing's sarcoma.
Neoplasms
PARP-1 Inhibition Increases Mitochondrial Metabolism through SIRT1 Activation.
Neoplasms
PARP-1 inhibition induces a late increase in the level of reactive oxygen species in cells after ionizing radiation.
Neoplasms
PARP-1 inhibition prevents CNS migration of dendritic cells during EAE, suppressing the encephalitogenic response and relapse severity.
Neoplasms
PARP-1 inhibition to treat cancer, ischemia, inflammation.
Neoplasms
PARP-1 inhibition with or without ionizing radiation confers reactive oxygen species-mediated cytotoxicity preferentially to cancer cells with mutant TP53.
Neoplasms
PARP-1 inhibition-induced activation of PI-3-kinase-Akt pathway promotes resistance to taxol.
Neoplasms
PARP-1 inhibitor modulate ?-catenin signaling to enhance cisplatin sensitivity in cancer cervix.
Neoplasms
PARP-1 inhibitors: a novel genetically specific agents for cancer therapy.
Neoplasms
PARP-1 inhibitors: are they the long-sought genetically specific drugs for BRCA1/2-associated breast cancers?
Neoplasms
PARP-1 may be involved in angiogenesis in epithelial ovarian cancer.
Neoplasms
PARP-1 Overexpression as an Independent Prognostic Factor in Adult Non-M3 Acute Myeloid Leukemia.
Neoplasms
PARP-1 promotes tumor recurrence after warm ischemic liver graft transplantation via neutrophil recruitment and polarization.
Neoplasms
PARP-1 protects against colorectal tumor induction, but promotes inflammation-driven colorectal tumor progression.
Neoplasms
PARP-1 protein expression in glioblastoma multiforme.
Neoplasms
PARP-1 regulates DNA repair factor availability.
Neoplasms
PARP-1 regulates epithelial-mesenchymal transition (EMT) in prostate tumorigenesis.
Neoplasms
PARP-1 Regulates Estrogen-Dependent Gene Expression in Estrogen Receptor ?-Positive Breast Cancer Cells.
Neoplasms
PARP-1 regulates metastatic melanoma through modulation of vimentin-induced malignant transformation.
Neoplasms
PARP-1 serves as a novel molecular marker for hepatocellular carcinoma in a Southern Chinese Zhuang population.
Neoplasms
PARP-1 Val762Ala polymorphism and risk of cancer: a meta-analysis based on 39 case-control studies.
Neoplasms
PARP-1 Val762Ala polymorphism is associated with risk of cervical carcinoma.
Neoplasms
PARP-1 Val762Ala polymorphism, CagA(+) H. pylori infection and risk for gastric cancer in Han Chinese population.
Neoplasms
PARP-1, a determinant of cell survival in response to DNA damage.
Neoplasms
PARP-1, PARP-2, and the cellular response to low doses of ionizing radiation.
Neoplasms
PARP-1/2 Inhibitor Olaparib Prevents or Partially Reverts EMT Induced by TGF-? in NMuMG Cells.
Neoplasms
PARP-1: Friend or Foe of DNA Damage and Repair in Tumorigenesis?
Neoplasms
PARP-Targeted Auger Therapy in p53 Mutant Colon Cancer Xenograft Mouse Models.
Neoplasms
Parp1 activation in mouse embryonic fibroblasts promotes Pol beta-dependent cellular hypersensitivity to alkylation damage.
Neoplasms
PARP1 activation increases expression of modified tumor suppressors and pathways underlying development of aggressive hepatoblastoma.
Neoplasms
PARP1 and CBP lose their footing in cancer.
Neoplasms
PARP1 and DNA-PKcs synergize to suppress p53 mutation and telomere fusions during T-lineage lymphomagenesis.
Neoplasms
PARP1 and phospho-p65 protein expression is increased in human HER2-positive breast cancers.
Neoplasms
PARP1 and PRC2 double deficiency promotes BRCA-proficient breast cancer growth by modification of the tumor microenvironment.
Neoplasms
PARP1 as a Marker of an Aggressive Clinical Phenotype in Cutaneous Melanoma-A Clinical and an In Vitro Study.
Neoplasms
PARP1 Co-Regulates EP300-BRG1-Dependent Transcription of Genes Involved in Breast Cancer Cell Proliferation and DNA Repair.
Neoplasms
PARP1 controls KLF4-mediated telomerase expression in stem cells and cancer cells.
Neoplasms
PARP1 deficiency protects against hyperglycemia-induced neointimal hyperplasia by upregulating TFPI2 activity in diabetic mice.
Neoplasms
PARP1 Deficiency Reduces Tumour Growth by Decreasing E2F1 Hyperactivation: A Novel Mechanism in the Treatment of Cancer.
Neoplasms
PARP1 depletion induces RIG-I-dependent signaling in human cancer cells.
Neoplasms
PARP1 enhances lung adenocarcinoma metastasis by novel mechanisms independent of DNA repair.
Neoplasms
PARP1 expression and its correlation with survival is tumour molecular subtype dependent in glioblastoma.
Neoplasms
PARP1 expression drives the synergistic antitumor activity of trabectedin and PARP1 inhibitors in sarcoma preclinical models.
Neoplasms
PARP1 expression in pediatric central nervous system tumors.
Neoplasms
PARP1 expression in soft tissue sarcomas is a poor-prognosis factor and a new potential therapeutic target.
Neoplasms
PARP1 gene polymorphisms and neuroblastoma susceptibility in Chinese children.
Neoplasms
PARP1 impact on DNA repair of platinum adducts: Preclinical and clinical read-outs.
Neoplasms
PARP1 in Carcinomas and PARP1 Inhibitors as Antineoplastic Drugs.
Neoplasms
PARP1 inhibition affects pleural mesothelioma cell viability and uncouples AKT/mTOR axis via SIRT1.
Neoplasms
PARP1 Inhibition Augments UVB-Mediated Mitochondrial Changes-Implications for UV-Induced DNA Repair and Photocarcinogenesis.
Neoplasms
PARP1 inhibition radiosensitizes HNSCC cells deficient in homologous recombination by disabling the DNA replication fork elongation response.
Neoplasms
PARP1 Inhibition Radiosensitizes Models of Inflammatory Breast Cancer to Ionizing Radiation.
Neoplasms
PARP1 Inhibitor Combined With Oxaliplatin Efficiently Suppresses Oxaliplatin Resistance in Gastric Cancer-Derived Organoids via Homologous Recombination and the Base Excision Repair Pathway.
Neoplasms
PARP1 inhibitor olaparib (Lynparza) exerts synthetic lethal effect against ligase 4-deficient melanomas.
Neoplasms
PARP1 inhibitors attenuate AKT phosphorylation via the upregulation of PHLPP1.
Neoplasms
PARP1 inhibitors trigger innate immunity via PARP1 trapping-induced DNA damage response.
Neoplasms
PARP1 Inhibitors: antitumor drug design.
Neoplasms
PARP1 is a novel independent prognostic factor for the poor prognosis of chordoma.
Neoplasms
PARP1 is activated at telomeres upon G4 stabilization: possible target for telomere-based therapy.
Neoplasms
PARP1 Is Overexpressed in Hematological Malignant Cell Lines: A Framework for Experimental Oncology.
Neoplasms
PARP1 is required for preserving telomeric integrity but is dispensable for A-NHEJ.
Neoplasms
PARP1 protects from benzo[a]pyrene diol epoxide-induced replication stress and mutagenicity.
Neoplasms
PARP1 rs1136410 C/C genotype associated with an increased risk of esophageal cancer in smokers.
Neoplasms
PARP1 rs1136410 Val762Ala contributes to an increased risk of overall cancer in the East Asian population: a meta-analysis.
Neoplasms
PARP1 rs1805407 Increases Sensitivity to PARP1 Inhibitors in Cancer Cells Suggesting an Improved Therapeutic Strategy.
Neoplasms
PARP1 Stabilizes CTCF Binding and Chromatin Structure To Maintain Epstein-Barr Virus Latency Type.
Neoplasms
PARP1 suppresses homologous recombination events in mice in vivo.
Neoplasms
PARP1 Suppresses the Transcription of PD-L1 by Poly(ADP-Ribosyl)ating STAT3.
Neoplasms
PARP1 Trapping and DNA Replication Stress Enhance Radiosensitization with Combined WEE1 and PARP Inhibitors.
Neoplasms
PARP1 Trapping by PARP Inhibitors Drives Cytotoxicity in Both Cancer Cells and Healthy Bone Marrow.
Neoplasms
PARP1 V762A polymorphism affects the prognosis of myelodysplastic syndromes.
Neoplasms
PARP1 Val762Ala polymorphism reduces enzymatic activity.
Neoplasms
Parp1-deficiency induces differentiation of ES cells into trophoblast derivatives.
Neoplasms
PARP1-dependent kinetics of recruitment of MRE11 and NBS1 proteins to multiple DNA damage sites.
Neoplasms
PARP1-mediated PARylation of TonEBP prevents R-loop-associated DNA damage.
Neoplasms
PARP1-modulated chromatin remodeling is a new target for cancer treatment.
Neoplasms
PARP1-siRNA suppresses human prostate cancer cell growth and progression.
Neoplasms
PARP10 Multi-Site Auto- and Histone MARylation Visualized by Acid-Urea Gel Electrophoresis.
Neoplasms
PARP10 promotes cellular proliferation and tumorigenesis by alleviating replication stress.
Neoplasms
PARP10 suppresses tumor metastasis through regulation of Aurora A activity.
Neoplasms
PARP14 inhibits microglial activation via LPAR5 to promote post-stroke functional recovery.
Neoplasms
PARP14 promotes the proliferation and gemcitabine chemoresistance of pancreatic cancer cells through activation of NF-?B pathway.
Neoplasms
PARP14 promotes the Warburg effect in hepatocellular carcinoma by inhibiting JNK1-dependent PKM2 phosphorylation and activation.
Neoplasms
PARP1: Structural insights and pharmacological targets for inhibition.
Neoplasms
PARP3 comes to light as a prime target in cancer therapy.
Neoplasms
PARP3 controls TGF? and ROS driven epithelial-to-mesenchymal transition and stemness by stimulating a TG2-Snail-E-cadherin axis.
Neoplasms
PARP3 interacts with FoxM1 to confer glioblastoma cell radioresistance.
Neoplasms
Parp3 promotes astrocytic differentiation through a tight regulation of Nox4-induced ROS and mTorc2 activation.
Neoplasms
PARP3, a new therapeutic target to alter Rictor/mTORC2 signaling and tumor progression in BRCA1-associated cancers.
Neoplasms
PARPi focus the spotlight on replication fork protection in cancer.
Neoplasms
PARPi Triggers the STING-Dependent Immune Response and Enhances the Therapeutic Efficacy of Immune Checkpoint Blockade Independent of BRCAness.
Neoplasms
PARPs and PAR as novel pharmacological targets for the treatment of stress granule-associated disorders.
Neoplasms
PARPs in lipid metabolism and related diseases.
Neoplasms
Parthanatos and its associated components: Promising therapeutic targets for cancer.
Neoplasms
Partial protection against collagen antibody-induced arthritis in PARP-1 deficient mice.
Neoplasms
Participation of the ATR/CHK1 pathway in replicative stress targeted therapy of high-grade ovarian cancer.
Neoplasms
Partnering with PARP inhibitors in acute myeloid leukemia with FLT3-ITD.
Neoplasms
Pathway-specific engineered mouse allograft models functionally recapitulate human serous epithelial ovarian cancer.
Neoplasms
Patient Counseling and Management of Symptoms During Olaparib Therapy for Recurrent Ovarian Cancer.
Neoplasms
Patients with bi-allelic BRCA1/2 inactivation respond to olaparib treatment across histologic tumor types.
Neoplasms
PBRM1 Deficiency Confers Synthetic Lethality to DNA Repair Inhibitors in Cancer.
Neoplasms
PCAF-Mediated Histone Acetylation Promotes Replication Fork Degradation by MRE11 and EXO1 in BRCA-Deficient Cells.
Neoplasms
PCAT-1, a Long Noncoding RNA, Regulates BRCA2 and Controls Homologous Recombination in Cancer.
Neoplasms
Pediatric high-grade glioma: identification of poly(ADP-ribose) polymerase as a potential therapeutic target.
Neoplasms
PEGylated lipid bilayer-supported mesoporous silica nanoparticle composite for synergistic co-delivery of axitinib and celastrol in multi-targeted cancer therapy.
Neoplasms
Persistent depletion of plasma gelsolin (pGSN) after exposure of mice to heavy silicon ions.
Neoplasms
Personalized Medicine in Gynecologic Cancer: Fact or Fiction?
Neoplasms
Perspectives on PARP inhibitors as pharmacotherapeutic strategies for breast cancer.
Neoplasms
Pertussis toxin blocks the inhibitory effect of muscarinic cholinergic agonists on cyclic AMP accumulation and prolactin secretion in GH3 anterior-pituitary tumour cells.
Neoplasms
Pertussis toxin-induced hyperacute autoimmune encephalomyelitis in Lewis rats is correlated with increased expression of inducible nitric oxide synthase and tumor necrosis factor alpha.
Neoplasms
PET imaging of PARP expression using [18F]olaparib.
Neoplasms
PET of Poly (ADP-Ribose) Polymerase Activity in Cancer: Preclinical Assessment and First In-Human Studies.
Neoplasms
Pharmacodynamic analyses in a multi-laboratory network: lessons from the poly(ADP-ribose) assay.
Neoplasms
Pharmacodynamic and genomic markers associated with response to the XPO1/CRM1 inhibitor selinexor (KPT-330): A report from the pediatric preclinical testing program.
Neoplasms
Pharmacodynamic genes do not influence risk of neutropenia in cancer patients treated with moderately high-dose irinotecan.
Neoplasms
Pharmacogenomic analysis of patient-derived tumor cells in gynecologic cancers.
Neoplasms
Pharmacokinetic drug evaluation of niraparib for the treatment of ovarian cancer.
Neoplasms
Pharmacokinetic Study of Rucaparib in Patients With Advanced Solid Tumors.
Neoplasms
Pharmacologic ascorbate induces neuroblastoma cell death by hydrogen peroxide mediated DNA damage and reduction in cancer cell glycolysis.
Neoplasms
Pharmacologic blockade of FAK autophosphorylation decreases human glioblastoma tumor growth and synergizes with temozolomide.
Neoplasms
Pharmacologic induction of innate immune signaling directly drives homologous recombination deficiency.
Neoplasms
Pharmacological Inhibition of Poly(ADP-ribose) Polymerase (PARP) Activity in PARP-1 Silenced Tumour Cells Increases Chemosensitivity to Temozolomide and to a N3-Adenine Selective Methylating Agent.
Neoplasms
Pharmacological inhibition of poly(ADP-ribose) polymerase (PARP) activity in PARP-1 silenced tumour cells increases chemosensitivity to temozolomide and to a N3-adenine selective methylating agent.
Neoplasms
Pharmacological inhibition of poly(ADP-ribose) polymerase inhibits angiogenesis.
Neoplasms
Pharmacological methods to transcriptionally modulate double-strand break DNA repair.
Neoplasms
Pharmacological targets and molecular mechanisms of plumbagin to treat colorectal cancer: A systematic pharmacology study.
Neoplasms
Phase 0 Clinical Trial of the Poly (ADP-Ribose) Polymerase Inhibitor ABT-888 in Patients With Advanced Malignancies.
Neoplasms
Phase 1 Combination Study of the CHK1 Inhibitor Prexasertib and the PARP Inhibitor Olaparib in High-grade Serous Ovarian Cancer and Other Solid Tumors.
Neoplasms
Phase 1 dose-escalation study of the PARP inhibitor CEP-9722 as monotherapy or in combination with temozolomide in patients with solid tumors.
Neoplasms
Phase 1 study of veliparib (ABT-888), a poly (ADP-ribose) polymerase inhibitor, with carboplatin and paclitaxel in advanced solid malignancies.
Neoplasms
Phase 1/2 trial of talazoparib in combination with temozolomide in children and adolescents with refractory/recurrent solid tumors including Ewing sarcoma: A Children's Oncology Group Phase 1 Consortium study (ADVL1411).
Neoplasms
Phase 2 Study of Talazoparib in Patients With Homologous Recombination Repair-Deficient Squamous Cell Lung Cancer: Lung-MAP Substudy S1400G.
Neoplasms
Phase I and pharmacokinetic study of veliparib, a PARP inhibitor, and pegylated liposomal doxorubicin (PLD) in recurrent gynecologic cancer and triple negative breast cancer with long-term follow-up.
Neoplasms
Phase I clinical study of oral olaparib in pediatric patients with refractory solid tumors: study protocol.
Neoplasms
Phase I combination study of the PARP inhibitor veliparib plus carboplatin and gemcitabine in patients with advanced ovarian cancer and other solid malignancies.
Neoplasms
Phase I dose-escalation and expansion study of PARP inhibitor, fluzoparib (SHR3162), in patients with advanced solid tumors.
Neoplasms
Phase I safety, pharmacokinetic and pharmacodynamic study of the poly (ADP-ribose) polymerase inhibitor veliparib with irinotecan in patients with advanced solid tumors.
Neoplasms
Phase I Study of PARP Inhibitor ABT-888 in Combination with Topotecan in Adults with Refractory Solid Tumors and Lymphomas.
Neoplasms
Phase I study of the PARP inhibitor talazoparib with radiation therapy for locally recurrent gynecologic cancers.
Neoplasms
Phase I study of the poly(ADP-ribose) polymerase inhibitor, AG014699, in combination with temozolomide in patients with advanced solid tumors.
Neoplasms
Phase I study to assess the safety and tolerability of olaparib in combination with bevacizumab in patients with advanced solid tumours.
Neoplasms
Phase I Trial of First-in-Class ATR Inhibitor M6620 (VX-970) as Monotherapy or in Combination With Carboplatin in Patients With Advanced Solid Tumors.
Neoplasms
Phase I Trial of the PARP Inhibitor Olaparib and AKT Inhibitor Capivasertib in Patients with BRCA1/2- and Non-BRCA1/2-Mutant Cancers.
Neoplasms
Phase I, Dose-Escalation, 2-Part Trial of Poly(ADP-Ribose) Polymerase Inhibitor Talazoparib in Patients with Advanced Germline BRCA1/2 Mutations and Selected Sporadic Cancers.
Neoplasms
Phase II Study of Olaparib (AZD-2281) After Standard Systemic Therapies for Disseminated Colorectal Cancer.
Neoplasms
Phase II trial of veliparib in patients with previously treated BRCA-mutated pancreas ductal adenocarcinoma.
Neoplasms
Phosphatase 1 nuclear targeting subunit mediates recruitment and function of poly (ADP-ribose) polymerase 1 in DNA repair.
Neoplasms
Phosphatase 1 Nuclear Targeting Subunit, a Novel DNA Repair Partner of PARP1.
Neoplasms
Phosphatase and Tensin Homolog Is a Potential Target for Ovarian Cancer Sensitization to Cytotoxic Agents.
Neoplasms
Phosphoinositide 3-kinase inhibitors induce DNA damage through nucleoside depletion.
Neoplasms
Phospholipase A2 activation in chemotactic peptide-stimulated HL60 granulocytes: synergism between diacylglycerol and Ca2+ in a protein kinase C-independent mechanism.
Neoplasms
Phosphorylation of ribosomal protein S6 confers PARP inhibitor resistance in BRCA1-deficient cancers.
Neoplasms
Phosphorylation regulates the interaction and complex formation between wt p53 protein and PARP-1.
Neoplasms
Photodynamic therapy induced Fas-mediated apoptosis in human carcinoma cells.
Neoplasms
Photodynamic Therapy of Pheophorbide a Inhibits the Proliferation of Human Breast Tumour via Both Caspase-dependent and -independent Apoptotic Pathways in In Vitro and In Vivo Models.
Neoplasms
Photodynamic therapy with the phthalocyanine photosensitizer Pc 4 of SW480 human colon cancer xenografts in athymic mice.
Neoplasms
Phthalocyanine 4 (Pc 4) photodynamic therapy of human OVCAR-3 tumor xenografts.
Neoplasms
Physiological ageing: role of p53 and PARP-1 tumor suppressors in the regulation of terminal senescence.
Neoplasms
Phytosphingosine in combination with ionizing radiation enhances apoptotic cell death in radiation-resistant cancer cells through ROS-dependent and -independent AIF release.
Neoplasms
PI3K inhibition impairs BRCA1/2 expression and sensitizes BRCA proficient triple negative breast cancer to PARP inhibition.
Neoplasms
PI3K-AKT-mTOR inhibitors in breast cancers: From tumor cell signaling to clinical trials.
Neoplasms
Pinus Roxburghii essential oil anticancer activity and chemical composition evaluation.
Neoplasms
PJ-34 inhibits PARP-1 expression and ERK phosphorylation in glioma-conditioned brain microvascular endothelial cells.
Neoplasms
PJ34, a poly(ADP-ribose) polymerase (PARP) inhibitor, reverses melphalan-resistance and inhibits repair of DNA double-strand breaks by targeting the FA/BRCA pathway in multidrug resistant multiple myeloma cell line RPMI8226/R.
Neoplasms
PJ34, an inhibitor of PARP-1, suppresses cell growth and enhances the suppressive effects of cisplatin in liver cancer cells.
Neoplasms
PLA2R1 promotes DNA damage and inhibits spontaneous tumor formation during aging.
Neoplasms
Placental promoter methylation of DNA repair genes and prenatal exposure to particulate air pollution: an ENVIRONAGE cohort study.
Neoplasms
Plasma and cerebrospinal fluid pharmacokinetics of ABT-888 after oral administration in non-human primates.
Neoplasms
Platinated benzonaphthyridone is a stronger inhibitor of poly(ADP-ribose) polymerase-1 and a more potent anticancer agent than is the parent inhibitor.
Neoplasms
Platinum(IV) prodrugs multiply targeting genomic DNA, histone deacetylases and PARP-1.
Neoplasms
Playing on the Dark Side: SMYD3 Acts as a Cancer Genome Keeper in Gastrointestinal Malignancies.
Neoplasms
Plectin-targeted liposomes enhance the therapeutic efficacy of a PARP inhibitor in the treatment of ovarian cancer.
Neoplasms
PLK1 (polo like kinase 1)-dependent autophagy facilitates gefitinib-induced hepatotoxicity by degrading COX6A1 (cytochrome c oxidase subunit 6A1).
Neoplasms
Plk1 Phosphorylation of Mre11 Antagonizes the DNA Damage Response.
Neoplasms
PLK1/NF-?B feedforward circuit antagonizes the mono-ADP-ribosyltransferase activity of PARP10 and facilitates HCC progression.
Neoplasms
Pol? inhibitors elicit BRCA-gene synthetic lethality and target PARP inhibitor resistance.
Neoplasms
Poly (ADP) ribose polymerase inhibition: A potential treatment of malignant peripheral nerve sheath tumor.
Neoplasms
Poly (ADP-ribose) polymerase (PARP) as target for the treatment of epithelial ovarian cancer: what to know.
Neoplasms
Poly (ADP-ribose) polymerase (PARP): rationale, preclinical and clinical evidences of its inhibition as breast cancer treatment.
Neoplasms
Poly (ADP-ribose) polymerase 1 mRNA levels strongly correlate with the prognosis of myelodysplastic syndromes.
Neoplasms
Poly (ADP-ribose) polymerase 1 protein expression in normal and neoplastic prostatic tissue.
Neoplasms
Poly (ADP-Ribose) Polymerase 1 Protein Expression in Normal Pancreas and Pancreatic Adenocarcinoma.
Neoplasms
Poly (ADP-ribose) polymerase 3 (PARP3), a potential repressor of telomerase activity.
Neoplasms
Poly (adp-ribose) polymerase as a novel therapeutic target in cancer.
Neoplasms
Poly (ADP-ribose) polymerase inhibitor efficacy in head and neck cancer.
Neoplasms
Poly (ADP-Ribose) Polymerase Inhibitor Hypersensitivity in Aggressive Myeloproliferative Neoplasms.
Neoplasms
Poly (ADP-Ribose) Polymerase Inhibitor, ABT888, Improved Cisplatin Effect in Human Oral Cell Carcinoma.
Neoplasms
Poly (ADP-ribose) polymerase inhibitors combined with other small-molecular compounds for the treatment of ovarian cancer.
Neoplasms
Poly (ADP-ribose) Polymerase Inhibitors in Cancer Treatment.
Neoplasms
Poly (ADP-ribose) polymerase inhibitors in solid tumours: Systematic review and meta-analysis.
Neoplasms
Poly (ADP-ribose) polymerase inhibitors in the management of ovarian cancer.
Neoplasms
Poly (ADP-ribose) polymerase inhibitors selectively induce cytotoxicity in TCF3-HLF-positive leukemic cells.
Neoplasms
Poly (ADP-Ribose) Polymerase Inhibitors: Talazoparib in Ovarian Cancer and Beyond.
Neoplasms
Poly (ADP-ribose) polymerase-1 (PARP1) as a therapeutic target in acute myeloid leukemia and myelodysplastic syndrome.
Neoplasms
Poly (ADP-Ribose) Polymerase-1 (PARP1) Deficiency and Pharmacological Inhibition by Pirenzepine Protects From Cisplatin-Induced Ototoxicity Without Affecting Antitumor Efficacy.
Neoplasms
Poly (ADP-ribose) polymerase-1 inhibition decreases proliferation through G2/M arrest in esophageal squamous cell carcinoma.
Neoplasms
Poly (ADP-ribose) polymerase-1 Inhibition: Preclinical and Clinical Development of Synthetic Lethality.
Neoplasms
Poly (ADP-ribose) polymerases (PARPs) 1-3 regulate astrocyte activation.
Neoplasms
Poly (ADP-Ribose) Polymerases (PARPs) and PARP Inhibitor-Targeted Therapeutics.
Neoplasms
Poly (ADP-ribose) polymerases inhibitor, Zj6413, as a potential therapeutic agent against breast cancer.
Neoplasms
Poly (ADP-Ribosyl) Polymerase 1 Inhibitors: A Patent Review.
Neoplasms
Poly adenosine diphosphate-ribosylation, a promising target for colorectal cancer treatment.
Neoplasms
Poly ADP-ribose polymerase (PARP) inhibitors transiently protect leukemia cells from alkylating agent induced cell death by three different effects.
Neoplasms
Poly ADP-ribose polymerase inhibition suppresses cisplatin toxicity in chronic myeloid leukemia cells.
Neoplasms
Poly(adenosine diphosphate ribose) polymerase inhibitors induce autophagy-mediated drug resistance in ovarian cancer cells, xenografts, and patient-derived xenograft models.
Neoplasms
Poly(adenosine diphosphate-ribose) polymerase 1 expression in malignant melanomas from photoexposed areas of the head and neck region.
Neoplasms
Poly(adenosine diphosphate-ribose) polymerase expression in serous ovarian carcinoma: correlation with p53, MIB-1, and outcome.
Neoplasms
Poly(Adenosine diphosphate-ribose) polymerase inhibitors in cancer treatment.
Neoplasms
Poly(adenosine diphosphate-ribosylation) of nuclear matrix proteins in alkylating agent resistant and sensitive cell lines.
Neoplasms
Poly(ADP-ribose) and carcinogenesis.
Neoplasms
Poly(ADP-ribose) binds to specific domains of p53 and alters its DNA binding functions.
Neoplasms
Poly(ADP-Ribose) Glycohydrolase (PARG) vs. Poly(ADP-Ribose) Polymerase (PARP) - Function in Genome Maintenance and Relevance of Inhibitors for Anti-cancer Therapy.
Neoplasms
Poly(ADP-ribose) polymerase (PARP) and DNA-fragmentation factor (DFF45): expression and correlation in normal, hyperplastic and neoplastic endometrial tissues.
Neoplasms
Poly(ADP-ribose) polymerase (PARP) inhibition or PARP-1 gene deletion reduces angiogenesis.
Neoplasms
Poly(ADP-ribose) polymerase (PARP) inhibitors: Exploiting a synthetic lethal strategy in the clinic.
Neoplasms
Poly(ADP-ribose) polymerase (PARP-1) in homologous recombination and as a target for cancer therapy.
Neoplasms
Poly(ADP-ribose) polymerase 1 in genome-wide expression control in Drosophila.
Neoplasms
Poly(ADP-ribose) polymerase 1 is necessary for coactivating hypoxia-inducible factor-1-dependent gene expression by Epstein-Barr virus latent membrane protein 1.
Neoplasms
Poly(ADP-ribose) polymerase 1 modulates the lethality of CHK1 inhibitors in carcinoma cells.
Neoplasms
Poly(ADP-ribose) polymerase 1 modulates the lethality of CHK1 inhibitors in mammary tumors.
Neoplasms
Poly(ADP-ribose) polymerase 1 promotes tumor cell survival by coactivating hypoxia-inducible factor-1-dependent gene expression.
Neoplasms
Poly(ADP-Ribose) polymerase 1: a therapeutic hope in gynecologic cancers.
Neoplasms
Poly(ADP-Ribose) Polymerase 1: Cellular Pluripotency, Reprogramming, and Tumorogenesis.
Neoplasms
Poly(ADP-ribose) polymerase 3 (PARP3), a newcomer in cellular response to DNA damage and mitotic progression.
Neoplasms
Poly(ADP-ribose) polymerase activity and inhibition in cancer.
Neoplasms
Poly(ADP-ribose) polymerase and cancer: in relation to the lectures presented by Dr Gilbert de Murcia.
Neoplasms
Poly(ADP-ribose) polymerase as a drug target for cardiovascular disease and cancer: an update.
Neoplasms
Poly(ADP-ribose) polymerase as a novel regulator of 17?-estradiol-induced cell growth through a control of the estrogen receptor/IGF-1 receptor/PDZK1 axis.
Neoplasms
Poly(ADP-ribose) polymerase from Ehrlich ascites tumor cells. Properties of the purified polymerase.
Neoplasms
Poly(ADP-ribose) polymerase gene expression status and genomic instability in human breast cancer.
Neoplasms
Poly(ADP-Ribose) Polymerase in Cervical Cancer Pathogenesis: Mechanism and Potential Role for PARP Inhibitors.
Neoplasms
Poly(ADP-ribose) polymerase in DNA damage-response pathway: implications for radiation oncology.
Neoplasms
Poly(ADP-ribose) polymerase in human breast cancer: a case-control analysis.
Neoplasms
Poly(ADP-ribose) polymerase inhibition as a model for synthetic lethality in developing radiation oncology targets.
Neoplasms
Poly(ADP-ribose) polymerase inhibition enhances p53-dependent and -independent DNA damage responses induced by DNA damaging agent.
Neoplasms
Poly(ADP-ribose) polymerase inhibition in cancer therapy: are we close to maturity?
Neoplasms
Poly(ADP-ribose) polymerase inhibition reduces tumor necrosis factor-induced inflammatory response in rheumatoid synovial fibroblasts.
Neoplasms
Poly(ADP-Ribose) Polymerase Inhibition Synergizes with 5-Fluorodeoxyuridine but not 5-Fluorouracil in Ovarian Cancer Cells.
Neoplasms
Poly(ADP-ribose) polymerase inhibition: a new direction for BRCA and triple-negative breast cancer?
Neoplasms
Poly(ADP-ribose) polymerase inhibition: past, present and future.
Neoplasms
Poly(ADP-ribose) polymerase inhibitor increases growth inhibition and reduces G(2)/M cell accumulation induced by temozolomide in malignant glioma cells.
Neoplasms
Poly(ADP-ribose) polymerase inhibitor induces accelerated senescence in irradiated breast cancer cells and tumors.
Neoplasms
Poly(ADP-ribose) polymerase inhibitors as cancer therapy.
Neoplasms
Poly(ADP-ribose) polymerase inhibitors as promising cancer therapeutics.
Neoplasms
Poly(ADP-ribose) polymerase inhibitors in cancer treatment: a clinical perspective.
Neoplasms
Poly(ADP-ribose) polymerase inhibitors in prostate and urothelial cancer.
Neoplasms
Poly(ADP-Ribose) Polymerase Inhibitors in Prostate Cancer: Molecular Mechanisms, and Preclinical and Clinical Data.
Neoplasms
Poly(ADP-ribose) polymerase inhibitors in triple-negative breast cancer.
Neoplasms
Poly(ADP-ribose) Polymerase Inhibitors Sensitize Cancer Cells to Death Receptor-mediated Apoptosis by Enhancing Death Receptor Expression.
Neoplasms
Poly(ADP-ribose) polymerase is a B-MYB coactivator.
Neoplasms
Poly(ADP-ribose) polymerase is hyperactivated in homologous recombination-defective cells.
Neoplasms
Poly(ADP-ribose) polymerase, a potential target for drugs: Cellular regulatory role of the polymer and the polymerase protein mediated by catalytic and macromolecular colligative actions (Review).
Neoplasms
Poly(ADP-ribose) polymerase-1 (PARP-1) inhibitors in cancer chemotherapy.
Neoplasms
Poly(ADP-ribose) polymerase-1 (PARP-1) pharmacogenetics, activity and expression analysis in cancer patients and healthy volunteers.
Neoplasms
Poly(ADP-ribose) polymerase-1 (PARP1) and p53 labelling index correlates with tumour grade in meningiomas.
Neoplasms
Poly(ADP-ribose) polymerase-1 activity facilitates the dissociation of nuclear proteins from platinum-modified DNA.
Neoplasms
Poly(ADP-ribose) polymerase-1 activity promotes NF-kappaB-driven transcription and microglial activation: implication for neurodegenerative disorders.
Neoplasms
Poly(ADP-ribose) polymerase-1 antagonizes DNA resection at double-strand breaks.
Neoplasms
Poly(ADP-ribose) polymerase-1 inhibition reverses temozolomide resistance in a DNA mismatch repair-deficient malignant glioma xenograft.
Neoplasms
Poly(ADP-ribose) polymerase-1 inhibitor 3-aminobenzamide enhances apoptosis induction by platinum complexes in cisplatin-resistant tumor cells.
Neoplasms
Poly(ADP-ribose) polymerase-1 inhibitor treatment regresses autochthonous Brca2/p53-mutant mammary tumors in vivo and delays tumor relapse in combination with carboplatin.
Neoplasms
Poly(ADP-ribose) polymerase-1 is a key mediator of cisplatin-induced kidney inflammation and injury.
Neoplasms
Poly(ADP-ribose) polymerase-1 is a positive regulator of the p53-mediated G1 arrest response following ionizing radiation.
Neoplasms
Poly(ADP-ribose) polymerase-1 mRNA expression in human breast cancer: a meta-analysis.
Neoplasms
Poly(ADP-ribose) polymerase-1 polymorphisms, expression and activity in selected human tumour cell lines.
Neoplasms
Poly(ADP-ribose) polymerase-1 regulates the stability of the wild-type p53 protein.
Neoplasms
Poly(ADP-ribose) polymerase-1 signaling to mitochondria in necrotic cell death requires RIP1/TRAF2-mediated JNK1 activation.
Neoplasms
Poly(ADP-ribose) polymerase: a guardian angel protecting the genome and suppressing tumorigenesis.
Neoplasms
Poly(ADP-ribose) polymerases: homology, structural domains and functions. Novel therapeutical applications.
Neoplasms
Poly(ADP-ribose) polymerases: managing genome stability.
Neoplasms
Poly(ADP-ribose)-dependent regulation of Snail1 protein stability.
Neoplasms
Poly(ADP-Ribose)-Polymerase-Catalyzed Hydrolysis of NAD(+): QM/MM Simulation of the Enzyme Reaction.
Neoplasms
Poly(ADP-ribose): a co-regulator of DNA methylation?
Neoplasms
Poly(ADP-Ribose)Polymerase (PARP) Inhibitors and Radiation Therapy.
Neoplasms
Poly(ADP-ribose)polymerase inhibition - where now?
Neoplasms
Poly(ADP-ribose)polymerase inhibition decreases angiogenesis.
Neoplasms
Poly(ADP-ribose)polymerase-1 (PARP-1) in carcinogenesis: potential role of PARP inhibitors in cancer treatment.
Neoplasms
Poly(ADP-ribose)polymerase1: A potential molecular marker to identify cancer during colposcopy procedures.
Neoplasms
Poly(ADP-ribosyl)ation in carcinogenesis.
Neoplasms
Poly(ADP-ribosyl)ation in relation to cancer and autoimmune disease.
Neoplasms
Poly(ADP-ribosyl)ation is involved in the epigenetic control of TET1 gene transcription.
Neoplasms
Poly(ADP-ribosyl)ation of BRD7 by PARP1 confers resistance to DNA-damaging chemotherapeutic agents.
Neoplasms
Poly(ADP-ribosyl)ation polymerases: mechanism and new target of anticancer therapy.
Neoplasms
Poly(ADP-ribosylation) and neoplastic transformation:Effect of PARP inhibitors.
Neoplasms
Poly(ADP-Ribosylation) in Age-Related Neurological Disease.
Neoplasms
Poly-(ADP-ribose) polymerase inhibitors: paradigm shift in the first-line treatment of newly diagnosed advanced ovarian cancer.
Neoplasms
Poly-(ADP-ribose)-polymerase inhibitors as radiosensitizers: a systematic review of pre-clinical and clinical human studies.
Neoplasms
Poly-ADP ribosylation in DNA damage response and cancer therapy.
Neoplasms
Poly-ADP-ribose polymerases (PARPs) as a therapeutic target in the treatment of selected cancers.
Neoplasms
Poly-ADP-ribosyl-polymerase inhibitor resistance mechanisms and their therapeutic implications.
Neoplasms
Poly-ADP-ribosylation of HMGB1 regulates TNFSF10/TRAIL resistance through autophagy.
Neoplasms
Poly-l-Lysine inhibits VEGF and c-Myc mediated tumor-angiogenesis and induces apoptosis in 2D and 3D tumor microenvironment of both MDA-MB-231 and B16F10 induced mice model.
Neoplasms
PolyADP-ribosylation and cancer.
Neoplasms
Polyclonal BRCA2 mutations following carboplatin treatment confer resistance to the PARP inhibitor rucaparib in a patient with mCRPC: a case report.
Neoplasms
Polylysine-modified polyethylenimine inducing tumor apoptosis as an efficient gene carrier.
Neoplasms
Polymer-lipid hybrid nanovesicle-enabled combination of immunogenic chemotherapy and RNAi-mediated PD-L1 knockdown elicits antitumor immunity against melanoma.
Neoplasms
Polymorphisms of DNA repair genes: ADPRT, XRCC1, and XPD and cancer risk in genetic epidemiology.
Neoplasms
Population Pharmacokinetics of Talazoparib in Patients With Advanced Cancer.
Neoplasms
Population-Attributable Risk Proportion of Clinical Risk Factors for Breast Cancer.
Neoplasms
Positive transcriptional regulation of the human micro opioid receptor gene by poly(ADP-ribose) polymerase-1 and increase of its DNA binding affinity based on polymorphism of G-172 -> T.
Neoplasms
Positron-Emission Tomographic Imaging of a Fluorine 18-Radiolabeled Poly(ADP-Ribose) Polymerase 1 Inhibitor Monitors the Therapeutic Efficacy of Talazoparib in SCLC Patient-Derived Xenografts.
Neoplasms
Possible role of poly(ADP-ribose) polymerase on the early stage of liver carcinogenesis by diethylnitrosamine in rats.
Neoplasms
Post-transcriptional regulation by poly(ADP-ribosyl)ation of the RNA-binding proteins.
Neoplasms
Post-Transcriptional Regulation of PARP7 Protein Stability Is Controlled by Androgen Signaling.
Neoplasms
Post-Traumatic Brain Injury: Genetic Susceptibility to Outcome.
Neoplasms
Post-traumatic caspase-3 expression in the adjacent areas of growth plate injury site: a morphological study.
Neoplasms
Potential biological role of poly (ADP-ribose) polymerase (PARP) in male gametes.
Neoplasms
Potential biomarkers and therapeutic targets in cervical cancer: Insights from the meta-analysis of transcriptomics data within network biomedicine perspective.
Neoplasms
Potential Use of Inhibitors of Tankyrases and PARP-1 as Treatment for Cancer and Other Diseases.
Neoplasms
Potentiation of cytotoxic drug activity in human tumour cell lines, by amine-substituted 2-arylbenzimidazole-4-carboxamide PARP-1 inhibitors.
Neoplasms
Potentiation of temozolomide and topotecan growth inhibition and cytotoxicity by novel poly(adenosine diphosphoribose) polymerase inhibitors in a panel of human tumor cell lines.
Neoplasms
Pre-clinical and clinical evaluation of PARP inhibitors as tumour-specific radiosensitisers.
Neoplasms
Precision medicine phase II study evaluating the efficacy of a double immunotherapy by durvalumab and tremelimumab combined with olaparib in patients with solid cancers and carriers of homologous recombination repair genes mutation in response or stable after olaparib treatment.
Neoplasms
Preclinical and first-in-human-brain-cancer applications of [18F]poly (ADP-ribose) polymerase inhibitor PET/MR.
Neoplasms
Preclinical evaluation of olaparib and metformin combination in BRCA1 wildtype ovarian cancer.
Neoplasms
Preclinical evaluation of radiation therapy of BRCA1-associated mammary tumors using a mouse model.
Neoplasms
Preclinical evaluation of the PARP inhibitor BMN-673 for the treatment of ovarian clear cell cancer.
Neoplasms
Preclinical evaluation of the PARP inhibitor, olaparib, in combination with cytotoxic chemotherapy in pediatric solid tumors.
Neoplasms
Preclinical modeling of a phase 0 clinical trial: qualification of a pharmacodynamic assay of poly (ADP-ribose) polymerase in tumor biopsies of mouse xenografts.
Neoplasms
Preclinical rationale for combination of crizotinib with mitomycin C for the treatment of advanced colorectal cancer.
Neoplasms
Predicting enhanced cell killing through PARP inhibition.
Neoplasms
Predictive and Prognostic Value of DNA Damage Response Associated Kinases in Solid Tumors.
Neoplasms
Predictive biomarkers for cancer therapy with PARP inhibitors.
Neoplasms
Predictive value of epithelial-mesenchymal-transition (EMT) signature and PARP-1 in prostate cancer radioresistance.
Neoplasms
Predictors and Modulators of Synthetic Lethality: An Update on PARP Inhibitors and Personalized Medicine.
Neoplasms
Preferential involvement of Go and Gz proteins in mediating rat natural killer cell lysis of allogeneic and tumor target cells.
Neoplasms
Preliminary evaluation of a novel 18F-labeled PARP-1 ligand for PET imaging of PARP-1 expression in prostate cancer.
Neoplasms
Premature mitotic entry induced by ATR inhibition potentiates olaparib inhibition-mediated genomic instability, inflammatory signaling and cytotoxicity in BRCA2-deficient cancer cells.
Neoplasms
Preserving genome integrity in human cells via DNA double-strand break repair.
Neoplasms
Prevalence of DNA Repair Gene Mutations in Blood and Tumor Tissue and Impact on Prognosis and Treatment in HNSCC.
Neoplasms
Prevalence of Germline Mutations in Genes Engaged in DNA Damage Repair by Homologous Recombination in Patients with Triple-Negative and Hereditary Non-Triple-Negative Breast Cancers.
Neoplasms
Prevalence of Homologous Recombination Pathway Gene Mutations in Melanoma: Rationale for a New Targeted Therapeutic Approach.
Neoplasms
Prevalence of Tissue BRCA Gene Mutation in Ovarian, Fallopian Tube, and Primary Peritoneal Cancers: A Multi-Institutional Study.
Neoplasms
Prevalence of tumor BRCA1 and BRCA2 dysfunction in unselected patients with ovarian cancer.
Neoplasms
Prexasertib, a checkpoint kinase inhibitor: from preclinical data to clinical development.
Neoplasms
Probing PARP1-inhibitor complexes for the development of novel inhibitors.
Neoplasms
Probing the Conformational Changes Associated with DNA Binding to PARP1.
Neoplasms
Probiotic Lactobacillus reuteri promotes TNF-induced apoptosis in human myeloid leukemia-derived cells by modulation of NF-kappaB and MAPK signalling.
Neoplasms
Production and release of tumor necrosis factor alfa, interleukin-1B and interleukin-6 by human mononuclear leukocytes stimulated with pertussis toxin.
Neoplasms
Profile of veliparib and its potential in the treatment of solid tumors.
Neoplasms
Progress in the treatment of ovarian cancer-lessons from homologous recombination deficiency-the first 10 years.
Neoplasms
Progression through mitosis promotes PARP inhibitor-induced cytotoxicity in homologous recombination-deficient cancer cells.
Neoplasms
Prolonged response to treatment based on cell-free DNA analysis and molecular profiling in three patients with metastatic cancer: a case series.
Neoplasms
Promoter methylation of DNA homologous recombination genes is predictive of the responsiveness to PARP inhibitor treatment in testicular germ cell tumors.
Neoplasms
Prophylactic window therapy with the clinical poly(ADP-ribose) polymerase inhibitor olaparib delays BRCA1-deficient mammary tumour formation in mice.
Neoplasms
Prostate Cancer Transcriptomic Subtypes.
Neoplasms
Protective effect of the poly(ADP-ribose) polymerase inhibitor PJ34 on mitochondrial depolarization-mediated cell death in hepatocellular carcinoma cells involves attenuation of c-Jun N-terminal kinase-2 and protein kinase B/Akt activation.
Neoplasms
Protective Effects of Cilostazol against Transient Focal Cerebral Ischemia and Hemorrhagic Transformation.
Neoplasms
Protective effects of the ethanolic extract of Melia toosendan fruit against colon cancer.
Neoplasms
Protein expression of DNA damage repair proteins dictates response to topoisomerase and PARP inhibitors in triple-negative breast cancer.
Neoplasms
Protein kinase C-eta regulates resistance to UV- and gamma-irradiation-induced apoptosis in glioblastoma cells by preventing caspase-9 activation.
Neoplasms
Protein kinases A and C positively regulate G protein-dependent activation of phosphatidylinositol-specific phospholipase C by tumor necrosis factor-alpha in MC3T3-E1 osteoblasts.
Neoplasms
Proteome-wide Profiling of Clinical PARP Inhibitors Reveals Compound-Specific Secondary Targets.
Neoplasms
Proteomic Analysis of the Downstream Signaling Network of PARP1.
Neoplasms
Proteomic Studies on the Management of High-Grade Serous Ovarian Cancer Patients: A Mini-Review.
Neoplasms
PTEN deficiency sensitizes endometrioid endometrial cancer to compound PARP-PI3K inhibition but not PARP inhibition as monotherapy.
Neoplasms
PTEN Deletion in Prostate Cancer Cells Does Not Associate with Loss of RAD51 Function: Implications for Radiotherapy and Chemotherapy.
Neoplasms
Purification of poly(ADP-ribose) polymerase from Ehrlich ascites tumor cells by chromatography on DNA-agarose.
Neoplasms
Putting poly (ADP-ribose) polymerase and other DNA repair inhibitors into clinical practice.
Neoplasms
Pyrosequencing analysis of BRCA1 methylation level in breast cancer cells.
Neoplasms
Pyruvate kinase M2 regulates homologous recombination-mediated DNA double-strand break repair.
Neoplasms
QSAR study of 2-(1-Propylpiperidin-4-yl)-1H-benzimidazole-4-carboxamide as PARP inhibitors for treatment of cancer.
Neoplasms
Quantification of cellular poly(ADP-ribosyl)ation by stable isotope dilution mass spectrometry reveals tissue- and drug-dependent stress response dynamics.
Neoplasms
Quantification of PARP Activity in Human Tissues: Ex Vivo Assays in Blood Cells and Immunohistochemistry in Human Biopsies.
Neoplasms
Quantitative correlation between cellular proliferation and nuclear poly (ADP-ribose) polymerase (PARP-1).
Neoplasms
Quartz Crystal Microbalance Detection of Poly(ADP-ribose) Polymerase-1 Based on Gold Nanorods Signal Amplification.
Neoplasms
Quercetin-3-O-(2"-galloyl)-?-l-rhamnopyranoside prevents TRAIL-induced apoptosis in human keratinocytes by suppressing the caspase-8- and Bid-pathways and the mitochondrial pathway.
Neoplasms
Racial and tissue-specific cancer risk associated with PARP1 (ADPRT) Val762Ala polymorphism: a meta-analysis.
Neoplasms
Rad51 Degradation: Role in Oncolytic Virus-Poly(ADP-Ribose) Polymerase Inhibitor Combination Therapy in Glioblastoma.
Neoplasms
RAD51 foci as a functional biomarker of homologous recombination repair and PARP inhibitor resistance in germline BRCA-mutated breast cancer.
Neoplasms
RAD51 Mediates Resistance of Cancer Stem Cells to PARP Inhibition in Triple-Negative Breast Cancer.
Neoplasms
RAD51-Mediated DNA Homologous Recombination Is Independent of PTEN Mutational Status.
Neoplasms
RAD51C-deficient cancer cells are highly sensitive to the poly (ADP-ribose) polymerase inhibitor, olaparib.
Neoplasms
RAD51D splice variants and cancer-associated mutations reveal XRCC2 interaction to be critical for homologous recombination.
Neoplasms
RAD52 as a Potential Target for Synthetic Lethality-Based Anticancer Therapies.
Neoplasms
Radiation-induced synthetic lethality: combination of poly(ADP-ribose) polymerase and RAD51 inhibitors to sensitize cells to proton irradiation.
Neoplasms
Radicicol, an inhibitor of Hsp90, enhances TRAIL-induced apoptosis in human epithelial ovarian carcinoma cells by promoting activation of apoptosis-related proteins.
Neoplasms
Radiosensitivity and Induction of Apoptosis by High LET Carbon Ion Beam and Low LET Gamma Radiation: A Comparative Study.
Neoplasms
Radiosensitivity Is an Acquired Vulnerability of PARPi-Resistant BRCA1-Deficient Tumors.
Neoplasms
Radiosensitization by PARP Inhibition in DNA Repair Proficient and Deficient Tumor Cells: Proliferative Recovery in Senescent Cells.
Neoplasms
Radiosensitization by PARP inhibition to proton beam irradiation in cancer cells.
Neoplasms
Radiosensitization by the PARP inhibitor olaparib in BRCA1-proficient and deficient high-grade serous ovarian carcinomas.
Neoplasms
Radiosensitization by the poly(ADP-ribose) polymerase inhibitor 4-amino-1,8-naphthalimide is specific of the S phase of the cell cycle and involves arrest of DNA synthesis.
Neoplasms
Radiosensitization Effect of PARP Inhibition in Cells Exposed to Low and High LET Radiation.
Neoplasms
Radiosensitization effects of nicotinamide on malignant and normal mouse tissue.
Neoplasms
Radiosensitization of human T-cell leukemia by thymidine and 41.8 degrees C hyperthermia in vitro.
Neoplasms
Radiosensitizing Potential of Curcumin in Different Cancer Models.
Neoplasms
Radiosynthesis and Evaluation of Talazoparib and Its Derivatives as PARP-1-Targeting Agents.
Neoplasms
RADX Promotes Genome Stability and Modulates Chemosensitivity by Regulating RAD51 at Replication Forks.
Neoplasms
Randomised phase II trial of olaparib, chemotherapy or olaparib and cediranib in patients with platinum-resistant ovarian cancer (OCTOVA): a study protocol.
Neoplasms
Randomized Trial of Oral Cyclophosphamide and Veliparib in High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers, or BRCA-Mutant Ovarian Cancer.
Neoplasms
Randomized, Double-Blind, Phase II Study of Temozolomide in Combination With Either Veliparib or Placebo in Patients With Relapsed-Sensitive or Refractory Small-Cell Lung Cancer.
Neoplasms
Rapamycin sensitizes cancer cells to growth inhibition by the PARP inhibitor olaparib.
Neoplasms
Rapamycin-resistant PARP1 overexpression is a potential therapeutic target in lymphangioleiomyomatosis (LAM).
Neoplasms
Rapid activation of epithelial-mesenchymal transition drives PARP inhibitor resistance in Brca2-mutant mammary tumours.
Neoplasms
Rapid fine conformational epitope mapping using comprehensive mutagenesis and deep sequencing.
Neoplasms
Rapid Progression of Metastatic Pancreatic Adenocarcinoma During Platinum-Based Therapy in a Patient Harboring a Pathogenic BRCA2 Germline Variant.
Neoplasms
Rapid regulation of telomere length is mediated by poly(ADP-ribose) polymerase-1.
Neoplasms
Rare mutations in XRCC2 increase the risk of breast cancer.
Neoplasms
RAS Synthetic Lethal Screens Revisited: Still Seeking the Elusive Prize?
Neoplasms
Rational combination therapy with PARP and MEK inhibitors capitalizes on therapeutic liabilities in RAS mutant cancers.
Neoplasms
Rational Design and Synthesis of Novel Dual PROTACs for Simultaneous Degradation of EGFR and PARP.
Neoplasms
Rationale for PARP inhibitors in combination therapy with camptothecins or temozolomide based on PARP trapping versus catalytic inhibition.
Neoplasms
RB Regulates DNA Double Strand Break Repair Pathway Choice by Mediating CtIP Dependent End Resection.
Neoplasms
RBR-type E3 ubiquitin ligase RNF144A targets PARP1 for ubiquitin-dependent degradation and regulates PARP inhibitor sensitivity in breast cancer cells.
Neoplasms
Re-evaluating PARP1 inhibitor in cancer.
Neoplasms
Re: Expression of Nuclear Matrix Proteins Binding Matrix Attachment Regions in Prostate Cancer. PARP-1: New Player in Tumor Progression.
Neoplasms
Re: Konrad H. Stopsack. Efficacy of PARP Inhibition in Metastatic Castration-resistant Prostate Cancer is Very Different with Non-BRCA DNA Repair Alterations: Reconstructing Prespecified Endpoints for Cohort B from the Phase 3 PROfound Trial of Olaparib. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2020.09.024.
Neoplasms
Recent advancements in PARP inhibitors-based targeted cancer therapy.
Neoplasms
Recent advances in cancer therapy targeting proteins involved in DNA double-strand break repair.
Neoplasms
Recent Advances in Enhancing the Therapeutic Index of PARP Inhibitors in Breast Cancer.
Neoplasms
Recent development in the discovery of PARP inhibitors as anticancer agents: a patent update (2016-2020).
Neoplasms
Recent Study of Dual HDAC/PARP Inhibitor for the Treatment of Tumor.
Neoplasms
Reciprocal positive selection for weakness - preventing olaparib resistance by inhibiting BRCA2.
Neoplasms
Recombinant IFN-alpha2b treatment activates poly (ADPR) polymerase-1 (PARP-1) in KB cancer cells.
Neoplasms
RecQ helicases and PARP1 team up in maintaining genome integrity.
Neoplasms
RECQ1 Promotes Stress Resistance and DNA Replication Progression Through PARP1 Signaling Pathway in Glioblastoma.
Neoplasms
Recruitment of KMT2C/MLL3 to DNA Damage Sites Mediates DNA Damage Responses and Regulates PARP Inhibitor Sensitivity in Cancer.
Neoplasms
Reduced ADP-ribosylation by PARP1 natural polymorphism V762A and by PARP1 inhibitors enhance Hepatitis B virus replication.
Neoplasms
Reduced PAK1 activity sensitizes FA/BRCA-proficient breast cancer cells to PARP inhibition.
Neoplasms
Reduced proficiency in homologous recombination underlies the high sensitivity of embryonal carcinoma testicular germ cell tumors to Cisplatin and poly (adp-ribose) polymerase inhibition.
Neoplasms
Reduced stability of regularly spliced but not alternatively spliced p53 protein in PARP-deficient mouse fibroblasts.
Neoplasms
Reduced tumor burden through increased oxidative stress in lung adenocarcinoma cells of PARP-1 and PARP-2 knockout mice.
Neoplasms
Reduction of tumor hypoxia and inhibition of DNA repair by nicotinamide after irradiation of SCCVII murine tumors and normal tissues.
Neoplasms
Refinement of high-risk endometrial cancer classification using DNA damage response biomarkers: a TransPORTEC initiative.
Neoplasms
Registered report: Systematic identification of genomic markers of drug sensitivity in cancer cells.
Neoplasms
Regulated necrosis-related molecule mRNA expression in humans and mice and in murine acute tissue injury and systemic autoimmunity leading to progressive organ damage, and progressive fibrosis.
Neoplasms
Regulation of DNA double-strand break repair pathway choice: a new focus on 53BP1.
Neoplasms
Regulation of E2F1-induced apoptosis by poly(ADP-ribosyl)ation.
Neoplasms
Regulation of NF-?B signalling by the mono-ADP-ribosyltransferase ARTD10.
Neoplasms
Regulation of p53 sequence-specific DNA-binding by covalent poly(ADP-ribosyl)ation.
Neoplasms
Regulation of poly(ADP-Ribose) polymerase 1 functions by post-translational modifications.
Neoplasms
Regulation of RAD51 at the Transcriptional and Functional Levels: What Prospects for Cancer Therapy?
Neoplasms
Regulation of the human poly(ADP-ribose) polymerase promoter by the ETS transcription factor.
Neoplasms
Regulatory changes of apoptotic factors in the bovine corpus luteum after induced luteolysis.
Neoplasms
Regulatory roles of tankyrase 1 at telomeres and in DNA repair: suppression of T-SCE and stabilization of DNA-PKcs.
Neoplasms
Relevance of poly (ADP-ribose) polymerase inhibitors in prostate cancer.
Neoplasms
Reorganization of metastamiRs in the evolution of metastatic aggressive neuroblastoma cells.
Neoplasms
Replication fork stability confers chemoresistance in BRCA-deficient cells.
Neoplasms
Replication Stress Drives Constitutive Activation of the DNA Damage Response and Radioresistance in Glioblastoma Stem-like Cells.
Neoplasms
Replication stress response in cancer stem cells as a target for chemotherapy.
Neoplasms
Replication Stress: An Achilles' Heel of Glioma Cancer Stem-like Cells.
Neoplasms
Replication-induced DNA damage after PARP inhibition causes G2 delay, and cell line-dependent apoptosis, necrosis and multinucleation.
Neoplasms
Reply to Johann S. de Bono, Maha Hussain, and Jinyu Kang's Letter to the Editor re: Konrad H. Stopsack. Efficacy of PARP Inhibition in Metastatic Castration-resistant Prostate Cancer is Very Different with Non-BRCA DNA Repair Alterations: Reconstructing Prespecified Endpoints for Cohort B from the Phase 3 PROfound Trial of Olaparib. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2020.09.024.
Neoplasms
Repositioning PARP inhibitors in the treatment of thoracic malignancies.
Neoplasms
Repression of BET activity sensitizes homologous recombination-proficient cancers to PARP inhibition.
Neoplasms
Repurposing of Clinically Approved Poly-(Adp-Ribose) Polymerase Inhibitors For The Therapy of Sepsis.
Neoplasms
Repurposing of mTOR Complex Inhibitors Attenuates MCL-1 and Sensitizes to PARP Inhibition.
Neoplasms
Requirement of down-regulation of NAD+ ADP-ribosyltransferase for the interferon-gamma-induced activation process of murine macrophage tumor cells.
Neoplasms
Rescue of hypoxia-inducible factor-1alpha-deficient tumor growth by wild-type cells is independent of vascular endothelial growth factor.
Neoplasms
Research progress of PARP inhibitor monotherapy and combination therapy for endometrial cancer.
Neoplasms
Research Progress on PARP14 as a Drug Target.
Neoplasms
Research progress on the association between environmental pollutants and the resistance mechanism of PARP inhibitors in ovarian cancer.
Neoplasms
Resistance to PARP inhibitors by SLFN11 inactivation can be overcome by ATR inhibition.
Neoplasms
Resistance to PARP-Inhibitors in Cancer Therapy.
Neoplasms
Resistance to second-generation androgen receptor antagonists in prostate cancer.
Neoplasms
Resistance-modifying agents. 9. Synthesis and biological properties of benzimidazole inhibitors of the DNA repair enzyme poly(ADP-ribose) polymerase.
Neoplasms
Response of Breast Cancer Cells to PARP Inhibitors Is Independent of BRCA Status.
Neoplasms
Response of DNA repair enzymes in murine fibrosarcoma, lymphosarcoma and ascites cells following gamma irradiation.
Neoplasms
Response of germline BRCA2-mutated advanced pancreatic acinar cell carcinoma to olaparib: A case report.
Neoplasms
Response of human prostate cancer cells and tumors to combining PARP inhibition with ionizing radiation.
Neoplasms
Response of subtype-specific human breast cancer-derived cells to poly(ADP-ribose) polymerase and checkpoint kinase 1 inhibition.
Neoplasms
Response prediction biomarkers and drug combinations of PARP inhibitors in prostate cancer.
Neoplasms
Response to olaparib in a PALB2 germline mutated prostate cancer and genetic events associated with resistance.
Neoplasms
Response to olaparib in metastatic castration-resistant prostate cancer with germline BRCA2 mutation: a case report.
Neoplasms
Response to olaparib in metastatic lung adenocarcinoma with germline BRCA2 mutation: a case report.
Neoplasms
Restoration of Temozolomide Sensitivity by PARP Inhibitors in Mismatch Repair Deficient Glioblastoma is Independent of Base Excision Repair.
Neoplasms
Restoration of TET2 Function Blocks Aberrant Self-Renewal and Leukemia Progression.
Neoplasms
Restoration of tissue factor pathway inhibitor-2 in a human glioblastoma cell line triggers caspase-mediated pathway and apoptosis.
Neoplasms
Restored replication fork stabilization, a mechanism of PARP inhibitor resistance, can be overcome by cell cycle checkpoint inhibition.
Neoplasms
Results of a phase II clinical trial of 6-mercaptopurine (6MP) and methotrexate in patients with BRCA-defective tumours.
Neoplasms
Resurrection of PARP Inhibitors in Breast Cancer.
Neoplasms
Resveratrol Induces Premature Senescence in Lung Cancer Cells via ROS-Mediated DNA Damage.
Neoplasms
Resveratrol-induced apoptosis in human breast cancer cells is mediated primarily through the caspase-3-dependent pathway.
Neoplasms
Retrospective screening of microarray data to identify candidate IFN-inducible genes in a HTLV-1 transformed model.
Neoplasms
REV7 counteracts DNA double-strand break resection and affects PARP inhibition.
Neoplasms
Revealing biomarkers associated with PARP inhibitors based on genetic interactions in cancer genome.
Neoplasms
Reversal of acquired cisplatin resistance by nicotinamide in vitro and in vivo.
Neoplasms
Reverse Screening Bioinformatics Approach to Identify Potential Anti Breast Cancer Targets Using Thymoquinone from Neutraceuticals Black Cumin Oil.
Neoplasms
Reverse the Resistance to PARP Inhibitors.
Neoplasms
Reversing oncogenic transformation with iron chelation.
Neoplasms
Reversion Mutations with Clinical Use of PARP Inhibitors: Many Genes, Many Versions.
Neoplasms
Reversion of malignant phenotype by 5-iodo-6-amino-1,2-benzopyrone a non-covalently binding ligand of poly(ADP-ribose) polymerase.
Neoplasms
Review of poly (ADP-ribose) polymerase (PARP) mechanisms of action and rationale for targeting in cancer and other diseases.
Neoplasms
Reviewing the characteristics of BRCA and PALB2-related cancers in the precision medicine era.
Neoplasms
Rewiring of human lung cell lineage and mitotic networks in lung adenocarcinomas.
Neoplasms
Rho/ROCK pathway as a target of tumor therapy.
Neoplasms
RING domain-deficient BRCA1 promotes PARP inhibitor and platinum resistance.
Neoplasms
Risk of fatigue and anemia in patients with advanced cancer treated with olaparib: A meta-analysis of randomized controlled trials.
Neoplasms
Risk of fatigue with PARP inhibitors in cancer patients: a systematic review and meta-analysis of 29 phase II/III randomized controlled trials.
Neoplasms
Risk of pneumonitis in cancer patients treated with PARP inhibitors: A meta-analysis of randomized controlled trials and a pharmacovigilance study of the FAERS database.
Neoplasms
Risk of selected gastrointestinal and hepatic toxicities in cancer patients treated with PARP inhibitors: A systematic review and meta-analysis.
Neoplasms
Risk of severe hematologic toxicities in cancer patients treated with PARP inhibitors: a meta-analysis of randomized controlled trials.
Neoplasms
Risk of severe hematologic toxicities in cancer patients treated with PARP inhibitors: results of monotherapy and combination therapy trials.
Neoplasms
Risk-Associated Long Noncoding RNA FOXD3-AS1 Inhibits Neuroblastoma Progression by Repressing PARP1-Mediated Activation of CTCF.
Neoplasms
RNF168 regulates R-loop resolution and genomic stability in BRCA1/2-deficient tumors.
Neoplasms
RNF8 regulates assembly of RAD51 at DNA double-strand breaks in the absence of BRCA1 and 53BP1.
Neoplasms
Role of Akt Activation in PARP Inhibitor Resistance in Cancer.
Neoplasms
Role of Biomarkers in the Development of PARP Inhibitors.
Neoplasms
Role of BRCA Mutations in Cancer Treatment with Poly(ADP-ribose) Polymerase (PARP) Inhibitors.
Neoplasms
Role of DNA repair machinery and p53 in the testicular germ cell cancer: a review.
Neoplasms
Role of nicotinamide in DNA damage, mutagenesis, and DNA repair.
Neoplasms
Role of PARP Inhibitors in Cancer Biology and Therapy.
Neoplasms
Role of PARP-1 and PARP-2 in the expression of apoptosis-regulating genes in HeLa cells.
Neoplasms
Role of PARP-1 in prostate cancer.
Neoplasms
Role of Parp-1 in suppressing spontaneous deletion mutation in the liver and brain of mice at adolescence and advanced age.
Neoplasms
Role of PARP1 regulation in radiation-induced rescue effect.
Neoplasms
Role of Poly (ADP-Ribose) Polymerase inhibitors beyond BReast CAncer Gene-mutated ovarian tumours: definition of homologous recombination deficiency?
Neoplasms
Role of poly (ADP-ribose) polymerase-1 and cytokines in acute renal injury in elderly Chinese patients with diabetes mellitus.
Neoplasms
Role of poly(ADP-ribose) polymerase (PARP) cleavage in apoptosis. Caspase 3-resistant PARP mutant increases rates of apoptosis in transfected cells.
Neoplasms
Role of poly(ADP-ribose) polymerase 1 (PARP-1) in cardiovascular diseases: the therapeutic potential of PARP inhibitors.
Neoplasms
Role of the ERK pathway for oxidant-induced parthanatos in human lymphocytes.
Neoplasms
Roles of DNA fragmentation factor and poly(ADP-ribose) polymerase in an amplification phase of tumor necrosis factor-induced apoptosis.
Neoplasms
Roles of DNA fragmentation factor and poly(ADP-ribose) polymerase-1 in sensitization of fibroblasts to tumor necrosis factor-induced apoptosis.
Neoplasms
Rosiglitazone enhances the radiosensitivity of p53-mutant HT-29 human colorectal cancer cells.
Neoplasms
Rottlerin suppresses growth of human pancreatic tumors in nude mice, and pancreatic cancer cells isolated from Kras(G12D) mice.
Neoplasms
Rotundarpene attenuates cholesterol oxidation product-induced apoptosis by suppressing the mitochondrial pathway and the caspase-8- and bid-dependent pathways.
Neoplasms
Rotundarpene prevents TRAIL-induced apoptosis in human keratinocytes by suppressing the caspase-8- and Bid-pathways and the mitochondrial pathway.
Neoplasms
Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial.
Neoplasms
Rucaparib Monotherapy in Patients With Pancreatic Cancer and a Known Deleterious BRCA Mutation.
Neoplasms
Rucaparib: First Global Approval.
Neoplasms
Ruxolitinib-induced defects in DNA repair cause sensitivity to PARP inhibitors in myeloproliferative neoplasms.
Neoplasms
Safe and targeted anticancer efficacy of a novel class of antioxidant-conjugated difluorodiarylidenyl piperidones: differential cytotoxicity in healthy and cancer cells.
Neoplasms
Safety and Clinical Activity of the Programmed Death-Ligand 1 Inhibitor Durvalumab in Combination With Poly (ADP-Ribose) Polymerase Inhibitor Olaparib or Vascular Endothelial Growth Factor Receptor 1-3 Inhibitor Cediranib in Women's Cancers: A Dose-Escalation, Phase I Study.
Neoplasms
Safety and dose modification for patients receiving niraparib.
Neoplasms
Safety and tolerability of the olaparib tablet formulation in Japanese patients with advanced solid tumours.
Neoplasms
Safety and tolerability of the poly(ADP-ribose) polymerase (PARP) inhibitor, olaparib (AZD2281) in combination with topotecan for the treatment of patients with advanced solid tumors: a phase I study.
Neoplasms
Safety profile of poly (ADP-ribose) polymerase (PARP) inhibitors in cancer: a network meta-analysis of randomized controlled trials.
Neoplasms
Safety, pharmacokinetics, and preliminary efficacy of the PARP inhibitor talazoparib in Japanese patients with advanced solid tumors: phase 1 study.
Neoplasms
Sapphyrins induce apoptosis in hematopoietic tumor-derived cell lines and show in vivo antitumor activity.
Neoplasms
Sarcophine-diol, a skin cancer chemopreventive agent, inhibits proliferation and stimulates apoptosis in mouse melanoma b(16)f(10) cell line.
Neoplasms
Schlafen-11 expression is associated with immune signatures and basal-like phenotype in breast cancer.
Neoplasms
Searching in mother nature for anti-cancer activity: anti-proliferative and pro-apoptotic effect elicited by green barley on leukemia/lymphoma cells.
Neoplasms
Secondary and tertiary ovarian cancer recurrence: what is the best management?
Neoplasms
Secondary BRCA1 and BRCA2 alterations and acquired chemoresistance.
Neoplasms
Secondary mutations in BRCA2 associated with clinical resistance to a PARP inhibitor.
Neoplasms
Secondary mutations of BRCA1/2 and drug resistance.
Neoplasms
Secretory phospholipase A(2) induces apoptosis through TNF-alpha and cytochrome c-mediated caspase cascade in murine macrophage RAW 264.7 cells.
Neoplasms
Segregation analysis of the BRCA2 c.9227G>T variant in multiple families suggests a pathogenic role in breast and ovarian cancer predisposition.
Neoplasms
Selective inhibition of BRCA2-deficient mammary tumor cell growth by AZD2281 and cisplatin.
Neoplasms
Selective involvement of caspase-3 in ceramide induced apoptosis in AK-5 tumor cells.
Neoplasms
Selective modulation by PARP-1 of HIF-1?-recruitment to chromatin during hypoxia is required for tumor adaptation to hypoxic conditions.
Neoplasms
Selective resistance to the PARP inhibitor olaparib in a mouse model for BRCA1-deficient metaplastic breast cancer.
Neoplasms
Selective Small Molecule Inhibition of Poly(ADP-Ribose) Glycohydrolase (PARG).
Neoplasms
Selective small molecule PARG inhibitor causes replication fork stalling and cancer cell death.
Neoplasms
Selective targeting of breast cancer cells through ROS-mediated mechanisms potentiates the lethality of paclitaxel by a novel diterpene, gelomulide K.
Neoplasms
Selective targeting of PARP-2 inhibits androgen receptor signaling and prostate cancer growth through disruption of FOXA1 function.
Neoplasms
Selenadiazole derivatives inhibit angiogenesis-mediated human breast tumor growth through suppressing VEGFR2-mediated ERK and AKT signaling pathway.
Neoplasms
Selenium effects on prostate cell growth.
Neoplasms
Sensitivity to inhibition of DNA repair by Olaparib in novel oropharyngeal cancer cell lines infected with Human Papillomavirus.
Neoplasms
Sensitivity to poly(ADP-ribose) polymerase (PARP) inhibition identifies ubiquitin-specific peptidase 11 (USP11) as a regulator of DNA double-strand break repair.
Neoplasms
Sensitization by glycerol for CDDP-therapy against human cultured cancer cells and tumors bearing mutated p53 gene.
Neoplasms
Sensitization of cancer cells through reduction of total Akt and downregulation of salinomycin-induced pAkt, pGSk3?, pTSC2, and p4EBP1 by cotreatment with MK-2206.
Neoplasms
Sensitization of Cancer Cells to Radiation and Topoisomerase I Inhibitor Camptothecin Using Inhibitors of PARP and Other Signaling Molecules.
Neoplasms
Sensitization to radiation and alkylating agents by inhibitors of poly(ADP-ribose) polymerase is enhanced in cells deficient in DNA double-strand break repair.
Neoplasms
Sensitizing effects of an organovanadium compound during adjuvant therapy with cyclophosphamide in a murine tumor model.
Neoplasms
Sensitizing Ewing sarcoma to chemo- and radiotherapy by inhibition of the DNA-repair enzymes DNA protein kinase (DNA-PK) and poly-ADP-ribose polymerase (PARP) 1/2.
Neoplasms
Sensitizing HR-proficient cancers to PARP inhibitors.
Neoplasms
Sequences and combinations of multifaceted therapy in advanced prostate cancer.
Neoplasms
Sequential Inhibition of PARP and WEE1 Minimizes Toxicity.
Neoplasms
Sequential Therapy with PARP and WEE1 Inhibitors Minimizes Toxicity while Maintaining Efficacy.
Neoplasms
Serine-linked PARP1 auto-modification controls PARP inhibitor response.
Neoplasms
ShallowHRD: detection of homologous recombination deficiency from shallow whole genome sequencing.
Neoplasms
Shaping the BRCAness mutational landscape by alternative double-strand break repair, replication stress and mitotic aberrancies.
Neoplasms
Shieldin complex promotes DNA end-joining and counters homologous recombination in BRCA1-null cells.
Neoplasms
Shogaols at proapoptotic concentrations induce G(2)/M arrest and aberrant mitotic cell death associated with tubulin aggregation.
Neoplasms
Shrimp shells extracted chitin in silver nanoparticle synthesis: Expanding its prophecy towards anticancer activity in human hepatocellular carcinoma HepG2 cells.
Neoplasms
ShRNA-mediated silencing of Gli2 gene inhibits proliferation and sensitizes human hepatocellular carcinoma cells towards TRAIL-induced apoptosis.
Neoplasms
Sialic acid surface decoration enhances cellular uptake and apoptosis-inducing activity of selenium nanoparticles.
Neoplasms
Sigma-2 ligands and PARP inhibitors synergistically trigger cell death in breast cancer cells.
Neoplasms
Silencing of CHFR Sensitizes Gastric Carcinoma to PARP Inhibitor Treatment.
Neoplasms
Silencing of HSulf-2 expression in MCF10DICS.com cells attenuate ductal carcinoma in situ progression to invasive ductal carcinoma in vivo.
Neoplasms
Similar response rates and survival with PARP inhibitors for patients with solid tumors harboring somatic versus Germline BRCA mutations: a Meta-analysis and systematic review.
Neoplasms
Simultaneous delivery of olaparib and carboplatin in PEGylated liposomes imparts this drug combination hypersensitivity and selectivity for breast tumor cells.
Neoplasms
Simultaneous detection of BRCA mutations and large genomic rearrangements in germline DNA and FFPE tumor samples.
Neoplasms
Simultaneous measurement of perillyl alcohol and its metabolite perillic acid in plasma and lung after inhalational administration in Wistar rats.
Neoplasms
Simultaneous Targeting of PARP1 and RAD52 Triggers Dual Synthetic Lethality in BRCA-Deficient Tumor Cells.
Neoplasms
Single cell resolution in vivo imaging of DNA damage following PARP inhibition.
Neoplasms
Single-cell and subcellular pharmacokinetic imaging allows insight into drug action in vivo.
Neoplasms
Single-particle analysis of full-length human poly(ADP-ribose) polymerase 1.
Neoplasms
Single-Particle Assay of Poly(ADP-ribose) Polymerase-1 Activity with Dark-Field Optical Microscopy.
Neoplasms
Sirtuins are Unaffected by PARP Inhibitors Containing Planar Nicotinamide Bioisosteres.
Neoplasms
Sirtuins in dermatology: applications for future research and therapeutics.
Neoplasms
Slug promotes survival during metastasis through suppression of Puma-mediated apoptosis.
Neoplasms
Small molecule inhibitors uncover synthetic genetic interactions of human flap endonuclease 1 (FEN1) with DNA damage response genes.
Neoplasms
Small Molecule Microarray Based Discovery of PARP14 Inhibitors.
Neoplasms
Small PARP inhibitor PJ-34 induces cell cycle arrest and apoptosis of adult T-cell leukemia cells.
Neoplasms
Small-Molecule Inhibitors of PARPs: From Tools for Investigating ADP-Ribosylation to Therapeutics.
Neoplasms
SMURF2-mediated ubiquitin signaling plays an essential role in the regulation of PARP1 PARylating activity, molecular interactions, and functions in mammalian cells.
Neoplasms
Soft tissue sarcomas: new opportunity of treatment with PARP inhibitors?
Neoplasms
Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition.
Neoplasms
Somatic mRNA Analysis of BRCA1 Splice Variants Provides a Direct Theranostic Impact on PARP Inhibitors.
Neoplasms
Somatic mutation of the cohesin complex subunit confers therapeutic vulnerabilities in cancer.
Neoplasms
Somatic mutations in the BRCA1 gene in Chinese women with sporadic breast cancer.
Neoplasms
Sonodynamic treatment as an innovative bimodal anticancer approach: shock wave-mediated tumor growth inhibition in a syngeneic breast cancer model.
Neoplasms
SP600125 overcomes antimitotic drug-resistance in cancer cells by increasing apoptosis with independence of P-gp inhibition.
Neoplasms
Specific cleavage of alpha-fodrin during Fas- and tumor necrosis factor-induced apoptosis is mediated by an interleukin-1beta-converting enzyme/Ced-3 protease distinct from the poly(ADP-ribose) polymerase protease.
Neoplasms
Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase.
Neoplasms
Specific killing of DNA damage-response deficient cells with inhibitors of poly(ADP-ribose) glycohydrolase.
Neoplasms
Spirooxindole derivative SOID-8 induces apoptosis associated with inhibition of JAK2/STAT3 signaling in melanoma cells.
Neoplasms
Stable depletion of poly (ADP-ribose) polymerase-1 reduces in vivo melanoma growth and increases chemosensitivity.
Neoplasms
STAT3 imparts BRCAness by impairing homologous recombination repair in Epstein-Barr virus-transformed B lymphocytes.
Neoplasms
State-of-the-art strategies for targeting the DNA damage response in cancer.
Neoplasms
Stepwise development of structure-activity relationship of diverse PARP-1 inhibitors through comparative and validated in silico modeling techniques and molecular dynamics simulation.
Neoplasms
Stereoisomers of Astaxanthin Inhibit Human Colon Cancer Cell Growth by Inducing G2/M Cell Cycle Arrest and Apoptosis.
Neoplasms
Stereospecific PARP trapping by BMN 673 and comparison with olaparib and rucaparib.
Neoplasms
Strategic Combination of DNA-Damaging Agent and PARP Inhibitor Results in Enhanced Cytotoxicity.
Neoplasms
Strategies for H-score normalization of preanalytical technical variables with potential utility to immunohistochemical-based biomarker quantitation in therapeutic reponse diagnostics.
Neoplasms
Strategies towards more effective anticancer therapies: targeting DNA damage response pathways.
Neoplasms
Strigolactone analogues induce apoptosis through activation of p38 and the stress response pathway in cancer cell lines and in conditionally reprogrammed primary prostate cancer cells.
Neoplasms
Stromal cell protection of B-lineage acute lymphoblastic leukemic cells during chemotherapy requires active Akt.
Neoplasms
Structural basis for allosteric PARP-1 retention on DNA breaks.
Neoplasms
Structural basis for inhibitor specificity in human poly(ADP-ribose) polymerase-3.
Neoplasms
Structural Basis of Detection and Signaling of DNA Single-Strand Breaks by Human PARP-1.
Neoplasms
Structural Implications for Selective Targeting of PARPs.
Neoplasms
Structural requirements of some 2-(1-propylpiperidin-4-yl)-1H-benzimidazole-4-carboxamide derivatives as poly (ADP-ribose) polymerase (PARP) for the treatment of cancer: QSAR approach.
Neoplasms
Structural Requirements of Some 2-(1-Propylpiperidin-4-yl)-1H-benzimidazole-4-carboxamide Derivatives as Poly (ADP-Ribose) Polymerase (PARP) for the Treatment of Cancer: QSAR Approach.
Neoplasms
Structurally related antitumor effects of flavanones in vitro and in vivo: involvement of caspase 3 activation, p21 gene expression, and reactive oxygen species production.
Neoplasms
Structure based pharmacophore study to identify possible natural selective PARP-1 trapper as anti-cancer agent.
Neoplasms
Structure elucidation and biological activity of two new trichothecenes from an endophyte, Myrothecium roridum.
Neoplasms
Structure of a (3+1) hybrid G-quadruplex in the PARP1 promoter.
Neoplasms
Structure, Dynamics, and Functionality of Tankyrase Inhibitor-Induced Degradasomes.
Neoplasms
Structure-Based Pharmacophore Modeling, Virtual Screening, Molecular Docking and Biological Evaluation for Identification of Potential Poly (ADP-Ribose) Polymerase-1 (PARP-1) Inhibitors.
Neoplasms
Structure-Guided Design and In-Cell Target Profiling of a Cell-Active Target Engagement Probe for PARP Inhibitors.
Neoplasms
Studying PAR-Dependent Chromatin Remodeling to Tackle PARPi Resistance.
Neoplasms
Studying Therapy Response and Resistance in Mouse Models for BRCA1-Deficient Breast Cancer.
Neoplasms
Stumbling blocks on the path to personalized medicine in breast cancer: the case of PARP inhibitors for BRCA1/2-associated cancers.
Neoplasms
Su Yang Decoction induces human colon carcinoma cell apoptosis by activating caspases.
Neoplasms
Suberoylanilide hydroxamic acid (SAHA) enhances olaparib activity by targeting homologous recombination DNA repair in ovarian cancer.
Neoplasms
Successes and Challenges of PARP Inhibitors in Cancer Therapy.
Neoplasms
Sulforaphane: a naturally occurring mammary carcinoma mitotic inhibitor, which disrupts tubulin polymerization.
Neoplasms
Sulfur and nitrogen mustards induce characteristic poly(ADP-ribosyl)ation responses in HaCaT keratinocytes with distinctive cellular consequences.
Neoplasms
Sulfur [18F]Fluoride Exchange Click Chemistry Enabled Ultrafast Late-Stage Radiosynthesis.
Neoplasms
Suppression of Homologous Recombination by insulin-like growth factor-1 inhibition sensitizes cancer cells to PARP inhibitors.
Neoplasms
Suppression of NF-kappa B survival signaling by nitrosylcobalamin sensitizes neoplasms to the anti-tumor effects of Apo2L/TRAIL.
Neoplasms
Suppression of proliferation and migration in highly-metastatic lung cancer cells as well as tumor growth by a new synthesized compound TBrC and its molecular mechanisms of action.
Neoplasms
Suppression of tumor growth using a recombinant adenoviral vector carrying the dominant-negative mutant gene Survivin-D53A in a nude mice model.
Neoplasms
Survival and proliferation of cells expressing caspase-uncleavable Poly(ADP-ribose) polymerase in response to death-inducing DNA damage by an alkylating agent.
Neoplasms
Survivin contributes to DNA repair by homologous recombination in breast cancer cells.
Neoplasms
Sustained Complete Response to Cytotoxic Therapy and the PARP Inhibitor Veliparib in Metastatic Castration-Resistant Prostate Cancer - A Case Report.
Neoplasms
Sustained Release Talazoparib Implants for Localized Treatment of
Neoplasms
Sustained, local delivery of the PARP inhibitor talazoparib prevents the development of mammary gland hyperplasia in Brca1-deficient mice.
Neoplasms
Syncytiotrophoblastic giant cells in teratocarcinoma-like tumors derived from Parp-disrupted mouse embryonic stem cells.
Neoplasms
Synergetic Effects of PARP Inhibitor AZD2281 and Cisplatin in Oral Squamous Cell Carcinoma in Vitro and in Vivo.
Neoplasms
Synergism between ATM and PARP1 Inhibition Involves DNA Damage and Abrogating the G2 DNA Damage Checkpoint.
Neoplasms
Synergism of PARP inhibitor fluzoparib (HS10160) and MET inhibitor HS10241 in breast and ovarian cancer cells.
Neoplasms
Synergistic Activity of PARP Inhibition by Talazoparib (BMN 673) with Temozolomide in Pediatric Cancer Models in the Pediatric Preclinical Testing Program.
Neoplasms
Synergistic Anti-Tumour Effect of Syk Inhibitor and Olaparib in Squamous Cell Carcinoma: Roles of Syk in EGFR Signalling and PARP1 Activation.
Neoplasms
Synergistic anticancer action of reversibly and irreversibly acting ligands of poly (ADP-ribose) polymerase.
Neoplasms
Synergistic anticancer effects of combined ?-tocotrienol and oridonin treatment is associated with the induction of autophagy.
Neoplasms
Synergistic chemosensitivity of triple-negative breast cancer cell lines to poly(ADP-Ribose) polymerase inhibition, gemcitabine, and cisplatin.
Neoplasms
Synergistic Cytotoxic Effect of Busulfan and the PARP Inhibitor Veliparib in Myeloproliferative Neoplasms.
Neoplasms
Synergistic effect of arginine-specific ADP-ribosyltransferase 1 and poly(ADP-ribose) polymerase-1 on apoptosis induced by cisplatin in CT26 cells.
Neoplasms
Synergistic Effects of Olaparib and DNA-damaging Agents in Oesophageal Squamous Cell Carcinoma Cell Lines.
Neoplasms
Synergistic effects of type I PRMT and PARP inhibitors against non-small cell lung cancer cells.
Neoplasms
Synergistic induction of apoptosis by combination treatment with mesupron and auranofin in human breast cancer cells.
Neoplasms
Synergistic inhibition of hepatocellular carcinoma growth by cotargeting chromatin modifying enzymes and poly (ADP-ribose) polymerases.
Neoplasms
Synergistic lethality between PARP-trapping and alantolactone-induced oxidative DNA damage in homologous recombination-proficient cancer cells.
Neoplasms
Synergistic loss of prostate cancer cell viability by coinhibition of HDAC and PARP.
Neoplasms
Synergistic role of Ku80 and poly(ADP-ribose) polymerase in suppressing chromosomal aberrations and liver cancer formation.
Neoplasms
Synergistic targeting of BRCA1 mutated breast cancers with PARP and CDK2 inhibition.
Neoplasms
Synergistic tumor suppression by adenovirus-mediated inhibitor of growth 4 and interleukin-24 gene cotransfer in hepatocarcinoma cells.
Neoplasms
Synthesis and anticancer activities of a novel class of mono- and di-metallic Pt(II)(salicylaldiminato)(DMSO or Picolino)Cl complexes.
Neoplasms
Synthesis and antiproliferative evaluation of certain indeno[1,2-c]quinoline derivatives. Part 2.
Neoplasms
Synthesis and biological evaluation of substituted 2-phenyl-2H-indazole-7-carboxamides as potent poly(ADP-ribose) polymerase (PARP) inhibitors.
Neoplasms
Synthesis and Cytotoxicity Studies of Bioactive Benzofurans from Lavandula agustifolia and Modified Synthesis of Ailanthoidol, Homoegonol, and Egonol.
Neoplasms
Synthesis and Evaluation of a Mitochondria-Targeting Poly(ADP-ribose) Polymerase-1 Inhibitor.
Neoplasms
Synthesis and evaluation of a new generation of orally efficacious benzimidazole-based poly(ADP-ribose) polymerase-1 (PARP-1) inhibitors as anticancer agents.
Neoplasms
Synthesis and Evaluation of a Radioiodinated Tracer with Specificity for Poly(ADP-ribose) Polymerase-1 (PARP-1) in Vivo.
Neoplasms
Synthesis and SAR of novel, potent and orally bioavailable benzimidazole inhibitors of poly(ADP-ribose) polymerase (PARP) with a quaternary methylene-amino substituent.
Neoplasms
Synthesis of coumarin analogs appended with quinoline and thiazole moiety and their apoptogenic role against murine ascitic carcinoma.
Neoplasms
Synthesis of disaccharide nucleoside analogues as potential poly(ADP-ribose) polymerase-1 inhibitors.
Neoplasms
Synthesis of novel dual target inhibitors of PARP and HSP90 and their antitumor activities.
Neoplasms
Synthesis, Bacteriostatic and Anticancer Activity of Novel Phenanthridines Structurally Similar to Benzo[c]phenanthridine Alkaloids.
Neoplasms
Synthesis, chemical characterization, PARP inhibition, DNA binding and cellular uptake of novel ruthenium(II)-arene complexes bearing benzamide derivatives in human breast cancer cells.
Neoplasms
Synthesis, Cytotoxicity, and Mechanistic Investigation of Platinum(IV) Anticancer Complexes Conjugated with Poly(ADP-ribose) Polymerase Inhibitors.
Neoplasms
Synthesis, preliminarily biological evaluation and molecular docking study of new Olaparib analogues as multifunctional PARP-1 and cholinesterase inhibitors.
Neoplasms
Synthesis, [¹?F] radiolabeling, and evaluation of poly (ADP-ribose) polymerase-1 (PARP-1) inhibitors for in vivo imaging of PARP-1 using positron emission tomography.
Neoplasms
Synthetic 1,4-anthracenedione analogs induce cytochrome c release, caspase-9, -3, and -8 activities, poly(ADP-ribose) polymerase-1 cleavage and internucleosomal DNA fragmentation in HL-60 cells by a mechanism which involves caspase-2 activation but not Fas signaling.
Neoplasms
Synthetic lethal genetic interactions between Rad54 and PARP-1 in mouse development and oncogenesis.
Neoplasms
Synthetic lethal interactions for the development of cancer therapeutics: biological and methodological advancements.
Neoplasms
Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors.
Neoplasms
Synthetic lethal targeting of RNF20 through PARP1 silencing and inhibition.
Neoplasms
Synthetic lethal targeting of TET2-mutant hematopoietic stem and progenitor cells (HSPCs) with TOP1-targeted drugs and PARP1 inhibitors.
Neoplasms
Synthetic lethal therapies for cancer: what's next after PARP inhibitors?
Neoplasms
Synthetic Lethality - Its Current Application and Potential in Oncological Treatment.
Neoplasms
Synthetic lethality and cancer therapy: lessons learned from the development of PARP inhibitors.
Neoplasms
Synthetic lethality and cancer: cohesin and PARP at the replication fork.
Neoplasms
Synthetic lethality between androgen receptor signalling and the PARP pathway in prostate cancer.
Neoplasms
Synthetic Lethality in Ovarian Cancer.
Neoplasms
Synthetic Lethality of Cohesins with PARPs and Replication Fork Mediators.
Neoplasms
Synthetic lethality of PARP and NAMPT inhibition in triple-negative breast cancer cells.
Neoplasms
Synthetic Lethality of PARP Inhibition and Ionizing Radiation is p53-dependent.
Neoplasms
Synthetic lethality of PARP inhibition in BRCA-network disrupted tumor cells is associated with interferon pathway activation and enhanced by interferon-?
Neoplasms
Synthetic lethality of PARP inhibition in cancers lacking BRCA1 and BRCA2 mutations.
Neoplasms
Synthetic lethality: exploiting the addiction of cancer to DNA repair.
Neoplasms
Synthetic triterpenoids inhibit growth, induce apoptosis and suppress pro-survival Akt, mTOR and NF-{kappa}B signaling proteins in colorectal cancer cells.
Neoplasms
Systematic Characterization of Recurrent Genomic Alterations in Cyclin-Dependent Kinases Reveals Potential Therapeutic Strategies for Cancer Treatment.
Neoplasms
Systematic inhibitor selectivity between PARP1 and PARP2 enzymes: Molecular implications for ovarian cancer personalized therapy.
Neoplasms
Systemic administration of GPI 15427, a novel poly(ADP-ribose) polymerase-1 inhibitor, increases the antitumor activity of temozolomide against intracranial melanoma, glioma, lymphoma.
Neoplasms
Systemic delivery of axitinib with nanohybrid liposomal nanoparticles inhibits hypoxic tumor growth.
Neoplasms
Systemic DNA damage response and metabolic syndrome as a premalignant state.
Neoplasms
Systemic therapy options in BRCA mutation-associated breast cancer.
Neoplasms
Systems analysis of dynamic transcription factor activity identifies targets for treatment in olaparib resistant cancer cells.
Neoplasms
Systems approach to rational combination therapy: PARP inhibitors.
Neoplasms
SYUNZ-16, a newly synthesized alkannin derivative, induces tumor cells apoptosis and suppresses tumor growth through inhibition of PKB/AKT kinase activity and blockade of AKT/FOXO signal pathway.
Neoplasms
Talazoparib Is a Potent Radiosensitizer in Small Cell Lung Cancer Cell Lines and Xenografts.
Neoplasms
Talazoparib monotherapy in metastatic castration-resistant prostate cancer with DNA repair alterations (TALAPRO-1): an open-label, phase 2 trial.
Neoplasms
Tankyrase as a Novel Molecular Target in Cancer and Fibrotic Diseases.
Neoplasms
Tankyrase inhibition augments neuronal insulin sensitivity and glucose uptake via AMPK-AS160 mediated pathway.
Neoplasms
Tankyrase Requires SAM Domain-Dependent Polymerization to Support Wnt-?-Catenin Signaling.
Neoplasms
Tankyrase-1 mRNA expression in bladder cancer and paired urine sediment: preliminary experience.
Neoplasms
Tankyrases as modulators of pro-tumoral functions: molecular insights and therapeutic opportunities.
Neoplasms
Tanshinone I and simvastatin inhibit melanoma tumour cell growth by regulating poly (ADP ribose) polymerase 1 expression.
Neoplasms
Targeted brain tumor radiotherapy using an Auger emitter.
Neoplasms
Targeted Degradation of PARP14 Using a Heterobifunctional Small Molecule.
Neoplasms
Targeted molecular therapies for ovarian cancer: an update and future perspectives (Review).
Neoplasms
Targeted radiosensitization of ETS fusion-positive prostate cancer through PARP1 inhibition.
Neoplasms
Targeted therapies in epithelial ovarian cancer: Molecular mechanisms of action.
Neoplasms
Targeted therapies in gynaecological cancers.
Neoplasms
Targeted therapies in gynecological cancers: a comprehensive review of clinical evidence.
Neoplasms
Targeted Therapy and Immune Therapy for Small Cell Lung Cancer.
Neoplasms
Targeted Therapy for Brain Tumours: Role of PARP Inhibitors.
Neoplasms
Targeted Therapy for Breast Cancer Prevention.
Neoplasms
Targeted therapy for breast cancer.
Neoplasms
Targeted therapy for cancer using PARP inhibitors.
Neoplasms
Targeted therapy for gynecologic cancers: Toward the era of precision medicine.
Neoplasms
Targeted therapy for ovarian cancer: the rapidly evolving landscape of PARP inhibitor use.
Neoplasms
Targeting ATR in cancer medicine.
Neoplasms
Targeting autophagy potentiates the anti-tumor effect of PARP inhibitor in pediatric chronic myeloid leukemia.
Neoplasms
Targeting autophagy reverses de novo resistance in homologous recombination repair proficient breast cancers to PARP inhibition.
Neoplasms
Targeting BRCA1 and BRCA2 Deficiencies with G-Quadruplex-Interacting Compounds.
Neoplasms
Targeting BRCA1 localization to augment breast tumor sensitivity to poly(ADP-ribose) polymerase inhibition.
Neoplasms
Targeting cervical cancer: Is there a role for poly (ADP-ribose) polymerase inhibition?
Neoplasms
Targeting Cyclin-Dependent Kinases for Treatment of Gynecologic Cancers.
Neoplasms
Targeting dePARylation for cancer therapy.
Neoplasms
Targeting dePARylation selectively suppresses DNA repair-defective and PARP inhibitor-resistant malignancies.
Neoplasms
Targeting Different Pathways Using Novel Combination Therapy in Triple Negative Breast Cancer.
Neoplasms
Targeting DNA Damage Repair Pathways in Pancreatic Adenocarcinoma.
Neoplasms
Targeting DNA damage response in cancer therapy.
Neoplasms
Targeting DNA damage response in head and neck cancers through abrogation of cell cycle checkpoints.
Neoplasms
Targeting DNA repair in breast cancer: A clinical and translational update.
Neoplasms
Targeting DNA Repair in Cancer: Beyond PARP Inhibitors.
Neoplasms
Targeting DNA repair to drive immune responses: it's time to reconsider the strategy for clinical translation.
Neoplasms
Targeting DNA repair with combination veliparib (ABT-888) and temozolomide in patients with metastatic castration-resistant prostate cancer.
Neoplasms
Targeting DNA repair, DNA metabolism and replication stress as anti-cancer strategies.
Neoplasms
Targeting DNA Repair: The Role of PARP Inhibition in the Treatment of Castration-Resistant Prostate Cancer.
Neoplasms
Targeting epidermal growth factor receptor/human epidermal growth factor receptor 2 signalling pathway by a dual receptor tyrosine kinase inhibitor afatinib for radiosensitisation in murine bladder carcinoma.
Neoplasms
Targeting Gi/o protein-coupled receptor signaling blocks HER2-induced breast cancer development and enhances HER2-targeted therapy.
Neoplasms
Targeting IDH1/2 mutant cancers with combinations of ATR and PARP inhibitors.
Neoplasms
Targeting immunosuppressive macrophages overcomes PARP inhibitor resistance in BRCA1-associated triple-negative breast cancer.
Neoplasms
Targeting MKK3 as a novel anticancer strategy: molecular mechanisms and therapeutical implications.
Neoplasms
Targeting Nrf2 in healthy and malignant ovarian epithelial cells: Protection versus promotion.
Neoplasms
Targeting OGG1 arrests cancer cell proliferation by inducing replication stress.
Neoplasms
Targeting PARP in Prostate Cancer: Novelty, Pitfalls, and Promise.
Neoplasms
Targeting PARP-1 allosteric regulation offers therapeutic potential against cancer.
Neoplasms
Targeting PARP-1 with metronomic therapy modulates MDSC suppressive function and enhances anti-PD-1 immunotherapy in colon cancer.
Neoplasms
Targeting PARP1 in XRCC1 deficient sporadic invasive breast cancer or pre-invasive ductal carcinoma in situ induces synthetic lethality and chemoprevention.
Neoplasms
Targeting poly (ADP) ribose polymerase I (PARP-1) and PARP-1 interacting proteins for cancer treatment.
Neoplasms
Targeting poly(ADP-ribose) polymerase activity for cancer therapy.
Neoplasms
Targeting poly(ADP-ribose) polymerase-1 as a promising approach for immunomodulation in multiple sclerosis?
Neoplasms
Targeting Poly(ADP-Ribose) Polymerase: A Two-Armed Strategy for Cancer Therapy.
Neoplasms
Targeting poly(ADP-ribosyl)ation: a promising approach in cancer therapy.
Neoplasms
Targeting progastrin enhances radiosensitization of colorectal cancer cells.
Neoplasms
Targeting Replicative Stress and DNA Repair by Combining PARP and Wee1 Kinase Inhibitors Is Synergistic in Triple Negative Breast Cancers with Cyclin E or BRCA1 Alteration.
Neoplasms
Targeting SMYD3 to Sensitize Homologous Recombination-Proficient Tumors to PARP-Mediated Synthetic Lethality.
Neoplasms
Targeting the ATR/CHK1 axis with PARP inhibition results in tumor regression in BRCA mutant ovarian cancer models.
Neoplasms
Targeting the BRCA1/2 tumor suppressors.
Neoplasms
Targeting the DNA Damage Response in Cancer.
Neoplasms
Targeting the DNA damage response in oncology: past, present and future perspectives.
Neoplasms
Targeting the nucleotide salvage factor DNPH1 sensitizes BRCA-deficient cells to PARP inhibitors.
Neoplasms
Targeting triple negative breast cancer: Is p53 the answer?
Neoplasms
Targets for Therapy of Bladder Cancer.
Neoplasms
Taurolidine: cytotoxic and mechanistic evaluation of a novel antineoplastic agent.
Neoplasms
TCDD-inducible poly(ADP-ribose) polymerase: a novel response to 2,3,7,8-tetrachlorodibenzo-p-dioxin.
Neoplasms
TCDD-Inducible Poly-ADP-Ribose Polymerase (TIPARP), A Novel Therapeutic Target Of Breast Cancer.
Neoplasms
TDP1 deficiency sensitizes human cells to base damage via distinct topoisomerase I and PARP mechanisms with potential applications for cancer therapy.
Neoplasms
TDP1 is critical for the repair of DNA breaks induced by sapacitabine, a nucleoside also targeting ATM- and BRCA-deficient tumors.
Neoplasms
Telomerase and poly(ADP-ribose) polymerase-1 activity sensing based on the high fluorescence selectivity and sensitivity of TOTO-1 towards G bases in single-stranded DNA and poly(ADP-ribose).
Neoplasms
Telomere instability in papillary bladder urothelial carcinomas: Comparison with grading and risk of recurrence.
Neoplasms
Temozolomide pharmacodynamics in patients with metastatic melanoma: dna damage and activity of repair enzymes O6-alkylguanine alkyltransferase and poly(ADP-ribose) polymerase-1.
Neoplasms
Tephrosin induces apoptosis of human pancreatic cancer cells through the generation of reactive oxygen species.
Neoplasms
Tephrosin-induced autophagic cell death in A549 non-small cell lung cancer cells.
Neoplasms
TERT regulates cell survival independent of telomerase enzymatic activity.
Neoplasms
TGF? induces "BRCAness" and sensitivity to PARP inhibition in breast cancer by regulating DNA-repair genes.
Neoplasms
TGF?R-SMAD3 Signaling Induces Resistance to PARP Inhibitors in the Bone Marrow Microenvironment.
Neoplasms
The Anti-Proliferative Activity of the Hybrid TMS-TMF-4f Compound Against Human Cervical Cancer Involves Apoptosis Mediated by STAT3 Inactivation.
Neoplasms
The antitumorigenic roles of BRCA1-BARD1 in DNA repair and replication.
Neoplasms
The ATM-Chk2 and ATR-Chk1 Pathways in DNA Damage Signaling and Cancer.
Neoplasms
The Au clusters induce tumor cell apoptosis via specifically targeting thioredoxin reductase 1 (TrxR1) and suppressing its activity.
Neoplasms
The BET inhibitor JQ1 attenuates double-strand break repair and sensitizes models of pancreatic ductal adenocarcinoma to PARP inhibitors.
Neoplasms
The bisphosphonate zoledronic acid has antimyeloma activity in vivo by inhibition of protein prenylation.
Neoplasms
The BRCA1ness signature is associated significantly with response to PARP inhibitor treatment versus control in the I-SPY 2 randomized neoadjuvant setting.
Neoplasms
The cancer-testis gene, MEIOB, sensitizes triple-negative breast cancer to PARP1 inhibitors by inducing homologous recombination deficiency.
Neoplasms
The CDK1 inhibitor RO3306 improves the response of BRCA-pro?cient breast cancer cells to PARP inhibition.
Neoplasms
The chromatin remodeler ALC1 underlies resistance to PARP inhibitor treatment.
Neoplasms
The clinical development of inhibitors of poly(ADP-ribose) polymerase.
Neoplasms
The clinical value of aberrant epigenetic changes of DNA damage repair genes in human cancer.
Neoplasms
The clinically active PARP inhibitor AG014699 ameliorates cardiotoxicity but does not enhance the efficacy of doxorubicin, despite improving tumor perfusion and radiation response in mice.
Neoplasms
The clinically used PARP inhibitor olaparib improves organ function, suppresses inflammatory responses and accelerates wound healing in a murine model of third-degree burn injury.
Neoplasms
The combination of A-966492 and Topotecan for effective radiosensitization on glioblastoma spheroids.
Neoplasms
The combination of BET and PARP inhibitors is synergistic in models of cholangiocarcinoma.
Neoplasms
The Combination of the PARP Inhibitor Olaparib and the WEE1 Inhibitor AZD1775 as a New Therapeutic Option for Small Cell Lung Cancer.
Neoplasms
The combination of the PARP inhibitor rucaparib and 5FU is an effective strategy for treating acute leukemias.
Neoplasms
The Controversial Roles of ADP-Ribosyl Hydrolases MACROD1, MACROD2 and TARG1 in Carcinogenesis.
Neoplasms
The Correlation Between PARP1 and BRCA1 in AR Positive Triple-negative Breast Cancer.
Neoplasms
The critical role of autophagy in cadmium-induced immunosuppression regulated by endoplasmic reticulum stress-mediated calpain activation in RAW264.7 mouse monocytes.
Neoplasms
The CST Complex Mediates End Protection at Double-Strand Breaks and Promotes PARP Inhibitor Sensitivity in BRCA1-Deficient Cells.
Neoplasms
The current landscape of molecular profiling in the treatment of epithelial ovarian cancer.
Neoplasms
The current status of PARP inhibitors in ovarian cancer.
Neoplasms
The Cytotoxic and Apoptotic Effects of the Brown Algae Colpomenia sinuosa are Mediated by the Generation of Reactive Oxygen Species.
Neoplasms
The deubiquitylating enzyme USP15 regulates homologous recombination repair and cancer cell response to PARP inhibitors.
Neoplasms
The development of PARP as a successful target for cancer therapy.
Neoplasms
The diverse roles and clinical relevance of PARPs in DNA damage repair: current state of the art.
Neoplasms
The DNA damage response (DDR) is induced by the C9orf72 repeat expansion in amyotrophic lateral sclerosis.
Neoplasms
The DNA damaging revolution.
Neoplasms
The DNA Damaging Revolution: PARP Inhibitors and Beyond.
Neoplasms
The early immunological response to acute ischemic stroke: Differential gene expression in subpopulations of mononuclear cells.
Neoplasms
The Effect of Poly(ADP-ribose) Polymerase-1 Gene 3'Untranslated Region Polymorphism in Colorectal Cancer Risk among Saudi Cohort.
Neoplasms
The effect of the nitroxide pirolin on oxidative stress induced by doxorubicin and taxanes in the rat brain.
Neoplasms
The Effects of Chemotherapeutics on the Ovarian Cancer Microenvironment.
Neoplasms
The efficacy and adverse effects of PARP inhibitor combined with chemotherapy compared with chemotherapy alone in the treatment of cancer patient: A protocol for systematic review.
Neoplasms
The efficacy and safety of olaparib in the treatment of cancers: a meta-analysis of randomized controlled trials.
Neoplasms
The Elephant and the Blind Men: Making Sense of PARP Inhibitors in Homologous Recombination Deficient Tumor Cells.
Neoplasms
The emerging potential of poly(ADP-ribose) polymerase inhibitors in the treatment of breast cancer.
Neoplasms
The emerging role of homologous recombination repair and PARP inhibitors in genitourinary malignancies.
Neoplasms
The Emerging Role of PARP Inhibitors in the Treatment of Epithelial Ovarian Cancer.
Neoplasms
The Emerging Role of Poly(ADP-Ribose) Polymerase Inhibitors in Cancer Treatment.
Neoplasms
The evolving landscape of predictive biomarkers of response to PARP inhibitors.
Neoplasms
The evolving management of metastatic triple negative breast cancer.
Neoplasms
The Ewing Family of Tumors Relies on BCL-2 and BCL-XL to Escape PARP Inhibitor Toxicity.
Neoplasms
The exposure of carcinogen-initiated primary neonatal rat hepatocytes to tumor promoters modulates both the transcripts and the enzymatic activity of nuclear poly(ADP-ribose) polymerase.
Neoplasms
The expression of gene transcripts of telomere-associated genes in human breast cancer: correlation with clinico-pathological parameters and clinical outcome.
Neoplasms
The Histone Methyltransferase SMYD2 Methylates PARP1 and Promotes Poly(ADP-ribosyl)ation Activity in Cancer Cells.
Neoplasms
The HSF1-PARP13-PARP1 complex facilitates DNA repair and promotes mammary tumorigenesis.
Neoplasms
The human papillomavirus type 16 E5 protein impairs TRAIL- and FasL-mediated apoptosis in HaCaT cells by different mechanisms.
Neoplasms
The implications of BRCA loss of heterozygosity (LOH) and deficient mismatch repair gene (dMMR) expression in the breast cancer of a patient with both inherited breast and ovarian cancer syndrome (BRCA2) and Lynch syndrome (MLH1).
Neoplasms
The Importance of Distinguishing Sporadic Cancers from Those Related to Cancer Predisposing Germline Mutations.
Neoplasms
The Indenoisoquinoline TOP1 Inhibitors Selectively Target Homologous Recombination-Deficient and Schlafen 11-Positive Cancer Cells and Synergize with Olaparib.
Neoplasms
The Inhibition and Treatment of Breast Cancer with Poly (ADP-ribose) Polymerase (PARP-1) Inhibitors.
Neoplasms
The Inhibitory Effects of HYDAMTIQ, a Novel PARP Inhibitor, on Growth in Human Tumor Cell Lines With Defective DNA Damage Response Pathways.
Neoplasms
The Interplay Between the DNA Damage Response, RNA Processing and Extracellular Vesicles.
Neoplasms
The key residues of active sites on the catalytic fragment for Paclitaxel interacting with poly (adp-ribose) polymerase.
Neoplasms
The kinase polypharmacology landscape of clinical PARP inhibitors.
Neoplasms
The Landscape and Therapeutic Implications of Molecular Profiles in Epithelial Ovarian Cancer.
Neoplasms
The level of Ets-1 protein is regulated by poly(ADP-ribose) polymerase-1 (PARP-1) in cancer cells to prevent DNA damage.
Neoplasms
The mechanism of cancer cell death by PARP inhibitors goes beyond DNA damage alone.
Neoplasms
The MET Inhibitor AZD6094 (Savolitinib, HMPL-504) Induces Regression in Papillary Renal Cell Carcinoma Patient-Derived Xenograft Models.
Neoplasms
The methanol-ethyl acetate partitioned fraction from Chinese olive fruits inhibits cancer cell proliferation and tumor growth by promoting apoptosis through the suppression of the NF-?B signaling pathway.
Neoplasms
The Modified Phenanthridine PJ34 Unveils an Exclusive Cell-Death Mechanism in Human Cancer Cells.
Neoplasms
The multifaceted roles of PARP1 in DNA repair and chromatin remodelling.
Neoplasms
The Multifactorial Role of PARP-1 in Tumor Microenvironment.
Neoplasms
The new-generation proteasome inhibitor oprozomib increases the sensitivity of cervical cancer cells to cisplatin-induced apoptosis.
Neoplasms
The novel mechanism of anticancer effect on gastric cancer through inducing G0/G1 cell cycle arrest and caspase-dependent apoptosis in vitro and in vivo by methionine enkephalin.
Neoplasms
The NQO1 bioactivatable drug, ?-Lapachone, alters the redox state of NQO1+ pancreatic cancer cells, causing perturbation in central carbon metabolism.
Neoplasms
The Nucleolus and PARP1 in Cancer Biology.
Neoplasms
The p.Ser64Leu and p.Pro104Leu missense variants of PALB2 identified in familial pancreatic cancer patients compromise the DNA damage response.
Neoplasms
The PARP Enzyme Family and the Hallmarks of Cancer Part 1. Cell Intrinsic Hallmarks.
Neoplasms
The PARP Enzyme Family and the Hallmarks of Cancer Part 2: Hallmarks Related to Cancer Host Interactions.
Neoplasms
The PARP inhibitor ABT-888 synergizes irinotecan treatment of colon cancer cell lines.
Neoplasms
The PARP inhibitor AZD2461 provides insights into the role of PARP3 inhibition for both synthetic lethality and tolerability with chemotherapy in preclinical models.
Neoplasms
The PARP inhibitor olaparib induces significant killing of ATM deficient lymphoid tumour cells in vitro and in vivo.
Neoplasms
The PARP inhibitor PJ-34 sensitizes cells to UVA-induced phototoxicity by a PARP independent mechanism.
Neoplasms
The PARP inhibitor, olaparib, depletes the ovarian reserve in mice: implications for fertility preservation.
Neoplasms
The PARP inhibitors, veliparib and olaparib, are effective chemopreventive agents for delaying mammary tumor development in BRCA1-deficient mice.
Neoplasms
The PARP Way to Epigenetic Changes.
Neoplasms
The PARP1 inhibitor BMN 673 exhibits immunoregulatory effects in a Brca1(-/-) murine model of ovarian cancer.
Neoplasms
The Phytosterol Peniocerol Inhibits Cell Proliferation and Tumor Growth in a Colon Cancer Xenograft Model.
Neoplasms
The Poly (ADP-Ribose) Polymerase Inhibitor Veliparib and Radiation Cause Significant Cell Line Dependent Metabolic Changes in Breast Cancer Cells.
Neoplasms
The Poly(ADP-ribose) Polymerase Enzyme Tankyrase Antagonizes Activity of the ?-Catenin Destruction Complex through ADP-ribosylation of Axin and APC2.
Neoplasms
The poly(ADP-Ribose) polymerase inhibitor ABT-888 reduces radiation-induced nuclear EGFR and augments head and neck tumor response to radiotherapy.
Neoplasms
The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial.
Neoplasms
The poly(ADP-ribose) polymerase inhibitor olaparib induces up-regulation of death receptors in primary acute myeloid leukemia blasts by NF-?B activation.
Neoplasms
The poly(ADP-ribose) polymerase-1 inhibitor 3-aminobenzamide suppresses cell growth and migration, enhancing suppressive effects of cisplatin in osteosarcoma cells.
Neoplasms
The potential for poly (ADP-ribose) polymerase inhibitors in cancer therapy.
Neoplasms
The potential of PARP inhibitors in genetic breast and ovarian cancers.
Neoplasms
The potential of PARP inhibitors in neuro-oncology.
Neoplasms
The potential role and application of PARP inhibitors in cancer treatment.
Neoplasms
The potentiation of the antitumor activity but not toxicity of bleomycin by 3-aminobenzamide.
Neoplasms
The Prognostic Value of BRCA1 and PARP Expression in Epithelial Ovarian Carcinoma: Immunohistochemical Detection.
Neoplasms
The Prognostic Values of PARP-1 Expression in Uveal Melanoma.
Neoplasms
The promise and current status of CDK12/13 inhibition for the treatment of cancer.
Neoplasms
The promise of combining inhibition of PI3K and PARP as cancer therapy.
Neoplasms
The Promise of Proteomics for the Study of ADP-Ribosylation.
Neoplasms
The resistance of macrophage-like tumour cell lines to growth inhibition by lipopolysaccharide and pertussis toxin.
Neoplasms
The role of BRCA1 in homologous recombination repair in response to replication stress: significance in tumorigenesis and cancer therapy.
Neoplasms
The role of homologous recombination deficiency testing in ovarian cancer and its clinical implications: do we need it?
Neoplasms
The role of inhibitors of poly(ADP-ribose) polymerase as resistance-modifying agents in cancer therapy.
Neoplasms
The role of nitric oxide in cancer.
Neoplasms
The role of PARP in DNA repair and its therapeutic exploitation.
Neoplasms
The role of PARP inhibitors in BRCA mutated pancreatic cancer.
Neoplasms
The Role of PARP Inhibitors in the Treatment of Gynecologic Malignancies.
Neoplasms
The Role of PARP Inhibitors in the Treatment of Prostate Cancer: Recent Advances in Clinical Trials.
Neoplasms
The Role of PARP-1 in Host-Pathogen Interaction and Cellular Stress Responses.
Neoplasms
The role of PARP1 in the DNA damage response and its application in tumor therapy.
Neoplasms
The role of poly adenosine diphosphate ribose polymerase inhibitors in breast and ovarian cancer: current status and future directions.
Neoplasms
The role of poly(ADP-ribose) polymerase inhibitors in the treatment of cancer and methods to overcome resistance: a review.
Neoplasms
The Role of Poly(ADP-ribose) Polymerase-1 in Rheumatoid Arthritis.
Neoplasms
The role of poly(ADP-ribosyl)ation in DNA damage response and cancer chemotherapy.
Neoplasms
The role of thiamine in cancer: possible genetic and cellular signaling mechanisms.
Neoplasms
The role of ubiquitin-dependent segregase p97 (VCP or Cdc48) in chromatin dynamics after DNA double strand breaks.
Neoplasms
The shieldin complex mediates 53BP1-dependent DNA repair.
Neoplasms
The Significance of Targeting Poly (ADP-Ribose) Polymerase-1 in Pancreatic Cancer for Providing a New Therapeutic Paradigm.
Neoplasms
The spectrum of tumors harboring BAP1 gene alterations.
Neoplasms
The status of poly(adenosine diphosphate-ribose) polymerase (PARP) inhibitors in ovarian cancer, part 1: olaparib.
Neoplasms
The status of poly(adenosine diphosphate-ribose) polymerase (PARP) inhibitors in ovarian cancer, part 2: extending the scope beyond olaparib and BRCA1/2 mutations.
Neoplasms
The Synergistic Effect of PARP Inhibitors and Immune Checkpoint Inhibitors.
Neoplasms
The synergistic proapoptotic effect of PARP-1 and HDAC inhibition in cutaneous T-cell lymphoma is mediated via Blimp-1.
Neoplasms
The telomeric PARP, tankyrases, as targets for cancer therapy.
Neoplasms
The therapeutic ratio is preserved for radiotherapy or cisplatin treatment in BRCA2-mutated prostate cancers.
Neoplasms
The trans cell cycle effects of PARP inhibitors underlie their selectivity toward BRCA1/2-deficient cells.
Neoplasms
The Treatment of Heterotopic Human Colon Xenograft Tumors in Mice with 5-Fluorouracil Attached to Magnetic Nanoparticles in Combination with Magnetic Hyperthermia Is More Efficient than Either Therapy Alone.
Neoplasms
The triple-negative subtype: new ideas for the poorest prognosis breast cancer.
Neoplasms
The tumor metabolome.
Neoplasms
The Ubiquitin Ligase TRIP12 Limits PARP1 Trapping and Constrains PARP Inhibitor Efficiency.
Neoplasms
The underlying mechanism for the PARP and BRCA synthetic lethality: Clearing up the misunderstandings.
Neoplasms
The ups and downs of DNA repair biomarkers for PARP inhibitor therapies.
Neoplasms
The ups and downs of Poly(ADP-ribose) Polymerase-1 inhibitors in cancer therapy-Current progress and future direction.
Neoplasms
The use of olaparib (AZD2281) potentiates SN-38 cytotoxicity in colon cancer cells by indirect inhibition of Rad51-mediated repair of DNA double-strand breaks.
Neoplasms
The Use of PARP Inhibitors in Cancer Therapy: Use as Adjuvant with Chemotherapy or Radiotherapy, Use as a Single Agent in Susceptible Patients, and Techniques Used to Identify Susceptible Patients.
Neoplasms
The Use of PARP Inhibitors in Cancer Therapy: Use as Adjuvant with Chemotherapy or Radiotherapy; Use as a Single Agent in Susceptible Patients; Techniques Used to Identify Susceptible Patients.
Neoplasms
The vitamin nicotinamide: translating nutrition into clinical care.
Neoplasms
Theoretical insights into molecular mechanism and energy criteria of PARP-2 enzyme inhibition by benzimidazole analogues.
Neoplasms
Therapeutic Application of PARP Inhibitors in Neuro-Oncology.
Neoplasms
Therapeutic applications of PARP inhibitors: Anticancer therapy and beyond.
Neoplasms
Therapeutic Approaches for Women Predisposed to Breast Cancer.
Neoplasms
Therapeutic considerations of PARP in stem cell biology: Relevance in cancer and beyond.
Neoplasms
Therapeutic Implications of Germline Testing in Patients With Advanced Cancers.
Neoplasms
Therapeutic Potential of Combining PARP Inhibitor and Immunotherapy in Solid Tumors.
Neoplasms
Therapeutic potential of investigational CHK-1 inhibitors for the treatment of solid tumors.
Neoplasms
Therapeutic potential of PARP inhibitors for metastatic breast cancer.
Neoplasms
Therapeutic Potential of PARP Inhibitors in the Treatment of Gastrointestinal Cancers.
Neoplasms
Therapeutic Potential of PARP Inhibitors in the Treatment of Metastatic Castration-Resistant Prostate Cancer.
Neoplasms
Therapeutic potential of poly(ADP-ribose) polymerase inhibitor AG014699 in human cancers with mutated or methylated BRCA1 or BRCA2.
Neoplasms
Therapeutic Strategies and Biomarkers to Modulate PARP Activity for Targeted Cancer Therapy.
Neoplasms
Therapeutic strategies for triple-negative breast cancer.
Neoplasms
Therapeutic targeting and patient selection for cancers with homologous recombination defects.
Neoplasms
Therapeutic targeting of Id2 reduces growth of human colorectal carcinoma in the murine liver.
Neoplasms
Therapeutic Targeting of MZF1-AS1/PARP1/E2F1 Axis Inhibits Proline Synthesis and Neuroblastoma Progression.
Neoplasms
Therapeutic Targeting of Poly(ADP-Ribose) Polymerase-1 (PARP1) in Cancer: Current Developments, Therapeutic Strategies, and Future Opportunities.
Neoplasms
Therapy of Smac mimetic SM-164 in combination with gemcitabine for pancreatic cancer.
Neoplasms
Therapy-related myeloid neoplasms following treatment with PARP inhibitors: new molecular insights.
Neoplasms
Thermal proteome profiling identifies oxidative-dependent inhibition of the transcription of major oncogenes as a new therapeutic mechanism for select anticancer compounds.
Neoplasms
Thorough in silico and in vitro cDNA analysis of 21 putative BRCA1 and BRCA2 splice variants and a complex tandem duplication in BRCA2 allowing the identification of activated cryptic splice donor sites in BRCA2 exon 11.
Neoplasms
Three apoptotic genes are upregulated in a patient with Alzheimer's disease and well-differentiated squamous cell carcinoma.
Neoplasms
Three phytosterols from sweet potato inhibit MCF7-xenograft-tumor growth through modulating gut microbiota homeostasis and SCFAs secretion.
Neoplasms
Three-component Castagnoli-Cushman reaction with ammonium acetate delivers 2-unsubstituted isoquinol-1-ones as potent inhibitors of poly(ADP-ribose) polymerase (PARP).
Neoplasms
Three-dimensional oxabicycloheptene sulfonate targets the homologous recombination and repair programmes through estrogen receptor ? antagonism.
Neoplasms
Thymoquinone enhances cisplatin-response through direct tumor effects in a syngeneic mouse model of ovarian cancer.
Neoplasms
TIP60 K430 SUMOylation attenuates its interaction with DNA-PKcs in S-phase cells: Facilitating homologous recombination and emerging target for cancer therapy.
Neoplasms
Tissue specific expression of p53 target genes suggests a key role for KILLER/DR5 in p53-dependent apoptosis in vivo.
Neoplasms
TNF-induced necroptosis and PARP-1-mediated necrosis represent distinct routes to programmed necrotic cell death.
Neoplasms
Top1-PARP1 association and beyond: from DNA topology to break repair.
Neoplasms
Total Synthesis and Biological Evaluation of Grassypeptolide?A.
Neoplasms
Tousled-like kinases stabilize replication forks and show synthetic lethality with checkpoint and PARP inhibitors.
Neoplasms
Toward specific functions of poly(ADP-ribose) polymerase-2.
Neoplasms
Towards small molecule inhibitors of mono-ADP-ribosyltransferases.
Neoplasms
Tranilast inhibits cell proliferation and migration and promotes apoptosis in murine breast cancer.
Neoplasms
Transcription-Associated Cyclin-Dependent Kinases as Targets and Biomarkers for Cancer Therapy.
Neoplasms
Transcription-induced DNA double strand breaks: both an oncogenic force and potential therapeutic target?
Neoplasms
Transcriptional coactivation of nuclear factor-kappaB-dependent gene expression by p300 is regulated by poly(ADP)-ribose polymerase-1.
Neoplasms
Transcriptional profiling of genes at the human common fragile site FRA1H in tumor-derived cell lines.
Neoplasms
Transcriptional Regulation of CCL2 by PARP1 Is a Driver for Invasiveness in Breast Cancer.
Neoplasms
Transcriptional repressor activating transcription factor 3 protects human umbilical vein endothelial cells from tumor necrosis factor-alpha-induced apoptosis through down-regulation of p53 transcription.
Neoplasms
Transcriptional roles of PARP1 in cancer.
Neoplasms
Transcriptomic heterogeneity of androgen receptor (AR) activity defines a de novo low AR-active subclass in treatment naïve primary prostate cancer.
Neoplasms
Transferrin-Conjugated Erianin-Loaded Liposomes Suppress the Growth of Liver Cancer by Modulating Oxidative Stress.
Neoplasms
Transferrin-conjugated liposomes loaded with carnosic acid inhibit liver cancer growth by inducing mitochondria-mediated apoptosis.
Neoplasms
Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors.
Neoplasms
Trastuzumab resistant HER2+ breast cancer cells retain sensitivity to poly (ADP-ribose) polymerase (PARP) inhibition.
Neoplasms
Treatment landscape of metastatic pancreatic cancer.
Neoplasms
Treatment of Pediatric Glioblastoma with Combination Olaparib and Temozolomide Demonstrates 2-Year Durable Response.
Neoplasms
Treatment with insulin inhibits poly(ADP-ribose)polymerase activation in a rat model of endotoxemia.
Neoplasms
Treatment with olaparib in a patient with PTEN-deficient endometrioid endometrial cancer.
Neoplasms
Trial watch - inhibiting PARP enzymes for anticancer therapy.
Neoplasms
Trichodermin induces cell apoptosis through mitochondrial dysfunction and endoplasmic reticulum stress in human chondrosarcoma cells.
Neoplasms
Trichosanthin inhibits breast cancer cell proliferation in both cell lines and nude mice by promotion of apoptosis.
Neoplasms
Trichothecin induces cell death in NF-?B constitutively activated human cancer cells via inhibition of IKK? phosphorylation.
Neoplasms
Triclabendazole Induces Pyroptosis by Activating Caspase-3 to Cleave GSDME in Breast Cancer Cells.
Neoplasms
TRIM44 links the UPS to SQSTM1/p62-dependent aggrephagy and removing misfolded proteins.
Neoplasms
TRIP13 regulates DNA repair pathway choice through REV7 conformational change.
Neoplasms
Triple-negative breast cancer and Poly(ADP-ribose) polymerase inhibitors.
Neoplasms
Triple-negative breast cancer: are we making headway at least?
Neoplasms
Triple-negative breast cancer: disease entity or title of convenience?
Neoplasms
Triple-negative breast cancer: molecular features, pathogenesis, treatment and current lines of research.
Neoplasms
Trolox enhances curcumin's cytotoxicity through induction of oxidative stress.
Neoplasms
Trop2 is a driver of metastatic prostate cancer with neuroendocrine phenotype via PARP1.
Neoplasms
Tryptophanyl-tRNA Synthetase Sensitizes Hormone Receptor-Positive Breast Cancer to Docetaxel-Based Chemotherapy.
Neoplasms
TSL-1502, a glucuronide prodrug of a poly (ADP-ribose) polymerase (PARP) inhibitor, exhibits potent anti-tumor activity in preclinical models.
Neoplasms
Tumor BRCA Test for Patients with Epithelial Ovarian Cancer: The Role of Molecular Pathology in the Era of PARP Inhibitor Therapy.
Neoplasms
Tumor burden is a potential marker of PARP inhibitor effects in ovarian cancer: a head-to-head observational series.
Neoplasms
Tumor Cell Recovery from Senescence Induced by Radiation with PARP Inhibition.
Neoplasms
Tumor growth inhibition by olaparib in BRCA2 germline-mutated patient-derived ovarian cancer tissue xenografts.
Neoplasms
Tumor necrosis factor alpha 'primes' the platelet-activating factor-induced superoxide production by human neutrophils: possible involvement of G proteins.
Neoplasms
Tumor necrosis factor-alpha induces apoptosis associated with poly(ADP-ribose) polymerase cleavage in HT-29 colon cancer cells.
Neoplasms
Tumor necrosis factor-like weak inducer of apoptosis and fibroblast growth factor-inducible 14 mediate cerebral ischemia-induced poly(ADP-ribose) polymerase-1 activation and neuronal death.
Neoplasms
Tumor regression mechanisms by IL-13 receptor-targeted cancer therapy involve apoptotic pathways.
Neoplasms
Tumor Suppression by PARP Inhibitors Is Potentiated by c-MET Inhibition.
Neoplasms
Tumor suppressive effect of PARP1 and FOXO3A in gastric cancers and its clinical implications.
Neoplasms
Tumor treating fields combined with a poly (adenosine diphosphate-ribose) polymerase inhibitor during radiotherapy for rapidly progressing IDH-wildtype diffuse astrocytoma: a case report.
Neoplasms
Tumor-induced apoptosis of T lymphocytes: elucidation of intracellular apoptotic events.
Neoplasms
Tumor-selective, antigen-independent delivery of a pH sensitive peptide-topoisomerase inhibitor conjugate suppresses tumor growth without systemic toxicity.
Neoplasms
Tumor-suppressive effects by adenovirus-mediated mda-7 gene transfer in non-small cell lung cancer cell in vitro.
Neoplasms
Tumor-targeted Nanoparticle Delivery of HuR siRNA Inhibits Lung Tumor Growth In Vitro and In Vivo By Disrupting the Oncogenic Activity of the RNA-binding Protein HuR.
Neoplasms
Tumors defective in homologous recombination rely on oxidative metabolism: relevance to treatments with PARP inhibitors.
Neoplasms
Tumour cell retention of rucaparib, sustained PARP inhibition and efficacy of weekly as well as daily schedules.
Neoplasms
Tumour lineage shapes BRCA-mediated phenotypes.
Neoplasms
Two decades beyond BRCA1/2: Homologous recombination, hereditary cancer risk and a target for ovarian cancer therapy.
Neoplasms
Two DNA repair gene polymorphisms on the risk of gastrointestinal cancers: a meta-analysis.
Neoplasms
Two experts and a newbie: [18F]PARPi vs [18F]FTT vs [18F]FPyPARP-a comparison of PARP imaging agents.
Neoplasms
Tyrosine kinase inhibitor-induced defects in DNA repair sensitize FLT3(ITD)-positive leukemia cells to PARP1 inhibitors.
Neoplasms
Tyrosyl-DNA phosphodiesterase 1 (TDP1) and Poly (ADP-Ribose) Polymerase-1 (PARP1) deficiency are cytotoxic to rhabdomyosarcoma cells.
Neoplasms
UBQLN4 Represses Homologous Recombination and Is Overexpressed in Aggressive Tumors.
Neoplasms
Uncoupling of PARP1 trapping and inhibition using selective PARP1 degradation.
Neoplasms
Uncovering synthetic lethal interactions for therapeutic targets and predictive markers in lung adenocarcinoma.
Neoplasms
Understanding and addressing barriers to successful adenovirus-based virotherapy for ovarian cancer.
Neoplasms
Understanding and overcoming resistance to PARP inhibitors in cancer therapy.
Neoplasms
Understanding Resistance Mechanisms and Expanding the Therapeutic Utility of PARP Inhibitors.
Neoplasms
Understanding specific functions of PARP-2: new lessons for cancer therapy.
Neoplasms
Understanding the causes of multidrug resistance in cancer: a comparison of doxorubicin and sunitinib.
Neoplasms
Understanding the DNA double-strand break repair and its therapeutic implications.
Neoplasms
Understanding the mechanism of amygdalin's multifunctional anti-cancer action using computational approach.
Neoplasms
Universal tumor DNA BRCA1/2 testing of ovarian cancer: prescreening PARPi treatment and genetic predisposition.
Neoplasms
Unrestrained poly-ADP-ribosylation provides insights into chromatin regulation and human disease.
Neoplasms
Unsymmetric Cisplatin-Based Pt(IV) Conjugates Containing a PARP-1 Inhibitor Pharmacophore Tested on Malignant Pleural Mesothelioma Cell Lines.
Neoplasms
Unusual metastasis in BRCA mutated pancreatic cancer while on maintenance Olaparib: Two case reports and review of the literature.
Neoplasms
Unveiling the mechanistic roles of chlorine substituted phthalazinone-based compounds containing chlorophenyl moiety towards the differential inhibition of poly (ADP-ribose) polymerase-1 in the treatment of lung cancer.
Neoplasms
Up-Regulation of PARP1 Expression Significantly Correlated with Poor Survival in Mucosal Melanomas.
Neoplasms
Update on PARP1 inhibitors in ovarian cancer.
Neoplasms
Update on Poly-ADP-ribose polymerase inhibition for ovarian cancer treatment.
Neoplasms
Update on the Role of Poly (ADP-Ribose) Polymerase Inhibitors in the DNA Repair-Deficient Pancreatic Cancers: A Narrative Review.
Neoplasms
Upregulation of Poly (ADP-Ribose) Polymerase-1 (PARP1) in Triple-Negative Breast Cancer and Other Primary Human Tumor Types.
Neoplasms
Use of Inosine Monophosphate Dehydrogenase Activity Assay to Determine the Specificity of PARP-1 Inhibitors.
Neoplasms
Use of poly ADP-ribose polymerase [PARP] inhibitors in cancer cells bearing DDR defects: the rationale for their inclusion in the clinic.
Neoplasms
Using Clickable NAD(+) Analogs to Label Substrate Proteins of PARPs.
Neoplasms
Using next-generation sequencing to redefine BRCAness in triple-negative breast cancer.
Neoplasms
Using PARP Inhibitors in Advanced Ovarian Cancer.
Neoplasms
USP1 Is Required for Replication Fork Protection in BRCA1-Deficient Tumors.
Neoplasms
Utility of Homologous Recombination Deficiency Biomarkers Across Cancer Types.
Neoplasms
Utilizing an interim futility analysis of the OVAL study (VB-111-701/GOG 3018) for potential reduction of risk: A phase III, double blind, randomized controlled trial of ofranergene obadenovec (VB-111) and weekly paclitaxel in patients with platinum resistant ovarian cancer.
Neoplasms
Validation of the use of a fluorescent PARP1 inhibitor for the detection of oral, oropharyngeal and oesophageal epithelial cancers.
Neoplasms
Valproate augments Niraparib killing of tumor cells.
Neoplasms
Variations in the mRNA expression of poly(ADP-ribose) polymerases, poly(ADP-ribose) glycohydrolase and ADP-ribosylhydrolase 3 in breast tumors and impact on clinical outcome.
Neoplasms
Vasoactivity of Rucaparib, a PARP-1 Inhibitor, is a Complex Process that Involves Myosin Light Chain Kinase, P2 Receptors, and PARP Itself.
Neoplasms
VEGI, a new member of the TNF family activates nuclear factor-kappa B and c-Jun N-terminal kinase and modulates cell growth.
Neoplasms
Veliparib Alone or in Combination with Mitomycin C in Patients with Solid Tumors With Functional Deficiency in Homologous Recombination Repair.
Neoplasms
Veliparib for the treatment of ovarian cancer.
Neoplasms
Veliparib in combination with radiotherapy for the treatment of MGMT unmethylated glioblastoma.
Neoplasms
Veliparib in ovarian cancer: a new synthetically lethal therapeutic approach.
Neoplasms
Veliparib Monotherapy to Patients With BRCA Germ Line Mutation and Platinum-Resistant or Partially Platinum-Sensitive Relapse of Epithelial Ovarian Cancer: A Phase I/II Study.
Neoplasms
Veliparib with carboplatin and paclitaxel in BRCA-mutated advanced breast cancer (BROCADE3): a randomised, double-blind, placebo-controlled, phase 3 trial.
Neoplasms
Veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in patients with BRCA1/2 locally recurrent/metastatic breast cancer: randomized phase II study.
Neoplasms
Verapamil enhances the sensitivity of oxaliplatin to tumor cells by influencing the PARP pathway.
Neoplasms
Verbascoside Inhibits Glioblastoma Cell Proliferation, Migration and Invasion While Promoting Apoptosis Through Upregulation of Protein Tyrosine Phosphatase SHP-1 and Inhibition of STAT3 Phosphorylation.
Neoplasms
Verteporfin inhibits cell proliferation and induces apoptosis in different subtypes of breast cancer cell lines without light activation.
Neoplasms
Verteporfin Inhibits PD-L1 through Autophagy and the STAT1-IRF1-TRIM28 Signaling Axis, Exerting Antitumor Efficacy.
Neoplasms
Virtual screening of small molecules databases for discovery of novel PARP-1 inhibitors: combination of in silico and in vitro studies.
Neoplasms
Vitamin C and Cell Death.
Neoplasms
Vitamin E ?-Tocotrienol Prolongs Survival in the LSL-KrasG12D/+;LSL-Trp53R172H/+;Pdx-1-Cre (KPC) Transgenic Mouse Model of Pancreatic Cancer.
Neoplasms
VLX600 Disrupts Homologous Recombination and Synergizes with PARP Inhibitors and Cisplatin by Inhibiting Histone Lysine Demethylases.
Neoplasms
Voies de réparation de l'ADN et cancers bronchiques non à petites cellules : perspectives cliniques.
Neoplasms
vPARP Adjusts MVP Expression in Drug-resistant Cell Lines in Conjunction with MDR Proteins.
Neoplasms
When and How to Use PARP Inhibitors in Prostate Cancer: A Systematic Review of the Literature with an Update on On-Going Trials.
Neoplasms
Whence High-Grade Serous Ovarian Cancer.
Neoplasms
Whole-body hyperthermia and ADPRT inhibition in experimental treatment of brain tumors.
Neoplasms
Wikstromol from Wikstroemia indica induces apoptosis and suppresses migration of MDA-MB-231 cells via inhibiting PI3K/Akt pathway.
Neoplasms
WNT inhibition creates a BRCA-like state in Wnt-addicted cancer.
Neoplasms
Wnt signaling inhibition confers induced synthetic lethality to PARP inhibitors.
Neoplasms
Wnt-5a and G-protein signaling are required for collagen-induced DDR1 receptor activation and normal mammary cell adhesion.
Neoplasms
Wnt/?-catenin signaling as a useful therapeutic target in hepatoblastoma.
Neoplasms
WRN helicase is a synthetic lethal target in microsatellite unstable cancers.
Neoplasms
X-ray-induced damage repair in exponentially growing and growth arrested confluent poly(adenosine diphosphate-ribose) polymerase-deficient V79 chinese hamster cell line.
Neoplasms
Xenografts of primary human gynecological tumors grown under the renal capsule of NOD/SCID mice show genetic stability during serial transplantation and respond to cytotoxic chemotherapy.
Neoplasms
XRCC1 promotes replication restart, nascent fork degradation and mutagenic DNA repair in BRCA2-deficient cells.
Neoplasms
XRN2 interactome reveals its synthetic lethal relationship with PARP1 inhibition.
Neoplasms
YQWY Decoction Improves Myocardial Remodeling via Activating the IL-10/Stat3 Signaling Pathway.
Neoplasms
Zebrafish as an in vivo screening tool to establish PARP inhibitor efficacy.
Neoplasms
[(18)F]FluorThanatrace uptake as a marker of PARP1 expression and activity in breast cancer.
Neoplasms
[18F]PARPi Imaging Is Not Affected by HPV Status In Vitro.
Neoplasms
[Analysis of PARP inhibitors induced anemia in advanced and relapsed epithelial ovarian cancer].
Neoplasms
[Apoptosis mechanism of taxol combined with resveratrol on human laryngeal carcinoma Hep-2 cells].
Neoplasms
[Aspirin inhibits the proliferation of breast cancer cells via inducing apoptosis and autophagy].
Neoplasms
[BRCA diagnostics of ovarian cancer : Molecular tumor testing since the introduction of PARP inhibitor therapy].
Neoplasms
[BRCA mutations: from Angelina Jolie to specific therapies].
Neoplasms
[BRCA1 and BRCA2 - pathologists starting kit].
Neoplasms
[Breakthrough breast cancer treatment--PARP inhibitor, BRCA, and triple negative breast cancer]
Neoplasms
[c-MYC, PARP1 and BIN1 as targets for therapy of cancer cell resistance].
Neoplasms
[Cancer therapy by PARP inhibitors].
Neoplasms
[Clinical development of PARP inhibitors].
Neoplasms
[Cytotoxicity of beta-lapachone, an naphthoquinone with possible therapeutic use]
Neoplasms
[Enhancement of bleomycin or hyperthermia induced tumor cell damage by ADPRT inhibitor]
Neoplasms
[Fermented wheat germ extract in the supportive therapy of colorectal cancer]
Neoplasms
[From poly(ADP-ribose) discovery to PARP inhibitors in cancer therapy].
Neoplasms
[Hereditary Breast and Ovarian Cancer Syndrome].
Neoplasms
[Hereditary breast cancer]
Neoplasms
[Hereditary breast carcinomas pathologist's perspective].
Neoplasms
[Homologous recombination repair deficiency as a predictive biomarker : Basic mechanisms and detection methods].
Neoplasms
[Identification of basal-like carcinomas in clinical practice: "triple zero/BRCA1-like" carcinomas]
Neoplasms
[Knock-down of DAB2 interacting protein (DAB2IP) promotes proliferation and inhibits apoptosis of bladder cancer cells].
Neoplasms
[Learning from My Experience: Outpatient Care for Cancer Multigene Genomic Testing].
Neoplasms
[Medical treatment options in BRCA-associated cancers].
Neoplasms
[Molecular basis of breast cancer related to BRCA 1 and BRCA2 genes: characteristics and targeting therapy]
Neoplasms
[Molecular characterisation defines several subtypes of pancreatic ductal adenocarcinoma].
Neoplasms
[Molecular Mechanisms of Carcinogenesis of Epithelial Ovarian Cancers].
Neoplasms
[Molecular Targeted Therapies for Hereditary Cancer Syndrome].
Neoplasms
[Molecular tumor board prostate cancer].
Neoplasms
[New therapeutic strategies in advanced stage breast and tubo-ovarian cancers].
Neoplasms
[Olaparib potentiates the antitumor effect of Taxol on 4T1 breast cancer].
Neoplasms
[PARP inhibitors and breast cancer: update and perspectives].
Neoplasms
[PARP inhibitors and radiotherapy: rational and prospects for a clinical use].
Neoplasms
[PARP inhibitors for cancer therapy].
Neoplasms
[PARP inhibitors--theoretical basis and clinical application].
Neoplasms
[PARP10 Influences the Proliferation of Colorectal Carcinoma Cells, a Preliminary Study].
Neoplasms
[Poly(ADP-ribose) polymerase (PARP) inhibitors in BRCA1/2 cancer therapy].
Neoplasms
[Poly(ADP-ribose) polymerase (PARP): physiological and pathological roles].
Neoplasms
[Recent therapeutic trends in triple-negative metastatic breast cancers: PARP inhibitors, immunotherapies and antibody-drug conjugates].
Neoplasms
[Research progresses of the PARP inhibitors for the treatment of cancer].
Neoplasms
[Role of proteins in Fas-mediated apoptosis in tumor cells and lymphocytes co-cultured in vitro]
Neoplasms
[Specific features of drug sensitivity of hereditary cancers].
Neoplasms
[Synthesis and activity evaluation of PARP-1 inhibitors with azaindole skeleton].
Neoplasms
[Testing of mutations in BRCA1 and BRCA2 genes in tumor tissues - possibilities and limitations].
Neoplasms
[The Antitumor Effects of Fisetin on Ovarian Cancer in vitro and in vivo.]
Neoplasms
[The clonal evolution of osteosarcomas].
Neoplasms
[The future of breast cancer radiotherapy: From one size fits all to taylor-made treatment.]
Neoplasms
[The long coding RNA GSTM3TV2 acts an oncogene to promote chemoresistance in pancreatic cancer].
Neoplasms
[The Role of Preoperative Chemotherapy Depending on Breast Cancer Subtype].
Neoplasms
{beta}2-Microglobulin Is a Signaling and Growth-Promoting Factor for Human Prostate Cancer Bone Metastasis.
Neoplasms, Germ Cell and Embryonal
Analysis of poly(ADP-ribose) polymerase-1 (PARP1) gene alteration in human germ cell tumor cell lines.
Neoplasms, Germ Cell and Embryonal
Genetic alteration of poly(ADP-ribose) polymerase-1 in human germ cell tumors.
Neoplasms, Germ Cell and Embryonal
Pan-Cancer Analysis of PARP1 Alterations as Biomarkers in the Prediction of Immunotherapeutic Effects and the Association of Its Expression Levels and Immunotherapy Signatures.
Neoplasms, Germ Cell and Embryonal
PARP expression in germ cell tumours.
Neoplasms, Germ Cell and Embryonal
Parp-1 deficiency in ES cells promotes invasive and metastatic lesions accompanying induction of trophoblast giant cells during tumorigenesis in uterine environment.
Neoplasms, Germ Cell and Embryonal
Poly(ADP-ribosyl)ation in relation to cancer and autoimmune disease.
Neoplasms, Germ Cell and Embryonal
Promoter methylation of DNA homologous recombination genes is predictive of the responsiveness to PARP inhibitor treatment in testicular germ cell tumors.
Neoplasms, Germ Cell and Embryonal
Reduced proficiency in homologous recombination underlies the high sensitivity of embryonal carcinoma testicular germ cell tumors to Cisplatin and poly (adp-ribose) polymerase inhibition.
Neoplasms, Germ Cell and Embryonal
Role of DNA repair machinery and p53 in the testicular germ cell cancer: a review.
Neoplastic Cells, Circulating
A Phase I Study of Veliparib in Combination with Metronomic Cyclophosphamide in Adults with Refractory Solid Tumors and Lymphomas.
Neoplastic Cells, Circulating
Identification of Somatically Acquired BRCA1/2 Mutations by cfDNA Analysis in Patients with Metastatic Breast Cancer.
Neoplastic Cells, Circulating
Randomized, Double-Blind, Phase II Study of Temozolomide in Combination With Either Veliparib or Placebo in Patients With Relapsed-Sensitive or Refractory Small-Cell Lung Cancer.
Neoplastic Cells, Circulating
Sequences and combinations of multifaceted therapy in advanced prostate cancer.
Neoplastic Cells, Circulating
The Combination of the PARP Inhibitor Olaparib and the WEE1 Inhibitor AZD1775 as a New Therapeutic Option for Small Cell Lung Cancer.
Neoplastic Syndromes, Hereditary
[Molecular Targeted Therapies for Hereditary Cancer Syndrome].
Nephritis
Differential regulation of cell death programs in males and females by Poly (ADP-Ribose) Polymerase-1 and 17? estradiol.
Nephritis
Poly(ADP-ribose) polymerase (PARP) polymorphisms associated with nephritis and arthritis in systemic lupus erythematosus.
Nephritis
Poly(ADP-ribose) polymerase-1 regulates the progression of autoimmune nephritis in males by inducing necrotic cell death and modulating inflammation.
Nervous System Autoimmune Disease, Experimental
Interleukin-37 (IL-37) Suppresses Pertussis Toxin-Induced Inflammatory Myopathy in a Rat Model.
Nervous System Diseases
PARP inhibition attenuates early brain injury through NF-?B/MMP-9 pathway in a rat model of subarachnoid hemorrhage.
Nervous System Diseases
PARP overactivation in neurological disorders.
Nervous System Diseases
Poly ADP-ribose polymerase-1: an international molecule of mystery.
Nervous System Diseases
Potential role of poly (ADP-ribose) polymerase in delayed cerebral vasospasm following subarachnoid hemorrhage in rats.
Nervous System Diseases
Sevoflurane Exposure Induces Neuronal Cell Parthanatos Initiated by DNA Damage in the Developing Brain via an Increase of Intracellular Reactive Oxygen Species.
Neuralgia
Animal models of diabetic neuropathic pain.
Neuralgia
Implications of intrathecal pertussis toxin animal model on the cellular mechanisms of neuropathic pain syndrome.
Neuralgia
Intrathecal pertussis toxin induces thermal hyperalgesia: involvement of excitatory and inhibitory amino acids.
Neuralgia
PARP inhibition or gene deficiency counteracts intraepidermal nerve fiber loss and neuropathic pain in advanced diabetic neuropathy.
Neuralgia
PARP-1-regulated TNF-? expression in the dorsal root ganglia and spinal dorsal horn contributes to the pathogenesis of neuropathic pain in rats.
Neuralgia
Poly(ADP-ribose) polymerase inhibition as a novel therapeutic approach against intraepidermal nerve fiber loss and neuropathic pain associated with advanced diabetic neuropathy: a commentary on "PARP Inhibition or gene deficiency counteracts intraepidermal nerve fiber loss and neuropathic pain in advanced diabetic neuropathy".
Neuralgia
Poly(ADP-ribose) polymerase inhibition reveals a potential mechanism to promote neuroprotection and treat neuropathic pain.
Neuralgia
Some new insights into the effects of opioids in phasic and tonic nociceptive tests.
Neuritis
Experimental allergic neuritis in the SJL/J mouse: induction of severe and reproducible disease with bovine peripheral nerve myelin and pertussis toxin with or without interleukin-12.
Neuritis
Myelin Protein Zero180-199 Peptide Induced Experimental Autoimmune Neuritis in C57BL/6 Mice.
Neuritis
P0 protein peptide 180-199 together with pertussis toxin induces experimental autoimmune neuritis in resistant C57BL/6 mice.
Neuritis, Autoimmune, Experimental
Experimental allergic neuritis in the SJL/J mouse: induction of severe and reproducible disease with bovine peripheral nerve myelin and pertussis toxin with or without interleukin-12.
Neuritis, Autoimmune, Experimental
Myelin Protein Zero180-199 Peptide Induced Experimental Autoimmune Neuritis in C57BL/6 Mice.
Neuritis, Autoimmune, Experimental
P0 protein peptide 180-199 together with pertussis toxin induces experimental autoimmune neuritis in resistant C57BL/6 mice.
Neuroblastoma
A combination of PARP and CHK1 inhibitors efficiently antagonizes MYCN-driven tumors.
Neuroblastoma
Agonist-induced down-regulation of muscarinic cholinergic and alpha 2-adrenergic receptors after inactivation of Ni by pertussis toxin.
Neuroblastoma
Alternative NHEJ Pathway Components Are Therapeutic Targets in High-Risk Neuroblastoma.
Neuroblastoma
Alternative NHEJ pathway proteins as components of MYCN oncogenic activity in human neural crest stem cell differentiation: implications for neuroblastoma initiation.
Neuroblastoma
An evaluation in vitro of PARP-1 inhibitors, rucaparib and olaparib, as radiosensitisers for the treatment of neuroblastoma.
Neuroblastoma
Apoptotic signaling in dopamine-induced cell death: the role of oxidative stress, p38 mitogen-activated protein kinase, cytochrome c and caspases.
Neuroblastoma
Association of PARP1 polymorphisms with response to chemotherapy in patients with high-risk neuroblastoma.
Neuroblastoma
ATR Inhibition Potentiates PARP Inhibitor Cytotoxicity in High Risk Neuroblastoma Cell Lines by Multiple Mechanisms.
Neuroblastoma
Biological Effects of MC2050, a Quinazoline-Based PARP-1 Inhibitor, in Human Neuroblastoma and EBV-Positive Burkitt's Lymphoma Cells.
Neuroblastoma
Bradykinin-induced generation of inositol 1,4,5-trisphosphate in fibroblasts and neuroblastoma cells: effect of pertussis toxin, extracellular calcium, and down-regulation of protein kinase C.
Neuroblastoma
Characterization of a neutralizing monoclonal antibody against botulinum ADP-ribosyltransferase, C3 exoenzyme.
Neuroblastoma
Characterization of Chikungunya virus infection in human neuroblastoma SH-SY5Y cells: role of apoptosis in neuronal cell death.
Neuroblastoma
Chronic exposure to pertussis toxin alters muscarinic receptor-mediated regulation of cyclic AMP metabolism in neuroblastoma x glioma NG108-15 hybrid cells.
Neuroblastoma
Chrysanthemum morifolium Ramat (CM) extract protects human neuroblastoma SH-SY5Y cells against MPP(+)-induced cytotoxicity.
Neuroblastoma
Combinations of PARP Inhibitors with Temozolomide Drive PARP1 Trapping and Apoptosis in Ewing's Sarcoma.
Neuroblastoma
Coupling of human D-1 dopamine receptors to different guanine nucleotide binding proteins. Evidence that D-1 dopamine receptors can couple to both Gs and G(o).
Neuroblastoma
Coupling of the human Y2 receptor for neuropeptide Y and peptide YY to guanine nucleotide inhibitory proteins in permeabilized SMS-KAN cells.
Neuroblastoma
Cr(VI) induces ROS-mediated mitochondrial-dependent apoptosis in neuronal cells via the activation of Akt/ERK/AMPK signaling pathway.
Neuroblastoma
CRISPR/Cas9 nickase mediated targeting of urokinase receptor gene inhibits neuroblastoma cell proliferation.
Neuroblastoma
Cytoprotective effects of phenolic acids on methylglyoxal-induced apoptosis in Neuro-2A cells.
Neuroblastoma
Deletion of 11q in neuroblastomas drives sensitivity to PARP inhibition.
Neuroblastoma
Differential radiosensitization by the poly(ADP-ribose) transferase inhibitor 3-aminobenzamide in human tumor cells of varying radiosensitivity.
Neuroblastoma
Effect of chronic D-Ala,2 D-Leu5-enkephalin or pertussis toxin treatment on the high-affinity state of delta opioid receptor in neuroblastoma x glioma NG108-15 hybrid cells.
Neuroblastoma
Effect of pertussis toxin treatment on the down-regulation of opiate receptors in neuroblastoma X glioma NG108-15 hybrid cells.
Neuroblastoma
Effects of pertussis toxin on cAMP and cGMP responses to carbamylcholine in N1E-115 neuroblastoma cells.
Neuroblastoma
Expression of Prenylated Rab Acceptor 1 Domain Family, Member 2 (PRAF2) in Neuroblastoma: Correlation with Clinical Features, Cellular Localization, and Cerulenin-Mediated Apoptosis Regulation.
Neuroblastoma
Functional trans-inactivation of insulin receptor kinase by growth-inhibitory angiotensin II AT2 receptor.
Neuroblastoma
Generation of reactive oxygen species mediates butein-induced apoptosis in neuroblastoma cells.
Neuroblastoma
Guanine nucleotide-sensitive, high affinity binding of carbachol to muscarinic cholinergic receptors of 1321N1 astrocytoma cells is insensitive to pertussis toxin.
Neuroblastoma
High level of apoptosis and low AKT activation in mass screening as opposed to standard neuroblastoma.
Neuroblastoma
Identification and characterization of functional angiotensin II receptors in human neuroblastoma cells.
Neuroblastoma
Identification of a guanine nucleotide-binding protein G(o) in human neuroblastoma.
Neuroblastoma
Inhibition of gamma ray-induced apoptosis by stimulatory heterotrimeric GTP binding protein involves Bcl-xL down-regulation in SH-SY5Y human neuroblastoma cells.
Neuroblastoma
Inhibition of poly(ADP-ribose) polymerase-1 enhances temozolomide and topotecan activity against childhood neuroblastoma.
Neuroblastoma
Inversion of Ca2+ current modulation during recovery of neuroblastoma cells from pertussis toxin pretreatment.
Neuroblastoma
Involvement of Gi in the inhibition of adenylate cyclase by cannabimimetic drugs.
Neuroblastoma
Knockdown of survivin (BIRC5) causes apoptosis in neuroblastoma via mitotic catastrophe.
Neuroblastoma
Loss of DNA Damage Response in Neuroblastoma and Utility of a PARP Inhibitor.
Neuroblastoma
Low levels of selenium compounds are selectively toxic for a human neuron cell line through ROS/RNS increase and apoptotic process activation.
Neuroblastoma
mda-7/IL-24 Induces Cell Death in Neuroblastoma through a Novel Mechanism Involving AIF and ATM.
Neuroblastoma
Morphological effects, rate of incorporation, and the enzymatic action of botulinum ADP-ribosyltransferase, known as C3 exoenzyme, on human neuroblastoma GOTO cells.
Neuroblastoma
Muscarinic cholinergic receptor-induced enhancement of PGE1-stimulated cAMP accumulation in neuroblastoma X glioma cells: prevention by pertussis toxin.
Neuroblastoma
Muscarinic receptor-mediated hydrolysis of phosphatidylinositols in human neuroblastoma (SH-SY5Y) cells is sensitive to pertussis toxin.
Neuroblastoma
MYCN expression induces replication stress and sensitivity to PARP inhibition in neuroblastoma.
Neuroblastoma
Neural differentiation of human neuroblastoma GOTO cells via a Rho-Rho kinase-phosphorylation signal transduction and continuous observation of a single GOTO cell during differentiation.
Neuroblastoma
Neurotensin, bradykinin and somatostatin inhibit cAMP production in neuroblastoma N1E115 cells via both pertussis toxin sensitive and insensitive mechanisms.
Neuroblastoma
Neurotensin-mediated inhibition of cyclic AMP formation in neuroblastoma N1E115 cells: involvement of the inhibitory GTP-binding component of adenylate cyclase.
Neuroblastoma
Oncolytic adenovirus-mediated short hairpin RNA targeting MYCN gene induces apoptosis by upregulating RKIP in neuroblastoma.
Neuroblastoma
Opioid peptides promote cholera-toxin-catalysed ADP-ribosylation of the inhibitory guanine-nucleotide-binding protein (Gi) in membranes of neuroblastoma x glioma hybrid cells.
Neuroblastoma
PARP inhibitors enhance replication stress and cause mitotic catastrophe in MYCN-dependent neuroblastoma.
Neuroblastoma
PARP Targeted Alpha-Particle Therapy Enhances Response to PD-1 Immune-Checkpoint Blockade in a Syngeneic Mouse Model of Glioblastoma.
Neuroblastoma
PARP-1 Modulates Amyloid Beta Peptide-Induced Neuronal Damage.
Neuroblastoma
PARP-1-targeted Auger emitters display high-LET cytotoxic properties in vitro but show limited therapeutic utility in solid tumor models of human neuroblastoma.
Neuroblastoma
PARP1 gene polymorphisms and neuroblastoma susceptibility in Chinese children.
Neuroblastoma
Peroxynitrite and hydrogen peroxide induced cell death in the NSC34 neuroblastoma x spinal cord cell line: role of poly (ADP-ribose) polymerase.
Neuroblastoma
Pertussis toxin decreases opiate receptor binding and adenylate inhibition in a neuroblastoma x glioma hybrid cell line.
Neuroblastoma
Pertussis toxin inhibits alpha 2-adrenoceptor-mediated inhibition of adenylate cyclase without affecting muscarinic regulation of [Ca2+]i or inositol phosphate generation in SH-SY5Y human neuroblastoma cells.
Neuroblastoma
PHF20 collaborates with PARP1 to promote stemness and aggressiveness of neuroblastoma cells through activation of SOX2 and OCT4.
Neuroblastoma
Poly (ADP-ribose) polymerase induction is an early signal of apoptosis in human neuroblastoma.
Neuroblastoma
Poly (ADP-Ribose) Polymerase Inhibitor MK-4827 together with Radiation as a Novel Therapy for Metastatic Neuroblastoma.
Neuroblastoma
Poly(ADP-ribose) polymerase-1 is a nuclear epigenetic regulator of mitochondrial DNA repair and transcription.
Neuroblastoma
Possible involvement of ADP-ribosylation of particular enzymes in cell death induced by nitric oxide-donors in human neuroblastoma cells.
Neuroblastoma
Protective effects of the antiparkinsonian drugs talipexole and pramipexole against 1-methyl-4-phenylpyridinium-induced apoptotic death in human neuroblastoma SH-SY5Y cells.
Neuroblastoma
Pyrido[2',1':2,3]imidazo[4,5-c]isoquinolin-5-amines as Potential Cytotoxic Agents against Human Neuroblastoma.
Neuroblastoma
Radiosensitizing Potential of Curcumin in Different Cancer Models.
Neuroblastoma
Rapid activation of poly(ADP-ribose) polymerase contributes to Sindbis virus and staurosporine-induced apoptotic cell death.
Neuroblastoma
Role of a protein regulating guanine nucleotide binding in phosphoinositide breakdown and calcium mobilization by bradykinin in neuroblastoma X glioma hybrid NG108-15 cells: effects of pertussis toxin and cholera toxin on receptor-mediated signal transduction.
Neuroblastoma
Sodium valproate potentiates staurosporine-induced apoptosis in neuroblastoma cells via Akt/survivin independently of HDAC inhibition.
Neuroblastoma
Specific uncoupling by islet-activating protein, pertussis toxin, of negative signal transduction via alpha-adrenergic, cholinergic, and opiate receptors in neuroblastoma x glioma hybrid cells.
Neuroblastoma
Suppressive effect of PARP-1 inhibitor on JC virus replication in vitro.
Neuroblastoma
Synergism in cytosolic Ca2+ mobilization between bradykinin and agonists for pertussis toxin-sensitive G-protein-coupled receptors in NG 108-15 cells.
Neuroblastoma
Synergistic induction of apoptosis in neuroblastoma cells using a combination of cytostatic drugs with interferon-gamma and TRAIL.
Neuroblastoma
Targeting PARP-1 with Alpha-Particles Is Potently Cytotoxic to Human Neuroblastoma in Preclinical Models.
Neuroblastoma
Temporal changes in chromatin, intracellular calcium, and poly(ADP-ribose) polymerase during Sindbis virus-induced apoptosis of neuroblastoma cells.
Neuroblastoma
The GTP-binding regulatory proteins of neuroblastoma x glioma, NG108-15, and glioma, C6, cells. Immunochemical evidence of a pertussis toxin substrate that is neither Ni nor No.
Neuroblastoma
The novel anti-neuroblastoma agent PF403, inhibits proliferation and invasion in vitro and in brain xenografts.
Neuroblastoma
The Polyphenol Oleuropein Aglycone Modulates the PARP1-SIRT1 Interplay: An In Vitro and In Vivo Study.
Neuroblastoma
The toxicity of nitrofuran compounds on melanoma and neuroblastoma cells is enhanced by Olaparib and ameliorated by melanin pigment.
Neuroblastoma
[Inhibition of tissue factor by siRNA enhances doxorubicin-induced apoptosis in human neuroblastoma]
Neurodegenerative Diseases
A new poly(ADP-ribose) polymerase inhibitor, FR261529 [2-(4-chlorophenyl)-5-quinoxalinecarboxamide], ameliorates methamphetamine-induced dopaminergic neurotoxicity in mice.
Neurodegenerative Diseases
A novel and potent poly(ADP-ribose) polymerase-1 inhibitor, FR247304 (5-chloro-2-[3-(4-phenyl-3,6-dihydro-1(2H)-pyridinyl)propyl]-4(3H)-quinazolinone), attenuates neuronal damage in in vitro and in vivo models of cerebral ischemia.
Neurodegenerative Diseases
Cell Death Mechanisms of Neurodegeneration.
Neurodegenerative Diseases
Ceramide in the Molecular Mechanisms of Neuronal Cell Death. The Role of Sphingosine-1-Phosphate.
Neurodegenerative Diseases
Development of a high-throughput screening-amenable assay for human poly(ADP-ribose) polymerase inhibitors.
Neurodegenerative Diseases
Development of a miniaturized assay for the high-throughput screening program for poly(ADP-ribose) polymerase-1.
Neurodegenerative Diseases
Drug repurposing studies of PARP inhibitors as a new therapy for inherited retinal degeneration.
Neurodegenerative Diseases
Early Treatment with Poly(ADP-Ribose) Polymerase-1 Inhibitor (JPI-289) Reduces Infarct Volume and Improves Long-Term Behavior in an Animal Model of Ischemic Stroke.
Neurodegenerative Diseases
Expression and Single Nucleotide Polymorphism of Poly (ADPRibose) Polymerase-1 in Gastrointestinal Tumours: Clinical Involvement.
Neurodegenerative Diseases
Extracellular poly(ADP-ribose) is a neurotrophic signal that upregulates glial cell line-derived neurotrophic factor (GDNF) levels in vitro and in vivo.
Neurodegenerative Diseases
Fused in Sarcoma (FUS) in DNA Repair: Tango with Poly(ADP-ribose) Polymerase 1 and Compartmentalisation of Damaged DNA.
Neurodegenerative Diseases
Identification and mechanism of action analysis of the new PARP-1 inhibitor 2?-hydroxygenkwanol A.
Neurodegenerative Diseases
Inhibition of poly(ADP-ribose) polymerase-1 alters expression of mitochondria-related genes in PC12 cells: relevance to mitochondrial homeostasis in neurodegenerative disorders.
Neurodegenerative Diseases
mTOR may interact with PARP-1 to regulate visible light-induced parthanatos in photoreceptors.
Neurodegenerative Diseases
Multifaceted Role of PARP-1 in DNA Repair and Inflammation: Pathological and Therapeutic Implications in Cancer and Non-Cancer Diseases.
Neurodegenerative Diseases
Natural Inhibitors of Poly(ADP-ribose) Polymerase-1.
Neurodegenerative Diseases
Neuroprotective effects of a novel poly(ADP-ribose) polymerase-1 inhibitor, 2-[3-[4-(4-chlorophenyl)-1-piperazinyl] propyl]-4(3H)-quinazolinone (FR255595), in an in vitro model of cell death and in mouse 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease.
Neurodegenerative Diseases
New insights of poly(ADP-ribosylation) in neurodegenerative diseases: A focus on protein phase separation and pathologic aggregation.
Neurodegenerative Diseases
Nicotinamide Inhibits Ethanol-Induced Caspase-3 and PARP-1 Over-activation and Subsequent Neurodegeneration in the Developing Mouse Cerebellum.
Neurodegenerative Diseases
Nicotinamide, a Poly [ADP-Ribose] Polymerase 1 (PARP-1) Inhibitor, as an Adjunctive Therapy for the Treatment of Alzheimer's Disease.
Neurodegenerative Diseases
Overexpression of Sirtuin 1 protein in neurons prevents and reverses experimental diabetic neuropathy.
Neurodegenerative Diseases
PARkinson's: From cellular mechanisms to potential therapeutics.
Neurodegenerative Diseases
PARP activity and inhibition in fetal and adult oligodendrocyte precursor cells: Effect on cell survival and differentiation.
Neurodegenerative Diseases
PARP-1 activation leads to cytosolic accumulation of TDP-43 in neurons.
Neurodegenerative Diseases
PARP-1 involvement in neurodegeneration: A focus on Alzheimer's and Parkinson's diseases.
Neurodegenerative Diseases
PARP-DNA trapping ability of PARP inhibitors jeopardizes astrocyte viability: Implications for CNS disease therapeutics.
Neurodegenerative Diseases
PARP10 deficiency manifests by severe developmental delay and DNA repair defect.
Neurodegenerative Diseases
PARPs and PAR as novel pharmacological targets for the treatment of stress granule-associated disorders.
Neurodegenerative Diseases
Poly (ADP-ribose) polymerase-1 as a promising drug target for neurodegenerative diseases.
Neurodegenerative Diseases
Poly(ADP-ribose) polymerase inhibitors: new pharmacological functions and potential clinical implications.
Neurodegenerative Diseases
Poly(ADP-ribose) polymerase is found in both the nucleus and cytoplasm of human CNS neurons.
Neurodegenerative Diseases
Poly(ADP-ribose) polymerase-1 activity promotes NF-kappaB-driven transcription and microglial activation: implication for neurodegenerative disorders.
Neurodegenerative Diseases
Poly(ADP-ribose) polymerase-1 protects neurons against apoptosis induced by oxidative stress.
Neurodegenerative Diseases
Poly(ADP-ribose) polymerases: homology, structural domains and functions. Novel therapeutical applications.
Neurodegenerative Diseases
Poly(ADP-ribose) signal in seizures-induced neuron death.
Neurodegenerative Diseases
Poly(ADP-ribosylated) proteins in ?-amyloid peptide-stimulated microglial cells.
Neurodegenerative Diseases
Poly(ADP-Ribosylation) in Age-Related Neurological Disease.
Neurodegenerative Diseases
Post-transcriptional regulation by poly(ADP-ribosyl)ation of the RNA-binding proteins.
Neurodegenerative Diseases
Potential clinical applications of poly(ADP-ribose) polymerase (PARP) inhibitors.
Neurodegenerative Diseases
Protection Against Chronic Hypoperfusion-Induced Retinal Neurodegeneration by PARP Inhibition via Activation of PI-3-kinase Akt Pathway and Suppression of JNK and p38 MAP Kinases.
Neurodegenerative Diseases
Synthesis and evaluation of an AZD2461 [18F]PET probe in non-human primates reveals the PARP-1 inhibitor to be non-blood-brain barrier penetrant.
Neurodegenerative Diseases
The expression of PARP, NF-kappa B and parvalbumin is increased in Parkinson disease.
Neurodegenerative Diseases
The impact of the phytotherapeutic agent quercetin on expression of genes and activity of signaling pathways.
Neurodegenerative Diseases
The PARP inhibitor benzamide protects against kainate and NMDA but not AMPA lesioning of the mouse striatum in vivo.
Neurodegenerative Diseases
The Promise of Proteomics for the Study of ADP-Ribosylation.
Neurodegenerative Diseases
The role of PARP1 in neurodegenerative diseases and aging.
Neurodegenerative Diseases
[Neuronal death: potential role of the nuclear enzyme, poly (ADP-ribose) polymerase]
Neurodegenerative Diseases
[Poly adenosine diphosphate-ribosylation and neurodegenerative diseases].
Neuroectodermal Tumors, Primitive
Antiangiogenic and proapoptotic effects of dietary restriction on experimental mouse and human brain tumors.
Neuroendocrine Tumors
Novel insights into the neuroendocrine control of inflammation: the role of GR and PARP1.
Neuroendocrine Tumors
Potentiation of 177Lu-octreotate peptide receptor radionuclide therapy of human neuroendocrine tumor cells by PARP inhibitor.
Neuroendocrine Tumors
The non-canonical target PARP16 contributes to polypharmacology of the PARP inhibitor talazoparib and its synergy with WEE1 inhibitors.
Neurofibrosarcoma
Poly (ADP) ribose polymerase inhibition: A potential treatment of malignant peripheral nerve sheath tumor.
Neurofibrosarcoma
Targeting Protein Translation by Rocaglamide and Didesmethylrocaglamide to Treat MPNST and Other Sarcomas.
Neuroinflammatory Diseases
Anthocyanins Improve Hippocampus-Dependent Memory Function and Prevent Neurodegeneration via JNK/Akt/GSK3? Signaling in LPS-Treated Adult Mice.
Neuroinflammatory Diseases
Cell Death Pathways: a Novel Therapeutic Approach for Neuroscientists.
Neuroinflammatory Diseases
Clinical perspectives of PARP inhibitors.
Neuroinflammatory Diseases
Combination strategy of PARP inhibitor with antioxidant prevent bioenergetic deficits and inflammatory changes in CCI-induced neuropathy.
Neuroinflammatory Diseases
Deletion of Topoisomerase 1 in excitatory neurons causes genomic instability and early onset neurodegeneration.
Neuroinflammatory Diseases
Early Treatment with Poly(ADP-Ribose) Polymerase-1 Inhibitor (JPI-289) Reduces Infarct Volume and Improves Long-Term Behavior in an Animal Model of Ischemic Stroke.
Neuroinflammatory Diseases
Edaravone abrogates LPS-induced behavioral anomalies, neuroinflammation and PARP-1.
Neuroinflammatory Diseases
Inhibition of poly(ADP-ribose) polymerase-1 alters expression of mitochondria-related genes in PC12 cells: relevance to mitochondrial homeostasis in neurodegenerative disorders.
Neuroinflammatory Diseases
Morin Mitigates Chronic Constriction Injury (CCI)-Induced Peripheral Neuropathy by Inhibiting Oxidative Stress Induced PARP Over-Activation and Neuroinflammation.
Neuroinflammatory Diseases
Neuroinflammation and B-Cell Phenotypes in Cervical and Lumbosacral Regions of the Spinal Cord in Experimental Autoimmune Encephalomyelitis in the Absence of Pertussis Toxin.
Neuroinflammatory Diseases
Nicotinamide treatment reduces the levels of oxidative stress, apoptosis, and PARP-1 activity in A?(1-42)-induced rat model of Alzheimer's disease.
Neuroinflammatory Diseases
Nicotinamide, a Poly [ADP-Ribose] Polymerase 1 (PARP-1) Inhibitor, as an Adjunctive Therapy for the Treatment of Alzheimer's Disease.
Neuroinflammatory Diseases
PARP inhibition attenuates neuroinflammation and oxidative stress in chronic constriction injury induced peripheral neuropathy.
Neuroinflammatory Diseases
PARP inhibition in vivo blocks alcohol-induced brain neurodegeneration and neuroinflammatory cytosolic phospholipase A2 elevations.
Neuroinflammatory Diseases
Poly (ADP-ribose) polymerase-1 inhibitor, 3-aminobenzamide pretreatment ameliorates lipopolysaccharide-induced neurobehavioral and neurochemical anomalies in mice.
Neuroinflammatory Diseases
Poly(ADP-ribose) polymerase 2 contributes to neuroinflammation and neurological dysfunction in mouse experimental autoimmune encephalomyelitis.
Neuroinflammatory Diseases
Repurposing of Clinically Approved Poly-(Adp-Ribose) Polymerase Inhibitors For The Therapy of Sepsis.
Neuroinflammatory Diseases
Synthesis and evaluation of an AZD2461 [18F]PET probe in non-human primates reveals the PARP-1 inhibitor to be non-blood-brain barrier penetrant.
Neuroinflammatory Diseases
Synthesis and release of neurotoxic kynurenine metabolites by human monocyte-derived macrophages.
Neuroinflammatory Diseases
Targeting Parthanatos in Ischemic Stroke.
Neuroinflammatory Diseases
Targeting poly(ADP-ribose) polymerase-1 as a promising approach for immunomodulation in multiple sclerosis?
Neuroinflammatory Diseases
The role of PARP1 in neurodegenerative diseases and aging.
Neuroinflammatory Diseases
Toll-like receptor 2 and poly(ADP-ribose) polymerase 1 promote central nervous system neuroinflammation in progressive EAE.
Neuroinflammatory Diseases
Ultra-low dose naloxone restores the antinociceptive effect of morphine in pertussis toxin-treated rats and prevents glutamate transporter downregulation by suppressing the p38 mitogen-activated protein kinase signaling pathway.
Neuroma, Acoustic
DNA repair gene polymorphisms and risk of adult meningioma, glioma, and acoustic neuroma.
Neutropenia
Efficacy and safety of PARP inhibitors in the treatment of advanced ovarian cancer: An updated systematic review and meta-analysis of randomized controlled trials.
Neutropenia
Haematologic toxicities with PARP inhibitors in cancer patients: an up-to-date meta-analysis of 29 randomized controlled trials.
Neutropenia
Pharmacodynamic genes do not influence risk of neutropenia in cancer patients treated with moderately high-dose irinotecan.
Neutropenia
Risk of severe hematologic toxicities in cancer patients treated with PARP inhibitors: a meta-analysis of randomized controlled trials.
Newcastle Disease
Biochemical Variations in Cytolytic Activity of Ortho- and Paramyxoviruses in Human Lung Tumor Cell Culture.
Nijmegen Breakage Syndrome
DNA Damage in Nijmegen Breakage Syndrome Cells Leads to PARP Hyperactivation and Increased Oxidative Stress.
Nijmegen Breakage Syndrome
Identification of proteins in the hamster DNA end-binding complex.
Non-alcoholic Fatty Liver Disease
Dual roles of ULK1 (unc-51 like autophagy activating kinase 1) in cytoprotection against lipotoxicity.
Non-alcoholic Fatty Liver Disease
Inhibiting poly ADP-ribosylation increases fatty acid oxidation and protects against fatty liver disease.
Non-alcoholic Fatty Liver Disease
Metabolic roles of poly(ADP-ribose) polymerases.
Non-alcoholic Fatty Liver Disease
Mitigative effects of the bioactive flavonol fisetin on high-fat/high-sucrose induced nonalcoholic fatty liver disease in rats.
Non-alcoholic Fatty Liver Disease
PARP1-mediated PPAR? poly(ADP-ribosyl)ation suppresses fatty acid oxidation in non-alcoholic fatty liver disease.
Non-alcoholic Fatty Liver Disease
PARPs in lipid metabolism and related diseases.
Non-alcoholic Fatty Liver Disease
SQSTM1/p62 activates NFE2L2/NRF2 via ULK1-mediated autophagic KEAP1 degradation and protects mouse liver from lipotoxicity.
non-specific serine/threonine protein kinase deficiency
p53 Inhibits Adeno-Associated Viral Vector Integration.
Obesity
Antagonistic crosstalk between SIRT1, PARP-1, and -2 in the regulation of chronic inflammation associated with aging and metabolic diseases.
Obesity
Enhanced susceptibility of ovaries from obese mice to 7,12-dimethylbenz[a]anthracene-induced DNA damage.
Obesity
Functional Interplay between Histone H2B ADP-Ribosylation and Phosphorylation Controls Adipogenesis.
Obesity
Obesity alters phosphoramide mustard-induced ovarian DNA repair in mice.
Obesity
PARP-1 DEFICIENCY EXACERBATES DIET-INDUCED OBESITY IN MICE.
Obesity
PARP-1 Flips the Epigenetic Switch on Obesity.
Obesity
PARPs in lipid metabolism and related diseases.
Obesity
The beneficial role of vitamin D in obesity: possible genetic and cell signaling mechanisms.
Obesity
Two new Loci for body-weight regulation identified in a joint analysis of genome-wide association studies for early-onset extreme obesity in French and german study groups.
Oligospermia
Association of common SNP rs1136410 in PARP1 gene with the susceptibility to male infertility with oligospermia.
Optic Nerve Injuries
Increased expression and activation of poly(ADP-ribose) polymerase (PARP) contribute to retinal ganglion cell death following rat optic nerve transection.
Osteoarthritis
Involvement of poly(ADP-ribose) polymerase 1 in ERBB2 expression in rheumatoid synovial cells.
Osteoarthritis
PARP-1 inhibition attenuates the inflammatory response in the cartilage of a rat model of osteoarthritis.
Osteoporosis
Loss of Gi G-Protein-Coupled Receptor Signaling in Osteoblasts Accelerates Bone Fracture Healing.
Osteosarcoma
Betulin inhibits mTOR and induces autophagy to promote apoptosis in human osteosarcoma cell lines.
Osteosarcoma
Blocking HSP90 Addiction Inhibits Tumor Cell Proliferation, Metastasis Development, and Synergistically Acts with Zoledronic Acid to Delay Osteosarcoma Progression.
Osteosarcoma
CCT128930 induces G1-phase arrest and apoptosis and synergistically enhances the anticancer efficiency of VS5584 in human osteosarcoma cells.
Osteosarcoma
ClC-5 Downregulation Induces Osteosarcoma Cell Apoptosis by Promoting Bax and tBid Complex Formation.
Osteosarcoma
Combinatorial screening using orthotopic patient derived xenograft-expanded early phase cultures of osteosarcoma identify novel therapeutic drug combinations.
Osteosarcoma
Differentiative pathway activated by 3-aminobenzamide, an inhibitor of PARP, in human osteosarcoma MG-63 cells.
Osteosarcoma
Effects of phorbol esters and pertussis toxin on agonist-stimulated cyclic AMP production in rat osteosarcoma cells.
Osteosarcoma
Evidence against roles for pertussis toxin sensitive G proteins or diacylglycerol generation in insulin-like growth factor-1 stimulated DNA synthesis in MG-63 osteosarcoma cells.
Osteosarcoma
Fluoroquinolone-mediated inhibition of cell growth, s-g(2)/m cell cycle arrest, and apoptosis in canine osteosarcoma cell lines.
Osteosarcoma
Hydrogen peroxide-induced poly(ADP-ribosyl)ation regulates osteogenic differentiation-associated cell death.
Osteosarcoma
Inhibition of mTOR signaling by oleanolic acid contributes to its anti-tumor activity in osteosarcoma cells.
Osteosarcoma
Inhibition of polo-like kinase 1 leads to the suppression of osteosarcoma cell growth in vitro and in vivo.
Osteosarcoma
Inhibition of poly(ADP-ribose) polymerase activation attenuates beta-lapachone-induced necrotic cell death in human osteosarcoma cells.
Osteosarcoma
Insulin-like growth factor-I receptor tyrosine kinase inhibitor cyclolignan picropodophyllin inhibits proliferation and induces apoptosis in multidrug resistant osteosarcoma cell lines.
Osteosarcoma
Interferon-? Sensitises Human Osteosarcoma Cells to Trail-mediated Apoptosis.
Osteosarcoma
Involvement of PARP and poly(ADP-ribosyl)ation in the early stages of apoptosis and DNA replication.
Osteosarcoma
Isoalantolactone inhibits constitutive NF-?B activation and induces reactive oxygen species-mediated apoptosis in osteosarcoma U2OS cells through mitochondrial dysfunction.
Osteosarcoma
Knockdown of PARP-1 Inhibits Proliferation and ERK Signals, Increasing Drug Sensitivity in Osteosarcoma U2OS Cells.
Osteosarcoma
Maclurin exerts anti-cancer effects in human osteosarcoma cells via prooxidative activity and modulations of PARP, p38, and ERK signaling.
Osteosarcoma
Oleanane triterpenoid CDDO-Me induces apoptosis in multidrug resistant osteosarcoma cells through inhibition of Stat3 pathway.
Osteosarcoma
Osteosarcoma cells with genetic signatures of BRCAness are susceptible to the PARP inhibitor talazoparib alone or in combination with chemotherapeutics.
Osteosarcoma
PARP1 modulates telomere sister chromatid exchange and telomere length homeostasis by regulating telomere localization of SLX4 in U2OS cells.
Osteosarcoma
Poly(ADP-ribose) polymerase-1 activity facilitates the dissociation of nuclear proteins from platinum-modified DNA.
Osteosarcoma
Poly(ADP-ribosyl)ation of p53 in vitro and in vivo modulates binding to its DNA consensus sequence.
Osteosarcoma
Regulation of DNAS1L3 endonuclease activity by poly(ADP-ribosyl)ation during etoposide-induced apoptosis. Role of poly(ADP-ribose) polymerase-1 cleavage in endonuclease activation.
Osteosarcoma
Replication Study: Systematic identification of genomic markers of drug sensitivity in cancer cells.
Osteosarcoma
Role of poly(ADP-ribose) polymerase (PARP) cleavage in apoptosis. Caspase 3-resistant PARP mutant increases rates of apoptosis in transfected cells.
Osteosarcoma
Selenocysteine inhibits human osteosarcoma cells growth through triggering mitochondrial dysfunction and ROS-mediated p53 phosphorylation.
Osteosarcoma
Tankyrase1 antisense oligodeoxynucleotides suppress the proliferation, migration and invasion through Hippo/YAP pathway in human osteosarcoma cells.
Osteosarcoma
Targeted inhibition of mTORC2 prevents osteosarcoma cell migration and promotes apoptosis.
Osteosarcoma
The effect of 3-aminobenzamide, inhibitor of poly(ADP-ribose) polymerase, on human osteosarcoma cells.
Osteosarcoma
The PARP inhibitor olaparib potentiates the effect of the DNA damaging agent doxorubicin in osteosarcoma.
Osteosarcoma
The poly(ADP-ribose) polymerase-1 inhibitor 3-aminobenzamide suppresses cell growth and migration, enhancing suppressive effects of cisplatin in osteosarcoma cells.
Osteosarcoma
Transient poly(ADP-ribosyl)ation of nuclear proteins and role of poly(ADP-ribose) polymerase in the early stages of apoptosis.
Osteosarcoma
[The clonal evolution of osteosarcomas].
Ototoxicity
Augmentation of NAD(+) by NQO1 attenuates cisplatin-mediated hearing impairment.
Ototoxicity
Baicalin attenuates gentamicin-induced cochlear hair cell ototoxicity.
Ototoxicity
Dunnione ameliorates cisplatin ototoxicity through modulation of NAD(+) metabolism.
Ototoxicity
Poly (ADP-Ribose) Polymerase-1 (PARP1) Deficiency and Pharmacological Inhibition by Pirenzepine Protects From Cisplatin-Induced Ototoxicity Without Affecting Antitumor Efficacy.
Ovarian Neoplasms
(+)-Strebloside-Induced Cytotoxicity in Ovarian Cancer Cells Is Mediated through Cardiac Glycoside Signaling Networks.
Ovarian Neoplasms
53BP1 as a potential predictor of response in PARP inhibitor-treated homologous recombination-deficient ovarian cancer.
Ovarian Neoplasms
53BP1 depletion causes PARP inhibitor resistance in ATM-deficient breast cancer cells.
Ovarian Neoplasms
A case of immune-mediated liver injury induced by Olaparib.
Ovarian Neoplasms
A comprehensive look of poly(ADP-ribose) polymerase inhibition strategies and future directions for cancer therapy.
Ovarian Neoplasms
A Critical Appraisal and Recommendations for Cost-Effectiveness Studies of Poly(ADP-Ribose) Polymerase Inhibitors in Advanced Ovarian Cancer.
Ovarian Neoplasms
A decade of clinical development of PARP inhibitors in perspective.
Ovarian Neoplasms
A first-in-class CDK4 inhibitor demonstrates in vitro, ex-vivo and in vivo efficacy against ovarian cancer.
Ovarian Neoplasms
A genome-wide association study identifies susceptibility loci for ovarian cancer at 2q31 and 8q24.
Ovarian Neoplasms
A genomic instability score in discriminating nonequivalent outcomes of BRCA1/2 mutations and in predicting outcomes of ovarian cancer treated with platinum-based chemotherapy.
Ovarian Neoplasms
A label-free PFP-based photoelectrochemical biosensor for highly sensitive detection of PARP-1 activity.
Ovarian Neoplasms
A PET imaging agent for evaluating PARP-1 expression in ovarian cancer.
Ovarian Neoplasms
A Population Pharmacokinetic Meta-Analysis of Veliparib, a PARP Inhibitor, Across Phase 1/2/3 Trials in Cancer Patients.
Ovarian Neoplasms
A profile on the FoundationFocus CDxBRCA tests.
Ovarian Neoplasms
A Quantitative Chemotherapy Genetic Interaction Map Reveals Factors Associated with PARP Inhibitor Resistance.
Ovarian Neoplasms
A quasi-quantitative dual multiplexed immunoblot method to simultaneously analyze ATM and H2AX Phosphorylation in human peripheral blood mononuclear cells.
Ovarian Neoplasms
A randomized Phase II study of veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in BRCA1/2 metastatic breast cancer: design and rationale.
Ovarian Neoplasms
A review of PARP inhibitors: from bench to bedside.
Ovarian Neoplasms
A Review on Poly (ADP-ribose) Polymerase (PARP) Inhibitors and Synthetic Methodologies.
Ovarian Neoplasms
A Small Compound KJ-28d Enhances the Sensitivity of Non-Small Cell Lung Cancer to Radio- and Chemotherapy.
Ovarian Neoplasms
A small molecule compound inhibits AKT pathway in ovarian cancer cell lines.
Ovarian Neoplasms
ABCB1 (MDR1) induction defines a common resistance mechanism in paclitaxel- and olaparib-resistant ovarian cancer cells.
Ovarian Neoplasms
Adherence to PARP inhibitor therapy among women with ovarian cancer.
Ovarian Neoplasms
Administration of the Tablet Formulation of Olaparib in Patients with Ovarian Cancer: Practical Guidance and Expectations.
Ovarian Neoplasms
ADP-Ribosylation Levels and Patterns Correlate with Gene Expression and Clinical Outcomes in Ovarian Cancers.
Ovarian Neoplasms
Advanced epithelial ovarian cancer: from standard chemotherapy to promising molecular pathway targets--where are we now?
Ovarian Neoplasms
Advancements in PARP1 Targeted Nuclear Imaging and Theranostic Probes.
Ovarian Neoplasms
Advances in PARP inhibitors for the treatment of breast cancer.
Ovarian Neoplasms
Advances in the Treatment of Ovarian Cancer Using PARP Inhibitors and the Underlying Mechanism of Resistance.
Ovarian Neoplasms
Advances in the treatment of platinum resistant epithelial ovarian cancer: an update on standard and experimental therapies.
Ovarian Neoplasms
Advances in the use of PARP inhibitor therapy for breast cancer.
Ovarian Neoplasms
Advances in the use of PARP inhibitors for BRCA1/2-associated breast cancer: talazoparib.
Ovarian Neoplasms
Advances in using PARP inhibitors to treat cancer.
Ovarian Neoplasms
Advancing Drug Development in Gynecologic Malignancies.
Ovarian Neoplasms
Adverse events of PARP inhibitors.
Ovarian Neoplasms
ALDH1A1 contributes to PARP inhibitor resistance via enhancing DNA repair in BRCA2-/- ovarian cancer cells.
Ovarian Neoplasms
Amplification of the Mutation-Carrying BRCA2 Allele Promotes RAD51 Loading and PARP Inhibitor Resistance in the Absence of Reversion Mutations.
Ovarian Neoplasms
An antimitotic and antivascular agent BPR0L075 overcomes multidrug resistance and induces mitotic catastrophe in paclitaxel-resistant ovarian cancer cells.
Ovarian Neoplasms
An Effective Epigenetic-PARP inhibitor Combination Therapy for Breast and Ovarian Cancers Independent of BRCA-mutations.
Ovarian Neoplasms
An ex vivo assay of XRT-induced Rad51 foci formation predicts response to PARP-inhibition in ovarian cancer.
Ovarian Neoplasms
An HTS-compatible HTRF assay measuring the glycohydrolase activity of human PARG.
Ovarian Neoplasms
An Update on Poly(ADP-ribose)polymerase-1 (PARP-1) Inhibitors: Opportunities and Challenges in Cancer Therapy.
Ovarian Neoplasms
Anti-angiogenesis for cancer: Current status and prospects.
Ovarian Neoplasms
Anti-Tumor Xanthones from Garcinia nujiangensis Suppress Proliferation, and Induce Apoptosis via PARP, PI3K/AKT/mTOR, and MAPK/ERK Signaling Pathways in Human Ovarian Cancers Cells.
Ovarian Neoplasms
Anticancer activity of pristimerin in ovarian carcinoma cells is mediated through the inhibition of prosurvival Akt/NF-?B/mTOR signaling.
Ovarian Neoplasms
Anticancer potential of diarylidenyl piperidone derivatives, HO-4200 and H-4318, in cisplatin resistant primary ovarian cancer.
Ovarian Neoplasms
Antiproliferative and apoptotic activities of tosylcyclonovobiocic acids as potent heat shock protein 90 inhibitors in human cancer cells.
Ovarian Neoplasms
Antitumor Activity of 3-Indolylmethanamines 31B and PS121912.
Ovarian Neoplasms
Antitumor activity of the poly(ADP-ribose) polymerase inhibitor rucaparib as monotherapy in patients with platinum-sensitive, relapsed, BRCA-mutated, high-grade ovarian cancer, and an update on safety.
Ovarian Neoplasms
Antitumor effect of a WEE1 inhibitor and potentiation of olaparib sensitivity by DNA damage response modulation in triple-negative breast cancer.
Ovarian Neoplasms
Apoptosis is augmented in high-grade serous ovarian cancer by the combined inhibition of Bcl-2/Bcl-xL and PARP.
Ovarian Neoplasms
Application and reflection of genomic scar assays in evaluating the efficacy of platinum salts and PARP inhibitors in cancer therapy.
Ovarian Neoplasms
Appraising iniparib, the PARP inhibitor that never was--what must we learn?
Ovarian Neoplasms
Assessment and management of diarrhea following VEGF receptor TKI treatment in patients with ovarian cancer.
Ovarian Neoplasms
Association between polymorphisms of XRCC1 and ADPRT genes and ovarian cancer survival with platinum-based chemotherapy in Chinese population.
Ovarian Neoplasms
ATM deficiency sensitizes mantle cell lymphoma cells to poly(ADP-ribose) polymerase-1 inhibitors.
Ovarian Neoplasms
ATR and p-ATR are emerging prognostic biomarkers and DNA damage response targets in ovarian cancer.
Ovarian Neoplasms
ATR inhibition broadly sensitizes ovarian cancer cells to chemotherapy independent of BRCA status.
Ovarian Neoplasms
Augmentation of response to chemotherapy by microRNA-506 through regulation of RAD51 in serous ovarian cancers.
Ovarian Neoplasms
Augmentation of the antitumor effects of PARP inhibitors in triple-negative breast cancer via degradation by hydrophobic tagging modulation.
Ovarian Neoplasms
Author Correction: Immunogenomic profiling determines responses to combined PARP and PD-1 inhibition in ovarian cancer.
Ovarian Neoplasms
Autoimmune response to PARP and BRCA1/BRCA2 in cancer.
Ovarian Neoplasms
Autophagy and protein kinase RNA-like endoplasmic reticulum kinase (PERK)/eukaryotic initiation factor 2 alpha kinase (eIF2?) pathway protect ovarian cancer cells from metformin-induced apoptosis.
Ovarian Neoplasms
AZD1775 Increases Sensitivity to Olaparib and Gemcitabine in Cancer Cells with p53 Mutations.
Ovarian Neoplasms
Bacillus intermedius ribonuclease (BINASE) induces apoptosis in human ovarian cancer cells.
Ovarian Neoplasms
Baseline clinical predictors of antitumor response to the PARP inhibitor olaparib in germline BRCA1/2 mutated patients with advanced ovarian cancer.
Ovarian Neoplasms
Berberine induces oxidative DNA damage and impairs homologous recombination repair in ovarian cancer cells to confer increased sensitivity to PARP inhibition.
Ovarian Neoplasms
BET Bromodomain Inhibition Synergizes with PARP Inhibitor in Epithelial Ovarian Cancer.
Ovarian Neoplasms
BET, SRC, and BCL2 family inhibitors are synergistic drug combinations with PARP inhibitors in ovarian cancer.
Ovarian Neoplasms
Bevacizumab or PARP-Inhibitors Maintenance Therapy for Platinum-Sensitive Recurrent Ovarian Cancer: A Network Meta-Analysis.
Ovarian Neoplasms
Beyond Breast and Ovarian Cancers: PARP Inhibitors for BRCA Mutation-Associated and BRCA-Like Solid Tumors.
Ovarian Neoplasms
Biologicals in the Upfront Treatment of Ovarian Cancer: Focus on Bevacizumab and Poly (ADP-Ribose) Polymerase Inhibitors.
Ovarian Neoplasms
Biomarkers of Response and Resistance to DNA Repair Targeted Therapies.
Ovarian Neoplasms
Blocking c-Met-mediated PARP1 phosphorylation enhances anti-tumor effects of PARP inhibitors.
Ovarian Neoplasms
BRCA 1/2-Mutation Related and Sporadic Breast and Ovarian Cancers: More Alike than Different.
Ovarian Neoplasms
BRCA Genetic Test and Risk-Reducing Salpingo-Oophorectomy for Hereditary Breast and Ovarian Cancer: State-of-the-Art.
Ovarian Neoplasms
BRCA in Gastrointestinal Cancers: Current Treatments and Future Perspectives.
Ovarian Neoplasms
BRCA somatic mutations and epigenetic BRCA modifications in serous ovarian cancer.
Ovarian Neoplasms
BRCA1 and BRCA2 mutations and clinical interpretation in 398 ovarian cancer patients: comparison with breast cancer variants in a similar population.
Ovarian Neoplasms
BRCA1- and BRCA2-related mutations: therapeutic implications in ovarian cancer.
Ovarian Neoplasms
BRCA1-2 diagnostic workflow from next-generation sequencing technologies to variant identification and final report.
Ovarian Neoplasms
BRCA1/2 mutation analysis in 41 ovarian cell lines reveals only one functionally deleterious BRCA1 mutation.
Ovarian Neoplasms
BRCA1/2 somatic mutation detection in formalin-fixed paraffin embedded tissue by next-generation sequencing in Korean ovarian cancer patients.
Ovarian Neoplasms
BRCA1/2 testing: therapeutic implications for breast cancer management.
Ovarian Neoplasms
Breast Cancer Predisposition Genes and Synthetic Lethality.
Ovarian Neoplasms
C/EBP? promotes poly(ADP-ribose) polymerase inhibitor resistance by enhancing homologous recombination repair in high-grade serous ovarian cancer.
Ovarian Neoplasms
Can integrative biomarker approaches improve prediction of platinum and PARP inhibitor response in ovarian cancer?
Ovarian Neoplasms
Cancer-derived exosomes as a delivery platform of CRISPR/Cas9 confer cancer cell tropism-dependent targeting.
Ovarian Neoplasms
Candidate biomarkers of PARP inhibitor sensitivity in ovarian cancer beyond the BRCA genes.
Ovarian Neoplasms
Candidate synthetic lethality partners to PARP inhibitors in the treatment of ovarian clear cell cancer.
Ovarian Neoplasms
Carboplatin and taxol resistance develops more rapidly in functional BRCA1 compared to dysfunctional BRCA1 ovarian cancer cells.
Ovarian Neoplasms
CCNE1 Is a Putative Therapeutic Target for ARID1A-Mutated Ovarian Clear Cell Carcinoma.
Ovarian Neoplasms
CDCA8, targeted by MYBL2, promotes malignant progression and olaparib insensitivity in ovarian cancer.
Ovarian Neoplasms
CDK9 inhibitor CDKI-73 is synergetic lethal with PARP inhibitor olaparib in BRCA1 wide-type ovarian cancer.
Ovarian Neoplasms
Cediranib suppresses homology-directed DNA repair through down-regulation of BRCA1/2 and RAD51.
Ovarian Neoplasms
Cediranib, a pan-VEGFR inhibitor, and olaparib, a PARP inhibitor, in combination therapy for high grade serous ovarian cancer.
Ovarian Neoplasms
Ceralasertib-Mediated ATR Inhibition Combined With Olaparib in Advanced Cancers Harboring DNA Damage Response and Repair Alterations (Olaparib Combinations).
Ovarian Neoplasms
Changes in gene expression variability reveal a stable synthetic lethal interaction network in BRCA2- ovarian cancers.
Ovarian Neoplasms
Characterization of a RAD51C-silenced high-grade serous ovarian cancer model during development of PARP inhibitor resistance.
Ovarian Neoplasms
Chemotherapy and PARP inhibitors in heavily pretreated BRCA1/2 mutation ovarian cancer (BMOC) patients.
Ovarian Neoplasms
Chemotherapy directly followed by poly(ADP-ribose) polymerase inhibition as an alternative to surgery in patients with BRCA-mutated ovarian cancer: a potential management strategy in the era of coronavirus disease 2019.
Ovarian Neoplasms
Chemotherapy reduces PARP1 in cancers of the ovary: implications for future clinical trials involving PARP inhibitors.
Ovarian Neoplasms
Choosing wisely: Selecting PARP inhibitor combinations to promote anti-tumor immune responses beyond BRCA mutations.
Ovarian Neoplasms
Circulating HOXA9-methylated tumour DNA: A novel biomarker of response to poly (ADP-ribose) polymerase inhibition in BRCA-mutated epithelial ovarian cancer.
Ovarian Neoplasms
Clinical Application of Poly(ADP-Ribose) Polymerase Inhibitors in High-Grade Serous Ovarian Cancer.
Ovarian Neoplasms
Clinical benefit of systemic therapies for recurrent ovarian cancer-ESMO-MCBS scores.
Ovarian Neoplasms
Clinical features and outcomes of germline mutation BRCA1-linked versus sporadic ovarian cancer patients.
Ovarian Neoplasms
Clinical perspectives of BET inhibition in ovarian cancer.
Ovarian Neoplasms
Clinical trials and future potential of targeted therapy for ovarian cancer.
Ovarian Neoplasms
Co-treatment with BEZ235 Enhances Sensitivity of BRCA1-negative Breast Cancer Cells to Olaparib.
Ovarian Neoplasms
Combination of erlotinib and a PARP inhibitor inhibits growth of A2780 tumor xenografts due to increased autophagy.
Ovarian Neoplasms
Combination of Niraparib, Cisplatin and Twist Knockdown in Cisplatin-Resistant Ovarian Cancer Cells Potentially Enhances Synthetic Lethality through ER-Stress Mediated Mitochondrial Apoptosis Pathway.
Ovarian Neoplasms
Combination of PARP Inhibitor Olaparib, and PD-L1 Inhibitor Durvalumab, in Recurrent Ovarian Cancer: a Proof-of-Concept Phase II Study.
Ovarian Neoplasms
Combination Platinum-based and DNA Damage Response-targeting Cancer Therapy: Evolution and Future Directions.
Ovarian Neoplasms
Combination treatment with cisplatin, paclitaxel and olaparib has synergistic and dose reduction potential in ovarian cancer cells.
Ovarian Neoplasms
Combinatorial therapy of immune checkpoint and cancer pathways provides a novel perspective on ovarian cancer treatment.
Ovarian Neoplasms
Combined inhibition of PI3K and PARP is effective in the treatment of ovarian cancer cells with wild-type PIK3CA genes.
Ovarian Neoplasms
Combined PARP and Immune Checkpoint Inhibition in Ovarian Cancer.
Ovarian Neoplasms
Combined Strategies with Poly (ADP-Ribose) Polymerase (PARP) Inhibitors for the Treatment of Ovarian Cancer: A Literature Review.
Ovarian Neoplasms
Combined Targeted Resequencing of Cytosine DNA Methylation and Mutations of DNA Repair Genes with Potential Use for Poly(ADP-Ribose) Polymerase 1 Inhibitor Sensitivity Testing.
Ovarian Neoplasms
Combining 53BP1 with BRCA1 as a biomarker to predict the sensitivity of poly(ADP-ribose) polymerase (PARP) inhibitors.
Ovarian Neoplasms
Combining PARP and CDK4/6 inhibitors in MYC driven ovarian cancer.
Ovarian Neoplasms
Combining PARP with ATR inhibition overcomes PARP inhibitor and platinum resistance in ovarian cancer models.
Ovarian Neoplasms
Combining PI3K and PARP inhibitors for breast and ovarian cancer treatment.
Ovarian Neoplasms
Comparative Assessment of Diagnostic Homologous Recombination Deficiency-Associated Mutational Signatures in Ovarian Cancer.
Ovarian Neoplasms
Comparative Efficacy and Safety of PARP Inhibitors as Maintenance Therapy in Platinum Sensitive Recurrent Ovarian Cancer: A Network Meta-Analysis.
Ovarian Neoplasms
Comparing poly (ADP-ribose) polymerase inhibitors with standard chemotherapy in BRCA-mutated, recurrent ovarian cancer: lessons learned from a negative trial.
Ovarian Neoplasms
Comparison of PARPis with Angiogenesis Inhibitors and Chemotherapy for Maintenance in Ovarian Cancer: A Network Meta-Analysis.
Ovarian Neoplasms
Comparison of Poly (ADP-ribose) Polymerase Inhibitors (PARPis) as Maintenance Therapy for Platinum-Sensitive Ovarian Cancer: Systematic Review and Network Meta-Analysis.
Ovarian Neoplasms
Complementary genetic screens identify the E3 ubiquitin ligase CBLC, as a modifier of PARP inhibitor sensitivity.
Ovarian Neoplasms
Concepts and Molecular Aspects in the Polypharmacology of PARP-1 Inhibitors.
Ovarian Neoplasms
Concordance between CA-125 and RECIST progression in patients with germline BRCA-mutated platinum-sensitive relapsed ovarian cancer treated in the SOLO2 trial with olaparib as maintenance therapy after response to chemotherapy.
Ovarian Neoplasms
Consolidated BRCA1/2 Variant Interpretation by MH BRCA Correlates with Predicted PARP Inhibitor Efficacy Association by MH Guide.
Ovarian Neoplasms
Controversies on the treatment of ovarian cancer with dose-dense chemotherapy.
Ovarian Neoplasms
Conventional chemotherapy and oncogenic pathway targeting in ovarian carcinosarcoma using a patient-derived tumorgraft.
Ovarian Neoplasms
Copy number deletion of RAD50 as predictive marker of BRCAness and PARP inhibitor response in BRCA wild type ovarian cancer.
Ovarian Neoplasms
Corrigendum to 'Chemotherapy and PARP inhibitors in heavily pretreated BRCA1/2 mutation ovarian cancer (BMOC) patients' [Gynecologic Oncology 152 (2019) 270-277].
Ovarian Neoplasms
Corrigendum to 'The forefront of ovarian cancer therapy: update on PARP inhibitors': [Annals of Oncology 31 (2020) 1148-1159].
Ovarian Neoplasms
Cost-effectiveness analysis comparing "PARP inhibitors-for-all" to the biomarker-directed use of PARP inhibitor maintenance therapy for newly diagnosed advanced stage ovarian cancer.
Ovarian Neoplasms
Cost-effectiveness of BRCA1 and BRCA2 mutation testing to target PARP inhibitor use in platinum-sensitive recurrent ovarian cancer.
Ovarian Neoplasms
Cost-Effectiveness of Niraparib and Olaparib as Maintenance Therapy for Patients with Platinum-Sensitive Recurrent Ovarian Cancer.
Ovarian Neoplasms
Crizotinib and PARP inhibitors act synergistically by triggering apoptosis in high-grade serous ovarian cancer.
Ovarian Neoplasms
CTLA-4 Blockade Synergizes Therapeutically with PARP Inhibition in BRCA1-Deficient Ovarian Cancer.
Ovarian Neoplasms
Current role of poly(ADP-ribose) polymerase inhibitors: which poly(ADP-ribose) polymerase inhibitor and when?
Ovarian Neoplasms
Current status and future prospects of PARP inhibitor clinical trials in ovarian cancer.
Ovarian Neoplasms
Current strategies for the targeted treatment of high-grade serous epithelial ovarian cancer and relevance of BRCA mutational status.
Ovarian Neoplasms
Current Systemic Treatment Landscape of Advanced Gynecologic Malignancies.
Ovarian Neoplasms
CX-5461 activates the DNA damage response and demonstrates therapeutic efficacy in high-grade serous ovarian cancer.
Ovarian Neoplasms
CX-5461 can destabilize replication forks in PARP inhibitor-resistant models of ovarian cancer.
Ovarian Neoplasms
Cytocidal Antitumor Effects against Human Ovarian Cancer Cells Induced by B-Lactam Steroid Alkylators with Targeted Activity against Poly (ADP-Ribose) Polymerase (PARP) Enzymes in a Cell-Free Assay.
Ovarian Neoplasms
Decapping protein EDC4 regulates DNA repair and phenocopies BRCA1.
Ovarian Neoplasms
Decision analysis for secondline maintenance treatment of platinum sensitive recurrent ovarian cancer: a review.
Ovarian Neoplasms
Defective DNA repair in hereditary ovarian cancers: Implications for therapy.
Ovarian Neoplasms
Defining and targeting wild-type BRCA high-grade serous ovarian cancer: DNA repair and cell cycle checkpoints.
Ovarian Neoplasms
Delivering widespread BRCA testing and PARP inhibition to patients with ovarian cancer.
Ovarian Neoplasms
Detecting the mutational signature of homologous recombination deficiency in clinical samples.
Ovarian Neoplasms
Development of a functional assay for homologous recombination status in primary cultures of epithelial ovarian tumor and correlation with sensitivity to poly(ADP-ribose) polymerase inhibitors.
Ovarian Neoplasms
Development of a multiparameter flow cytometric assay as a potential biomarker for homologous recombination deficiency in women with high-grade serous ovarian cancer.
Ovarian Neoplasms
Development of new poly(ADP-ribose) polymerase (PARP) inhibitors in ovarian cancer: Quo Vadis?
Ovarian Neoplasms
Development of Olaparib for BRCA-Deficient Recurrent Epithelial Ovarian Cancer.
Ovarian Neoplasms
Development of PARP inhibitors in gynecological malignancies.
Ovarian Neoplasms
Differences in PARP Inhibitors for the Treatment of Ovarian Cancer: Mechanisms of Action, Pharmacology, Safety, and Efficacy.
Ovarian Neoplasms
Differential regulation of breast cancer bone metastasis by PARP1 and PARP2.
Ovarian Neoplasms
Directing the use of DDR kinase inhibitors in cancer treatment.
Ovarian Neoplasms
Discovery of potent 2,4-difluoro-linker poly(ADP-ribose) polymerase 1 inhibitors with enhanced water solubility and in vivo anticancer efficacy.
Ovarian Neoplasms
Discovery, mechanism and metabolism studies of 2,3-difluorophenyl-linker-containing PARP1 inhibitors with enhanced in vivo efficacy for cancer therapy.
Ovarian Neoplasms
Distinct implications of different BRCA mutations: efficacy of cytotoxic chemotherapy, PARP inhibition and clinical outcome in ovarian cancer.
Ovarian Neoplasms
Diverse BRCA1 and BRCA2 Reversion Mutations in Circulating Cell-Free DNA of Therapy-Resistant Breast or Ovarian Cancer.
Ovarian Neoplasms
Diverse mechanisms of PARP inhibitor resistance in ovarian cancer.
Ovarian Neoplasms
DNA Damage Repair Inhibitor for Breast Cancer Treatment.
Ovarian Neoplasms
DNA damage response as a therapeutic target in gynecological cancers.
Ovarian Neoplasms
DNA double-strand break repair pathway choice - from basic biology to clinical exploitation.
Ovarian Neoplasms
DNA repair proteins as therapeutic targets in ovarian cancer.
Ovarian Neoplasms
DNA replication stress and emerging prospects for PARG inhibitors in ovarian cancer therapy.
Ovarian Neoplasms
DNA Replication Vulnerabilities Render Ovarian Cancer Cells Sensitive to Poly(ADP-Ribose) Glycohydrolase Inhibitors.
Ovarian Neoplasms
Drug conjugation to hyaluronan widens therapeutic indications for ovarian cancer.
Ovarian Neoplasms
Drug therapy for hereditary cancers.
Ovarian Neoplasms
DUETTE: a phase II randomized, multicenter study to investigate the efficacy and tolerability of a second maintenance treatment in patients with platinum-sensitive relapsed epithelial ovarian cancer, who have previously received poly(ADP-ribose) polymerase (PARP) inhibitor maintenance treatment.
Ovarian Neoplasms
Dynamic variations in epithelial-to-mesenchymal transition (EMT), ATM, and SLFN11 govern response to PARP inhibitors and cisplatin in small cell lung cancer.
Ovarian Neoplasms
Editorial.
Ovarian Neoplasms
Effect of Amino Acids on the Generation of Ginsenoside Rg3 Epimers by Heat Processing and the Anticancer Activities of Epimers in A2780 Human Ovarian Cancer Cells.
Ovarian Neoplasms
Effect of Itraconazole and Rifampin on the Pharmacokinetics of Olaparib in Patients With Advanced Solid Tumors: Results of Two Phase I Open-label Studies.
Ovarian Neoplasms
Effect of PARP Inhibitors as Maintenance Treatment on Restricted Mean Survival Time in Platinum-Sensitive Recurrent Ovarian Cancer: A Systematic Review and Meta-analysis.
Ovarian Neoplasms
Effective use of PI3K inhibitor BKM120 and PARP inhibitor Olaparib to treat PIK3CA mutant ovarian cancer.
Ovarian Neoplasms
Effects of Combined Treatment with Ionizing Radiation and the PARP Inhibitor Olaparib in BRCA Mutant and Wild Type Patient-Derived Pancreatic Cancer Xenografts.
Ovarian Neoplasms
Effects of PARP-1 inhibitor and ERK inhibitor on epithelial mesenchymal transitions of the ovarian cancer SKOV3 cells.
Ovarian Neoplasms
Effects of poly (ADP-ribosyl) polymerase (PARP) inhibitor on cisplatin resistance & proliferation of the ovarian cancer C13* cells.
Ovarian Neoplasms
Efficacy and Prognostic Factors for PARP Inhibitors in Patients With Ovarian Cancer.
Ovarian Neoplasms
Efficacy and safety of anti-PD-1-based therapy in combination with PARP inhibitors for patients with advanced solid tumors in a real-world setting.
Ovarian Neoplasms
Efficacy and safety of olaparib maintenance therapy in platinum-sensitive ovarian cancer patients with BRCA mutations: a meta-analysis on randomized controlled trials.
Ovarian Neoplasms
Efficacy and safety of olaparib monotherapy in germline BRCA1/2 mutation carriers with advanced ovarian cancer and three or more lines of prior therapy.
Ovarian Neoplasms
Efficacy and Safety of PARP Inhibitor Combination Therapy in Recurrent Ovarian Cancer: A Systematic Review and Meta-Analysis.
Ovarian Neoplasms
Efficacy and safety of PARP inhibitors as the maintenance therapy in ovarian cancer: a meta-analysis of nine randomized controlled trials.
Ovarian Neoplasms
Efficacy and safety of PARP inhibitors in the treatment of advanced ovarian cancer: An updated systematic review and meta-analysis of randomized controlled trials.
Ovarian Neoplasms
Efficacy of Chemotherapy in BRCA1/2 Mutation Carrier Ovarian Cancer in the Setting of PARP Inhibitor Resistance: A Multi-Institutional Study.
Ovarian Neoplasms
Emerging drugs for the treatment of ovarian cancer: a focused review of PARP inhibitors.
Ovarian Neoplasms
Emerging role of immune checkpoint inhibitors in the treatment of ovarian cancer.
Ovarian Neoplasms
Emerging treatment options for ovarian cancer: focus on rucaparib.
Ovarian Neoplasms
Emerging treatment options for recurrent ovarian cancer: the potential role of olaparib.
Ovarian Neoplasms
Enhanced Efficacy of Combined Therapy with Checkpoint Kinase 1 Inhibitor and Rucaparib Via Regulation of Rad-51 Expression in BRCA Wild-Type Epithelial Ovarian Cancer Cells.
Ovarian Neoplasms
Enhanced non-homologous end joining contributes toward synthetic lethality of pathological RAD51C mutants with poly (ADP-ribose) polymerase.
Ovarian Neoplasms
Enhancing chemotherapy response with bmi-1 silencing in ovarian cancer.
Ovarian Neoplasms
Epigenetic synthetic lethality approaches in cancer therapy.
Ovarian Neoplasms
ERCC1-XPF deficiency is a predictor of olaparib induced synthetic lethality and platinum sensitivity in epithelial ovarian cancers.
Ovarian Neoplasms
ESMO recommendations on predictive biomarker testing for homologous recombination deficiency and PARP inhibitor benefit in ovarian cancer.
Ovarian Neoplasms
Evaluating the potential of kinase inhibitors to suppress DNA repair and sensitise ovarian cancer cells to PARP inhibitors.
Ovarian Neoplasms
Evaluation of rucaparib and companion diagnostics in the PARP inhibitor landscape for recurrent ovarian cancer therapy.
Ovarian Neoplasms
Evaluation of the epidemiological and prognosis significance of ESR2 rs3020450 polymorphism in ovarian cancer.
Ovarian Neoplasms
Evidence for tight coupling of Gi protein-mediated lysophosphatidic acid receptor to stimulated cytokine production in ovarian cancer cell.
Ovarian Neoplasms
EVOLVE: A Multicenter Open-Label Single-Arm Clinical and Translational Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer after PARP Inhibition Progression.
Ovarian Neoplasms
Exceptional Response to Olaparib in a Patient With Recurrent Ovarian Cancer and an Entire BRCA1 Germline Gene Deletion.
Ovarian Neoplasms
Exploiting interconnected synthetic lethal interactions between PARP inhibition and cancer cell reversible senescence.
Ovarian Neoplasms
Exploiting replicative stress in gynecological cancers as a therapeutic strategy.
Ovarian Neoplasms
Exploiting the Prevalence of Homologous Recombination Deficiencies in High-Grade Serous Ovarian Cancer.
Ovarian Neoplasms
Exploring and comparing adverse events between PARP inhibitors.
Ovarian Neoplasms
Expression of PD-L1 in ovarian cancer and its synergistic antitumor effect with PARP inhibitor.
Ovarian Neoplasms
Expression of potential biomarkers associated with homologous recombination repair in patients with ovarian or triple-negative breast cancer.
Ovarian Neoplasms
Expression profiles of vault components MVP, TEP1 and vPARP and their correlation to other multidrug resistance proteins in ovarian cancer.
Ovarian Neoplasms
Extending the scope of PARP inhibitors in ovarian cancer.
Ovarian Neoplasms
EZH2 contributes to the response to PARP inhibitors through its PARP-mediated poly-ADP ribosylation in breast cancer.
Ovarian Neoplasms
EZH2 Inhibition Sensitizes CARM1-High, Homologous Recombination Proficient Ovarian Cancers to PARP Inhibition.
Ovarian Neoplasms
FDA Approval of PARP Inhibitors and the Impact on Genetic Counseling and Genetic Testing Practices.
Ovarian Neoplasms
FDA Approval Summary: Olaparib Monotherapy or in Combination with Bevacizumab for the Maintenance Treatment of Patients with Advanced Ovarian Cancer.
Ovarian Neoplasms
FDA approves PARP inhibitor for ovarian cancer.
Ovarian Neoplasms
First-line PARP inhibition in ovarian cancer - standard of care for all?
Ovarian Neoplasms
First-line PARP inhibitors in ovarian cancer: summary of an ESMO Open - Cancer Horizons round-table discussion.
Ovarian Neoplasms
Front-line ovarian cancer maintenance therapy: PARP inhibitors for all?
Ovarian Neoplasms
Frontline PARP inhibitor maintenance therapy in ovarian cancer: A Society of Gynecologic Oncology practice statement.
Ovarian Neoplasms
Frontline therapy of ovarian cancer: trials and tribulations.
Ovarian Neoplasms
Further Analyses Highlight Benefits of PARP Inhibitors As Frontline Maintenance in Ovarian Cancer.
Ovarian Neoplasms
Gene Panel Tumor Testing in Ovarian Cancer Patients Significantly Increases the Yield of Clinically Actionable Germline Variants beyond BRCA1/BRCA2.
Ovarian Neoplasms
Genetic and epigenetic heterogeneity of epithelial ovarian cancer and the clinical implications for molecular targeted therapy.
Ovarian Neoplasms
Genetic Screens Reveal FEN1 and APEX2 as BRCA2 Synthetic Lethal Targets.
Ovarian Neoplasms
Genome-wide analysis of gynecologic cancer: The Cancer Genome Atlas in ovarian and endometrial cancer.
Ovarian Neoplasms
Genomic instability in breast and ovarian cancers: translation into clinical predictive biomarkers.
Ovarian Neoplasms
Genomic LOH May Predict Rucaparib Response in Ovarian Cancer.
Ovarian Neoplasms
Genomic scars as biomarkers of homologous recombination deficiency and drug response in breast and ovarian cancers.
Ovarian Neoplasms
Genomic, Transcriptomic, and Functional Alterations in DNA Damage Response Pathways as Putative Biomarkers of Chemotherapy Response in Ovarian Cancer.
Ovarian Neoplasms
Genomic-Based Therapy of Gynecologic Malignancies.
Ovarian Neoplasms
Germline and somatic mutations of homologous recombination-associated genes in Japanese ovarian cancer patients.
Ovarian Neoplasms
Germline mutations in Black patients with ovarian, fallopian tube and primary peritoneal carcinomas.
Ovarian Neoplasms
GnRH-R-Targeted Lytic Peptide Sensitizes BRCA Wild-type Ovarian Cancer to PARP Inhibition.
Ovarian Neoplasms
Gynecologic Cancers: Emerging Novel Strategies for Targeting DNA Repair Deficiency.
Ovarian Neoplasms
HER2 Overexpression Renders Human Breast Cancers Sensitive to PARP Inhibition Independently of Any Defect in Homologous Recombination DNA Repair.
Ovarian Neoplasms
Hereditary ovarian carcinomas: clinico-biological features and treatment.
Ovarian Neoplasms
Hereditary pancreatic cancer.
Ovarian Neoplasms
High poly(adenosine diphosphate-ribose) polymerase expression and poor survival in advanced-stage serous ovarian cancer.
Ovarian Neoplasms
High resolution melting profiles (HRMPs) obtained by magnetic induction cycler (MIC) have been used to monitor the BRCA2 status highlighted by next generation tumor sequencing (NGTS): a combined approach in a diagnostic environment.
Ovarian Neoplasms
HO-3867, a STAT3 inhibitor induces apoptosis by inactivation of STAT3 activity in BRCA1-mutated ovarian cancer cells.
Ovarian Neoplasms
Homologous recombination deficiency and ovarian cancer.
Ovarian Neoplasms
Homologous recombination deficiency in ovarian cancer: a review of its epidemiology and management.
Ovarian Neoplasms
How safe is rucaparib in ovarian cancer?
Ovarian Neoplasms
Identification of biomarkers complementary to homologous recombination deficiency for improving the clinical outcome of ovarian serous cystadenocarcinoma.
Ovarian Neoplasms
Identification of BRCA1-deficient ovarian cancers.
Ovarian Neoplasms
Identification of DNA Repair Pathways that Affect the Survival of Ovarian Cancer Cells Treated with a PARP Inhibitor in a Novel Drug Combination.
Ovarian Neoplasms
Identification of Novel Biomarkers of Homologous Recombination Defect in DNA Repair to Predict Sensitivity of Prostate Cancer Cells to PARP-Inhibitors.
Ovarian Neoplasms
Identification of PARP-7 substrates reveals a role for MARylation in microtubule control in ovarian cancer cells.
Ovarian Neoplasms
Identifying and Overcoming Mechanisms of PARP Inhibitor Resistance in Homologous Recombination Repair-Deficient and Repair-Proficient High Grade Serous Ovarian Cancer Cells.
Ovarian Neoplasms
Identifying the need to refine the potential patient risk factors for niraparib-induced thrombocytopenia.
Ovarian Neoplasms
Immune System and DNA Repair Defects in Ovarian Cancer: Implications for Locoregional Approaches.
Ovarian Neoplasms
Immunogenomic profiling determines responses to combined PARP and PD-1 inhibition in ovarian cancer.
Ovarian Neoplasms
Immunotherapy in ovarian, endometrial and cervical cancer: State of the art and future perspectives.
Ovarian Neoplasms
Impact of proactive high-throughput functional assay data on BRCA1 variant interpretation in 3684 patients with breast or ovarian cancer.
Ovarian Neoplasms
In silico screening identifies a novel small molecule inhibitor that counteracts PARP inhibitor resistance in ovarian cancer.
Ovarian Neoplasms
In vivo anti-tumor activity of the PARP inhibitor niraparib in homologous recombination deficient and proficient ovarian carcinoma.
Ovarian Neoplasms
Increased oxidative stress mediates the antitumor effect of PARP inhibition in ovarian cancer.
Ovarian Neoplasms
Increased single-strand annealing rather than non-homologous end-joining predicts hereditary ovarian carcinoma.
Ovarian Neoplasms
Inducing Synthetic Lethality using PARP Inhibitors.
Ovarian Neoplasms
Induction of apoptosis by the new anticancer drug XK469 in human ovarian cancer cell lines.
Ovarian Neoplasms
Inherited gynaecological cancers.
Ovarian Neoplasms
Inhibition of Hec1 expression enhances the sensitivity of human ovarian cancer cells to paclitaxel.
Ovarian Neoplasms
Inhibition of poly(ADP)-ribose polymerase as a therapeutic strategy for breast cancer.
Ovarian Neoplasms
Inhibition of Poly(ADP-Ribose) Polymerase Enhances Radiochemosensitivity in Cancers Proficient in DNA Double-Strand Break Repair.
Ovarian Neoplasms
Inhibition of poly(ADP-ribose) polymerase induces synthetic lethality in BRIP1 deficient ovarian epithelial cells.
Ovarian Neoplasms
Inhibition of proliferation and invasiveness of ovarian cancer C13* cells by a poly(ADP-ribose) polymerase inhibitor and the role of nuclear factor-?B.
Ovarian Neoplasms
Inhibition of the MYC-regulated glutaminase metabolic axis is an effective synthetic lethal approach for treating chemoresistant cancers.
Ovarian Neoplasms
Inhibitory PARP w terapii raka jajnika.
Ovarian Neoplasms
Intraperitoneal delivery of NanoOlaparib for disseminated late-stage cancer treatment.
Ovarian Neoplasms
Involvement of homologous recombination in the synergism between cisplatin and poly(ADP-ribose) polymerase inhibition.
Ovarian Neoplasms
It is not all about BRCA: Cullin-Ring ubiquitin Ligases in ovarian cancer.
Ovarian Neoplasms
Lack of MRE11-RAD50-NBS1 (MRN) complex detection occurs frequently in low-grade epithelial ovarian cancer.
Ovarian Neoplasms
Latest clinical evidence and further development of PARP inhibitors in ovarian cancer.
Ovarian Neoplasms
Layer-by-layer nanoparticles for novel delivery of cisplatin and PARP inhibitors for platinum-based drug resistance therapy in ovarian cancer.
Ovarian Neoplasms
Let-7e Suppresses DNA Damage Repair and Sensitizes Ovarian Cancer to Cisplatin through Targeting PARP1.
Ovarian Neoplasms
Leveraging DNA repair deficiency in gynecologic oncology.
Ovarian Neoplasms
Lived experiences of women reporting fatigue during PARP inhibitor maintenance treatment for advanced ovarian cancer: A qualitative study.
Ovarian Neoplasms
Long-term response to Olaparib in carcinomatous meningitis of a
BRCA2
mutated ovarian cancer: A case report.
Ovarian Neoplasms
Long-term safety in patients with recurrent ovarian cancer treated with niraparib versus placebo: Results from the phase III ENGOT-OV16/NOVA trial.
Ovarian Neoplasms
Loss of CHD1 causes DNA repair defects and enhances prostate cancer therapeutic responsiveness.
Ovarian Neoplasms
Loss of E2F7 confers resistance to poly-ADP-ribose polymerase (PARP) inhibitors in BRCA2-deficient cells.
Ovarian Neoplasms
Loss of INPP4B causes a DNA repair defect through loss of BRCA1, ATM and ATR and can be targeted with PARP inhibitor treatment.
Ovarian Neoplasms
Lovastatin induces apoptosis of ovarian cancer cells and synergizes with doxorubicin: potential therapeutic relevance.
Ovarian Neoplasms
Low ATM protein expression and depletion of p53 correlates with olaparib sensitivity in gastric cancer cell lines.
Ovarian Neoplasms
LRRK2 inhibition potentiates PARP inhibitor cytotoxicity through inhibiting homologous recombination-mediated DNA double strand break repair.
Ovarian Neoplasms
Lysophosphatidic acid and endothelin-induced proliferation of ovarian cancer cell lines is mitigated by neutralization of granulin-epithelin precursor (GEP), a prosurvival factor for ovarian cancer.
Ovarian Neoplasms
Magnitude of benefit of the addition of poly ADP-ribose polymerase (PARP) inhibitors to therapy for malignant tumor: A meta-analysis.
Ovarian Neoplasms
Magnolol down-regulates HER2 gene expression, leading to inhibition of HER2-mediated metastatic potential in ovarian cancer cells.
Ovarian Neoplasms
Maintenance Poly (ADP-ribose) Polymerase Inhibitor Therapy for Ovarian Cancer: Precision Oncology or One Size Fits All?
Ovarian Neoplasms
Major clinical research advances in gynecologic cancer in 2018.
Ovarian Neoplasms
Major clinical research advances in gynecologic cancer in 2019.
Ovarian Neoplasms
Major clinical research advances in gynecologic cancer in 2020.
Ovarian Neoplasms
Making the best of PARP inhibitors in ovarian cancer.
Ovarian Neoplasms
Manage wisely: poly (ADP-ribose) polymerase inhibitor (PARPi) treatment and adverse events.
Ovarian Neoplasms
Management of Adverse Events During Rucaparib Treatment for Relapsed Ovarian Cancer: A Review of Published Studies and Practical Guidance.
Ovarian Neoplasms
Management of nausea and vomiting from poly(ADP-ribose) polymerase inhibitor therapy for advanced ovarian cancer.
Ovarian Neoplasms
Management of newly diagnosed or recurrent ovarian cancer.
Ovarian Neoplasms
Managing recurrent ovarian cancer in daily clinical practice: case studies and evidence review with a focus on the use of trabectedin.
Ovarian Neoplasms
Mapping genetic interactions in cancer: a road to rational combination therapies.
Ovarian Neoplasms
Mechanism and current progress of Poly ADP-ribose polymerase (PARP) inhibitors in the treatment of ovarian cancer.
Ovarian Neoplasms
Mechanisms of PARP inhibitor resistance in ovarian cancer.
Ovarian Neoplasms
Mechanisms of PARP inhibitor sensitivity and resistance.
Ovarian Neoplasms
Medicinal chemistry approaches of poly ADP-Ribose polymerase 1 (PARP1) inhibitors as anticancer agents - A recent update.
Ovarian Neoplasms
MicroRNA-506-3p increases the response to PARP inhibitors and cisplatin by targeting EZH2/?-catenin in serous ovarian cancers.
Ovarian Neoplasms
MiR-216b increases cisplatin sensitivity in ovarian cancer cells by targeting PARP1.
Ovarian Neoplasms
MiR-509-3 augments the synthetic lethality of PARPi by regulating HR repair in PDX model of HGSOC.
Ovarian Neoplasms
miR-9 regulation of BRCA1 and ovarian cancer sensitivity to cisplatin and PARP inhibition.
Ovarian Neoplasms
Missed therapeutic and prevention opportunities in women with BRCA-mutated epithelial ovarian cancer and their families due to low referral rates for genetic counseling and BRCA testing: A review of the literature.
Ovarian Neoplasms
MKP-1 suppresses PARP-1 degradation to mediate cisplatin resistance.
Ovarian Neoplasms
Modulation of Early Mitotic Inhibitor 1 (EMI1) depletion on the sensitivity of PARP inhibitors in BRCA1 mutated triple-negative breast cancer cells.
Ovarian Neoplasms
Molecular and clinical predictors of improvement in progression-free survival with maintenance PARP inhibitor therapy in women with platinum-sensitive, recurrent ovarian cancer: A meta-analysis.
Ovarian Neoplasms
Molecular disruption of DNA polymerase ? for platinum sensitisation and synthetic lethality in epithelial ovarian cancers.
Ovarian Neoplasms
Molecular Pathways: Targeting DNA Repair Pathway Defects Enriched in Metastasis.
Ovarian Neoplasms
Molecular profiling and commercial predication assays in ovarian cancer: still not ready for prime time?
Ovarian Neoplasms
Molecular Testing Identifies Determinants of Exceptional Response and Guides Precision Therapy in a Patient with Lethal, Treatment-emergent Neuroendocrine Prostate Cancer.
Ovarian Neoplasms
Monepantel induces autophagy in human ovarian cancer cells through disruption of the mTOR/p70S6K signalling pathway.
Ovarian Neoplasms
Movement of Poly-ADP Ribose (PARP) Inhibition into Frontline Treatment of Ovarian Cancer.
Ovarian Neoplasms
Moving From Mutation to Actionability.
Ovarian Neoplasms
Moving From Poly (ADP-Ribose) Polymerase Inhibition to Targeting DNA Repair and DNA Damage Response in Cancer Therapy.
Ovarian Neoplasms
Moving toward personalized medicine: treatment-focused genetic testing of women newly diagnosed with ovarian cancer.
Ovarian Neoplasms
Multifaceted Impact of MicroRNA 493-5p on Genome-Stabilizing Pathways Induces Platinum and PARP Inhibitor Resistance in BRCA2-Mutated Carcinomas.
Ovarian Neoplasms
Mutation landscape of germline and somatic BRCA1/2 in patients with high-grade serous ovarian cancer.
Ovarian Neoplasms
MYC status as a determinant of synergistic response to Olaparib and Palbociclib in ovarian cancer.
Ovarian Neoplasms
Myelodysplastic syndrome and acute myeloid leukaemia in patients treated with PARP inhibitors: a safety meta-analysis of randomised controlled trials and a retrospective study of the WHO pharmacovigilance database.
Ovarian Neoplasms
NADP+ is an endogenous PARP inhibitor in DNA damage response and tumor suppression.
Ovarian Neoplasms
Nanoformulation of Talazoparib Delays Tumor Progression and Ascites Formation in a Late Stage Cancer Model.
Ovarian Neoplasms
Nanoparticle-mediated delivery of siRNA targeting Parp1 extends survival of mice bearing tumors derived from Brca1-deficient ovarian cancer cells.
Ovarian Neoplasms
NEAT1 Knockdown Suppresses the Cisplatin Resistance in Ovarian Cancer by Regulating miR-770-5p/PARP1 Axis.
Ovarian Neoplasms
New developments in molecular targeted therapy of ovarian cancer.
Ovarian Neoplasms
New developments in the treatment of ovarian cancer--future perspectives.
Ovarian Neoplasms
New quantitative mass spectrometry approaches reveal different ADP-ribosylation phases dependent on the levels of oxidative stress.
Ovarian Neoplasms
New strategies in ovarian cancer: translating the molecular complexity of ovarian cancer into treatment advances.
Ovarian Neoplasms
New strategies in the treatment of ovarian cancer: current clinical perspectives and future potential.
Ovarian Neoplasms
New Targeted Agents in Gynecologic Cancers: Synthetic Lethality, Homologous Recombination Deficiency, and PARP Inhibitors.
Ovarian Neoplasms
New Therapies for Ovarian Cancer.
Ovarian Neoplasms
New treatment option for ovarian cancer: PARP inhibitors.
Ovarian Neoplasms
Next-generation sequencing-based BRCA testing on cytological specimens from ovarian cancer ascites reveals high concordance with tumour tissue analysis.
Ovarian Neoplasms
Next-Generation Sequencing-based genomic profiling of brain metastases of primary ovarian cancer identifies high number of BRCA-mutations.
Ovarian Neoplasms
Niraparib activates interferon signaling and potentiates anti-PD-1 antibody efficacy in tumor models.
Ovarian Neoplasms
Niraparib as Maintenance Therapy in Germline ATM-mutated and Somatic BRCA2-mutated Ovarian Cancer with Brain Metastases: A Case Report and Literature Review.
Ovarian Neoplasms
Niraparib for the treatment of ovarian cancer.
Ovarian Neoplasms
Niraparib for the Treatment of Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer.
Ovarian Neoplasms
Niraparib in the maintenance treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer: safety and efficacy.
Ovarian Neoplasms
Niraparib in the treatment of previously treated advanced ovarian, fallopian tube or primary peritoneal cancer.
Ovarian Neoplasms
Niraparib maintenance therapy in patients with platinum-sensitive recurrent ovarian cancer using an individualized starting dose (NORA): a randomized, double-blind, placebo-controlled phase III trial?.
Ovarian Neoplasms
Niraparib Maintenance Therapy in Patients With Recurrent Ovarian Cancer After a Partial Response to the Last Platinum-Based Chemotherapy in the ENGOT-OV16/NOVA Trial.
Ovarian Neoplasms
Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial.
Ovarian Neoplasms
Niraparib Slows Ovarian Cancer Progression.
Ovarian Neoplasms
Nobiletin Triggers Reactive Oxygen Species-Mediated Pyroptosis through Regulating Autophagy in Ovarian Cancer Cells.
Ovarian Neoplasms
Non-small cell lung cancer cells with deficiencies in homologous recombination genes are sensitive to PARP inhibitors.
Ovarian Neoplasms
Novel pharmacological effects of poly (ADP-ribose) polymerase inhibitor rucaparib on the lactate dehydrogenase pathway.
Ovarian Neoplasms
Novel targeted therapeutics: inhibitors of MDM2, ALK and PARP.
Ovarian Neoplasms
Novel Therapeutics for Ovarian Cancer: The 11th Biennial Rivkin Center Ovarian Cancer Research Symposium.
Ovarian Neoplasms
Novel therapeutics: response and resistance in ovarian cancer.
Ovarian Neoplasms
Novel therapies, including enzastaurin, in the treatment of ovarian cancer.
Ovarian Neoplasms
Olaparib , PARP1 inhibitor in ovarian cancer.
Ovarian Neoplasms
Olaparib approved for advanced ovarian cancer.
Ovarian Neoplasms
Olaparib as maintenance treatment for patients with platinum-sensitive relapsed ovarian cancer.
Ovarian Neoplasms
Olaparib Combined with an ATR or Chk1 Inhibitor as a Treatment Strategy for Acquired Olaparib-Resistant BRCA1 Mutant Ovarian Cells.
Ovarian Neoplasms
Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial.
Ovarian Neoplasms
Olaparib for the treatment of BRCA-mutated advanced ovarian cancer.
Ovarian Neoplasms
Olaparib for the treatment of epithelial ovarian cancer.
Ovarian Neoplasms
Olaparib for the treatment of ovarian cancer.
Ovarian Neoplasms
Olaparib for the treatment of relapsed ovarian cancer with a BRCA1/2 mutation.
Ovarian Neoplasms
Olaparib hydroxamic acid derivatives as dual PARP and HDAC inhibitors for cancer therapy.
Ovarian Neoplasms
Olaparib in the management of ovarian cancer.
Ovarian Neoplasms
Olaparib in the therapy of advanced ovarian cancer: first real world experiences in safety and efficacy from China.
Ovarian Neoplasms
Olaparib induced senescence under P16 or P53 dependent manner in ovarian cancer.
Ovarian Neoplasms
Olaparib maintenance monotherapy in platinum-sensitive, relapsed ovarian cancer without germline BRCA mutations: OPINION Phase IIIb study design.
Ovarian Neoplasms
Olaparib maintenance therapy in patients with newly diagnosed advanced ovarian cancer and a BRCA1 and/or BRCA2 mutation: SOLO1 China cohort.
Ovarian Neoplasms
Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial.
Ovarian Neoplasms
Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation.
Ovarian Neoplasms
Olaparib monotherapy in patients with advanced relapsed ovarian cancer and a germline BRCA1/2 mutation: a multi-study analysis of response rates and safety.
Ovarian Neoplasms
Olaparib shows promise in multiple tumor types.
Ovarian Neoplasms
Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial.
Ovarian Neoplasms
Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial.
Ovarian Neoplasms
Olaparib: a promising PARP inhibitor in ovarian cancer therapy.
Ovarian Neoplasms
Olaparib: an oral PARP-1 and PARP-2 inhibitor with promising activity in ovarian cancer.
Ovarian Neoplasms
Oncologist-led BRCA 'mainstreaming' in the ovarian cancer clinic: A study of 255 patients and its impact on their management.
Ovarian Neoplasms
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial.
Ovarian Neoplasms
Ovarian Cancer Translational Activity of the Multicenter Italian Trial in Ovarian Cancer (MITO) Group: Lessons Learned in 10 Years of Experience.
Ovarian Neoplasms
Ovarian Cancer Treatments Strategy: Focus on PARP Inhibitors and Immune Check Point Inhibitors.
Ovarian Neoplasms
Ovarian Cancer-associated Mutations Disable Catalytic Activity of CDK12, a Kinase That Promotes Homologous Recombination Repair and Resistance to Cisplatin and Poly(ADP-ribose) Polymerase Inhibitors.
Ovarian Neoplasms
Ovarian Cancers Harbor Defects in Nonhomologous End Joining Resulting in Resistance to Rucaparib.
Ovarian Neoplasms
Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial.
Ovarian Neoplasms
Overcoming PARP inhibitor resistance in ovarian cancer: what are the most promising strategies?
Ovarian Neoplasms
Pancreatic acinar cell carcinoma is associated with BRCA2 germline mutations: a case report and literature review.
Ovarian Neoplasms
Pancreatic cancer: BRCA mutation and personalized treatment.
Ovarian Neoplasms
Panobinostat sensitizes cyclin E high, homologous recombination-proficient ovarian cancer to olaparib.
Ovarian Neoplasms
PARP (Poly(ADP-Ribose) Polymerase) Inhibitors in Platinum-Sensitive Recurrent Ovarian Cancer: A Meta-Analysis of Randomized Controlled Trials.
Ovarian Neoplasms
PARP goes the weasel! Emerging role of PARP inhibitors in acute leukemias.
Ovarian Neoplasms
PARP inhibition and synthetic lethality in ovarian cancer.
Ovarian Neoplasms
PARP inhibition as frontline therapy in ovarian cancer.
Ovarian Neoplasms
PARP inhibition causes premature loss of cohesion in cancer cells.
Ovarian Neoplasms
PARP Inhibition Elicits STING-Dependent Antitumor Immunity in Brca1-Deficient Ovarian Cancer.
Ovarian Neoplasms
PARP inhibition in BRCA-mutated breast and ovarian cancers.
Ovarian Neoplasms
PARP Inhibition in Cancer: An Update on Clinical Development.
Ovarian Neoplasms
PARP inhibition in ovarian cancer: state of the science.
Ovarian Neoplasms
PARP inhibition in platinum-based chemotherapy: Chemopotentiation and neuroprotection.
Ovarian Neoplasms
PARP inhibition in recurrent ovarian cancer.
Ovarian Neoplasms
PARP inhibition in the ovarian cancer patient: Current approvals and future directions.
Ovarian Neoplasms
PARP Inhibition Induces Enrichment of DNA Repair-Proficient CD133 and CD117 Positive Ovarian Cancer Stem Cells.
Ovarian Neoplasms
PARP inhibition promotes ferroptosis via repressing SLC7A11 and synergizes with ferroptosis inducers in BRCA-proficient ovarian cancer.
Ovarian Neoplasms
PARP inhibition: A promising therapeutic target in ovarian cancer.
Ovarian Neoplasms
PARP inhibition: targeting the Achilles' heel of DNA repair to treat germline and sporadic ovarian cancers.
Ovarian Neoplasms
PARP Inhibitor in Platinum-Resistant Ovarian Cancer: Single-Center Real-World Experience.
Ovarian Neoplasms
PARP inhibitor maintenance for primary ovarian cancer - A missed opportunity for precision medicine.
Ovarian Neoplasms
PARP inhibitor maintenance therapy for patients with platinum-sensitive recurrent ovarian cancer: a cost-effectiveness analysis.
Ovarian Neoplasms
PARP inhibitor resistance: the underlying mechanisms and clinical implications.
Ovarian Neoplasms
PARP inhibitors and immunotherapy in ovarian and endometrial cancers.
Ovarian Neoplasms
PARP inhibitors and more.
Ovarian Neoplasms
PARP inhibitors and quality of life in ovarian cancer.
Ovarian Neoplasms
PARP Inhibitors and the Evolving Landscape of Ovarian Cancer Management: A Review.
Ovarian Neoplasms
PARP inhibitors and the treatment of breast cancer: beyond BRCA1/2?
Ovarian Neoplasms
PARP Inhibitors as Frontline Treatment in Patients With Ovarian Cancer.
Ovarian Neoplasms
PARP inhibitors as maintenance therapy in newly diagnosed advanced ovarian cancer: a meta-analysis.
Ovarian Neoplasms
Parp inhibitors as maintenance treatment in platinum sensitive recurrent ovarian cancer: An updated meta-analysis of randomized clinical trials according to BRCA mutational status.
Ovarian Neoplasms
PARP inhibitors decrease response to subsequent platinum-based chemotherapy in patients with BRCA mutated ovarian cancer.
Ovarian Neoplasms
PARP Inhibitors Display Differential Efficacy in Models of BRCA Mutant High-Grade Serous Ovarian Cancer.
Ovarian Neoplasms
PARP inhibitors for all ovarian cancers.
Ovarian Neoplasms
PARP inhibitors for BRCA wild type ovarian cancer; gene alterations, homologous recombination deficiency and combination therapy.
Ovarian Neoplasms
PARP inhibitors for BRCA1/2-mutated and sporadic ovarian cancer: current practice and future directions.
Ovarian Neoplasms
PARP inhibitors for ovarian cancer.
Ovarian Neoplasms
PARP Inhibitors for Ovarian Cancer: Current Indications, Future Combinations, and Novel Assets in Development to Target DNA Damage Repair.
Ovarian Neoplasms
PARP inhibitors for targeted treatment in ovarian cancer.
Ovarian Neoplasms
Parp Inhibitors for the Treatment of Ovarian Cancer.
Ovarian Neoplasms
PARP inhibitors in BRCA gene-mutated ovarian cancer and beyond.
Ovarian Neoplasms
PARP inhibitors in BRCA mutation-associated ovarian cancer.
Ovarian Neoplasms
PARP inhibitors in breast and ovarian cancer with BRCA mutations: a meta-analysis of survival.
Ovarian Neoplasms
PARP inhibitors in epithelial ovarian cancer.
Ovarian Neoplasms
PARP Inhibitors in First-Line Therapy of Ovarian Cancer: Are There Any Doubts?
Ovarian Neoplasms
PARP inhibitors in older patients with ovarian and breast cancer: Young International Society of Geriatric Oncology review paper.
Ovarian Neoplasms
PARP Inhibitors in Ovarian Cancer Treatment.
Ovarian Neoplasms
PARP inhibitors in ovarian cancer.
Ovarian Neoplasms
PARP Inhibitors in Ovarian Cancer.
Ovarian Neoplasms
PARP inhibitors in ovarian cancer.
Ovarian Neoplasms
PARP Inhibitors in Ovarian Cancer.
Ovarian Neoplasms
PARP Inhibitors in Ovarian Cancer. Reply.
Ovarian Neoplasms
PARP Inhibitors in Ovarian Cancer: A Trailblazing and Transformative Journey.
Ovarian Neoplasms
PARP inhibitors in ovarian cancer: An overview of the practice-changing trials.
Ovarian Neoplasms
PARP inhibitors in ovarian cancer: Clinical evidence for informed treatment decisions.
Ovarian Neoplasms
PARP inhibitors in ovarian cancer: Current status and future promise.
Ovarian Neoplasms
PARP inhibitors in ovarian cancer: evidence for maintenance and treatment strategies.
Ovarian Neoplasms
PARP inhibitors in ovarian cancer: evidence, experience and clinical potential.
Ovarian Neoplasms
PARP inhibitors in ovarian cancer: Sensitivity prediction and resistance mechanisms.
Ovarian Neoplasms
PARP Inhibitors in Ovarian Cancer: The Route to "Ithaca".
Ovarian Neoplasms
PARP Inhibitors in Pancreatic Cancer: From Phase I to Plenary Session.
Ovarian Neoplasms
PARP Inhibitors in Patients With Newly Diagnosed Advanced Ovarian Cancer: A Meta-Analysis of Randomized Clinical Trials.
Ovarian Neoplasms
PARP inhibitors in platinum-sensitive high-grade serous ovarian cancer.
Ovarian Neoplasms
PARP Inhibitors in the Management of Ovarian Cancer: ASCO Guideline.
Ovarian Neoplasms
PARP inhibitors in the treatment of ovarian cancer: a review.
Ovarian Neoplasms
PARP Inhibitors in the Treatment of Triple-Negative Breast Cancer.
Ovarian Neoplasms
PARP inhibitors promote stromal fibroblast activation by enhancing CCL5 autocrine signaling in ovarian cancer.
Ovarian Neoplasms
PARP inhibitors.
Ovarian Neoplasms
PARP inhibitors: A new era of targeted therapy.
Ovarian Neoplasms
PARP Inhibitors: Clinical Relevance, Mechanisms of Action and Tumor Resistance.
Ovarian Neoplasms
PARP inhibitors: Clinical utility and possibilities of overcoming resistance.
Ovarian Neoplasms
PARP Theranostic Auger Emitters Are Cytotoxic in BRCA Mutant Ovarian Cancer and Viable Tumors from Ovarian Cancer Patients Enable Ex-Vivo Screening of Tumor Response.
Ovarian Neoplasms
PARP-1 Expression Quantified by [
Ovarian Neoplasms
PARP-1 inhibitor modulate ?-catenin signaling to enhance cisplatin sensitivity in cancer cervix.
Ovarian Neoplasms
PARP-1 may be involved in angiogenesis in epithelial ovarian cancer.
Ovarian Neoplasms
PARP1 blockade is synthetically lethal in XRCC1 deficient sporadic epithelial ovarian cancers.
Ovarian Neoplasms
PARP1 Is Targeted by miR-519a-3p and Promotes the Migration, Invasion, and Tube Formation of Ovarian Cancer Cells.
Ovarian Neoplasms
PARP1 rs1805407 Increases Sensitivity to PARP1 Inhibitors in Cancer Cells Suggesting an Improved Therapeutic Strategy.
Ovarian Neoplasms
PARP1 Suppresses the Transcription of PD-L1 by Poly(ADP-Ribosyl)ating STAT3.
Ovarian Neoplasms
PARP1 Trapping by PARP Inhibitors Drives Cytotoxicity in Both Cancer Cells and Healthy Bone Marrow.
Ovarian Neoplasms
Patient preferences for maintenance PARP inhibitor therapy in ovarian cancer treatment.
Ovarian Neoplasms
Patient-derived ovarian cancer organoids capture the genomic profiles of primary tumours applicable for drug sensitivity and resistance testing.
Ovarian Neoplasms
Pharmaceutical Management of Ovarian Cancer: Current Status.
Ovarian Neoplasms
Pharmacokinetics and clinical response to single agent rucaparib in a dialysis dependent patient with BRCA associated breast and recurrent ovarian cancer.
Ovarian Neoplasms
Pharmacological ascorbate induces 'BRCAness' and enhances the effects of Poly(ADP-Ribose) polymerase inhibitors against BRCA1/2 wild-type ovarian cancer.
Ovarian Neoplasms
Phase 1 Combination Study of the CHK1 Inhibitor Prexasertib and the PARP Inhibitor Olaparib in High-grade Serous Ovarian Cancer and Other Solid Tumors.
Ovarian Neoplasms
Phase I combination study of the PARP inhibitor veliparib plus carboplatin and gemcitabine in patients with advanced ovarian cancer and other solid malignancies.
Ovarian Neoplasms
Phase I study of olaparib in combination with liposomal doxorubicin in patients with advanced solid tumours.
Ovarian Neoplasms
Phase I Study of Rucaparib in Combination with Bevacizumab in Ovarian Cancer Patients: Maximum Tolerated Dose and Pharmacokinetic Profile.
Ovarian Neoplasms
Phase I Trial of First-in-Class ATR Inhibitor M6620 (VX-970) as Monotherapy or in Combination With Carboplatin in Patients With Advanced Solid Tumors.
Ovarian Neoplasms
Phase II, open-label, randomized, multicenter study comparing the efficacy and safety of olaparib, a poly (ADP-ribose) polymerase inhibitor, and pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer.
Ovarian Neoplasms
Platinum and PARP Inhibitor Resistance Due to Overexpression of MicroRNA-622 in BRCA1-Mutant Ovarian Cancer.
Ovarian Neoplasms
Plectin-targeted liposomes enhance the therapeutic efficacy of a PARP inhibitor in the treatment of ovarian cancer.
Ovarian Neoplasms
Poly (adenosine diphosphate [ADP]-ribose) polymerase (PARP) inhibitors as maintenance therapy in women with newly diagnosed ovarian cancer: a systematic review and meta-analysis.
Ovarian Neoplasms
Poly (ADP-ribose) polymerase (PARP) inhibitor regimens for ovarian cancer in phase III randomized controlled trials: a network meta-analysis.
Ovarian Neoplasms
Poly (ADP-ribose) polymerase 1 transcriptional regulation: a novel crosstalk between histone modification H3K9ac and ETS1 motif hypomethylation in BRCA1-mutated ovarian cancer.
Ovarian Neoplasms
Poly (ADP-ribose) polymerase inhibitors combined with other small-molecular compounds for the treatment of ovarian cancer.
Ovarian Neoplasms
Poly (ADP-ribose) polymerase inhibitors in the management of ovarian cancer.
Ovarian Neoplasms
Poly (ADP-ribose) Polymerase Inhibitors in the Management of Ovarian Cancer: A Drug Class Review.
Ovarian Neoplasms
Poly (ADP-Ribose) Polymerase Inhibitors: Talazoparib in Ovarian Cancer and Beyond.
Ovarian Neoplasms
Poly (ADP-Ribose) Polymerases (PARPs) and PARP Inhibitor-Targeted Therapeutics.
Ovarian Neoplasms
Poly(adenosine diphosphate ribose) polymerase inhibitors induce autophagy-mediated drug resistance in ovarian cancer cells, xenografts, and patient-derived xenograft models.
Ovarian Neoplasms
Poly(ADP-ribose) polymerase (PARP) inhibitors and ovarian cancer.
Ovarian Neoplasms
Poly(ADP-ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer.
Ovarian Neoplasms
Poly(ADP-ribose) polymerase activity and inhibition in cancer.
Ovarian Neoplasms
Poly(ADP-Ribose) Polymerase Inhibition Synergizes with 5-Fluorodeoxyuridine but not 5-Fluorouracil in Ovarian Cancer Cells.
Ovarian Neoplasms
Poly(ADP-ribose) polymerase inhibitor therapeutic effect: are we just scratching the surface?
Ovarian Neoplasms
Poly(ADP-ribose) polymerase inhibitors as maintenance treatment in patients with newly diagnosed advanced ovarian cancer: a meta-analysis.
Ovarian Neoplasms
Poly(ADP-ribose) polymerase inhibitors in triple-negative breast cancer.
Ovarian Neoplasms
Poly(ADP-ribose) Polymerase Inhibitors Sensitize Cancer Cells to Death Receptor-mediated Apoptosis by Enhancing Death Receptor Expression.
Ovarian Neoplasms
Poly(ADP-ribosyl)ation polymerases: mechanism and new target of anticancer therapy.
Ovarian Neoplasms
Poly-ADP-ribose polymerase inhibitor use in ovarian cancer: expanding indications and novel combination strategies.
Ovarian Neoplasms
Poly-ADP-ribosyl-polymerase inhibitor resistance mechanisms and their therapeutic implications.
Ovarian Neoplasms
Potential role of HGF-PARP-1 signaling in invasion of ovarian cancer cells.
Ovarian Neoplasms
Practical guidance for the management of side effects during rucaparib therapy in a multidisciplinary UK setting.
Ovarian Neoplasms
Practical guidance on the use of olaparib capsules as maintenance therapy for women with BRCA mutations and platinum-sensitive recurrent ovarian cancer.
Ovarian Neoplasms
Preclinical evaluation of olaparib and metformin combination in BRCA1 wildtype ovarian cancer.
Ovarian Neoplasms
Predictive value of RAD51 on the survival and drug responsiveness of ovarian cancer.
Ovarian Neoplasms
Predictors and Modulators of Synthetic Lethality: An Update on PARP Inhibitors and Personalized Medicine.
Ovarian Neoplasms
Prevalence and clinical significance of BRCA1/2 germline and somatic mutations in Taiwanese patients with ovarian cancer.
Ovarian Neoplasms
Prevalence of hereditary breast and ovarian cancer (HBOC) predisposition gene mutations among 882 HBOC high-risk Chinese individuals.
Ovarian Neoplasms
Prexasertib, a cell cycle checkpoint kinases 1 and 2 inhibitor, increases
Ovarian Neoplasms
Profile of olaparib in the treatment of advanced ovarian cancer.
Ovarian Neoplasms
Prognostic nomogram for progression-free survival in patients with BRCA mutations and platinum-sensitive recurrent ovarian cancer on maintenance olaparib therapy following response to chemotherapy.
Ovarian Neoplasms
Progress in the treatment of ovarian cancer-lessons from homologous recombination deficiency-the first 10 years.
Ovarian Neoplasms
Prolonged response to treatment based on cell-free DNA analysis and molecular profiling in three patients with metastatic cancer: a case series.
Ovarian Neoplasms
Promoter hypomethylation, especially around the E26 transformation-specific motif, and increased expression of poly (ADP-ribose) polymerase 1 in BRCA-mutated serous ovarian cancer.
Ovarian Neoplasms
Proteomic Analysis of the Downstream Signaling Network of PARP1.
Ovarian Neoplasms
Quality of life during olaparib maintenance therapy in platinum-sensitive relapsed serous ovarian cancer.
Ovarian Neoplasms
Quantification of PARP Activity in Human Tissues: Ex Vivo Assays in Blood Cells and Immunohistochemistry in Human Biopsies.
Ovarian Neoplasms
Randomized Trial of Oral Cyclophosphamide and Veliparib in High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers, or BRCA-Mutant Ovarian Cancer.
Ovarian Neoplasms
Rapid Progression of Metastatic Pancreatic Adenocarcinoma During Platinum-Based Therapy in a Patient Harboring a Pathogenic BRCA2 Germline Variant.
Ovarian Neoplasms
Ratio-Dependent Synergism of a Doxorubicin and Olaparib Combination in 2D and Spheroid Models of Ovarian Cancer.
Ovarian Neoplasms
Rationale for combination PARP inhibitor and antiangiogenic treatment in advanced epithelial ovarian cancer: A review.
Ovarian Neoplasms
Recent advances in targeting DNA repair pathways for the treatment of ovarian cancer and their clinical relevance.
Ovarian Neoplasms
Recent Patents for Homologous Recombination Deficiency Assays Among Women with Ovarian Cancer.
Ovarian Neoplasms
Recent progress in the diagnosis and treatment of ovarian cancer.
Ovarian Neoplasms
Reciprocal positive selection for weakness - preventing olaparib resistance by inhibiting BRCA2.
Ovarian Neoplasms
Recommendations for the implementation of BRCA testing in ovarian cancer patients and their relatives.
Ovarian Neoplasms
RECQL4, Negatively Regulated by miR-10a-5p, Facilitates Cell Proliferation and Invasion via MAFB in Ovarian Cancer.
Ovarian Neoplasms
Repression of BET activity sensitizes homologous recombination-proficient cancers to PARP inhibition.
Ovarian Neoplasms
Research progress on the association between environmental pollutants and the resistance mechanism of PARP inhibitors in ovarian cancer.
Ovarian Neoplasms
Response of germline BRCA2-mutated advanced pancreatic acinar cell carcinoma to olaparib: A case report.
Ovarian Neoplasms
Response to Olaparib in a Patient with Germline BRCA2 Mutation and Breast Cancer Leptomeningeal Carcinomatosis.
Ovarian Neoplasms
REV7 counteracts DNA double-strand break resection and affects PARP inhibition.
Ovarian Neoplasms
Risk of selected gastrointestinal toxicities associated with poly (ADP-ribose) polymerase (PARP) inhibitors in the treatment of ovarian cancer: a meta-analysis of published trials.
Ovarian Neoplasms
Role of BRCA Mutations in Cancer Treatment with Poly(ADP-ribose) Polymerase (PARP) Inhibitors.
Ovarian Neoplasms
Role of Olaparib as Maintenance Treatment for Ovarian Cancer: The Evidence to Date.
Ovarian Neoplasms
Role of Poly (ADP-Ribose) Polymerase inhibitors beyond BReast CAncer Gene-mutated ovarian tumours: definition of homologous recombination deficiency?
Ovarian Neoplasms
Role of Poly Adenosine Diphosphate Ribose Polymerase Inhibitors in Advanced Stage Ovarian Cancer.
Ovarian Neoplasms
Roles for APRIN (PDS5B) in homologous recombination and in ovarian cancer prediction.
Ovarian Neoplasms
Rucaparib and Niraparib in Advanced Ovarian Cancer.
Ovarian Neoplasms
Rucaparib Approved for Ovarian Cancer.
Ovarian Neoplasms
Rucaparib in ovarian cancer: extending the use of PARP inhibitors in the recurrent disease.
Ovarian Neoplasms
Rucaparib in the landscape of PARP inhibition in ovarian cancer.
Ovarian Neoplasms
Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial.
Ovarian Neoplasms
Rucaparib: A Poly(ADP-Ribose) Polymerase Inhibitor for BRCA-Mutated Relapsed Ovarian Cancer.
Ovarian Neoplasms
Rucaparib: An emerging parp inhibitor for treatment of recurrent ovarian cancer.
Ovarian Neoplasms
Rucaparib: the past, present, and future of a newly approved PARP inhibitor for ovarian cancer.
Ovarian Neoplasms
Safety evaluation of olaparib for treating ovarian cancer.
Ovarian Neoplasms
SEOM clinical guideline in ovarian cancer (2020).
Ovarian Neoplasms
Sequential therapeutic targeting of ovarian Cancer harboring dysfunctional BRCA1.
Ovarian Neoplasms
Sharing real-world experiences to optimize the management of olaparib toxicities: a practical guidance from an Italian expert panel.
Ovarian Neoplasms
Simultaneous detection of BRCA mutations and large genomic rearrangements in germline DNA and FFPE tumor samples.
Ovarian Neoplasms
Single-particle analysis of full-length human poly(ADP-ribose) polymerase 1.
Ovarian Neoplasms
Somatic mRNA Analysis of BRCA1 Splice Variants Provides a Direct Theranostic Impact on PARP Inhibitors.
Ovarian Neoplasms
Somatic mutations in BRCA1 and BRCA2 could expand the number of patients that benefit from poly (ADP ribose) polymerase inhibitors in ovarian cancer.
Ovarian Neoplasms
SPSB1 enhances ovarian cancer cell survival by destabilizing p21.
Ovarian Neoplasms
Stenoparib, an Inhibitor of Cellular Poly(ADP-Ribose) Polymerase, Blocks Replication of the SARS-CoV-2 and HCoV-NL63 Human Coronaviruses In Vitro.
Ovarian Neoplasms
Strategic Combination Therapies for Ovarian Cancer.
Ovarian Neoplasms
Structure-based design of an agonistic peptide targeting Fas.
Ovarian Neoplasms
Success for First-Line PARP Inhibition in Ovarian Cancer.
Ovarian Neoplasms
Successes and limitations of targeted cancer therapy in ovarian cancer.
Ovarian Neoplasms
Successful Treatment of Patients with Refractory High-Grade Serous Ovarian Cancer with GOPC-ROS1 Fusion Using Crizotinib: A Case Report.
Ovarian Neoplasms
Synergetic Effects of PARP Inhibitor AZD2281 and Cisplatin in Oral Squamous Cell Carcinoma in Vitro and in Vivo.
Ovarian Neoplasms
Synergism of PARP inhibitor fluzoparib (HS10160) and MET inhibitor HS10241 in breast and ovarian cancer cells.
Ovarian Neoplasms
Synergistic Effect of Bazedoxifene and PARP Inhibitor in the Treatment of Ovarian Cancer Regardless of BRCA Mutation.
Ovarian Neoplasms
Synthesis of (aminoalkyl)cycleanine analogues: cytotoxicity, cellular uptake, and apoptosis induction in ovarian cancer cells.
Ovarian Neoplasms
Synthesis of novel dual target inhibitors of PARP and HSP90 and their antitumor activities.
Ovarian Neoplasms
Synthetic lethal therapies for cancer: what's next after PARP inhibitors?
Ovarian Neoplasms
Synthetic Lethality - Its Current Application and Potential in Oncological Treatment.
Ovarian Neoplasms
Synthetic lethality between BRCA1 deficiency and poly(ADP-ribose) polymerase inhibition is modulated by processing of endogenous oxidative DNA damage.
Ovarian Neoplasms
Synthetic lethality in malignant pleural mesothelioma with PARP1 inhibition.
Ovarian Neoplasms
Synthetic Lethality in Ovarian Cancer.
Ovarian Neoplasms
Synthetic oleanane triterpenoid, CDDO-Me, induces apoptosis in ovarian cancer cells by inhibiting prosurvival AKT/NF-?B/mTOR signaling.
Ovarian Neoplasms
Synthetic viability by BRCA2 and PARP1/ARTD1 deficiencies.
Ovarian Neoplasms
Systematic inhibitor selectivity between PARP1 and PARP2 enzymes: Molecular implications for ovarian cancer personalized therapy.
Ovarian Neoplasms
Targeted agents and combinations in ovarian cancer: where are we now?
Ovarian Neoplasms
Targeted composite value-based endpoints in platinum-sensitive recurrent ovarian cancer.
Ovarian Neoplasms
Targeted therapies in epithelial ovarian cancer: Molecular mechanisms of action.
Ovarian Neoplasms
Targeted therapies in gynaecological cancers.
Ovarian Neoplasms
Targeted Therapies in the Management of Ovarian Cancer: A Focus on Older Patients.
Ovarian Neoplasms
Targeted therapy for gynecologic cancers: Toward the era of precision medicine.
Ovarian Neoplasms
Targeted therapy for ovarian cancer: the rapidly evolving landscape of PARP inhibitor use.
Ovarian Neoplasms
Targeted therapy in ovarian cancer.
Ovarian Neoplasms
Targeted therapy: ARIEL3 - broad benefit of PARP inhibitors in ovarian cancer.
Ovarian Neoplasms
Targeting BRCA1/2 deficient ovarian cancer with CNDAC-based drug combinations.
Ovarian Neoplasms
Targeting CARM1 in ovarian cancer with EZH2 and PARP inhibitors.
Ovarian Neoplasms
Targeting DNA repair and replication stress in the treatment of ovarian cancer.
Ovarian Neoplasms
Targeting DNA Repair in Cancer: Beyond PARP Inhibitors.
Ovarian Neoplasms
Targeting DNA repair: the genome as a potential biomarker.
Ovarian Neoplasms
Targeting genetic and epigenetic alterations in the treatment of serous ovarian cancer.
Ovarian Neoplasms
Targeting Human Poly(ADP-Ribose) Polymerase-1 with Natural Medicines and Its Potential Applications in Ovarian Cancer Therapeutics.
Ovarian Neoplasms
Targeting on poly(ADP-ribose) polymerase activity with DNA-damaging hybrid lactam-steroid alkylators in wild-type and BRCA1-mutated ovarian cancer cells.
Ovarian Neoplasms
Targeting the ATR/CHK1 axis with PARP inhibition results in tumor regression in BRCA mutant ovarian cancer models.
Ovarian Neoplasms
The Association of Polymorphisms in Base Excision Repair Genes with Ovarian Cancer Susceptibility in Chinese Women: A Two-Center Case-Control Study.
Ovarian Neoplasms
The BET inhibitor INCB054329 reduces homologous recombination efficiency and augments PARP inhibitor activity in ovarian cancer.
Ovarian Neoplasms
The BRCA1 ubiquitin ligase and homologous recombination repair.
Ovarian Neoplasms
The BRCA1-?11q Alternative Splice Isoform Bypasses Germline Mutations and Promotes Therapeutic Resistance to PARP Inhibition and Cisplatin.
Ovarian Neoplasms
The CHK1 Inhibitor Prexasertib Exhibits Monotherapy Activity in High-Grade Serous Ovarian Cancer Models and Sensitizes to PARP Inhibition.
Ovarian Neoplasms
The CHK1 inhibitor SRA737 synergizes with PARP1 inhibitors to kill carcinoma cells.
Ovarian Neoplasms
The current landscape of molecular profiling in the treatment of epithelial ovarian cancer.
Ovarian Neoplasms
The current status of PARP inhibitors in ovarian cancer.
Ovarian Neoplasms
The development of PARP inhibitors in ovarian cancer: from bench to bedside.
Ovarian Neoplasms
The Development of Rucaparib/Rubraca®: A Story of the Synergy Between Science and Serendipity.
Ovarian Neoplasms
The DNA damaging revolution.
Ovarian Neoplasms
The DNA Damaging Revolution: PARP Inhibitors and Beyond.
Ovarian Neoplasms
The dystonia gene THAP1 controls DNA double-strand break repair choice.
Ovarian Neoplasms
The effect of age on efficacy, safety and patient-centered outcomes with rucaparib: A post hoc exploratory analysis of ARIEL3, a phase 3, randomized, maintenance study in patients with recurrent ovarian carcinoma.
Ovarian Neoplasms
The effect of food on the pharmacokinetics of niraparib, a poly(ADP-ribose) polymerase (PARP) inhibitor, in patients with recurrent ovarian cancer.
Ovarian Neoplasms
The efficacy and safety of niraparib for ovarian cancer: a single-center observational study from China.
Ovarian Neoplasms
The efficacy and safety of olaparib in the treatment of cancers: a meta-analysis of randomized controlled trials.
Ovarian Neoplasms
The efficacy and safety of the addition of poly ADP-ribose polymerase (PARP) inhibitors to therapy for ovarian cancer: a systematic review and meta-analysis.
Ovarian Neoplasms
The Era of PARP inhibitors in ovarian cancer: "Class Action" or not? A systematic review and meta-analysis.
Ovarian Neoplasms
The financial burden of PARP inhibitors on patients, payors, and financial assistance programs: Who bears the cost?
Ovarian Neoplasms
The First Nationwide Multicenter Prevalence Study of Germline BRCA1 and BRCA2 Mutations in Chinese Ovarian Cancer Patients.
Ovarian Neoplasms
The forefront of ovarian cancer therapy: update on PARP inhibitors.
Ovarian Neoplasms
The Importance of Distinguishing Sporadic Cancers from Those Related to Cancer Predisposing Germline Mutations.
Ovarian Neoplasms
The influence of long non-coding RNAs on the response to chemotherapy in ovarian cancer.
Ovarian Neoplasms
The integration of BRCA testing into oncology clinics.
Ovarian Neoplasms
The irreversible ERBB1/2/4 inhibitor neratinib interacts with the PARP1 inhibitor niraparib to kill ovarian cancer cells.
Ovarian Neoplasms
The Landscape and Therapeutic Implications of Molecular Profiles in Epithelial Ovarian Cancer.
Ovarian Neoplasms
The maze of PARP inhibitors in ovarian cancer.
Ovarian Neoplasms
The PARP1 inhibitor BMN 673 exhibits immunoregulatory effects in a Brca1(-/-) murine model of ovarian cancer.
Ovarian Neoplasms
The potential of PARP inhibitors in genetic breast and ovarian cancers.
Ovarian Neoplasms
The potential role of miRNAs in therapy of breast and ovarian cancers associated with BRCA1 mutation.
Ovarian Neoplasms
The preferences of women with ovarian cancer for oral versus intravenous recurrence regimens.
Ovarian Neoplasms
The Prognostic Relevance of Poly (ADP-Ribose) Polymerase Expression in Ovarian Cancer Tissue of Wild Type and BRCA-Mutation Carrier Patients.
Ovarian Neoplasms
The Prognostic Value of PARP Expression in High-Grade Epithelial Ovarian Cancer.
Ovarian Neoplasms
The promising PARP inhibitors in ovarian cancer therapy: From Olaparib to others.
Ovarian Neoplasms
The Role of Cediranib in Ovarian Cancer.
Ovarian Neoplasms
The role of PARP inhibitors in germline BRCA-associated pancreatic ductal adenocarcinoma.
Ovarian Neoplasms
The Role of PARP Inhibitors in the Ovarian Cancer Microenvironment: Moving Forward From Synthetic Lethality.
Ovarian Neoplasms
The Role of PARP Inhibitors in the Treatment of Ovarian Carcinomas.
Ovarian Neoplasms
The Role of PARPs in Inflammation-and Metabolic-Related Diseases: Molecular Mechanisms and Beyond.
Ovarian Neoplasms
The role of poly(ADP-ribose) polymerase inhibitors in the treatment of cancer and methods to overcome resistance: a review.
Ovarian Neoplasms
The safety of antiangiogenic agents and PARP inhibitors in platinum-sensitive recurrent ovarian cancer.
Ovarian Neoplasms
The status of poly(adenosine diphosphate-ribose) polymerase (PARP) inhibitors in ovarian cancer, part 1: olaparib.
Ovarian Neoplasms
The status of poly(adenosine diphosphate-ribose) polymerase (PARP) inhibitors in ovarian cancer, part 2: extending the scope beyond olaparib and BRCA1/2 mutations.
Ovarian Neoplasms
The systemic treatment of recurrent ovarian cancer revisited.
Ovarian Neoplasms
The Ubiquitin Ligase TRIP12 Limits PARP1 Trapping and Constrains PARP Inhibitor Efficiency.
Ovarian Neoplasms
The ups and downs of Poly(ADP-ribose) Polymerase-1 inhibitors in cancer therapy-Current progress and future direction.
Ovarian Neoplasms
The WRN helicase: resolving a new target in microsatellite unstable cancers.
Ovarian Neoplasms
Therapeutic applications of PARP inhibitors in ovarian cancer.
Ovarian Neoplasms
Therapeutic applications of PARP inhibitors: Anticancer therapy and beyond.
Ovarian Neoplasms
Therapeutic Implications of Germline Testing in Patients With Advanced Cancers.
Ovarian Neoplasms
Therapeutic Potential of PARP Inhibitors in the Treatment of Metastatic Castration-Resistant Prostate Cancer.
Ovarian Neoplasms
Therapeutic potential of the poly(ADP-ribose) polymerase inhibitor rucaparib for the treatment of sporadic human ovarian cancer.
Ovarian Neoplasms
Therapeutic targeting and patient selection for cancers with homologous recombination defects.
Ovarian Neoplasms
Thyroid hormones derivatives reduce proliferation and induce cell death and DNA damage in ovarian cancer.
Ovarian Neoplasms
Total and out-of-pocket costs for PARP inhibitors among insured ovarian cancer patients.
Ovarian Neoplasms
Translational Highlights in Breast and Ovarian Cancer 2019 - Immunotherapy, DNA Repair, PI3K Inhibition and CDK4/6 Therapy.
Ovarian Neoplasms
Triapine Disrupts CtIP-Mediated Homologous Recombination Repair and Sensitizes Ovarian Cancer Cells to PARP and Topoisomerase Inhibitors.
Ovarian Neoplasms
Tumor burden is a potential marker of PARP inhibitor effects in ovarian cancer: a head-to-head observational series.
Ovarian Neoplasms
Two decades beyond BRCA1/2: Homologous recombination, hereditary cancer risk and a target for ovarian cancer therapy.
Ovarian Neoplasms
U.S. Food and Drug Administration-Approved Poly (ADP-Ribose) Polymerase Inhibitor Maintenance Therapy for Recurrent Ovarian Cancer: A Cost-Effectiveness Analysis.
Ovarian Neoplasms
UBE2S promotes the progression and Olaparib resistance of ovarian cancer through Wnt/?-catenin signaling pathway.
Ovarian Neoplasms
UK BRCA mutation testing in patients with ovarian cancer.
Ovarian Neoplasms
Understanding Exceptional Responses to Poly (ADP-ribose) Polymerase Inhibition in Sporadic Ovarian Cancer.
Ovarian Neoplasms
Unveiling the mechanistic roles of chlorine substituted phthalazinone-based compounds containing chlorophenyl moiety towards the differential inhibition of poly (ADP-ribose) polymerase-1 in the treatment of lung cancer.
Ovarian Neoplasms
Update in the use and evaluation of poly (ADP-ribose) polymerase inhibitors in epithelial ovarian cancer: current and pending clinical research.
Ovarian Neoplasms
Update on PARP Inhibitors in Breast Cancer.
Ovarian Neoplasms
Update on PARP1 inhibitors in ovarian cancer.
Ovarian Neoplasms
Update on Poly-ADP-ribose polymerase inhibition for ovarian cancer treatment.
Ovarian Neoplasms
Use of poly ADP-ribose polymerase [PARP] inhibitors in cancer cells bearing DDR defects: the rationale for their inclusion in the clinic.
Ovarian Neoplasms
Using PARP Inhibitors in Advanced Ovarian Cancer.
Ovarian Neoplasms
Using PARP Inhibitors in Frontline Maintenance Therapy for Ovarian Cancer.
Ovarian Neoplasms
Using PARP Inhibitors in the Treatment of Patients With Ovarian Cancer.
Ovarian Neoplasms
USP13 regulates the RAP80-BRCA1 complex dependent DNA damage response.
Ovarian Neoplasms
Veliparib for the treatment of ovarian cancer.
Ovarian Neoplasms
What Is the Place of PARP Inhibitors in Ovarian Cancer Treatment?
Ovarian Neoplasms
When in the treatment continuum to use PARP inhibition in ovarian cancer.
Ovarian Neoplasms
ZD4054, a specific antagonist of the endothelin A receptor, inhibits tumor growth and enhances paclitaxel activity in human ovarian carcinoma in vitro and in vivo.
Ovarian Neoplasms
[BRCA diagnostics of ovarian cancer : Molecular tumor testing since the introduction of PARP inhibitor therapy].
Ovarian Neoplasms
[Cancer therapy by PARP inhibitors].
Ovarian Neoplasms
[DNA repair as a therapeutic target].
Ovarian Neoplasms
[From poly(ADP-ribose) discovery to PARP inhibitors in cancer therapy].
Ovarian Neoplasms
[Medical treatment options in BRCA-associated cancers].
Ovarian Neoplasms
[Molecular Targeted Therapies for Hereditary Cancer Syndrome].
Ovarian Neoplasms
[On the prospects of using the DNA repair inhibitors in radiotherapy of tumors].
Ovarian Neoplasms
[PARP INHIBITORS FOR ADJUVANT TREATMENT FOR OVARIAN CANCER].
Ovarian Neoplasms
[PARP inhibitors--theoretical basis and clinical application].
Ovarian Neoplasms
[PARP inhibitors: new therapeutic agents in breast and ovarian cancer].
Ovarian Neoplasms
[Recommended Extension of Indication Criteria for Genetic Testing of BRCA1 and BRCA2 Mutations in Hereditary Breast and Ovarian Cancer Syndrome].
Ovarian Neoplasms
[Testing of mutations in BRCA1 and BRCA2 genes in tumor tissues - possibilities and limitations].
Ovarian Neoplasms
[The Antitumor Effects of Fisetin on Ovarian Cancer in vitro and in vivo.]
Overweight
Reduced mitogenicity of sera following weight loss in premenopausal women.
Pancreatic Neoplasms
A decade of clinical development of PARP inhibitors in perspective.
Pancreatic Neoplasms
A novel somatic BRCA2 point mutation in a metastatic pancreatic cancer patient: a case report.
Pancreatic Neoplasms
A PARP inhibitor in pancreatic cancer: Enhancement anti-tumour activity of chemoradiation therapy against pancreatic cancer?
Pancreatic Neoplasms
A Review on Poly (ADP-ribose) Polymerase (PARP) Inhibitors and Synthetic Methodologies.
Pancreatic Neoplasms
Acquired multiple secondary BRCA2 mutations upon PARPi resistance in a metastatic pancreatic cancer patient harboring a BRCA2 germline mutation.
Pancreatic Neoplasms
Activation of Nur77 by selected 1,1-Bis(3'-indolyl)-1-(p-substituted phenyl)methanes induces apoptosis through nuclear pathways.
Pancreatic Neoplasms
Analysis Suggests Wider Use for PARP Inhibitors.
Pancreatic Neoplasms
ATM-Mutated Pancreatic Cancer: Clinical and Molecular Response to Gemcitabine/Nab-Paclitaxel After Genome-Based Therapy Resistance.
Pancreatic Neoplasms
Autoimmune response to PARP and BRCA1/BRCA2 in cancer.
Pancreatic Neoplasms
BART inhibits pancreatic cancer cell invasion by inhibiting ARL2-mediated RhoA inactivation.
Pancreatic Neoplasms
BRCA in Gastrointestinal Cancers: Current Treatments and Future Perspectives.
Pancreatic Neoplasms
BRCA2 secondary mutation-mediated resistance to platinum and PARP inhibitor-based therapy in pancreatic cancer.
Pancreatic Neoplasms
BRCAness as a Biomarker of Susceptibility to PARP Inhibitors in Glioblastoma Multiforme.
Pancreatic Neoplasms
C12orf48, termed PARP-1 binding protein, enhances poly(ADP-ribose) polymerase-1 (PARP-1) activity and protects pancreatic cancer cells from DNA damage.
Pancreatic Neoplasms
Combination of AZD2281 (Olaparib) and GX15-070 (Obatoclax) results in synergistic antitumor activities in preclinical models of pancreatic cancer.
Pancreatic Neoplasms
Combination therapy of poly (ADP-ribose) polymerase inhibitor 3-aminobenzamide and gemcitabine shows strong antitumor activity in pancreatic cancer cells.
Pancreatic Neoplasms
Combinative effects of ?-Lapachone and APO866 on pancreatic cancer cell death through reactive oxygen species production and PARP-1 activation.
Pancreatic Neoplasms
Combinatorial Efficacy of Olaparib with Radiation and ATR Inhibitor Requires PARP1 Protein in Homologous Recombination-Proficient Pancreatic Cancer.
Pancreatic Neoplasms
Combined inhibition of Wee1 and PARP1/2 for radiosensitization in pancreatic cancer.
Pancreatic Neoplasms
Combined PARP and ATR inhibition potentiates genome instability and cell death in ATM-deficient cancer cells.
Pancreatic Neoplasms
Complete pathological response to olaparib and bevacizumab in advanced cervical cancer following chemoradiation in a BRCA1 mutation carrier: a case report.
Pancreatic Neoplasms
Cost-Effectiveness of Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer.
Pancreatic Neoplasms
Curcumin analogues exhibit enhanced growth suppressive activity in human pancreatic cancer cells.
Pancreatic Neoplasms
Current treatment landscape and emerging therapies for pancreatic cancer.
Pancreatic Neoplasms
Cytoplasmic PARP-1 promotes pancreatic cancer tumorigenesis and resistance.
Pancreatic Neoplasms
DNA damage induced by KP372-1 hyperactivates PARP1 and enhances lethality of pancreatic cancer cells with PARP inhibition.
Pancreatic Neoplasms
Down-expression of poly(ADP-ribose) polymerase in p53-regulated pancreatic cancer cells.
Pancreatic Neoplasms
Effect of the XIAP inhibitor Embelin on TRAIL-induced apoptosis of pancreatic cancer cells.
Pancreatic Neoplasms
Effects of Combined Treatment with Ionizing Radiation and the PARP Inhibitor Olaparib in BRCA Mutant and Wild Type Patient-Derived Pancreatic Cancer Xenografts.
Pancreatic Neoplasms
Efficacy of the Combination of a PARP Inhibitor and UVC on Cancer Cells as Imaged by Focus Formation by the DNA Repair-related Protein 53BP1 Linked to Green Fluorescent Protein.
Pancreatic Neoplasms
Enoxacin with UVA Irradiation Induces Apoptosis in the AsPC1 Human Pancreatic Cancer Cell Line Through ROS Generation.
Pancreatic Neoplasms
Epidermal Growth Factor Receptor-Targeting Peptide Nanoparticles Simultaneously Deliver Gemcitabine and Olaparib To Treat Pancreatic Cancer with Breast Cancer 2 ( BRCA2) Mutation.
Pancreatic Neoplasms
Evidence for the efficacy of Iniparib, a PARP-1 inhibitor, in BRCA2-associated pancreatic cancer.
Pancreatic Neoplasms
FAK and IGF-IR interact to provide survival signals in human pancreatic adenocarcinoma cells.
Pancreatic Neoplasms
Gemcitabine induces poly (ADP-ribose) polymerase-1 (PARP-1) degradation through autophagy in pancreatic cancer.
Pancreatic Neoplasms
Gemcitabine-Based Chemoradiotherapy Enhanced by a PARP Inhibitor in Pancreatic Cancer Cell Lines.
Pancreatic Neoplasms
Genomic instability in pancreatic adenocarcinoma: a new step towards precision medicine and novel therapeutic approaches.
Pancreatic Neoplasms
Genotype-phenotype correlation in BRCA1/2 mutation-associated pancreatic cancer.
Pancreatic Neoplasms
Germinal BRCA1-2 pathogenic variants (gBRCA1-2pv) and pancreatic cancer: epidemiology of an Italian patient cohort.
Pancreatic Neoplasms
Growth of pancreatic cancers with hemizygous chromosomal 17p loss of MYBBP1A can be preferentially targeted by PARP inhibitors.
Pancreatic Neoplasms
Health-related quality of life in patients with a germline BRCA mutation and metastatic pancreatic cancer receiving maintenance olaparib.
Pancreatic Neoplasms
Hereditary pancreatic cancer.
Pancreatic Neoplasms
High nuclear poly-(ADP-ribose)-polymerase expression is prognostic of improved survival in pancreatic cancer.
Pancreatic Neoplasms
Inactivation of the prolyl isomerase Pin1 sensitizes BRCA1-proficient breast cancer to PARP inhibition.
Pancreatic Neoplasms
JF-305, a pancreatic cancer cell line is highly sensitive to the PARP inhibitor olaparib.
Pancreatic Neoplasms
Knockdown of glucose-regulated protein 78 enhances poly(ADP-ribose) polymerase cleavage in human pancreatic cancer cells exposed to endoplasmic reticulum stress.
Pancreatic Neoplasms
Leukotriene B4 receptor antagonist LY293111 inhibits proliferation and induces apoptosis in human pancreatic cancer cells.
Pancreatic Neoplasms
Maintenance Rucaparib Controls Some Pancreatic Cancers.
Pancreatic Neoplasms
Maintenance therapies in metastatic pancreatic cancer: present and future with a focus on PARP inhibitors.
Pancreatic Neoplasms
Metformin Inhibits Gemcitabine Induced Apoptosis in Pancreatic Cancer Cell Lines.
Pancreatic Neoplasms
MicroRNA-7 modulates cellular senescence to relieve gemcitabine resistance by targeting PARP1/NF-?B signaling in pancreatic cancer cells.
Pancreatic Neoplasms
More PARP Inhibitors in Pancreatic Cancer?
Pancreatic Neoplasms
MTA2 sensitizes gastric cancer cells to PARP inhibition by induction of DNA replication stress.
Pancreatic Neoplasms
Nuclear translocation of the receptor tyrosine kinase c-MET reduces the treatment efficacies of olaparib and gemcitabine in pancreatic ductal adenocarcinoma cells.
Pancreatic Neoplasms
Olaparib Monotherapy for Previously Treated Pancreatic Cancer With DNA Damage Repair Genetic Alterations Other Than Germline BRCA Variants: Findings From 2 Phase 2 Nonrandomized Clinical Trials.
Pancreatic Neoplasms
Opportunities for Utilization of DNA Repair Inhibitors in Homologous Recombination Repair-Deficient and Proficient Pancreatic Adenocarcinoma.
Pancreatic Neoplasms
Optimize radiochemotherapy in pancreatic cancer: PARP inhibitors a new therapeutic opportunity.
Pancreatic Neoplasms
Oral Poly(ADP-Ribose) Polymerase-1 Inhibitor BSI-401 Has Antitumor Activity and Synergizes with Oxaliplatin against Pancreatic Cancer, Preventing Acute Neurotoxicity.
Pancreatic Neoplasms
Overexpression of heat shock protein 27 (HSP27) increases gemcitabine sensitivity in pancreatic cancer cells through S-phase arrest and apoptosis.
Pancreatic Neoplasms
Paradigm Shifting of Systemic Chemotherapy for Unresectable Pancreatic Cancer in Japan.
Pancreatic Neoplasms
PARP inhibition - opportunities in pancreatic cancer.
Pancreatic Neoplasms
PARP inhibition in treatment of pancreatic cancer.
Pancreatic Neoplasms
PARP Inhibitor Drugs In The Treatment Of Breast, Ovarian, Prostate And Pancreatic Cancers: An Update of Clinical Trials.
Pancreatic Neoplasms
PARP Inhibitors in Pancreatic Cancer: From Phase I to Plenary Session.
Pancreatic Neoplasms
PARP inhibitors in pancreatic cancer: molecular mechanisms and clinical applications.
Pancreatic Neoplasms
PARP inhibitors: shifting the paradigm in the treatment of pancreatic cancer.
Pancreatic Neoplasms
Parp-1 genetic ablation in Ela-myc mice unveils novel roles for Parp-1 in pancreatic cancer.
Pancreatic Neoplasms
PARP-1 Regulates Resistance of Pancreatic Cancer to TRAIL Therapy.
Pancreatic Neoplasms
PARP10 (ARTD10) modulates mitochondrial function.
Pancreatic Neoplasms
PARP14 promotes the proliferation and gemcitabine chemoresistance of pancreatic cancer cells through activation of NF-?B pathway.
Pancreatic Neoplasms
Phase II Study of Maintenance Rucaparib in Patients With Platinum-Sensitive Advanced Pancreatic Cancer and a Pathogenic Germline or Somatic Variant in BRCA1, BRCA2, or PALB2.
Pancreatic Neoplasms
Poly (ADP-ribose) polymerase inhibitor, an effective radiosensitizer in lung and pancreatic cancers.
Pancreatic Neoplasms
Poly(ADP-ribose) polymerase inhibition in pancreatic cancer.
Pancreatic Neoplasms
Poly(ADP-Ribose) Polymerase Inhibitors in Pancreatic Cancer: A New Treatment Paradigms and Future Implications.
Pancreatic Neoplasms
Poly(ADP-Ribose) Polymerases: New Players in the Pathogenesis of Exocrine Pancreatic Diseases.
Pancreatic Neoplasms
Predictive and prognostic biomarkers in personalized gastrointestinal cancer treatment.
Pancreatic Neoplasms
Quinazolinedione SIRT6 inhibitors sensitize cancer cells to chemotherapeutics.
Pancreatic Neoplasms
Radioimmunotherapy of human pancreatic cancer xenografts in NOD-scid mice with [64Cu]Cu-NOTA-panitumumab F(ab')2 alone or combined with radiosensitizing gemcitabine and the PARP inhibitor, rucaparib.
Pancreatic Neoplasms
Radiosensitization Effect of PARP Inhibition in Cells Exposed to Low and High LET Radiation.
Pancreatic Neoplasms
Radiosensitization of Pancreatic Cancer Cells In Vitro and In Vivo through Poly (ADP-ribose) Polymerase Inhibition with ABT-888.
Pancreatic Neoplasms
Radiosensitizing Pancreatic Cancer with PARP Inhibitor and Gemcitabine: An In Vivo and a Whole-Transcriptome Analysis after Proton or Photon Irradiation.
Pancreatic Neoplasms
Rucaparib Monotherapy in Patients With Pancreatic Cancer and a Known Deleterious BRCA Mutation.
Pancreatic Neoplasms
Selective radiosensitization of p53 mutant pancreatic cancer cells by combined inhibition of Chk1 and PARP1.
Pancreatic Neoplasms
Synergistic targeting and resistance to PARP inhibition in DNA damage repair-deficient pancreatic cancer.
Pancreatic Neoplasms
Targeted PARP Inhibition Combined with FGFR1 Blockade is Synthetically Lethal to Malignant Cells in Patients with Pancreatic Cancer.
Pancreatic Neoplasms
Targeting PARP-1 allosteric regulation offers therapeutic potential against cancer.
Pancreatic Neoplasms
Tephrosin induces apoptosis of human pancreatic cancer cells through the generation of reactive oxygen species.
Pancreatic Neoplasms
The promise and current status of CDK12/13 inhibition for the treatment of cancer.
Pancreatic Neoplasms
The role of PARP inhibitors in BRCA mutated pancreatic cancer.
Pancreatic Neoplasms
The Significance of Targeting Poly (ADP-Ribose) Polymerase-1 in Pancreatic Cancer for Providing a New Therapeutic Paradigm.
Pancreatic Neoplasms
Ultra-violet irradiation induces apoptosis via mitochondrial pathway in pancreatic cancer cells.
Pancreatic Neoplasms
Update on the Role of Poly (ADP-Ribose) Polymerase Inhibitors in the DNA Repair-Deficient Pancreatic Cancers: A Narrative Review.
Pancreatic Neoplasms
Using a novel NQO1 bioactivatable drug, beta-lapachone (ARQ761), to enhance chemotherapeutic effects by metabolic modulation in pancreatic cancer.
Pancreatic Neoplasms
[Medical treatment options in BRCA-associated cancers].
Pancreatic Neoplasms
[The long coding RNA GSTM3TV2 acts an oncogene to promote chemoresistance in pancreatic cancer].
Pancreatitis
Absence of endogenous interleukin-6 enhances the inflammatory response during acute pancreatitis induced by cerulein in mice.
Pancreatitis
Does the 3-aminobenzamide effect on bacterial translocation affect experimental acute necrotizing pancreatitis?
Pancreatitis
Effects of 3-aminobenzamide, an inhibitor of poly (ADP-ribose) polymerase, in a mouse model of acute pancreatitis induced by cerulein.
Pancreatitis
Effects of The Poly(ADP-ribose) Polymerase Inhibitor Olaparib in Cerulein-Induced Pancreatitis.
Pancreatitis
Inhibition of Poly(ADP-Ribose) Polymerase Attenuates Acute Kidney Injury in Sodium Taurocholate-Induced Acute Pancreatitis in Rats.
Pancreatitis
Inhibition of poly(ADP-ribose) polymerase attenuates the severity of acute pancreatitis and associated lung injury.
Pancreatitis
Parp1 deficient mice are protected from streptozotocin-induced diabetes but not caerulein-induced pancreatitis, independent of the induction of Reg family genes.
Pancreatitis
Poly(ADP-Ribose) Polymerase 1 Promotes Inflammation and Fibrosis in a Mouse Model of Chronic Pancreatitis.
Pancreatitis
Poly(ADP-ribose) polymerase inhibition suppresses inflammation and promotes recovery from adrenal injury in a rat model of acute necrotizing pancreatitis.
Pancreatitis
Poly(ADP-Ribose) Polymerases: New Players in the Pathogenesis of Exocrine Pancreatic Diseases.
Pancreatitis
Stabilization of exocytosis by dynamic F-actin coating of zymogen granules in pancreatic acini.
Pancreatitis
Therapeutic treatment with poly(ADP-ribose) polymerase inhibitors attenuates the severity of acute pancreatitis and associated liver and lung injury.
Pancreatitis, Acute Necrotizing
Poly(ADP-ribose) polymerase inhibition suppresses inflammation and promotes recovery from adrenal injury in a rat model of acute necrotizing pancreatitis.
Pancreatitis, Chronic
Poly(ADP-Ribose) Polymerase 1 Promotes Inflammation and Fibrosis in a Mouse Model of Chronic Pancreatitis.
Panniculitis
Pancreatic acinar cell carcinoma is associated with BRCA2 germline mutations: a case report and literature review.
Papilloma
Immunotherapy in ovarian, endometrial and cervical cancer: State of the art and future perspectives.
Papilloma
Murine hypothalamic destruction with vascular cell apoptosis subsequent to combined administration of human papilloma virus vaccine and pertussis toxin.
Papilloma
Parp-1 deficiency does not increase the frequency of tumors in the oral cavity and esophagus of ICR/129Sv mice by 4-nitroquinoline 1-oxide, a carcinogen producing bulky adducts.
Papilloma
Poly(ADP-ribosyl)ation and aging.
Papilloma
Retraction: Murine hypothalamic destruction with vascular cell apoptosis subsequent to combined administration of human papilloma virus vaccine and pertussis toxin.
Papillomavirus Infections
Expression of BAG-1 and PARP-1 in Precursor Lesions and Invasive Cervical Cancer Associated with Human Papillomavirus (HPV).
Paraganglioma
Pan-Cancer Analysis of PARP1 Alterations as Biomarkers in the Prediction of Immunotherapeutic Effects and the Association of Its Expression Levels and Immunotherapy Signatures.
Paralysis
CCR5 knockout suppresses experimental autoimmune encephalomyelitis in C57BL/6 mice.
Paralysis
HIV-1 Tat protein attenuates the clinical course of experimental autoimmune encephalomyelitis (EAE).
Paralysis
Maraviroc attenuates the pathogenesis of experimental autoimmune encephalitis.
Paralysis
Myelin oligodendrocyte glycoprotein (MOG35-55)-induced experimental autoimmune encephalomyelitis is ameliorated in interleukin-32 alpha transgenic mice.
Paraproteinemias
Altered mRNA expression of telomere-associated genes in monoclonal gammopathy of undetermined significance and multiple myeloma.
Paraproteinemias
Exploiting MYC-induced PARPness to target genomic instability in multiple myeloma.
Paraproteinemias
Targeting the MALAT1/PARP1/LIG3 complex induces DNA damage and apoptosis in multiple myeloma.
Parasitic Diseases
Transient inhibition of poly(ADP-ribose) polymerase expression and activity by Toxoplasma gondii is dispensable for parasite-mediated blockade of host cell apoptosis and intracellular parasite replication.
Paratuberculosis
Induction of humoral immunity in response to immunization with recombinant Mycobacterium bovis BCG expressing the S1 subunit of Bordetella pertussis toxin.
Parkinson Disease
A new poly(ADP-ribose) polymerase inhibitor, FR261529 [2-(4-chlorophenyl)-5-quinoxalinecarboxamide], ameliorates methamphetamine-induced dopaminergic neurotoxicity in mice.
Parkinson Disease
A PARP-1 Feed-Forward Mechanism To Accelerate ?-Synuclein Toxicity in Parkinson's Disease.
Parkinson Disease
Association analysis of PARP1 polymorphisms with Parkinson's disease.
Parkinson Disease
Computational Analysis Indicates That PARP1 Acts as a Histone Deacetylases Interactor Sharing Common Lysine Residues for Acetylation, Ubiquitination, and SUMOylation in Alzheimer's and Parkinson's Disease.
Parkinson Disease
Effects of Poly (ADP-ribose) Polymerase Inhibitor 3-Aminobenzamide on Blood-Brain Barrier and Dopaminergic Neurons of Rats with Lipopolysaccharide-Induced Parkinson's Disease.
Parkinson Disease
Evaluation of a Low-Toxicity PARP Inhibitor as a Neuroprotective Agent for Parkinson's Disease.
Parkinson Disease
FAF1 mediates regulated necrosis through PARP1 activation upon oxidative stress leading to dopaminergic neurodegeneration.
Parkinson Disease
Functions of poly(ADP-ribose) polymerase (PARP) in DNA repair, genomic integrity and cell death.
Parkinson Disease
Implication of poly (ADP-ribose) polymerase (PARP) in neurodegeneration and brain energy metabolism. Decreases in mouse brain NAD+ and ATP caused by MPTP are prevented by the PARP inhibitor benzamide.
Parkinson Disease
Increase in anti-apoptotic molecules, nucleolin, and heat shock protein 70, against upregulated LRRK2 kinase activity.
Parkinson Disease
Mediation of cell death by poly(ADP-ribose) polymerase-1.
Parkinson Disease
Neuroprotective effects of a novel poly(ADP-ribose) polymerase-1 inhibitor, 2-[3-[4-(4-chlorophenyl)-1-piperazinyl] propyl]-4(3H)-quinazolinone (FR255595), in an in vitro model of cell death and in mouse 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease.
Parkinson Disease
PARP Inhibitors and Parkinson's Disease.
Parkinson Disease
Parp mutations protect against mitochondrial dysfunction and neurodegeneration in a PARKIN model of Parkinson's disease.
Parkinson Disease
PARP-1 involvement in neurodegeneration: A focus on Alzheimer's and Parkinson's diseases.
Parkinson Disease
PARP1 and CASP3 gene expression in a patient with multiple head and neck squamous cell carcinoma and Parkinson disease.
Parkinson Disease
Parthanatos mediates AIMP2-activated age-dependent dopaminergic neuronal loss.
Parkinson Disease
Peroxynitrite and mitochondrial dysfunction in the pathogenesis of Parkinson's disease.
Parkinson Disease
Pharmacological inhibition of PARP-1 reduces alpha-synuclein- and MPP+-induced cytotoxicity in Parkinson's disease in vitro models.
Parkinson Disease
Poly (ADP-ribose) in the pathogenesis of Parkinson's disease.
Parkinson Disease
Poly (ADP-ribose) polymerase 1 and Parkinson's disease: A study in post-mortem human brain.
Parkinson Disease
Poly (ADP-ribose) polymerase 1 inhibition prevents neurodegeneration and promotes ?-synuclein degradation via transcription factor EB-dependent autophagy in mutant ?-synucleinA53T model of Parkinson's disease.
Parkinson Disease
Poly (ADP-ribose) polymerase-1 (PARP-1) -410C/T polymorphism in Sicilian patients with Parkinson's disease.
Parkinson Disease
Poly (ADP-ribose) polymerase-1 (PARP-1) genetic variants are protective against Parkinson's disease.
Parkinson Disease
Poly (ADP-ribose) polymerase-1 as a promising drug target for neurodegenerative diseases.
Parkinson Disease
Poly(ADP-ribose) polymerase activation mediates 1-methyl-4-phenyl-1, 2,3,6-tetrahydropyridine (MPTP)-induced parkinsonism.
Parkinson Disease
Rhododendrin-Induced RNF146 Expression via Estrogen Receptor ? Activation is Cytoprotective Against 6-OHDA-Induced Oxidative Stress.
Parkinson Disease
Structure and function of poly(ADP-ribose) polymerase-1: role in oxidative stress-related pathologies.
Parkinson Disease
The expression of PARP, NF-kappa B and parvalbumin is increased in Parkinson disease.
Parkinson Disease
The neuroprotective effect of nicotine in Parkinson's disease models is associated with inhibiting PARP-1 and caspase-3 cleavage.
Parkinson Disease
Untangling the genetic link between type 1 and type 2 diabetes using functional genomics.
Parkinson Disease
[Neuronal death: potential role of the nuclear enzyme, poly (ADP-ribose) polymerase]
Parkinsonian Disorders
Inhibition of poly(ADP-ribose) polymerase activity is insufficient to induce tetraploidy.
Parkinsonian Disorders
NMDA but not non-NMDA excitotoxicity is mediated by Poly(ADP-ribose) polymerase.
Parkinsonian Disorders
Poly(ADP-ribose) polymerase activation mediates 1-methyl-4-phenyl-1, 2,3,6-tetrahydropyridine (MPTP)-induced parkinsonism.
Parkinsonian Disorders
Poly(ADP-Ribose) polymerase-1 in acute neuronal death and inflammation: a strategy for neuroprotection.
Parkinsonian Disorders
Poly(ADP-ribosyl)ation enzyme-1 as a target for neuroprotection in acute central nervous system injury.
Parkinsonian Disorders
Whooping cough and Parkinson's disease. The Europarkinson Preparatory Activity Research Group.
Periodontal Diseases
5-Aminoisoquinolin-1(2H)-one, a water-soluble poly (ADP-ribose) polymerase (PARP) inhibitor reduces the evolution of experimental periodontitis in rats.
Periodontal Diseases
Role of poly(ADP-ribose) polymerase activation in the pathogenesis of periodontitis in diabetes.
Periodontitis
5-Aminoisoquinolin-1(2H)-one, a water-soluble poly (ADP-ribose) polymerase (PARP) inhibitor reduces the evolution of experimental periodontitis in rats.
Periodontitis
Hematogenous apoptotic mechanism in salivary glands in chronic periodontitis.
Periodontitis
Role of poly(ADP-ribose) polymerase activation in the pathogenesis of periodontitis in diabetes.
Periodontitis
Role of the activation of the nuclear enzyme poly(ADP-ribose) polymerase in the pathogenesis of periodontitis.
Peripheral Nervous System Diseases
Can Poly (ADP-Ribose) Polymerase Inhibitors Palliate Paclitaxel-Induced Peripheral Neuropathy in Patients With Cancer?
Peripheral Nervous System Diseases
Concurrent targeting of nitrosative stress-PARP pathway corrects functional, behavioral and biochemical deficits in experimental diabetic neuropathy.
Peripheral Nervous System Diseases
Evaluation of orally active poly(ADP-ribose) polymerase inhibitor in streptozotocin-diabetic rat model of early peripheral neuropathy.
Peripheral Nervous System Diseases
Morin Mitigates Chronic Constriction Injury (CCI)-Induced Peripheral Neuropathy by Inhibiting Oxidative Stress Induced PARP Over-Activation and Neuroinflammation.
Peripheral Nervous System Diseases
Nicotinamide reverses neurological and neurovascular deficits in streptozotocin diabetic rats.
Peripheral Nervous System Diseases
PARP inhibition alleviates diabetes-induced systemic oxidative stress and neural tissue 4-hydroxynonenal adduct accumulation: Correlation with peripheral nerve function.
Peripheral Nervous System Diseases
PARP inhibition attenuates neuroinflammation and oxidative stress in chronic constriction injury induced peripheral neuropathy.
Peripheral Nervous System Diseases
Poly (ADP-Ribose) Polymerase Inhibition for Chemotherapy-Induced Peripheral Neuropathy: A Meta-Analysis of Placebo-Controlled Trials.
Peripheral Nervous System Diseases
Poly(ADP-ribose)polymerase inhibition counteracts renal hypertrophy and multiple manifestations of peripheral neuropathy in diabetic Akita mice.
Peritoneal Fibrosis
Poly(ADP-ribose) polymerase-1 in high glucose-induced epithelial-mesenchymal transition during peritoneal fibrosis.
Peritoneal Neoplasms
A Phase I study of veliparib (ABT-888) in combination with low-dose fractionated whole abdominal radiation therapy in patients with advanced solid malignancies and peritoneal carcinomatosis.
Peritonitis
Moesin regulates neutrophil rolling velocity in vivo.
Peritonitis
Spleen tyrosine kinase Syk is necessary for E-selectin-induced alpha(L)beta(2) integrin-mediated rolling on intercellular adhesion molecule-1.
Persistent Hyperplastic Primary Vitreous
Modulating EGFR-MTORC1-autophagy as a potential therapy for persistent fetal vasculature (PFV) disease.
Persistent Infection
Production of extracellular virulence factors by Pseudomonas aeruginosa isolates obtained from tracheal, urinary tract, and wound infections.
Pheochromocytoma
Accentuation by pertussis toxin of the 5-hydroxytryptamine-induced potentiation of ATP-evoked responses in rat pheochromocytoma cells.
Pheochromocytoma
Betagamma subunits of G(i/o) suppress EGF-induced ERK5 phosphorylation, whereas ERK1/2 phosphorylation is enhanced.
Pheochromocytoma
Ergothioneine rescues PC12 cells from beta-amyloid-induced apoptotic death.
Pheochromocytoma
Inhibition of Poly(ADP-ribose) Polymerase-1 Enhances Gene Expression of Selected Sirtuins and APP Cleaving Enzymes in Amyloid Beta Cytotoxicity.
Pheochromocytoma
Neuromodulatory effects of atrial natriuretic factor are independent of guanylate cyclase in adrenergic neuronal pheochromocytoma cells.
Pheochromocytoma
Nitric oxide induces apoptosis via AP-1-driven upregulation of COX-2 in rat pheochromocytoma cells.
Pheochromocytoma
Nupr1 Modulates Methamphetamine-Induced Dopaminergic Neuronal Apoptosis and Autophagy through CHOP-Trib3-Mediated Endoplasmic Reticulum Stress Signaling Pathway.
Pheochromocytoma
Pan-Cancer Analysis of PARP1 Alterations as Biomarkers in the Prediction of Immunotherapeutic Effects and the Association of Its Expression Levels and Immunotherapy Signatures.
Pheochromocytoma
Pertussis toxin B-oligomer suppresses human immunodeficiency virus-1 Tat-induced neuronal apoptosis through feedback inhibition of phospholipase C-beta by protein kinase C.
Pheochromocytoma
PolyADP-ribosylation is involved in neurotrophic activity.
Pheochromocytoma
Supraphysiological doses of performance enhancing anabolic-androgenic steroids exert direct toxic effects on neuron-like cells.
Pheochromocytoma
Tetrachlorobenzoquinone triggers the cleavage of Bid and promotes the cross-talk of extrinsic and intrinsic apoptotic signalings in pheochromocytoma (PC) 12 cells.
Photosensitivity Disorders
Caspase-resistant vimentin suppresses apoptosis after photodynamic treatment with a silicon phthalocyanine in Jurkat cells.
Photosensitivity Disorders
Mechanism of colon cancer cell apoptosis mediated by pyropheophorbide-a methylester photosensitization.
Photosensitivity Disorders
Photodynamic therapy-induced death of MCF-7 human breast cancer cells: a role for caspase-3 in the late steps of apoptosis but not for the critical lethal event.
Pituitary Neoplasms
Pertussis toxin blocks somatostatin's inhibition of stimulated cyclic AMP accumulation in anterior pituitary tumor cells.
Pituitary Neoplasms
Pertussis toxin distinguishes between muscarinic receptor-mediated inhibition of adenylate cyclase and stimulation of phosphoinositide hydrolysis in Flow 9000 cells.
Pituitary Neoplasms
Pertussis toxin inhibits somatostatin-induced K+ conductance in human pituitary tumor cells.
Pituitary Neoplasms
Pertussis toxin modifies the characteristics of both the inhibitory GTP binding proteins and the somatostatin receptor in anterior pituitary tumor cells.
Pituitary Neoplasms
Pertussis toxin treatment blocks the inhibition of somatostatin and increases the stimulation by forskolin of cyclic AMP accumulation and adrenocorticotropin secretion from mouse anterior pituitary tumor cells.
Pituitary Neoplasms
Phospholipase C activation in rat pituitary adenoma (GH) cells.
Pituitary Neoplasms
The role of poly (adenosine 5'-diphosphate-ribose) polymerase in the response of pituitary tumor cells to reactive oxygen species.
Placenta, Retained
Poly(ADP-ribose) polymerase in bovine retained and not retained placenta.
Plasmacytoma
Characterization of the poly(ADP-ribose) polymerase associated with free cytoplasmic mRNA-protein particles.
Pleurisy
Critical role of L-selectin and histamine H4 receptor in zymosan-induced neutrophil recruitment from the bone marrow: comparison with carrageenan.
Pleurisy
Identification of autoantibodies associated with systemic lupus erythematosus.
Pneumococcal Infections
Vaccines, emerging viruses, and how to avoid disaster.
Pneumonia
Activation of poly(ADP-Ribose) polymerase-1 is a central mechanism of lipopolysaccharide-induced acute lung inflammation.
Pneumonia
Alveolar epithelial injury and pleural empyema in acute P. aeruginosa pneumonia in anesthetized rabbits.
Pneumonia
Asthma and poly(ADP-ribose) polymerase inhibition: a new therapeutic approach.
Pneumonia
Functional Polymorphisms of Base Excision Repair Genes XRCC1 and APEX1 Predict Risk of Radiation Pneumonitis in Patients with Non-Small Cell Lung Cancer Treated with Definitive Radiation Therapy.
Pneumonia
Gene knockout or pharmacological inhibition of poly(ADP-ribose) polymerase-1 prevents lung inflammation in a murine model of asthma.
Pneumonia
Inhibition of poly (adenosine diphosphate-ribose) polymerase attenuates lung-kidney crosstalk induced by intratracheal lipopolysaccharide instillation in rats.
Pneumonia
Inhibition of poly (ADP-ribose) polymerase attenuates acute lung injury in an ovine model of sepsis.
Pneumonia
Macrophages induce the inflammatory response in the pulmonary Arthus reaction through G alpha i2 activation that controls C5aR and Fc receptor cooperation.
Pneumonia
PARP inhibitor, olaparib ameliorates acute lung and kidney injury upon intratracheal administration of LPS in mice.
Pneumonia
PARP-1 inhibition ameliorates elastase induced lung inflammation and emphysema in mice.
Pneumonia
Pharmacological inhibition of poly (ADP-ribose) polymerase by olaparib ameliorates influenza-virus-induced pneumonia in mice.
Pneumonia
Phenotypic comparison of Pseudomonas aeruginosa strains isolated from a variety of clinical sites.
Pneumonia
Poly (ADP-ribose) polymerase 14 and its enzyme activity regulates T(H)2 differentiation and allergic airway disease.
Pneumonia
Poly(ADP-ribose) polymerase inhibition with HYDAMTIQ reduces allergen-induced asthma-like reaction, bronchial hyper-reactivity and airway remodelling.
Pneumonia
Poly(ADP-ribose) polymerase-1 inhibition prevents eosinophil recruitment by modulating Th2 cytokines in a murine model of allergic airway inflammation: a potential specific effect on IL-5.
Pneumonia
Poly(ADP-Ribose)Polymerase-1 in Lung Inflammatory Disorders: A Review.
Pneumonia
Post-allergen challenge inhibition of poly(ADP-ribose) polymerase harbors therapeutic potential for treatment of allergic airway inflammation.
Pneumonia
Pseudomonas aeruginosa exoenzyme S induces transcriptional expression of proinflammatory cytokines and chemokines.
Pneumonia
Pseudomonas aeruginosa exoenzyme S is a mitogen but not a superantigen for human T lymphocytes.
Pneumonia
Risk of pneumonitis in cancer patients treated with PARP inhibitors: A meta-analysis of randomized controlled trials and a pharmacovigilance study of the FAERS database.
Pneumonia
Silica nanoparticles induce lung inflammation in mice via ROS/PARP/TRPM2 signaling-mediated lysosome impairment and autophagy dysfunction.
Pneumonia
The Role of ExoS in Dissemination of Pseudomonas aeruginosa during Pneumonia.
Pneumonia
The role of poly(ADP-ribose) polymerase-1 inhibitor in carrageenan-induced lung inflammation in mice.
Pneumonia
TRPM2 channels in alveolar epithelial cells mediate bleomycin-induced lung inflammation.
Pneumonia
Ubiquitin-Specific Protease 14 (USP14) Aggravates Inflammatory Response and Apoptosis of Lung Epithelial Cells in Pneumonia by Modulating Poly (ADP-Ribose) Polymerase-1 (PARP-1).
Poliomyelitis
A Randomized, Controlled Study of DTaP-IPV-HB-PRP-T, a Fully Liquid Hexavalent Vaccine, Administered in a 3-, 5- and 11- to 12-month Schedule.
Poliomyelitis
Effect of HLA genotype or CTLA-4 polymorphism on cytokine response in healthy children.
Poliomyelitis
Humoral immunity of dTap-IPV vaccine (REPEVAX(®)) administered one month after dT-IPV vaccine (REVAXIS(®)) in adults with unknown vaccination history.
Poliomyelitis
Immunogenicity and reactogenicity of diphtheria, tetanus and pertussis toxoids combined with inactivated polio vaccine, when administered concomitantly with or as a diluent for a Hib conjugate vaccine.
Poliomyelitis
Immunogenicity and Safety of Monovalent Acellular Pertussis Vaccine at Birth: A Randomized Clinical Trial.
Poliomyelitis
Repeated administration of whole-cell and acellular pertussis vaccines affects haemodynamics and autonomic responsiveness.
Porcine Reproductive and Respiratory Syndrome
Resolution of the cellular proteome of the nucleocapsid protein from a highly pathogenic isolate of porcine reproductive and respiratory syndrome virus identifies PARP-1 as a cellular target whose interaction is critical for virus biology.
Pre-Eclampsia
CLDN1 regulates trophoblast apoptosis and proliferation in preeclampsia.
Pre-Eclampsia
Contribution of poly(ADP-ribose) polymerase to endothelial dysfunction and hypertension in a rat model of pre-eclampsia.
Pre-Eclampsia
Excessive stimulation of poly(ADP-ribosyl)ation contributes to endothelial dysfunction in pre-eclampsia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Curcumin Induces Apoptosis in Pre-B Acute Lymphoblastic Leukemia Cell Lines Via PARP-1 Cleavage.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Decreased PARP and procaspase-2 protein levels are associated with cellular drug resistance in childhood acute lymphoblastic leukemia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
DNA repair gene XRCC1 polymorphisms in childhood acute lymphoblastic leukemia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Good early treatment response in childhood acute lymphoblastic leukemia is associated with Bax nuclear accumulation and PARP cleavage.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Inhibiting Polo-like kinase 1 causes growth reduction and apoptosis in pediatric acute lymphoblastic leukemia cells.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
LMO2 Confers Synthetic Lethality to PARP Inhibition in DLBCL.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Modulation of ceramide metabolism in T-leukemia cell lines potentiates apoptosis induced by the cationic antimicrobial peptide bovine lactoferricin.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
PARP-1 expression in CD34+ leukemic cells in childhood acute lymphoblastic leukemia: relation to response to initial therapy and other prognostic factors.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Searching in mother nature for anti-cancer activity: anti-proliferative and pro-apoptotic effect elicited by green barley on leukemia/lymphoma cells.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
TET1 promotes growth of T-cell acute lymphoblastic leukemia and can be antagonized via PARP inhibition.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
The interleukin 1beta-converting enzyme inhibitor CrmA prevents Apo1/Fas- but not glucocorticoid-induced poly(ADP-ribose) polymerase cleavage and apoptosis in lymphoblastic leukemia cells.
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
Autophagy Inhibition Potentiates the Anticancer Effects of a Bendamustine Derivative NL-101 in Acute T Lymphocytic Leukemia.
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
Inhibition of phosphatidylinositol 3'-kinase induces preferentially killing of PTEN-null T leukemias through AKT pathway.
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
LMO2 Confers Synthetic Lethality to PARP Inhibition in DLBCL.
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
Mechanisms of JP-8 jet fuel toxicity. I. Induction of apoptosis in rat lung epithelial cells.
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
TET1 promotes growth of T-cell acute lymphoblastic leukemia and can be antagonized via PARP inhibition.
Primary Ovarian Insufficiency
Promising anti- cervical carcinoma and inflammatory agent, Resveratrol targets poly (ADP-ribose) polymerase 1 (PARP-1) induced premature ovarian failure with a potent enzymatic modulatory activity.
Primary Ovarian Insufficiency
Resveratrol inhibits inflammatory signaling implicated in ionizing radiation-induced premature ovarian failure through antagonistic crosstalk between silencing information regulator 1 (SIRT1) and poly(ADP-ribose) polymerase 1 (PARP-1).
Progeria
All-trans retinoic acid and rapamycin normalize Hutchinson Gilford progeria fibroblast phenotype.
Progeria
Mechanisms controlling the smooth muscle cell death in progeria via down-regulation of poly(ADP-ribose) polymerase 1.
Prostatic Hyperplasia
Expression of PARP-1 and its active polymer PAR in prostate cancer and benign prostatic hyperplasia in Chinese patients.
Prostatic Neoplasms
6-(3,4-Dihydro-1H-isoquinoline-2-yl)-N-(6-methoxypyridine-2-yl) nicotinamide-26 (DIMN-26) decreases cell proliferation by induction of apoptosis and downregulation of androgen receptor signaling in human prostate cancer cells.
Prostatic Neoplasms
?-Santalol, a derivative of sandalwood oil, induces apoptosis in human prostate cancer cells by causing caspase-3 activation.
Prostatic Neoplasms
A novel 3',5'-diprenylated chalcone induces concurrent apoptosis and GSDME-dependent pyroptosis through activating PKC?/JNK signal in prostate cancer.
Prostatic Neoplasms
A novel bis-indole destabilizes microtubules and displays potent in vitro and in vivo antitumor activity in prostate cancer.
Prostatic Neoplasms
A novel CRISPR-engineered prostate cancer cell line defines the AR-V transcriptome and identifies PARP inhibitor sensitivities.
Prostatic Neoplasms
A Novel Use for Olaparib for Treatment of Metastatic Castration-Recurrent Prostate Cancer.
Prostatic Neoplasms
A Study of the Anti-Cancer Effects of the Hexane Fraction of the Methanol Extract of Forsythiae Fructus.
Prostatic Neoplasms
A transcriptomic model for homologous recombination deficiency in prostate cancer.
Prostatic Neoplasms
Aberrations of DNA Repair Pathways in Prostate Cancer: Future Implications for Clinical Practice?
Prostatic Neoplasms
Abiraterone-Olaparib Combo Aids Men with mCRPC.
Prostatic Neoplasms
Acquired Resistance to Poly (ADP-ribose) Polymerase Inhibitor Olaparib in BRCA2-Associated Prostate Cancer Resulting From Biallelic BRCA2 Reversion Mutations Restores Both Germline and Somatic Loss-of-Function Mutations.
Prostatic Neoplasms
Activity of durvalumab plus olaparib in metastatic castration-resistant prostate cancer in men with and without DNA damage repair mutations.
Prostatic Neoplasms
Activity of Platinum-Based Chemotherapy in Patients With Advanced Prostate Cancer With and Without DNA Repair Gene Aberrations.
Prostatic Neoplasms
Advanced Prostate Cancer with ATM Loss: PARP and ATR Inhibitors.
Prostatic Neoplasms
Age-related activity of Poly (ADP-Ribose) Polymerase (PARP) in men with localized prostate cancer.
Prostatic Neoplasms
Analysis of Circulating Cell-Free DNA Identifies Multiclonal Heterogeneity of BRCA2 Reversion Mutations Associated with Resistance to PARP Inhibitors.
Prostatic Neoplasms
Analysis of Transcriptome, Selected Intracellular Signaling Pathways, Proliferation and Apoptosis of LNCaP Cells Exposed to High Leptin Concentrations.
Prostatic Neoplasms
Androgen Receptor and Poly(ADP-ribose) Glycohydrolase Inhibition Increases Efficiency of Androgen Ablation in Prostate Cancer Cells.
Prostatic Neoplasms
Androgen receptor inhibitor-induced "BRCAness" and PARP inhibition are synthetically lethal for castration-resistant prostate cancer.
Prostatic Neoplasms
Anticancer effects of eleven triterpenoids derived from Antrodia camphorata.
Prostatic Neoplasms
Antineoplastic effect of beta-elemene on prostate cancer cells and other types of solid tumour cells.
Prostatic Neoplasms
Artocarpus altilis (Parkinson) Fosberg Extracts and Geranyl Dihydrochalcone Inhibit STAT3 Activity in Prostate Cancer DU145 Cells.
Prostatic Neoplasms
ATM Loss Confers Greater Sensitivity to ATR Inhibition than PARP Inhibition in Prostate Cancer.
Prostatic Neoplasms
ATR Inhibition Induces CDK1-SPOP Signaling and Enhances Anti-PD-L1 Cytotoxicity in Prostate Cancer.
Prostatic Neoplasms
Auraptene Induces Apoptosis via Myeloid Cell Leukemia 1-Mediated Activation of Caspases in PC3 and DU145 Prostate Cancer Cells.
Prostatic Neoplasms
Auriculasin-induced ROS causes prostate cancer cell death via induction of apoptosis.
Prostatic Neoplasms
Autoimmune response to PARP and BRCA1/BRCA2 in cancer.
Prostatic Neoplasms
BCL2-overexpressing prostate cancer cells rely on PARP1-dependent end-joining and are sensitive to combined PARP inhibitor and radiation therapy.
Prostatic Neoplasms
Beware Liquid Biopsies to Guide PARP Blockade.
Prostatic Neoplasms
Beyond hormone therapy for prostate cancer with PARP inhibitors.
Prostatic Neoplasms
Biomarkers Associating with PARP Inhibitor Benefit in Prostate Cancer in the TOPARP-B Trial.
Prostatic Neoplasms
Bitter melon extract impairs prostate cancer cell-cycle progression and delays prostatic intraepithelial neoplasia in TRAMP model.
Prostatic Neoplasms
BRCA1 Versus BRCA2 and PARP Inhibitor Sensitivity in Prostate Cancer: More Different Than Alike?
Prostatic Neoplasms
BRCAness and prostate cancer: diagnostic and therapeutic considerations.
Prostatic Neoplasms
Breviscapine (BVP) inhibits prostate cancer progression through damaging DNA by minichromosome maintenance protein-7 (MCM-7) modulation.
Prostatic Neoplasms
Buforin IIb induces androgen-independent prostate cancer cells apoptosis though p53 pathway in vitro.
Prostatic Neoplasms
Carnosic acid modulates Akt/IKK/NF-?B signaling by PP2A and induces intrinsic and extrinsic pathway mediated apoptosis in human prostate carcinoma PC-3 cells.
Prostatic Neoplasms
CDK12-Altered Prostate Cancer: Clinical Features and Therapeutic Outcomes to Standard Systemic Therapies, Poly (ADP-Ribose) Polymerase Inhibitors, and PD-1 Inhibitors.
Prostatic Neoplasms
Changing face of metastatic prostate cancer: the law of diminishing returns holds true.
Prostatic Neoplasms
Circulating Cell-Free DNA to Guide Prostate Cancer Treatment with PARP Inhibition.
Prostatic Neoplasms
Clinical Development of PARP Inhibitors in Treating Metastatic Castration-Resistant Prostate Cancer.
Prostatic Neoplasms
Clinical Evolution of Epithelial-Mesenchymal Transition in Human Carcinomas.
Prostatic Neoplasms
Combined inhibition of PI3K and PARP is effective in the treatment of ovarian cancer cells with wild-type PIK3CA genes.
Prostatic Neoplasms
Covid-19 pathogenesis in prostatic cancer and TMPRSS2-ERG regulatory genetic pathway.
Prostatic Neoplasms
CX-5461 sensitises DNA damage repair proficient castrate-resistant prostate cancer to PARP inhibition.
Prostatic Neoplasms
Design and Synthesis of a Trifunctional Molecular System "Programmed" to Block Epidermal Growth Factor Receptor Tyrosine Kinase, Induce High Levels of DNA Damage, and Inhibit the DNA Repair Enzyme (Poly(ADP-ribose) Polymerase) in Prostate Cancer Cells.
Prostatic Neoplasms
Design, synthesis and in vitro cytotoxicity studies of novel ?-carbolinium bromides.
Prostatic Neoplasms
Detection of molecular signatures of homologous recombination deficiency in prostate cancer with or without BRCA1/2 mutations.
Prostatic Neoplasms
Development of PARP inhibitor combinations for castration resistant prostate cancer unselected for homologous recombination repair mutations.
Prostatic Neoplasms
Development of PARP inhibitors in gynecological malignancies.
Prostatic Neoplasms
Diosmetin suppresses human prostate cancer cell proliferation through the induction of apoptosis and cell cycle arrest.
Prostatic Neoplasms
DNA damage repair gene mutation testing and genetic counseling in men with/without prostate cancer: a systematic review.
Prostatic Neoplasms
DNA damage response and prostate cancer: defects, regulation and therapeutic implications.
Prostatic Neoplasms
DNA Repair and Prostate Cancer: A Field Ripe for Harvest.
Prostatic Neoplasms
DNA Repair Gene Alterations and PARP Inhibitor Response in Patients With Metastatic Castration-Resistant Prostate Cancer.
Prostatic Neoplasms
DNA Repair in Prostate Cancer: Biology and Clinical Implications.
Prostatic Neoplasms
DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer.
Prostatic Neoplasms
Does PTEN Loss Impair DNA Double-Strand Break Repair by Homologous Recombination?
Prostatic Neoplasms
Downregulation of mTOR by lentivirus inhibits prostate cancer cell growth.
Prostatic Neoplasms
Drug and molecular radiotherapy combinations for metastatic castration resistant prostate cancer.
Prostatic Neoplasms
DTX3L and ARTD9 inhibit IRF1 expression and mediate in cooperation with ARTD8 survival and proliferation of metastatic prostate cancer cells.
Prostatic Neoplasms
Dual roles of PARP-1 promote cancer growth and progression.
Prostatic Neoplasms
Dynamic Regulation of Rad51 by E2F1 and p53 in Prostate Cancer Cells upon DrugInduced DNA Damage under Hypoxia.
Prostatic Neoplasms
Effective use of PI3K inhibitor BKM120 and PARP inhibitor Olaparib to treat PIK3CA mutant ovarian cancer.
Prostatic Neoplasms
Effects of INPP4B gene transfection combined with PARP inhibitor on castration therapy-resistant prostate cancer cell line, PC3.
Prostatic Neoplasms
Efficacy of PARP Inhibition in Metastatic Castration-resistant Prostate Cancer is Very Different with Non-BRCA DNA Repair Alterations: Reconstructing Prespecified Endpoints for Cohort B from the Phase 3 PROfound Trial of Olaparib.
Prostatic Neoplasms
Emerging Therapies in Metastatic Prostate Cancer.
Prostatic Neoplasms
Emerging treatments for metastatic castration-resistant prostate cancer: Immunotherapy, PARP inhibitors, and PSMA-targeted approaches.
Prostatic Neoplasms
Essential role for G proteins in prostate cancer cell growth and signaling.
Prostatic Neoplasms
Evaluation of the radiosensitizing potency of chemotherapeutic agents in prostate cancer cells.
Prostatic Neoplasms
Evidence of a novel antiapoptotic factor: role of inhibitor of differentiation or DNA binding (Id-1) in anticancer drug-induced apoptosis.
Prostatic Neoplasms
Evolving Role of Immunotherapy in Metastatic Castration Refractory Prostate Cancer.
Prostatic Neoplasms
Exploring the selectivity of guanine scaffold in anticancer drug development by computational repurposing approach.
Prostatic Neoplasms
Expression of nuclear matrix proteins binding matrix attachment regions in prostate cancer. PARP-1: New player in tumor progression.
Prostatic Neoplasms
Expression of PARP-1 and its active polymer PAR in prostate cancer and benign prostatic hyperplasia in Chinese patients.
Prostatic Neoplasms
Fibronectin protects prostate cancer cells from tumor necrosis factor-alpha-induced apoptosis via the AKT/survivin pathway.
Prostatic Neoplasms
Gene therapy for prostate cancer by targeting poly(ADP-ribose) polymerase.
Prostatic Neoplasms
Genetic biomarkers to guide poly(ADP-ribose) polymerase inhibitor precision treatment of prostate cancer.
Prostatic Neoplasms
Genetic polymorphisms in XRCC1 associated with radiation therapy in prostate cancer.
Prostatic Neoplasms
Germline and somatic mutations in prostate cancer: focus on defective DNA repair, PARP inhibitors and immunotherapy.
Prostatic Neoplasms
Growth Inhibitory and Pro-Apoptotic Effects of Ornamental Pomegranate Extracts in Du145 Human Prostate Cancer Cells.
Prostatic Neoplasms
HIV-1 protease inhibitor, ritonavir: a potent inhibitor of CYP3A4, enhanced the anticancer effects of docetaxel in androgen-independent prostate cancer cells in vitro and in vivo.
Prostatic Neoplasms
Homologous recombination deficiency (HRD) score in germline BRCA2- versus ATM-altered prostate cancer.
Prostatic Neoplasms
Homologous recombination repair gene mutations in Chinese localized and locally advanced prostate cancer patients.
Prostatic Neoplasms
Honing in on PARPi Response in Prostate Cancer: from HR Pathway to Gene-by-Gene Granularity.
Prostatic Neoplasms
Human RecQL4 Helicase Plays Critical Roles in Prostate Carcinogenesis.
Prostatic Neoplasms
ICAM-1 and AMPK regulate cell detachment and apoptosis by N-methyl-N'-nitro-N-nitrosoguanidine, a widely spread environmental chemical, in human hormone-refractory prostate cancers.
Prostatic Neoplasms
Identification of probe-quality degraders for Poly(ADP-ribose) polymerase-1 (PARP-1).
Prostatic Neoplasms
Impact of mutations in homologous recombination repair genes on treatment outcomes for metastatic castration resistant prostate cancer.
Prostatic Neoplasms
In prostate cancer cells the interaction of C/EBPalpha with Ku70, Ku80, and poly(ADP-ribose) polymerase-1 increases sensitivity to DNA damage.
Prostatic Neoplasms
In vivo studies of the PARP inhibitor, AZD-2281, in combination with fractionated radiotherapy: An exploration of the therapeutic ratio.
Prostatic Neoplasms
Inactivation of ATP citrate lyase by Cucurbitacin B: A bioactive compound from cucumber, inhibits prostate cancer growth.
Prostatic Neoplasms
Induction of apoptosis and modulation of homologous recombination DNA repair pathway in prostate cancer cells by the combination of AZD2461 and valproic acid.
Prostatic Neoplasms
Induction of apoptosis in hormone-resistant human prostate cancer PC3 cells by inactivated Sendai virus.
Prostatic Neoplasms
Induction of morphological and biochemical apoptosis following prolonged mitotic blockage by halichondrin B macrocyclic ketone analog E7389.
Prostatic Neoplasms
Inhibition of Myeloid Cell Leukemia 1 and Activation of Caspases Are Critically Involved in Gallotannin-induced Apoptosis in Prostate Cancer Cells.
Prostatic Neoplasms
Inhibition of PARP1 by small interfering RNA enhances docetaxel activity against human prostate cancer PC3 cells.
Prostatic Neoplasms
Inhibition of phosphatidylinositol-3-kinase causes cell death through a protein kinase B (PKB)-dependent mechanism and growth arrest through a PKB-independent mechanism.
Prostatic Neoplasms
Inhibition of proteasome activity by various fruits and vegetables is associated with cancer cell death.
Prostatic Neoplasms
Integrating PARP Inhibitors Into Advanced Prostate Cancer Therapeutics.
Prostatic Neoplasms
Ionizing Radiation Combined with PARP1 Inhibitor Reduces Radioresistance in Prostate Cancer with RB1/TP53 Loss.
Prostatic Neoplasms
KNK437, a benzylidene lactam compound, sensitises prostate cancer cells to the apoptotic effect of hyperthermia.
Prostatic Neoplasms
Loss of CHD1 causes DNA repair defects and enhances prostate cancer therapeutic responsiveness.
Prostatic Neoplasms
Loss of MAP3K7 Sensitizes Prostate Cancer Cells to CDK1/2 Inhibition and DNA Damage by Disrupting Homologous Recombination.
Prostatic Neoplasms
Loss of PTEN-assisted G2/M checkpoint impedes homologous recombination repair and enhances radio-curability and PARP inhibitor treatment response in prostate cancer.
Prostatic Neoplasms
Lx2-32c, a novel semi-synthetic taxane, exerts antitumor activity against prostate cancer cells in vitro and in vivo.
Prostatic Neoplasms
Management of Castration-Resistant, Taxane-Resistant Prostate Cancer.
Prostatic Neoplasms
Mechanistic rationale for inhibition of poly(ADP-ribose) polymerase in ETS gene fusion-positive prostate cancer.
Prostatic Neoplasms
Methylseleninic acid potentiates multiple types of cancer cells to ABT-737-induced apoptosis by targeting Mcl-1 and Bad.
Prostatic Neoplasms
MLS-2384, a new 6-bromoindirubin derivative with dual JAK/Src kinase inhibitory activity, suppresses growth of diverse cancer cells.
Prostatic Neoplasms
Molecular landscape of prostate cancer: implications for current clinical trials.
Prostatic Neoplasms
Molecular mechanisms of synergistic induction of apoptosis by the combination therapy with hyperthermia and cisplatin in prostate cancer cells.
Prostatic Neoplasms
Molecular Pathways: Targeting DNA Repair Pathway Defects Enriched in Metastasis.
Prostatic Neoplasms
Molecular Testing Identifies Determinants of Exceptional Response and Guides Precision Therapy in a Patient with Lethal, Treatment-emergent Neuroendocrine Prostate Cancer.
Prostatic Neoplasms
Moving beyond PARP Inhibition in ATM-Deficient Prostate Cancer.
Prostatic Neoplasms
Mutational Profile of Aggressive, Localised Prostate Cancer from African Caribbean Men Versus European Ancestry Men.
Prostatic Neoplasms
Mutations in TP53 or DNA damage repair genes define poor prognostic subgroups in primary prostate cancer.
Prostatic Neoplasms
N-substituted piperazinopyridylsteroid derivatives as abiraterone analogues inhibit growth and induce pro-apoptosis in human hormone-independent prostate cancer cell lines.
Prostatic Neoplasms
Nanoformulation of Olaparib Amplifies PARP Inhibition and Sensitizes PTEN/TP53-Deficient Prostate Cancer to Radiation.
Prostatic Neoplasms
Non-BRCA DNA Damage Repair Gene Alterations and Response to the PARP Inhibitor Rucaparib in Metastatic Castration-Resistant Prostate Cancer: analysis from the phase 2 TRITON2 study.
Prostatic Neoplasms
Non-NAD-like PARP-1 inhibitors in prostate cancer treatment.
Prostatic Neoplasms
NPRL2 reduces the niraparib sensitivity of castration-resistant prostate cancer via interacting with UBE2M and enhancing neddylation.
Prostatic Neoplasms
Olaparib and rucaparib for the treatment of DNA repair-deficient metastatic castration-resistant prostate cancer.
Prostatic Neoplasms
Olaparib combined with abiraterone in patients with metastatic castration-resistant prostate cancer: a randomised, double-blind, placebo-controlled, phase 2 trial.
Prostatic Neoplasms
Olaparib effective in four advanced cancers.
Prostatic Neoplasms
Olaparib for Metastatic Castration-Resistant Prostate Cancer.
Prostatic Neoplasms
Olaparib is effective in combination with, and as maintenance therapy after, first-line endocrine therapy in prostate cancer cells.
Prostatic Neoplasms
Olaparib shows promise in multiple tumor types.
Prostatic Neoplasms
Olaparib Targets Some Advanced Prostate Cancers.
Prostatic Neoplasms
Overexpressed ABCB1 Induces Olaparib-Taxane Cross-Resistance in Advanced Prostate Cancer.
Prostatic Neoplasms
PARP and CDK4/6 Inhibitor Combination Therapy Induces Apoptosis and Suppresses Neuroendocrine Differentiation in Prostate Cancer.
Prostatic Neoplasms
PARP inhibition in BRCA2-mutated prostate cancer.
Prostatic Neoplasms
PARP inhibition in castration-resistant prostate cancer.
Prostatic Neoplasms
PARP inhibition in prostate cancer.
Prostatic Neoplasms
PARP Inhibition in Prostate Cancer: A Promising Approach.
Prostatic Neoplasms
PARP inhibition sensitizes to low dose-rate radiation TMPRSS2-ERG fusion gene-expressing and PTEN-deficient prostate cancer cells.
Prostatic Neoplasms
PARP Inhibition Suppresses GR-MYCN-CDK5-RB1-E2F1 Signaling and Neuroendocrine Differentiation in Castration-Resistant Prostate Cancer.
Prostatic Neoplasms
PARP inhibitor combinations in prostate cancer.
Prostatic Neoplasms
PARP inhibitor receives FDA breakthrough therapy designation in castration resistant prostate cancer: beyond germline BRCA mutations.
Prostatic Neoplasms
PARP inhibitor veliparib and HDAC inhibitor SAHA synergistically co-target the UHRF1/BRCA1 DNA damage repair complex in prostate cancer cells.
Prostatic Neoplasms
PARP inhibitor-induced torsades de pointes in long QT syndrome: a case report.
Prostatic Neoplasms
PARP Inhibitors and Prostate Cancer: To Infinity and Beyond BRCA.
Prostatic Neoplasms
PARP inhibitors and stratified treatment of prostate cancer.
Prostatic Neoplasms
PARP inhibitors as a new therapeutic option in metastatic prostate cancer: a systematic review.
Prostatic Neoplasms
PARP Inhibitors for Advanced Prostate Cancer: Validating Predictive Biomarkers.
Prostatic Neoplasms
PARP inhibitors for homologous recombination-deficient prostate cancer.
Prostatic Neoplasms
PARP inhibitors in advanced prostate cancer: when to use them?
Prostatic Neoplasms
PARP inhibitors in castration-resistant prostate cancer.
Prostatic Neoplasms
PARP Inhibitors in Metastatic Prostate Cancer: Evidence to Date.
Prostatic Neoplasms
PARP Inhibitors in Prostate and Urothelial Cancers.
Prostatic Neoplasms
PARP Inhibitors in Prostate Cancer.
Prostatic Neoplasms
PARP Inhibitors in Prostate Cancer: A Promise Delivered.
Prostatic Neoplasms
PARP inhibitors in prostate cancer: practical guidance for busy clinicians.
Prostatic Neoplasms
PARP inhibitors in prostate cancer: time to narrow patient selection?
Prostatic Neoplasms
PARP Inhibitors in Prostate CancerThe Preclinical Rationale and Current Clinical Development.
Prostatic Neoplasms
PARP-1 and CASP3 genes are up-regulated in LNCaP and PC-3 prostate cancer cell lines.
Prostatic Neoplasms
PARP-1 regulates epithelial-mesenchymal transition (EMT) in prostate tumorigenesis.
Prostatic Neoplasms
PARP9 is overexpressed in human breast cancer and promotes cancer cell migration.
Prostatic Neoplasms
Pharmacokinetics and safety of rucaparib in patients with advanced solid tumors and hepatic impairment.
Prostatic Neoplasms
Phenoxodiol inhibits growth of metastatic prostate cancer cells.
Prostatic Neoplasms
Piperine, a Bioactive Component of Pepper Spice Exerts Therapeutic Effects on Androgen Dependent and Androgen Independent Prostate Cancer Cells.
Prostatic Neoplasms
Poly (ADP-ribose) polymerase (PARP) inhibitors for the treatment of advanced germline BRCA2 mutant prostate cancer.
Prostatic Neoplasms
Poly (ADP-ribose) polymerase 1 protein expression in normal and neoplastic prostatic tissue.
Prostatic Neoplasms
Poly (ADP-Ribose) Polymerase 1 Protein Expression in Normal Pancreas and Pancreatic Adenocarcinoma.
Prostatic Neoplasms
Poly (ADP-ribose) polymerase inhibitor: an evolving paradigm in the treatment of prostate cancer.
Prostatic Neoplasms
Poly(ADP-ribose) polymerase inhibitors in prostate and urothelial cancer.
Prostatic Neoplasms
Poly(ADP-Ribose) Polymerase Inhibitors in Prostate Cancer: Molecular Mechanisms, and Preclinical and Clinical Data.
Prostatic Neoplasms
Poly(ADP-ribosyl)ation in relation to cancer and autoimmune disease.
Prostatic Neoplasms
Polyclonal BRCA2 mutations following carboplatin treatment confer resistance to the PARP inhibitor rucaparib in a patient with mCRPC: a case report.
Prostatic Neoplasms
Practical considerations for optimising homologous recombination repair mutation testing in patients with metastatic prostate cancer.
Prostatic Neoplasms
Pre-clinical and clinical evaluation of PARP inhibitors as tumour-specific radiosensitisers.
Prostatic Neoplasms
Predictive value of epithelial-mesenchymal-transition (EMT) signature and PARP-1 in prostate cancer radioresistance.
Prostatic Neoplasms
Preliminary evaluation of a novel 18F-labeled PARP-1 ligand for PET imaging of PARP-1 expression in prostate cancer.
Prostatic Neoplasms
Proscillaridin A induces apoptosis, inhibits STAT3 activation and augments doxorubicin toxicity in prostate cancer cells.
Prostatic Neoplasms
Prostate cancer and PARP inhibitors: progress and challenges.
Prostatic Neoplasms
Prostate cancer radiosensitization through poly(ADP-Ribose) polymerase-1 hyperactivation.
Prostatic Neoplasms
Prostate cancer: Potential of PARP inhibition plus ADT in prostate cancer.
Prostatic Neoplasms
Quercetin augments TRAIL-induced apoptotic death: involvement of the ERK signal transduction pathway.
Prostatic Neoplasms
Quercetin regulates insulin like growth factor signaling and induces intrinsic and extrinsic pathway mediated apoptosis in androgen independent prostate cancer cells (PC-3).
Prostatic Neoplasms
Quercetin-6-C-?-D-glucopyranoside, natural analog of quercetin exhibits anti-prostate cancer activity by inhibiting Akt-mTOR pathway via aryl hydrocarbon receptor.
Prostatic Neoplasms
Quo Vadis Advanced Prostate Cancer Therapy? Novel Treatment Perspectives and Possible Future Directions.
Prostatic Neoplasms
Radiation-induced PARP activation is enhanced through EGFR-ERK signaling.
Prostatic Neoplasms
Radiosynthesis of 3 H- and 14 C-labeled Veliparib.
Prostatic Neoplasms
Re: Expression of Nuclear Matrix Proteins Binding Matrix Attachment Regions in Prostate Cancer. PARP-1: New Player in Tumor Progression.
Prostatic Neoplasms
Re: Konrad H. Stopsack. Efficacy of PARP Inhibition in Metastatic Castration-resistant Prostate Cancer is Very Different with Non-BRCA DNA Repair Alterations: Reconstructing Prespecified Endpoints for Cohort B from the Phase 3 PROfound Trial of Olaparib. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2020.09.024.
Prostatic Neoplasms
Real-World Treatment Patterns and Overall Survival of Patients with Metastatic Castration-Resistant Prostate Cancer in the US Prior to PARP Inhibitors.
Prostatic Neoplasms
Recent Development and Future Prospects of Molecular Targeted Therapy in Prostate Cancer.
Prostatic Neoplasms
Relevance of poly (ADP-ribose) polymerase inhibitors in prostate cancer.
Prostatic Neoplasms
Reply to Johann S. de Bono, Maha Hussain, and Jinyu Kang's Letter to the Editor re: Konrad H. Stopsack. Efficacy of PARP Inhibition in Metastatic Castration-resistant Prostate Cancer is Very Different with Non-BRCA DNA Repair Alterations: Reconstructing Prespecified Endpoints for Cohort B from the Phase 3 PROfound Trial of Olaparib. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2020.09.024.
Prostatic Neoplasms
Research Progress on PARP14 as a Drug Target.
Prostatic Neoplasms
Resistance Mechanisms to Taxanes and PARP Inhibitors in Advanced Prostate Cancer.
Prostatic Neoplasms
Resistance to second-generation androgen receptor antagonists in prostate cancer.
Prostatic Neoplasms
Response of human prostate cancer cells and tumors to combining PARP inhibition with ionizing radiation.
Prostatic Neoplasms
Response prediction biomarkers and drug combinations of PARP inhibitors in prostate cancer.
Prostatic Neoplasms
Response to olaparib in a PALB2 germline mutated prostate cancer and genetic events associated with resistance.
Prostatic Neoplasms
Role of PARP-1 in prostate cancer.
Prostatic Neoplasms
Rucaparib in Men With Metastatic Castration-Resistant Prostate Cancer Harboring a BRCA1 or BRCA2 Gene Alteration.
Prostatic Neoplasms
Salen-Mn compounds induces cell apoptosis in human prostate cancer cells through promoting AMPK activity and cell autophagy.
Prostatic Neoplasms
Sanggenol L Induces Apoptosis and Cell Cycle Arrest via Activation of p53 and Suppression of PI3K/Akt/mTOR Signaling in Human Prostate Cancer Cells.
Prostatic Neoplasms
Selenite-induced p53 Ser-15 phosphorylation and caspase-mediated apoptosis in LNCaP human prostate cancer cells.
Prostatic Neoplasms
Sequences and combinations of multifaceted therapy in advanced prostate cancer.
Prostatic Neoplasms
SGO1 induces proliferation and metastasis of prostate cancer through AKT-mediated signaling pathway.
Prostatic Neoplasms
Significance of BRCA2 and RB1 Co-loss in Aggressive Prostate Cancer Progression.
Prostatic Neoplasms
SILAC-Based Mass Spectrometry Analysis Reveals That Epibrassinolide Induces Apoptosis via Activating Endoplasmic Reticulum Stress in Prostate Cancer Cells.
Prostatic Neoplasms
Similar incidence of DNA damage response pathway alterations between clinically localized and metastatic prostate cancer.
Prostatic Neoplasms
Standard treatments induce antigen-specific immune responses in prostate cancer.
Prostatic Neoplasms
Stratifying prostate patients for olaparib.
Prostatic Neoplasms
Structurally unique PARP-1 inhibitors for the treatment of prostate cancer.
Prostatic Neoplasms
Sustained Complete Response to Cytotoxic Therapy and the PARP Inhibitor Veliparib in Metastatic Castration-Resistant Prostate Cancer - A Case Report.
Prostatic Neoplasms
Synergistic action of combined PARP and ATR inhibition in prostate cancer with ATM loss.
Prostatic Neoplasms
Synergistic loss of prostate cancer cell viability by coinhibition of HDAC and PARP.
Prostatic Neoplasms
Synthesis of procaspases-3 and -7 during apoptosis in prostate cancer cells.
Prostatic Neoplasms
Synthetic lethal therapies for cancer: what's next after PARP inhibitors?
Prostatic Neoplasms
Synthetic lethality between androgen receptor signalling and the PARP pathway in prostate cancer.
Prostatic Neoplasms
Talazoparib monotherapy in metastatic castration-resistant prostate cancer with DNA repair alterations (TALAPRO-1): an open-label, phase 2 trial.
Prostatic Neoplasms
Targeted radiosensitization of ETS fusion-positive prostate cancer through PARP1 inhibition.
Prostatic Neoplasms
Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012.
Prostatic Neoplasms
Targeting c-MET to Enhance the Efficacy of Olaparib in Prostate Cancer.
Prostatic Neoplasms
Targeting defective DNA repair in prostate cancer.
Prostatic Neoplasms
Targeting DNA Damage Response in Prostate and Breast Cancer.
Prostatic Neoplasms
Targeting DNA repair with combination veliparib (ABT-888) and temozolomide in patients with metastatic castration-resistant prostate cancer.
Prostatic Neoplasms
Targeting DNA Repair: The Role of PARP Inhibition in the Treatment of Castration-Resistant Prostate Cancer.
Prostatic Neoplasms
Targeting genotoxic and proteotoxic stress-response pathways in human prostate cancer by clinically available PARP inhibitors, vorinostat and disulfiram.
Prostatic Neoplasms
Targeting PARP in Prostate Cancer: Novelty, Pitfalls, and Promise.
Prostatic Neoplasms
Targeting Plk1 to Enhance Efficacy of Olaparib in Castration-Resistant Prostate Cancer.
Prostatic Neoplasms
Targeting poly(ADP-ribose) polymerase and the c-Myb-regulated DNA damage response pathway in castration-resistant prostate cancer.
Prostatic Neoplasms
The 25th Annual Prostate Cancer Foundation Scientific Retreat Report.
Prostatic Neoplasms
The ADPRT V762A genetic variant contributes to prostate cancer susceptibility and deficient enzyme function.
Prostatic Neoplasms
The combined effect of USP7 inhibitors and PARP inhibitors in hormone-sensitive and castration-resistant prostate cancer cells.
Prostatic Neoplasms
The Correlation Between PARP1 and BRCA1 in AR Positive Triple-negative Breast Cancer.
Prostatic Neoplasms
The emerging role of PARP inhibitors in prostate cancer.
Prostatic Neoplasms
The multifaceted roles of PARP1 in DNA repair and chromatin remodelling.
Prostatic Neoplasms
The Novel ATR Inhibitor BAY 1895344 Is Efficacious as Monotherapy and Combined with DNA Damage-Inducing or Repair-Compromising Therapies in Preclinical Cancer Models.
Prostatic Neoplasms
The novel toluidine sulphonamide EL102 shows pre-clinical in vitro and in vivo activity against prostate cancer and circumvents MDR1 resistance.
Prostatic Neoplasms
The promising role of poly(ADP-ribose) polymerase inhibitors in prostate cancer.
Prostatic Neoplasms
The Role of PARP Inhibitors in the Treatment of Prostate Cancer: Recent Advances in Clinical Trials.
Prostatic Neoplasms
The tip of the iceberg: predicting PARP inhibitor efficacy in prostate cancer.
Prostatic Neoplasms
The TMPRSS2-ERG Gene Fusion Blocks XRCC4-Mediated Nonhomologous End-Joining Repair and Radiosensitizes Prostate Cancer Cells to PARP Inhibition.
Prostatic Neoplasms
Therapeutic Potential of Combining PARP Inhibitor and Immunotherapy in Solid Tumors.
Prostatic Neoplasms
Therapeutic Potential of PARP Inhibitors in the Treatment of Gastrointestinal Cancers.
Prostatic Neoplasms
Therapeutic Potential of PARP Inhibitors in the Treatment of Metastatic Castration-Resistant Prostate Cancer.
Prostatic Neoplasms
Transcription-induced DNA double strand breaks: both an oncogenic force and potential therapeutic target?
Prostatic Neoplasms
Treating Prostate Cancer by Antibody-Drug Conjugates.
Prostatic Neoplasms
Treatment and Patient Selection for Patients with Metastatic Castration-resistant Prostate After Progression on Docetaxel and Abiraterone/Enzalutamide: When to Play Your CARD and When to Do Your PARP.
Prostatic Neoplasms
Trop2 is a driver of metastatic prostate cancer with neuroendocrine phenotype via PARP1.
Prostatic Neoplasms
Untangling the PROfound Trial for Advanced Prostate Cancer: Is There Really a Role for Olaparib?
Prostatic Neoplasms
Vulnerabilities of PTEN-TP53-deficient prostate cancers to compound PARP-PI3K inhibition.
Prostatic Neoplasms
When and How to Use PARP Inhibitors in Prostate Cancer: A Systematic Review of the Literature with an Update on On-Going Trials.
Prostatic Neoplasms
[DNA damage repair: An emerging strategy in metastatic prostate cancer].
Prostatic Neoplasms
[Molecular tumor board prostate cancer].
protein acetyllysine n-acetyltransferase deficiency
Poly(ADP-ribose) polymerase 1 contributes to oxidative stress through downregulation of sirtuin 3 during cisplatin nephrotoxicity.
Protein Deficiency
Ageing and PARP.
protein-tyrosine-phosphatase deficiency
A cell type-specific role of protein tyrosine phosphatase non-receptor type 2 in regulating ER stress signalling.
Proteinuria
PARP inhibition ameliorates nephropathy in an animal model of type 2 diabetes: focus on oxidative stress, inflammation, and fibrosis.
Proteinuria
Therapeutic options following second-line platinum-based chemotherapy in patients with recurrent ovarian cancer: Comparison of active surveillance and maintenance treatment.
protoporphyrin ferrochelatase deficiency
Frataxin Deficiency Promotes Excess Microglial DNA Damage and Inflammation that Is Rescued by PJ34.
Pseudomonas Infections
Production of exoenzyme S during Pseudomonas aeruginosa infections of burned mice.
Pseudomonas Infections
Use of transposon mutants to assess the role of exoenzyme S in chronic pulmonary disease due to Pseudomonas aeruginosa.
Pseudorabies
Inhibition of PARP1 Dampens Pseudorabies Virus Infection through DNA Damage-Induced Antiviral Innate Immunity.
Psoriasis
Nitric oxide-peroxynitrite-poly(ADP-ribose) polymerase pathway in the skin.
Psoriasis
Poly(ADP-ribose) polymerase-1 depletion enhances the severity of inflammation in an imiquimod-induced model of psoriasis.
Pulmonary Disease, Chronic Obstructive
Flavone as PARP-1 inhibitor: its effect on lipopolysaccharide induced gene-expression.
Pulmonary Disease, Chronic Obstructive
Gene knockout or pharmacological inhibition of poly(ADP-ribose) polymerase-1 prevents lung inflammation in a murine model of asthma.
Pulmonary Disease, Chronic Obstructive
Immunotherapy of COVID-19 with poly (ADP-ribose) polymerase inhibitors: starting with nicotinamide.
Pulmonary Disease, Chronic Obstructive
Increased DNA damage in progression of COPD: a response by poly(ADP-ribose) polymerase-1.
Pulmonary Disease, Chronic Obstructive
Increased PARP Activity and DNA Damage in NSCLC Patients: The Influence of COPD.
Pulmonary Disease, Chronic Obstructive
Inhibition of acute pulmonary and systemic inflammation by 1,7-dimethylxanthine.
Pulmonary Disease, Chronic Obstructive
Pan-Cancer Analysis of PARP1 Alterations as Biomarkers in the Prediction of Immunotherapeutic Effects and the Association of Its Expression Levels and Immunotherapy Signatures.
Pulmonary Disease, Chronic Obstructive
PARP-1 inhibition ameliorates elastase induced lung inflammation and emphysema in mice.
Pulmonary Disease, Chronic Obstructive
Poly (ADP-ribose) polymerase-1-inhibiting flavonoids attenuate cytokine release in blood from male patients with chronic obstructive pulmonary disease or type 2 diabetes.
Pulmonary Disease, Chronic Obstructive
Poly(ADP-Ribose)Polymerase-1 in Lung Inflammatory Disorders: A Review.
Pulmonary Disease, Chronic Obstructive
Systemic poly(ADP-ribose) polymerase-1 activation, chronic inflammation, and oxidative stress in COPD patients.
Pulmonary Disease, Chronic Obstructive
Theophylline prevents NAD+ depletion via PARP-1 inhibition in human pulmonary epithelial cells.
Pulmonary Edema
Excitotoxicity in the lung: N-methyl-D-aspartate-induced, nitric oxide-dependent, pulmonary edema is attenuated by vasoactive intestinal peptide and by inhibitors of poly(ADP-ribose) polymerase.
Pulmonary Fibrosis
Effects of PARP-1 Deficiency and Histamine H4 Receptor Inhibition in an Inflammatory Model of Lung Fibrosis in Mice.
Pulmonary Fibrosis
Taurine and niacin offer a novel therapeutic modality in prevention of chemically-induced pulmonary fibrosis in hamsters.
Purpura
Defective activation of the MAPK/ERK pathway, leading to PARP1 and DNMT1 dysregulation, is a common defect in IgA nephropathy and Henoch-Schönlein purpura.
Rectal Neoplasms
Colorectal cancers differ in respect of PARP-1 protein expression.
Rectal Neoplasms
DNA repair single-nucleotide polymorphisms in colorectal cancer and their role as modifiers of the effect of cigarette smoking and alcohol in the Singapore Chinese Health Study.
Rectal Neoplasms
PARP inhibitors and chemoradiation for rectal cancer.
Rectal Neoplasms
Polyunsaturated fatty acids, DNA repair single nucleotide polymorphisms and colorectal cancer in the Singapore Chinese Health Study.
Renal Insufficiency
Development of renal failure in PargParp-1 null and Timm23 hypomorphic mice.
Reoviridae Infections
Reovirus transport--studies using lymphocytosis promoting factor.
Reperfusion Injury
25-Hydroxycholesterol protects against myocardial ischemia-reperfusion injury via inhibiting PARP activity.
Reperfusion Injury
A new, potent poly(ADP-ribose) polymerase inhibitor improves cardiac and vascular dysfunction associated with advanced aging.
Reperfusion Injury
A nonradiometric, high-throughput assay for poly(ADP-ribose) glycohydrolase (PARG): application to inhibitor identification and evaluation.
Reperfusion Injury
A novel and orally active poly(ADP-ribose) polymerase inhibitor, KR-33889 [2-[methoxycarbonyl(4-methoxyphenyl) methylsulfanyl]-1H-benzimidazole-4-carboxylic acid amide], attenuates injury in in vitro model of cell death and in vivo model of cardiac ischemia.
Reperfusion Injury
Absence of poly(ADP-ribose)polymerase-1 alters nuclear factor-kappa B activation and gene expression of apoptosis regulators after reperfusion injury.
Reperfusion Injury
Activation of poly(ADP-ribose) polymerase contributes to the endothelial dysfunction associated with hypertension and aging.
Reperfusion Injury
Activation of poly(ADP-ribose) polymerase in circulating leukocytes during myocardial infarction.
Reperfusion Injury
Beneficial effects of poly (ADP-ribose) polymerase inhibition against the reperfusion injury in heart transplantation.
Reperfusion Injury
BGP-15, a nicotinic amidoxime derivate protecting heart from ischemia reperfusion injury through modulation of poly(ADP-ribose) polymerase.
Reperfusion Injury
Cellular responses to DNA damage in the absence of Poly(ADP-ribose) polymerase.
Reperfusion Injury
Continuous inhibition of poly(ADP-ribose) polymerase does not reduce reperfusion injury in isolated rat heart.
Reperfusion Injury
Correlation of morphological findings with functional reserve in the aging donor: role of the poly (ADP-ribose) polymerase.
Reperfusion Injury
Detection of poly(ADP-ribose) polymerase activation in oxidatively stressed cells and tissues using biotinylated NAD substrate.
Reperfusion Injury
Differential regulation of activator protein-1 and heat shock factor-1 in myocardial ischemia and reperfusion injury: role of poly(ADP-ribose) polymerase-1.
Reperfusion Injury
Effect of cilostazol pretreatment on the PARP/AIF-mediated apoptotic pathway in rat cerebral ischemia-reperfusion models.
Reperfusion Injury
Effect of PJ-34 PARP-inhibitor on rat liver microcirculation and antioxidant status.
Reperfusion Injury
Effects of 3-aminobenzamide on unilateral testicular ischemia-reperfusion injury: what is the role of PARP inhibition?
Reperfusion Injury
Effects of poly(ADP-ribose) polymerase inhibition on inflammatory cell migration in a murine model of asthma.
Reperfusion Injury
Hydrogen-rich saline reduces cell death through inhibition of DNA oxidative stress and overactivation of poly (ADP-ribose) polymerase-1 in retinal ischemia-reperfusion injury.
Reperfusion Injury
Improved poststorage cardiac function by poly (ADP-ribose) polymerase inhibition: role of phosphatidylinositol 3-kinase Akt pathway.
Reperfusion Injury
In vitro effect of the potent poly(ADP-ribose) polymerase (PARP) inhibitor INO-1001 alone and in combination with aspirin, eptifibatide, tirofiban, enoxaparin or alteplase on haemostatic parameters.
Reperfusion Injury
Inhibition of poly(adenosine diphosphate-ribose) polymerase decreases long-term histologic damage in testicular ischemia-reperfusion injury.
Reperfusion Injury
Inhibition of poly(ADP-ribose) polymerase activity protects hippocampal cells against morphological and ultrastructural alteration evoked by ischemia-reperfusion injury.
Reperfusion Injury
Inhibition of the activity of poly (ADP-ribose) polymerase in ischemia-reperfusion injury.
Reperfusion Injury
Investigating the Effect of the Poly(Adp-ribose) Polymerase Inhibitor 5-aminoisoquinolinone and the Na+-H+ Exchanger Inhibitor Zoniporide on Isolated Perfused Rat Hearts during Ischemia-reperfusion Injury.
Reperfusion Injury
Matrix Metalloproteinase-2 (MMP-2) Gene Deletion Enhances MMP-9 Activity, Impairs PARP-1 Degradation, and Exacerbates Hepatic Ischemia and Reperfusion Injury in Mice.
Reperfusion Injury
Mediation of poly(ADP-ribose) polymerase-1-dependent cell death by apoptosis-inducing factor.
Reperfusion Injury
Minocycline Protects Cardiac Myocytes Against Simulated Simulated Ischemia-Reperfusion Injury by Inhibiting Poly(ADP-ribose) Polymerase-1.
Reperfusion Injury
MiR-124 Negatively Regulated PARP1 to Alleviate Renal Ischemia-reperfusion Injury by Inhibiting TNF?/RIP1/RIP3 Pathway.
Reperfusion Injury
Modulation of Poly(ADP-Ribose) Polymerase-1 (PARP-1)-Mediated Oxidative Cell Injury by Ring Finger Protein 146 (RNF146) in Cardiac Myocytes.
Reperfusion Injury
Neuroprotective effects of NU1025, a PARP inhibitor in cerebral ischemia are mediated through reduction in NAD depletion and DNA fragmentation.
Reperfusion Injury
Neuroprotective effects of poly (ADP-ribose) polymerase inhibitors in transient focal cerebral ischemia of rats.
Reperfusion Injury
Neuroprotective Properties of Picroside II in a Rat Model of Focal Cerebral Ischemia.
Reperfusion Injury
Poly (ADP-Ribose) Polymerase Inhibitor Treatment as a Novel Therapy Attenuating Renal Ischemia-Reperfusion Injury.
Reperfusion Injury
Poly(ADP-ribose) Polymerase (PARP) and PARP Inhibitors: Mechanisms of Action and Role in Cardiovascular Disorders.
Reperfusion Injury
Poly(ADP-ribose) polymerase 1 activation links ischemic acute kidney injury to interstitial fibrosis.
Reperfusion Injury
Poly(ADP-ribose) polymerase and renal hypothermic preservation injury.
Reperfusion Injury
Poly(ADP-ribose) polymerase during reperfusion after transient forebrain ischemia: its role in brain edema and cell death.
Reperfusion Injury
Poly(ADP-ribose) polymerase inhibition attenuates biventricular reperfusion injury after orthotopic heart transplantation.
Reperfusion Injury
Poly(ADP-ribose) polymerase inhibition improves postischemic myocardial function after cardioplegia-cardiopulmonary bypass.
Reperfusion Injury
Poly(ADP-ribose) polymerase inhibition prevents reactive oxygen species induced inhibition of aldehyde dehydrogenase2 activity.
Reperfusion Injury
Poly(ADP-Ribose) polymerase inhibition reduces reperfusion injury after heart transplantation.
Reperfusion Injury
Poly(ADP-ribose) polymerase triggers the microvascular mechanisms of hepatic ischemia-reperfusion injury.
Reperfusion Injury
Poly(ADP-ribose) polymerase-1 and apoptosis inducing factor in neurotoxicity.
Reperfusion Injury
Poly(ADP-ribose) polymerase-1: what have we learned from the deficient mouse model?
Reperfusion Injury
Poly(ADP-ribose) polymerase: the nuclear target in signal transduction and its role in brain ischemia-reperfusion injury.
Reperfusion Injury
Poly(ADP-ribosyl)ation in asthma and other lung diseases.
Reperfusion Injury
Post-treatment with an inhibitor of poly(ADP-ribose) polymerase attenuates cerebral damage in focal ischemia.
Reperfusion Injury
Postischemic poly (ADP-ribose) polymerase (PARP) inhibition reduces ischemia reperfusion injury in a hind-limb ischemia model.
Reperfusion Injury
Protective effect of cardioplegia with poly (ADP-ribose) polymerase-1 inhibitor against myocardial ischemia-reperfusion injury: in vitro study of isolated rat heart model.
Reperfusion Injury
Protective effects of nigranoic acid on cerebral ischemia-reperfusion injury and its mechanism involving apoptotic signaling pathway.
Reperfusion Injury
Purines inhibit poly(ADP-ribose) polymerase activation and modulate oxidant-induced cell death.
Reperfusion Injury
Quantification of PARP Activity in Human Tissues: Ex Vivo Assays in Blood Cells and Immunohistochemistry in Human Biopsies.
Reperfusion Injury
Resistance to acute septic peritonitis in poly(ADP-ribose) polymerase-1-deficient mice.
Reperfusion Injury
Role of poly-(ADP-ribose) polymerase in transplant acute tubular necrosis and its relationship with delayed renal function.
Reperfusion Injury
Sp1 Targeted PARP1 Inhibition Protects Cardiomyocytes From Myocardial Ischemia-Reperfusion Injury via Downregulation of Autophagy.
Reperfusion Injury
Spermidine is protective against kidney ischemia and reperfusion injury through inhibiting DNA nitration and PARP1 activation.
Reperfusion Injury
The activity and inhibition of poly(ADP-ribose) polymerase-1 in equine peripheral blood mononuclear cells in vitro.
Reperfusion Injury
The effect of poly (adenosine diphosphate-ribose) polymerase inhibitors on biochemical changes in testicular ischemia-reperfusion injury.
Reperfusion Injury
The effect of reperfusion on neuroprotection using an inhibitor of poly(ADP-ribose) polymerase.
Reperfusion Injury
Therapeutic Strategies and Biomarkers to Modulate PARP Activity for Targeted Cancer Therapy.
Respiratory Distress Syndrome
Characterization of a unique ADP-ribosyltransferase of Mycoplasma penetrans.
Respiratory Distress Syndrome
Poly(ADP-ribosyl)ation in asthma and other lung diseases.
Respiratory Insufficiency
[Acute poisoning by chemical warfare agent: sulfur mustard]
Respiratory Syncytial Virus Infections
Pertussis toxin sensitization alters the pathogenesis of subsequent respiratory syncytial virus infection.
Respiratory Tract Infections
Pertussis toxin inhibits early chemokine production to delay neutrophil recruitment in response to Bordetella pertussis respiratory tract infection in mice.
Respiratory Tract Infections
Pertussis toxin permeabilization enhances the traversal of Escherichia coli K1, macrophages, and monocytes in a cerebral endothelial barrier model in vitro.
Respiratory Tract Infections
Pertussis toxin targets airway macrophages to promote Bordetella pertussis infection of the respiratory tract.
Respiratory Tract Infections
Pseudomonas aeruginosa exoenzyme S as a pathogenic determinant in respiratory infections.
Respiratory Tract Infections
Suppression of serum antibody responses by pertussis toxin after respiratory tract colonization by Bordetella pertussis and identification of an immunodominant lipoprotein.
Respiratory Tract Infections
[Humoral reaction to Bordetella pertussis antigens: pertussis toxin, filamentous hemagglutinin and lipopolysaccharide in children with clinical symptoms of whooping cough. I. Antibody level for B pertussis antigens in children without respiratory tract infection symptoms]
Respiratory Tract Infections
[The frequency of detection of IgA, IgG and IgM antibodies to pertussis toxin in patients with respiratory tract infections in Poland]
Retinal Degeneration
Drug repurposing studies of PARP inhibitors as a new therapy for inherited retinal degeneration.
Retinal Degeneration
Excessive activation of poly(ADP-ribose) polymerase contributes to inherited photoreceptor degeneration in the retinal degeneration 1 mouse.
Retinal Degeneration
Fluorescent detection of PARP activity in unfixed tissue.
Retinal Degeneration
Intravitreal administration of adalimumab delays retinal degeneration in rd10 mice.
Retinal Degeneration
MUTYH promotes oxidative microglial activation and inherited retinal degeneration.
Retinal Degeneration
N -ethyl- N -nitrosourea induces retinal photoreceptor damage in adult rats.
Retinal Degeneration
Olaparib significantly delays photoreceptor loss in a model for hereditary retinal degeneration.
Retinal Degeneration
PARP1 gene knock-out increases resistance to retinal degeneration without affecting retinal function.
Retinal Degeneration
Photoreceptor cell death mechanisms in inherited retinal degeneration.
Retinal Degeneration
SIMULTANEOUS CELL DEATH AND UPREGULATION OF POLY(ADP-RIBOSE) POLYMERASE-1 (PARP-1) EXPRESSION IN EARLY POSTNATAL MOUSE RETINA.
Retinal Detachment
PJ34 Protects Photoreceptors from Cell Death by Inhibiting PARP-1 Induced Parthanatos after Experimental Retinal Detachment.
Retinal Diseases
Excessive activation of poly(ADP-ribose) polymerase contributes to inherited photoreceptor degeneration in the retinal degeneration 1 mouse.
Retinal Diseases
PARP Inhibitor Protects Against Chronic Hypoxia/Reoxygenation-Induced Retinal Injury by Regulation of MAPKs, HIF1?, Nrf2, and NF?B.
Retinal Diseases
Poly(ADP-Ribose) Polymerase-1 inhibition potentiates cell death and phosphorylation of DNA damage response proteins in oxidative stressed retinal cells.
Retinal Dystrophies
Temporal progression of PARP activity in the Prph2 mutant rd2 mouse: Neuroprotective effects of the PARP inhibitor PJ34.
Retinitis Pigmentosa
Drug repurposing studies of PARP inhibitors as a new therapy for inherited retinal degeneration.
Retinitis Pigmentosa
Efficacy of PARP inhibition in Pde6a mutant mouse models for retinitis pigmentosa depends on the quality and composition of individual human mutations.
Retinitis Pigmentosa
Mice deficient in UXT exhibit retinitis pigmentosa-like features via aberrant autophagy activation.
Retinitis Pigmentosa
Olaparib significantly delays photoreceptor loss in a model for hereditary retinal degeneration.
Retinoblastoma
Activation of PKC but not of ERK is required for vitamin E-succinate-induced apoptosis of HL-60 cells.
Retinoblastoma
Barrier-to-autointegration factor proteome reveals chromatin-regulatory partners.
Retinoblastoma
cAMP increasing agents attenuate the generation of apoptosis by etoposide in promonocytic leukemia cells.
Retinoblastoma
Caspase-3 activation during the process of apoptosis induced by a vacuolar type H(+)-ATPase inhibitor.
Retinoblastoma
Caspase-dependent activation of calpain during drug-induced apoptosis.
Retinoblastoma
d-3-Deoxy-dioctanoylphosphatidylinositol induces cytotoxicity in human MCF-7 breast cancer cells via a mechanism that involves downregulation of the D-type cyclin-retinoblastoma pathway.
Retinoblastoma
Dysregulation of the cyclin-dependent kinase inhibitor p21WAF1/CIP1/MDA6 increases the susceptibility of human leukemia cells (U937) to 1-beta-D-arabinofuranosylcytosine-mediated mitochondrial dysfunction and apoptosis.
Retinoblastoma
Fas-mediated apoptosis in T cells involves the dephosphorylation of the retinoblastoma protein by type 1 protein phosphatases.
Retinoblastoma
Histone deacetylase inhibitors valproic acid and depsipeptide sensitize retinoblastoma cells to radiotherapy by increasing H2AX phosphorylation and p53 acetylation-phosphorylation.
Retinoblastoma
Induction of cell cycle changes and modulation of apoptogenic/anti-apoptotic and extracellular signaling regulatory protein expression by water extracts of I'm-Yunity (PSP).
Retinoblastoma
Inhibitory effects of fenofibrate on apoptosis and cell proliferation in human endothelial cells in high glucose.
Retinoblastoma
Interferon-lambda induces G1 phase arrest or apoptosis in oesophageal carcinoma cells and produces anti-tumour effects in combination with anti-cancer agents.
Retinoblastoma
LRP1 Regulates Retinal Angiogenesis by Inhibiting PARP-1 Activity and Endothelial Cell Proliferation.
Retinoblastoma
Novel histone deacetylase inhibitors in the treatment of thyroid cancer.
Retinoblastoma
p53-independent dephosphorylation and cleavage of retinoblastoma protein during tamoxifen-induced apoptosis in human breast carcinoma cells.
Retinoblastoma
Sodium salicylate induces apoptosis in HCT116 colorectal cancer cells through activation of p38MAPK.
Retinoblastoma
The histone deacetylase inhibitor MS-275 promotes differentiation or apoptosis in human leukemia cells through a process regulated by generation of reactive oxygen species and induction of p21CIP1/WAF1 1.
Retinoblastoma
The proteasome inhibitor bortezomib induces apoptosis in human retinoblastoma cell lines in vitro.
Retinoblastoma
Transcriptional down-regulation of poly(ADP-ribose) polymerase gene expression by E1A binding to pRb proteins protects murine keratinocytes from radiation-induced apoptosis.
Retinopathy of Prematurity
Poly(ADP-ribose) polymerase inhibitors counteract diabetes- and hypoxia-induced retinal vascular endothelial growth factor overexpression.
Rhabdomyosarcoma
Differentiation of BA-HAN-1C rhabdomyosarcoma cells is controlled by a pertussis toxin sensitive signaling pathway.
Rhabdomyosarcoma
Enhancement of Soft Tissue Sarcoma Cell Radiosensitivity by Poly(ADP-ribose) Polymerase-1 Inhibitors.
Rhabdomyosarcoma
PARP inhibitors affect growth, survival and radiation susceptibility of human alveolar and embryonal rhabdomyosarcoma cell lines.
Rhabdomyosarcoma
Tyrosyl-DNA phosphodiesterase 1 (TDP1) and Poly (ADP-Ribose) Polymerase-1 (PARP1) deficiency are cytotoxic to rhabdomyosarcoma cells.
Rhabdomyosarcoma
Visualizing Engrafted Human Cancer and Therapy Responses in Immunodeficient Zebrafish.
Rhabdomyosarcoma, Alveolar
Radiosensitizing Potential of Curcumin in Different Cancer Models.
Rhabdomyosarcoma, Embryonal
PARP inhibitors affect growth, survival and radiation susceptibility of human alveolar and embryonal rhabdomyosarcoma cell lines.
Rheumatic Diseases
Identification of autoantibodies associated with systemic lupus erythematosus.
Rhinitis, Allergic
Investigation of poly (ADP-ribose) polymerase-1 genetic variants as a possible risk for allergic rhinitis.
Rhinitis, Allergic
Involvement of chemical mediators in nasal allergic responses of HDC-KO mice.
ring-type e3 ubiquitin transferase deficiency
BRCA1 deficiency and synthetic lethality in leukemias; not only gene mutation matters.
ring-type e3 ubiquitin transferase deficiency
DSB repair pathway choice is regulated by recruitment of 53BP1 through cell cycle-dependent regulation of Sp1.
ring-type e3 ubiquitin transferase deficiency
Haploinsufficiency of Parp1 accelerates Brca1-associated centrosome amplification, telomere shortening, genetic instability, apoptosis, and embryonic lethality.
ring-type e3 ubiquitin transferase deficiency
High incidence of protein-truncating TP53 mutations in BRCA1-related breast cancer.
ring-type e3 ubiquitin transferase deficiency
Identification by array comparative genomic hybridization of a new amplicon on chromosome 17q highly recurrent in BRCA1 mutated triple negative breast cancer.
ring-type e3 ubiquitin transferase deficiency
Selective resistance to the PARP inhibitor olaparib in a mouse model for BRCA1-deficient metaplastic breast cancer.
ring-type e3 ubiquitin transferase deficiency
Shieldin complex promotes DNA end-joining and counters homologous recombination in BRCA1-null cells.
ring-type e3 ubiquitin transferase deficiency
Synthetic lethality between BRCA1 deficiency and poly(ADP-ribose) polymerase inhibition is modulated by processing of endogenous oxidative DNA damage.
rna-directed dna polymerase deficiency
Impact of telomerase ablation on organismal viability, aging, and tumorigenesis in mice lacking the DNA repair proteins PARP-1, Ku86, or DNA-PKcs.
rna-directed dna polymerase deficiency
PARP1 Is a TRF2-associated poly(ADP-ribose)polymerase and protects eroded telomeres.
Rubella
Immunity to vaccine-preventable diseases among paediatric healthcare workers in Denmark, 2019.
Salmonella Infections
Absence of poly(ADP-ribose) polymerase 1 delays the onset of Salmonella enterica serovar Typhimurium-induced gut inflammation.
Salmonella Infections
Quantitative proteomic analysis of host epithelial cells infected by Salmonella enterica serovar Typhimurium.
Salmonella Infections
Salmonella induces macrophage death by caspase-1-dependent necrosis.
Sarcoma
Activity of trabectedin and the PARP inhibitor rucaparib in soft-tissue sarcomas.
Sarcoma
Differential Sensitivity of Taxol-induced Apoptosis in U2OS and SaOS2 Osteogenic Sarcoma Cells.
Sarcoma
Doxorubicin-induced suppression of poly(ADP-ribose) polymerase-1 (PARP-1) activity and expression and its implication for PARP inhibitors in clinical trials.
Sarcoma
Enhancement of Soft Tissue Sarcoma Cell Radiosensitivity by Poly(ADP-ribose) Polymerase-1 Inhibitors.
Sarcoma
Fused in Sarcoma (FUS) in DNA Repair: Tango with Poly(ADP-ribose) Polymerase 1 and Compartmentalisation of Damaged DNA.
Sarcoma
IFN regulatory factor 8 sensitizes soft tissue sarcoma cells to death receptor-initiated apoptosis via repression of FLICE-like protein expression.
Sarcoma
Individual and Combined Expression of DNA Damage Response Molecules PARP1, ?H2AX, BRCA1, and BRCA2 Predict Shorter Survival of Soft Tissue Sarcoma Patients.
Sarcoma
MCM4 Is a Novel Biomarker Associated With Genomic Instability, BRCAness Phenotype, and Therapeutic Potentials in Soft-Tissue Sarcoma.
Sarcoma
Molecular signatures of BRCAness analysis identifies PARP inhibitor Niraparib as a novel targeted therapeutic strategy for soft tissue Sarcomas.
Sarcoma
Next-generation sequencing for the management of sarcomas with no known driver mutations.
Sarcoma
PARP inhibition in UV-associated angiosarcoma preclinical models.
Sarcoma
PARP inhibitors affect growth, survival and radiation susceptibility of human alveolar and embryonal rhabdomyosarcoma cell lines.
Sarcoma
PARP inhibitors: A new era of targeted therapy.
Sarcoma
PARP1 expression drives the synergistic antitumor activity of trabectedin and PARP1 inhibitors in sarcoma preclinical models.
Sarcoma
PARP1 expression in soft tissue sarcomas is a poor-prognosis factor and a new potential therapeutic target.
Sarcoma
Radiosensitizing Potential of Curcumin in Different Cancer Models.
Sarcoma
Regulation of transmembrane signal transduction of insulin-like growth factor II by competence type growth factors or viral ras p21.
Sarcoma
Sarcoma stratification by combined pH2AX and MAP17 (PDZK1IP1) levels for a better outcome on doxorubicin plus olaparib treatment.
Sarcoma
SLFN11 is widely expressed in pediatric sarcoma and induces variable sensitization to replicative stress caused by DNA damaging agents.
Sarcoma
Soft tissue sarcomas: new opportunity of treatment with PARP inhibitors?
Sarcoma
The RNA-binding Protein Fused in Sarcoma (FUS) Functions Downstream of Poly(ADP-ribose) Polymerase (PARP) in Response to DNA Damage.
Sarcoma
Trabectedin and olaparib in patients with advanced and non-resectable bone and soft-tissue sarcomas (TOMAS): an open-label, phase 1b study from the Italian Sarcoma Group.
Sarcoma, Ewing
Co-regulated expression of dbl and poly(ADP-ribose) polymerase in Ewing's sarcoma cells and dbl-transformed NIH3T3 fibroblasts.
Sarcoma, Ewing
Combinations of PARP Inhibitors with Temozolomide Drive PARP1 Trapping and Apoptosis in Ewing's Sarcoma.
Sarcoma, Ewing
Combining poly(ADP-ribose) polymerase 1 (PARP-1) inhibition and radiation in Ewings sarcoma results in lethal DNA damage.
Sarcoma, Ewing
Constraints to DNA unwinding near radiation-induced strand breaks in Ewing's sarcoma cells.
Sarcoma, Ewing
Correction: The PARP inhibitor olaparib enhances the sensitivity of Ewing sarcoma to trabectedin.
Sarcoma, Ewing
Current questions in bone sarcomas.
Sarcoma, Ewing
Differential regulation of the response to DNA damage in Ewing's sarcoma cells by ETS1 and EWS/FLI-1.
Sarcoma, Ewing
Ewing sarcoma protein promotes dissociation of poly(ADP-ribose) polymerase 1 from chromatin.
Sarcoma, Ewing
Ewing's sarcoma precursors are highly enriched in embryonic osteochondrogenic progenitors.
Sarcoma, Ewing
EWS-FLI1 increases transcription to cause R-loops and block BRCA1 repair in Ewing sarcoma.
Sarcoma, Ewing
EWS/FLI Confers Tumor Cell Synthetic Lethality to CDK12 Inhibition in Ewing Sarcoma.
Sarcoma, Ewing
Expression of functional Y1 receptors for neuropeptide Y in human Ewing's sarcoma cell lines.
Sarcoma, Ewing
Expression of the human Bcl-2 increases resistance of Ewing's sarcoma cells to apoptosis and inhibits poly(ADP-ribose) polymerase cleavage induced by radiation.
Sarcoma, Ewing
Identification of a rearrangement in the 5' upstream region of the poly(ADP-ribose) polymerase pseudogene on chromosome 13 in Ewing's sarcoma cells.
Sarcoma, Ewing
Inhibition of SOX2 induces cell apoptosis and G1/S arrest in Ewing's sarcoma through the PI3K/Akt pathway.
Sarcoma, Ewing
Matrix screen identifies synergistic combination of PARP inhibitors and nicotinamide phosphoribosyltransferase (NAMPT) inhibitors in Ewing sarcoma.
Sarcoma, Ewing
Nanoformulation of Talazoparib Increases Maximum Tolerated Doses in Combination With Temozolomide for Treatment of Ewing Sarcoma.
Sarcoma, Ewing
New strategies in ewing sarcoma: lost in translation?
Sarcoma, Ewing
PARP Inhibitors Sensitize Ewing Sarcoma Cells to Temozolomide-Induced Apoptosis via the Mitochondrial Pathway.
Sarcoma, Ewing
PARP-1 inhibition as a targeted strategy to treat Ewing's sarcoma.
Sarcoma, Ewing
Phase 1/2 trial of talazoparib in combination with temozolomide in children and adolescents with refractory/recurrent solid tumors including Ewing sarcoma: A Children's Oncology Group Phase 1 Consortium study (ADVL1411).
Sarcoma, Ewing
Phase II study of olaparib in patients with refractory Ewing sarcoma following failure of standard chemotherapy.
Sarcoma, Ewing
Poly(ADP-ribose) polymerase inhibitors in Ewing sarcoma.
Sarcoma, Ewing
Poly(ADP-ribose) polymerase turnover alterations do not contribute to PARP overexpression in Ewing's sarcoma cells.
Sarcoma, Ewing
Polymerase independent repression of FoxO1 transcription by sequence-specific PARP1 binding to FoxO1 promoter.
Sarcoma, Ewing
Radiation-induced apoptosis of Ewing's sarcoma cells: DNA fragmentation and proteolysis of poly(ADP-ribose) polymerase.
Sarcoma, Ewing
Registered report: Systematic identification of genomic markers of drug sensitivity in cancer cells.
Sarcoma, Ewing
Regulation of the human poly(ADP-ribose) polymerase promoter by the ETS transcription factor.
Sarcoma, Ewing
Replication Study: Systematic identification of genomic markers of drug sensitivity in cancer cells.
Sarcoma, Ewing
SARC025 arms 1 and 2: A phase 1 study of the poly(ADP-ribose) polymerase inhibitor niraparib with temozolomide or irinotecan in patients with advanced Ewing sarcoma.
Sarcoma, Ewing
SLFN11 Is a Transcriptional Target of EWS-FLI1 and a Determinant of Drug Response in Ewing Sarcoma.
Sarcoma, Ewing
Synergistic Activity of PARP Inhibition by Talazoparib (BMN 673) with Temozolomide in Pediatric Cancer Models in the Pediatric Preclinical Testing Program.
Sarcoma, Ewing
Systematic identification of genomic markers of drug sensitivity in cancer cells.
Sarcoma, Ewing
The Ewing Family of Tumors Relies on BCL-2 and BCL-XL to Escape PARP Inhibitor Toxicity.
Sarcoma, Ewing
The PARP inhibitor olaparib enhances the sensitivity of Ewing sarcoma to trabectedin.
Sarcoma, Synovial
Synovial sarcoma cell lines showed reduced DNA repair activity and sensitivity to a PARP inhibitor.
Sarcopenia
Dysregulation of SIRT-1 in aging mice increases skeletal muscle fatigue by a PARP-1-dependent mechanism.
Scabies
Dynamics of Scabin toxin. A proposal for the binding mode of the DNA substrate.
Scabies
Mapping the DNA-Binding Motif of Scabin Toxin, a Guanine Modifying Enzyme from Streptomyces scabies.
Scabies
Scabin, a novel DNA-acting ADP-ribosyltransferase from Streptomyces scabies.
Scleroderma, Diffuse
Poly(ADP-ribose) polymerase activity in systemic lupus erythematosis and systemic sclerosis.
Scleroderma, Systemic
Calcinosis in Systemic Sclerosis: Updates in Pathophysiology, Evaluation, and Treatment.
Scleroderma, Systemic
Identification of autoantibodies associated with systemic lupus erythematosus.
Scleroderma, Systemic
PARP activity and NAD concentration in PMC from patients affected by systemic sclerosis and lupus erythematosus.
Scleroderma, Systemic
Poly(ADP-ribose) polymerase activity in systemic lupus erythematosis and systemic sclerosis.
Scleroderma, Systemic
Poly(ADP-ribose) polymerase-1 regulates fibroblast activation in systemic sclerosis.
Seizures
Death mechanisms in status epilepticus-generated neurons and effects of additional seizures on their survival.
Seizures
Evidence for G protein modulation of experimental-generalized absence seizures in rat.
Seizures
Intracerebroventricular pertussis toxin enhances sensitivity to chemical convulsants and decreases the protective efficacy of carbamazepine in mice.
Seizures
Intracerebroventricular pertussis toxin enhances sensitivity to N-methyl-D-aspartate-induced seizures in mice.
Seizures
Mechanisms of p75-mediated death of hippocampal neurons. Role of caspases.
Seizures
PARP1 activation/expression modulates regional-specific neuronal and glial responses to seizure in a hemodynamic-independent manner.
Seizures
Parp1 hyperactivity couples DNA breaks to aberrant neuronal calcium signalling and lethal seizures.
Seizures
Pertussis toxin decreases absence seizures and GABA(B) receptor binding in thalamus of a genetically prone rat (GAERS).
Seizures
Pertussis toxin potentiates seizures induced by pilocarpine, kainic acid and N-methyl-D-aspartate.
Seizures
Poly(ADP-ribose) polymerase inhibition protects epileptic hippocampal neurons from apoptosis via suppressing Akt-mediated apoptosis-inducing factor translocation in vitro.
Seizures
Poly(ADP-ribose) polymerase inhibitor is neuroprotective in epileptic rat via apoptosis-inducing factor and Akt signaling.
Seizures
Poly(ADP-ribose) signal in seizures-induced neuron death.
Seizures
Regulation of hippocampal Fas receptor and death-inducing signaling complex after kainic acid treatment in mice.
Seizures
Suppression of kindled seizure following intraamygdaloid injection of pertussis toxin in rats.
Sepsis
Differentiation-Associated Downregulation of Poly(ADP-Ribose) Polymerase-1 Expression in Myoblasts Serves to Increase Their Resistance to Oxidative Stress.
Sepsis
Distinct fates of monocytes and T cells directly activated by Pseudomonas aeruginosa exoenzyme S.
Sepsis
ExoU expression by Pseudomonas aeruginosa correlates with acute cytotoxicity and epithelial injury.
Sepsis
Inflammatory cytokines and lipopolysaccharide induce Fas-mediated apoptosis in renal tubular cells.
Sepsis
Inhibition of poly (ADP-ribose) polymerase attenuates acute lung injury in an ovine model of sepsis.
Sepsis
Liposomal NAD(+) prevents diminished O(2) consumption by immunostimulated Caco-2 cells.
Sepsis
Local Administration of the Poly ADP-Ribose Polymerase (PARP) Inhibitor, PJ34 During Hindlimb Ischemia Modulates Skeletal Muscle Reperfusion Injury.
Sepsis
Multifaceted Role of PARP-1 in DNA Repair and Inflammation: Pathological and Therapeutic Implications in Cancer and Non-Cancer Diseases.
Sepsis
PARP Inhibitors: An Innovative Approach to the Treatment of Inflammation and Metabolic Disorders in Sepsis.
Sepsis
Pneumonia-induced sepsis and gut injury: effects of a poly-(ADP-ribose) polymerase inhibitor.
Sepsis
Poly (ADP-ribose) polymerase activation and circulatory shock.
Sepsis
Poly (ADP-ribose) Polymerase1-Sirtuin1 functional interplay regulates LPS-mediated High Mobility Group Box-1 secretion.
Sepsis
Poly (ADP-ribose) synthetase inhibitor has a heart protective effect in a rat model of experimental sepsis.
Sepsis
Potential role of poly(adenosine 5'-diphosphate-ribose) polymerase activation in the pathogenesis of myocardial contractile dysfunction associated with human septic shock.
Sepsis
Redox mechanisms of vascular cell dysfunction in sepsis.
Sepsis
Repurposing of Clinically Approved Poly-(Adp-Ribose) Polymerase Inhibitors For The Therapy of Sepsis.
Sepsis
Resistance to acute septic peritonitis in poly(ADP-ribose) polymerase-1-deficient mice.
Sepsis
Role of Exogenous Hsp72 on Liver Dysfunction during Sepsis.
Sepsis
Role of nitrosative stress and activation of poly(ADP-ribose) polymerase-1 in cardiovascular failure associated with septic and hemorrhagic shock.
Sepsis
Role of poly(adenosine diphosphate-ribose) polymerase 1 in septic peritonitis.
Sepsis
Temporally Distinct Regulation of Pathways Contributing to Cardiac Proteostasis During the Acute and Recovery Phases of Sepsis.
Sepsis
The decrease of PKCalpha is associated with hepatic apoptosis at early and late phases of polymicrobial sepsis.
Sepsis
The PARP inhibitor olaparib exerts beneficial effects in mice subjected to cecal ligature and puncture and in cells subjected to oxidative stress without impairing DNA integrity: A potential opportunity for repurposing a clinically used oncological drug for the experimental therapy of sepsis.
Sepsis
The parp-1 inhibitor ino-1001 facilitates hemodynamic stabilization without affecting DNA repair in porcine thoracic aortic cross-clamping-induced ischemia/reperfusion.
Sepsis
[Progress of nicotinamide in preventing infection and sepsis].
Sertoli Cell-Only Syndrome
Role of poly(ADP-ribosyl)ation during human spermatogenesis.
Severe Acute Respiratory Syndrome
Severe acute respiratory syndrome coronavirus triggers apoptosis via protein kinase R but is resistant to its antiviral activity.
Sezary Syndrome
Therapeutic and prognostic significance of PARP-1 in advanced mycosis fungoides and Sezary syndrome.
Shock, Septic
Association of poly(ADP-ribose) polymerase activity in circulating mononuclear cells with myocardial dysfunction in patients with septic shock.
Shock, Septic
Crosstalk between PARP-1 and NF-kappaB modulates the promotion of skin neoplasia.
Shock, Septic
Decrease of the inflammatory response and induction of the Akt/protein kinase B pathway by poly-(ADP-ribose) polymerase 1 inhibitor in endotoxin-induced septic shock.
Shock, Septic
Impaired mitochondrial function induced by serum from septic shock patients is attenuated by inhibition of nitric oxide synthase and poly(ADP-ribose) synthase.
Shock, Septic
Increase of myocardial inhibitory G-proteins in catecholamine-refractory septic shock or in septic multiorgan failure.
Shock, Septic
Inhibition of PARP overactivation protects acute kidney injury of septic shock.
Shock, Septic
Poly (ADP-ribose) polymerase activation and circulatory shock.
Shock, Septic
Poly (ADP-Ribose) Polymerase-1 (PARP-1) as Immune Regulator.
Shock, Septic
Regulation of kinase cascades and transcription factors by a poly(ADP-ribose) polymerase-1 inhibitor, 4-hydroxyquinazoline, in lipopolysaccharide-induced inflammation in mice.
Shock, Septic
Resistance to acute septic peritonitis in poly(ADP-ribose) polymerase-1-deficient mice.
Shock, Septic
Role of poly(ADP-ribose) polymerase activation in endotoxin-induced cardiac collapse in rodents.
Shock, Septic
The enzymatic and DNA binding activity of PARP-1 are not required for NF-kappa B coactivator function.
Shock, Septic
The functional role of poly(ADP-ribose)polymerase 1 as novel coactivator of NF-kappaB in inflammatory disorders.
Shock, Septic
The PARP inhibitor olaparib exerts beneficial effects in mice subjected to cecal ligature and puncture and in cells subjected to oxidative stress without impairing DNA integrity: A potential opportunity for repurposing a clinically used oncological drug for the experimental therapy of sepsis.
Shock, Septic
The Role of Poly(ADP-ribose) Polymerase-1 in Rheumatoid Arthritis.
Shwartzman Phenomenon
Cholera and pertussis exotoxins protect mice against the lethal Schwartzman reaction and antagonize the effects of lipopolysaccharide on second messenger systems.
Silicosis
Poly(ADP-ribosyl)ation in asthma and other lung diseases.
Sjogren's Syndrome
Identification of autoantibodies associated with systemic lupus erythematosus.
Skin Diseases
Mice lacking ADPRT and poly(ADP-ribosyl)ation develop normally but are susceptible to skin disease.
Skin Diseases
Nitric oxide-peroxynitrite-poly(ADP-ribose) polymerase pathway in the skin.
Skin Diseases
PARP14 limits severity of allergic skin disease.
Skin Neoplasms
Induction of apoptosis in A431 skin cancer cells by Cissus quadrangularis Linn stem extract by altering Bax-Bcl-2 ratio, release of cytochrome c from mitochondria and PARP cleavage.
Skin Neoplasms
PARP-1 protein expression in glioblastoma multiforme.
Skin Neoplasms
Poly (ADP-ribose) polymerase 1 protein expression in normal and neoplastic prostatic tissue.
Skin Neoplasms
Upregulation of Poly (ADP-Ribose) Polymerase-1 (PARP1) in Triple-Negative Breast Cancer and Other Primary Human Tumor Types.
Sleep Apnea, Obstructive
The relationship between obstructive sleep apnea and intra-epidermal nerve fiber density, PARP activation and foot ulceration in patients with type 2 diabetes.
Small Cell Lung Carcinoma
A genetic snapshot of small cell lung cancer.
Small Cell Lung Carcinoma
A Phase I Dose-Escalation Study of Veliparib Combined with Carboplatin and Etoposide in Patients with Extensive-Stage Small Cell Lung Cancer and Other Solid Tumors.
Small Cell Lung Carcinoma
Activation of the PI3K/mTOR Pathway following PARP Inhibition in Small Cell Lung Cancer.
Small Cell Lung Carcinoma
Clinical significance of NQO1 polymorphism and expression of p53, SOD2, PARP1 in limited-stage small cell lung cancer.
Small Cell Lung Carcinoma
Correction to: The dual HDAC-PI3K inhibitor CUDC-907 displays single-agent activity and synergizes with PARP inhibitor olaparib in small cell lung cancer.
Small Cell Lung Carcinoma
Dynamic variations in epithelial-to-mesenchymal transition (EMT), ATM, and SLFN11 govern response to PARP inhibitors and cisplatin in small cell lung cancer.
Small Cell Lung Carcinoma
Improved radiosynthesis of 123I-MAPi, an auger theranostic agent.
Small Cell Lung Carcinoma
MiR-335 regulates the chemo-radioresistance of small cell lung cancer cells by targeting PARP-1.
Small Cell Lung Carcinoma
MiR-7-5p-mediated downregulation of PARP1 impacts DNA homologous recombination repair and resistance to doxorubicin in small cell lung cancer.
Small Cell Lung Carcinoma
Nanoemulsion-Based Delivery of Fluorescent PARP Inhibitors in Mouse Models of Small Cell Lung Cancer.
Small Cell Lung Carcinoma
PARP Inhibitor Activity Correlates with SLFN11 Expression and Demonstrates Synergy with Temozolomide in Small Cell Lung Cancer.
Small Cell Lung Carcinoma
PARP inhibitors for small cell lung cancer and their potential for integration into current treatment approaches.
Small Cell Lung Carcinoma
PARP Inhibitors: Extending Benefit Beyond BRCA Mutant Cancers.
Small Cell Lung Carcinoma
Proteomic markers of DNA repair and PI3K pathway activation predict response to the PARP inhibitor BMN 673 in small cell lung cancer.
Small Cell Lung Carcinoma
Proteomic Profiling Identifies Dysregulated Pathways in Small Cell Lung Cancer and Novel Therapeutic Targets Including PARP1.
Small Cell Lung Carcinoma
The Combination of the PARP Inhibitor Olaparib and the WEE1 Inhibitor AZD1775 as a New Therapeutic Option for Small Cell Lung Cancer.
Small Cell Lung Carcinoma
The dual HDAC-PI3K inhibitor CUDC-907 displays single-agent activity and synergizes with PARP inhibitor olaparib in small cell lung cancer.
Small Cell Lung Carcinoma
The MYC Paralog-PARP1 Axis as a Potential Therapeutic Target in MYC Paralog-Activated Small Cell Lung Cancer.
Small Cell Lung Carcinoma
The non-canonical target PARP16 contributes to polypharmacology of the PARP inhibitor talazoparib and its synergy with WEE1 inhibitors.
Small Cell Lung Carcinoma
Veliparib in Combination with Carboplatin and Etoposide in Patients with Treatment-Naïve Extensive-Stage Small Cell Lung Cancer: A Phase 2 Randomized Study.
Small Cell Lung Carcinoma
XPO1 inhibition synergizes with PARP1 inhibition in small cell lung cancer by targeting nuclear transport of FOXO3a.
Spermatic Cord Torsion
Inhibition of poly(adenosine diphosphate-ribose) polymerase decreases long-term histologic damage in testicular ischemia-reperfusion injury.
Spermatic Cord Torsion
The effect of poly (adenosine diphosphate-ribose) polymerase inhibitors on biochemical changes in testicular ischemia-reperfusion injury.
Spermatic Cord Torsion
The efficiency of Poly(ADP-Ribose) Polymerase (PARP) cleavage on detection of apoptosis in an experimental model of testicular torsion.
Spinal Cord Compression
Apoptosis in human compressive myelopathy due to metastatic neoplasia.
Spinal Cord Injuries
3-aminobenzamide, one of poly(ADP-ribose)polymerase-1 inhibitors, rescuesapoptosisin rat models of spinal cord injury.
Spinal Cord Injuries
Inhibitors of poly(ADP-ribose) polymerase modulate signal transduction pathways and secondary damage in experimental spinal cord trauma.
Spinal Cord Injuries
Involvement of poly(ADP-ribose) polymerase-1 in development of spinal cord injury in Chinese individuals: a Chinese clinical study.
Spinal Cord Injuries
Nitric Oxide and Superoxide Anion Differentially Activate Poly(ADP-ribose) Polymerase-1 and Bax to Induce Nuclear Translocation of Apoptosis-Inducing Factor and Mitochondrial Release of Cytochrome c after Spinal Cord Injury.
Spinal Cord Injuries
Poly(ADP-ribose) polymerase activity contributes to peroxynitrite-induced spinal cord neuronal cell death in vitro.
Spinal Cord Injuries
Poly(ADP-Ribose) polymerase-1 in acute neuronal death and inflammation: a strategy for neuroprotection.
Spinal Cord Injuries
Poly(ADP-ribosyl)ation enzyme-1 as a target for neuroprotection in acute central nervous system injury.
Spinal Cord Injuries
Role of ABT888, a Novel Poly(ADP-Ribose) Polymerase (PARP) Inhibitor in Countering Autophagy and Apoptotic Processes Associated to Spinal Cord Injury.
Spinal Cord Injuries
Role of free radicals and poly(ADP-ribose)polymerase-1 in the development of spinal cord injury: new potential therapeutic targets.
Spinal Cord Injuries
The selective poly(ADP)ribose-polymerase 1 inhibitor INO1001 reduces spinal cord injury during porcine aortic cross-clamping-induced ischemia/reperfusion injury.
Spinal Cord Injuries
Unusual increase in lumbar network excitability of the rat spinal cord evoked by the PARP-1 inhibitor PJ-34 through inhibition of glutamate uptake.
Squamous Cell Carcinoma of Head and Neck
A phase I trial adding poly(ADP-ribose) polymerase inhibitor veliparib to induction carboplatin-paclitaxel in patients with head and neck squamous cell carcinoma: Alliance A091101.
Squamous Cell Carcinoma of Head and Neck
Abrogation of head and neck squamous cell carcinoma growth by epidermal growth factor receptor ligand fused to pseudomonas exotoxin transforming growth factor alpha-PE38.
Squamous Cell Carcinoma of Head and Neck
Acquisition of relative interstrand crosslinker resistance and PARP inhibitor sensitivity in Fanconi anemia head and neck cancers.
Squamous Cell Carcinoma of Head and Neck
Association of Poly (ADP-Ribose) Polymerase 1 Variants with Oral Squamous Cell Carcinoma Susceptibility in a South Indian Population.
Squamous Cell Carcinoma of Head and Neck
Autophagy suppression enhances DNA damage and cell death upon treatment with PARP inhibitor Niraparib in laryngeal squamous cell carcinoma.
Squamous Cell Carcinoma of Head and Neck
Brusatol, a Nrf2 Inhibitor Targets STAT3 Signaling Cascade in Head and Neck Squamous Cell Carcinoma.
Squamous Cell Carcinoma of Head and Neck
Combined EGFR1 and PARP1 Inhibition Enhances the Effect of Radiation in Head and Neck Squamous Cell Carcinoma Models.
Squamous Cell Carcinoma of Head and Neck
Combining PARP and DNA-PK Inhibitors With Irradiation Inhibits HPV-Negative Head and Neck Cancer Squamous Carcinoma Growth.
Squamous Cell Carcinoma of Head and Neck
DNA double strand break repair defect and sensitivity to poly ADP-ribose polymerase (PARP) inhibition in human papillomavirus 16-positive head and neck squamous cell carcinoma.
Squamous Cell Carcinoma of Head and Neck
Dual disruption of DNA repair and telomere maintenance for the treatment of head and neck cancer.
Squamous Cell Carcinoma of Head and Neck
Dual Inhibition of PARP and the Intra-S/G2 Cell Cycle Checkpoints Results in Highly Effective Radiosensitization of HPV-Positive HNSCC Cells.
Squamous Cell Carcinoma of Head and Neck
Effect of ethanol extracts of Antrodia cinnamomea on head and neck squamous cell carcinoma cell line.
Squamous Cell Carcinoma of Head and Neck
Fanconi anemia and homologous recombination gene variants are associated with functional DNA repair defects in vitro and poor outcome in patients with advanced head and neck squamous cell carcinoma.
Squamous Cell Carcinoma of Head and Neck
Histone deacetylase inhibitor suberoylanilide hydroxamic acid induces apoptosis through both mitochondrial and Fas (Cd95) signaling in head and neck squamous carcinoma cells.
Squamous Cell Carcinoma of Head and Neck
Inhibition of growth and survival of human head and neck squamous cell carcinoma cells by curcumin via modulation of nuclear factor-kappaB signaling.
Squamous Cell Carcinoma of Head and Neck
Novel C-Terminal Hsp90 Inhibitor for Head and Neck Squamous Cell Cancer (HNSCC) with in vivo Efficacy and Improved Toxicity Profiles Compared with Standard Agents.
Squamous Cell Carcinoma of Head and Neck
Novel targeted therapies in head and neck cancer.
Squamous Cell Carcinoma of Head and Neck
Oct4 confers stemness and radioresistance to head and neck squamous cell carcinoma by regulating the homologous recombination factors PSMC3IP and RAD54L.
Squamous Cell Carcinoma of Head and Neck
Optical Imaging of PARP1 in Response to Radiation in Oral Squamous Cell Carcinoma.
Squamous Cell Carcinoma of Head and Neck
Overexpression of chromatin assembly factor-1 p60, poly(ADP-ribose) polymerase 1 and nestin predicts metastasizing behaviour of oral cancer.
Squamous Cell Carcinoma of Head and Neck
Pan-Cancer Analysis of PARP1 Alterations as Biomarkers in the Prediction of Immunotherapeutic Effects and the Association of Its Expression Levels and Immunotherapy Signatures.
Squamous Cell Carcinoma of Head and Neck
PARP inhibition enhances radiotherapy of SMAD4 deficient human head and neck squamous cell carcinomas in experimental models.
Squamous Cell Carcinoma of Head and Neck
PARP inhibitors in head and neck cancer: Molecular mechanisms, preclinical and clinical data.
Squamous Cell Carcinoma of Head and Neck
PARP-1 inhibitors sensitize HNSCC cells to APR-246 by inactivation of thioredoxin reductase 1 (TrxR1) and promotion of ROS accumulation.
Squamous Cell Carcinoma of Head and Neck
PARP1 and CASP3 gene expression in a patient with multiple head and neck squamous cell carcinoma and Parkinson disease.
Squamous Cell Carcinoma of Head and Neck
PARP1 inhibition radiosensitizes HNSCC cells deficient in homologous recombination by disabling the DNA replication fork elongation response.
Squamous Cell Carcinoma of Head and Neck
Poly(ADP-ribose) polymerase turnover alterations do not contribute to PARP overexpression in Ewing's sarcoma cells.
Squamous Cell Carcinoma of Head and Neck
Prevalence of DNA Repair Gene Mutations in Blood and Tumor Tissue and Impact on Prognosis and Treatment in HNSCC.
Squamous Cell Carcinoma of Head and Neck
Radiosensitization of head and neck squamous cell carcinoma lines by DNA-PK inhibitors is more effective than PARP-1 inhibition and is enhanced by SLFN11 and hypoxia.
Squamous Cell Carcinoma of Head and Neck
Radiosensitizing Potential of Curcumin in Different Cancer Models.
Squamous Cell Carcinoma of Head and Neck
Sam68 reduces cisplatin-induced apoptosis in tongue carcinoma.
Squamous Cell Carcinoma of Head and Neck
Synergetic Effects of PARP Inhibitor AZD2281 and Cisplatin in Oral Squamous Cell Carcinoma in Vitro and in Vivo.
Squamous Cell Carcinoma of Head and Neck
Targeted therapy in head and neck cancer.
Squamous Cell Carcinoma of Head and Neck
Targeting DNA damage response in head and neck cancers through abrogation of cell cycle checkpoints.
Squamous Cell Carcinoma of Head and Neck
Targeting of ?1 integrins impairs DNA repair for radiosensitization of head and neck cancer cells.
Squamous Cell Carcinoma of Head and Neck
The inhibition of PARP but not EGFR results in the radiosensitization of HPV/p16-positive HNSCC cell lines.
Squamous Cell Carcinoma of Head and Neck
The radiobiology of HPV-positive and HPV-negative head and neck squamous cell carcinoma.
Squamous Cell Carcinoma of Head and Neck
Xanthorrhizol Induces Apoptosis Through ROS-Mediated MAPK Activation in Human Oral Squamous Cell Carcinoma Cells and Inhibits DMBA-Induced Oral Carcinogenesis in Hamsters.
Starvation
A New Pathway Promotes Adaptation of Human Glioblastoma Cells to Glucose Starvation.
Starvation
ADP-ribosylation, DNA repair, cell differentiation and cancer.
Starvation
Cell death induced by serum deprivation in luteal cells involves the intrinsic pathway of apoptosis.
Starvation
Cisplatin resistance coupled to enhanced sensitivity to metabolic interventions.
Starvation
Cleavage of poly (ADP-ribose) polymerase-1 is involved in the process of porcine ovarian follicular atresia.
Starvation
Gemcitabine induces poly (ADP-ribose) polymerase-1 (PARP-1) degradation through autophagy in pancreatic cancer.
Starvation
Heart/Cardiac Muscle: Cocaine- and amphetamine-regulated transcript (CART) peptide as an in vivo regulator of cardiac function in Rana ridibunda frog.
Starvation
Hepatitis B virus X gene differentially modulates cell cycle progression and apoptotic protein expression in hepatocyte versus hepatoma cell lines.
Starvation
Nedd5, a mammalian septin, is a novel cytoskeletal component interacting with actin-based structures.
Starvation
PARP-1 inhibition prevents oxidative and nitrosative stress-induced endothelial cell death via transactivation of the VEGF receptor 2.
Starvation
PARP1 promote autophagy in cardiomyocytes via modulating FoxO3a transcription.
Starvation
Poly(ADP-Ribose) Polymerase-1 Mediates Angiotensin II-Induced Expression of Plasminogen Activator Inhibitor-1 and Fibronectin in Rat Mesangial Cells.
Starvation
Prothymosin alpha and cell death mode switch, a novel target for the prevention of cerebral ischemia-induced damage.
Starvation
ROS-induced DNA damage and PARP-1 are required for optimal induction of starvation-induced autophagy.
Starvation
Signaling interplay between PARP1 and ROS regulates stress-induced cell death and developmental changes in Dictyostelium discoideum.
Status Epilepticus
Mitochondrial Dysfunction Mediated by Poly(ADP-Ribose) Polymerase-1 Activation Contributes to Hippocampal Neuronal Damage Following Status Epilepticus.
Status Epilepticus
P2X7 receptor-mediated PARP1 activity regulates astroglial death in the rat hippocampus following status epilepticus.
Status Epilepticus
PKC, AKT and ERK1/2-Mediated Modulations of PARP1, NF-?B and PEA15 Activities Distinctly Regulate Regional Specific Astroglial Responses Following Status Epilepticus.
Status Epilepticus
Regulation of limbic status epilepticus by hippocampal galanin type 1 and type 2 receptors.
Status Epilepticus
Status epilepticus may be caused by loss of adenosine anticonvulsant mechanisms.
Stomach Diseases
Helicobacter pylori activation of PARP-1: Usurping a versatile regulator of host cellular health.
Stomach Neoplasms
A mutational signature in gastric cancer suggests therapeutic strategies.
Stomach Neoplasms
A novel compound, L34, induced apoptosis in human gastric cancer cells.
Stomach Neoplasms
Adenovirus-mediated E2F-1 gene transfer induces an apoptotic response in human gastric carcinoma cells that is enhanced by cyclin dependent kinase inhibitors.
Stomach Neoplasms
ADPRT Val762Ala and XRCC1 Arg194Trp Polymorphisms and Risk of Gastric Cancer in Sichuan of China.
Stomach Neoplasms
Allele-specific expression mediates primary resistance to poly (ADP-ribose) polymerase inhibitor therapy in a case of BRCA1/2 double-germline mutant gastric cancer.
Stomach Neoplasms
Association between PSCA, TNF-?, PARP1 and TP53 Gene Polymorphisms and Gastric Cancer Susceptibility in the Brazilian Population.
Stomach Neoplasms
ATM expression predicts Veliparib and Irinotecan sensitivity in gastric cancer by mediating P53 independent regulation of cell cycle and apoptosis.
Stomach Neoplasms
CHFR regulates the mitotic checkpoint by targeting PARP-1 for ubiquitination and degradation.
Stomach Neoplasms
Chk1 inhibition potentiates the therapeutic efficacy of PARP inhibitor BMN673 in gastric cancer.
Stomach Neoplasms
Cochinchina momordica seed extract induces apoptosis and cell cycle arrest in human gastric cancer cells via PARP and p53 signal pathways.
Stomach Neoplasms
Combination of talaporfin photodynamic therapy and Poly (ADP-Ribose) polymerase (PARP) inhibitor in gastric cancer.
Stomach Neoplasms
Combined treatment with PI3K inhibitor BKM120 and PARP inhibitor olaparib is effective in inhibiting the gastric cancer cells with ARID1A deficiency.
Stomach Neoplasms
Complexity in the Gastric Cancer Genome and a Biomarker-Driven Trial of Poly (ADP-Ribose) Polymerase Inhibition in Gastric Cancer.
Stomach Neoplasms
Deubiquitinylase USP47 Promotes RelA Phosphorylation and Survival in Gastric Cancer Cells.
Stomach Neoplasms
Esculetin induces apoptosis in human gastric cancer cells through a cyclophilin D-mediated mitochondrial permeability transition pore associated with ROS.
Stomach Neoplasms
Extract of Solanum muricatum (Pepino/CSG) inhibits tumor growth by inducing apoptosis.
Stomach Neoplasms
Fas expression is downregulated in gastric cancer.
Stomach Neoplasms
Functional long non-coding RNAs associated with gastric cancer susceptibility and evaluation of the epidemiological efficacy in a central Chinese population.
Stomach Neoplasms
Ginkgolic acid (GA) suppresses gastric cancer growth by inducing apoptosis and suppressing STAT3/JAK2 signaling regulated by ROS.
Stomach Neoplasms
High PARP-1 expression is associated with tumor invasion and poor prognosis in gastric cancer.
Stomach Neoplasms
Identification and epidemiological evaluation of gastric cancer risk factors: based on a field synopsis and meta-analysis in Chinese population.
Stomach Neoplasms
Immature colon carcinoma transcript-1 promotes proliferation of gastric cancer cells.
Stomach Neoplasms
In silico identification of poly(ADP-ribose)polymerase-1 inhibitors and their chemosensitizing effects against cisplatin-resistant human gastric cancer cells.
Stomach Neoplasms
Inhibition of c-MET increases the antitumour activity of PARP inhibitors in gastric cancer models.
Stomach Neoplasms
Inhibition of CREPT restrains gastric cancer growth by regulation of cycle arrest, migration and apoptosis via ROS-regulated p53 pathway.
Stomach Neoplasms
Inhibition of PARP1 activity enhances chemotherapeutic efficiency in cisplatin-resistant gastric cancer cells.
Stomach Neoplasms
Knockdown of RNF6 inhibits gastric cancer cell growth by suppressing STAT3 signaling.
Stomach Neoplasms
Lentivirus-mediated inhibition of USP39 suppresses the growth of gastric cancer cells via PARP activation.
Stomach Neoplasms
LncRNA ZEB2-AS1 contributes to the tumorigenesis of gastric cancer via activating the Wnt/?-catenin pathway.
Stomach Neoplasms
Low ATM protein expression and depletion of p53 correlates with olaparib sensitivity in gastric cancer cell lines.
Stomach Neoplasms
Luteolin exerts a marked antitumor effect in cMet-overexpressing patient-derived tumor xenograft models of gastric cancer.
Stomach Neoplasms
Lymph Node Metastasis of Gastric Cancer Is Associated with the Interaction Between Poly (ADP-Ribose) Polymerase 1 and Matrix Metallopeptidase 2.
Stomach Neoplasms
Metformin inhibits gastric cancer via the inhibition of HIF1?/PKM2 signaling.
Stomach Neoplasms
miR-106a Is frequently upregulated in gastric cancer and inhibits the extrinsic apoptotic pathway by targeting FAS.
Stomach Neoplasms
MTA2 sensitizes gastric cancer cells to PARP inhibition by induction of DNA replication stress.
Stomach Neoplasms
Pan-Cancer Analysis of PARP1 Alterations as Biomarkers in the Prediction of Immunotherapeutic Effects and the Association of Its Expression Levels and Immunotherapy Signatures.
Stomach Neoplasms
PARP inhibitors in gastric cancer: beacon of hope.
Stomach Neoplasms
PARP inhibitors target ATM+p53-defective gastric cancer.
Stomach Neoplasms
PARP-1 Val762Ala polymorphism, CagA(+) H. pylori infection and risk for gastric cancer in Han Chinese population.
Stomach Neoplasms
PARP1 Polymorphisms Increase the Risk of Gastric Cancer in a Chinese Population.
Stomach Neoplasms
PARP10 (ARTD10) modulates mitochondrial function.
Stomach Neoplasms
PARP1: A potential biomarker for gastric cancer.
Stomach Neoplasms
Polymorphisms of XRCC1 and ADPRT genes and risk of noncardia gastric cancer in a Chinese population: a case-control study.
Stomach Neoplasms
Randomized, Double-Blind Phase II Trial With Prospective Classification by ATM Protein Level to Evaluate the Efficacy and Tolerability of Olaparib Plus Paclitaxel in Patients With Recurrent or Metastatic Gastric Cancer.
Stomach Neoplasms
Resveratrol engages selective apoptotic signals in gastric adenocarcinoma cells.
Stomach Neoplasms
Silencing of CHFR Sensitizes Gastric Carcinoma to PARP Inhibitor Treatment.
Stomach Neoplasms
SOX2 inhibits cell proliferation and metastasis, promotes apoptotic by downregulating CCND1 and PARP in gastric cancer.
Stomach Neoplasms
Tanshinone IIA inhibits gastric carcinoma AGS cells by decreasing the protein expression of VEGFR and blocking Ras/Raf/MEK/ERK pathway.
Stomach Neoplasms
The molecular mechanisms of Aloin induce gastric cancer cells apoptosis by targeting High Mobility Group Box 1.
Stomach Neoplasms
Tumor suppressive effect of PARP1 and FOXO3A in gastric cancers and its clinical implications.
Stomach Neoplasms
Tumor-suppressive effects of 1,25-dihydroxyvitamin D3 in gastric cancer cells.
Stomach Neoplasms
Ultrafine particles of Ulmus davidiana var. japonica induce apoptosis of gastric cancer cells via activation of caspase and endoplasmic reticulum stress.
Stomach Neoplasms
Variant of SNPs at lncRNA NEAT1 contributes to gastric cancer susceptibility in Chinese Han population.
Stomach Neoplasms
What Will We Expect From Novel Therapies to Esophageal and Gastric Malignancies?
Stomach Neoplasms
[Correlation of Genetic Polymorphisms in DNA Repair Genes ADPRT and XRCC1 to Risk of Gastric Cancer.]
Stomach Ulcer
The use of nano-quercetin to arrest mitochondrial damage and MMP-9 upregulation during prevention of gastric inflammation induced by ethanol in rat.
Stroke
A newly synthesized poly(ADP-ribose) polymerase inhibitor, DR2313 [2-methyl-3,5,7,8-tetrahydrothiopyrano[4,3-d]-pyrimidine-4-one]: pharmacological profiles, neuroprotective effects, and therapeutic time window in cerebral ischemia in rats.
Stroke
A novel and potent poly(ADP-ribose) polymerase-1 inhibitor, FR247304 (5-chloro-2-[3-(4-phenyl-3,6-dihydro-1(2H)-pyridinyl)propyl]-4(3H)-quinazolinone), attenuates neuronal damage in in vitro and in vivo models of cerebral ischemia.
Stroke
A review on PARP1 inhibitors: Pharmacophore modeling, virtual and biological screening studies to identify novel PARP1 inhibitors.
Stroke
Alternative mechanisms of inhibiting activity of poly (ADP-ribose) polymerase-1.
Stroke
Anti-inflammatory effects of a novel, potent inhibitor of poly (ADP-ribose) polymerase.
Stroke
Anti-inflammatory mechanism of taurine against ischemic stroke is related to down-regulation of PARP and NF-?B.
Stroke
Cell Death Mechanisms of Neurodegeneration.
Stroke
Clinical perspectives of PARP inhibitors.
Stroke
Combinatorial-approached neuroprotection using pan-caspase inhibitor and poly (ADP-ribose) polymerase (PARP) inhibitor following experimental stroke in rats; is there additional benefit?
Stroke
Crosstalk between PARP-1 and NF-kappaB modulates the promotion of skin neoplasia.
Stroke
Delayed PARP-1 Inhibition Alleviates Post-stroke Inflammation in Male Versus Female Mice: Differences and Similarities.
Stroke
Development of a high-throughput screening-amenable assay for human poly(ADP-ribose) polymerase inhibitors.
Stroke
Development of a miniaturized assay for the high-throughput screening program for poly(ADP-ribose) polymerase-1.
Stroke
Downregulation of Iduna is associated with AIF nuclear translocation in neonatal brain after hypoxia-ischemia.
Stroke
Early Treatment with Poly(ADP-Ribose) Polymerase-1 Inhibitor (JPI-289) Reduces Infarct Volume and Improves Long-Term Behavior in an Animal Model of Ischemic Stroke.
Stroke
Emerging role of PARP-1 and PARthanatos in ischemic stroke.
Stroke
Evaluation of the poly(ADP-ribose) polymerase gene in human stroke.
Stroke
Functions of poly(ADP-ribose) polymerase (PARP) in DNA repair, genomic integrity and cell death.
Stroke
Iduna protects the brain from glutamate excitotoxicity and stroke by interfering with poly(ADP-ribose) polymer-induced cell death.
Stroke
Inhibition of poly(ADP-ribose) polymerase suppresses inflammation and promotes recovery after ischemic injury.
Stroke
Inhibitors of poly(ADP-ribose) polymerase modulate signal transduction pathways and secondary damage in experimental spinal cord trauma.
Stroke
Investigating the allosteric reverse signalling of PARP inhibitors with microsecond molecular dynamic simulations and fluorescence anisotropy.
Stroke
Ischemic brain injury is mediated by the activation of poly(ADP-ribose)polymerase.
Stroke
Local Administration of the Poly ADP-Ribose Polymerase (PARP) Inhibitor, PJ34 During Hindlimb Ischemia Modulates Skeletal Muscle Reperfusion Injury.
Stroke
Long-lasting neuroprotection and neurological improvement in stroke models with new, potent and brain permeable inhibitors of poly(ADP-ribose) polymerase.
Stroke
Mediation of cell death by poly(ADP-ribose) polymerase-1.
Stroke
Mitochondrial dysfunction induced by nuclear poly(ADP-ribose) polymerase-1: a treatable cause of cell death in stroke.
Stroke
Molecular targets in cerebral ischemia for developing novel therapeutics.
Stroke
Muscle-specific sirtuin1 gain-of-function ameliorates skeletal muscle atrophy in a pre-clinical mouse model of cerebral ischemic stroke.
Stroke
Natural Inhibitors of Poly(ADP-ribose) Polymerase-1.
Stroke
Neuronal caspase-3 and PARP-1 correlate differentially with apoptosis and necrosis in ischemic human stroke.
Stroke
Nicotinamide offers multiple protective mechanisms in stroke as a precursor for NAD+, as a PARP inhibitor and by partial restoration of mitochondrial function.
Stroke
Nicotinamide therapy protects against both necrosis and apoptosis in a stroke model.
Stroke
Novel modulators of poly(ADP-ribose) polymerase.
Stroke
Nuclear-translocated Glyceraldehyde-3-phosphate Dehydrogenase Promotes Poly(ADP-ribose) Polymerase-1 Activation during Oxidative/Nitrosative Stress in Stroke.
Stroke
PARP inhibitors: New partners in the therapy of cancer and inflammatory diseases.
Stroke
PARP14 inhibits microglial activation via LPAR5 to promote post-stroke functional recovery.
Stroke
Parthanatos, a messenger of death.
Stroke
Pharmacologic inhibition of poly(adenosine diphosphate-ribose) polymerase may represent a novel therapeutic approach in chronic heart failure.
Stroke
Pharmacological inhibition of poly(ADP-ribose) polymerase in cardiovascular disorders: future directions.
Stroke
Poly (adp-ribose) polymerase inhibitors as potential therapeutic agents in stroke and neurotrauma.
Stroke
Poly (ADP-ribose) polymerase, nitric oxide and cell death.
Stroke
Poly (ADP-Ribose) Polymerase-1 (PARP-1) as Immune Regulator.
Stroke
Poly (ADP-ribose) polymerase-1 as a promising drug target for neurodegenerative diseases.
Stroke
Poly(ADP-ribose) Polymerase (PARP) and PARP Inhibitors: Mechanisms of Action and Role in Cardiovascular Disorders.
Stroke
Poly(ADP-ribose) polymerase and the therapeutic effects of its inhibitors.
Stroke
Poly(ADP-ribose) polymerase as a drug target for cardiovascular disease and cancer: an update.
Stroke
Poly(ADP-ribose) polymerase impairs early and long-term experimental stroke recovery.
Stroke
Poly(ADP-ribose) polymerase inhibition protect neurons and the white matter and regulates the translocation of apoptosis-inducing factor in stroke.
Stroke
Poly(ADP-Ribose) Polymerase Inhibitor PJ34 Reduces Brain Damage after Stroke in the Neonatal Mouse Brain.
Stroke
Poly(ADP-ribose) polymerase inhibitors.
Stroke
Poly(ADP-ribose) polymerase inhibitors: new pharmacological functions and potential clinical implications.
Stroke
Poly(ADP-ribose) polymerase-1 (PARP-1) and its therapeutic implications.
Stroke
Poly(ADP-ribose) polymerase-1 in the nervous system.
Stroke
Poly(ADP-ribose) polymerase-1 inhibition increases expression of heat shock proteins and attenuates heat stroke-induced liver injury.
Stroke
Poly(ADP-Ribose) Polymerases in Host-Pathogen Interactions, Inflammation, and Immunity.
Stroke
Poly(ADP-ribose) polymerases: homology, structural domains and functions. Novel therapeutical applications.
Stroke
Poly(ADP-Ribose)Polymerase 1 (PARP-1) Activation and Ca(2+) Permeable ?-Amino-3-Hydroxy-5-Methyl-4-Isoxazolepropionic Acid (AMPA) Channels in Post-Ischemic Brain Damage: New Therapeutic Opportunities?
Stroke
Poly(ADP-ribose)polymerase 1 (PARP-1) and postischemic brain damage.
Stroke
Poly(ADP-ribose)polymerase inhibition - where now?
Stroke
Polymorphism of PARP-1 indicates an increased risk and a worse initial severity of ischemic stroke.
Stroke
Post-ischemic brain damage: targeting PARP-1 within the ischemic neurovascular units as a realistic avenue to stroke treatment.
Stroke
Potential clinical applications of poly(ADP-ribose) polymerase (PARP) inhibitors.
Stroke
Prevention of rt-PA induced blood-brain barrier component degradation by the poly(ADP-ribose)polymerase inhibitor PJ34 after ischemic stroke in mice.
Stroke
Protective effects of PJ34, a novel, potent inhibitor of poly(ADP-ribose) polymerase (PARP) in in vitro and in vivo models of stroke.
Stroke
Reduction of hemorrhagic transformation by PJ34, a poly(ADP-ribose)polymerase inhibitor, after permanent focal cerebral ischemia in mice.
Stroke
Regulatory T cells increase after treatment with poly (ADP-ribose) polymerase-1 inhibitor in ischemic stroke patients.
Stroke
Role of Cytotoxic Protease Granzyme-b in Neuronal Degeneration during Human Stroke.
Stroke
Sex differences in minocycline-induced neuroprotection after experimental stroke.
Stroke
Sex differences in the effects of PARP inhibition on microglial phenotypes following neonatal stroke.
Stroke
Sex differences in the response to activation of the poly (ADP-ribose) polymerase pathway after experimental stroke.
Stroke
Sex Differences in the Response to Poly(ADP-ribose) Polymerase-1 Deletion and Caspase Inhibition After Stroke.
Stroke
Structure and function of poly(ADP-ribose) polymerase-1: role in oxidative stress-related pathologies.
Stroke
Targeting Parthanatos in Ischemic Stroke.
Stroke
The enzymatic and DNA binding activity of PARP-1 are not required for NF-kappa B coactivator function.
Stroke
The neuroprotective effect of cerebral poly(ADP-ribose)polymerase inhibition in a rat model of global ischemia.
Stroke
The Role of Poly(ADP-ribose) Polymerase-1 in Rheumatoid Arthritis.
Stroke
Therapeutic applications of PARP inhibitors: Anticancer therapy and beyond.
Stroke
[Gender-specific factors of ischemic stroke among atrial fibrillation patients].
Strongyloidiasis
The impact of prenatal exposure to parasitic infections and to anthelminthic treatment on antibody responses to routine immunisations given in infancy: Secondary analysis of a randomised controlled trial.
Subarachnoid Hemorrhage
Inhibition of poly(ADP-ribose) polymerase attenuates cerebral vasospasm after subarachnoid hemorrhage in rabbits.
Subarachnoid Hemorrhage
PARP inhibition attenuates early brain injury through NF-?B/MMP-9 pathway in a rat model of subarachnoid hemorrhage.
Subarachnoid Hemorrhage
Potential role of poly (ADP-ribose) polymerase in delayed cerebral vasospasm following subarachnoid hemorrhage in rats.
Sunburn
Nitric oxide-peroxynitrite-poly(ADP-ribose) polymerase pathway in the skin.
superoxide dismutase deficiency
Role of Oxidative Stress and AT1 Receptors in Cerebral Vascular Dysfunction with Aging.
Synovitis
Intraperitoneal injection of the SIRT1 activator SRT1720 attenuates the progression of experimental osteoarthritis in mice.
Tachycardia
"Pertussis toxin induces tachycardia and impairs the increase in blood pressure produced by alpha 2-adrenergic agonists".
Tachycardia
Effect of pertussis toxin on the heart muscarinic-cholinergic receptors and their function.
Tachycardia
The effects of pertussis toxin on vasoconstrictor and vasodilator agents in the pithed rat may not be an indicator of G-protein receptor coupling.
Telangiectasis
Casticin induces DNA damage and inhibits DNA repair-associated protein expression in B16F10 mouse melanoma cancer cells.
Telangiectasis
Concordance of ATM (Ataxia Telangiectasia Mutated) Immunohistochemistry between Biopsy or Metastatic Tumor Samples and Primary Tumors in Gastric Cancer Patients.
Telangiectasis
Loss of PIDD limits NF-?B activation and cytokine production but not cell survival or transformation after DNA damage.
Telangiectasis
Targeting IDH1/2 mutant cancers with combinations of ATR and PARP inhibitors.
Teratocarcinoma
Parp-1 deficiency in ES cells promotes invasive and metastatic lesions accompanying induction of trophoblast giant cells during tumorigenesis in uterine environment.
Teratocarcinoma
Syncytiotrophoblastic giant cells in teratocarcinoma-like tumors derived from Parp-disrupted mouse embryonic stem cells.
Teratocarcinoma
Trophoblast functions, angiogenesis and remodeling of the maternal vasculature in the placenta.
Teratoma
PARP expression in germ cell tumours.
Teratozoospermia
Spermatid Head Elongation with Normal Nuclear Shaping Requires ADP-Ribosyltransferase PARP11 (ARTD11) in Mice.
Testicular Neoplasms
PARP expression in germ cell tumours.
Tetanus
A Belgian Serosurveillance/Seroprevalence Study of Diphtheria, Tetanus and Pertussis Using a Luminex xMAP Technology-Based Pentaplex.
Tetanus
A fully liquid DTaP-IPV-Hep B-PRP-T hexavalent vaccine for primary and booster vaccination of healthy Mexican children.
Tetanus
A mutant pertussis toxin molecule that lacks ADP-ribosyltransferase activity, PT-9K/129G, is an effective mucosal adjuvant for intranasally delivered proteins.
Tetanus
A randomized controlled trial of two acellular pertussis-diphtheria-tetanus vaccines in primary immunization in Ghana: antibody responses and adverse reactions.
Tetanus
Acellular pertussis vaccine given by accelerated schedule: response of preterm infants.
Tetanus
Adequate tetanus but poor diphtheria and pertussis response to a Tdap booster in adolescents with juvenile systemic lupus erythematosus.
Tetanus
Adverse effects and sero-responses to an acellular pertussis/diphtheria/tetanus vaccine when combined with Haemophilus influenzae type b vaccine in an accelerated schedule.
Tetanus
Adverse reactions of a pertussis toxoid vaccine in a double-blind placebo-controlled trial.
Tetanus
Antibody persistence 2 and 3 years after booster vaccination of adolescents with recombinant acellular pertussis monovalent aPgen or combined TdaPgen vaccines.
Tetanus
Antibody response to diphtheria-tetanus-pertussis immunization in preterm infants who receive dexamethasone for chronic lung disease.
Tetanus
Antibody responses of healthy infants to concurrent administration of a bivalent haemophilus influenzae type b-hepatitis B vaccine with diphtheria-tetanus-pertussis, polio and measles-mumps-rubella vaccines.
Tetanus
Antibody responses to Bordetella pertussis and other childhood vaccines in infants born to mothers who received pertussis vaccine in pregnancy- a prospective, observational cohort study from the UK.
Tetanus
Association of Routine Infant Vaccinations With Antibody Levels Among Preterm Infants.
Tetanus
Clinical reactions and immunogenicity of the BIKEN acellular diphtheria and tetanus toxoids and pertussis vaccine in 4- through 6-year-old US children.
Tetanus
Comparative safety and immunogenicity of an acellular versus whole-cell pertussis component of diphtheria-tetanus-pertussis vaccines in Senegalese infants.
Tetanus
Comparative study of a whole-cell pertussis vaccine and a recombinant acellular pertussis vaccine. The Italian Multicenter Group for the Study of Recombinant Acellular Pertussis Vaccine.
Tetanus
Comparison of 13 acellular pertussis vaccines: overview and serologic response.
Tetanus
Comparison of a fifth dose of a five-component acellular or a whole cell pertussis vaccine in children four to six years of age.
Tetanus
Comparison of the safety and immunogenicity of acellular (BIKEN) and whole-cell pertussis vaccines in 15- to 20-month-old children.
Tetanus
Decline of serologic immunity to diphtheria, tetanus and pertussis with age suggested a full life vaccination in mainland China.
Tetanus
Development and validation of a multiplex immunoassay for the simultaneous determination of serum antibodies to Bordetella pertussis, diphtheria and tetanus.
Tetanus
Development and Validation of Magnetic Bead Pentaplex Immunoassay for Simultaneous Quantification of murine serum IgG antibodies to Acellular Pertussis, Diphtheria and Tetanus Antigens used in combination vaccines.
Tetanus
Diphtheria, tetanus and pertussis antibodies in 10-year-old children before and after a booster dose of three toxoids: implications for the timing of a booster dose.
Tetanus
Effect of combination with an acellular pertussis, diphtheria, tetanus vaccine on antibody response to Hib vaccine (PRP-T).
Tetanus
Effect of HLA genotype or CTLA-4 polymorphism on cytokine response in healthy children.
Tetanus
Effect of local massage on vaccination: DTP and DTPa.
Tetanus
Effect of priming with diphtheria and tetanus toxoids combined with whole-cell pertussis vaccine or with acellular pertussis vaccine on the safety and immunogenicity of a booster dose of an acellular pertussis vaccine containing a genetically inactivated pertussis toxin in fifteen- to twenty-one-month-old children. Italian Multicenter Group for the Study of Recombinant Acellular Pertussis Vaccine.
Tetanus
Enhanced post-licensure safety surveillance of a new recombinant acellular pertussis vaccine licensed as a monovalent (aP, Pertagen®) and tetanus, reduced-dose diphtheria combination (TdaP, Boostagen®) vaccine for immunization of adolescents and adults in Thailand.
Tetanus
Entrapping of impermeant probes of different size into nonpermeabilized synaptosomes as a method to study presynaptic mechanisms.
Tetanus
Evaluation of a guinea pig model to assess interference in the immunogenicity of different components of a combination vaccine comprising diphtheria, tetanus and acellular pertussis (DTaP) vaccine and haemophilus influenzae type b capsular polysaccharide conjugate vaccine.
Tetanus
Experience with monocomponent acellular pertussis combination vaccines for infants, children, adolescents and adults-A review of safety, immunogenicity, efficacy and effectiveness studies and 15 years of field experience.
Tetanus
Expression and purification of a trivalent pertussis toxin-diphtheria toxin-tetanus toxin fusion protein in Escherichia coli.
Tetanus
Extensive swelling after booster doses of acellular pertussis-tetanus-diphtheria vaccines.
Tetanus
Fast, antigen-saving multiplex immunoassay to determine levels and avidity of mouse serum antibodies to pertussis, diphtheria, and tetanus antigens.
Tetanus
Generation of adult-like antibody avidity profiles after early-life immunization with protein vaccines.
Tetanus
Generation of plant-derived recombinant DTP subunit vaccine.
Tetanus
Humoral and cellular immune responses in mice immunized with recombinant Mycobacterium bovis Bacillus Calmette-Guérin producing a pertussis toxin-tetanus toxin hybrid protein.
Tetanus
Humoral immunity of dTap-IPV vaccine (REPEVAX(®)) administered one month after dT-IPV vaccine (REVAXIS(®)) in adults with unknown vaccination history.
Tetanus
Identification of peptides that mimic the pertussis toxin binding site on bovine fetuin.
Tetanus
Identifying long-term memory B-cells in vaccinated children despite waning antibody levels specific for Bordetella pertussis proteins.
Tetanus
Immune response to a Tdap booster in vertically HIV-infected adolescents.
Tetanus
Immunity against vaccine-preventable diseases in Finnish pediatric healthcare workers in 2015.
Tetanus
Immunogenicity and reactogenicity of a single dose of a diphtheria--tetanus--acellular pertussis component vaccine (DTaP) compared to a diphtheria--tetanus toxoid (Td) and a diphtheria toxoid vaccine (d) in adults.
Tetanus
Immunogenicity and reactogenicity of the component acellular pertussis vaccine produced by a combination of column purified pertussis toxin and filamentous haemagglutinin.
Tetanus
Immunogenicity and safety after booster vaccination of diphtheria, tetanus, and acellular pertussis in young adults: an open randomized controlled trial in Japan.
Tetanus
Immunogenicity and Safety of Monovalent Acellular Pertussis Vaccine at Birth: A Randomized Clinical Trial.
Tetanus
Immunogenicity of a combined DTPa-HB vaccine co-administered with Haemophilus influenzae type B conjugate vaccine (PRP-T) for primary and booster vaccinations.
Tetanus
Immunogenicity of combined diphtheria, tetanus, and pertussis vaccine given at 2, 3, and 4 months versus 3, 5, and 9 months of age.
Tetanus
Immunogenicity of primary DPT vaccination.
Tetanus
Immunogenicity study of a combined diphtheria, tetanus, acellular pertussis, inactivated poliomyelitis vaccine used to reconstitute a freeze-dried Haemophilus influenzae type b vaccine (DTaP-IPV//PRP-T) administered simultaneously with a hepatitis B vaccine at two, three and four months of life.
Tetanus
Influence of maternal vaccination against diphtheria, tetanus, and pertussis on the avidity of infant antibody responses to a pertussis containing vaccine in Belgium.
Tetanus
Interchangeability of meningococcal group C conjugate vaccines with different carrier proteins in the United Kingdom infant immunisation schedule.
Tetanus
Local reactions and IgE antibodies to pertussis toxin after acellular diphtheria-tetanus-pertussis immunization.
Tetanus
Measuring immunoglobulin g antibodies to tetanus toxin, diphtheria toxin, and pertussis toxin with single-antigen enzyme-linked immunosorbent assays and a bead-based multiplex assay.
Tetanus
Neutralizing antibodies and immunoprotection against pertussis and tetanus obtained by use of a recombinant pertussis toxin-tetanus toxin fusion protein.
Tetanus
On technological and immunological benefits of multivalent single-injection microsphere vaccines.
Tetanus
Optimization of rPDT fusion protein expression by Escherichia coli in pilot scale fermentation: a statistical experimental design approach.
Tetanus
Persistence of antibody after accelerated immunisation with diphtheria/tetanus/pertussis vaccine.
Tetanus
Pertussis toxin enhanced IgG1 and IgE responses to primary tetanus immunization are mediated by interleukin-4 and persist during secondary responses to tetanus alone.
Tetanus
Pertussis toxin-induced alterations of murine hepatic drug metabolism following administration of diphtheria and tetanus toxoids and pertussis vaccine adsorbed.
Tetanus
Pertussis vaccination during pregnancy in Belgium: Follow-up of infants until 1 month after the fourth infant pertussis vaccination at 15 months of age.
Tetanus
Pertussis vaccination during pregnancy in Belgium: Results of a prospective controlled cohort study.
Tetanus
Pertussis vaccination during pregnancy in Vietnam: Results of a randomized controlled trial Pertussis vaccination during pregnancy.
Tetanus
Production of tumor necrosis factors alpha and beta by human mononuclear leukocytes stimulated with mitogens, bacteria, and malarial parasites.
Tetanus
Quantitative determination of bioactive proteins in diphtheria tetanus acellular pertussis (DTaP) vaccine by liquid chromatography tandem mass spectrometry.
Tetanus
Quartz crystal microbalance investigation of the interaction of bacterial toxins with ganglioside containing solid supported membranes.
Tetanus
Reactogenicity and immunogenicity of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine (Tdap) in pregnant and nonpregnant women.
Tetanus
Regulatory factors that determine growth and phenotype of normal human melanocytes.
Tetanus
Safety and immunogenicity of a combined pentavalent diphtheria, tetanus, acellular pertussis, inactivated poliovirus and Haemophilus influenzae type b-tetanus conjugate vaccine in infants, compared with a whole cell pertussis pentavalent vaccine.
Tetanus
Safety and immunogenicity of six acellular pertussis vaccines and one whole-cell pertussis vaccine given as a fifth dose in four- to six-year-old children.
Tetanus
Seroprevalence and placental transportation of maternal antibodies specific for Neisseria meningitidis serogroup C, Haemophilus influenzae type B, diphtheria, tetanus, and pertussis.
Tetanus
Seroprevalence of antibodies against diphtheria, tetanus, and pertussis among healthy Thai adolescents.
Tetanus
Serum antibodies to diphtheria-tetanus-pertussis vaccine components in Argentine children.
Tetanus
Serum antibodies to the components of diphtheria-tetanus-pertussis vaccine in Polish children related to vaccination status.
Tetanus
Specific T cell deletion by transfected human monocytes expressing fas ligand and antigen.
Tetanus
Spotlight on Tdap? vaccine (Covaxis®) as a single-booster immunization for the prevention of tetanus, diphtheria, and pertussis: in children (aged ?4 years), adolescents, and adults.
Tetanus
Tdap booster to adolescents with juvenile idiopathic arthritis on and off anti-TNF agents is safe and immunogenic.
Tetanus
Tdap(5) vaccine (covaxis®): a review of its use as a single-booster immunization for the prevention of tetanus, diphtheria, and pertussis in children (aged ?4 years), adolescents, and adults.
Tetanus
The Effect of Maternal Pertussis Immunization on Infant Vaccine Responses to a Booster Pertussis-Containing Vaccine in Vietnam.
Tetanus
The inhibition by pertussis and tetanus toxins of evoked catecholamine release from intact and permeabilized bovine adrenal chromaffin cells.
Tetanus
The quantitative analysis of the mechanism involved in pertussis toxin-mediated cell clustering and its implications in the in vitro quality control of diphtheria tetanus and whole cell pertussis vaccines.
Tetanus
The use of microcalorimetry to characterize tetanus neurotoxin, pertussis toxin and filamentous haemagglutinin.
Tetanus
Validation of the toxin-binding inhibition (ToBI) test for the estimation of the potency of the tetanus toxoïd component in vaccines.
Tetanus
Waning vaccine immunity and vaccination responses in children treated for acute lymphoblastic leukemia: A Canadian Immunization Research Network Study.
Tetanus
[Induction of protective immunity for Bordetella pertussis by nasal inoculation of pertussis vaccine in mice]
Tetanus
[Seroepidemiological Studies on Pertussis, Diphtheria and Tetanus among Nursing Students Enrolled between 1994 and 2011 in the Kitakyushu District].
Thrombocytopenia
Avatrombopag Optimizes Response to Niraparib by Managing Thrombocytopenia Associated with Poly-ADP Ribose Polymerase (PARP) Inhibition in Ovarian Cancer and Breast Cancer: A Case Series.
Thrombocytopenia
Efficacy and safety of PARP inhibitors in the treatment of advanced ovarian cancer: An updated systematic review and meta-analysis of randomized controlled trials.
Thrombocytopenia
Haematologic toxicities with PARP inhibitors in cancer patients: an up-to-date meta-analysis of 29 randomized controlled trials.
Thrombocytopenia
Identifying the need to refine the potential patient risk factors for niraparib-induced thrombocytopenia.
Thrombocytopenia
PARP inhibitor treatment of advanced breast cancer beyond the BRCA-mutated type: a meta-analysis.
Thrombocytopenia
Pharmacological differentiation by pertussis toxin of the in vivo acute responses to fMLP and PAF in guinea-pig lungs.
Thrombocytopenia
Risk of severe hematologic toxicities in cancer patients treated with PARP inhibitors: a meta-analysis of randomized controlled trials.
Thrombosis
[Endothelial dysfunction and atherosclerosis]
Thymoma
Advances in the use of PARP inhibitor therapy for breast cancer.
Thymoma
Effect of pertussis toxin and PGE2 on the functioning of the IL-2 promoter in interleukin-1 treated EL4.NOB-1 thymoma cells.
Thymoma
IL-1 stimulates a diverging signaling pathway in EL4 6.1 thymoma cells. IL-2 release, but not IL-2 receptor expression, is sensitive to pertussis toxin.
Thymoma
Metastatic Thymoma Harboring a Deleterious BRCA2 Mutation Derives Durable Clinical Benefit from Olaparib.
Thymoma
Pan-Cancer Analysis of PARP1 Alterations as Biomarkers in the Prediction of Immunotherapeutic Effects and the Association of Its Expression Levels and Immunotherapy Signatures.
Thyroid Cancer, Papillary
LncRNA-SLC6A9-5:2: A potent sensitizer in 131I-resistant papillary thyroid carcinoma with PARP-1 induction.
Thyroid Carcinoma, Anaplastic
PARP inhibitor olaparib increases the oncolytic activity of dl922-947 in in vitro and in vivo model of anaplastic thyroid carcinoma.
Thyroid Neoplasms
Amifostine does not protect thyroid cancer cells in DNA damaging in vitro models.
Thyroid Neoplasms
Anti-proliferative and anti-invasive effects of ferulic acid in TT medullary thyroid cancer cells interacting with URG4/URGCP.
Thyroid Neoplasms
Association between polymorphisms in DNA base excision repair genes XRCC1, APE1, and ADPRT and differentiated thyroid carcinoma.
Thyroid Neoplasms
Computational modeling reveals MAP3K8 as mediator of resistance to vemurafenib in thyroid cancer stem cells.
Thyroid Neoplasms
Effects of PPARgamma agonists on cell survival and focal adhesions in a Chinese thyroid carcinoma cell line.
Thyroid Neoplasms
Galectin-3 Inhibitors Suppress Anoikis Resistance and Invasive Capacity in Thyroid Cancer Cells.
Thyroid Neoplasms
Human sodium-iodide symporter (hNIS) gene expression is inhibited by a trans-active transcriptional repressor, NIS-repressor, containing PARP-1 in thyroid cancer cells.
Thyroid Neoplasms
Interaction among susceptibility genotypes of PARP1 SNPs in thyroid carcinoma.
Thyroid Neoplasms
LncRNA-SLC6A9-5:2: A potent sensitizer in 131I-resistant papillary thyroid carcinoma with PARP-1 induction.
Thyroid Neoplasms
Molecular mechanisms of the effects of low concentrations of taxol in anaplastic thyroid cancer cells.
Thyroid Neoplasms
Synergy between HDAC and PARP Inhibitors on Proliferation of a Human Anaplastic Thyroid Cancer-Derived Cell Line.
Thyroid Neoplasms
The PARP inhibitor PJ34 modifies proliferation, NIS expression and epigenetic marks in thyroid cancer cell lines.
Thyroiditis
Association of three SNPs in the PARP-1 gene with Hashimoto's thyroiditis.
Tics
Resistance to DNA-damaging treatment in non-small cell lung cancer tumor-initiating cells involves reduced DNA-PK/ATM activation and diminished cell cycle arrest.
Torsades de Pointes
PARP inhibitor-induced torsades de pointes in long QT syndrome: a case report.
Tourette Syndrome
Association of poly(ADP-ribose) polymerase-1 polymorphism with Tourette syndrome.
Trauma, Nervous System
Poly(ADP-ribose) polymerase inhibitors.
Tremor
Induction of type 1 immune pathology in the brain following immunization without central nervous system autoantigen in transgenic mice with astrocyte-targeted expression of IL-12.
Triple Negative Breast Neoplasms
A marker of homologous recombination predicts pathological complete response to neoadjuvant chemotherapy in primary breast cancer.
Triple Negative Breast Neoplasms
A P53-Independent DNA Damage Response Suppresses Oncogenic Proliferation and Genome Instability.
Triple Negative Breast Neoplasms
A Phase 1 trial of the poly(ADP-ribose) polymerase inhibitor olaparib (AZD2281) in combination with the anti-angiogenic cediranib (AZD2171) in recurrent epithelial ovarian or triple-negative breast cancer.
Triple Negative Breast Neoplasms
ABC4 Consensus: First Latin American Meeting-Assessment, Comments, and Application of Its Recommendations.
Triple Negative Breast Neoplasms
Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial.
Triple Negative Breast Neoplasms
Adoptive cell therapy of triple negative breast cancer with redirected cytokine-induced killer cells.
Triple Negative Breast Neoplasms
Advances in Preventive Therapy for Estrogen-Receptor-Negative Breast Cancer.
Triple Negative Breast Neoplasms
Antitumor effect of a WEE1 inhibitor and potentiation of olaparib sensitivity by DNA damage response modulation in triple-negative breast cancer.
Triple Negative Breast Neoplasms
Appraising iniparib, the PARP inhibitor that never was--what must we learn?
Triple Negative Breast Neoplasms
Association BRCA mutation status between BMN 673 (talazoparib), an oral PARP inhibitor, in triple-negative breast cancer.
Triple Negative Breast Neoplasms
Augmentation of the antitumor effects of PARP inhibitors in triple-negative breast cancer via degradation by hydrophobic tagging modulation.
Triple Negative Breast Neoplasms
BKM120 sensitizes BRCA-proficient triple negative breast cancer cells to olaparib through regulating FOXM1 and Exo1 expression.
Triple Negative Breast Neoplasms
Blocking c-Met and EGFR reverses acquired resistance of PARP inhibitors in triple-negative breast cancer.
Triple Negative Breast Neoplasms
Blocking Fra-1 sensitizes triple-negative breast cancer to PARP inhibitor.
Triple Negative Breast Neoplasms
BMN 673 (talazoparib): A potent PARP inhibitor for triple negative breast cancer with different genetic profile.
Triple Negative Breast Neoplasms
BRCA Gene Mutations and Poly(ADP-Ribose) Polymerase Inhibitors in Triple-Negative Breast Cancer.
Triple Negative Breast Neoplasms
Can patients with metastatic breast cancer be cured after introduction of newer and more effective agents?
Triple Negative Breast Neoplasms
CDK12 Inhibition Reverses De Novo and Acquired PARP Inhibitor Resistance in BRCA Wild-Type and Mutated Models of Triple-Negative Breast Cancer.
Triple Negative Breast Neoplasms
CHFR-mediated degradation of RNF126 confers sensitivity to PARP inhibitors in triple-negative breast cancer cells.
Triple Negative Breast Neoplasms
CMF revisited in the 21st century.
Triple Negative Breast Neoplasms
Co-targeting poly(ADP-ribose) polymerase (PARP) and histone deacetylase (HDAC) in triple-negative breast cancer: Higher synergism in BRCA mutated cells.
Triple Negative Breast Neoplasms
Combination of Olaparib and radiotherapy for triple negative breast cancer: preliminary results of the RADIOPARP phase I trial.
Triple Negative Breast Neoplasms
Combination of Olaparib with radiotherapy for triple-negative breast cancers: One-year toxicity report of the RADIOPARP Phase I trial.
Triple Negative Breast Neoplasms
Corrigendum to "Gold nanoparticle conjugated Rad6 inhibitor induces cell death in triple negative breast cancer cells by inducing mitochondrial dysfunction and PARP-1 hyperactivation: Synthesis and characterization" [Nanomedicine 12 (3) (2016), 745-757].
Triple Negative Breast Neoplasms
Corrigendum: PARP inhibitor increases chemosensitivity by upregulating miR-664b-5p in BRCA1-mutated triple-negative breast cancer.
Triple Negative Breast Neoplasms
Crystal structure-based discovery of a novel synthesized PARP1 inhibitor (OL-1) with apoptosis-inducing mechanisms in triple-negative breast cancer.
Triple Negative Breast Neoplasms
Current Issues of Targeted Therapy in Metastatic Triple-Negative Breast Cancer.
Triple Negative Breast Neoplasms
Current Status of Poly(ADP-ribose) Polymerase Inhibitors as Novel Therapeutic Agents for Triple-Negative Breast Cancer.
Triple Negative Breast Neoplasms
DDB2 depletion sensitizes triple-negative breast cancer cells to PARP inhibition by destabilizing Rad51.
Triple Negative Breast Neoplasms
Decreased miR-206 expression in BRCA1 wild-type triple-negative breast cancer cells after concomitant treatment with gemcitabine and a Poly(ADP-ribose) polymerase-1 inhibitor.
Triple Negative Breast Neoplasms
Defective repair of oxidative dna damage in triple-negative breast cancer confers sensitivity to inhibition of poly(ADP-ribose) polymerase.
Triple Negative Breast Neoplasms
Deglycosylation of PD-L1 by 2-deoxyglucose reverses PARP inhibitor-induced immunosuppression in triple-negative breast cancer.
Triple Negative Breast Neoplasms
Design and synthesis of some barbituric and 1,3-dimethylbarbituric acid derivatives: A non-classical scaffold for potential PARP1 inhibitors.
Triple Negative Breast Neoplasms
Design, Synthesis, and Characterization of an Orally Active Dual-Specific ULK1/2 Autophagy Inhibitor that Synergizes with the PARP Inhibitor Olaparib for the Treatment of Triple-Negative Breast Cancer.
Triple Negative Breast Neoplasms
Dextran-modified Quercetin-Cu(II)/hyaluronic acid nanomedicine with natural poly(ADP-ribose) polymerase inhibitor and dual targeting for programmed synthetic lethal therapy in triple-negative breast cancer.
Triple Negative Breast Neoplasms
Differential anti-proliferative activities of poly(ADP-ribose) polymerase (PARP) inhibitors in triple-negative breast cancer cells.
Triple Negative Breast Neoplasms
Discovery of First-in-Class Dual PARP and EZH2 Inhibitors for Triple-Negative Breast Cancer with Wild-Type BRCA.
Triple Negative Breast Neoplasms
Discovery of novel PARP/PI3K dual inhibitors with high efficiency against BRCA-proficient triple negative breast cancer.
Triple Negative Breast Neoplasms
Doubling down on the PI3K-AKT-mTOR pathway enhances the antitumor efficacy of PARP inhibitor in triple negative breast cancer model beyond BRCA-ness.
Triple Negative Breast Neoplasms
Downregulation of miR-221-3p and upregulation of its target gene PARP1 are prognostic biomarkers for triple negative breast cancer patients and associated with poor prognosis.
Triple Negative Breast Neoplasms
E2A Modulates Stemness, Metastasis, and Therapeutic Resistance of Breast Cancer.
Triple Negative Breast Neoplasms
Effect of AR antagonist combined with PARP1 inhibitor on sporadic triple-negative breast cancer bearing AR expression and methylation-mediated BRCA1 dysfunction.
Triple Negative Breast Neoplasms
Efficacy and mechanism of the combination of PARP and CDK4/6 inhibitors in the treatment of triple-negative breast cancer.
Triple Negative Breast Neoplasms
Erratum to "Doubling Down on the PI3K-AKTmTOR Pathway Enhances the Antitumor Efficacy of PARP Inhibitor in Triple Negative Breast Cancer Model beyond BRCA-ness" [Neoplasia 16 (2014) 43-72].
Triple Negative Breast Neoplasms
Establishment and Characterization of a Brca1-/-, p53-/- Mouse Mammary Tumor Cell Line.
Triple Negative Breast Neoplasms
Expert Insights on Triple-Negative Breast Cancer: Preparing for the Next Wave of Treatments.
Triple Negative Breast Neoplasms
Exploiting Chromosomal Instability of PTEN-Deficient Triple-Negative Breast Cancer Cell Lines for the Sensitization against PARP1 Inhibition in a Replication-Dependent Manner.
Triple Negative Breast Neoplasms
Expression of potential biomarkers associated with homologous recombination repair in patients with ovarian or triple-negative breast cancer.
Triple Negative Breast Neoplasms
Frame-shift mediated reduction of gain-of-function p53 R273H and deletion of the R273H C-terminus in breast cancer cells result in replication-stress sensitivity.
Triple Negative Breast Neoplasms
Functional consequences of a rare missense BARD1 c.403G>A germline mutation identified in a triple-negative breast cancer patient.
Triple Negative Breast Neoplasms
Gallic acid and curcumin induce cytotoxicity and apoptosis in human breast cancer cell MDA-MB-231.
Triple Negative Breast Neoplasms
Gold nanoparticle conjugated Rad6 inhibitor induces cell death in triple negative breast cancer cells by inducing mitochondrial dysfunction and PARP-1 hyperactivation: Synthesis and characterization.
Triple Negative Breast Neoplasms
H-Ferritin-nanocaged olaparib: a promising choice for both BRCA-mutated and sporadic triple negative breast cancer.
Triple Negative Breast Neoplasms
Heterogeneous drug penetrance of veliparib and carboplatin measured in triple negative breast tumors.
Triple Negative Breast Neoplasms
Histone deacetylase inhibitor treatment induces 'BRCAness' and synergistic lethality with PARP inhibitor and cisplatin against human triple negative breast cancer cells.
Triple Negative Breast Neoplasms
Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), enhances anti-tumor effects of the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib in triple-negative breast cancer cells.
Triple Negative Breast Neoplasms
HMGA2 as a functional antagonist of PARP1 inhibitors in tumor cells.
Triple Negative Breast Neoplasms
Homologous recombination DNA repair deficiency and PARP inhibition activity in primary triple negative breast cancer.
Triple Negative Breast Neoplasms
Immune Checkpoint and Poly(ADP-Ribose) Polymerase Inhibition for Recurrent Platinum-Resistant Ovarian and Metastatic Triple-Negative Breast Cancers.
Triple Negative Breast Neoplasms
Inducing Synthetic Lethality using PARP Inhibitors.
Triple Negative Breast Neoplasms
Induction of BRCAness in Triple-Negative Breast Cancer by a CDK12/13 Inhibitor Improves Chemotherapy.
Triple Negative Breast Neoplasms
Iniparib, a PARP1 inhibitor for the potential treatment of cancer, including triple-negative breast cancer.
Triple Negative Breast Neoplasms
INPP4B overexpression enhances the antitumor efficacy of PARP inhibitor AG014699 in MDA-MB-231 triple-negative breast cancer cells.
Triple Negative Breast Neoplasms
Integrating poly(ADP-ribose) polymerase (PARP) inhibitors in the treatment of early breast cancer.
Triple Negative Breast Neoplasms
Is there an epigenetic component underlying the resistance of triple-negative breast cancers to parp inhibitors?
Triple Negative Breast Neoplasms
Judy Garber on PARP Inhibitors for Triple-Negative Breast Cancer.
Triple Negative Breast Neoplasms
Metabotropic glutamate receptor-1: a potential therapeutic target for the treatment of breast cancer.
Triple Negative Breast Neoplasms
Metallointercalator [Ru(dppz)2(PIP)]2+ Renders BRCA Wild-Type Triple-Negative Breast Cancer Cells Hypersensitive to PARP Inhibition.
Triple Negative Breast Neoplasms
Metformin reverses PARP inhibitors-induced epithelial-mesenchymal transition and PD-L1 upregulation in triple-negative breast cancer.
Triple Negative Breast Neoplasms
MiRNA and LncRNA as Potential Biomarkers in Triple-Negative Breast Cancer: A Review.
Triple Negative Breast Neoplasms
Modulation of Early Mitotic Inhibitor 1 (EMI1) depletion on the sensitivity of PARP inhibitors in BRCA1 mutated triple-negative breast cancer cells.
Triple Negative Breast Neoplasms
mTOR Inhibitors Suppress Homologous Recombination Repair and Synergize with PARP Inhibitors via Regulating SUV39H1 in BRCA-Proficient Triple-Negative Breast Cancer.
Triple Negative Breast Neoplasms
MUC1-C Integrates Chromatin Remodeling and PARP1 Activity in the DNA Damage Response of Triple-Negative Breast Cancer Cells.
Triple Negative Breast Neoplasms
New insight into the significance of KLF4 PARylation in genome stability, carcinogenesis, and therapy.
Triple Negative Breast Neoplasms
New Perspectives for Resistance to PARP Inhibitors in Triple-Negative Breast Cancer.
Triple Negative Breast Neoplasms
New RAD51 Inhibitors to Target Homologous Recombination in Human Cells.
Triple Negative Breast Neoplasms
Novel targeted therapeutics: inhibitors of MDM2, ALK and PARP.
Triple Negative Breast Neoplasms
p66ShcA potentiates the cytotoxic response of triple-negative breast cancers to PARP inhibitors.
Triple Negative Breast Neoplasms
Pan-cancer analysis of genomic scar signatures associated with homologous recombination deficiency suggests novel indications for existing cancer drugs.
Triple Negative Breast Neoplasms
PARP inhibitor and platinum agent in triple negative breast cancer: utilizing innovative trial design to bring together something "new" and something "old".
Triple Negative Breast Neoplasms
PARP Inhibitor Efficacy Depends on CD8+ T-cell Recruitment via Intratumoral STING Pathway Activation in BRCA-Deficient Models of Triple-Negative Breast Cancer.
Triple Negative Breast Neoplasms
PARP inhibitor increases chemosensitivity by upregulating miR-664b-5p in BRCA1-mutated triple-negative breast cancer.
Triple Negative Breast Neoplasms
PARP Inhibitor Olaparib Use in a BRCA1-Positive Patient With Metastatic Triple-Negative Breast Cancer, Without the Initial Use of Platinum-Based Chemotherapy, Showing Significant Rapid Near Resolution of Large Liver Metastasis While Patient Experienced Gout-Like Symptoms.
Triple Negative Breast Neoplasms
PARP Inhibitors for the Treatment and Prevention of Breast Cancer.
Triple Negative Breast Neoplasms
PARP inhibitors in BRCA1-/BRCA2-associated and triple-negative breast cancers.
Triple Negative Breast Neoplasms
PARP Inhibitors in Breast Cancer.
Triple Negative Breast Neoplasms
PARP inhibitors in breast cancer: BRCA and beyond.
Triple Negative Breast Neoplasms
PARP Inhibitors in the Treatment of Triple-Negative Breast Cancer.
Triple Negative Breast Neoplasms
PARP Inhibitors in Triple-Negative Breast Cancer Including Those With BRCA Mutations.
Triple Negative Breast Neoplasms
PARP1 and PRC2 double deficiency promotes BRCA-proficient breast cancer growth by modification of the tumor microenvironment.
Triple Negative Breast Neoplasms
PARP1 Trapping by PARP Inhibitors Drives Cytotoxicity in Both Cancer Cells and Healthy Bone Marrow.
Triple Negative Breast Neoplasms
PARP3, a new therapeutic target to alter Rictor/mTORC2 signaling and tumor progression in BRCA1-associated cancers.
Triple Negative Breast Neoplasms
Pathway-Enriched Gene Signature Associated with 53BP1 Response to PARP Inhibition in Triple-Negative Breast Cancer.
Triple Negative Breast Neoplasms
Phase I and pharmacokinetic study of veliparib, a PARP inhibitor, and pegylated liposomal doxorubicin (PLD) in recurrent gynecologic cancer and triple negative breast cancer with long-term follow-up.
Triple Negative Breast Neoplasms
Phase I Study of Veliparib (ABT-888) Combined with Cisplatin and Vinorelbine in Advanced Triple-Negative Breast Cancer and/or BRCA Mutation-Associated Breast Cancer.
Triple Negative Breast Neoplasms
Phase I trial of the oral PARP inhibitor olaparib in combination with paclitaxel for first- or second-line treatment of patients with metastatic triple-negative breast cancer.
Triple Negative Breast Neoplasms
PI3K inhibition impairs BRCA1/2 expression and sensitizes BRCA proficient triple negative breast cancer to PARP inhibition.
Triple Negative Breast Neoplasms
Poly(ADP-Ribose) polymerase inhibition: "Targeted" therapy for triple-negative breast cancer.
Triple Negative Breast Neoplasms
Poly(ADP-ribose) polymerase inhibition: a new direction for BRCA and triple-negative breast cancer?
Triple Negative Breast Neoplasms
Poly(ADP-ribose) polymerase inhibitors in triple-negative breast cancer.
Triple Negative Breast Neoplasms
Polymorphisms in PARP1 predict disease-free survival of triple-negative breast cancer patients treated with anthracycline/taxane based adjuvant chemotherapy.
Triple Negative Breast Neoplasms
Polymorphisms in poly (ADP-ribose) polymerase-1 (PARP1) promoter and 3' untranslated region and their association with PARP1 expression in breast cancer patients.
Triple Negative Breast Neoplasms
Prosopis juliflora (Sw.), DC induces apoptosis and cell cycle arrest in triple negative breast cancer cells: in vitro and in vivo investigations.
Triple Negative Breast Neoplasms
Protein expression of DNA damage repair proteins dictates response to topoisomerase and PARP inhibitors in triple-negative breast cancer.
Triple Negative Breast Neoplasms
Rad51 inhibition sensitizes breast cancer stem cells to PARP inhibitor in triple-negative breast cancer.
Triple Negative Breast Neoplasms
RAD51 Mediates Resistance of Cancer Stem Cells to PARP Inhibition in Triple-Negative Breast Cancer.
Triple Negative Breast Neoplasms
Randomized phase II trial of cyclophosphamide and the oral poly (ADP-ribose) polymerase inhibitor veliparib in patients with recurrent, advanced triple-negative breast cancer.
Triple Negative Breast Neoplasms
Rapamycin sensitizes cancer cells to growth inhibition by the PARP inhibitor olaparib.
Triple Negative Breast Neoplasms
Response of subtype-specific human breast cancer-derived cells to poly(ADP-ribose) polymerase and checkpoint kinase 1 inhibition.
Triple Negative Breast Neoplasms
Synergistic chemosensitivity of triple-negative breast cancer cell lines to poly(ADP-Ribose) polymerase inhibition, gemcitabine, and cisplatin.
Triple Negative Breast Neoplasms
Synthetic lethal interactions between EGFR and PARP inhibition in human triple negative breast cancer cells.
Triple Negative Breast Neoplasms
Synthetic lethality of PARP and NAMPT inhibition in triple-negative breast cancer cells.
Triple Negative Breast Neoplasms
Synthetic Lethality of PARP Inhibitors in Combination with MYC Blockade Is Independent of BRCA Status in Triple-Negative Breast Cancer.
Triple Negative Breast Neoplasms
Targeted therapy for breast cancer.
Triple Negative Breast Neoplasms
Targeting immunosuppressive macrophages overcomes PARP inhibitor resistance in BRCA1-associated triple-negative breast cancer.
Triple Negative Breast Neoplasms
The cancer-testis gene, MEIOB, sensitizes triple-negative breast cancer to PARP1 inhibitors by inducing homologous recombination deficiency.
Triple Negative Breast Neoplasms
The Correlation Between PARP1 and BRCA1 in AR Positive Triple-negative Breast Cancer.
Triple Negative Breast Neoplasms
The role of PARP inhibition in triple-negative breast cancer: Unraveling the wide spectrum of synthetic lethality.
Triple Negative Breast Neoplasms
Therapeutic potential of PARP inhibitors for metastatic breast cancer.
Triple Negative Breast Neoplasms
Transcriptional Regulation of CCL2 by PARP1 Is a Driver for Invasiveness in Breast Cancer.
Triple Negative Breast Neoplasms
Translating the role of PARP inhibitors in triple-negative breast cancer.
Triple Negative Breast Neoplasms
Treatment of triple-negative breast cancer using anti-EGFR-directed radioimmunotherapy combined with radiosensitizing chemotherapy and PARP inhibitor.
Triple Negative Breast Neoplasms
Triple-negative breast cancer and Poly(ADP-ribose) polymerase inhibitors.
Triple Negative Breast Neoplasms
Triple-negative breast cancer: molecular features, pathogenesis, treatment and current lines of research.
Triple Negative Breast Neoplasms
Upregulation of Poly (ADP-Ribose) Polymerase-1 (PARP1) in Triple-Negative Breast Cancer and Other Primary Human Tumor Types.
Triple Negative Breast Neoplasms
Using multiple targeted therapies in oncology: considerations for use, and progress to date in breast cancer.
Triple Negative Breast Neoplasms
XRCC1 deficient triple negative breast cancers are sensitive to ATR, ATM and Wee1 inhibitor either alone or in combination with olaparib.
Triple Negative Breast Neoplasms
Zebrafish Xenografts Unveil Sensitivity to Olaparib beyond BRCA Status.
Triple Negative Breast Neoplasms
[Effects of Olaparib, a PARP-1 Inhibitor, on Triple Negative Breast Cancer Cells with a BRCA1 Mutation].
Triple Negative Breast Neoplasms
[Effects of poly(ADP-ribose)polymerase inhibitor AG014699 combined with chemotherapy on the proliferation of triple-negative breast cancer cell line MDA-MB-231].
Triple Negative Breast Neoplasms
[PARP inhibitors--theoretical basis and clinical application].
Triple Negative Breast Neoplasms
[Triple-negative breast cancer: molecular characteristics and potential therapeutic approaches].
Tuberculosis
Early IFN-? production together with decreased expression of TLR3 and TLR9 characterizes EAE development conditional on the presence of myelin.
Tuberculosis
Evaluation of IL-17 Serum Level, Brain Inflammation and Demyelination in Experimental Autoimmune Encephalomyelitis C57BL/6 Mice Model with Different Doses of Myelin Oligodendrocyte Glycoprotein.
Tuberculosis
Experimental autoimmune vasculitis: an animal model of anti-neutrophil cytoplasmic autoantibody-associated systemic vasculitis.
Tuberculosis
Induction of polyclonal antibodies to the S1 subunit of pertussis toxin by synthetic peptides coupled to PPD: effect of conjugation method, adjuvant, priming and animal species.
Tuberculosis
Is rheumatoid arthritis a consequence of natural selection for enhanced tuberculosis resistance?
Tuberculosis
Mechanical hypernociception in experimental autoimmune encephalomyelitis.
Tuberculosis
Protection against autoimmune disease by bacterial agents. II. PPD and pertussis toxin as proteins active in protecting mice against experimental autoimmune encephalomyelitis.
Tuberculosis
Protective effects of pharmacological therapies in animal models of multiple sclerosis: a review of studies 2014-2019.
Tuberculosis
Spontaneous induction of immunoregulation by an endogenous retinal antigen.
Tuberculosis
Titration of myelin oligodendrocyte glycoprotein (MOG) - Induced experimental autoimmune encephalomyelitis (EAE) model.
Tuberculosis
Use of type I and type IV hypersensitivity responses to define the immunopharmacological profile of drugs.
Typhoid Fever
Specific lung mucosal and systemic immune responses after oral immunization of mice with Salmonella typhimurium aroA, Salmonella typhi Ty21a, and invasive Escherichia coli expressing recombinant pertussis toxin S1 subunit.
Ureteral Obstruction
Loss of poly(ADP-ribose) polymerase 1 attenuates renal fibrosis and inflammation during unilateral ureteral obstruction.
Urinary Bladder Neoplasms
1,1-Bis(3'-indolyl)-1-(p-chlorophenyl)methane activates the orphan nuclear receptor Nurr1 and inhibits bladder cancer growth.
Urinary Bladder Neoplasms
CD44 and RHAMM are essential for rapid growth of bladder cancer driven by loss of Glycogen Debranching Enzyme (AGL).
Urinary Bladder Neoplasms
Chloroquine and hydroxychloroquine inhibit bladder cancer cell growth by targeting basal autophagy and enhancing apoptosis.
Urinary Bladder Neoplasms
Cisplatin sensitivity of testis tumour cells is due to deficiency in interstrand-crosslink repair and low ERCC1-XPF expression.
Urinary Bladder Neoplasms
Detection of Molecular Signatures of Homologous Recombination Deficiency in Bladder Cancer.
Urinary Bladder Neoplasms
Genetic Variants of XRCC1, APE1, and ADPRT Genes and Risk of Bladder Cancer.
Urinary Bladder Neoplasms
Genetic variation in the base excision repair pathway and bladder cancer risk.
Urinary Bladder Neoplasms
Guggulsterone induces apoptosis and inhibits lysosomal-dependent migration in human bladder cancer cells.
Urinary Bladder Neoplasms
Heptaphylline suppresses the proliferation and migration of human bladder cancer cells via induction of intrinsic apoptosis, autophagy and inhibition of ?-catenin signalling pathway.
Urinary Bladder Neoplasms
High-order interactions among genetic variants in DNA base excision repair pathway genes and smoking in bladder cancer susceptibility.
Urinary Bladder Neoplasms
Immunomodulatory effects of recombinant BCG expressing pertussis toxin on TNF-alpha and IL-10 in a bladder cancer model.
Urinary Bladder Neoplasms
In vitro Evidence of Human Immune Responsiveness Shows the Improved Potential of a Recombinant BCG Strain for Bladder Cancer Treatment.
Urinary Bladder Neoplasms
Intravesical therapy with pertussis toxin before radical cystectomy in patients with bladder cancer: a Phase I study.
Urinary Bladder Neoplasms
New combinatorial strategies to improve the PARP inhibitors efficacy in the urothelial bladder Cancer treatment.
Urinary Bladder Neoplasms
Overexpression of immunoglobulin G prompts cell proliferation and inhibits cell apoptosis in human urothelial carcinoma.
Urinary Bladder Neoplasms
Overexpression of PML induced apoptosis in bladder cancer cell by caspase dependent pathway.
Urinary Bladder Neoplasms
PARP-1 inhibition with or without ionizing radiation confers reactive oxygen species-mediated cytotoxicity preferentially to cancer cells with mutant TP53.
Urinary Bladder Neoplasms
The role of microRNA-binding site polymorphisms in DNA repair genes as risk factors for bladder cancer and breast cancer and their impact on radiotherapy outcomes.
Urinary Bladder Neoplasms
The SMAD2/3 pathway is involved in hepaCAM-induced apoptosis by inhibiting the nuclear translocation of SMAD2/3 in bladder cancer cells.
Urinary Bladder Neoplasms
[Knock-down of DAB2 interacting protein (DAB2IP) promotes proliferation and inhibits apoptosis of bladder cancer cells].
Urinary Bladder Neoplasms
[The molecular mechanism of PML in inducing apoptosis of bladder cancer cell line]
Urinary Retention
PARP inhibition prevents oxidative injury of bladder induced by acute urinary retention and subsequent emptying.
Uterine Cervical Neoplasms
A phase I trial of paclitaxel, cisplatin, and veliparib in the treatment of persistent or recurrent carcinoma of the cervix: an NRG Oncology Study (NCT#01281852).
Uterine Cervical Neoplasms
A Phase I-II Evaluation of Veliparib (NSC #737664), Topotecan, and Filgrastim or Pegfilgrastim in the Treatment of Persistent or Recurrent Carcinoma of the Uterine Cervix: An NRG Oncology/Gynecologic Oncology Group Study.
Uterine Cervical Neoplasms
Atorvastatin suppresses the progression of cervical cancer via regulation of autophagy.
Uterine Cervical Neoplasms
B5, a thioredoxin reductase inhibitor, induces apoptosis in human cervical cancer cells by suppressing the thioredoxin system, disrupting mitochondrion-dependent pathways and triggering autophagy.
Uterine Cervical Neoplasms
Base excision repair pathway: PARP1 genotypes as modulators of therapy response in cervical cancer patients.
Uterine Cervical Neoplasms
Bcl-2 confers survival in cisplatin treated cervical cancer cells: circumventing cisplatin dose-dependent toxicity and resistance.
Uterine Cervical Neoplasms
Beyond Chemotherapy: An Overview and Review of Targeted Therapy in Cervical Cancer.
Uterine Cervical Neoplasms
Blockade of BAFF Receptor BR3 on T Cells Enhances Their Activation and Cytotoxicity.
Uterine Cervical Neoplasms
Caspase-independent cell death by arsenic trioxide in human cervical cancer cells: reactive oxygen species-mediated poly(ADP-ribose) polymerase-1 activation signals apoptosis-inducing factor release from mitochondria.
Uterine Cervical Neoplasms
Complete pathological response to olaparib and bevacizumab in advanced cervical cancer following chemoradiation in a BRCA1 mutation carrier: a case report.
Uterine Cervical Neoplasms
Cucurbitacin D exhibits potent anti-cancer activity in cervical cancer.
Uterine Cervical Neoplasms
Current Systemic Treatment Landscape of Advanced Gynecologic Malignancies.
Uterine Cervical Neoplasms
Differential osmosensing signalling pathways and G-protein involvement in human cervical cells with different tumour potential.
Uterine Cervical Neoplasms
Down-regulation of LHPP in cervical cancer influences cell proliferation, metastasis and apoptosis by modulating AKT.
Uterine Cervical Neoplasms
Emodin induces apoptosis of human cervical cancer cells through poly(ADP-ribose) polymerase cleavage and activation of caspase-9.
Uterine Cervical Neoplasms
Expression of BAG-1 and PARP-1 in Precursor Lesions and Invasive Cervical Cancer Associated with Human Papillomavirus (HPV).
Uterine Cervical Neoplasms
Expression of DNA damage response proteins in cervical cancer patients treated with radical chemoradiotherapy.
Uterine Cervical Neoplasms
Gene Expression Analysis Identifies Novel Targets for Cervical Cancer Therapy.
Uterine Cervical Neoplasms
Hazelnut (Corylus avellana L.) Shells Extract: Phenolic Composition, Antioxidant Effect and Cytotoxic Activity on Human Cancer Cell Lines.
Uterine Cervical Neoplasms
Identification of Vaccinia-H1 Related Phosphatase as an Anticancer Target for 1,2,3,4,6-O-Pentagalloylglucose.
Uterine Cervical Neoplasms
Immuno-related polymorphisms and cervical cancer risk: The IARC multicentric case-control study.
Uterine Cervical Neoplasms
Immunotherapy in ovarian, endometrial and cervical cancer: State of the art and future perspectives.
Uterine Cervical Neoplasms
Induction of apoptosis by the inhibitors of poly(ADP-ribose)polymerase in HeLa cells.
Uterine Cervical Neoplasms
Interferon ? improves the efficacy of low dose cisplatin by inhibiting NF-?B/p-Akt signaling on HeLa cells.
Uterine Cervical Neoplasms
Involvement of PARP-1 Val762Ala polymorphism in the onset of cervical cancer in caucasian women.
Uterine Cervical Neoplasms
MAPK4 deletion enhances radiation effects and triggers synergistic lethality with simultaneous PARP1 inhibition in cervical cancer.
Uterine Cervical Neoplasms
MFAP5 suppression inhibits migration/invasion, regulates cell cycle and induces apoptosis via promoting ROS production in cervical cancer.
Uterine Cervical Neoplasms
MicroRNA-7-5p Promotes Cisplatin Resistance of Cervical Cancer Cells and Modulation of Cellular Energy Homeostasis by Regulating the Expression of the PARP-1 and BCL2 Genes.
Uterine Cervical Neoplasms
MiRNA-211 triggers an autophagy-dependent apoptosis in cervical cancer cells: regulation of Bcl-2.
Uterine Cervical Neoplasms
MSX1 induces G0/G1 arrest and apoptosis by suppressing Notch signaling and is frequently methylated in cervical cancer.
Uterine Cervical Neoplasms
Olaparib modulates DNA repair efficiency, sensitizes cervical cancer cells to cisplatin and exhibits anti-metastatic property.
Uterine Cervical Neoplasms
Pan-Cancer Analysis of PARP1 Alterations as Biomarkers in the Prediction of Immunotherapeutic Effects and the Association of Its Expression Levels and Immunotherapy Signatures.
Uterine Cervical Neoplasms
PARP-1 activity (PAR) determines the sensitivity of cervical cancer to olaparib.
Uterine Cervical Neoplasms
PARP-1 inhibitor modulate ?-catenin signaling to enhance cisplatin sensitivity in cancer cervix.
Uterine Cervical Neoplasms
PD-L1, PARP1, and MMRs as potential therapeutic biomarkers for neuroendocrine cervical cancer.
Uterine Cervical Neoplasms
PI3K p110? inhibition sensitizes cervical cancer cells with aberrant PI3K signaling activation to PARP inhibitor BMN673.
Uterine Cervical Neoplasms
Poly(ADP-Ribose) Polymerase in Cervical Cancer Pathogenesis: Mechanism and Potential Role for PARP Inhibitors.
Uterine Cervical Neoplasms
Poly(ADP-ribose)polymerase1: A potential molecular marker to identify cancer during colposcopy procedures.
Uterine Cervical Neoplasms
Potential biomarkers and therapeutic targets in cervical cancer: Insights from the meta-analysis of transcriptomics data within network biomedicine perspective.
Uterine Cervical Neoplasms
Rational design and fabrication of a cancer-targeted chitosan nanocarrier to enhance selective cellular uptake and anticancer efficacy of selenocystine.
Uterine Cervical Neoplasms
Reactive oxygen species-dependent activation of Bax and poly(ADP-ribose) polymerase-1 is required for mitochondrial cell death induced by triterpenoid pristimerin in human cervical cancer cells.
Uterine Cervical Neoplasms
RHCG suppresses cervical cancer progression through inhibiting migration and inducing apoptosis regulated by TGF-?1.
Uterine Cervical Neoplasms
RNF114 suppresses metastasis through regulation of PARP10 in cervical cancer cells.
Uterine Cervical Neoplasms
Rucaparib antagonize multidrug resistance in cervical cancer cells through blocking the function of ABC transporters.
Uterine Cervical Neoplasms
Single nucleotide polymorphisms in DNA repair genes and risk of cervical cancer: A case-control study.
Uterine Cervical Neoplasms
Structure-activity insights of harmine targeting DNA, ROS inducing cytotoxicity with PARP mediated apoptosis against cervical cancer, anti-biofilm formation and in vivo therapeutic study.
Uterine Cervical Neoplasms
Synergistic interaction between tetra-arsenic oxide and paclitaxel in human cancer cells in vitro.
Uterine Cervical Neoplasms
Targeted delivery of a novel anticancer compound anisomelic acid using chitosan-coated porous silica nanorods for enhancing the apoptotic effect.
Uterine Cervical Neoplasms
Targeting cervical cancer: Is there a role for poly (ADP-ribose) polymerase inhibition?
Uterine Cervical Neoplasms
The Anti-Proliferative Activity of the Hybrid TMS-TMF-4f Compound Against Human Cervical Cancer Involves Apoptosis Mediated by STAT3 Inactivation.
Uterine Cervical Neoplasms
The poly (ADP-ribose) polymerase inhibitor rucaparib suppresses proliferation and serves as an effective radiosensitizer in cervical cancer.
Uterine Cervical Neoplasms
The Role of PARP Inhibitors in the Treatment of Gynecologic Malignancies.
Uterine Cervical Neoplasms
Triptolide inactivates Akt and induces caspase-dependent death in cervical cancer cells via the mitochondrial pathway.
Uterine Cervical Neoplasms
Up-regulated lncRNA XIST contributes to progression of cervical cancer via regulating miR-140-5p and ORC1.
Uveitis
Clinical Effect of IRT-5 Probiotics on Immune Modulation of Autoimmunity or Alloimmunity in the Eye.
Uveitis
Mycophenolate mofetil and cyclophosphamide treatments suppress inflammation intensity in an experimental model of autoimmune uveitis.
Uveitis
Paradoxical effect of pertussis toxin on the delayed hypersensitivity response to autoantigens in mice.
Uveitis
Pertussis toxin inhibits induction of tissue-specific autoimmune disease by disrupting G protein-coupled signals.
Uveitis
Structure and function of poly(ADP-ribose) polymerase-1: role in oxidative stress-related pathologies.
Uveitis
The critical points in induction of experimental autoimmune uveitis.
Uveitis, Anterior
Experimental autoimmune anterior uveitis (EAAU). II. Dose-dependent induction and adoptive transfer using a melanin-bound antigen of the retinal pigment epithelium.
Vaccinia
Galectin-3 is an amplifier of inflammation in atherosclerotic plaque progression through macrophage activation and monocyte chemoattraction.
Vaccinia
Molluscum contagiosum virus inhibitors of apoptosis: The MC159 v-FLIP protein blocks Fas-induced activation of procaspases and degradation of the related MC160 protein.
Vaccinia
PARP-1 controls NK cell recruitment to the site of viral infection.
Vaccinia
Vaccinia virus encodes a previously uncharacterized mitochondrial-associated inhibitor of apoptosis.
Varicocele
Effects of varicocele upon the expression of apoptosis-related proteins.
Varicocele
Inhibition of poly(ADP-ribose) polymerase may have preventive potential for varicocoele-associated testicular damage in rats.
Varicocele
Potential Role of Poly(ADP-Ribose) Polymerase Activation in the Pathogenesis of Experimental Left Varicocele.
Varicose Veins
Expression of molecular mediators of apoptosis and their role in the pathogenesis of lower-extremity varicose veins.
Vascular Calcification
Poly(ADP-ribose) polymerase 1 accelerates vascular calcification by upregulating Runx2.
Vascular Diseases
Effect and mechanism of poly (ADP-ribose) polymerase-1 in aldosterone-induced apoptosis.
Vascular Diseases
Hemorheological methods in drug research.
Vascular Diseases
PARP-1 (Poly[ADP-Ribose] Polymerase 1) Inhibition Protects From Ang II (Angiotensin II)-Induced Abdominal Aortic Aneurysm in Mice.
Vascular Diseases
The neuroprotective effect of cerebral poly(ADP-ribose)polymerase inhibition in a rat model of global ischemia.
Vascular Ring
Enhanced G-protein-induced relaxation in portal hypertensive rats: role of nitric oxide.
Vascular System Injuries
Diabetic endothelial dysfunction: role of reactive oxygen and nitrogen species production and poly(ADP-ribose) polymerase activation.
Vascular System Injuries
Poly(ADP-ribose) polymerase inhibitor PJ-34 reduces mesenteric vascular injury induced by experimental cardiopulmonary bypass with cardiac arrest.
Vasospasm, Intracranial
Inhibition of poly(ADP-ribose) polymerase attenuates cerebral vasospasm after subarachnoid hemorrhage in rabbits.
Vasospasm, Intracranial
Potential role of poly (ADP-ribose) polymerase in delayed cerebral vasospasm following subarachnoid hemorrhage in rats.
Ventilator-Induced Lung Injury
Inflammatory and transcriptional roles of poly (ADP-ribose) polymerase in ventilator-induced lung injury.
Ventilator-Induced Lung Injury
The role of poly (ADP-ribose) polymerase in ventilator-induced lung injury.
Ventricular Premature Complexes
Mechanism of epinephrine-induced dysrhythmias in rat involves local cholinergic activation.
Vesicular Stomatitis
ADP-ribosyltransferase PARP11 modulates the interferon antiviral response by mono-ADP-ribosylating the ubiquitin E3 ligase ?-TrCP.
Vesicular Stomatitis
DNA damage sensors ATM, ATR, DNA-PKcs, and PARP-1 are dispensable for human immunodeficiency virus type 1 integration.
Vesicular Stomatitis
Poly(ADP-ribose) polymerase 1 is not strictly required for infection of murine cells by retroviruses.
Virus Diseases
ADP-ribosyltransferase PARP11 modulates the interferon antiviral response by mono-ADP-ribosylating the ubiquitin E3 ligase ?-TrCP.
Virus Diseases
ARTC2.2/P2RX7 Signaling during Cell Isolation Distorts Function and Quantification of Tissue-Resident CD8+ T Cell and Invariant NKT Subsets.
Virus Diseases
Caspase-mediated cleavage of adenovirus early region 1A proteins.
Virus Diseases
Flavivirus activates phosphatidylinositol 3-kinase signaling to block caspase-dependent apoptotic cell death at the early stage of virus infection.
Virus Diseases
Induction of apoptosis and cleavage of poly(ADP-ribose) polymerase by cytopathic bovine viral diarrhea virus infection.
Virus Diseases
Inhibition of PARP1 Dampens Pseudorabies Virus Infection through DNA Damage-Induced Antiviral Innate Immunity.
Virus Diseases
NAD+ Degrading Enzymes, Evidence for Roles During Infection.
Virus Diseases
NuMA and nuclear lamins are cleaved during viral infection--inhibition of caspase activity prevents cleavage and rescues HeLa cells from measles virus-induced but not from rhinovirus 1B-induced cell death.
Virus Diseases
PARP-1 controls NK cell recruitment to the site of viral infection.
Virus Diseases
PARP-1 mediated cell death is directly activated by ZIKV infection.
Virus Diseases
PARPs and ADP-ribosylation in RNA biology: from RNA expression and processing to protein translation and proteostasis.
Virus Diseases
Pertussis toxin sensitization alters the pathogenesis of subsequent respiratory syncytial virus infection.
Virus Diseases
Poly(ADP-ribose) polymerase activity in various U937 cell subclones with different susceptibility to HIV-1 infection: its dramatic decrease following persistent virus infection.
Virus Diseases
Poly(ADP-ribose) polymerase inhibitors: new pharmacological functions and potential clinical implications.
Virus Diseases
Poly(ADP-ribose) polymerase-1 is required for efficient HIV-1 integration.
Virus Diseases
Rapid activation of poly(ADP-ribose) polymerase contributes to Sindbis virus and staurosporine-induced apoptotic cell death.
Virus Diseases
Reovirus transport--studies using lymphocytosis promoting factor.
Virus Diseases
Role of Poly(ADP-ribose) Polymerase (PARP1) in Viral Infection and its Implication in SARS-CoV-2 Pathogenesis.
Virus Diseases
SARS-CoV-2: Understanding the Transcriptional Regulation of ACE2 and TMPRSS2 and the Role of Single Nucleotide Polymorphism (SNP) at Codon 72 of p53 in the Innate Immune Response against Virus Infection.
Virus Diseases
The potential association between PARP14 and SARS-CoV-2 infection (COVID-19).
Virus Diseases
Topological DNA damage, telomere attrition and T cell senescence during chronic viral infections.
Wasting Syndrome
Hepatocyte-Specific Deletion of TIPARP, a Negative Regulator of the Aryl Hydrocarbon Receptor, Is Sufficient to Increase Sensitivity to Dioxin-Induced Wasting Syndrome.
Werner Syndrome
Ageing and PARP.
Werner Syndrome
Genetic cooperation between the Werner syndrome protein and poly(ADP-ribose) polymerase-1 in preventing chromatid breaks, complex chromosomal rearrangements, and cancer in mice.
Werner Syndrome
Identification and biochemical characterization of a Werner's syndrome protein complex with Ku70/80 and poly(ADP-ribose) polymerase-1.
Werner Syndrome
Identification of proteins in the hamster DNA end-binding complex.
Werner Syndrome
In vivo misregulation of genes involved in apoptosis, development and oxidative stress in mice lacking both functional Werner syndrome protein and poly(ADP-ribose) polymerase-1.
Werner Syndrome
Increased frequency of multiradial chromosome structures in mouse embryonic fibroblasts lacking functional Werner syndrome protein and poly(ADP-ribose) polymerase-1.
Werner Syndrome
Poly(ADP-ribose) polymerase 1 regulates both the exonuclease and helicase activities of the Werner syndrome protein.
Werner Syndrome
Poly(ADP-ribosyl)ation, PARP, and aging.
Werner Syndrome
Repair of telomeric DNA prior to replicative senescence.
Werner Syndrome
The emerging role of poly(ADP-ribose) polymerase-1 in longevity.
Whooping Cough
"Antigonadal" activity of the neurohypophysial hormones in cultured rat testicular cells: abolition by pertussis toxin.
Whooping Cough
"Cleaved Lymphocytes" Could Be Induced by Pertussis Toxin Injection in Mice, and Are Actually Not Lymphocytes.
Whooping Cough
"Pertussis toxin induces tachycardia and impairs the increase in blood pressure produced by alpha 2-adrenergic agonists".
Whooping Cough
'Cross talk' between opioid peptide and adrenergic receptor signaling in isolated rat heart.
Whooping Cough
(1S,3R)-1-aminocyclopentane-1,3-dicarboxylic acid attenuates N-methyl-D-aspartate-induced neuronal cell death in cortical cultures via a reduction in delayed Ca2+ accumulation.
Whooping Cough
(1S,3R)-1-aminocyclopentane-1,3-dicarboxylic acid-induced burst firing is mediated by a native pertussis toxin-sensitive metabotropic receptor at rat dorsolateral septal nucleus neurons.
Whooping Cough
(R)-methanandamide inhibits receptor-induced calcium responses by depleting internal calcium stores in cultured astrocytes.
Whooping Cough
-Myocardial protection by preconditioning. Experimental and clinical significance-.
Whooping Cough
1 alpha,25-dihydroxyvitamin D3-induced increments in hepatocyte cytosolic calcium and lysophosphatidylinositol: inhibition by pertussis toxin and 1 beta,25-dihydroxyvitamin D3.
Whooping Cough
1,25(OH)2-vitamin D-3 stimulates phospholipase A2 activity via a guanine nucleotide-binding protein in chick myoblasts.
Whooping Cough
1,25(OH)2-vitamin D3 stimulation of phospholipases C and D in muscle cells involves extracellular calcium and a pertussis-sensitive G protein.
Whooping Cough
1,25(OH)2D3 regulates protein kinase C activity through two phospholipid-dependent pathways involving phospholipase A2 and phospholipase C in growth zone chondrocytes.
Whooping Cough
1,25-dihydroxyvitamin D3 but not TPA activates PLD in Caco-2 cells via pp60(c-src) and RhoA.
Whooping Cough
1,25-dihydroxyvitamin D3 induces responsiveness to the chemotactic peptide f-Met-Leu-Phe in the human monocytic line U937: dissociation between calcium and oxidative metabolic responses.
Whooping Cough
1-Fluoro-2,4-dinitrobenzene and its derivatives act as secretagogues on rodent mast cells.
Whooping Cough
11-Dehydro-thromboxane B2, a stable thromboxane metabolite, is a full agonist of chemoattractant receptor-homologous molecule expressed on TH2 cells (CRTH2) in human eosinophils and basophils.
Whooping Cough
12(S)-hydroxyeicosatetraenoic acid and 13(S)-hydroxyoctadecadienoic acid regulation of protein kinase C-alpha in melanoma cells: role of receptor-mediated hydrolysis of inositol phospholipids.
Whooping Cough
15-Hydroxyeicosatetraenoic acid (15-HETE) receptors. Involvement in the 15-HETE-induced stimulation of the cryptic 5-lipoxygenase in PT-18 mast/basophil cells.
Whooping Cough
17?-estradiol potentiates TREK1 channel activity through G protein-coupled estrogen receptor.
Whooping Cough
17Beta-estradiol inhibits high-voltage-activated calcium channel currents in rat sensory neurons via a non-genomic mechanism.
Whooping Cough
17beta-estradiol-mediated neuroprotection and ERK activation require a pertussis toxin-sensitive mechanism involving GRK2 and beta-arrestin-1.
Whooping Cough
1?,25-dihydroxyvitamin D3 and resolvin D1 retune the balance between amyloid-? phagocytosis and inflammation in Alzheimer's disease patients.
Whooping Cough
1alpha,25(OH)2D3 causes a rapid increase in phosphatidylinositol-specific PLC-beta activity via phospholipase A2-dependent production of lysophospholipid.
Whooping Cough
2-Arachidonoylglycerol enhances the phagocytosis of opsonized zymosan by HL-60 cells differentiated into macrophage-like cells.
Whooping Cough
2-arachidonoylglycerol induces the migration of HL-60 cells differentiated into macrophage-like cells and human peripheral blood monocytes through the cannabinoid CB2 receptor-dependent mechanism.
Whooping Cough
2-arachidonoylglycerol, an endogenous cannabinoid receptor ligand, induces rapid actin polymerization in HL-60 cells differentiated into macrophage-like cells.
Whooping Cough
2-arachidonoylglycerol, an endogenous cannabinoid receptor ligand, induces the migration of EoL-1 human eosinophilic leukemia cells and human peripheral blood eosinophils.
Whooping Cough
2-Arachidonylglyceryl ether and abnormal cannabidiol-induced vascular smooth muscle relaxation in rabbit pulmonary arteries via receptor-pertussis toxin sensitive G proteins-ERK1/2 signaling.
Whooping Cough
2-Azido-[32P]NAD+, a photoactivatable probe for G-protein structure: evidence for holotransducin oligomers in which the ADP-ribosylated carboxyl terminus of alpha interacts with both alpha and gamma subunits.
Whooping Cough
2-Chloroadenosine potentiates the alpha 1-adrenergic activation of phospholipase C through a mechanism involving arachidonic acid and glutamate in striatal astrocytes.
Whooping Cough
2-Chloroadenosine reduces the N calcium current of cultured mouse sensory neurones in a pertussis toxin-sensitive manner.
Whooping Cough
2-chloroadenosine stimulates granule exocytosis from mouse natural killer cells: evidence for signal transduction through a novel extracellular receptor.
Whooping Cough
2-methoxyestradiol binding of GPR30 down-regulates angiotensin AT(1) receptor.
Whooping Cough
24,25-(OH)2D3 regulates protein kinase C through two distinct phospholipid-dependent mechanisms.
Whooping Cough
27-hydroxycholesterol induces production of tumor necrosis factor-alpha from macrophages.
Whooping Cough
2[125I]Iodomelatonin binding and interaction with beta-adrenergic signaling in chick heart/coronary artery physiology.
Whooping Cough
3-Isobutyl-1-methylxanthine inhibits sustained calcium current independently of cyclic AMP in neuronal and endocrine cells.
Whooping Cough
3-Morpholinylsydnonimine inhibits glutamatergic transmission in rat rostral ventrolateral medulla via peroxynitrite formation and adenosine release.
Whooping Cough
36Cl- flux measurements on GABAA receptor-activated chloride exchange. Multiple mechanisms of the chloride channel inactivation.
Whooping Cough
3H-naloxone benzoylhydrazone binding in MOR-1-transfected Chinese hamster ovary cells: evidence for G-protein-dependent antagonist binding.
Whooping Cough
5'-AMP-activated protein kinase is inactivated by adrenergic signalling in adult cardiac myocytes.
Whooping Cough
5(S)-Hydroxy-6,8,11,14-E,Z,Z,Z-eicosatetraenoate stimulates PC3 cell signaling and growth by a receptor-dependent mechanism.
Whooping Cough
5-Aminosalicylate stimulates phospholipase D activity in macrophages.
Whooping Cough
5-HT inhibits N-type but not L-type Ca(2+) channels via 5-HT1A receptors in lamprey spinal neurons.
Whooping Cough
5-HT potentiation of the GABA(A) response in the rat sacral dorsal commissural neurones.
Whooping Cough
5-HT receptors couple to activation of Akt, but not extracellular-regulated kinase (ERK), in cultured hippocampal neurons.
Whooping Cough
5-HT(7) receptors activate the mitogen activated protein kinase extracellular signal related kinase in cultured rat hippocampal neurons.
Whooping Cough
5-HT1A agonists induce central cholinergic antinociception.
Whooping Cough
5-HT1A and histamine H1 receptors in HeLa cells stimulate phosphoinositide hydrolysis and phosphate uptake via distinct G protein pools.
Whooping Cough
5-HT1A receptor activates Na+/H+ exchange in CHO-K1 cells through Gialpha2 and Gialpha3.
Whooping Cough
5-HT1A receptor-mediated activation of G-protein-gated inwardly rectifying K+ current in rat periaqueductal gray neurons.
Whooping Cough
5-HT1A receptor-mediated inhibition of acetylcholine release from guinea pig myenteric plexus: potential mechanisms.
Whooping Cough
5-HT1B receptor agonist CGS12066 presynaptically inhibits glutamate release in rat hippocampus.
Whooping Cough
5-HT1B Receptor-Mediated Activation of ERK1/2 Requires Both G?i/o and ?-Arrestin Proteins.
Whooping Cough
5-hydroxyicosatetraenoate stimulates neutrophils by a stereospecific, G protein-linked mechanism.
Whooping Cough
5-Hydroxytryptamine 1B receptors mediate presynaptic inhibition of monosynaptic IPSC in the rat dorsolateral septal nucleus.
Whooping Cough
5-Hydroxytryptamine 5-HT1D receptors mediating inhibition of cyclic AMP accumulation in Madin-Darby canine kidney (MDCK) cells.
Whooping Cough
5-hydroxytryptamine evokes endothelial nitric oxide synthase activation in bovine aortic endothelial cell cultures.
Whooping Cough
5-hydroxytryptamine induces mast cell adhesion and migration.
Whooping Cough
5-Hydroxytryptamine induces phospholipase C-mediated hydrolysis of phosphoinositides through 5-hydroxytryptamine-2 receptors in cultured fetal mouse ventricular myocytes.
Whooping Cough
5-Hydroxytryptamine receptor-mediated phosphoinositide hydrolysis in canine cultured tracheal smooth muscle cells.
Whooping Cough
5-Hydroxytryptamine-induced phosphoinositide hydrolysis and Ca2+ mobilisation in canine cultured aorta smooth muscle cells.
Whooping Cough
5-Hydroxytryptamine1-like receptors linked to increases in intracellular calcium concentration and inhibition of cyclic AMP accumulation in cultured vascular smooth muscle cells derived from bovine basilar artery.
Whooping Cough
5-Hydroxytryptamine1A receptor synthetic peptides. Mechanisms of adenylyl cyclase inhibition.
Whooping Cough
5-hydroxytryptamine1A receptor-mediated increases in receptor expression and activation of nuclear factor-kappaB in transfected Chinese hamster ovary cells.
Whooping Cough
5-Hydroxytryptamine1A receptors are linked to a Gi-adenylate cyclase complex in rat hippocampus.
Whooping Cough
5-Hydroxytryptamine2A receptors expressed in rat renal mesangial cells inhibit cyclic AMP accumulation.
Whooping Cough
5-Methoxytryptamine inhibits cyclic AMP accumulation in cultured retinal neurons through activation of a pertussis toxin-sensitive site distinct from the 2-[125I]iodomelatonin binding site.
Whooping Cough
5-Oxo-eicosanoids and hematopoietic cytokines cooperate in stimulating neutrophil function and the mitogen-activated protein kinase pathway.
Whooping Cough
5-Oxo-Eicosatetraenoic Acid-Induced Chemotaxis: Identification of a Responsible Receptor hGPCR48 and Negative Regulation by G Protein G12/13.
Whooping Cough
5-Oxo-ETE from Nasal Epithelial Cells Upregulates Eosinophil Cation Protein by Eosinophils in Nasal Polyps in vitro.
Whooping Cough
8-Iso-PGF2 alpha induces beta 2-integrin-mediated rapid adhesion of human polymorphonuclear neutrophils: a link between oxidative stress and ischemia/reperfusion injury.
Whooping Cough
?(2) -Adrenoceptors activate noradrenaline-mediated glycogen turnover in chick astrocytes.
Whooping Cough
?(2)-Adrenergic and M(2)-muscarinic receptors decrease basal t-tubular L-type Ca2+ channel activity and suppress ventricular contractility in heart failure.
Whooping Cough
?-1 Receptor Inhibition of ASIC1a Channels is Dependent on a Pertussis Toxin-Sensitive G-Protein and an AKAP150/Calcineurin Complex.
Whooping Cough
?-Arrestin Recruitment and G Protein Signaling by the Atypical Human Chemokine Decoy Receptor CCX-CKR.
Whooping Cough
?-Defensins activate human mast cells via Mas-related gene X2.
Whooping Cough
?-hydroxybutyrate and hydroxycarboxylic acid receptor 2 agonists activate the AKT, ERK and AMPK pathways, which are involved in bovine neutrophil chemotaxis.
Whooping Cough
?-Hydroxybutyric Acid Inhibits Growth Hormone-Releasing Hormone Synthesis and Secretion Through the GPR109A/Extracellular Signal-Regulated 1/2 Signalling Pathway in the Hypothalamus.
Whooping Cough
?-Hydroxybutyric Sodium Salt Inhibition of Growth Hormone and Prolactin Secretion via the cAMP/PKA/CREB and AMPK Signaling Pathways in Dairy Cow Anterior Pituitary Cells.
Whooping Cough
?-opioid receptor activation leads to neurite outgrowth and neuronal differentiation via a STAT5B-G?i/o pathway.
Whooping Cough
?-Opioid receptors stimulate the metabolic sensor AMP-activated protein kinase through coincident signaling with G(q/11)-coupled receptors.
Whooping Cough
?-Tetrahydrocannabinol induces cytotoxicity in macrophage J774-1 cells: involvement of cannabinoid receptor 2 and p38 MAPK.
Whooping Cough
?2-Adrenergic Disruption of ? Cell BDNF-TrkB Receptor Tyrosine Kinase Signaling.
Whooping Cough
?2-adrenergic receptor-coupled phosphoinositide 3-kinase constrains cAMP-dependent increases in cardiac inotropy through phosphodiesterase 4 activation.
Whooping Cough
?2-adrenoceptor agonists can both stimulate and inhibit glucose uptake in mouse soleus muscle through ligand-directed signalling.
Whooping Cough
A 23-kilodalton protein, distinct from BvgA, expressed by virulent Bordetella pertussis binds to the promoter region of vir-regulated toxin genes.
Whooping Cough
A 43 kDa form of the GTP-binding protein Gi3 in human erythrocytes.
Whooping Cough
A 5-HT1-like receptor mediates a pertussis toxin-sensitive inhibition of rat ventromedial hypothalamic neurones in vitro.
Whooping Cough
A Belgian Serosurveillance/Seroprevalence Study of Diphtheria, Tetanus and Pertussis Using a Luminex xMAP Technology-Based Pentaplex.
Whooping Cough
A biased non-G?i OXE-R antagonist demonstrates that G?i protein subunit is not directly involved in neutrophil, eosinophil, and monocyte activation by 5-oxo-ETE.
Whooping Cough
A binding motif for Hsp90 in the A chains of ADP-ribosylating toxins that move from the endoplasmic reticulum to the cytosol.
Whooping Cough
A bioluminescent assay for agonist activity at potentially any G-protein-coupled receptor.
Whooping Cough
A Bivalent Recombinant Mycobacterium bovis BCG Expressing the S1 Subunit of the Pertussis Toxin Induces a Polyfunctional CD4+ T Cell Immune Response.
Whooping Cough
A boarding school outbreak of pertussis in adolescents: value of laboratory diagnostic methods.
Whooping Cough
A Bordetella pertussis acellular vaccine candidate: antigenic characterization and antibody induction.
Whooping Cough
A C-terminally truncated human parathyroid hormone receptor is functional and activates multiple G proteins.
Whooping Cough
A cAMP independent inhibitory action of high doses of forskolin in rat Leydig cells.
Whooping Cough
A cathelicidin family of human antibacterial peptide LL-37 induces mast cell chemotaxis.
Whooping Cough
A chemoattractant-mediated Gi-coupled pathway activates adenylyl cyclase in human neutrophils.
Whooping Cough
A cholera toxin-sensitive G-protein stimulates exocytosis in sea urchin eggs.
Whooping Cough
A cholera toxin-sensitive guanyl nucleotide binding protein mediates the movement of pituitary luteinizing hormone into a releasable pool: loss of this event is associated with the onset of homologous desensitization to gonadotropin-releasing hormone.
Whooping Cough
A clonal rat pancreatic delta cell line (Rin14B) expresses a high number of galanin receptors negatively coupled to a pertussis-toxin-sensitive cAMP-production pathway.
Whooping Cough
A cluster of aromatic amino acids in the i2 loop plays a key role for Gs coupling in prostaglandin EP2 and EP3 receptors.
Whooping Cough
A cocktail of humanized anti-pertussis toxin antibodies limits disease in murine and baboon models of whooping cough.
Whooping Cough
A comparative analysis of B cell-mediated myelin oligodendrocyte glycoprotein-experimental autoimmune encephalomyelitis pathogenesis in B cell-deficient mice reveals an effect on demyelination.
Whooping Cough
A comparative study of endothelin- and platelet-activating-factor-mediated signal transduction and prostaglandin synthesis in rat Kupffer cells.
Whooping Cough
A comparative study of the role of adenylate cyclase in the release of adrenocorticotropin from the ovine and rat anterior pituitary.
Whooping Cough
A comparative trial of the reactogenicity and immunogenicity of Takeda acellular pertussis vaccine combined with tetanus and diphtheria toxoids. Outcome in 3- to 8-month-old infants, 9- to 23-month-old infants and children, and 24- to 30-month-old children.
Whooping Cough
A comparison of bradykinin, angiotensin II and muscarinic stimulation of cultured bovine adrenal chromaffin cells.
Whooping Cough
A comparison of EDHF-mediated and anandamide-induced relaxations in the rat isolated mesenteric artery.
Whooping Cough
A comparison of post-receptor signal transduction events in Jurkat cells transfected with either IL-8R1 or IL-8R2. Chemokine mediated activation of p42/p44 MAP-kinase (ERK-2).
Whooping Cough
A comparison of the ability of Leu8- and Pro8-oxytocin to regulate intracellular Ca2+ and Ca2+-activated K+ channels at human and marmoset oxytocin receptors.
Whooping Cough
A comparison of the antagonist affinities for the Gi- and Gs-coupled states of the human adenosine A1-receptor.
Whooping Cough
A comparison of the effects of concanavalin-A and tetradecanoylphorbol acetate on the modulation of parathyroid function by extracellular calcium and neomycin in dispersed bovine parathyroid cells.
Whooping Cough
A comparison of the effects of divalent and trivalent cations on parathyroid hormone release, 3',5'-cyclic-adenosine monophosphate accumulation, and the levels of inositol phosphates in bovine parathyroid cells.
Whooping Cough
A comparison of the effects of signal transduction inhibitors on oxidative burst and degranulation in IL-I beta stimulated bovine neutrophils.
Whooping Cough
A continuous, fluorescence-based assay of ?-opioid receptor activation in AtT-20 cells.
Whooping Cough
A controlled study of the relationship between Bordetella pertussis infections and sudden unexpected deaths among German infants.
Whooping Cough
A controlled trial of two acellular vaccines and one whole-cell vaccine against pertussis. Progetto Pertosse Working Group.
Whooping Cough
A CpG-containing oligodeoxynucleotide as an efficient adjuvant counterbalancing the Th1/Th2 immune response in diphtheria-tetanus-pertussis vaccine.
Whooping Cough
A cross sectional survey measuring sero-incidence of pertussis infection among Japanese junior and senior high school students in 2013 and 2014.
Whooping Cough
A cross-sectional study of Bordetella pertussis seroprevalence and estimated duration of vaccine protection against pertussis in St. Petersburg, Russia.
Whooping Cough
A cysteine-3 to serine mutation of the G-protein Gi1 alpha abrogates functional activation by the alpha 2A-adrenoceptor but not interactions with the beta gamma complex.
Whooping Cough
A defect late in stimulus-secretion coupling impairs insulin secretion in Goto-Kakizaki diabetic rats.
Whooping Cough
A deletion mutation in the third cytoplasmic loop of the mouse m1 muscarinic acetylcholine receptor unmasks cryptic G-protein binding sites.
Whooping Cough
A developmental role for the heterotrimeric G protein Go alpha in a migratory population of embryonic neurons.
Whooping Cough
A developmentally regulated switch in neuronal responsiveness to NCAM and N-cadherin in the rat hippocampus.
Whooping Cough
A diet enriched with cocoa prevents IgE synthesis in a rat allergy model.
Whooping Cough
A direct inhibitory action of prostaglandins upon ACTH secretion at the late stages of the secretory pathway of AtT-20 cells.
Whooping Cough
A direct interaction between G-protein beta gamma subunits and the Raf-1 protein kinase.
Whooping Cough
A distinct G(i) protein-coupled receptor for sphingosylphosphorylcholine in human leukemia HL-60 cells and human neutrophils.
Whooping Cough
A dopaminergic inhibitory postsynaptic potential mediated by an increased potassium conductance.
Whooping Cough
A dose-response study of forskolin, stimulatory hormone, and guanosine triphosphate analog on adenylate cyclase from several sources.
Whooping Cough
A DPDPE-induced enhancement of inward rectifier potassium current via opioid receptor in neuroblastomaxglioma NG108-15 cells.
Whooping Cough
A Drosophila melanogaster G protein alpha subunit gene is expressed primarily in embryos and pupae.
Whooping Cough
A dual role of protein kinase C in insulin signal transduction via adenylyl cyclase signaling system in muscle tissues of vertebrates and invertebrates.
Whooping Cough
A farnesylated G-protein suppresses Akt phosphorylation in INS 832/13 cells and normal rat islets: Regulation by pertussis toxin and PGE(2).
Whooping Cough
A fully liquid DTaP-IPV-Hep B-PRP-T hexavalent vaccine for primary and booster vaccination of healthy Mexican children.
Whooping Cough
A Functional and Neuropathological Testing Paradigm Reveals New Disability-Based Parameters and Histological Features for P0180-190-Induced Experimental Autoimmune Neuritis in C57BL/6 Mice.
Whooping Cough
A functional assay to measure postsynaptic gamma-aminobutyric acidB responses in cultured spinal cord neurons: heterologous regulation of the same K+ channel.
Whooping Cough
A functional C5a anaphylatoxin receptor in a teleost species.
Whooping Cough
A G protein beta gamma dimer-mediated pathway contributes to mitogen-activated protein kinase activation by thyrotropin-releasing hormone receptors in transfected COS-7 cells.
Whooping Cough
A G protein couples serotonin and GABAB receptors to the same channels in hippocampus.
Whooping Cough
A G Protein Mediates the Inhibition of the Voltage-Dependent Potassium M Current by Muscarine, LHRH, Substance P and UTP in Bullfrog Sympathetic Neurons.
Whooping Cough
A G protein-associated ERK pathway is involved in LPS-induced proliferation and a PTK-associated p38 MAPK pathway is involved in LPS-induced differentiation in resting B cells.
Whooping Cough
A G protein-coupled ?7 nicotinic receptor regulates signaling and TNF-? release in microglia.
Whooping Cough
A Galphas protein-coupled membrane receptor, distinct from the classical oestrogen receptor, transduces rapid effects of oestradiol on [Ca2+]i in female rat distal colon.
Whooping Cough
A General Lack of IgG Against Pertussis Toxin in Chinese Pregnant Women and Newborns.
Whooping Cough
A genetically inactivated two-component acellular pertussis vaccine, alone or combined with tetanus and reduced-dose diphtheria vaccines, in adolescents: a phase 2/3, randomised controlled non-inferiority trial.
Whooping Cough
A Go-like protein in Drosophila melanogaster and its expression in memory mutants.
Whooping Cough
A Gq-type G protein couples muscarinic receptors to inositol phosphate and calcium signaling in exocrine cells from the avian salt gland.
Whooping Cough
A GTP-binding protein activates chloride channels in a renal epithelium.
Whooping Cough
A GTP-binding protein in rat liver nuclei serving as the specific substrate of pertussis toxin-catalyzed ADP-ribosylation.
Whooping Cough
A guanine nucleotide regulatory protein controls polyphosphoinositide metabolism, Ca2+ mobilization, and cellular responses to chemoattractants in human monocytes.
Whooping Cough
A guanine nucleotide-binding protein mediates 1,25-dihydroxy-vitamin D-3-dependent rapid stimulation of Ca2+ uptake in skeletal muscle.
Whooping Cough
A guanine nucleotide-binding protein mediates the inhibition of voltage-dependent calcium current by somatostatin in a pituitary cell line.
Whooping Cough
A guanine nucleotide-binding protein mediates the inhibition of voltage-dependent calcium currents by dopamine in rat lactotrophs.
Whooping Cough
A guanine nucleotide-binding regulatory protein in human sperm mediates acrosomal exocytosis induced by the human zona pellucida.
Whooping Cough
A heterotrimeric G protein of the Gi family is required for cAMP-triggered trafficking of aquaporin 2 in kidney epithelial cells.
Whooping Cough
A heterotrimeric G protein, G alpha i-3, on Golgi membranes regulates the secretion of a heparan sulfate proteoglycan in LLC-PK1 epithelial cells.
Whooping Cough
A heterotrimeric G protein-phospholipase A2 signaling cascade is involved in the regulation of peroxisomal motility in CHO cells.
Whooping Cough
A heterotrimeric Gi3-protein controls autophagic sequestration in the human colon cancer cell line HT-29.
Whooping Cough
A high seroprevalence of antibodies to pertussis toxin among Japanese adults: Qualitative and quantitative analyses.
Whooping Cough
A high-affinity bradykinin receptor in membranes from rat myometrium is coupled to pertussis toxin-sensitive G-proteins of the Gi family.
Whooping Cough
A humanized model for multiple sclerosis using HLA-DR2 and a human T-cell receptor.
Whooping Cough
A knockout mutation of a constitutive GPCR in Tetrahymena decreases both G-protein activity and chemoattraction.
Whooping Cough
A label-free impedance-based whole cell assay revealed a new G protein-coupled receptor ligand for mouse microglial cell migration.
Whooping Cough
A leading role for NADPH oxidase in an in-vitro study of experimental autoimmune encephalomyelitis.
Whooping Cough
A lysophosphatidic acid receptor lacking the PDZ-binding domain is constitutively active and stimulates cell proliferation.
Whooping Cough
A mastoparan analog without lytic effects and its stimulatory mechanisms in mast cells.
Whooping Cough
A mechanism additional to cyclic AMP accumulation for vasoactive intestinal peptide-induced prolactin release.
Whooping Cough
A mechanism of action for anaphylatoxin C3a stimulation of mast cells.
Whooping Cough
A mechanistic approach into a diabetic serum factor-mediated release of beta-glucuronidase in normal neutrophils.
Whooping Cough
A membrane-delimited pathway of G-protein regulation of the guard-cell inward K+ channel.
Whooping Cough
A metabotropic L-glutamate receptor agonist: pharmacological difference between rat central neurones and crayfish neuromuscular junctions.
Whooping Cough
A model for the interaction of muscarinic receptors, agonists, and two distinct effector substances.
Whooping Cough
A modified vaccine reduces the rate of large injection site reactions to the preschool booster dose of diphtheria-tetanus-acellular pertussis vaccine: results of a randomized, controlled trial.
Whooping Cough
A molecularly identified P2Y receptor simultaneously activates phospholipase C and inhibits adenylyl cyclase and is nonselectively activated by all nucleoside triphosphates.
Whooping Cough
A monoclonal anti-idiotypic antibody to opioid receptors labels desipramine-induced opioid binding sites on rat C6 glioma cells and attenuates thymidine incorporation into DNA.
Whooping Cough
A mutant pertussis toxin molecule that lacks ADP-ribosyltransferase activity, PT-9K/129G, is an effective mucosal adjuvant for intranasally delivered proteins.
Whooping Cough
A nasal whole-cell pertussis vaccine induces specific systemic and cross-reactive mucosal antibody responses in human volunteers.
Whooping Cough
A neuroactive steroid inhibits guinea pig airway sensory nerves via Maxi-K channel activation.
Whooping Cough
A neutrophil GTP-binding protein that regulates cell free NADPH oxidase activation is located in the cytosolic fraction.
Whooping Cough
A new assay for invasion of HeLa 229 cells by Bordetella pertussis: effects of inhibitors, phenotypic modulation, and genetic alterations.
Whooping Cough
A new EAE model of brain demyelination induced by intracerebroventricular pertussis toxin.
Whooping Cough
A New Electrochemiluminescence-Based Multiplex Assay for the Assessment of Human Antibody Responses to Bordetella pertussis Vaccines.
Whooping Cough
A New Generation of FRET Sensors for Robust Measurement of G?i1, G?i2 and G?i3 Activation Kinetics in Single Cells.
Whooping Cough
A new GTP-binding protein in brain tissues serving as the specific substrate of islet-activating protein, pertussis toxin.
Whooping Cough
A new GTP-binding protein in differentiated human leukemic (HL-60) cells serving as the specific substrate of islet-activating protein, pertussis toxin.
Whooping Cough
A new lipophilic amino alcohol, chemically similar to compound FTY720, attenuates the pathogenesis of experimental autoimmune encephalomyelitis by PI3K/Akt pathway inhibition.
Whooping Cough
A new potassium ion current induced by stimulation of M2-cholinoreceptors in fish atrial myocytes.
Whooping Cough
A newly identified peptide, proadrenomedullin N-terminal 20 peptide, induces hypotensive action via pertussis toxin-sensitive mechanisms.
Whooping Cough
A newly synthesized molecule derived from ruthenium cation, with antitumour activity, activates NADPH oxidase in human neutrophils.
Whooping Cough
A non-inactivating K+ current sensitive to muscarinic receptor activation in rat cultured cerebellar granule neurons.
Whooping Cough
A novel action of collapsin: collapsin-1 increases antero- and retrograde axoplasmic transport independently of growth cone collapse.
Whooping Cough
A novel action of palmitoyl-L-carnitine in human vascular endothelial cells.
Whooping Cough
A novel approach to detect toxin-catalyzed ADP-ribosylation in intact cells: its use to study the action of Pasteurella multocida toxin.
Whooping Cough
A novel biologic function of serum amyloid A. Induction of T lymphocyte migration and adhesion.
Whooping Cough
A novel bivalent acellular pertussis vaccine based on the 69 kDa protein and FHA.
Whooping Cough
A novel calcium signalling response in the breast cancer cell line MDA-468.
Whooping Cough
A Novel Carbamoyloxy Arylalkanoyl Arylpiperazine Compound (SKL-NP) Inhibits Hyperpolarization-Activated Cyclic Nucleotide-Gated (HCN) Channel Currents in Rat Dorsal Root Ganglion Neurons.
Whooping Cough
A novel cardioprotective role of RhoA: new signaling mechanism for adenosine.
Whooping Cough
A novel cholera toxin-sensitive G-protein (Gc) regulating receptor-mediated phosphoinositide signalling in human pituitary clonal cells.
Whooping Cough
A novel collagen-binding peptide promotes osteogenic differentiation via Ca(2+)/calmodulin-dependent protein kinase II/ERK/AP-1 signaling pathway in human bone marrow-derived mesenchymal stem cells.
Whooping Cough
A novel extracellular nucleotide receptor coupled to phosphoinositidase-C in pituitary cells.
Whooping Cough
A novel function of sphingosine-1-phosphate to activate a non-selective cation channel in human endothelial cells.
Whooping Cough
A novel G protein alpha subunit containing atypical guanine nucleotide-binding domains is differentially expressed in a molluscan nervous system.
Whooping Cough
A novel G protein alpha subunit in embryo of the ascidian, Halocynthia roretzi.
Whooping Cough
A novel guanine nucleotide-binding protein coupled to the alpha 1-adrenergic receptor. II. Purification, characterization, and reconstitution.
Whooping Cough
A novel hypothalamic peptide, pituitary adenylate cyclase activating peptide, modulates Sertoli cell function in vitro.
Whooping Cough
A novel mechanism for coupling of m4 muscarinic acetylcholine receptors to calmodulin-sensitive adenylyl cyclases: crossover from G protein-coupled inhibition to stimulation.
Whooping Cough
A novel mechanism for the inhibition of adenylate cyclase via inhibitory GTP-binding proteins. Calmodulin-dependent inhibition of the cyclase catalyst by the beta gamma-subunits of GTP-binding proteins.
Whooping Cough
A novel mechanism for the melatonin inhibition of testosterone secretion by rat Leydig cells: reduction of GnRH-induced increase in cytosolic Ca2+.
Whooping Cough
A novel mechanism of action of corticotropin releasing factor in rat Leydig cells.
Whooping Cough
A novel membrane receptor with high affinity for lysosphingomyelin and sphingosine 1-phosphate in atrial myocytes.
Whooping Cough
A novel method for the extraction of outer membrane vesicles (OMVs) from Bordetella pertussis Tohama strain.
Whooping Cough
A novel nonpeptide ligand for formyl peptide receptor-like 1.
Whooping Cough
A Novel Nutrient Sensing Mechanism Underlies Substrate-induced Regulation of Monocarboxylate Transporter 1.
Whooping Cough
A novel P2-purinoceptor expressed by a subpopulation of astrocytes from the dorsal spinal cord of the rat.
Whooping Cough
A novel pathway for receptor-mediated post-translational activation of inducible nitric oxide synthase.
Whooping Cough
A novel process for preparing an acellular pertussis vaccine composed of non-pyrogenic toxoids of pertussis toxin and filamentous hemagglutinin.
Whooping Cough
A novel regulatory role for stromal-derived factor-1 signaling in bone morphogenic protein-2 osteogenic differentiation of mesenchymal C2C12 cells.
Whooping Cough
A novel role for protein phosphatase 2A in receptor-mediated regulation of the cardiac sarcolemmal Na+/H+ exchanger NHE1.
Whooping Cough
A Novel Role for Somatostatin in the Survival of Mouse Pancreatic Beta Cells.
Whooping Cough
A novel role for testicular descent; temperature-dependent induction of pertussis toxin-sensitive Gi protein function in postnatal rat Leydig cells.
Whooping Cough
A novel signaling pathway for beta-adrenergic receptor-mediated activation of phosphoinositide 3-kinase in H9c2 cardiomyocytes.
Whooping Cough
A novel site of action of a high affinity A1 adenosine receptor antagonist.
Whooping Cough
A novel strategy to engineer functional fluorescent inhibitory G-protein alpha subunits.
Whooping Cough
A novel synergistic stimulation of Swiss 3T3 cells by extracellular ATP and mitogens with opposite effects on cAMP levels.
Whooping Cough
A P2 purinoceptor activated by ADP in rat medullar neurons.
Whooping Cough
A permissive role of pertussis toxin substrate G-protein in P2-purinergic stimulation of phosphoinositide turnover and arachidonate release in FRTL-5 thyroid cells. Cooperative mechanism of signal transduction systems.
Whooping Cough
A pertussis toxin resistant alpha 2-adrenoceptor pathway in fish melanophores.
Whooping Cough
A pertussis toxin sensitive G-protein-independent pathway is involved in serum amyloid A-induced formyl peptide receptor 2-mediated CCL2 production.
Whooping Cough
A pertussis toxin substrate regulates alpha 1-adrenergic dependent phosphatidylinositol hydrolysis in cultured rat myocytes.
Whooping Cough
A pertussis toxin-insensitive calcium influx mediated by neuropeptide Y2 receptors in a human neuroblastoma cell line.
Whooping Cough
A pertussis toxin-sensitive 8-lipoxygenase pathway is activated by a nicotinic acetylcholine receptor in aplysia neurons.
Whooping Cough
A pertussis toxin-sensitive G protein in hippocampal long-term potentiation.
Whooping Cough
A pertussis toxin-sensitive G protein is required to induce histamine release from rat peritoneal mast cells by bradykinin.
Whooping Cough
A pertussis toxin-sensitive G protein mediates inhibition by morphine of spontaneous electrical activity of oxytocin neurones in anaesthetized rats.
Whooping Cough
A pertussis toxin-sensitive G-protein mediates some aspects of insulin action in BC3H-1 murine myocytes.
Whooping Cough
A pertussis toxin-sensitive G-protein mediates the alpha 2-adrenergic receptor inhibition of melatonin release in photoreceptive chick pineal cell cultures.
Whooping Cough
A pertussis toxin-sensitive GTP-binding protein couples endothelin to phospholipase C in rat mesangial cells.
Whooping Cough
A pertussis toxin-sensitive GTP-binding protein in the human neutrophil regulates multiple receptors, calcium mobilization, and lectin-induced capping.
Whooping Cough
A pertussis toxin-sensitive GTP-binding protein plays a role in the G0-G1 transition of rat hepatocytes following establishment in primary culture.
Whooping Cough
A pertussis toxin-sensitive mechanism of endothelin action in porcine coronary artery smooth muscle.
Whooping Cough
A pertussis toxin-sensitive process controls thymocyte emigration.
Whooping Cough
A pertussis-toxin-sensitive protein controls exocytosis in chromaffin cells at a step distal to the generation of second messengers.
Whooping Cough
A pertussis/cholera toxin sensitive G-protein may mediate vasopressin-induced inositol phosphate formation in smooth muscle cell.
Whooping Cough
A pertussis/choleratoxin-sensitive N protein may mediate chemoattractant receptor signal transduction.
Whooping Cough
A pharmacological characterization of the mGluR1 alpha subtype of the metabotropic glutamate receptor expressed in a cloned baby hamster kidney cell line.
Whooping Cough
A pharmacological investigation of the contribution of muscarinic receptor-linked potassium channels to the reversal by carbachol of positive inotropic responses of rabbit left atrium to cyclic AMP-generating agents.
Whooping Cough
A phase I, randomized, controlled, dose-ranging study of investigational acellular pertussis (aP) and reduced tetanus-diphtheria-acellular pertussis (TdaP) booster vaccines in adults.
Whooping Cough
A phase variant of Bordetella pertussis with a mutation in a new locus involved in the regulation of pertussis toxin and adenylate cyclase toxin expression.
Whooping Cough
A phorbol ester augments cAMP content and adenylyl cyclase activity in neonatal rat cardiac myocytes despite reduced beta adrenoceptor density.
Whooping Cough
A placebo-controlled trial of a pertussis-toxoid vaccine.
Whooping Cough
A pore-forming toxin produced by Aeromonas sobria activates Ca2+ dependent Cl- secretion.
Whooping Cough
A potassium conductance contributes to the action of somatostatin-14 to suppress ACTH secretion.
Whooping Cough
A potential role for guanine nucleotide-binding protein in the regulation of endosomal proton transport.
Whooping Cough
A predominant role for inhibition of the adenylate cyclase/protein kinase A pathway in ERK activation by cannabinoid receptor 1 in N1E-115 neuroblastoma cells.
Whooping Cough
A presynaptic action of the neurosteroid pregnenolone sulfate on GABAergic synaptic transmission.
Whooping Cough
A proinflammatory chemokine, CCL3, sensitizes the heat- and capsaicin-gated ion channel TRPV1.
Whooping Cough
A proposed mechanism of ADP-ribosylation catalyzed by the pertussis toxin S1 subunit.
Whooping Cough
A prostaglandin E receptor coupled to a pertussis toxin-sensitive guanine nucleotide regulatory protein in rabbit cortical collecting tubule cells.
Whooping Cough
A protein kinase C inhibitor, staurosporine, activates phospholipase D via a pertussis toxin-sensitive GTP-binding protein in rabbit peritoneal neutrophils.
Whooping Cough
A proteoliposome formulation derived from Bordetella pertussis induces protection in two murine challenge models.
Whooping Cough
A quantitative analysis for the ADP-ribosylation activity of pertussis toxin: an enzymatic-HPLC coupled assay applicable to formulated whole cell and acellular pertussis vaccine products.
Whooping Cough
A randomised controlled trial with a diphtheria-tetanus-acellular pertussis (dTpa) vaccine in adults.
Whooping Cough
A randomized comparison of reactogenicity and immunogenicity of two whole-cell pertussis vaccines.
Whooping Cough
A randomized controlled trial of two acellular pertussis-diphtheria-tetanus vaccines in primary immunization in Ghana: antibody responses and adverse reactions.
Whooping Cough
A Randomized, Controlled Study of DTaP-IPV-HB-PRP-T, a Fully Liquid Hexavalent Vaccine, Administered in a 3-, 5- and 11- to 12-month Schedule.
Whooping Cough
A rapid ELISA-based method for screening Bordetella pertussis strain production of antigens included in current acellular pertussis vaccines.
Whooping Cough
A rapid, nongenomic action of glucocorticoids in rat B103 neuroblastoma cells.
Whooping Cough
A Real Time Chemotaxis Assay Unveils Unique Migratory Profiles amongst Different Primary Murine Macrophages.
Whooping Cough
A Real-Time, Fluorescence-Based Assay for Measuring ?-Opioid Receptor Modulation of Adenylyl Cyclase Activity in Chinese Hamster Ovary Cells.
Whooping Cough
A recombinant inwardly rectifying potassium channel coupled to GTP-binding proteins.
Whooping Cough
A region of the third intracellular loop of the short form of the D2 dopamine receptor dictates Gi coupling specificity.
Whooping Cough
A role for a pertussis toxin-sensitive trimeric G-protein in store-operated Ca2+ inflow in hepatocytes.
Whooping Cough
A role for extracellular calcium in the regulation of placental lactogen release by angiotensin-II and dopamine in human term trophoblastic cells.
Whooping Cough
A role for G protein-coupled lysophospholipid receptors in sphingolipid-induced Ca2+ signaling in MC3T3-E1 osteoblastic cells.
Whooping Cough
A role for heterotrimeric GTP-binding proteins and ERK1/2 in insulin-mediated, nitric-oxide-dependent, cyclic GMP production in human umbilical vein endothelial cells.
Whooping Cough
A role for M2 and M3 muscarinic receptors in the contraction of rat and human small airways.
Whooping Cough
A role for surface lymphotoxin in experimental autoimmune encephalomyelitis independent of LIGHT.
Whooping Cough
A role for the human sperm glycine receptor/Cl(-) channel in the acrosome reaction initiated by recombinant ZP3.
Whooping Cough
A role of protein kinase C mu in signalling from the human adenosine A1 receptor to the nucleus.
Whooping Cough
A role of the B-oligomer moiety of islet-activating protein, pertussis toxin, in development of the biological effects on intact cells.
Whooping Cough
A safety and immunogenicity comparison of 12 acellular pertussis vaccines and one whole-cell pertussis vaccine given as a fourth dose in 15- to 20-month-old children.
Whooping Cough
A search for serologic correlates of immunity to Bordetella pertussis cough illnesses.
Whooping Cough
A semi-synthetic glycoconjugate antigen prepared by chemical glycosilation of pertussis toxin by a meningococcal group C oligosaccharide hapten.
Whooping Cough
A sensitive chemiluminescence assay for pertussis toxin and for evaluation of cell-free pertussis toxoids.
Whooping Cough
A sensitive method for measuring neutralizing antibodies to Bordetella pertussis toxin: optimized ADP-ribosylation of transducin.
Whooping Cough
A sex difference in the effect of prostaglandins on hormone-stimulated glycogenolysis in primary cultures of rat hepatocytes.
Whooping Cough
A signaling pathway for stimulation of Na+ uptake induced by angiotensin II in primary cultured rabbit renal proximal tubule cells.
Whooping Cough
A simple and sensitive ELISA of antibodies to pertussis antigens.
Whooping Cough
A Simple Approach to Induce Experimental Autoimmune Neuritis in C57BL/6 Mice for Functional and Neuropathological Assessments.
Whooping Cough
A single nucleotide polymorphism in Tyk2 controls susceptibility to experimental allergic encephalomyelitis.
Whooping Cough
A single species of A1 adenosine receptor expressed in Chinese hamster ovary cells not only inhibits cAMP accumulation but also stimulates phospholipase C and arachidonate release.
Whooping Cough
A slowly ADP-ribosylated pertussis-toxin-sensitive GTP-binding regulatory protein is required for vasopressin-stimulated Ca2+ inflow in hepatocytes.
Whooping Cough
A somatostatin receptor inhibits noradrenaline release from chick sympathetic neurons through pertussis toxin-sensitive mechanisms: comparison with the action of alpha 2-adrenoceptors.
Whooping Cough
A specific beta gamma-subunit of transducin stimulates ADP-ribosylation of the alpha-subunit by pertussis toxin.
Whooping Cough
A spectroscopic and conformational study of pertussis toxin.
Whooping Cough
A step sensitive to pertussis toxin and phorbol ester in human neutrophils regulates chemotaxis and capping but not phagocytosis.
Whooping Cough
A study comparing the actions of gabapentin and pregabalin on the electrophysiological properties of cultured DRG neurones from neonatal rats.
Whooping Cough
A subtype of kappa-opioid receptor mediates inhibition of high-affinity GTPase inherent in Gi1 in guinea pig cerebellar membranes.
Whooping Cough
A synthetic decapeptide from a conserved ZP3 protein domain induces the G protein-regulated acrosome reaction in bovine spermatozoa.
Whooping Cough
A ten year follow-up after immunization with a two component acellular pertussis vaccine.
Whooping Cough
A threshold level of coupled G-proteins is required to transduce neutrophil responses.
Whooping Cough
A trace component of ginseng that inhibits Ca2+ channels through a pertussis toxin-sensitive G protein.
Whooping Cough
A transduction pathway associated with receptors coupled to the inhibitory guanine nucleotide binding protein Gi that amplifies ATP-mediated arachidonic acid release.
Whooping Cough
A truncated form of CKbeta8-1 is a potent agonist for human formyl peptide-receptor-like 1 receptor.
Whooping Cough
A truncated recombinant alpha subunit of Gi3 with a reduced affinity for beta gamma dimers and altered guanosine 5'-3-O-(thio)triphosphate binding.
Whooping Cough
A two-dimensional model of cell movement. Well differentiated human rectal adenocarcinoma cells move as coherent sheets upon TPA stimulation.
Whooping Cough
A two-phase within-host model for immune response and its application to serological profiles of pertussis.
Whooping Cough
A two-step mechanism by which corticotropin-releasing hormone releases hypothalamic beta-endorphin: the role of vasopressin and G-proteins.
Whooping Cough
A tyrosine kinase regulates alpha-adrenoceptor-stimulated contraction and phospholipase D activation in the rat aorta.
Whooping Cough
A unique sequence of the Bordetella pertussis toxin operon.
Whooping Cough
A urokinase-sensitive region of the human urokinase receptor is responsible for its chemotactic activity.
Whooping Cough
A versatile, non genetically modified organism (GMO)-based strategy for controlling low-producer mutants in Bordetella pertussis cultures using antigenic modulation.
Whooping Cough
A voltage-independent calcium current inhibitory pathway activated by muscarinic agonists in rat sympathetic neurons requires both Galpha q/11 and Gbeta gamma.
Whooping Cough
A voltage-independent K+ conductance activated by cell swelling in Ehrlich cells is modulated by a G-protein-mediated process.
Whooping Cough
A WB 4101-sensitive alpha-1 adrenergic receptor subtype modulates repolarization in canine Purkinje fibers.
Whooping Cough
A(2B) adenosine receptors inhibit superoxide production from mitochondrial complex I in rabbit cardiomyocytes via a mechanism sensitive to Pertussis toxin.
Whooping Cough
A-type potassium current modulated by A1 adenosine receptor in frog melanotrophs.
Whooping Cough
A1 Adenosine Receptor Modulation of Adenylyl Cyclase of a Deep-living Teleost Fish, Antimora rostrata.
Whooping Cough
A1 adenosine receptor-mediated Ins(1,4,5)P3 generation in allergic rabbit airway smooth muscle.
Whooping Cough
A1 adenosine receptors expressed in CHO-cells couple to adenylyl cyclase and to phospholipase C.
Whooping Cough
A1 adenosine receptors potently regulate heart rate in mammalian embryos.
Whooping Cough
A1 and A2 adenosine receptor modulation of contractility in the cauda epididymis of the guinea-pig.
Whooping Cough
A1 and A2 adenosine receptors in rabbit cortical collecting tubule cells. Modulation of hormone-stimulated cAMP.
Whooping Cough
A1-adenosine receptor-mediated inhibition of adipocyte adenylate cyclase and lipolysis in Zucker rats.
Whooping Cough
A3 adenosine receptor activation triggers phosphorylation of protein kinase B and protects rat basophilic leukemia 2H3 mast cells from apoptosis.
Whooping Cough
A3 adenosine receptors in human astrocytoma cells: agonist-mediated desensitization, internalization, and down-regulation.
Whooping Cough
AB5 ADP-ribosylating toxins: comparative anatomy and physiology.
Whooping Cough
AB5 toxins.
Whooping Cough
Aberrant Gi protein coupled receptor-mediated cell survival signaling in rheumatoid arthritis B cell lines.
Whooping Cough
Abeta peptides can enter the brain through a defective blood-brain barrier and bind selectively to neurons.
Whooping Cough
Ability of delta-opioid receptors to interact with multiple G-proteins is independent of receptor density.
Whooping Cough
Abnormal dopamine sensitivity in some human prolactinomas.
Whooping Cough
Abnormal regulation of G protein alpha(i2) subunit in skin fibroblasts from insulin-resistant hypertensive individuals.
Whooping Cough
Abnormal regulation of renal proximal tubule Na(+)-K(+)-ATPase by G proteins in spontaneously hypertensive rats.
Whooping Cough
Abnormal T cell activation caused by the imbalance of the IL-1/IL-1R antagonist system is responsible for the development of experimental autoimmune encephalomyelitis.
Whooping Cough
Abnormalities of the myocytes in ischaemic cardiomyopathy.
Whooping Cough
Abscisic acid is an endogenous cytokine in human granulocytes with cyclic ADP-ribose as second messenger.
Whooping Cough
Abscisic acid stimulation of phospholipase D in the barley aleurone is G-protein-mediated and localized to the plasma membrane.
Whooping Cough
Absence of D2S dopamine receptor in the prolactin-secreting MMQ pituitary clone: characterization of a wild D2L receptor coupled to native transduction mechanisms.
Whooping Cough
Absence of exon 10 of the human luteinizing hormone (LH) receptor impairs LH, but not human chorionic gonadotropin action.
Whooping Cough
Absence of the inhibitory effect of guanine nucleotides on adenylate cyclase activity in white adipocyte membranes of the ob/ob mouse. Effect of the ob gene.
Whooping Cough
Accelerated maternal responding following intra-VTA pertussis toxin treatment.
Whooping Cough
Acceleration of desipramine-induced changes on the dopamine receptor-coupled adenylate cyclase system by pertussis toxin.
Whooping Cough
Accentuated antagonism by angiotensin II on guinea-pig cardiac L-type Ca-currents enhanced by beta-adrenergic stimulation.
Whooping Cough
Accentuation by pertussis toxin of the 5-hydroxytryptamine-induced potentiation of ATP-evoked responses in rat pheochromocytoma cells.
Whooping Cough
Accumulation of a precursor of subunit S1 of pertussis toxin in cell envelopes of Bordetella pertussis in response to the membrane perturbant phenethyl alcohol.
Whooping Cough
Acellular and "low" pertussis vaccines: adverse events and the role of mutations.
Whooping Cough
Acellular and whole cell pertussis vaccines protect against the lethal effects of intracerebral challenge by two different T-cell dependent humoral routes.
Whooping Cough
Acellular pertussis vaccine as a booster dose for seventeen- to nineteen-month-old children immunized with either whole cell or acellular pertussis vaccine at two, four and six months of age.
Whooping Cough
Acellular pertussis vaccine based on outer membrane vesicles capable of conferring both long-lasting immunity and protection against different strain genotypes.
Whooping Cough
Acellular pertussis vaccine composed of genetically inactivated pertussis toxin.
Whooping Cough
Acellular pertussis vaccine composed of genetically inactivated pertussis toxin: safety and immunogenicity in 12- to 24- and 2- to 4-month-old children.
Whooping Cough
Acellular pertussis vaccine given by accelerated schedule: response of preterm infants.
Whooping Cough
Acellular pertussis vaccine in adults: adverse reactions and immune response.
Whooping Cough
Acellular pertussis vaccine in children with perinatal human immunodeficiency virus-type 1 infection.
Whooping Cough
Acellular pertussis vaccine prepared by a simple extraction and toxoiding procedure.
Whooping Cough
Acellular pertussis vaccines and the role of pertactin and fimbriae.
Whooping Cough
Acellular pertussis vaccines containing genetically detoxified pertussis toxin induce long-lasting humoral and cellular responses in adults.
Whooping Cough
Acellular pertussis vaccines developed in Japan and their application for disease control.
Whooping Cough
Acellular pertussis vaccines: evaluation of reversion in a nude mouse model.
Whooping Cough
Acellular pertussis vaccines: neutralization by immune sera of the lethality of pertussis toxin and viable Bordetella pertussis for chick embryos.
Whooping Cough
Acellular vaccines induce cell-mediated immunity to Bordetella pertussis antigens in infants undergoing primary vaccination against pertussis.
Whooping Cough
Acetyl-l-carnitine induces muscarinic antinocieption in mice and rats.
Whooping Cough
Acetylcholine activates nonselective cation channels in guinea pig ileum through a G protein.
Whooping Cough
Acetylcholine activation of K+ channels in cell-free membrane of atrial cells.
Whooping Cough
Acetylcholine and adenosine activate the G protein-gated muscarinic K+ channel in ferret ventricular myocytes.
Whooping Cough
Acetylcholine and cholecystokinin receptors functionally couple by different G-proteins to phospholipase C in pancreatic acinar cells.
Whooping Cough
Acetylcholine elicits a rebound stimulation of Ca2+ current mediated by pertussis toxin-sensitive G protein and cAMP-dependent protein kinase A in atrial myocytes.
Whooping Cough
Acetylcholine elicits metabolically mediated M2-muscarinic hyperpolarization in isolated rabbit sympathetic neurons.
Whooping Cough
Acetylcholine inhibition in rabbit sinoatrial node is prevented by pertussis toxin.
Whooping Cough
Acetylcholine leads to free radical production dependent on K(ATP) channels, G(i) proteins, phosphatidylinositol 3-kinase and tyrosine kinase.
Whooping Cough
Acetylcholine modulation of high-voltage-activated calcium channels in the neurones acutely dissociated from rat paratracheal ganglia.
Whooping Cough
Acetylcholine reversal of isoproterenol-stimulated sodium currents in rabbit ventricular myocytes.
Whooping Cough
Acetylcholine reverses isoproterenol-induced depression of Vmax in residual Na channel-dependent action potentials of guinea-pig cardiac muscles.
Whooping Cough
Acetylcholine stimulates cortical precursor cell proliferation in vitro via muscarinic receptor activation and MAP kinase phosphorylation.
Whooping Cough
Acetylcholine-induced calcium signaling associated with muscarinic receptor activation in cultured myenteric neurons.
Whooping Cough
Acetylcholine-induced desensitization of muscarinic contractile response in Guinea pig ileum is inhibited by pertussis toxin treatment.
Whooping Cough
Acetylcholine-induced desensitization of the contractile response to histamine in Guinea pig ileum is prevented by either pertussis toxin treatment or by selective inactivation of muscarinic M(3) receptors.
Whooping Cough
Acetylcholine-sensitive muscarinic K+ channels in mammalian ventricular myocytes.
Whooping Cough
ACh-induced rebound stimulation of L-type Ca(2+) current in guinea-pig ventricular myocytes, mediated by Gbetagamma-dependent activation of adenylyl cyclase.
Whooping Cough
Acidic stimuli activates two distinct pathways in taste receptor cells from rat fungiform papillae.
Whooping Cough
Acidification of serotonin-containing secretory vesicles induced by a plasma membrane calcium receptor.
Whooping Cough
Acquisition by innervated cardiac myocytes of a pertussis toxin-specific regulatory protein linked to the alpha 1-receptor.
Whooping Cough
Acquisition of specific antibodies and their influence on cell-mediated immune response in neonatal cord blood after maternal pertussis vaccination during pregnancy.
Whooping Cough
Acrosome reaction induced by recombinant human zona pellucida 3 peptides rhuZP3a22 approximately 176 and rhuZP3b177 approximately 348 and their mechanism.
Whooping Cough
Actin assembly in electropermeabilized neutrophils: role of G-proteins.
Whooping Cough
Actin depolymerization and inhibition of capping induced by pentoxifylline in human lymphocytes and neutrophils.
Whooping Cough
Actin reorganization in airway smooth muscle cells involves Gq and Gi-2 activation of Rho.
Whooping Cough
Action of alpha 2A-adrenergic receptors in circular smooth muscle of canine proximal colon.
Whooping Cough
Action of brefeldin A blocked by activation of a pertussis-toxin-sensitive G protein.
Whooping Cough
Action of calcitonin gene-related peptide on rat aortic smooth muscle.
Whooping Cough
Action of insulin modulated by pertussis toxin in rat adipocytes.
Whooping Cough
Action of lipid peroxidation products on phosphoinositide specific phospholipase C.
Whooping Cough
Action of the cardiac alpha 1-adrenergic receptor. Activation of cyclic AMP degradation.
Whooping Cough
Actions of angiotensin II and noradrenaline on smooth muscle cells of the canine mesenteric artery.
Whooping Cough
Actions of epoxyeicosatrienoic acid on large-conductance Ca(2+)-activated K(+) channels in pituitary GH(3) cells.
Whooping Cough
Actions of peptide YY and neuropeptide Y on chief cells from guinea pig stomach.
Whooping Cough
Actions of pertussis toxin on the inhibitory effects of dopamine and somatostatin on prolactin and growth hormone release from ovine anterior pituitary cells.
Whooping Cough
Actions of somatostatins on gastric smooth muscle cells.
Whooping Cough
Activated G protein-coupled receptor induces tyrosine phosphorylation of STAT3 and agonist-selective serine phosphorylation via sustained stimulation of mitogen-activated protein kinase. Resultant effects on cell proliferation.
Whooping Cough
Activating and inactivating mutations of the alpha subunit of Gi2 protein have opposite effects on proliferation of NIH 3T3 cells.
Whooping Cough
Activation and inhibition of neuronal G protein-gated inwardly rectifying K(+) channels by P2Y nucleotide receptors.
Whooping Cough
Activation and modulation of neuronal K+ channels by GABA.
Whooping Cough
Activation by 2-arachidonoylglycerol, an endogenous cannabinoid receptor ligand, of p42/44 mitogen-activated protein kinase in HL-60 cells.
Whooping Cough
Activation by chemotactic peptide of a receptor-operated Ca2+ entry pathway in differentiated HL60 cells.
Whooping Cough
Activation by thiol of the latent NAD glycohydrolase and ADP-ribosyltransferase activities of Bordetella pertussis toxin (islet-activating protein).
Whooping Cough
Activation effects of a prion protein fragment [PrP-(106-126)] on human leucocytes.
Whooping Cough
Activation mechanism of a neuromodulator-gated pacemaker ionic current.
Whooping Cough
Activation of 5-HT(7) receptor in rat glomerulosa cells is associated with an increase in adenylyl cyclase activity and calcium influx through T-type calcium channels.
Whooping Cough
Activation of 5-HT1A receptors expressed in NIH-3T3 cells induces focus formation and potentiates EGF effect on DNA synthesis.
Whooping Cough
Activation of ?-opioid receptors inhibits calcium-currents in the vestibular afferent neurons of the rat through a cAMP dependent mechanism.
Whooping Cough
Activation of a beta-adrenergic-sensitive signal transduction pathway by the secosteroid hormone 1,25-(OH)2-vitamin D3 in chick heart.
Whooping Cough
Activation of a Ca2+-dependent K+ current in mouse fibroblasts by lysophosphatidic acid requires a pertussis toxin-sensitive G protein and Ras.
Whooping Cough
Activation of a calcium-permeable cation channel CD20 expressed in Balb/c 3T3 cells by insulin-like growth factor-I.
Whooping Cough
Activation of a common potassium channel in molluscan neurones by glutamate, dopamine and muscarinic agonist.
Whooping Cough
Activation of a frizzled-2/beta-adrenergic receptor chimera promotes Wnt signaling and differentiation of mouse F9 teratocarcinoma cells via Galphao and Galphat.
Whooping Cough
Activation of a G protein in mouse sperm by the zona pellucida, an egg-associated extracellular matrix.
Whooping Cough
Activation of a G protein promotes agonist responses to calcium channel ligands.
Whooping Cough
Activation of a Gi protein in digitonin/cholate-solubilized membrane preparations of mouse sperm by the zona pellucida, an egg-specific extracellular matrix.
Whooping Cough
Activation of a Gi protein in mouse sperm membranes by solubilized proteins of the zona pellucida, the egg's extracellular matrix.
Whooping Cough
Activation of a K+ conductance by bradykinin and by inositol-1,4,5-trisphosphate in rat glioma cells: involvement of intracellular and extracellular Ca2+.
Whooping Cough
Activation of a keratinocyte phospholipase A2 by bradykinin and 4 beta-phorbol 12-myristate 13-acetate. Evidence for a receptor-GTP-binding protein versus a protein-kinase-C mediated mechanism.
Whooping Cough
Activation of a mitogen-activated protein kinase (ERK2) by the 5-hydroxytryptamine1A receptor is sensitive not only to inhibitors of phosphatidylinositol 3-kinase, but to an inhibitor of phosphatidylcholine hydrolysis.
Whooping Cough
Activation of a muscarinic receptor selectively inhibits a rapidly inactivated Ca2+ current in rat sympathetic neurons.
Whooping Cough
Activation of a pertussis toxin-sensitive, inhibitory G-protein is necessary for steroid-mediated oocyte maturation in spotted seatrout.
Whooping Cough
Activation of a pertussis-toxin-sensitive guanine-nucleotide-binding regulatory protein during desensitization of Dictyostelium discoideum cells to chemotactic signals.
Whooping Cough
Activation of a phosphatidylcholine-specific phospholipase C by colony stimulating factor 1 receptor requires tyrosine phosphorylation and a guanine nucleotide-binding protein.
Whooping Cough
Activation of a PTX-insensitive G protein is involved in histamine-induced recombinant M-channel modulation.
Whooping Cough
Activation of A(3) adenosine receptor induces calcium entry and chloride secretion in A(6) cells.
Whooping Cough
Activation of adenosine A(1) receptor modulates dopamine D(1) receptor activity in stably cotransfected human embryonic kidney 293 cells.
Whooping Cough
Activation of adenosine A1 and bradykinin receptors increases protein kinase C and phospholipase D activity in smooth muscle cells.
Whooping Cough
Activation of adenylate cyclase by human recombinant sst5 receptors expressed in CHO-K1 cells and involvement of Galphas proteins.
Whooping Cough
Activation of adenylate cyclase in rat fat cells promotes an increase in GTP content which controls the enzyme activity.
Whooping Cough
Activation of Akt/protein kinase B after stimulation with angiotensin II in vascular smooth muscle cells.
Whooping Cough
Activation of alpha 1- and alpha 2-adrenoceptors inhibits noradrenaline release in rabbit renal arteries: effects of pertussis toxin and N-ethylmaleimide.
Whooping Cough
Activation of alpha 1-adrenoceptors modulates the inwardly rectifying potassium currents of mammalian atrial myocytes.
Whooping Cough
Activation of alpha 2-adrenergic receptors decreases Ca2+ influx to inhibit insulin secretion in a hamster beta-cell line: an action mediated by a guanosine triphosphate-binding protein.
Whooping Cough
Activation of alpha-1A adrenoceptors mobilizes calcium from the intracellular stores in myocytes from rat portal vein.
Whooping Cough
Activation of alpha-2 adrenergic receptors inhibits norepinephrine release by a pertussis toxin-insensitive pathway independent of changes in cytosolic calcium in cultured rat sympathetic neurons.
Whooping Cough
Activation of alpha-2-adrenoceptors results in an increase in F-actin formation in HIT-T15 pancreatic B-cells.
Whooping Cough
Activation of apical P2U purine receptors permits inhibition of adrenaline-evoked cyclic AMP accumulation in cultured equine sweat gland epithelial cells.
Whooping Cough
Activation of beta-adrenergic receptors inhibits Ca2+ entry-mediated generation of inositol phosphates in the guinea pig myometrium, a cyclic AMP-independent event.
Whooping Cough
Activation of BK channels in GH3 cells by a c-PLA2-dependent G-protein signaling pathway.
Whooping Cough
Activation of c-Jun N-terminal kinase (JNK) by lysophosphatidic acid in Swiss 3T3 fibroblasts.
Whooping Cough
Activation of Ca(2+)-dependent K+ current by acetylcholine and histamine in a human gastric epithelial cell line.
Whooping Cough
Activation of calcium-permeable cation channel by insulin in Chinese hamster ovary cells expressing human insulin receptors.
Whooping Cough
Activation of CD47 receptors causes histamine secretion from mast cells.
Whooping Cough
Activation of cell membrane potassium conductance by mercury in cultured renal epithelioid (MDCK) cells.
Whooping Cough
Activation of cellular phospholipase A2 by Clostridium difficile toxin B.
Whooping Cough
Activation of choline kinase by extracellular Ca2+ is Ca(2+)-sensing receptor, Galpha12 and Rho-dependent in breast cancer cells.
Whooping Cough
Activation of constitutive 5-hydroxytryptamine(1B) receptor by a series of mutations in the BBXXB motif: positioning of the third intracellular loop distal junction and its G(o)alpha protein interactions.
Whooping Cough
Activation of corticotropin-releasing factor 2 receptor inhibits Purkinje neuron P-type calcium currents via G(o)alpha-dependent PKC eposilon pathway.
Whooping Cough
Activation of delta-, kappa-, and mu-opioid receptors induces phosphorylation of tuberin in transfected HEK 293 cells and native cells.
Whooping Cough
Activation of delta-opioid receptors inhibits neuronal-like calcium channels and distal steps of Ca(2+)-dependent secretion in human small-cell lung carcinoma cells.
Whooping Cough
Activation of dense human tonsilar B cells. Induction of c-myc gene expression via two distinct signal transduction pathways.
Whooping Cough
Activation of distinct T cell subsets involved in IgM antibody response of mice by pertussis toxin from Bordetella pertussis strain Maeno.
Whooping Cough
Activation of dopamine D4 receptor inhibits an L-type calcium current in cerebellar granule cells.
Whooping Cough
Activation of dopamine receptors does not affect phosphoinositide turnover in NCB-20 cells.
Whooping Cough
Activation of early events of the mitogenic response by a P2Y purinoceptor with covalently bound 3'-O-(4-benzoyl)-benzoyladenosine 5'-triphosphate.
Whooping Cough
Activation of endothelial cell phospholipase D by sphingosine and sphingosine-1-phosphate.
Whooping Cough
Activation of endothelial nitric oxide synthase by proanthocyanidin-rich fraction from Croton celtidifolius (Euphorbiaceae): involvement of extracellular calcium influx in rat thoracic aorta.
Whooping Cough
Activation of extracellular signal regulated protein kinase by neuropeptide Y and pancreatic polypeptide in CHO cells expressing the NPY Y(1), Y(2), Y(4) and Y(5) receptor subtypes.
Whooping Cough
Activation of G protein by opioid receptors: role of receptor number and G-protein concentration.
Whooping Cough
Activation of G protein-coupled K+ channels by dopamine in human GH-producing cells.
Whooping Cough
Activation of G proteins bidirectionally affects apoptosis of cultured cerebellar granule neurons.
Whooping Cough
Activation of G proteins by (Rp) and (Sp) diastereomers of guanosine 5'-[beta-thio]triphosphate in hamster fibroblasts. Differential stereospecificity of Gi, Gs and Gp.
Whooping Cough
Activation of G proteins may inhibit or stimulate surfactant secretion in rat alveolar type II cells.
Whooping Cough
Activation of G proteins mediates flow-induced prostaglandin E2 production in osteoblasts.
Whooping Cough
Activation of G(i) induces mechanical hyperalgesia poststress or inflammation.
Whooping Cough
Activation of galanin receptor 1 inhibits locus coeruleus neurons via GIRK channels.
Whooping Cough
Activation of Galpha (i) and subsequent uncoupling of receptor-Galpha(i) signaling by Pasteurella multocida toxin.
Whooping Cough
Activation of Gbetagamma signaling downstream of Wnt-11/Xfz7 regulates Cdc42 activity during Xenopus gastrulation.
Whooping Cough
Activation of Gi protein by peptide structures of the muscarinic M2 receptor second intracellular loop.
Whooping Cough
Activation of Gi-like proteins, a receptor-independent effect of kinins in mast cells.
Whooping Cough
Activation of Go-coupled dopamine D2 receptors inhibits ERK1/ERK2 in pituitary cells. A key step in the transcriptional suppression of the prolactin gene.
Whooping Cough
Activation of group I metabotropic glutamate receptors induces long-term depression at sensory synapses in superficial spinal dorsal horn.
Whooping Cough
Activation of group II mGlu receptors inhibits voltage-gated Ca2+ currents in myenteric neurons.
Whooping Cough
Activation of group III metabotropic glutamate receptors inhibits the production of RANTES in glial cell cultures.
Whooping Cough
Activation of growth hormone secretagogue type 1a receptor inhibits T-type Ca2+ channel currents through pertussis toxin-sensitive novel protein kinase C pathway in mouse spermatogenic cells.
Whooping Cough
Activation of GTP formation and high-affinity GTP hydrolysis by mastoparan in various cell membranes. G-protein activation via nucleoside diphosphate kinase, a possible general mechanism of mastoparan action.
Whooping Cough
Activation of guanosine 5'-[gamma-(35)S]thio-triphosphate binding through M(1) muscarinic receptors in transfected Chinese Hamster ovary cell membranes: 2. Testing the "two-states" model of receptor activation.
Whooping Cough
Activation of guanylate cyclase by E. coli heat-stable enterotoxin (STa). Modulation by NAD and pertussis toxin.
Whooping Cough
Activation of heat shock protein (hsp)70 and proto-oncogene expression by alpha1 adrenergic agonist in rat aorta with age.
Whooping Cough
Activation of heterologously expressed D3 dopamine receptors: comparison with D2 dopamine receptors.
Whooping Cough
Activation of heterotrimeric G proteins by Smoothened.
Whooping Cough
Activation of HIF-1? by ?-Opioid Receptors Induces COX-2 Expression in Breast Cancer Cells and Leads to Paracrine Activation of Vascular Endothelial Cells.
Whooping Cough
Activation of human basophils through the IL-8 receptor.
Whooping Cough
Activation of human colon mast cells through proteinase activated receptor-2.
Whooping Cough
Activation of human monocytes by a formyl peptide receptor 2-derived pepducin.
Whooping Cough
Activation of human monocytes via a non-neurokinin substance P receptor that is coupled to Gi protein, calcium, phospholipase D, MAP kinase, and IL-6 production.
Whooping Cough
Activation of human monocytic cells by lysophosphatidic acid and sphingosine-1-phosphate.
Whooping Cough
Activation of human neutrophils by a synthetic anti-microbial peptide, KLKLLLLLKLK-NH2, via cell surface calreticulin.
Whooping Cough
Activation of human neutrophils by chlordane: induction of superoxide production and phagocytosis but not chemotaxis or apoptosis.
Whooping Cough
Activation of human neutrophils by mastoparan. Reorganization of the cytoskeleton, formation of phosphatidylinositol 3,4,5-trisphosphate, secretion up-regulation of complement receptor type 3 and superoxide anion production are stimulated by mastoparan.
Whooping Cough
Activation of human neutrophils by Mycobacterium tuberculosis-derived sulfolipid-1.
Whooping Cough
Activation of human neutrophils by substance P. Effect on oxidative metabolism, exocytosis, cytosolic Ca2+ concentration and inositol phosphate formation.
Whooping Cough
Activation of human neutrophils by technical toxaphene.
Whooping Cough
Activation of human neutrophils by the plant lectin Viscum album agglutinin-I: modulation of de novo protein synthesis and evidence that caspases are involved in induction of apoptosis.
Whooping Cough
Activation of human tonsil and skin mast cells by agonists of proteinase activated receptor-2.
Whooping Cough
Activation of I(2)-imidazoline receptors enhances supraspinal morphine analgesia in mice: a model to detect agonist and antagonist activities at these receptors.
Whooping Cough
Activation of inositol phospholipid breakdown in HL60 cells by P2-purinergic receptors for extracellular ATP. Evidence for mediation by both pertussis toxin-sensitive and pertussis toxin-insensitive mechanisms.
Whooping Cough
Activation of inositol phospholipid turnover and calcium signaling in rat Sertoli cells by P2-purinergic receptors: modulation of follicle-stimulating hormone responses.
Whooping Cough
Activation of inwardly rectifying potassium channels by muscarinic receptor-linked G protein in isolated human ventricular myocytes.
Whooping Cough
Activation of LH receptors expressed in GnRH neurons stimulates cyclic AMP production and inhibits pulsatile neuropeptide release.
Whooping Cough
Activation of lipolysis and cyclic AMP accumulation in rabbit adipocytes by isoproterenol in the presence of forskolin or pertussis toxin.
Whooping Cough
Activation of M1 muscarinic receptors triggers transmitter release from rat sympathetic neurons through an inhibition of M-type K+ channels.
Whooping Cough
Activation of M3 muscarinic receptors inhibits T-type Ca(2+) channel currents via pertussis toxin-sensitive novel protein kinase C pathway in small dorsal root ganglion neurons.
Whooping Cough
Activation of macrophages to express cytocidal activity correlates with inhibition of their responsiveness to macrophage colony-stimulating factor (CSF-1): involvement of a pertussis toxin-sensitive reaction.
Whooping Cough
Activation of MAP kinase by the LHRH receptor through a dual mechanism involving protein kinase C and a pertussis toxin-sensitive G protein.
Whooping Cough
Activation of MAPK by TRH requires clathrin-dependent endocytosis and PKC but not receptor interaction with beta-arrestin or receptor endocytosis.
Whooping Cough
Activation of mast cell K+ channels through multiple G protein-linked receptors.
Whooping Cough
Activation of MEKK by formyl-methionyl-leucyl-phenylalanine in human neutrophils. Mapping pathways for mitogen-activated protein kinase activation.
Whooping Cough
Activation of mesangial cells with TNF-alpha stimulates M-CSF gene expression and monocyte proliferation: evidence for involvement of protein kinase C and protein tyrosine kinase.
Whooping Cough
Activation of metabotropic glutamate receptors by L-AP4 stimulates survival of rat cerebellar granule cells in culture.
Whooping Cough
Activation of microtubule-associated protein kinase (Erk) and p70 S6 kinase by D2 dopamine receptors.
Whooping Cough
Activation of mislocalized opsin kills rod cells: a novel mechanism for rod cell death in retinal disease.
Whooping Cough
Activation of mitogen-activated protein kinase and arachidonate release via two G protein-coupled receptors expressed in the rat hippocampus.
Whooping Cough
Activation of mitogen-activated protein kinase by muscarinic receptors in astroglial cells: role in DNA synthesis and effect of ethanol.
Whooping Cough
Activation of mitogen-activated protein kinase by oxidized low-density lipoprotein in canine cultured vascular smooth muscle cells.
Whooping Cough
Activation of mitogen-activated protein kinase couples neurotensin receptor stimulation to induction of the primary response gene Krox-24.
Whooping Cough
Activation of mitogen-activated protein kinase in BC3H1 myocytes by fluoroaluminate.
Whooping Cough
Activation of mitogen-activated protein kinases by formyl peptide receptors is regulated by the cytoplasmic tail.
Whooping Cough
Activation of mitogen-activated protein kinases by stimulation of the central cannabinoid receptor CB1.
Whooping Cough
Activation of mu-opioid receptor induces expression of c-fos and junB via mitogen-activated protein kinase cascade.
Whooping Cough
Activation of muscarinic cholinergic receptors in mouse neuroblastoma x rat glioma hybrid cells: rapid induction of enhanced capacity of prostaglandin E1 receptors to stimulate cyclic AMP accumulation.
Whooping Cough
Activation of muscarinic K+ current by beta-adrenergic receptors in cultured atrial myocytes transfected with beta1 subunit of heterotrimeric G proteins.
Whooping Cough
Activation of muscarinic K+ current in guinea-pig atrial myocytes by a serum factor.
Whooping Cough
Activation of muscarinic K+ current in guinea-pig atrial myocytes by sphingosine-1-phosphate.
Whooping Cough
Activation of muscarinic M(4) receptor augments NGF-induced pro-survival Akt signaling in PC12 cells.
Whooping Cough
Activation of muscarinic m5 receptors inhibits recombinant KCNQ2/KCNQ3 K+ channels expressed in HEK293T cells.
Whooping Cough
Activation of muscarinic receptors elicits inotropic responses in ventricular muscle from rats with heart failure through myosin light chain phosphorylation.
Whooping Cough
Activation of muscarinic receptors in PC12 cells. Correlation between cytosolic Ca2+ rise and phosphoinositide hydrolysis.
Whooping Cough
Activation of muscarinic receptors inhibits spinal dorsal horn projection neurons: role of GABAB receptors.
Whooping Cough
Activation of Na+/Ca2+ exchange by adenosine in ewe heart sarcolemma is mediated by a pertussis toxin-sensitive G protein.
Whooping Cough
Activation of NADPH oxidase by purine and pyrimidine nucleotides involves G proteins and is potentiated by chemotactic peptides.
Whooping Cough
Activation of natriuretic peptide receptor-C attenuates the enhanced oxidative stress in vascular smooth muscle cells from spontaneously hypertensive rats: implication of Gialpha protein.
Whooping Cough
Activation of neuromedin U type 1 receptor inhibits L-type Ca2+ channel currents via phosphatidylinositol 3-kinase-dependent protein kinase C epsilon pathway in mouse hippocampal neurons.
Whooping Cough
Activation of nitric oxide release and oxidative metabolism by leukotrienes B4, C4, and D4 in human polymorphonuclear leukocytes.
Whooping Cough
Activation of nuclear Ca(2+)/calmodulin-dependent protein kinase II and brain-derived neurotrophic factor gene expression by stimulation of dopamine D2 receptor in transfected NG108-15 cells.
Whooping Cough
Activation of nucleotide receptors inhibits high-threshold calcium currents in NG108-15 neuronal hybrid cells.
Whooping Cough
Activation of nucleotide receptors inhibits M-type K current [IK(M)] in neuroblastoma x glioma hybrid cells.
Whooping Cough
Activation of opioid and muscarinic receptors stimulates basal adenylyl cyclase but inhibits Ca2+/calmodulin- and forskolin-stimulated enzyme activities in rat olfactory bulb.
Whooping Cough
Activation of p21-activated kinase 1 is required for lysophosphatidic acid-induced focal adhesion kinase phosphorylation and cell motility in human melanoma A2058 cells.
Whooping Cough
Activation of p21-activated kinase 1-nuclear factor kappaB signaling by Kaposi's sarcoma-associated herpes virus G protein-coupled receptor during cellular transformation.
Whooping Cough
Activation of P2Y1 receptor triggers two calcium signaling pathways in bone marrow erythroblasts.
Whooping Cough
Activation of P2Y2 receptors by UTP and ATP stimulates mitogen-activated kinase activity through a pathway that involves related adhesion focal tyrosine kinase and protein kinase C.
Whooping Cough
Activation of p38 mitogen-activated protein kinase by oxidized LDL in vascular smooth muscle cells: mediation via pertussis toxin-sensitive G proteins and association with oxidized LDL-induced cytotoxicity.
Whooping Cough
Activation of p42/p44 mitogen-activated protein kinase by angiotensin II, vasopressin, norepinephrine, and prostaglandin F2alpha in hepatocytes is sustained, and like the effect of epidermal growth factor, mediated through pertussis toxin-sensitive mechanisms.
Whooping Cough
Activation of Pak1/Akt/eNOS signaling following sphingosine-1-phosphate release as part of a mechanism protecting cardiomyocytes against ischemic cell injury.
Whooping Cough
Activation of particulate guanylate cyclase by adrenomedullin in cultured SV-40 transformed cat iris sphincter smooth muscle (SV-CISM-2) cells.
Whooping Cough
Activation of permeabilized neutrophils: role of anions.
Whooping Cough
Activation of pertussis toxin-sensitive CXCL12 (SDF-1) receptors mediates transendothelial migration of T lymphocytes across lymph node high endothelial cells.
Whooping Cough
Activation of phosphatidylinositol 3-kinase by concanavalin A through dual signaling pathways, G-protein-coupled and phosphotyrosine-related, and an essential role of the G-protein-coupled signals for the lectin-induced respiratory burst in human monocytic THP-1 cells.
Whooping Cough
Activation of phosphatidylinositol 3-kinase/Akt signaling pathway and endogenous nitric oxide are needed for the antiarrhythmic effect of centrally administered rilmenidine.
Whooping Cough
Activation of phosphoinositide turnover and protein kinase C by neurotransmitters that modulate calcium channels in embryonic chick sensory neurons.
Whooping Cough
Activation of phosphoinositide-specific phospholipase C of rat neutrophils by the chemotactic aldehydes 4-hydroxy-2,3-trans-nonenal and 4-hydroxy-2,3-trans-octenal.
Whooping Cough
Activation of phospholipase A2 by the human endothelin receptor in Chinese hamster ovary cells involves Gi protein-mediated calcium influx.
Whooping Cough
Activation of phospholipase A2 by the nociceptin receptor expressed in Chinese hamster ovary cells.
Whooping Cough
Activation of phospholipase C and phospholipase D by stimulation of adenosine A1, bradykinin or P2U receptors does not correlate well with protein kinase C activation.
Whooping Cough
Activation of phospholipase C by G-protein beta gamma subunits in DDT1MF-2 cells.
Whooping Cough
Activation of phospholipase C by heat shock requires GTP analogs and is resistant to pertussis toxin.
Whooping Cough
Activation of phospholipase C via adenosine receptors provides synergistic signals for secretion in antigen-stimulated RBL-2H3 cells. Evidence for a novel adenosine receptor.
Whooping Cough
Activation of phospholipase C-beta1 via Galphaq/11 during calcium mobilization by calcitonin gene-related peptide.
Whooping Cough
Activation of phospholipase D by E-series prostaglandins in human erythroleukemia cells.
Whooping Cough
Activation of phospholipase D by endothelin-1 in rat myometrium. Role of calcium and protein kinase C.
Whooping Cough
Activation of phospholipase D by interleukin-8 in human neutrophils.
Whooping Cough
Activation of phospholipase D in rabbit neutrophils by fMet-Leu-Phe is mediated by a pertussis toxin-sensitive GTP-binding protein that may be distinct from a phospholipase C-regulating protein.
Whooping Cough
Activation of phospholipase D signaling pathway by epidermal growth factor in osteoblastic cells.
Whooping Cough
Activation of PI3K/Akt signaling has a dominant negative effect on IL-12 production by macrophages infected with Leishmania amazonensis promastigotes.
Whooping Cough
Activation of PKCbeta(II) and PKCtheta is essential for LDL-induced cell proliferation of human aortic smooth muscle cells via Gi-mediated Erk1/2 activation and Egr-1 upregulation.
Whooping Cough
Activation of porcine oocytes via an exogenously introduced rat muscarinic M1 receptor.
Whooping Cough
Activation of presynaptic GABAB receptors inhibits evoked IPSCs in rat magnocellular neurons in vitro.
Whooping Cough
Activation of protein kinase B by adenosine A1 and A3 receptors in newborn rat cardiomyocytes.
Whooping Cough
Activation of protein kinase B by the A(1)-adenosine receptor in DDT(1)MF-2 cells.
Whooping Cough
Activation of protein kinase C inhibits hormonal stimulation of the GTPase activity of Gi in human platelets.
Whooping Cough
Activation of PtdIns(4,5)P2-sensitive phospholipase C in rabbit tracheal epithelial cells.
Whooping Cough
Activation of Ras and mitogen-activated protein kinase pathway by terminal complement complexes is G protein dependent.
Whooping Cough
Activation of rat frizzled-1 promotes Wnt signaling and differentiation of mouse F9 teratocarcinoma cells via pathways that require Galpha(q) and Galpha(o) function.
Whooping Cough
Activation of rat peritoneal mast cells by substance P and mastoparan.
Whooping Cough
Activation of serum response element by D2 dopamine receptor is governed by Gbetagamma-mediated MAPK and Rho pathways and regulated by RGS proteins.
Whooping Cough
Activation of signaling pathways in HL60 cells and human neutrophils by farnesylthiosalicylate.
Whooping Cough
Activation of sphingosine-1-phosphate receptor S1P5 inhibits oligodendrocyte progenitor migration.
Whooping Cough
Activation of spinal ?2 adrenergic receptors induces hyperglycemia in mouse though activating sympathetic outflow.
Whooping Cough
Activation of Src family kinase activity by the G protein-coupled thrombin receptor in growth-responsive fibroblasts.
Whooping Cough
Activation of superoxide formation and lysozyme release in human neutrophils by the synthetic lipopeptide Pam3Cys-Ser-(Lys)4. Involvement of guanine-nucleotide-binding proteins and synergism with chemotactic peptides.
Whooping Cough
Activation of Syk in neutrophils by antineutrophil cytoplasm antibodies occurs via Fcgamma receptors and CD18.
Whooping Cough
Activation of the Ca2+ message system by parathyroid hormone is dependent on the cell cycle.
Whooping Cough
Activation of the cloned human kappa opioid receptor by agonists enhances [35S]GTPgammaS binding to membranes: determination of potencies and efficacies of ligands.
Whooping Cough
Activation of the de novo biosynthesis of sphingolipids mediates angiotensin II type 2 receptor-induced apoptosis.
Whooping Cough
Activation of the extracellular signal-regulated kinase 2 by metabotropic glutamate receptors.
Whooping Cough
Activation of the formyl peptide receptor by the HIV-derived peptide T-20 suppresses interleukin-12 p70 production by human monocytes.
Whooping Cough
Activation of the G(i) heterotrimeric G protein by ANCA IgG F(ab')2 fragments is necessary but not sufficient to stimulate the recruitment of those downstream mediators used by intact ANCA IgG.
Whooping Cough
Activation of the Gi protein-RHOA axis by non-canonical Hedgehog signaling is independent of primary cilia.
Whooping Cough
Activation of the human FPRL-1 receptor promotes Ca2+ mobilization in U87 astrocytoma cells.
Whooping Cough
Activation of the human neutrophil 5-lipoxygenase by exogenous arachidonic acid: involvement of pertussis toxin-sensitive guanine nucleotide-binding proteins.
Whooping Cough
Activation of the human neutrophil 5-lipoxygenase by leukotriene B4.
Whooping Cough
Activation of the human peripheral cannabinoid receptor results in inhibition of adenylyl cyclase.
Whooping Cough
Activation of the mitogen-activated protein kinase cascade by pertussis toxin-sensitive and -insensitive pathways in cultured ventricular cardiomyocytes.
Whooping Cough
Activation of the mitogen-activated protein kinase pathway by fMet-leu-Phe in the absence of Lyn and tyrosine phosphorylation of SHC in transfected cells.
Whooping Cough
Activation of the mitogen-activated protein kinases Erk1/2 by erythropoietin receptor via a G(i )protein beta gamma-subunit-initiated pathway.
Whooping Cough
Activation of the muscarinic K+ channel by P2-purinoceptors via pertussis toxin-sensitive G proteins in guinea-pig atrial cells.
Whooping Cough
Activation of the p38 and p42/p44 mitogen-activated protein kinase families by the histamine H(1) receptor in DDT(1)MF-2 cells.
Whooping Cough
Activation of the prostaglandin FP receptor in human granulosa cells.
Whooping Cough
Activation of the Ras-GRF/CDC25Mm exchange factor by lysophosphatidic acid.
Whooping Cough
Activation of the respiratory burst and tyrosine phosphorylation of proteins in human neutrophils: no direct relationship and involvement of protein kinase C-dependent and -independent signaling pathways.
Whooping Cough
Activation of the respiratory burst in eosinophil leucocytes--a transduction sequence decoupled from cytosolic Ca2+ rise.
Whooping Cough
Activation of the respiratory burst in murine phagocytes by certain guanine ribonucleosides modified at the 7 and 8 positions: possible involvement of a pertussis toxin-sensitive G-protein.
Whooping Cough
Activation of the superoxide-generating NADPH oxidase of macrophages by sodium dodecyl sulfate in a soluble cell-free system: evidence for involvement of a G protein.
Whooping Cough
Activation of the {beta}-catenin/T-cell-specific transcription factor/lymphoid enhancer factor-1 pathway by plasminogen activators in ECV304 carcinoma cells.
Whooping Cough
Activation of type II adenylate cyclase by D2 and D4 but not D3 dopamine receptors.
Whooping Cough
Activation of various G-protein coupled receptors modulates Ca2+ channel currents via PTX-sensitive and voltage-dependent pathways in rat intracardiac neurons.
Whooping Cough
Activation of voltage-dependent calcium channels of mammalian sperm is required for zona pellucida-induced acrosomal exocytosis.
Whooping Cough
Activation of Wiskott-Aldrich syndrome protein and its association with other proteins by stromal cell-derived factor-1alpha is associated with cell migration in a T-lymphocyte line.
Whooping Cough
Activation-independent exposure of the GPIIb-IIIa fibrinogen receptor.
Whooping Cough
Activator of G-protein signaling in asymmetric cell divisions of the sea urchin embryo.
Whooping Cough
Activators of protein kinase C selectively enhance inactivation of a calcium current component of cultured sensory neurons in a pertussis toxin-sensitive manner.
Whooping Cough
Active Induction of Experimental Autoimmune Encephalomyelitis (EAE) with MOG35-55 in the Mouse.
Whooping Cough
Active induction of experimental autoimmune encephalomyelitis by MOG35-55 peptide immunization is associated with differential responses in separate compartments of the choroid plexus.
Whooping Cough
Active Induction of Experimental Autoimmune Encephalomyelitis in C57BL/6 Mice.
Whooping Cough
Active lymphocyte traffic induced in the periphery by cytokines and phytohemagglutinin: three different mechanisms?
Whooping Cough
Active movement of T cells away from a chemokine.
Whooping Cough
Active transducin alpha subunit carries PDE6 to detergent-resistant membranes in rod photoreceptor outer segments.
Whooping Cough
Activin A induces dendritic cell migration through the polarized release of CXCL12 and CXCL14.
Whooping Cough
Activin-A modulates growth hormone secretion from cultures of rat anterior pituitary cells.
Whooping Cough
Activities of complete and truncated forms of pertussis toxin subunits S1 and S2 synthesized by Escherichia coli.
Whooping Cough
Activity of adenosine diphosphates and triphosphates on a P2Y(T) -type receptor in brain capillary endothelial cells.
Whooping Cough
Acute and chronic effects of dexfenfluramine on the porcine coronary artery.
Whooping Cough
Acute and chronic opiate-regulation of adenylate cyclase in brain: specific effects in locus coeruleus.
Whooping Cough
Acute and delayed renal protection against renal ischemia and reperfusion injury with A1 adenosine receptors.
Whooping Cough
Acute ethanol-induced adenosine diphosphate ribosylation regulates the functional activity of rat striatal pertussis toxin-sensitive g proteins.
Whooping Cough
Acute exacerbation of idiopathic pulmonary fibrosis induced by pertussis: the first case report.
Whooping Cough
Acute inhibition of the betaine transporter by ATP and adenosine in renal MDCK cells.
Whooping Cough
Acute morphine alters GABAergic transmission in the central amygdala during naloxone-precipitated morphine withdrawal: role of cyclic AMP.
Whooping Cough
Acute stress-induced hyperinsulinemia in the pertussis toxin-treated rat: possible role of humoral beta-cell-tropic factors.
Whooping Cough
Acute-phase, but not constitutive serum amyloid A (SAA) is chemotactic for cultured human aortic smooth muscle cells.
Whooping Cough
Adaptation of Bordetella pertussis to vaccination: a cause for its reemergence?
Whooping Cough
Adaptations to chronic agonist exposure of mu-opioid receptor-expressing Chinese hamster ovary cells.
Whooping Cough
Adaptive responses of human monocytes infected by bordetella pertussis: the role of adenylate cyclase hemolysin.
Whooping Cough
Additive activation of hepatic NF-kappaB by ethanol and hepatitis B protein X (HBX) or HCV core protein: involvement of TNF-alpha receptor 1-independent and -dependent mechanisms.
Whooping Cough
Additive induction of Egr-1 (zif/268) mRNA expression in neuroblastoma x glioma hybrid NG108-15 cells via cholinergic muscarinic, alpha 2-adrenergic, and bradykinin receptors.
Whooping Cough
Adenine nucleotides directly stimulate pertussis toxin.
Whooping Cough
Adenine nucleotides inhibit recombinant N-type calcium channels via G protein-coupled mechanisms in HEK 293 cells; involvement of the P2Y13 receptor-type.
Whooping Cough
Adenine nucleotides promote dissociation of pertussis toxin subunits.
Whooping Cough
Adenine-induced inhibition of Na(+)-ATPase activity: Evidence for involvement of the Gi protein-coupled receptor in the cAMP signaling pathway.
Whooping Cough
Adenosine 3',5'-cyclic monophosphate-stimulated Ca++ efflux and acetylcholine release in ileal myenteric plexus are mediated by N-type Ca++ channels: inhibition by the kappa opioid receptor agonist.
Whooping Cough
Adenosine 5'-triphosphate, phorbol ester, and pertussis toxin effects on atrial natriuretic peptide stimulation of guanylate cyclase in a human renal cell line.
Whooping Cough
Adenosine A(1) receptor stimulation inhibits alpha(1)-adrenergic activation of the cardiac sarcolemmal Na(+)/H(+) exchanger.
Whooping Cough
Adenosine A(1) receptor-mediated transactivation of the EGF receptor produces a neuroprotective effect on cortical neurons in vitro.
Whooping Cough
Adenosine A(2a)-receptor activation increases contractility in isolated perfused hearts.
Whooping Cough
Adenosine A1 agonists and the Ca2+ channel agonist bay K 8644 produce a synergistic stimulation of the GTPase activity of Go in rat frontal cortical membranes.
Whooping Cough
Adenosine A1 and A2b receptors coupled to distinct interactive signaling pathways in intestinal muscle cells.
Whooping Cough
Adenosine A1 and class II metabotropic glutamate receptors mediate shared presynaptic inhibition of retinotectal transmission.
Whooping Cough
Adenosine A1 but not A2a receptor agonist reduces hyperalgesia caused by a surgical incision in rats: a pertussis toxin-sensitive G protein-dependent process.
Whooping Cough
Adenosine A1 receptor activation mediates NMDA receptor activity in a pertussis toxin-sensitive manner during normoxia but not anoxia in turtle cortical neurons.
Whooping Cough
Adenosine A1 receptor-induced upregulation of protein kinase C: role of pertussis toxin-sensitive G protein(s).
Whooping Cough
Adenosine A1 receptor-mediated activation of phospholipase C-beta 3 in intestinal muscle: dual requirement for alpha and beta gamma subunits of Gi3.
Whooping Cough
Adenosine A1 receptor-mediated inhibition of in vitro prolactin secretion from the rat anterior pituitary.
Whooping Cough
Adenosine A1 receptor-mediated inhibition of vasopressin action in inner medullary collecting duct.
Whooping Cough
Adenosine A1 receptor-mediated modulation of dopamine D1 receptors in stably cotransfected fibroblast cells.
Whooping Cough
Adenosine A1 receptors inhibit both adenylate cyclase activity and TRH-activated Ca2+ channels by a pertussis toxin-sensitive mechanism in GH3 cells.
Whooping Cough
Adenosine A1 receptors mediate mobilization of calcium in human bronchial smooth muscle cells.
Whooping Cough
Adenosine A1 receptors mediate retinotectal presynaptic inhibition: uncoupling by C-kinase and role in LTP during regeneration.
Whooping Cough
Adenosine A1-receptor coupling to phosphoinositide metabolism in pregnant guinea pig myometrium.
Whooping Cough
Adenosine A1-receptor stimulated increases in intracellular calcium in the smooth muscle cell line, DDT1MF-2.
Whooping Cough
Adenosine A1-receptors inhibit cAMP and Ca2+ mediated calcitonin secretion in C-cells.
Whooping Cough
Adenosine A2a and A2b receptors in cultured fetal chick heart cells. High- and low-affinity coupling to stimulation of myocyte contractility and cAMP accumulation.
Whooping Cough
Adenosine A2a-receptor activation enhances cardiomyocyte shortening via Ca2+-independent and -dependent mechanisms.
Whooping Cough
Adenosine A3 receptor-mediated regulation of p38 and extracellular-regulated kinase ERK1/2 via phosphatidylinositol-3'-kinase.
Whooping Cough
Adenosine acting at an A1 receptor decreases N-type calcium current in mouse motoneurons.
Whooping Cough
Adenosine activates the K+ channel and enhances cytosolic Ca2+ release via a P2Y purinoceptor in hippocampal neurons.
Whooping Cough
Adenosine activation of a nuclear pool of protein kinase C in rat splenocytes.
Whooping Cough
Adenosine acts as an endogenous activator of the cellular antioxidant defense system.
Whooping Cough
Adenosine and 5-HT inhibit substance P release from nerve endings in myenteric ganglia by distinct mechanisms.
Whooping Cough
Adenosine and muscarinic cholinergic receptors attenuate cyclic AMP accumulation by different mechanisms in 1321N1 astrocytoma cells.
Whooping Cough
Adenosine attenuates calcium paradox injury: role of adenosine A1 receptor.
Whooping Cough
Adenosine diphosphate ribosylation of G proteins by pertussis and cholera toxin in isolated membranes. Different requirements for and effects of guanine nucleotides and Mg2+.
Whooping Cough
Adenosine induces C1- efflux in endothelial cells via a pertussis toxin-sensitive G protein.
Whooping Cough
Adenosine induces vasoconstriction through Gi-dependent activation of phospholipase C in isolated perfused afferent arterioles of mice.
Whooping Cough
Adenosine inhibition of the hormonal response in the Sertoli cell is reversed by pertussis toxin.
Whooping Cough
Adenosine inhibitory effect on enhanced growth of aortic smooth muscle cells from streptozotocin-induced diabetic rats.
Whooping Cough
Adenosine inhibits activity of hypocretin/orexin neurons by the A1 receptor in the lateral hypothalamus: a possible sleep-promoting effect.
Whooping Cough
Adenosine inhibits fMLP-stimulated adherence and superoxide anion generation by human neutrophils at an early step in signal transduction.
Whooping Cough
Adenosine inhibits histamine-induced phosphoinositide hydrolysis mediated via pertussis toxin-sensitive G protein in human astrocytoma cells.
Whooping Cough
Adenosine inhibits L- and N-type calcium channels in pituitary melanotrophs. Evidence for the involvement of a G protein in calcium channel gating.
Whooping Cough
Adenosine inhibits the renal plasma-membrane (Ca2+ + Mg2+)-ATPase through a pathway sensitive to cholera toxin and sphingosine.
Whooping Cough
Adenosine inhibits the synaptic potentials in rat septal nucleus neurons mediated through pre- and postsynaptic A1-adenosine receptors.
Whooping Cough
Adenosine inhibits voltage-dependent Ca2+ currents in rat dissociated supraoptic neurones via A1 receptors.
Whooping Cough
Adenosine modulates voltage-gated Ca2+ channels in adult rat sympathetic neurons.
Whooping Cough
Adenosine nucleotides acting at the human P2Y1 receptor stimulate mitogen-activated protein kinases and induce apoptosis.
Whooping Cough
Adenosine potentiates the delayed-rectifier potassium conductance but has no effect on the hyperpolarization-activated Ih current in frog melanotrophs.
Whooping Cough
Adenosine receptor activation potentiates phosphoinositide hydrolysis and arachidonic acid release in DDT1-MF2 cells: putative interrelations.
Whooping Cough
Adenosine receptor down-regulation and insulin resistance following prolonged incubation of adipocytes with an A1 adenosine receptor agonist.
Whooping Cough
Adenosine receptor mediates motility in human melanoma cells.
Whooping Cough
Adenosine receptor-induced cAMP changes in D384 astrocytoma cells and the effect of bradykinin thereon.
Whooping Cough
Adenosine receptor-mediated calcium mobilization in cortical collecting tubule cells.
Whooping Cough
Adenosine receptor-mediated relaxation in coronary artery: evidence for a guanyl nucleotide-binding regulatory protein involvement.
Whooping Cough
Adenosine receptors mediate a pertussis toxin-insensitive prejunctional inhibition of noradrenaline release on a papillary muscle model.
Whooping Cough
Adenosine regulates a chloride channel via protein kinase C and a G protein in a rabbit cortical collecting duct cell line.
Whooping Cough
Adenosine release and uptake in cerebellar granule neurons both occur via an equilibrative nucleoside carrier that is modulated by G proteins.
Whooping Cough
Adenosine stimulation of AMP deaminase activity in adult rat cardiac myocytes.
Whooping Cough
Adenosine triphosphate activates mitogen-activated protein kinase in human granulosa-luteal cells.
Whooping Cough
Adenosine triphosphate-induced oxygen radical production and CD11b up-regulation: Ca(++) mobilization and actin reorganization in human eosinophils.
Whooping Cough
Adenosine, through the A(1) receptor, inhibits vesicular MHC class I cross-presentation by resting DC.
Whooping Cough
Adenosine-dependent enhancement by methylxanthines of excitatory synaptic transmission in hippocampus of rats.
Whooping Cough
Adenosine-mediated inhibition of casein production by mouse mammary glands in culture.
Whooping Cough
Adenosine-sensitive afterdepolarizations and triggered activity in guinea pig ventricular myocytes.
Whooping Cough
Adenosine-sensitive phosphoinositide turnover in a newly established renal cell line.
Whooping Cough
Adenosinergic modulation of ethanol-induced motor incoordination in the rat motor cortex.
Whooping Cough
Adenylate cyclase activity in microdissected rat liver tissue: periportal to pericentral activity gradient.
Whooping Cough
Adenylate cyclase activity of v-ras-k transformed rat epithelial thyroid cells.
Whooping Cough
Adenylate cyclase in human cytotrophoblasts: characterization and its role in modulating human chorionic gonadotropin secretion.
Whooping Cough
Adenylate cyclase system in fetal rat keratinizing epidermal cells (FRSK cells) and SV40-transformed human keratinocytes.
Whooping Cough
Adenylate cyclase toxin is critical for colonization and pertussis toxin is critical for lethal infection by Bordetella pertussis in infant mice.
Whooping Cough
Adenylate cyclase toxin-mediated delivery of the S1 subunit of pertussis toxin into mammalian cells.
Whooping Cough
Adenylyl cyclase activity in clonally derived human myoblast cultures: evidence for myoblast heterogeneity.
Whooping Cough
Adenylyl cyclase and G-proteins in Phytomonas.
Whooping Cough
Adenylyl cyclase inhibitory pathway is differentially modified in rat white and brown fat by high-energy diets.
Whooping Cough
Adenylyl cyclase integrates multiple G protein signals to modulate calcium currents in neonatal rabbit heart.
Whooping Cough
Adenylyl cyclase interaction with the D2 dopamine receptor family; differential coupling to Gi, Gz, and Gs.
Whooping Cough
Adenylyl cyclase is involved in desensitization and recovery of ATP-stimulated Cl- secretion in MDCK cells.
Whooping Cough
Adenylyl cyclase type II activity is regulated by two different mechanisms: implications for acute and chronic opioid exposure.
Whooping Cough
Adenylyl cyclase type-VIII activity is regulated by G(betagamma) subunits.
Whooping Cough
Adequate tetanus but poor diphtheria and pertussis response to a Tdap booster in adolescents with juvenile systemic lupus erythematosus.
Whooping Cough
Adhesion of human haematopoietic (CD34+) stem cells to human liver compartments is integrin and CD44 dependent and modulated by CXCR3 and CXCR4.
Whooping Cough
Adipocyte plasma membranes contain two Gi subtypes but are devoid of Go.
Whooping Cough
Adjuvant action of cholera toxin and pertussis toxin in the induction of IgA antibody response to orally administered antigen.
Whooping Cough
Adjuvant effect of pertussis toxin on the production of anti-ovalbumin IgE in mice and lack of direct correlation between PCA and ELISA.
Whooping Cough
Adjuvant immunotherapy of C6 glioma in rats with pertussis toxin.
Whooping Cough
Adjuvanticity of native and detoxified adenylate cyclase toxin of Bordetella pertussis towards co-administered antigens.
Whooping Cough
Adjuvanticity of pertussis toxin is mediated by differential effects on the activity of T suppressor, T amplifier and T helper cells.
Whooping Cough
Adoptive transfer of tumor-primed, in vitro-activated, CD4+ T effector cells (TEs) combined with CD8+ TEs provides intratumoral TE proliferation and synergistic antitumor response.
Whooping Cough
ADP and, indirectly, ATP are potent inhibitors of cAMP production in intact isoproterenol-stimulated C6 glioma cells.
Whooping Cough
ADP receptor antagonists inhibit platelet aggregation induced by the chemokines SDF-1, MDC and TARC.
Whooping Cough
ADP ribosylation by cholera toxin identifies three G-proteins that are activated by the galanin receptor. Studies with RINm5F cell membranes.
Whooping Cough
ADP-ribosyl proteins formed by pertussis toxin are specifically cleaved by mercury ions.
Whooping Cough
ADP-ribosylating and vacuolating cytotoxin of Mycoplasma pneumoniae represents unique virulence determinant among bacterial pathogens.
Whooping Cough
ADP-ribosylation activity in pertussis vaccines and its relationship to the in vivo histamine-sensitisation test.
Whooping Cough
ADP-ribosylation and early transcription regulation by bacteriophage T4.
Whooping Cough
ADP-ribosylation factor and Rho proteins mediate fMLP-dependent activation of phospholipase D in human neutrophils.
Whooping Cough
ADP-ribosylation of adenylate cyclase by pertussis toxin. Effects on inhibitory agonist binding.
Whooping Cough
ADP-ribosylation of alpha i3C20 by the S1 subunit and deletion peptides of S1 of pertussis toxin.
Whooping Cough
ADP-ribosylation of alpha-Gi proteins by pertussis toxin. Positional dissection of acceptor sites using membrane anchored synthetic peptides.
Whooping Cough
ADP-ribosylation of bovine S-antigen by cholera toxin.
Whooping Cough
ADP-ribosylation of cerebrocortical synaptosomal proteins by cholera, pertussis and botulinum toxins.
Whooping Cough
ADP-ribosylation of G proteins with pertussis toxin.
Whooping Cough
ADP-ribosylation of membrane proteins by bacterial toxins in the presence of NAD glycohydrolase.
Whooping Cough
ADP-ribosylation of signal-transducing guanine nucleotide-binding proteins by pertussis toxin.
Whooping Cough
ADP-ribosylation of the specific membrane protein by islet-activating protein, pertussis toxin, associated with inhibition of a chemotactic peptide-induced arachidonate release in neutrophils. A possible role of the toxin substrate in Ca2+-mobilizing biosignaling.
Whooping Cough
ADP-ribosylation of transducin by pertussis toxin blocks the light-stimulated hydrolysis of GTP and cGMP in retinal photoreceptors.
Whooping Cough
ADP-ribosylation of transducin by pertussis toxin.
Whooping Cough
ADP-ribosylation with pertussis toxin modulates the GTP-sensitive opioid ligand binding in digitonin-soluble extracts of rat brain membranes.
Whooping Cough
ADP-ribosyltransferase activity of pertussis toxin and immunomodulation by Bordetella pertussis.
Whooping Cough
ADP-ribosyltransferase mutations in the catalytic S-1 subunit of pertussis toxin.
Whooping Cough
Adrenal medullary opioid receptors are linked to GTP-binding proteins, pertussis toxin substrates.
Whooping Cough
Adrenaline inhibits depolarization-induced increases in capacitance the presence of elevated [Ca2+]i in insulin secreting cells.
Whooping Cough
Adrenaline-, not somatostatin-induced hyperpolarization is accompanied by a sustained inhibition of insulin secretion in INS-1 cells. Activation of sulphonylurea K+ATP channels is not involved.
Whooping Cough
Adrenergic agonists induce heterologous sensitization of adenylate cyclase in NS20Y-D(2L) cells.
Whooping Cough
Adrenergic and cholinergic inhibition of Ca2+ channels mediated by different GTP-binding proteins in rat sympathetic neurones.
Whooping Cough
Adrenergic control of cAMP generation in rat inner medullary collecting tubule cells.
Whooping Cough
Adrenergic inhibition of insulin secretion involves pertussis toxin-sensitive and -insensitive mechanisms.
Whooping Cough
Adrenergic receptor-mediated regulation of cultured rabbit airway smooth muscle cell proliferation.
Whooping Cough
Adrenergic receptors coupled to adenylate cyclase in human cerebromicrovascular endothelium.
Whooping Cough
Adrenergic receptors inhibit TRPV1 activity in the dorsal root ganglion neurons of rats.
Whooping Cough
Adrenergic regulation of the intracellular [Ca2+] and voltage-operated Ca2+ channel currents in the rat prostate neuroendocrine cells.
Whooping Cough
Adrenergic stimulation of vascular prostacyclin: role of alpha 1-receptors in smooth muscle cells.
Whooping Cough
Adrenergic-cholinergic interactions in left atria: a study using K+ channel agonists, antagonist and pertussis toxin.
Whooping Cough
Adrenoceptor-activation of oxygen consumption in rat parotid acini.
Whooping Cough
Adrenomedullin inhibits insulin exocytosis via pertussis toxin-sensitive G protein-coupled mechanism.
Whooping Cough
Adult formulation of a five component acellular pertussis vaccine combined with diphtheria and tetanus toxoids and inactivated poliovirus vaccine is safe and immunogenic in adolescents and adults.
Whooping Cough
Adult immunization with acellular pertussis vaccine.
Whooping Cough
Adult pertussis is unrecognized public health problem in Thailand.
Whooping Cough
Advanced glycation end products (AGEs) activate mast cells.
Whooping Cough
Adverse effects and sero-responses to an acellular pertussis/diphtheria/tetanus vaccine when combined with Haemophilus influenzae type b vaccine in an accelerated schedule.
Whooping Cough
Adverse events and antibody response to accelerated immunisation in term and preterm infants.
Whooping Cough
Adverse reactions and antibody response to an acellular pertussis toxoid vaccine in adult volunteers.
Whooping Cough
Adverse reactions and antibody response to four doses of acellular or whole cell pertussis vaccine combined with diphtheria and tetanus toxoids in the first 19 months of life.
Whooping Cough
Adverse reactions and antibody responses to acellular pertussis vaccine.
Whooping Cough
Adverse reactions and serologic response to a booster dose of acellular pertussis vaccine in children immunized with acellular or whole-cell vaccine as infants.
Whooping Cough
Adverse reactions of a pertussis toxoid vaccine in a double-blind placebo-controlled trial.
Whooping Cough
Aerolysin and pertussis toxin share a common receptor-binding domain.
Whooping Cough
Aerolysin induces G-protein activation and Ca2+ release from intracellular stores in human granulocytes.
Whooping Cough
Aerosol infection test for evaluation of pertussis vaccine.
Whooping Cough
Afamin stimulates osteoclastogenesis and bone resorption via Gi-coupled receptor and Ca2+/calmodulin-dependent protein kinase (CaMK) pathways.
Whooping Cough
Affinity cross-linked delta-opioid receptor in NG108-15 cells is low molecular weight (25 kDa) and coupled to GTP-binding proteins.
Whooping Cough
Affinity purification of pancreastatin receptor-Gq/11 protein complex from rat liver membranes.
Whooping Cough
Age increases cardiac Galpha(i2) expression, resulting in enhanced coupling to G protein-coupled receptors.
Whooping Cough
Age increases expression and receptor-mediated activation of G alpha i in human atria.
Whooping Cough
Age related differences in dynamics of specific memory B cell populations after clinical pertussis infection.
Whooping Cough
Age-associated reductions in cardiac beta1- and beta2-adrenergic responses without changes in inhibitory G proteins or receptor kinases.
Whooping Cough
Age-dependent alterations of human recombinant GM-CSF effects on human granulocytes.
Whooping Cough
Age-dependent changes in response of rat prostatic tissues to isoproterenol and forskolin: changes with sexual maturation in function of G proteins.
Whooping Cough
Age-dependent changes in transmembrane signalling: identification of G proteins in human lymphocytes and polymorphonuclear leukocytes.
Whooping Cough
Age-related alterations in adenylyl cyclase system of rat hearts.
Whooping Cough
Age-related alterations in the signal transduction pathways of the elastin-laminin receptor.
Whooping Cough
Age-related and testicular regression-induced changes in adenosine 3',5'-monophosphate responses in cultured hamster Sertoli cells.
Whooping Cough
Age-related changes in beta-adrenergic neuroeffector systems in the human heart.
Whooping Cough
Age-related changes in G proteins in rat aorta.
Whooping Cough
Age-related differences in antibody avidities to pertussis toxin and filamentous hemagglutinin in a healthy Japanese population.
Whooping Cough
Age-related differences in patterns of increased Bordetella pertussis antibodies.
Whooping Cough
Age-related loss of calcitriol stimulation of phosphoinositide hydrolysis in rat skeletal muscle.
Whooping Cough
Age-related regional sensitivity to pertussis toxin-mediated reduction in GABAB receptor binding in rat brain.
Whooping Cough
Age-specific long-term course of IgG antibodies to pertussis toxin after symptomatic infection with Bordetella pertussis.
Whooping Cough
Aggregation of pigment granules in single cultured Xenopus laevis melanophores by melatonin analogues.
Whooping Cough
Aging and calcitriol regulation of IP3 production in rat skeletal muscle and intestine.
Whooping Cough
Agmatine induced NO dependent rat mesenteric artery relaxation and its impairment in salt-sensitive hypertension.
Whooping Cough
Agomelatine modulates calcium signaling through protein kinase C and phospholipase C-mediated mechanisms in rat sensory neurons.
Whooping Cough
Agonist activation of delta-opioid receptor but not mu-opioid receptor potentiates fetal calf serum or tyrosine kinase receptor-mediated cell proliferation in a cell-line-specific manner.
Whooping Cough
Agonist activation of p42 and p44 mitogen-activated protein kinases following expression of the mouse delta opioid receptor in Rat-1 fibroblasts: effects of receptor expression levels and comparisons with G-protein activation.
Whooping Cough
Agonist Activity of the delta-antagonists TIPP and TIPP-psi in cellular models expressing endogenous or transfected delta-opioid receptors.
Whooping Cough
Agonist and antagonist binding to alpha 2-adrenergic receptors in purified membranes from human platelets. Implications of receptor-inhibitory nucleotide-binding protein stoichiometry.
Whooping Cough
Agonist and inverse agonist actions of beta-blockers at the human beta 2-adrenoceptor provide evidence for agonist-directed signaling.
Whooping Cough
Agonist and inverse agonist activity at the dopamine D3 receptor measured by guanosine 5'--gamma-thio-triphosphate--35S- binding.
Whooping Cough
Agonist dose-dependent PKA and GRK phosphorylation regulate {beta}2 adrenoceptor coupling to Gi proteins in cardiomyocytes.
Whooping Cough
Agonist function of the neurokinin receptor antagonist, [D-Arg1,D-Phe5,D-Trp7,9,Leu11]substance P, in monocytes.
Whooping Cough
Agonist interaction with alkylation-sensitive and -resistant alpha-1 adrenoceptor subtypes.
Whooping Cough
Agonist interactions with cardiac muscarinic receptors. Effects of Mg2+, guanine nucleotides, and monovalent cations.
Whooping Cough
Agonist occupation of an alpha2A-adrenoreceptor-Gi1alpha fusion protein results in activation of both receptor-linked and endogenous Gi proteins. Comparisons of their contributions to GTPase activity and signal transduction and analysis of receptor-G protein activation stoichiometry.
Whooping Cough
Agonist occupation of serotonin1A receptors in the rat hippocampus prevents their inactivation by pertussis toxin.
Whooping Cough
Agonist properties of pindolol at h5-HT1A receptors coupled to mitogen-activated protein kinase.
Whooping Cough
Agonist receptors and G proteins as mediators of platelet activation.
Whooping Cough
Agonist stimulation of Na+/K+/Cl- cotransport in rat glomerular mesangial cells. Evidence for protein kinase C-dependent and Ca2+/calmodulin-dependent pathways.
Whooping Cough
Agonist stimulation of the serotonin1A receptor causes suppression of anoxia-induced apoptosis via mitogen-activated protein kinase in neuronal HN2-5 cells.
Whooping Cough
Agonist-, antagonist-, and inverse agonist-regulated trafficking of the delta-opioid receptor correlates with, but does not require, G protein activation.
Whooping Cough
Agonist-biased signaling at the sst2A receptor: the multi-somatostatin analogs KE108 and SOM230 activate and antagonize distinct signaling pathways.
Whooping Cough
Agonist-dependent cannabinoid receptor signalling in human trabecular meshwork cells.
Whooping Cough
Agonist-dependent delivery of M(2) muscarinic acetylcholine receptors to the cell surface after pertussis toxin treatment.
Whooping Cough
Agonist-dependent, cholera toxin-catalyzed ADP-ribosylation of pertussis toxin-sensitive G-proteins following transfection of the human alpha 2-C10 adrenergic receptor into rat 1 fibroblasts. Evidence for the direct interaction of a single receptor with two pertussis toxin-sensitive G-proteins, Gi2 and Gi3.
Whooping Cough
Agonist-directed trafficking of porcine alpha(2A)-adrenergic receptor signaling in Chinese hamster ovary cells: l-isoproterenol selectively activates G(s).
Whooping Cough
Agonist-independent modulation of L-type Ca currents by basal Gs protein activities in single guinea pig ventricular myocytes.
Whooping Cough
Agonist-independent tonic inhibitory influence of Gi on adenylate cyclase activity in rabbit ventricular myocardium and its removal by pertussis toxin: a role of empty receptor-mediated Gi activation.
Whooping Cough
Agonist-Induced Activation of Histamine H3 Receptor Signals to Extracellular Signal-Regulated Kinases 1 and 2 through PKC-, PLD- and EGFR-dependent Mechanisms.
Whooping Cough
Agonist-induced desensitization of human ?3-adrenoceptors expressed in human embryonic kidney cells.
Whooping Cough
Agonist-induced desensitization, internalization, and phosphorylation of the sst2A somatostatin receptor.
Whooping Cough
Agonist-induced down-regulation of human 5-HT1A and 5-HT2 receptors in Swiss 3T3 cells.
Whooping Cough
Agonist-induced down-regulation of muscarinic cholinergic and alpha 2-adrenergic receptors after inactivation of Ni by pertussis toxin.
Whooping Cough
Agonist-induced down-regulation of the angiotensin II receptor in primary cultures of rat hepatocytes.
Whooping Cough
Agonist-induced GTPgamma35S binding mediated by human 5-HT(2C) receptors expressed in human embryonic kidney 293 cells.
Whooping Cough
Agonist-induced inhibition of inositol-trisphosphate-activated IK(Ca) in NG108-15 neuroblastoma hybrid cells.
Whooping Cough
Agonist-induced phosphorylation and desensitization of human m2 muscarinic cholinergic receptors in Sf9 insect cells.
Whooping Cough
Agonist-induced phosphorylation of somatostatin receptor subtype 1 (sst1). Relationship to desensitization and internalization.
Whooping Cough
Agonist-induced, G protein-dependent and -independent down-regulation of the mu opioid receptor. The receptor is a direct substrate for protein-tyrosine kinase.
Whooping Cough
Agonist-induced, GTP-dependent phosphoinositide hydrolysis in postmortem human brain membranes.
Whooping Cough
Agonist-mediated activation of PLA2 initiates Ca2+ mobilization in intestinal longitudinal smooth muscle.
Whooping Cough
Agonist-mediated downregulation of G alpha i via the alpha 2-adrenergic receptor is targeted by receptor-Gi interaction and is independent of receptor signaling and regulation.
Whooping Cough
Agonist-mediated tyrosine phosphorylation of isoforms of the shc adapter protein by the delta opioid receptor.
Whooping Cough
Agonist-selective dynamic compartmentalization of human Mu opioid receptor as revealed by resolutive FRAP analysis.
Whooping Cough
Agonist-sensitive binding of a photoreactive GTP analog to a G-protein alpha-subunit in membranes of HL-60 cells.
Whooping Cough
Agonist-specific activation of the beta2-adrenoceptor/Gs-protein and beta2-adrenoceptor/Gi-protein pathway in adult rat ventricular cardiomyocytes.
Whooping Cough
Agonist-specific down-regulation of the human delta-opioid receptor.
Whooping Cough
Agonist-stimulated high-affinity GTPase in Dictyostelium membranes.
Whooping Cough
Agonists activate Gi1 alpha or Gi2 alpha fused to the human mu opioid receptor differently.
Whooping Cough
Agonists cause nuclear translocation of phosphatidylinositol 3-kinase gamma. A Gbetagamma-dependent pathway that requires the p110gamma amino terminus.
Whooping Cough
Agonists for G-protein-coupled receptor 84 (GPR84) alter cellular morphology and motility but do not induce pro-inflammatory responses in microglia.
Whooping Cough
Agonists of the P2Y(AC)-receptor activate MAP kinase by a ras-independent pathway in rat C6 glioma.
Whooping Cough
Agouti-related peptide and MC3/4 receptor agonists both inhibit excitatory hypothalamic ventromedial nucleus neurons.
Whooping Cough
AGS3 and G?i3 Are Concomitantly Upregulated as Part of the Spindle Orientation Complex during Differentiation of Human Neural Progenitor Cells.
Whooping Cough
AhR Activation by TCDD (2,3,7,8-Tetrachlorodibenzo-p-dioxin) Attenuates Pertussis Toxin-Induced Inflammatory Responses by Differential Regulation of Tregs and Th17 Cells Through Specific Targeting by microRNA.
Whooping Cough
AKT-independent Reelin signaling requires interactions of heterotrimeric Go and Src.
Whooping Cough
Alarmin function of cathelicidin antimicrobial peptide LL37 through IL-36? induction in human epidermal keratinocytes.
Whooping Cough
Albumin endocytosis is regulated by heterotrimeric GTP-binding protein G alpha i-3 in opossum kidney cells.
Whooping Cough
Aldosterone inhibits apical NHE3 and HCO3- absorption via a nongenomic ERK-dependent pathway in medullary thick ascending limb.
Whooping Cough
Aldosterone stimulates vacuolar H+-ATPase activity in renal acid-secretory intercalated cells mainly via a protein kinase C dependent pathway.
Whooping Cough
Aldosterone stimulation of GTP hydrolysis in membranes from renal epithelia.
Whooping Cough
Alkylation of cysteine 41, but not cysteine 200, decreases the ADP-ribosyltransferase activity of the S1 subunit of pertussis toxin.
Whooping Cough
All five cloned human somatostatin receptors (hSSTR1-5) are functionally coupled to adenylyl cyclase.
Whooping Cough
All species of the genus Bordetella contain genes for pertussis toxin of Bordetella pertussis.
Whooping Cough
Allele frequencies of Bordetella pertussis virulence-associated genes identified from pediatric patients with severe respiratory infections.
Whooping Cough
Allopregnanolone activates GABA(A) receptor/Cl(-) channels in a multiphasic manner in embryonic rat hippocampal neurons.
Whooping Cough
Allosteric interactions at the m1, m2 and m3 muscarinic receptor subtypes.
Whooping Cough
Allosteric modulation of metabotropic glutamate receptor 4 activates IDO1-dependent, immunoregulatory signaling in dendritic cells.
Whooping Cough
Alpha 1 adrenoceptor activation potentiates taurine response mediated by protein kinase C in substantia nigra neurons.
Whooping Cough
Alpha 1-adrenergic inhibition of the beta-adrenergically activated Cl- current in guinea pig ventricular myocytes.
Whooping Cough
Alpha 1-adrenergic receptor coupling with phospholipase-C is negatively regulated by protein kinase-C in primary cultures of hypothalamic neurons and glial cells.
Whooping Cough
Alpha 1-adrenergic receptor mediates arachidonic acid release in spinal cord neurons independent of inositol phospholipid turnover.
Whooping Cough
Alpha 1-adrenergic receptor-linked guanine nucleotide-binding protein in muscle and kidney epithelial cells.
Whooping Cough
Alpha 1-adrenergic regulation of TSH-stimulated cyclic AMP accumulation in rat thyroid cells.
Whooping Cough
Alpha 1-adrenergic signaling in human airway epithelial cells involves inositol lipid and phosphate metabolism.
Whooping Cough
Alpha 1-adrenergic stimulation of in vitro growth hormone release and cytosolic free Ca2+ in rat somatotrophs.
Whooping Cough
Alpha 1-adrenoceptor-mediated inhibition of cellular cAMP accumulation in neonatal rat ventricular myocytes.
Whooping Cough
Alpha 1-adrenoceptors reduce background K+ current in rabbit ventricular myocytes.
Whooping Cough
Alpha 1B-adrenoceptor-mediated stimulation of Ca2+ mobilization and cAMP accumulation in isolated rat hepatocytes.
Whooping Cough
Alpha 2 adrenergic receptor subtypes expressed in Chinese hamster ovary cells activate differentially mitogen-activated protein kinase by a p21ras independent pathway.
Whooping Cough
Alpha 2 adrenoceptor potentiates glycine receptor-mediated taurine response through protein kinase A in rat substantia nigra neurons.
Whooping Cough
Alpha 2-adrenergic agonist enrichment of spinophilin at the cell surface involves beta gamma subunits of Gi proteins and is preferentially induced by the alpha 2A-subtype.
Whooping Cough
Alpha 2-adrenergic agonists stimulate DNA synthesis in Chinese hamster lung fibroblasts transfected with a human alpha 2-adrenergic receptor gene.
Whooping Cough
Alpha 2-adrenergic and muscarinic cholinergic receptors have opposing actions on cyclic AMP levels in SK-N-SH human neuroblastoma cells.
Whooping Cough
Alpha 2-adrenergic inhibition of Cl- transport by opercular epithelium is mediated by intracellular Ca2+.
Whooping Cough
Alpha 2-adrenergic inhibition of pancreatic islet glucose utilization is mediated by an inhibitory guanine nucleotide regulatory protein.
Whooping Cough
Alpha 2-adrenergic receptor stimulation mobilizes intracellular Ca2+ in human erythroleukemia cells.
Whooping Cough
Alpha 2-adrenergic receptor stimulation of phospholipase A2 and of adenylate cyclase in transfected Chinese hamster ovary cells is mediated by different mechanisms.
Whooping Cough
Alpha 2-adrenergic receptors activate phospholipase C in renal epithelial cells.
Whooping Cough
Alpha 2-adrenergic receptors in brown adipose tissue of infant rats--II. Studies on function and regulation.
Whooping Cough
Alpha 2-adrenergic receptors mediate inhibition of cyclic AMP production in neurons in primary culture.
Whooping Cough
Alpha 2-adrenergic receptors regulate Na(+)-H+ exchange via a cAMP-dependent mechanism.
Whooping Cough
Alpha 2-adrenergic stimulation promotes preadipocyte proliferation. Involvement of mitogen-activated protein kinases.
Whooping Cough
alpha 2-Adrenoceptors potentiate angiotensin II- and vasopressin-induced renal vasoconstriction in spontaneously hypertensive rats.
Whooping Cough
Alpha 2-C10 adrenergic receptors expressed in rat 1 fibroblasts can regulate both adenylylcyclase and phospholipase D-mediated hydrolysis of phosphatidylcholine by interacting with pertussis toxin-sensitive guanine nucleotide-binding proteins.
Whooping Cough
Alpha 2A adrenergic receptors inhibit cAMP accumulation in embryonic stem cells which lack Gi alpha 2.
Whooping Cough
Alpha 2A-adrenergic receptor stimulated calcium release is transduced by Gi-associated G(beta gamma)-mediated activation of phospholipase C.
Whooping Cough
Alpha 2A-adrenoceptors mediate activation of non-selective cation channels via Gi-proteins in human erythroleukaemia (HEL) cells. No evidence for a functional role of imidazoline receptors in modulating calcium.
Whooping Cough
alpha 2B-adrenergic receptor activates MAPK via a pathway involving arachidonic acid metabolism, matrix metalloproteinases, and epidermal growth factor receptor transactivation.
Whooping Cough
Alpha adrenergic receptor subtypes involved in prostaglandin synthesis are coupled to Ca++ channels through a pertussis toxin-sensitive guanine nucleotide-binding protein.
Whooping Cough
Alpha i-3 cDNA encodes the alpha subunit of Gk, the stimulatory G protein of receptor-regulated K+ channels.
Whooping Cough
Alpha(2) adrenoceptors regulate proliferation of human intestinal epithelial cells.
Whooping Cough
alpha(2A)-adrenoceptor: G(alphai1) protein-mediated pertussis toxin-resistant attenuation of G(s) coupling to the cyclic AMP pathway.
Whooping Cough
alpha(2B)-Adrenergic receptors activate MAPK and modulate proliferation of primary cultured proximal tubule cells.
Whooping Cough
Alpha-1 adrenergic stimulation of 1,4,5-inositol trisphosphate formation in ventricular myocytes.
Whooping Cough
alpha-1-Adrenergic receptor stimulation causes arachidonic acid release through pertussis toxin-sensitive GTP-binding protein and JNK activation in rabbit aortic smooth muscle cells.
Whooping Cough
Alpha-2 adrenoceptor mediated changes in aqueous dynamics: effect of pertussis toxin.
Whooping Cough
Alpha-2 adrenoceptors modulate the somatostatinergic system and G protein levels in the rat hippocampus.
Whooping Cough
Alpha-2 agonists induce amnesia through activation of the Gi-protein signalling pathway.
Whooping Cough
Alpha-adrenergic control of volume-regulated Cl- currents in rabbit atrial myocytes. Characterization of a novel ionic regulatory mechanism.
Whooping Cough
Alpha-adrenergic inhibition of rat pancreatic beta-cell replication and insulin secretion is mediated through a pertussis toxin-sensitive G-protein regulating islet cAMP content.
Whooping Cough
Alpha-adrenergic receptors regulate human lymphocyte amiloride-sensitive sodium channels.
Whooping Cough
alpha-Adrenergic-mediated activation of human reconstituted fibrinogen receptor (integrin alphaIIbbeta3) in Chinese hamster ovary cells.
Whooping Cough
Alpha-adrenoceptor activation of polyphosphoinositide hydrolysis in the rat tail artery.
Whooping Cough
Alpha-adrenoceptor mediated responses of the cauda epididymis of the guinea-pig.
Whooping Cough
alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid, but not N-methyl-D-aspartate, activates mitogen-activated protein kinase through G-protein beta gamma subunits in rat cortical neurons.
Whooping Cough
Alpha-bag cell peptide inhibits bag cell adenylate cyclase via a GTP-dependent mechanism.
Whooping Cough
Alpha-cobratoxin inhibits T-type calcium currents through muscarinic M4 receptor and G?-protein ?? subunits-dependent protein kinase A pathway in dorsal root ganglion neurons.
Whooping Cough
Alpha-fetoprotein contributes to THP-1 cell invasion and chemotaxis via protein kinase and Gi-protein-dependent pathways.
Whooping Cough
Alpha1 adrenergic receptors activate phosphatidylinositol 3-kinase in human vascular smooth muscle cells. Role in mitogenesis.
Whooping Cough
Alpha1-antitrypsin suppresses TNF-alpha and MMP-12 production by cigarette smoke-stimulated macrophages.
Whooping Cough
Alpha2-adrenergic receptor-mediated Ca2+ influx and release in porcine myometrial cells.
Whooping Cough
alpha2-Adrenoceptor activation increases calcium channel currents in single vascular smooth muscle cells isolated from human omental resistance arteries.
Whooping Cough
Alpha2-adrenoceptor regulation of adenylyl cyclase in CHO cells: dependence on receptor density, receptor subtype and current activity of adenylyl cyclase.
Whooping Cough
alpha2-Adrenoceptor stimulation promotes actin polymerization and focal adhesion in 3T3F442A and BFC-1beta preadipocytes.
Whooping Cough
Alpha2-adrenoceptor-mediated enhancement of glycine response in rat sacral dorsal commissural neurons.
Whooping Cough
Alpha2-adrenoceptor-mediated inhibition of cultured sympathetic neurons: changes in alpha2A/D-adrenoceptor-deficient mice.
Whooping Cough
Alpha2-adrenoceptors couple to inhibition of R-type calcium currents in myenteric neurons.
Whooping Cough
Alpha2-adrenoceptors in opossum kidney cells couple to stimulation of mitogen-activated protein kinase independently of adenylyl cyclase inhibition.
Whooping Cough
Alpha2-adrenoreceptor activation inhibits LTP and LTD in the basolateral amygdala: involvement of Gi/o-protein-mediated modulation of Ca2+-channels and inwardly rectifying K+-channels in LTD.
Whooping Cough
alpha4 Integrin/FN-CS1 mediated leukocyte adhesion to brain microvascular endothelial cells under flow conditions.
Whooping Cough
Alteration of G protein levels in antigen-challenged guinea pigs.
Whooping Cough
Alteration of lymphocyte opioid receptors in methadone maintenance subjects.
Whooping Cough
Alteration of mast cell responsiveness to adenosine by pertussis toxin.
Whooping Cough
Alteration of the GTP-dependent inhibitory pathway of rat striatal adenylate cyclase by phorbol esters.
Whooping Cough
Alterations in alpha 1-adrenergic receptor-mediated phosphatidylinositol turnover in hypoxic cardiac myocytes.
Whooping Cough
Alterations in detergent solubility of heterotrimeric G proteins after chronic activation of G(i/o)-coupled receptors: changes in detergent solubility are in correlation with onset of adenylyl cyclase superactivation.
Whooping Cough
Alterations in G-proteins and beta-adrenergic responsive adenylyl cyclase in rat urinary bladder during aging.
Whooping Cough
Alterations in G-proteins in congestive heart failure in cardiomyopathic (UM-X7.1) hamsters.
Whooping Cough
Alterations of cytosolic calcium in LLC-PK1 cells induced by vasopressin and exogenous purines.
Whooping Cough
Alterations of G protein function in cardiac tissues from streptozotocin-induced chronic diabetic rats.
Whooping Cough
Alterations of the preproenkephalin system in cardiac hypertrophy and its role in atrioventricular conduction.
Whooping Cough
Altered activity of the inhibitory guanyl nucleotide-binding component (Ni) induced by pertussis toxin. Uncoupling of Ni from receptor with continued coupling of Ni to the catalytic unit.
Whooping Cough
Altered adenylyl cyclase responsiveness subsequent to point mutations of Asp 128 in the third transmembrane domain of the delta-opioid receptor.
Whooping Cough
Altered beta-adrenergic receptor-stimulated cAMP formation in cultured skin fibroblasts from Alzheimer donors.
Whooping Cough
Altered endothelium-dependent and -independent hyperpolarization and endothelium-dependent relaxation in carotid arteries isolated from streptozotocin-induced diabetic rats.
Whooping Cough
Altered expression of inhibitory guanine nucleotide regulatory proteins (Gi alpha) in spontaneously hypertensive rats.
Whooping Cough
Altered expression of inhibitory guanine nucleotide regulatory proteins (Gi-proteins) in experimental hepatocellular carcinoma.
Whooping Cough
Altered guanine nucleoside triphosphate binding to transducin by cholera toxin-catalysed ADP-ribosylation.
Whooping Cough
Altered phosphatidylinositol breakdown after K-elastin stimulation in PMNLs of elderly.
Whooping Cough
Altered responses to modulators of guanine nucleotide binding protein activity in endotoxin tolerance.
Whooping Cough
Altered sinus nodal and atrioventricular nodal function in freely moving mice overexpressing the A1 adenosine receptor.
Whooping Cough
Altered subcellular signaling in murine peritoneal macrophages upon chronic morphine exposure.
Whooping Cough
Alternate coupling of receptors to Gs and Gi in pancreatic and submandibular gland cells.
Whooping Cough
Alternative splicing event modifying ADGRL1/latrophilin-1 cytoplasmic tail promotes both opposing and dual cAMP signaling pathways.
Whooping Cough
Alternative splicing produces transcripts encoding two forms of the alpha subunit of GTP-binding protein Go.
Whooping Cough
Aluminum-induced mitogenesis in MC3T3-E1 osteoblasts: potential mechanism underlying neoosteogenesis.
Whooping Cough
Amifostine ameliorates induction of experimental autoimmune encephalomyelitis: Effect on reactive oxygen species/NLRP3 pathway.
Whooping Cough
Amiloride interacts with guanine nucleotide regulatory proteins and attenuates the hormonal inhibition of adenylate cyclase.
Whooping Cough
Amino acid-specific ADP-ribosylation. Sensitivity to hydroxylamine of [cysteine(ADP-ribose)]protein and [arginine(ADP-ribose)]protein linkages.
Whooping Cough
Amino acid-specific ADP-ribosylation: structural characterization and chemical differentiation of ADP-ribose-cysteine adducts formed nonenzymatically and in a pertussis toxin-catalyzed reaction.
Whooping Cough
Aminooxypentane-RANTES induces CCR3 activation and internalization of CCR3 from the surface of human eosinophils.
Whooping Cough
Amitriptyline pretreatment preserves the antinociceptive effect of morphine in pertussis toxin-treated rats by lowering CSF excitatory amino acid concentrations and reversing the downregulation of glutamate transporters.
Whooping Cough
Ammonium decreases human polymorphonuclear leukocyte cytoskeletal actin.
Whooping Cough
Ammonium triggers calcium elevation in cultured mouse microglial cells by initiating Ca(2+) release from thapsigargin-sensitive intracellular stores.
Whooping Cough
AMPA receptor activates a G-protein that suppresses a cGMP-gated current.
Whooping Cough
Amplification of alpha 1D-adrenoceptor mediated contractions in rat aortic rings partially depolarised with KCl.
Whooping Cough
Amplification of cyclic AMP generation reveals agonistic effects of certain beta-adrenergic antagonists.
Whooping Cough
Amplification of the rat M2 muscarinic receptor gene by the polymerase chain reaction: functional expression of the M2 muscarinic receptor.
Whooping Cough
Amygdaloid kindling elicits persistent changes in pertussis toxin-catalyzed ADP-ribosylation.
Whooping Cough
Amylin (islet amyloid polypeptide) inhibition of insulin release in the perfused rat pancreas: implication of the adenylate cyclase/cAMP system.
Whooping Cough
Amyloid beta peptides trigger CD47-dependent mast cell secretory and phagocytic responses.
Whooping Cough
Amyloid beta protein (25-35) phosphorylates MARCKS through tyrosine kinase-activated protein kinase C signaling pathway in microglia.
Whooping Cough
Amyloid beta protein (25-35) stimulation of phospholipase C in LA-N-2 cells.
Whooping Cough
Amyloid precursor protein family-induced neuronal death is mediated by impairment of the neuroprotective calcium/calmodulin protein kinase IV-dependent signaling pathway.
Whooping Cough
Amyloid-beta induces chemotaxis and oxidant stress by acting at formylpeptide receptor 2, a G protein-coupled receptor expressed in phagocytes and brain.
Whooping Cough
Amyloid-beta precursor protein mediates neuronal toxicity of amyloid beta through Go protein activation.
Whooping Cough
An abnormal signal transduction pathway in CD4-CD8- double-negative lymph node cells of MRL lpr/lpr mice.
Whooping Cough
An acellular pertussis vaccine in healthy adults: safety and immunogenicity. Pennridge Pediatric Associates.
Whooping Cough
An adenosine derivative cooperates with TSH and Graves' IgG to induce Ca2+ mobilization in single human thyroid cells.
Whooping Cough
An adenosine receptor agonist-induced modulation of TSH-dependent cell growth in FRTL-5 thyroid cells mediated by inhibitory G protein, Gi.
Whooping Cough
An adhesion-associated agonist from the zona pellucida activates G protein-promoted elevations of internal Ca2+ and pH that mediate mammalian sperm acrosomal exocytosis.
Whooping Cough
An agonist-induced switch in G protein coupling of the gonadotropin-releasing hormone receptor regulates pulsatile neuropeptide secretion.
Whooping Cough
An alpha 40 subunit of a GTP-binding protein immunologically related to Go mediates a dopamine-induced decrease of Ca2+ current in snail neurons.
Whooping Cough
An amyloid-like C-terminal domain of thrombospondin-1 displays CD47 agonist activity requiring both VVM motifs.
Whooping Cough
An analysis of the occurrence of convulsions and death after childhood vaccination.
Whooping Cough
An antimicrobial peptide tachyplesin acts as a secondary secretagogue and amplifies lipopolysaccharide-induced hemocyte exocytosis.
Whooping Cough
An antimicrobial peptide with angiogenic properties, AG-30/5C, activates human mast cells through the MAPK and NF-?B pathways.
Whooping Cough
An aplysia dopamine1-like receptor: molecular and functional characterization.
Whooping Cough
An apoplastic mechanism for short-term effects of rare earth elements at lower concentrations.
Whooping Cough
An arginine residue is the site of receptor-stimulated, cholera toxin-catalysed ADP-ribosylation of pertussis toxin-sensitive G-proteins.
Whooping Cough
An autocrine motility factor secreted by the Dunning R-3327 rat prostatic adenocarcinoma cell subtype AT2.1.
Whooping Cough
An electrophysiological study of excitatory purinergic neuromuscular transmission in longitudinal smooth muscle of chicken anterior mesenteric artery.
Whooping Cough
An ELISA method to estimate the mono ADP-ribosyltransferase activities: e.g in pertussis toxin and vaccines.
Whooping Cough
An endogenous inhibitor of the ADP-ribosylation of GTP-binding proteins by pertussis toxin is present in bovine brain.
Whooping Cough
An enzyme-linked-immunosorbent assay method for detection of immunoglobulins to pertussis toxin.
Whooping Cough
An essential role for G?(i2) in Smoothened-stimulated epithelial cell proliferation in the mammary gland.
Whooping Cough
An evaluation of serious neurological disorders following immunization: a comparison of whole-cell pertussis and acellular pertussis vaccines.
Whooping Cough
An examination of the relationship between mu-opioid antinociceptive efficacy and G-protein coupling using pertussis and cholera toxins.
Whooping Cough
An excitatory muscarinic response in neonatal rat ventricular myocytes and its modulation by sympathetic innervation.
Whooping Cough
An fMLP receptor is involved in activation of phagocytosis by hemocytes from specific insect species.
Whooping Cough
An hour after immunization peritoneal B-1 cells are activated to migrate to lymphoid organs where within 1 day they produce IgM antibodies that initiate elicitation of contact sensitivity.
Whooping Cough
An ibotenate-selective metabotropic glutamate receptor mediates protein phosphorylation in cultured hippocampal pyramidal neurons.
Whooping Cough
An immunosuppressive agent, FTY720, increases intracellular concentration of calcium ion and induces apoptosis in HL-60.
Whooping Cough
An improved ELISA system for the measurement of IgG antibodies against pertussis toxin (PT) and filamentous hemagglutinin (FHA) in human sera.
Whooping Cough
An in vitro assay system as a potential replacement for the histamine sensitisation test for acellular pertussis based combination vaccines.
Whooping Cough
An international collaborative study of the effect of active pertussis toxin on the modified Kendrick test for acellular pertussis vaccines.
Whooping Cough
An intracellular guanine nucleotide release protein for G0. GAP-43 stimulates isolated alpha subunits by a novel mechanism.
Whooping Cough
An Intrinsic gamma-aminobutyric acid (GABA)ergic system in the adrenal cortex: findings from human and rat adrenal glands and the NCI-H295R cell line.
Whooping Cough
An investigation of Japanese neonatal and maternal antibody status against pertussis.
Whooping Cough
An investigation of whether agonist-selective receptor conformations occur with respect to M2 and M4 muscarinic acetylcholine receptor signalling via Gi/o and Gs proteins.
Whooping Cough
An M2 muscarinic receptor subtype coupled to both adenylyl cyclase and phosphoinositide turnover.
Whooping Cough
An M2-like muscarinic receptor enhances a delayed rectifier K+ current in rat sympathetic neurones.
Whooping Cough
An N-ethylmaleimide-sensitive G-protein modulates Aplysia Ca2+ channels.
Whooping Cough
An observational study of antibody responses to a primary or subsequent pertussis booster vaccination in Australian healthcare workers.
Whooping Cough
An RGD sequence in the P2Y(2) receptor interacts with alpha(V)beta(3) integrins and is required for G(o)-mediated signal transduction.
Whooping Cough
Analgesic alpha-conotoxins Vc1.1 and Rg1A inhibit N-type calcium channels in rat sensory neurons via GABAB receptor activation.
Whooping Cough
Analogous IgG subclass response to pertussis toxin in vaccinated children, healthy or affected by whooping cough.
Whooping Cough
Analyses of secondary structures in DNA by pyrosequencing.
Whooping Cough
Analyses of the cag pathogenicity island of Helicobacter pylori.
Whooping Cough
Analysis of adenosine actions on Ca2+ currents and synaptic transmission in cultured rat hippocampal pyramidal neurones.
Whooping Cough
Analysis of behavior and trafficking of dendritic cells within the brain during toxoplasmic encephalitis.
Whooping Cough
Analysis of Bordetella pertussis clinical isolates circulating in European countries during the period 1998-2012.
Whooping Cough
Analysis of Bordetella pertussis pertactin and pertussis toxin types from Queensland, Australia, 1999-2003.
Whooping Cough
Analysis of Bordetella pertussis populations in European countries with different vaccination policies.
Whooping Cough
Analysis of Bordetella pertussis virulence gene regulation by use of transcriptional fusions in Escherichia coli.
Whooping Cough
Analysis of calcium homeostasis in activated human polymorphonuclear leukocytes. Evidence for two distinct mechanisms for lowering cytosolic calcium.
Whooping Cough
Analysis of delta-opioid receptor activities stably expressed in CHO cell lines: function of receptor density?
Whooping Cough
Analysis of experimental autoimmune encephalomyelitis induced in F344 rats by pertussis toxin administration.
Whooping Cough
Analysis of inverse agonism at the delta opioid receptor after expression in Rat 1 fibroblasts.
Whooping Cough
Analysis of naïve lung CD4 T cells provides evidence of functional lung to lymph node migration.
Whooping Cough
Analysis of neurogenesis during experimental autoimmune encephalomyelitis reveals pitfalls of bioluminescence imaging.
Whooping Cough
Analysis of proteins encoded by the ptx and ptl genes of Bordetella bronchiseptica and Bordetella parapertussis.
Whooping Cough
Analysis of receptor-G protein interactions in permeabilized cells.
Whooping Cough
Analysis of relative levels of production of pertussis toxin subunits and Ptl proteins in Bordetella pertussis.
Whooping Cough
Analysis of retinal cellular infiltrate in experimental autoimmune uveoretinitis reveals multiple regulatory cell populations.
Whooping Cough
Analysis of second messenger pathways stimulated by different chemokines acting at the chemokine receptor CCR5.
Whooping Cough
Analysis of signaling events associated with activation of neutrophil superoxide anion production by eosinophil granule major basic protein.
Whooping Cough
Analysis of subassemblies of pertussis toxin subunits in vivo and their interaction with the ptl transport apparatus.
Whooping Cough
Analysis of Swedish Bordetella pertussis isolates with three typing methods: characterization of an epidemic lineage.
Whooping Cough
Analysis of the In Vivo Transcriptome of Bordetella pertussis during Infection of Mice.
Whooping Cough
Analysis of the proliferative response to lysophosphatidic acid in primary cultures of mammary epithelium: differences between normal and tumor cells.
Whooping Cough
Analysis of the role of Bphs/Hrh1 in the genetic control of responsiveness to pertussis toxin.
Whooping Cough
Analyzing titers of antibodies against bacterial and viral antigens, and bacterial toxoids in the intravenous immunoglobulins utilized in Taiwan.
Whooping Cough
Anandamide and WIN 55212-2 inhibit cyclic AMP formation through G-protein-coupled receptors distinct from CB1 cannabinoid receptors in cultured astrocytes.
Whooping Cough
Anandamide inhibits Fc?RI-dependent degranulation and cytokine synthesis in mast cells through CB2 and GPR55 receptor activation. Possible involvement of CB2-GPR55 heteromers.
Whooping Cough
Anandamide transport inhibitor AM404 and structurally related compounds inhibit synaptic transmission between rat hippocampal neurons in culture independent of cannabinoid CB1 receptors.
Whooping Cough
Anandamide, a brain endogenous compound, interacts specifically with cannabinoid receptors and inhibits adenylate cyclase.
Whooping Cough
Anandamide, an endogenous cannabimimetic eicosanoid, binds to the cloned human cannabinoid receptor and stimulates receptor-mediated signal transduction.
Whooping Cough
Anandamide, an endogenous cannabinoid, inhibits calcium currents as a partial agonist in N18 neuroblastoma cells.
Whooping Cough
Anandamide-induced mobilization of cytosolic Ca2+ in endothelial cells.
Whooping Cough
Anandamide-induced neuroblastoma cell rounding via the CB1 cannabinoid receptors.
Whooping Cough
Anandamide-induced vasorelaxation in rabbit aortic rings has two components: G protein dependent and independent.
Whooping Cough
Anandamide-mediated CB1/CB2 cannabinoid receptor--independent nitric oxide production in rabbit aortic endothelial cells.
Whooping Cough
Anaphylatoxins C5a and C3a induce nuclear factor kappaB activation in human peripheral blood monocytes.
Whooping Cough
Anaphylaxis and mortality induced by treatment of mice with anti-VLA-4 antibody and pertussis toxin.
Whooping Cough
Anaphylaxis to a self-peptide in the absence of mast cells or histamine.
Whooping Cough
Androgens increase intracellular calcium concentration and inositol 1,4,5-trisphosphate and diacylglycerol formation via a pertussis toxin-sensitive G-protein.
Whooping Cough
Anesthetic barbiturates enhance Gs alpha-dependent cyclic AMP production in S49 mouse lymphoma cells.
Whooping Cough
ANG II AT1 and AT2 receptors both inhibit bFGF-induced proliferation of bovine adrenocortical cells.
Whooping Cough
Angioedema as a predominant symptom of Bordetella pertussis infection.
Whooping Cough
Angiogenic activity of human CC chemokine CCL15 in vitro and in vivo.
Whooping Cough
Angiogenic and Arthritogenic Properties of the Soluble Form of CD13.
Whooping Cough
Angiogenic factors stimulate mast-cell migration.
Whooping Cough
Angiogenic Host Defense Peptide AG-30/5C and Bradykinin B2 Receptor Antagonist Icatibant Are G Protein Biased Agonists for MRGPRX2 in Mast Cells.
Whooping Cough
Angiogenic oligosaccharides of hyaluronan induce multiple signaling pathways affecting vascular endothelial cell mitogenic and wound healing responses.
Whooping Cough
Angiogenin depresses aortic smooth muscle cell cAMP by a pertussis toxin sensitive mechanism.
Whooping Cough
Angiogenin stimulates endothelial cell prostacyclin secretion by activation of phospholipase A2.
Whooping Cough
Angiopeptin (BIM23014C) inhibits vascular smooth muscle cell migration in vitro through a G-protein-mediated pathway and is associated with inhibition of adenylyl cyclase and cyclic AMP accumulation.
Whooping Cough
Angiostatic and chemotactic activities of the CXC chemokine CXCL4L1 (platelet factor-4 variant) are mediated by CXCR3.
Whooping Cough
Angiotensin AT(1) receptor phosphorylation and desensitization in a hepatic cell line. Roles of protein kinase c and phosphoinositide 3-kinase.
Whooping Cough
Angiotensin AT(1)-receptors depolarize neonatal spinal motoneurons and other ventral horn neurons via two different conductances.
Whooping Cough
Angiotensin AT1 receptors in Clone 9 rat liver cells: Ca2+ signaling and c-fos expression.
Whooping Cough
Angiotensin blocks substance P release from renal sensory nerves by inhibiting PGE2-mediated activation of cAMP.
Whooping Cough
Angiotensin II (A-II) steroidogenic refractoriness in Y-1 cells in the presence of A-II receptors negatively coupled to adenylate cyclase.
Whooping Cough
Angiotensin II activates mitogen-activated protein kinase via protein kinase C and Ras/Raf-1 kinase in bovine adrenal glomerulosa cells.
Whooping Cough
Angiotensin II activates the ouabain-insensitive Na+-ATPase from renal proximal tubules through a G-protein.
Whooping Cough
Angiotensin II and acetylcholine differentially activate mobilization of inositol phosphates in Xenopus laevis ovarian follicles.
Whooping Cough
Angiotensin II and dopamine modulate both cAMP and inositol phosphate productions in anterior pituitary cells. Involvement in prolactin secretion.
Whooping Cough
Angiotensin II and guanine nucleotides stimulate formation of inositol 1,4,5-trisphosphate and its metabolites in permeabilized adrenal glomerulosa cells.
Whooping Cough
Angiotensin II AT1 receptor/signaling mechanisms in the biphasic effect of the peptide on proximal tubular Na+,K+-ATPase.
Whooping Cough
Angiotensin II counteracts the effects of cAMP/PKA on NHE3 activity and phosphorylation in proximal tubule cells.
Whooping Cough
Angiotensin II directly increases rabbit renal brush-border membrane sodium transport: presence of local signal transduction system.
Whooping Cough
Angiotensin II effects on the cytosolic free Ca2+ concentration in N1E-115 neuroblastoma cells: kinetic properties of the Ca2+ transient measured in single fura-2-loaded cells.
Whooping Cough
Angiotensin II induced alteration of cyclic adenosine 3',5'-monophosphate generation in the hypertrophic myocardium of Dahl salt-sensitive rat on a high-salt diet.
Whooping Cough
Angiotensin II induces a rapid and transient increase of reactive oxygen species.
Whooping Cough
Angiotensin II induces diverse signal transduction pathways via both Gq and Gi proteins in liver epithelial cells.
Whooping Cough
Angiotensin II inhibits calcium and M current channels in rat sympathetic neurons via G proteins.
Whooping Cough
Angiotensin II inhibits protein kinase A-dependent chloride conductance in heart via pertussis toxin-sensitive G proteins.
Whooping Cough
Angiotensin II is retained in gonadotrophs of pituitary cell aggregates cultured in serum-free medium but does not mimic the effects of exogenous angiotensins and luteinizing-hormone-releasing hormone on growth hormone release.
Whooping Cough
Angiotensin II negatively modulates L-type calcium channels through a pertussis toxin-sensitive G protein in adrenal glomerulosa cells.
Whooping Cough
Angiotensin II phosphorylation of extracellular signal-regulated kinases in rat anterior pituitary cells.
Whooping Cough
Angiotensin II potentiates agonist-induced 3',5'-cyclic adenosine monophosphate production by cultured bovine adrenal cells through protein kinase C and calmodulin pathways.
Whooping Cough
Angiotensin II receptor recognized by DuP753 regulates two distinct guanine nucleotide-binding protein signaling pathways.
Whooping Cough
Angiotensin II receptor subtypes in cultured rat renal mesangial cells.
Whooping Cough
Angiotensin II receptor-mediated calcium influx in bovine adrenal glomerulosa cells.
Whooping Cough
Angiotensin II receptor-mediated stimulation of cytosolic-free calcium and inositol phosphates in chick myocytes.
Whooping Cough
Angiotensin II receptors and inhibitory actions in Leydig cells.
Whooping Cough
Angiotensin II receptors and mechanisms of action in adrenal glomerulosa cells.
Whooping Cough
Angiotensin II receptors negatively coupled to adenylate cyclase in rat myocardial sarcolemma. Involvement of inhibitory guanine nucleotide regulatory protein.
Whooping Cough
Angiotensin II stimulates angiotensinogen synthesis in hepatocytes by a pertussis toxin-sensitive mechanism.
Whooping Cough
Angiotensin II stimulates early proximal bicarbonate absorption in the rat by decreasing cyclic adenosine monophosphate.
Whooping Cough
Angiotensin II stimulates protein phosphatase 2A activity in cultured neuronal cells via type 2 receptors in a pertussis toxin sensitive fashion.
Whooping Cough
Angiotensin II stimulates T-type Ca2+ channel currents via activation of a G protein, Gi.
Whooping Cough
Angiotensin II stimulates the synthesis of angiotensinogen in hepatocytes by inhibiting adenylylcyclase activity and stabilizing angiotensinogen mRNA.
Whooping Cough
Angiotensin II stimulates tyrosine phosphorylation of the focal adhesion-associated protein paxillin in aortic smooth muscle cells.
Whooping Cough
Angiotensin II stimulation of Na-H antiporter activity is cAMP independent in OKP cells.
Whooping Cough
Angiotensin II stimulation of the stress-activated protein kinases in renal mesangial cells is mediated by the angiotensin AT1 receptor subtype.
Whooping Cough
Angiotensin II type 1 receptor signals through Raf-1 by a protein kinase C-dependent, Ras-independent mechanism.
Whooping Cough
Angiotensin II type 1 receptor-mediated activation of Ras in cultured rat vascular smooth muscle cells.
Whooping Cough
Angiotensin II type 1 receptor-mediated increase in cytosolic Ca(2+) and proliferation in mesothelial cells.
Whooping Cough
Angiotensin II type 1 receptors stimulate protein synthesis in human cardiac fibroblasts via a Ca2+-sensitive PKC-dependent tyrosine kinase pathway.
Whooping Cough
Angiotensin II type 2 receptor inhibits epidermal growth factor receptor transactivation by increasing association of SHP-1 tyrosine phosphatase.
Whooping Cough
Angiotensin II type 2 receptor inhibits vascular endothelial growth factor-induced migration and in vitro tube formation of human endothelial cells.
Whooping Cough
Angiotensin II type 2 receptor stimulation increases the rate of NG108-15 cell migration via actin depolymerization.
Whooping Cough
Angiotensin II type 2 receptor stimulation of neuronal delayed-rectifier potassium current involves phospholipase A2 and arachidonic acid.
Whooping Cough
Angiotensin II type 2 receptor stimulation of neuronal K+ currents involves an inhibitory GTP binding protein.
Whooping Cough
Angiotensin II type 2 receptor-mediated stimulation of protein phosphatase 2A in rat hypothalamic/brainstem neuronal cocultures.
Whooping Cough
Angiotensin II type 2 receptors mediate inhibition of mitogen-activated protein kinase cascade and functional activation of SHP-1 tyrosine phosphatase.
Whooping Cough
Angiotensin II type 2 receptors stimulate collagen synthesis in cultured vascular smooth muscle cells.
Whooping Cough
Angiotensin II upregulates type-1 angiotensin II receptors in renal proximal tubule.
Whooping Cough
Angiotensin II-induced inotropism requires an endocardial endothelium-nitric oxide mechanism in the in-vitro heart of Anguilla anguilla.
Whooping Cough
Angiotensin II-induced protein tyrosine phosphorylation in neonatal rat cardiac fibroblasts.
Whooping Cough
Angiotensin II-induced renal vasoconstriction in genetic hypertension.
Whooping Cough
Angiotensin II-induced stimulation of voltage-dependent Ca2+ currents in an adrenal cortical cell line.
Whooping Cough
Angiotensin II-mediated activation of L-type calcium channels involves phosphatidylinositol hydrolysis-independent activation of protein kinase C in rat portal vein myocytes.
Whooping Cough
Angiotensin II-mediated signal transduction events in cystic fibrosis pancreatic duct cells.
Whooping Cough
Angiotensin II-stimulated induction of sis-inducing factor is mediated by pertussis toxin-insensitive G(q) proteins in cardiac myocytes.
Whooping Cough
Angiotensin-converting enzyme inhibitors regulate the Na(+)-K+ pump via effects on angiotensin metabolism.
Whooping Cough
Animal models for pertussis vaccine neurotoxicity.
Whooping Cough
Annexin-1 mediates TNF-alpha-stimulated matrix metalloproteinase secretion from rheumatoid arthritis synovial fibroblasts.
Whooping Cough
Anomalous features of human neutrophil activation by influenza A virus are shared by related viruses and sialic acid-binding lectins.
Whooping Cough
ANP stimulates phospholipase C in cultured RIMCT cells: roles of protein kinases and G protein.
Whooping Cough
Antagonism by riluzole of entry of calcium evoked by NMDA and veratridine in rat cultured granule cells: evidence for a dual mechanism of action.
Whooping Cough
Antagonism of contractants and relaxants at the level of intracellular calcium and phosphoinositide turnover in the rat uterus.
Whooping Cough
Antagonism of LTD4-evoked relaxation in canine renal artery and vein.
Whooping Cough
Antagonist interaction with the human 5-HT(7) receptor mediates the rapid and potent inhibition of non-G-protein-stimulated adenylate cyclase activity: a novel GPCR effect.
Whooping Cough
Antagonists of epithelial chloride channels inhibit cAMP synthesis.
Whooping Cough
Antagonizing the different stages of kappa opioid receptor activation selectively and independently attenuates acquisition and consolidation of associative memories.
Whooping Cough
Anterior uveitis in murine relapsing experimental autoimmune encephalomyelitis (EAE), a mouse model of multiple sclerosis (MS).
Whooping Cough
Anti-adrenergic effect of adenosine on Na(+)-Ca(2+) exchange current recorded from guinea-pig ventricular myocytes.
Whooping Cough
Anti-IL-6 receptor antibody improves pain symptoms in mice with experimental autoimmune encephalomyelitis.
Whooping Cough
Anti-IL-6 Receptor Antibody Inhibits Spontaneous Pain at the Pre-onset of Experimental Autoimmune Encephalomyelitis in Mice.
Whooping Cough
Anti-immunoglobulin pretreatment induces a calcium-mobilization response to the chemotactic agent N-formylmethionylleucylphenylalanine in Daudi lymphoblastoid cells.
Whooping Cough
Anti-inflammatory Activity of Caspian Cobra (Naja naja oxiana) Snake Venom on the Serum Level of Interleukin-27 and Histopathological Changes in Myelin Oligodendrocyte Glycoprotein-experimental Autoimmune Encephalomyelitisinduced Mice.
Whooping Cough
Anti-inflammatory effect of angiotensin type 1 receptor antagonist on endotoxin-induced uveitis in rats.
Whooping Cough
Anti-Inflammatory Effect of Geniposide on Regulating the Functions of Rheumatoid Arthritis Synovial Fibroblasts via Inhibiting Sphingosine-1-Phosphate Receptors1/3 Coupling G?i/G?s Conversion.
Whooping Cough
Anti-inflammatory effects of nicotinic acid in adipocytes demonstrated by suppression of fractalkine, RANTES, and MCP-1 and upregulation of adiponectin.
Whooping Cough
Anti-inflammatory effects of the partially purified extract of radix Stephaniae tetrandrae: comparative studies of its active principles tetrandrine and fangchinoline on human polymorphonuclear leukocyte functions.
Whooping Cough
Anti-inflammatory preconditioning by agonists of adenosine A1 receptor.
Whooping Cough
Anti-invasive activities of experimental chemotherapeutic agents.
Whooping Cough
Anti-migratory and anti-invasive effect of somatostatin in human neuroblastoma cells: involvement of Rac and MAP kinase activity.
Whooping Cough
Anti-myelin antibodies play an important role in the susceptibility to develop proteolipid protein-induced experimental autoimmune encephalomyelitis.
Whooping Cough
Anti-pertussis antibody kinetics following DTaP-IPV booster vaccination in Norwegian children 7-8 years of age.
Whooping Cough
Anti-pertussis toxin IgG and anti-filamentous hemagglutinin IgG production in children immunized with pertussis acellular vaccine and comparison of these titers with the sera of pertussis convalescent children.
Whooping Cough
Anti-proliferative effect of a putative endocannabinoid, 2-arachidonylglyceryl ether in prostate carcinoma cells.
Whooping Cough
Antibacterial agents and release of periplasmic pertussis toxin from Bordetella pertussis.
Whooping Cough
Antibodies against the carboxyl-terminal 5-kDa peptide of the alpha subunit of transducin crossreact with the 40-kDa but not the 39-kDa guanine nucleotide binding protein from brain.
Whooping Cough
Antibodies directed against alpha subunits of Gi, Gx/z, GO and GS transducer proteins reduced the morphine withdrawal syndrome in mice.
Whooping Cough
Antibodies directed against synthetic peptides distinguish between GTP-binding proteins in neutrophil and brain.
Whooping Cough
Antibodies induced by oral immunization of mice with a recombinant protein produced in tobacco plants harboring Bordetella pertussis epitopes.
Whooping Cough
Antibodies recognizing protective pertussis toxin epitopes are preferentially elicited by natural infection versus acellular immunization.
Whooping Cough
Antibodies to
Whooping Cough
Antibodies to an alpha subunit of skeletal muscle calcium channels regulate parathyroid cell secretion.
Whooping Cough
Antibodies to Bordetella pertussis adenylate cyclase toxin in neonatal and maternal sera.
Whooping Cough
Antibodies to filamentous hemagglutinin of Bordetella pertussis and protection against whooping cough in schoolchildren.
Whooping Cough
Antibodies to pertussis antigens in pediatric health care workers.
Whooping Cough
Antibodies to the GTP binding protein, Go, antagonize noradrenaline-induced calcium current inhibition in NG108-15 hybrid cells.
Whooping Cough
Antibodies to the ras gene product inhibit adenylate cyclase and accelerate progesterone-induced cell division in Xenopus laevis oocytes.
Whooping Cough
Antibodies which recognize the C-terminus of the inhibitory guanine-nucleotide-binding protein (Gi) demonstrate that opioid peptides and foetal-calf serum stimulate the high-affinity GTPase activity of two separate pertussis-toxin substrates.
Whooping Cough
Antibody and cell-mediated immune responses to booster immunization with a new acellular pertussis vaccine in school children.
Whooping Cough
Antibody binding to cell surface amyloid precursor protein induces neuronal injury by deregulating the phosphorylation of focal adhesion signaling related proteins.
Whooping Cough
Antibody capture assay reveals bell-shaped concentration-response isotherms for h5-HT(1A) receptor-mediated Galpha(i3) activation: conformational selection by high-efficacy agonists, and relationship to trafficking of receptor signaling.
Whooping Cough
Antibody decay after immunisation of health-care workers with an acellular pertussis vaccine.
Whooping Cough
Antibody levels to pertussis toxin in preschool children in a non-vaccinating country (Sweden).
Whooping Cough
Antibody persistence 2 and 3 years after booster vaccination of adolescents with recombinant acellular pertussis monovalent aPgen or combined TdaPgen vaccines.
Whooping Cough
Antibody persistence after vaccination of adolescents with monovalent and combined acellular pertussis vaccines containing genetically inactivated pertussis toxin: a phase 2/3 randomised, controlled, non-inferiority trial.
Whooping Cough
Antibody response from whole-cell pertussis vaccine immunized Brazilian children against different strains of Bordetella pertussis.
Whooping Cough
Antibody response patterns to Bordetella pertussis antigens in vaccinated (primed) and unvaccinated (unprimed) young children with pertussis.
Whooping Cough
Antibody response to diphtheria-tetanus-pertussis immunization in preterm infants who receive dexamethasone for chronic lung disease.
Whooping Cough
Antibody response to pertussis toxin and filamentous haemagglutinin in NIH mice immunized with the International Standard for Pertussis Vaccine.
Whooping Cough
Antibody response to pertussis toxin in patients with clinical pertussis measured by enzyme-linked immunosorbent assay.
Whooping Cough
Antibody responses and persistence in the two years after immunization with two acellular vaccines and one whole-cell vaccine against pertussis.
Whooping Cough
Antibody responses in the serum and respiratory tract of mice following oral vaccination with liposomes coated with filamentous hemagglutinin and pertussis toxoid.
Whooping Cough
Antibody responses of healthy infants to concurrent administration of a bivalent haemophilus influenzae type b-hepatitis B vaccine with diphtheria-tetanus-pertussis, polio and measles-mumps-rubella vaccines.
Whooping Cough
Antibody responses to Bordetella pertussis and other childhood vaccines in infants born to mothers who received pertussis vaccine in pregnancy- a prospective, observational cohort study from the UK.
Whooping Cough
Antibody responses to Bordetella pertussis antigens and clinical correlations in elderly community residents.
Whooping Cough
Antibody responses to individual Bordetella pertussis fimbrial antigens Fim2 or Fim3 following immunisation with five component acellular pertussis vaccine or disease.
Whooping Cough
Antibody responses to pertussis toxin display different kinetics after clinical Bordetella pertussis infection than after vaccination with an acellular pertussis vaccine.
Whooping Cough
Antibody-induced activation of beta1 integrin receptors stimulates cAMP-dependent migration of breast cells on laminin-5.
Whooping Cough
Antibody-mediated inhibition of Bordetella pertussis adenylate-cyclase hemolysin-induced macrophage cytotoxicity is influenced by variations in the bacterial population.
Whooping Cough
Antibody-mediated neutralization of pertussis toxin-induced mitogenicity of human peripheral blood mononuclear cells.
Whooping Cough
Antidepressants activate the lysophosphatidic acid receptor LPA(1) to induce insulin-like growth factor-I receptor transactivation, stimulation of ERK1/2 signaling and cell proliferation in CHO-K1 fibroblasts.
Whooping Cough
Antidepressants induce profibrotic responses via the lysophosphatidic acid receptor LPA1.
Whooping Cough
Antiendothelial cell antibodies mediate enhanced leukocyte adhesion to cytokine-activated endothelial cells through a novel mechanism requiring cooperation between Fc{gamma}RIIa and CXCR1/2.
Whooping Cough
Antigen receptor-mediated protein tyrosine kinase activity is regulated by a pertussis toxin-sensitive G protein.
Whooping Cough
Antigenic divergence of Bordetella pertussis isolates in Taiwan.
Whooping Cough
Antigenic divergence suggested by correlation between antigenic variation and pulsed-field gel electrophoresis profiles of Bordetella pertussis isolates in Japan.
Whooping Cough
Antigenic heterogeneity in subunit S1 of pertussis toxin.
Whooping Cough
Antigenic variants in Bordetella pertussis strains isolated from vaccinated and unvaccinated children.
Whooping Cough
Antiinflammatory effects in experimental meningitis of prokaryotic peptides that mimic selectins.
Whooping Cough
Antilipolytic effect of calcium-sensing receptor in human adipocytes.
Whooping Cough
Antilipolytic effects of insulin and adenylate cyclase inhibitors on isolated human fat cells.
Whooping Cough
Antimicrobial peptides human beta-defensin (hBD)-3 and hBD-4 activate mast cells and increase skin vascular permeability.
Whooping Cough
Antimicrobial peptides human beta-defensins and cathelicidin LL-37 induce the secretion of a pruritogenic cytokine IL-31 by human mast cells.
Whooping Cough
Antimicrobial peptides human beta-defensins stimulate epidermal keratinocyte migration, proliferation and production of proinflammatory cytokines and chemokines.
Whooping Cough
Antimigraine drug, zolmitriptan, inhibits high-voltage activated calcium currents in a population of acutely dissociated rat trigeminal sensory neurons.
Whooping Cough
Antineoplastic effects of melatonin on a rare malignancy of mesenchymal origin: melatonin receptor-mediated inhibition of signal transduction, linoleic acid metabolism and growth in tissue-isolated human leiomyosarcoma xenografts.
Whooping Cough
Antineutrophil cytoplasm autoantibodies from patients with systemic vasculitis activate neutrophils through distinct signaling cascades: comparison with conventional Fcgamma receptor ligation.
Whooping Cough
Antinociception following application of DAMGO to the basolateral amygdala results from a direct interaction of DAMGO with Mu opioid receptors in the amygdala.
Whooping Cough
Antinociceptive action of myricitrin: involvement of the K+ and Ca2+ channels.
Whooping Cough
Antinociceptive properties of the new alkaloid, cis-8, 10-di-N-propyllobelidiol hydrochloride dihydrate isolated from Siphocampylus verticillatus: evidence for the mechanism of action.
Whooping Cough
Antiproliferative effect of sphingosylphosphorylcholine in thyroid FRO cancer cells mediated by cell cycle arrest in the G2/M phase.
Whooping Cough
Antiproliferative properties of sphingosine-1-phosphate in human hepatic myofibroblasts.
Whooping Cough
Antiproliferative property of sphingosine 1-phosphate in rat hepatocytes involves activation of Rho via Edg-5.
Whooping Cough
Antiproliferative signaling of luteinizing hormone-releasing hormone in human endometrial and ovarian cancer cells through G protein alpha(I)-mediated activation of phosphotyrosine phosphatase.
Whooping Cough
Antipsychotics with inverse agonist activity at the dopamine D3 receptor.
Whooping Cough
Antisecretory effects of somatostatin and vasopressin in the rat colon descendens in vitro.
Whooping Cough
Antisense oligodeoxynucleotides to GS protein alpha-subunit sequence accelerate differentiation of fibroblasts to adipocytes.
Whooping Cough
Antisense oligonucleotides against receptor kinase GRK2 disrupt target selectivity of beta-adrenergic receptors in atrial myocytes.
Whooping Cough
Antitoxin in human pertussis immune globulins.
Whooping Cough
Antitumor effects of cannabidiol, a nonpsychoactive cannabinoid, on human glioma cell lines.
Whooping Cough
Apelin (65-77) activates extracellular signal-regulated kinases via a PTX-sensitive G protein.
Whooping Cough
Apelin (65-77) activates p70 S6 kinase and is mitogenic for umbilical endothelial cells.
Whooping Cough
Apelin Decreases Lipolysis via Gq, Gi, and AMPK-Dependent Mechanisms.
Whooping Cough
Apelin is necessary for the maintenance of insulin sensitivity.
Whooping Cough
Apelin stimulates myosin light chain phosphorylation in vascular smooth muscle cells.
Whooping Cough
Apelin-13 enhances arcuate POMC neuron activity via inhibiting M-current.
Whooping Cough
Apelin-13 upregulates Egr-1 expression in rat vascular smooth muscle cells through the PI3K/Akt and PKC signaling pathways.
Whooping Cough
Apical and basolateral effects of PTH in OK cells: transport inhibition, messenger production, effects of pertussis toxin, and interaction with a PTH analog.
Whooping Cough
Apical localization of the alpha subunit of GTP-binding protein Go in choroidal and ciliated ependymocytes.
Whooping Cough
Aplysia synaptosomes. I. Preparation and biochemical and morphological characterization of subcellular membrane fractions.
Whooping Cough
Apolipoprotein CIII-induced THP-1 cell adhesion to endothelial cells involves pertussis toxin-sensitive G protein- and protein kinase C alpha-mediated nuclear factor-kappaB activation.
Whooping Cough
Apomorphine- and oxytocin-induced penile erection and yawning in male rats: effect of pertussis toxin.
Whooping Cough
Apoptotic effect of sphingosine 1-phosphate and increased sphingosine 1-phosphate hydrolysis on mesangial cells cultured at low cell density.
Whooping Cough
Appearance of Fim3 and ptxP3-Bordetella pertussis strains, in two regions of Sweden with different vaccination programs.
Whooping Cough
Application of xCELLigence real-time cell analysis to the microplate assay for pertussis toxin induced clustering in CHO cells.
Whooping Cough
Approaches to the control of acellular pertussis vaccines.
Whooping Cough
Aquaporin-4 autoantibodies cause asymptomatic aquaporin-4 loss and activate astrocytes in mouse.
Whooping Cough
Arachidonic acid as a second messenger for hypotonicity-induced calcium transients in rat IMCD cells.
Whooping Cough
Arachidonic acid as a second messenger. Interactions with a GTP-binding protein of human neutrophils.
Whooping Cough
Arachidonic acid for loading induced prostacyclin and prostaglandin E(2) release from osteoblasts and osteocytes is derived from the activities of different forms of phospholipase A(2).
Whooping Cough
Arachidonic acid inhibits hormone-stimulated cAMP accumulation in the medullary thick ascending limb of the rat kidney by a mechanism sensitive to pertussis toxin.
Whooping Cough
Arachidonic acid mediates interferon-gamma-induced sphingomyelin hydrolysis and monocytic marker expression in HL-60 cell line.
Whooping Cough
Arachidonic acid metabolism in isolated pancreatic islets. VI. Carbohydrate insulin secretagogues must be metabolized to induce eicosanoid release.
Whooping Cough
Arachidonic acid release from rat Leydig cells: the involvement of G protein, phospholipase A2 and regulation of cAMP production.
Whooping Cough
Arachidonic acid-induced mobilization of calcium in human neutrophils: evidence for a multicomponent mechanism of action.
Whooping Cough
Arachidonylcyclopropylamide increases microglial cell migration through cannabinoid CB2 and abnormal-cannabidiol-sensitive receptors.
Whooping Cough
Are GABAB receptors involved in the pharmacological effects of ethanol?
Whooping Cough
Are murine marginal-zone macrophages the splenic white pulp analog of high endothelial venules?
Whooping Cough
Are several G proteins involved in the different effects of endothelin-1 in mouse striatal astrocytes?
Whooping Cough
Aromatic D-amino acids act as chemoattractant factors for human leukocytes through a G protein-coupled receptor, GPR109B.
Whooping Cough
Arsenic activates endothelin-1 Gi protein-coupled receptor signaling to inhibit stem cell differentiation in adipogenesis.
Whooping Cough
Arsenic requires sphingosine-1-phosphate type 1 receptors to induce angiogenic genes and endothelial cell remodeling.
Whooping Cough
Arsenic-stimulated lipolysis and adipose remodeling is mediated by G-protein-coupled receptors.
Whooping Cough
Artocarpol A stimulation of superoxide anion generation in neutrophils involved the activation of PLC, PKC and p38 mitogen-activated PK signaling pathways.
Whooping Cough
Asbestos-induced activation of the respiratory burst in rabbit neutrophils.
Whooping Cough
Ascaris suum-derived products induce human neutrophil activation via a G protein-coupled receptor that interacts with the interleukin-8 receptor pathway.
Whooping Cough
Ascorbate-induced oxidative stress mediates TRP channel activation and cytotoxicity in human etoposide-sensitive and -resistant retinoblastoma cells.
Whooping Cough
Asiasari radix inhibits immunoglobulin E production on experimental models in vitro and in vivo.
Whooping Cough
Aspirin inhibits tumor necrosis factoralpha gene expression in murine tissue macrophages.
Whooping Cough
Aspirin-triggered lipoxin A4 and lipoxin A4 up-regulate transcriptional corepressor NAB1 in human neutrophils.
Whooping Cough
Assay of Bordetella pertussis heat-labile toxin with human embryonic lung cells.
Whooping Cough
Assay of pertussis vaccine reactivity factors by measurement of the paw swelling response, endotoxin and histamine-sensitizing factor.
Whooping Cough
Assays for Determining Pertussis Toxin Activity in Acellular Pertussis Vaccines.
Whooping Cough
Assays for G-protein-coupled receptor signaling using RGS-insensitive Galpha subunits.
Whooping Cough
Assembly and sealing of tight junctions: possible participation of G-proteins, phospholipase C, protein kinase C and calmodulin.
Whooping Cough
Assembly dynamics of actin in adherent human neutrophils.
Whooping Cough
Assessing the reactogenicity of Tdap vaccine administered during pregnancy and antibodies to Bordetella pertussis antigens in maternal and cord sera of Thai women.
Whooping Cough
Assessment of agonism at G-protein coupled receptors by phosphatidic acid and lysophosphatidic acid in human embryonic kidney 293 cells.
Whooping Cough
Assessment of cell-signaling pathways in the regulation of mammalian target of rapamycin (mTOR) by amino acids in rat adipocytes.
Whooping Cough
Assessment of Frizzled 6 membrane mobility by FRAP supports G protein coupling and reveals WNT-Frizzled selectivity.
Whooping Cough
Assessment of IgA anti-PT and IgG anti-ACT reflex testing to improve Bordetella pertussis serodiagnosis in recently vaccinated subjects.
Whooping Cough
Assessment of IgG avidity against pertussis toxin and filamentous hemagglutinin via an adapted enzyme-linked immunosorbent assay (ELISA) using ammonium thiocyanate.
Whooping Cough
Assessment of mechanisms involved in antinociception caused by sesquiterpene polygodial.
Whooping Cough
Assessment of the extracellular and intracellular actions of sphingosine 1-phosphate by using the p42/p44 mitogen-activated protein kinase cascade as a model.
Whooping Cough
Assessment of the immunogenicity and reactogenicity of a quadrivalent diphtheria, tetanus, acellular pertussis and hepatitis B (DTPa-HBV) vaccine administered in a single injection with Haemophilus influenzae type b conjugate vaccine, to infants at 2, 4 and 6 months of age.
Whooping Cough
Assignment of functional domains involved in ADP-ribosylation and B-oligomer binding within the carboxyl terminus of the S1 subunit of pertussis toxin.
Whooping Cough
Association Between Third-Trimester Tdap Immunization and Neonatal Pertussis Antibody Concentration.
Whooping Cough
Association of a solubilized prostaglandin E2 receptor from renal medulla with a pertussis toxin-reactive guanine nucleotide regulatory protein.
Whooping Cough
Association of guinea pig lung bombesin receptors with pertussis toxin-sensitive guanine nucleotide binding proteins.
Whooping Cough
Association of heterotrimeric G(i) with the insulin-like growth factor-I receptor. Release of G(betagamma) subunits upon receptor activation.
Whooping Cough
Association of heterotrimeric GTP binding regulatory protein (Go) with mitosis.
Whooping Cough
Association of interacting genes in the toll-like receptor signaling pathway and the antibody response to pertussis vaccination.
Whooping Cough
Association of ligand-receptor complexes with actin filaments in human neutrophils: a possible regulatory role for a G-protein.
Whooping Cough
Association of Pertussis Toxin with Severe Pertussis Disease.
Whooping Cough
Association of Routine Infant Vaccinations With Antibody Levels Among Preterm Infants.
Whooping Cough
Association of the N-formyl-Met-Leu-Phe receptor in human neutrophils with a GTP-binding protein sensitive to pertussis toxin.
Whooping Cough
Association of two pertussis toxin-sensitive G-proteins with the D2-dopamine receptor from bovine striatum.
Whooping Cough
Astrocyte mGlu(2/3)-mediated cAMP potentiation is calcium sensitive: studies in murine neuronal and astrocyte cultures.
Whooping Cough
Astrocytes are target cells for endothelins and sarafotoxin.
Whooping Cough
Astrocytes possess prostaglandin F2 alpha receptors coupled to phospholipase C.
Whooping Cough
Asymmetric distribution of muscarinic acetylcholine receptors in Madin-Darby canine kidney cells.
Whooping Cough
Asymmetrical distribution of G-proteins among the apical and basolateral membranes of rat enterocytes.
Whooping Cough
Atherogenic lipoproteins enhance mesangial cell expression of platelet-derived growth factor: role of protein tyrosine kinase and cyclic AMP-dependent protein kinase A.
Whooping Cough
ATP acting on P2Y receptors triggers calcium mobilization in primary cultures of rat neurohypophysial astrocytes (pituicytes).
Whooping Cough
ATP activates the potassium channel and enhances cytosolic Ca2+ release via a P2Y purinoceptor linked to pertussis toxin-insensitive G-protein in brain artery endothelial cells.
Whooping Cough
ATP and A1 adenosine receptor agonists mobilize intracellular calcium and activate K+ and Cl- currents in normal and cystic fibrosis airway epithelial cells.
Whooping Cough
ATP and adenosine prevent via different pathways the activation of caspases in apoptotic AKR-2B fibroblasts.
Whooping Cough
ATP and G proteins affect the runup of the Ca2+ current in bovine chromaffin cells.
Whooping Cough
ATP and its metabolite adenosine act synergistically to mobilize intracellular calcium via the formation of inositol 1,4,5-trisphosphate in a smooth muscle cell line.
Whooping Cough
ATP causes release of intracellular Ca2+ via the phospholipase C beta/IP3 pathway in astrocytes from the dorsal spinal cord.
Whooping Cough
ATP increases extracellular dopamine level through stimulation of P2Y purinoceptors in the rat striatum.
Whooping Cough
ATP inhibits glutamate synaptic release by acting at P2Y receptors in pyramidal neurons of hippocampal slices.
Whooping Cough
ATP inhibits the hydrosmotic effect of AVP in rabbit CCT: evidence for a nucleotide P2u receptor.
Whooping Cough
ATP modulation of calcium channels in chromaffin cells.
Whooping Cough
ATP priming of macrophage-derived chemokine responses in CHO cells expressing the CCR4 receptor.
Whooping Cough
ATP produces potassium currents via P3 purinoceptor in the follicle cell layer of Xenopus oocytes.
Whooping Cough
ATP receptor regulation of adenylate cyclase and protein kinase C activity in cultured renal LLC-PK1 cells.
Whooping Cough
ATP regulates muscarine-sensitive potassium current in dissociated bull-frog primary afferent neurones.
Whooping Cough
ATP shortens atrial action potential duration in the dog: role of adenosine, the vagus nerve, and G protein.
Whooping Cough
ATP stimulates Na+-glucose cotransporter activity via cAMP and p38 MAPK in renal proximal tubule cells.
Whooping Cough
ATP stimulates secretion in human neutrophils and HL60 cells via a pertussis toxin-sensitive guanine nucleotide-binding protein coupled to phospholipase C.
Whooping Cough
ATP stimulates sympathetic transmitter release via presynaptic P2X purinoceptors.
Whooping Cough
ATP- and EGF-stimulated phosphatidulinositol synthesis by two different pathways, phospholipase D and diacylglycerol kinase, in A-431 epidermoid carcinoma cells.
Whooping Cough
ATP-evoked increase in intracellular calcium via the P2Y receptor in proliferating bovine trophoblast cells.
Whooping Cough
ATP-evoked inositol phosphates formation through activation of P2U purinergic receptors in cultured astrocytes: regulation by PKC subtypes alpha, delta, and theta.
Whooping Cough
ATP-evoked potassium currents in rat striatal neurons are mediated by a P2 purinergic receptor.
Whooping Cough
ATP-induced arachidonic acid release in cultured astrocytes is mediated by Gi protein coupled P2Y1 and P2Y2 receptors.
Whooping Cough
ATP-induced Ca2+ influx is regulated via a pertussis toxin-sensitive mechanism in a PC12 cell clone.
Whooping Cough
ATP-induced calcium transient in cultured rat aortic smooth muscle cells.
Whooping Cough
ATP-induced cytoplasmic [Ca2+] increases in isolated cochlear outer hair cells. Involved receptor and channel mechanisms.
Whooping Cough
ATP-induced rise in apamin-sensitive Ca(2+)-dependent K+ conductance in adult rat hepatocytes.
Whooping Cough
ATP-induced secretion in PC12 cells and photoaffinity labeling of receptors.
Whooping Cough
Atrial natriuretic factor effects on cyclic nucleotides in a human renal cell line.
Whooping Cough
Atrial natriuretic factor increases cyclic GMP and cyclic AMP levels in a directly photosensitive pineal organ.
Whooping Cough
Atrial natriuretic factor intracellular signaling in the rat submandibular gland.
Whooping Cough
Atrial natriuretic factor negatively modulates secretin intracellular signaling in the exocrine pancreas.
Whooping Cough
Atrial natriuretic factor reduces cyclic adenosine monophosphate content of human fibroblasts by enhancing phosphodiesterase activity.
Whooping Cough
Atrial natriuretic factor stimulates migration by human neutrophils.
Whooping Cough
Atrial natriuretic peptide (ANP)-induced inhibition of glucagon secretion: mechanism of action in isolated rat pancreatic islets.
Whooping Cough
Atrial natriuretic peptide clearance receptor participates in modulating endothelial permeability.
Whooping Cough
Atrial natriuretic peptide inhibits iodide uptake and thyroglobulin messenger ribonucleic acid expression in cultured bovine thyroid follicles.
Whooping Cough
Atrial natriuretic peptide inhibits the actions of FSH and forskolin in meiotic maturation of pig oocytes via different signalling pathways.
Whooping Cough
Atrial natriuretic peptide modulates alveolar type 2 cell adenylyl and guanylyl cyclases and inhibits surfactant secretion.
Whooping Cough
Atrial natriuretic peptide modulates the hyperpolarization-activated current (If) in human atrial myocytes.
Whooping Cough
Atrial natriuretic peptide-C receptor-induced attenuation of adenylyl cyclase signaling activates phosphatidylinositol turnover in A10 vascular smooth muscle cells.
Whooping Cough
Atropine augments cardiac contractility by inhibiting cAMP-specific phosphodiesterase type 4.
Whooping Cough
Attenuated Bordetella pertussis Vaccine Candidate BPZE1 Promotes Human Dendritic Cell CCL21-Induced Migration and Drives a Th1/Th17 Response.
Whooping Cough
Attenuated Bordetella pertussis: new live vaccines for intranasal immunisation.
Whooping Cough
Attenuation of changes in G(i)-proteins and adenylyl cyclase in heart failure by an ACE inhibitor, imidapril.
Whooping Cough
Attenuation of chick heart adenylate cyclase by muscarinic receptors after pertussis toxin treatment.
Whooping Cough
Attenuation of muscarinic cholinergic inhibition by islet-activating protein in the heart.
Whooping Cough
Attenuation of parasite cAMP levels in T. cruzi-host cell membrane interactions in vitro.
Whooping Cough
Attenuation of signal flow from P2Y6 receptor by protein kinase C-alpha in SK-N-BE(2)C human neuroblastoma cells.
Whooping Cough
Attenuation of Th1 effector cell responses and susceptibility to experimental allergic encephalomyelitis in histamine H2 receptor knockout mice is due to dysregulation of cytokine production by antigen-presenting cells.
Whooping Cough
Attenuation of the low-density-lipoprotein-activated phosphoinositide signalling system by calcium blockers in human lymphocytes.
Whooping Cough
Atypical cannabinoid stimulates endothelial cell migration via a Gi/Go-coupled receptor distinct from CB1, CB2 or EDG-1.
Whooping Cough
Augmentation of calcium channel currents in response to G protein activation by GTP gamma S in chick sensory neurons.
Whooping Cough
Augmentation of glucose induced insulin secretion by pertussis vaccine, phentolamine and benextramine: involvement of mechanisms additional to prevention of the inhibitory actions of catecholamines in rats.
Whooping Cough
Augmentation of receptor-mediated adenylyl cyclase activity by Gi-coupled prostaglandin receptor subtype EP3 in a Gbetagamma subunit-independent manner.
Whooping Cough
Augmentation of the antibody response by antigen-specific glycosylation-enhancing factor.
Whooping Cough
Augmentation of tumor necrosis factor-alpha-induced monocytic differentiation of a myelomonocytic leukemia (WEHI-3B JCS) by pertussis toxin.
Whooping Cough
Augmented glucose-induced insulin release in mice lacking G(o2), but not G(o1) or G(i) proteins.
Whooping Cough
Autocrine antiapoptotic stimulation of cultured adult T-cell leukemia cells by overexpression of the chemokine I-309.
Whooping Cough
Autocrine biological effects of glycosyl inositol phosphate produced by reconstituted pig thyroid follicles: role of pertussis toxin sensitive G proteins.
Whooping Cough
Autocrine enhancement of leukotriene synthesis by endogenous leukotriene B4 and platelet-activating factor in human neutrophils.
Whooping Cough
Autocrine growth effect of IL-8 and GROalpha on a human pancreatic cancer cell line, Capan-1.
Whooping Cough
Autocrine motility factor and its receptor: role in cell locomotion and metastasis.
Whooping Cough
Autocrine motility factor is a growth factor.
Whooping Cough
Autocrine motility factor stimulates a three-fold increase in inositol trisphosphate in human melanoma cells.
Whooping Cough
Autocrine Regulation of Re-Epithelialization After Wounding by Chemokine Receptors CCR1, CCR10, CXCR1, CXCR2, and CXCR3.
Whooping Cough
Autoimmune experimental orchitis and chronic glomerulonephritis with end stage renal disease are controlled by Cgnz1 for susceptibility to end organ damage.
Whooping Cough
Autoinhibition of transmitter release from PC12 cells and sympathetic neurons through a P2Y receptor-mediated inhibition of voltage-gated Ca2+ channels.
Whooping Cough
Autonomic regulation of cardiac chloride current.
Whooping Cough
Autonomic regulation of delayed rectifier K+ current in mammalian heart involves G proteins.
Whooping Cough
Autoreactive T cells promote post-traumatic healing in the central nervous system.
Whooping Cough
Autoreceptor-induced inhibition of neuropeptide Y release from PC-12 cells is mediated by Y2 receptors.
Whooping Cough
Autoreceptor-mediated purinergic and cholinergic inhibition of motor nerve terminal calcium currents in the rat.
Whooping Cough
Autoregulation of acute progesterone and adenosine 3',5'-monophosphate responses to follicle-stimulating hormone (FSH) in porcine granulosa cells: effects of FSH, cholera toxin, forskolin, and pertussis toxin.
Whooping Cough
Autotaxin and lysophosphatidic acid stimulate intestinal cell motility by redistribution of the actin modifying protein villin to the developing lamellipodia.
Whooping Cough
Autotaxin promotes motility via G protein-coupled phosphoinositide 3-kinase gamma in human melanoma cells.
Whooping Cough
Auxin-dependent cell division and cell elongation. 1-Naphthaleneacetic acid and 2,4-dichlorophenoxyacetic acid activate different pathways.
Whooping Cough
Azithromycin is as effective as and better tolerated than erythromycin estolate for the treatment of pertussis.
Whooping Cough
B cell differentiation factor-induced B cell maturation: regulation via reduction in cAMP.
Whooping Cough
B cell differentiation factor-induced human B cell maturation: stimulation of intracellular calcium release.
Whooping Cough
B- and T-cell responses to the mycobacterium surface antigen PstS-1 in the respiratory tract and adjacent tissues. Role of adjuvants and routes of immunization.
Whooping Cough
B-cell responses after intranasal vaccination with the novel attenuated Bordetella pertussis vaccine strain BPZE1 in a randomized phase I clinical trial.
Whooping Cough
B-oligomer of pertussis toxin inhibits HIV-1 LTR-driven transcription through suppression of NF-kappaB p65 subunit activity.
Whooping Cough
B1 and B2 kinin receptors on cultured rabbit superior mesenteric artery smooth muscle cells: receptor-specific stimulation of inositol phosphate formation and arachidonic acid release by des-Arg9-bradykinin and bradykinin.
Whooping Cough
Baclofen induces spontaneous, rhythmic sharp waves in the rat hippocampal slice.
Whooping Cough
Bacteria and their toxins tamed for immunotherapy.
Whooping Cough
Bacterial ADP-ribosylating toxins: form, function, and recombinant vaccine development.
Whooping Cough
Bacterial entry to the splenic white pulp initiates antigen presentation to CD8+ T cells.
Whooping Cough
Bacterial secrets of secretion: EuroConference on the biology of type IV secretion processes.
Whooping Cough
Bacterial toxin modulation of the eukaryotic cell cycle: are all cytolethal distending toxins created equally?
Whooping Cough
Bacterial toxins affect early events of T lymphocyte activation.
Whooping Cough
Bacterial toxins: potential weapons against HIV infection.
Whooping Cough
Bacterial type AB? enterotoxins--structure, function and mechanism of action.
Whooping Cough
Baculovirus-expressed recombinant human zona pellucida glycoprotein-B induces acrosomal exocytosis in capacitated spermatozoa in addition to zona pellucida glycoprotein-C.
Whooping Cough
Basal levels of adenosine modulate mGluR5 on rat hippocampal astrocytes.
Whooping Cough
Basic fibroblast growth factor-stimulated endothelial cell movement is mediated by a pertussis toxin-sensitive pathway regulating phospholipase A2 activity.
Whooping Cough
Basolateral localization and transcytosis of gonadotropin and thyrotropin receptors expressed in Madin-Darby canine kidney cells.
Whooping Cough
Basophil activation through ASGM1 stimulation triggers PAF release and anaphylaxis-like shock in mice.
Whooping Cough
Behavioral Conditioning of Immune Responses with Cyclosporine A in a Murine Model of Experimental Autoimmune Uveitis.
Whooping Cough
Beneficial role of simvastatin in experimental autoimmune myositis.
Whooping Cough
Berberine possesses muscarinic agonist-like properties in cultured rodent cardiomyocytes.
Whooping Cough
beta 2-adrenergic receptor activates extracellular signal-regulated kinases (ERKs) via the small G protein rap1 and the serine/threonine kinase B-Raf.
Whooping Cough
Beta 2-adrenergic receptor signaling acts via NO release to mediate ACh-induced activation of ATP-sensitive K+ current in cat atrial myocytes.
Whooping Cough
beta 2-adrenergic receptor-induced p38 MAPK activation is mediated by protein kinase A rather than by Gi or gbeta gamma in adult mouse cardiomyocytes.
Whooping Cough
Beta 3- and alpha1-adrenergic Erk1/2 activation is Src- but not Gi-mediated in Brown adipocytes.
Whooping Cough
Beta adrenergic modulation of cardiac rhythm in a rat model of altered sympathetic neural development.
Whooping Cough
Beta adrenergic receptor activation attenuates the generation of inositol phosphates in the pregnant rat myometrium. Correlation with inhibition of Ca++ influx, a cAMP-independent mechanism.
Whooping Cough
Beta gamma subunits of GTP-binding proteins inhibit muscarinic receptor stimulation of phospholipase C.
Whooping Cough
Beta gamma-mediated enhancement of corticotropin-releasing hormone-stimulated adenylyl cyclase activity by activation of gamma-aminobutyric acid(B) receptors in membranes of rat frontal cortex.
Whooping Cough
Beta(2)-Adrenergic activation increases glycogen synthesis in L6 skeletal muscle cells through a signalling pathway independent of cyclic AMP.
Whooping Cough
Beta(2)-adrenergic and several other G protein-coupled receptors in human atrial membranes activate both G(s) and G(i).
Whooping Cough
Beta(2)-adrenergic receptor lacking the cyclic AMP-dependent protein kinase consensus sites fully activates extracellular signal-regulated kinase 1/2 in human embryonic kidney 293 cells: lack of evidence for G(s)/G(i) switching.
Whooping Cough
Beta(2)-adrenergic receptors potentiate glucocorticoid receptor transactivation via G protein beta gamma-subunits and the phosphoinositide 3-kinase pathway.
Whooping Cough
Beta(2)-adrenoceptor agonist clenbuterol reduces infarct size and myocardial apoptosis after myocardial ischaemia/reperfusion in anaesthetized rats.
Whooping Cough
Beta(3)-mediated engulfment of apoptotic tumor cells by dendritic cells is dependent on CAMKII: inhibition by HIV-1 Tat.
Whooping Cough
Beta-adrenergic and cholinergic modulation of inward rectifier K+ channel function and phosphorylation in guinea-pig ventricle.
Whooping Cough
beta-adrenergic and cholinergic modulation of the inwardly rectifying K+ current in guinea-pig ventricular myocytes.
Whooping Cough
Beta-adrenergic and somatostatin receptors regulate Na-H exchange independent of cAMP.
Whooping Cough
Beta-adrenergic cardiac hypertrophy is mediated primarily by the beta(1)-subtype in the rat heart.
Whooping Cough
beta-adrenergic modulation of maxi-K channels in vascular smooth muscle via Gi through a membrane-delimited pathway.
Whooping Cough
Beta-adrenergic modulation of Na-K pump activity in young and adult canine cardiac Purkinje fibers.
Whooping Cough
beta-Adrenergic receptor activation induces internalization of cardiac Cav1.2 channel complexes through a beta-Arrestin 1-mediated pathway.
Whooping Cough
Beta-adrenergic receptor subtype-specific signaling in cardiac myocytes from beta(1) and beta(2) adrenoceptor knockout mice.
Whooping Cough
Beta-adrenergic receptor-G protein-adenylate cyclase complex in experimental canine congestive heart failure produced by rapid ventricular pacing.
Whooping Cough
Beta-adrenergic regulation of cyclic AMP synthesis in cultured human syncytiotrophoblast.
Whooping Cough
beta-Adrenergic-responsive activation of extracellular signal-regulated protein kinases in salivary cells: role of epidermal growth factor receptor and cAMP.
Whooping Cough
Beta-adrenoceptor mediated signal transduction in congestive heart failure in cardiomyopathic (UM-X7.1) hamsters.
Whooping Cough
Beta-adrenoceptor, vasoactive intestinal polypeptide (VIP) and neuropeptide tyrosine (NPY) receptors functionally coupled to adenylate cyclase in the human neuroblastoma SK-N-MC cell line.
Whooping Cough
Beta-adrenoceptor-linked signal transduction in ischemic-reperfused heart and scavenging of oxyradicals.
Whooping Cough
Beta-adrenoceptor-mediated vascular relaxation in spontaneously hypertensive rats.
Whooping Cough
Beta-amyloid peptide binding protein does not couple to G protein in a heterologous Xenopus expression system.
Whooping Cough
beta-Amyloid peptide, substance P, and SEC receptor ligand activate cytoplasmic Ca2+ in neutrophil-like HL-60 cells: effect of chemotactic peptide antagonist BocMLF.
Whooping Cough
beta-Amyloid-induced IL-1 beta release from an activated human monocyte cell line is calcium- and G-protein-dependent.
Whooping Cough
Beta-arrestin 2-dependent angiotensin II type 1A receptor-mediated pathway of chemotaxis.
Whooping Cough
beta-Arrestin recruitment assay for the identification of agonists of the sphingosine 1-phosphate receptor EDG1.
Whooping Cough
beta-arrestin-dependent, G protein-independent ERK1/2 activation by the beta2 adrenergic receptor.
Whooping Cough
beta-Arrestin-mediated PDE4 cAMP phosphodiesterase recruitment regulates beta-adrenoceptor switching from Gs to Gi.
Whooping Cough
Beta-arrestin2 enhances beta2-adrenergic receptor-mediated nuclear translocation of ERK.
Whooping Cough
Beta-chemokine TCA3 binds to and activates rat vascular smooth muscle cells.
Whooping Cough
Beta-defensins: linking innate and adaptive immunity through dendritic and T cell CCR6.
Whooping Cough
Beta1-adrenoceptors in rat anterior pituitary may be constitutively active. Inverse agonism of CGP 20712A on basal 3',5'-cyclic adenosine 5'-monophosphate levels.
Whooping Cough
beta2-Adrenergic signaling in human heart: shift from the cyclic AMP to the arachidonic acid pathway.
Whooping Cough
Beta3-adrenoceptor in the eel (Anguilla anguilla) heart: negative inotropy and NO-cGMP-dependent mechanism.
Whooping Cough
Beta3-adrenoceptors modulate left ventricular relaxation in the rat heart via the NO-cGMP-PKG pathway.
Whooping Cough
betagamma dimers derived from Go and Gi proteins contribute different components of adrenergic inhibition of Ca2+ channels in rat sympathetic neurones.
Whooping Cough
betagamma Dimers mediate synergy of dopamine D2 and adenosine A2 receptor-stimulated PKA signaling and regulate ethanol consumption.
Whooping Cough
Betagamma subunits of G(i/o) suppress EGF-induced ERK5 phosphorylation, whereas ERK1/2 phosphorylation is enhanced.
Whooping Cough
Betagamma subunits of pertussis toxin-sensitive G proteins mediate A1 adenosine receptor agonist-induced activation of phospholipase C in collaboration with thyrotropin. A novel stimulatory mechanism through the cross-talk of two types of receptors.
Whooping Cough
bFGF activates endothelial Ca2+-activated K+ channels involving G-proteins and tyrosine kinases.
Whooping Cough
Biased ?-opioid receptor agonists diversely regulate lateral mobility and functional coupling of the receptor to its cognate G proteins.
Whooping Cough
Bicarbonate induces sensitization of cyclic AMP accumulation by intact 1321N1 human astrocytoma cells.
Whooping Cough
Bidirectional modulation of exocytosis by angiotensin II involves multiple G-protein-regulated transduction pathways in chromaffin cells.
Whooping Cough
Bilateral ureteral obstruction alters levels of the G-protein subunits G alpha s and G alpha q/11.
Whooping Cough
Bile acids regulate hepatic gluconeogenic genes and FXR via G-alpha-i protein coupled receptor(s) and the AKT pathway.
Whooping Cough
Bimodal acute effects of A1 adenosine receptor activation on Na+/H+ exchanger 3 in opossum kidney cells.
Whooping Cough
Bimodal regulation of cyclic AMP by muscarinic receptors. Involvement of multiple G proteins and different forms of adenylyl cyclase.
Whooping Cough
Binding and agonist/antagonist actions of M35, galanin(1-13)-bradykinin(2-9)amide chimeric peptide, in Rin m 5F insulinoma cells.
Whooping Cough
Binding interaction of gamma aminobutyric acid A and B receptors in cell culture.
Whooping Cough
Binding kinetics of delta opioid receptors differ for microsomal and synaptic sites.
Whooping Cough
Binding of A1 adenosine receptor ligand [3H]8-cyclopentyl-1,3-dipropylxanthine in coronary smooth muscle.
Whooping Cough
Binding of ATP by pertussis toxin and isolated toxin subunits.
Whooping Cough
Binding of IgG containing immune complexes to human neutrophil Fc gamma RII and Fc gamma RIII induces actin polymerization by a pertussis toxin-insensitive transduction pathway.
Whooping Cough
Binding of NAD+ to pertussis toxin.
Whooping Cough
Binding of pertussis toxin to eucaryotic cells and glycoproteins.
Whooping Cough
Binding of pertussis toxin to lipid vesicles containing glycolipids.
Whooping Cough
Binding of the cytosolic p200 protein to Golgi membranes is regulated by heterotrimeric G proteins.
Whooping Cough
Binding of the non-typeable Haemophilus influenzae lipooligosaccharide to the PAF receptor initiates host cell signalling.
Whooping Cough
Binding, coupling, and mRNA subtype heterogeneity of alpha 1-adrenergic receptors in cultured human RPE.
Whooping Cough
Biochemical analysis of mutations at tyrosine-98 of the S1 subunit of pertussis toxin.
Whooping Cough
Biochemical and biological activities of recombinant S1 subunit of pertussis toxin.
Whooping Cough
Biochemical and functional characterization of high-affinity urotensin II receptors in rat cortical astrocytes.
Whooping Cough
Biochemical and immunochemical localization of GTP-binding proteins in the rat ileal enterocyte.
Whooping Cough
Biochemical and physical analyses of newly synthesized muscarinic acetylcholine receptors in cultured embryonic chicken cardiac cells.
Whooping Cough
Biochemical demonstration of mu-opioid receptor association with Gsalpha: enhancement following morphine exposure.
Whooping Cough
Biochemical discrimination of the predominant pertussis toxin substrate of rabbit neutrophils from brain Gi and Go: isoelectric focusing improves resolution of pertussis toxin substrates.
Whooping Cough
Biochemical events associated with the stimulation of rabbit neutrophils by platelet-activating factor.
Whooping Cough
Biochemical evidence for somatostatin receptors in murine neuroblastoma clone N1E-115.
Whooping Cough
Biochemical investigation of cell motile activity in rheumatoid synovial fluid.
Whooping Cough
Biochemical properties of pertussis toxin.
Whooping Cough
Biologic activities of the beta-chemokine TCA3 on neutrophils and macrophages.
Whooping Cough
Biological actions of the free acid of hepoxilin A3 on human neutrophils.
Whooping Cough
Biological activities of novel lipid mediator sphingosine 1-phosphate in rat hepatic stellate cells.
Whooping Cough
Biological basis and possible physiological implications of melatonin receptor-mediated signaling in the rat epididymis.
Whooping Cough
Biologically active sequence (KDI) mediates the neurite outgrowth function of the gamma-1 chain of laminin-1.
Whooping Cough
Biosensing with G-protein coupled receptor systems.
Whooping Cough
Biosynthesis and functions of leukotriene C4.
Whooping Cough
Biosynthesis of paf-acether in cultured-mouse mast cells: the role of calcium and G proteins.
Whooping Cough
Biosynthesis of somatostatin in canine fundic D cells.
Whooping Cough
Biphasic actions of prostaglandin E(2) on the renal afferent arteriole : role of EP(3) and EP(4) receptors.
Whooping Cough
Biphasic alterations of cAMP levels and inhibition of norepinephrine release in iris-ciliary body by bremazocine.
Whooping Cough
Biphasic and synergistic activation of p44mapk (ERK1) by growth factors: correlation between late phase activation and mitogenicity.
Whooping Cough
Biphasic dose-response curve to muscarine on the rat superior cervical ganglion.
Whooping Cough
Biphasic dose-response curves to arecoline in rat atria-mediation by a single promiscuous receptor or two receptor subtypes?
Whooping Cough
Biphasic effect of cAMP-elevating agents on ICAM-1 expression stimulated by retinoic acid and interferon gamma.
Whooping Cough
Biphasic effect of interleukin-1 beta on arginine vasopressin-induced cellular cyclic adenosine monophosphate production in cultured rat renal papillary collecting tubule cells.
Whooping Cough
Biphasic effects of cannabinoids on acetylcholine release in the hippocampus: site and mechanism of action.
Whooping Cough
Biphasic effects of carbachol on stimulated cAMP accumulation in mouse parotid acini.
Whooping Cough
Biphasic Erk1/2 activation sequentially involving Gs and Gi signaling is required in beta3-adrenergic receptor-induced primary smooth muscle cell proliferation.
Whooping Cough
Biphasic kinetics of inositol 1,4,5-trisphosphate accumulation in gastrin-stimulated parietal cells. Effects of pertussis toxin and extracellular calcium.
Whooping Cough
Biphasic modulation of intracellular Ca2+ concentration by interleukin-1beta in cortical synaptosomes: involvement of a pertussis toxin-sensitive G-protein and mitogen-activated protein kinase.
Whooping Cough
Biphasic modulation of voltage-dependent currents of retinal cones by cannabinoid CB1 receptor agonist WIN 55212-2.
Whooping Cough
Biphasic regulation of paracellular permeability in human cervical cells by two distinct nucleotide receptors.
Whooping Cough
Biphasic response to human galanin of extracellular acidification in human Bowes melanoma cells.
Whooping Cough
Biphasic, opposing modulation of cloned neuronal alpha1E Ca channels by distinct signaling pathways coupled to M2 muscarinic acetylcholine receptors.
Whooping Cough
Bitter tastants induce relaxation of rat thoracic aorta precontracted with high K(+).
Whooping Cough
Bitter taste receptors as targets for tocolytics in preterm labor therapy.
Whooping Cough
Bitter taste receptors stimulate phagocytosis in human macrophages through calcium, nitric oxide, and cyclic-GMP signaling.
Whooping Cough
Block of light responses of salamander rods by pertussis toxin and reversal by nicotinamide.
Whooping Cough
Blockade by pertussis toxin of the opioid effect on guinea pig ileum. Contractility and electrophysiological neuronal recording.
Whooping Cough
Blockade of a late inhibitory postsynaptic potential in hippocampal CA3 neurons in vitro reveals a late depolarizing potential that is augmented by pentobarbital.
Whooping Cough
Blockade of Ca2+-activated K+ channels inhibits proliferation of human endothelial cells induced by basic fibroblast growth factor.
Whooping Cough
Blockade of endothelial Gi protein enhances early engraftment in intraportal cell transplant to mouse liver.
Whooping Cough
Blockade of Gi/o proteins modifies electrical activity of S-myenteric neurons from guinea-pig ileum.
Whooping Cough
Blockade of K+ channels induced by AMPA/kainate receptor activation in mouse oligodendrocyte precursor cells is mediated by Na+ entry.
Whooping Cough
Blockade of morphine analgesia by both pertussis and cholera toxins in the periaqueductal gray and locus coeruleus.
Whooping Cough
Blockade of receptor-activated G(i) signaling in osteoblasts in vivo leads to site-specific increases in cortical and cancellous bone formation.
Whooping Cough
Blockage of amyloid beta peptide-induced cytosolic free calcium by fullerenol-1, carboxylate C60 in PC12 cells.
Whooping Cough
Blood lipid mediator sphingosine 1-phosphate potently stimulates platelet-derived growth factor-A and -B chain expression through S1P1-Gi-Ras-MAPK-dependent induction of Kruppel-like factor 5.
Whooping Cough
Blood mononuclear cell production of TNF-alpha and IL-8: engagement of different signal transduction pathways including the p42 MAP kinase pathway.
Whooping Cough
Blood- and skin-derived monocytes/macrophages respond to C3a but not to C3a(desArg) with a transient release of calcium via a pertussis toxin-sensitive signal transduction pathway.
Whooping Cough
Blood-brain barrier disruption and lesion localisation in experimental autoimmune encephalomyelitis with predominant cerebellar and brainstem involvement.
Whooping Cough
Bombesin activation of phospholipase C beta 1 in rat acinar pancreatic cells involves the pertussis toxin-sensitive G alpha i3 protein.
Whooping Cough
Bombesin and glucocorticoids stimulate human breast cancer cells to produce endothelin, a paracrine mitogen for breast stromal cells.
Whooping Cough
Bombesin and neuromedin B stimulate the activation of p42(mapk) and p74(raf-1) via a protein kinase C-independent pathway in Rat-1 cells.
Whooping Cough
Bombesin and thrombin affect discrete pools of intracellular calcium through different G-proteins.
Whooping Cough
Bombesin enhancement of cAMP accumulation in Swiss 3T3 cells: evidence of a dual mechanism of action.
Whooping Cough
Bombesin induces a reduction of somatostatin inhibition of adenylyl cyclase activity, Gi function, and somatostatin receptors in rat exocrine pancreas.
Whooping Cough
Bombesin, neuromedin B and neuromedin C interact with a common rat pancreatic phosphoinositide-coupled receptor, but are differentially regulated by guanine nucleotides.
Whooping Cough
Bombyx adipokinetic hormone receptor activates extracellular signal-regulated kinase 1 and 2 via G protein-dependent PKA and PKC but ?-arrestin-independent pathways.
Whooping Cough
Bone Gla protein messenger ribonucleic acid is regulated by both 1,25-dihydroxyvitamin D3 and 3',5'-cyclic adenosine monophosphate in rat osteosarcoma cells.
Whooping Cough
Bone marrow is a major reservoir and site of recruitment for central memory CD8+ T cells.
Whooping Cough
Booster immunization of children with an acellular pertussis vaccine enhances Th2 cytokine production and serum IgE responses against pertussis toxin but not against common allergens.
Whooping Cough
Booster response to acellular pertussis vaccine in children primed with acellular or whole cell vaccines.
Whooping Cough
Boosting Teenagers With Acellular Pertussis Vaccines Containing Recombinant or Chemically Inactivated Pertussis Toxin: A Randomized Clinical Trial.
Whooping Cough
Bordetella adenylate cyclase is a virulence associated factor and an immunoprotective antigen.
Whooping Cough
Bordetella adenylate cyclase: host toxicity and diagnostic utility.
Whooping Cough
Bordetella Dermonecrotic Toxin Is a Neurotropic Virulence Factor That Uses CaV3.1 as the Cell Surface Receptor.
Whooping Cough
Bordetella parapertussis and Bordetella bronchiseptica contain transcriptionally silent pertussis toxin genes.
Whooping Cough
Bordetella pertussis adenylate cyclase: effects of affinity-purified adenylate cyclase on human polymorphonuclear leukocyte functions.
Whooping Cough
Bordetella pertussis adenylate cyclase: isolation and purification by calmodulin-sepharose 4B chromatography.
Whooping Cough
Bordetella pertussis and Bordetella parapertussis infection in an Austrian pediatric outpatient clinic.
Whooping Cough
Bordetella pertussis and Bordetella parapertussis: two immunologically distinct species.
Whooping Cough
Bordetella pertussis and vaccination: the persistence of a genetically monomorphic pathogen.
Whooping Cough
Bordetella pertussis autoregulates pertussis toxin production through the metabolism of cysteine.
Whooping Cough
Bordetella pertussis diagnosis in children under five years of age in the Regional Hospital of Cajamarca, Northern Peru.
Whooping Cough
Bordetella pertussis from functional genomics to intranasal vaccination.
Whooping Cough
Bordetella pertussis induces apoptosis in macrophages: role of adenylate cyclase-hemolysin.
Whooping Cough
Bordetella pertussis infection exacerbates influenza virus infection through pertussis toxin-mediated suppression of innate immunity.
Whooping Cough
Bordetella pertussis infection in mice: correlation of specific antibodies against two antigens, pertussis toxin, and filamentous hemagglutinin with mouse protectivity in an intracerebral or aerosol challenge system.
Whooping Cough
Bordetella pertussis infection in paediatric healthcare workers.
Whooping Cough
Bordetella pertussis infection of human respiratory epithelial cells up-regulates intercellular adhesion molecule-1 expression: role of filamentous hemagglutinin and pertussis toxin.
Whooping Cough
Bordetella pertussis infection of primary human monocytes alters HLA-DR expression.
Whooping Cough
Bordetella pertussis infection: pathogenesis, diagnosis, management, and the role of protective immunity.
Whooping Cough
Bordetella Pertussis infections in vaccinated and unvaccinated adolescents and adults, as assessed in a national prospective randomized Acellular Pertussis Vaccine Trial (APERT).
Whooping Cough
Bordetella pertussis isolates in Finland: serotype and fimbrial expression.
Whooping Cough
Bordetella pertussis lipopolysaccharide resists the bactericidal effects of pulmonary surfactant protein A.
Whooping Cough
Bordetella pertussis modulates human macrophage defense gene expression.
Whooping Cough
Bordetella pertussis PCR: simultaneous targeting of signature sequences.
Whooping Cough
Bordetella pertussis Strain Lacking Pertactin and Pertussis Toxin.
Whooping Cough
Bordetella pertussis strains with increased toxin production associated with pertussis resurgence.
Whooping Cough
Bordetella Pertussis Toxin does not induce the release of pro-inflammatory cytokines in human whole blood.
Whooping Cough
Bordetella pertussis toxin induces the release of inflammatory cytokines and dendritic cell activation in whole blood: impaired responses in human newborns.
Whooping Cough
Bordetella pertussis vaccine strains and circulating isolates in Serbia.
Whooping Cough
Bordetella Pertussis virulence factors in the continuing evolution of whooping cough vaccines for improved performance.
Whooping Cough
Bordetella pertussis, the Causative Agent of Whooping Cough, Evolved from a Distinct, Human-Associated Lineage of B. bronchiseptica.
Whooping Cough
Bordetella pertussis: new concepts in pathogenesis and treatment.
Whooping Cough
Both adenylate cyclase and hemolytic activities are required by Bordetella pertussis to initiate infection.
Whooping Cough
Both alpha(1A)- and alpha(1B)-adrenergic receptors crosstalk to down regulate beta(1)-ARs in mouse heart: coupling to differential PTX-sensitive pathways.
Whooping Cough
Both dopamine and the putative dopamine D3 receptor antagonist PNU-99194A induce a biphasic inhibition of phorbol ester-stimulated arachidonic acid release from CHO cells transfected with the dopamine D3 receptor.
Whooping Cough
Both ET(A) and ET(B) receptors are involved in mitogen-activated protein kinase activation and DNA synthesis of astrocytes: study using ET(B) receptor-deficient rats (aganglionosis rats).
Whooping Cough
Both G i and G o heterotrimeric G proteins are required to exert the full effect of norepinephrine on the beta-cell K ATP channel.
Whooping Cough
Both GABAA and GABAB receptors participate in suppression of [CA2+]i pulsing in toad melanotrophs.
Whooping Cough
Both Gs and Gi proteins are critically involved in isoproterenol-induced cardiomyocyte hypertrophy.
Whooping Cough
Both overlapping and distinct signaling pathways for somatostatin receptor subtypes SSTR1 and SSTR2 in pituitary cells.
Whooping Cough
Both pertussis toxin-sensitive and insensitive g-proteins link melatonin receptor to inhibition of adenylate cyclase in the ovine pars tuberalis.
Whooping Cough
Botulinum C2 toxin ADP-ribosylates actin.
Whooping Cough
Bovine pituitary, kidney, uterine and mammary gland extracts contain bovine mammary epithelium growth factors that synergise with IGF-I and fetal calf serum: indication for involvement of GTP-binding proteins.
Whooping Cough
Bovine serum albumin-estrogen compounds differentially alter gonadotropin-releasing hormone-1 neuronal activity.
Whooping Cough
Bradycardia induced by Mesobuthus tamulus scorpion venom involves muscarinic receptor-G-protein-coupled cell signaling pathways.
Whooping Cough
Bradykinin activates airway parasympathetic ganglion neurons by inhibiting M-currents.
Whooping Cough
Bradykinin activates protein kinase C in cultured cortical collecting tubular cells.
Whooping Cough
Bradykinin B2 receptor-mediated proliferation via activation of the Ras/Raf/MEK/MAPK pathway in rat vascular smooth muscle cells.
Whooping Cough
Bradykinin B2 receptors activate Na+/H+ exchange in mIMCD-3 cells via Janus kinase 2 and Ca2+/calmodulin.
Whooping Cough
Bradykinin binding to B2 kinin receptors and stimulation of phosphoinositide turnover and arachidonic acid release in primary cultures of cells from late pregnant rat myometrium.
Whooping Cough
Bradykinin excites rat sympathetic neurons by inhibition of M current through a mechanism involving B2 receptors and G alpha q/11.
Whooping Cough
Bradykinin induced a positive chronotropic effect via stimulation of T- and L-type calcium currents in heart cells.
Whooping Cough
Bradykinin induces the bi-phasic production of lysophosphatidyl inositol and diacylglycerol in a dorsal root ganglion X neurotumor hybrid cell line, F-11.
Whooping Cough
Bradykinin inhibition of N- and L-type calcium channel currents in NG108-15 cells.
Whooping Cough
Bradykinin inhibits adenylate cyclase activity in guinea pig ileum membranes via a separate high-affinity bradykinin B2 receptor.
Whooping Cough
Bradykinin modulates potassium and calcium currents in neuroblastoma hybrid cells via different pertussis toxin-insensitive pathways.
Whooping Cough
Bradykinin modulates the electrophysiology of cultured rat sensory neurons through a pertussis toxin-insensitive G protein.
Whooping Cough
Bradykinin receptor localization and cell signaling pathways used by bradykinin in the regulation of gonadotropin-releasing hormone secretion.
Whooping Cough
Bradykinin receptors of cerebral microvessels stimulate phosphoinositide turnover.
Whooping Cough
Bradykinin stimulates a rise in cytosolic calcium in renal glomerular mesangial cells via a pertussis toxin insensitive pathway.
Whooping Cough
Bradykinin stimulates GTP hydrolysis in NG108-15 membranes by a high-affinity, pertussis toxin-insensitive GTPase.
Whooping Cough
Bradykinin stimulates NF-kappaB activation and interleukin 1beta gene expression in cultured human fibroblasts.
Whooping Cough
Bradykinin stimulates production of inositol (1,4,5) trisphosphate in cultured mesangial cells of the rat via a BK2-kinin receptor.
Whooping Cough
Bradykinin stimulation of inositol phosphate and calcium responses in insensitive to pertussis toxin in NG115-401L neuronal cells.
Whooping Cough
Bradykinin stimulation of inositol polyphosphate production in porcine aortic endothelial cells.
Whooping Cough
Bradykinin-activated membrane-associated phospholipase C in Madin-Darby canine kidney cells.
Whooping Cough
Bradykinin-activated transmembrane signals are coupled via No or Ni to production of inositol 1,4,5-trisphosphate, a second messenger in NG108-15 neuroblastoma-glioma hybrid cells.
Whooping Cough
Bradykinin-induced activation of nociceptors: receptor and mechanistic studies on the neonatal rat spinal cord-tail preparation in vitro.
Whooping Cough
Bradykinin-induced chloride conductance in murine proximal tubule epithelial cells.
Whooping Cough
Bradykinin-induced generation of inositol 1,4,5-trisphosphate in fibroblasts and neuroblastoma cells: effect of pertussis toxin, extracellular calcium, and down-regulation of protein kinase C.
Whooping Cough
Bradykinin-induced microglial migration mediated by B1-bradykinin receptors depends on Ca2+ influx via reverse-mode activity of the Na+/Ca2+ exchanger.
Whooping Cough
Bradykinin-induced phosphoinositide hydrolysis and Ca2+ mobilization in canine cultured tracheal epithelial cells.
Whooping Cough
Bradykinin-stimulated p42/p44 MAPK activation associated with cell proliferation in corneal keratocytes.
Whooping Cough
Brain pertussis toxin-sensitive G proteins are involved in the flavoxate hydrochloride-induced suppression of the micturition reflex in rats.
Whooping Cough
Break of unresponsiveness of delayed-type hypersensitivity to sheep red blood cells by pertussis toxin.
Whooping Cough
Breast cancer cell response to calcitonin: modulation by growth-regulating agents.
Whooping Cough
Bromocriptine stimulates Na+, K(+)-ATPase in renal proximal tubules via the cAMP pathway.
Whooping Cough
Bromocriptine transcriptionally activates the multidrug resistance gene (pgp2/mdr1b) by a novel pathway.
Whooping Cough
Bromocriptine, a dopamine D2 receptor agonist, inhibits adenylyl cyclase activity in rat olfactory epithelium.
Whooping Cough
Bu Shen Yi Sui Capsule Alleviates Neuroinflammation and Demyelination by Promoting Microglia toward M2 Polarization, Which Correlates with Changes in miR-124 and miR-155 in Experimental Autoimmune Encephalomyelitis.
Whooping Cough
Buprenorphine prevents and reverses the expression of chronic etorphine-induced sensitization of adenylyl cyclase in SK-N-SH human neuroblastoma cells.
Whooping Cough
Butyrate and propionate induced activated or non-activated neutrophil apoptosis via HDAC inhibitor activity but without activating GPR-41/GPR-43 pathways.
Whooping Cough
Butyrate Attenuates Inflammation and Lipolysis Generated by the Interaction of Adipocytes and Macrophages.
Whooping Cough
Butyrate enhancement of inteleukin-1? production via activation of oxidative stress pathways in lipopolysaccharide-stimulated THP-1 cells.
Whooping Cough
C-C chemokines induce the chemotaxis of NK and IL-2-activated NK cells. Role for G proteins.
Whooping Cough
C-peptide and its C-terminal fragments improve erythrocyte deformability in type 1 diabetes patients.
Whooping Cough
C-peptide colocalizes with macrophages in early arteriosclerotic lesions of diabetic subjects and induces monocyte chemotaxis in vitro.
Whooping Cough
C-peptide increases the expression of vasopressin-activated calcium-mobilizing receptor gene through a G protein-dependent pathway.
Whooping Cough
C-peptide makes a comeback.
Whooping Cough
C-peptide reverses TGF-beta1-induced changes in renal proximal tubular cells: implications for treatment of diabetic nephropathy.
Whooping Cough
C-peptide signals via Galpha i to protect against TNF-alpha-mediated apoptosis of opossum kidney proximal tubular cells.
Whooping Cough
C-peptide stimulates ERK1/2 and JNK MAP kinases via activation of protein kinase C in human renal tubular cells.
Whooping Cough
C-peptide stimulates rat renal tubular Na+, K(+)-ATPase activity in synergism with neuropeptide Y.
Whooping Cough
C-terminal deletion of metabotropic glutamate receptor 1 selectively abolishes coupling to Galphaq.
Whooping Cough
C-terminal modifications of pertussis toxin-sensitive G-protein alpha-subunits differentially affect immunoreactivity. Evidence against endogenous ADP-ribosylation in human heart, lung, thrombocytes and adipose tissue.
Whooping Cough
C-terminal parathyroid hormone-related protein (PTHrP) (107-139) stimulates intracellular Ca(2+) through a receptor different from the type 1 PTH/PTHrP receptor in osteoblastic osteosarcoma UMR 106 cells.
Whooping Cough
C-type natriuretic peptide activates a non-selective cation current in acutely isolated rat cardiac fibroblasts via natriuretic peptide C receptor-mediated signalling.
Whooping Cough
C-type natriuretic peptide and brain natriuretic peptide inhibit adenylyl cyclase activity: interaction with ANF-R2/ANP-C receptors.
Whooping Cough
C-type natriuretic peptide attenuates evoked dopamine efflux by influencing Goalpha.
Whooping Cough
C-type natriuretic peptide enhances amylase release through NPR-C receptors in the exocrine pancreas.
Whooping Cough
C-type natriuretic peptide neuromodulates via "clearance" receptors.
Whooping Cough
C3 toxin activates the stress signaling pathways, JNK and p38, but antagonizes the activation of AP-1 in rat-1 cells.
Whooping Cough
C3a activates reactive oxygen radical species production and intracellular calcium transients in human eosinophils.
Whooping Cough
C3a activates the respiratory burst in human polymorphonuclear neutrophilic leukocytes via pertussis toxin-sensitive G-proteins.
Whooping Cough
C3a and C5a are chemotactic factors for human mesenchymal stem cells, which cause prolonged ERK1/2 phosphorylation.
Whooping Cough
C3a and C5a are chemotaxins for human mast cells and act through distinct receptors via a pertussis toxin-sensitive signal transduction pathway.
Whooping Cough
C3a and C5a stimulate chemotaxis of human mast cells.
Whooping Cough
C3A binds to the seven transmembrane anaphylatoxin receptor expressed by epithelial cells and triggers the production of IL-8.
Whooping Cough
C3a enhances nerve growth factor-induced NFAT activation and chemokine production in a human mast cell line, HMC-1.
Whooping Cough
C3a receptor on dibutyryl-cAMP-differentiated U937 cells and human neutrophils: the human C3a receptor characterized by functional responses and 125I-C3a binding.
Whooping Cough
C5a controls TLR-induced IL-10 and IL-12 production independent of phosphoinositide 3-kinase.
Whooping Cough
C5a differentially stimulates the ERK1/2 and p38 MAPK phosphorylation through independent signaling pathways to induced chemotactic migration in RAW264.7 macrophages.
Whooping Cough
C5a stimulates production of plasminogen activator inhibitor-1 in human mast cells and basophils.
Whooping Cough
C5a stimulus-secretion coupling in rat basophilic leukaemia (RBL-2H3) cells transfected with the human C5a receptor is mediated by pertussis and cholera toxin-sensitive G proteins.
Whooping Cough
C?type natriuretic peptide prevents angiotensin II?induced atrial connexin 40 and 43 dysregulation by activating AMP?activated kinase signaling.
Whooping Cough
Ca(++)-dependent constitutive nitric oxide synthase is not involved in the cyclic GMP-increasing effects of carbachol in ventricular cardiomyocytes.
Whooping Cough
Ca(2+) signaling via sigma(1)-receptors: novel regulatory mechanism affecting intracellular Ca(2+) concentration.
Whooping Cough
Ca(2+)-dependent and -independent mechanism of cyclic-AMP reduction: mediation by bradykinin B2 receptors.
Whooping Cough
Ca(2+)-inactivated K+ current is modulated by endothelin-1 in B-16 murine melanoma cells.
Whooping Cough
Ca(2+)-mobilizing endothelin-A receptors inhibit voltage-gated Ca(2+) influx through G(i/o) signaling pathway in pituitary lactotrophs.
Whooping Cough
Ca(2+)-permeable AMPA receptors induce phosphorylation of cAMP response element-binding protein through a phosphatidylinositol 3-kinase-dependent stimulation of the mitogen-activated protein kinase signaling cascade in neurons.
Whooping Cough
Ca2+ channel activation by platelet-derived growth factor-induced tyrosine phosphorylation and Ras guanine triphosphate-binding proteins in rat glomerular mesangial cells.
Whooping Cough
Ca2+ channel and adenylyl cyclase modulation by cloned mu-opioid receptors in GH3 cells.
Whooping Cough
Ca2+ channel inhibition by kappa opioid receptors expressed in Xenopus oocytes.
Whooping Cough
Ca2+ dependent purinergic regulation of p42 and p44 MAP kinases in astroglial cultured cells.
Whooping Cough
Ca2+ influx and neurite growth in response to purified N-cadherin and laminin.
Whooping Cough
Ca2+ influx stimulated by vasopressin is mediated by phosphoinositide hydrolysis in rat smooth muscle cells.
Whooping Cough
Ca2+ influx, phosphoinositide hydrolysis, and histamine release induced by lysophosphatidylserine in mast cells.
Whooping Cough
Ca2+ inhibition of beta-adrenergic receptor- and forskolin-stimulated cAMP accumulation in C6-2B rat glioma cells is independent of protein kinase C.
Whooping Cough
Ca2+ ionophore A23187 and thrombin inhibit the pertussis-toxin-induced ADP-ribosylation of the alpha-subunit of the inhibitory guanine-nucleotide-binding protein and other proteins in human platelets.
Whooping Cough
Ca2+ mobilization by the LH receptor expressed in Xenopus oocytes independent of 3',5'-cyclic adenosine monophosphate formation: evidence for parallel activation of two signaling pathways.
Whooping Cough
Ca2+ participates in alpha1B-adrenoceptor-mediated cAMP response in HEK293 cells.
Whooping Cough
Ca2+ preconditioning elicits a unique protection against the Ca2+ paradox injury in rat heart. Role of adenosine. Fixed.
Whooping Cough
Ca2+ release from inositol 1,4,5-trisphosphate-sensitive Ca2+ store by antidepressant drugs in cultured neurons of rat frontal cortex.
Whooping Cough
Ca2+ signalling in K562 human erythroleukaemia cells: effect of dimethyl sulphoxide and role of G-proteins in thrombin- and thromboxane A2-activated pathways.
Whooping Cough
Ca2+-channel-dependent and -independent inhibition of exocytosis by extracellular ATP in voltage-clamped rat adrenal chromaffin cells.
Whooping Cough
Ca2+-independent feedback inhibition of acetylcholine release in frog neuromuscular junction.
Whooping Cough
Ca2+-independent synergistic augmentation of O2- production by FMLP and PMA in HL-60 cells.
Whooping Cough
Ca2+-sensing receptors in intestinal epithelium.
Whooping Cough
Ca2+-stimulated catecholamine release from alpha-toxin-permeabilized PC12 cells: biochemical evidence for exocytosis and its modulation by protein kinase C and G proteins.
Whooping Cough
Cadmium inhibits GABA-activated ion currents by increasing intracellular calcium level in snail neurons.
Whooping Cough
Caffeine to prevent respiratory failure and improve outcome in infant pertussis.
Whooping Cough
Calcitonin gene-related peptide (CGRP) activates human neutrophils--inhibition by chemotactic peptide antagonist BOC-MLP.
Whooping Cough
Calcitonin gene-related peptide activates different signaling pathways in mesenteric lymphatics of guinea pigs.
Whooping Cough
Calcitonin gene-related peptide receptor independently stimulates 3',5'-cyclic adenosine monophosphate and Ca2+ signaling pathways.
Whooping Cough
Calcitonin gene-related peptide: mechanisms of modulation of antral endocrine cells and cholinergic neurons.
Whooping Cough
Calcitonin induces IL-6 production via both PKA and PKC pathways in the pituitary folliculo-stellate cell line.
Whooping Cough
Calcitonin inhibits accumulation of cyclic AMP in stimulated peritoneal macrophages from normal rats but not from osteopetrotic (incisors-absent) littermates.
Whooping Cough
Calcitonin reverts pertussis toxin blockade of the opioid analgesia in mice.
Whooping Cough
Calcitonin-gene-related peptide activates the muscarinic-gated K+ current in atrial cells.
Whooping Cough
Calcitriol attenuates the thyrotropin-releasing hormone-stimulated inositol phosphate production in clonal rat pituitary (GH4C1) cells.
Whooping Cough
Calcium changes in immune complex-stimulated human neutrophils. Simultaneous measurement of receptor occupancy and activation reveals full population stimulus binding but subpopulation activation.
Whooping Cough
Calcium channel currents and their inhibition by (-)-baclofen in rat sensory neurones: modulation by guanine nucleotides.
Whooping Cough
Calcium current modulation in frog sympathetic neurones: multiple neurotransmitters and G proteins.
Whooping Cough
Calcium entry stimulated by swelling of Madin-Darby canine kidney cells.
Whooping Cough
Calcium flux-independent NMDA receptor activity is required for A? oligomer-induced synaptic loss.
Whooping Cough
Calcium handling and purinoceptor subtypes involved in ATP-induced contraction in rat small mesenteric arteries.
Whooping Cough
Calcium inflow in cells transfected with cloned rat and porcine calcitonin receptors.
Whooping Cough
Calcium influx into mouse spermatozoa activated by solubilized mouse zona pellucida, monitored with the calcium fluorescent indicator, fluo-3. Inhibition of the influx by three inhibitors of the zona pellucida induced acrosome reaction: tyrphostin A48, pertussis toxin, and 3-quinuclidinyl benzilate.
Whooping Cough
Calcium influx into neurons can solely account for cell contact-dependent neurite outgrowth stimulated by transfected L1.
Whooping Cough
Calcium influx mediated by the Escherichia coli heat-stable enterotoxin B (STB).
Whooping Cough
Calcium inhibition of cardiac adenylyl cyclase. Evidence for two distinct sites of inhibition.
Whooping Cough
Calcium mobilization and cell proliferation activated by extracellular ATP in human ovarian tumour cells.
Whooping Cough
Calcium mobilization and protease-activated receptor cleavage after thrombin stimulation in motor neurons.
Whooping Cough
Calcium mobilization and signal transduction in the neutrophils.
Whooping Cough
Calcium mobilization in fluoride activated human neutrophils.
Whooping Cough
Calcium mobilization, prostaglandin E2 and alpha 2-adrenoceptor modulation of glucose utilization and insulin secretion in pancreatic islets.
Whooping Cough
Calcium release from intracellular stores evoked by extracellular ATP in a Xenopus renal epithelial cell line.
Whooping Cough
Calcium signaling capacity of the CD11b/CD18 integrin on human neutrophils.
Whooping Cough
Calcium signaling induced by angiotensin II in the pancreatic acinar cell line AR42J.
Whooping Cough
Calcium signalling by G protein-coupled sphingolipid receptors in bovine aortic endothelial cells.
Whooping Cough
Calcium signals activated by arachidonic acid in embryonic chick ciliary ganglion neurons.
Whooping Cough
Calcium waves in fluid flow stimulated osteoblasts are G protein mediated.
Whooping Cough
Calcium- and G-protein-dependent activation of arachidonic acid release by concanavalin-A-stimulated mouse macrophages.
Whooping Cough
Calcium-and G-protein-related spasmolytic effects of nonsteroidal anti-inflammatory drugs on rat uterus contractions in vitro.
Whooping Cough
Calcium-controlled secretion is effected through a guanine nucleotide regulatory protein in parathyroid cells.
Whooping Cough
Calcium-dependent release of arachidonic acid in response to purinergic receptor activation in airway epithelium.
Whooping Cough
Calcium-independent inhibitory G-protein signaling induces persistent presynaptic muting of hippocampal synapses.
Whooping Cough
Calcium-sensing receptor modulates extracellular Ca2+ entry via TRPC-encoded receptor-operated channels in human aortic smooth muscle cells.
Whooping Cough
Calcium-sensing receptor-mediated activation of phospholipase C-gamma1 is downstream of phospholipase C-beta and protein kinase C in MC3T3-E1 osteoblasts.
Whooping Cough
Calcium-sensing receptor-mediated ERK1/2 activation requires Galphai2 coupling and dynamin-independent receptor internalization.
Whooping Cough
Calibration of pertussis toxin BRP batch 1 in a standardised CHO cell-based clustering assay.
Whooping Cough
Calpain inhibition induces activation of the distinct signalling pathways and cell migration in human monocytes.
Whooping Cough
Calpain inhibitors stimulate phagocyte functions via activation of human formyl peptide receptors.
Whooping Cough
Calpain regulates neutrophil chemotaxis.
Whooping Cough
Calpain-mediated regulation of the distinct signaling pathways and cell migration in human neutrophils.
Whooping Cough
cAMP analogues downregulate the expression of granulocyte macrophage colony-stimulating factor (GM-CSF) in human bone marrow stromal cells in vitro.
Whooping Cough
cAMP antagonizes ERK-dependent antiapoptotic action of insulin.
Whooping Cough
cAMP cascade (PKA, Epac, adenylyl cyclase, Gi, and phosphodiesterases) regulates myelin phagocytosis mediated by complement receptor-3 and scavenger receptor-AI/II in microglia and macrophages.
Whooping Cough
cAMP imaging of cells treated with pertussis toxin, cholera toxin, and anthrax edema toxin.
Whooping Cough
cAMP modulates transepithelial resistance response of LLC-PK1 renal epithelia to tumor necrosis factor.
Whooping Cough
cAMP production by piglet cerebral vascular smooth muscle cells: pH(o), pH(i), and permissive action of PGI(2).
Whooping Cough
cAMP signaling mechanisms with aging in rats.
Whooping Cough
cAMP stimulates osteoblast-like differentiation of calcifying vascular cells. Potential signaling pathway for vascular calcification.
Whooping Cough
cAMP-dependent inhibition is dominant in regulating superoxide production in the bone-resorbing osteoclasts.
Whooping Cough
cAMP-independent dilation of coronary arterioles to adenosine : role of nitric oxide, G proteins, and K(ATP) channels.
Whooping Cough
Can immunization affect the development of allergy?
Whooping Cough
Canine mast cell adenosine receptors: cloning and expression of the A3 receptor and evidence that degranulation is mediated by the A2B receptor.
Whooping Cough
Cannabichromene is a cannabinoid CB2 receptor agonist.
Whooping Cough
Cannabidiol inhibits human glioma cell migration through a cannabinoid receptor-independent mechanism.
Whooping Cough
Cannabidiol, a novel inverse agonist for GPR12.
Whooping Cough
Cannabinoid agonists induce contractile responses through Gi/o-dependent activation of phospholipase C in the bovine ciliary muscle.
Whooping Cough
Cannabinoid agonists stimulate [3H]GABA release in the globus pallidus of the rat when G(i) protein-receptor coupling is restricted: role of dopamine D2 receptors.
Whooping Cough
Cannabinoid CB1 receptor elevation of intracellular calcium in neuroblastoma SH-SY5Y cells: interactions with muscarinic and delta-opioid receptors.
Whooping Cough
Cannabinoid CB1 receptor of cat cerebral arterial muscle functions to inhibit L-type Ca2+ channel current.
Whooping Cough
Cannabinoid CB1 receptor-mediated inhibition of glutamate release from rat hippocampal synaptosomes.
Whooping Cough
Cannabinoid CB1 receptor-mediated inhibition of prolactin release and signaling mechanisms in GH4C1 cells.
Whooping Cough
Cannabinoid CB1 receptors fail to cause relaxation, but couple via Gi/Go to the inhibition of adenylyl cyclase in carotid artery smooth muscle.
Whooping Cough
Cannabinoid ligand-receptor signaling in the mouse uterus.
Whooping Cough
Cannabinoid receptor 1 but not 2 mediates macrophage phagocytosis by G(?)i/o /RhoA/ROCK signaling pathway.
Whooping Cough
Cannabinoid receptor 1 suppresses transient receptor potential vanilloid 1-induced inflammatory responses to corneal injury.
Whooping Cough
Cannabinoid Receptor 2 Signalling Bias Elicited by 2,4,6-Trisubstituted 1,3,5-Triazines.
Whooping Cough
Cannabinoid Receptor Activation Correlates with the Proapoptotic Action of the ?2-Adrenergic Agonist (R,R')-4-Methoxy-1-Naphthylfenoterol in HepG2 Hepatocarcinoma Cells.
Whooping Cough
Cannabinoid receptor agonists inhibit depolarization-induced calcium influx in cerebellar granule neurons.
Whooping Cough
Cannabinoid receptor agonists inhibit glutamatergic synaptic transmission in rat hippocampal cultures.
Whooping Cough
Cannabinoid receptor CB1 activates the Na+/H+ exchanger NHE-1 isoform via Gi-mediated mitogen activated protein kinase signaling transduction pathways.
Whooping Cough
Cannabinoid receptor subtype influence on neuritogenesis in human SH-SY5Y cells.
Whooping Cough
Cannabinoid receptor-independent cytotoxic effects of cannabinoids in human colorectal carcinoma cells: synergism with 5-fluorouracil.
Whooping Cough
Cannabinoid receptor-induced neurite outgrowth is mediated by Rap1 activation through G(alpha)o/i-triggered proteasomal degradation of Rap1GAPII.
Whooping Cough
Cannabinoid receptor-mediated translocation of NO-sensitive guanylyl cyclase and production of cyclic GMP in neuronal cells.
Whooping Cough
Cannabinoid receptors and modulation of cyclic AMP accumulation in the rat brain.
Whooping Cough
Cannabinoid receptors and the cytokine network.
Whooping Cough
Cannabinoid receptors differentially modulate potassium A and D currents in hippocampal neurons in culture.
Whooping Cough
Cannabinoid-induced depression of synaptic transmission is switched to stimulation when dopaminergic tone is increased in the globus pallidus of the rodent.
Whooping Cough
Cannabinoid-receptor-independent cell signalling by N-acylethanolamines.
Whooping Cough
Cannabinoids ablate release of TNFalpha in rat microglial cells stimulated with lypopolysaccharide.
Whooping Cough
Cannabinoids enhance human B-cell growth at low nanomolar concentrations.
Whooping Cough
Cannabinoids enhance NMDA-elicited Ca2+ signals in cerebellar granule neurons in culture.
Whooping Cough
Cannabinoids inhibit agonist-stimulated formation of inositol phosphates in rat hippocampal cultures.
Whooping Cough
Cannabinoids inhibit N-type calcium channels in neuroblastoma-glioma cells.
Whooping Cough
Cannabinoids modulate potassium current in cultured hippocampal neurons.
Whooping Cough
Cannabinoids promote oligodendrocyte progenitor survival: involvement of cannabinoid receptors and phosphatidylinositol-3 kinase/Akt signaling.
Whooping Cough
Cannabinomimetic behavioral effects of and adenylate cyclase inhibition by two new endogenous anandamides.
Whooping Cough
Cap formation in a B-lymphocyte cell line is inhibited by pertussis toxin and phorbol ester.
Whooping Cough
Caprine sperm acrosome reaction: promotion by progesterone and homologous zona pellucida.
Whooping Cough
Capsaicin-induced ion fluxes increase cyclic GMP but not cyclic AMP levels in rat sensory neurones in culture.
Whooping Cough
Captopril inhibits the hydroosmotic effect of ADH in the cortical collecting tubule.
Whooping Cough
CaR activation increases TNF production by mTAL cells via a Gi-dependent mechanism.
Whooping Cough
Carbachol activates a novel sodium current in isolated guinea pig ventricular myocytes via M2 muscarinic receptors.
Whooping Cough
Carbachol and bradykinin increase the production of diacylglycerol from sources other than inositol-containing phospholipids in PC12 cells.
Whooping Cough
Carbachol depolarizes and accelerates pacemaker activity in the sinoatrial node of chicks treated with pertussis toxin.
Whooping Cough
Carbachol enhances forskolin-stimulated cyclic AMP accumulation via activation of calmodulin system in human neuroblastoma SH-SY5Y cells.
Whooping Cough
Carbachol inhibition of Ca2+ currents in ventricular cells obtained from neonatal and adult rats.
Whooping Cough
Carbachol inhibits stimulant-induced increases in fundic D-cell cytosolic Ca2+ concentration.
Whooping Cough
Carbachol mimics phorbol esters in its ability to enhance cyclic GMP production by STa, the heat-stable toxin of Escherichia coli.
Whooping Cough
Carbachol-induced actin reorganization involves Gi activation of Rho in human airway smooth muscle cells.
Whooping Cough
Carbachol-induced decrease in thyroid cell adenylyl cyclase activity is independent of calcium and phosphodiesterase activation.
Whooping Cough
Carbachol-induced secretion and homologous desensitization in rat basophilic leukemia (RBL-2H3) cells transfected with human m2 muscarinic acetylcholine receptors.
Whooping Cough
Carbachol-stimulated calcium entry in SH-SY5Y human neuroblastoma cells: which route?
Whooping Cough
Carbamylcholine inhibits beta-adrenergic receptor-coupled Gs protein function proximal to adenylate cyclase.
Whooping Cough
Carbohydrate moiety of follitropin receptor is not required for high affinity hormone-binding or for functional coupling between receptor and guanine nucleotide-binding protein in bovine calf testis membranes.
Whooping Cough
Carboxyl domain of glutamate receptor directs its coupling to metabolic pathways.
Whooping Cough
Cardiac alpha 1-adrenoceptors stimulate a high-affinity GTPase activity in sarcolemmal membranes from rabbit atrial and ventricular myocytes.
Whooping Cough
Cardiac effects of long-term active immunization with the second extracellular loop of human ?1- and/or ?3-adrenoceptors in Lewis rats.
Whooping Cough
Cardiac role of frog ANF: negative inotropism and binding sites in Rana esculenta.
Whooping Cough
Cardiac swelling-induced chloride current is enhanced by endothelin.
Whooping Cough
Cardiac-specific overexpression of human beta2 adrenoceptors in mice exposes coupling to both Gs and Gi proteins.
Whooping Cough
Cardiomyocyte S1P1 Receptor-mediated Extracellular Signal-related Kinase Signaling and Desensitization.
Whooping Cough
Cardiomyocytes undergo apoptosis in human immunodeficiency virus cardiomyopathy through mitochondrion- and death receptor-controlled pathways.
Whooping Cough
Cardioprotection specific for the G protein Gi2 in chronic adrenergic signaling through beta 2-adrenoceptors.
Whooping Cough
Cardioprotective effects of acute and chronic opioid treatment are mediated via different signaling pathways.
Whooping Cough
Cardiovascular responses to milrinone in pertussis toxin-pretreated pithed rats.
Whooping Cough
CART peptide stimulation of G protein-mediated signaling in differentiated PC12 Cells: Identification of PACAP 6-38 as a CART receptor antagonist.
Whooping Cough
Casein kinase 2 Is activated and essential for Wnt/beta-catenin signaling.
Whooping Cough
Caspase activation is accelerated by the inhibition of arsenite-induced, membrane rafts-dependent Akt activation.
Whooping Cough
Caspase-dependent apoptosis of cells expressing the chemokine receptor CXCR4 is induced by cell membrane-associated human immunodeficiency virus type 1 envelope glycoprotein (gp120).
Whooping Cough
Catecholamine modulation of calcium currents in clonal pancreatic beta-cells.
Whooping Cough
Catecholamine stimulated lipolysis in differentiated human preadipocytes in a serum-free, defined medium.
Whooping Cough
Catecholamines are not linked to myometrial phospholipase C and uterine contraction in late pregnant and parturient mouse.
Whooping Cough
Catecholamines stimulate the proliferation and alkaline phosphatase activity of MC3T3-E1 osteoblast-like cells.
Whooping Cough
Catestatin (CgA344-364) stimulates rat mast cell release of histamine in a manner comparable to mastoparan and other cationic charged neuropeptides.
Whooping Cough
Catestatin, a neuroendocrine antimicrobial peptide, induces human mast cell migration, degranulation and production of cytokines and chemokines.
Whooping Cough
Cathepsin G, a neutrophil-derived serine protease, increases susceptibility of macrophages to acute human immunodeficiency virus type 1 infection.
Whooping Cough
Cathine and norephedrine, both phenylpropanolamines, accelerate capacitation and then inhibit spontaneous acrosome loss.
Whooping Cough
Cationic-amphiphilic arpromidine-derived guanidines and a histamine trifluoromethyl-toluidide derivative may activate pertussis toxin-sensitive G-proteins by a receptor-independent mechanism.
Whooping Cough
Caveolae modulate excitation-contraction coupling and beta(2)-adrenergic signalling in adult rat ventricular myocytes.
Whooping Cough
Caveolar localization dictates physiologic signaling of beta 2-adrenoceptors in neonatal cardiac myocytes.
Whooping Cough
CB1 allosteric modulator Org27569 is an antagonist/inverse agonist of ERK1/2 signaling.
Whooping Cough
CB1 cannabinoid receptor-dependent and -independent inhibition of depolarization-induced calcium influx in oligodendrocytes.
Whooping Cough
CB1 cannabinoid receptor-mediated cell migration.
Whooping Cough
CB1 cannabinoid receptor-mediated increases in cyclic AMP accumulation are correlated with reduced Gi/o function.
Whooping Cough
CB1 receptor-G protein association. Subtype selectivity is determined by distinct intracellular domains.
Whooping Cough
CB1 receptor-independent actions of SR141716 on G-protein signaling: coapplication with the mu-opioid agonist Tyr-D-Ala-Gly-(NMe)Phe-Gly-ol unmasks novel, pertussis toxin-insensitive opioid signaling in mu-opioid receptor-Chinese hamster ovary cells.
Whooping Cough
CB2 cannabinoid receptor targets mitogenic Gi protein - cyclin D1 axis in osteoblasts.
Whooping Cough
CC chemokine ligand 20 partially controls adhesion of naive B cells to activated endothelial cells under shear stress.
Whooping Cough
CC chemokine receptor-3 undergoes prolonged ligand-induced internalization.
Whooping Cough
CC family chemokines directly regulate myoblast responses to skeletal muscle injury.
Whooping Cough
CCK and gastrin inhibit adenylate cyclase activity through a pertussis toxin-sensitive mechanism in the tumoral rat pancreatic acinar cell line AR 4-2J.
Whooping Cough
CCK-8-evoked cationic currents in substantia nigra dopaminergic neurons are mediated by InsP3-induced Ca2+ release.
Whooping Cough
CCL2 and CXCL1 trigger calcitonin gene-related peptide release by exciting primary nociceptive neurons.
Whooping Cough
CCR1 acts downstream of NFAT2 in osteoclastogenesis and enhances cell migration.
Whooping Cough
CCR2 expression by brain microvascular endothelial cells is critical for macrophage transendothelial migration in response to CCL2.
Whooping Cough
CCR5 internalisation and signalling have different dependence on membrane lipid raft integrity.
Whooping Cough
CCR5 knockout suppresses experimental autoimmune encephalomyelitis in C57BL/6 mice.
Whooping Cough
CCR6 ligands inhibit HIV by inducing APOBEC3G.
Whooping Cough
CCR7 ligands are required for development of experimental autoimmune encephalomyelitis through generating IL-23-dependent Th17 cells.
Whooping Cough
CCR7 ligands control basal T cell motility within lymph node slices in a phosphoinositide 3-kinase-independent manner.
Whooping Cough
CCR8-dependent activation of the RAS/MAPK pathway mediates anti-apoptotic activity of I-309/ CCL1 and vMIP-I.
Whooping Cough
CD3/T-cell receptor coupling to a pertussis and cholera toxin-insensitive G-protein.
Whooping Cough
CD47 mediates killing of breast tumor cells via Gi-dependent inhibition of protein kinase A.
Whooping Cough
CD47 regulates collagen I-induced cyclooxygenase-2 expression and intestinal epithelial cell migration.
Whooping Cough
CD69 in resting and activated T lymphocytes. Its association with a GTP binding protein and biochemical requirements for its expression.
Whooping Cough
CD69-induced monocyte apoptosis involves multiple nonredundant signaling pathways.
Whooping Cough
CD8 T-cell Recruitment Into the Central Nervous System of Cuprizone-Fed Mice: Relevance to Modeling the Etiology of Multiple Sclerosis.
Whooping Cough
CD8+ T cell suppressor factors and the control of infection, replication and transcription of human immunodeficiency virus.
Whooping Cough
Celecoxib simulates respiratory burst through pertussis toxin-sensitive G-protein, a possible signal for beta 2-integrin expression on human neutrophils.
Whooping Cough
Cell cycle analysis of Chinese hamster ovary cells stimulated by phosphatidic acid in serum-free culture.
Whooping Cough
Cell cycle-dependent coupling of the calcitonin receptor to different G proteins.
Whooping Cough
Cell cycle-dependent coupling of the vasopressin V1a receptor to different G proteins.
Whooping Cough
Cell signaling and estrogens in female rat osteoblasts: a possible involvement of unconventional nonnuclear receptors.
Whooping Cough
Cell signalling pathway involved in PACAP-induced AR4-2J cell proliferation.
Whooping Cough
Cell surface antigens of Bordetella pertussis.
Whooping Cough
Cell surface beta-1,4-galactosyltransferase-I activates G protein-dependent exocytotic signaling.
Whooping Cough
Cell surface CCR5 density determines the postentry efficiency of R5 HIV-1 infection.
Whooping Cough
Cell surface-anchored SR-PSOX/CXC chemokine ligand 16 mediates firm adhesion of CXC chemokine receptor 6-expressing cells.
Whooping Cough
Cell type-specific angiotensin II-evoked signal transduction pathways: critical roles of Gbetagamma subunit, Src family, and Ras in cardiac fibroblasts.
Whooping Cough
Cell type-specific differences in the coupling of recombinant mGlu1alpha receptors to endogenous G protein sub-populations.
Whooping Cough
Cell-based assay of nongenomic actions of progestins revealed inhibitory G protein coupling to membrane progestin receptor ? (mPR?).
Whooping Cough
Cell-density-dependent expression of the alpha(2)-adrenergic response by epidermal growth factor (EGF) in primary cultures of adult rat hepatocytes.
Whooping Cough
Cell-density-dependent expression of the beta-adrenergic response by epidermal growth factor (EGF) in primary cultures of adult rat hepatocytes.
Whooping Cough
Cell-mediated and antibody responses to Bordetella pertussis antigens in children vaccinated with acellular or whole-cell pertussis vaccines. The Progetto Pertosse-CMI Working Group.
Whooping Cough
Cell-mediated immune responses to antigens of Bordetella pertussis and protection against pertussis in school children.
Whooping Cough
Cell-mediated immunity and antibody responses to Bordetella pertussis antigens in children with a history of pertussis infection and in recipients of an acellular pertussis vaccine.
Whooping Cough
Cell-signaling evidence for adenosine stimulation of coronary smooth muscle proliferation via the A1 adenosine receptor.
Whooping Cough
Cell-specific coupling of PGE2 to different transduction pathways in arginine vasopressin- and glucagon-sensitive segments of the rat renal tubule.
Whooping Cough
Cell-specific coupling of the cloned human 5-HT1F receptor to multiple signal transduction pathways.
Whooping Cough
Cell-specific expression of guanine nucleotide-binding proteins in rat testicular cells.
Whooping Cough
Cell-specific signaling of the 5-HT1A receptor. Modulation by protein kinases C and A.
Whooping Cough
Cell-surface bound pertussis toxin induces polyclonal T cell responses with high levels of interferon-gamma in the absence of interleukin-12.
Whooping Cough
Cell-surface expression, progestin binding, and rapid nongenomic signaling of zebrafish membrane progestin receptors alpha and beta in transfected cells.
Whooping Cough
Cellular Basis for Bimatoprost Effects on Human Conventional Outflow.
Whooping Cough
Cellular cyclic AMP levels modulate insulin sensitivity and responsiveness--evidence against a significant role of Gi in insulin signal transduction.
Whooping Cough
Cellular distribution and biochemical characterization of G proteins in skeletal muscle: comparative location with voltage-dependent calcium channels.
Whooping Cough
Cellular distribution of G protein Go alpha in pituitary lactotrophs: effects of dopamine.
Whooping Cough
Cellular expression of functional chemokine receptor CCR5 and CXCR4 in human embryonic neurons.
Whooping Cough
Cellular immunity in adolescents and adults following acellular pertussis vaccine administration.
Whooping Cough
Cellular internalization of proinsulin C-peptide.
Whooping Cough
Cellular mechanism of acetylcholine-induced response in dissociated outer hair cells of guinea-pig cochlea.
Whooping Cough
Cellular mechanism of action of cognitive enhancers: effects of nefiracetam on neuronal Ca2+ channels.
Whooping Cough
Cellular mechanism of lithium-induced nephrogenic diabetes insipidus in rats.
Whooping Cough
Cellular mechanisms by which oxytocin mediates ovine endometrial prostaglandin F2alpha synthesis: role of G(i) proteins and mitogen-activated protein kinases.
Whooping Cough
Cellular mechanisms of adrenaline-induced hyperpolarization in renal epitheloid MDCK cells.
Whooping Cough
Cellular mechanisms of ATP-induced hyperpolarization in renal epitheloid MDCK-cells.
Whooping Cough
Cellular mechanisms of bradykinin-induced hyperpolarization in renal epitheloid MDCK-cells.
Whooping Cough
Cellular mechanisms of melatonin action.
Whooping Cough
Cellular mechanisms of somatostatin inhibition of calcium influx in the anterior pituitary cell line AtT-20.
Whooping Cough
Cellular mechanisms underlying adenosine actions on cholinergic transmission in enteric neurons.
Whooping Cough
Cellular mechanisms underlying cholinergic and noradrenergic modulation of neuronal firing mode in the cat and guinea pig dorsal lateral geniculate nucleus.
Whooping Cough
Cellular mechanisms underlying cognition-enhancing actions of nefiracetam (DM-9384).
Whooping Cough
Cellular pertussis vaccine containing a Bordetella pertussis strain that produces a nontoxic pertussis toxin molecule.
Whooping Cough
Cellular responses to stimulation of the M5 muscarinic acetylcholine receptor as seen in murine L cells.
Whooping Cough
Cellular signalling by lipoproteins in cultured smooth muscle cells from spontaneously hypertensive rats.
Whooping Cough
Cellular signalling of PGE2 and its selective receptor analogue sulprostone in rabbit cortical collecting duct.
Whooping Cough
Cementum specific components which influence periodontal connective tissue cells.
Whooping Cough
Central and peripheral actions of somatostatin on the growth hormone-IGF-I axis.
Whooping Cough
Central effects of quinpirole on blood pressure of spontaneously hypertensive rats.
Whooping Cough
Central G-alpha subunit protein-mediated control of cardiovascular function, urine output, and vasopressin secretion in conscious Sprague-Dawley rats.
Whooping Cough
Central pertussis toxin abolishes the intestinal inhibition induced by intracerebroventricular morphine.
Whooping Cough
Centrally administered pertussis toxin inhibits microglia migration to the spinal cord and prevents dissemination of disease in an EAE mouse model.
Whooping Cough
Ceramide 1-(2-cyanoethyl) phosphate enhances store-operated Ca2+ entry in thyroid FRTL-5 cells.
Whooping Cough
Ceramide 1-phosphate enhances calcium entry through voltage-operated calcium channels by a protein kinase C-dependent mechanism in GH4C1 rat pituitary cells.
Whooping Cough
Ceramide 1-phosphate increases intracellular free calcium concentrations in thyroid FRTL-5 cells: evidence for an effect mediated by inositol 1,4,5-trisphosphate and intracellular sphingosine 1-phosphate.
Whooping Cough
Ceramide 1-phosphate induces macrophage chemoattractant protein-1 release: involvement in ceramide 1-phosphate-stimulated cell migration.
Whooping Cough
Ceramide 1-phosphate regulates cell migration and invasion of human pancreatic cancer cells.
Whooping Cough
Ceramide 1-phosphate stimulates glucose uptake in macrophages.
Whooping Cough
Ceramide 1-phosphate stimulates proliferation of C2C12 myoblasts.
Whooping Cough
Cerebellar CB(1) receptor mediation of Delta(9)-THC-induced motor incoordination and its potentiation by ethanol and modulation by the cerebellar adenosinergic A(1) receptor in the mouse.
Whooping Cough
Cerebral muscarinic acetylcholine receptors interact with three kinds of GTP-binding proteins in a reconstitution system of purified components.
Whooping Cough
CFTR is activated through stimulation of purinergic P2Y(2) receptors.
Whooping Cough
Change of intracellular calcium of neural cells induced by extracellular ATP.
Whooping Cough
Changes in binding of iodomelatonin to membranes of Leydig cells and steroidogenesis after prolonged in vitro exposure to melatonin.
Whooping Cough
Changes in cAMP formation in mononuclear leukocytes of heart and renal transplant recipients.
Whooping Cough
Changes in expression of a functional Gi protein in cultured rat heart cells.
Whooping Cough
Changes in G protein pattern and in G protein-dependent signaling during erythropoietin- and dimethylsulfoxide-induced differentiation of murine erythroleukemia cells.
Whooping Cough
Changes in genetic diversity of the Bordetella pertussis population in the United Kingdom between 1920 and 2006 reflect vaccination coverage and emergence of a single dominant clonal type.
Whooping Cough
Changes in inositol 1,4,5-trisphosphate mass in agonist-stimulated human neutrophils.
Whooping Cough
Changes in intracellular Ca2+ by activation of P2 receptors in submucosal neurons in short-term cultures.
Whooping Cough
Changes in intracellular free calcium in isolated myometrial cells: role of extracellular and intracellular calcium and possible involvement of guanine nucleotide-sensitive proteins.
Whooping Cough
Changes in the acoustic startle response and prepulse inhibition of acoustic startle in rats after local injection of pertussis toxin into the ventral tegmental area.
Whooping Cough
Changes in the Dutch Bordetella pertussis population in the first 20 years after the introduction of whole-cell vaccines.
Whooping Cough
Changes in the guanine nucleotide-binding proteins, Gi and Go, during differentiation of 3T3-L1 cells.
Whooping Cough
Changes in vascular smooth muscle function in hypertension.
Whooping Cough
Changes of ADP-ribosylation of GTP-binding protein by pertussis toxin in human platelets during long-term treatment of manic depression with lithium carbonate.
Whooping Cough
Changes of cytosolic calcium ion concentrations in human endothelial cells in response to thrombin, platelet-activating factor, and leukotriene B4.
Whooping Cough
Changes of the Swedish Bordetella pertussis population in incidence peaks during an acellular pertussis vaccine period between 1997 and 2004.
Whooping Cough
Characterisation of human recombinant somatostatin receptors. 4. Modulation of phospholipase C activity.
Whooping Cough
Characterisation of the fish sst3 receptor, a member of the SRIF1 receptor family: atypical pharmacological features.
Whooping Cough
Characteristics and distribution of endogenous RFamide-related peptide-1.
Whooping Cough
Characteristics and potency of an acellular pertussis vaccine composed of pertussis toxin, filamentous hemagglutinin, and pertactin.
Whooping Cough
Characteristics of acid extrusion from Chinese hamster ovary cells expressing different prostaglandin EP receptors.
Whooping Cough
Characteristics of lysophosphatidylcholine-induced Ca2+ response in human neuroblastoma SH-SY5Y cells.
Whooping Cough
Characteristics of nitric oxide-mediated cholinergic modulation of calcium current in rabbit sino-atrial node.
Whooping Cough
Characterization and clinical study on the acellular pertussis vaccine produced by a combination of column purified pertussis toxin and filamentous hemagglutinin.
Whooping Cough
Characterization and detoxification of an easily prepared acellular pertussis vaccine. Antigenic role of the A protomer of pertussis toxin.
Whooping Cough
Characterization and distribution of alpha 2-adrenergic receptors in the human intestinal mucosa.
Whooping Cough
Characterization and functional expression of a somatostatin receptor coupled to adenylyl cyclase.
Whooping Cough
Characterization and possible mechanisms of alpha 2-adrenergic receptor-mediated sensitization of forskolin-stimulated cyclic AMP production in HT29 cells.
Whooping Cough
Characterization and regulation of the human ML1A melatonin receptor stably expressed in Chinese hamster ovary cells.
Whooping Cough
Characterization and subcellular distribution of G-proteins in highly purified skeletal muscle fractions from rabbit and frog.
Whooping Cough
Characterization of a Ca2+ response to both UTP and ATP at human P2Y11 receptors: evidence for agonist-specific signaling.
Whooping Cough
Characterization of a complement-fragment-C5a-stimulated calcium-influx mechanism in U937 monocytic cells.
Whooping Cough
Characterization of a cyclosporin A-sensitive activation pathway in cultured T and natural killer cells.
Whooping Cough
Characterization of a G protein-activated phosphoinositide 3-kinase in vascular smooth muscle cell nuclei.
Whooping Cough
Characterization of a G-protein from the mandibular organ of the lobster Homarus americanus (Nephropidae, Decapoda).
Whooping Cough
Characterization of a Gi-protein from Trypanosoma cruzi epimastigote membranes.
Whooping Cough
Characterization of a hyperpolarization-activated time-dependent potassium current in canine cardiomyocytes from pulmonary vein myocardial sleeves and left atrium.
Whooping Cough
Characterization of a key neutralizing epitope on pertussis toxin recognized by monoclonal antibody 1B7.
Whooping Cough
Characterization of a mastoparan-stimulated nucleotidase from bovine brain.
Whooping Cough
Characterization of a metabotropic glutamate receptor: direct negative coupling to adenylyl cyclase and involvement of a pertussis toxin-sensitive G protein.
Whooping Cough
Characterization of a neuronal cell line expressing native human melanin-concentrating hormone receptor 1 (MCHR1).
Whooping Cough
Characterization of a novel chemotactic factor for neutrophils in the bronchial secretions of patients with cystic fibrosis.
Whooping Cough
Characterization of a novel sphingosine 1-phosphate receptor, Edg-8.
Whooping Cough
Characterization of a novel subtype of human G protein-coupled receptor for lysophosphatidic acid.
Whooping Cough
Characterization of a rabbit kidney prostaglandin F(2{alpha}) receptor exhibiting G(i)-restricted signaling that inhibits water absorption in the collecting duct.
Whooping Cough
Characterization of a Rat Model of Myeloperoxidase-Anti-Neutrophil Cytoplasmic Antibody-Associated Crescentic Glomerulonephritis.
Whooping Cough
Characterization of a receptor for insect tachykinin-like peptide agonists by functional expression in a stable Drosophila Schneider 2 cell line.
Whooping Cough
Characterization of a stimulatory adenosine A2a receptor in adult rat ventricular myocyte.
Whooping Cough
Characterization of a streptococcal antitumor glycoprotein (SAGP).
Whooping Cough
Characterization of a unique ADP-ribosyltransferase of Mycoplasma penetrans.
Whooping Cough
Characterization of a zebrafish (Danio rerio) sphingosine 1-phosphate receptor expressed in the embryonic brain.
Whooping Cough
Characterization of adenosine A1 receptors in intact DDT1 MF-2 smooth muscle cells.
Whooping Cough
Characterization of adenosine receptors in brush-border membranes from pig kidney.
Whooping Cough
Characterization of alpha 2-adrenoceptors in a plasma membrane enriched fraction from the insulin-secreting cell line RINm5F.
Whooping Cough
Characterization of alpha 2-macroglobulin binding to human trabecular meshwork cells: presence of the alpha 2-macroglobulin signaling receptor.
Whooping Cough
Characterization of an activation factor released from human neutrophils after stimulation by triclinic monosodium urate crystals.
Whooping Cough
Characterization of an atypical muscarinic cholinoceptor mediating contraction of the guinea-pig isolated uterus.
Whooping Cough
Characterization of an orphan G protein-coupled receptor, GPR20, that constitutively activates Gi proteins.
Whooping Cough
Characterization of anandamide- and fluoroanandamide-induced antinociception and cross-tolerance to delta 9-THC after intrathecal administration to mice: blockade of delta 9-THC-induced antinociception.
Whooping Cough
Characterization of beta-adrenoceptor mediated smooth muscle relaxation and the detection of mRNA for beta1-, beta2- and beta3-adrenoceptors in rat ileum.
Whooping Cough
Characterization of Bordetella bronchiseptica strains using phenotypic and genotypic markers.
Whooping Cough
Characterization of botulinum C3-catalyzed ADP-ribosylation of rho proteins and identification of mammalian C3-like ADP-ribosyltransferase.
Whooping Cough
Characterization of bradykinin receptors in canine cultured corneal epithelial cells: pharmacological and functional studies.
Whooping Cough
Characterization of bradykinin-induced phosphoinositide turnover in neurohybrid NCB-20 cells.
Whooping Cough
Characterization of cloned somatostatin receptors SSTR4 and SSTR5.
Whooping Cough
Characterization of co-purified acellular pertussis vaccines.
Whooping Cough
Characterization of cytosolic pertussis toxin-sensitive GTP-binding protein in mastocytoma P-815 cells.
Whooping Cough
Characterization of dopamine receptors mediating inhibition of excitatory synaptic transmission in the rat hippocampal slice.
Whooping Cough
Characterization of effects of endothelin-1 on the L-type Ca2+ current in human atrial myocytes.
Whooping Cough
Characterization of endocrine gland-derived vascular endothelial growth factor signaling in adrenal cortex capillary endothelial cells.
Whooping Cough
Characterization of ep prostanoid receptor subtypes in primary cultures of bovine ciliary epithelial cells by immunofluorescent microscopy and functional studies.
Whooping Cough
Characterization of ERK1/2 signalling pathways induced by adenosine receptor subtypes in newborn rat cardiomyocytes.
Whooping Cough
Characterization of fMet-Leu-Phe-stimulated phospholipase C in streptolysin-O-permeabilised cells.
Whooping Cough
Characterization of functional neuropeptide Y receptors in a human neuroblastoma cell line.
Whooping Cough
Characterization of G-protein alpha subunits in the Gq class: expression in murine tissues and in stromal and hematopoietic cell lines.
Whooping Cough
Characterization of G-protein signaling in ventricular myocytes from the adult mouse heart: differences from the rat.
Whooping Cough
Characterization of G-proteins in rat glomeruli.
Whooping Cough
Characterization of galanin receptor in canine small intestinal circular muscle synaptosomes.
Whooping Cough
Characterization of galanin receptors in the insulin-secreting cell line Rin m 5F: evidence for coupling with a pertussis toxin-sensitive guanosine triphosphate regulatory protein.
Whooping Cough
Characterization of genetically inactivated pertussis toxin mutants: candidates for a new vaccine against whooping cough.
Whooping Cough
Characterization of ghrelin receptor activity in a rat pituitary cell line RC-4B/C.
Whooping Cough
Characterization of heterotrimeric G-proteins in adult Acanthocheilonema viteae.
Whooping Cough
Characterization of histamine-induced catecholamine secretion from bovine adrenal medullary chromaffin cells.
Whooping Cough
Characterization of human A(2B) adenosine receptors: radioligand binding, western blotting, and coupling to G(q) in human embryonic kidney 293 cells and HMC-1 mast cells.
Whooping Cough
Characterization of human chorionic gonadotropin as a novel angiogenic factor.
Whooping Cough
Characterization of human melanoma cell lines according to their migratory properties in vitro.
Whooping Cough
Characterization of human neutrophil and endothelial cell ligand-operated extracellular acidification rate by microphysiometry: impact of reoxygenation.
Whooping Cough
Characterization of human phagocytic cell receptors for C5A and platelet activating factor expressed in Xenopus oocytes.
Whooping Cough
Characterization of human recombinant alpha(2A)-adrenoceptors expressed in Chinese hamster lung cells using extracellular acidification rate changes.
Whooping Cough
Characterization of human recombinant somatostatin sst5 receptors mediating activation of phosphoinositide metabolism.
Whooping Cough
Characterization of IL-17+ interphotoreceptor retinoid-binding protein-specific T cells in experimental autoimmune uveitis.
Whooping Cough
Characterization of increased K+ permeability associated with the stimulation of receptors for immunoglobulin E on rat basophilic leukemia cells.
Whooping Cough
Characterization of individual human antibodies binding pertussis toxin stimulated by acellular immunization.
Whooping Cough
Characterization of influenza A virus activation of the human neutrophil.
Whooping Cough
Characterization of inhibition by haloperidol and chlorpromazine of a voltage-activated K+ current in rat phaeochromocytoma cells.
Whooping Cough
Characterization of ion currents elicited by a stream of fluid during spontaneous and ligand-induced chloride current oscillation in Xenopus laevis oocytes.
Whooping Cough
Characterization of lithium-induced enzyme release from human polymorphonuclear leukocytes.
Whooping Cough
Characterization of lysophosphatidic acid and sphingosine-1-phosphate-mediated signal transduction in rat cortical oligodendrocytes.
Whooping Cough
Characterization of mastoparan-induced histamine release from RBL-2H3 cells.
Whooping Cough
Characterization of melatonin binding sites in the brain and retina of the frog Rana perezi.
Whooping Cough
Characterization of melatonin receptors and signal transduction system in rat arteries forming the circle of Willis.
Whooping Cough
Characterization of membrane melatonin receptor in mouse peritoneal macrophages: inhibition of adenylyl cyclase by a pertussis toxin-sensitive G protein.
Whooping Cough
Characterization of metabotropic glutamate receptors coupled to a pertussis toxin sensitive G-protein in bovine brain coated vesicles.
Whooping Cough
Characterization of monoclonal antibodies directed against domains of pertussis toxin involved in receptor recognition.
Whooping Cough
Characterization of murine lung inflammation after infection with parental Bordetella pertussis and mutants deficient in adhesins or toxins.
Whooping Cough
Characterization of murine monoclonal antibodies that recognize defined epitopes of pertussis toxin and neutralize its toxic effect on Chinese hamster ovary cells.
Whooping Cough
Characterization of muscarinic receptor-mediated cationic currents in longitudinal smooth muscle cells of mouse small intestine.
Whooping Cough
Characterization of mutant strains producing pertussis toxin cross reacting materials.
Whooping Cough
Characterization of Na+-permeable cation channels in LLC-PK1 renal epithelial cells.
Whooping Cough
Characterization of neuropeptide Y-mediated corticotropin-releasing factor synthesis and release from human placental trophoblasts.
Whooping Cough
Characterization of nitric oxide-stimulated ADP-ribosylation of various proteins from the mouse macrophage cell line ANA-1 using sodium nitroprusside and the novel nitric oxide-donating compound diethylamine dinitric oxide.
Whooping Cough
Characterization of noradrenaline-stimulated cyclic GMP formation in brain astrocytes in culture.
Whooping Cough
Characterization of P2Y receptor subtypes functionally expressed on neonatal rat cardiac myofibroblasts.
Whooping Cough
Characterization of PACAP receptors and signaling pathways in rabbit gastric muscle cells.
Whooping Cough
Characterization of PD 121981- and CGP 42112-induced unmasking of low concentration effects of angiotensin II in rabbit abdominal aorta.
Whooping Cough
Characterization of pertussis toxin analogs containing mutations in B-oligomer subunits.
Whooping Cough
Characterization of pertussis toxin by LC-MS/MS.
Whooping Cough
Characterization of pertussis toxoid by two-dimensional liquid chromatography-tandem mass spectrometry.
Whooping Cough
Characterization of pertussis-like toxin from Salmonella spp. that catalyzes ADP-ribosylation of G proteins.
Whooping Cough
Characterization of PGE(2) receptors (EP) and their role as mediators of 1alpha,25-(OH)(2)D(3) effects on growth zone chondrocytes.
Whooping Cough
Characterization of PHA and anti-T3 induced transduction mechanisms in a human T-cell leukaemia line.
Whooping Cough
Characterization of phagocyte P2 nucleotide receptors expressed in Xenopus oocytes.
Whooping Cough
Characterization of phosphatidylinositol-specific phospholipase C (PI-PLC) from Lilium daviddi pollen.
Whooping Cough
Characterization of Phospholipase A(2) Activation by Plasmin in Cultured Bovine Endothelial Cells.
Whooping Cough
Characterization of phospholipase C activity of the plasma membrane and cytosol of an osteoblast-like cell line.
Whooping Cough
Characterization of prostaglandin E2-induced Ca2+ mobilization in single bovine adrenal chromaffin cells by digital image microscopy.
Whooping Cough
Characterization of rac and cdc42 activation in chemoattractant-stimulated human neutrophils using a novel assay for active GTPases.
Whooping Cough
Characterization of reference materials for human antiserum to pertussis antigens by an international collaborative study.
Whooping Cough
Characterization of relaxin-stimulated cyclic AMP in cultured rat anterior pituitary cells: influence of dopamine, somatostatin and gender.
Whooping Cough
Characterization of serological responses to pertussis.
Whooping Cough
Characterization of signaling pathways of P2Y and P2U purinoceptors in bovine pulmonary artery endothelial cells.
Whooping Cough
Characterization of somatostatin receptor subtypes.
Whooping Cough
Characterization of somatostatin receptors on human neuroblastoma tumors.
Whooping Cough
Characterization of specific subcellular 15-hydroxyeicosatetraenoic acid (15-HETE) binding sites on rat basophilic leukemia cells.
Whooping Cough
Characterization of sphingosine 1-phosphate-induced actions and its signaling pathways in rat hepatocytes.
Whooping Cough
Characterization of synthetic human granulocyte chemotactic protein 2: usage of chemokine receptors CXCR1 and CXCR2 and in vivo inflammatory properties.
Whooping Cough
Characterization of the adenosine receptor in cultured embryonic chick atrial myocytes: coupling to modulation of contractility and adenylate cyclase activity and identification by direct radioligand binding.
Whooping Cough
Characterization of the alpha 1B-adrenergic receptors of chicken hepatocytes. Signal transduction and actions.
Whooping Cough
Characterization of the alpha1-adrenergic chronotropic response in neuropeptide Y-treated cardiomyocytes.
Whooping Cough
Characterization of the biologic activities of a recombinant human zona pellucida protein 3 expressed in human ovarian teratocarcinoma (PA-1) cells.
Whooping Cough
Characterization of the biological activities of uridine diphosphate in human dendritic cells: Influence on chemotaxis and CXCL8 release.
Whooping Cough
Characterization of the Ca2+ responses evoked by ATP and other nucleotides in mammalian brain astrocytes.
Whooping Cough
Characterization of the carbohydrate binding and ADP-ribosyltransferase activities of chemically detoxified pertussis toxins.
Whooping Cough
Characterization of the cloned human mu opioid receptor.
Whooping Cough
Characterization of the contractile P2Y14 receptor in mouse coronary and cerebral arteries.
Whooping Cough
Characterization of the endothelin-1-induced regulation of L-type Ca2+ current in rabbit ventricular myocytes.
Whooping Cough
Characterization of the G protein coupling of a somatostatin receptor to the K+ATP channel in insulin-secreting mammalian HIT and RIN cell lines.
Whooping Cough
Characterization of the G protein coupling of SRIF and beta-adrenergic receptors to the maxi KCa channel in insulin-secreting cells.
Whooping Cough
Characterization of the G protein involved in the muscarinic stimulation of adenylyl cyclase of rat olfactory bulb.
Whooping Cough
Characterization of the gonadotrophin-releasing hormone receptor in alpha T3-1 pituitary gonadotroph cells.
Whooping Cough
Characterization of the human and mouse sphingosine 1-phosphate receptor, S1P5 (Edg-8): structure-activity relationship of sphingosine1-phosphate receptors.
Whooping Cough
Characterization of the human gene for Gx alpha, a pertussis toxin-insensitive regulatory GTP-binding protein.
Whooping Cough
Characterization of the integrin and activation steps mediating human eosinophil and neutrophil adhesion to chronically inflamed airway endothelium.
Whooping Cough
Characterization of the key antigenic components of pertussis vaccine based on outer membrane vesicles.
Whooping Cough
Characterization of the m4 muscarinic receptor Ca2+ response in a subclone of PC-12 cells by single cell flow cytometry. Inhibition of the response by bradykinin.
Whooping Cough
Characterization of the Mas-related gene family: structural and functional conservation of human and rhesus MrgX receptors.
Whooping Cough
Characterization of the membrane-associated GTPase activity: effects of chemotactic factors and toxins.
Whooping Cough
Characterization of the metabotropic glutamate receptor in mouse cerebellar granule cells: lack of effect of 2,3-dihydroxy-6-nitro-7-sulphamoylbenzo(F)-quinoxaline (NBQX).
Whooping Cough
Characterization of the migration of lung and blood T cells in response CXCL12 in a three-dimensional matrix.
Whooping Cough
Characterization of the MMQ cell, a prolactin-secreting clonal cell line that is responsive to dopamine.
Whooping Cough
Characterization of the murine immune response to the murine TSH receptor ectodomain: induction of hypothyroidism and TSH receptor antibodies.
Whooping Cough
Characterization of the muscarinic receptor subtypes in the bovine corneal epithelial cells.
Whooping Cough
Characterization of the PGE2 receptor subtype in bovine chondrocytes in culture.
Whooping Cough
Characterization of the phosphoinositide-linked dopamine receptor in a mouse hippocampal-neuroblastoma hybrid cell line.
Whooping Cough
Characterization of the plasma membrane bound GTPase from rabbit neutrophils. I. Evidence for an Ni-like protein coupled to the formyl peptide, C5a, and leukotriene B4 chemotaxis receptors.
Whooping Cough
Characterization of the prostaglandin E receptor expressed on a cultured mast cell line, BNu-2cl3.
Whooping Cough
Characterization of the signal transduction pathway activated in human monocytes and dendritic cells by MPIF-1, a specific ligand for CC chemokine receptor 1.
Whooping Cough
Characterization of the signal transduction pathways mediating noradrenaline-stimulated MAPK activation and c-fos expression in oligodendrocyte progenitors.
Whooping Cough
Characterization of the signalling pathways involved in ATP and basic fibroblast growth factor-induced astrogliosis.
Whooping Cough
Characterization of the toxic mechanism triggered by Alzheimer's amyloid-beta peptides via p75 neurotrophin receptor in neuronal hybrid cells.
Whooping Cough
Characterization of the vasorelaxant mechanisms of the endocannabinoid anandamide in rat aorta.
Whooping Cough
Characterization of transducin from bovine retinal rod outer segments. Participation of the amino-terminal region of T alpha in subunit interaction.
Whooping Cough
Characterization of two Achromobacter xylosoxidans isolates from patients with pertussis-like symptoms.
Whooping Cough
Characterization of two adhesins of Bordetella pertussis for human ciliated respiratory-epithelial cells.
Whooping Cough
Characterization of umami receptor and coupling G protein in mouse taste cells.
Whooping Cough
Characterization of V642I-AbetaPP-induced cytotoxicity in primary neurons.
Whooping Cough
Characterization of vasopressin-mediated GSH efflux from Hep G2 cells: significance of protein kinase C.
Whooping Cough
Characterization of vir-activated TnphoA gene fusions in Bordetella pertussis.
Whooping Cough
Characterization of [125I]acidic fibroblast growth factor binding to the cloned human fibroblast growth factor receptor, FGF-flg, on NIH 3T3 cell membranes: inhibitory effects of heparin, pertussis toxin and guanine nucleotides.
Whooping Cough
Chemerin contributes to inflammation by promoting macrophage adhesion to VCAM-1 and fibronectin through clustering of VLA-4 and VLA-5.
Whooping Cough
Chemerin-induced arterial contraction is Gi- and calcium-dependent.
Whooping Cough
Chemical modification of islet-activating protein, pertussis toxin. Essential role of free amino groups in its lymphocytosis-promoting activity.
Whooping Cough
Chemoattractant properties of PR-39, a neutrophil antibacterial peptide.
Whooping Cough
Chemoattractant receptor-induced hydrolysis of phosphatidylinositol 4,5-bisphosphate in human polymorphonuclear leukocyte membranes. Requirement for a guanine nucleotide regulatory protein.
Whooping Cough
Chemoattractant receptor-induced phosphorylation of L-selectin.
Whooping Cough
Chemoattractant receptor-specific differences in G protein activation rates regulate effector enzyme and functional responses.
Whooping Cough
Chemoattractant receptors activate distinct pathways for chemotaxis and secretion. Role of G-protein usage.
Whooping Cough
Chemoattractant receptors and lymphocyte egress from extralymphoid tissue: changing requirements during the course of inflammation.
Whooping Cough
Chemoattractant-induced activation of c-fos gene expression in human monocytes.
Whooping Cough
Chemoattractant-induced activation of vacuolar H+ pumps and of an H(+)-selective conductance in neutrophils.
Whooping Cough
Chemoattractant-stimulated GTPase activity is decreased on membranes from polymorphonuclear leukocytes incubated in chemoattractant.
Whooping Cough
Chemoattractant-stimulated NF-kappaB activation is dependent on the low molecular weight GTPase RhoA.
Whooping Cough
Chemoattraction of neutrophils by substance P and transforming growth factor-beta 1 is inadequately explained by current models of lipid remodeling.
Whooping Cough
Chemokine fractalkine/CX3CL1 negatively modulates active glutamatergic synapses in rat hippocampal neurons.
Whooping Cough
Chemokine production by G protein-coupled receptor activation in a human mast cell line: roles of extracellular signal-regulated kinase and NFAT.
Whooping Cough
Chemokine receptor CCR5 functionally couples to inhibitory G proteins and undergoes desensitization.
Whooping Cough
Chemokine receptor CCR6 transduces signals that activate p130Cas and alter cAMP-stimulated ion transport in human intestinal epithelial cells.
Whooping Cough
Chemokine receptor CCR7 required for T lymphocyte exit from peripheral tissues.
Whooping Cough
Chemokine receptor CXCR2 activates distinct pathways for chemotaxis and calcium mobilization.
Whooping Cough
Chemokine receptor expression and signaling in macaque and human fetal neurons and astrocytes: implications for the neuropathogenesis of AIDS.
Whooping Cough
Chemokine receptor-8 (CCR8) mediates human vascular smooth muscle cell chemotaxis and metalloproteinase-2 secretion.
Whooping Cough
Chemokine regulation of hematopoiesis and the involvement of pertussis toxin-sensitive G alpha i proteins.
Whooping Cough
Chemokine release from human rhinovirus-infected airway epithelial cells promotes fibroblast migration.
Whooping Cough
Chemokine stromal cell-derived factor-1alpha modulates VLA-4 integrin-dependent adhesion to fibronectin and VCAM-1 on bone marrow hematopoietic progenitor cells.
Whooping Cough
Chemokine stromal cell-derived factor-1alpha modulates VLA-4 integrin-mediated multiple myeloma cell adhesion to CS-1/fibronectin and VCAM-1.
Whooping Cough
Chemokine-directed trafficking of receptor stimulus to different g proteins: selective inducible and constitutive signaling by human herpesvirus 6-encoded chemokine receptor u51.
Whooping Cough
Chemokine-independent preference for T-helper-1 cells in transendothelial migration.
Whooping Cough
Chemokines as regulators of T cell differentiation.
Whooping Cough
Chemokines regulate cellular polarization and adhesion receptor redistribution during lymphocyte interaction with endothelium and extracellular matrix. Involvement of cAMP signaling pathway.
Whooping Cough
Chemokines regulate IL-6 and IL-8 production by fibroblast-like synoviocytes from patients with rheumatoid arthritis.
Whooping Cough
Chemotactic 5-oxo-eicosatetraenoic acids induce oxygen radical production, Ca2+-mobilization, and actin reorganization in human eosinophils via a pertussis toxin-sensitive G-protein.
Whooping Cough
Chemotactic activity of pertussis toxin on murine lymphocytes. Its potential role on lymphocyte accumulation in the lung.
Whooping Cough
Chemotactic agonists induce cytokine generation in eosinophils.
Whooping Cough
Chemotactic factor induced tyrosine phosphorylation of membrane associated proteins in rabbit peritoneal neutrophils.
Whooping Cough
Chemotactic factor-induced recruitment and activation of Tec family kinases in human neutrophils. Implication of phosphatidynositol 3-kinases.
Whooping Cough
Chemotactic peptide activation of human neutrophils and HL-60 cells. Pertussis toxin reveals correlation between inositol trisphosphate generation, calcium ion transients, and cellular activation.
Whooping Cough
Chemotactic peptide fMetLeuPhe induces translocation of the TRPV2 channel in macrophages.
Whooping Cough
Chemotactic peptide receptor-supported ADP-ribosylation of a pertussis toxin substrate GTP-binding protein by cholera toxin in neutrophil-type HL-60 cells.
Whooping Cough
Chemotactic peptide, calcium and guanine nucleotide regulation of phospholipase C activity in membranes from DMSO-differentiated HL60 cells.
Whooping Cough
Chemotactic peptide-induced activation of Ras in human neutrophils is associated with inhibition of p120-GAP activity.
Whooping Cough
Chemotactic responses of osteoblastic MC3T3-E1 cells toward zinc chloride.
Whooping Cough
Chemotaxins C5a and fMLP induce release of calprotectin (leucocyte L1 protein) from polymorphonuclear cells in vitro.
Whooping Cough
Chemotaxis and differentiation of human adipose tissue CD34+/CD31- progenitor cells: role of stromal derived factor-1 released by adipose tissue capillary endothelial cells.
Whooping Cough
Chemotaxis and transendothelial migration of CD34(+) hematopoietic progenitor cells induced by the inflammatory mediator leukotriene D4 are mediated by the 7-transmembrane receptor CysLT1.
Whooping Cough
Chemotaxis of chinese hamster ovary cells expressing the human neutrophil formyl peptide receptor: role of signal transduction molecules and alpha5beta1 integrin.
Whooping Cough
Chemotaxis of rat mast cells toward adenine nucleotides.
Whooping Cough
Chick embryo, a model to study the lethal activity of pertussis toxin, infectivity of Bordetella pertussis, and their neutralization by immune sera.
Whooping Cough
Chick RGS2L demonstrates concentration-dependent selectivity for pertussis toxin-sensitive and -insensitive pathways that inhibit L-type Ca2+ channels.
Whooping Cough
Chicken liver contains a large quantity of a G-protein-linked neurotensin receptor.
Whooping Cough
Chimeric Galpha(q) mutants harboring the last five carboxy-terminal residues of Galpha(i2) or Galpha(o) are resistant to pertussis toxin-catalyzed ADP-ribosylation.
Whooping Cough
Chinese hamster ovary (CHO) cell clustering does not correlate with in vivo histamine-sensitization when measuring residual activity of aldehyde-treated pertussis toxin (PT).
Whooping Cough
Chloride channel blockers inhibit ACTH secretion from mouse pituitary tumor cells.
Whooping Cough
Chloride channels in cultured human skeletal muscle are regulated by G proteins.
Whooping Cough
Chloride channels in myocytes from rabbit colon are regulated by a pertussis toxin-sensitive G protein.
Whooping Cough
Chloride efflux in cyclic AMP-induced configurational change of bovine pulmonary artery endothelial cells.
Whooping Cough
Cholecystokinin activates Gi1-, Gi2-, Gi3- and several Gs-proteins in rat pancreatic acinar cells.
Whooping Cough
Cholecystokinin type B receptor-mediated inhibition of A-type K+ channels enhances sensory neuronal excitability through the phosphatidylinositol 3-kinase and c-Src-dependent JNK pathway.
Whooping Cough
Cholera and pertussis exotoxins protect mice against the lethal Schwartzman reaction and antagonize the effects of lipopolysaccharide on second messenger systems.
Whooping Cough
Cholera and pertussis toxins amplify prostacyclin synthesis in aortic smooth muscle cells.
Whooping Cough
Cholera and pertussis toxins increase acidification of endocytic vesicles without altering ion conductances.
Whooping Cough
Cholera and pertussis toxins inhibit differently hypothermic and anti-opioid effects of neuropeptide FF.
Whooping Cough
Cholera and pertussis toxins modify regulation of glucose transport activity in rat adipose cells: evidence for mediation of a cAMP-independent process by G-proteins.
Whooping Cough
Cholera and pertussis toxins reveal multiple regulation of cAMP levels in the rabbit carotid body.
Whooping Cough
Cholera toxin accentuates the antagonism by acetylcholine of higenamine-induced positive chronotropy is isolated right atria of mice.
Whooping Cough
Cholera toxin ADP-ribosylates the receptor-coupled form of pertussis toxin-sensitive G-proteins.
Whooping Cough
Cholera toxin and dibutyryl cyclic adenosine 3',5'-monophosphate sensitize gonadotropin-releasing hormone-stimulated inositol phosphate production to inhibition in protein kinase-C (PKC)-depleted cells: evidence for cross-talk between a cholera toxin-sensitive G-protein and PKC.
Whooping Cough
Cholera toxin and pertussis toxin on opioid- and alpha 2-mediated supraspinal analgesia in mice.
Whooping Cough
Cholera toxin and pertussis toxin provoke differential effects on luteinizing hormone release, inositol phosphate production, and gonadotropin-releasing hormone (GnRH) receptor binding in the gonadotrope: evidence for multiple guanyl nucleotide binding proteins in GnRH action.
Whooping Cough
Cholera toxin and pertussis toxin regulate the Fc receptor-mediated phagocytic response of human neutrophils in a manner analogous to regulation by monoclonal antibody 1C2.
Whooping Cough
Cholera toxin and pertussis toxin stimulate prostaglandin E2 synthesis in a murine macrophage cell line.
Whooping Cough
Cholera toxin and pertussis toxin substrates and endogenous ADP-ribosyltransferase activity in Drosophila melanogaster.
Whooping Cough
Cholera toxin antagonizes morphine-induced catalepsy through a cyclic AMP-independent mechanism.
Whooping Cough
Cholera toxin blocks glucagon-mediated inhibition of the liver plasma membrane (Ca2+-Mg2+)-ATPase.
Whooping Cough
Cholera toxin but not pertussis toxin inhibits angiotensin II-enhanced contractions in the rat portal vein.
Whooping Cough
Cholera toxin can ADP-ribosylate Gs as well as Gi in ACTH-unresponsive human adrenocortical cancer.
Whooping Cough
Cholera toxin directly stimulates pregnenolone generation with increasing Ca2+ efflux in bovine adrenocortical mitochondria.
Whooping Cough
Cholera toxin inhibits interleukin-2-induced, but enhances pertussis toxin-induced T-cell proliferation: regulation by cyclic nucleotides.
Whooping Cough
Cholera toxin modulation of angiotensin II-stimulated inositol phosphate production in cultured vascular smooth muscle cells.
Whooping Cough
Cholera toxin treatment produces down-regulation of the alpha-subunit of the stimulatory guanine-nucleotide-binding protein (Gs).
Whooping Cough
Cholera-toxin and corticotropin modulation of inositol phosphate accumulation induced by vasopressin and angiotensin II in rat glomerulosa cells.
Whooping Cough
Cholesterol regulates contractility and inotropic response to ?2-adrenoceptor agonist in the mouse atria: Involvement of Gi-protein-Akt-NO-pathway.
Whooping Cough
Choline-linked phosphoglycerides. A source of phosphatidic acid and diglycerides in stimulated neutrophils.
Whooping Cough
Cholinergic inhibition of cAMP accumulation in Sertoli cells cultured from immature hamsters.
Whooping Cough
Cholinergic M2 muscarinic receptor-mediated inhibition of endogenous noradrenaline release from the isolated vascularly perfused rat stomach.
Whooping Cough
Cholinergic modulation of the Ca2+ response to bradykinin in neuroblastoma cells.
Whooping Cough
Cholinergic receptor signaling modulates spontaneous firing of sinoatrial nodal cells via integrated effects on PKA-dependent Ca(2+) cycling and I(KACh).
Whooping Cough
Cholinergic stimulation of phosphoinositide hydrolysis in rat anterior pituitary.
Whooping Cough
Cholinergic stimulation of phosphoinositide metabolism in isolated rat glomeruli.
Whooping Cough
Cholinergic-induced [3H] noradrenaline release in rat brain cortical slices is mediated via a pertussis toxin sensitive GTP binding protein and involves activation of protein kinase C.
Whooping Cough
Cholinoceptor activation subserving the effects of interferon gamma on the contractility of rat ileum.
Whooping Cough
Chromatographic resolution and immunologic identification of the alpha 40 and alpha 41 subunits of guanine nucleotide-binding regulatory proteins from bovine brain.
Whooping Cough
Chronic activation of ORL1 receptor induces supersensitization of adenylyl cyclase.
Whooping Cough
Chronic coronary arterial stenosis impairs alpha 1-adrenoreceptor signaling and cardiac performance in rats.
Whooping Cough
Chronic ethanol increases the cannabinoid receptor agonist anandamide and its precursor N-arachidonoylphosphatidylethanolamine in SK-N-SH cells.
Whooping Cough
Chronic ethanol promotes the neuronal differentiation of NG108-15 cells independently of toxin-sensitive G-proteins.
Whooping Cough
Chronic ethanol treatment increases expression of inhibitory G-proteins and reduces adenylylcyclase activity in the central nervous system of two lines of ethanol-sensitive mice.
Whooping Cough
Chronic experimental autoimmune encephalomyelitis induced by the 89-101 myelin basic protein peptide in B10RIII (H-2r) mice.
Whooping Cough
Chronic exposure of NG 108-15 cells to inhibitory acting drugs reduces stimulatory prostaglandin E1 receptor number.
Whooping Cough
Chronic exposure of NG 108-15 cells to opiate agonists does not alter the amount of the guanine nucleotide-binding proteins Gi and Go.
Whooping Cough
Chronic exposure to pertussis toxin alters muscarinic receptor-mediated regulation of cyclic AMP metabolism in neuroblastoma x glioma NG108-15 hybrid cells.
Whooping Cough
Chronic lymphocytic leukemia B cells express functional CXCR4 chemokine receptors that mediate spontaneous migration beneath bone marrow stromal cells.
Whooping Cough
Chronic mechanical hypersensitivity in experimental autoimmune encephalomyelitis is regulated by disease severity and neuroinflammation.
Whooping Cough
Chronic morphine administration and in vivo pertussis toxin treatment induce hyperalgesia and enhance 3H-nitrendipine binding.
Whooping Cough
Chronic morphine treatment increases stimulatory beta-2 adrenoceptor signaling in A431 cells stably expressing the mu opioid receptor.
Whooping Cough
Chronic morphine treatment up-regulates mu opioid receptor binding in cells lacking filamin A.
Whooping Cough
Chronic morphine-induced changes in mu-opioid receptors and G proteins of different subcellular loci in rat brain.
Whooping Cough
Chronic muscarinic cholinoceptor stimulation increases adenylyl cyclase responsiveness in rat cardiomyocytes by a decrease in the level of inhibitory G-protein alpha-subunits.
Whooping Cough
Chronic myelogenous leukemia-derived basophilic granulocytes express a functional active receptor for the anaphylatoxin C3a.
Whooping Cough
Chronic opioid treatment induces adenylyl cyclase V superactivation. Involvement of Gbetagamma.
Whooping Cough
Chronic oxytocin pretreatment inhibits adenylyl cyclase activity in cultured rat myometrial cells.
Whooping Cough
Chronic receptor-mediated activation of Gi/o proteins alters basal t-tubular and sarcolemmal L-type Ca2+ channel activity through phosphatases in heart failure.
Whooping Cough
Chronic treatment with dexmedetomidine desensitizes alpha 2-adrenergic signal transduction.
Whooping Cough
Chronic treatment with the opioid antagonist naltrexone favours the coupling of spinal cord ?-opioid receptors to G?z protein subunits.
Whooping Cough
CiC3-1a-mediated chemotaxis in the deuterostome invertebrate Ciona intestinalis (Urochordata).
Whooping Cough
Cigarette smoke extract-induced interleukin-6 expression is regulated by phospholipase D1 in human bronchial epithelial cells.
Whooping Cough
Ciproxifan, a histamine H3 receptor antagonist and inverse agonist, presynaptically inhibits glutamate release in rat hippocampus.
Whooping Cough
Circulation of pertussis and poor protection against diphtheria among middle-aged adults in 18 European countries.
Whooping Cough
CK beta-11/macrophage inflammatory protein-3 beta/EBI1-ligand chemokine is an efficacious chemoattractant for T and B cells.
Whooping Cough
Cl- currents activated via purinergic receptors in Xenopus follicles.
Whooping Cough
CL316243 induces phosphatidylinositol 3,4,5-triphosphate production in rat adipocytes in an adenosine deaminase-, pertussis toxin-, or wortmannin-sensitive manner.
Whooping Cough
Class A scavenger receptors mediate cell adhesion via activation of G(i/o) and formation of focal adhesion complexes.
Whooping Cough
Clinical and Histopathological Assessment on an Animal Model with Experimental Autoimmune Encephalomyelitis.
Whooping Cough
Clinical Effect of IRT-5 Probiotics on Immune Modulation of Autoimmunity or Alloimmunity in the Eye.
Whooping Cough
Clinical experience of a tricomponent acellular pertussis vaccine combined with diphtheria and tetanus toxoids for primary vaccination in 22,505 infants.
Whooping Cough
Clinical reactions and immunogenicity of the BIKEN acellular diphtheria and tetanus toxoids and pertussis vaccine in 4- through 6-year-old US children.
Whooping Cough
Clinical validation of a polymerase chain reaction assay for the diagnosis of pertussis by comparison with serology, culture, and symptoms during a large pertussis vaccine efficacy trial.
Whooping Cough
Clinical, metabolic, and antibody responses of adult volunteers to an investigational vaccine composed of pertussis toxin inactivated by hydrogen peroxide.
Whooping Cough
Clinicopathological study of a myelin oligodendrocyte glycoprotein-induced demyelinating disease in LEW.1AV1 rats.
Whooping Cough
Cloned M1 muscarinic receptors mediate both adenylate cyclase inhibition and phosphoinositide turnover.
Whooping Cough
Clonidine and cirazoline inhibit activation of nicotinic channels in PC-12 cells.
Whooping Cough
Clonidine inhibits fluid absorption in the rabbit proximal convoluted renal tubule.
Whooping Cough
Cloning and characterization of a cDNA coding for the alpha-subunit of a stimulatory G protein from Schistosoma mansoni.
Whooping Cough
Cloning and characterization of a G protein alpha-subunit-encoding gene from the basidiomycete, Coprinus congregatus.
Whooping Cough
Cloning and expression of a human somatostatin-14-selective receptor variant (somatostatin receptor 4) located on chromosome 20.
Whooping Cough
Cloning and Expression of S1 Subunit of Pertussis Toxin in Escherichia coli.
Whooping Cough
Cloning and functional characterization of the mouse C3a anaphylatoxin receptor gene.
Whooping Cough
Cloning and functional expression of a cDNA encoding a mouse type 2 neuropeptide Y receptor.
Whooping Cough
Cloning and functional expression of a novel Gi protein-coupled receptor for adenine from mouse brain.
Whooping Cough
Cloning and functional expression of CC CKR5, a human monocyte CC chemokine receptor selective for MIP-1(alpha), MIP-1(beta), and RANTES.
Whooping Cough
Cloning and functional expression of the first Drosophila melanogaster sulfakinin receptor DSK-R1.
Whooping Cough
Cloning and pharmacological characterisation of the guinea pig 5-ht5A receptor.
Whooping Cough
Cloning and sequencing of the pertussis toxin genes: operon structure and gene duplication.
Whooping Cough
Cloning of a molluscan G protein alpha subunit of the Gq class which is expressed differentially in identified neurons.
Whooping Cough
Cloning, expression and regulation of angiotensin II receptors.
Whooping Cough
Cloning, expression, and characterization of a membrane progestin receptor and evidence it is an intermediary in meiotic maturation of fish oocytes.
Whooping Cough
Cloning, expression, and gene structure of a G protein-coupled glutamate receptor from rat brain.
Whooping Cough
Cloning, expression, functional coupling and pharmacological characterization of the rat dopamine D4 receptor.
Whooping Cough
Cloning, heterologous expression and developmental regulation of a Drosophila receptor for tachykinin-like peptides.
Whooping Cough
Cloning, nucleotide sequence, and hybridization studies of the type IIb heat-labile enterotoxin gene of Escherichia coli.
Whooping Cough
Cloning, pharmacological characterisation and distribution of the rat G-protein-coupled P2Y(13) receptor.
Whooping Cough
Cloning, sequence analysis, and permanent expression of a human alpha 2-adrenergic receptor in Chinese hamster ovary cells. Evidence for independent pathways of receptor coupling to adenylate cyclase attenuation and activation.
Whooping Cough
Clostridium difficile toxin A stimulates intracellular calcium release and chemotactic response in human granulocytes.
Whooping Cough
Clostridium perfringens alpha-toxin activates the sphingomyelin metabolism system in sheep erythrocytes.
Whooping Cough
Clostridium perfringens alpha-toxin induces rabbit neutrophil adhesion.
Whooping Cough
Clustered cases of Bordetella pertussis infection cause high levels of IgG antibodies against pertussis toxin in adolescents in Gaobeidian city, China.
Whooping Cough
Clusterin stimulates the chemotactic migration of macrophages through a pertussis toxin sensitive G-protein-coupled receptor and G??-dependent pathways.
Whooping Cough
cNMP-AMs mimic and dissect bacterial nucleotidyl cyclase toxin effects.
Whooping Cough
CNP-induced changes in pHi, cGMP/cAMP and mRNA expression of natriuretic peptide receptors in human trabecular meshwork cells.
Whooping Cough
Co-existence of two types of [Ca2+]i-inducing protease-activated receptors (PAR-1 and PAR-2) in rat astrocytes and C6 glioma cells.
Whooping Cough
Co-expression of mu and delta opioid receptors as receptor-G protein fusions enhances both mu and delta signalling via distinct mechanisms.
Whooping Cough
Co-expression of the Bordetella pertussis leader peptidase I results in enhanced processing and expression of the pertussis toxin S1 subunit in Escherichia coli.
Whooping Cough
Co-operation of phosphatidylinositol transfer protein with phosphoinositide 3-kinase gamma in the formylmethionyl-leucylphenylalanine-dependent production of phosphatidylinositol 3,4,5-trisphosphate in human neutrophils.
Whooping Cough
Co-purification of A1 adenosine receptors and guanine nucleotide-binding proteins from bovine brain.
Whooping Cough
Co-stimulation of PAFR and CD36 is required for oxLDL-induced human macrophages activation.
Whooping Cough
Co-stimulation of T cells via CD28 inhibits human IgE production; reversal by pertussis toxin.
Whooping Cough
Coagulation Factor Xa inhibits cancer cell migration via Protease-activated receptor-1 activation.
Whooping Cough
Cocaine- and amphetamine-regulated transcript (CART) peptide activates the extracellular signal-regulated kinase (ERK) pathway in AtT20 cells via putative G-protein coupled receptors.
Whooping Cough
Codeine induces human mast cell chemokine and cytokine production: involvement of G-protein activation.
Whooping Cough
Coexistence of CD14-dependent and independent pathways for stimulation of human monocytes by gram-positive bacteria.
Whooping Cough
Coexisting NPY and NE synergistically regulate renal tubular Na+, K(+)-ATPase activity.
Whooping Cough
Coexpression of delta-opioid receptors with micro receptors in GH3 cells changes the functional response to micro agonists from inhibitory to excitatory.
Whooping Cough
Coexpression of ligand-gated P2X and G protein-coupled P2Y receptors in smooth muscle. Preferential activation of P2Y receptors coupled to phospholipase C (PLC)-beta1 via Galphaq/11 and to PLC-beta3 via Gbetagammai3.
Whooping Cough
Coexpression of several types of metabotropic nucleotide receptors in single cerebellar astrocytes.
Whooping Cough
Coexpression of Y1, Y2, and Y4 receptors in smooth muscle coupled to distinct signaling pathways.
Whooping Cough
Coincidence detection at the level of phospholipase C activation mediated by the m4 muscarinic acetylcholine receptor.
Whooping Cough
Colchicine and cytochalasin B enhance cyclic AMP accumulation via postreceptor actions.
Whooping Cough
Cold-induced reduction in Gi alpha proteins in brown adipose tissue. Effects on the cellular hypersensitization to noradrenaline caused by pertussis-toxin treatment.
Whooping Cough
Collaborative study for the calibration of the replacement International Standard for pertussis toxin for use in histamine sensitisation and CHO cell clustering assays.
Whooping Cough
Collaborative study for the establishment of a European Phamacopoeia Biological reference preparation for Bordetella pertussis mouse antiserum for serological potency testing of acellular pertussis vaccines.
Whooping Cough
Collaborative study for the evaluation of enzyme-linked immunosorbent assays used to measure human antibodies to Bordetella pertussis antigens.
Whooping Cough
Collaborative Study for the Standardisation of the Histamine Sensitizing Test in Mice and the CHO Cell-based Assay for the Residual Toxicity Testing of Acellular Pertussis Vaccines.
Whooping Cough
Collaborative study on a Guinea pig serological method for the assay of acellular pertussis vaccines.
Whooping Cough
Collaborative study on test systems to assess toxicity of whole cell pertussis vaccine.
Whooping Cough
Collagen Synthesis Is Suppressed in Dermal Fibroblasts by the Human Antimicrobial Peptide LL-37.
Whooping Cough
Collagen type IV stimulates an increase in intracellular Ca2+ in pancreatic acinar cells via activation of phospholipase C.
Whooping Cough
Collagen-binding motif peptide, a cleavage product of osteopontin, stimulates human neutrophil chemotaxis via pertussis toxin-sensitive G protein-mediated signaling.
Whooping Cough
Colocalization and complex formation between prosaposin and monosialoganglioside GM3 in neural cells.
Whooping Cough
Colonic smooth muscle cells possess a different subtype of somatostatin receptor from gastric smooth muscle cells.
Whooping Cough
Colony-stimulating factor 1 activates protein kinase C in human monocytes.
Whooping Cough
Colony-stimulating factor 1-induced Na+ influx into human monocytes involves activation of a pertussis toxin-sensitive GTP-binding protein.
Whooping Cough
Combined pharmacological preconditioning with a G-protein-coupled receptor agonist, a mitochondrial KATP channel opener and a nitric oxide donor mimics ischaemic preconditioning.
Whooping Cough
Combined tetanus-diphtheria and pertussis vaccine during pregnancy: transfer of maternal pertussis antibodies to the newborn.
Whooping Cough
Commensal-Epithelial Signaling Mediated via Formyl Peptide Receptors.
Whooping Cough
Common alpha 2- and opiate effector mechanisms in the locus coeruleus: intracellular studies in brain slices.
Whooping Cough
Common ancestry between IncN conjugal transfer genes and macromolecular export systems of plant and animal pathogens.
Whooping Cough
Common and distinct intracellular signaling pathways in human neutrophils utilized by platelet activating factor and FMLP.
Whooping Cough
Common features of the NAD-binding and catalytic site of ADP-ribosylating toxins.
Whooping Cough
Common signaling pathways link activation of murine PAR-1, LPA, and S1P receptors to proliferation of astrocytes.
Whooping Cough
Comodulation of CXCR4 and CD26 in human lymphocytes.
Whooping Cough
Comparative aspects of the role of neuropeptide Y in the regulation of the vertebrate heart.
Whooping Cough
Comparative biological activities of whole cell pertussis vaccine and a new acellular preparation.
Whooping Cough
Comparative effects of cholera and Bordetella pertussis toxins on cyclic AMP and GTP levels and on lipolysis in rat adipocytes incubated in vitro.
Whooping Cough
Comparative effects of receptor inactivation, 17 beta-estradiol and pertussis toxin on dopaminergic inhibition of prolactin secretion in vitro.
Whooping Cough
Comparative efficacy of acellular pertussis vaccines: an analysis of recent trials.
Whooping Cough
Comparative evaluation of Mycobacterium vaccae as a surrogate cloning host for use in the study of mycobacterial genetics.
Whooping Cough
Comparative genomic profiling of Dutch clinical Bordetella pertussis isolates using DNA microarrays: identification of genes absent from epidemic strains.
Whooping Cough
Comparative genomics of prevaccination and modern Bordetella pertussis strains.
Whooping Cough
Comparative safety and immunogenicity of an acellular versus whole-cell pertussis component of diphtheria-tetanus-pertussis vaccines in Senegalese infants.
Whooping Cough
Comparative studies of phosphoinositide hydrolysis induced by endothelin-related peptides in cultured cerebellar astrocytes, C6-glioma and cerebellar granule cells.
Whooping Cough
Comparative studies on the binding specificities of pertussis toxin and different lectins to human erythrocytes.
Whooping Cough
Comparative study of a whole-cell pertussis vaccine and a recombinant acellular pertussis vaccine. The Italian Multicenter Group for the Study of Recombinant Acellular Pertussis Vaccine.
Whooping Cough
Comparative study of different sources of pertussis toxin (PT) as coating antigens in IgG anti-PT enzyme-linked immunosorbent assays.
Whooping Cough
Comparing the pathogenesis of experimental autoimmune encephalomyelitis in CD4-/- and CD8-/- DBA/1 mice defines qualitative roles of different T cell subsets.
Whooping Cough
Comparison between the vasoactive actions of endothelin and arginine vasopressin in pithed rats after pretreatment with BAY K 8644, nifedipine or pertussis toxin.
Whooping Cough
Comparison of 13 acellular pertussis vaccines: overview and serologic response.
Whooping Cough
Comparison of a diphtheria and tetanus toxoids and bicomponent acellular pertussis vaccine with diphtheria and tetanus toxoids and whole-cell pertussis vaccine in infants.
Whooping Cough
Comparison of a fifth dose of a five-component acellular or a whole cell pertussis vaccine in children four to six years of age.
Whooping Cough
Comparison of a three-component acellular pertussis vaccine with a whole-cell pertussis vaccine in 4- through 6-year-old children. Elmwood Pediatric Associates, Pennridge Pediatric Associates.
Whooping Cough
Comparison of a three-component acellular pertussis vaccine with whole cell pertussis vaccine in two-month-old children.
Whooping Cough
Comparison of acellular pertussis vaccine with whole cell vaccine as a booster in children 15 to 18 months and 4 to 6 years of age.
Whooping Cough
Comparison of acellular pertussis vaccines-induced immunity against infection due to Bordetella pertussis variant isolates in a mouse model.
Whooping Cough
Comparison of alpha 1-adrenergic receptor subtypes and signal transduction in SK-N-MC and NB41A3 neuronal cell lines.
Whooping Cough
Comparison of alpha 1A- and alpha 1B-adrenoceptor coupling to inositol phosphate formation in rat kidney.
Whooping Cough
Comparison of anti-pertussis toxin ELISA and agglutination assays to assess immune responses to pertussis.
Whooping Cough
Comparison of autocrine mechanisms promoting motility in two metastatic cell lines: human melanoma and ras-transfected NIH3T3 cells.
Whooping Cough
Comparison of culture and PCR for detection of Bordetella pertussis and Bordetella parapertussis under routine laboratory conditions.
Whooping Cough
Comparison of diphtheria-tetanus-two component acellular pertussis vaccines in United States and Japanese infants at 2, 4, and 6 months of age.
Whooping Cough
Comparison of endothelium-dependent relaxation in carotid arteries from Japanese white and Watanabe heritable hyperlipidemic rabbits.
Whooping Cough
Comparison of extracellular ATP and UTP signalling in rat renal mesangial cells. No indications for the involvement of separate purino- and pyrimidino-ceptors.
Whooping Cough
Comparison of five calculation modes for antibody ELISA procedures using pertussis serology as a model.
Whooping Cough
Comparison of functional antagonism between isoproterenol and M2 muscarinic receptors in guinea pig ileum and trachea.
Whooping Cough
Comparison of functional profiles at human recombinant somatostatin sst2 receptor: simultaneous determination of intracellular Ca2+ and luciferase expression in CHO-K1 cells.
Whooping Cough
Comparison of intrinsic activities of the putative sphingosine 1-phosphate receptor subtypes to regulate several signaling pathways in their cDNA-transfected Chinese hamster ovary cells.
Whooping Cough
Comparison of mechanisms of IL-3 induced histamine release and IL-3 priming effect on human basophils.
Whooping Cough
Comparison of mu opioid receptor binding on intact neuroblastoma cells with guinea pig brain and neuroblastoma cell membranes.
Whooping Cough
Comparison of nasopharyngeal culture, polymerase chain reaction (PCR) and serological test for diagnosis of pertussis.
Whooping Cough
Comparison of pertussis toxin (PT)-neutralizing activities and mouse-protective activities of anti-PT mouse monoclonal antibodies.
Whooping Cough
Comparison of polymerase chain reaction, culture, and western immunoblot serology for diagnosis of Bordetella pertussis infection.
Whooping Cough
Comparison of real-time PCR and pyrosequencing for typing Bordetella pertussis toxin subunit 1 variants.
Whooping Cough
Comparison of second messenger formation in human keratinocytes following stimulation with epidermal growth factor and bradykinin.
Whooping Cough
Comparison of sensitization elicited by amphetamine and pertussis toxin: characterization of locomotor behavior and limbic dopamine release.
Whooping Cough
Comparison of serological and real-time PCR assays to diagnose Bordetella pertussis infection in 2007.
Whooping Cough
Comparison of signal transduction mechanisms of alpha-2C and alpha-1A adrenergic receptor-stimulated prostaglandin synthesis.
Whooping Cough
Comparison of signaling pathways activated by the relaxin family peptide receptors, RXFP1 and RXFP2, using reporter genes.
Whooping Cough
Comparison of stimulation by chemotactic formyl peptide analogs between GTPase activity in neutrophil plasma membranes and granule enzyme release from intact neutrophils.
Whooping Cough
Comparison of the actions of adenosine at pre- and postsynaptic receptors in the rat hippocampus in vitro.
Whooping Cough
Comparison of the actions of baclofen at pre- and postsynaptic receptors in the rat hippocampus in vitro.
Whooping Cough
Comparison of the bioactivity of reference preparations for assaying Bordetella pertussis toxin activity in vaccines by the histamine sensitisation and Chinese hamster ovary-cell tests: assessment of validity of expression of activity in terms of protein concentration.
Whooping Cough
Comparison of the Bordetella pertussis and Bordetella parapertussis isolates circulating in Saint Petersburg between 1998 and 2000 with Russian vaccine strains.
Whooping Cough
Comparison of the effects of ions and GTP on substance P binding to membrane-bound and solubilized specific sites.
Whooping Cough
Comparison of the lectin-like activity of pertussis toxin with two plant lectins that have differential specificities for alpha (2-6) and alpha (2-3)-linked sialic acid.
Whooping Cough
Comparison of the ligand binding and signaling properties of human dopamine D(2) and D(3) receptors in Chinese hamster ovary cells.
Whooping Cough
Comparison of the pharmacological antagonism of M2 and M3 muscarinic receptors expressed in isolation and in combination.
Whooping Cough
Comparison of the pharmacology and signal transduction of the human cannabinoid CB1 and CB2 receptors.
Whooping Cough
Comparison of the relative efficacy and potency of mu-opioid agonists to activate Galpha(i/o) proteins containing a pertussis toxin-insensitive mutation.
Whooping Cough
Comparison of the safety and immunogenicity of acellular (BIKEN) and whole-cell pertussis vaccines in 15- to 20-month-old children.
Whooping Cough
Comparison of the timing of acute blood-brain barrier breakdown to rabbit immunoglobulin G in the cerebellum and spinal cord of mice with experimental autoimmune encephalomyelitis.
Whooping Cough
Compartmentation of alpha 2-adrenergic receptors in human erythroleukemia (HEL) cells.
Whooping Cough
Compartmentation of receptors and guanine nucleotide-binding proteins in NG108-15 cells: lack of cross-talk in agonist binding among the alpha 2-adrenergic, muscarinic, and opiate receptors.
Whooping Cough
Competition between zonae pellucidae and a proteinase inhibitor for sperm binding.
Whooping Cough
Complement 5a controls motility of murine microglial cells in vitro via activation of an inhibitory G-protein and the rearrangement of the actin cytoskeleton.
Whooping Cough
Complement c3a and c5a induce different signal transduction cascades in endothelial cells.
Whooping Cough
Complement C3a receptors in the pituitary gland: a novel pathway by which an innate immune molecule releases hormones involved in the control of inflammation.
Whooping Cough
Complement fragment C3a stimulates Ca2+ influx in neutrophils via a pertussis-toxin-sensitive G protein.
Whooping Cough
Complement selectively elicits glutamate release from nerve endings in different regions of mammal central nervous system.
Whooping Cough
Complete inhibition of purinoceptor agonist-induced nociception by spinorphin, but not by morphine.
Whooping Cough
Complex chemoattractive and chemorepellent Kit signals revealed by direct imaging of murine mast cells in microfluidic gradient chambers.
Whooping Cough
Complex involvement of pertussis toxin-sensitive G proteins in the regulation of type 1alpha metabotropic glutamate receptor signaling in baby hamster kidney cells.
Whooping Cough
Complex regulation of calcium current in cardiac cells. Dependence on a pertussis toxin-sensitive substrate, adenosine triphosphate, and an alpha 1-adrenoceptor.
Whooping Cough
Components of purified sarcolemma from porcine skeletal muscle.
Whooping Cough
Components of the signaling pathway linking the 1-methyladenine receptor to MPF activation and maturation in starfish oocytes.
Whooping Cough
Computational evaluation of a fusion protein consisted of pertussis toxin and filamentous hemagglutinin from Bordetella pertussis to target Claudin-4 using C-terminal fragment of Clostridium perfringens enterotoxin.
Whooping Cough
Computer modelling of the NAD binding site of ADP-ribosylating toxins: active-site structure and mechanism of NAD binding.
Whooping Cough
Concanavalin A stimulation of O2 consumption in electropermeabilized neutrophils via a pertussis toxin-insensitive G protein.
Whooping Cough
Concentration-dependent dual effect of anandamide on sensory neuropeptide release from isolated rat tracheae.
Whooping Cough
Concentrations of Immunoglobulin G Antibodies Against Pertussis Toxin Does Not Decrease Over a Long Period of Time in Japan.
Whooping Cough
Concomitant activation of adenylyl cyclase suppresses the opposite influences of CB(1) cannabinoid receptor agonists on tyrosine hydroxylase expression.
Whooping Cough
Concomitant regulation of Ca2+ mobilization and G13 expression in human erythroleukemia cells.
Whooping Cough
Concomitant treatment with pertussis toxin plus temozolomide increases the survival of rats bearing intracerebral RG2 glioma.
Whooping Cough
Concomitant use of VAQTA® with PedvaxHIB® and Infanrix® in 12 to 17 month old children.
Whooping Cough
Concurrent stimulation of cannabinoid CB1 and dopamine D2 receptors augments cAMP accumulation in striatal neurons: evidence for a Gs linkage to the CB1 receptor.
Whooping Cough
Concurrent stimulation of cannabinoid CB1 and dopamine D2 receptors enhances heterodimer formation: a mechanism for receptor cross-talk?
Whooping Cough
Conditional activation of cAMP signal transduction by protein kinase C. The effect of phorbol esters on adenylyl cyclase in permeabilized and intact cells.
Whooping Cough
Conditional stimulation of type V and VI adenylyl cyclases by G protein betagamma subunits.
Whooping Cough
Conditional transformation mediated via a pertussis toxin-sensitive receptor signalling pathway.
Whooping Cough
Confocal microscopy study of pertussis toxin and toxoids on CHO-cells.
Whooping Cough
Conformational dependence of collagenase (matrix metalloproteinase-1) up-regulation by elastin peptides in cultured fibroblasts.
Whooping Cough
Conformational dynamics of Kir3.1/Kir3.2 channel activation via ?-opioid receptors.
Whooping Cough
Conformational study of a short Pertussis toxin T cell epitope incorporated in a multiple antigen peptide template by CD and two-dimensional NMR. Analysis of the structural effects on the activity of synthetic immunogens.
Whooping Cough
Conformations of the alpha 39, alpha 41, and beta.gamma components of brain guanine nucleotide-binding proteins. Analysis by limited proteolysis.
Whooping Cough
Conjugated bile acids activate the sphingosine-1-phosphate receptor 2 in primary rodent hepatocytes.
Whooping Cough
Conjugated bile acids promote ERK1/2 and AKT activation via a pertussis toxin-sensitive mechanism in murine and human hepatocytes.
Whooping Cough
Conjugated bile acids regulate hepatocyte glycogen synthase activity in vitro and in vivo via Galphai signaling.
Whooping Cough
Conjugated linoleic acid induces human adipocyte delipidation: autocrine/paracrine regulation of MEK/ERK signaling by adipocytokines.
Whooping Cough
Conjugated linoleic acid isomers and trans fatty acids inhibit fatty acid transport in hepatoma 7288CTC and inguinal fat pads in Buffalo rats.
Whooping Cough
Connective tissue and its growth factor CTGF distinguish the morphometric and molecular remodeling of the bladder in a model of neurogenic bladder.
Whooping Cough
Conservation of a common motif in enzymes catalyzing ADP-ribose transfer. Identification of domains in mammalian transferases.
Whooping Cough
Conserved transducer coupling but different effector linkage upon expression of the myeloid fMet-Leu-Phe receptor in insulin secreting cells.
Whooping Cough
Consistent induction of chronic experimental autoimmune encephalomyelitis in C57BL/6 mice for the longitudinal study of pathology and repair.
Whooping Cough
Constitutive activation of NF-kappa B and secretion of interleukin-8 induced by the G protein-coupled receptor of Kaposi's sarcoma-associated herpesvirus involve G alpha(13) and RhoA.
Whooping Cough
Constitutive activation of the mu opioid receptor by mutation of D3.49(164), but not D3.32(147): D3.49(164) is critical for stabilization of the inactive form of the receptor and for its expression.
Whooping Cough
Constitutive activity of G-protein-coupled receptors: cause of disease and common property of wild-type receptors.
Whooping Cough
Constitutive activity of human prostaglandin E receptor EP3 isoforms.
Whooping Cough
Constitutive activity of the delta-opioid receptor expressed in C6 glioma cells: identification of non-peptide delta-inverse agonists.
Whooping Cough
Constitutive chemokine production results in activation of leukocyte function-associated antigen-1 on adult T-cell leukemia cells.
Whooping Cough
Constitutive G(i2)-dependent activation of adenylyl cyclase type II by the 5-HT1A receptor. Inhibition by anxiolytic partial agonists.
Whooping Cough
Constitutive inhibitory G protein activity upon adenylyl cyclase-dependent cardiac contractility is limited to adenylyl cyclase type 6.
Whooping Cough
Constitutive inositol phosphate formation in cytomegalovirus-infected human fibroblasts is due to expression of the chemokine receptor homologue pUS28.
Whooping Cough
Constitutive precoupling to G(i) and increased agonist potency in the alpha(2B)-adrenoceptor.
Whooping Cough
Constitutive somatostatin receptor activity determines tonic pituitary cell response.
Whooping Cough
Constitutively active mutants of the alpha 2-adrenergic receptor.
Whooping Cough
Construction and characterisation of Salmonella typhimurium aroA simultaneously expressing the five pertussis toxin subunits.
Whooping Cough
Construction and characterization of Bordetella pertussis toxin mutants.
Whooping Cough
Construction and characterization of genetically inactivated pertussis toxin.
Whooping Cough
Construction of a diphtheria toxin A fragment-C180 peptide fusion protein which elicits a neutralizing antibody response against diphtheria toxin and pertussis toxin.
Whooping Cough
Construction of an unmarked recombinant BCG expressing a pertussis antigen by auxotrophic complementation: Protection against Bordetella pertussis challenge in neonates.
Whooping Cough
Construction of Bordetella pertussis strains that overproduce genetically inactivated pertussis toxin.
Whooping Cough
Construction of Bordetella pertussis strains with enhanced production of genetically-inactivated Pertussis Toxin and Pertactin by unmarked allelic exchange.
Whooping Cough
Construction of minitransposons for constitutive and inducible expression of pertussis toxin in bvg-negative Bordetella bronchiseptica.
Whooping Cough
Contact-activated migration of melanoma B16 and sarcoma XC cells.
Whooping Cough
Continuous activation of pituitary adenylate cyclase-activating polypeptide receptors elicits antipodal effects on cyclic AMP and inositol phospholipid signaling pathways in CATH.a cells: role of protein synthesis and protein kinases.
Whooping Cough
Continuous intrathecal opioid treatment abolishes the regulatory effects of magnesium and guanine nucleotides on mu opioid receptor binding in rat spinal membranes.
Whooping Cough
Contractile function and response to agonists in myocytes from failing human heart.
Whooping Cough
Contractile role of M2 and M3 muscarinic receptors in gastrointestinal smooth muscle.
Whooping Cough
Contractile roles of the M2 and M3 muscarinic receptors in the guinea pig colon.
Whooping Cough
Contrary effects of sphingosine-1-phosphate on expression of ?-smooth muscle actin in transforming growth factor ?1-stimulated lung fibroblasts.
Whooping Cough
Contribution of cAMP to the inhibitory effect of non-steroidal anti-inflammatory drugs in rat uterine smooth muscle.
Whooping Cough
Contribution of extracellular signal-regulated kinase to UTP-induced interleukin-6 biosynthesis in HaCaT keratinocytes.
Whooping Cough
Contribution of Kir3.1, Kir3.2A and Kir3.2C subunits to native G protein-gated inwardly rectifying potassium currents in cultured hippocampal neurons.
Whooping Cough
Contribution of ligand structure to activation of alpha 2-adrenergic receptor subtype coupling to Gs.
Whooping Cough
Contribution of membrane progesterone receptor ? to the induction of progesterone-mediated apoptosis associated with mitochondrial membrane disruption and caspase cascade activation in Jurkat cell lines.
Whooping Cough
Contribution of pertussis toxin to the pathogenesis of pertussis disease.
Whooping Cough
Contribution of the B oligomer to the protective activity of genetically attenuated pertussis toxin.
Whooping Cough
Contribution of the extracellular cAMP-adenosine pathway to dual coupling of ?2-adrenoceptors to Gs and Gi proteins in mouse skeletal muscle.
Whooping Cough
Control of aldosterone production by angiotensin II is mediated by two guanine nucleotide regulatory proteins.
Whooping Cough
Control of cyclic adenosine 3',5'-monophosphate production in osteoclasts: calcitonin-induced persistent activation and homologous desensitization of adenylate cyclase.
Whooping Cough
Control of PDGF-induced reactive oxygen species (ROS) generation and signal transduction in human lens epithelial cells.
Whooping Cough
Control of PTH secretion is mediated through calcium channels and is blocked by pertussis toxin treatment of parathyroid cells.
Whooping Cough
Control of the amiloride-sensitive Na+ current in mouse salivary ducts by intracellular anions is mediated by a G protein.
Whooping Cough
Control of the expression and activity of the Galpha-interacting protein (GAIP) in human intestinal cells.
Whooping Cough
Control of voltage-dependent Ca2+ channels by G protein-coupled receptors.
Whooping Cough
Convergent regulation of neuronal differentiation and Erk and Akt kinases in human neural progenitor cells by lysophosphatidic acid, sphingosine 1-phosphate, and LIF: specific roles for the LPA1 receptor.
Whooping Cough
Conversion of adrenergic mechanism from an alpha- to a beta-type during primary culture of rat hepatocytes. Accompanying decreases in the function of the inhibitory guanine nucleotide regulatory component of adenylate cyclase identified as the substrate of islet-activating protein.
Whooping Cough
Cooperation between thrombospondin-1 type 1 repeat peptides and alpha(v)beta(3) integrin ligands to promote melanoma cell spreading and focal adhesion kinase phosphorylation.
Whooping Cough
Cooperation of G12/13 and Gi proteins via lysophosphatidic acid receptor-2 (LPA2) signaling enhances cancer cell survival to cisplatin.
Whooping Cough
Cooperation of Gq, Gi, and G12/13 in protein kinase D activation and phosphorylation induced by lysophosphatidic acid.
Whooping Cough
Cooperation of thyrotropin, but not basic fibroblast growth factor, with an adenosine receptor agonist in Ca2+ mobilization from thapsigargin-sensitive pools in single FRTL-5 thyroid cells.
Whooping Cough
Cooperative enhancement of insulinotropic action of GLP-1 by acetylcholine uncovers paradoxical inhibitory effect of beta cell muscarinic receptor activation on adenylate cyclase activity.
Whooping Cough
Cooperative mitogenic signaling by G protein-coupled receptors and growth factors is dependent on G(q/11).
Whooping Cough
Coordinate, biphasic activation of p44 mitogen-activated protein kinase and S6 kinase by growth factors in hamster fibroblasts. Evidence for thrombin-induced signals different from phosphoinositide turnover and adenylylcyclase inhibition.
Whooping Cough
Copresence of prostaglandin EP2 and EP3 receptors on gastric enterochromaffin-like cell carcinoid in African rodents.
Whooping Cough
Coregulation of natively expressed pertussis toxin-sensitive muscarinic receptors with G-protein-activated potassium channels.
Whooping Cough
Coronary arteriolar dilation to acidosis: role of ATP-sensitive potassium channels and pertussis toxin-sensitive G proteins.
Whooping Cough
Correlation between behavioral sensitization to cocaine and G protein ADP-ribosylation in the ventral tegmental area.
Whooping Cough
Correlation between chemotactic peptide-induced changes in chlorotetracycline fluorescence and F-actin content in human neutrophils: a role for membrane-associated calcium in the regulation of actin polymerization?
Whooping Cough
Correlation between keratinocyte expression of Ia and the intensity and duration of contact hypersensitivity responses in mice.
Whooping Cough
Correlation between low/high affinity ratios for 5-HT(1A) receptors and intrinsic activity.
Whooping Cough
Correlation between pertussis toxin IgG antibodies in postvaccination sera and subsequent protection against pertussis.
Whooping Cough
Correlation between ribosylation of pertussis toxin substrates and inhibition of peptidoglycan-, muramyl dipeptide- and lipopolysaccharide-induced mitogenic stimulation in B lymphocytes.
Whooping Cough
Correlation of IgA, IgM and IgG antibody-detecting assays based on filamentous haemagglutinin, pertussis toxin and Bordetella pertussis sonicate in a strictly adult population.
Whooping Cough
Corrigendum to "Accelerated maternal responding following intra-VTA pertussis toxin treatment" [Behav. Brain Res. 223 (October (2)) (2011) 322-328; Epub 2011 May 6].
Whooping Cough
Corticotropin releasing factor-induced ERK phosphorylation in AtT20 cells occurs via a cAMP-dependent mechanism requiring EPAC2.
Whooping Cough
Corticotropin-releasing factor increases [Ca2+]i via receptor-mediated Ca2+ channels in human epidermoid A-431 cells.
Whooping Cough
Corticotropin-releasing factor induces phosphorylation of phospholipase C-gamma at tyrosine residues via its receptor 2beta in human epidermoid A-431 cells.
Whooping Cough
Corticotropin-releasing factor receptors and actions in rat Leydig cells.
Whooping Cough
Corticotropin-releasing factor-like peptides increase cytosolic [Ca2+] in human epidermoid A-431 cells.
Whooping Cough
Corticotropin-releasing factor: an antireproductive hormone of the testis.
Whooping Cough
Cortisol inhibition of calcium currents in guinea pig hippocampal CA1 neurons via G-protein-coupled activation of protein kinase C.
Whooping Cough
Cortisol inhibition of growth hormone-releasing hormone-stimulated growth hormone release from cultured sheep pituitary cells.
Whooping Cough
Cough production, leucocytosis and serology of rats infected intrabronchially with Bordetella pertussis.
Whooping Cough
Could dual G-protein coupling explain [D-Met2]FMRFamide's mixed action in vivo?
Whooping Cough
Coupling between inositol phosphate formation and DNA synthesis in smooth muscle cells stimulated with neurokinin A.
Whooping Cough
Coupling between phosphoinositide breakdown and early mitogenic events in fibroblasts. Studies with fluoroaluminate, vanadate, and pertussis toxin.
Whooping Cough
Coupling factor 6 enhances the spontaneous microaggregation of platelets by decreasing cytosolic cAMP irrespective of antiplatelet therapy.
Whooping Cough
Coupling function of endogenous alpha(1)- and beta-adrenergic receptors in mouse cardiomyocytes.
Whooping Cough
Coupling mechanisms of alpha 2-adrenoceptors.
Whooping Cough
Coupling of 5-HT1A autoreceptors to inhibition of mitogen-activated protein kinase activation via G beta gamma subunit signaling.
Whooping Cough
Coupling of a cloned rat dopamine-D2 receptor to inhibition of adenylyl cyclase and prolactin secretion.
Whooping Cough
Coupling of a mutated form of the human beta 2-adrenergic receptor to Gi and Gs. Requirement for multiple cytoplasmic domains in the coupling process.
Whooping Cough
Coupling of a purified goldfish brain kainate receptor with a pertussis toxin-sensitive G protein.
Whooping Cough
Coupling of a transfected human brain A1 adenosine receptor in CHO-K1 cells to calcium mobilisation via a pertussis toxin-sensitive mechanism.
Whooping Cough
Coupling of adenosine A1 receptors to a G-protein in coated vesicles isolated from bovine brain: presence of pertussis and cholera toxin substrates.
Whooping Cough
Coupling of adenosine receptors to a pertussis toxin-sensitive G protein in the human heart.
Whooping Cough
Coupling of Airway Smooth Muscle TAS2Rs to Intracellular Signaling and Relaxation is via G?i1,2,3.
Whooping Cough
Coupling of an endogenous 5-HT1B-like receptor to increases in intracellular calcium through a pertussis toxin-sensitive mechanism in CHO-K1 cells.
Whooping Cough
Coupling of antagonistic signalling pathways in modulation of neutrophil function.
Whooping Cough
Coupling of beta-adrenergic receptors to cardiac L-type Ca2+ channels: preferential coupling of the beta1 versus beta2 receptor subtype and evidence for PKA-independent activation of the channel.
Whooping Cough
Coupling of beta2-adrenoceptor to Gi proteins and its physiological relevance in murine cardiac myocytes.
Whooping Cough
Coupling of boswellic acid-induced Ca2+ mobilisation and MAPK activation to lipid metabolism and peroxide formation in human leucocytes.
Whooping Cough
Coupling of bradykinin receptors to phospholipase C in cultured fibroblasts is mediated by a G-protein.
Whooping Cough
Coupling of canine serotonin 5-HT(1B) and 5-HT(1D) receptor subtypes to the formation of inositol phosphates by dual interactions with endogenous G(i/o) and recombinant G(alpha15) proteins.
Whooping Cough
Coupling of ETB endothelin receptor to mitogen-activated protein kinase stimulation and DNA synthesis in primary cultures of rat astrocytes.
Whooping Cough
Coupling of exogenous receptors to phospholipase C in Xenopus oocytes through pertussis toxin-sensitive and -insensitive pathways. Cross-talk through heterotrimeric G-proteins.
Whooping Cough
Coupling of expressed alpha 1B- and alpha 1D-adrenergic receptor to multiple signaling pathways is both G protein and cell type specific.
Whooping Cough
Coupling of gonadotropin-releasing hormone receptor to Gi protein in human reproductive tract tumors.
Whooping Cough
Coupling of guanine nucleotide inhibitory protein to somatostatin receptors on pancreatic acinar membranes.
Whooping Cough
Coupling of hepatic prostaglandin receptors to adenylate cyclase through a pertussis toxin sensitive guanine nucleotide regulatory protein.
Whooping Cough
Coupling of human alpha 2-adrenoceptor subtypes to regulation of cAMP production in transfected S115 cells.
Whooping Cough
Coupling of human D-1 dopamine receptors to different guanine nucleotide binding proteins. Evidence that D-1 dopamine receptors can couple to both Gs and G(o).
Whooping Cough
Coupling of human delta-opioid receptor to retinal rod transducin in Chinese hamster ovary cells.
Whooping Cough
Coupling of I(1) imidazoline receptors to the cAMP pathway: studies with a highly selective ligand, benazoline.
Whooping Cough
Coupling of inhibitory receptors with Gi-proteins in hamster adipocytes: comparison between adenosine A1 receptor and alpha 2-adrenoceptor.
Whooping Cough
Coupling of m2 and m4 muscarinic acetylcholine receptor subtypes to Ca(2+)-dependent K+ channels in transformed NL308 neuroblastoma x fibroblast hybrid cells.
Whooping Cough
Coupling of metabotropic glutamate receptor 8 to N-type Ca2+ channels in rat sympathetic neurons.
Whooping Cough
Coupling of muscarinic m1, m2 and m3 acetylcholine receptors, expressed in Chinese hamster ovary cells, to pertussis toxin-sensitive/insensitive guanine nucleotide-binding proteins.
Whooping Cough
Coupling of oxytocin receptor to G proteins in rat myometrium during labor: Gi receptor interaction.
Whooping Cough
Coupling of serotonin 5-HT1B receptors to activation of mitogen-activated protein kinase (ERK-2) and p70 S6 kinase signaling systems.
Whooping Cough
Coupling of TGF-beta-induced mitogenesis to G-protein activation in AKR-2B cells.
Whooping Cough
Coupling of the alpha 2-adrenergic receptor to the inhibitory G-protein Gi and adenylate cyclase in HT29 cells.
Whooping Cough
Coupling of the C5a receptor to Gi in U-937 cells and in cells transfected with C5a receptor cDNA.
Whooping Cough
Coupling of the cloned mu-opioid receptor with the omega-conotoxin-sensitive Ca2+ current in NG108-15 cells.
Whooping Cough
Coupling of the expressed alpha 1B-adrenergic receptor to the phospholipase C pathway in Xenopus oocytes. The role of Go.
Whooping Cough
Coupling of the guanine nucleotide regulatory protein to chemotactic peptide receptors in neutrophil membranes and its uncoupling by islet-activating protein, pertussis toxin. A possible role of the toxin substrate in Ca2+-mobilizing receptor-mediated signal transduction.
Whooping Cough
Coupling of the human A1 adenosine receptor to different heterotrimeric G proteins: evidence for agonist-specific G protein activation.
Whooping Cough
Coupling of the human Y2 receptor for neuropeptide Y and peptide YY to guanine nucleotide inhibitory proteins in permeabilized SMS-KAN cells.
Whooping Cough
Coupling of the insulin-like growth factor-I receptor tyrosine kinase to Gi2 in human intestinal smooth muscle: Gbetagamma -dependent mitogen-activated protein kinase activation and growth.
Whooping Cough
Coupling of the muscarinic m2 receptor to G protein-activated K(+) channels via Galpha(z) and a receptor-Galpha(z) fusion protein. Fusion between the receptor and Galpha(z) eliminates catalytic (collision) coupling.
Whooping Cough
Coupling of the nucleotide P2Y4 receptor to neuronal ion channels.
Whooping Cough
Coupling of the thrombin receptor to G12 may account for selective effects of thrombin on gene expression and DNA synthesis in 1321N1 astrocytoma cells.
Whooping Cough
Coupling of the thyrotropin-releasing hormone receptor to phospholipase C by a GTP-binding protein distinct from the inhibitory or stimulatory GTP-binding protein.
Whooping Cough
Coupling of two endothelin receptor subtypes to differing signal transduction in transfected Chinese hamster ovary cells.
Whooping Cough
Coupling specificity of NOP opioid receptors to pertussis-toxin-sensitive Galpha proteins in adult rat stellate ganglion neurons using small interference RNA.
Whooping Cough
Coupling to Gs and G(q/11) of histamine H2 receptors heterologously expressed in adult rat atrial myocytes.
Whooping Cough
Covalent cross-linking of prostaglandin E receptor from bovine adrenal medulla with a pertussis toxin-insensitive guanine nucleotide-binding protein.
Whooping Cough
CpG-containing oligodeoxynucleotide promotes microglial cell uptake of amyloid beta 1-42 peptide by up-regulating the expression of the G-protein- coupled receptor mFPR2.
Whooping Cough
CR4056, a powerful analgesic imidazoline-2 receptor ligand, inhibits the inflammation-induced PKC? phosphorylation and membrane translocation in sensory neurons.
Whooping Cough
Crawling phagocytes recruited in the brain vasculature after pertussis toxin exposure through IL6, ICAM1, and ITG?M.
Whooping Cough
CRF1 Receptor Signaling via the ERK1/2-MAP and Akt Kinase Cascades: Roles of Src, EGF Receptor, and PI3-Kinase Mechanisms.
Whooping Cough
Critical involvement of p38 MAP kinase in pertussis toxin-induced cytoskeletal reorganization and lung permeability.
Whooping Cough
Critical role of L-selectin and histamine H4 receptor in zymosan-induced neutrophil recruitment from the bone marrow: comparison with carrageenan.
Whooping Cough
Critical role of methionine-722 in the stimulation of human brain G-proteins and neurotoxicity induced by London familial Alzheimer's disease (FAD) mutated V717G-APP(714-723).
Whooping Cough
Critical role of the chymase/angiotensin-(1-12) axis in modulating cardiomyocyte contractility.
Whooping Cough
Cross talk between stimulatory and inhibitory guanosine 5'-triphosphate binding proteins: role in activation and desensitization of the adenylate cyclase response to vasopressin.
Whooping Cough
Cross talk between substance P and melittin-activated cellular signaling pathways in rat lactotroph-enriched cell cultures.
Whooping Cough
Cross-linking a maturation-dependent ram sperm plasma membrane antigen induces the acrosome reaction.
Whooping Cough
Cross-linking of G-proteins to the prolactin receptor in rat NB2 lymphoma cells.
Whooping Cough
Cross-regulation of VPAC2 receptor internalization by m2 receptors via c-Src-mediated phosphorylation of GRK2.
Whooping Cough
Cross-talk among epidermal growth factor, Ap(5)A, and nucleotide receptors causing enhanced ATP Ca(2+) signaling involves extracellular kinase activation in cerebellar astrocytes.
Whooping Cough
Cross-talk between Ca2+ influx and phosphoinositide hydrolysis by extracellular adenosine triphosphate in rat PC12 pheochromocytoma cells.
Whooping Cough
Cross-talk between glucagon- and adenosine-mediated signalling systems in rat hepatocytes: effects on cyclic AMP-phosphodiesterase activity.
Whooping Cough
Cross-talk between metabotropic glutamate receptor 7 and beta adrenergic receptor signaling at cerebrocortical nerve terminals.
Whooping Cough
Cross-talk between TGF-?1 and Muscarinic M2 Receptors Augments Airway Smooth Muscle Proliferation.
Whooping Cough
Cross-talk of parathyroid hormone-responsive dual signal transduction systems in osteoblastic osteosarcoma cells: its role in PTH-induced homologous desensitization of intracellular calcium response.
Whooping Cough
Crosslinking of surface antigens causes mobilization of intracellular ionized calcium in T lymphocytes.
Whooping Cough
Crosstalk between CXCR4/stromal derived factor-1 and VLA-4/VCAM-1 pathways regulates neutrophil retention in the bone marrow.
Whooping Cough
Crosstalk between prostaglandin E2 and leukotriene B4 regulates phagocytosis in alveolar macrophages via combinatorial effects on cyclic AMP.
Whooping Cough
Crosstalk of sterol-dependent and non-sterol-dependent signaling in human monocytes after in vitro addition of LDL.
Whooping Cough
Cryptic gonadotropin-releasing hormone receptors of rat pituitary cells in culture are unmasked by epidermal growth factor.
Whooping Cough
Cryptide signaling: Amphiphilic peptide-induced exocytotic mechanisms in mast cells.
Whooping Cough
Crystal structure of the catalytic domain of Pseudomonas exotoxin A complexed with a nicotinamide adenine dinucleotide analog: implications for the activation process and for ADP ribosylation.
Whooping Cough
Crystal structure of the pertussis toxin-ATP complex: a molecular sensor.
Whooping Cough
Crystal-induced neutrophil activation. I. Initiation and modulation of calcium mobilization and superoxide production by microcrystals.
Whooping Cough
Crystal-induced neutrophil activation. II. Evidence for the activation of a phosphatidylcholine-specific phospholipase D.
Whooping Cough
Curosurf modulates cAMP accumulation in human monocytes through a membrane-controlled mechanism.
Whooping Cough
Cutting edge: C-C chemokine receptor 6 is essential for arrest of a subset of memory T cells on activated dermal microvascular endothelial cells under physiologic flow conditions in vitro.
Whooping Cough
Cutting edge: CCR4 mediates antigen-primed T cell binding to activated dendritic cells.
Whooping Cough
Cutting edge: Interleukin 4-dependent mast cell proliferation requires autocrine/intracrine cysteinyl leukotriene-induced signaling.
Whooping Cough
Cutting edge: lipoxins rapidly stimulate nonphlogistic phagocytosis of apoptotic neutrophils by monocyte-derived macrophages.
Whooping Cough
Cutting edge: MyD88 is required for resistance to Toxoplasma gondii infection and regulates parasite-induced IL-12 production by dendritic cells.
Whooping Cough
CX3C-chemokine, fractalkine-enhanced adhesion of THP-1 cells to endothelial cells through integrin-dependent and -independent mechanisms.
Whooping Cough
CXC chemokine receptor 4 expression and function in human anaplastic thyroid cancer cells.
Whooping Cough
CXC chemokine receptor 4 signaling upon co-activation with stromal cell-derived factor-1? and ubiquitin.
Whooping Cough
CXCL10 contributes to p38-mediated apoptosis in primary T lymphocytes in vitro.
Whooping Cough
CXCL12 activation of CXCR4 regulates mucosal host defense through stimulation of epithelial cell migration and promotion of intestinal barrier integrity.
Whooping Cough
CXCL12 chemokine expression and secretion regulates colorectal carcinoma cell anoikis through bim-mediated intrinsic apoptosis.
Whooping Cough
CXCL12 mediates CCR7-independent homing of central memory cells, but not naive T cells, in peripheral lymph nodes.
Whooping Cough
CXCL12-mediated induction of plasminogen activator inhibitor-1 expression in human CXCR4 positive astroglioma cells.
Whooping Cough
CXCL16 signals via Gi, phosphatidylinositol 3-kinase, Akt, I kappa B kinase, and nuclear factor-kappa B and induces cell-cell adhesion and aortic smooth muscle cell proliferation.
Whooping Cough
CXCL4-induced migration of activated T lymphocytes is mediated by the chemokine receptor CXCR3.
Whooping Cough
CXCR2- and E-selectin-induced neutrophil arrest during inflammation in vivo.
Whooping Cough
CXCR3 chemokine receptor-induced chemotaxis in human airway epithelial cells: role of p38 MAPK and PI3K signaling pathways.
Whooping Cough
CXCR3 internalization following T cell-endothelial cell contact: preferential role of IFN-inducible T cell alpha chemoattractant (CXCL11).
Whooping Cough
CXCR3 is involved in tubulointerstitial injury in human glomerulonephritis.
Whooping Cough
CXCR3-mediated chemotaxis of human T cells is regulated by a Gi- and phospholipase C-dependent pathway and not via activation of MEK/p44/p42 MAPK nor Akt/PI-3 kinase.
Whooping Cough
CXCR4 and a cell-extrinsic mechanism control immature B lymphocyte egress from bone marrow.
Whooping Cough
CXCR4 chemokine receptors (CD184) and alpha4beta1 integrins mediate spontaneous migration of human CD34+ progenitors and acute myeloid leukaemia cells beneath marrow stromal cells (pseudoemperipolesis).
Whooping Cough
Cyclic adenosine 3',5'-monophosphate metabolism in activated T-cell clones.
Whooping Cough
Cyclic AMP can partially restore platelet-derived growth factor-stimulated prostaglandin E2 biosynthesis, and calcium mobilization in EJ-ras-transformed NIH-3T3 cells.
Whooping Cough
Cyclic AMP content and invasive capacity of metastatic variants of the BW-5147 murine T-cell lymphoma.
Whooping Cough
Cyclic AMP counteracts mitogen-induced inositol phosphate generation and increases in intracellular Ca2+ concentrations in human lymphocytes.
Whooping Cough
Cyclic AMP differentiates two separate but interacting pathways of phosphoinositide hydrolysis in the DDT1-MF2 smooth muscle cell line.
Whooping Cough
Cyclic AMP imaging in adult cardiac myocytes reveals far-reaching beta1-adrenergic but locally confined beta2-adrenergic receptor-mediated signaling.
Whooping Cough
Cyclic AMP levels in lung and spleen tissue of mice treated with pertussis toxin.
Whooping Cough
Cyclic AMP mediates keratinocyte directional migration in an electric field.
Whooping Cough
Cyclic AMP regulates the calcium transients released from IP(3)-sensitive stores by activation of rat kappa-opioid receptors expressed in CHO cells.
Whooping Cough
Cyclic AMP-dependent induction of serotonin N-acetyltransferase activity in photoreceptor-enriched chick retinal cell cultures: characterization and inhibition by dopamine.
Whooping Cough
Cyclic AMP-dependent inotropic effects are differentially regulated by muscarinic G(i) -dependent constitutive inhibition of adenylyl cyclase in failing rat ventricle.
Whooping Cough
Cyclic AMP-dependent regulation of the number of [3H]batrachotoxinin benzoate binding sites on rat cardiac myocytes.
Whooping Cough
Cyclic AMP-independent, dual regulation of voltage-dependent Ca2+ currents by LHRH and somatostatin in a pituitary cell line.
Whooping Cough
Cyclic GMP-dependent protein kinase blocks pertussis toxin-sensitive hormone receptor signaling pathways in Chinese hamster ovary cells.
Whooping Cough
Cyclic guanosine monophosphate analogs do not reverse bacterial toxin modulation of lactogen-stimulated NB2 cell mitogenesis.
Whooping Cough
Cyclic phosphatidic acid elicits neurotrophin-like actions in embryonic hippocampal neurons.
Whooping Cough
Cyclic strain-mediated regulation of endothelial matrix metalloproteinase-2 expression and activity.
Whooping Cough
Cyclic strain-mediated regulation of vascular endothelial cell migration and tube formation.
Whooping Cough
Cyclic stretch activates ERK1/2 via G proteins and EGFR in alveolar epithelial cells.
Whooping Cough
Cyclic tensile stretch inhibition of nitric oxide release from osteoblast-like cells is both G protein and actin-dependent.
Whooping Cough
Cyclical modulation of sphingosine-1-phosphate receptor 1 surface expression during lymphocyte recirculation and relationship to lymphoid organ transit.
Whooping Cough
Cycloheximide abolishes pertussis toxin induced increase in glutamate release from cerebellar granule neurones.
Whooping Cough
Cycloheximide abolishes pertussis toxin-induced increase in glutamate release from cerebellar granule neurones.
Whooping Cough
CysLT1 receptor-induced human airway smooth muscle cells proliferation requires ROS generation, EGF receptor transactivation and ERK1/2 phosphorylation.
Whooping Cough
CysLT1 signal transduction in differentiated U937 cells involves the activation of the small GTP-binding protein Ras.
Whooping Cough
Cysteinyl leukotrienes induce IL-4 release from cord blood-derived human eosinophils.
Whooping Cough
Cytochalasin B enhancement of the diacylglycerol response in formyl peptide-stimulated neutrophils.
Whooping Cough
Cytochalasin B triggers a novel pertussis toxin sensitive pathway in TNF-alpha primed neutrophils.
Whooping Cough
Cytochalasin-induced nitroblue tetrazolium dye (NBT) reduction in polymorphonuclear leukocytes.
Whooping Cough
Cytodifferentiation Enhances Erk Activation Induced by Endothelin-1 in Primary Cultured Astrocytes.
Whooping Cough
Cytokine and chemokine based control of HIV infection and replication.
Whooping Cough
Cytokine mRNA expression and proliferative responses induced by pertussis toxin, filamentous hemagglutinin, and pertactin of Bordetella pertussis in the peripheral blood mononuclear cells of infected and immunized schoolchildren and adults.
Whooping Cough
Cytokine regulation of adenylate cyclase activity in LLC-PK1 cells.
Whooping Cough
Cytokine-like 1 Chemoattracts Monocytes/Macrophages via CCR2.
Whooping Cough
Cytokines inhibit proliferation and insulin secretion by clonal rat insulinoma cells (RINm5F) non-synergistically and in a pertussis toxin-insensitive manner.
Whooping Cough
Cytomegalovirus induction of interleukin-6 in lung fibroblasts occurs independently of active infection and involves a G protein and the transcription factor, NF-kappaB.
Whooping Cough
Cytoplasmic domain of natriuretic peptide receptor C constitutes Gi activator sequences that inhibit adenylyl cyclase activity.
Whooping Cough
Cytoplasmic domain of natriuretic peptide receptor-C inhibits adenylyl cyclase. Involvement of a pertussis toxin-sensitive G protein.
Whooping Cough
Cytoplasmic kinase and phosphatase activities can induce PsaF gene expression in the absence of functional plastids: evidence that phosphorylation/dephosphorylation events are involved in interorganellar crosstalk.
Whooping Cough
Cytoplasmic pH change induced by leukotriene B4 in human neutrophils.
Whooping Cough
Cytoplasmic pH regulation in activated human neutrophils: effects of adenosine and pertussis toxin on Na+/H+ exchange and metabolic acidification.
Whooping Cough
Cytoskeletal alterations as a parameter for assessment of toxicity.
Whooping Cough
Cytoskeleton-dependent tyrosine phosphorylation of the p130(Cas) family member HEF1 downstream of the G protein-coupled calcitonin receptor. Calcitonin induces the association of HEF1, paxillin, and focal adhesion kinase.
Whooping Cough
Cytosol promotes the guanine nucleotide-induced release of the alpha subunit of Gi2 from the membrane of mouse mastocytoma P-815 cells.
Whooping Cough
Cytosolic Na+ controls and epithelial Na+ channel via the Go guanine nucleotide-binding regulatory protein.
Whooping Cough
Cytosolic phospholipase C activity: I. Evidence for coupling with cytosolic guanine nucleotide-binding protein, Gi alpha.
Whooping Cough
Cytotoxic action of lindane in cerebellar granule neurons is mediated by interaction with inducible GABA(B) receptors.
Whooping Cough
Cytotoxic mechanisms by M239V presenilin 2, a little-analyzed Alzheimer's disease-causative mutant.
Whooping Cough
Cytotoxicity of intracellular a?42 amyloid oligomers involves Ca2+ release from the endoplasmic reticulum by stimulated production of inositol trisphosphate.
Whooping Cough
D-2 dopamine receptor activation reduces free [3H]arachidonate release induced by hypophysiotropic peptides in anterior pituitary cells.
Whooping Cough
D-2 dopamine receptor-mediated inhibition of pro-opiomelanocortin synthesis in rat intermediate lobe. Abolition by pertussis toxin or activators of adenylate cyclase.
Whooping Cough
D-2-amino-5-phosphonopentanoic acid inhibits intrathecal pertussis toxin-induced thermal hyperalgesia and protein kinase Cgamma up-regulation.
Whooping Cough
D-erythro-N,N-dimethylsphingosine inhibits bFGF-induced proliferation of cerebral, aortic and coronary smooth muscle cells.
Whooping Cough
D-Peptide analogues of Boc-Phe-Leu-Phe-Leu-Phe-COOH induce neovascularization via endothelial N-formyl peptide receptor 3.
Whooping Cough
D1 agonist-induced excitation of substantia nigra pars reticulata neurons: mediation by D1 receptors on striatonigral terminals via a pertussis toxin-sensitive coupling pathway.
Whooping Cough
D1 dopamine receptors can interact with both stimulatory and inhibitory guanine nucleotide binding proteins.
Whooping Cough
D2 dopamine receptor stimulation of mitogenesis in transfected Chinese hamster ovary cells: relationship to dopamine stimulation of tyrosine phosphorylations.
Whooping Cough
D2 dopamine receptor-mediated antiproliferation in a small cell lung cancer cell line, NCI-H69.
Whooping Cough
D2 dopamine receptors interact directly with N-type calcium channels and regulate channel surface expression levels.
Whooping Cough
D2 dopamine receptors modulate Galpha-subunit coupling of the CB1 cannabinoid receptor.
Whooping Cough
D2 dopamine receptors stimulate mitogenesis through pertussis toxin-sensitive G proteins and Ras-involved ERK and SAP/JNK pathways in rat C6-D2L glioma cells.
Whooping Cough
D2 dopaminergic receptors: normal and abnormal transduction mechanisms.
Whooping Cough
D2 inhibition of stimulated Fos immunoreactivity in cultured tyrosine hydroxylase-ir hypothalamic neurons.
Whooping Cough
D2 receptors mediate dopamine suppression of irANF release and pro-ANF mRNA expression of rat hypothalamic neurons in culture.
Whooping Cough
D2, D3, and D4 dopamine receptors couple to G protein-regulated potassium channels in Xenopus oocytes.
Whooping Cough
D2-like receptor-mediated inhibition of Na+-K+-ATPase activity is dependent on the opening of K+ channels.
Whooping Cough
D2L, D2S, and D3 dopamine receptors stably transfected into NG108-15 cells couple to a voltage-dependent potassium current via distinct G protein mechanisms.
Whooping Cough
D2S, D2L, D3, and D4 dopamine receptors couple to a voltage-dependent potassium current in N18TG2 x mesencephalon hybrid cell (MES-23.5) via distinct G proteins.
Whooping Cough
D3 dopamine receptor activates phospholipase D through a pertussis toxin-insensitive pathway.
Whooping Cough
D3 dopamine receptor signals to activation of phospholipase D through a complex with Rho.
Whooping Cough
D4 dopamine receptor-mediated signaling events determined in transfected Chinese hamster ovary cells.
Whooping Cough
Datura stramonium agglutinin released histamine from rat peritoneal mast cells that was inhibited by pertussis toxin, haptenic sugar and N-acetylglucosamine-specific lectins: involvement of glycoproteins with N-acetylglucosamine residues.
Whooping Cough
DCG-IV selectively attenuates rapidly triggered NMDA-induced neurotoxicity in cortical neurons.
Whooping Cough
Deaminovasopressin has direct and modulatory effects on ventricular automaticity in the rat heart.
Whooping Cough
Deciphering the role of Gi2 in opioid-induced adenylyl cyclase supersensitization.
Whooping Cough
Decline of IgG pertussis toxin measured in umbilical cord blood, and neonatal and early infant serum.
Whooping Cough
Decline of serologic immunity to diphtheria, tetanus and pertussis with age suggested a full life vaccination in mainland China.
Whooping Cough
Decrease in [Ca2+]c but not in cAMP Mediates L-AP4 inhibition of glutamate release: PKC-mediated suppression of this inhibitory pathway.
Whooping Cough
Decreased glucose-induced cAMP and insulin release in islets of diabetic rats: reversal by IBMX, glucagon, GIP.
Whooping Cough
Decreased insulin content and secretion in RIN 1046-38 cells overexpressing alpha 2-adrenergic receptors.
Whooping Cough
Decreased MAPK- and PGE2-dependent IL-11 production in Gialpha2-/- colonic myofibroblasts.
Whooping Cough
Decreased potency of glucagon on transformed-induced MDCK cells does not reflect an alteration of adenylate cyclase components.
Whooping Cough
Deduced amino acid sequence of bovine retinal Go alpha: similarities to other guanine nucleotide-binding proteins.
Whooping Cough
Defective CD4T cell priming and resistance to experimental autoimmune encephalomyelitis in TNF-deficient mice due to innate immune hypo-responsiveness.
Whooping Cough
Defective gamma-aminobutyric acid type B receptor-activated inwardly rectifying K+ currents in cerebellar granule cells isolated from weaver and Girk2 null mutant mice.
Whooping Cough
Defective myogenesis in NFB-s mutant associated with a saturable suppression of MYF5 activity.
Whooping Cough
Defective regulation of phosphatidylcholine-specific phospholipases C and D in a kindred with Tangier disease. Evidence for the involvement of phosphatidylcholine breakdown in HDL-mediated cholesterol efflux mechanisms.
Whooping Cough
Defibrotide augments the anticandidial activity of NK cells.
Whooping Cough
Degranulation and cytokine expression in human cord blood-derived mast cells cultured in serum-free medium with recombinant human stem cell factor.
Whooping Cough
Dehydroepiandrosterone inhibits intracellular calcium release in beta-cells by a plasma membrane-dependent mechanism.
Whooping Cough
Dehydroepiandrosterone protects vascular endothelial cells against apoptosis through a Galphai protein-dependent activation of phosphatidylinositol 3-kinase/Akt and regulation of antiapoptotic Bcl-2 expression.
Whooping Cough
Dehydroepiandrosterone stimulates endothelial proliferation and angiogenesis through extracellular signal-regulated kinase 1/2-mediated mechanisms.
Whooping Cough
Dehydroepiandrosterone stimulates nitric oxide release in vascular endothelial cells: evidence for a cell surface receptor.
Whooping Cough
Delayed cardioprotection is mediated via a non-peptide delta opioid agonist, SNC-121, independent of opioid receptor stimulation.
Whooping Cough
Delayed role of tumor necrosis factor- alpha in overcoming the effects of pertussis toxin.
Whooping Cough
Delayed-type hypersensitivity responses in mice treated with pertussis toxin and betamethasone.
Whooping Cough
Deletion analysis of the m4 muscarinic acetylcholine receptor. Molecular determinants for activation of but not coupling to the Gi guanine-nucleotide-binding regulatory protein regulate receptor internalization.
Whooping Cough
Deletion of the sphingosine kinase-1 gene influences cell fate during hypoxia and glucose deprivation in adult mouse cardiomyocytes.
Whooping Cough
Delineation of muscarinic receptor domains conferring selectivity of coupling to guanine nucleotide-binding proteins and second messengers.
Whooping Cough
Delineation of the minimal encephalitogenic epitope within the immunodominant region of myelin oligodendrocyte glycoprotein: diverse V beta gene usage by T cells recognizing the core epitope encephalitogenic for T cell receptor V beta b and T cell receptor V beta a H-2b mice.
Whooping Cough
Delivery of a Salmonella Typhi exotoxin from a host intracellular compartment.
Whooping Cough
Delta opiate receptors account for the castration-induced unmasking of gonadotropin-releasing hormone binding sites in the rat pituitary.
Whooping Cough
Delta opioid modulation of the binding of guanosine-5'-O-(3-[35S]thio)triphosphate to NG108-15 cell membranes: characterization of agonist and inverse agonist effects.
Whooping Cough
Delta opioid receptor down-regulation is independent of functional G protein yet is dependent on agonist efficacy.
Whooping Cough
Delta opioid receptors expressed by stably transfected jurkat cells signal through the map kinase pathway in a ras-independent manner.
Whooping Cough
Delta(9)-Tetrahydrocannabinol enhances MCF-7 cell proliferation via cannabinoid receptor-independent signaling.
Whooping Cough
delta(9)-Tetrahydrocannabinol increases nerve growth factor production by prostate PC-3 cells. Involvement of CB1 cannabinoid receptor and Raf-1.
Whooping Cough
delta- and mu-opioid receptor mobilization of intracellular calcium in SH-SY5Y human neuroblastoma cells.
Whooping Cough
Delta-opioid agonist-stimulated inositol phosphate formation in isolated, rabbit iris-ciliary bodies: role of G(i/o) proteins and Gbetagamma-subunits.
Whooping Cough
delta-Opioid receptor activates cAMP phosphodiesterase activities in neuroblastoma x glioma NG108-15 hybrid cells.
Whooping Cough
delta-Opioid receptor-stimulated Akt signaling in neuroblastomaxglioma (NG108-15) hybrid cells involves receptor tyrosine kinase-mediated PI3K activation.
Whooping Cough
Delta-opioid receptors on astroglial cells in primary culture: mobilization of intracellular free calcium via a pertussis sensitive G protein.
Whooping Cough
delta-Opioids stimulate inositol 1,4,5-trisphosphate formation, and so mobilize Ca2+ from intracellular stores, in undifferentiated NG108-15 cells.
Whooping Cough
Delta9-tetrahydrocannabinol induces apoptosis in human prostate PC-3 cells via a receptor-independent mechanism.
Whooping Cough
Delta9-tetrahydrocannabinol stimulates glucose utilization in C6 glioma cells.
Whooping Cough
Demonstration of both A1 and A2 adenosine receptors in DDT1 MF-2 smooth muscle cells.
Whooping Cough
Demonstration of functional M3-muscarinic receptors in ventricular cardiomyocytes of adult rats.
Whooping Cough
Demonstration of GTP-binding proteins and ADP-ribosylated proteins in rat liver Golgi fraction.
Whooping Cough
Demonstration of mast cell chemotactic activity in bronchoalveolar lavage fluid collected from asthmatic patients before and during pollen season.
Whooping Cough
Demonstration of mast cell chemotactic activity in synovial fluid from rheumatoid patients.
Whooping Cough
Demonstration of the presence of G-proteins in hepatic microsomal fraction.
Whooping Cough
Dendritic cells distinguish individual chemokine signals through CCR7 and CXCR4.
Whooping Cough
Dependence and cross-dependence in the guinea-pig myenteric plexus.
Whooping Cough
Dependence of prolactin release on coupling between Ca(2+) mobilization and voltage-gated Ca(2+) influx pathways in rat lactotrophs.
Whooping Cough
Depolarization and activation of dihydropyridine-sensitive Ca2+ channels stimulate inositol phosphate accumulation in photoreceptor-enriched chick retinal cell cultures.
Whooping Cough
Depolarization-induced calcium channel facilitation in rod photoreceptors is independent of G proteins and phosphorylation.
Whooping Cough
Depolarization-induced suppression of GABAergic inhibition in rat hippocampal pyramidal cells: G protein involvement in a presynaptic mechanism.
Whooping Cough
Depression of cardiac L-type calcium current by a scorpion venom fraction M1 following muscarinic receptors interaction involving adenylate cyclase pathway.
Whooping Cough
Depression of excitability by sphingosine 1-phosphate in rat ventricular myocytes.
Whooping Cough
Depression of liver metabolism and induction of cytokine release by diphtheria and tetanus toxoids and pertussis vaccines: role of Bordetella pertussis cells in toxicity.
Whooping Cough
Deregulation of granulocyte-macrophage colony-stimulating factor (GM-CSF) receptor in murine macrophage cell line J774A.1.
Whooping Cough
Deregulation of hamster fibroblast proliferation by mutated ras oncogenes is not mediated by constitutive activation of phosphoinositide-specific phospholipase C.
Whooping Cough
Dermonecrotic toxin and tracheal cytotoxin, putative virulence factors of Bordetella avium.
Whooping Cough
Description and evaluation of serologic assays used in a multicenter trial of acellular pertussis vaccines.
Whooping Cough
Description of a hybridoma bank towards Bordetella pertussis toxin and surface antigens.
Whooping Cough
Desensitization and functional antagonism by beta-adrenoceptor and muscarinic receptor agonists, respectively: a comparison with receptor alkylation for calculation of apparent agonist affinity.
Whooping Cough
Desensitization and resensitization of beta 1- and putative beta 4-adrenoceptor mediated responses occur in parallel in a rat model of cardiac failure.
Whooping Cough
Desensitization in rat parotid to beta-adrenergic agonists and counteracting effects of forskolin are conserved in membrane and detergent-solubilized adenylate cyclase catalyst activity.
Whooping Cough
Desensitization of cardiac beta-adrenoceptor signaling with heart failure produced by myocardial infarction in the rat. Evidence for the role of Gi but not Gs or phosphorylating proteins.
Whooping Cough
Desensitization of somatostatin-induced inhibition of low extracellular magnesium concentration-induced calcium spikes in cultured rat hippocampal neurons.
Whooping Cough
Desensitization of the canine A2a adenosine receptor: delineation of multiple processes.
Whooping Cough
Desensitization of the epidermal adenylate cyclase system: agonists and phorbol esters desensitize by independent mechanisms.
Whooping Cough
Desensitization of vasopressin sensitive adenylate cyclase by vasopressin and phorbol esters.
Whooping Cough
Desensitization to parathyroid hormone in renal cells from aged rats is associated with alterations in G-protein activity.
Whooping Cough
Designing a new multi-epitope pertussis vaccine with highly population coverage based on a novel sequence and structural filtration algorithm.
Whooping Cough
Detection and quantitation of heterotrimeric G proteins by fluorescence resonance energy transfer.
Whooping Cough
Detection and subcellular localization of three Ptl proteins involved in the secretion of pertussis toxin from Bordetella pertussis.
Whooping Cough
Detection of anti-pertussis toxin IgG in oral fluids for use in diagnosis and surveillance of Bordetella pertussis infection in children and young adults.
Whooping Cough
Detection of antibodies against fimbria type 3 (Fim3) is useful diagnostic assay for pertussis.
Whooping Cough
Detection of antibodies inhibiting the ADP-ribosyltransferase activity of pertussis toxin in human serum.
Whooping Cough
Detection of arginine-ADP-ribosylated protein using recombinant ADP-ribosylarginine hydrolase.
Whooping Cough
Detection of Bordetella pertussis from Clinical Samples by Culture and End-Point PCR in Malaysian Patients.
Whooping Cough
Detection of Bordetella pertussis using a PCR test in infants younger than one year old hospitalized with whooping cough in five Peruvian hospitals.
Whooping Cough
Detection of G proteins in purified bovine brain myelin.
Whooping Cough
Detection of residual pertussis toxin in vaccines using a modified ribosylation assay.
Whooping Cough
Detection of subunits of pertussis toxin in Tn5-induced Bordetella mutants deficient in toxin biological activity.
Whooping Cough
Detection of the major pertussis toxin substrate of human leukocytes with antisera raised against synthetic peptides.
Whooping Cough
Determinants of alpha 2-adrenergic receptor activation of G proteins: evidence for a precoupled receptor/G protein state.
Whooping Cough
Determinants of natriuretic peptide gene expression.
Whooping Cough
Determinants of the G protein-dependent opioid modulation of neuronal calcium channels.
Whooping Cough
Determinants Present in the Receptor Carboxy Tail Are Responsible for Differences in Subtype-Specific Coupling of beta-Adrenergic Receptors to Phosphoinositide 3-Kinase.
Whooping Cough
Determination of antibodies to pertussis toxin in working reference preparations of anti-pertussis sera from various national control laboratories.
Whooping Cough
Determination of circulating antibodies directed to pertussis toxin and of agglutinogens in children vaccinated with either the whole cell or component pertussis vaccine in France, Japan and Senegal.
Whooping Cough
Determination of pertactin IgG antibodies for the diagnosis of pertussis.
Whooping Cough
Determination of serum neutralizing antibodies reveals important difference in quality of antibodies against pertussis toxin in children after infection.
Whooping Cough
Determination of T cell epitopes on the S1 subunit of pertussis toxin.
Whooping Cough
Determination of [35S]guanosine-5'-O-(3-thio)triphosphate binding mediated by cholinergic muscarinic receptors in membranes from Chinese hamster ovary cells and rat striatum using an anti-G protein scintillation proximity assay.
Whooping Cough
Detoxification of Bordetella pertussis organisms or pertussis toxin with glutaraldehyde for preparation of pertussis vaccine.
Whooping Cough
Detoxification of pertussis toxin by site-directed mutagenesis.
Whooping Cough
Detoxification of pertussis toxin by site-directed mutagenesis: a review of connaught strategy to develop a recombinant pertussis vaccine.
Whooping Cough
Development and Characterization of an Allergic Asthma Rat Model for Interventional Studies.
Whooping Cough
Development and clinical testing of an acellular pertussis vaccine containing genetically detoxified pertussis toxin.
Whooping Cough
Development and evaluation of dual-target real-time polymerase chain reaction assays to detect Bordetella spp.
Whooping Cough
Development and implementation of standardized method for detecting immunogenicity of acellular pertussis vaccines in Korea.
Whooping Cough
Development and migration of plasma cells in the mouse lymph node.
Whooping Cough
Development and use of a receptor antibody to characterize the interaction between somatostatin receptor subtype 1 and G proteins.
Whooping Cough
Development and validation of a multiplex immunoassay for the simultaneous determination of serum antibodies to Bordetella pertussis, diphtheria and tetanus.
Whooping Cough
Development and validation of a robust multiplex serological assay to quantify antibodies specific to pertussis antigens.
Whooping Cough
Development and Validation of Magnetic Bead Pentaplex Immunoassay for Simultaneous Quantification of murine serum IgG antibodies to Acellular Pertussis, Diphtheria and Tetanus Antigens used in combination vaccines.
Whooping Cough
Development of a carbohydrate binding assay for the B-oligomer of pertussis toxin and toxoid.
Whooping Cough
Development of a homogeneous MAP kinase reporter gene screen for the identification of agonists and antagonists at the CXCR1 chemokine receptor.
Whooping Cough
Development of a qualitative assay for screening of Bordetella pertussis isolates for pertussis toxin production.
Whooping Cough
Development of a rapid diagnostic test for pertussis: direct detection of pertussis toxin in respiratory secretions.
Whooping Cough
Development of a selective agonist at the somatostatin receptor subtype sstr1.
Whooping Cough
Development of acellular pertussis vaccines.
Whooping Cough
Development of an improved animal model of experimental autoimmune myositis.
Whooping Cough
Development of G protein-mediated Ca2+ channel regulation in mouse embryonic stem cell-derived neurons.
Whooping Cough
Development of muscarinic analgesics derived from epibatidine: role of the M4 receptor subtype.
Whooping Cough
Development of muscarinic-cholinergic stimulation of inositol phosphate production in cultured embryonic chick atrial cells. Evidence for a switch in guanine-nucleotide-binding protein coupling.
Whooping Cough
Development of neutralising human recombinant antibodies to pertussis toxin.
Whooping Cough
Development of safer pertussis DNA vaccine expressing non-toxic C180 polypeptide of pertussis toxin S1 subunit.
Whooping Cough
Development of the inhibitory guanine nucleotide-binding regulatory protein in the rat testis.
Whooping Cough
Developmental changes in adenylyl cyclase and GTP binding proteins in brown fat.
Whooping Cough
Developmental changes in beta2-adrenergic receptor signaling in ventricular myocytes: the role of Gi proteins and caveolae microdomains.
Whooping Cough
Developmental changes in guanine nucleotide regulatory proteins in the rat myocardial alpha 1-adrenergic receptor complex.
Whooping Cough
Developmental changes in the levels of substrates for cholera toxin-catalyzed and pertussis toxin-catalyzed ADP-ribosylation in rat cardiac cell membranes.
Whooping Cough
Developmental changes in the muscarinic stimulation of canine Purkinje fibers.
Whooping Cough
Developments in reduction and replacement of in vivo toxicity and potency tests for pertussis vaccines.
Whooping Cough
Dexamethasone effects on beta-adrenergic receptors and adenylate cyclase regulatory proteins Gs and Gi in ROS 17/2.8 cells.
Whooping Cough
Dexmedetomidine induces both relaxations and contractions, via different {alpha}2-adrenoceptor subtypes, in the isolated mesenteric artery and aorta of the rat.
Whooping Cough
Dexmedetomidine Inhibits ASIC Activity via Activation of ?2A Adrenergic Receptors in Rat Dorsal Root Ganglion Neurons.
Whooping Cough
Dexmedetomidine injection into the locus ceruleus produces antinociception.
Whooping Cough
Dexras1 inhibits adenylyl cyclase.
Whooping Cough
dgq: a drosophila gene encoding a visual system-specific G alpha molecule.
Whooping Cough
Diabetes decreases sensitivity of adipocyte lipolysis to inhibition by Gi-linked receptor agonists.
Whooping Cough
Diacylglycerol and ceramide formation induced by dopamine D2S receptors via Gbeta gamma -subunits in Balb/c-3T3 cells.
Whooping Cough
Diacylglycerol mass measurements in stimulated HL-60 phagocytes.
Whooping Cough
Diacylglycerol production induced by growth hormone in Ob1771 preadipocytes arises from phosphatidylcholine breakdown.
Whooping Cough
Diadenosine polyphosphates induce intracellular Ca2+ mobilization in human neutrophils via a pertussis toxin sensitive G-protein.
Whooping Cough
Diagnostic evaluation of polymerase chain reaction discriminative for Bordetella pertussis, B. parapertussis, and B. bronchiseptica.
Whooping Cough
Diagnostic performance of commercial serological assays measuring Bordetella pertussis IgG antibodies.
Whooping Cough
Dibutyryl Cyclic AMP Inhibits the Progression of Experimental Autoimmune Encephalomyelitis and Potentiates Recruitment of Endogenous Neural Stem Cells.
Whooping Cough
Dibutyryl cyclic AMP-induced morphological differentiation of rat brain astrocytes increases alpha 1-adrenoceptor induced phosphoinositide breakdown by a mechanism involving protein synthesis.
Whooping Cough
Dichotomous effects of beta-chemokines on HIV replication in monocytes and monocyte-derived macrophages.
Whooping Cough
Dieldrin induces human neutrophil superoxide production via protein kinases C and tyrosine kinases.
Whooping Cough
Dietary fish oil deactivates a growth-promoting signaling pathway in hepatoma 7288CTC in Buffalo rats.
Whooping Cough
Difference in effects of sodium fluoride and cholecystokinin on diacylglycerol accumulation and calcium increase in guinea pig gastric chief cells.
Whooping Cough
Differences between presynaptic and postsynaptic GABAB mechanisms in rat hippocampal pyramidal cells.
Whooping Cough
Differences in agonist-independent and -dependent 5-hydroxytryptamine2C receptor-mediated cell division.
Whooping Cough
Differences in antibody response to whole-cell pertussis vaccines.
Whooping Cough
Differences in avidity of IgG antibodies to pertussis toxin after acellular pertussis booster vaccination and natural infection.
Whooping Cough
Differences in coughing and other responses to intrabronchial infection with Bordetella pertussis among strains of rats.
Whooping Cough
Differences in CXCR4-mediated signaling in B cells.
Whooping Cough
Differences in efficacy and Na(+) sensitivity between alpha(2B) and alpha(2D) adrenergic receptors: implications for R and R* states.
Whooping Cough
Differences in epitope-specific antibodies to pertussis toxin after infection and acellular vaccinations.
Whooping Cough
Differences in platelet-activating factor receptor mediated Ca++ response between hamster and guinea pig alveolar macrophages.
Whooping Cough
Differences in signal transduction between Fc gamma receptors (Fc gamma RII, Fc gamma RIII) and FMLP receptors in neutrophils. Effects of colchicine on pertussis toxin sensitivity and diacylglycerol formation.
Whooping Cough
Differences in signal transduction of two 5-HT4 receptor splice variants: compound specificity and dual coupling with Galphas- and Galphai/o-proteins.
Whooping Cough
Differences in the actions of calcium versus lanthanum to influence parathyroid hormone release.
Whooping Cough
Differences in the genomic content of Bordetella pertussis isolates before and after introduction of pertussis vaccines in four European countries.
Whooping Cough
Differences in the operational characteristics of the human recombinant somatostatin receptor types, sst1 and sst2, in mouse fibroblast (Ltk-) cells.
Whooping Cough
Differences in the regulation of fibroblast contraction of floating versus stressed collagen matrices.
Whooping Cough
Differences of humoral and cellular immune response to an acellular pertussis booster in adolescents with a whole cell or acellular primary vaccination.
Whooping Cough
Different abilities of two types of Fc gamma receptor on guinea-pig macrophages to trigger the phosphatidylinositol turnover.
Whooping Cough
Different activation of L-arginine pathway by bradykinin, serotonin, and clonidine in coronary arteries.
Whooping Cough
Different alpha1-adrenoceptor-induced inositol phosphate formation in the two portions of rat vas deferens.
Whooping Cough
Different concentrations of pertussis toxin have opposite effects on agonist-induced PGE2 formation in mesangial cells.
Whooping Cough
Different domains in the third intracellular loop of the GLP-1 receptor are responsible for Galpha(s) and Galpha(i)/Galpha(o) activation.
Whooping Cough
Different effects of phorbol ester on angiotensin II- and stable GTP analogue-induced activation of polyphosphoinositide phosphodiesterase in membranes isolated from rat renal mesangial cells.
Whooping Cough
Different effects of the different natural CC chemokine receptor 2b ligands on beta-arrestin recruitment, G?i signaling, and receptor internalization.
Whooping Cough
Different endothelin receptor subtypes are involved in phospholipid signalling in the proximal tubule of rat kidney.
Whooping Cough
Different G proteins are involved in the biphasic response of clonal rat pituitary cells to thyrotropin-releasing hormone.
Whooping Cough
Different G proteins mediate somatostatin-induced inward rectifier K+ currents in murine brain and endocrine cells.
Whooping Cough
Different G proteins mediate the opioid inhibition or enhancement of evoked [5-methionine]enkephalin release.
Whooping Cough
Different G(i)-coupled chemoattractant receptors signal qualitatively different functions in human neutrophils.
Whooping Cough
Different GTP-binding proteins mediate regulation of calcium channels by acetylcholine and noradrenaline in rat sympathetic neurons.
Whooping Cough
Different guanosine triphosphate-binding proteins couple vasopressin receptor to phospholipase C and phospholipase A2 in glomerular mesangial cells.
Whooping Cough
Different IgG-subclass distributions after whole-cell and acellular pertussis infant primary vaccinations in healthy and pertussis infected children.
Whooping Cough
Different mechanisms are involved in intracellular calcium increase by insulin-like growth factors 1 and 2 in articular chondrocytes: voltage-gated calcium channels, and/or phospholipase C coupled to a pertussis-sensitive G-protein.
Whooping Cough
Different pathways for activation of extracellular signal-regulated kinase through thromboxane A2 receptor isoforms.
Whooping Cough
Different patterns of Ca(2+) signals are induced by low compared to high concentrations of P2Y agonists in microglia.
Whooping Cough
Different proliferative responses of Gi/o-protein-coupled receptors in human myometrial smooth muscle cells. A possible role of calcium.
Whooping Cough
Different regulation of ERK1/2 activation by beta-adrenergic receptor subtypes in adult mouse cardiomyocytes.
Whooping Cough
Different response patterns of several ligands at the sphingosine-1-phosphate receptor subtype 3 (S1P(3)).
Whooping Cough
Different sensitivities of the responses of human neutrophils stimulated with immune complex and C5a anaphylatoxin to pertussis toxin.
Whooping Cough
Different sensitivity to phorbol esters and pertussis toxin of bombesin- and platelet-derived growth factor-induced, phospholipase C-mediated hydrolysis of phosphoinositides in NIH/3T3 cells.
Whooping Cough
Different signal transduction pathways are coupled to the nucleotide receptor and the P2Y receptor in C6 glioma cells.
Whooping Cough
Different sites of action of arachidonic acid on steroidogenesis in rat Leydig cells.
Whooping Cough
Different stimulatory opioid effects on intracellular Ca(2+) in SH-SY5Y cells.
Whooping Cough
Different T cell memory in preadolescents after whole-cell or acellular pertussis vaccination.
Whooping Cough
Different tachykinin receptor subtypes are coupled to the phosphoinositide or cyclic AMP signal transduction pathways in rat submandibular cells.
Whooping Cough
Different types of ADP-ribose protein bonds formed by botulinum C2 toxin, botulinum ADP-ribosyltransferase C3 and pertussis toxin.
Whooping Cough
Different types of glutamate receptors in isolated and identified neurones of the mollusc Planorbarius corneus.
Whooping Cough
Differential action of somatostatin on peptide-induced release of acetylcholine.
Whooping Cough
Differential activation of dibutyryl cAMP-differentiated HL-60 human leukemia cells by chemoattractants.
Whooping Cough
Differential activation of Gi and Gs proteins by E- and I-type prostaglandins in membranes from the human erythroleukaemia cell line, HEL.
Whooping Cough
Differential activation of Gq/11 and Gi(3) proteins at 5-hydroxytryptamine(2C) receptors revealed by antibody capture assays: influence of receptor reserve and relationship to agonist-directed trafficking.
Whooping Cough
Differential activation of signal transduction pathways mediating oxidative burst by chicken heterophils in response to stimulation with lipopolysaccharide and lipoteichoic acid.
Whooping Cough
Differential activation of signal transduction pathways mediating phagocytosis, oxidative burst, and degranulation by chicken heterophils in response to stimulation with opsonized Salmonella enteritidis.
Whooping Cough
Differential activation of the stimulatory and inhibitory guanine nucleotide-binding proteins by fluoroaluminate in cells and in membranes.
Whooping Cough
Differential agonist activity of somatostatin and L-362855 at human recombinant sst4 receptors.
Whooping Cough
Differential agonist regulation of the human kappa-opioid receptor.
Whooping Cough
Differential alterations in cardiac adrenergic signaling in chronic hypoxia or norepinephrine infusion.
Whooping Cough
Differential alterations in left and right ventricular G-proteins in congestive heart failure due to myocardial infarction.
Whooping Cough
Differential binding of BvgA to two classes of virulence genes of Bordetella pertussis directs promoter selectivity by RNA polymerase.
Whooping Cough
Differential calcium regulation of proinflammatory activities in human neutrophils exposed to the neuropeptide pituitary adenylate cyclase-activating protein.
Whooping Cough
Differential calcium signalling by m2 and m3 muscarinic acetylcholine receptors in a single cell type.
Whooping Cough
Differential cardiotoxic/cardioprotective effects of beta-adrenergic receptor subtypes in myocytes and fibroblasts in doxorubicin cardiomyopathy.
Whooping Cough
Differential Cav2.1 and Cav2.3 channel inhibition by baclofen and ?-conotoxin Vc1.1 via GABAB receptor activation.
Whooping Cough
Differential CCR1-mediated chemotaxis signaling induced by human CC chemokine HCC-4/CCL16 in HOS cells.
Whooping Cough
Differential cholera-toxin sensitivity of supraspinal antinociception induced by the cannabinoid agonists delta9-THC, WIN 55,212-2 and anandamide in mice.
Whooping Cough
Differential cholera-toxin- and pertussis-toxin-catalysed ADP-ribosylation of G-proteins coupled to formyl-peptide and leukotriene B4 receptors.
Whooping Cough
Differential coupling of 5-HT(1) receptors to G proteins of the G(i) family.
Whooping Cough
Differential coupling of D1 and D5 dopamine receptors to guanine nucleotide binding proteins in transfected GH4C1 rat somatomammotrophic cells.
Whooping Cough
Differential coupling of dopaminergic D2 receptors expressed in different cell types. Stimulation of phosphatidylinositol 4,5-bisphosphate hydrolysis in LtK- fibroblasts, hyperpolarization, and cytosolic-free Ca2+ concentration decrease in GH4C1 cells.
Whooping Cough
Differential coupling of G protein alpha subunits to seven-helix receptors expressed in Xenopus oocytes.
Whooping Cough
Differential coupling of m1, m2 and m3 muscarinic receptor subtypes to inositol 1,4,5-trisphosphate and adenosine 3',5'-cyclic monophosphate accumulation in Chinese hamster ovary cells.
Whooping Cough
Differential coupling of mu-competitive and mu-noncompetitive delta opiate receptors to guanine nucleotide binding proteins in rat brain membranes.
Whooping Cough
Differential coupling of muscarinic m2 and m3 receptors to adenylyl cyclases V/VI in smooth muscle. Concurrent M2-mediated inhibition via Galphai3 and m3-mediated stimulation via Gbetagammaq.
Whooping Cough
Differential coupling of muscarinic receptors to Ca2+ mobilization and cyclic AMP in SH-SY5Y and IMR 32 neuroblastoma cells.
Whooping Cough
Differential coupling of the formyl peptide receptor to adenylate cyclase and phospholipase C by the pertussis toxin-insensitive Gz protein.
Whooping Cough
Differential coupling with pertussis toxin-sensitive G proteins of dopamine and somatostatin receptors involved in regulation of adenohypophyseal secretion.
Whooping Cough
Differential detection of B. pertussis from B. parapertussis using a polymerase chain reaction (PCR) in presence of SYBR green1 and amplicon melting analysis.
Whooping Cough
Differential effect of adenosine on rhabdomyosarcoma migration and proliferation.
Whooping Cough
Differential effect of Bordetella pertussis on experimental posterior uveitis in the black-hooded Lister rat.
Whooping Cough
Differential effect of high extracellular Ca2+ on K+ and Cl- conductances in murine osteoclasts.
Whooping Cough
Differential effect of pertussis toxin on adenosine and muscarinic inhibition of cyclic AMP accumulation in canine ventricular myocytes.
Whooping Cough
Differential effect of pertussis toxin on pre- and postjunctional alpha 2-adrenoceptors in the cardiovascular system of the pithed rat.
Whooping Cough
Differential effect of pertussis toxin on the affinity state for agonists of renal alpha 1- and alpha 2- adrenoceptors.
Whooping Cough
Differential effect of shear stress on extracellular signal-regulated kinase and N-terminal Jun kinase in endothelial cells. Gi2- and Gbeta/gamma-dependent signaling pathways.
Whooping Cough
Differential effects of bacterial toxins on mitogenic actions of sodium fluoride and those of aluminum fluoride in human TE85 osteosarcoma cells.
Whooping Cough
Differential effects of cholera toxin and pertussis toxin on the c-fos and c-jun mRNA expression in rat C6 glioma cells.
Whooping Cough
Differential effects of cytokines on long-term mitogenic and secretory responses of fetal rat pancreatic beta-cells.
Whooping Cough
Differential effects of endothelin-1 on basal and isoprenaline-enhanced Ca2+ current in guinea-pig ventricular myocytes.
Whooping Cough
Differential effects of fluoride and a non-hydrolysable GTP analogue on adenylate cyclase and G-proteins in Ceratitis capitata neural tissue.
Whooping Cough
Differential effects of G protein coupled receptors on hematopoietic progenitor cell growth depend on their signaling capacities.
Whooping Cough
Differential effects of genistein on apoptosis induced by fluoride and pertussis toxin in human and rat pancreatic islets and RINm5F cells.
Whooping Cough
Differential effects of lovastatin on mitogen induced calcium influx in human cultured vascular smooth muscle cells.
Whooping Cough
Differential effects of pertussis toxin and lithium on muscarinic responses in the atria and ileum: evidence for receptor heterogeneity.
Whooping Cough
Differential effects of pertussis toxin on body temperature changes induced by neuropeptide Y and NPY2-36.
Whooping Cough
Differential effects of pertussis toxin on insulin-stimulated phosphatidylcholine hydrolysis and glycerolipid synthesis de novo. Studies in BC3H-1 myocytes and rat adipocytes.
Whooping Cough
Differential effects of pertussis toxin on muscarinic responses in isolated atria and smooth muscle.
Whooping Cough
Differential effects of pertussis toxin on the muscarinic regulation of Ca2+ and K+ currents in frog cardiac myocytes.
Whooping Cough
Differential Effects of the G?5-RGS7 Complex on Muscarinic M3 Receptor-Induced Ca2+ Influx and Release.
Whooping Cough
Differential expression of Ia by murine keratinocytes and gut epithelium in response to recombinant gamma-interferon.
Whooping Cough
Differential expression of MCP-1 and its receptor CCR2 in glucose primed human mesangial cells.
Whooping Cough
Differential functional effects of two 5-HT4 receptor isoforms in adult cardiomyocytes.
Whooping Cough
Differential G protein-mediated coupling of D2 dopamine receptors to K+ and Ca2+ currents in rat anterior pituitary cells.
Whooping Cough
Differential G protein-mediated coupling of neurotransmitter receptors to Ca2+ channels in rat dorsal root ganglion neurons in vitro.
Whooping Cough
Differential IL-10 production by DCs determines the distinct adjuvant effects of LPS and PTX in EAE induction.
Whooping Cough
Differential inhibition of fatty acid transport in tissue-isolated steroid receptor negative human breast cancer xenografts perfused in situ with isomers of conjugated linoleic acid.
Whooping Cough
Differential interaction of beta 1- and beta 3-adrenergic receptors with Gi in rat adipocytes.
Whooping Cough
Differential intracellular signaling of the GalR1 and GalR2 galanin receptor subtypes.
Whooping Cough
Differential involvement of Galpha16 in CC chemokine-induced stimulation of phospholipase Cbeta, ERK, and chemotaxis.
Whooping Cough
Differential involvement of hippocampal G-protein subtypes in the memory process of rats.
Whooping Cough
Differential ion current activation by human 5-HT(1A) receptors in Xenopus oocytes: evidence for agonist-directed trafficking of receptor signalling.
Whooping Cough
Differential isoprenylation of carboxy-terminal mutants of an inhibitory G-protein alpha-subunit: neither farnesylation nor geranylgeranylation is sufficient for membrane attachment.
Whooping Cough
Differential localization of the mRNAs for the pertussis toxin insensitive G-protein alpha sub-units Gq, G11, and Gz in the rat brain, and regulation of their expression after striatal deafferentation.
Whooping Cough
Differential mechanisms of dopamine and somatostatin inhibition of prolactin secretion from anterior pituitary cells.
Whooping Cough
Differential modulation of ATP-induced calcium signalling by A1 and A2 adenosine receptors in cultured cortical astrocytes.
Whooping Cough
Differential modulation of rod and cone calcium currents in tiger salamander retina by D2 dopamine receptors and cAMP.
Whooping Cough
Differential modulatory effects of cholera toxin and pertussis toxin on pain behavior induced by TNF-alpha, interleukin-1beta and interferon-gamma injected intrathecally.
Whooping Cough
Differential modulatory roles of cholera toxin and pertussis toxin in the regulation of pain responses induced by excitatory amino acids administered intrathecally in mice.
Whooping Cough
Differential negative coupling of type 3 metabotropic glutamate receptor to cyclic GMP levels in neurons and astrocytes.
Whooping Cough
Differential osmosensing signalling pathways and G-protein involvement in human cervical cells with different tumour potential.
Whooping Cough
Differential phospholipase D activation by bradykinin and sphingosine 1-phosphate in NIH 3T3 fibroblasts overexpressing gelsolin.
Whooping Cough
Differential potentiation of arachidonic acid release by rat alpha2 adrenergic receptor subtypes.
Whooping Cough
Differential prevention of morphine amnesia by antisense oligodeoxynucleotides directed against various Gi-protein alpha subunits.
Whooping Cough
Differential properties of pre- and postsynaptic 5-hydroxytryptamine1A receptors in the dorsal raphe and hippocampus: II. Effect of pertussis and cholera toxins.
Whooping Cough
Differential purification of autocrine motility factor derived from a murine protein-free fibrosarcoma.
Whooping Cough
Differential regulation by cAMP-dependent protein kinase and protein kinase C of the mu opioid receptor coupling to a G protein-activated K+ channel.
Whooping Cough
Differential regulation of 46 and 54 kDa jun N-terminal kinases and p38 mitogen-activated protein kinase by human alpha(1A)-adrenoceptors expressed in Rat-1 cells.
Whooping Cough
Differential regulation of accessory mitogenic signaling receptors by the T cell antigen receptor.
Whooping Cough
Differential regulation of airway mucin gene expression and mucin secretion by extracellular nucleotide triphosphates.
Whooping Cough
Differential regulation of beta 1 and beta 2 integrin avidity by chemoattractants in eosinophils.
Whooping Cough
Differential regulation of Bordetella pertussis virulence factors.
Whooping Cough
Differential regulation of cAMP by endogenous versus transfected formylpeptide chemoattractant receptors: implications for Gi-coupled receptor signaling.
Whooping Cough
Differential regulation of Cav2.2 channel exon 37 variants by alternatively spliced ?-opioid receptors.
Whooping Cough
Differential regulation of cyclic AMP synthesis by estrogen in MCF7 cells.
Whooping Cough
Differential Regulation of ERK1/2 and mTORC1 Through T1R1/T1R3 in MIN6 Cells.
Whooping Cough
Differential regulation of estrogen receptor alpha, glucocorticoid receptor and retinoic acid receptor alpha transcriptional activity by melatonin is mediated via different G proteins.
Whooping Cough
Differential regulation of extracellular signal-regulated protein kinase 1 and Jun N-terminal kinase 1 by Ca2+ and protein kinase C in endothelin-stimulated Rat-1 cells.
Whooping Cough
Differential regulation of formyl peptide and platelet-activating factor receptors. Role of phospholipase Cbeta3 phosphorylation by protein kinase A.
Whooping Cough
Differential regulation of G protein subunit expression in mouse oocytes, eggs, and early embryos.
Whooping Cough
Differential regulation of G protein-gated inwardly rectifying K(+) channel kinetics by distinct domains of RGS8.
Whooping Cough
Differential regulation of glutamate decarboxylase and preproenkephalin mRNA levels in the rat striatum.
Whooping Cough
Differential regulation of inositol 1,4,5-trisphosphate by co-existing P2Y-purinoceptors and nucleotide receptors on bovine aortic endothelial cells.
Whooping Cough
Differential regulation of Na+ and Cl- conductances by PTX-sensitive G proteins in fetal lung apical membrane vesicles.
Whooping Cough
Differential regulation of receptor-stimulated cyclic adenosine monophosphate production by polyvalent cations in MC3T3-E1 osteoblasts.
Whooping Cough
Differential regulation of sphingosine-1-phosphate- and VEGF-induced endothelial cell chemotaxis. Involvement of G(ialpha2)-linked Rho kinase activity.
Whooping Cough
Differential regulation of thrombin- or ATP-induced mobilization of intracellular Ca2+ by prostacyclin receptor in mouse mastocytoma cells.
Whooping Cough
Differential requirement of G alpha12, G alpha13, G alphaq, and G beta gamma for endothelin-1-induced c-Jun NH2-terminal kinase and extracellular signal-regulated kinase activation.
Whooping Cough
Differential response of cortical plate and ventricular zone cells to GABA as a migration stimulus.
Whooping Cough
Differential response of mast cells separated from various organs and basophils of dogs to the fluoroquinolone antimicrobial levofloxacin.
Whooping Cough
Differential response of the Ras exchange factor, Ras-GRF to tyrosine kinase and G protein mediated signals.
Whooping Cough
Differential roles of Edg-1 and Edg-5, sphingosine 1-phosphate receptors, in the signaling pathways in C6 glioma cells.
Whooping Cough
Differential roles of Fas ligand in spontaneous and actively induced autoimmune encephalomyelitis.
Whooping Cough
Differential roles of protein kinase C and pertussis toxin-sensitive G-binding proteins in modulation of melanoma cell proliferation and motility by thrombospondin 1.
Whooping Cough
Differential roles of spinal cholera toxin- and pertussis toxin-sensitive G proteins in nociceptive responses caused by formalin, capsaicin, and substance P in mice.
Whooping Cough
Differential routes of Ca2+ influx in Swiss 3T3 fibroblasts in response to receptor stimulation.
Whooping Cough
Differential sensitivity of 5-HT1B auto and heteroreceptors.
Whooping Cough
Differential sensitivity of alpha o and alpha i to ADP-ribosylation by pertussis toxin in the intact cultured embryonic chick ventricular myocyte. Relationship to the role of G proteins in the coupling of muscarinic cholinergic receptors to inhibition of adenylate cyclase activity.
Whooping Cough
Differential sensitivity of arachidonic acid release and 1,2-diacylglycerol formation to pertussis toxin, GDP beta S and NaF in saponin-permeabilized human platelets: possible evidence for distinct GTP-binding proteins involving phospholipase C and A2 activation.
Whooping Cough
Differential sensitivity of phosphoinositide metabolism to sodium fluoride and carbachol treatments in PC12 cells.
Whooping Cough
Differential sensitivity of progesterone- and zona pellucida-induced acrosome reactions to pertussis toxin.
Whooping Cough
Differential sensitivity of the short and long human dopamine D2 receptor subtypes to protein kinase C.
Whooping Cough
Differential sensitivity to pertussis toxin of 3T3 cells transformed with different oncogenes.
Whooping Cough
Differential signaling pathways in platelet-activating factor-induced proliferation and interleukin-6 production by rat vascular smooth muscle cells.
Whooping Cough
Differential signalling by muscarinic receptors in smooth muscle: m2-mediated inactivation of myosin light chain kinase via Gi3, Cdc42/Rac1 and p21-activated kinase 1 pathway, and m3-mediated MLC20 (20 kDa regulatory light chain of myosin II) phosphorylation via Rho-associated kinase/myosin phosphatase targeting subunit 1 and protein kinase C/CPI-17 pathway.
Whooping Cough
Differential Signalling by Splice Variants of the Human Free Fatty Acid Receptor, GPR120.
Whooping Cough
Differential signalling of the chemokine receptor CXCR4 by stromal cell-derived factor 1 and the HIV glycoprotein in rat neurons and astrocytes.
Whooping Cough
Differential superactivation of adenylyl cyclase isozymes after chronic activation of the CB(1) cannabinoid receptor.
Whooping Cough
Differential Susceptibility of Guanine Nucleotide-binding Proteins to Pertussis Toxin-catalyzed ADP-ribosylation in Brain Membranes of Two Congeneric Marine Fishes.
Whooping Cough
Differential T- and B-Cell Responses to Pertussis in Acellular Vaccine-Primed versus Whole-Cell Vaccine-Primed Children 2 Years after Preschool Acellular Booster Vaccination.
Whooping Cough
Differential translocation of rho family GTPases by lysophosphatidic acid, endothelin-1, and platelet-derived growth factor.
Whooping Cough
Differentially expressed genes in Bordetella pertussis strains belonging to a lineage which recently spread globally.
Whooping Cough
Differentiation of BA-HAN-1C rhabdomyosarcoma cells is controlled by a pertussis toxin sensitive signaling pathway.
Whooping Cough
Differentiation of muscarinic receptors mediating negative chronotropic and vasoconstrictor responses to acetylcholine in isolated rat hearts.
Whooping Cough
Differentiation of Neuro-2a neuroblastoma cells by an antibody to GM3 ganglioside.
Whooping Cough
Differentiation of renal Na(+)-K(+)-ATPase in control and streptozotocin-induced diabetic mice by G-protein acting toxins and phorbol esters.
Whooping Cough
Differentiation-linked activation of the respiratory burst in a monocytic cell line (U937) via Fc gamma RII. A study of activation pathways and their regulation.
Whooping Cough
DIgLONs inhibit initiation of neurite outgrowth from forebrain neurons via an IgLON-containing receptor complex.
Whooping Cough
Dihydropiridine inhibition of K+ and maitotoxin stimulated calcium fluxes in PC12 cells: effect of pertussis toxin.
Whooping Cough
Dihydropyridine modulation of voltage-activated calcium channels in PC12 cells: effect of pertussis toxin pretreatment.
Whooping Cough
Dihydropyridine receptors as voltage sensors for a depolarization-evoked, IP3R-mediated, slow calcium signal in skeletal muscle cells.
Whooping Cough
Dihydropyridine- and omega-conotoxin-sensitive Ca2+ currents in cerebellar neurons: persistent block of L-type channels by a pertussis toxin-sensitive G-protein.
Whooping Cough
Dihydrosphingosine 1-phosphate stimulates MMP1 gene expression via activation of ERK1/2-Ets1 pathway in human fibroblasts.
Whooping Cough
Dimers of G-protein coupled receptors as versatile storage and response units.
Whooping Cough
Dimethylsphingosine increases cytosolic calcium and intracellular pH in human T lymphocytes.
Whooping Cough
Diminished basal phosphorylation level of phospholamban in the postinfarction remodeled rat ventricle: role of beta-adrenergic pathway, G(i) protein, phosphodiesterase, and phosphatases.
Whooping Cough
Diminution of contractile response by kappa-opioid receptor agonists in isolated rat ventricular cardiomyocytes is mediated via a pertussis toxin-sensitive G protein.
Whooping Cough
Dinucleoside polyphosphates and their interaction with other nucleotide signaling pathways.
Whooping Cough
Dioleoyl phosphatidic acid increases intracellular Ca2+ through endogenous LPA receptors in C6 glioma and L2071 fibroblasts.
Whooping Cough
Dioleoyl phosphatidic acid induces morphological changes through an endogenous LPA receptor in C6 glioma cells.
Whooping Cough
Diphtheria, tetanus and pertussis antibodies in 10-year-old children before and after a booster dose of three toxoids: implications for the timing of a booster dose.
Whooping Cough
Diphtheria-tetanus-acellular pertussis vaccine adsorbed (Triacelluvax; DTaP3-CB): a review of its use in the prevention of Bordetella pertussis infection.
Whooping Cough
Direct action of pertussis toxin in isolated hamster fat cells.
Whooping Cough
Direct activation of GTP-binding proteins by venom peptides that contain cationic clusters within their alpha-helical structures.
Whooping Cough
Direct activation of second messenger pathways mimics cell adhesion molecule-dependent neurite outgrowth.
Whooping Cough
Direct and biochemical interaction between dopamine D3 receptor and elongation factor-1Bbetagamma.
Whooping Cough
Direct autocrine inhibition and cAMP-dependent potentiation of single L-type Ca2+ channels in bovine chromaffin cells.
Whooping Cough
Direct coupling of a G-protein to dihydropyridine binding sites.
Whooping Cough
Direct Coupling of a Seven-Transmembrane-Span Receptor to a G?i G-Protein Regulatory Motif Complex.
Whooping Cough
Direct coupling of opioid receptors to both stimulatory and inhibitory guanine nucleotide-binding proteins in F-11 neuroblastoma-sensory neuron hybrid cells.
Whooping Cough
Direct coupling of the somatostatin receptor to potassium channels by a G protein.
Whooping Cough
Direct dopamine D2-receptor-mediated modulation of arachidonic acid release in transfected CHO cells without the concomitant administration of a Ca2+-mobilizing agent.
Whooping Cough
Direct effect of adenosine on prolactin secretion at the level of the single rat lactotroph: involvement of pertussis toxin-sensitive and -insensitive transducing mechanisms.
Whooping Cough
Direct effects of wheat germ agglutinin on inositol phosphate formation and cytosolic-free calcium level in intestine 407 cells.
Whooping Cough
Direct evidence for functional coupling of the vasoactive intestinal peptide receptor to Gi3 in native lung membranes.
Whooping Cough
Direct evidence for involvement of a guanine nucleotide-binding protein in chemotactic peptide-stimulated formation of inositol bisphosphate and trisphosphate in differentiated human leukemic (HL-60) cells. Reconstitution with Gi or Go of the plasma membranes ADP-ribosylated by pertussis toxin.
Whooping Cough
Direct evidence for two distinct G proteins coupling with thrombin receptors in human neuroblastoma SH-EP cells.
Whooping Cough
Direct glucocorticoid inhibition of insulin secretion. An in vitro study of dexamethasone effects in mouse islets.
Whooping Cough
Direct inhibition of voltage-dependent Ca(2+) fluxes by ethanol and higher alcohols in rabbit T-tubule membranes.
Whooping Cough
Direct inhibitory effects of a somatostatin analog, SMS 201-995, on AR4-2J cell proliferation via pertussis toxin-sensitive guanosine triphosphate-binding protein-independent mechanism.
Whooping Cough
Direct modulation by androgens of the response of human bone cells (SaOS-2) to human parathyroid hormone (PTH) and PTH-related protein.
Whooping Cough
Direct modulation of voltage-dependent calcium channels by muscarinic activation of a pertussis toxin-sensitive G-protein in hippocampal neurons.
Whooping Cough
Direct molecular typing of Bordetella pertussis from clinical specimens submitted for diagnostic quantitative (real-time) PCR.
Whooping Cough
Direct neuropeptide Y-induced modulation of gonadotrope intracellular calcium transients and gonadotropin secretion.
Whooping Cough
Direct regulation of vascular smooth muscle contraction by mastoparan-7.
Whooping Cough
Direct relationship between intracellular calcium mobilization and phospholipase D activation in prostaglandin E-stimulated human erythroleukemia cells.
Whooping Cough
Direct role of plasma membrane-expressed gp120/41 in toxicity to human astrocytes induced by HIV-1-infected macrophages.
Whooping Cough
Direct stimulation of adenylate cyclase by mechanical forces in S49 mouse lymphoma cells during hyposmotic swelling.
Whooping Cough
Directed shift of fatty acids from phospholipids to triacylglycerols in HL-60 cells induced by nanomolar concentrations of triethyl lead chloride: involvement of a pertussis toxin-sensitive pathway.
Whooping Cough
Discovery of Compounds Inhibiting the ADP-Ribosyltransferase Activity of Pertussis Toxin.
Whooping Cough
Discrimination between plasma membrane and intracellular target sites of sphingosylphosphorylcholine.
Whooping Cough
Disodium cromoglycate inhibits production of immunoglobulin E.
Whooping Cough
Disparate effects of interferon-gamma and tumor necrosis factor-alpha on early neutrophil respiratory burst and fungicidal responses to Candida albicans hyphae in vitro.
Whooping Cough
Disparate effects of neuropeptide Y and clonidine on the excretion of sodium and water in the rat.
Whooping Cough
Disparity in Fc?RI-Induced Degranulation of Primary Human Lung and Skin Mast Cells Exposed to Adenosine.
Whooping Cough
Dispensable role of chemokine receptors in migration of mycobacterial antigen-specific CD4+ T cells into Mycobacterium-infected lung.
Whooping Cough
Disruption of G(i/o) protein signaling in the nucleus accumbens results in a D1 dopamine receptor-mediated hyperactivity.
Whooping Cough
Disruption of inhibitory G-proteins mediates a reduction in atrial beta-adrenergic signaling by enhancing eNOS expression.
Whooping Cough
Dissecting human T cell responses against Bordetella species.
Whooping Cough
Dissection of lymphocyte function-associated antigen 1-dependent adhesion and signal transduction in human natural killer cells shown by the use of cholera or pertussis toxin.
Whooping Cough
Dissection of thymocyte signaling pathways by in vivo expression of pertussis toxin ADP-ribosyltransferase.
Whooping Cough
Dissemination of lymphocytic choriomeningitis virus from the gastric mucosa requires G protein-coupled signaling.
Whooping Cough
Dissociating the enhancing and inhibitory effects of pertussis toxin on autoimmune disease.
Whooping Cough
Dissociation between muscarinic receptor-mediated inhibition of adenylate cyclase and autoreceptor inhibition of [3H] acetylcholine release in rat hippocampus.
Whooping Cough
Dissociation of antiproliferative and antihormonal effects of the somatostatin analog octreotide on 7315b pituitary tumor cells.
Whooping Cough
Dissociation of bradykinin-induced prostaglandin formation from phosphatidylinositol turnover in Swiss 3T3 fibroblasts: evidence for G protein regulation of phospholipase A2.
Whooping Cough
Dissociation of mitogen-activated protein kinase activation from p125 focal adhesion kinase tyrosine phosphorylation in Swiss 3T3 cells stimulated by bombesin, lysophosphatidic acid, and platelet-derived growth factor.
Whooping Cough
Dissociation of opioid receptor upregulation and functional supersensitivity.
Whooping Cough
Dissociation of second messenger activation by parathyroid hormone fragments in osteosarcoma cells.
Whooping Cough
Distinct Ca2+ requirement for NO production between proteinase-activated receptor 1 and 4 (PAR1 and PAR4) in vascular endothelial cells.
Whooping Cough
Distinct cellular expression of pertussis toxin-sensitive GTP-binding proteins in rat cerebellum.
Whooping Cough
Distinct components of morphine effects on cardiac myocytes are mediated by the kappa and delta opioid receptors.
Whooping Cough
Distinct guanine nucleotide binding and release properties of the three Gi proteins.
Whooping Cough
Distinct kinetic and spatial patterns of PKC- and EGFR-dependent activation of extracellular signal-regulated kinases 1 and 2 by humane nicotinic acid receptor GPR109A.
Whooping Cough
Distinct mechanisms for Ca2+ entry induced by OKT3 and Ca2+ depletion in Jurkat T cells.
Whooping Cough
Distinct mode of G protein activation due to single residue substitution of active IGF-II receptor peptide Arg2410-Lys2423: evidence for stimulation acceptor region other than C-terminus of Gi alpha.
Whooping Cough
Distinct modes of molecular regulation of CCL3 induced calcium flux in monocytic cells.
Whooping Cough
Distinct muscarinic receptor subtypes suppress excitatory and inhibitory synaptic responses in cortical neurons.
Whooping Cough
Distinct muscarinic receptors enhance spontaneous GABA release and inhibit electrically evoked GABAergic synaptic transmission in the chick lateral spiriform nucleus.
Whooping Cough
Distinct muscarinic receptors, G proteins and phospholipases in esophageal and lower esophageal sphincter circular muscle.
Whooping Cough
Distinct pathways for beta-adrenoceptor-induced up-regulation of muscarinic acetylcholine receptors and inhibitory G-protein alpha-subunits in chicken cardiomyocytes.
Whooping Cough
Distinct Pathways of ERK1/2 Activation by Hydroxy-Carboxylic Acid Receptor-1.
Whooping Cough
Distinct pathways regulate transforming growth factor beta 1-stimulated proto-oncogene and extracellular matrix gene expression.
Whooping Cough
Distinct Physiological Effects of ?1- and ?2-Adrenoceptors in Mouse Ventricular Myocytes: Insights from a Compartmentalized Mathematical Model.
Whooping Cough
Distinct receptors and different transduction mechanisms for ATP and adenosine at the frog motor nerve endings.
Whooping Cough
Distinct regions of C-terminus of the high affinity neurotensin receptor mediate the functional coupling with pertussis toxin sensitive and insensitive G-proteins.
Whooping Cough
Distinct roles for Galpha(i)2 and Gbetagamma in signaling to DNA synthesis and Galpha(i)3 in cellular transformation by dopamine D2S receptor activation in BALB/c 3T3 cells.
Whooping Cough
Distinct roles for Galphai2, Galphai3, and Gbeta gamma in modulation offorskolin- or Gs-mediated cAMP accumulation and calcium mobilization by dopamine D2S receptors.
Whooping Cough
Distinct roles of Ca2+ mobilization and G protein usage on regulation of Toll-like receptor function in human and murine mast cells.
Whooping Cough
Distinct roles of receptor phosphorylation, G protein usage, and mitogen-activated protein kinase activation on platelet activating factor-induced leukotriene C(4) generation and chemokine production.
Whooping Cough
Distinct sequence elements control the specificity of G protein activation by muscarinic acetylcholine receptor subtypes.
Whooping Cough
Distinct signalling pathways of murine histamine H1- and H4-receptors expressed at comparable levels in HEK293 cells.
Whooping Cough
Distinct tyrosine kinase activation and Triton X-100 insolubility upon Fc gamma RII or Fc gamma RIIIB ligation in human polymorphonuclear leukocytes. Implications for immune complex activation of the respiratory burst.
Whooping Cough
Distinctive G Protein-Dependent Signaling by Protease-Activated Receptor 2 (PAR2) in Smooth Muscle: Feedback Inhibition of RhoA by cAMP-Independent PKA.
Whooping Cough
Distinctive G protein-dependent signaling in smooth muscle by sphingosine 1-phosphate receptors S1P1 and S1P2.
Whooping Cough
Distribution and pharmacological characterization of muscarinic-cholinergic receptors in the cockroach brain.
Whooping Cough
Distribution and role of heterotrimeric G proteins in the secretory pathway of polarized epithelial cells.
Whooping Cough
Distribution of pertussis antibodies among different age groups in Japan.
Whooping Cough
Distribution of the alpha-subunit of the guanine nucleotide-binding protein Gi2 and its comparison to G alpha o.
Whooping Cough
Disulfanyl peptide decreases melanin synthesis via receptor-mediated ERK activation and the subsequent downregulation of MITF and tyrosinase.
Whooping Cough
Diuretic and renal protective effects of 8-(noradamantan-3-yl)-1,3-dipropylxanthine (KW-3902), a novel adenosine A1-receptor antagonist, via pertussis toxin insensitive mechanism.
Whooping Cough
Diuretic response to adenosine A(1) receptor blockade in normotensive and spontaneously hypertensive rats: role of pertussis toxin-sensitive G-proteins.
Whooping Cough
Divalent cations suppress 3',5'-adenosine monophosphate accumulation by stimulating a pertussis toxin-sensitive guanine nucleotide-binding protein in cultured bovine parathyroid cells.
Whooping Cough
Divergent regulation of beta 2-adrenoceptors and adenylate cyclase in the Cyc- mouse T lymphoma cell line TL2-9.
Whooping Cough
Divergent stimulatory and inhibitory actions of carbamoylcholine on gastric D-cells.
Whooping Cough
Diverging signal transduction pathways activated by interleukin-8 and related chemokines in human neutrophils: interleukin-8, but not NAP-2 or GRO alpha, stimulates phospholipase D activity.
Whooping Cough
Diverse chemotactic responses of Dictyostelium discoideum amoebae in the developing (temporal) and stationary (spatial) concentration gradients of folic acid, cAMP, Ca(2+) and Mg(2+).
Whooping Cough
Diverse functions of muscarinic acetylcholine receptor subtypes.
Whooping Cough
Diverse prostaglandin receptors activate distinct signal transduction pathways in rat myometrium.
Whooping Cough
Diverse signal transduction pathways mediated by endogenous P2 receptors in cultured rat cerebral cortical neurons.
Whooping Cough
Diversified serum IgG response involving non-myelin CNS proteins during experimental autoimmune encephalomyelitis.
Whooping Cough
DNA binding of the Bordetella pertussis H1 homolog alters in vitro DNA flexibility.
Whooping Cough
DNA microarray analysis reveals a role for lysophosphatidic acid in the regulation of anti-inflammatory genes in MC3T3-E1 cells.
Whooping Cough
DNA synthesis and neuronal apoptosis caused by familial Alzheimer disease mutants of the amyloid precursor protein are mediated by the p21 activated kinase PAK3.
Whooping Cough
DNA topology affects transcriptional regulation of the pertussis toxin gene of Bordetella pertussis in Escherichia coli and in vitro.
Whooping Cough
DNA vaccine encoding pertussis toxin S1 subunit induces protection against Bordetella pertussis in mice.
Whooping Cough
Do beta 2-adrenergic receptors modulate Ca2+ in adult rat ventricular myocytes?
Whooping Cough
Do early childhood immunizations influence the development of atopy and do they cause allergic reactions?
Whooping Cough
DOCA-enhanced sites of vasopressin-stimulated cAMP formation in rat cortical collecting tubule.
Whooping Cough
Does Bordetella pertussis vaccine offer any cross-protection against Bordetella bronchiseptica? Implications for pet owners with cystic fibrosis.
Whooping Cough
Does Breastfeeding Protect Young Infants From Pertussis? Case-control Study and Immunologic Evaluation.
Whooping Cough
Does cyclic guanosine monophosphate mediate noradrenaline-induced inhibition of islet insulin secretion stimulated by glucose and palmitate?
Whooping Cough
Does interleukin 2 stimulus-response coupling result in generation of intracellular second messengers?
Whooping Cough
Does the guanine nucleotide regulatory protein Ni mediate progesterone inhibition of Xenopus oocyte adenylate cyclase?
Whooping Cough
Does whole-cell pertussis vaccine protect black South African infants? Assessment of post-vaccination events and antibody responses to pertussis toxin, filamentous haemagglutinin and agglutinogens 2 and 3.
Whooping Cough
Domain-dependent action of urokinase on smooth muscle cell responses.
Whooping Cough
Dominance of G(s) in doubly G(s)/G(i)-coupled chimaeric A(1)/A(2A) adenosine receptors in HEK-293 cells.
Whooping Cough
Dominant role of betagamma subunits of G-proteins in oxytocin-evoked burst firing.
Whooping Cough
Dopamine (D2) or gamma-aminobutyric acid (GABAB) receptor activation hyperpolarizes rat melanotrophs and pertussis toxin blocks these responses and the accompanying fall in [Ca2+]i.
Whooping Cough
Dopamine actions on calcium currents, potassium currents and hormone release in rat melanotrophs.
Whooping Cough
Dopamine activates inward rectifier K+ channel in acutely dissociated rat substantia nigra neurones.
Whooping Cough
Dopamine agonist inhibits vascular endothelial growth factor protein production and secretion in granulosa cells.
Whooping Cough
Dopamine agonist-mediated inhibition of acetylcholine release in rat striatum is modified by thyroid hormone status.
Whooping Cough
Dopamine D(2) receptor activation causes mitogenesis via p44/42 mitogen-activated protein kinase in opossum kidney cells.
Whooping Cough
Dopamine D(2) receptor-induced COX-2-mediated production of prostaglandin E(2) in D(2)-transfected Chinese hamster ovary cells without simultaneous administration of a Ca(2+)-mobilizing agent.
Whooping Cough
Dopamine D1 and D2 receptor Co-activation generates a novel phospholipase C-mediated calcium signal.
Whooping Cough
Dopamine D2 receptor regulation of the dopamine transporter expressed in Xenopus laevis oocytes is voltage-independent.
Whooping Cough
Dopamine D2 receptor stimulation of Na+/H+ exchange assessed by quantification of extracellular acidification.
Whooping Cough
Dopamine D2 receptors modulate pyramidal neurons in mouse medial prefrontal cortex through a stimulatory G protein pathway.
Whooping Cough
Dopamine D2, receptor-mediated modulation of the GABAergic inhibition of substantia nigra pars reticulata neurons.
Whooping Cough
Dopamine D2-like receptor signaling suppresses human osteoclastogenesis.
Whooping Cough
Dopamine D2-like receptor-mediated opening of K+ channels in opossum kidney cells.
Whooping Cough
Dopamine D2L receptor couples to G alpha i2 and G alpha i3 but not G alpha i1, leading to the inhibition of adenylate cyclase in transfected cell lines.
Whooping Cough
Dopamine D2L receptors stimulate Na+/K(+)-ATPase activity in murine LTK- cells.
Whooping Cough
Dopamine D3 receptor-mediated inhibition of Na+/H+ exchanger activity in normotensive and spontaneously hypertensive rat proximal tubular epithelial cells.
Whooping Cough
Dopamine D4 receptors regulate intracellular calcium concentration in cultured chicken cone photoreceptor cells: relationship to dopamine receptor-mediated inhibition of cAMP formation.
Whooping Cough
Dopamine inhibition of NaKATPase activity in proximal convoluted tubule cells.
Whooping Cough
Dopamine inhibition of proopiomelanocortin gene expression in the intermediate lobe of the pituitary. Interactions with corticotropin-releasing factor and the beta-adrenergic receptors and the adenylate cyclase system.
Whooping Cough
Dopamine inhibition: enhancement of GABA activity and potassium channel activation in hypothalamic and arcuate nucleus neurons.
Whooping Cough
Dopamine inhibits a sustained calcium current through activation of alpha adrenergic receptors and a GTP-binding protein in adult rat sympathetic neurons.
Whooping Cough
Dopamine Inhibits Basal Prolactin Release in Pituitary Lactotrophs through Pertussis Toxin-Sensitive and -Insensitive Signaling Pathways.
Whooping Cough
Dopamine inhibits cytosolic Ca2+ increases in rat lactotroph cells. Evidence of a dual mechanism of action.
Whooping Cough
Dopamine inhibits inositol phosphate production, arachidonic acid formation, and corticosteroid release by frog adrenal gland through a pertussis toxin-sensitive G-protein.
Whooping Cough
Dopamine inhibits prolactin secretion stimulated by the calcium channel agonist Bay-K-8644 through a pertussis toxin-sensitive G protein in anterior pituitary cells.
Whooping Cough
Dopamine inhibits two characterized voltage-dependent calcium currents in identified rat lactotroph cells.
Whooping Cough
Dopamine neuron membrane physiology: characterization of the transient outward current (IA) and demonstration of a common signal transduction pathway for IA and IK.
Whooping Cough
Dopamine presynaptically depresses fast inhibitory synaptic transmission via D4 receptor-protein kinase A pathway in the rat dorsolateral septal nucleus.
Whooping Cough
Dopamine regulates cell cycle regulatory proteins via cAMP, Ca(2+)/PKC, MAPKs, and NF-kappaB in mouse embryonic stem cells.
Whooping Cough
Dopamine regulates phosphate uptake by opossum kidney cells through multiple counter-regulatory receptors.
Whooping Cough
Dopamine regulates the electrical activity of frog melanotrophs through a G protein-mediated mechanism.
Whooping Cough
Dopamine selectively induces migration and homing of naive CD8+ T cells via dopamine receptor D3.
Whooping Cough
Dopamine stimulates 45Ca2+ uptake through cAMP, PLC/PKC, and MAPKs in renal proximal tubule cells.
Whooping Cough
Dopamine-D2S receptor inhibition of calcium influx, adenylyl cyclase, and mitogen-activated protein kinase in pituitary cells: distinct Galpha and Gbetagamma requirements.
Whooping Cough
Dopamine-induced inhibition of endogenous acetylcholine release from the isolated ileal synaptosomal preparations of guinea-pig mediated via alpha-adrenoceptors.
Whooping Cough
Dopamine-induced synaptic depression in the parabrachial nucleus is independent of CTX- and PTX-sensitive G-proteins, PKA and PLC signalling pathways.
Whooping Cough
Dopaminergic inhibition of catecholamine secretion from chromaffin cells: evidence that inhibition is mediated by D4 and D5 dopamine receptors.
Whooping Cough
Dopaminergic inhibition of DNA synthesis in pituitary tumor cells is associated with phosphotyrosine phosphatase activity.
Whooping Cough
Dopaminergic receptors linked to adenylate cyclase in human cerebromicrovascular endothelium.
Whooping Cough
Dopaminergic regulation of dopamine release from PC12 cells via a pertussis toxin-sensitive G protein.
Whooping Cough
Dopaminergic transmission between identified neurons from the mollusk, Lymnaea stagnalis.
Whooping Cough
Dose-dependent activation of antiapoptotic and proapoptotic pathways by ethanol treatment in human vascular endothelial cells: differential involvement of adenosine.
Whooping Cough
Dose-dependent activation of Ca2+-activated K+ channels by ethanol contributes to improved endothelial cell functions.
Whooping Cough
Dose-related opposite modulation by nociceptin/orphanin FQ of substance P nociception in the nociceptors and spinal cord.
Whooping Cough
Down-modulation of programmed death 1 alters regulatory T cells and promotes experimental autoimmune encephalomyelitis.
Whooping Cough
Down-regulation of Gi sub-types by prolonged incubation of adipocytes with an A1 adenosine receptor agonist.
Whooping Cough
Down-regulation of mu-opioid receptor by full but not partial agonists is independent of G protein coupling.
Whooping Cough
DsbA and DsbC are required for secretion of pertussis toxin by Bordetella pertussis.
Whooping Cough
DTaP vaccines from north american vaccine (NAVA): composition and critical parameters.
Whooping Cough
Dual coupling of cloned human 5-hydroxytryptamine1D alpha and 5-hydroxytryptamine1D beta receptors stably expressed in murine fibroblasts: inhibition of adenylate cyclase and elevation of intracellular calcium concentrations via pertussis toxin-sensitive G protein(s).
Whooping Cough
Dual coupling of heterologously-expressed rat P2Y6 nucleotide receptors to N-type Ca2+ and M-type K+ currents in rat sympathetic neurones.
Whooping Cough
Dual coupling of the cloned 5-HT1A receptor to both adenylyl cyclase and phospholipase C is mediated via the same Gi protein.
Whooping Cough
Dual effect of thrombin on voltage-dependent Ca2+ channels of portal vein smooth muscle cells.
Whooping Cough
Dual effects of anandamide on NMDA receptor-mediated responses and neurotransmission.
Whooping Cough
Dual effects of angiotensin II on calcium currents in neonatal rat nodose neurons.
Whooping Cough
Dual effects of calcitonin and calcitonin gene-related peptide on intracellular cyclic 3',5'-monophosphate in a human breast cancer cell line.
Whooping Cough
Dual effects of DAMGO [D-Ala2,N-Me-Phe4,Gly5-ol]-enkephalin and CTAP (D-Phe-Cys-Tyr-D-Trp-Arg-Thr-Pen-Thr-NH2) on adenylyl cyclase activity: implications for mu-opioid receptor Gs coupling.
Whooping Cough
Dual effects of endothelins -1, -2 and -3 on guinea pig field-stimulated ileum: possible mediation by two receptors coupled to pertussis toxin-insensitive mechanisms.
Whooping Cough
Dual effects of hexanol and halothane on the regulation of calcium sensitivity in airway smooth muscle.
Whooping Cough
Dual effects of mastoparan on intracellular free Ca2+ concentrations in human astrocytoma cells.
Whooping Cough
Dual effects of muscarinic M(2) acetylcholine receptors on the synthesis of cyclic AMP in CHO cells: dependence on time, receptor density and receptor agonists.
Whooping Cough
Dual effects of pertussis toxin on in vitro invasive behavior of metastatic lymphoma variants.
Whooping Cough
Dual effects of pertussis toxin on lymphoid cells in culture.
Whooping Cough
Dual effects of pertussis toxin on murine neutrophils in vivo. I. Pertussis toxin inhibits extravasation potential of mature neutrophils while simultaneously stimulating granulopoiesis.
Whooping Cough
Dual mechanisms for lysophospholipid induction of proliferation of human breast carcinoma cells.
Whooping Cough
Dual mechanisms involved in development of diverse biological activities of islet-activating protein, pertussis toxin, as revealed by chemical modification of lysine residues in the toxin molecule.
Whooping Cough
Dual mechanisms involved in the development of diverse biological activities of islet-activating protein, (pertussis toxin) as revealed by chemical modification of the toxin molecule.
Whooping Cough
Dual modulation by adenosine of ATP-activated channels through GTP-binding proteins in rat pheochromocytoma PC12 cells.
Whooping Cough
Dual modulation by adenosine of gastrin release from canine G-cells in primary culture.
Whooping Cough
Dual modulation of an inwardly rectifying potassium conductance.
Whooping Cough
Dual modulation of calcium channel current via recombinant alpha2-adrenoceptors in pheochromocytoma (PC-12) cells.
Whooping Cough
Dual modulation of cell survival and cell death by beta(2)-adrenergic signaling in adult mouse cardiac myocytes.
Whooping Cough
Dual opioid modulation of the action potential duration of mouse dorsal root ganglion neurons in culture.
Whooping Cough
Dual pathways for GTP-dependent regulation of chemoattractant-activated K+ conductance in murine J774 monocytes.
Whooping Cough
Dual pathways of receptor-mediated cyclic GMP generation in NG108-15 cells as differentiated by susceptibility to islet-activating protein, pertussis toxin.
Whooping Cough
Dual pertussis toxin-sensitive pathway of zymosan-induced activation in guinea pig macrophages. An anti-CR3 antibody-inhibitable stimulation of phagocytosis and -resistant stimulation of O2- production and arachidonate release.
Whooping Cough
Dual regulation by mu, delta and kappa opioid receptor agonists of K+ conductance of DRG neurons and neuroblastoma X DRG neuron hybrid F11 cells.
Whooping Cough
Dual regulation of cyclic AMP formation by thrombin in HEL cells, a leukaemic cell line with megakaryocytic properties.
Whooping Cough
Dual regulation of human syncytial adenylyl cyclase.
Whooping Cough
Dual regulation of neutrophil adenylate cyclase by fluoride and its relationship to cellular activation.
Whooping Cough
Dual regulation of PLA2 and PGI2 production by G proteins in bovine aortic endothelial cells.
Whooping Cough
Dual regulation of PTH-stimulated adenylate cyclase activity by GTP.
Whooping Cough
Dual role of GTP-binding proteins in the control of endothelial prostacyclin.
Whooping Cough
Dual signal transduction through delta opioid receptors in a transfected human T-cell line.
Whooping Cough
Dual signaling and effector pathways mediate human eosinophil activation by platelet-activating factor.
Whooping Cough
Dual signaling of human Mel1a melatonin receptors via G(i2), G(i3), and G(q/11) proteins.
Whooping Cough
Dual Transmembrane Signalling Mechanisms in Eosinophils: Evidence for Two Functionally Distinct Receptors for Platelet-Activating Factor.
Whooping Cough
Duality in the mastoparan action on glucose transport in rat adipocytes.
Whooping Cough
Duality of G protein-coupled mechanisms for beta-adrenergic activation of NKCC activity in skeletal muscle.
Whooping Cough
Duration of protection against Bordetella pertussis infection elicited by whole-cell and acellular vaccine priming in Polish children and adolescents.
Whooping Cough
Dynamic Mass Redistribution as a Means to Measure and Differentiate Signaling via Opioid and Cannabinoid Receptors.
Whooping Cough
Dynamic regulation of glycinergic input to spinal dorsal horn neurones by muscarinic receptor subtypes in rats.
Whooping Cough
Dynamics of fast synaptic excitation during trains of stimulation in myenteric neurons of guinea-pig ileum.
Whooping Cough
Dynamics of pertussis toxin IgG after symptomatic pertussis in children and adults.
Whooping Cough
Dynamics of the diradylglycerol responses of stimulated phagocytes.
Whooping Cough
Dynorphin A and cAMP-dependent protein kinase independently regulate neuronal calcium currents.
Whooping Cough
Dynorphins directly inhibit neuronal nicotinic acetylcholine receptors in PC12 cells.
Whooping Cough
Dysfunction of the beta- and alpha-adrenergic systems in a model of congestive heart failure. The pacing-overdrive dog.
Whooping Cough
Early alterations of Gi/Go protein-dependent transductional processes in the retina of diabetic animals.
Whooping Cough
Early IFN-? production together with decreased expression of TLR3 and TLR9 characterizes EAE development conditional on the presence of myelin.
Whooping Cough
Early PDGF-induced alterations in cytosolic free calcium are required for mitogenesis.
Whooping Cough
Early reversible induction of leukotriene synthesis in chicken myelomonocytic cells transformed by a temperature-sensitive mutant of avian leukemia virus E26.
Whooping Cough
Early signal transduction by the receptor to the chemokine monocyte chemotactic protein-1 in a murine T cell hybrid.
Whooping Cough
Ebselen, a redox regulator containing a selenium atom, induces neurofilament M expression in cultured rat pheochromocytoma PC12 cells via activation of mitogen-activated protein kinase.
Whooping Cough
Eclosion hormone-stimulated cGMP levels in the central nervous system of Manduca sexta: inhibition by lipid metabolism blockers, increase in inositol(1,4,5)trisphosphate and further evidence against the involvement of nitric oxide.
Whooping Cough
Edg-6 as a putative sphingosine 1-phosphate receptor coupling to Ca(2+) signaling pathway.
Whooping Cough
EDG1 is a functional sphingosine-1-phosphate receptor that is linked via a Gi/o to multiple signaling pathways, including phospholipase C activation, Ca2+ mobilization, Ras-mitogen-activated protein kinase activation, and adenylate cyclase inhibition.
Whooping Cough
EDG3 is a functional receptor specific for sphingosine 1-phosphate and sphingosylphosphorylcholine with signaling characteristics distinct from EDG1 and AGR16.
Whooping Cough
Effect of 12-hydroxyeicosatetraenoic acid on cytosolic calcium in human neutrophils.
Whooping Cough
Effect of 5-hydroxytryptamine on intracellular calcium dynamics in cultured rat vascular smooth muscle cells.
Whooping Cough
Effect of acellular pertussis vaccine on the development of allergic sensitization to environmental allergens in adults.
Whooping Cough
Effect of adenosine deaminase, N6-phenylisopropyladenosine and hypothyroidism on the responsiveness of rat brown adipocytes to noradrenaline.
Whooping Cough
Effect of adenosine on the ouabain-insensitive Na+-ATPase activity from basolateral membrane of the proximal tubule.
Whooping Cough
Effect of adenylate cyclase stimulation on meiotic resumption and cyclic AMP content of zona-free and cumulus-enclosed bovine oocytes in vitro.
Whooping Cough
Effect of age on vascular beta2-adrenergic receptor desensitization is not mediated by the receptor coupling to Galphai proteins.
Whooping Cough
Effect of alpha-adrenoceptor subtype-selective inverse agonists on non-pregnant and late-pregnant cervical resistance in vitro in the rat.
Whooping Cough
Effect of alpha2-adrenoceptor stimulation on isolated canine Purkinje fiber contraction.
Whooping Cough
Effect of angiotensin converting enzyme (ACE) and angiotensins on human sperm functions.
Whooping Cough
Effect of angiotensin II and III on inositol polyphosphate production in differentiated NG108-15 hybrid cells.
Whooping Cough
Effect of Aspergillus terreus mycotoxins on nitric oxide synthase activity in human erythroid K-562 cells.
Whooping Cough
Effect of atrial natriuretic peptide on reactive oxygen species-induced by hydrogen peroxide in THP-1 monocytes: role in cell growth, migration and cytokine release.
Whooping Cough
Effect of atriopeptin II on Ca influx, contractile behavior and cyclic nucleotide content of cultured neonatal rat myocardial cells.
Whooping Cough
Effect of bacterial toxins on human B cell activation. I. Mitogenic activity of pertussis toxin.
Whooping Cough
Effect of bacterial toxins on spermine-induced inhibition of adenylate cyclase activity of cultured heart cells.
Whooping Cough
Effect of BIBP3226 on inositol phosphate accumulation and cytosolic calcium level in control and NPY Y1 receptor expressing CHO-K1 cells.
Whooping Cough
Effect of Bordetella pertussis toxin on ADP-ribosylation of membrane proteins, adenylate cyclase activity and insulin release in rat pancreatic islets.
Whooping Cough
Effect of calcitonin gene-related peptide on skeletal muscle via specific binding site and G protein.
Whooping Cough
Effect of carbachol in the absence and presence of phenylephrine on Rb+ efflux and tension in rabbit left atria.
Whooping Cough
Effect of cholera toxin and pertussis toxin on opioid tolerance and dependence in the guinea-pig myenteric plexus.
Whooping Cough
Effect of cholera toxin and pertussis toxin on prostaglandin H synthase-2, prostaglandin E2, and matrix metalloproteinase production by human monocytes.
Whooping Cough
Effect of cholera toxin and pertussis toxin on the growth of A431 cells: kinetics of cyclic AMP and inositol trisphosphate in toxin-treated cells.
Whooping Cough
Effect of cholera toxin on histamine release from bone marrow-derived mouse mast cells.
Whooping Cough
Effect of chronic D-Ala,2 D-Leu5-enkephalin or pertussis toxin treatment on the high-affinity state of delta opioid receptor in neuroblastoma x glioma NG108-15 hybrid cells.
Whooping Cough
Effect of combination with an acellular pertussis, diphtheria, tetanus vaccine on antibody response to Hib vaccine (PRP-T).
Whooping Cough
Effect of D-glucose feeding on mortality induced by sepsis.
Whooping Cough
Effect of delta-opioid antagonists on the functional coupling between opioid receptors and G-proteins in rat brain membranes.
Whooping Cough
Effect of different detoxification procedures on the residual pertussis toxin activities in vaccines.
Whooping Cough
Effect of dihydroergocryptine and dihydroergocristine on cyclic AMP accumulation and prolactin release in vitro: evidence for a dopaminomimetic action.
Whooping Cough
Effect of elastin peptides and N-formyl-methionyl-leucyl phenylalanine on cytosolic free calcium in polymorphonuclear leukocytes of healthy middle-aged and elderly subjects.
Whooping Cough
Effect of endothelin-1 on phospholipase D activity in osteoblast-like cells.
Whooping Cough
Effect of erythromycin treatment on antibody responses in pertussis.
Whooping Cough
Effect of fluoride, pertussis and cholera toxin on the release of arachidonic acid and the formation of prostaglandin E2, D2, superoxide and inositol phosphates in rat liver macrophages.
Whooping Cough
Effect of G protein heterotrimer composition on coupling of neurotransmitter receptors to N-type Ca(2+) channel modulation in sympathetic neurons.
Whooping Cough
Effect of GABA Receptor Agonists or Antagonists Injected Spinally on the Blood Glucose Level in Mice.
Whooping Cough
Effect of gender, race, and parental education on immunogenicity and reported reactogenicity of acellular and whole-cell pertussis vaccines.
Whooping Cough
Effect of GHRH and peptides from the vasoactive intestinal peptide family on cAMP production of human cancer cell lines in vitro.
Whooping Cough
Effect of Gi protein ADP-ribosylation induced by pertussis toxin on dopamine-mediated behaviors.
Whooping Cough
Effect of granulocyte-macrophage colony-stimulating factor on superoxide production in cytoplasts and intact human neutrophils: role of protein kinase and G-proteins.
Whooping Cough
Effect of heat inactivation of serum on Bordetella pertussis antibody determination by enzyme-linked immunosorbent assay.
Whooping Cough
Effect of heat shock, [Ca2+]i, and cAMP on inositol trisphosphate in human epidermoid A-431 cells.
Whooping Cough
Effect of heptakis (2,6-0-dimethyl)beta-cyclodextrin on cell growth and the production of pertussis toxin and filamentous hemagglutinin in Bordetella pertussis.
Whooping Cough
Effect of heptakis (2,6-O-dimethyl) beta-cyclodextrin on the production of pertussis toxin by Bordetella pertussis.
Whooping Cough
Effect of HLA genotype or CTLA-4 polymorphism on cytokine response in healthy children.
Whooping Cough
Effect of hydrogen peroxide on VIP-induced relaxation of the cat lower esophageal sphincter.
Whooping Cough
Effect of hydromechanical forces on the production of filamentous haemagglutinin and pertussis toxin of Bordetella pertussis.
Whooping Cough
Effect of hyperreactivity to endotoxin on the toxicity of pertussis vaccine and pertussis toxin in mice.
Whooping Cough
Effect of ICV pertussis toxin and N-ethylmaleimide on the levels of substance P and serotonin in brain and spinal cord of the rat.
Whooping Cough
Effect of IL-1 beta on responses of cultured human airway smooth muscle cells to bronchodilator agonists.
Whooping Cough
Effect of in vivo injection of cholera and pertussis toxin on glucose transport in rat skeletal muscle.
Whooping Cough
Effect of inactivated poliovirus vaccine on the antibody response to Bordetella pertussis antigens when combined with diphtheria-pertussis-tetanus vaccine.
Whooping Cough
Effect of inhibitors of distinct signalling pathways on neutrophil Q2- generation in response to tumor necrosis factor-alpha, and antibodies against CD18 and CD11a: evidence for a common and unique pattern of sensitivity to wortmannin and protein tyrosine kinase inhibitors.
Whooping Cough
Effect of insulin and angiotensin II on cell calcium in human skin fibroblasts.
Whooping Cough
Effect of intrathecal injection of pertussis toxin on substance P, norepinephrine and serotonin contents in various neural structures of arthritic rats.
Whooping Cough
Effect of islet-activating pertussis toxin on the binding characteristics of Ca2+-mobilizing hormones and on agonist activation of phosphorylase in hepatocytes.
Whooping Cough
Effect of light on phosphatidate phosphohydrolase activity of retina rod outer segments: the role of transducin.
Whooping Cough
Effect of Linker Length and Composition on Heterobivalent Ligand-Mediated Receptor Cross-Talk between the A1 Adenosine and ?2 Adrenergic Receptors.
Whooping Cough
Effect of local massage on vaccination: DTP and DTPa.
Whooping Cough
Effect of low-density lipoproteins, mevinolin, and G proteins on Ca2+ response in cultured chick atrial cells.
Whooping Cough
Effect of lysophosphatidic acid on motility, polarisation and metabolic burst of human neutrophils.
Whooping Cough
Effect of lysophosphatidic acid on the ovum transport in mouse oviducts.
Whooping Cough
Effect of lysophosphatidic acid on the preimplantation development of mouse embryos.
Whooping Cough
Effect of lysophosphatidylglycerol on several signaling molecules in OVCAR-3 human ovarian cancer cells: involvement of pertussis toxin-sensitive G-protein coupled receptor.
Whooping Cough
Effect of monoclonal antibody to pertussis toxin on toxin activity.
Whooping Cough
Effect of mutations causing overexpression of RNA polymerase alpha subunit on regulation of virulence factors in Bordetella pertussis.
Whooping Cough
Effect of N6-(L-2-phenylisopropyl)adenosine and insulin on cAMP metabolism in 3T3-L1 adipocytes.
Whooping Cough
Effect of neurotransmitters on axoplasmic transport: acetylcholine effect on superior cervical ganglion cells.
Whooping Cough
Effect of NMDA receptor ligands on mast cell histamine release, a reappraisal.
Whooping Cough
Effect of nonhydrolyzable guanosine phosphate on IgE-mediated activation of phospholipase C and histamine release from rodent mast cells.
Whooping Cough
EFFECT OF PEPTIDOGLYCANE OF STAPHYLOCOCCUS AUREUS CELL WALL ON THE MECHANISM OF REGULATION OF CONTRACTILE ACTIVITY OF RAT MYOMETRIUM BY ADENYLATE CYCLASE SYSTEM.
Whooping Cough
Effect of pertussis and cholera toxins administered supraspinally on CA3 hippocampal neuronal cell death and the blood glucose level induced by kainic acid in mice.
Whooping Cough
Effect of pertussis pretreatment on plasma glucose and insulin responses to lithium in rats.
Whooping Cough
Effect of pertussis toxin and B-oligomer on platelet-activating factor-induced generation of inositol phosphates in porcine alveolar macrophages.
Whooping Cough
Effect of pertussis toxin and herbimycin A on proteinase-activated receptor 2-mediated cyclooxygenase 2 expression in Helicobacter pylori-infected gastric epithelial AGS cells.
Whooping Cough
Effect of pertussis toxin and N-ethylmaleimide on voltage-dependent and -independent calcium current modulation in serotonergic neurons.
Whooping Cough
Effect of pertussis toxin and neomycin on G-protein-regulated polyphosphoinositide phosphodiesterase. A comparison between HL60 membranes and permeabilized HL60 cells.
Whooping Cough
Effect of pertussis toxin and PGE2 on the functioning of the IL-2 promoter in interleukin-1 treated EL4.NOB-1 thymoma cells.
Whooping Cough
Effect of pertussis toxin and the cGMP lowering agent LY83583 on the relaxation induced by nitrates in isolated bovine mesenteric artery. A comparison between glyceryl trinitrate, isosorbide dinitrate and isosorbide 5-mononitrate.
Whooping Cough
Effect of pertussis toxin injected into the ventral tegmental area on amphetamine-induced Fos protein in the nucleus accumbens.
Whooping Cough
Effect of pertussis toxin on A1-receptor-mediated inhibition of insulin secretion.
Whooping Cough
Effect of pertussis toxin on alpha 2-adrenoceptors: decreased formation of the high-affinity state for agonists.
Whooping Cough
Effect of pertussis toxin on baclofen- and diphenhydramine-induced amnesia.
Whooping Cough
Effect of pertussis toxin on calcium influx in three contraction models.
Whooping Cough
Effect of pertussis toxin on hormonal responsiveness of rat hepatocytes.
Whooping Cough
Effect of pertussis toxin on insulin-induced signal transduction in rat adipocytes and soleus muscles.
Whooping Cough
Effect of pertussis toxin on islet insulin secretion in obese (fa/fa) Zucker rats.
Whooping Cough
Effect of pertussis toxin on morphine, diphenhydramine, baclofen, clomipramine and physostigmine antinociception.
Whooping Cough
Effect of pertussis toxin on normorphine-dependence and on acute inhibitory effects of normorphine and clonidine in guinea-pig isolated ileum.
Whooping Cough
Effect of pertussis toxin on parathyroid hormone-stimulated cyclic AMP production in cultured kidney cells.
Whooping Cough
Effect of pertussis toxin on radioligand binding to rat brain adenosine A1 receptors.
Whooping Cough
Effect of pertussis toxin on susceptibility of infant rats to Haemophilus influenzae type b.
Whooping Cough
Effect of pertussis toxin on the adrenergic regulation of plasma renin activity.
Whooping Cough
Effect of pertussis toxin on the heart acetylcholine muscarinic receptor affinity.
Whooping Cough
Effect of pertussis toxin on the heart muscarinic-cholinergic receptors and their function.
Whooping Cough
Effect of pertussis toxin on the hormonal regulation of cyclic AMP levels in hamster fat cells.
Whooping Cough
Effect of pertussis toxin on the induction of nitric oxide synthesis in murine macrophages and on protection in vivo.
Whooping Cough
Effect of pertussis toxin on the inhibition of secretory activity by prostaglandin E2, somatostatin, epidermal growth factor and 12-O-tetradecanoylphorbol 13-acetate in parietal cells from rat stomach.
Whooping Cough
Effect of pertussis toxin on the interaction of azepexole and halothane.
Whooping Cough
Effect of pertussis toxin on the phosphodiesteratic cleavage of the polyphosphoinositides by guanosine 5'-O-thiotriphosphate and thrombin in permeabilized human platelets.
Whooping Cough
Effect of pertussis toxin on the response of rat medial prefrontal cortex cells to the iontophoresis of serotonin receptor agonists.
Whooping Cough
Effect of pertussis toxin on water metabolism in the rat.
Whooping Cough
Effect of pertussis toxin pretreated centrally on blood glucose level induced by stress.
Whooping Cough
Effect of pertussis toxin treatment on postjunctional alpha-1 and alpha-2 adrenoceptor function in the cardiovascular system of the pithed rat.
Whooping Cough
Effect of pertussis toxin treatment on the down-regulation of opiate receptors in neuroblastoma X glioma NG108-15 hybrid cells.
Whooping Cough
Effect of pertussis toxin treatment on the putative adenosine A3 receptor-mediated hypotensive response in the rat.
Whooping Cough
Effect of phenylephrine and prazosin on the somatostatinergic system in the rat frontoparietal cortex.
Whooping Cough
Effect of phorbol ester and pertussis toxin on the enhancement of noradrenaline release by angiotensin II in mouse atria.
Whooping Cough
Effect of platelet-activating factor (PAF) on cytosolic free calcium in human peripheral blood mononuclear leukocytes.
Whooping Cough
Effect of prednisolone on the toxicity of Bordetella pertussis for mice.
Whooping Cough
Effect of prenylcysteine analogues on chemoattractant receptor-mediated G protein activation.
Whooping Cough
Effect of Prepregnancy Pertussis Vaccination in Young Infants.
Whooping Cough
Effect of pretreatment with pertussis toxin on the development of physical dependence on morphine.
Whooping Cough
Effect of priming with diphtheria and tetanus toxoids combined with whole-cell pertussis vaccine or with acellular pertussis vaccine on the safety and immunogenicity of a booster dose of an acellular pertussis vaccine containing a genetically inactivated pertussis toxin in fifteen- to twenty-one-month-old children. Italian Multicenter Group for the Study of Recombinant Acellular Pertussis Vaccine.
Whooping Cough
Effect of prostaglandin E2 on phospholipase D activity in osteoblast-like MC3T3-E1 cells.
Whooping Cough
Effect of prostaglandin F2 alpha on Ca2+ influx in osteoblast-like cells: function of tyrosine kinase.
Whooping Cough
Effect of prostaglandin F2 alpha on human parathyroid adenomas: evidence for uncoupling of parathyroid hormone secretion and cAMP accumulation.
Whooping Cough
Effect of prostaglandins on glycogenesis and glycogenolysis in primary cultures of rat hepatocytes--a role of prostaglandin D2 in the liver.
Whooping Cough
Effect of protein kinase C inhibitor (H-7) and calmodulin antagonist (W-7) on pertussis toxin-induced IL-1 production by human adherent monocytes. Comparison with lipopolysaccharide as a stimulator of IL-1 production.
Whooping Cough
Effect of proteolytic enzymes, storage and reduction on the structure and biological activity of pertussigen, a toxin from Bordetella pertussis.
Whooping Cough
Effect of PT-treatment on ANP-mediated inhibition of adenylate cyclase and amylase release in rat parotid gland.
Whooping Cough
Effect of ranakinin, a novel tachykinin, on cytosolic free calcium in frog adrenochromaffin cells.
Whooping Cough
Effect of ras-gene transformation on the inhibition of NIH3T3 cell growth by pertussis toxin.
Whooping Cough
Effect of relevant culture parameters on Pertussis Toxin expression by Bordetella pertussis.
Whooping Cough
Effect of resolvins on sensitisation of TRPV1 and visceral hypersensitivity in IBS.
Whooping Cough
Effect of retinoic acid on prostaglandin F2 alpha-induced prostaglandin E2 synthesis in osteoblast-like cells.
Whooping Cough
Effect of schedule on reactogenicity and antibody persistence of acellular and whole-cell pertussis vaccines: value of laboratory tests as predictors of clinical performance.
Whooping Cough
Effect of site-directed mutagenic alterations on ADP-ribosyltransferase activity of the A subunit of Escherichia coli heat-labile enterotoxin.
Whooping Cough
Effect of sodium fluoride on the generation of lipoxygenase products from human polymorphonuclear granulocytes, mononuclear cells and platelets--indication for the involvement of G proteins.
Whooping Cough
Effect of somatostatin on adenylate cyclase activity in normal and neoplastic thyroid tissue.
Whooping Cough
Effect of somatostatin on contractile and relaxant responses of tracheal smooth muscle in rabbits.
Whooping Cough
Effect of sphingosine derivatives on calcium fluxes in thyroid FRTL-5 cells.
Whooping Cough
Effect of Sphingosine-1-Phosphate on Intracellular Free Ca2+ in Cat Esophageal Smooth Muscle Cells.
Whooping Cough
Effect of substance P and neurokinin A on rat parietal cell function.
Whooping Cough
Effect of sulpiride on somatostatin receptors, somatostatin-like immunoreactivity and modulation of adenylyl cyclase activity in the rat brain.
Whooping Cough
Effect of temperature and host factors on the activities of pertussis toxin and Bordetella adenylate cyclase.
Whooping Cough
Effect of the genetic background and specific mutation on adenylate cyclase activity in obesity syndromes.
Whooping Cough
Effect of thrombin on calcium homeostasis in chick embryonic heart cells. Receptor-operated calcium entry with inositol trisphosphate and a pertussis toxin-sensitive G protein as second messengers.
Whooping Cough
Effect of thyroid hormones on G proteins in synaptosomes of chick embryo.
Whooping Cough
Effect of transforming growth factor-alpha and parathyroid hormone-related protein on phosphate transport in renal cells.
Whooping Cough
Effect of trifluoperazine on renal epithelioid Madin-Darby canine kidney cells.
Whooping Cough
Effect of tumor necrosis factor and granulocyte/macrophage colony-stimulating factor on neutrophil degranulation.
Whooping Cough
Effect of tumor necrosis factor on GTP binding and GTPase activity in HL-60 and L929 cells.
Whooping Cough
Effect of tumor necrosis factor-alpha on the reciprocal G-protein-induced regulation of norepinephrine release by the alpha2-adrenergic receptor.
Whooping Cough
Effect of tumor necrosis factor-alpha on the stimulus-coupled responses of neutrophils and their modulation by various inhibitors.
Whooping Cough
Effect of vaccination on Bordetella pertussis strains, China.
Whooping Cough
Effector coupling mechanisms of the cloned 5-HT1A receptor.
Whooping Cough
Effector coupling of somatostatin receptor subtypes on human endocrine tumors.
Whooping Cough
Effector coupling of stably transfected human A3 adenosine receptors in CHO cells.
Whooping Cough
Effector function for RAS oncogene in interleukin-3-dependent myeloid cells involves diminished efficacy of prostaglandin E1-mediated inhibition of proliferation.
Whooping Cough
Effects and mechanisms of melatonin on immune responses in mice of different months.
Whooping Cough
Effects and mechanisms of melatonin on inflammatory and immune responses of adjuvant arthritis rat.
Whooping Cough
Effects of (+)-pentazocine and 1,3-di-o-tolylguanidine (DTG), sigma (sigma) ligands, on micturition in anaesthetized rats.
Whooping Cough
Effects of 5-oxo-6,8,11,14-eicosatetraenoic acid on expression of CD11b, actin polymerization, and adherence in human neutrophils.
Whooping Cough
Effects of 8-iso-prostaglandin E2 and 8-iso-prostaglandin F2 alpha on the release of noradrenaline from the isolated rat stomach.
Whooping Cough
Effects of acidic and basic fibroblast growth factors on osteoblastic cells.
Whooping Cough
Effects of adenosine A1-agonist and -antagonist on urinary volume and Na excretion in IAP-treated and non-treated rats.
Whooping Cough
Effects of adenosine analog PIA (n-phenylisopropyladenosine) on FSH-stimulated cyclic AMP (cAMP) production in the rat seminiferous epithelium.
Whooping Cough
Effects of adenosine and pertussis toxin on lipolysis in adipocytes from exercise-trained male rats.
Whooping Cough
Effects of adenosine on cAMP production and cytosolic Ca2+ in cultured rabbit medullary thick limb cells.
Whooping Cough
Effects of adenosine receptor and muscarinic cholinergic receptor agonists on cardiac protein phosphorylation. Influence of pertussis toxin.
Whooping Cough
Effects of adenylate cyclase toxin from Bordetella pertussis on human neutrophil interactions with Coccidioides immitis and Staphylococcus aureus.
Whooping Cough
Effects of ADP-ribosylation of GTP-binding protein by pertussis toxin on immunoglobulin E-dependent and -independent histamine release from mast cells and basophils.
Whooping Cough
Effects of age on muscarinic agonist-induced contraction and IP accumulation in airway smooth muscle.
Whooping Cough
Effects of alpha 2-adrenergic agonism, imidazolines, and G-protein on insulin secretion in beta cells.
Whooping Cough
Effects of alpha 2-adrenergic agonist preincubation on subsequent forskolin-stimulated adenylate cyclase activity and [3H]forskolin binding in membranes from HT29 cells.
Whooping Cough
Effects of angiotensin II and angiotensin III on airway epithelial short-circuit current: involvement of pertussis toxin-sensitive G protein.
Whooping Cough
Effects of angiotensin II and nonpeptide receptor antagonists on transduction pathways in rat proximal tubule.
Whooping Cough
Effects of angiotensin II on the action potential durations of atrial myocytes in hypertensive rats.
Whooping Cough
Effects of ATP on phosphoinositide hydrolysis and prostaglandin E2 generation in rabbit astrocytes.
Whooping Cough
Effects of beta-casomorphins on neuronal survival in culture of embryonic chick dorsal root ganglion neurons.
Whooping Cough
Effects of beta-endorphin on mu and delta opioid receptor-coupled G-protein activity: low-Km GTPase studies.
Whooping Cough
Effects of beta-phenylethylamine on dopaminergic neurons of the ventral tegmental area in the rat: a combined electrophysiological and microdialysis study.
Whooping Cough
Effects of betahistine at histamine H3 receptors: mixed inverse agonism/agonism in vitro and partial inverse agonism in vivo.
Whooping Cough
Effects of blockade of endogenous Gi signaling in Tie2-expressing cells on bone formation in a mouse model of heterotopic ossification.
Whooping Cough
Effects of Bordetella pertussis toxin on catecholamine inhibition of insulin release from intact and electrically permeabilized rat islets.
Whooping Cough
Effects of Bordetella pertussis toxin pretreatment on the antiarrhythmic action of ischaemic preconditioning in anaesthetized rats.
Whooping Cough
Effects of Bu Shen Yi sui capsule on NogoA/NgR and its signaling pathways RhoA/ROCK in mice with experimental autoimmune encephalomyelitis.
Whooping Cough
Effects of calcium channel antagonists and pertussis toxin on noradrenaline-induced contractions in pulmonary artery from pulmonary hypertensive rats.
Whooping Cough
Effects of calcium on light-activated GTP-binding proteins in squid photoreceptor membranes.
Whooping Cough
Effects of calcium-antagonists on dopamine release in the central nervous system--possible interactions with D2-autoreceptors and guanosine triphosphate-binding proteins.
Whooping Cough
Effects of cannabidiol on the function of ?7-nicotinic acetylcholine receptors.
Whooping Cough
Effects of cannabinoids on caffeine contractures in slow and fast skeletal muscle fibers of the frog.
Whooping Cough
Effects of cannabinoids on synaptic transmission in the frog neuromuscular junction.
Whooping Cough
Effects of cannabinoids on tension induced by acetylcholine and choline in slow skeletal muscle fibers of the frog.
Whooping Cough
Effects of CB(1) cannabinoid receptor activation on cerebellar granule cell nitric oxide synthase activity.
Whooping Cough
Effects of cholera and pertussis toxins on prolactin stimulation of lactose synthesis and ornithine decarboxylase activity in mouse mammary gland explants.
Whooping Cough
Effects of chronic morphine exposure on opioid inhibition of adenylyl cyclase in 7315c cell membranes: a useful model for the study of tolerance at mu opioid receptors.
Whooping Cough
Effects of chronic receptor blockade on excitation-contraction coupling in rat aortic rings.
Whooping Cough
Effects of clenbuterol on contractility and Ca2+ homeostasis of isolated rat ventricular myocytes.
Whooping Cough
Effects of continuous exposure to stromal cell-derived factor-1 alpha on T cell rolling and tight adhesion to monolayers of activated endothelial cells.
Whooping Cough
Effects of cyclic AMP-affecting agents on contractile reactivity of isolated mesenteric and renal resistance arteries of the rat.
Whooping Cough
Effects of cyclosporine A on cyclic AMP generation and GTP-binding proteins in isolated islets.
Whooping Cough
Effects of dexamethasone and indomethacin on the vascular beta 2-adrenolytic action of pertussis toxin in rats; a prostaglandin-mediated phenomenon.
Whooping Cough
Effects of diethyldithiocarbamate on activating mechanisms of neutrophils.
Whooping Cough
Effects of drugs acting on adrenergic and adenosine receptors on the intraocular pressure and the activity of adenylyl cyclase in ciliary processes and their sensitivity to pertussis toxin.
Whooping Cough
Effects of ECL cell extracts and granule/vesicle-enriched fractions from rat oxyntic mucosa on cAMP and IP(3) in rat osteoblast-like cells.
Whooping Cough
Effects of endogenous cannabinoid anandamide on cardiac Na(+)/Ca(2+) exchanger.
Whooping Cough
Effects of endogenous cannabinoid anandamide on excitation-contraction coupling in rat ventricular myocytes.
Whooping Cough
Effects of endothelin on mitogen-activated protein kinase activity and protein synthesis in isolated adult feline cardiac myocytes.
Whooping Cough
Effects of endothelin on rat renal proximal tubule Na(+)-Pi cotransport and Na+/H+ exchange.
Whooping Cough
Effects of endothelin-1 on Ca2+ signaling in guinea-pig ventricular myocytes: role of protein kinase C.
Whooping Cough
Effects of eosinophils on mast cells: a new pathway for the perpetuation of allergic inflammation.
Whooping Cough
Effects of epidermal growth factor on signal transduction in rabbit parietal cells.
Whooping Cough
Effects of estrogenic xenobiotics on human and mouse spermatozoa.
Whooping Cough
Effects of ethanol in vitro on the beta adrenergic receptor-coupled adenylate cyclase system.
Whooping Cough
Effects of ethanol on mitogen-activated protein kinase and stress-activated protein kinase cascades in normal and regenerating liver.
Whooping Cough
Effects of exercise on myocardial adenylate cyclase and Gi alpha expression in senescence.
Whooping Cough
Effects of extracellular nucleotides in the pituitary: adenosine triphosphate receptor-mediated intracellular responses in gonadotrope-derived alpha T3-1 cells.
Whooping Cough
Effects of fluoride and cholera and pertussis toxins on sensory transduction in the carotid body.
Whooping Cough
Effects of follicle stimulating hormone, cholera toxin, pertussis toxin and forskolin on adenosine cyclic 3',5'-monophosphate output by granulosa cells from Booroola ewes with or without the F gene.
Whooping Cough
Effects of G protein and cGMP on phytochrome-mediated amaranthin synthesis inAmaranthus caudatus seedlings.
Whooping Cough
Effects of galanin on amylase secretion from dispersed rat pancreatic acini.
Whooping Cough
Effects of genistein, tyrphostin, and pertussis toxin on EGF-induced mitogenesis in primary culture and clonal osteoblastic cells.
Whooping Cough
Effects of ginsenoside on G protein-coupled inwardly rectifying K(+) channel activity expressed in Xenopus oocytes.
Whooping Cough
Effects of glucagon like peptide-1(7-36) amide on the cytoplasmic Ca(2+)-concentration in rat islet cells.
Whooping Cough
Effects of GTP gamma S on muscarinic receptor-stimulated inositol phospholipid hydrolysis in permeabilized smooth muscle from the small intestine.
Whooping Cough
Effects of GTP, forskolin, sodium fluoride, serotonin, dopamine, and carbachol on adenylate cyclase in Teleost retina.
Whooping Cough
Effects of guanyl nucleotides and rhodopsin on ADP-ribosylation of the inhibitory GTP-binding component of adenylate cyclase by pertussis toxin.
Whooping Cough
Effects of histamine on polyphosphoinositide metabolism in NG108-15 cells.
Whooping Cough
Effects of histamine on the metabolism of isolated rat hepatocytes: roles of H1- and H2-histamine receptors.
Whooping Cough
Effects of homo- and heterodimeric isoforms of PDGF on signalling events in rat renal mesangial cells.
Whooping Cough
Effects of human fibroblasts on invasiveness of oral cancer cells in vitro: isolation of a chemotactic factor from human fibroblasts.
Whooping Cough
Effects of human low-density lipoproteins on superoxide production by formyl-methionyl-leucyl-phenylalanine activated polymorphonuclear leukocytes.
Whooping Cough
Effects of hypothyroidism on brown adipose tissue adenylyl cyclase activity.
Whooping Cough
Effects of insulin on inositol phosphate production in cultured rat hepatocytes.
Whooping Cough
Effects of insulin, adenosine, and prostaglandin on alpha-adrenergic-stimulated respiration in brown adipocytes.
Whooping Cough
Effects of insulin, pertussis toxin and cholera toxin on protein synthesis and diacylglycerol production in 3T3 fibroblasts: evidence for a G-protein mediated activation of phospholipase C in the insulin signal mechanism.
Whooping Cough
Effects of insulin-like growth factor I and II on DNA synthesis and proliferation in primary cultures of adult rat hepatocytes.
Whooping Cough
Effects of interleukin-1 on calcium signaling and the increase of filamentous actin in isolated and in situ articular chondrocytes.
Whooping Cough
Effects of intrapancreatic neuronal activation on cholecystokinin-induced exocrine secretion of isolated perfused rat pancreas.
Whooping Cough
Effects of intrathecal or intracerebroventricular pretreatment with pertussis toxin on antinociception induced by beta-endorphin or morphine administered intracerebroventricularly in mice.
Whooping Cough
Effects of islet-activating protein on insulin- and isoprenaline-stimulated glucose transport in isolated rat adipocytes.
Whooping Cough
Effects of isoflurane on voltage-dependent calcium fluxes in rabbit T-tubule membranes: comparison with alcohols.
Whooping Cough
Effects of kappa- and mu-opioid receptor agonists on Ca2+ channels in neuroblastoma cells: involvement of the orphan opioid receptor.
Whooping Cough
Effects of lidocaine on sarcolemmal fluidity and cellular cAMP in rat cardiomyocytes.
Whooping Cough
Effects of lithium ion on ADP ribosylation of inhibitory GTP-binding protein by pertussis toxin, islet-activating protein.
Whooping Cough
Effects of lithium on receptor-mediated activation of G proteins in rat brain cortical membranes.
Whooping Cough
Effects of litter removal on the lipolytic response and the regulatory components of the adenylate cyclase in adipocytes isolated from lactating rats.
Whooping Cough
Effects of locally applied D1 and D2 agonists on striatal neurons with 6-OHDA and pertussis toxin lesions.
Whooping Cough
Effects of low density lipoproteins and mevinolin on cholesterol content and muscarinic cholinergic responsiveness in cultured chick atrial cells. Regulation of levels of muscarinic receptors and guanine nucleotide regulatory proteins.
Whooping Cough
Effects of low-sodium diet on regulation of platelet alpha 2-adrenergic receptors in young and elderly humans.
Whooping Cough
Effects of lysophosphatidic acid on proliferation of stellate cells and hepatocytes in culture.
Whooping Cough
Effects of mastoparan and related peptides on phosphoinositide breakdown in HL-60 cells and cell-free preparations.
Whooping Cough
Effects of mutations on enzyme activity and immunoreactivity of the S1 subunit of pertussis toxin.
Whooping Cough
Effects of neuropeptide Y on cell length and membrane currents in isolated guinea pig ventricular myocytes.
Whooping Cough
Effects of neuropeptide Y on forskolin, alpha 2- and beta-adrenoceptor-regulated cAMP levels in the rat brain slice.
Whooping Cough
Effects of nicotine on the immune response. II. Chronic nicotine treatment induces T cell anergy.
Whooping Cough
Effects of nifedipine, BAY K 8644, and pertussis toxin on pressor response to sarafotoxin-b in pithed rats.
Whooping Cough
Effects of nitric oxide on adenylyl cyclase stimulation in N18TG2 neuroblastoma cells.
Whooping Cough
Effects of oestradiol and tamoxifen on oxytocin-induced phospholipase C activation in human myometrial cells.
Whooping Cough
Effects of orexin (hypocretin) on GIRK channels.
Whooping Cough
Effects of organometals on cellular signaling. I. Influence of metabolic inhibitors on metal-induced arachidonic acid liberation.
Whooping Cough
Effects of parathyroid hormone on cytosolic calcium of rat adipocytes.
Whooping Cough
Effects of parathyroid hormone-related protein on human mesangial cells in culture.
Whooping Cough
Effects of Pasteurella haemolytica A1 culture supernatant on mechanisms controlling bovine alveolar macrophage oxygen radical production.
Whooping Cough
Effects of pertussis and cholera toxin on the interferon-gamma stimulated immunocytochemical staining of ICAM-1 and inositol phosphate formation in a human renal carcinoma cell line.
Whooping Cough
Effects of pertussis and cholera toxins on alpha-adrenoceptor function in rat tail artery: differences in hypertension.
Whooping Cough
Effects of pertussis toxin (PT) on T-cell populations sensitized for delayed-type hypersensitivity in mice.
Whooping Cough
Effects of pertussis toxin and galpha-protein-specific antibodies on phosphoinositide hydrolysis in rat brain membranes after cholinergic denervation and hippocampal sympathetic ingrowth.
Whooping Cough
Effects of pertussis toxin and indomethacin on murine lymphocytes in the bronchoalveolar lavage fluids.
Whooping Cough
Effects of pertussis toxin and its binding subunit on IL-1 signalling in T cells.
Whooping Cough
Effects of pertussis toxin on adenylate cyclase responses to prostaglandin E2 and calcitonin in human breast cancer cells.
Whooping Cough
Effects of pertussis toxin on alpha 1-agonist-mediated phosphatidylinositide turnover and myocardial cell hypertrophy in neonatal rat ventricular myocytes.
Whooping Cough
Effects of pertussis toxin on behavioral responses during different withdrawal periods from chronic cocaine treatment.
Whooping Cough
Effects of pertussis toxin on behavioural responses of guinea-pigs to centrally administered substance P, quinpirole, carbachol, U-50,488H, morphine and morphine withdrawal.
Whooping Cough
Effects of pertussis toxin on cAMP and cGMP responses to carbamylcholine in N1E-115 neuroblastoma cells.
Whooping Cough
Effects of pertussis toxin on caudate neuron electrophysiology: studies with dopamine D1 and D2 agonists.
Whooping Cough
Effects of pertussis toxin on D2-dopamine receptor in rat striatum: evidence for coupling of Ni regulatory protein with D2-receptor.
Whooping Cough
Effects of pertussis toxin on delayed-type hypersensitivity responses and on the activity of suppressor T cells on the responses.
Whooping Cough
Effects of pertussis toxin on electroacupuncture-produced anti-hyperalgesia in inflamed rats.
Whooping Cough
Effects of pertussis toxin on extracellular signal-regulated kinase activation in hepatocytes by hormones and receptor-independent agents: evidence suggesting a stimulatory role of G(i) proteins at a level distal to receptor coupling.
Whooping Cough
Effects of pertussis toxin on growth factor-stimulated inositol phosphate formation and DNA synthesis in Swiss 3T3 cells.
Whooping Cough
Effects of pertussis toxin on inhibition of synaptosomal tyrosine hydroxylase activity by apomorphine.
Whooping Cough
Effects of pertussis toxin on intraocular pressure and adenylate cyclase activity of ciliary processes in rabbits.
Whooping Cough
Effects of pertussis toxin on opioid regulation of catecholamine release from rat and guinea pig brain slices.
Whooping Cough
Effects of pertussis toxin on resorption of 19-day-old fetal rat long bones.
Whooping Cough
Effects of pertussis toxin on signal transductions via P2-purinergic receptors in A-431 human epidermoidal carcinoma cells.
Whooping Cough
Effects of pertussis toxin on the affinity of exocytosis for Ca2+ in bovine adrenal chromaffin cells.
Whooping Cough
Effects of pertussis toxin on the alpha 2-adrenoceptor-inhibitory GTP-binding protein-adenylate cyclase system in rat brain: pharmacological and neurochemical studies.
Whooping Cough
Effects of pertussis toxin on the behavioural and ECoG spectrum changes induced by clonidine and yohimbine after their microinfusion into the locus coeruleus.
Whooping Cough
Effects of pertussis toxin on the erythropoietin-stimulated proliferation and differentiation of erythroid-responsive cells.
Whooping Cough
Effects of pertussis toxin on vasodilation and cyclic GMP in bovine mesenteric arteries and demonstration of a 40 kD soluble protein ribosylation substrate for pertussis toxin.
Whooping Cough
Effects of Pertussis Toxin Suggest a Role for G-Proteins in the Inhibition of Acetylcholine Release from Rat Myenteric Plexus by Opioid and Presynaptic Muscarinic Receptors.
Whooping Cough
Effects of pertussis toxin treatment of rats on estradiol-induced adenohypophyseal growth reaction and on adrenergic lipolysis.
Whooping Cough
Effects of pertussis toxin treatment on human natural killer cell function.
Whooping Cough
Effects of pertussis toxin treatment on metabolism in hamster brown adipocytes.
Whooping Cough
Effects of pertussis toxin treatment on the metabolism of rat adipocytes.
Whooping Cough
Effects of pertussis toxin, dibutyryl-cyclic-AMP, bromo-cyclic-AMP and forskolin on the behavioural and electrocortical power spectrum changes induced by microinfusion of interleukin-2 into the locus coeruleus.
Whooping Cough
Effects of phorbol esters and pertussis toxin on agonist-stimulated cyclic AMP production in rat osteosarcoma cells.
Whooping Cough
Effects of phorbol esters and pertussis toxin on calcitonin-stimulated accumulation of cyclic AMP in neonatal mouse calvarial bones.
Whooping Cough
Effects of phosducin on the GTPase cycle of Go.
Whooping Cough
Effects of phosphorylation of inhibitory GTP-binding protein by cyclic AMP-dependent protein kinase on its ADP-ribosylation by pertussis toxin, islet-activating protein.
Whooping Cough
Effects of phosphotyrosine phosphatase inhibition on insulin secretion and intracellular signaling events in rat pancreatic islets.
Whooping Cough
Effects of prostaglandin E2 on amiloride-blockable Na+ channels in a distal nephron cell line (A6).
Whooping Cough
Effects of prostaglandins on gastrin release from canine antral mucosal cells in primary culture.
Whooping Cough
Effects of protein kinase C activation on cyclic AMP and testosterone production of rat Leydig cells in vitro.
Whooping Cough
Effects of protein kinase C and A activation on ATP-stimulated release of [3H]noradrenaline from PC12 cells.
Whooping Cough
Effects of purine and pyrimidine nucleotides on intracellular Ca2+ in human eosinophils: activation of purinergic P2Y receptors.
Whooping Cough
Effects of quinapril, losartan and hydralazine on cardiac hypertrophy and beta-adrenergic neuroeffector mechanisms in transgenic (mREN2)27 rats.
Whooping Cough
Effects of ras-encoded proteins and platelet-derived growth factor on inositol phospholipid turnover in NRK cells.
Whooping Cough
Effects of recombinant human interleukin-1 beta on accumulation of inflammatory peritoneal macrophages in mice treated with pertussis toxin.
Whooping Cough
Effects of respiratory burst inhibitors on nitric oxide production by human neutrophils.
Whooping Cough
Effects of Ro 5-4864 and PK 11195 in rat duodenum and vas deferens.
Whooping Cough
Effects of S-nitroso-cysteine on proteins that regulate exocytosis in PC12 cells: inhibitory effects on translocation of synaptophysin and ADP-ribosylation of GTP-binding proteins.
Whooping Cough
Effects of serotonin on caudal raphe neurons: activation of an inwardly rectifying potassium conductance.
Whooping Cough
Effects of serotonin on caudal raphe neurons: inhibition of N- and P/Q-type calcium channels and the afterhyperpolarization.
Whooping Cough
Effects of sodium and GTP on the binding kinetics of [3H]diprenorphine in NG 108-15 cell membranes.
Whooping Cough
Effects of sodium on agonist efficacy for G-protein activation in mu-opioid receptor-transfected CHO cells and rat thalamus.
Whooping Cough
Effects of somatostatin on cultured human mesangial cells.
Whooping Cough
Effects of sphingosine-1-phosphate and ceramide-1-phosphate on rat intestinal smooth muscle cells: implications for postoperative ileus.
Whooping Cough
Effects of sphingosine-1-phosphate and lysophosphatidic acid on human osteoblastic cells.
Whooping Cough
Effects of spinally and supraspinally injected 3-isobutyl-1-methylxanthine, cholera toxin, and pertussis toxin on cold water swimming stress-induced antinociception in the mouse.
Whooping Cough
Effects of spinally and supraspinally injected 3-isobutyl-1-methylxanthine, cholera toxin, and pertussis toxin on immobilization stress-induced antinociception in the mouse.
Whooping Cough
Effects of sulfhydryl-modifying reagents, 3-nitro-2-pyridinesulfenyl compounds, on the coupling between inhibitory receptors and GTP-binding proteins Gi/Go in rat brain membranes.
Whooping Cough
Effects of synthesized elastin peptides on human leukocytes.
Whooping Cough
Effects of systemically applied allopurinol and prednisolone on experimental autoimmune uveitis.
Whooping Cough
Effects of T-588, a novel cognitive enhancer, on ADP-ribosylation of G(s alpha) by cholera toxin and cyclic AMP accumulation in rat cerebral cortex.
Whooping Cough
Effects of TGF-beta1 on prolactin synthesis and secretion: an in-vitro study.
Whooping Cough
Effects of the amphiphilic peptides mastoparan and adenoregulin on receptor binding, G proteins, phosphoinositide breakdown, cyclic AMP generation, and calcium influx.
Whooping Cough
Effects of the amphiphilic peptides melittin and mastoparan on calcium influx, phosphoinositide breakdown and arachidonic acid release in rat pheochromocytoma PC12 cells.
Whooping Cough
Effects of the nootropic drug nefiracetam on the GABAA receptor-channel complex in dorsal root ganglion neurons.
Whooping Cough
Effects of thrombin, phorbol myristate acetate and prostaglandin D2 on 40-41 kDa protein that is ADP ribosylated by pertussis toxin in platelets.
Whooping Cough
Effects of tiazofurin on guanine nucleotide binding regulatory proteins in HL-60 cells.
Whooping Cough
Effects of transient oxygen-glucose deprivation on G-proteins and G-protein-coupled receptors in rat CA3 pyramidal cells in vitro.
Whooping Cough
Effects of triiodothyronine administration on the adenylyl cyclase system in brown adipose tissue of rat.
Whooping Cough
Effects of tyrosine kinase inhibitors on cell death induced by sodium fluoride and pertussis toxin in the pancreatic beta-cell line, RINm5F.
Whooping Cough
Effects of UTP on Na+, Cl- and K+ transport in primary cultures from human sweat gland coils.
Whooping Cough
Effects of zinc on production of active oxygen species by rat neutrophils.
Whooping Cough
Effects of [(pF)Phe(4)]nociceptin/orphanin FQ-(1-13)NH(2) on GTPgamma(35)S binding and cAMP formation in Chinese hamster ovary cells expressing the human nociceptin/orphanin FQ receptor.
Whooping Cough
Efficacy and safety of immunization with phosphorylated tau against neurofibrillary tangles in mice.
Whooping Cough
Efficacy of chemically cross-linked antigens for acellular pertussis vaccine.
Whooping Cough
Efficacy of pertussis components in an acellular vaccine, as assessed in a murine model of respiratory infection and a murine intracerebral challenge model.
Whooping Cough
Efficacy of pertussis vaccines consisted of antigens detoxified with tea-leaf catechins.
Whooping Cough
Efficient neutrophil extracellular trap induction requires mobilization of both intracellular and extracellular calcium pools and is modulated by cyclosporine A.
Whooping Cough
Efficient production of active and mutated ADP-ribosyltransferase (S1) of pertussis toxin using affinity expression cassette polymerase chain reaction.
Whooping Cough
EGF inhibits secretagogue-induced cAMP production and amylase secretion by Gi proteins in pancreatic acini.
Whooping Cough
EGF modulates phosphoinositide levels in ovarian granulosa cells stimulated by luteinizing hormone.
Whooping Cough
Egg Envelope Glycoproteins ZP1 and ZP3 Mediate Sperm-Egg Interaction in the Japanese Quail.
Whooping Cough
Eicosanoid production by human aortic endothelial cells in response to endothelin.
Whooping Cough
Eicosapentaenoic acid suppresses cell proliferation in MCF-7 human breast cancer xenografts in nude rats via a pertussis toxin-sensitive signal transduction pathway.
Whooping Cough
Elastin peptides activate extracellular signal-regulated kinase 1/2 via a Ras-independent mechanism requiring both p110gamma/Raf-1 and protein kinase A/B-Raf signaling in human skin fibroblasts.
Whooping Cough
Electrically evoked release of [(3)H]noradrenaline from mouse cultured sympathetic neurons: release-modulating heteroreceptors.
Whooping Cough
Electrophysiologic responses and adenylate cyclase activities of mouse spinal cord-dorsal root ganglion explants rendered tolerant by chronic exposure to morphine or pertussis toxin.
Whooping Cough
Electrophysiological effects of alpha 2-adrenergic stimulation in canine cardiac Purkinje fibers.
Whooping Cough
Electrophysiological evidence for postsynaptic 5-HT(1A) receptor control of dorsal raphe 5-HT neurones.
Whooping Cough
Elevated axonal membrane permeability and its correlation with motor deficits in an animal model of multiple sclerosis.
Whooping Cough
Elevated Ca(2+) influx-inducing activity toward mast cells in pretransfusion sera from patients who developed transfusion-related adverse reactions.
Whooping Cough
Elevated levels of the guanine nucleotide binding protein, Go, are associated with differentiation of neuroblastoma x glioma hybrid cells.
Whooping Cough
Elevation of intracellular cyclic AMP concentration fails to inhibit adrenaline-induced hyperpolarization in amphibian sympathetic neurons.
Whooping Cough
Elucidation of linear epitopes of pertussis toxin using overlapping synthetic decapeptides: identification of a human B-cell determinant in the S1 subunit indicative of acute infections.
Whooping Cough
Emodin accentuates atrial natriuretic peptide secretion in cardiac atria.
Whooping Cough
Emodin augments calcium activated chloride channel in colonic smooth muscle cells by Gi/Go protein.
Whooping Cough
Endocannabinoids modulate N-type calcium channels and G-protein-coupled inwardly rectifying potassium channels via CB1 cannabinoid receptors heterologously expressed in mammalian neurons.
Whooping Cough
Endocrine disrupting chemical atrazine causes degranulation through Gq/11 protein-coupled neurosteroid receptor in mast cells.
Whooping Cough
Endocytosis and retrograde transport of pertussis toxin to the Golgi complex as a prerequisite for cellular intoxication.
Whooping Cough
Endocytosis and uptake of lucifer yellow by cultured atrial myocytes and isolated intact atria from adult rats. Regulation and subcellular localization.
Whooping Cough
Endocytosis of CF in marginal cells of stria vascularis regulated by ROCK and MLCK signaling cascade, but not G-proteins.
Whooping Cough
Endocytosis of Microperoxidase in Marginal Cells Is Mainly Regulated by RhoA Signaling Cascade, but Not by Rho-Associated Protein Kinase, Myosin Light-Chain Kinase and Myosin Phosphatase.
Whooping Cough
Endogenous ACh tonically stimulates ANP secretion in rat atria.
Whooping Cough
Endogenous adenosine, A1 adenosine receptor, and pertussis toxin sensitive guanine nucleotide binding protein mediate hypoxia induced AV nodal conduction block in guinea pig heart in vivo.
Whooping Cough
Endogenous ADP-ribosylation of Gs subunit and autonomous regulation of adenylate cyclase.
Whooping Cough
Endogenous angiotensin II receptors in Xenopus oocytes and eggs.
Whooping Cough
Endogenous cannabinoid anandamide directly inhibits voltage-dependent Ca(2+) fluxes in rabbit T-tubule membranes.
Whooping Cough
Endogenous cannabinoid anandamide inhibits nicotinic acetylcholine receptor function in mouse thalamic synaptosomes.
Whooping Cough
Endogenous cannabinoid, anandamide, acts as a noncompetitive inhibitor on 5-HT3 receptor-mediated responses in Xenopus oocytes.
Whooping Cough
Endogenous delta-opioid and ORL1 receptors couple to phosphorylation and activation of p38 MAPK in NG108-15 cells and this is regulated by protein kinase A and protein kinase C.
Whooping Cough
Endogenous GABA attenuates CNS white matter dysfunction following anoxia.
Whooping Cough
Endogenous inhibitor of the ADP-ribosylation of (a) G-protein(s) as catalyzed by pertussis toxin is present in rat liver.
Whooping Cough
Endogenous modulation of ACh release by somatostatin and the differential roles of Ca2+ channels.
Whooping Cough
Endogenous opioid receptor-like receptor in human neuroblastoma SK-N-SH cells: activation of inhibitory G protein and homologous desensitization.
Whooping Cough
Endogenous peptidergic modulation of perisynaptic Schwann cells at the frog neuromuscular junction.
Whooping Cough
Endogenous platelet-activating factor is critically involved in effector functions of eosinophils stimulated with IL-5 or IgG.
Whooping Cough
Endogenous prostaglandin E2 and insulin-like growth factor 1 can modulate the levels of parathyroid hormone receptor in human osteoarthritic osteoblasts.
Whooping Cough
Endogenous regulator of g protein signaling proteins reduce {mu}-opioid receptor desensitization and down-regulation and adenylyl cyclase tolerance in C6 cells.
Whooping Cough
Endogenous regulator of G protein signaling proteins suppress Galphao-dependent, mu-opioid agonist-mediated adenylyl cyclase supersensitization.
Whooping Cough
Endogenous regulator of G-protein signaling proteins modify N-type calcium channel modulation in rat sympathetic neurons.
Whooping Cough
Endogenous regulators of G protein signaling differentially modulate full and partial mu-opioid agonists at adenylyl cyclase as predicted by a collision coupling model.
Whooping Cough
Endogenous regulators of G protein signaling proteins regulate presynaptic inhibition at rat hippocampal synapses.
Whooping Cough
Endogenous RGS proteins and Galpha subtypes differentially control muscarinic and adenosine-mediated chronotropic effects.
Whooping Cough
Endogenous RGS proteins attenuate Galpha(i)-mediated lysophosphatidic acid signaling pathways in ovarian cancer cells.
Whooping Cough
Endogenous somatostatin inhibits histamine release from canine gastric mucosal cells in primary culture.
Whooping Cough
Endogenous somatostatin receptors mobilize calcium from inositol 1,4,5-trisphosphate-sensitive stores in NG108-15 cells.
Whooping Cough
Endogenous trypsin receptors in Xenopus oocytes: linkage to internal calcium stores.
Whooping Cough
Endomorphin-1 potentiates HIV-1 expression in human brain cell cultures: implication of an atypical mu-opioid receptor.
Whooping Cough
Endomorphins inhibit high-threshold Ca2+ channel currents in rodent NG108-15 cells overexpressing mu-opioid receptors.
Whooping Cough
Endomorphins potentiate acid-sensing ion channel currents and enhance the lactic acid-mediated increase in arterial blood pressure: effects amplified in hindlimb ischaemia.
Whooping Cough
Endorphin suppresses FSH-stimulated proliferation of isolated neonatal Sertoli cells by a pertussis toxin-sensitive mechanism.
Whooping Cough
Endostatin, the proteolytic fragment of collagen XVIII, induces vasorelaxation.
Whooping Cough
Endothelial atypical cannabinoid receptor: do we have enough evidence?
Whooping Cough
Endothelial beta2 adrenergic signaling to AKT: role of Gi and SRC.
Whooping Cough
Endothelial CD47 Promotes Vascular Endothelial-Cadherin Tyrosine Phosphorylation and Participates in T Cell Recruitment at Sites of Inflammation In Vivo.
Whooping Cough
Endothelial cell-surface gp60 activates vesicle formation and trafficking via G(i)-coupled Src kinase signaling pathway.
Whooping Cough
Endothelial cells stimulate T cell NFAT nuclear translocation in the presence of cyclosporin A: involvement of the wnt/glycogen synthase kinase-3 beta pathway.
Whooping Cough
Endothelial differentiation gene receptors in pancreatic islets and INS-1 cells.
Whooping Cough
Endothelial differentiation gene-1, a new downstream gene is involved in RTEF-1 induced angiogenesis in endothelial cells.
Whooping Cough
Endothelial inositol phosphate generation and prostacyclin production in response to G-protein activation by AlF4-.
Whooping Cough
Endothelial NADPH oxidase: mechanism of activation by low-density lipoprotein.
Whooping Cough
Endothelial P2-purinoceptors: subtypes and signal transduction.
Whooping Cough
Endothelin (ET)-1-induced inhibition of ATP release from PC-12 cells is mediated by the ETB receptor: differential response to ET-1 on ATP, neuropeptide Y, and dopamine levels.
Whooping Cough
Endothelin 1 stimulates beta1Pix-dependent activation of Cdc42 through the G(salpha) pathway.
Whooping Cough
Endothelin activates large-conductance K+ channels in rat lactotrophs: reversal by long-term exposure to dopamine agonist.
Whooping Cough
Endothelin activates voltage-dependent Ca2+ current by a G protein-dependent mechanism in rabbit cardiac myocytes.
Whooping Cough
Endothelin and increased contractility in adult rat ventricular myocytes. Role of intracellular alkalosis induced by activation of the protein kinase C-dependent Na(+)-H+ exchanger.
Whooping Cough
Endothelin B receptor mediates ET-1 effects on cAMP and PGE2 accumulation in rat IMCD.
Whooping Cough
Endothelin downregulates SERCA2 gene and protein expression in adult rat ventricular myocytes: regulation by pertussis toxin-sensitive Gi protein and cAMP.
Whooping Cough
Endothelin enhances the contractile responsiveness of adult rat ventricular myocytes to calcium by a pertussis toxin-sensitive pathway.
Whooping Cough
Endothelin ET A- and ET B-receptor-mediated inhibition of noradrenaline release from isolated rat stomach.
Whooping Cough
Endothelin ETA receptor regulates signaling and ANF gene expression via multiple G protein-linked pathways.
Whooping Cough
Endothelin ETB receptors couple to two distinct signaling pathways in porcine kidney epithelial LLC-PK1 cells.
Whooping Cough
Endothelin increases the synthesis and secretion of atrial natriuretic peptide in neonatal rat cardiocytes.
Whooping Cough
Endothelin inhibits adenylate cyclase and stimulates phosphoinositide hydrolysis in adult cardiac myocytes.
Whooping Cough
Endothelin inhibits vasopressin-stimulated water permeability in rat terminal inner medullary collecting duct.
Whooping Cough
Endothelin mobilizes Ca2+ from a caffeine- and ryanodine-insensitive intracellular pool in rat atrial cells.
Whooping Cough
Endothelin rapidly stimulates mitogen-activated protein kinase activity in rat mesangial cells.
Whooping Cough
Endothelin receptor binding and cellular signal transduction in neurohybrid NG108-15 cells.
Whooping Cough
Endothelin receptor is coupled to phospholipase C via a pertussis toxin-insensitive guanine nucleotide-binding regulatory protein in vascular smooth muscle cells.
Whooping Cough
Endothelin receptor subtype B mediates synthesis of nitric oxide by cultured bovine endothelial cells.
Whooping Cough
Endothelin receptor subtypes are coupled to adenylate cyclase via different guanyl nucleotide-binding proteins in vasculature.
Whooping Cough
Endothelin receptor type A signals both the accumulation of inositol phosphates and the inhibition of cyclic AMP generation in rat myometrium: stimulation and desensitization.
Whooping Cough
Endothelin receptors and coupled GTP-binding proteins in glomerular mesangial cells.
Whooping Cough
Endothelin receptors and their cellular signal transduction mechanism in human cultured prostatic smooth muscle cells.
Whooping Cough
Endothelin receptors in rat cerebellum: activation of phosphoinositide hydrolysis is transduced by multiple G-proteins.
Whooping Cough
Endothelin stimulates 86Rb efflux in rat glioma C6-Bu-1 cells.
Whooping Cough
Endothelin stimulates multiple responses in isolated adult ventricular cardiac myocytes.
Whooping Cough
Endothelin stimulates phospholipase D in striatal astrocytes.
Whooping Cough
Endothelin stimulates platelet-activating factor synthesis by cultured rat Kupffer cells.
Whooping Cough
Endothelin(B) receptor activates NHE-3 by a Ca2+-dependent pathway in OKP cells.
Whooping Cough
Endothelin- and ATP-induced inhibition of adenylyl cyclase activity in C6 glioma cells: role of Gi and calcium.
Whooping Cough
Endothelin- and sarafotoxin-induced phosphoinositide hydrolysis in cultured canine tracheal smooth muscle cells.
Whooping Cough
Endothelin- and sarafotoxin-induced phosphoinositide hydrolysis in cultured cerebellar granule cells: biochemical and pharmacological characterization.
Whooping Cough
Endothelin-1 activates endothelial cell nitric-oxide synthase via heterotrimeric G-protein betagamma subunit signaling to protein jinase B/Akt.
Whooping Cough
Endothelin-1 activates mitogen-activated protein kinases through two independent signalling pathways in rat astrocytes.
Whooping Cough
Endothelin-1 activates p38 mitogen-activated protein kinase and cytosolic phospholipase A2 in cat iris sphincter smooth muscle cells.
Whooping Cough
Endothelin-1 and insulin activate the steady-state voltage dependent R-type Ca2+ channel in aortic smooth muscle cells via a pertussis toxin and cholera toxin sensitive G-protein.
Whooping Cough
Endothelin-1 decreases glutamate uptake in primary cultured rat astrocytes.
Whooping Cough
Endothelin-1 increases glucose transporter glut1 mRNA accumulation in 3T3-L1 adipocytes by a mitogen-activated protein kinase-dependent pathway.
Whooping Cough
Endothelin-1 induces p66Shc activation through EGF receptor transactivation: Role of beta(1)Pix/Galpha(i3) interaction.
Whooping Cough
Endothelin-1 inhibition of cardiac ATP-sensitive K+ channels via pertussis-toxin-sensitive G-proteins.
Whooping Cough
Endothelin-1 inhibits L-type Ca currents enhanced by isoproterenol in guinea-pig ventricular myocytes.
Whooping Cough
Endothelin-1 inhibits the slow component of cardiac delayed rectifier K+ currents via a pertussis toxin-sensitive mechanism.
Whooping Cough
Endothelin-1 is synthesized and inhibits cyclic adenosine monophosphate- dependent anion secretion by an autocrine/paracrine mechanism in gallbladder epithelial cells.
Whooping Cough
Endothelin-1 modulates insulin signaling through phosphatidylinositol 3-kinase pathway in vascular smooth muscle cells.
Whooping Cough
Endothelin-1 partially inhibits ATP-sensitive K+ current in guinea pig ventricular cells.
Whooping Cough
Endothelin-1 receptor binding and cellular signal transduction in cultured human brain endothelial cells.
Whooping Cough
Endothelin-1 receptors on cultured rat articular chondrocytes: regulation by age, growth factors, and cytokines, and effect on cAMP production.
Whooping Cough
Endothelin-1 regulates proliferative responses, both alone and synergistically with PDGF, in rat tracheal smooth muscle cells.
Whooping Cough
Endothelin-1 stimulates the release of arachidonic acid and prostaglandins in cultured human ciliary muscle cells: activation of phospholipase A2.
Whooping Cough
Endothelin-1 stimulates the release of preloaded [3H]D-aspartate from cultured cerebellar granule cells.
Whooping Cough
Endothelin-1 suppression of rat adipocyte precursor cell differentiation in serum-free culture.
Whooping Cough
Endothelin-1 Upregulates Activin Receptor-Like Kinase-1 Expression via Gi/RhoA/Sp-1/Rho Kinase Pathways in Human Pulmonary Arterial Endothelial Cells.
Whooping Cough
Endothelin-2 is a macrophage chemoattractant: implications for macrophage distribution in tumors.
Whooping Cough
Endothelin-3 activates a voltage-gated Ca channel via a pertussis toxin sensitive mechanism leading to dopamine release from PC12 cells.
Whooping Cough
Endothelin-3 stimulates production of endothelium-derived nitric oxide via phosphoinositide breakdown.
Whooping Cough
Endothelin-dependent actions in cultured AT-1 cardiac myocytes. The role of the epsilon isoform of protein kinase C.
Whooping Cough
Endothelin-elicited stimulation of phospholipase C is mediated by guanine nucleotide binding protein(s).
Whooping Cough
Endothelin-evoked Release of Arachidonic Acid from Mouse Astrocytes in Primary Culture.
Whooping Cough
Endothelin-induced activation of phosphoinositide turnover, calcium mobilization, and transmitter release in cultured neurons and neurally related cell types.
Whooping Cough
Endothelin-induced cytoskeletal actin re-organization in cultured astrocytes: inhibition by C3 ADP-ribosyltransferase.
Whooping Cough
Endothelin-induced increases in vascular smooth muscle Ca2+ do not depend on dihydropyridine-sensitive Ca2+ channels.
Whooping Cough
Endothelin-induced inositol phosphate formation in rat kidney. Studies on receptor subtypes, G-proteins and regulation during ontogenesis.
Whooping Cough
Endothelin-induced protein tyrosine phosphorylation of cultured astrocytes: its relationship to cytoskeletal actin organization.
Whooping Cough
Endothelin-mediated vascular growth requires p42/p44 mitogen-activated protein kinase and p70 S6 kinase cascades via transactivation of epidermal growth factor receptor.
Whooping Cough
EndothelinB receptor activation enhances parathyroid hormone-induced calcium signals in UMR-106 cells.
Whooping Cough
Endothelins increase tyrosine phosphorylation of astrocytic focal adhesion kinase and paxillin accompanied by their association with cytoskeletal components.
Whooping Cough
Endothelins inhibit adenylate cyclase in brain capillary endothelial cells.
Whooping Cough
Endothelins stimulate cyclic AMP accumulation in the isolated rat anterior pituitary gland: possible involvement of ETA receptor activation and prostaglandin E2 production.
Whooping Cough
Endothelins stimulate tyrosine phosphorylation and activity of p42/mitogen-activated protein kinase in astrocytes.
Whooping Cough
Endothelium-dependent inhibition of ergonovine-induced contraction is impaired in porcine coronary arteries with regenerated endothelium.
Whooping Cough
Endothelium-derived hyperpolarizing factor mediated relaxations in pig coronary arteries do not involve Gi/o proteins.
Whooping Cough
Endotoxin activation of mitogen-activated protein kinase in THP-1 cells; diminished activation following endotoxin desensitization.
Whooping Cough
Endotoxin tolerance impairs a pertussis-toxin-sensitive G-protein regulating tumour necrosis factor release by macrophages from tumour-bearing rats.
Whooping Cough
Endotoxin tolerance is associated with altered GTP-binding protein function.
Whooping Cough
Endotoxin-mediated synthesis of nitric oxide is dependent on Gq protein signal transduction.
Whooping Cough
Endotoxins in cholera and pertussis toxins interfere with in vivo responses to these agents in the albino rabbit eye.
Whooping Cough
Engagement of CD47 inhibits the contact hypersensitivity response via the suppression of motility and B7 expression by Langerhans cells.
Whooping Cough
Engineering bacterial toxin for the development of new vaccine against pertussis.
Whooping Cough
Engineering of an Iranian Bordetella pertussis strain producing inactive pertussis toxin.
Whooping Cough
Engineering of genetically detoxified pertussis toxin analogs for development of a recombinant whooping cough vaccine.
Whooping Cough
Enhanced adhesive capacities of the naturally occurring Ile249-Met280 variant of the chemokine receptor CX3CR1.
Whooping Cough
Enhanced alpha 1-adrenergic responsiveness in cardiomyopathic hamster cardiac myocytes. Relation to the expression of pertussis toxin-sensitive G protein and alpha 1-adrenergic receptors.
Whooping Cough
Enhanced cAMP accumulation after termination of cholinergic action in the heart.
Whooping Cough
Enhanced cAMP response of naturally occurring mutant of human beta3-adrenergic receptor.
Whooping Cough
Enhanced cardiac L-type calcium current response to beta2-adrenergic stimulation in heart failure.
Whooping Cough
Enhanced cyclic AMP responses in GH3 pituitary cells pretreated with muscarinic receptor agonists.
Whooping Cough
Enhanced epinephrine-induced platelet aggregation in individuals carrying the G protein beta3 subunit 825T allele.
Whooping Cough
Enhanced expression of Gi? proteins contributes to the hyperproliferation of vascular smooth muscle cells from spontaneously hypertensive rats via MAP kinase- and PI3 kinase-independent pathways.
Whooping Cough
Enhanced expression of GTP-binding proteins in differentiated U937 monocytic cells: possible involvement of tyrosine kinase and protein kinase C.
Whooping Cough
Enhanced expression of inhibitory guanine nucleotide regulatory protein in spontaneously hypertensive rats. Relationship to adenylate cyclase inhibition.
Whooping Cough
Enhanced fMLP-stimulated chemotaxis in human neutrophils from individuals carrying the G protein beta3 subunit 825 T-allele.
Whooping Cough
Enhanced G protein activation in IDDM patients with diabetic nephropathy.
Whooping Cough
Enhanced G protein activation in immortalized lymphoblasts from patients with essential hypertension.
Whooping Cough
Enhanced G(i) signaling selectively negates beta2-adrenergic receptor (AR)--but not beta1-AR-mediated positive inotropic effect in myocytes from failing rat hearts.
Whooping Cough
Enhanced G-protein-induced relaxation in portal hypertensive rats: role of nitric oxide.
Whooping Cough
Enhanced GABA(B) receptor in neoplastic rat liver: induction of DNA synthesis by baclofen in hepatocyte cultures.
Whooping Cough
Enhanced Gi-protein-mediated mitogenesis following chronic ethanol exposure in a rat model of experimental hepatocellular carcinoma.
Whooping Cough
Enhanced HIV-1 replication by chemokines constitutively expressed in secondary lymphoid tissues.
Whooping Cough
Enhanced immune response against pertussis toxoid by IgA-loaded chitosan-dextran sulfate nanoparticles.
Whooping Cough
Enhanced inhibition of L-type Ca2+ current by beta3-adrenergic stimulation in failing rat heart.
Whooping Cough
Enhanced interaction between renovascular alpha(2)-adrenoceptors and angiotensin II receptors in genetic hypertension.
Whooping Cough
Enhanced IPC by activation of pertussis toxin-sensitive and -insensitive G protein-coupled purinoceptors.
Whooping Cough
Enhanced negative chronotropy by inhibitory receptors in transgenic heart overexpressing beta(2)-adrenoceptors.
Whooping Cough
Enhanced negative inotropic effect of an adenosine A1-receptor agonist in rat left atria in hypothyroidism.
Whooping Cough
Enhanced post-licensure safety surveillance of a new recombinant acellular pertussis vaccine licensed as a monovalent (aP, Pertagen®) and tetanus, reduced-dose diphtheria combination (TdaP, Boostagen®) vaccine for immunization of adolescents and adults in Thailand.
Whooping Cough
Enhanced sensitisation of mice with diphtheria tetanus acellular pertussis vaccine to local swelling reaction to the booster immunisation.
Whooping Cough
Enhanced type 1alpha metabotropic glutamate receptor-stimulated phosphoinositide signaling after pertussis toxin treatment.
Whooping Cough
Enhanced vascular reactivity to mastoparan, a G protein activator, in genetically hypertensive rats.
Whooping Cough
Enhancement by baclofen of the Gs-coupled receptor-mediated cAMP production in Xenopus oocytes expressing rat brain cortex poly (A)+ RNA: a role of G-protein beta gamma subunits.
Whooping Cough
Enhancement by sphingosine 1-phosphate in vasopressin-induced phosphoinositide hydrolysis in aortic smooth-muscle cells: involvement of p38 MAP kinase.
Whooping Cough
Enhancement in beta-adrenergic responsiveness of adenylate cyclase in rat liver during regeneration after carbon tetrachloride administration.
Whooping Cough
Enhancement of adenylate cyclase activity in S49 lymphoma cells by phorbol esters. Withdrawal of GTP-dependent inhibition.
Whooping Cough
Enhancement of adenylate cyclase stimulation by prostaglandin E receptor EP3 subtype isoforms with different efficiencies.
Whooping Cough
Enhancement of an L-type calcium current in AtT-20 cells; a novel effect of the m4 muscarinic receptor.
Whooping Cough
Enhancement of ATP-sensitive potassium current in cat ventricular myocytes by beta-adrenoreceptor stimulation.
Whooping Cough
Enhancement of bradykinin-induced prostacyclin synthesis in porcine aortic endothelial cells by pertussis toxin. Possible implication of lipocortin I.
Whooping Cough
Enhancement of cyclic AMP accumulation mediated by 5-HT after chronic amitriptyline treatment in NG 108-15 cells.
Whooping Cough
Enhancement of delayed rectifier K+ current by P2-purinoceptor stimulation in guinea-pig atrial cells.
Whooping Cough
Enhancement of differentiation of cultured adipogenic cells (TA1) by pertussis toxin.
Whooping Cough
Enhancement of differentiation of rat adipocyte precursor cells by pertussis toxin.
Whooping Cough
Enhancement of histamine-induced vascular leakage by pertussis toxin in SJL/J mice but not BALB/c mice.
Whooping Cough
Enhancement of HIV-1 replication in human macrophages is induced by CD8+ T cell soluble factors.
Whooping Cough
Enhancement of interleukin-4 production by pertussis toxin.
Whooping Cough
Enhancement of lysophosphatidic acid-induced ERK phosphorylation by phospholipase D1 via the formation of phosphatidic acid.
Whooping Cough
Enhancement of neuronal calcium channel currents by the nootropic agent, nefiracetam (DM-9384), in NG108-15 cells.
Whooping Cough
Enhancement of parathyroid hormone-responsive renal cortical adenylate cyclase activity by a cytosol protein activator from rat reticulocytes.
Whooping Cough
Enhancement of stress-induced synthesis of stress proteins by mastoparan in C6 rat glioma cells.
Whooping Cough
Enhancement of Th1 Lung Immunity Induced by Recombinant Mycobacterium bovis BCG Attenuates Airway Allergic Disease.
Whooping Cough
Enhancement of the locomotor response to apomorphine in pertussis toxin-treated animals depends on the site of pertussis toxin injection into the ventral tegmental area.
Whooping Cough
Enhancement of the migration of metastatic human breast cancer cells by phosphatidic acid.
Whooping Cough
Enhancement of the positive inotropic effect mediated by alpha 1-adrenoceptors in pertussis toxin-treated rabbit papillary muscles.
Whooping Cough
Enhancing effects of pertussis toxin B oligomer on the immunogenicity of influenza vaccine administered intranasally.
Whooping Cough
Enkephalin activates the phospholipase C/Ca2+ system through cross-talk between opioid receptors and P2-purinergic or bradykinin receptors in NG 108-15 cells. A permissive role for pertussis toxin-sensitive G-proteins.
Whooping Cough
Enkephalin induces Ca2+ mobilization in single cells of bradykinin-sensitized differentiated neuroblastoma hybridoma (NG108-15) cells.
Whooping Cough
Entamoeba invadens contains the components of a classical adrenergic signaling system.
Whooping Cough
Enteric glia exhibit P2U receptors that increase cytosolic calcium by a phospholipase C-dependent mechanism.
Whooping Cough
Entrapping of impermeant probes of different size into nonpermeabilized synaptosomes as a method to study presynaptic mechanisms.
Whooping Cough
Environmental regulation of expression of virulence determinants in Bordetella pertussis.
Whooping Cough
Enzymatic and immunological detection of G protein alpha-subunits in the pathogenic fungus Candida albicans.
Whooping Cough
Enzymatic and nonenzymatic ADP-ribosylation of cysteine.
Whooping Cough
Enzymatic digestion of the milk protein beta-casein releases potent chemotactic peptide(s) for monocytes and macrophages.
Whooping Cough
Enzyme-linked immunosorbent assay for detecting anti-pertussis toxin antibody in mouse.
Whooping Cough
Eosinophil activation by eotaxin--eotaxin primes the production of reactive oxygen species from eosinophils.
Whooping Cough
Eosinophil adoptive transfer system to directly evaluate pulmonary eosinophil trafficking in vivo.
Whooping Cough
Eosinophil leukocyte degranulation in response to serum-opsonized beads: C5a and platelet-activating factor enhance ECP release, with roles for protein kinases A and C.
Whooping Cough
Eosinophil migration induced by mast cell chymase is mediated by extracellular signal-regulated kinase pathway.
Whooping Cough
Eosinophil-derived neurotoxin (EDN), an antimicrobial protein with chemotactic activities for dendritic cells.
Whooping Cough
Eosinophils utilize multiple chemokine receptors for chemotaxis to the parasitic nematode Strongyloides stercoralis.
Whooping Cough
Eotaxin influences the development of embryonic hematopoietic progenitors in the mouse.
Whooping Cough
Eotaxin modulates myelopoiesis and mast cell development from embryonic hematopoietic progenitors.
Whooping Cough
Eotaxin-2 activates chemotaxis-related events and release of reactive oxygen species via pertussis toxin-sensitive G proteins in human eosinophils.
Whooping Cough
Eotaxin-3 is a natural antagonist for CCR2 and exerts a repulsive effect on human monocytes.
Whooping Cough
Eotaxin/CCL11 suppresses IL-8/CXCL8 secretion from human dermal microvascular endothelial cells.
Whooping Cough
EP receptor-mediated inhibition by prostaglandin E(1) of cardiac L-type Ca(2+) current of rabbits.
Whooping Cough
EP(4) prostanoid receptor coupling to a pertussis toxin-sensitive inhibitory G protein.
Whooping Cough
EP1 Prostanoid Receptor Coupling to Gi/o Upregulates the Expression of Hypoxia-Inducible Factor-1{alpha} Through Activation of a Phosphoinositide-3 Kinase Signaling Pathway.
Whooping Cough
EP2 receptor activates dual G protein signaling pathways that mediate contrasting proinflammatory and relaxatory responses in term pregnant human myometrium.
Whooping Cough
EP3 Receptor Isoforms are Differentially Expressed in Subpopulations of Primate Granulosa Cells and Couple to Unique G-Proteins.
Whooping Cough
Epidermal growth factor activates phospholipase C in rat hepatocytes via a different mechanism from that in A431 or rat1hER cells.
Whooping Cough
Epidermal growth factor activates phospholipase C-gamma 1 via G(i)1-2 proteins in isolated pancreatic acinar membranes.
Whooping Cough
Epidermal growth factor activation of rat parotid gland adenylate cyclase and mediation by a GTP-binding regulatory protein.
Whooping Cough
Epidermal growth factor and angiotensin II stimulate formation of inositol 1,4,5- and inositol 1,3,4-trisphosphate in hepatocytes. Differential inhibition by pertussis toxin and phorbol 12-myristate 13-acetate.
Whooping Cough
Epidermal growth factor and transforming growth factor alpha stimulate or inhibit proliferation of a human renal adenocarcinoma cell line depending on cell status: differentiation of the two pathways by G protein involvement.
Whooping Cough
Epidermal growth factor differentially augments G(i)-mediated stimulation of c-Jun N-terminal kinase activity.
Whooping Cough
Epidermal growth factor enhances glomerular mesangial cell soluble phospholipase A2 activity.
Whooping Cough
EPIDERMAL GROWTH FACTOR INCREASES LYSOPHOSPHATIDIC ACID PRODUCTION IN HUMAN OVARIAN CANCER CELLS: ROLES FOR PHOSPHOLIPASE D2 AND RECEPTOR TRANSACTIVATION.
Whooping Cough
Epidermal growth factor inhibits bombesin-induced activation of phospholipase C-beta1 in rat pancreatic acinar cells.
Whooping Cough
Epidermal growth factor receptor transactivation mediates substance P-induced mitogenic responses in U-373 MG cells.
Whooping Cough
Epidermal growth factor stimulates hydrolysis of phosphatidylinositol 4,5-bisphosphate, generation of diacylglycerol and exocytosis in mouse spermatozoa.
Whooping Cough
Epidermal growth factor stimulates the production of phosphatidylinositol monophosphate and the breakdown of polyphosphoinositides in A431 cells.
Whooping Cough
Epidermal growth factor-induced activation and translocation of phospholipase C-gamma 1 to the cytoskeleton in rat hepatocytes.
Whooping Cough
Epidermal growth factor-induced phosphoinositide hydrolysis in permeabilized 3T3 cells: lack of guanosine triphosphate dependence and inhibition by tyrosine-containing peptides.
Whooping Cough
Epidermal growth factor-mediated signaling of G(i)-protein to activation of phospholipases in rat-cultured hepatocytes.
Whooping Cough
Epidermal growth factor-stimulated phosphoinositide hydrolysis in cultured rat inner medullary collecting tubule cells. Regulation by G protein, calcium, and protein kinase C.
Whooping Cough
Epidermal micro-perforation potentiates the efficacy of epicutaneous vaccination.
Whooping Cough
Epidermal-growth-factor-induced formation of inositol phosphates in human A431 cells. Differences from the effect of bradykinin.
Whooping Cough
Epigenetic activation of Gi-2 protein, the product of a putative protooncogene, mediates tumor promotion in vitro.
Whooping Cough
Epileptogenesis reduces the sensitivity of presynaptic gamma-aminobutyric acidB receptors on glutamatergic afferents in the amygdala.
Whooping Cough
Epinephrine activates both Gs and Gi pathways, but norepinephrine activates only the Gs pathway through human beta2-adrenoceptors overexpressed in mouse heart.
Whooping Cough
Epinephrine impairs insulin release by a mechanism distal to calcium mobilization. Similarity to lipoxygenase inhibitors.
Whooping Cough
Epinephrine induces changes in the subcellular distribution of the inhibitory GTP-binding protein Gi alpha-2 and a 38-kDa phosphorylated protein in the human platelet.
Whooping Cough
Epinephrine-induced hyperpolarization of islet cells without KATP channels.
Whooping Cough
Epithelial anion transporter pendrin contributes to inflammatory lung pathology in mouse models of Bordetella pertussis infection.
Whooping Cough
Epithelial cell-derived human beta-defensin-2 acts as a chemotaxin for mast cells through a pertussis toxin-sensitive and phospholipase C-dependent pathway.
Whooping Cough
Epithelial-mesenchymal transformation in the embryonic heart is mediated through distinct pertussis toxin-sensitive and TGFbeta signal transduction mechanisms.
Whooping Cough
Epitope specificity of three anti-pertussis toxin monoclonal antibodies with dissimilar effects in assays of toxin neutralizing activity.
Whooping Cough
Epitopes on the S1 subunit of pertussis toxin recognized by monoclonal antibodies.
Whooping Cough
Epoxyeicosatrienoic acid stimulates ADP-ribosylation of a 52 kDa protein in rat liver cytosol.
Whooping Cough
Epstein-Barr Virus Induced Gene 2 (EBI2) Mediates Allergen-induced, Leukocyte Migration into Airways.
Whooping Cough
Equol-Stimulated Mitochondrial Reactive Oxygen Species Activate Endothelial Nitric Oxide Synthase and Redox Signaling in Endothelial Cells: Roles for F-Actin and GPR30.
Whooping Cough
ER-resident G(i2) protein controls Sar1 translocation onto the ER during budding of transport vesicles.
Whooping Cough
Erk1/2- and p38 MAP kinase-dependent phosphorylation and activation of cPLA2 by m3 and m2 receptors.
Whooping Cough
ERK2 mediates oxytocin-stimulated PGE2 synthesis.
Whooping Cough
Essential role for extracellular Ca(2+) in JNK activation by mechanical stretch in bladder smooth muscle cells.
Whooping Cough
Essential role for G proteins in prostate cancer cell growth and signaling.
Whooping Cough
Essential role of EP3 subtype in prostaglandin E2-induced adhesion of mouse cultured and peritoneal mast cells to the Arg-Gly-Asp-enriched matrix.
Whooping Cough
Essential role of G protein-gated inwardly rectifying potassium channels in gonadotropin-induced regulation of GnRH neuronal firing and pulsatile neurosecretion.
Whooping Cough
Essential role of neutrophils in anti-type II collagen antibody and lipopolysaccharide-induced arthritis.
Whooping Cough
Essential role of the consensus nucleotide-binding site of PtlH in secretion of pertussis toxin from Bordetella pertussis.
Whooping Cough
Essential roles of sphingosine 1-phosphate/S1P1 receptor axis in the migration of neural stem cells toward a site of spinal cord injury.
Whooping Cough
Establishment and application of a multiple cross displacement amplification combined with nanoparticles-based biosensor method for the detection of Bordetella pertussis.
Whooping Cough
Establishment and characterization of an optimized mouse model of multiple sclerosis-induced neuropathic pain using behavioral, pharmacologic, histologic and immunohistochemical methods.
Whooping Cough
Establishment of diagnostic cutoff points for levels of serum antibodies to pertussis toxin, filamentous hemagglutinin, and fimbriae in adolescents and adults in the United States.
Whooping Cough
Establishment of Pertussis toxin BRP batch 2 for CHO clustering assay.
Whooping Cough
Estimated and reported incidence of pertussis in Estonian adults: A seroepidemiological study.
Whooping Cough
Estimating Bordetella pertussis seroprevalence in adolescents and young adults in Mexico using the 2012 National Health and Nutrition Survey (ENSANUT).
Whooping Cough
Estimation of agonist activity at G protein-coupled receptors: analysis of M2 muscarinic receptor signaling through Gi/o,Gs, and G15.
Whooping Cough
Estradiol increases cAMP in the oviductal secretory cells through a nongenomic mechanism.
Whooping Cough
Estradiol increases cyclic adenosine monophosphate in rat pulmonary vascular smooth muscle cells by a nongenomic mechanism.
Whooping Cough
Estradiol signaling via sequestrable surface receptors.
Whooping Cough
Estradiol up-regulates the stimulatory GTP-binding protein expression in the MCF-7 human mammary carcinoma cell line.
Whooping Cough
Estradiol-stimulated increases in uterine eosinophils and nuclear type II estrogen-binding sites are prevented by pertussis toxin.
Whooping Cough
Estrogen inhibits D2S receptor-regulated Gi3 and Gs protein interactions to stimulate prolactin production and cell proliferation in lactotropic cells.
Whooping Cough
Estrogen mediated inhibition of dopamine transport in the striatum: regulation by G alpha i/o.
Whooping Cough
Estrogen modulates in vitro atrial bradycardia induced by Indian red scorpion venom via G-protein coupled mechanisms.
Whooping Cough
Estrogen Receptor Activation Protects Against TNF-?-Induced Endothelial Dysfunction.
Whooping Cough
Estrogen receptor transactivation in MCF-7 breast cancer cells by melatonin and growth factors.
Whooping Cough
Estrogen uncouples beta-adrenergic receptor from the stimulatory guanine nucleotide-binding protein in female rat hypothalamus.
Whooping Cough
Estrogens promote human testicular germ cell cancer through a membrane-mediated activation of extracellular regulated kinase and protein kinase A.
Whooping Cough
ET-1 cooperates with EGF to induce mitogenesis via a PTX-sensitive pathway in airway smooth muscle cells.
Whooping Cough
ET-1 induced Elevation of intracellular calcium in clonal neuronal and embryonic kidney cells involves endogenous endothelin-A receptors linked to phospholipase C through G?(q/11).
Whooping Cough
ET-1 stimulates Ca2+ currents in cardiac cells.
Whooping Cough
ET-1 stimulates ERK signaling pathway through sequential activation of PKC and Src in rat myometrial cells.
Whooping Cough
ET-1 stimulates pulmonary arterial smooth muscle cell proliferation via induction of reactive oxygen species.
Whooping Cough
ET-1-associated vasomotion and vasospasm in lymphatic vessels of the guinea-pig mesentery.
Whooping Cough
ETA and ETB receptors cooperate in DNA synthesis via opposing regulations of cAMP in human lung cell line.
Whooping Cough
Ethanol acts synergistically with a D2 dopamine agonist to cause translocation of protein kinase C.
Whooping Cough
Ethanol alters angiotensin II stimulated mitogen activated protein kinase in hepatocytes: agonist selectivity and ethanol metabolic independence.
Whooping Cough
Ethanol differentially increases alpha 2-adrenergic and muscarinic acetylcholine receptor gene expression in NG108-15 cells.
Whooping Cough
Ethanol enhances basal and flow-stimulated nitric oxide synthase activity in vitro by activating an inhibitory guanine nucleotide binding protein.
Whooping Cough
Ethanol extract of Glycyrrhizae Radix modulates the responses of antigen-specific splenocytes in experimental autoimmune encephalomyelitis.
Whooping Cough
Ethanol inhibits zymosan-stimulated eicosanoid production in mouse peritoneal macrophages.
Whooping Cough
Ethanol triggers neural crest apoptosis through the selective activation of a pertussis toxin-sensitive G protein and a phospholipase Cbeta-dependent Ca2+ transient.
Whooping Cough
Etorphine elicits anomalous excitatory opioid effects on sensory neurons treated with GM1 ganglioside or pertussis toxin in contrast to its potent inhibitory effects on naive or chronic morphine-treated cells.
Whooping Cough
Etorphine inhibits cell growth and induces apoptosis in SK-N-SH cells: involvement of pertussis toxin-sensitive G proteins.
Whooping Cough
Eukaryotic mono(ADP-ribosyl)transferase that ADP-ribosylates GTP-binding regulatory Gi protein.
Whooping Cough
European Sero-Epidemiology Network 2: standardisation of immunoassay results for pertussis requires homogeneity in the antigenic preparations.
Whooping Cough
European Sero-Epidemiology Network: standardisation of the assay results for pertussis.
Whooping Cough
EUVAC.NET collaborative study: Evaluation and standardisation of serology for diagnosis of pertussis.
Whooping Cough
Evading the proteasome: absence of lysine residues contributes to pertussis toxin activity by evasion of proteasome degradation.
Whooping Cough
Evaluation of a commercial loop-mediated isothermal amplification assay for diagnosis of Bordetella pertussis infection.
Whooping Cough
Evaluation of a guinea pig model to assess interference in the immunogenicity of different components of a combination vaccine comprising diphtheria, tetanus and acellular pertussis (DTaP) vaccine and haemophilus influenzae type b capsular polysaccharide conjugate vaccine.
Whooping Cough
Evaluation of a multitarget real-time PCR assay for detection of Bordetella species during a pertussis outbreak in New Hampshire in 2011.
Whooping Cough
Evaluation of a single-sample serological technique for diagnosing pertussis in unvaccinated children.
Whooping Cough
Evaluation of a tetraplex microsphere assay for Bordetella pertussis antibodies.
Whooping Cough
Evaluation of activation of G proteins in response to thyroid stimulating hormone in thyroid gland cells from euthyroid and hyperthyroid cats.
Whooping Cough
Evaluation of an immunoglobulin G enzyme-linked immunosorbent assay for pertussis toxin and filamentous hemagglutinin in diagnosis of pertussis in Senegal.
Whooping Cough
Evaluation of Anti-PT Antibody Response after Pertussis Vaccination and Infection: The Importance of Both Quantity and Quality.
Whooping Cough
Evaluation of antibodies elicited by immunization with pertussis toxin.
Whooping Cough
Evaluation of Antidiabetic Effects of the Traditional Medicinal Plant Gynostemma pentaphyllum and the Possible Mechanisms of Insulin Release.
Whooping Cough
Evaluation of efficacy in terms of antibody levels and cell-mediated immunity of acellular pertussis vaccines in a murine model of respiratory infection.
Whooping Cough
Evaluation of experimental autoimmune uveitis in mice treated with FTY720.
Whooping Cough
Evaluation of IL-17 Serum Level, Brain Inflammation and Demyelination in Experimental Autoimmune Encephalomyelitis C57BL/6 Mice Model with Different Doses of Myelin Oligodendrocyte Glycoprotein.
Whooping Cough
Evaluation of inactivated Bordetella pertussis as a delivery system for the immunization of mice with Pneumococcal Surface Antigen A.
Whooping Cough
Evaluation of novel cyclic analogues of apelin.
Whooping Cough
Evaluation of PCR for diagnosis of Bordetella pertussis and Bordetella parapertussis infections.
Whooping Cough
Evaluation of pertussis in U.S. Marine Corps trainees.
Whooping Cough
Evaluation of Pertussis Toxin Expression in B2 and THIJS Media.
Whooping Cough
Evaluation of pooled and individual components of Bordetella pertussis as antigens in an enzyme immunoassay for diagnosis of pertussis.
Whooping Cough
Evaluation of real-time PCR for diagnosis of Bordetella pertussis infection.
Whooping Cough
Evaluation of serologic assays for diagnosis of whooping cough.
Whooping Cough
Evaluation of serology and nasopharyngeal cultures for diagnosis of pertussis in a vaccine efficacy trial.
Whooping Cough
Evaluation of the effects of peptide antibiotics human beta-defensins-1/-2 and LL-37 on histamine release and prostaglandin D(2) production from mast cells.
Whooping Cough
Evaluation of the role of second messenger systems in tumor necrosis factor-stimulated resorption of fetal rat limb bones.
Whooping Cough
Evaluation of two serological methods for potency testing of whole cell pertussis vaccines.
Whooping Cough
Evidence against a role for a pertussis toxin-sensitive G protein in Ca2+ mobilization in rat parotid acinar cells.
Whooping Cough
Evidence against a role of a pertussis toxin-sensitive guanine nucleotide-binding protein in the alpha 1-adrenoceptor-mediated positive inotropic effect in the heart.
Whooping Cough
Evidence against roles for pertussis toxin sensitive G proteins or diacylglycerol generation in insulin-like growth factor-1 stimulated DNA synthesis in MG-63 osteosarcoma cells.
Whooping Cough
Evidence for a beta2-adrenergic/arachidonic acid pathway in ventricular cardiomyocytes. Regulation by the beta1-adrenergic/camp pathway.
Whooping Cough
Evidence for a catalytic role of glutamic acid 129 in the NAD-glycohydrolase activity of the pertussis toxin S1 subunit.
Whooping Cough
Evidence for a cyclic AMP-dependent pathway in angiotensin AT1-receptor activation of human omental arteries.
Whooping Cough
Evidence for a direct negative coupling between dopamine-D2 receptors and PLC by heterotrimeric Gi1/2 proteins in rat anterior pituitary cell membranes.
Whooping Cough
Evidence for a discrete UTP receptor in cardiac endothelial cells.
Whooping Cough
Evidence for a dual control of macroautophagic sequestration and intracellular trafficking of N-linked glycoproteins by the trimeric G(i3) protein in HT-29 cells.
Whooping Cough
Evidence for a functionally active inhibitory guanine nucleotide-binding regulatory protein in the swine ovary.
Whooping Cough
Evidence for a GTP-binding protein involved in interferon-gamma transduction signal.
Whooping Cough
Evidence for a ninth gene, ptlI, in the locus encoding the pertussis toxin secretion system of Bordetella pertussis and formation of a PtlI-PtlF complex.
Whooping Cough
Evidence for a pertussis toxin sensitive calcium entry pathway in thyroid FRTL-5 cells.
Whooping Cough
Evidence for a pertussis toxin-sensitive G protein involved in the control of meiotic reinitiation of Xenopus laevis oocytes.
Whooping Cough
Evidence for a pertussis toxin-sensitive signalling pathway in the dual action of angiotensin II on growth hormone release in pituitary cell aggregates.
Whooping Cough
Evidence for a role of G protein beta gamma subunits in the enhancement of cAMP accumulation and DNA synthesis by adenosine in human cells.
Whooping Cough
Evidence for a Role of Opioids in Epoxyeicosatrienoic Acid (EET)-induced Cardioprotection in Rat Hearts.
Whooping Cough
Evidence for an intracellular niche for Bordetella pertussis in broncho-alveolar lavage cells of mice.
Whooping Cough
Evidence for cannabinoid receptor-dependent and -independent mechanisms of action in leukocytes.
Whooping Cough
Evidence for cocaine and methylecgonidine stimulation of M(2) muscarinic receptors in cultured human embryonic lung cells.
Whooping Cough
Evidence for coupling of bradykinin receptors to a guanine-nucleotide binding protein to stimulate arachidonate liberation in the osteoblast-like cell line, MC3T3-E1.
Whooping Cough
Evidence for cross-talk between M2 and M3 muscarinic acetylcholine receptors in the regulation of second messenger and extracellular signal-regulated kinase signalling pathways in Chinese hamster ovary cells.
Whooping Cough
Evidence for deactivation of both ectosolic and cytosolic 5'-nucleotidase by adenosine A1 receptor activation in the rat cardiomyocytes.
Whooping Cough
Evidence for expression of a Ras-like and a stage specific GTP binding homologous protein by Plasmodium falciparum.
Whooping Cough
Evidence for G beta gamma-mediated cross-talk in primary cultures of lung alveolar cells. Pertussis toxin-sensitive production of cAMP.
Whooping Cough
Evidence for G protein mediation of serotonin- and GABAB-induced hyperpolarization of rat dorsal raphe neurons.
Whooping Cough
Evidence for G protein modulation of experimental-generalized absence seizures in rat.
Whooping Cough
Evidence for G proteins in rat parotid plasma membranes and secretory granule membranes.
Whooping Cough
Evidence for G-Protein Regulation of Inward K+ Channel Current in Guard Cells of Fava Bean.
Whooping Cough
Evidence for guanosine triphosphate--binding proteins in Trypanosoma cruzi.
Whooping Cough
Evidence for inhibition by protein kinase A of receptor/G alpha(q)/phospholipase C (PLC) coupling by a mechanism not involving PLCbeta2.
Whooping Cough
Evidence for involvement of a GTP-binding protein in activation of Ca2+ influx by epidermal growth factor in A431 cells: effects of fluoride and bacterial toxins.
Whooping Cough
Evidence for involvement of guanine nucleotide-binding regulatory proteins in the activation of phospholipases by hormones.
Whooping Cough
Evidence for kinetic disparity among pertussis toxin substrate G-proteins coupled to opiate receptors.
Whooping Cough
Evidence for m2 and m3 muscarinic receptor involvement in cholinergic excitatory junction potentials through synergistic activation of cation channels in the longitudinal muscle of mouse ileum.
Whooping Cough
Evidence for paracrine modulation of voltage-dependent calcium channels by amperometric analysis in cultured porcine adrenal chromaffin cells.
Whooping Cough
Evidence for paracrine signaling between macrophages and bovine adrenal chromaffin cell Ca(2+) channels.
Whooping Cough
Evidence for participation of calcineurin in potentiation of agonist-stimulated cyclic AMP formation by the calcium-mobilizing hormone, angiotensin II.
Whooping Cough
Evidence for pharmacologically distinct subsets of GABAB receptors.
Whooping Cough
Evidence for PI3K-dependent CXCR3 agonist-induced degranulation of human cord blood-derived mast cells.
Whooping Cough
Evidence for pleiotropic signaling at the mouse beta3-adrenoceptor revealed by SR59230A [3-(2-Ethylphenoxy)-1-[(1,S)-1,2,3,4-tetrahydronapth-1-ylamino]-2S-2-propanol oxalate].
Whooping Cough
Evidence for receptor-mediated inhibition of intrinsic activity of GTP-binding protein, Gi1 and Gi2, but not G0 in reconstitution experiments.
Whooping Cough
Evidence for the dual coupling of the rat neurotensin receptor with pertussis toxin-sensitive and insensitive G-proteins.
Whooping Cough
Evidence for the implication of phosphoinositol signal transduction in mu-opioid inhibition of DNA synthesis.
Whooping Cough
Evidence for the inhibitory subunit of adenylate cyclase (Ni) in nervous and heart tissue of Aplysia.
Whooping Cough
Evidence for the interaction of mast cell-degranulating peptide with pertussis toxin-sensitive G proteins in mast cells.
Whooping Cough
Evidence for the involvement of a pertussis toxin-insensitive G-protein in egg activation of the frog, Xenopus laevis.
Whooping Cough
Evidence for the involvement of Gi2 in activation of extracellular signal-regulated kinases in hepatocytes.
Whooping Cough
Evidence for the involvement of multiple signalling pathways in C5a-induced actin polymerization and nucleation in human monocyte-like cells.
Whooping Cough
Evidence for the presence of cholinergic muscarinic receptors negatively linked to adenylate cyclase in the iris-ciliary body.
Whooping Cough
Evidence for the presence of G-proteins, adenylyl cyclase and phospholipase C activities in lymphatic smooth muscle cell membranes.
Whooping Cough
Evidence for the presence of P2-purinoceptors at the surface of human articular chondrocytes in monolayer culture.
Whooping Cough
Evidence for the presence of serotonin receptors negatively coupled to adenylate cyclase in the rabbit iris-ciliary body.
Whooping Cough
Evidence for the role of heterotrimeric guanine nucleotide-binding regulatory proteins in the regulation of the mouse sperm adenylyl cyclase by the egg's zona pellucida.
Whooping Cough
Evidence for tight coupling of Gi protein-mediated lysophosphatidic acid receptor to stimulated cytokine production in ovarian cancer cell.
Whooping Cough
Evidence for transduction of mu but not kappa opioid modulation of extracellular signal-regulated kinase activity by G(z) and G(12) proteins.
Whooping Cough
Evidence for two atypical conformations of beta-adrenoceptors and their interaction with Gi proteins.
Whooping Cough
Evidence for two different stimulatory adenylate cyclase coupling mechanisms in rat renal papilla.
Whooping Cough
Evidence for two GTPases activated by thrombin in membranes of human platelets.
Whooping Cough
Evidence from studies with hepatocyte suspensions that store-operated Ca2+ inflow requires a pertussis toxin-sensitive trimeric G-protein.
Whooping Cough
Evidence of Bordetella pertussis infection in vaccinated 1-year-old Danish children.
Whooping Cough
Evidence of endogenous mono-ADP-ribosylation of cardiac proteins via anti-ADP-ribosylarginine immunoreactivity.
Whooping Cough
Evidence of heterotrimeric G-protein involvement in regulated exocytosis from permeabilized pancreatic acini.
Whooping Cough
Evidence of increased circulation of Bordetella pertussis in the Italian adult population from seroprevalence data (2012-2013).
Whooping Cough
Evidence of the receptor-mediated influence of melatonin on pancreatic glucagon secretion via the G?q protein-coupled and PI3K signaling pathways.
Whooping Cough
Evidence of TRPV1 receptor and PKC signaling pathway in the antinociceptive effect of amyrin octanoate.
Whooping Cough
Evidence suggesting that the mouse sperm acrosome reaction initiated by the zona pellucida involves an alpha7 nicotinic acetylcholine receptor.
Whooping Cough
Evidence that 2-arachidonoylglycerol but not N-palmitoylethanolamine or anandamide is the physiological ligand for the cannabinoid CB2 receptor. Comparison of the agonistic activities of various cannabinoid receptor ligands in HL-60 cells.
Whooping Cough
Evidence that a guanine nucleotide-binding protein linked to a muscarinic receptor inhibits directly phospholipase C.
Whooping Cough
Evidence that a pertussis-toxin-sensitive substrate is involved in the stimulation by epidermal growth factor and vasopressin of plasma-membrane Ca2+ inflow in hepatocytes.
Whooping Cough
Evidence that a receptor-operated event on the neutrophil mediates neutrophil accumulation in vivo. Pretreatment of 111In-neutrophils with pertussis toxin in vitro inhibits their accumulation in vivo.
Whooping Cough
Evidence that activation of a common G-protein by receptors for leukotriene B4 and N-formylmethionyl-leucyl-phenylalanine in HL-60 cells occurs by different mechanisms.
Whooping Cough
Evidence that angiotensin II and lipoxygenase products activate c-Jun NH2-terminal kinase.
Whooping Cough
Evidence that antipsychotic drugs are inverse agonists at D2 dopamine receptors.
Whooping Cough
Evidence that Arg-295, Glu-378, and Glu-380 are active-site residues of the ADP-ribosyltransferase activity of iota toxin.
Whooping Cough
Evidence that conditionally immortalized human osteoblasts express an osteocalcin receptor.
Whooping Cough
Evidence that G(z)-proteins couple to hypothalamic 5-HT(1A) receptors in vivo.
Whooping Cough
Evidence that guanosine triphosphate (GTP)-binding proteins control a synaptic response in brain: effect of pertussis toxin and GTP gamma S on the late inhibitory postsynaptic potential of hippocampal CA3 neurons.
Whooping Cough
Evidence that inward rectifier K+ channels mediate relaxation by the PGI2 receptor agonist cicaprost via a cyclic AMP-independent mechanism.
Whooping Cough
Evidence that lipopolysaccharide and pertussis toxin bind to different domains on the same p73 receptor on murine splenocytes.
Whooping Cough
Evidence that M3 muscarinic receptors in rat parotid gland couple to two second messenger systems.
Whooping Cough
Evidence that muscarinic cholinergic receptors selectively interact with either the cyclic AMP or the inositol phosphate second-messenger response systems.
Whooping Cough
Evidence that myocardial pertussis toxin substrates are uniquely altered in acute murine Chagas' disease in a manner unrelated to myocardial dysfunction.
Whooping Cough
Evidence that receptor-linked G protein inhibits exocytosis by a post-second-messenger mechanism in AtT-20 cells.
Whooping Cough
Evidence that separate PGE2 receptors modulate water and sodium transport in rabbit cortical collecting duct.
Whooping Cough
Evidence that the action of calcitonin on rat osteoclasts is mediated by two G proteins acting via separate post-receptor pathways.
Whooping Cough
Evidence that the appressorial development in barley powdery mildew is controlled by MAP kinase activity in conjunction with the cAMP pathway.
Whooping Cough
Evidence that the ATP-induced increase in vasomotion of guinea-pig mesenteric lymphatics involves an endothelium-dependent release of thromboxane A2.
Whooping Cough
Evidence that the epidermal growth factor receptor and non-tyrosine kinase hormone receptors stimulate phosphoinositide hydrolysis by independent pathways.
Whooping Cough
Evidence that the substance P-induced enhancement of pacemaking in lymphatics of the guinea-pig mesentery occurs through endothelial release of thromboxane A2.
Whooping Cough
Evidence that thrombin-stimulated DNA synthesis in pulmonary arterial fibroblasts involves phosphatidylinositol 3-kinase-dependent p70 ribosomal S6 kinase activation.
Whooping Cough
Evidence that thyrotropin-releasing hormone-induced increases in GTPase activity and phosphoinositide metabolism in GH3 cells are mediated by a guanine nucleotide-binding protein other than Gs or Gi.
Whooping Cough
Evidence that UTP and ATP regulate phospholipase C through a common extracellular 5'-nucleotide receptor in human airway epithelial cells.
Whooping Cough
Evidence that v-Src-induced phospholipase D activity is mediated by a G protein.
Whooping Cough
Evolution of Bordetella pertussis over a 23-year period in France, 1996 to 2018.
Whooping Cough
Evolutionary relationships in the genus Bordetella.
Whooping Cough
Evolutionary trees for the genus Bordetella.
Whooping Cough
Evolving insights regarding mechanisms for the inhibition of insulin release by norepinephrine and heterotrimeric G proteins.
Whooping Cough
Examination of the signal transduction pathways leading to activation of extracellular signal-regulated kinase by formyl-methionyl-leucyl-phenylalanine in rat neutrophils.
Whooping Cough
Excitation of locus coeruleus neurons by vasoactive intestinal peptide: evidence for a G-protein-mediated inward current.
Whooping Cough
Excitatory amino acid receptor-stimulated phosphoinositide turnover in primary cerebrocortical cultures.
Whooping Cough
Excitatory amino acids inhibit stimulated phosphoinositide hydrolysis in the rat prefrontal cortex.
Whooping Cough
Existence of GPR40 functioning in a human breast cancer cell line, MCF-7.
Whooping Cough
Exocytosis from permeabilized bovine adrenal chromaffin cells is differently modulated by guanosine 5'-[gamma-thio]triphosphate and guanosine 5'-[beta gamma-imido]triphosphate. Evidence for the involvement of various guanine nucleotide-binding proteins.
Whooping Cough
Exocytosis in chromaffin cells: evidence for a MgATP-independent step that requires a pertussis toxin-sensitive GTP-binding protein.
Whooping Cough
Exocytosis in electropermeabilized neutrophils. Responsiveness to calcium and guanosine 5'-[gamma-thio]triphosphate.
Whooping Cough
Exocytosis in mast cells by basic secretagogues: evidence for direct activation of GTP-binding proteins.
Whooping Cough
Exocytotic enzyme release from rabbit polymorphonuclear leukocytes after treatment with fluoride and calcium.
Whooping Cough
Exotoxin-insensitive G proteins mediate synaptically evoked muscarinic sodium current in rabbit sympathetic neurones.
Whooping Cough
Experience with monocomponent acellular pertussis combination vaccines for infants, children, adolescents and adults-A review of safety, immunogenicity, efficacy and effectiveness studies and 15 years of field experience.
Whooping Cough
Experimental allergic neuritis in the SJL/J mouse: induction of severe and reproducible disease with bovine peripheral nerve myelin and pertussis toxin with or without interleukin-12.
Whooping Cough
Experimental and clinical aspects of melatonin and clock genes in diabetes.
Whooping Cough
Experimental arthritis and uveitis in rats associated with Mycobacterium butyricum.
Whooping Cough
Experimental autoimmune anterior uveitis (EAAU). II. Dose-dependent induction and adoptive transfer using a melanin-bound antigen of the retinal pigment epithelium.
Whooping Cough
Experimental autoimmune anterior uveitis. Induction with melanin-associated antigen from the iris and ciliary body.
Whooping Cough
Experimental autoimmune anterior uveitis. The preparation of uveitogenic ocular melanin.
Whooping Cough
Experimental autoimmune encephalomyelitis (EAE) induced by antigen pulsed dendritic cells in the C57BL/6 mouse: influence of injection route.
Whooping Cough
Experimental Autoimmune Encephalomyelitis (EAE) Model of Cynomolgus Macaques Induced by Recombinant Human MOG1-125 (rhMOG1-125) Protein and MOG34-56 Peptide.
Whooping Cough
Experimental autoimmune encephalomyelitis accelerates remyelination after lysophosphatidylcholine-induced demyelination in the corpus callosum.
Whooping Cough
Experimental Autoimmune Encephalomyelitis Develops in CC Chemokine Receptor 7-deficient Mice with Altered T-cell Responses.
Whooping Cough
Experimental autoimmune encephalomyelitis in cynomolgus monkeys.
Whooping Cough
Experimental autoimmune encephalomyelitis in the Wistar rat: dependence of MBP-specific T cell responsiveness on B7 costimulation.
Whooping Cough
Experimental autoimmune posterior uveitis accompanied by epitheloid cell accumulations (EAPU). A new type of experimental ocular disease induced by immunization with PEP-65, a pigment epithelial polypeptide preparation.
Whooping Cough
Experimental autoimmune uveoretinitis (EAU) in rats: abrogation of resistance to the induction and augmentation of the inflammation by pertussis toxin.
Whooping Cough
Experimental autoimmune uveoretinitis in mice. Induction by a single eliciting event and dependence on quantitative parameters of immunization.
Whooping Cough
Experimental autoimmune uveoretinitis in the rat and mouse.
Whooping Cough
Experimental autoimmune vasculitis: an animal model of anti-neutrophil cytoplasmic autoantibody-associated systemic vasculitis.
Whooping Cough
Experimental melanin-protein induced uveitis (EMIU) is the sole type of uveitis evoked by a diversity of ocular melanin preparations and melanin-derived soluble polypeptides.
Whooping Cough
Experimental priming of encephalitogenic Th1/Th17 cells requires pertussis toxin-driven IL-1? production by myeloid cells.
Whooping Cough
Experimental researches on the role of phosphoinositide-specific phospholipase C in 4-hydroxynonenal induced exocytosis.
Whooping Cough
Experimental studies on the mechanism of phospholipase C activation by the lipid peroxidation products 4-hydroxynonenal and 2-nonenal.
Whooping Cough
Exploring cargo transport mechanics in the type IV secretion systems.
Whooping Cough
Exposure of astrocytes to thrombin reduces levels of the metabotropic glutamate receptor mGluR5.
Whooping Cough
Expression and a role of functionally coupled P2Y receptors in human dendritic cells.
Whooping Cough
Expression and activation of matrix metalloproteinase-9 and NADPH oxidase in tissues and plasma of experimental autoimmune encephalomyelitis in mice.
Whooping Cough
Expression and agonist responsiveness of CXCR3 variants in human T lymphocytes.
Whooping Cough
Expression and characterization of a 5-oxo-6E,8Z,11Z,14Z-eicosatetraenoic acid receptor highly expressed on human eosinophils and neutrophils.
Whooping Cough
Expression and characterization of the bovine histamine H1 receptor in cDNA-transfected C6 astroglioma cells.
Whooping Cough
Expression and function of adenosine receptors in human dendritic cells.
Whooping Cough
Expression and function of umami receptors T1R1/T1R3 in gastric smooth muscle.
Whooping Cough
Expression and functional characterization of a melatonin-sensitive receptor in Xenopus oocytes.
Whooping Cough
Expression and functional role of formyl peptide receptor in human bone marrow-derived mesenchymal stem cells.
Whooping Cough
Expression and immunogenicity of pertussis toxin S1 subunit-tetanus toxin fragment C fusions in Salmonella typhi vaccine strain CVD 908.
Whooping Cough
Expression and immunological properties of the five subunits of pertussis toxin.
Whooping Cough
Expression and modulation of 5-hydroxytryptamine1A receptors in P11 cells.
Whooping Cough
Expression and molecular pharmacology of the mouse CRTH2 receptor.
Whooping Cough
Expression and muscarinic receptor coupling of Lyn kinase in cultured human airway smooth muscle cells.
Whooping Cough
Expression and mutagenesis of recombinant cholera toxin A subunit.
Whooping Cough
Expression and pharmacological characterization of a stimulatory subtype of adenosine receptor in fetal chick ventricular myocytes.
Whooping Cough
Expression and potential functions of G-protein alpha subunits in embryos of Xenopus laevis.
Whooping Cough
Expression and purification of a trivalent pertussis toxin-diphtheria toxin-tetanus toxin fusion protein in Escherichia coli.
Whooping Cough
Expression and purification of functional G protein alpha subunits using a baculovirus expression system.
Whooping Cough
Expression and regulation of adenylyl cyclase isoforms in the human adrenal gland.
Whooping Cough
Expression and secretion of beta-glucuronidase and Pertussis toxin S1 by Streptomyces lividans.
Whooping Cough
Expression and secretion of pertussis toxin subunit S1 in Bacillus subtilis.
Whooping Cough
Expression and secretion of the S-1 subunit and C180 peptide of pertussis toxin in Escherichia coli.
Whooping Cough
Expression and secretion of the S2 subunit of pertussis toxin in Bacillus brevis.
Whooping Cough
Expression and Signaling of Formyl-Peptide Receptors in the Brain.
Whooping Cough
Expression and Signaling of G Protein-Coupled Estrogen Receptor (GPER) in Rat Sertoli Cells.
Whooping Cough
Expression of a C terminally truncated form of pertussis toxin S1 subunit effectively induces protection against pertussis toxin following DNA-based immunization.
Whooping Cough
Expression of a cloned P2Y purinergic receptor that couples to phospholipase C.
Whooping Cough
Expression of a functional endothelin (ETA) receptor in human meningiomas.
Whooping Cough
Expression of a G protein subunit, alpha i-1, in Balb/c 3T3 cells leads to agonist-specific changes in growth regulation.
Whooping Cough
Expression of a mutant Gi2 alpha subunit inhibits ATP and thrombin stimulation of cytoplasmic phospholipase A2-mediated arachidonic acid release independent of Ca2+ and mitogen-activated protein kinase regulation.
Whooping Cough
Expression of a pertussis toxin S1 fragment by inducible promoters in oral Streptococcus and the induction of immune responses during oral colonization in mice.
Whooping Cough
Expression of a synthetic pertussis toxin operon in Escherichia coli.
Whooping Cough
Expression of adenylyl cyclase isoforms in neutrophils.
Whooping Cough
Expression of adhesion molecules by sphingosine 1-phosphate and histamine in endothelial cells.
Whooping Cough
Expression of alpha 2-receptor-mediated responses by insulin in primary culture of rat hepatocytes.
Whooping Cough
Expression of an atrial G-protein-activated potassium channel in Xenopus oocytes.
Whooping Cough
Expression of Astrocytic Type 2 Angiotensin Receptor in Central Nervous System Inflammation Correlates With Blood-Brain Barrier Breakdown.
Whooping Cough
Expression of bacterial cytotoxin genes in mammalian target cells.
Whooping Cough
Expression of Bordetella pertussis Antigens Fused to Different Vectors and Their Effectiveness as Vaccines.
Whooping Cough
Expression of Ca(2+)-mobilizing endothelin(A) receptors and their role in the control of Ca(2+) influx and growth hormone secretion in pituitary somatotrophs.
Whooping Cough
Expression of connective tissue growth factor in human renal fibroblasts: regulatory roles of RhoA and cAMP.
Whooping Cough
Expression of cytokines by human astrocytomas following stimulation by C3a and C5a anaphylatoxins: specific increase in interleukin-6 mRNA expression.
Whooping Cough
Expression of DP2 (CRTh2), a prostaglandin D? receptor, in human mast cells.
Whooping Cough
Expression of functional chemokine receptors by rat cerebellar neurons.
Whooping Cough
Expression of functional GPR35 in human iNKT cells.
Whooping Cough
Expression of functional Y1 receptors for neuropeptide Y in human Ewing's sarcoma cell lines.
Whooping Cough
Expression of GTP-binding proteins and protein kinase C isozymes in platelet-like particles derived from megakaryoblastic leukemia cells (MEG-01).
Whooping Cough
Expression of Histamine HReceptors in Xenopus Oocytes Injected with Messenger Ribonucleic Acid from Bovine Adrenal Medulla: Pertussis Toxin Insensitive Activation of Membrane Chloride Currents.
Whooping Cough
Expression of human platelet-activating factor receptor gene in EoL-1 cells following butyrate-induced differentiation.
Whooping Cough
Expression of melatoninergic receptors in human placental choriocarcinoma cell lines.
Whooping Cough
Expression of membrane progesterone receptors (mPRs) in rat peripheral glial cell membranes and their potential role in the modulation of cell migration and protein expression.
Whooping Cough
Expression of muscarinic M2 receptors in cultured human airway smooth muscle cells.
Whooping Cough
Expression of opioid receptors during heart ontogeny in normotensive and hypertensive rats.
Whooping Cough
Expression of P2Y receptors in cell lines derived from the human lung.
Whooping Cough
Expression of pertussis toxin adenosine diphosphate-ribosyltransferase in a T-cell hybridoma reduces metastatic capacity.
Whooping Cough
Expression of pertussis toxin correlates with pathogenesis in Bordetella species.
Whooping Cough
Expression of pertussis toxin in Bordetella bronchiseptica and Bordetella parapertussis carrying recombinant plasmids.
Whooping Cough
Expression of pertussis toxin subunit S4 as an intracytoplasmic protein in Bacillus subtilis.
Whooping Cough
Expression of protease-activated receptors (PARs) in OLN-93 oligodendroglial cells and mechanism of PAR-1-induced calcium signaling.
Whooping Cough
Expression of RGS2 alters the coupling of metabotropic glutamate receptor 1a to M-type K+ and N-type Ca2+ channels.
Whooping Cough
Expression of somatostatin receptor genes and their role in inhibiting Cl- secretion in HT-29cl.19A colonocytes.
Whooping Cough
Expression of the C-C chemokine receptor CCR3 in human airway epithelial cells.
Whooping Cough
Expression of the mammalian calcium signaling response to Trypanosoma cruzi in Xenopus laevis oocytes.
Whooping Cough
Expression of the mu-opioid receptor in CHO cells: ability of mu-opioid ligands to promote alpha-azidoanilido[32P]GTP labeling of multiple G protein alpha subunits.
Whooping Cough
Expression of the nerve growth factor gene is controlled by the microtubule network.
Whooping Cough
Expression of the S-1 catalytic subunit of pertussis toxin in Escherichia coli.
Whooping Cough
Expression of the S1 sub-unit of pertussis toxin using a recombinant baculovirus.
Whooping Cough
Expression of the type 2 receptor for cysteinyl leukotrienes (CysLT2R) by human mast cells: Functional distinction from CysLT1R.
Whooping Cough
Expression of the type-II phospholipase A2 in alveolar macrophages. Down-regulation by an inflammatory signal.
Whooping Cough
Expression of val-12 mutant ras p21 in an IL-3-dependent murine myeloid cell line is associated with loss of serum-dependence and increases in membrane PIP2-specific phospholipase C activity.
Whooping Cough
Expression, activity and cytotoxicity of pertussis toxin S1 subunit in transfected mammalian cells.
Whooping Cough
Extensive swelling after booster doses of acellular pertussis-tetanus-diphtheria vaccines.
Whooping Cough
External quality assessment of pertussis serology in Germany.
Whooping Cough
External support modulates G protein expression and receptor coupling in experimental vein grafts.
Whooping Cough
Extra Virgin Olive Oil Phenols Vasodilate Rat MesentericResistance Artery via Phospholipase C (PLC)-CalciumMicrodomains-Potassium Channels (BKCa) Signals.
Whooping Cough
Extracellular ATP activates different signalling pathways in rat Sertoli cells.
Whooping Cough
Extracellular ATP and ADP stimulate proliferation of porcine aortic smooth muscle cells.
Whooping Cough
Extracellular ATP and UTP activate the protein kinase B/Akt cascade via the P2Y(2) purinoceptor in renal mesangial cells.
Whooping Cough
Extracellular ATP augments mesangial cell growth induced by multiple growth factors.
Whooping Cough
Extracellular ATP elevates cytoplasmatic free Ca2+ in HeLa cells by the interaction with a 5'-nucleotide receptor.
Whooping Cough
Extracellular ATP has stimulatory effects on the expression and release of IL-6 via purinergic receptors in normal human epidermal keratinocytes.
Whooping Cough
Extracellular ATP increases [CA(2+)](i) in distal tubule cells. I. Evidence for a P2Y2 purinoceptor.
Whooping Cough
Extracellular ATP itself elicits superoxide generation in guinea pig peritoneal macrophages.
Whooping Cough
Extracellular ATP mediates Ca2+ signaling in cultured myenteric neurons via a PLC-dependent mechanism.
Whooping Cough
Extracellular ATP or ADP induce chemotaxis of cultured microglia through Gi/o-coupled P2Y receptors.
Whooping Cough
Extracellular ATP stimulates increases in Na+/K+ pump activity, intracellular pH and uridine uptake in cultures of mammalian cells.
Whooping Cough
Extracellular ATP stimulates polyphosphoinositide hydrolysis and prostaglandin synthesis in rat renal mesangial cells. Involvement of a pertussis toxin-sensitive guanine nucleotide binding protein and feedback inhibition by protein kinase C.
Whooping Cough
Extracellular ATP-mediated phospholipase A(2) activation in rat thyroid FRTL-5 cells: regulation by a G(i)/G(o) protein, Ca(2+), and mitogen-activated protein kinase.
Whooping Cough
Extracellular calcium and platelet-derived growth factor promote receptor-mediated chemotaxis in osteoblasts through different signaling pathways.
Whooping Cough
Extracellular calcium as a candidate mediator of prostate cancer skeletal metastasis.
Whooping Cough
Extracellular lipid-mediated signaling in tumor-cell activation and pseudopod protrusion.
Whooping Cough
Extracellular matrix proteins are potent agonists of human smooth muscle cell migration.
Whooping Cough
Extracellular mRNA induces dendritic cell activation by stimulating tumor necrosis factor-alpha secretion and signaling through a nucleotide receptor.
Whooping Cough
Extracellular nucleotide-induced [Ca2+]i elevation in rat basilar smooth muscle cells.
Whooping Cough
Extracellular nucleotides act through P2U purinoceptors to elevate [Ca2+]i and enhance basic fibroblast growth factor-induced proliferation in sheep chondrocytes.
Whooping Cough
Extracellular signal-regulated kinase 1/2 activation by myometrial oxytocin receptor involves Galpha(q)Gbetagamma and epidermal growth factor receptor tyrosine kinase activation.
Whooping Cough
Extracellular signal-regulated kinase 1/2 control Ca(2+)-independent force development in histamine-stimulated bovine tracheal smooth muscle.
Whooping Cough
Extracellular signal-regulated kinase activation by parathyroid hormone in distal tubule cells.
Whooping Cough
Extracellular signal-regulated kinase-1 and -2 respond differently to mitogenic and differentiative signaling pathways in myoblasts.
Whooping Cough
Extracellular signal-regulated kinases and g protein-coupled receptors in megakaryocytic human erythroleukemia cells: selective activation, differential regulation, and dissociation from mitogenesis.
Whooping Cough
F11 neuroblastoma x DRG neuron hybrid cells express inhibitory mu- and delta-opioid receptors which increase voltage-dependent K+ currents upon activation.
Whooping Cough
Facilitation and inhibition of G-protein regulated protein secretion by melatonin.
Whooping Cough
Facilitation of T-type calcium current in bullfrog atrial cells: voltage-dependent relief of a G protein inhibitory tone.
Whooping Cough
Facilitation of transmitter release from rat sympathetic neurons via presynaptic P2Y(1) receptors.
Whooping Cough
Facilitative actions of the protein kinase-C effector system on hormonally stimulated adenosine 3',5'-monophosphate production by swine luteal cells.
Whooping Cough
Facilitative interactions between vasoactive intestinal polypeptide and receptor type-selective opioids: implications for sensory afferent regulation of spinal opioid action.
Whooping Cough
Facilitatory coupling between a glutamate metabotropic receptor and dihydropyridine-sensitive calcium channels in cultured cerebellar granule cells.
Whooping Cough
Facilitatory effects of diltiazem on dopamine release in the central nervous system. Focus on interactions with D2 autoreceptors and guanosine triphosphate binding proteins.
Whooping Cough
Factors affecting prostacyclin receptor agonist efficacy in different cell types.
Whooping Cough
Factors determining specificity of signal transduction by G-protein-coupled receptors. Regulation of signal transfer from receptor to G-protein.
Whooping Cough
Factors determining the specificity of signal transduction by guanine nucleotide-binding protein-coupled receptors. I. Coupling of alpha 2-adrenergic receptor subtypes to distinct G-proteins.
Whooping Cough
Factors determining the specificity of signal transduction by guanine nucleotide-binding protein-coupled receptors. III. Coupling of alpha 2-adrenergic receptor subtypes in a cell type-specific manner.
Whooping Cough
Factors determining the specificity of signal transduction by guanine nucleotide-binding protein-coupled receptors. Integration of stimulatory and inhibitory input to the effector adenylyl cyclase.
Whooping Cough
Failure of pertussis toxin to inhibit activation of guanylate cyclase by the heat-stable enterotoxin of Escherichia coli (STa) in the T84 cell line.
Whooping Cough
Failure of [32P]ADP-ribosylation by pertussis toxin to determine Gi alpha content in membranes from various human tissues. Improved radioimmunological quantification using the 125I-labelled C-terminal decapeptide of retinal transducin.
Whooping Cough
Fast, antigen-saving multiplex immunoassay to determine levels and avidity of mouse serum antibodies to pertussis, diphtheria, and tetanus antigens.
Whooping Cough
Fast, local signal transduction between the mu opioid receptor and Ca2+ channels.
Whooping Cough
Fat cell adenylate cyclase system. Enhanced inhibition by adenosine and GTP in the hypothyroid rat.
Whooping Cough
Fatal pertussis in the neonatal mouse model is associated with pertussis toxin-mediated pathology beyond the airways.
Whooping Cough
Fc gamma receptor activation of neutrophils in cryoglobulin-induced leukocytoclastic vasculitis.
Whooping Cough
Fc gamma receptor-mediated functions in neutrophils are modulated by adenosine receptor occupancy. A1 receptors are stimulatory and A2 receptors are inhibitory.
Whooping Cough
FcepsilonRI-mediated mast cell migration: signaling pathways and dependence on cytosolic free Ca2+ concentration.
Whooping Cough
Fear-potentiated startle: a neural and pharmacological analysis.
Whooping Cough
Feasibility study of a combined diphtheria-tetanus-acellular pertussis-hepatitis B (DTPa-HBV) vaccine, and comparison of clinical reactions and immune responses with diphtheria-tetanus-acellular pertussis (DTPa) and hepatitis B vaccines applied as mixed or injected into separate limbs.
Whooping Cough
Feasible improvements in vaccines in the Expanded Programme on Immunization.
Whooping Cough
Features of the translocation of protein kinase C in neutrophils stimulated with the chemotactic peptide f-Met-Leu-Phe.
Whooping Cough
Fed-batch cultivation of Bordetella pertussis: metabolism and Pertussis Toxin production.
Whooping Cough
Fertilization promoting peptide and adenosine, acting as first messengers, regulate cAMP production and consequent protein tyrosine phosphorylation in a capacitation-dependent manner.
Whooping Cough
FFA2-, but not FFA3-agonists inhibit GSIS of human pseudoislets: a comparative study with mouse islets and rat INS-1E cells.
Whooping Cough
Fibroblast growth factor potentiates receptor- and nonreceptor-mediated stimulation of adenylate cyclase in hamster fibroblasts.
Whooping Cough
Fibroblast-like synoviocytes support B-cell pseudoemperipolesis via a stromal cell-derived factor-1- and CD106 (VCAM-1)-dependent mechanism.
Whooping Cough
Fibronectin increases RhoA activity through inhibition of PKA in the human gastric cancer cell line SGC-7901.
Whooping Cough
Fibronectin promotes calcium signaling by interferon-gamma in human neutrophils via G-protein and sphingosine kinase-dependent mechanisms.
Whooping Cough
Fibronectin upregulates gelatinase B (MMP-9) and induces coordinated expression of gelatinase A (MMP-2) and its activator MT1-MMP (MMP-14) by human T lymphocyte cell lines. A process repressed through RAS/MAP kinase signaling pathways.
Whooping Cough
Filamentous hemagglutinin and pertussis toxin from Bordetella pertussis modulate immune responses to unrelated antigens.
Whooping Cough
Filamentous hemagglutinin and pertussis toxin promote adherence of Bordetella pertussis to cilia.
Whooping Cough
Filamentous hemagglutinin has a major role in mediating adherence of Bordetella pertussis to human WiDr cells.
Whooping Cough
Filamentous hemagglutinin of Bordetella bronchiseptica is required for efficient establishment of tracheal colonization.
Whooping Cough
Fimbrial phase variation in Bordetella pertussis: a novel mechanism for transcriptional regulation.
Whooping Cough
Fingolimod inhibits glutamate release through activation of S1P1 receptors and the G protein ?? subunit-dependent pathway in rat cerebrocortical nerve terminals.
Whooping Cough
Fingolimod protects cultured cortical neurons against excitotoxic death.
Whooping Cough
First report and detailed characterization of B. pertussis isolates not expressing Pertussis Toxin or Pertactin.
Whooping Cough
Fish somatostatin sst3 receptor: comparison of radioligand and GTPgammaS binding, adenylate cyclase and phospholipase C activities reveals different agonist-dependent pharmacological signatures.
Whooping Cough
Fixation traps formyl peptide receptors in high and low affinity forms that can be regulated by GTP[S] in the absence of ligand.
Whooping Cough
FK506 and pertussis toxin distinguish growth-induced locomotor activation from attractant-stimulated locomotion in human blood lymphocytes.
Whooping Cough
Flow-induced prostacyclin production is mediated by a pertussis toxin-sensitive G protein.
Whooping Cough
Flt-1-mediated down-regulation of endothelial cell proliferation through pertussis toxin-sensitive G proteins, beta gamma subunits, small GTPase CDC42, and partly by Rac-1.
Whooping Cough
Fluorescence correlation spectroscopy detects galanin receptor diversity on insulinoma cells.
Whooping Cough
Fluorescence spectroscopy studies of HEK293 cells expressing DOR-G(i)1? fusion protein; the effect of cholesterol depletion.
Whooping Cough
Fluorescent labeling of signal-transducing G-proteins. Pertussis toxin-catalyzed etheno-ADP ribosylation of transducin.
Whooping Cough
Fluoride activation of neutrophils: similarities to formylmethionyl-leucyl-phenylalanine.
Whooping Cough
Fluoride can activate the respiratory burst independently of Ca2+, stimulation of phosphoinositide turnover and protein kinase C translocation in primed human neutrophils.
Whooping Cough
Fluoride mobilizes intracellular calcium and promotes Ca2+ influx in rat proximal tubules.
Whooping Cough
Fluoride produces endothelium-dependent relaxation and endothelium-independent contraction in coronary artery.
Whooping Cough
Fluoride-mediated activation of guinea pig neutrophils.
Whooping Cough
Fluoride-mediated activation of the respiratory burst in electropermeabilized neutrophils.
Whooping Cough
Fluoroaluminate induces pertussis toxin-sensitive protein phosphorylation: differences in MC3T3-E1 osteoblastic and NIH3T3 fibroblastic cells.
Whooping Cough
Fluoroaluminate stimulates phosphorylation of p130 Cas and Fak and increases attachment and spreading of preosteoblastic MC3T3-E1 cells.
Whooping Cough
Fluoroaluminates mimic muscarinic- and oxytocin-receptor-mediated generation of inositol phosphates and contraction in the intact guinea-pig myometrium. Role for a pertussis/cholera-toxin-insensitive G protein.
Whooping Cough
Fluprostenol activates phospholipase C and Ca2+ mobilization in human myometrial cells.
Whooping Cough
FMLP activates Ras and Raf in human neutrophils. Potential role in activation of MAP kinase.
Whooping Cough
FMLP- and TNF-stimulated monoclonal Lym-1 antibody-dependent lysis of B lymphoblastoid tumour targets by neutrophils.
Whooping Cough
fMLP-induced in vitro nitric oxide production and its regulation in murine peritoneal macrophages.
Whooping Cough
FMRFamide modulation of secretory machinery underlying presynaptic inhibition of synaptic transmission requires a pertussis toxin-sensitive G-protein.
Whooping Cough
FMS*Calciumfluor increases alkaline phosphatase expression during osteogenesis in vitro of tibia-derived rat osteoblasts by activation of G alpha 0/G alpha i proteins.
Whooping Cough
FMS*Calciumfluor specifically increases mRNA levels and induces signaling via MAPK 42,44 and not FAK in differentiating rat osteoblasts.
Whooping Cough
Foetal-calf serum stimulates a pertussis-toxin-sensitive high-affinity GTPase activity in rat glioma C6 BU1 cells.
Whooping Cough
Follicle-stimulating hormone evokes an increase in intracellular free calcium ion concentrations in single ovarian (granulosa) cells.
Whooping Cough
Follicle-stimulating hormone receptor-mediated uptake of 45Ca2+ by cultured rat Sertoli cells does not require activation of cholera toxin- or pertussis toxin-sensitive guanine nucleotide binding proteins or adenylate cyclase.
Whooping Cough
Follicular Fluid High-Density Lipoprotein (FF-HDL)-Associated Sphingosine 1-Phosphate (S1P) Promotes Human Granulosa Lutein Cell Migration via S1P Receptor Type 3 (S1PR3) and Small G Protein RAC1.
Whooping Cough
Food allergens are protected from degradation during CD23-mediated transepithelial transport.
Whooping Cough
Formation and function of eicosanoids in the central nervous system.
Whooping Cough
Formation of inositol (1,4,5) trisphosphate and increase of cytosolic Ca2+ mediated by Fc receptors in human neutrophils.
Whooping Cough
Formyl peptide receptor expression in birds.
Whooping Cough
Formyl peptide receptor signaling in HL-60 cells through sphingosine kinase.
Whooping Cough
Formyl peptide-receptor like-1 requires lipid raft and extracellular signal-regulated protein kinase to activate inhibitor-kappaB kinase in human U87 astrocytoma cells.
Whooping Cough
Formyl peptides and ATP stimulate Ca2+ and Na+ inward currents through non-selective cation channels via G-proteins in dibutyryl cyclic AMP-differentiated HL-60 cells. Involvement of Ca2+ and Na+ in the activation of beta-glucuronidase release and superoxide production.
Whooping Cough
Formyl-Met-Leu-Phe induces calcium-dependent tyrosine phosphorylation of Rel-1 in neutrophils.
Whooping Cough
Forskolin-induced homologous desensitization via an adenosine 3',5'-monophosphate-dependent mechanism(s) in human osteoblast-like SaOS-2 cells.
Whooping Cough
Forskolin-resistant Y1 mutants harbor defects associated with the guanyl nucleotide-binding regulatory protein, Gs.
Whooping Cough
Four single-basepair mutations in the ptx promoter of Bordetella bronchiseptica are sufficient to activate the expression of pertussis toxin.
Whooping Cough
FPRL1-mediated induction of superoxide in LL-37-stimulated IMR90 human fibroblast.
Whooping Cough
Fractalkine (CX3CL1) stimulated by nuclear factor kappaB (NF-kappaB)-dependent inflammatory signals induces aortic smooth muscle cell proliferation through an autocrine pathway.
Whooping Cough
Fractalkine and CX3CR1 mediate a novel mechanism of leukocyte capture, firm adhesion, and activation under physiologic flow.
Whooping Cough
Fractalkine reduces N-methyl-d-aspartate-induced calcium flux and apoptosis in human neurons through extracellular signal-regulated kinase activation.
Whooping Cough
Fractalkine stimulates angiogenesis by activating the Raf-1/MEK/ERK- and PI3K/Akt/eNOS-dependent signal pathways.
Whooping Cough
Fractalkine-mediated endothelial cell injury by NK cells.
Whooping Cough
Free fatty acid receptor 3 activation suppresses neurogenic motility in rat proximal colon.
Whooping Cough
Free fatty acid receptor 4 inhibitory signaling in delta cells regulates islet hormone secretion in mice.
Whooping Cough
Frequency of pertussis in children with prolongued cough.
Whooping Cough
Frequency of serological evidence of Bordetella infections and mixed infections with other respiratory pathogens in university students with cough illnesses.
Whooping Cough
FSH directly regulates chondrocyte dedifferentiation and cartilage development.
Whooping Cough
FSH mediated cAMP signalling upregulates the expression of G? subunits in pubertal rat Sertoli cells.
Whooping Cough
Fulminant pertussis: a multi-center study with new insights into the clinico-pathological mechanisms.
Whooping Cough
Function of the cytoplasmic tail of human calcitonin receptor-like receptor in complex with receptor activity-modifying protein 2.
Whooping Cough
Functional activation of human neutrophils by recombinant monocyte-derived neutrophil chemotactic factor/IL-8.
Whooping Cough
Functional alpha 2-adrenergic receptor-Gs coupling undergoes agonist-promoted desensitization in a subtype-selective manner.
Whooping Cough
Functional alpha 2-adrenoceptors in rat adipocytes: inhibition of cyclic AMP accumulation.
Whooping Cough
Functional alpha2C-adrenoceptors in human neuroblastoma SH-SY5Y cells.
Whooping Cough
Functional analysis of a dominant negative mutant of G alpha i2.
Whooping Cough
Functional analysis of a human A(1) adenosine receptor/green fluorescent protein/G(i1)alpha fusion protein following stable expression in CHO cells.
Whooping Cough
Functional analysis of guinea pig ?1-adrenoceptor.
Whooping Cough
Functional analysis of the D2L dopamine receptor expressed in a cAMP-responsive luciferase reporter cell line.
Whooping Cough
Functional analysis of the pertussis toxin promoter.
Whooping Cough
Functional and molecular characterization of CCK receptors in the rat pancreatic acinar cell line AR 4-2J.
Whooping Cough
Functional and molecular characterization of VIP receptor--effector system in rat developing immunocompetent cells: G protein involvement.
Whooping Cough
Functional and molecular evidence for P2X receptors in LLC-PK1 cells.
Whooping Cough
Functional and molecular properties of the human recombinant Y4 receptor: resistance to agonist-promoted desensitization.
Whooping Cough
Functional and structural consequences of chemokine (C-X-C motif) receptor 4 activation with cognate and non-cognate agonists.
Whooping Cough
Functional annotation of the putative orphan Caenorhabditis elegans G-protein-coupled receptor C10C6.2 as a FLP15 peptide receptor.
Whooping Cough
Functional assessment of recombinant human alpha(2)-adrenoceptor subtypes with cytosensor microphysiometry.
Whooping Cough
Functional beta-adrenergic receptor signalling on nuclear membranes in adult rat and mouse ventricular cardiomyocytes.
Whooping Cough
Functional characterization and mRNA expression of pituitary adenylate cyclase activating polypeptide (PACAP) type I receptors in rat peritoneal macrophages.
Whooping Cough
Functional characterization of 5-HT1A and 5-HT1B serotonin receptor signaling through G-protein-activated inwardly rectifying K+ channels in a fluorescence-based membrane potential assay.
Whooping Cough
Functional characterization of a human receptor for neuropeptide FF and related peptides.
Whooping Cough
Functional characterization of a rat dopamine D-2 receptor cDNA expressed in a mammalian cell line.
Whooping Cough
Functional characterization of alpha1-adrenergic receptors in experimental vein grafts.
Whooping Cough
Functional characterization of an endogenous Xenopus oocyte adenosine receptor.
Whooping Cough
Functional characterization of P2Y and P2X receptors in human eosinophils.
Whooping Cough
Functional characterization of the Na(+)-H+ exchanger in rat mast cells: crosstalks between different kinase pathways.
Whooping Cough
Functional characterization of three mutations of the endothelin B receptor gene in patients with Hirschsprung's disease: evidence for selective loss of Gi coupling.
Whooping Cough
Functional compartmentalization of ATP is involved in angiotensin II-mediated closure of cardiac ATP-sensitive K+ channels.
Whooping Cough
Functional compartments in rat mast cells for cAMP and calcium on histamine release.
Whooping Cough
Functional coupling between endothelin receptors and multiple G-proteins in rat heart myocytes.
Whooping Cough
Functional coupling between heterologously expressed dopamine D(2) receptors and KCNQ channels.
Whooping Cough
Functional coupling between human E-type Ca2+ channels and mu opioid receptors expressed in Xenopus oocytes.
Whooping Cough
Functional coupling of cerebral ?-aminobutyric acid (GABA)(B) receptor with adenylate cyclase system: effect of phaclofen.
Whooping Cough
Functional coupling of human L-type Ca2+ channels and angiotensin AT1A receptors coexpressed in xenopus laevis oocytes: involvement of the carboxyl-terminal Ca2+ sensors.
Whooping Cough
Functional coupling of human metabotropic glutamate receptor hmGlu1d: comparison to splice variants hmGlu1a and -1b.
Whooping Cough
Functional coupling of mu-receptor-Galphai-tethered proteins in AtT20 cells.
Whooping Cough
Functional coupling of SSTR4, a major hippocampal somatostatin receptor, to adenylate cyclase inhibition, arachidonate release and activation of the mitogen-activated protein kinase cascade.
Whooping Cough
Functional coupling of the alpha 2-adrenergic receptor-adenylate cyclase complex in the pregnant human myometrium.
Whooping Cough
Functional coupling of the beta 2-adrenoceptor to a pertussis toxin-sensitive G protein in cardiac myocytes.
Whooping Cough
Functional coupling of the delta-, mu-, and kappa-opioid receptors to mitogen-activated protein kinase and arachidonate release in Chinese hamster ovary cells.
Whooping Cough
Functional coupling of the human dopamine D3 receptor in a transfected NG 108-15 neuroblastoma-glioma hybrid cell line.
Whooping Cough
Functional coupling of the NK1 tachykinin receptor to phospholipase D in chinese hamster ovary cells and astrocytoma cells.
Whooping Cough
Functional coupling of the nociceptin/orphanin FQ receptor in dog brain membranes.
Whooping Cough
Functional cross-talk between endothelial muscarinic and alpha2-adrenergic receptors in rabbit cerebral arteries.
Whooping Cough
Functional differences and interactions between phenotypic subpopulations of olfactory ensheathing cells in promoting CNS axonal regeneration.
Whooping Cough
Functional differences between monocyte chemotactic protein-1 receptor A and monocyte chemotactic protein-1 receptor B expressed in a Jurkat T cell.
Whooping Cough
Functional domains of delta- and mu-opioid receptors responsible for adenylyl cyclase inhibition.
Whooping Cough
Functional domains of the mouse beta3-adrenoceptor associated with differential G protein coupling.
Whooping Cough
Functional evidence for biased inhibition of G protein signaling by YM-254890 in human coronary artery endothelial cells.
Whooping Cough
Functional expression and characterization of human D2 and D3 dopamine receptors.
Whooping Cough
Functional expression and FRET analysis of green fluorescent proteins fused to G-protein subunits in rat sympathetic neurons.
Whooping Cough
Functional expression of a novel ginsenoside Rf binding protein from rat brain mRNA in Xenopus laevis oocytes.
Whooping Cough
Functional expression of CXCR4 (CD184) on small-cell lung cancer cells mediates migration, integrin activation, and adhesion to stromal cells.
Whooping Cough
Functional expression of formyl peptide receptor family in human NK cells.
Whooping Cough
Functional expression of human 5-HT1A receptors and differential coupling to second messengers in CHO cells.
Whooping Cough
Functional expression of human D3 dopamine receptors in differentiated neuroblastoma x glioma NG108-15 cells.
Whooping Cough
Functional expression of metabotropic GABA(B) receptors in primary cultures of astrocytes from rat cerebral cortex.
Whooping Cough
Functional expression of N-formyl peptide receptors in human bone marrow-derived mesenchymal stem cells.
Whooping Cough
Functional expression of the CXC-chemokine receptor-4/fusin on mouse microglial cells and astrocytes.
Whooping Cough
Functional expression of the GABAB receptor in human airway smooth muscle.
Whooping Cough
Functional expression of the human receptor for colony-stimulating factor 1 (CSF-1) in hamster fibroblasts: CSF-1 stimulates Na+/H+ exchange and DNA-synthesis in the absence of phosphoinositide breakdown.
Whooping Cough
Functional expression of the macrophage colony-stimulating factor receptor in human THP-1 monocytic leukemia cells.
Whooping Cough
Functional expression of the murine D2, D3, and D4 dopamine receptors in Xenopus laevis oocytes.
Whooping Cough
Functional expression of the P2Y14 receptor in human neutrophils.
Whooping Cough
Functional expression of the P2Y14 receptor in murine T-lymphocytes.
Whooping Cough
Functional expression, activation and desensitization of opioid receptor-like receptor ORL1 in neuroblastoma x glioma NG108-15 hybrid cells.
Whooping Cough
Functional high efficiency expression of cloned leukocyte chemoattractant receptor cDNAs.
Whooping Cough
Functional interaction of melatonin receptors and D1 dopamine receptors in cultured chick retinal neurons.
Whooping Cough
Functional interaction of prostaglandin E receptor EP3 subtype with guanine nucleotide-binding proteins, showing low-affinity ligand binding.
Whooping Cough
Functional interaction of purified muscarinic receptors with purified inhibitory guanine nucleotide regulatory proteins reconstituted in phospholipid vesicles.
Whooping Cough
Functional interactions between colony-stimulating factors and the insulin family hormones for human myeloid leukemic cells.
Whooping Cough
Functional maturation of human T lymphocytes is accompanied by changes in the G-protein pattern.
Whooping Cough
Functional maturation of somatostatin neurons and somatostatin receptors during development of mouse hypothalamus in vivo and in vitro.
Whooping Cough
Functional modification by cholera-toxin-catalyzed ADP-ribosylation of a guanine-nucleotide-binding regulatory protein serving as the substrate of pertussis toxin.
Whooping Cough
Functional platelet-activating factor receptors linked to inositol lipid hydrolysis, calcium mobilization and tyrosine kinase activity in the human endometrial HEC-1B cell line.
Whooping Cough
Functional recognition of a distinct receptor preferential for leukotriene E4 in mice lacking the cysteinyl leukotriene 1 and 2 receptors.
Whooping Cough
Functional reconstitution of detergent-solubilized bovine calf testis luteinizing hormone/chorionic gonadotropin receptor into phospholipid vesicles.
Whooping Cough
Functional reconstitution of prostaglandin E receptor from bovine adrenal medulla with guanine nucleotide binding proteins.
Whooping Cough
Functional regulation of GTP-binding protein coupled to insulin-like growth factor-I receptor by lithium during G1 phase of the rat thyroid cell cycle.
Whooping Cough
Functional remodeling in post-myocardial infarcted rats: focus on beta-adrenoceptor subtypes.
Whooping Cough
Functional responses of cloned muscarinic receptors expressed in CHO-K1 cells.
Whooping Cough
Functional role of a conserved motif in TM6 of the rat mu opioid receptor: constitutively active and inactive receptors result from substitutions of Thr6.34(279) with Lys and Asp.
Whooping Cough
Functional role of amino-terminal serine16 and serine27 of G alphaZ in receptor and effector coupling.
Whooping Cough
Functional role of M2 muscarinic receptors in the guinea pig ileum.
Whooping Cough
Functional SDF1 alpha/CXCR4 signaling in the developing spinal cord.
Whooping Cough
Functional selectivity of G protein signaling by agonist peptides and thrombin for the protease-activated receptor-1.
Whooping Cough
Functional somatostatin receptors on a rat pancreatic acinar cell line.
Whooping Cough
Functional specialization of fibronectin-binding beta 1-integrins in T lymphocyte migration.
Whooping Cough
Functional studies in the human submandibular duct cell line, HSG-PA, suggest a second salivary gland receptor subtype for nucleotides.
Whooping Cough
Functional trans-inactivation of insulin receptor kinase by growth-inhibitory angiotensin II AT2 receptor.
Whooping Cough
Functional uncoupling between the receptor and G-protein as the result of PKC activation, observed in Aplysia neurons.
Whooping Cough
Functional uncoupling of muscarinic receptors from adenylate cyclase in rat cardiac membranes by the active component of islet-activating protein, pertussis toxin.
Whooping Cough
Functional uncoupling of the inhibitory alpha 1-adrenergic response from a G-protein in innervated cultured cardiac cells by K+ depolarization.
Whooping Cough
Functionally distinct G proteins selectively couple different receptors to PI hydrolysis in the same cell.
Whooping Cough
Functionally distinct muscarinic receptors on gastric somatostatin cells.
Whooping Cough
Functionally Selective Inhibition of the Oxytocin Receptor by Retosiban in Human Myometrial Smooth Muscle.
Whooping Cough
Further analyses of mechanisms underlying the antinociceptive effect of the triterpene 3?, 6?, 16?-trihydroxylup-20(29)-ene in mice.
Whooping Cough
Further analysis of ATP-mediated activation of K+ channels in renal epithelioid Madin Darby canine kidney (MDCK) cells.
Whooping Cough
Further analysis of the sequence of the S1 subunit of pertussis toxin.
Whooping Cough
Further characterization of 5-HT- and 5-HT3 receptor agonists'-stimulated phosphoinositol phosphates accumulation.
Whooping Cough
Further characterization of alpha N-acetyl beta-endorphin-(1-31) regulatory activity, I: Effect on opioid- and alpha 2-mediated supraspinal antinociception in mice.
Whooping Cough
Further characterization of Japanese acellular pertussis vaccine prepared in 1988 by 6 Japanese manufacturers.
Whooping Cough
Further characterization of the D2 dopamine receptor expressed in MMQ cells.
Whooping Cough
Further contributions to an improved pertussis vaccine: I. Molecular mechanisms of pertussis toxin.
Whooping Cough
Further Elucidation of a Pertussis Toxin-Sensitive Transmembrane Signaling Mechanism Involved in Central alpha(2)-Adrenoceptor Activation in the Rat.
Whooping Cough
Further evaluation of the pertussis component vaccine produced by apoceruloplasmin affinity chromatography.
Whooping Cough
Further evidence for a phospholipase C-coupled G protein in hamster fibroblasts. Induction of inositol phosphate formation by fluoroaluminate and vanadate and inhibition by pertussis toxin.
Whooping Cough
Further evidence for the involvement of a phosphoprotein in the respiratory burst oxidase of human neutrophils.
Whooping Cough
Further evidence that the CCK2 receptor is coupled to two transduction pathways using site-directed mutagenesis.
Whooping Cough
Fusion expression and immunogenicity of Bordetella pertussis PTS1-FHA protein: implications for the vaccine development.
Whooping Cough
Future vaccine development at NICHD.
Whooping Cough
Fyn kinase-directed activation of SH2 domain-containing protein-tyrosine phosphatase SHP-2 by Gi protein-coupled receptors in Madin-Darby canine kidney cells.
Whooping Cough
G alpha 12 and G alpha 13 subunits define a fourth class of G protein alpha subunits.
Whooping Cough
G alpha 16, a G protein alpha subunit specifically expressed in hematopoietic cells.
Whooping Cough
G alpha i-G alpha s chimeras define the function of alpha chain domains in control of G protein activation and beta gamma subunit complex interactions.
Whooping Cough
G alpha q/11 mediates neurotensin excitation of substantia nigra dopaminergic neurons.
Whooping Cough
G alpha(i-2) mediates renal LLC-PK1 growth by a Raf-independent activation of p42/p44 MAP kinase.
Whooping Cough
G beta gamma subunits mediate mitogen-activated protein kinase activation by the tyrosine kinase insulin-like growth factor 1 receptor.
Whooping Cough
G protein activation and cyclic AMP modulation by naloxone benzoylhydrazone in distinct layers of rat olfactory bulb.
Whooping Cough
G protein activation by human dopamine D3 receptors in high-expressing Chinese hamster ovary cells: A guanosine-5'-O-(3-[35S]thio)- triphosphate binding and antibody study.
Whooping Cough
G protein activation inhibits amiloride-blockable highly selective sodium channels in A6 cells.
Whooping Cough
G Protein Activation Stimulates Phospholipase D Signaling in Plants.
Whooping Cough
G protein activation: a receptor-independent mode of action for cationic amphiphilic neuropeptides and venom peptides.
Whooping Cough
G protein beta 5 subunit interactions with alpha subunits and effectors.
Whooping Cough
G protein beta gamma subunits from bovine brain and retina: equivalent catalytic support of ADP-ribosylation of alpha subunits by pertussis toxin but differential interactions with Gs alpha.
Whooping Cough
G protein beta gamma subunits stimulate phosphorylation of Shc adapter protein.
Whooping Cough
G protein beta2 subunit interacts directly with neuropathy target esterase and regulates its activity.
Whooping Cough
G protein beta3 subunit 825T allele and enhanced coronary vasoconstriction on alpha(2)-adrenoceptor activation.
Whooping Cough
G protein betagamma11 complex translocation is induced by Gi, Gq and Gs coupling receptors and is regulated by the alpha subunit type.
Whooping Cough
G protein control of inositol lipids in intact vascular smooth muscle.
Whooping Cough
G protein control of potassium channel activity in a mast cell line.
Whooping Cough
G protein coupled receptor signaled apoptosis is associated with activation of a cation insensitive acidic endonuclease and intracellular acidification.
Whooping Cough
G protein coupling of antigen receptor-stimulated polyphosphoinositide hydrolysis in B cells.
Whooping Cough
G protein coupling of CGS 21680 binding sites in the rat hippocampus and cortex is different from that of adenosine A1 and striatal A2A receptors.
Whooping Cough
G protein coupling of the rat A1-adenosine receptor--partial purification of a protein which stabilizes the receptor-G protein association.
Whooping Cough
G protein coupling profile of mGluR6 and expression of G alpha proteins in retinal ON bipolar cells.
Whooping Cough
G protein coupling to M1 and M3 muscarinic receptors in sublingual glands.
Whooping Cough
G protein diversity: a distinct class of alpha subunits is present in vertebrates and invertebrates.
Whooping Cough
G protein expression and adenylate cyclase regulation in ventricular cardiomyocytes from STZ-diabetic rats.
Whooping Cough
G protein expression and second messenger formation in human granulosa cells.
Whooping Cough
G protein function in the ischaemic myocardium.
Whooping Cough
G protein G alpha i-2 inhibits outwardly rectifying chloride channels in human airway epithelial cells.
Whooping Cough
G protein G alpha q/11 and G alpha i1,2 are activated by pancreastatin receptors in rat liver: studies with GTP-gamma 35S and azido-GTP-alpha-32P.
Whooping Cough
G protein in stimulation of PI hydrolysis by CCK in isolated rat pancreatic acinar cells.
Whooping Cough
G Protein independent phosphorylation and internalization of the delta-opioid receptor.
Whooping Cough
G protein is coupled to presynaptic glutamate and GABA receptors in lobster neuromuscular synapse.
Whooping Cough
G protein modulates thyroid hormone-induced Na(+) channel activation in ventricular myocytes.
Whooping Cough
G protein modulation of omega-conotoxin binding sites in neuroblastoma x glioma NG 108-15 hybrid cells.
Whooping Cough
G protein preferences for dopamine D2 inhibition of prolactin secretion and DNA synthesis in GH4 pituitary cells.
Whooping Cough
G protein specificity of the muscarine-induced increase in an inward rectifier potassium current in AtT-20 cells.
Whooping Cough
G protein specificity: traffic direction required.
Whooping Cough
G protein subunit, alpha i-3, activates a pertussis toxin-sensitive Na+ channel from the epithelial cell line, A6.
Whooping Cough
G protein subunits and the stimulation of phospholipase C by Gs-and Gi-coupled receptors: Lack of receptor selectivity of Galpha(16) and evidence for a synergic interaction between Gbeta gamma and the alpha subunit of a receptor activated G protein.
Whooping Cough
G protein threshold behavior in the human neutrophil oxidant response: measurement of G proteins available for signaling in responding and nonresponding subpopulations.
Whooping Cough
G protein {beta}{gamma} subunits mediate presynaptic inhibition of transmitter release from rat superior cervical ganglion neurones in culture.
Whooping Cough
G protein-activated K+ channels: a reporter for rapid activation of G proteins by lysophosphatidic acid in Xenopus oocytes.
Whooping Cough
G protein-adrenergic interactions in the heart.
Whooping Cough
G protein-associated, specific membrane binding sites mediate the neuroprotective effect of dehydroepiandrosterone.
Whooping Cough
G protein-coupled APJ receptor signaling induces focal adhesion formation and cell motility.
Whooping Cough
G protein-coupled endothelial receptor for atypical cannabinoid ligands modulates a Ca2+-dependent K+ current.
Whooping Cough
G protein-coupled estrogen receptor 1 (GPER1)/GPR30 increases ERK1/2 activity through PDZ motif-dependent and -independent mechanisms.
Whooping Cough
G protein-coupled inward rectifier modulated by dopamine agonists in cultured substantia nigra neurons.
Whooping Cough
G protein-coupled receptor 35 contributes to mucosal repair in mice via migration of colonic epithelial cells.
Whooping Cough
G protein-coupled receptor internalization signaling is required for cardioprotection in ischemic preconditioning.
Whooping Cough
G protein-coupled receptor-induced sensitization of phospholipase C stimulation by receptor tyrosine kinases.
Whooping Cough
G protein-coupled receptors mediate a fast excitatory postsynaptic current in CA3 pyramidal neurons in hippocampal slices.
Whooping Cough
G protein-coupled receptors mediate two functionally distinct pathways of tyrosine phosphorylation in rat 1a fibroblasts. Shc phosphorylation and receptor endocytosis correlate with activation of Erk kinases.
Whooping Cough
G protein-dependent activation of smooth muscle eNOS via natriuretic peptide clearance receptor.
Whooping Cough
G protein-independent activation of an inward Na(+) current by muscarinic receptors in mouse pancreatic beta-cells.
Whooping Cough
G protein-independent G1 cell cycle block and apoptosis with morphine in adenocarcinoma cells: involvement of p53 phosphorylation.
Whooping Cough
G protein-mediated activation of a nonspecific cation current in cultured rat retinal pigment epithelial cells.
Whooping Cough
G protein-mediated FMRFamidergic modulation of calcium influx in dissociated heart muscle cells from squid, Loligo forbesii.
Whooping Cough
G protein-mediated inhibition of inwardly rectifying K+ channels in guinea pig chromaffin cells.
Whooping Cough
G protein-mediated inhibition of phospholipase C activity in a solubilized membrane preparation.
Whooping Cough
G protein-mediated inhibitory effect of a nitric oxide donor on the L-type Ca2+ current in rat ventricular myocytes.
Whooping Cough
G protein-mediated mitogen-activated protein kinase activation by two dopamine D2 receptors.
Whooping Cough
G protein-mediated suppression of L-type Ca2+ current by interleukin-1 beta in cultured rat ventricular myocytes.
Whooping Cough
G proteins and endothelium-dependent relaxations.
Whooping Cough
G proteins and phospholipase C mediate thrombin-induced generation of plasminogen activator inhibitor-1 from vascular smooth muscle cells.
Whooping Cough
G proteins and regulation of pyruvate dehydrogenase activity by insulin in human circulating lymphocytes.
Whooping Cough
G proteins couple alpha-adrenergic and GABAb receptors to inhibition of peptide secretion from peripheral sensory neurons.
Whooping Cough
G proteins G?i1/3 are critical targets for Bordetella pertussis toxin-induced vasoactive amine sensitization.
Whooping Cough
G proteins in adipocytes and preadipocytes: characterization, subcellular distribution, and potential roles for Gi2 and/or Gi3 in the control of cell proliferation.
Whooping Cough
G proteins in aortic endothelial cells and bradykinin-induced formation of nitric oxide.
Whooping Cough
G proteins in Aplysia: biochemical characterization and regional and subcellular distribution.
Whooping Cough
G proteins in carotid body chemoreception.
Whooping Cough
G proteins mediate suppression of Ca2+-activated K current by acetylcholine in smooth muscle cells.
Whooping Cough
G proteins of the Gq family couple the H2 histamine receptor to phospholipase C.
Whooping Cough
G proteins regulate calcium channels in the luminal membranes of the rabbit nephron.
Whooping Cough
G proteins subserve relaxations mediated by adenosine receptors in human coronary artery.
Whooping Cough
G regulatory proteins and muscarinic receptor signal transduction in mucous acini of rat submandibular gland.
Whooping Cough
G(i) protein-mediated functional compartmentalization of cardiac beta(2)-adrenergic signaling.
Whooping Cough
G(i)-coupled GPCR signaling controls the formation and organization of human pluripotent colonies.
Whooping Cough
G(i)-dependent suppression of beta(1)-adrenoceptor effects in ventricular myocytes from NE-treated guinea pigs.
Whooping Cough
G(i)-mediated Cas tyrosine phosphorylation in vascular endothelial cells stimulated with sphingosine 1-phosphate: possible involvement in cell motility enhancement in cooperation with Rho-mediated pathways.
Whooping Cough
G(i-1)/G(i-2)-dependent signaling by single-transmembrane natriuretic peptide clearance receptor.
Whooping Cough
G(i/o) Protein-Dependent and -Independent Actions of Pertussis Toxin (PTX).
Whooping Cough
G(o) activation is required for both appetitive and aversive memory acquisition in Drosophila.
Whooping Cough
G(o) protein does not regulate ATP-stimulated [Ca2+]i elevation or noradrenaline release in PC12 cells.
Whooping Cough
G(o) signaling is required for Drosophila associative learning.
Whooping Cough
G(o)-protein alpha-subunits activate mitogen-activated protein kinase via a novel protein kinase C-dependent mechanism.
Whooping Cough
G(o)2 and Gi3 proteins mediate the action of somatostatin on membrane Ca2+ and K+ currents in ovine pituitary somatotrophs.
Whooping Cough
G(s) protein dysfunction in allergen-challenged human isolated passively sensitized bronchi.
Whooping Cough
G(z alpha) deficient mice: enzyme levels in the autonomic nervous system, neuronal survival and effect of genetic background.
Whooping Cough
G(z) can mediate the acute actions of mu- and kappa-opioids but is not involved in opioid-induced adenylyl cyclase supersensitization.
Whooping Cough
G(z) signaling: emerging divergence from G(i) signaling.
Whooping Cough
G-protein activation by putative antagonists at mutant Thr373Lys alpha2A adrenergic receptors.
Whooping Cough
G-protein activation decreases isoflurane inhibition of N-type Ba2+ currents.
Whooping Cough
G-protein activation mediates prepulse facilitation of Ca2+ channel currents in bovine chromaffin cells.
Whooping Cough
G-protein activators induce a potassium conductance in murine macrophages.
Whooping Cough
G-protein activity requirement for polymethylmethacrylate and titanium particle-induced fibroblast interleukin-6 and monocyte chemoattractant protein-1 release in vitro.
Whooping Cough
G-protein alpha subunit Gi(alpha)2 mediates erythropoietin signal transduction in human erythroid precursors.
Whooping Cough
G-protein alpha-subunits in cytosolic and membranous fractions of human neutrophils.
Whooping Cough
G-protein beta gamma subunits mediate specific phosphorylation of the protein-tyrosine phosphatase SH-PTP1 induced by lysophosphatidic acid.
Whooping Cough
G-protein control of cardiac potassium channels.
Whooping Cough
G-protein coupled activation of potassium channels by endogenous neuropeptides in snail neurons.
Whooping Cough
G-protein coupled progesterone receptors in the plasma membrane of fungus Rhizopus nigricans.
Whooping Cough
G-Protein coupled progesterone receptors in the plasma membrane of fungus Rhizopus nigricans.
Whooping Cough
G-protein coupling and signalling of Y1-like neuropeptide Y receptors in SK-N-MC cells.
Whooping Cough
G-protein dependent potentiation of calcium release from sarcoplasmic reticulum of skeletal muscle.
Whooping Cough
G-protein dissociation, GTP-GDP exchange and GTPase activity in control and PMA treated neutrophils stimulated by fMet-Leu-Phe.
Whooping Cough
G-protein distribution in canine cardiac sarcoplasmic reticulum and sarcolemma: comparison to rabbit skeletal muscle membranes and to brain and erythrocyte G-proteins.
Whooping Cough
G-protein expression and intimal hyperplasia after arterial injury: a role for Galpha(i) proteins.
Whooping Cough
G-protein from Medicago sativa: functional association to photoreceptors.
Whooping Cough
G-protein involvement in matrix-mediated motility and invasion of high and low experimental metastatic B16 melanoma clones.
Whooping Cough
G-protein involvement in muscarinic receptor-stimulation of inositol phosphates in longitudinal smooth muscle from the small intestine of the guinea-pig.
Whooping Cough
G-protein level quantification in platelets and leukocytes from patients with panic disorder.
Whooping Cough
G-protein mediated responses to localized serotonin application in an invertebrate photoreceptor.
Whooping Cough
G-protein mediates voltage regulation of agonist binding to muscarinic receptors: effects on receptor-Na+ channel interaction.
Whooping Cough
G-protein mediation of cannabinoid-induced phospholipase activation.
Whooping Cough
G-protein modulation of alpha 1A (P/Q) type calcium channel expressed in GH3 cells.
Whooping Cough
G-protein modulation of neuronal class E (alpha 1E) calcium channel expressed in GH3 cells.
Whooping Cough
G-protein modulators alter the swimming behavior and calcium influx of Paramecium tetraurelia.
Whooping Cough
G-protein mRNA levels during adipocyte differentiation.
Whooping Cough
G-protein regulation of an L-type calcium channel current in canine jejunal circular smooth muscle.
Whooping Cough
G-protein regulation of outwardly rectified epithelial chloride channels incorporated into planar bilayer membranes.
Whooping Cough
G-protein regulation of the solubilized human zona pellucida-mediated acrosome reaction and zona pellucida binding.
Whooping Cough
G-Protein types involved in calcium channel inhibition at a presynaptic nerve terminal.
Whooping Cough
G-protein-coupled glucocorticoid receptors on the pituitary cell membrane.
Whooping Cough
G-protein-coupled receptor cell signaling pathways mediating embryonic chick retinal growth cone collapse induced by lysophosphatidic acid and sphingosine-1-phosphate.
Whooping Cough
G-protein-coupled receptor independent, immunomodulatory properties of chemokine CXCL9.
Whooping Cough
G-protein-coupled receptor-mediated activation of rap GTPases: characterization of a novel Galphai regulated pathway.
Whooping Cough
G-Protein-coupled receptors and Fcgamma-receptors mediate activation of Akt/protein kinase B in human phagocytes.
Whooping Cough
G-protein-coupled receptors in HL-60 human leukemia cells.
Whooping Cough
G-protein-dependency of orexin/hypocretin receptor signalling in recombinant Chinese hamster ovary cells.
Whooping Cough
G-protein-dependent and -independent pathways regulate proteinase-activated receptor-2 mediated p65 NFkappaB serine 536 phosphorylation in human keratinocytes.
Whooping Cough
G-protein-mediated epidermal growth factor signal transduction in a human breast cancer cell line. Evidence for two intracellular pathways distinguishable by pertussis toxin.
Whooping Cough
G-protein-mediated regulation of the insulin-responsive glucose transporter in isolated cardiac myocytes.
Whooping Cough
G-protein-mediated signal transduction for meiosis reinitiation in starfish oocyte.
Whooping Cough
G-protein-mediated signaling in cholesterol-enriched arterial smooth muscle cells. 2. Role of protein kinase C-delta in the regulation of eicosanoid production.
Whooping Cough
G-protein-sensitive guanylyl cyclase activity associated with plasma membranes.
Whooping Cough
G-proteins and adenylyl cyclase in ovarian granulosa cells of amago salmon (Oncorhynchus rhodurus).
Whooping Cough
G-proteins and egg activation.
Whooping Cough
G-proteins and endothelial responses.
Whooping Cough
G-proteins and phospholipase activation in endothelial cells.
Whooping Cough
G-proteins are involved in 5-HT receptor-mediated modulation of N- and P/Q- but not T-type Ca2+ channels.
Whooping Cough
G-proteins are involved in contractile responses of isolated mesenteric resistance arteries to agonists.
Whooping Cough
G-proteins are involved in riluzole inhibition of high voltage-activated calcium channels in rat dorsal root ganglion neurons.
Whooping Cough
G-proteins as targets for non-immunological histamine releasers.
Whooping Cough
G-proteins coupled to phosphoinositide hydrolysis in the cochlear and vestibular sensory epithelia of the rat are insensitive to cholera and pertussis toxins.
Whooping Cough
G-proteins in alpha 1-adrenoceptor mediated prostatic smooth muscle contraction.
Whooping Cough
G-proteins in guinea pig airway smooth muscle: identification and functional involvement.
Whooping Cough
G-proteins in rat blood vessels--I. Identification.
Whooping Cough
G-proteins in rat blood vessels--II. Assessment of functional involvement.
Whooping Cough
G-proteins in skeletal muscle. Evidence for a 40 kDa pertussis-toxin substrate in purified transverse tubules.
Whooping Cough
G-proteins in Torpedo marmorata electric organ. Differential distribution in pre- and post-synaptic membranes and synaptic vesicles.
Whooping Cough
G-proteins mediate inhibition and activation of Ca(2+)-induced exocytosis from SLO-permeabilized peptidergic nerve endings.
Whooping Cough
G-proteins modulate amiloride-sensitive sodium channels.
Whooping Cough
G-proteins modulate prolactin- and interleukin-2-stimulated mitogenesis in rat Nb2 lymphoma cells.
Whooping Cough
G-proteins of fat-cells. Role in hormonal regulation of intracellular inositol 1,4,5-trisphosphate.
Whooping Cough
G-proteins, the inositol lipid signalling pathway, and secretion.
Whooping Cough
G12/13 and Gq mediate S1P2-induced inhibition of Rac and migration in vascular smooth muscle in a manner dependent on Rho but not Rho kinase.
Whooping Cough
G?(i2) signaling: friend or foe in cardiac injury and heart failure?
Whooping Cough
G?14 subunit-mediated inhibition of voltage-gated Ca2+ and K+ channels via neurokinin-1 receptors in rat celiac-superior mesenteric ganglion neurons.
Whooping Cough
G?i)- and G?i3-specific regulation of voltage-dependent L-type calcium channels in cardiomyocytes.
Whooping Cough
G?i-biased apelin analog protects against isoproterenol-induced myocardial dysfunction in rats.
Whooping Cough
G?o represses insulin secretion by reducing vesicular docking in pancreatic beta-cells.
Whooping Cough
G?s proteins activate p72(Syk) and p60-c-Src tyrosine kinases to mediate sickle red blood cell adhesion to endothelium via LW-?v?3 and CD44-CD44 interactions.
Whooping Cough
G?s signalling of the CB1 receptor and the influence of receptor number.
Whooping Cough
GABA and Gi/o differentially control circadian rhythms and synchrony in clock neurons.
Whooping Cough
GABA is toxic for mouse striatal neurones through a transporter-mediated process.
Whooping Cough
GABA mediates autoreceptor feedback inhibition in the rat carotid body via presynaptic GABAB receptors and TASK-1.
Whooping Cough
GABA mediation of the dual effects of somatostatin on guinea pig ileal myenteric cholinergic transmission.
Whooping Cough
GABA(B) heterodimeric receptors promote Ca(2+) influx via store-operated channels in rat cortical neurons and transfected chinese hamster ovary cells.
Whooping Cough
GABA(B) presynaptically modulates suprachiasmatic input to hypothalamic paraventricular magnocellular neurons.
Whooping Cough
GABA(B) receptor activation inhibits N- and P/Q-type calcium channels in cultured lamprey sensory neurons.
Whooping Cough
GABA(B) receptor activation protects GABA(A) receptor from cyclic AMP-dependent down-regulation in rat cerebellar granule cells.
Whooping Cough
GABA(B) receptor-mediated stimulation of adenylyl cyclase activity in membranes of rat olfactory bulb.
Whooping Cough
GABA(B) receptors in anterior pituitary cells. Mechanism of action coupled to endocrine effects.
Whooping Cough
GABA-induced motility of spinal neuroblasts develops along a ventrodorsal gradient and can be mimicked by agonists of GABAA and GABAB receptors.
Whooping Cough
GABA-induced potassium channels in cultured neurons.
Whooping Cough
GABAB receptor activation inhibits Ca2(+)-activated 86Rb-efflux in cultured spinal cord neurons via G-protein mechanism.
Whooping Cough
GABAB receptor activation inhibits Ca2+-activated potassium channels in synaptosomes: involvement of G-proteins.
Whooping Cough
GABAB receptor activation inhibits exocytosis in rat pancreatic beta-cells by G-protein-dependent activation of calcineurin.
Whooping Cough
GABAB receptor-mediated inhibition of Ca2+ currents and synaptic transmission in cultured rat hippocampal neurones.
Whooping Cough
GABAB receptor-mediated inhibition of spontaneous inhibitory synaptic currents in rat midbrain culture.
Whooping Cough
GABAB receptor-mediated presynaptic potentiation of ATP ionotropic receptors in rat midbrain synaptosomes.
Whooping Cough
GABAB receptor-mediated regulation of glutamate-activated calcium transients in hypothalamic and cortical neuron development.
Whooping Cough
GABAB receptors are expressed in human aortic smooth muscle cells and regulate the intracellular Ca(2+) concentration.
Whooping Cough
GABAB receptors expressed in Xenopus oocytes by guinea pig cerebral mRNA are functionally coupled with Ca2(+)-dependent Cl- channels and with K+ channels, through GTP-binding proteins.
Whooping Cough
GABAB receptors inhibit low-voltage activated and high-voltage activated Ca(2+) channels in sensory neurons via distinct mechanisms.
Whooping Cough
GABAB receptors modulate catecholamine secretion in chromaffin cells by a mechanism involving cyclic AMP formation.
Whooping Cough
GABAB receptors-associated proteins: potential drug targets in neurological disorders?
Whooping Cough
GABAB-mediated upregulation of the high-voltage-activated Ca2+ channels in rat dorsal root ganglia.
Whooping Cough
GABAB1 and GABAB2 receptor subunits co-expressed in cultured human RPE cells regulate intracellular Ca2+ via Gi/o-protein and phospholipase C pathways.
Whooping Cough
GABAergic transmission to gonadotropin-releasing hormone (GnRH) neurons is regulated by GnRH in a concentration-dependent manner engaging multiple signaling pathways.
Whooping Cough
Gabapentin-mediated inhibition of voltage-activated Ca2+ channel currents in cultured sensory neurones is dependent on culture conditions and channel subunit expression.
Whooping Cough
Gadolinium inhibits prostate cancer PC3 cell migration and suppresses osteoclast differentiation in vitro.
Whooping Cough
Galanin activates an inwardly rectifying potassium conductance and inhibits a voltage-dependent calcium conductance in mudpuppy parasympathetic neurons.
Whooping Cough
Galanin activates nucleotide-dependent K+ channels in insulin-secreting cells via a pertussis toxin-sensitive G-protein.
Whooping Cough
Galanin and galanin receptor type 1 suppress proliferation in squamous carcinoma cells: activation of the extracellular signal regulated kinase pathway and induction of cyclin-dependent kinase inhibitors.
Whooping Cough
Galanin can inhibit insulin release by a mechanism other than membrane hyperpolarization or inhibition of adenylate cyclase.
Whooping Cough
Galanin induces opposite effects via different intracellular pathways in smooth muscle cells from dog colon.
Whooping Cough
Galanin inhibition of enteric cholinergic neurotransmission: guanosine triphosphate-binding protein interactions with adenylate cyclase.
Whooping Cough
Galanin inhibition of enterochromaffin-like cell function.
Whooping Cough
Galanin inhibits dopamine secretion and activates a potassium channel in pheochromocytoma cells.
Whooping Cough
Galanin inhibits glucagon-like peptide-1 secretion through pertussis toxin-sensitive G protein and ATP-dependent potassium channels in rat ileal L-cells.
Whooping Cough
Galanin inhibits insulin secretion by direct interference with exocytosis.
Whooping Cough
Galanin inhibits proinsulin gene expression stimulated by the insulinotropic hormone glucagon-like peptide-I(7-37) in mouse insulinoma beta TC-1 cells.
Whooping Cough
Galanin inhibits somatostatin release by the rat islet cell tumor in culture, Rin-m.
Whooping Cough
Galanin inhibits tyrosine hydroxylase expression in midbrain dopaminergic neurons.
Whooping Cough
Galanin receptor 2 utilizes distinct signaling pathways to suppress cell proliferation and induce apoptosis in HNSCC.
Whooping Cough
Galanin receptor in the rat pancreatic beta cell line Rin m 5F. Molecular characterization by chemical cross-linking.
Whooping Cough
Galanin stimulates Ca2+ mobilization, inositol phosphate accumulation, and clonal growth in small cell lung cancer cells.
Whooping Cough
Galanin stimulates cortisol secretion from human adrenocortical cells through the activation of galanin receptor subtype 1 coupled to the adenylate cyclase-dependent signaling cascade.
Whooping Cough
Galanin suppresses calcium conductance and activates inwardly rectifying potassium channels in myenteric neurones from guinea-pig small intestine.
Whooping Cough
Galectin-1 stimulates monocyte chemotaxis via the p44/42 MAP kinase pathway and a Pertussis toxin sensitive pathway.
Whooping Cough
Galectin-3 is an amplifier of inflammation in atherosclerotic plaque progression through macrophage activation and monocyte chemoattraction.
Whooping Cough
Galectin-3 stimulates uptake of extracellular Ca2+ in human Jurkat T-cells.
Whooping Cough
Galparan induces in vivo acetylcholine release in the frontal cortex.
Whooping Cough
Galparan: a powerful insulin-releasing chimeric peptide acting at a novel site.
Whooping Cough
Galpha i2 enhances in vivo activation of and insulin signaling to GLUT4.
Whooping Cough
Galpha(12/13) mediates alpha(1)-adrenergic receptor-induced cardiac hypertrophy.
Whooping Cough
Galpha(i2) enhances insulin signaling via suppression of protein-tyrosine phosphatase 1B.
Whooping Cough
Galpha(i2), Galpha(i3)and Galpha(o) are all required for normal muscarinic inhibition of the cardiac calcium channels in nodal/atrial-like cultured cardiocytes.
Whooping Cough
Galpha(q/11) and gbetagamma proteins and membrane signaling of calcitriol and estradiol.
Whooping Cough
Galpha12 stimulates c-Jun NH2-terminal kinase through the small G proteins Ras and Rac.
Whooping Cough
Galphai is not required for chemotaxis mediated by Gi-coupled receptors.
Whooping Cough
Galphai protein-dependant extracellular signal-regulated kinase-1/2 activation is required for HIV-1 reverse transcription.
Whooping Cough
GalphaL1 (Galpha14) couples the opioid receptor-like1 receptor to stimulation of phospholipase C.
Whooping Cough
Galphas-biased beta2-adrenergic receptor signaling from restoring synchronous contraction in the failing heart.
Whooping Cough
Gamma aminobutyric acid B receptor-mediated inhibition of adenylate cyclase in cultured cerebellar granule cells: blockade by islet-activating protein.
Whooping Cough
gamma-aminobutyric acid type B receptors are expressed and functional in mammalian cardiomyocytes.
Whooping Cough
gamma-Aminobutyric acid-B receptors inhibit glutamate release from cerebellar granule cells: consequences of inhibiting cyclic AMP formation and calcium influx.
Whooping Cough
gamma-Hydroxybutyrate receptor binding in rat brain is inhibited by guanyl nucleotides and pertussis toxin.
Whooping Cough
Ganglioside modulation of neural cell adhesion molecule and N-cadherin-dependent neurite outgrowth.
Whooping Cough
Gangliosides GM1 and GM2 induce vascular smooth muscle cell proliferation via extracellular signal-regulated kinase 1/2 pathway.
Whooping Cough
Gap junction assembly: PTX-sensitive G proteins regulate the distribution of connexin43 within cells.
Whooping Cough
GAP-43 amino terminal peptides modulate growth cone morphology and neurite outgrowth.
Whooping Cough
Gastric somatostatin: a paracrine regulator of acid secretion.
Whooping Cough
Gastrin induces IP3 formation through phospholipase C gamma 1 and pp60c-src kinase.
Whooping Cough
Gastrin stimulation of histamine synthesis in enterochromaffin-like cells from rabbit fundic mucosa.
Whooping Cough
Gastrin-releasing peptide-induced expression of prostaglandin synthase-2 in Swiss 3T3 cells.
Whooping Cough
Gating properties of GIRK channels activated by Galpha(o)- and Galpha(i)-coupled muscarinic m2 receptors in Xenopus oocytes: the role of receptor precoupling in RGS modulation.
Whooping Cough
Gbeta gamma -independent constitutive association of Galpha s with SHP-1 and angiotensin II receptor AT2 is essential in AT2-mediated ITIM-independent activation of SHP-1.
Whooping Cough
Gbeta gamma mediate differentiation of vascular smooth muscle cells.
Whooping Cough
Gbetagamma dimers released in response to thyrotropin activate phosphoinositide 3-kinase and regulate gene expression in thyroid cells.
Whooping Cough
Gbetagamma signaling promotes breast cancer cell migration and invasion.
Whooping Cough
Gbetagamma-activated inwardly rectifying K(+) (GIRK) channel activation kinetics via Galphai and Galphao-coupled receptors are determined by Galpha-specific interdomain interactions that affect GDP release rates.
Whooping Cough
Gbetagamma-dependent phosphoinositide 3-kinase activation in hearts with in vivo pressure overload hypertrophy.
Whooping Cough
GCP-2-induced internalization of IL-8 receptors: hierarchical relationships between GCP-2 and other ELR(+)-CXC chemokines and mechanisms regulating CXCR2 internalization and recycling.
Whooping Cough
Gene Polymorphism in Toll-like Receptor 4: Effect on Antibody Production and Persistence After Acellular Pertussis Vaccination During Adolescence.
Whooping Cough
Gene replacement in Bordetella pertussis by transformation with linear DNA.
Whooping Cough
Generation of a constitutive Na+-dependent inward-rectifier current in rat adult atrial myocytes by overexpression of Kir3.4.
Whooping Cough
Generation of adult-like antibody avidity profiles after early-life immunization with protein vaccines.
Whooping Cough
Generation of human monoclonal antibodies that confer protection against pertussis toxin.
Whooping Cough
Generation of inositol phosphates in bitter taste transduction.
Whooping Cough
Generation of inositol phosphates, cytosolic Ca2+, and ionic fluxes in PC12 cells treated with bradykinin.
Whooping Cough
Generation of plant-derived recombinant DTP subunit vaccine.
Whooping Cough
Genes coding for proteins in central nervous system myelin.
Whooping Cough
Genes for two homologous G-protein alpha subunits map to different human chromosomes.
Whooping Cough
Genetic analysis of a region of the Bordetella pertussis chromosome encoding filamentous hemagglutinin and the pleiotropic regulatory locus vir.
Whooping Cough
Genetic analysis of Bordetella pertussis in Ontario, Canada reveals one predominant clone.
Whooping Cough
Genetic analysis of pertussis toxin promoter activation in Bordetella pertussis.
Whooping Cough
Genetic analysis of the influence of pertussis toxin on experimental allergic encephalomyelitis susceptibility: an environmental agent can override genetic checkpoints.
Whooping Cough
Genetic and antigenic analysis of Bordetella pertussis isolates recovered from clinical cases in Ontario, Canada, before and after the introduction of the acellular pertussis vaccine.
Whooping Cough
Genetic and biochemical analyses of BvgA interaction with the secondary binding region of the fha promoter of Bordetella pertussis.
Whooping Cough
Genetic deficiency of C3 as well as CNS-targeted expression of the complement inhibitor sCrry ameliorates experimental autoimmune uveoretinitis.
Whooping Cough
Genetic disruption of G proteins, G(i2)alpha or G(o)alpha, does not abolish inotropic and chronotropic effects of stimulating muscarinic cholinoceptors in atrium.
Whooping Cough
Genetic diversity and population dynamics of Bordetella pertussis in China between 1950-2007.
Whooping Cough
Genetic exchange of the S2 and S3 subunits in pertussis toxin.
Whooping Cough
Genetic stability of the live attenuated Bordetella pertussis vaccine candidate BPZE1.
Whooping Cough
Genetic studies of the molecular basis of whooping cough.
Whooping Cough
Genetic susceptibility to experimental autoimmune uveoretinitis in the rat is associated with an elevated Th1 response.
Whooping Cough
Genetic Variation in the Magnitude and Longevity of the IgG Subclass Response to a Diphtheria-Tetanus-Acellular Pertussis (DTaP) Vaccine in Mice.
Whooping Cough
Genetic Variation of Bordetella pertussis in Austria.
Whooping Cough
Genetically derived toxoids for use as vaccines and adjuvants.
Whooping Cough
Genetically detoxified pertussis toxin (PT-9K/129G): implications for immunization and vaccines.
Whooping Cough
Genetically detoxified pertussis toxin displays near identical structure to its wild-type and exhibits robust immunogenicity.
Whooping Cough
Genetically detoxified pertussis toxin induces superior antigen specific CD4 T cell responses compared to chemically detoxified pertussis toxin.
Whooping Cough
Genetically detoxified pertussis toxin induces Th1/Th17 immune response through MAPKs and IL-10-dependent mechanisms.
Whooping Cough
Genetically modified pertussis toxin: a quantum leap?
Whooping Cough
Genetics of pertussis toxin.
Whooping Cough
Genital antibody responses in mice after intranasal infection with an attenuated candidate vector strain of Bordetella pertussis.
Whooping Cough
Genome diversity and evolutionary characteristics of clinical isolates of Bordetella pertussis circulating in Iran.
Whooping Cough
Genome-Wide Association Mapping of the Antibody Response to Diphtheria, Tetanus and Acellular Pertussis Vaccine in Mice.
Whooping Cough
Genome-wide gene expression analysis of Bordetella pertussis isolates associated with a resurgence in pertussis: elucidation of factors involved in the increased fitness of epidemic strains.
Whooping Cough
Genomic dissection of Australian Bordetella pertussis isolates from the 2008-2012 epidemic.
Whooping Cough
Genomics of Bordetella pertussis toxins.
Whooping Cough
Genotypic variation in the Bordetella pertussis virulence factors pertactin and pertussis toxin in historical and recent clinical isolates in the United Kingdom.
Whooping Cough
Ghrelin and obestatin promote the allergic action in rat peritoneal mast cells as basic secretagogues.
Whooping Cough
Ghrelin Attenuates Neuroinflammation and Demyelination in Experimental Autoimmune Encephalomyelitis Involving NLRP3 Inflammasome Signaling Pathway and Pyroptosis.
Whooping Cough
Ghrelin signaling in human mesenteric arteries.
Whooping Cough
Ghrelin signalling in guinea-pig femoral artery smooth muscle cells.
Whooping Cough
Ghrelin suppresses Purkinje neuron P-type Ca(2+) channels via growth hormone secretagogue type 1a receptor, the ?? subunits of Go-protein, and protein kinase a pathway.
Whooping Cough
Ghrelin uses Galphai2 and activates voltage-dependent K+ channels to attenuate glucose-induced Ca2+ signaling and insulin release in islet beta-cells: novel signal transduction of ghrelin.
Whooping Cough
Gi affects the agonist-binding properties of beta-adrenoceptors in the presence of Gs.
Whooping Cough
Gi alpha 1-mediated cardiac electrophysiological remodeling and arrhythmia in hypertrophic cardiomyopathy.
Whooping Cough
Gi alpha and Gi beta are part of a signalling complex in Balb/c3T3 cells: phosphorylation of Gi beta in growth-factor-activated fibroblasts.
Whooping Cough
Gi and Gq/11 proteins are involved in dissemination of myeloid leukemia cells to the liver and spleen, whereas bone marrow colonization involves Gq/11 but not Gi.
Whooping Cough
Gi is involved in ethanol inhibition of L-type calcium channels in undifferentiated but not differentiated PC-12 cells.
Whooping Cough
Gi protein activation of gonadotropin-releasing hormone-mediated protein dephosphorylation in human endometrial carcinoma.
Whooping Cough
Gi protein mediates adenylate cyclase inhibition by neurohypophyseal hormones in fish gill.
Whooping Cough
Gi protein-mediated translocation of serine/threonine phosphatase to the plasma membrane and apoptosis of ovarian cancer cell in response to gonadotropin-releasing hormone antagonist cetrorelix.
Whooping Cough
Gi proteins and calcium in dynorphin-induced hypothermia and behaviour.
Whooping Cough
Gi proteins regulate adenylyl cyclase activity independent of receptor activation.
Whooping Cough
Gi proteins regulate lipopolysaccharide and Staphylococcus aureus induced cytokine production but not (1--> 3)-beta-D-glucan induced cytokine suppression.
Whooping Cough
Gi proteins use a novel beta gamma- and Ras-independent pathway to activate extracellular signal-regulated kinase and mobilize AP-1 transcription factors in Jurkat T lymphocytes.
Whooping Cough
Gi- and protein kinase C-mediated heterologous potentiation of phospholipase C signaling by G protein-coupled receptors.
Whooping Cough
Gi-coupled GABAB Receptors Cross-Regulate Phospholipase C and Calcium in Airway Smooth Muscle.
Whooping Cough
Gi-coupled P2Y-ADP receptor mediates GSK-3 phosphorylation and beta-catenin nuclear translocation in granule neurons.
Whooping Cough
Gi-dependent cell signaling responses of the human P2Y14-receptor in model cell systems.
Whooping Cough
Gi-mediated activation of mitogen-activated protein kinase (MAPK) pathway by receptor mimetic basic secretagogues of connective tissue-type mast cells: bifurcation of arachidonic acid-induced release upstream of MAPK.
Whooping Cough
Gi-mediated activation of the p21ras-mitogen-activated protein kinase pathway by alpha 2-adrenergic receptors expressed in fibroblasts.
Whooping Cough
Gi-mediated activation of the p42/p44 mitogen-activated protein kinases by receptor mimetic basic secretagogues is abrogated by inhibitors of endocytosis.
Whooping Cough
Gi-mediated activation of the Ras/MAP kinase pathway involves a 100 kDa tyrosine-phosphorylated Grb2 SH3 binding protein, but not Src nor Shc.
Whooping Cough
Gi-mediated translocation of GLUT4 is independent of p85/p110alpha and p110gamma phosphoinositide 3-kinases but might involve the activation of Akt kinase.
Whooping Cough
Gi-mediated tyrosine phosphorylation of Grb2 (growth-factor-receptor-bound protein 2)-bound dynamin-II by lysophosphatidic acid.
Whooping Cough
Gi-protein-coupled 5-HT1B/D receptor agonist sumatriptan induces type I hyperalgesic priming.
Whooping Cough
Gi/Go couple met-enkephalin to inhibition of cholinergic and beta-adrenergic stimulation of lacrimal secretion.
Whooping Cough
Gi2 and Gi3 proteins mediate the inhibition of adenylyl cyclase by galanin in the RINm5F cell.
Whooping Cough
Gi2 and protein kinase C are required for thyrotropin-releasing hormone-induced stimulation of voltage-dependent Ca2+ channels in rat pituitary GH3 cells.
Whooping Cough
Gi2 proteins couple somatostatin receptors to low-conductance K+ channels in rat pancreatic alpha-cells.
Whooping Cough
Gi2 signaling enhances proliferation of neural progenitor cells in the developing brain.
Whooping Cough
Gi2-mediated activation of the MAP kinase cascade.
Whooping Cough
Gialpha3 protein-coupled dopamine D3 receptor-mediated inhibition of renal NHE3 activity in SHR proximal tubular cells is a PLC-PKC-mediated event.
Whooping Cough
Ginseng and ginsenoside Rg3, a newly identified active ingredient of ginseng, modulate Ca2+ channel currents in rat sensory neurons.
Whooping Cough
Ginseng root extract inhibits calcium channels in rat sensory neurons through a similar path, but different receptor, as mu-type opioids.
Whooping Cough
Ginsenoside Rb1 Enhances Keratinocyte Migration by a Sphingosine-1-Phosphate-Dependent Mechanism.
Whooping Cough
Ginsenoside Rb1 protects against 6-hydroxydopamine-induced oxidative stress by increasing heme oxygenase-1 expression through an estrogen receptor-related PI3K/Akt/Nrf2-dependent pathway in human dopaminergic cells.
Whooping Cough
Gintonin, newly identified compounds from ginseng, is novel lysophosphatidic acids-protein complexes and activates G protein-coupled lysophosphatidic acid receptors with high affinity.
Whooping Cough
GIPC interacts with the beta1-adrenergic receptor and regulates beta1-adrenergic receptor-mediated ERK activation.
Whooping Cough
GIPC participates in G protein signaling downstream of insulin-like growth factor 1 receptor.
Whooping Cough
Glial receptors and their intervention in astrocyto-astrocytic and astrocyto-neuronal interactions.
Whooping Cough
Glicentin and oxyntomodulin modulate both the phosphoinositide and cyclic adenosine monophosphate signaling pathways in gastric myocytes.
Whooping Cough
Global population structure and evolution of Bordetella pertussis and their relationship with vaccination.
Whooping Cough
GLP-1-(7-36) amide, -(1-37), and -(1-36) amide: potent cAMP-dependent stimuli of rat parietal cell function.
Whooping Cough
Glucagon desensitization of adenylate cyclase and stimulation of inositol phospholipid metabolism does not involve the inhibitory guanine nucleotide regulatory protein Gi, which is inactivated upon challenge of hepatocytes with glucagon.
Whooping Cough
Glucagon increases contractility in ventricle but not in atrium of the rat heart.
Whooping Cough
Glucagon receptor mediates calcium signaling by coupling to G alpha q/11 and G alpha i/o in HEK293 cells.
Whooping Cough
Glucagon release is regulated by tyrosine phosphatase and PI3-kinase activity.
Whooping Cough
Glucagon-(19-29) exerts a biphasic action on the liver plasma membrane Ca2+ pump which is mediated by G proteins.
Whooping Cough
Glucagon-induced heterologous desensitization of the MDCK cell adenylyl cyclase. Increases in the apparent levels of the inhibitory regulator (Ni).
Whooping Cough
Glucagon-like peptide-1 increases cAMP but fails to augment contraction in adult rat cardiac myocytes.
Whooping Cough
Glucagon-mediated Ca2+ signaling in BHK cells expressing cloned human glucagon receptors.
Whooping Cough
Glucocorticoid receptor activation leads to up-regulation of adenosine A1 receptors and down-regulation of adenosine A2 responses in DDT1 MF-2 smooth muscle cells.
Whooping Cough
Glucocorticoid treatment reduces prostacyclin synthesis in response to limited stimuli.
Whooping Cough
Glucocorticoids and dopamine-1 receptors on vascular smooth muscle cells.
Whooping Cough
Glucose activates the carboxyl methylation of gamma subunits of trimeric GTP-binding proteins in pancreatic beta cells. Modulation in vivo by calcium, GTP, and pertussis toxin.
Whooping Cough
Glucose augmentation of mastoparan-stimulated insulin secretion in rat and human pancreatic islets.
Whooping Cough
Glucose regulates the expression of Gi-proteins in cultured BC3H-1 myocytes.
Whooping Cough
Glucose sensing in the intestinal epithelium.
Whooping Cough
Glucose stimulates islet beta-cell mitogenesis through GTP-binding proteins and by protein kinase C-dependent mechanisms.
Whooping Cough
Glucose transport stimulation by bradykinin in Swiss 3T3 fibroblasts: a pertussis toxin-sensitive mechanism operates without involvement of arachidonic acid and cyclic AMP.
Whooping Cough
Glucose uptake by C6 glioma cells is mediated by G(q alpha).
Whooping Cough
GluK1 inhibits calcium dependent and independent transmitter release at associational/commissural synapses in area CA3 of the hippocampus.
Whooping Cough
Glutamate activates a K+ conductance increase in Aplysia neurons that appears to be independent of G proteins.
Whooping Cough
Glutamate elicits an outward K+ current which is normally suppressed by a Ca2+/calmodulin-dependent protein kinase II.
Whooping Cough
Glutamate inhibits adenylate cyclase activity in dispersed rat hippocampal cells directly via an N-methyl-D-aspartate-like metabotropic receptor.
Whooping Cough
Glutamate metabotropic receptor inhibition of voltage-gated calcium currents in visceral sensory neurons.
Whooping Cough
Glutamate receptors activate Ca2+ mobilization and Ca2+ influx into astrocytes.
Whooping Cough
Glutamate stimulates oligodendrocyte progenitor migration mediated via an alphav integrin/myelin proteolipid protein complex.
Whooping Cough
Glutamate stimulates the phosphorylation of glial fibrillary acidic protein in slices of immature rat hippocampus via a metabotropic receptor.
Whooping Cough
Glutamate-induced swelling of single astroglial cells in primary culture.
Whooping Cough
Glutamate-stimulated activation of DNA synthesis via mitogen-activated protein kinase in primary astrocytes: involvement of protein kinase C and related adhesion focal tyrosine kinase.
Whooping Cough
Glutaraldehyde in whole-cell Bordetella pertussis vaccine.
Whooping Cough
Glutaraldehyde inactivated pertussis vaccine: a less histamine sensitizing vaccine.
Whooping Cough
Glutathione-induced enhancement of neutrophil locomotion.
Whooping Cough
Glycochenodeoxycholic acid promotes proliferation of intestinal epithelia via reduction of cyclic AMP and increase in H2AX phosphorylation after exposure to ?-rays.
Whooping Cough
Glycogenolytic and antiglycogenolytic prostaglandin E2 actions in rat hepatocytes are mediated via different signalling pathways.
Whooping Cough
GM1 ganglioside induces phosphorylation and activation of Trk and Erk in brain.
Whooping Cough
GnRH-associated peptide decreases cyclic AMP accumulation in the GH3 pituitary cell line.
Whooping Cough
Go contributes to olfactory reception in Drosophila melanogaster.
Whooping Cough
Go G-proteins mediate rapid heterologous desensitization of G-protein coupled receptors in Xenopus oocytes.
Whooping Cough
Go is required for the release of IL-8 and TNF-?, but not degranulation in human mast cells.
Whooping Cough
Go, a guanine nucleotide-binding protein: immunohistochemical localization in rat brain resembles distribution of second messenger systems.
Whooping Cough
Go, a major brain GTP binding protein in search of a function: purification, immunological and biochemical characteristics.
Whooping Cough
Gonadotropin-releasing hormone (GnRH)-receptor coupling to inositol phosphate and prolactin production in GH3 cells stably transfected with rat GnRH receptor complementary deoxyribonucleic acid.
Whooping Cough
Gonadotropin-releasing hormone activates a rapid Ca2+-independent phosphodiester hydrolysis of polyphosphoinositides in pituitary gonadotrophs.
Whooping Cough
Gonadotropin-releasing hormone receptor couples to multiple G proteins in rat gonadotrophs and in GGH3 cells: evidence from palmitoylation and overexpression of G proteins.
Whooping Cough
gp120 envelope glycoproteins of human immunodeficiency viruses competitively antagonize signaling by coreceptors CXCR4 and CCR5.
Whooping Cough
Gp120-induced Bob/GPR15 activation: a possible cause of human immunodeficiency virus enteropathy.
Whooping Cough
GP55 inhibits both cell adhesion and growth of neurons, but not non-neuronal cells, via a G-protein-coupled receptor.
Whooping Cough
GPR35 is a functional receptor in rat dorsal root ganglion neurons.
Whooping Cough
GPR55 and the vascular receptors for cannabinoids.
Whooping Cough
GPRC6A Mediates Responses to Osteocalcin in ?-Cells In Vitro and Pancreas In Vivo.
Whooping Cough
Gq/11-coupled receptors and protein synthesis in rat cardiomyocytes: role of Gi-proteins and protein kinase C-isozymes.
Whooping Cough
Graded G-protein uncoupling by pertussis toxin treatment of human polymorphonuclear leukocytes.
Whooping Cough
Granulocyte colony-stimulating factor promotes adhesion of neutrophils.
Whooping Cough
Granulocyte-macrophage colony stimulating factor activates proteoglycan, type II collagen, and cAMP production by rat articular chondrocytes through specific binding sites.
Whooping Cough
Granulocyte-macrophage colony-stimulating factor and human neutrophils: role of guanine nucleotide regulatory proteins.
Whooping Cough
Granulocyte-macrophage colony-stimulating factor DNA prime-protein boost strategy to enhance efficacy of a recombinant pertussis DNA vaccine.
Whooping Cough
Granulocyte-macrophage colony-stimulating factor induces human melanoma-cell migration.
Whooping Cough
Granulocyte-macrophage colony-stimulating factor primes neutrophils by activating a pertussis toxin-sensitive G protein not associated with phosphatidylinositol turnover.
Whooping Cough
Granulocyte-macrophage colony-stimulating factor primes phospholipase D activity in human neutrophils in vitro: role of calcium, G-proteins and tyrosine kinases.
Whooping Cough
Granulysin, a cytolytic molecule, is also a chemoattractant and proinflammatory activator.
Whooping Cough
Granzyme B mediates neurotoxicity through a G-protein-coupled receptor.
Whooping Cough
GRIN1 regulates mu-opioid receptor activities by tethering the receptor and G protein in the lipid raft.
Whooping Cough
GRK2 contributes to glucose mediated calcium responses and insulin secretion in pancreatic islet cells.
Whooping Cough
GRK2-mediated trans-phosphorylation contributes to the loss of function of mu opioid receptors induced by neuropeptide FF (NPFF2) receptors.
Whooping Cough
GRK5 deficiency leads to reduced hippocampal acetylcholine level via impaired presynaptic M2/M4 autoreceptor desensitization.
Whooping Cough
GRO is Chemotactic for Human Intestinal Intraepithelial Lymphocytes.
Whooping Cough
Group 1 mGlu receptors elevate [Ca2+]i in rat cultured cortical type 2 astrocytes: [Ca2+]i synergy with adenosine A1 receptors.
Whooping Cough
Group I secreted PLA2 and arachidonic acid metabolites in the maintenance of cat LES tone.
Whooping Cough
Group I secreted PLA2 in the maintenance of human lower esophageal sphincter tone.
Whooping Cough
Group-I metabotropic glutamate receptors, mGlu1a and mGlu5a, couple to extracellular signal-regulated kinase (ERK) activation via distinct, but overlapping, signalling pathways.
Whooping Cough
Growth and cell cycle abnormalities of fibroblasts from Tangier disease patients.
Whooping Cough
Growth and protein phosphorylation in the Nb2 lymphoma: effect of prolactin, cAMP, and agents that activate adenylate cyclase.
Whooping Cough
Growth factor upregulation of a phosphoinositide-coupled metabotropic glutamate receptor in cortical astrocytes.
Whooping Cough
Growth factor-induced cell division is paralleled by translocation of Gi alpha to the nucleus.
Whooping Cough
Growth factor-like action of lysophosphatidic acid on human B lymphoblasts.
Whooping Cough
Growth factor-like action of lysophosphatidic acid: mitogenic signalling mediated by G proteins.
Whooping Cough
Growth factors, signaling pathways, and the regulation of proliferation and differentiation in BC3H1 muscle cells. I. A pertussis toxin-sensitive pathway is involved.
Whooping Cough
Growth factors, signaling pathways, and the regulation of proliferation and differentiation in BC3H1 muscle cells. II. Two signaling pathways distinguished by pertussis toxin and a potential role for the ras oncogene.
Whooping Cough
Growth hormone and dexamethasone stimulate lipolysis and activate adenylyl cyclase in rat adipocytes by selectively shifting Gi alpha2 to lower density membrane fractions.
Whooping Cough
Growth hormone inhibits activation of phosphatidylinositol phospholipase C in adipose plasma membranes: evidence for a growth hormone-induced change in G protein function.
Whooping Cough
Growth hormone-induced diacylglycerol and ceramide formation via Galpha i3 and Gbeta gamma in GH4 pituitary cells. Potentiation by dopamine-D2 receptor activation.
Whooping Cough
Growth regulation of multi-factor-dependent myeloid cell lines: IL-4, TGF-beta and pertussis toxin modulate IL-3- or GM-CSF-induced growth by controlling cell cycle length.
Whooping Cough
Growth regulation of primary human keratinocytes by prostaglandin E receptor EP2 and EP3 subtypes.
Whooping Cough
Growth response of human coronary smooth muscle cells to angiotensin II and influence of angiotensin AT1 receptor blockade.
Whooping Cough
Growth responses to angiotensin II in bovine adrenal glomerulosa cells.
Whooping Cough
Growth-inhibitory effect of a streptococcal antitumor glycoprotein on human epidermoid carcinoma A431 cells: involvement of dephosphorylation of epidermal growth factor receptor.
Whooping Cough
Gs and Gi coupling of adrenomedullin in adult rat ventricular myocytes.
Whooping Cough
Gs and Gq/11 couple vasoactive intestinal peptide and cholinergic stimulation to lacrimal secretion.
Whooping Cough
GTP analogues promote release of the alpha subunit of the guanine nucleotide binding protein, Gi2, from membranes of rat glioma C6 BU1 cells.
Whooping Cough
GTP binding regulatory proteins of adenylate cyclase in Schistosoma mansoni at different stages of development.
Whooping Cough
GTP gamma S causes contraction of skinned frog skeletal muscle via the DHP-sensitive Ca2+ channels of sealed T-tubules.
Whooping Cough
GTP gamma S increases thrombin-mediated inositol trisphosphate accumulation in permeabilized human endothelial cells.
Whooping Cough
GTP gamma S-induced solubilization of actin and myosin from rabbit peritoneal neutrophil membrane.
Whooping Cough
GTP-binding protein couples with metabotropic glutamate receptor in bovine retinal on-bipolar cell.
Whooping Cough
GTP-binding protein G alpha Z: its down-regulation by dexamethasone and its credentials as a mediator of antigen-induced responses in RBL-2H3 cells.
Whooping Cough
GTP-binding protein gamma12 subunit phosphorylation by protein kinase C--identification of the phosphorylation site and factors involved in cultured cells and rat tissues in vivo.
Whooping Cough
GTP-binding protein involvement in membrane currents evoked by carbachol and histamine in guinea-pig ileal muscle.
Whooping Cough
GTP-binding protein mediated phospholipase A2 activation in rat liver during the progression of sepsis.
Whooping Cough
GTP-binding proteins and adenylate cyclase activity in v-Ki-ras transformed NIH/3T3 fibroblast cells.
Whooping Cough
GTP-binding proteins associated with serotonin-activated adenylate cyclase in Fasciola hepatica.
Whooping Cough
GTP-binding proteins associated with the human placental syncytiotrophoblast plasma membrane.
Whooping Cough
GTP-binding proteins Gi and Go transplanted onto Xenopus oocyte by rat brain messenger RNA.
Whooping Cough
GTP-binding proteins in a cyanobacterium Anabaena cylindrica.
Whooping Cough
GTP-binding proteins in bovine brain nuclear membranes.
Whooping Cough
GTP-binding proteins in etiolated epicotyls of Pisum sativum (Alaska) seedlings.
Whooping Cough
GTP-binding proteins in human platelet membranes serving as the specific substrate of islet-activating protein, pertussis toxin.
Whooping Cough
GTP-binding proteins in luminal and basolateral membranes from pars convoluta and pars recta of rabbit kidney proximal tubule.
Whooping Cough
GTP-binding proteins inhibit cAMP activation of chloride channels in cystic fibrosis airway epithelial cells.
Whooping Cough
GTP-binding proteins mediate acetylcholine inhibition of voltage dependent calcium channels in hippocampal neurons.
Whooping Cough
GTP-binding proteins mediate noradrenaline effects on calcium and chloride currents in rat portal vein myocytes.
Whooping Cough
GTP-binding proteins mediate the M2-muscarinic effect on the action potential in isolated sympathetic neurons of rabbits.
Whooping Cough
GTP-binding proteins mediate transmitter inhibition of voltage-dependent calcium channels.
Whooping Cough
GTP-binding proteins regulate high conductance anion channels in rat bile duct epithelial cells.
Whooping Cough
GTP-binding proteins transduce signals generated via human FC gamma receptor IIIA (CD16).
Whooping Cough
GTP-dependent hydrolysis of phosphatidylinositol-4,5-bisphosphate by soluble phospholipase C from adult human epidermis.
Whooping Cough
GTP-dependent inhibition of insulin secretion by epinephrine in permeabilized RINm5F cells. Lack of correlation between insulin secretion and cyclic AMP levels.
Whooping Cough
GTPgammaS-induced actin polymerisation in vitro: ATP- and phosphoinositide-independent signalling via Rho-family proteins and a plasma membrane-associated guanine nucleotide exchange factor.
Whooping Cough
GTP[S] stimulates migration of electropermeabilized neutrophils via a pertussis toxin-sensitive G-protein.
Whooping Cough
Guanine nucleotide activation and inhibition of adenylate cyclase as modified by islet-activating protein, pertussis toxin, in mouse 3T3 fibroblasts.
Whooping Cough
Guanine nucleotide binding protein involvement in early steps of phytochrome-regulated gene expression.
Whooping Cough
Guanine nucleotide binding proteins and the regulation of cyclic AMP synthesis in NS20Y neuroblastoma cells: role of D1 dopamine and muscarinic receptors.
Whooping Cough
Guanine nucleotide binding proteins in cultured renal epithelia: studies with pertussis toxin and aldosterone.
Whooping Cough
Guanine nucleotide binding proteins in opioid-dependent patients.
Whooping Cough
Guanine nucleotide binding proteins in the dual regulation of lacrimal function.
Whooping Cough
Guanine nucleotide binding proteins mediate D2 dopamine receptor activation of a potassium channel in rat lactotrophs.
Whooping Cough
Guanine nucleotide binding proteins mediate the chemotactic signal of transforming growth factor-beta 1 in rat IL-2 activated natural killer cells.
Whooping Cough
Guanine nucleotide effects on catecholamine secretion from digitonin-permeabilized adrenal chromaffin cells.
Whooping Cough
Guanine nucleotide regulation of phospholipase C activity in permeabilized rabbit neutrophils. Inhibition by pertussis toxin and sensitization to submicromolar calcium concentrations.
Whooping Cough
Guanine nucleotide regulation of the pertussis and cholera toxin substrates of rat glioma C6 BU1 cells.
Whooping Cough
Guanine nucleotide regulatory proteins, Gq and Gi1/2, mediate platelet-activating factor-stimulated phosphoinositide metabolism in immortalized hippocampal cells.
Whooping Cough
Guanine nucleotide- and muscarinic agonist-dependent phosphoinositide metabolism in synaptoneurosomes from cerebral cortex of immature rats.
Whooping Cough
Guanine nucleotide-binding inhibitory protein-mediated inhibition of adenylyl cyclase is enhanced in spontaneously hypertensive rat preglomerular arteriolar smooth muscle cells.
Whooping Cough
Guanine nucleotide-binding protein Go-induced coupling of neuropeptide Y receptors to Ca2+ channels in sensory neurons.
Whooping Cough
Guanine nucleotide-binding protein in sea urchin eggs serving as the specific substrate of islet-activating protein, pertussis toxin.
Whooping Cough
Guanine nucleotide-binding protein regulation of microsomal phospholipase D activity of canine cerebral cortex.
Whooping Cough
Guanine nucleotide-binding protein, alpha i-3, directly activates a cation channel in rat renal inner medullary collecting duct cells.
Whooping Cough
Guanine nucleotide-binding proteins involved in transmembrane signaling.
Whooping Cough
Guanine nucleotide-binding proteins modulate desmethoxyverapamil binding to calcium channels in vascular smooth muscle.
Whooping Cough
Guanine nucleotide-binding regulatory proteins in retinal pigment epithelial cells.
Whooping Cough
Guanine nucleotide-dependent pertussis-toxin-insensitive stimulation of inositol phosphate formation by carbachol in a membrane preparation from human astrocytoma cells.
Whooping Cough
Guanine nucleotide-dependent, pertussis toxin-insensitive regulation of phosphoinositide turnover by bradykinin in bovine pulmonary artery endothelial cells.
Whooping Cough
Guanine nucleotide-induced polymerization of actin in electropermeabilized human neutrophils.
Whooping Cough
Guanine nucleotide-sensitive, high affinity binding of carbachol to muscarinic cholinergic receptors of 1321N1 astrocytoma cells is insensitive to pertussis toxin.
Whooping Cough
Guanine nucleotides and pertussis toxin alter agonist binding to rat septal V(1)-vasopressin receptors.
Whooping Cough
Guanine nucleotides and pertussis toxin reduce the affinity of histamine H3 receptors on AtT-20 cells.
Whooping Cough
Guanine nucleotides induce Ca2+-independent insulin secretion from permeabilized RINm5F cells.
Whooping Cough
Guanine nucleotides inhibit poly-L-arginine-induced membrane damage in polymorphonuclear leukocytes.
Whooping Cough
Guanine nucleotides reduce the free calcium requirement for secretion of granule constituents from permeabilized human neutrophils.
Whooping Cough
Guanine-induced inhibition of renal Na(+)-ATPase activity: Evidence for the involvement of the Gi protein-coupled receptor.
Whooping Cough
Guanine-nucleotide-binding proteins Gi and Gs in fat-cells from normal, hypothyroid and obese human subjects.
Whooping Cough
Guanosine 5'-(gamma-thio) triphosphate (GTP gamma S) inhibits phosphorylation of insulin receptor and a novel GTP-binding protein, Gir, from human placenta.
Whooping Cough
Guanosine 5'-O-(3-thiotriphosphate) and cations regulate melatonin receptors, and melatonin inhibits cyclic AMP production in the spinal cord.
Whooping Cough
Guanosine 5'-O-(3-thiotriphosphate) and guanosine 5'-O-(2-thiodiphosphate) activate G proteins and potentiate fibroblast growth factor-induced DNA synthesis in hamster fibroblasts.
Whooping Cough
Guanosine 5'-O-(3-thiotriphosphate) causes endothelium-dependent, pertussis toxin-sensitive relaxations in porcine coronary arteries.
Whooping Cough
Guanosine 5'-O-(3-thiotriphosphate) reduces ADP-ribosylation of the inhibitory guanine nucleotide-binding regulatory protein of adenylyl cyclase (Ni) by pertussis toxin without causing dissociation of the subunits of Ni. Evidence of existence of heterotrimeric pt+ and pt- conformations of Ni.
Whooping Cough
Guanosine 5'-O-(3-thiotrisphosphate) potentiates both thrombin- and platelet-derived growth factor-induced inositol phosphate release in permeabilized vascular smooth muscle cells. Signaling mechanisms distinguished by sensitivity to pertussis toxin and phorbol esters.
Whooping Cough
Guanosine 5'-triphosphate binding protein (Gi) and two additional pertussis toxin substrates associated with muscarinic receptors in rat heart myocytes: characterization and age dependency.
Whooping Cough
Guanosine triphosphate can directly regulate cortisol production by activating Ca(2+)-messenger systems in bovine adrenal fasciculata cells.
Whooping Cough
Guanylin, uroguanylin, and heat-stable euterotoxin activate guanylate cyclase C and/or a pertussis toxin-sensitive G protein in human proximal tubule cells.
Whooping Cough
Guidance of CNS growth cones by substratum grooves and ridges: effects of inhibitors of the cytoskeleton, calcium channels and signal transduction pathways.
Whooping Cough
Guinea pig cysteinyl leukotriene receptor 2 (gpCysLT2) mediates cell proliferation and intracellular calcium mobilization by LTC4 and LTD4.
Whooping Cough
Guinea pig hepatocyte alpha 1A-adrenoceptors: characterization, signal transduction and regulation.
Whooping Cough
Guinea pig histamine H1 receptor. II. Stable expression in Chinese hamster ovary cells reveals the interaction with three major signal transduction pathways.
Whooping Cough
Guinea-pig treatment with pertussis toxin suppresses macrophage-dependent bronchoconstriction by fMLP and fails to inhibit the effects of PAF.
Whooping Cough
Gx/z and Gi2 transducer proteins on mu/delta opioid-mediated supraspinal antinociception.
Whooping Cough
Gz coupling to the rat kappa-opioid receptor.
Whooping Cough
Gz, a guanine nucleotide-binding protein with unique biochemical properties.
Whooping Cough
Gz- and not Gi-proteins are coupled to pre-junctional ?-opioid receptors in bovine airways.
Whooping Cough
Gz-mediated hormonal inhibition of cyclic AMP accumulation.
Whooping Cough
Göttingen Minipigs as a Model to Evaluate Longevity, Functionality, and Memory of Immune Response Induced by Pertussis Vaccines.
Whooping Cough
H-Ras signals to cytoskeletal machinery in induction of integrin-mediated adhesion of T cells.
Whooping Cough
H1-histamine receptors on human astrocytoma cells.
Whooping Cough
H3 autoreceptors modulate histamine synthesis through calcium/calmodulin- and cAMP-dependent protein kinase pathways.
Whooping Cough
H3 receptor-mediated inhibition of intestinal acetylcholine release: pharmacological characterization of signal transduction pathways.
Whooping Cough
Haemodynamic characterization of young normotensive men carrying the 825T-allele of the G-protein beta3 subunit.
Whooping Cough
Halothane and pertussis toxin-sensitive G proteins in airway smooth muscle.
Whooping Cough
Halothane inhibits bradykinin-stimulated prostacyclin production in endothelial cells.
Whooping Cough
Halothane inhibits spontaneous calcium oscillations via adenosine A1 receptors.
Whooping Cough
Halothane interaction with guanine nucleotide binding proteins in mouse heart.
Whooping Cough
Halothane myocardial depression: interactions with the adenylate cyclase system.
Whooping Cough
HDL and sphingosine-1-phosphate activate stat3 in prostate cancer DU145 cells via ERK1/2 and S1P receptors, and promote cell migration and invasion.
Whooping Cough
Head-activator induced mitosis of NH15-CA2 cells requires calcium influx and hyperpolarization.
Whooping Cough
Heart contains two substrates (Mr = 40,000 and 41,000) for pertussis toxin-catalyzed ADP-ribosylation that co-purify with Ns.
Whooping Cough
Heart/Cardiac Muscle: Cocaine- and amphetamine-regulated transcript (CART) peptide as an in vivo regulator of cardiac function in Rana ridibunda frog.
Whooping Cough
Heat shock increases cytosolic free Ca2+ concentration via Na(+)-Ca2+ exchange in human epidermoid A 431 cells.
Whooping Cough
Heat stress stimulates high affinity GTPase in cervical carcinoma cells.
Whooping Cough
Heat treatment induces an increase in intracellular cyclic AMP content in human epidermoid A-431 cells.
Whooping Cough
Heat-aggregated IgA prepared from patients with IgA nephropathy increases priming of human neutrophils to produce inositol triphosphate following FMet-Leu-Phe stimulation in vitro.
Whooping Cough
Helicobacter pylori neutrophil-activating protein induces release of histamine and interleukin-6 through G protein-mediated MAPKs and PI3K/Akt pathways in HMC-1 cells.
Whooping Cough
Helicobacter pylori picB, a homologue of the Bordetella pertussis toxin secretion protein, is required for induction of IL-8 in gastric epithelial cells.
Whooping Cough
Helicobacter pylori-induced prostaglandin E(2) synthesis involves activation of cytosolic phospholipase A(2) in epithelial cells.
Whooping Cough
Helminth-conditioned dendritic cells prime CD4+ T cells to IL-4 production in vivo.
Whooping Cough
Hemagglutination activities of purified pertussis toxin and filamentous hemagglutinin against erythrocytes from various animals.
Whooping Cough
Heme induces neutrophil migration and reactive oxygen species generation through signaling pathways characteristic of chemotactic receptors.
Whooping Cough
Hemoglobin causes release of inositol trisphosphate from vascular smooth muscle.
Whooping Cough
Hemolysis induced by Bacillus cereus sphingomyelinase.
Whooping Cough
Hemolytically inactive C5b67 complex: an agonist of polymorphonuclear leukocytes.
Whooping Cough
Heparan sulfate proteoglycan on endothelium efficiently induces integrin-mediated T cell adhesion by immobilizing chemokines in patients with rheumatoid synovitis.
Whooping Cough
Hepoxilin A3 induces changes in cytosolic calcium, intracellular pH and membrane potential in human neutrophils.
Whooping Cough
Hesperidin, a Citrus Flavonoid, Has the Ameliorative Effects Against Experimental Autoimmune Encephalomyelitis (EAE) in a C57BL/J6 Mouse Model.
Whooping Cough
Heterodimerization of mu- and delta-opioid receptors occurs at the cell surface only and requires receptor-G protein interactions.
Whooping Cough
Heterogeneity of angiotensin II AT2 receptors in the rat brain.
Whooping Cough
Heterogeneity of ATP receptors in aortic endothelial cells. Involvement of P2y and P2u receptors in inositol phosphate response.
Whooping Cough
Heterogeneity of P2u- and P2y-purinergic receptor regulation of phospholipases in MDCK cells.
Whooping Cough
Heterogeneity of the motility responses in malignant tumor cells: a biological basis for the diversity and homing of metastatic cells.
Whooping Cough
Heterologous desensitization and reduced G protein ADP-ribosylation following exposure to alpha 2-adrenoceptor and muscarinic receptor agonists.
Whooping Cough
Heterologous desensitization of adenylate cyclase with prostaglandin E1 alters sensitivity to inhibitory as well as stimulatory agonists.
Whooping Cough
Heterologous desensitization of the inhibitory A1 adenosine receptor-adenylate cyclase system in rat adipocytes. Regulation of both Ns and Ni.
Whooping Cough
Heterologous desensitization of the liver adenylyl cyclase: analysis of the role of G-proteins.
Whooping Cough
Heterologous expression and coupling of G protein-gated inwardly rectifying K+ channels in adult rat sympathetic neurons.
Whooping Cough
Heterologous expression of a green fluorescent protein-pertussis toxin S1 subunit fusion construct disrupts calcium channel modulation in rat superior cervical ganglion neurons.
Whooping Cough
Heterologous regulations of cAMP responses in pregnant rat myometrium. Evolution from a stimulatory to an inhibitory prostaglandin E2 and prostacyclin effect.
Whooping Cough
Heteromeric association creates a P2Y-like adenosine receptor.
Whooping Cough
Heterotrimeric G protein activation rapidly inhibits outgrowth of optic axons from adult and embryonic mouse, and goldfish retinal explants.
Whooping Cough
Heterotrimeric G protein betagamma subunits stimulate FLJ00018, a guanine nucleotide exchange factor for Rac1 and Cdc42.
Whooping Cough
Heterotrimeric G protein Gi is involved in a signal transduction pathway for ATP release from erythrocytes.
Whooping Cough
Heterotrimeric G proteins and the platelet-derived growth factor receptor-beta contribute to hypoxic proliferation of smooth muscle cells.
Whooping Cough
Heterotrimeric G proteins are implicated in gibberellin induction of a-amylase gene expression in wild oat aleurone
Whooping Cough
Heterotrimeric G proteins containing G alpha i3 regulate multiple effector enzymes in the same cell. Activation of phospholipases C and A2 and inhibition of adenylyl cyclase.
Whooping Cough
Heterotrimeric G-protein and signal transduction in the nematode-trapping fungus Arthrobotrys dactyloides.
Whooping Cough
Heterotrimeric G-protein candidates for Ge in the ACTH secretory pathway.
Whooping Cough
Heterotrimeric G-proteins activate Cl- channels through stimulation of a cyclooxygenase-dependent pathway in a model liver cell line.
Whooping Cough
Heterotrimeric G-proteins are implicated in the regulation of apoptosis in pancreatic beta-cells.
Whooping Cough
Heterotrimeric G?(i) proteins are regulated by lipopolysaccharide and are anti-inflammatory in endotoxemia and polymicrobial sepsis.
Whooping Cough
Heterotrimeric Gi protein is associated with the inositol 1,4,5-trisphosphate receptor complex and modulates calcium flux.
Whooping Cough
Heterotrimeric Gi/Go proteins modulate endothelial TLR signaling independent of the MyD88-dependent pathway.
Whooping Cough
Heterotrimeric guanosine triphosphate-binding protein-coupled modulatory actions of motilin on K+ channels and postsynaptic ?-aminobutyric acid receptors in mouse medial vestibular nuclear neurons.
Whooping Cough
Higenamine, a Dual Agonist for ? 1- and ? 2-Adrenergic Receptors Identified by Screening a Traditional Chinese Medicine Library.
Whooping Cough
High affinity binding of 125I-neurotensin to dispersed cells from chicken liver and brain.
Whooping Cough
High carbachol increases the electrically induced [Ca2+]i transient in the single isolated ventricular myocyte of rats.
Whooping Cough
High concentrations of a cGMP-stimulated phosphodiesterase mediate ANP-induced decreases in cAMP and steroidogenesis in adrenal glomerulosa cells.
Whooping Cough
High concentrations of adrenergic antagonists prolong sciatic nerve blockade by tetrodotoxin.
Whooping Cough
High concentrations of histamine stimulate equine polymorphonuclear neutrophils to produce reactive oxygen species.
Whooping Cough
High constitutive activity of the human formyl peptide receptor.
Whooping Cough
High density lipoprotein stimulated migration of macrophages depends on the scavenger receptor class B, type I, PDZK1 and Akt1 and is blocked by sphingosine 1 phosphate receptor antagonists.
Whooping Cough
High density lipoprotein-associated lysosphingolipids reduce E-selectin expression in human endothelial cells.
Whooping Cough
High density lipoprotein-associated sphingosine 1-phosphate promotes endothelial barrier function.
Whooping Cough
High density lipoprotein-induced angiogenesis requires the activation of Ras/MAP kinase in human coronary artery endothelial cells.
Whooping Cough
High density lipoprotein-induced signaling of the MAPK pathway involves scavenger receptor type BI-mediated activation of Ras.
Whooping Cough
High density lipoproteins induce cell cycle entry in vascular smooth muscle cells via mitogen activated protein kinase-dependent pathway.
Whooping Cough
High dose combination pertussis toxin induces autoimmune inner ear disease in Sprague-Dawley rats.
Whooping Cough
High expression of sphingosine kinase 1 and S1P receptors in chemotherapy-resistant prostate cancer PC3 cells and their camptothecin-induced up-regulation.
Whooping Cough
High extracellular calcium attenuates adipogenesis in 3T3-L1 preadipocytes.
Whooping Cough
High glucose concentration causes a rise in [Ca2+]i of cardiac myocytes.
Whooping Cough
High glucose inhibits fructose uptake in renal proximal tubule cells: involvement of cAMP, PLC/PKC, p44/42 MAPK, and cPLA2.
Whooping Cough
High glucose stimulates Ca2+ uptake via cAMP and PLC/PKC pathways in primary cultured renal proximal tubule cells.
Whooping Cough
HIGH GLUCOSE-INDUCED INHIBITION OF 2-DEOXYGLUCOSE UPTAKE IS MEDIATED BY cAMP, PROTEIN KINASE C, OXIDATIVE STRESS AND MITOGEN-ACTIVATED PROTEIN KINASES IN MOUSE EMBRYONIC STEM CELLS.
Whooping Cough
High IFN-alpha expression is associated with the induction of experimental autoimmune uveitis (EAU) in Fischer 344 rat.
Whooping Cough
High levels of antibody in adults three years after vaccination with a reduced antigen content diphtheria-tetanus-acellular pertussis vaccine.
Whooping Cough
High prevalence of Bordetella pertussis in children under 5 years old hospitalized with acute respiratory infections in Lima, Peru.
Whooping Cough
High rate of vaccine failure after administration of acellular pertussis vaccine pre- and post-liver transplantation in children at a children's hospital in Japan.
Whooping Cough
High-density lipoprotein determines adult mouse cardiomyocyte fate after hypoxia-reoxygenation through lipoprotein-associated sphingosine 1-phosphate.
Whooping Cough
High-density lipoprotein increases intracellular calcium levels by releasing calcium from internal stores in human endothelial cells.
Whooping Cough
High-density lipoprotein induces cyclooxygenase-2 expression and prostaglandin I-2 release in endothelial cells through sphingosine kinase-2.
Whooping Cough
High-density lipoprotein stimulates endothelial cell migration and survival through sphingosine 1-phosphate and its receptors.
Whooping Cough
High-density lipoprotein stimulates endothelial cell movement by a mechanism distinct from basic fibroblast growth factor.
Whooping Cough
High-glucose incubation of human umbilical-vein endothelial cells does not alter expression and function either of G-protein alpha-subunits or of endothelial NO synthase.
Whooping Cough
High-intensity p38 kinase activity is critical for p21(cip1) induction and the antiproliferative function of G(i) protein-coupled receptors.
Whooping Cough
High-throughput screening for small-molecule activators of neutrophils: identification of novel N-formyl peptide receptor agonists.
Whooping Cough
Highly sensitive histamine-sensitization test for residual activity of pertussis toxin in acellular pertussis vaccine.
Whooping Cough
Histamine activates Cl- and K+ currents in guinea-pig tracheal myocytes: convergence with muscarinic signalling pathway.
Whooping Cough
Histamine activates phospholipase C in human airway epithelial cells via a phorbol ester-sensitive pathway.
Whooping Cough
Histamine activates phosphorylase and inositol phosphate production in guinea pig hepatocytes.
Whooping Cough
Histamine and bradykinin stimulate the phosphoinositide turnover in human umbilical vein endothelial cells via different G-proteins.
Whooping Cough
Histamine H(3) receptor-mediated inhibition of endogenous acetylcholine release from the isolated, vascularly perfused rat stomach.
Whooping Cough
Histamine H(3) receptors mediate inhibition of noradrenaline release from intestinal sympathetic nerves.
Whooping Cough
Histamine h(4) and h(2) receptors control histamine-induced interleukin-16 release from human CD8(+) T cells.
Whooping Cough
Histamine H1 receptors in C6 glial cells are coupled to calcium-dependent potassium channels via release of calcium from internal stores.
Whooping Cough
Histamine H1-receptor-mediated inositol phospholipid hydrolysis in DDT1MF-2 cells: agonist and antagonist properties.
Whooping Cough
Histamine H1-receptors in HL-60 monocytes are coupled to Gi-proteins and pertussis toxin-insensitive G-proteins and mediate activation of Ca2+ influx without concomitant Ca2+ mobilization from intracellular stores.
Whooping Cough
Histamine H1-receptors on astrocytes in primary cultures: a possible target for histaminergic neurones.
Whooping Cough
Histamine H2 receptor signaling x environment interactions determine susceptibility to experimental allergic encephalomyelitis.
Whooping Cough
Histamine H3 receptor activation inhibits dopamine D1 receptor-induced cAMP accumulation in rat striatal slices.
Whooping Cough
Histamine H3-receptor activation augments voltage-dependent Ca2+ current via GTP hydrolysis in rabbit saphenous artery.
Whooping Cough
Histamine H3-receptor-induced attenuation of norepinephrine exocytosis: a decreased protein kinase a activity mediates a reduction in intracellular calcium.
Whooping Cough
Histamine H3-receptor-induced inhibition of duodenal cholinergic transmission is independent of intracellular cyclic AMP and GMP.
Whooping Cough
Histamine H4 receptor mediates chemotaxis and calcium mobilization of mast cells.
Whooping Cough
Histamine increases cytosolic Ca2+ in dibutyryl-cAMP-differentiated HL-60 cells via H1 receptors and is an incomplete secretagogue.
Whooping Cough
Histamine induces cytoskeletal changes in human eosinophils via the H(4) receptor.
Whooping Cough
Histamine modulates high-voltage-activated calcium channels in neurons dissociated from the rat tuberomammillary nucleus.
Whooping Cough
Histamine provokes turnover of inositol phospholipids in guinea pig and human airway epithelial cells via an H1-receptor/G protein-dependent mechanism.
Whooping Cough
Histamine receptor-dependent and/or -independent activation of guanine nucleotide-binding proteins by histamine and 2-substituted histamine derivatives in human leukemia (HL-60) and human erythroleukemia (HEL) cells.
Whooping Cough
Histamine release from basophils in childhood: age dependency and inhibition by pertussis infection and pertussis toxin.
Whooping Cough
Histamine release, an undesired effect of thrombin inhibitors with basic character, is mediated through direct activation of G(i) proteins.
Whooping Cough
Histamine stimulates human lung fibroblast migration.
Whooping Cough
Histamine-induced microvascular leakage in pial venules: differences between the SJL/J and BALB/c inbred strains of mice.
Whooping Cough
Histamine-stimulated and GTP-binding proteins-mediated phospholipase A2 activation in rabbit platelets.
Whooping Cough
Histamine-stimulated phospholipase C signalling in the adrenal chromaffin cell: effects on inositol phospholipid metabolism and tyrosine hydroxylase phosphorylation.
Whooping Cough
Histidine regulation of cyclic AMP metabolism in cultured renal epithelial LLC-PK1 cells.
Whooping Cough
Histone H4 directly stimulates neutrophil activation through membrane permeabilization.
Whooping Cough
Histopathological analysis of rat mesentery as a method for evaluating neutrophil migration: differential effects of dexamethasone and pertussis toxin.
Whooping Cough
History of whooping cough in nonvaccinated Swedish children, related to serum antibodies to pertussis toxin and filamentous hemagglutinin.
Whooping Cough
HIV coreceptor downregulation as antiviral principle: SDF-1alpha-dependent internalization of the chemokine receptor CXCR4 contributes to inhibition of HIV replication.
Whooping Cough
HIV-1 coreceptor activity of CCR5 and its inhibition by chemokines: independence from G protein signaling and importance of coreceptor downmodulation.
Whooping Cough
HIV-1 gp120 and chemokine activation of Pyk2 and mitogen-activated protein kinases in primary macrophages mediated by calcium-dependent, pertussis toxin-insensitive chemokine receptor signaling.
Whooping Cough
HIV-1 Tat protein attenuates the clinical course of experimental autoimmune encephalomyelitis (EAE).
Whooping Cough
HIV-1 Tat protein mimicry of chemokines.
Whooping Cough
HIV-1 Tat triggers TGF-beta production and NK cell apoptosis that is prevented by pertussis toxin B.
Whooping Cough
HIV-specific T cell cytotoxicity mediated by RANTES via the chemokine receptor CCR3.
Whooping Cough
HL-1 cells express an inwardly rectifying K(+) current activated via muscarinic receptors comparable to that in mouse atrial myocytes.
Whooping Cough
HOCl production by human neutrophils activated by surface-associated IgG: requirement for influx of extracellular calcium.
Whooping Cough
Holo-APP and G-protein-mediated signaling are required for sAPP?-induced activation of the Akt survival pathway.
Whooping Cough
Homer1a-dependent crosstalk between NMDA and metabotropic glutamate receptors in mouse neurons.
Whooping Cough
Homocysteine effects classical pathway of GPCR down regulation: Galpha(q/11), Galpha (12/13), G (i/o).
Whooping Cough
Homocysteine inhibits arterial endothelial cell growth through transcriptional downregulation of fibroblast growth factor-2 involving G protein and DNA methylation.
Whooping Cough
Homologous and heterologous beta-adrenergic desensitization in hepatocytes. Additivity and effect of pertussis toxin.
Whooping Cough
Homologous and heterologous desensitisation of somatostatin-induced increases in intracellular Ca2+ and inositol 1,4,5-trisphosphate in CHO-K1 cells expressing human recombinant somatostatin sst5 receptors.
Whooping Cough
Homologous and heterologous protection after single intranasal administration of live attenuated recombinant Bordetella pertussis.
Whooping Cough
Homologous sensitisation of embryonic chick atrial myocytes to adenosine: mediation by adenosine A1 receptor and guanine nucleotide binding protein.
Whooping Cough
Homotypic lysosome fusion in macrophages: analysis using an in vitro assay.
Whooping Cough
Hormonal regulation of Gi2 alpha-subunit phosphorylation in intact hepatocytes.
Whooping Cough
Hormonal regulation of MAP kinase in cultured rat inner medullary collecting tubule cells.
Whooping Cough
Hormonal regulation of mitogen-activated protein kinase activity in bovine adrenocortical cells: cross-talk between phosphoinositides, adenosine 3',5'-monophosphate, and tyrosine kinase receptor pathways.
Whooping Cough
Hormonal regulation of phospholipase Cepsilon through distinct and overlapping pathways involving G12 and Ras family G-proteins.
Whooping Cough
Hormonal regulation of rat renal proximal tubule brush-border membrane ionic permeability.
Whooping Cough
Hormonal stimulation of adenylyl cyclase through Gi-protein beta gamma subunits.
Whooping Cough
Hormone-defined cell system for studying G-protein coupled receptor agonist-activated growth modulation: delta-opioid and serotonin-5HT2C receptor activation show opposite mitogenic effects.
Whooping Cough
Hormone-sensitive adenylate cyclase of prolactin-producing rat pituitary adenoma (GH4C1) cells: molecular organization.
Whooping Cough
House dust mite allergen activates human eosinophils via formyl peptide receptor and formyl peptide receptor-like 1.
Whooping Cough
How common is whooping cough in a nonvaccinating country?
Whooping Cough
How does the G protein, Gi2, transduce mitogenic signals?
Whooping Cough
How to make sense of pertussis immunogenicity data.
Whooping Cough
HSP-72 synthesis is promoted by increase in [Ca2+]i or activation of G proteins but not pHi or cAMP.
Whooping Cough
Human 5-HT1A receptor expressed in insect cells activates endogenous G(o)-like G protein(s).
Whooping Cough
Human adenosine A1 receptor and P2Y2-purinoceptor-mediated activation of the mitogen-activated protein kinase cascade in transfected CHO cells.
Whooping Cough
Human airway epithelial monolayers promote selective transmigration of memory T cells: a transepithelial model of lymphocyte migration into the airways.
Whooping Cough
Human and rat cutaneous mast cells: involvement of a G protein in the response to peptidergic stimuli.
Whooping Cough
Human angiotensin II type-2 receptor inhibition of insulin-mediated ERK-2 activity via a G-protein coupled signaling pathway.
Whooping Cough
Human antibody response to the B oligomer of pertussis toxin.
Whooping Cough
Human apolipoprotein A-I induces cyclooxygenase-2 expression and prostaglandin I-2 release in endothelial cells through ATP-binding cassette transporter A1.
Whooping Cough
Human B cells express the orphan chemokine receptor CRAM-A/B in a maturation-stage-dependent and CCL5-modulated manner.
Whooping Cough
Human beta-defensin-2 functions as a chemotactic agent for tumour necrosis factor-alpha-treated human neutrophils.
Whooping Cough
Human bone marrow endothelial cells elaborate non-stromal-cell-derived factor-1 (SDF-1)-dependent chemoattraction and SDF-1-dependent transmigration of haematopoietic progenitors.
Whooping Cough
Human bronchial epithelial cells express PAR-2 with different sensitivity to thermolysin.
Whooping Cough
Human catestatin enhances migration and proliferation of normal human epidermal keratinocytes.
Whooping Cough
Human CC chemokine CCL23, a ligand for CCR1, induces endothelial cell migration and promotes angiogenesis.
Whooping Cough
Human cellular immune responses to Bordetella pertussis infection.
Whooping Cough
Human chondrocytes express functional chemokine receptors and release matrix-degrading enzymes in response to C-X-C and C-C chemokines.
Whooping Cough
Human chymase stimulates Ca2+ signaling in human polymorphonuclear cells.
Whooping Cough
Human dendritic cell maturation and cytokine secretion upon stimulation with Bordetella pertussis filamentous haemagglutinin.
Whooping Cough
Human eosinophils induce histamine release from antigen-activated rat peritoneal mast cells: a possible role for mast cells in late-phase allergic reactions.
Whooping Cough
Human eotaxin represents a potent activator of the respiratory burst of human eosinophils.
Whooping Cough
Human epidermoid A431 cells express functional nicotinic acid receptor HM74a.
Whooping Cough
Human fat cell lipolysis is primarily regulated by inhibitory modulators acting through distinct mechanisms.
Whooping Cough
Human fetal skin fibroblast migration stimulated by the autocrine growth factor bFGF is mediated by phospholipase A(2) via arachidonic acid without the involvement of pertussis toxin-sensitive G-protein.
Whooping Cough
Human fractalkine mediates leukocyte adhesion but not capture under physiological shear conditions; a mechanism for selective monocyte recruitment.
Whooping Cough
Human galectin-3 is a novel chemoattractant for monocytes and macrophages.
Whooping Cough
Human Gi protein alpha-subunit: deduction of amino acid structure from a cloned cDNA.
Whooping Cough
Human granulocyte-macrophage colony-stimulating factor and other cytokines prime human neutrophils for enhanced arachidonic acid release and leukotriene B4 synthesis.
Whooping Cough
Human growth hormone increases cytosolic free calcium in cultured human IM-9 lymphocytes: a novel mechanism of growth hormone transmembrane signalling.
Whooping Cough
Human H9 cells proliferation is differently controlled by vasoactive intestinal peptide or peptide histidine methionine: implication of a GTP-insensitive form of VPAC1 receptor.
Whooping Cough
Human immunodeficiency virus type 1 Tat and methamphetamine affect the release and activation of matrix-degrading proteinases.
Whooping Cough
Human immunodeficiency virus type 1 Tat protein decreases cyclic AMP synthesis in rat microglia cultures.
Whooping Cough
Human immunodeficiency virus-1 infection requires pertussis toxin sensitive G-protein-coupled signalling and mediates cAMP downregulation.
Whooping Cough
Human immunodeficiency virus-induced apoptosis of human breast cancer cells via CXCR4 is mediated by the viral envelope protein but does not require CD4.
Whooping Cough
Human kidney-2 cells harbor functional dopamine D1 receptors that require Gi? for Gq/11? signaling.
Whooping Cough
Human leukocyte elastase induces keratinocyte proliferation by epidermal growth factor receptor activation.
Whooping Cough
Human metabotropic glutamate receptor 2 couples to the MAP kinase cascade in chinese hamster ovary cells.
Whooping Cough
Human monocytes respond to leukotriene B4 with a transient increase in cytosolic calcium.
Whooping Cough
Human mu-opioid receptor overexpressed in Sf9 insect cells functionally coupled to endogenous Gi/o proteins.
Whooping Cough
Human neutrophil stimulation by influenza virus: relationship of cytoplasmic pH changes to cell activation.
Whooping Cough
Human NK cells express CC chemokine receptors 4 and 8 and respond to thymus and activation-regulated chemokine, macrophage-derived chemokine, and I-309.
Whooping Cough
Human osteoblasts express functional CXC chemokine receptors 3 and 5: activation by their ligands, CXCL10 and CXCL13, significantly induces alkaline phosphatase and beta-N-acetylhexosaminidase release.
Whooping Cough
Human P2Y2 receptor polymorphism: identification and pharmacological characterization of two allelic variants.
Whooping Cough
Human pancreatic tumor growth hormone (GH) - releasing factor and cyclic adenosine 3',5'- monophosphate evoke GH release from anterior pituitary cells: the effects of pertussis toxin, cholera toxin, forskolin, and cycloheximide.
Whooping Cough
Human Peptides ?-Defensin-1 and -5 Inhibit Pertussis Toxin.
Whooping Cough
Human plasmin induces a receptor-mediated arachidonate release coupled with G proteins in endothelial cells.
Whooping Cough
Human platelets exhibit chemotaxis using functional N-formyl peptide receptors.
Whooping Cough
Human polymorphonuclear leukocyte activating factor isolated from Aleurites Fordii Hemsl. (Euphorbiaceae) seed.
Whooping Cough
Human recombinant chromogranin A-derived vasostatin-1 mimics preconditioning via an adenosine/nitric oxide signaling mechanism.
Whooping Cough
Human recombinant histamine-releasing factor activates human eosinophils and the eosinophilic cell line, AML14-3D10.
Whooping Cough
Human RFamide-related peptide-1 diminishes cellular and integrated cardiac contractile performance.
Whooping Cough
Human Rhinovirus Infection of Epithelial Cells Modulates Airway Smooth Muscle Migration.
Whooping Cough
Human Salivary Histatin-1 Promotes Osteogenic Cell Spreading on Both Bio-Inert Substrates and Titanium SLA Surfaces.
Whooping Cough
Human serum antibody responses to Bordetella pertussis infection and pertussis vaccination.
Whooping Cough
Human T cell clones define S1 subunit as the most immunogenic moiety of pertussis toxin and determine its epitope map.
Whooping Cough
Human T lymphocyte mitogenesis in response to the B oligomer of pertussis toxin is associated with an early elevation in cytosolic calcium concentrations.
Whooping Cough
Humanised monoclonal antibodies neutralise pertussis toxin by receptor blockade and reduced retrograde trafficking.
Whooping Cough
Humoral and cellular immune responses in mice immunized with recombinant Mycobacterium bovis Bacillus Calmette-Guérin producing a pertussis toxin-tetanus toxin hybrid protein.
Whooping Cough
Humoral immunity of dTap-IPV vaccine (REPEVAX(®)) administered one month after dT-IPV vaccine (REVAXIS(®)) in adults with unknown vaccination history.
Whooping Cough
Hydrodynamic properties of adenosine Ri receptors solubilized from rat cerebral-cortical membranes.
Whooping Cough
Hydrogen peroxide signaling mediates DHEA-induced vascular endothelial cell proliferation.
Whooping Cough
Hydrophobic binding of pertussis toxin is enhanced by oligosaccharide receptors.
Whooping Cough
Hydrophobic photolabelling of pertussis toxin subunits interacting with lipids.
Whooping Cough
Hydrophobicity and subunit interactions of rod outer segment proteins investigated using Triton X-114 phase partitioning.
Whooping Cough
Hydrophobicity of residue351 of the G protein Gi1 alpha determines the extent of activation by the alpha 2A-adrenoceptor.
Whooping Cough
Hyper-osmotic stress induces volume change and calcium transients in chondrocytes by transmembrane, phospholipid, and G-protein pathways.
Whooping Cough
Hyperactivation of phospholipase C does not support the enhanced proliferation of aortic smooth muscle cells from spontaneously hypertensive rats.
Whooping Cough
Hyperosmolar solution effects in guinea pig airways. III. Studies on the identity of epithelium-derived relaxing factor in isolated perfused trachea using pharmacological agents.
Whooping Cough
Hyperpolarization is not responsible for the acetylcholine-induced negative chronotropic action in the presence of isoproterenol.
Whooping Cough
Hyperpolarizing muscarinic responses of freshly dissociated rat hippocampal CA1 neurones.
Whooping Cough
Hypersensitization of the Orexin 1 receptor by the CB1 receptor: evidence for cross-talk blocked by the specific CB1 antagonist, SR141716.
Whooping Cough
Hypertrophic agonists stimulate the activities of the protein kinases c-Raf and A-Raf in cultured ventricular myocytes.
Whooping Cough
Hypertrophic effect of selective beta(1)-adrenoceptor stimulation on ventricular cardiomyocytes from adult rat.
Whooping Cough
Hypocretin (orexin) receptor subtypes differentially enhance acetylcholine release and activate g protein subtypes in rat pontine reticular formation.
Whooping Cough
Hypocretin/orexin suppresses corticotroph responsiveness in vitro.
Whooping Cough
Hypoglycaemia and acute stress-induced hyperinsulinaemia in mice infected with Bordetella pertussis or treated with pertussis toxin.
Whooping Cough
Hyposmotic stress causes ATP release and stimulates Na, K-ATPase activity in porcine lens.
Whooping Cough
Hypothalamic administration of cAMP agonist/PKA activator inhibits both schedule feeding and NPY-induced feeding in rats.
Whooping Cough
Hypotonic stimulation induced Ca2+ release from IP3-sensitive internal stores in a green monkey kidney cell line.
Whooping Cough
Hypoxia induces differentiation of pulmonary artery adventitial fibroblasts into myofibroblasts.
Whooping Cough
Hypoxia-induced increased permeability of endothelial monolayers occurs through lowering of cellular cAMP levels.
Whooping Cough
Hypoxia-induced Mitogenic Factor/FIZZ1 Induces Intracellular Calcium Release Through the PLC-IP3 Pathway.
Whooping Cough
Hypoxia-induced proliferative response of vascular adventitial fibroblasts is dependent on g protein-mediated activation of mitogen-activated protein kinases.
Whooping Cough
Hypoxic preconditioning in isolated rat hearts: non-involvement of activation of adenosine A1 receptor, Gi protein, and ATP-sensitive K+ channel.
Whooping Cough
I-309/T cell activation gene-3 chemokine protects murine T cell lymphomas against dexamethasone-induced apoptosis.
Whooping Cough
Idazoxan down-regulates beta-adrenoceptors on C6 glioma cells in vitro.
Whooping Cough
Identification and characterisation of GPR100 as a novel human G-protein-coupled bradykinin receptor.
Whooping Cough
Identification and characterization of a potent, selective nonpeptide agonist of the CC chemokine receptor CCR8.
Whooping Cough
Identification and characterization of a second melanin-concentrating hormone receptor, MCH-2R.
Whooping Cough
Identification and characterization of autocrine-motility-factor-like activity in oral squamous-cell-carcinoma cells.
Whooping Cough
Identification and characterization of functional angiotensin II receptors in human neuroblastoma cells.
Whooping Cough
Identification and characterization of human surfactant protein A binding protein of Mycoplasma pneumoniae.
Whooping Cough
Identification and characterization of multiple subtypes of muscarinic acetylcholine receptors and their physiological functions in canine hearts.
Whooping Cough
Identification and characterization of muscarinic receptors potentiating the stimulation of adenylyl cyclase activity by corticotropin-releasing hormone in membranes of rat frontal cortex.
Whooping Cough
Identification and characterization of P2Y2 nucleotide receptors in human retinal pigment epithelial cells.
Whooping Cough
Identification and characterization of PtlC, an essential component of the pertussis toxin secretion system.
Whooping Cough
Identification and characterization of the carbohydrate ligands recognized by pertussis toxin via a glycan microarray and surface plasmon resonance.
Whooping Cough
Identification and characterization of the CXCR4 chemokine receptor in human T cell lines: ligand binding, biological activity, and HIV-1 infectivity.
Whooping Cough
Identification and Characterization of ZEL-H16 as a Novel Agonist of the Histamine H(3) Receptor.
Whooping Cough
Identification and functional characterization of adenylate cyclase-linked receptors for parathyroid hormone-like peptides on immortalized human keratinocytes.
Whooping Cough
Identification and molecular characterization of a m5 muscarinic receptor in A2058 human melanoma cells. Coupling to inhibition of adenylyl cyclase and stimulation of phospholipase A2.
Whooping Cough
Identification and partial characterization of genes that are transactivated by different pathways in quiescent mouse cells stimulated with serum.
Whooping Cough
Identification and purification from bovine brain of a guanine-nucleotide-binding protein distinct from Gs, Gi and Go.
Whooping Cough
Identification and purification of a novel G protein from neutrophils.
Whooping Cough
Identification of a 43-kilodalton human T lymphocyte membrane protein as a receptor for pertussis toxin.
Whooping Cough
Identification of a Bordetella pertussis regulatory factor required for transcription of the pertussis toxin operon in Escherichia coli.
Whooping Cough
Identification of a botulinum C3-like enzyme in bovine brain that catalyzes ADP-ribosylation of GTP-binding proteins.
Whooping Cough
Identification of a cis-regulatory element mediating somatostatin inhibition of epidermal growth factor-stimulated gastrin gene transcription.
Whooping Cough
Identification of a compound that directly stimulates phospholipase C activity.
Whooping Cough
Identification of a DNA fragment in the genome of Bordetella pertussis carrying repeated DNA sequences also present in other Bordetella species.
Whooping Cough
Identification of a G protein alpha subunit from Neurospora crassa that is a member of the Gi family.
Whooping Cough
Identification of a G protein in rough endoplasmic reticulum of canine pancreas.
Whooping Cough
Identification of a GTP-binding protein alpha subunit that lacks an apparent ADP-ribosylation site for pertussis toxin.
Whooping Cough
Identification of a guanine nucleotide-binding protein G(o) in human neuroblastoma.
Whooping Cough
Identification of a human cDNA encoding a functional high affinity lipoxin A4 receptor.
Whooping Cough
Identification of a murine cysteinyl leukotriene receptor by expression in Xenopus laevis oocytes.
Whooping Cough
Identification of a neuronal cell surface receptor for a growth inhibitory chondroitin sulfate proteoglycan (NG2).
Whooping Cough
Identification of a new GTP-binding protein. A Mr = 43,000 substrate for pertussis toxin.
Whooping Cough
Identification of a novel extracellular cation-sensing G-protein-coupled receptor.
Whooping Cough
Identification of a novel human eicosanoid receptor coupled to G(i/o).
Whooping Cough
Identification of a P2Y-purinergic receptor that inhibits adenylyl cyclase.
Whooping Cough
Identification of a potent inverse agonist at a constitutively active mutant of human P2Y12 receptor.
Whooping Cough
Identification of a potent serum factor that causes desensitization of the receptor for C-Type natriuretic peptide.
Whooping Cough
Identification of a protein hydrolysate responsive G protein-coupled receptor in enterocytes.
Whooping Cough
Identification of a region in the S1 subunit of pertussis toxin that is required for enzymatic activity and that contributes to the formation of a neutralizing antigenic determinant.
Whooping Cough
Identification of a second putative receptor of platelet-activating factor from human polymorphonuclear leukocytes.
Whooping Cough
Identification of a structural element in phospholipase C beta2 that interacts with G protein betagamma subunits.
Whooping Cough
Identification of a uridine nucleotide-selective G-protein-linked receptor that activates phospholipase C.
Whooping Cough
Identification of A1 adenosine receptors in rat cochlea coupled to inhibition of adenylyl cyclase.
Whooping Cough
Identification of alpha-subunits of trimeric GTP-binding proteins in human platelets by RT-PCR.
Whooping Cough
Identification of amino acid residues essential for the enzymatic activities of pertussis toxin.
Whooping Cough
Identification of amino acids that are selectively involved in Gi/o activation by rat melanin-concentrating hormone receptor 1.
Whooping Cough
Identification of an active-site residue in subunit S1 of pertussis toxin by photocrosslinking to NAD.
Whooping Cough
Identification of an additional supraspinal component to the analgesic mechanism of action of buprenorphine.
Whooping Cough
Identification of an essential signaling cascade for mitogen-activated protein kinase activation by angiotensin II in cultured rat vascular smooth muscle cells. Possible requirement of Gq-mediated p21ras activation coupled to a Ca2+/calmodulin-sensitive tyrosine kinase.
Whooping Cough
Identification of B-cell epitopes on the S4 subunit of pertussis toxin.
Whooping Cough
Identification of B16-F1 melanoma autocrine motility-like factor receptor.
Whooping Cough
Identification of binding proteins for pertussis toxin on pancreatic beta cell-derived insulin-secreting cells.
Whooping Cough
Identification of biomarkers to detect residual pertussis toxin using microarray analysis of dendritic cells.
Whooping Cough
Identification of Bordetella pertussis infection by shared-primer PCR.
Whooping Cough
Identification of Bphs, an autoimmune disease locus, as histamine receptor H1.
Whooping Cough
Identification of cannabinoid receptors in cultures of rat cerebellar granule cells.
Whooping Cough
Identification of CCR8 as the specific receptor for the human beta-chemokine I-309: cloning and molecular characterization of murine CCR8 as the receptor for TCA-3.
Whooping Cough
Identification of CCR8: a human monocyte and thymus receptor for the CC chemokine I-309.
Whooping Cough
Identification of cDNA encoding an additional alpha subunit of a human GTP-binding protein: expression of three alpha i subtypes in human tissues and cell lines.
Whooping Cough
Identification of CXCR4 domains that support coreceptor and chemokine receptor functions.
Whooping Cough
Identification of distinct signalling pathways for somatostatin receptors SSTR1 and SSTR2 as revealed by microphysiometry.
Whooping Cough
Identification of endothelin receptors in cultured cerebellar neurons.
Whooping Cough
Identification of G protein alpha-subunits in RINm5F cells and their selective interaction with galanin receptor.
Whooping Cough
Identification of G protein subtypes in peripheral nerve and cultured Schwann cells.
Whooping Cough
Identification of G protein-coupled receptors potently stimulating migration of human transitional-cell carcinoma cells.
Whooping Cough
Identification of G-protein alpha-subunits during distinct stages of lens cell differentiation.
Whooping Cough
Identification of G-proteins in rat parotid gland plasma membranes and granule membranes: presence of distinct components in granule membranes.
Whooping Cough
Identification of gangliosides as inhibitors of ADP-ribosyltransferases of pertussis toxin and exoenzyme C3 from Clostridium botulinum.
Whooping Cough
Identification of heterotrimeric and low molecular weight GTP-binding proteins in rabbit skeletal muscle longitudinal sarcoplasmic reticulum.
Whooping Cough
Identification of human neutrophil-derived cathepsin G and azurocidin/CAP37 as chemoattractants for mononuclear cells and neutrophils.
Whooping Cough
Identification of human T-cell epitopes on the S4 subunit of pertussis toxin.
Whooping Cough
Identification of linear B-cell determinants of pertussis toxin associated with the receptor recognition site of the S3 subunit.
Whooping Cough
Identification of murine T-cell epitopes on the S4 subunit of pertussis toxin.
Whooping Cough
Identification of N-arachidonoyl dopamine as a highly biased ligand at cannabinoid CB1 receptors.
Whooping Cough
Identification of NCAM-binding peptides promoting neurite outgrowth via a heterotrimeric G-protein-coupled pathway.
Whooping Cough
Identification of neuropeptide Y receptors in cultured astrocytes from neonatal rat brain.
Whooping Cough
Identification of Novel Competing ?(2)AR Phospho-Extracellular Signal Regulated Kinase 1/2 Signaling Pathways in Human Trabecular Meshwork Cells.
Whooping Cough
Identification of novel GTP-binding proteins in the human neutrophil.
Whooping Cough
Identification of novel phytocannabinoids from Ganoderma by label-free dynamic mass redistribution assay.
Whooping Cough
Identification of novel synthetic peptide showing angiogenic activity in human endothelial cells.
Whooping Cough
Identification of peptides that mimic the pertussis toxin binding site on bovine fetuin.
Whooping Cough
Identification of pertussis-specific effector memory T cells in preschool children.
Whooping Cough
Identification of proteins resembling G-protein alpha subunits in locust muscle.
Whooping Cough
Identification of Salmonella typhi promoters activated by invasion of eukaryotic cells.
Whooping Cough
Identification of single C motif-1/lymphotactin receptor XCR1.
Whooping Cough
Identification of somatostatin receptors by covalent labeling with a novel photoreactive somatostatin analog.
Whooping Cough
Identification of T- and B-cell epitopes of the S2 and S3 subunits of pertussis toxin by use of synthetic peptides.
Whooping Cough
Identification of the border between fibronectin type III homologous repeats 2 and 3 of the neural cell adhesion molecule L1 as a neurite outgrowth promoting and signal transducing domain.
Whooping Cough
Identification of the C3a Receptor (C3AR1) as the Target of the VGF-derived Peptide TLQP-21 in Rodent Cells.
Whooping Cough
Identification of the functional region on the superantigen Yersinia pseudotuberculosis-derived mitogen responsible for induction of lymphocyte proliferation by using synthetic peptides.
Whooping Cough
Identification of the G-protein alpha-subunit encoded by alpha o2 cDNA as a 39 kDa pertussis toxin substrate.
Whooping Cough
Identification of the peptides that stimulate the phosphoinositide hydrolysis in lymphocyte cell lines from peptide libraries.
Whooping Cough
Identification of the pertussis and cholera toxin substrates in normal and N-ras transformed NIH3T3 fibroblasts and an assessment of their involvement in bombesin-stimulation of inositol phospholipid metabolism.
Whooping Cough
Identification of the pertussis toxin-sensitive G proteins in platelets, megakaryocytes, and human erythroleukemia cells.
Whooping Cough
Identification of the vasodilatory endothelial cannabinoid receptor in the human pulmonary artery.
Whooping Cough
Identification of three pertussis toxin substrates (41, 40 and 39 kDa proteins) in mammalian brain. Comparison of predicted amino acid sequences from G-protein alpha-subunit genes and cDNAs with partial amino acid sequences from purified proteins.
Whooping Cough
Identification of three separate guanine nucleotide-binding proteins that interact with the delta-opioid receptor in NG108-15 neuroblastoma x glioma hybrid cells.
Whooping Cough
Identification of two isoforms of mouse neuropeptide Y-Y1 receptor generated by alternative splicing. Isolation, genomic structure, and functional expression of the receptors.
Whooping Cough
Identification of two novel GTP-binding protein alpha-subunits that lack apparent ADP-ribosylation sites for pertussis toxin.
Whooping Cough
Identification, molecular cloning, expression, and characterization of a cysteinyl leukotriene receptor.
Whooping Cough
Identification, purification, and partial sequence analysis of autotaxin, a novel motility-stimulating protein.
Whooping Cough
Identifying long-term memory B-cells in vaccinated children despite waning antibody levels specific for Bordetella pertussis proteins.
Whooping Cough
Identifying the Critical Domain of LL-37 Involved in Mediating Neutrophil Activation in the Presence of Influenza Virus: Functional and Structural Analysis.
Whooping Cough
Identifying the G protein, Gz alpha, and its associated proteins in nervous tissue using mass spectrometry and microsequencing techniques.
Whooping Cough
Identity of adenylyl cyclase isoform determines the G protein mediating chronic opioid-induced adenylyl cyclase supersensitivity.
Whooping Cough
Idiopathic pulmonary fibrosis fibroblasts migrate and proliferate to CC chemokine ligand 21.
Whooping Cough
IFN-gamma up-regulates the human C5a receptor (CD88) in myeloblastic U937 cells and related cell lines.
Whooping Cough
IFN-gamma-induced chemokines synergize with pertussis toxin to promote T cell entry to the central nervous system.
Whooping Cough
IFN-gamma-mediated protection against intracerebral challenge with Bordetella pertussis in mice.
Whooping Cough
IFNgamma induces functional chemokine receptor expression in human mesangial cells.
Whooping Cough
IgE-Independent Activation of Human Mast Cells Indicates their Role in the Late Phase Reaction of Allergic Inflammation.
Whooping Cough
IGF-I and insulin induce different intracellular calcium signals in skeletal muscle cells.
Whooping Cough
IgG responses after booster vaccination with different pertussis vaccines in Dutch children 4 years of age: Effect of vaccine antigen content.
Whooping Cough
iGIST-A Kinetic Bioassay for Pertussis Toxin Based on Its Effect on Inhibitory GPCR Signaling.
Whooping Cough
IL-1 beta alters beta-adrenergic receptor adenylyl cyclase system function in human airway epithelial cells.
Whooping Cough
IL-1 signaling is critical for expansion but not generation of autoreactive GM-CSF+ Th17 cells.
Whooping Cough
IL-1 stimulates a diverging signaling pathway in EL4 6.1 thymoma cells. IL-2 release, but not IL-2 receptor expression, is sensitive to pertussis toxin.
Whooping Cough
IL-1-induced Bhlhe40 identifies pathogenic T helper cells in a model of autoimmune neuroinflammation.
Whooping Cough
IL-10 enhances CCL2 release and chemotaxis induced by CCL16 in human monocytes.
Whooping Cough
IL-10 plays an important role in the homeostatic regulation of the autoreactive repertoire in naive mice.
Whooping Cough
IL-15 induces mast cell migration via a pertussis toxin-sensitive receptor.
Whooping Cough
IL-16 promotes leukotriene C(4) and IL-4 release from human eosinophils via CD4- and autocrine CCR3-chemokine-mediated signaling.
Whooping Cough
IL-1beta activates p44/42 and p38 mitogen-activated protein kinases via different pathways in cat esophageal smooth muscle cells.
Whooping Cough
IL-1R signaling is required to overcome the effects of pertussis toxin and for efficient infection or vaccination induced immunity against Bordetella pertussis.
Whooping Cough
IL-2 secretion is pertussis toxin sensitive in a T lymphocyte hybridoma.
Whooping Cough
IL-3 Primes and Evokes Histamine Release from Human Basophils but not Mast Cells.
Whooping Cough
IL-3 stimulated haemopoietic stem cell proliferation: evidence for G protein independent mitogenic signalling events.
Whooping Cough
IL-6 and IL-8 release is mediated via multiple signaling pathways after stimulating dendritic cells with lysophospholipids.
Whooping Cough
IL-8 activates endothelial cell CXCR1 and CXCR2 through Rho and Rac signaling pathways.
Whooping Cough
IL-8 induces a transient arrest of rolling eosinophils on human endothelial cells.
Whooping Cough
IL-8 induces the locomotion of human IL-2-activated natural killer cells. Involvement of a guanine nucleotide binding (Go) protein.
Whooping Cough
IL-8 production by human polymorphonuclear leukocytes. The chemoattractant formyl-methionyl-leucyl-phenylalanine induces the gene expression and release of IL-8 through a pertussis toxin-sensitive pathway.
Whooping Cough
IL1 induces proliferation and IL6 mRNA expression in a human astrocytoma cell line: positive and negative modulation by chorela toxin and cAMP.
Whooping Cough
Imipramine's selective suppression of an L-type calcium channel in neurons of murine dorsal root ganglia involves G proteins.
Whooping Cough
Immediate and neurotoxic effects of HIV protein gp120 act through CXCR4 receptor.
Whooping Cough
Immobilization Stress With ?2-Adrenergic Stimulation Induces Regional and Transient Reduction of Cardiac Contraction Through Gi Coupling in Rats.
Whooping Cough
Immortalized schwann cells express endothelin receptors coupled to adenylyl cyclase and phospholipase C.
Whooping Cough
Immune effector cells induced by complete Freund's adjuvant exert an inhibitory effect on antigen-specific type 2 T helper responses.
Whooping Cough
Immune response to a Tdap booster in vertically HIV-infected adolescents.
Whooping Cough
Immune response to dimeric subunits of the pertussis toxin B oligomer.
Whooping Cough
Immune response to the B oligomer of pertussis toxin.
Whooping Cough
Immune responses and antibody decay after immunization of adolescents and adults with an acellular pertussis vaccine: the APERT Study.
Whooping Cough
Immune responses to Bordetella pertussis infection and vaccination.
Whooping Cough
Immune suppression and induction of gamma interferon by pertussis toxin.
Whooping Cough
Immunity against vaccine-preventable diseases in Finnish pediatric healthcare workers in 2015.
Whooping Cough
Immunity to pertussis 5 years after booster immunization during adolescence.
Whooping Cough
Immunity to vaccine-preventable diseases among paediatric healthcare workers in Denmark, 2019.
Whooping Cough
Immunization of Teenagers with a Fifth Dose of Reduced DTaP-IPV Induces High Levels of Pertussis Antibodies with a Significant Increase in Opsonophagocytic Activity.
Whooping Cough
Immuno-affinity purification and characterization of the alpha subunits of G0 type G proteins from various bovine tissues.
Whooping Cough
Immunochemical and electrophoretic characterization of the major pertussis toxin substrate of the RAW264 macrophage cell line.
Whooping Cough
Immunochemical comparison of pertussis toxin substrates in brain and peripheral tissues.
Whooping Cough
Immunochemical detection of GTP-binding protein in cephalopod photoreceptors by anti-peptide antibodies.
Whooping Cough
Immunochemical detection of guanine nucleotide binding proteins mono-ADP-ribosylated by bacterial toxins.
Whooping Cough
Immunochemical evidence for a novel pertussis toxin substrate in human neutrophils.
Whooping Cough
Immunocytochemical and biochemical characterization of guanine nucleotide-binding regulatory proteins in mammalian spermatozoa.
Whooping Cough
Immunocytochemical localization of the guanine nucleotide-binding protein Go in primary cultures of neuronal and glial cells.
Whooping Cough
Immunodetectable levels of the inhibitory guanine nucleotide-binding regulatory proteins in failing human heart: discordance with measurements of adenylate cyclase activity and levels of pertussis toxin substrate.
Whooping Cough
Immunoelectron microscopy of antigens of Bordetella pertussis using monoclonal antibodies to agglutinogens 2 and 3, filamentous haemagglutinin, pertussis toxin, pertactin and adenylate cyclase toxin.
Whooping Cough
Immunogenicity after one, two or three doses and impact on the antibody response to coadministered antigens of a nonavalent pneumococcal conjugate vaccine in infants of Soweto, South Africa.
Whooping Cough
Immunogenicity and protective efficacy of a newly developed tri-component diphtheria, tetanus, and acellular pertussis vaccine in a murine model.
Whooping Cough
Immunogenicity and protective efficacy of neonatal vaccination against Bordetella pertussis in a murine model: evidence for early control of pertussis.
Whooping Cough
Immunogenicity and protective efficacy of pertussis toxin subunit S1 produced by Bacillus subtilis.
Whooping Cough
Immunogenicity and reactogenicity of a combined adsorbed tetanus toxoid, low dose diphtheria toxoid, five component acellular pertussis and inactivated polio vaccine in six-year-old children.
Whooping Cough
Immunogenicity and reactogenicity of a reduced-antigen-content diphtheria-tetanus-acellular pertussis vaccine as a single-dose booster in Singaporean adults.
Whooping Cough
Immunogenicity and reactogenicity of a single dose of a diphtheria--tetanus--acellular pertussis component vaccine (DTaP) compared to a diphtheria--tetanus toxoid (Td) and a diphtheria toxoid vaccine (d) in adults.
Whooping Cough
Immunogenicity and reactogenicity of diphtheria, tetanus and pertussis toxoids combined with inactivated polio vaccine, when administered concomitantly with or as a diluent for a Hib conjugate vaccine.
Whooping Cough
Immunogenicity and reactogenicity of the component acellular pertussis vaccine produced by a combination of column purified pertussis toxin and filamentous haemagglutinin.
Whooping Cough
Immunogenicity and safety after booster vaccination of diphtheria, tetanus, and acellular pertussis in young adults: an open randomized controlled trial in Japan.
Whooping Cough
Immunogenicity and safety of a monovalent, multicomponent acellular pertussis vaccine in 15 month-6-year-old German children. Monovalent Acellular Pertussis Vaccine Study Group.
Whooping Cough
Immunogenicity and safety of a pertussis vaccine composed of pertussis toxin inactivated by hydrogen peroxide, in 18- to 23-month-old children.
Whooping Cough
Immunogenicity and safety of a tetravalent diphtheria-tetanus-acellular pertussis-inactivated poliovirus vaccine.
Whooping Cough
Immunogenicity and Safety of Monovalent Acellular Pertussis Vaccine at Birth: A Randomized Clinical Trial.
Whooping Cough
Immunogenicity of a combined DTPa-HB vaccine co-administered with Haemophilus influenzae type B conjugate vaccine (PRP-T) for primary and booster vaccinations.
Whooping Cough
Immunogenicity of a hexavalent combination vaccine in rhesus monkeys.
Whooping Cough
Immunogenicity of a three-component acellular pertussis vaccine administered at birth.
Whooping Cough
Immunogenicity of an acellular pertussis vaccine composed of genetically inactivated pertussis toxin combined with filamentous hemagglutinin and pertactin in infants and children.
Whooping Cough
Immunogenicity of combined diphtheria, tetanus, and pertussis vaccine given at 2, 3, and 4 months versus 3, 5, and 9 months of age.
Whooping Cough
Immunogenicity of glutaraldehyde inactivated pertussis vaccine.
Whooping Cough
Immunogenicity of primary DPT vaccination.
Whooping Cough
Immunogenicity study of a combined diphtheria, tetanus, acellular pertussis, inactivated poliomyelitis vaccine used to reconstitute a freeze-dried Haemophilus influenzae type b vaccine (DTaP-IPV//PRP-T) administered simultaneously with a hepatitis B vaccine at two, three and four months of life.
Whooping Cough
Immunoglobulin A antibodies to pertussis toxin and filamentous hemagglutinin in saliva from patients with pertussis.
Whooping Cough
Immunoglobulin A with protease activity secreted in human milk activates PAR-2 receptors, of intestinal epithelial cells HT-29, and promotes beta-defensin-2 expression.
Whooping Cough
Immunoglobulin E and G responses to pertussis toxin after booster immunization in relation to atopy, local reactions and aluminium content of the vaccines.
Whooping Cough
Immunoglobulin E and G responses to pertussis toxin in children immunised with adsorbed and non-adsorbed whole cell pertussis vaccines.
Whooping Cough
Immunoglobulin E response to pertussis toxin in whooping cough and after immunization with a whole-cell and an acellular pertussis vaccine.
Whooping Cough
Immunohistochemical studies on melanin associated antigen (MAA) induced experimental autoimmune anterior uveitis (EAAU).
Whooping Cough
Immunologic and epidemiologic experience of vaccination with a monocomponent pertussis toxoid vaccine.
Whooping Cough
Immunological and biochemical differentiation of guanyl nucleotide binding proteins: interaction of Go alpha with rhodopsin, anti-Go alpha polyclonal antibodies, and a monoclonal antibody against transducin alpha subunit and Gi alpha.
Whooping Cough
Immunological and molecular characterization of Go alpha-like proteins in the Drosophila central nervous system.
Whooping Cough
Immunological characterization of guanine nucleotide-binding proteins: effects of a monoclonal antibody against the gamma subunit of transducin on guanine nucleotide-binding protein-receptor interactions.
Whooping Cough
Immunological localization of the GTP-binding protein Go in different tissues of vertebrates and invertebrates.
Whooping Cough
Immunological persistence in 5 y olds previously vaccinated with hexavalent DTPa-HBV-IPV/Hib at 3, 5, and 11 months of age.
Whooping Cough
Immunomagnetic separation and solid-phase detection of Bordetella pertussis.
Whooping Cough
Immunomodulation By Subchronic Low Dose 2,3,7,8-Tetrachlorodibenzo-p-Dioxin in Experimental Autoimmune Encephalomyelitis in the Absence of Pertussis Toxin.
Whooping Cough
Immunomodulation of murine experimental autoimmune encephalomyelitis by pertussis toxin: the protective activity, but not the disease-enhancing activity, can be attributed to the nontoxic B-oligomer.
Whooping Cough
Immunomodulatory effects of recombinant BCG expressing pertussis toxin on TNF-alpha and IL-10 in a bladder cancer model.
Whooping Cough
Immunoprecipitation of a pertussis toxin substrate of the G(o) family from rat islets of Langerhans.
Whooping Cough
Impact of a pertussis booster vaccination program in adolescents and adults on the epidemiology of pertussis in Austria.
Whooping Cough
Impact of hypercholesterolemia on acidosis-induced coronary microvascular dilation.
Whooping Cough
Impact of infant and preschool pertussis vaccinations on memory B-cell responses in children at 4 years of age.
Whooping Cough
Impact of maternally derived pertussis antibody titers on infant whole-cell pertussis vaccine response in a low income setting.
Whooping Cough
Impact of pertussis-specific IgA, IgM, and IgG antibodies in mother's own breast milk and donor breast milk during preterm infant digestion.
Whooping Cough
Impaired 3',5'-cyclic adenosine monophosphate-mediated signaling in immediate early responsive gene X-1-deficient vascular smooth muscle cells.
Whooping Cough
Impaired cardiac muscarinic receptor function in dogs with heart failure.
Whooping Cough
Impaired formation of the second messenger cAMP in mononuclear blood cells of children with pertussis.
Whooping Cough
Impaired G protein function in gallbladder muscle from progesterone-treated guinea pigs.
Whooping Cough
Impaired G-proteins and cyclic nucleotide phosphodiesterase activity in T-lymphocytes from patients with sarcoidosis.
Whooping Cough
Impaired inhibitory G-protein function contributes to increased calcium currents in rats with diabetic neuropathy.
Whooping Cough
Impaired long-term maintenance and function of Bordetella pertussis specific B cell memory.
Whooping Cough
Impaired substance P release from renal sensory nerves in SHR involves a pertussis toxin-sensitive mechanism.
Whooping Cough
Impairment of beta-adrenergic signaling in healthy peripheral blood mononuclear cells exposed to serum from patients with septic shock: involvement of the inhibitory pathway of adenylyl cyclase stimulation.
Whooping Cough
Implication of Galpha i proteins and Src tyrosine kinases in endotoxin-induced signal transduction events and mediator production.
Whooping Cough
Implication of matrix metalloproteinases 2 and 9 in ceramide 1-phosphate-stimulated macrophage migration.
Whooping Cough
Implications of intrathecal pertussis toxin animal model on the cellular mechanisms of neuropathic pain syndrome.
Whooping Cough
Importance of ADP-ribosylation in the morphological changes of PC12 cells induced by cholera toxin.
Whooping Cough
Importance of CCL2-CCR2A/2B signaling for monocyte migration into spheroids of breast cancer-derived fibroblasts.
Whooping Cough
Importance of holotoxin assembly in Ptl-mediated secretion of pertussis toxin from Bordetella pertussis.
Whooping Cough
Improved pertussis toxin production by Bordetella pertussis through adjusting the growth medium's ionic composition.
Whooping Cough
Improved protocols for histamine sensitization testing of acellular pertussis vaccines.
Whooping Cough
Improved purification of transducin subunits from bovine retinal rod outer segments.
Whooping Cough
In human macrophages the complement component C5a induces the expression of oncostatin M via AP-1 activation.
Whooping Cough
In the developing hippocampus kainate receptors control the release of GABA from mossy fiber terminals via a metabotropic type of action.
Whooping Cough
In the developing rat hippocampus, endogenous activation of presynaptic kainate receptors reduces GABA release from mossy fiber terminals.
Whooping Cough
In vitro activation of murine DRG neurons by CGRP-mediated mucosal mast cell degranulation.
Whooping Cough
In vitro activation of murine peritoneal macrophages by monocyte chemoattractant protein-1: upregulation of CD11b, production of proinflammatory cytokines, and the signal transduction pathway.
Whooping Cough
In vitro activation of murine peritoneal macrophages by ultraviolet B radiation: upregulation of CD18, production of NO, proinflammatory cytokines and a signal transduction pathway.
Whooping Cough
In vitro and in vivo induction of nitric oxide by murine macrophages stimulated with Bordetella pertussis.
Whooping Cough
In vitro complement activation favoring soluble C5b-9 complex formation alters myocellular sodium homeostasis.
Whooping Cough
In vitro effect of chlorpyrifos oxon on muscarinic receptors and adenylate cyclase.
Whooping Cough
In vitro effects of 17 beta-oestradiol on the sensitivity of receptors coupled to adenylate cyclase on striatal neurons in primary culture.
Whooping Cough
In vitro Evidence of Human Immune Responsiveness Shows the Improved Potential of a Recombinant BCG Strain for Bladder Cancer Treatment.
Whooping Cough
In vitro formation and expansion of cysts derived from human renal cortex epithelial cells.
Whooping Cough
In vitro hypoxia impairs beta2-adrenergic receptor signaling in primary rat alveolar epithelial cells.
Whooping Cough
In vitro induction of antigen specific antibody synthesis and proliferation of T lymphocytes with acellular pertussis vaccines, pertussis toxin and filamentous haemagglutinin in humans.
Whooping Cough
In vitro model of angiogenesis using a human endothelium-derived permanent cell line: contributions of induced gene expression, G-proteins, and integrins.
Whooping Cough
In vitro modulation of growth hormone (GH) secretion from early to midgestation human fetal pituitaries by GH-releasing factor and somatostatin: role of Gs-adenylate cyclase-Gi complex and Ca2+ channels.
Whooping Cough
In vitro studies on responses to pentoxifylline and aminophylline of rat mesenteric resistance vessels.
Whooping Cough
In vivo anti-LAP mAb enhances IL-17/IFN-? responses and abrogates anti-CD3-induced oral tolerance.
Whooping Cough
In Vivo Dissection of Two Intracellular Pathways Involved in the Spinal Oxytocin-Induced Antinociception in the Rat.
Whooping Cough
In vivo evidence that lithium inactivates Gi modulation of adenylate cyclase in brain.
Whooping Cough
In vivo IL-1beta-induced modulation of G-protein alphaO subunit subclass in the hypothalamic ventromedial nucleus: implications to IL-1beta-associated anorexia.
Whooping Cough
In Vivo Models and In Vitro Assays for the Assessment of Pertussis Toxin Activity.
Whooping Cough
In Vivo Neutralization of Pertussis Toxin with Pertussis Antitoxin.
Whooping Cough
In vivo pertussis toxin administration: effects on the function and levels of Gi alpha proteins and their messenger ribonucleic acids.
Whooping Cough
In vivo pertussis toxin treatment attenuates some, but not all, adenosine A1 effects in slices of the rat hippocampus.
Whooping Cough
In vivo pertussis toxin treatment reduces contraction of rat resistance arteries but not that of mouse trachea.
Whooping Cough
In vivo pharmacology of butylthio[2.2.2] (LY297802 / NNC11-1053), an orally acting antinociceptive muscarinic agonist.
Whooping Cough
In Xenopus oocytes the human C3a and C5a receptors elicit a promiscuous response to the anaphylatoxins.
Whooping Cough
Inactivation of (Gialpha) proteins increases arrhythmogenic effects of beta-adrenergic stimulation in the heart.
Whooping Cough
Inactivation of enhanced expression of G(i) proteins by pertussis toxin attenuates the development of high blood pressure in spontaneously hypertensive rats.
Whooping Cough
Inactivation of G(i) proteins by pertussis toxin diminishes the effectiveness of adrenergic stimuli in conduit arteries from spontaneously hypertensive rats.
Whooping Cough
Inactivation of Gi and G(o) proteins in nucleus accumbens reduces both cocaine and heroin reinforcement.
Whooping Cough
Inactivation of Gi proteins induces an antidepressant-like effect in the mouse forced-swimming test.
Whooping Cough
Inactivation of pertussis toxin-sensitive guanyl nucleotide-binding proteins increase parathyroid hormone receptors and reverse agonist-induced receptor down-regulation in ROS 17/2.8 cells.
Whooping Cough
Inactivation of raf-1 by a protein-tyrosine phosphatase stimulated by GTP and reconstituted by Galphai/o subunits.
Whooping Cough
Incidence and reproduction numbers of pertussis: estimates from serological and social contact data in five European countries.
Whooping Cough
Incidence of pertussis in persons < or =15 years of age in Valencia, Spain: seroprevalence of antibodies to pertussis toxin (PT) in children, adolescents and adults.
Whooping Cough
Incidence of pertussis infection in healthcare workers.
Whooping Cough
Incidence of seropositivity to bordetella pertussis and mycoplasma pneumoniae infection in patients with chronic laryngotracheitis.
Whooping Cough
Incomplete functional differentiation of HL-60 leukemic cells by synthetic lipopeptides. Partial inhibition by pertussis toxin of enhanced superoxide formation.
Whooping Cough
Increase in cytosolic free Ca2+ in corticotropin-stimulated white adipocytes.
Whooping Cough
Increase in functional activity rather than in amount of Gi-alpha in failing human heart with dilated cardiomyopathy.
Whooping Cough
Increase in Gs and cyclic AMP generation in HIT cells. Evidence that the 45-kDa alpha-subunit of Gs has greater functional activity than the 52-kDa alpha-subunit.
Whooping Cough
Increase in intradermal vascular permeability caused by pertussis toxin from Bordetella pertussis.
Whooping Cough
Increase in mRNA Level of Orexin1 and 2 Receptors Following Induction of Experimental Autoimmune Encephalomyelitis in Mice.
Whooping Cough
Increase in [Ca2+]i by CCh in adult rat sympathetic neurons are not dependent on intracellular Ca2+ pools.
Whooping Cough
Increase of Gi alpha in human hearts with dilated but not ischemic cardiomyopathy.
Whooping Cough
Increase of myocardial inhibitory G-proteins in catecholamine-refractory septic shock or in septic multiorgan failure.
Whooping Cough
Increase of the 40,000-mol wt pertussis toxin substrate (G protein) in the failing human heart.
Whooping Cough
Increase of [Ca(2+)]i and release of arachidonic acid via activation of M2 receptor coupled to Gi and rho proteins in oesophageal muscle.
Whooping Cough
Increased Agonist Affinity at the ?-Opioid Receptor Induced by Prolonged Agonist Exposure.
Whooping Cough
Increased cAMP Signaling Can Ameliorate the Hypertensive Condition in Spontaneously Hypertensive Rats.
Whooping Cough
Increased cytosolic Ca2+ inhibits AVP-stimulated adenylyl cyclase activity in rat IMCT cells by activation of PKC.
Whooping Cough
Increased incorporation of arachidonic acid into phospholipids in zymosan-stimulated mouse peritoneal macrophages.
Whooping Cough
Increased intracellular cyclic adenosine monophosphate inhibits T lymphocyte-mediated cytolysis by two distinct mechanisms.
Whooping Cough
Increased levels of active pertussis toxin may aid a pertussis vaccine to pass the mouse body weight gain test.
Whooping Cough
Increased nociceptive input rapidly modulates spinal GABAergic transmission through endogenously released glutamate.
Whooping Cough
Increased plasma corticosterone, aggressiveness and brain monoamine changes induced by central injection of pertussis toxin.
Whooping Cough
Increased population prevalence of low pertussis toxin antibody levels in young children preceding a record pertussis epidemic in Australia.
Whooping Cough
Increased production of nitric oxide in coronary arteries during congestive heart failure.
Whooping Cough
Increased sensitivity of fat cell adenylate cyclase to stimulatory agonists during fasting is not related to impaired inhibitory coupling system.
Whooping Cough
Increased sensitivity of neonate atrial myocytes to adenosine A1 receptor stimulation in regulation of the L-type Ca2+ current.
Whooping Cough
Incubation of bovine thyroid slices with thyrotropin is associated with a decrease in the ability of pertussis toxin to adenosine diphosphate-ribosylate guanine nucleotide regulatory component(s).
Whooping Cough
Independence of, and interactions between, cannabinoid and opioid signal transduction pathways in N18TG2 cells.
Whooping Cough
Independent activation of endogenous p21-activated protein kinase-3 (PAK3) and JNK by thrombin in CCL39 fibroblasts.
Whooping Cough
Independent coupling of the human tachykinin NK2 receptor to phospholipases C and A2 in transfected Chinese hamster ovary cells.
Whooping Cough
Indications from Mn-quenching of Fura-2 fluorescence in melanotrophs that dopamine and baclofen close Ca channels that are spontaneously open but not those opened by high [K+]O; and that Cd preferentially blocks the latter.
Whooping Cough
Indirect inhibition by bradykinin of cyclic AMP generation in isolated rat glomeruli and mesangial cells.
Whooping Cough
Indomethacin causes prostaglandin D(2)-like and eotaxin-like selective responses in eosinophils and basophils.
Whooping Cough
Indomethacin differentiates the renal effects of sphingosine-1-phosphate and sphingosylphosphorylcholine.
Whooping Cough
Induction by chemokines of lipid mediator synthesis in granulocyte-macrophage colony-stimulating factor-treated human neutrophils.
Whooping Cough
Induction of a novel morphological response in Chinese hamster ovary cells by pertussis toxin.
Whooping Cough
Induction of a specific antibody response to Bordetella pertussis antigens in cultures of human peripheral blood mononuclear cells.
Whooping Cough
Induction of actin polymerization in permeabilized neutrophils. Role of ATP.
Whooping Cough
Induction of adenosine A1 receptor expression by pertussis toxin via an adenosine 5'-diphosphate ribosylation-independent pathway.
Whooping Cough
Induction of adherent activity in mastocytoma P-815 cells by the cooperation of two prostaglandin E2 receptor subtypes, EP3 and EP4.
Whooping Cough
Induction of antigen-specific T cell responses in human volunteers after intranasal immunization with a whole-cell pertussis vaccine.
Whooping Cough
Induction of Autoimmunity by Expansion of Autoreactive CD4+CD62Llow Cells In Vivo.
Whooping Cough
Induction of c-fos proto-oncogene by a chemotactic peptide in human peripheral granulocytes.
Whooping Cough
Induction of c-jun independent of PKC, pertussis toxin-sensitive G protein, and polyamines in quiescent SV40-transformed 3T3 T cells.
Whooping Cough
Induction of CD4(+) and CD8(+) Bordetella pertussis toxin subunit S1 specific T cells by immunization with synthetic peptides.
Whooping Cough
Induction of COX-2 and reactive gliosis by P2Y receptors in rat cortical astrocytes is dependent on ERK1/2 but independent of calcium signalling.
Whooping Cough
Induction of dendritic cell maturation by pertussis toxin and its B subunit differentially initiate Toll-like receptor 4-dependent signal transduction pathways.
Whooping Cough
Induction of dendritic cell migration upon Toxoplasma gondii infection potentiates parasite dissemination.
Whooping Cough
Induction of eosinophil cytokine generation by chemoattractants.
Whooping Cough
Induction of Experimental Allergic Encephalomyelitis in C57/BL6 Mice: An Animal Model for Multiple Sclerosis, Hossein Mostafavi, and Bahman Zeynali.
Whooping Cough
Induction of experimental autoimmune neuritis in CD4-8-C57BL/6J mice.
Whooping Cough
Induction of helper T cells by pertussis toxin during in vivo priming to insulin.
Whooping Cough
Induction of human neutrophil chemotaxis by Candida albicans-derived beta-1,6-long glycoside side-chain-branched beta-glucan.
Whooping Cough
Induction of humoral immunity in response to immunization with recombinant Mycobacterium bovis BCG expressing the S1 subunit of Bordetella pertussis toxin.
Whooping Cough
Induction of intercellular adhesion molecule-1 on human brain endothelial cells by HIV-1 gp120: role of CD4 and chemokine coreceptors.
Whooping Cough
Induction of macrophage apoptosis by Bordetella pertussis adenylate cyclase-hemolysin.
Whooping Cough
Induction of mast cell accumulation, histamine release and skin edema by N49 phospholipase A2.
Whooping Cough
Induction of microvascular leakage and histamine release by promutoxin, an Arg49 phospholipase A2.
Whooping Cough
Induction of muscarinic cholinergic responsiveness in Xenopus oocytes by mRNA isolated from rat brain.
Whooping Cough
Induction of natural killer cell migration by monocyte chemotactic protein-1, -2 and -3.
Whooping Cough
Induction of nitric oxide synthase mRNA by shear stress requires intracellular calcium and G-protein signals and is modulated by PI 3 kinase.
Whooping Cough
Induction of polyclonal antibodies to the S1 subunit of pertussis toxin by synthetic peptides coupled to PPD: effect of conjugation method, adjuvant, priming and animal species.
Whooping Cough
Induction of polyclonal CD8+ T cell activation and effector function by Pertussis toxin.
Whooping Cough
Induction of promiscuous G protein coupling of the follicle-stimulating hormone (FSH) receptor: a novel mechanism for transducing pleiotropic actions of FSH isoforms.
Whooping Cough
Induction of signal transduction in human neutrophils by Candida albicans hyphae: the role of pertussis toxin-sensitive guanosine triphosphate-binding proteins.
Whooping Cough
Induction of the fibrinogen receptor on human platelets by intracellular mediators.
Whooping Cough
Induction of tryptase and histamine release from human colon mast cells by IgE dependent or independent mechanisms.
Whooping Cough
Induction of type 1 immune pathology in the brain following immunization without central nervous system autoantigen in transgenic mice with astrocyte-targeted expression of IL-12.
Whooping Cough
Infection of L6E9 myoblasts with Trypanosoma cruzi alters adenylate cyclase activity and guanine nucleotide binding proteins.
Whooping Cough
Infection of newborn piglets with Bordetella pertussis: a new model for pertussis.
Whooping Cough
Infiltration of tumors by systemically transferred tumor-reactive T lymphocytes is required for antitumor efficacy.
Whooping Cough
Inflammation controls B lymphopoiesis by regulating chemokine CXCL12 expression.
Whooping Cough
Inflammation- and ischemia-induced shedding of venular glycocalyx.
Whooping Cough
Inflammatory activation of neutrophils by Helicobacter pylori; a mechanism insensitive to pertussis toxin.
Whooping Cough
Inflammatory and contractile agents sensitize specific adenylyl cyclase isoforms in human airway smooth muscle.
Whooping Cough
Inflammatory effects of resistin on human smooth muscle cells: up-regulation of fractalkine and its receptor, CX3CR1 expression by TLR4 and Gi-protein pathways.
Whooping Cough
Inflammatory Responses Induced by Lipopolysaccharide Are Amplified in Primary Human Monocytes but Suppressed in Macrophages by Complement Protein C5a.
Whooping Cough
Influence of aluminum on the regulation of PTH- and 1,25(OH)2D3-dependent pathways in the rat osteosarcoma cell line ROS 17/2.8.
Whooping Cough
Influence of anti-beta-receptor antibodies on cardiac adenylate cyclase in patients with idiopathic dilated cardiomyopathy.
Whooping Cough
Influence of bacterial toxins and forskolin upon vasopressin-induced inositol phosphate accumulation in WRK 1 cells.
Whooping Cough
Influence of C-peptide on early glomerular changes in diabetic mice.
Whooping Cough
Influence of CR3 (CD11b/CD18) expression on phagocytosis of Bordetella pertussis by human neutrophils.
Whooping Cough
Influence of dietary omega-3 fatty acids on transmembrane signalling in rat submandibular salivary gland.
Whooping Cough
Influence of flupirtine on a G-protein coupled inwardly rectifying potassium current in hippocampal neurones.
Whooping Cough
Influence of G protein type on agonist efficacy.
Whooping Cough
Influence of Hesperidin on the Systemic and Intestinal Rat Immune Response.
Whooping Cough
Influence of lipoxin A(4) and other lipoxygenase-derived eicosanoids on tissue factor expression.
Whooping Cough
Influence of maternal vaccination against diphtheria, tetanus, and pertussis on the avidity of infant antibody responses to a pertussis containing vaccine in Belgium.
Whooping Cough
Influence of pertussis toxin on CD1a isoform expression in human dendritic cells.
Whooping Cough
Influence of pertussis toxin on parathyroid hormone stimulated cyclic AMP production and phosphate transport in opossum kidney cells.
Whooping Cough
Influence of pertussis toxin on superficial bladder carcinoma in rats.
Whooping Cough
Influence of pertussis toxin on the calcitonin-opioid interaction in isolated tissues.
Whooping Cough
Influence of pertussis toxin on the effects of guanine nucleotide on adenylate cyclase in rat striatal membranes.
Whooping Cough
Influence of pertussis toxin on thermic responses to morphine and neurotensin in rats.
Whooping Cough
Influence of pertussis toxin pretreatment on the development of L-NAME-induced hypertension.
Whooping Cough
Influence of receptor number on functional responses elicited by agonists acting at the human adenosine A(1) receptor: evidence for signaling pathway-dependent changes in agonist potency and relative intrinsic activity.
Whooping Cough
Influence of the Adjuvants and Genetic Background on the Asthma Model Using Recombinant Der f 2 in Mice.
Whooping Cough
Influences of pertussis toxin, guanine nucleotides and forskolin on adenylate cyclase in striatal membranes of infant, adult and senescent rats.
Whooping Cough
Inhaled Bordetella pertussis vaccine decreases airway responsiveness in guinea pigs.
Whooping Cough
Inhibition and activation of interleukin 2 synthesis by direct modification of guanosine triphosphate-binding proteins.
Whooping Cough
Inhibition and superactivation of the calcium-stimulated isoforms of adenylyl cyclase: role of Gbetagamma dimers.
Whooping Cough
Inhibition by 5-hydroxytryptamine of the beta adrenoceptor-mediated positive inotropic responses to catecholamines in rabbit papillary muscles: direct interaction with beta adrenoceptors.
Whooping Cough
Inhibition by anandamide of gap junctions and intercellular calcium signalling in striatal astrocytes.
Whooping Cough
Inhibition by brimonidine of forskolin-induced nitrite production in isolated pig ciliary processes.
Whooping Cough
Inhibition by CTLA4Ig of experimental allergic encephalomyelitis.
Whooping Cough
Inhibition by fluoxetine of voltage-activated ion channels in rat PC12 cells.
Whooping Cough
Inhibition by galanin and by high K+ of human basophil histamine release triggered by calcium ionophores but not responses induced by anti-IgE, chemotactic peptide or phorbol ester.
Whooping Cough
Inhibition by glucagon of the cGMP-inhibited low-Km cAMP phosphodiesterase in heart is mediated by a pertussis toxin-sensitive G-protein.
Whooping Cough
Inhibition by islet-activating protein of a chemotactic peptide-induced early breakdown of inositol phospholipids and Ca2+ mobilization in guinea pig neutrophils.
Whooping Cough
Inhibition by islet-activating protein, pertussis toxin, of P2-purinergic receptor-mediated iodide efflux and phosphoinositide turnover in FRTL-5 cells.
Whooping Cough
Inhibition by islet-activating protein, pertussis toxin, of retinoic acid-induced differentiation of human leukemic (HL-60) cells.
Whooping Cough
Inhibition by pertussis toxin of fibroblast growth factor-stimulated hexose transport in Swiss 3T3 cells.
Whooping Cough
Inhibition by pertussis toxin of guanyl nucleotides exchange on transducin in bovine rod cell membranes.
Whooping Cough
Inhibition by pertussis toxin of the activation of Na(+)-dependent uridine transport in dimethyl-sulphoxide-induced HL-60 leukaemia cells.
Whooping Cough
Inhibition by pertussis toxin of the soporific effects induced by stimulation of dopamine D2 autoreceptors in the ventral tegmental area in rats.
Whooping Cough
Inhibition by PGE2 of glucagon-induced increase in phosphoenolpyruvate carboxykinase mRNA and acceleration of mRNA degradation in cultured rat hepatocytes.
Whooping Cough
Inhibition by somatostatin of amylase secretion induced by calcium and cyclic AMP in rat pancreatic acini.
Whooping Cough
Inhibition by SR 59119A of isoprenaline-, forskolin- and VIP-induced relaxation of human isolated bronchi.
Whooping Cough
Inhibition by Wnt-1 or Wnt-3a of nerve growth factor-induced differentiation of PC12 cells is reversed by bisindolylmaleimide-I but not by several other PKC inhibitors.
Whooping Cough
Inhibition of a TREK-like K+ channel current by noradrenaline requires both ?1- and ?2-adrenoceptors in rat atrial myocytes.
Whooping Cough
Inhibition of acetylcholine release from guinea pig myenteric neurons by neuropeptide Y: GTP-binding protein mediation.
Whooping Cough
Inhibition of acid secretion by bombesin is partly mediated by release of fundic somatostatin.
Whooping Cough
Inhibition of ACTH secretion in mouse pituitary tumor cells by activation of muscarinic cholinergic receptors.
Whooping Cough
Inhibition of adenylate cyclase activity in the goldfish melanophore is mediated by alpha2-adrenoceptors and a pertussis toxin-sensitive GTP-binding protein.
Whooping Cough
Inhibition of adenylate cyclase from luteinized rat ovary by monovalent cations: roles of the stimulatory guanine nucleotide-binding regulatory component and stimulatory hormone receptor.
Whooping Cough
Inhibition of adenylate cyclase in bovine ciliary process and rabbit iris ciliary body to alpha 2-adrenergic agonists.
Whooping Cough
Inhibition of adenylyl cyclase activity by a homogeneous population of dopamine receptors: selective blockade by antisera directed against Gi1 and/or Gi2.
Whooping Cough
Inhibition of adenylyl cyclase activity in brain membrane fractions by arachidonic acid and related unsaturated fatty acids.
Whooping Cough
Inhibition of adenylyl cyclase by alpha chemokines IL-8 and GRO-alpha in Chinese hamster ovary cells expressing R1 and R2 receptors.
Whooping Cough
Inhibition of adenylyl cyclase by neuronal P2Y receptors.
Whooping Cough
Inhibition of adenylyl cyclases by 12(S)-hydroxyeicosatetraenoic acid.
Whooping Cough
Inhibition of alpha(1)-adrenergic-mediated responses in rat ventricular myocytes by adenosine A(1) receptor activation: role of the K(ATP) channel.
Whooping Cough
Inhibition of AMPA receptor-stimulated 57Co2+ influx by D- and L-2-amino-4-phosphonobutanoic acid (D- and L-AP4) and L-serine-O-phosphate (L-SOP) in cultured cerebellar granule cells.
Whooping Cough
Inhibition of angiotensin II-stimulated inositol phosphate production by D2-dopamine receptor is calcium-dependent in human trophoblastic cells.
Whooping Cough
Inhibition of atherogenesis in BLT1-deficient mice reveals a role for LTB4 and BLT1 in smooth muscle cell recruitment.
Whooping Cough
Inhibition of ATP-induced cAMP formation by 5'-p-fluorosulfonylbenzoyladenosine in NG108-15 cells.
Whooping Cough
Inhibition of basal and corticotropin-releasing hormone-stimulated adenylate cyclase activity and cytosolic Ca2+ levels by somatostatin in human corticotropin-secreting pituitary adenomas.
Whooping Cough
Inhibition of bombesin-induced mitogenesis by pertussis toxin: dissociation from phospholipase C pathway.
Whooping Cough
Inhibition of bovine rod outer segment GTPase by Bordetella pertussis toxin.
Whooping Cough
Inhibition of Ca(2+) entry caused by depolarization in acetylcholine-stimulated antral mucous cells of guinea pig: G protein regulation of Ca(2+) permeable channels.
Whooping Cough
Inhibition of Ca(2+) signalling by the sphingosine 1-phosphate receptor S1P(1).
Whooping Cough
Inhibition of Ca(2+)-induced calcitonin secretion by somatostatin: roles of voltage dependent Ca2+ channels and G-proteins.
Whooping Cough
Inhibition of Ca2+ channels via alpha 2-adrenergic and muscarinic receptors in pheochromocytoma (PC-12) cells.
Whooping Cough
Inhibition of calcium currents by noradrenaline, somatostatin and opioids in guinea-pig submucosal neurones.
Whooping Cough
Inhibition of calcium currents in cultured myenteric neurons by neuropeptide Y: evidence for direct receptor/channel coupling.
Whooping Cough
Inhibition of calcium currents in rat colon sensory neurons by K- but not mu- or delta-opioids.
Whooping Cough
Inhibition of calcium spikes by gamma-amino-butyric acid in the neurons of Lymnaea stagnalis L.
Whooping Cough
Inhibition of calcium transients in cultured vascular smooth muscle cells by pertussis toxin.
Whooping Cough
Inhibition of cAMP accumulation by intracellular calcium mobilization in C6-2B cells stably transfected with substance K receptor cDNA.
Whooping Cough
Inhibition of cAMP production by alpha 2-adrenoceptor stimulation in rabbit retina.
Whooping Cough
Inhibition of chemokine (C-X-C motif) ligand 12/chemokine (C-X-C motif) receptor 4 axis (CXCL12/CXCR4)-mediated cell migration by targeting mammalian target of rapamycin (mTOR) pathway in human gastric carcinoma cells.
Whooping Cough
Inhibition of cholinergic transmission by opiates in ileal myenteric plexus is mediated by kappa receptor. Involvement of regulatory inhibitory G protein and calcium N-channels.
Whooping Cough
Inhibition of cyclic AMP accumulation by endothelin is pertussis toxin sensitive and calcium independent in isolated adult feline cardiac myocytes.
Whooping Cough
Inhibition of delayed rectifier K+ conductance in cultured rat cerebellar granule neurons by activation of calcium-permeable AMPA receptors.
Whooping Cough
Inhibition of dopamine release by prostaglandin EP3 receptor via pertussis toxin-sensitive and -insensitive pathways in PC12 cells.
Whooping Cough
Inhibition of EGF-induced ERK/MAP kinase-mediated astrocyte proliferation by mu opioids: integration of G protein and beta-arrestin 2-dependent pathways.
Whooping Cough
Inhibition of endothelin-mediated topoisomerase I activation by pertussis toxin.
Whooping Cough
Inhibition of endothelium-dependent relaxations by phorbol myristate acetate in canine coronary arteries: role of a pertussis toxin-sensitive G-protein.
Whooping Cough
Inhibition of epithelial Na+ transport by atriopeptin, protein kinase c, and pertussis toxin.
Whooping Cough
Inhibition of fatty acid transport and proliferative activity in tissue-isolated human squamous cell cancer xenografts perfused in situ with melatonin or eicosapentaenoic or conjugated linoleic acids.
Whooping Cough
Inhibition of fetal rat pancreatic beta-cell replication by interleukin-1 beta in vitro is not mediated through pertussis toxin-sensitive G-proteins, a decrease in cyclic AMP, or protease activation.
Whooping Cough
Inhibition of formation of cyclic AMP and cyclic GMP by vasopressin in smooth-muscle cells is insensitive to pertussis toxin.
Whooping Cough
Inhibition of FSH-stimulated cAMP accumulation by mono(2-ethylhexyl) phthalate in primary rat Sertoli cell cultures.
Whooping Cough
Inhibition of G alpha i2 activation by G alpha i3 in CXCR3-mediated signaling.
Whooping Cough
Inhibition of G protein in human sperm and its influence on acrosome reaction and zona pellucida binding.
Whooping Cough
Inhibition of G-protein betagamma-subunit functions by phosducin-like protein.
Whooping Cough
Inhibition of Gi proteins by low density lipoprotein attenuates bradykinin-stimulated release of endothelial-derived nitric oxide.
Whooping Cough
Inhibition of glucagon-signaling and downstream actions by interleukin 1beta and tumor necrosis factor alpha in cultured primary rat hepatocytes.
Whooping Cough
Inhibition of glucose stimulated insulin secretion by neuropeptide Y is mediated via the Y1 receptor and inhibition of adenylyl cyclase in RIN 5AH rat insulinoma cells.
Whooping Cough
Inhibition of glycogen synthesis by epidermal growth factor in hepatocytes. The role of cell density and pertussis toxin-sensitive GTP-binding proteins.
Whooping Cough
Inhibition of GTPase activity of Gi proteins and decreased agonist affinity at M2 muscarinic acetylcholine receptors by spermine and methoctramine.
Whooping Cough
Inhibition of hepatic adenylate cyclase by NADH.
Whooping Cough
Inhibition of hormonally induced inositol trisphosphate production in Transfected GH4 sup>C1 cells: A novel role for the D5 subtype of the dopamine receptor.
Whooping Cough
Inhibition of human thyroid adenylyl cyclase by 2-iodoaldehydes.
Whooping Cough
Inhibition of immunoglobulin E production by Poncirus trifoliata fruit extract.
Whooping Cough
Inhibition of inositol phosphate production is a late, Ca2+-dependent effect of D2 dopaminergic receptor activation in rat lactotroph cells.
Whooping Cough
Inhibition of insulin secretion from rat pancreatic islets by dexmedetomidine and medetomidine, two sedatives frequently used in clinical settings.
Whooping Cough
Inhibition of interleukin 3 and colony-stimulating factor 1-stimulated marrow cell proliferation by pertussis toxin.
Whooping Cough
Inhibition of interleukin-1beta-induced COX-2 and EP3 gene expression by sodium salicylate enhances pancreatic islet beta-cell function.
Whooping Cough
Inhibition of intra- and extra-cellular Tat function and HIV expression by pertussis toxin B-oligomer.
Whooping Cough
Inhibition of inward rectifier K+ currents by angiotensin II in rat atrial myocytes: lack of effects in cells from spontaneously hypertensive rats.
Whooping Cough
Inhibition of inwardly rectifying K+ current by external Ca2+ ions in freshly isolated rabbit osteoclasts.
Whooping Cough
Inhibition of isoproterenol-induced lipolysis in rat inguinal adipocytes in vitro by physiological melatonin via a receptor-mediated mechanism.
Whooping Cough
Inhibition of L-type Ca(2+) current by ginsenoside Rd in rat ventricular myocytes.
Whooping Cough
Inhibition of L-type calcium channels by internal GTP [gamma S] in mouse pancreatic beta cells.
Whooping Cough
Inhibition of L-type calcium currents in guinea pig ventricular myocytes by the kappa-opioid agonist U50488H does not involve binding to opiate receptors.
Whooping Cough
Inhibition of lipid phosphate phosphatase activity by VPC32183 suppresses the ability of diacylglycerol pyrophosphate to activate ERK(1/2) MAP kinases.
Whooping Cough
Inhibition of lipolysis by agents acting via adenylate cyclase in fat cells from infants and adults.
Whooping Cough
Inhibition of lymphocyte and neutrophil chemotaxis by pertussis toxin.
Whooping Cough
Inhibition of lymphocyte circulation in mice by pertussis toxin.
Whooping Cough
Inhibition of lymphoma invasion and liver metastasis formation by pertussis toxin.
Whooping Cough
Inhibition of M-type K+ and N-type Ca2+ channels by the human gonadotropin-releasing-hormone receptor heterologously expressed in adult neurons.
Whooping Cough
Inhibition of metabotropic glutamate receptor 5 induces cellular stress through pertussis toxin-sensitive G i -proteins in murine BV-2 microglia cells.
Whooping Cough
Inhibition of mink lung epithelial cell proliferation by transforming growth factor-beta is coupled through a pertussis-toxin-sensitive substrate.
Whooping Cough
Inhibition of monocyte oxidative responses by Bordetella pertussis adenylate cyclase toxin.
Whooping Cough
Inhibition of muscle cell relaxation by somatostatin: tissue-specific, cAMP-dependent, pertussis toxin-sensitive.
Whooping Cough
Inhibition of N- and P/Q-type calcium channels by postsynaptic GABAB receptor activation in rat supraoptic neurones.
Whooping Cough
Inhibition of N-type Ca2+ channel currents in human neuroblastoma (SH-SY5Y) cells by muscarine via stimulation of M3 receptors.
Whooping Cough
Inhibition of N-type calcium channels by activation of GPR35, an orphan receptor, heterologously expressed in rat sympathetic neurons.
Whooping Cough
Inhibition of NAD+ glycohydrolase and ADP-ribosyl cyclase activities of leukocyte cell surface antigen CD38 by gangliosides.
Whooping Cough
Inhibition of noradrenaline release by neuropeptide Y in mouse atria does not involve inhibition of adenylate cyclase or a pertussis toxin-susceptible G protein.
Whooping Cough
Inhibition of oxytocin-stimulated phosphoinositide turnover in rat myometrium by pertussis and cholera toxins may involve protein kinase A activation.
Whooping Cough
Inhibition of parathyroid hormone release by maitotoxin, a calcium channel activator.
Whooping Cough
Inhibition of parathyroid hormone-responsive adenylate cyclase in clonal osteoblast-like cells by transforming growth factor alpha and epidermal growth factor.
Whooping Cough
Inhibition of parietal cell H+ secretion by transforming growth factor alpha: a possible autocrine regulatory mechanism.
Whooping Cough
Inhibition of pertussis toxin binding to model receptors by antipeptide antibodies directed at an antigenic domain of the S2 subunit.
Whooping Cough
Inhibition of pertussis toxin catalyzed ADP-ribosylation of G-proteins by membrane depolarization in rat brain synaptoneurosomes.
Whooping Cough
Inhibition of platelet-activating factor-induced retinal impairments by cholera and pertussis toxins.
Whooping Cough
Inhibition of potassium and calcium currents in neurones by molecularly-defined P2Y receptors.
Whooping Cough
Inhibition of prolactin release by gonadotropin-releasing hormone-associated Peptide in benign, dopamine-sensitive and in malignant, dopamine-resistant pituitary tumors.
Whooping Cough
Inhibition of prolactin secretion by endothelin-3 is pertussis toxin-sensitive.
Whooping Cough
Inhibition of protein phosphatase 2A (PP2A) mimics suckling-induced sensitization of mammotropes: involvement of a pertussis toxin (PTX) sensitive G-protein and the adenylate cyclase (AC).
Whooping Cough
Inhibition of quantal transmitter release in the absence of calcium influx by a G protein-linked adenosine receptor at hippocampal synapses.
Whooping Cough
Inhibition of receptor-mediated release of arachidonic acid by pertussis toxin.
Whooping Cough
Inhibition of renal Na+-ATPase activity by inosine is mediated by A1 receptor-induced inhibition of the cAMP signaling pathway.
Whooping Cough
Inhibition of Rho-Kinase Abrogates Migration of Human Transitional Cell Carcinoma Cells: Results of an in vitro Study.
Whooping Cough
Inhibition of spontaneous beta 2-adrenergic activation rescues beta 1-adrenergic contractile response in cardiomyocytes overexpressing beta 2-adrenoceptor.
Whooping Cough
Inhibition of stimulated amylase secretion by adrenomedullin in rat pancreatic acini.
Whooping Cough
Inhibition of striatal GABA release by the adenosine A2a receptor is not mediated by increases in cyclic AMP.
Whooping Cough
Inhibition of swine microglial cell phagocytosis of Cryptococcus neoformans by femtomolar concentrations of morphine.
Whooping Cough
Inhibition of T cell homing by down-regulation of CD62L and the induction of a Th-2 response as a method to prevent acute allograft rejection in mice.
Whooping Cough
Inhibition of the cAMP signaling cascade via cannabinoid receptors: a putative mechanism of immune modulation by cannabinoid compounds.
Whooping Cough
Inhibition of the effects of adenosine on force of contraction and the slow calcium inward current by pertussis toxin is associated with myocardial lesions.
Whooping Cough
Inhibition of the GTPase activity of transducin by an NAD+:arginine ADP-ribosyltransferase from turkey erythrocytes.
Whooping Cough
Inhibition of the hyperpolarization-activated current (if) of rabbit SA node myocytes by niflumic acid.
Whooping Cough
Inhibition of the L-type calcium channel by the five muscarinic receptors (m1-m5) expressed in NIH 3T3 cells.
Whooping Cough
Inhibition of the magnesium-sensitive TRPM7-like channel in cardiac myocytes by nonhydrolysable GTP analogs: involvement of phosphoinositide metabolism.
Whooping Cough
Inhibition of the omega-conotoxin-sensitive calcium current by distinct G proteins.
Whooping Cough
Inhibition of the T-type Ca2+ current by the dopamine D1 receptor in rat adrenal glomerulosa cells: requirement of the combined action of the G betagamma protein subunit and cyclic adenosine 3',5'-monophosphate.
Whooping Cough
Inhibition of thyrotropin-stimulated adenosine 3',5'-monophosphate formation in rat thyroid cells by an adenosine analog. Evidence that the inhibition is mediated by the putative inhibitory guanine nucleotide regulatory protein.
Whooping Cough
Inhibition of transmitter release from rat sympathetic neurons via presynaptic M(1) muscarinic acetylcholine receptors.
Whooping Cough
Inhibition of tumor necrosis factor-induced p42/p44 mitogen-activated protein kinase activation by sodium salicylate.
Whooping Cough
Inhibition of tumour necrosis factor and reversal of endotoxin-induced shock by U-83836E, a 'second generation' lazaroid in rats.
Whooping Cough
Inhibition of vasopressin-stimulated cyclic AMP accumulation by alpha-2 adrenoceptor agonists in isolated papillary collecting ducts.
Whooping Cough
Inhibition of voltage-dependent Ca(2+)-current by alpha-adrenoceptor agonists in smooth muscle cells.
Whooping Cough
Inhibition of voltage-dependent Ca2+ channels via alpha 2-adrenergic and opioid receptors in cultured bovine adrenal chromaffin cells.
Whooping Cough
Inhibition of voltage-dependent Ca2+ currents and activation of pertussis toxin-sensitive G-proteins via muscarinic receptors in GH3 cells.
Whooping Cough
Inhibition of voltage-dependent calcium channels by prostaglandin E2 in rat melanotrophs.
Whooping Cough
Inhibitors of ADP-ribosylating bacterial toxins based on oxacarbenium ion character at their transition states.
Whooping Cough
Inhibitors of diacylglycerol metabolism reduce time to the onset of glutamate release potentation by mGlu7 receptors.
Whooping Cough
Inhibitors of tryptase as mast cell-stabilizing agents in the human airways: effects of tryptase and other agonists of proteinase-activated receptor 2 on histamine release.
Whooping Cough
Inhibitory action of forskolin on adenylate cyclase activity and cyclic AMP generation.
Whooping Cough
Inhibitory action of pertussis toxin on parathyroid hormone and prostaglandin E2-stimulated bone resorption in cultured neonatal mouse calvaria.
Whooping Cough
Inhibitory action of somatostatin on cAMP dependent pepsinogen secretion from rat gastric chief cells: involvement of pertussis toxin-sensitive G-protein.
Whooping Cough
Inhibitory actions of cyclic adenosine monophosphate and pertussis toxin define two distinct epidermal growth factor-regulated pathways leading to activation of mitogen-activated protein kinase in rat hepatocytes.
Whooping Cough
Inhibitory actions of somatostatin on cyclic AMP and aldosterone production in agonist-stimulated adrenal glomerulosa cells.
Whooping Cough
Inhibitory and stimulatory regulation of Rac and cell motility by the G12/13-Rho and Gi pathways integrated downstream of a single G protein-coupled sphingosine-1-phosphate receptor isoform.
Whooping Cough
Inhibitory effect of ?-hydroxybutyric acid on L-type Ca(2+) current under ?-adrenergic stimulation in guinea pig cardiac ventricular myocytes.
Whooping Cough
Inhibitory effect of adenosine on electrical activity of frog melanotrophs mediated through A1 purinergic receptors.
Whooping Cough
Inhibitory effect of fluvastatin on lysophosphatidylcholine-induced nonselective cation current in Guinea pig ventricular myocytes.
Whooping Cough
Inhibitory effect of hypochlorous acid on lower esophageal sphincter tone relaxation by vasoactive intestinal peptide.
Whooping Cough
Inhibitory effect of melatonin on gonadotropin-releasing hormone-induced Ca2+ oscillations in pituitary cells of newborn rats.
Whooping Cough
Inhibitory effect of muscarinic receptor activation on Ca2+ channel current in smooth muscle cells of guinea-pig ileum.
Whooping Cough
Inhibitory effect of neuropeptide Y and its analogues on inositol 1,4,5-trisphosphate level in rat cardiomyocytes.
Whooping Cough
Inhibitory effect of octopamine on the release of endogenous acetylcholine from isolated myenteric synaptosomes of guinea-pig.
Whooping Cough
Inhibitory effect of somatostatin on cAMP accumulation and calcitonin secretion in C-cells: involvement of pertussis toxin-sensitive G-proteins.
Whooping Cough
Inhibitory effect on immunoglobulin E production in vivo and in vitro by Siegesbeckia glabrescens.
Whooping Cough
Inhibitory effects of C4a on chemoattractant and secretagogue functions of the other anaphylatoxins via Gi protein-adenylyl cyclase inhibition pathway in mast cells.
Whooping Cough
Inhibitory effects of glibenclamide and pertussis toxin on the attenuation of ischemia-induced myocardial acidosis following ischemic preconditioning in dogs.
Whooping Cough
Inhibitory effects of opioids on voltage-dependent Ca(2+) channels and catecholamine secretion in cultured porcine adrenal chromaffin cells.
Whooping Cough
Inhibitory effects of pertussis toxin on a depolarization-evoked Ca2+ influx in NG108-15 cells.
Whooping Cough
Inhibitory effects of pertussis toxin on the cAMP generating system in human mononuclear leucocytes.
Whooping Cough
Inhibitory G protein-mediated modulation of slow delayed rectifier potassium channels contributes to increased susceptibility to arrhythmogenesis in aging heart.
Whooping Cough
Inhibitory glutamate response on cyclic AMP formation in cultured astrocytes.
Whooping Cough
Inhibitory GTP-binding regulatory protein Gi3 can couple angiotensin II receptors to inhibition of adenylyl cyclase in hepatocytes.
Whooping Cough
Inhibitory guanine nucleotide regulatory protein activation of mitogen-activated protein kinase in experimental hepatocellular carcinoma in vitro.
Whooping Cough
Inhibitory guanine-nucleotide-binding-regulatory protein alpha subunits in medaka (Oryzias latipes) oocytes--cDNA cloning and decreased expression of proteins during oocyte maturation.
Whooping Cough
Inhibitory guanosine triphosphate-binding protein-mediated regulation of vasopressin action in isolated single medullary tubules of mouse kidney.
Whooping Cough
Inhibitory interaction of cannabinoid CB1 receptor and dopamine D2 receptor agonists on voltage-gated currents of goldfish cones.
Whooping Cough
Inhibitory modulation of fast and slow Ca(2+)-currents in neuroblastoma x glioma cells during differentiation.
Whooping Cough
Inhibitory phosphorylation of soluble guanylyl cyclase by muscarinic m2 receptors via Gbetagamma-dependent activation of c-Src kinase.
Whooping Cough
Inhibitory prejunctional muscarinic receptors at sympathetic nerves do not operate through a cyclic AMP dependent pathway.
Whooping Cough
Inhibitory role of the somatostatin receptor SST2 on the intracrine-regulated cell proliferation induced by the 210-amino acid fibroblast growth factor-2 isoform: implication of JAK2.
Whooping Cough
Inhibitory signaling by CB1 receptors in smooth muscle mediated by GRK5/?-arrestin activation of ERK1/2 and Src kinase.
Whooping Cough
Initiation and regulation of CNS autoimmunity.
Whooping Cough
Initiation of immune responses in brain is promoted by local dendritic cells.
Whooping Cough
Initiation of RVD response in human platelets: mechanical-biochemical transduction involves pertussis-toxin-sensitive G protein and phospholipase A2.
Whooping Cough
Innate defense regulator IDR-1018 activates human mast cells through G protein-, phospholipase C-, MAPK- and NF-?B-sensitive pathways.
Whooping Cough
Inosine stimulates chemotaxis, Ca2+-transients and actin polymerization in immature human dendritic cells via a pertussis toxin-sensitive mechanism independent of adenosine receptors.
Whooping Cough
Inositol 1,4,5-triphosphate-induced granule secretion in platelets. Evidence that the activation of phospholipase C mediated by platelet thromboxane receptors involves a guanine nucleotide binding protein-dependent mechanism distinct from that of thrombin.
Whooping Cough
Inositol 1,4,5-trisphosphate formation and ryanodine-sensitive oscillations of cytosolic free Ca2+ concentrations in neuroblastoma x fibroblast hybrid NL308 cells expressing m2 and m4 muscarinic acetylcholine receptor subtypes.
Whooping Cough
Inositol 1,4,5-trisphosphate-independent Ca(2+) mobilization triggered by a lipid factor isolated from vitreous body.
Whooping Cough
Inositol 1-,4-,5-trisphosphate-dependent Ca2+ signaling by the recombinant human PTH/PTHrP receptor stably expressed in a human kidney cell line.
Whooping Cough
Inositol phosphate formation and chloride current responses induced by acetylcholine and serotonin through GTP-binding proteins in Xenopus oocyte after injection of rat brain messenger RNA.
Whooping Cough
Inositol phosphate metabolism in bradykinin-stimulated human A431 carcinoma cells. Relationship to calcium signalling.
Whooping Cough
Inositol phosphates modulate human red blood cell Ca(2+)-adenosine triphosphatase activity in vitro by a guanine nucleotide regulatory protein.
Whooping Cough
Inositol phospholipid turnover in PAF transmembrane signalling.
Whooping Cough
Inositol trisphosphate mediates cloned muscarinic receptor-activated conductances in transfected mouse fibroblast A9 L cells.
Whooping Cough
Inositol trisphosphate/Ca2+ as messengers of bradykinin B2 and muscarinic acetylcholine m1-m4 receptors in neuroblastoma-derived hybrid cells.
Whooping Cough
Inositol-1,4,5-trisphosphate accumulation induced by urinary pheromones in female rat vomeronasal epithelium.
Whooping Cough
Inotropic changes induced by fluoroaluminates in rabbit left atrial muscles: possible involvement of G proteins.
Whooping Cough
Inotropic responses to human gene 2 (B29) relaxin in a rat model of myocardial infarction (MI): effect of pertussis toxin.
Whooping Cough
Insoluble immune complex-stimulated neutrophil leukotriene B4 production is dependent on Fc gamma RII and Fc gamma RIII and independent of pertussis toxin-sensitive signal transduction pathways.
Whooping Cough
Insulin activates G alpha il,2 protein in rat hepatoma (HTC) cell membranes.
Whooping Cough
Insulin activates glycerol-3-phosphate acyltransferase (de novo phosphatidic acid synthesis) through a phospholipid-derived mediator. Apparent involvement of Gi alpha and activation of a phospholipase C.
Whooping Cough
Insulin activates GTP binding to a 40 kDa protein in fat cells.
Whooping Cough
Insulin activation of cyclic AMP phosphodiesterase in intact ureteral segments.
Whooping Cough
Insulin affects the ability of Gi to be ADP-ribosylated but does not elicit its phosphorylation in intact hepatocytes.
Whooping Cough
Insulin enhances endothelial alpha2-adrenergic vasorelaxation by a pertussis toxin mechanism.
Whooping Cough
Insulin enhances vascular endothelial growth factor, interleukin-8, and plasminogen activator inhibitor 1 but not interleukin-6 release by human adipocytes.
Whooping Cough
Insulin inhibits pertussis toxin-catalyzed ADP-ribosylation of G-proteins. Evidence for a novel interaction between insulin receptors and G-proteins.
Whooping Cough
Insulin releasing effects of mastoparan and amphiphilic substance P receptor antagonists on RINm5F insulinoma cells.
Whooping Cough
Insulin secretion and action.
Whooping Cough
Insulin secretion is stimulated by ethanol extract of Anemarrhena asphodeloides in isolated islet of healthy Wistar and diabetic Goto-Kakizaki Rats.
Whooping Cough
Insulin secretion stimulated by L-arginine and its metabolite L-ornithine depends on G?(i2).
Whooping Cough
Insulin sensitizes a cultured rat osteogenic sarcoma cell line to hormones which activate adenylate cyclase.
Whooping Cough
Insulin stimulates a novel GTPase activity in human platelets.
Whooping Cough
Insulin stimulates the release of a subset of GPI-anchored proteins in a G-protein independent manner.
Whooping Cough
Insulin stimulation of cyclic AMP phosphodiesterase is independent from the G-protein pathways involved in adenylate cyclase regulation.
Whooping Cough
Insulin stimulation of Na/H antiport in L-6 cells: a different mechanism in myoblasts and myotubes.
Whooping Cough
Insulin-dependent release of 5'-nucleotidase and alkaline phosphatase from liver plasma membranes.
Whooping Cough
Insulin-induced activation of NADPH-dependent H2O2 generation in human adipocyte plasma membranes is mediated by Galphai2.
Whooping Cough
Insulin-induced expression of prostacyclin receptors on platelets is mediated through ADP-ribosylation of Gi alpha protein.
Whooping Cough
Insulin-like growth factor binding protein-3 stimulates phosphatidylinositol 3-kinase in MCF-7 breast carcinoma cells.
Whooping Cough
Insulin-like Growth Factor Binding Protein-5 Stimulates Growth of Human Intestinal Muscle Cells by Activation of G{alpha}i3.
Whooping Cough
Insulin-like growth factor binding proteins increase intracellular calcium levels in two different cell lines.
Whooping Cough
Insulin-like growth factor II inhibits glucose-induced insulin exocytosis.
Whooping Cough
Insulin-like growth factor II signaling through the insulin-like growth factor II/mannose-6-phosphate receptor promotes exocytosis in insulin-secreting cells.
Whooping Cough
Insulin-like growth factor II stimulates calcium influx in competent BALB/c 3T3 cells primed with epidermal growth factor. Characteristics of calcium influx and involvement of GTP-binding protein.
Whooping Cough
Insulin-like growth factor-1 induces an inositol 1,4,5-trisphosphate-dependent increase in nuclear and cytosolic calcium in cultured rat cardiac myocytes.
Whooping Cough
Insulin-like growth factor-I induces alpha(1B)-adrenergic receptor phosphorylation through G beta gamma and epidermal growth factor receptor transactivation.
Whooping Cough
Insulin-like growth factor-I potentiates thyrotropin stimulation of adenylyl cyclase in FRTL-5 cells.
Whooping Cough
Insulin-like growth factor-II/mannose 6-phosphate receptor is incapable of activating GTP-binding proteins in response to mannose 6-phosphate, but capable in response to insulin-like growth factor-II.
Whooping Cough
Insulin-like growth factors enhance phagocytosis by human neutrophils in vitro.
Whooping Cough
Insulin-like growth factors mediate heterotrimeric G protein-dependent ERK1/2 activation by transactivating sphingosine 1-phosphate receptors.
Whooping Cough
Insulin-like growth factors stimulate chemotaxis in human melanoma cells.
Whooping Cough
Insulin-stimulated NADH/NAD+ redox state increases NAD(P)H oxidase activity in cultured rat vascular smooth muscle cells.
Whooping Cough
Insulin-stimulated phosphatidylcholine hydrolysis, diacylglycerol/protein kinase C signalling, and hexose transport in pertussis toxin-treated BC3H-1 myocytes.
Whooping Cough
Insulinotropic toxins as molecular probes for analysis of glucagon-likepeptide-1 receptor-mediated signal transduction in pancreatic beta-cells.
Whooping Cough
Integration of G-protein coupled receptor signaling pathways for activation of a transcription factor (EGR-3).
Whooping Cough
Integrin activation by bacterial fimbriae through a pathway involving CD14, Toll-like receptor 2, and phosphatidylinositol-3-kinase.
Whooping Cough
Integrin alpha v beta 3 and phospholipase C regulate prostacyclin formation of endothelial cells caused by ancrod-generated fibrin.
Whooping Cough
Integrin alphavbeta3 mediates chemotactic and haptotactic motility in human melanoma cells through different signaling pathways.
Whooping Cough
Integrin-associated protein stimulates alpha2beta1-dependent chemotaxis via Gi-mediated inhibition of adenylate cyclase and extracellular-regulated kinases.
Whooping Cough
Integrin-dependence of lymphocyte entry into the splenic white pulp.
Whooping Cough
Integrin-dependent homotypic adhesion of neutrophils. Arachidonic acid activates Raf-1/Mek/Erk via a 5-lipoxygenase- dependent pathway.
Whooping Cough
Integrin-mediated localization of Bordetella pertussis within macrophages: role in pulmonary colonization.
Whooping Cough
Interaction between calcium channel ligands and guanine nucleotides in cultured rat sensory and sympathetic neurones.
Whooping Cough
Interaction between mGluR8 and calcium channels in photoreceptors is sensitive to pertussis toxin and occurs via G protein betagamma subunit signaling.
Whooping Cough
Interaction between neuronal nitric oxide synthase and inhibitory G protein activity in heart rate regulation in conscious mice.
Whooping Cough
Interaction between Src homology 2 domain bearing protein tyrosine phosphatase substrate-1 and CD47 mediates the adhesion of human B lymphocytes to nonactivated endothelial cells.
Whooping Cough
Interaction between the RGS domain of RGS4 with G protein alpha subunits mediates the voltage-dependent relaxation of the G protein-gated potassium channel.
Whooping Cough
Interaction of adenosine with vasopressin in the inner medullary collecting duct.
Whooping Cough
Interaction of agonists and selective antagonists with gastric smooth muscle muscarinic receptors.
Whooping Cough
Interaction of alpha1-adrenoceptor subtypes with different G proteins induces opposite effects on cardiac L-type Ca2+ channel.
Whooping Cough
Interaction of beta-adrenergic receptors with the inhibitory guanine nucleotide-binding protein of adenylate cyclase in membranes prepared from cyc- S49 lymphoma cells.
Whooping Cough
Interaction of Bordetella pertussis virulence components with neutrophils: effect on chemiluminescence induced by a chemotactic peptide and by intact bacteria.
Whooping Cough
Interaction of Bordetella pertussis with mast cells, modulation of cytokine secretion by pertussis toxin.
Whooping Cough
Interaction of D2-dopamine receptor with two pertussis toxin sensitive G proteins in human placenta.
Whooping Cough
Interaction of GTP-binding proteins with calmodulin.
Whooping Cough
Interaction of GTP-binding regulatory proteins with chemosensory receptors.
Whooping Cough
Interaction of guanine-nucleotide-binding regulatory proteins with chemotactic peptide receptors in differentiated human leukemic HL-60 cells.
Whooping Cough
Interaction of halothane with inhibitory G-proteins in the human myocardium.
Whooping Cough
Interaction of human Tamm-Horsfall glycoprotein with Bordetella pertussis toxin.
Whooping Cough
Interaction of monoclonal antibodies with pertussis toxin and its subunits.
Whooping Cough
Interaction of pertussis toxin with cells and model membranes.
Whooping Cough
Interaction of pertussis toxin with human T lymphocytes.
Whooping Cough
Interaction of purified bovine brain A1-adenosine receptors with guanine nucleotide-binding proteins of human platelet membranes following reconstitution.
Whooping Cough
Interaction of substance P, compound 48/80 and mastoparan with the alpha-subunit C-terminus of G protein.
Whooping Cough
Interaction of the alpha-2 adrenergic- and opioid receptor with the cGMP system in the mouse cerebellum.
Whooping Cough
Interaction of the frog brain kainate receptor expressed in Chinese hamster ovary cells with a GTP-binding protein.
Whooping Cough
Interaction of the human somatostatin receptor 3 with the multiple PDZ domain protein MUPP1 enables somatostatin to control permeability of epithelial tight junctions.
Whooping Cough
Interaction of the inhibitory GTP regulatory component with soluble cerebral cortical adenylate cyclase.
Whooping Cough
Interaction of the pertussis toxin peptide containing residues 30-42 with DR1 and the T-cell receptors of 12 human T-cell clones.
Whooping Cough
Interaction of vascular alpha-1 adrenoceptors with multiple signal transduction pathways.
Whooping Cough
Interaction of Wnt and a Frizzled homologue triggers G-protein-linked phosphatidylinositol signalling.
Whooping Cough
Interaction of [3H]spiperone with rat striatal dopamine D-2 receptors: kinetic evidence for antagonist-induced formation of ternary complex.
Whooping Cough
Interaction with caveolin-1 modulates G protein coupling of mouse ?3-adrenoceptor.
Whooping Cough
Interactions between a lymphoma membrane-associated guanosine 5'-triphosphate-binding protein and the cytoskeleton during receptor patching and capping.
Whooping Cough
Interactions between adenylate cyclase inhibitors and beta-adrenoceptors in isolated human fat cells.
Whooping Cough
Interactions between the amyloid precursor protein C-terminal domain and G proteins mediate calcium dysregulation and amyloid beta toxicity in Alzheimer's disease.
Whooping Cough
Interactions in platelets between G proteins and the agonists that stimulate phospholipase C and inhibit adenylyl cyclase.
Whooping Cough
Interactions of alpha-melanotropin and agouti on B16 melanoma cells: evidence for inverse agonism of agouti.
Whooping Cough
Interactions of bradykinin, calcium, G-protein and protein kinase in the activation of phospholipase A2 in bovine pulmonary artery endothelial cells.
Whooping Cough
Interactions of cannabidiol with endocannabinoid signalling in hippocampal tissue.
Whooping Cough
Interactions of intracerebroventricular pertussis toxin treatment with the ataxic and hypothermic effects of ethanol.
Whooping Cough
Interactions of lithium and drugs that affect signal transduction on behaviour in rats.
Whooping Cough
Interactions of multiple signaling pathways in neuropeptide Y-mediated bimodal vascular smooth muscle cell growth.
Whooping Cough
Interactions of phosducin with defined G protein beta gamma-subunits.
Whooping Cough
Interactions of the alpha2A-adrenoceptor with multiple Gi-family G-proteins: studies with pertussis toxin-resistant G-protein mutants.
Whooping Cough
Interactive effects of pertussis toxin and the phorbol ester tumour promotor, phorbol dibutyrate, on T-lymphocyte mitogenesis and the expression of phenotypic determinants.
Whooping Cough
Interchangeability of meningococcal group C conjugate vaccines with different carrier proteins in the United Kingdom infant immunisation schedule.
Whooping Cough
Interchangeability of two diphtheria and tetanus toxoids, acellular pertussis, inactivated poliovirus, Haemophilus influenzae type b conjugate vaccines as a fourth dose in 15-20-month-old toddlers.
Whooping Cough
Interferon-gamma and lipopolysaccharide reduce cAMP responses in cultured glial cells: reversal by a type IV phosphodiesterase inhibitor.
Whooping Cough
Interferon-gamma elicits a G-protein-dependent Ca2+ signal in human neutrophils after depletion of intracellular Ca2+ stores.
Whooping Cough
Interferon-gamma levels in serum and bronchoalveolar lavage fluid of mice infected with Bordetella pertussis.
Whooping Cough
Interferon-gamma-stimulated and GTP-binding-proteins-mediated phospholipase A2 activation in human neuroblasts.
Whooping Cough
Interferon-inducible protein-10 and lymphotactin induce the chemotaxis and mobilization of intracellular calcium in natural killer cells through pertussis toxin-sensitive and -insensitive heterotrimeric G-proteins.
Whooping Cough
Interleukin (IL)-8-induced in vitro human lymphocyte migration is inhibited by cholera and pertussis toxins and inhibitors of protein kinase C.
Whooping Cough
Interleukin 1 and tumor necrosis factor stimulate human vascular endothelial cells to promote transendothelial neutrophil passage.
Whooping Cough
Interleukin 1 beta and tumour necrosis factor alpha inhibit acid secretion in cultured rabbit parietal cells by multiple pathways.
Whooping Cough
Interleukin 1b and anaphylatoxins exert a synergistic effect on NGF expression by astrocytes.
Whooping Cough
Interleukin 3-stimulated proliferation is sensitive to pertussis toxin: evidence for a guanyl nucleotide regulatory protein-mediated signal transduction mechanism.
Whooping Cough
Interleukin-1 beta inhibition of insulin release in rat pancreatic islets: possible involvement of G-proteins in the signal transduction pathway.
Whooping Cough
Interleukin-1 beta inhibits Ca2+ channel currents in hippocampal neurons through protein kinase C.
Whooping Cough
Interleukin-1 beta stimulation of 45Ca2+ release from rat striatal slices.
Whooping Cough
Interleukin-1 induces a pertussis toxin-sensitive increase in diacylglycerol accumulation in mouse thymoma cells.
Whooping Cough
Interleukin-1 inhibits voltage-dependent P/Q-type Ca2+ channel associated with the inhibition of the rise of intracellular free Ca2+ concentration and catecholamine release in adrenal chromaffin cells.
Whooping Cough
Interleukin-1 is a motility factor for human breast carcinoma cells in vitro: additive effect with interleukin-6.
Whooping Cough
Interleukin-1 signal transduction. Increased GTP binding and hydrolysis in membranes of a murine thymoma line (EL4).
Whooping Cough
Interleukin-1 stimulates the expression of type I and type II interleukin-1 receptors in the rat insulinoma cell line Rinm5F; sequencing a rat type II interleukin-1 receptor cDNA.
Whooping Cough
Interleukin-1 stimulates the release of interleukin-6 from cultured human pituitary adenoma cells.
Whooping Cough
Interleukin-12 is produced by macrophages in response to live or killed Bordetella pertussis and enhances the efficacy of an acellular pertussis vaccine by promoting induction of Th1 cells.
Whooping Cough
Interleukin-13 is a monocyte chemoattractant.
Whooping Cough
Interleukin-1beta-dependent changes in the hippocampus following parenteral immunization with a whole cell pertussis vaccine.
Whooping Cough
Interleukin-1beta-induced inhibition of hair growth in vitro is mediated by cyclic AMP.
Whooping Cough
Interleukin-1beta-induced prostaglandin E2 production in human myometrial cells: role of a pertussis toxin-sensitive component.
Whooping Cough
Interleukin-36? is expressed by neutrophils and can activate microglia, but has no role in experimental autoimmune encephalomyelitis.
Whooping Cough
Interleukin-37 (IL-37) Suppresses Pertussis Toxin-Induced Inflammatory Myopathy in a Rat Model.
Whooping Cough
Interleukin-6 and interleukin-15 are selectively regulated by lipopolysaccharide and interferon-gamma in primary pig adipocytes.
Whooping Cough
Interleukin-6 production by endothelial cells via stimulation of protease-activated receptors is amplified by endotoxin and tumor necrosis factor-alpha.
Whooping Cough
Interleukin-6 synthesis induced by prostaglandin E2: cross-talk regulation by protein kinase C.
Whooping Cough
Interleukin-8 production induced by the endozepine triakontatetraneuropeptide in human neutrophils: role of calcium and pharmacological investigation of signal transduction pathways.
Whooping Cough
Interleukin-8 receptors R1 and R2 activate mitogen-activated protein kinases and induce c-fos, independent of Ras and Raf-1 in Chinese hamster ovary cells.
Whooping Cough
Interleukin-8 secreted by endothelial cells induces chemotaxis of melanoma cells through the chemokine receptor CXCR1.
Whooping Cough
Interleukin-8 stimulates cell proliferation in non-small cell lung cancer through epidermal growth factor receptor transactivation.
Whooping Cough
Interleukin-8: An autocrine inflammatory mediator.
Whooping Cough
Internalization and recycling of human mu opioid receptors expressed in Sf9 insect cells.
Whooping Cough
Internalization of the human nicotinic acid receptor GPR109A is regulated by G(i), GRK2, and arrestin3.
Whooping Cough
Internalization of the radioiodinated somatostatin analog [125I-Tyr3]octreotide by mouse and human pituitary tumor cells: increase by unlabeled octreotide.
Whooping Cough
Internalization of [DOTA degrees,125I-Tyr3]Octreotide by somatostatin receptor-positive cells in vitro and in vivo: implications for somatostatin receptor-targeted radio-guided surgery.
Whooping Cough
Internalization pathway of C3b receptors in human neutrophils and its transmodulation by chemoattractant receptors stimulation.
Whooping Cough
International Bordetella pertussis assay standardization and harmonization meeting report. Centers for Disease Control and Prevention, Atlanta, Georgia, United States, 19-20 July 2007.
Whooping Cough
International Union of Pharmacology LVII: Recommendations for the Nomenclature of Receptors for Relaxin Family Peptides.
Whooping Cough
Intestinal secretory factor released by macrophages stimulated with Clostridium difficile toxin A: role of interleukin 1beta.
Whooping Cough
Intra-accumbens pertussis toxin sensitizes rats to the locomotor activating effects of a single cocaine challenge.
Whooping Cough
Intracellular acidification, guanine-nucleotide binding proteins, and cytoskeletal actin.
Whooping Cough
Intracellular beta-blockade: overexpression of Galpha(i2) depresses the beta-adrenergic response in intact myocardium.
Whooping Cough
Intracellular Ca(2+) signaling in endothelial cells by the angiogenesis inhibitors endostatin and angiostatin.
Whooping Cough
Intracellular Ca2+, inositol 1,4,5-trisphosphate and additional signalling in the stimulation by platelet-activating factor of prostaglandin E2 formation in P388D1 macrophage-like cells.
Whooping Cough
Intracellular calcium ion responses to somatostatin in cells from human somatotroph adenomas.
Whooping Cough
Intracellular calcium mobilization and phospholipid degradation in sphingosylphosphorylcholine-stimulated human airway epithelial cells.
Whooping Cough
Intracellular calcium mobilization in response to the activation of human wild-type and chimeric gonadotropin receptors.
Whooping Cough
Intracellular calcium mobilization triggered by a glutamate receptor in rat cultured hippocampal cells.
Whooping Cough
Intracellular calcium rise produced by platelet-activating factor is deactivated by fMet-Leu-Phe and this requires uninterrupted activation sequence: role of protein kinase C.
Whooping Cough
Intracellular Cl- modulates Ca2+-induced exocytosis from rat melanotrophs through GTP-binding proteins.
Whooping Cough
Intracellular control of calcium and potassium currents in cardiac cells.
Whooping Cough
Intracellular coupling of prostaglandin inhibition of acid secretion in isolated rabbit gastric parietal cells.
Whooping Cough
Intracellular cross-talk between receptors coupled to phospholipase C via pertussis toxin sensitive and insensitive G-proteins.
Whooping Cough
Intracellular cross-talk between receptors coupled to phospholipase C via pertussis toxin-sensitive and insensitive G-proteins in DDT1MF-2 cells.
Whooping Cough
Intracellular cross-talk between thyrotropin receptor and A1 adenosine receptor in regulation of phospholipase C and adenylate cyclase in COS-7 cells transfected with their receptor genes.
Whooping Cough
Intracellular delivery of a cytolytic T-lymphocyte epitope peptide by pertussis toxin to major histocompatibility complex class I without involvement of the cytosolic class I antigen processing pathway.
Whooping Cough
Intracellular disassembly and activity of pertussis toxin require interaction with ATP.
Whooping Cough
Intracellular dynamics of alkaline phosphatase-containing granules in electropermeabilized human neutrophils.
Whooping Cough
Intracellular elevations of free calcium induced by activation of histamine H1 receptors in interphase and mitotic HeLa cells: hormone signal transduction is altered during mitosis.
Whooping Cough
Intracellular GTP gamma S restores the ability of morphine to hyperpolarize rat locus coeruleus neurons after blockade by pertussis toxin.
Whooping Cough
Intracellular mechanisms for alpha 1-adrenergic regulation of the transient outward current in rabbit atrial myocytes.
Whooping Cough
Intracellular mechanisms involved in leukotriene C4-stimulated adhesion of U-937 cells.
Whooping Cough
Intracellular pathways triggered by galanin to induce contraction of pig ileum smooth muscle cells.
Whooping Cough
Intracellular regulation of enzyme secretion from rat osteoclasts and evidence for a functional role in bone resorption.
Whooping Cough
Intracellular retention of the two isoforms of the D(2) dopamine receptor promotes endoplasmic reticulum disruption.
Whooping Cough
Intracellular sigma1 receptor modulates phospholipase C and protein kinase C activities in the brainstem.
Whooping Cough
Intracellular signal transduction by the extracellular calcium-sensing receptor of Xenopus melanotrope cells.
Whooping Cough
Intracellular signal transduction for migration and actin remodeling in vascular smooth muscle cells after sphingosylphosphorylcholine stimulation.
Whooping Cough
Intracellular Signal-transducing elements involved in transendothelial migration of lymphoma cells.
Whooping Cough
Intracellular signaling leads to the hypertrophic effect of neuropeptide Y.
Whooping Cough
Intracellular signaling mechanisms leading to synergistic effects of endothelin-1 and stem cell factor on proliferation of cultured human melanocytes. Cross-talk via trans-activation of the tyrosine kinase c-kit receptor.
Whooping Cough
Intracellular signaling pathway of FGF-2-modulated corneal endothelial cell migration during wound healing in vitro.
Whooping Cough
Intracellular signalling by binding sites for the antipsoriatic agent monomethylfumarate on human granulocytes.
Whooping Cough
Intracellular third loop domain of angiotensin II type-2 receptor. Role in mediating signal transduction and cellular function.
Whooping Cough
Intracellular trafficking and membrane translocation of pertussis toxin into host cells.
Whooping Cough
Intracellular Trafficking and Translocation of Pertussis Toxin.
Whooping Cough
Intracerebroventricular injection of antibodies directed against Gs alpha enhances the supraspinal antinociception induced by morphine, beta-endorphin and clonidine in mice.
Whooping Cough
Intracerebroventricular pertussis toxin enhances sensitivity to chemical convulsants and decreases the protective efficacy of carbamazepine in mice.
Whooping Cough
Intracerebroventricular pertussis toxin enhances sensitivity to N-methyl-D-aspartate-induced seizures in mice.
Whooping Cough
Intracerebroventricular treatment of mice with pertussis toxin induces hyperalgesia and enhances 3H-nitrendipine binding to synaptic membranes: similarity with morphine tolerance.
Whooping Cough
Intracerebroventricularly administered pertussis toxin blocks the central vasopressor action of neuropeptide Y(13-36) in the awake unrestrained male rat.
Whooping Cough
Intracrine cysteinyl leukotriene receptor-mediated signaling of eosinophil vesicular transport-mediated interleukin-4 secretion.
Whooping Cough
Intradermal application of nociceptin increases vascular permeability in rats: the possible involvement of histamine release from mast cells.
Whooping Cough
Intrahippocampal injection of pertussis toxin blocks adenosine suppression of synaptic responses.
Whooping Cough
Intranasal murine model of Bordetella pertussis infection: II. Sequence variation and protection induced by a tricomponent acellular vaccine.
Whooping Cough
Intrathecal administration of low-dose nociceptin/orphanin FQ induces allodynia via c-Jun N-terminal kinase and monocyte chemoattractant protein-1.
Whooping Cough
Intrathecal pertussis toxin attenuates the morphine withdrawal syndrome in normal but not in arthritic rats.
Whooping Cough
Intrathecal pertussis toxin but not cyclic AMP blocks kappa opioid-induced antinociception in rat.
Whooping Cough
Intrathecal pertussis toxin induces thermal hyperalgesia: involvement of excitatory and inhibitory amino acids.
Whooping Cough
Intrathecal pertussis toxin produces hyperalgesia and allodynia in mice.
Whooping Cough
Intrathecal pertussis toxin treatment attenuates opioid antinociception and reduces high-affinity state of opioid receptors.
Whooping Cough
Intravesical therapy with pertussis toxin before radical cystectomy in patients with bladder cancer: a Phase I study.
Whooping Cough
Intravitreal injection of anti-Interleukin (IL)-6 antibody attenuates experimental autoimmune uveitis in mice.
Whooping Cough
Intrinsic planar polarity mechanisms influence the position-dependent regulation of synapse properties in inner hair cells.
Whooping Cough
Intrinsic signaling function of APP as a novel target of three V642 mutations linked to familial Alzheimer's disease.
Whooping Cough
Invasion of HeLa 229 cells by virulent Bordetella pertussis.
Whooping Cough
Invasiveness in hepatocyte and fibroblast monolayers and metastatic potential of T-cell hybridomas in mice.
Whooping Cough
Inverse agonism at adrenergic and opioid receptors: studies with wild type and constitutively active mutant receptors.
Whooping Cough
Inverse agonist and pharmacochaperone properties of MK-0524 on the prostanoid DP1 receptor.
Whooping Cough
Inverse agonistic effect of ICI-174,864 on the cloned delta-opioid receptor: role of G protein and adenylyl cyclase activation.
Whooping Cough
Inverse regulation of leptin mRNA expression by short- and long-chain fatty acids in cultured bovine adipocytes.
Whooping Cough
Inversion of Ca2+ current modulation during recovery of neuroblastoma cells from pertussis toxin pretreatment.
Whooping Cough
Investigating pertussis toxin and its impact on vaccination.
Whooping Cough
Investigation in a murine model of possible mechanisms of enhanced local reactions to post-primary diphtheria-tetanus toxoid boosters in recipients of acellular pertussis-diphtheria-tetanus vaccine.
Whooping Cough
Investigation of a pertussis outbreak and comparison of two acellular booster pertussis vaccines in a junior school in South East England, 2019.
Whooping Cough
Investigation of brain sites mediating cannabinoid-induced antinociception in rats: evidence supporting periaqueductal gray involvement.
Whooping Cough
Investigation of cellular and humoral immune responses to whole cell and acellular pertussis vaccines.
Whooping Cough
Investigation of effects of different commercial source of bovine serum albumin on the binding of pertussis toxin to the glycoprotein fetuin.
Whooping Cough
Investigation of G protein-initiated, Ca2+-dependent release of ATP from endothelial cells.
Whooping Cough
Investigation of presumptive mobilization pathways for calcium in the steroidogenic action of big prothoracicotropic hormone.
Whooping Cough
Investigation of the Cellular Immune Response to Recombinant Fragments of Filamentous Hemagglutinin and Pertactin of Bordetella pertussis in BALB/c Mice.
Whooping Cough
Investigation of the lectin-like binding domains in pertussis toxin using synthetic peptide sequences. Identification of a sialic acid binding site in the S2 subunit of the toxin.
Whooping Cough
Investigations into neuropeptide Y-mediated presynaptic inhibition in cultured hippocampal neurones of the rat.
Whooping Cough
Involvement of 5-HT1B and 5-HT1D receptors in sumatriptan mediated vasocontractile response in rabbit common carotid artery.
Whooping Cough
Involvement of a botulinum toxin-sensitive 22-kDa G protein in stimulated exocytosis of human neutrophils.
Whooping Cough
Involvement of a Gardos-type potassium channel in head activator-induced mitosis of BON cells.
Whooping Cough
Involvement of a GTP-binding protein in mediation of serotonin and acetylcholine responses in Xenopus oocytes injected with rat brain messenger RNA.
Whooping Cough
Involvement of a GTP-binding protein in stimulating action of angiotensin II on calcium channels in vascular smooth muscle cells.
Whooping Cough
Involvement of a guanine-nucleotide-binding component in membrane IgM-stimulated phosphoinositide breakdown.
Whooping Cough
Involvement of a guanine-nucleotide-binding protein-mediated mechanism in the enhancement of arachidonic acid liberation by phorbol 12-myristate 13-acetate and Ca2+ in saponin-permeabilized platelets.
Whooping Cough
Involvement of A pertussis Toxin Sensitive G-Protein in the Inhibition of Inwardly Rectifying K Currents by Platelet-Activating Factor in Guinea-Pig Atrial Cardiomyocytes.
Whooping Cough
Involvement of a pertussis toxin-sensitive G protein in the action of gastrin on gastric parietal cells.
Whooping Cough
Involvement of a pertussis toxin-sensitive G protein in the mitogenic signaling pathways of sphingosine 1-phosphate.
Whooping Cough
Involvement of a pertussis toxin-sensitive G protein in the regulation of angiotensinogen production by an angiotensin II analog in HepG2 cells.
Whooping Cough
Involvement of a pertussis toxin-sensitive G-protein in the pharmacological properties of septo-hippocampal neurones.
Whooping Cough
Involvement of a pertussis toxin-sensitive G-protein-coupled phospholipase A2 in lipopolysaccharide-stimulated prostaglandin E2 synthesis in cultured rat mesangial cells.
Whooping Cough
Involvement of a pertussis-toxin sensitive G protein in the induction of gene expression by insulin.
Whooping Cough
Involvement of a putative G-protein-coupled receptor and a branching pathway in argipressin (4-8) signal transduction in rat hippocampus.
Whooping Cough
Involvement of a signal transduction mechanism in ATP-induced mucin release from cultured airway goblet cells.
Whooping Cough
Involvement of a specific guanine nucleotide binding protein in receptor immunoglobulin stimulated inositol phospholipid hydrolysis.
Whooping Cough
Involvement of an inhibitory G-protein in the signal transduction pathway of maturation-inducing hormone (17 alpha,20 beta-dihydroxy-4-pregnen-3-one) action in rainbow trout (Oncorhynchus mykiss) oocytes.
Whooping Cough
Involvement of both G(q/11) and G(s) proteins in gonadotropin-releasing hormone receptor-mediated signaling in L beta T2 cells.
Whooping Cough
Involvement of both inhibitory and stimulatory guanine nucleotide binding proteins in the expression of chronic opiate regulation of adenylate cyclase activity in NG108-15 cells.
Whooping Cough
Involvement of c-Jun N-terminal kinase in amyloid precursor protein-mediated neuronal cell death.
Whooping Cough
Involvement of calcium and G proteins in the acute release of tissue-type plasminogen activator and von Willebrand factor from cultured human endothelial cells.
Whooping Cough
Involvement of calyculin A inhibitable protein phosphatases in the cyclic AMP signal transduction pathway of mouse corticotroph tumour (AtT20) cells.
Whooping Cough
Involvement of cAMP-dependent protein kinase and pertussis toxin-sensitive G-proteins in CGRP mediated JNK activation in human neuroblastoma cell line.
Whooping Cough
Involvement of cAMP-dependent protein kinase in mu-opioid modulation of NMDA-mediated synaptic currents.
Whooping Cough
Involvement of chemical mediators in nasal allergic responses of HDC-KO mice.
Whooping Cough
Involvement of CXCR4 and IL-2 in the homing and retention of human NK and NK T cells to the bone marrow and spleen of NOD/SCID mice.
Whooping Cough
Involvement of dihydropyridine-sensitive calcium channels in the GABAA potentiation of TRH-induced TSH release.
Whooping Cough
Involvement of distinct G-proteins in the action of vasopressin on rat glomerulosa cells.
Whooping Cough
Involvement of G i/o proteins in nerve growth factor-stimulated phosphorylation and degradation of tuberin in PC-12 cells and cortical neurons.
Whooping Cough
Involvement of G protein betagamma-subunits in diverse signaling induced by G(i/o)-coupled receptors: study using the Xenopus oocyte expression system.
Whooping Cough
Involvement of G protein-coupled receptor 30 (GPR30) in rapid action of estrogen in primate LHRH neurons.
Whooping Cough
Involvement of G proteins in the effect of carbachol and cholecystokinin in rat pancreatic islets.
Whooping Cough
Involvement of G proteins in the effect of insulin-like growth factor I on gonadotropin-induced rat granulosa cell differentiation.
Whooping Cough
Involvement of G(i) proteins and Src tyrosine kinase in TNFalpha production induced by lipopolysaccharide, group B Streptococci and Staphylococcus aureus.
Whooping Cough
Involvement of G(i/o) in the PAR-4-induced NO production in endothelial cells.
Whooping Cough
Involvement of G-protein alpha il subunits in activation of G-protein gated inward rectifying K+ channels (GIRK1) by human NPY1 receptors.
Whooping Cough
Involvement of G-protein betagamma subunits on the influence of inhibitory alpha2-autoreceptors on the angiotensin AT1-receptor modulation of noradrenaline release in the rat vas deferens.
Whooping Cough
Involvement of G-proteins and adenylate cyclase in the action of gonad-stimulating substance on starfish ovarian follicle cells.
Whooping Cough
Involvement of G-proteins in chitosan-induced Anthraquinone synthesis in Rubia tinctorum
Whooping Cough
Involvement of Gi in the inhibition of adenylate cyclase by cannabimimetic drugs.
Whooping Cough
Involvement of Gi protein-dependent BKCa channel activation in ?2-adrenoceptor-mediated dilation of retinal arterioles in rats.
Whooping Cough
Involvement of Gi/o proteins and GIRK channels in the potentiation of morphine-induced spinal analgesia in acutely inflamed mice.
Whooping Cough
Involvement of Gialpha2 in sodium butyrate-induced erythroblastic differentiation of K562 cells.
Whooping Cough
Involvement of glutamate neurotransmission and N-methyl-d-aspartate receptor in the activation of midbrain dopamine neurons by 5-HT1A receptor agonists: an electrophysiological study in the rat.
Whooping Cough
Involvement of Gq/11 in both integrin signal-dependent and -independent pathways regulating endothelin-induced neural progenitor proliferation.
Whooping Cough
Involvement of Gs and Gi proteins in dual coupling of the luteinizing hormone receptor to adenylyl cyclase and phospholipase C.
Whooping Cough
Involvement of GTP-binding proteins in actin polymerization in human neutrophils.
Whooping Cough
Involvement of guanine nucleotide binding proteins in neutrophil activation and priming by GM-CSF.
Whooping Cough
Involvement of heterotrimeric G proteins in phagocytosis and recycling from the phagosomal compartment.
Whooping Cough
Involvement of inositol 1,4,5-trisphosphate-regulated stores of intracellular calcium in calcium dysregulation and neuron cell death caused by HIV-1 protein tat.
Whooping Cough
Involvement of intermediary metabolites in the pathway of extracellular Ca2+-induced mitogen-activated protein kinase activation in human fibroblasts.
Whooping Cough
Involvement of intracellular Ca2+ release mechanism in adenosine-induced cardiac Ca2+ current inhibition.
Whooping Cough
Involvement of kappa-opioids in the mouse cerebellar adenosinergic modulation of ethanol-induced motor incoordination.
Whooping Cough
Involvement of KCNQ2 subunits in [3H]dopamine release triggered by depolarization and pre-synaptic muscarinic receptor activation from rat striatal synaptosomes.
Whooping Cough
Involvement of MAP kinase and c-fos signaling in the inhibition of cell growth by somatostatin.
Whooping Cough
Involvement of MAP kinase signal transduction pathway in UVB-induced activation of macrophages in vitro.
Whooping Cough
Involvement of MAP kinases in the control of cPLA(2) and arachidonic acid release in endothelial cells.
Whooping Cough
Involvement of mitogen-activated protein kinases in the signal transduction pathway of bone marrow-derived macrophage activation in response to in vitro treatment with thymosin alpha 1.
Whooping Cough
Involvement of multiple P2Y receptors and signaling pathways in the action of adenine nucleotides diphosphates on human monocyte-derived dendritic cells.
Whooping Cough
Involvement of Ni protein in the functional coupling of the atrial natriuretic factor (ANF) receptor to adenylate cyclase in rat lung plasma membranes.
Whooping Cough
Involvement of nitric oxide and peptides in the inhibitory non-adrenergic, non-cholinergic (NANC) response in bovine mesenteric artery.
Whooping Cough
Involvement of p38 MAP kinase-mediated cytochrome c release on sphingosine-1-phosphate (S1P)- and N-monomethyl-S1P-induced cell death of PC12 cells.
Whooping Cough
Involvement of pertussis toxin sensitive G-proteins in conditioned fear-potentiated startle: possible involvement of the amygdala.
Whooping Cough
Involvement of pertussis toxin sensitive GTP binding protein in adenosine triphosphate and thrombin-mediated responses in vascular smooth muscle cells.
Whooping Cough
Involvement of pertussis toxin-sensitive and -insensitive G proteins in alpha-thrombin signalling on cultured human vascular smooth muscle cells.
Whooping Cough
Involvement of pertussis toxin-sensitive and -insensitive GTP-binding proteins in luteinizing hormone exocytosis distal to second messenger generation.
Whooping Cough
Involvement of pertussis toxin-sensitive G-proteins in the hormonal inhibition of dihydropyridine-sensitive Ca2+ currents in an insulin-secreting cell line (RINm5F).
Whooping Cough
Involvement of pertussis toxin-sensitive GTP-binding protein in prostaglandin F2 alpha- induced phosphoinositide hydrolysis in osteoblast-like cells.
Whooping Cough
Involvement of pertussis toxin-sensitive GTP-binding proteins in sphingosine 1-phosphate-induced activation of phospholipase C-Ca2+ system in HL60 leukemia cells.
Whooping Cough
Involvement of pertussis toxin-sensitive mechanism in retinoic acid-induced differentiation of human leukemic HL-60 cells.
Whooping Cough
Involvement of pertussis-toxin-sensitive G protein in muscarinic-receptor-mediated inhibition of K(+)-activated 4-nitrophenylphosphatase activity of cardiac sarcolemma.
Whooping Cough
Involvement of phosphoinositide turnover in tracheary element differentiation in Zinnia elegans L. cells.
Whooping Cough
Involvement of phospholipase D2 in lysophosphatidate-induced transactivation of platelet-derived growth factor receptor-beta in human bronchial epithelial cells.
Whooping Cough
Involvement of phospholipases D1 and D2 in sphingosine 1-phosphate-induced ERK (extracellular-signal-regulated kinase) activation and interleukin-8 secretion in human bronchial epithelial cells.
Whooping Cough
Involvement of postsynaptic alpha 2-adrenoceptors and guanine nucleotide-binding protein in guanabenz-induced cardiovascular suppressant effects in the rat.
Whooping Cough
Involvement of prenylated proteins in calcium signaling induced by LTD4 in differentiated U937 cells.
Whooping Cough
Involvement of protein kinase A in cannabinoid receptor-mediated protection from oxidative neuronal injury.
Whooping Cough
Involvement of protein kinase A in the regulation of intracellular free calcium and phosphoinositide turnover in rat myometrium.
Whooping Cough
Involvement of protein kinase and G proteins in the signal transduction of benzophenanthridine alkaloid biosynthesis.
Whooping Cough
Involvement of protein kinase C activation in alpha 2-adrenoceptor-mediated contractions of rabbit saphenous vein.
Whooping Cough
Involvement of protein kinase C and RhoA in protease-activated receptor 1-mediated F-actin reorganization and cell growth in rat cardiomyocytes.
Whooping Cough
Involvement of Protein Kinase C and RhoA in Protease-Activated Receptor 1-Mediated F-Actin Reorganization and Cell Growth in Rat Cardiomyocytes.
Whooping Cough
Involvement of protein kinase C in HIV-1 gp120-induced apoptosis in primary endothelium.
Whooping Cough
Involvement of protein kinase C in the UTP-mediated potentiation of cyclic AMP accumulation in mouse J774 macrophages.
Whooping Cough
Involvement of protein kinase-C in the effect of angiotensin-II on adenosine 3',5'-monophosphate production in lactotroph cells.
Whooping Cough
Involvement of Ras and Raf in the Gi-coupled acetylcholine muscarinic m2 receptor activation of mitogen-activated protein (MAP) kinase kinase and MAP kinase.
Whooping Cough
Involvement of Rho and p38 MAPK in endothelin-1-induced expression of PGHS-2 mRNA in osteoblast-like cells.
Whooping Cough
Involvement of Rho and tyrosine kinase in angiotensin II-induced actin reorganization in mesothelial cells.
Whooping Cough
Involvement of S1P1 receptor pathway in angiogenic effects of a novel adenosine-like nucleic acid analog COA-Cl in cultured human vascular endothelial cells.
Whooping Cough
Involvement of signal transducing GTP-binding proteins in renal artery alpha 1-adrenoceptor mediated smooth muscle contraction.
Whooping Cough
Involvement of signaling pathways in bovine sperm motility, and effect of ergot alkaloids.
Whooping Cough
Involvement of sphingomyelin hydrolysis and the mitogen-activated protein kinase cascade in the Delta9-tetrahydrocannabinol-induced stimulation of glucose metabolism in primary astrocytes.
Whooping Cough
Involvement of sphingosine 1-phosphate (S1P) receptor type 1 and type 4 in migratory response of mouse T cells toward S1P.
Whooping Cough
Involvement of the 90-kDa Heat Shock Protein (Hsp-90) in CB2 Cannabinoid Receptor-Mediated Cell Migration: A New Role of Hsp-90 in Migration Signaling of a G Protein-Coupled Receptor.
Whooping Cough
Involvement of the beta gamma subunits of inhibitory GTP-binding protein in chemoattractant receptor-mediated potentiation of cyclic AMP formation in guinea pig neutrophils.
Whooping Cough
Involvement of the betagamma subunits of G proteins in the cAMP response induced by stimulation of the histamine H1 receptor.
Whooping Cough
Involvement of the carboxyl terminus of the third intracellular loop of the cannabinoid CB1 receptor in constitutive activation of Gs.
Whooping Cough
Involvement of the extracellular signal regulated kinase pathway in hydrocarbon-induced reactive oxygen species formation in human neutrophil granulocytes.
Whooping Cough
Involvement of the Gi/o/cGMP/PKG pathway in the AT2-mediated inhibition of outer cortex proximal tubule Na+-ATPase by Ang-(1-7).
Whooping Cough
Involvement of the M2 muscarinic receptor in contractions of the guinea pig trachea, guinea pig esophagus, and rat fundus.
Whooping Cough
Involvement of the mu-opiate receptor in peripheral analgesia.
Whooping Cough
Involvement of the peroxisome proliferator-activated receptor (PPAR) alpha in vascular response of endocannabinoids in the bovine ophthalmic artery.
Whooping Cough
Involvement of the pertussis toxin-sensitive GTP-binding protein in regulation of expression and function of granulocyte complement receptor type 1 and type 3.
Whooping Cough
Involvement of the Rho-kinase/myosin light chain kinase pathway on human monocyte chemotaxis induced by ATL-1, an aspirin-triggered lipoxin A4 synthetic analog.
Whooping Cough
Involvement of tyrosine kinase in capacitative Ca2+ entry pathway in rat glioma C6 cells.
Whooping Cough
Involvement of tyrosine kinase in growth factor-induced phospholipase C activation in NIH3T3 cells.
Whooping Cough
Involvement of tyrosine kinases and STAT3 in Humanin-mediated neuroprotection.
Whooping Cough
Ion fluxes through the progesterone-activated channel of the sperm plasma membrane.
Whooping Cough
Ionizing Radiation Increases Adhesiveness of Human Aortic Endothelial Cells via a Chemokine-Dependent Mechanism.
Whooping Cough
Ionomycin induces prostaglandin E2 formation in murine osteoblastic MC3T3-E1 cells via mechanisms independent of its ionophoric nature.
Whooping Cough
Ionotropic histamine receptors and H2 receptors modulate supraoptic oxytocin neuronal excitability and dye coupling.
Whooping Cough
Is a guanine nucleotide-binding protein involved in excitation-contraction coupling in skeletal muscle?
Whooping Cough
Is a rise in intracellular concentration of free calcium necessary or sufficient for stimulated cytoskeletal-associated actin?
Whooping Cough
Is autism a G-alpha protein defect reversible with natural vitamin A?
Whooping Cough
Is the heterologous expression of metabotropic glutamate receptors (mGluRs) an appropriate method to study the mGluR function? Experience with human embryonic kidney 293 cells transfected with mGluR1.
Whooping Cough
Is the inhibitory effect of somatostatin on the heart due to K+ channel activation?
Whooping Cough
Ischemia of rat brain decreases pertussis toxin-catalyzed [32P]ADP ribosylation of GTP-binding proteins (Gi1 and G0) in membranes.
Whooping Cough
Ischemic preconditioning is associated with a delay in ischemia-induced reduction of beta-adrenergic signal transduction in rabbit hearts.
Whooping Cough
Islet amyloid polypeptide regulates multiple steps in stimulus-secretion coupling of beta cells in rat pancreatic islets.
Whooping Cough
Islet-activating protein impairs alpha 2-adrenoceptor-mediated inhibitory regulation of human platelet adenylate cyclase.
Whooping Cough
Islet-activating protein inhibits leukotriene D4- and leukotriene C4- but not bradykinin- or calcium ionophore-induced prostacyclin synthesis in bovine endothelial cells.
Whooping Cough
Islet-activating protein inhibits the beta-adrenergic receptor facilitation elicited by gamma-aminobutyric acidB receptors.
Whooping Cough
Islet-activating protein prevents nicotinic acid-induced GTPase stimulation and GTP but not GTP gamma S-induced adenylate cyclase inhibition in rat adipocytes.
Whooping Cough
Islet-activating protein, pertussis toxin, inhibits Ca2+-induced and guanine nucleotide-dependent releases of histamine and arachidonic acid from rat mast cells.
Whooping Cough
Islet-activating protein, pertussis toxin: a specific uncoupler of receptor-mediated inhibition of adenylate cyclase.
Whooping Cough
Isobutylmethylxanthine stimulates adenylate cyclase by blocking the inhibitory regulatory protein, Gi.
Whooping Cough
Isoflurane preconditioning decreases glutamate receptor overactivation-induced Purkinje neuronal injury in rat cerebellar slices.
Whooping Cough
Isoflurane preconditions myocardium against infarction via activation of inhibitory guanine nucleotide binding proteins.
Whooping Cough
Isoforms of the EP3 subtype of human prostaglandin E2 receptor transduce both intracellular calcium and cAMP signals.
Whooping Cough
Isolation and characterization of natural human IgG with a morphine-like activity.
Whooping Cough
Isolation and mode of action of rabbit corticostatic (antiadrenocorticotropin) peptides.
Whooping Cough
Isolation of GTP-binding proteins from myeloid HL-60 cells. Identification of two pertussis toxin substrates.
Whooping Cough
Isolation of pertussis toxin subunit proteins by reverse-phase high-performance liquid chromatography and reconstitution of the holotoxin molecule.
Whooping Cough
Isolation of three types of Gi from bovine spleen.
Whooping Cough
Isolation of Zn2+ as an endogenous agonist of GPR39 from fetal bovine serum.
Whooping Cough
Isomorphous binding of mercury-substituted thiosaccharides to pertussis toxin crystals yields crystallographic phases.
Whooping Cough
Isoprenaline can activate the acetylcholine-induced K+ current in canine atrial myocytes via Gs-derived betagamma subunits.
Whooping Cough
Isoprenaline-induced increase in the 40/41 kDa pertussis toxin substrates and functional consequences on contractile response in rat heart.
Whooping Cough
Isoproterenol and cAMP regulation of the human brain natriuretic peptide gene involves Src and Rac.
Whooping Cough
Isoproterenol and GTP gamma S inhibit L-type calcium channels of differentiating rat skeletal muscle cells.
Whooping Cough
Isoproterenol enhances a calcium-independent potassium current in mouse anterior pituitary tumor cells.
Whooping Cough
Isoproterenol modulates the calcium channels through two different mechanisms in smooth-muscle cells from rabbit portal vein.
Whooping Cough
Isovaleric acid ameliorates ovariectomy-induced osteoporosis by inhibiting osteoclast differentiation.
Whooping Cough
Isozyme-selective stimulation of phospholipase C-beta 2 by G protein beta gamma-subunits.
Whooping Cough
Juxtaglomerular cell CaSR stimulation decreases renin release via activation of the PLC/IP(3) pathway and the ryanodine receptor.
Whooping Cough
K+ channel and adenylate cyclase involvement in regulation of Ca2+-evoked release of [3H]dopamine from synaptosomes.
Whooping Cough
K+ channel involvement in induction of synaptic enhancement by mast cell degranulating (MCD) peptide.
Whooping Cough
K-ras transformation greatly increases the toxin-dependent ADP-ribosylation of GTP binding proteins in thyroid cells. Involvement of an inhibitor of the ADP-ribosylation reaction.
Whooping Cough
Kainate receptor modulation of GABA release involves a metabotropic function.
Whooping Cough
Kainate receptor modulation of glutamatergic synaptic transmission in the CA2 region of the hippocampus.
Whooping Cough
Kainate Receptor-Mediated Depression of Glutamate Release Involves Protein Kinase A in the Cerebellum.
Whooping Cough
Kainate receptors coupled to G(i)/G(o) proteins in the rat hippocampus.
Whooping Cough
Kainate receptors depress excitatory synaptic transmission at CA3-->CA1 synapses in the hippocampus via a direct presynaptic action.
Whooping Cough
Kaposi sarcoma-associated herpes virus (KSHV) G protein-coupled receptor (vGPCR) activates the ORF50 lytic switch promoter: a potential positive feedback loop for sustained ORF50 gene expression.
Whooping Cough
Kaposi's sarcoma-associated herpesvirus G protein-coupled receptor signals through multiple pathways in endothelial cells.
Whooping Cough
Kappa opiate agonists inhibit Ca2+ influx in rat spinal cord-dorsal root ganglion cocultures. Involvement of a GTP-binding protein.
Whooping Cough
kappa Opioid receptor interacts with Na(+)/H(+)-exchanger regulatory factor-1/Ezrin-radixin-moesin-binding phosphoprotein-50 (NHERF-1/EBP50) to stimulate Na(+)/H(+) exchange independent of G(i)/G(o) proteins.
Whooping Cough
Kappa opioid receptor-mediated suppression of voltage-activated potassium current in a catecholaminergic neuronal cell line.
Whooping Cough
Kappa- and delta-opioids block sympathetically dependent hyperalgesia.
Whooping Cough
kappa-Opioid agonist modulation of [3H]thymidine incorporation into DNA: evidence for the involvement of pertussis toxin-sensitive G protein-coupled phosphoinositide turnover.
Whooping Cough
kappa-Opioid inhibits catecholamine biosynthesis in PC12 rat pheochromocytoma cell.
Whooping Cough
kappa-Opioid receptor activates an inwardly rectifying K+ channel by a G protein-linked mechanism: coexpression in Xenopus oocytes.
Whooping Cough
kappa-opioid receptor stimulation inhibits cardiac hypertrophy induced by beta1-adrenoceptor stimulation in the rat.
Whooping Cough
kappa-Opioid receptor-transfected cell lines: modulation of adenylyl cyclase activity following acute and chronic opioid treatments.
Whooping Cough
kappa-Opioid tolerance and dependence in cultures of dopaminergic midbrain neurons.
Whooping Cough
KATP channels in the nodose ganglia mediate the orexigenic actions of ghrelin.
Whooping Cough
Khellin, but not 8-methoxypsoralen, inhibits adenylyl cyclase system in HeLa cells.
Whooping Cough
Kinetic and biochemical correlation between sustained p44ERK1 (44 kDa extracellular signal-regulated kinase 1) activation and lysophosphatidic acid-stimulated DNA synthesis in Rat-1 cells.
Whooping Cough
Kinetic basis for the voltage-dependent inhibition of N-type calcium current by somatostatin and norepinephrine in chick sympathetic neurons.
Whooping Cough
Kinetic isotope effect characterization of the transition state for oxidized nicotinamide adenine dinucleotide hydrolysis by pertussis toxin.
Whooping Cough
Kinetics and reversibility of thyrotropin-releasing hormone-stimulated guanine nucleotide exchange in membranes from GH4C1 cells.
Whooping Cough
Kinetics of asthma- and allergy-associated immune response gene expression in peripheral blood mononuclear cells from vaccinated infants after in vitro re-stimulation with vaccine antigen.
Whooping Cough
Kinetics of IL-17- and interferon-gamma-producing PLPp-specific CD4 T cells in EAE induced by coinjection of PLPp/IFA with pertussis toxin in SJL mice.
Whooping Cough
Kinetics of maternal pertussis-specific antibodies in infants of mothers vaccinated with tetanus, diphtheria and acellular pertussis (Tdap) during pregnancy.
Whooping Cough
Kinetics of the IgG antibody response to pertussis toxin after infection with B. pertussis.
Whooping Cough
Knockdown of Inhibitory Guanine Nucleotide Binding Protein Gi?-2 by Antisense Oligodeoxynucleotides Attenuates the Development of Hypertension and Tachycardia in Spontaneously Hypertensive Rats.
Whooping Cough
Knockout of adenylyl cyclase isoform 5 or 6 differentially modifies the ?1-adrenoceptor-mediated inotropic response.
Whooping Cough
Kombucha ameliorates experimental autoimmune encephalomyelitis through activation of Treg and Th2 cells.
Whooping Cough
KSR-1 binds to G-protein betagamma subunits and inhibits beta gamma-induced mitogen-activated protein kinase activation.
Whooping Cough
Kynurenic acid as a ligand for orphan G protein-coupled receptor GPR35.
Whooping Cough
Kynurenic acid triggers firm arrest of leukocytes to vascular endothelium under flow conditions.
Whooping Cough
L- and D-lactate enhance DNA repair and modulate the resistance of cervical carcinoma cells to anticancer drugs via histone deacetylase inhibition and hydroxycarboxylic acid receptor 1 activation.
Whooping Cough
L-AP4 inhibits calcium currents and synaptic transmission via a G-protein-coupled glutamate receptor.
Whooping Cough
L-channel modulation by alpha-1 adrenoceptor activation in neonatal rat ventricular cells: intracellular mechanisms.
Whooping Cough
L-glutamate and acetylcholine mobilise Ca2+ from the same intracellular pool in cerebellar granule cells using transduction mechanisms with different Ca2+ sensitivities.
Whooping Cough
L-selectin stimulation enhances functional expression of surface CXCR4 in lymphocytes: implications for cellular activation during adhesion and migration.
Whooping Cough
Label-free detection and identification of protein ligands captured by receptors in a polymerized planar lipid bilayer using MALDI-TOF MS.
Whooping Cough
Label-free impedance responses of endogenous and synthetic chemokine receptor CXCR3 agonists correlate with G(i)-protein pathway activation.
Whooping Cough
Label-free versus conventional cellular assays: Functional investigations on the human histamine H1 receptor.
Whooping Cough
Laboratory diagnosis of pertussis infections: the role of PCR and serology.
Whooping Cough
Lack of effect of pertussis toxin on TNF-alpha-induced formation of reactive oxygen intermediates by human neutrophils.
Whooping Cough
Lack of endogenous adenosine receptor activation explains the insensitivity of neonatal rat Leydig cells to treatment with pertussis toxin.
Whooping Cough
Lack of involvement of G proteins in the activation of cardiac CFTR Cl- current by genistein.
Whooping Cough
Lack of involvement of pertussis toxin-sensitive G-proteins in norepinephrine-induced vasoconstriction of rat aorta smooth muscle.
Whooping Cough
Lack of stereospecificity in lysophosphatidic acid enantiomer-induced calcium mobilization in human erythroleukemia cells.
Whooping Cough
Lactate and short chain fatty acids produced by microbial fermentation downregulate proinflammatory responses in intestinal epithelial cells and myeloid cells.
Whooping Cough
Lactate Modulates the Activity of Primary Cortical Neurons through a Receptor-Mediated Pathway.
Whooping Cough
Lamellipod extension and K+ current in osteoclasts are regulated by different types of G proteins.
Whooping Cough
Laminin enhances beta(2)-adrenergic receptor stimulation of L-type Ca(2+) current via cytosolic phospholipase A(2) signalling in cat atrial myocytes.
Whooping Cough
Lanthanum enhances in vitro osteoblast differentiation via pertussis toxin-sensitive gi protein and ERK signaling pathway.
Whooping Cough
Lanthanum suppresses osteoblastic differentiation via pertussis toxin-sensitive G protein signaling in rat vascular smooth muscle cells.
Whooping Cough
Latrophilin-2 is a novel component of the epithelial-mesenchymal transition within the atrioventricular canal of the embryonic chicken heart.
Whooping Cough
Latrotoxin stimulates secretion in permeabilized cells by regulating an intracellular Ca2+ - and ATP-dependent event: a role for protein kinase C.
Whooping Cough
LDL increases (CA++)i in human endothelial cells and augments thrombin-induced cell signalling.
Whooping Cough
LDL stimulates mitogen-activated protein kinase phosphatase-1 expression, independent of LDL receptors, in vascular smooth muscle cells.
Whooping Cough
Lectin domains in the toxin of Bordetella pertussis: selectin mimicry linked to microbial pathogenesis.
Whooping Cough
Lectin-like binding of pertussis toxin to a 165-kilodalton Chinese hamster ovary cell glycoprotein.
Whooping Cough
Lectinlike properties of pertussis toxin.
Whooping Cough
Leptin Elicits LTC4 Synthesis by Eosinophils Mediated by Sequential Two-Step Autocrine Activation of CCR3 and PGD2 Receptors.
Whooping Cough
Lethal infection by Bordetella pertussis mutants in the infant mouse model.
Whooping Cough
Letter to the Editor: An Alternative Temperature-based Histamine-sensitisation Test for Absence of Residual Pertussis Toxin in Acellular Pertussis Vaccines.
Whooping Cough
Leu27 insulin-like growth factor-II, an insulin-like growth factor-II analog, attenuates depolarization-evoked GABA release from adult rat hippocampal and cortical slices.
Whooping Cough
Leucine Facilitates Insulin Signaling through a G?i Protein-dependent Signaling Pathway in Hepatocytes.
Whooping Cough
Leucine-2-alanine enkephalin induced delta opioid receptors internalization expressed stably in CHO cells.
Whooping Cough
Leukocyte infiltration, but not neurodegeneration, in the CNS of transgenic mice with astrocyte production of the CXC chemokine ligand 10.
Whooping Cough
Leukotactin-1-induced ERK activation is mediated via Gi/Go protein/PLC/PKC delta/Ras cascades in HOS cells.
Whooping Cough
Leukotactin-1/CCL15 induces cell migration and differentiation of human eosinophilic leukemia EoL-1 cells through PKCdelta activation.
Whooping Cough
Leukotriene B(4) enhances tumour necrosis factor-alpha-induced CCL27 production in human keratinocytes.
Whooping Cough
Leukotriene B4 activates the NADPH oxidase in eosinophils by a pertussis toxin-sensitive mechanism that is largely independent of arachidonic acid mobilization.
Whooping Cough
Leukotriene B4 enhances the activity of nuclear factor-kappaB pathway through BLT1 and BLT2 receptors in atherosclerosis.
Whooping Cough
Leukotriene B4 mediates vascular smooth muscle cell migration through ?v?3 integrin transactivation.
Whooping Cough
Leukotriene B4 Receptor Type 2 Accelerates the Healing of Intestinal Lesions by Promoting Epithelial Cell Proliferation.
Whooping Cough
Leukotriene B4 stimulates human monocyte-derived dendritic cell chemotaxis.
Whooping Cough
Leukotriene B4 stimulation of phagocytes results in the formation of inositol 1,4,5-trisphosphate. A second messenger for Ca2+ mobilization.
Whooping Cough
Leukotriene B4 stimulation of phosphatidylinositol turnover in macrophages and inhibition by pertussis toxin.
Whooping Cough
Leukotriene D(4) activates MAPK through a Ras-independent but PKCepsilon-dependent pathway in intestinal epithelial cells.
Whooping Cough
Leukotriene D(4) induces gene expression in human monocytes through cysteinyl leukotriene type I receptor.
Whooping Cough
Leukotriene D(4)-induced Rho-mediated actin reorganization in human bronchial smooth muscle cells.
Whooping Cough
Leukotriene D4 activates mitogen-activated protein kinase through a protein kinase Calpha-Raf-1-dependent pathway in human monocytic leukemia THP-1 cells.
Whooping Cough
Leukotriene D4 and E4 induce transmembrane signaling in human epithelial cells. Single cell analysis reveals diverse pathways at the G-protein level for the influx and the intracellular mobilization of Ca2+.
Whooping Cough
Leukotriene D4 induced calcium changes in U937 cells may utilize mechanisms additional to inositol phosphate production that are pertussis toxin insensitive but are blocked by phorbol myristate acetate.
Whooping Cough
Leukotriene D4 induces a rapid increase in cAMP in the human epithelial cell line, Int 407: a potential role for this signal in the regulation of calcium influx through the plasma membrane.
Whooping Cough
Leukotriene D4 potentiates fibronectin-induced migration of human lung fibroblasts.
Whooping Cough
Leukotriene D4-induced contraction of cat esophageal and lower esophageal sphincter circular smooth muscle.
Whooping Cough
Leukotriene D4-induced proliferation of glomerular epithelial cells: PKC- and Na+-H+ exchanger-mediated response.
Whooping Cough
Leukotriene-D4 induced cell shrinkage in Ehrlich ascites tumor cells.
Whooping Cough
Levels of anti-pertussis antibodies related to protection after household exposure to Bordetella pertussis.
Whooping Cough
LH action in the Leydig cell: modulation by angiotensin II and corticotropin releasing hormone, and regulation of P450(17) alpha mRNA.
Whooping Cough
LH release is facilitated by agents that alter cyclic AMP-generating system.
Whooping Cough
Lidocaine enhances Galphai protein function.
Whooping Cough
Ligand binding and functional characterization of muscarinic acetylcholine receptors on the TE671/RD human cell line.
Whooping Cough
Ligand Binding and Functional Properties of the Rat Somatostatin Receptor SSTR4 Stably Expressed in Chinese Hamster Ovary Cells.
Whooping Cough
Ligand binding and G protein coupling of muscarinic receptors in airway smooth muscle.
Whooping Cough
Ligand-biased activation of extracellular signal-regulated kinase 1/2 leads to differences in opioid induced antinociception and tolerance.
Whooping Cough
Ligand-dependent autophosphorylation of the insulin receptor is positively regulated by Gi-proteins.
Whooping Cough
Ligand-independent activation of peroxisome proliferator-activated receptor-gamma by insulin and C-peptide in kidney proximal tubular cells: dependent on phosphatidylinositol 3-kinase activity.
Whooping Cough
Ligand-induced adhesion to activated endothelium and to vascular cell adhesion molecule-1 in lymphocytes transfected with the N-formyl peptide receptor.
Whooping Cough
Ligand-induced alpha2-adrenoceptor endocytosis: relationship to Gi protein activation.
Whooping Cough
Ligand-induced changes in surface mu-opioid receptor number: relationship to G protein activation?
Whooping Cough
Ligand-induced formation of the leukotriene B4 receptor-G protein complex of human polymorphonuclear leukocytes.
Whooping Cough
Ligand-receptor dynamics and signal amplification in the neutrophil.
Whooping Cough
Ligand-specific stimulation/inhibition of cAMP formation by a novel endothelin receptor subtype.
Whooping Cough
Ligation of CD23 triggers cyclic AMP generation in human B lymphocytes.
Whooping Cough
Ligation of low-density lipoprotein receptor-related protein with antibodies elevates intracellular calcium and inositol 1,4, 5-trisphosphate in macrophages.
Whooping Cough
Ligation of the alpha 2-macroglobulin signaling receptor on macrophages induces synthesis of platelet activating factor.
Whooping Cough
Light activation of phosphatidylethanolamine N-methyltransferase in rod outer segments and its modulation by association states of transducin.
Whooping Cough
Light activation of phospholipase A2 in rod outer segments of bovine retina and its modulation by GTP-binding proteins.
Whooping Cough
Light and norepinephrine similarly prevent damping of the melatonin rhythm in cultured chick pineal cells: regulation of coupling between the pacemaker and overt rhythms?
Whooping Cough
Light transduction in invertebrate hyperpolarizing photoreceptors: possible involvement of a Go-regulated guanylate cyclase.
Whooping Cough
Light-dependent GTP-binding proteins in squid photoreceptors.
Whooping Cough
Light-induced changes in the content of inositol phosphates in squid (Loligo pealei) retina.
Whooping Cough
Light-induced, GTP-binding protein mediated membrane currents of Xenopus oocytes injected with rhodopsin of cephalopods.
Whooping Cough
Limited distribution of pertussis toxin in rat brain after injection into the lateral cerebral ventricles.
Whooping Cough
Linkage between somatostatin and acid secretion: evidence from use of pertussis toxin.
Whooping Cough
Lipid and membrane interactions of neuropeptide Y.
Whooping Cough
Lipid modification at the N terminus of photoreceptor G-protein alpha-subunit.
Whooping Cough
Lipid peroxidation product 4-hydroxy-2-nonenal acts synergistically with serotonin in inducing vascular smooth muscle cell proliferation.
Whooping Cough
Lipocortin 1 and the control of cPLA2 activity in A549 cells. Glucocorticoids block EGF stimulation of cPLA2 phosphorylation.
Whooping Cough
Lipocortin-1 and the control of arachidonic acid release in cell signalling. Glucocorticoids (changed from glucorticoids) inhibit G protein-dependent activation of cPLA2 activity.
Whooping Cough
Lipopeptides are effective stimulators of tyrosine phosphorylation in human myeloid cells.
Whooping Cough
Lipophilic beta-adrenoceptor antagonists and local anesthetics are effective direct activators of G-proteins.
Whooping Cough
Lipopolysaccharide induces autotaxin expression in human monocytic THP-1 cells.
Whooping Cough
Lipopolysaccharide induces interleukin-6 release from rat peritoneal macrophages in vitro: evidence for a novel mechanism.
Whooping Cough
Lipopolysaccharide interaction with S2 subunit of pertussis toxin.
Whooping Cough
Lipopolysaccharide priming of human neutrophils for an enhanced respiratory burst. Role of intracellular free calcium.
Whooping Cough
Lipopolysaccharide response is linked to the GTP binding protein, Gi2, in the promonocytic cell line U937.
Whooping Cough
Lipopolysaccharide structure-function relationship in activation versus reprogramming of mouse peritoneal macrophages.
Whooping Cough
Lipopolysaccharides from Bordetella pertussis and Bordetella parapertussis differently modulate human dendritic cell functions resulting in divergent prevalence of Th17-polarized responses.
Whooping Cough
Lipopolysaccharides in a traditional pertussis vaccine.
Whooping Cough
Lipoprotein(a) stimulates growth of human mesangial cells and induces activation of phospholipase C via pertussis toxin-sensitive G proteins.
Whooping Cough
Lipoprotein-stimulated surfactant secretion in alveolar type II cells: mediation by heterotrimeric G proteins.
Whooping Cough
Lipoteichoic acid-stimulated p42/p44 MAPK activation via Toll-like receptor 2 in tracheal smooth muscle cells.
Whooping Cough
Lipoxin A4 and lipoxin B4 stimulate the release but not the oxygenation of arachidonic acid in human neutrophils: dissociation between lipid remodeling and adhesion.
Whooping Cough
Lipoxin A4 antagonizes the mitogenic effects of leukotriene D4 in human renal mesangial cells. Differential activation of MAP kinases through distinct receptors.
Whooping Cough
Lipoxin A4 induces hyperadhesiveness in human endothelial cells for neutrophils.
Whooping Cough
Lipoxin A4 stable analogs are potent mimetics that stimulate human monocytes and THP-1 cells via a G-protein-linked lipoxin A4 receptor.
Whooping Cough
Lipoxin A4 stimulates a cytosolic Ca2+ increase in human bronchial epithelium.
Whooping Cough
Lipoxin, leukotriene, and PDGF receptors cross-talk to regulate mesangial cell proliferation.
Whooping Cough
Lipoxins are potential endogenous antiinflammatory mediators in asthma.
Whooping Cough
Lithium activates mammalian Na+/H+ exchangers: isoform specificity and inhibition by genistein.
Whooping Cough
Lithium administration modulates platelet Gi in humans.
Whooping Cough
Lithium does not alter ADP-ribosylation of Gi/Go catalyzed by pertussis toxin in rat brain.
Whooping Cough
Lithium stimulation of rat pancreatic beta-cell replication is mediated through pertussis toxin-sensitive GTP-binding proteins and occurs independently of Ca2+ influx, cAMP, or protein kinase C activation.
Whooping Cough
Liver myofibroblasts regulate infiltration and positioning of lymphocytes in human liver.
Whooping Cough
Local anesthetic effects on priming and activation of human neutrophils.
Whooping Cough
Local injection of pertussis toxin attenuates morphine withdrawal excitation of rat supraoptic nucleus neurones.
Whooping Cough
Local massage after vaccination enhances the immunogenicity of diphtheria-tetanus-pertussis vaccine.
Whooping Cough
Local reactions and IgE antibodies to pertussis toxin after acellular diphtheria-tetanus-pertussis immunization.
Whooping Cough
Localisation of a receptor-recognition domain on the S3 subunit of pertussis toxin by peptide mapping.
Whooping Cough
Localization and characterization of the subtypes(s) of muscarinic receptor involved in prostacyclin synthesis in rabbit heart.
Whooping Cough
Localization of a region of the S1 subunit of pertussis toxin required for efficient ADP-ribosyltransferase activity.
Whooping Cough
Localization of G alpha 0 to growth cones in PC12 cells: role of G alpha 0 association with receptors and G beta gamma.
Whooping Cough
Localization of Gi alpha proteins in the centrosomes and at the midbody: implication for their role in cell division.
Whooping Cough
Localization of IP in rabbit kidney and functional role of the PGI(2)/IP system in cortical collecting duct.
Whooping Cough
Localization of marginal zone macrophages is regulated by C-C chemokine ligands 21/19.
Whooping Cough
Localization of several G-protein subunits to the apical and basolateral membranes of cortical tubular cells from the rat kidney.
Whooping Cough
Localization of the GTP-binding protein Gi alpha in myelomonocytic progenitor cells is regulated by proliferation (GM-CSF, IL-3) and differentiation (TNF) signals.
Whooping Cough
Localization of the promoter for the ptl genes of Bordetella pertussis, which encode proteins essential for secretion of pertussis toxin.
Whooping Cough
Locus controlling Bordetella pertussis-induced histamine sensitization (Bphs), an autoimmune disease-susceptibility gene, maps distal to T-cell receptor beta-chain gene on mouse chromosome 6.
Whooping Cough
Long lasting inhibition of adenylyl cyclase selectively mediated by inositol 1,4,5-trisphosphate-evoked calcium release.
Whooping Cough
Long term beta-adrenoceptor-mediated up-regulation of Gi alpha and G(o) alpha mRNA levels and pertussis toxin-sensitive guanine nucleotide-binding proteins in rat heart.
Whooping Cough
Long term serologic follow-up after pertussis immunization.
Whooping Cough
Long-term antidepressant treatments result in a tonic activation of forebrain 5-HT1A receptors.
Whooping Cough
Long-term depression of a sympathetic ganglionic response to opioids by prolonged synaptic activity and by phorbol esters.
Whooping Cough
Long-term functional impairment of hemopoietic progenitor cells engineered to express the S1 catalytic subunit of pertussis toxin.
Whooping Cough
Long-term human serum antibody responses after immunization with whole-cell pertussis vaccine in France.
Whooping Cough
Long-term neuroleptic treatments counteract dopamine D2 agonist inhibition of adenylate cyclase but do not affect pertussis toxin ADP-ribosylation in the rat brain.
Whooping Cough
Losartan-sensitive AII receptors linked to depolarization-dependent cortisol secretion through a novel signaling pathway.
Whooping Cough
Loss of activation of Gs but not Gi following expression of an alpha2A-adrenoceptor-Gi1alpha fusion protein.
Whooping Cough
Loss of beta-adrenoceptor response in myocytes overexpressing the Na+/Ca(2+)-exchanger.
Whooping Cough
Loss of dendritic cell migration and impaired resistance to Leishmania donovani infection in mice deficient in CCL19 and CCL21.
Whooping Cough
Loss of endothelial pertussis toxin-sensitive G protein function in atherosclerotic porcine coronary arteries.
Whooping Cough
Loss of Gi G-Protein-Coupled Receptor Signaling in Osteoblasts Accelerates Bone Fracture Healing.
Whooping Cough
Loss of microglial ramification in microglia-astrocyte cocultures: involvement of adenylate cyclase, calcium, phosphatase, and Gi-protein systems.
Whooping Cough
Loss of multi-epitope specificity in memory CD4(+) T cell responses to B. Pertussis with age.
Whooping Cough
Loss of the inhibitory function of the guanine nucleotide regulatory component of adenylate cyclase due to its ADP ribosylation by islet-activating protein, pertussis toxin, in adipocyte membranes.
Whooping Cough
Loss of vascular adenosine A1 receptors with age in the rat heart.
Whooping Cough
Low density lipoprotein and apoprotein B induce increases in inositol trisphosphate and cytosolic free Ca2+ via pertussis toxin-sensitive GTP-binding protein in vascular smooth muscle cells.
Whooping Cough
Low Detection Rate of Bordetella pertussis Using the BioFire FilmArray Respiratory Panel 2plus.
Whooping Cough
Low doses of bisphenol A and diethylstilbestrol impair Ca2+ signals in pancreatic alpha-cells through a nonclassical membrane estrogen receptor within intact islets of Langerhans.
Whooping Cough
Low doses of bisphenol A promote human seminoma cell proliferation by activating PKA and PKG via a membrane G-protein-coupled estrogen receptor.
Whooping Cough
Low levels of antipertussis antibodies plus lack of history of pertussis correlate with susceptibility after household exposure to Bordetella pertussis.
Whooping Cough
Low levels of pertussis toxin adenosine diphosphate ribosylation in the schizophrenic brain.
Whooping Cough
Low pertussis antibody levels in maternal and umbilical cord blood samples in Turkey.
Whooping Cough
Low pertussis toxin antibody levels in two regional cohorts of Canadian pregnant women.
Whooping Cough
Low-affinity receptor-mediated induction of superoxide by N-formyl-methionyl-leucyl-phenylalanine and WKYMVm in IMR90 human fibroblasts.
Whooping Cough
Low-density lipoprotein (LDL) binds to a G-protein coupled receptor in human platelets. Evidence that the proaggregatory effect induced by LDL is modulated by down-regulation of binding sites and desensitization of its mediated signaling.
Whooping Cough
Low-density lipoprotein in hypercholesterolemic human plasma induces vascular endothelial cell apoptosis by inhibiting fibroblast growth factor 2 transcription.
Whooping Cough
Low-Density Lipoprotein Induced Expression of Connective Tissue Growth Factor via Transactivation of Sphingosine 1-Phosphate Receptors in Mesangial Cells.
Whooping Cough
LPA and S1P increase corneal epithelial and endothelial cell transcellular resistance.
Whooping Cough
LPA is a novel lipid regulator of mesangial cell hexokinase activity and HKII isoform expression.
Whooping Cough
LPA modulates monocyte migration directly and via LPA-stimulated endothelial cells.
Whooping Cough
LPA protects intestinal epithelial cells from apoptosis by inhibiting the mitochondrial pathway.
Whooping Cough
LPA(1) -induced migration requires nonmuscle myosin II light chain phosphorylation in breast cancer cells.
Whooping Cough
LPA1 mediates antidepressant-induced ERK1/2 signalling and protection from oxidative stress in glial cells.
Whooping Cough
LPA1 receptor-mediated thromboxane A2 release is responsible for lysophosphatidic acid-induced vascular smooth muscle contraction.
Whooping Cough
LPA1 receptors mediate stimulation, whereas LPA2 receptors mediate inhibition, of migration of pancreatic cancer cells in response to lysophosphatidic acid and malignant ascites.
Whooping Cough
LPA2 receptor mediates mitogenic signals in human colon cancer cells.
Whooping Cough
LPS induced inflammatory responses in human peripheral blood mononuclear cells is mediated through NOX4 and Gi? dependent PI-3kinase signalling.
Whooping Cough
LPS induces eosinophil migration via CCR3 signaling through a mechanism independent of RANTES and Eotaxin.
Whooping Cough
Luminal prostaglandin E receptors regulate salt and water transport in rabbit cortical collecting duct.
Whooping Cough
Lupinus mutabilis Extract Exerts an Anti-Diabetic Effect by Improving Insulin Release in Type 2 Diabetic Goto-Kakizaki Rats.
Whooping Cough
Luteinizing hormone (LH) drives diverse intracellular calcium second messenger signals in isolated porcine ovarian thecal cells: preferential recruitment of intracellular Ca2+ oscillatory cells by higher concentrations of LH.
Whooping Cough
Luteinizing hormone secretion is enhanced by pertussis toxin, cholera toxin, and forskolin. Evidence for the involvement of the cyclic AMP-generating system.
Whooping Cough
Luteinizing hormone-releasing hormone (LHRH) attenuates morphine-induced inhibition of cyclic AMP (cAMP) in opioid-responsive SK-N-SH cells.
Whooping Cough
Luteinizing hormone/choriogonadotropin-dependent, cholera toxin-catalyzed adenosine 5'-diphosphate (ADP)-ribosylation of the long and short forms of Gs alpha and pertussis toxin-catalyzed ADP-ribosylation of Gi alpha*.
Whooping Cough
LY320135, a novel cannabinoid CB1 receptor antagonist, unmasks coupling of the CB1 receptor to stimulation of cAMP accumulation.
Whooping Cough
Lymph node-derived donor encephalitogenic CD4+ T cells in C57BL/6 mice adoptive transfer experimental autoimmune encephalomyelitis highly express GM-CSF and T-bet.
Whooping Cough
Lymphatic endothelial cell sphingosine kinase activity is required for lymphocyte egress and lymphatic patterning.
Whooping Cough
Lymphocyte proliferation induced by pertussis toxin utilizes a pathway parallel to transforming growth factor-beta-sensitive growth.
Whooping Cough
Lymphocyte receptors for pertussis toxin.
Whooping Cough
Lymphocyte trafficking through the blood-brain barrier is dependent on endothelial cell heterotrimeric G-protein signaling.
Whooping Cough
Lymphokine secretion and cytotoxic activity of human CD4+ T-cell clones against Bordetella pertussis.
Whooping Cough
Lymphotoxin induces secretion of granule proteins from adherent neutrophils: possible role of intracellular free calcium.
Whooping Cough
Lysophosphatidate-induced cell proliferation: identification and dissection of signaling pathways mediated by G proteins.
Whooping Cough
Lysophosphatidic acid (LPA) in malignant ascites stimulates motility of human pancreatic cancer cells through LPA1.
Whooping Cough
Lysophosphatidic acid (LPA) induces plasma exudation and histamine release in mice via LPA receptors.
Whooping Cough
Lysophosphatidic acid accelerates the development of human mast cells.
Whooping Cough
Lysophosphatidic acid activates ?-catenin/T cell factor signaling, which contributes to the suppression of apoptosis in H19-7 cells.
Whooping Cough
Lysophosphatidic acid activates NF-kappaB in fibroblasts. A requirement for multiple inputs.
Whooping Cough
Lysophosphatidic acid activates nuclear factor kappa B and induces proinflammatory gene expression in endothelial cells.
Whooping Cough
Lysophosphatidic acid activation of phosphatidylcholine-hydrolysing phospholipase D and actin polymerization by a pertussis toxin-sensitive mechanism.
Whooping Cough
Lysophosphatidic acid alters cerebrovascular reactivity in piglets.
Whooping Cough
Lysophosphatidic acid and bFGF control different modes in proliferating myoblasts.
Whooping Cough
Lysophosphatidic acid and EGF stimulate mitogenesis in human airway smooth muscle cells.
Whooping Cough
Lysophosphatidic acid and intracellular signalling in vascular smooth muscle cells.
Whooping Cough
Lysophosphatidic acid and receptor-mediated activation of endothelial nitric-oxide synthase.
Whooping Cough
Lysophosphatidic acid and sphingosine 1-phosphate stimulate endothelial cell wound healing.
Whooping Cough
Lysophosphatidic acid as a mediator for proinflammatory agonists in a human corneal epithelial cell line.
Whooping Cough
Lysophosphatidic acid as a novel cell survival/apoptotic factor.
Whooping Cough
Lysophosphatidic acid as a regulator of endothelial/leukocyte interaction.
Whooping Cough
Lysophosphatidic acid augments fibroblast-mediated contraction of released collagen gels.
Whooping Cough
Lysophosphatidic acid cooperates with 1alpha,25(OH)2D3 in stimulating human MG63 osteoblast maturation.
Whooping Cough
Lysophosphatidic acid enhanced the angiogenic capability of human chondrocytes by regulating Gi/NF-kB-dependent angiogenic factor expression.
Whooping Cough
Lysophosphatidic acid in malignant ascites stimulates migration of human mesenchymal stem cells.
Whooping Cough
Lysophosphatidic acid increases soluble ST2 expression in mouse lung and human bronchial epithelial cells.
Whooping Cough
Lysophosphatidic acid induced nuclear translocation of nuclear factor-kappaB in Panc-1 cells by mobilizing cytosolic free calcium.
Whooping Cough
Lysophosphatidic acid induces a pertussis toxin-sensitive Ca(2+)-activated Cl- current in Xenopus laevis oocytes.
Whooping Cough
Lysophosphatidic acid induces chemotaxis in MC3T3-E1 osteoblastic cells.
Whooping Cough
Lysophosphatidic acid induces chemotaxis, oxygen radical production, CD11b up-regulation, Ca2+ mobilization, and actin reorganization in human eosinophils via pertussis toxin-sensitive G proteins.
Whooping Cough
Lysophosphatidic acid induces human natural killer cell chemotaxis and intracellular calcium mobilization.
Whooping Cough
Lysophosphatidic acid induces hypertrophy of neonatal cardiac myocytes via activation of Gi and Rho.
Whooping Cough
Lysophosphatidic acid induces interleukin-13 (IL-13) receptor alpha2 expression and inhibits IL-13 signaling in primary human bronchial epithelial cells.
Whooping Cough
Lysophosphatidic acid induces osteocyte dendrite outgrowth.
Whooping Cough
Lysophosphatidic acid induces rapid and sustained decreases in epidermal growth factor receptor binding via different signaling pathways in BEAS-2B airway epithelial cells.
Whooping Cough
Lysophosphatidic acid induces thrombospondin-1 production in primary cultured rat cortical astrocytes.
Whooping Cough
Lysophosphatidic acid induction of tissue factor expression in aortic smooth muscle cells.
Whooping Cough
Lysophosphatidic acid inhibits CC chemokine ligand 5/RANTES production by blocking IRF-1-mediated gene transcription in human bronchial epithelial cells.
Whooping Cough
Lysophosphatidic acid is a mediator of Trp-Lys-Tyr-Met-Val-d-Met-induced calcium influx.
Whooping Cough
Lysophosphatidic acid is an osteoblast mitogen whose proliferative actions involve G(i) proteins and protein kinase C, but not P42/44 mitogen-activated protein kinases.
Whooping Cough
Lysophosphatidic acid mimics serum-induced sensitization of cyclic AMP accumulation.
Whooping Cough
Lysophosphatidic acid modulates alpha(1b)-adrenoceptor phosphorylation and function: roles of Gi and phosphoinositide 3-kinase.
Whooping Cough
Lysophosphatidic acid modulates c-Met redistribution and hepatocyte growth factor/c-Met signaling in human bronchial epithelial cells through PKC delta and E-cadherin.
Whooping Cough
Lysophosphatidic acid possesses dual action in cell proliferation.
Whooping Cough
Lysophosphatidic acid potentiates ACh receptor currents by G-protein-mediated activation of protein kinase C.
Whooping Cough
Lysophosphatidic acid prevents apoptosis in fibroblasts via G(i)-protein-mediated activation of mitogen-activated protein kinase.
Whooping Cough
Lysophosphatidic acid protects and rescues intestinal epithelial cells from radiation- and chemotherapy-induced apoptosis.
Whooping Cough
Lysophosphatidic acid protects cancer cells from histone deacetylase (HDAC) inhibitor-induced apoptosis through activation of HDAC.
Whooping Cough
Lysophosphatidic acid rapidly induces protein kinase D activation through a pertussis toxin-sensitive pathway.
Whooping Cough
Lysophosphatidic acid receptor signaling in mammalian retinal pigment epithelial cells.
Whooping Cough
Lysophosphatidic acid receptor-2 (LPA2)-mediated signaling enhances chemoresistance in melanoma cells treated with anticancer drugs.
Whooping Cough
Lysophosphatidic acid regulates blood glucose by stimulating myotube and adipocyte glucose uptake.
Whooping Cough
Lysophosphatidic acid regulation of cyclic AMP accumulation in cultured human airway smooth muscle cells.
Whooping Cough
Lysophosphatidic acid sensitizes mechanical stress-induced Ca2+ response via activation of phospholipase C and tyrosine kinase in cultured smooth muscle cells.
Whooping Cough
Lysophosphatidic acid signals through mitogen-activated protein kinase-extracellular signal regulated kinase in ovarian theca cells expressing the LPA1/edg2-receptor: involvement of a nonclassical pathway?
Whooping Cough
Lysophosphatidic acid signals through multiple receptors in osteoclasts to elevate cytosolic calcium concentration, evoke retraction, and promote cell survival.
Whooping Cough
Lysophosphatidic acid stimulates calcium transients in enteric glia.
Whooping Cough
Lysophosphatidic acid stimulates cell proliferation in rat chondrocytes.
Whooping Cough
Lysophosphatidic acid stimulates intestinal restitution via cytoskeletal activation and remodeling.
Whooping Cough
Lysophosphatidic acid stimulates neuronal differentiation of cortical neuroblasts through the LPA1-G(i/o) pathway.
Whooping Cough
Lysophosphatidic Acid Stimulates Ovarian Cancer Cell Migration via a Ras-MEK Kinase 1 Pathway.
Whooping Cough
Lysophosphatidic acid stimulates p21-activated kinase in vascular smooth muscle cells.
Whooping Cough
Lysophosphatidic acid stimulates phospholipase D activity and cell proliferation in PC-3 human prostate cancer cells.
Whooping Cough
Lysophosphatidic acid stimulates protein kinase C isoforms alpha, beta, epsilon, and zeta in a pertussis toxin sensitive pathway in vascular smooth muscle cells.
Whooping Cough
Lysophosphatidic acid transactivates both c-Met and epidermal growth factor receptor, and induces cyclooxygenase-2 expression in human colon cancer LoVo cells.
Whooping Cough
Lysophosphatidic Acid Triggers Apoptosis in HeLa Cells through the Upregulation of Tumor Necrosis Factor Receptor Superfamily Member 21.
Whooping Cough
Lysophosphatidic acid triggers calcium entry through a non-store-operated pathway in human neutrophils.
Whooping Cough
Lysophosphatidic acid triggers cathepsin B-mediated invasiveness of human endometriotic cells.
Whooping Cough
Lysophosphatidic acid-induced activation of protein Ser/Thr kinases in cultured rat 3Y1 fibroblasts. Possible involvement in rho p21-mediated signalling.
Whooping Cough
Lysophosphatidic acid-induced association of SHP-2 with SHPS-1: roles of RHO, FAK, and a SRC family kinase.
Whooping Cough
Lysophosphatidic acid-induced Ca(2+) mobilization in the neural retina of chick embryo.
Whooping Cough
Lysophosphatidic acid-induced calcium mobilization and proliferation in kidney proximal tubular cells.
Whooping Cough
Lysophosphatidic acid-induced changes in cAMP profiles in young and senescent human fibroblasts as a clue to the ageing process.
Whooping Cough
Lysophosphatidic acid-induced membrane ruffling and brain-derived neurotrophic factor gene expression are mediated by ATP release in primary microglia.
Whooping Cough
Lysophosphatidic acid-induced neurite retraction in PC12 cells: neurite-protective effects of cyclic AMP signaling.
Whooping Cough
Lysophosphatidic acid-induced oxidized low-density lipoprotein uptake is class A scavenger receptor-dependent in macrophages.
Whooping Cough
Lysophosphatidic acid-induced proliferation-related signals in astrocytes.
Whooping Cough
Lysophosphatidic acid-induced, pertussis toxin-sensitive nociception through a substance P release from peripheral nerve endings in mice.
Whooping Cough
Lysophosphatidic acid-mediated Ca2+ mobilization in human SH-SY5Y neuroblastoma cells is independent of phosphoinositide signalling, but dependent on sphingosine kinase activation.
Whooping Cough
Lysophosphatidic acid-mediated signal-transduction pathways involved in the induction of the early-response genes prostaglandin G/H synthase-2 and Egr-1: a critical role for the mitogen-activated protein kinase p38 and for Rho proteins.
Whooping Cough
Lysophosphatidylcholine activates mesangial cell PKC and MAP kinase by PLCgamma-1 and tyrosine kinase-Ras pathways.
Whooping Cough
Lysophosphatidylcholine activates p38 and p42/44 mitogen-activated protein kinases in monocytic THP-1 cells, but only p38 activation is involved in its stimulated chemotaxis.
Whooping Cough
Lysophosphatidylcholine as a death effector in the lipoapoptosis of hepatocytes.
Whooping Cough
Lysophosphatidylcholine as an effector of fatty acid-induced insulin resistance.
Whooping Cough
Lysophosphatidylcholine induces changes in physicochemical, morphological, and functional properties of mouse zona pellucida: a possible role of phospholipase A2 in sperm-zona pellucida interaction.
Whooping Cough
Lysophosphatidylcholine induces mast cell secretion and protein kinase C activation.
Whooping Cough
Lysophosphatidylcholine is a regulator of tyrosine kinase activity and intracellular Ca(2+) level in Jurkat T cell line.
Whooping Cough
Lysophosphatidylcholine modifies G protein-dependent signaling in porcine endothelial cells.
Whooping Cough
Lysophosphatidylcholine regulates human microvascular endothelial cell expression of chemokines.
Whooping Cough
Lysophosphatidylcholine stimulates MAP kinase activity in rat vascular smooth muscle cells.
Whooping Cough
Lysophosphatidylcholine- and MCP-1-induced chemotaxis of monocytes requires potassium channel activity.
Whooping Cough
Lysophosphatidylethanolamine in Grifola frondosa as a neurotrophic activator via activation of MAPK.
Whooping Cough
Lysophosphatidylethanolamine stimulates chemotactic migration and cellular invasion in SK-OV3 human ovarian cancer cells: involvement of pertussis toxin-sensitive G-protein coupled receptor.
Whooping Cough
Lysophosphatidylethanolamine utilizes LPA1 and CD97 in MDA-MB-231 breast cancer cells.
Whooping Cough
Lysophosphatidylglycerol stimulates chemotactic migration and tube formation in human umbilical vein endothelial cells.
Whooping Cough
Lysophosphatidylglycerol stimulates chemotactic migration in human natural killer cells.
Whooping Cough
Lysophosphatidylserine increases membrane potentials in rat C6 glioma cells.
Whooping Cough
Lysophosphatidylserine induces calcium signaling through Ki16425/VPC32183-sensitive GPCR in bone marrow-derived mast cells and in C6 glioma and colon cancer cells.
Whooping Cough
Lysophosphatidylserine stimulates chemotactic migration in U87 human glioma cells.
Whooping Cough
Lysophosphatidylserine Stimulates L2071 Mouse Fibroblast Chemotactic Migration via a Process Involving Pertussis Toxin-Sensitive Trimeric G-Proteins.
Whooping Cough
Lysophosphatidylserine stimulates leukemic cells but not normal leukocytes.
Whooping Cough
Lysophospholipids and chemokines activate distinct signal transduction pathways in T helper 1 and T helper 2 cells.
Whooping Cough
Lysophospholipids control integrin-dependent adhesion in splenic B cells through G(i) and G(12)/G(13) family G-proteins but not through G(q)/G(11).
Whooping Cough
Lysophospholipids elevate [Ca2+]i and trigger exocytosis in bovine chromaffin cells.
Whooping Cough
Lysophospholipids increase ICAM-1 expression in HUVEC through a Gi- and NF-kappaB-dependent mechanism.
Whooping Cough
Lysophospholipids of different classes mobilize neutrophil secretory vesicles and induce redundant signaling through G2A.
Whooping Cough
LysoPtdOH Enhances CXCL16 Production Stimulated by LPS from Macrophages and Regulates T cell Migration.
Whooping Cough
Lysosphingolipid receptor-mediated diuresis and natriuresis in anaesthetized rats.
Whooping Cough
Lysozyme, a mediator of sepsis, impairs the cardiac neural adrenergic response by nonendothelial release of NO and inhibitory G protein signaling.
Whooping Cough
M(2) and M(3) muscarinic receptor-mediated contractions in longitudinal smooth muscle of the ileum studied with receptor knockout mice.
Whooping Cough
m-chlorophenylpiperazine and m-trifluoromethylphenylpiperazine are partial agonists at cloned 5-HT2A receptors expressed in fibroblasts.
Whooping Cough
M-current suppression in PC12 cells by bradykinin is mediated by a pertussis toxin-insensitive G-protein and modulated by intracellular calcium.
Whooping Cough
M1 acetylcholine receptor-mediated phosphatidylinositol turnover in adult and senescent rat brain slices.
Whooping Cough
M1 muscarinic receptors increase calcium current and phosphoinositide turnover in guinea-pig ventricular cardiocytes.
Whooping Cough
M1, M3 and M5 muscarinic receptors stimulate mitogen-activated protein kinase.
Whooping Cough
M2 muscarinic autoreceptors modulate acetylcholine release in prefrontal cortex of C57BL/6J mouse.
Whooping Cough
M2 muscarinic receptor-mediated inhibition of the Ca2+ current in rat magnocellular cholinergic basal forebrain neurones.
Whooping Cough
M2 muscarinic receptors in pontine reticular formation of C57BL/6J mouse contribute to rapid eye movement sleep generation.
Whooping Cough
M2 muscarinic receptors induce airway smooth muscle activation via a dual, Gbetagamma-mediated inhibition of large conductance Ca2+-activated K+ channel activity.
Whooping Cough
M2, M3, and M4 receptor subtypes contribute to muscarinic potentiation of GABAergic inputs to spinal dorsal horn neurons.
Whooping Cough
m3 Muscarinic receptor-induced and Gi-mediated heterologous potentiation of phospholipase C stimulation: role of phosphoinositide synthesis.
Whooping Cough
M3 muscarinic receptors on murine HSDM1C1 cells: further functional, regulatory, and receptor binding studies.
Whooping Cough
M4 muscarinic receptor activation modulates calcium channel currents in rat intracardiac neurons.
Whooping Cough
m4 muscarinic receptor subtype activates an inwardly rectifying potassium conductance in AtT20 cells.
Whooping Cough
Macaque trophoblast migration is regulated by RANTES.
Whooping Cough
Macrophage colony-stimulating factor rapidly enhances beta-migrating very low density lipoprotein metabolism in macrophages through activation of a Gi/o protein signaling pathway.
Whooping Cough
Macrophage depletion prevents leukocyte adhesion and disease induction in experimental melanin-protein induced uveitis.
Whooping Cough
Macrophages and dendritic cells in IRBP-induced experimental autoimmune uveoretinitis in B10RIII mice.
Whooping Cough
Macrophages induce the inflammatory response in the pulmonary Arthus reaction through G alpha i2 activation that controls C5aR and Fc receptor cooperation.
Whooping Cough
mADP-RTs: versatile virulence factors from bacterial pathogens of plants and mammals.
Whooping Cough
Magnetic bead isolation of neutrophil plasma membranes and quantification of membrane-associated guanine nucleotide binding proteins.
Whooping Cough
Magnolol induces cytosolic-free Ca2+ elevation in rat neutrophils primarily via inositol trisphosphate signalling pathway.
Whooping Cough
Maintained L-type Ca2+ channel activity in excised patches of PTX-treated granule cells of the cerebellum.
Whooping Cough
Maintenance of biological activity of pertussis toxin radioiodinated while bound to fetuin-agarose.
Whooping Cough
Maintenance of Y receptor dimers in epithelial cells depends on interaction with G-protein heterotrimers.
Whooping Cough
Maitotoxin activates cation channels distinct from the receptor-activated non-selective cation channels of HL-60 cells.
Whooping Cough
Maitotoxin induces phosphoinositide turnover and modulates glutamatergic and muscarinic cholinergic receptor function in cultured cerebellar neurons.
Whooping Cough
Maitotoxin, a potent, general activator of phosphoinositide breakdown.
Whooping Cough
Maitotoxin-induced intracellular calcium rise in PC12 cells: involvement of dihydropyridine-sensitive and omega-conotoxin-sensitive calcium channels and phosphoinositide breakdown.
Whooping Cough
Major pertussis-toxin-sensitive GTP-binding protein of bovine lung. Purification, characterization and production of specific antibodies.
Whooping Cough
Manganese stimulates stellation of cultured rat cortical astrocytes.
Whooping Cough
Manipulation of olfactory ensheathing cell signaling mechanisms: effects on their support for neurite regrowth from adult CNS neurons in coculture.
Whooping Cough
Mannose 6-phosphate/insulin-like growth factor II receptor fails to interact with G-proteins. Analysis of mutant cytoplasmic receptor domains.
Whooping Cough
Mannosylated self-peptide inhibits the development of experimental autoimmune encephalomyelitis via expansion of nonencephalitogenic T cells.
Whooping Cough
MAPK activation via 5-hydroxytryptamine 1A receptor is involved in the neuroprotective effects of xaliproden.
Whooping Cough
MAPkinase: a second site of G-protein regulation of B-cell activation via the antigen receptors.
Whooping Cough
Mapping of linear B-cell epitopes of the S2 subunit of pertussis toxin.
Whooping Cough
Mapping of the carboxyl terminus within the tertiary structure of transducin's alpha subunit using the heterobifunctional cross-linking reagent, 125I-N-(3-iodo-4-azidophenylpropionamido-S-(2-thiopyridyl) cysteine.
Whooping Cough
Maraviroc attenuates the pathogenesis of experimental autoimmune encephalitis.
Whooping Cough
Marked increase in L-selectin-negative T cells in neonatal pertussis. The lymphocytosis explained?
Whooping Cough
Marrow engraftment of hematopoietic stem and progenitor cells is independent of Galphai-coupled chemokine receptors.
Whooping Cough
Masked excitatory action of noradrenaline on rat islet beta-cells via activation of phospholipase C.
Whooping Cough
Mass spectrometric analysis of multiple pertussis toxins and toxoids.
Whooping Cough
Mast cell activation by pedicellarial toxin of sea urchin, Toxopneustes pileolus.
Whooping Cough
Mast cell adenosine induced calcium mobilization via Gi3 and Gq proteins.
Whooping Cough
Mast cell chymase induces expression of chemokines for neutrophils in eosinophilic EoL-1 cells and mouse peritonitis eosinophils.
Whooping Cough
Mast cell degranulating (MCD) peptide and its optical isomer activate GTP binding protein in rat mast cells.
Whooping Cough
Mast cell migration to Th2 stimulated airway smooth muscle from asthmatics.
Whooping Cough
Mast cell tryptase is a mitogen for cultured fibroblasts.
Whooping Cough
Mastoparan elicits prostaglandin E2 generation and inhibits inositol phosphate accumulation via different mechanisms in rabbit astrocytes.
Whooping Cough
Mastoparan inhibits beta-adrenoceptor-G(s) signaling by changing the localization of Galpha(s) in lipid rafts.
Whooping Cough
Mastoparan inhibits phosphoinositide hydrolysis via pertussis toxin-insensitive [corrected] G-protein in human astrocytoma cells.
Whooping Cough
Mastoparan may activate GTP hydrolysis by Gi-proteins in HL-60 membranes indirectly through interaction with nucleoside diphosphate kinase.
Whooping Cough
Mastoparan selectively activates phospholipase D2 in cell membranes.
Whooping Cough
Mastoparan stimulates exocytosis at a Ca(2+)-independent late site in stimulus-secretion coupling. Studies with the RINm5F beta-cell line.
Whooping Cough
Mastoparan transiently permeabilizes Swiss 3T3 cells and induces c-fos proto-oncogene expression. Role of calcium and G protein activation.
Whooping Cough
Mastoparan, a novel mitogen for Swiss 3T3 cells, stimulates pertussis toxin-sensitive arachidonic acid release without inositol phosphate accumulation.
Whooping Cough
Mastoparan, a peptide toxin from wasp venom, mimics receptors by activating GTP-binding regulatory proteins (G proteins).
Whooping Cough
Mastoparan, a wasp venom peptide, identifies two discrete mechanisms for elevating cytosolic calcium and inositol trisphosphates in human polymorphonuclear leukocytes.
Whooping Cough
Mastoparan, a wasp venom peptide, stimulates release of prolactin from cultured rat anterior pituitary cells.
Whooping Cough
Mastoparan, a wasp venom, activates platelets via pertussis toxin-sensitive GTP-binding proteins.
Whooping Cough
Mastoparan, a wasp venom, stimulates insulin release by pancreatic islets through pertussis toxin sensitive GTP-binding protein.
Whooping Cough
Mastoparan-induced apoptosis of cultured cerebellar granule neurons is initiated by calcium release from intracellular stores.
Whooping Cough
Mastoparan-induced hormone release from rat pancreatic islets.
Whooping Cough
Mastoparan-induced phosphatidylcholine hydrolysis by phospholipase D activation in human astrocytoma cells.
Whooping Cough
Mastoparan-stimulated prolactin secretion in rat pituitary GH3 cells involves activation of Gq/11 proteins.
Whooping Cough
Maternal allergen immunisation to prevent sensitisation in offspring: Th2-polarising adjuvants are more efficient than a Th1-polarising adjuvant in mice.
Whooping Cough
Maternal Immunization Earlier in Pregnancy Maximizes Antibody Transfer and Expected Infant Seropositivity Against Pertussis.
Whooping Cough
Maternal pertussis vaccination and its effects on the immune response of infants aged up to 12 months in the Netherlands: an open-label, parallel, randomised controlled trial.
Whooping Cough
Maternally derived antibodies against Bordetella pertussis antigens pertussis toxin and filamentous hemagglutinin in preterm and full term newborns.
Whooping Cough
Matrix metalloproteinase-1 activates a pertussis toxin-sensitive signaling pathway that stimulates the release of matrix metalloproteinase-9.
Whooping Cough
Matrix metalloproteinase-9 release from human leukocytes.
Whooping Cough
Maturation and insulin-like immunoreactivity in rat submandibular salivary glands: possible implication of G regulatory proteins.
Whooping Cough
MCP-1 induces inflammatory activation of human tubular epithelial cells: involvement of the transcription factors, nuclear factor-kappaB and activating protein-1.
Whooping Cough
MCP-1 is selectively expressed in the late phase by cytokine-stimulated human neutrophils: TNF-alpha plays a role in maximal MCP-1 mRNA expression.
Whooping Cough
MCP-1 receptor binding affinity is up-regulated by pre-stimulation with MCP-1 in an actin polymerization-dependent manner.
Whooping Cough
MCP-1-dependent signaling in CCR2(-/-) aortic smooth muscle cells.
Whooping Cough
MCP-1-mediated chemotaxis requires activation of non-overlapping signal transduction pathways.
Whooping Cough
Measurement of agonist efficacy using an alpha2A-adrenoceptor-Gi1alpha fusion protein.
Whooping Cough
Measurement of free cytosolic calcium in single cells: method and application.
Whooping Cough
Measures to control an outbreak of pertussis in a neonatal intermediate care nursery after exposure to a healthcare worker.
Whooping Cough
Measuring immunoglobulin g antibodies to tetanus toxin, diphtheria toxin, and pertussis toxin with single-antigen enzyme-linked immunosorbent assays and a bead-based multiplex assay.
Whooping Cough
Mechanical hypernociception in experimental autoimmune encephalomyelitis.
Whooping Cough
Mechanical regulation of native and the recombinant calcium channel.
Whooping Cough
Mechanical stimulation induces Ca2+i transients and membrane depolarization in cultured endothelial cells. Effects on Ca2+i in co-perfused smooth muscle cells.
Whooping Cough
Mechanical stimulation of skeletal muscle increases prostaglandin F2 alpha production, cyclooxygenase activity, and cell growth by a pertussis toxin sensitive mechanism.
Whooping Cough
Mechanical stimulation regulates voltage-gated potassium currents in cardiac microvascular endothelial cells.
Whooping Cough
Mechanical strain and fluid movement both activate extracellular regulated kinase (ERK) in osteoblast-like cells but via different signaling pathways.
Whooping Cough
Mechanical stress and human aortic smooth muscle cell proliferation.
Whooping Cough
Mechanism and regulation of neutrophil priming by platelet-activating factor.
Whooping Cough
Mechanism by which pertussis toxin breaks unresponsiveness of delayed-type hypersensitivity to sheep red blood cells in mice.
Whooping Cough
Mechanism for increase of gastrin release by secretin in Zollinger-Ellison syndrome.
Whooping Cough
Mechanism for the antitumor and anticachectic effects of n-3 fatty acids.
Whooping Cough
Mechanism for the gastrokinetic action of domperidone. In vitro studies in guinea pigs.
Whooping Cough
Mechanism involved in the mobilization of neutrophil calcium by 5-hydroxyeicosatetraenoate.
Whooping Cough
Mechanism of acetylcholine-induced inhibition of Ca current in bullfrog atrial myocytes.
Whooping Cough
Mechanism of action of ATP on canine pulmonary vagal C fibre nerve terminals.
Whooping Cough
Mechanism of action of endothelin-1 in the canine pulmonary circulation.
Whooping Cough
Mechanism of action of gamma-aminobutyric acid on frog melanotrophs.
Whooping Cough
Mechanism of action of GTP in the induction of Ca2+ release from hepatic microsomes.
Whooping Cough
Mechanism of action of maternal serum on the interleukin2 receptor expression.
Whooping Cough
Mechanism of action of peptide YY to inhibit gastric motility.
Whooping Cough
Mechanism of activation of ERK and H-K-ATPase by isoproterenol in rat cortical collecting duct.
Whooping Cough
Mechanism of activation of lymphocyte Na+/H+ exchange by concanavalin A. A calcium- and protein kinase C-independent pathway.
Whooping Cough
Mechanism of adenosine receptor-induced renal vasoconstriction in rats.
Whooping Cough
Mechanism of alpha 2-adrenoceptor agonist-induced diuresis.
Whooping Cough
Mechanism of arachidonic acid liberation in platelet-activating factor-stimulated human polymorphonuclear neutrophils.
Whooping Cough
Mechanism of association of adenylate cyclase toxin with the surface of Bordetella pertussis: a role for toxin-filamentous haemagglutinin interaction.
Whooping Cough
Mechanism of bradykinin-induced Ca(2+) mobilization in MG63 human osteosarcoma cells.
Whooping Cough
Mechanism of cicaprost-induced desensitization in rat pulmonary artery smooth muscle cells involves a PKA-mediated inhibition of adenylyl cyclase.
Whooping Cough
Mechanism of cytokine inhibition of beta-adrenergic agonist stimulation of cyclic AMP in rat cardiac myocytes. Impairment of signal transduction.
Whooping Cough
Mechanism of cytokine-induced modulation of beta-adrenoceptor responsiveness in airway smooth muscle.
Whooping Cough
Mechanism of D(2) agonist-induced inhibition of GH secretion from human GH-secreting adenoma cells.
Whooping Cough
Mechanism of down-regulation of alpha-2 adrenergic receptor subtypes.
Whooping Cough
Mechanism of endothelial nitric oxide-dependent vasorelaxation induced by wine polyphenols in rat thoracic aorta.
Whooping Cough
Mechanism of enhanced sensitivity to bradykinin in pertussis toxin-treated fibroblasts: toxin increases bradykinin-stimulated prostaglandin formation.
Whooping Cough
Mechanism of epinephrine-induced dysrhythmias in rat involves local cholinergic activation.
Whooping Cough
Mechanism of ET(A)-receptor stimulation-induced increases in intracellular Ca2+ in SK-N-MC cells.
Whooping Cough
Mechanism of extracellular ATP-induced proliferation of vascular smooth muscle cells.
Whooping Cough
Mechanism of galanin-induced contraction of longitudinal smooth muscle of the rat jejunum.
Whooping Cough
Mechanism of galanin-inhibited insulin release. Occurrence of a pertussis-toxin-sensitive inhibition of adenylate cyclase.
Whooping Cough
Mechanism of histamine release induced by levofloxacin, a fluoroquinolone antibacterial agent.
Whooping Cough
Mechanism of impaired beta-adrenoceptor responsiveness in atopic sensitized airway smooth muscle.
Whooping Cough
Mechanism of induction of prostaglandin E2 production by endothelin 1 in cultured rat mesangial cells.
Whooping Cough
Mechanism of inhibition of a tumor lipid-mobilizing factor by eicosapentaenoic acid.
Whooping Cough
Mechanism of inhibition of adenylate cyclase by phospholipase C-catalyzed hydrolysis of phosphatidylcholine. Involvement of a pertussis toxin-sensitive G protein and protein kinase C.
Whooping Cough
Mechanism of inhibition of calcium channels in rat nucleus tractus solitarius by neurotransmitters.
Whooping Cough
Mechanism of inhibition of transducin GTPase activity by fluoride and aluminum.
Whooping Cough
Mechanism of inhibition of transducin guanosine triphosphatase activity by vanadate.
Whooping Cough
Mechanism of isoproterenol-induced heterologous desensitization of mucin secretion from rat submandibular glands. Regulation of phosphorylation of Gi proteins controls the cell response to the subsequent stimulation.
Whooping Cough
Mechanism of isoproterenol-induced RGS2 up-regulation in astrocytes.
Whooping Cough
Mechanism of Li inhibition of vasopressin-sensitive adenylate cyclase in cultured renal epithelial cells.
Whooping Cough
Mechanism of lipid mobilization associated with cancer cachexia: interaction between the polyunsaturated fatty acid, eicosapentaenoic acid, and inhibitory guanine nucleotide-regulatory protein.
Whooping Cough
Mechanism of macrophage injury following traumatic hemorrhagic shock: through PTX-sensitive G-protein-mediated signal transduction pathway.
Whooping Cough
Mechanism of mu-opioid receptor-mediated presynaptic inhibition in the rat hippocampus in vitro.
Whooping Cough
Mechanism of muscarinic control of the high-threshold calcium current in rabbit sino-atrial node myocytes.
Whooping Cough
Mechanism of N-formyl-methionyl-leucyl-phenylalanine- and platelet-activating factor-induced arachidonic acid release in guinea pig alveolar macrophages: involvement of a GTP-binding protein and role of protein kinase A and protein kinase C.
Whooping Cough
Mechanism of Na+/Ca2+ exchanger activation by hydrogen peroxide in guinea-pig ventricular myocytes.
Whooping Cough
Mechanism of neuropeptide Y inhibition of vasopressin action in rat cortical collecting tubule.
Whooping Cough
Mechanism of neutrophil activation by an unopsonized inflammatory particulate. Monosodium urate crystals induce pertussis toxin-insensitive hydrolysis of phosphatidylinositol 4,5-bisphosphate.
Whooping Cough
Mechanism of neutrophil activation by NAF, a novel monocyte-derived peptide agonist.
Whooping Cough
Mechanism of noradrenaline-induced heterologous desensitization of adenylate cyclase stimulation in rat heart muscle cells: increase in the level of inhibitory G-protein alpha-subunits.
Whooping Cough
Mechanism of peptide-induced mast cell degranulation. Translocation and patch-clamp studies.
Whooping Cough
Mechanism of pertussis toxin action on the adenylate cyclase system. Inhibition of the turn-on reaction of the inhibitory regulatory site.
Whooping Cough
Mechanism of pertussis toxin B oligomer-mediated protection against Bordetella pertussis respiratory infection.
Whooping Cough
Mechanism of phytoestrogen puerarin-mediated cytoprotection following oxidative injury: estrogen receptor-dependent up-regulation of PI3K/Akt and HO-1.
Whooping Cough
Mechanism of prejunctional muscarinic receptor-mediated inhibition of neurogenic vasodilation in cerebral arteries.
Whooping Cough
Mechanism of prostaglandin E2-induced arachidonic acid release in osteoblast-like cells: independence from phosphoinositide hydrolysis.
Whooping Cough
Mechanism of release of Ca2+ from intracellular stores in response to ionomycin in oocytes of the frog Xenopus laevis.
Whooping Cough
Mechanism of retinoic acid induced attenuation of PTH action in UMR 106-01 cells.
Whooping Cough
Mechanism of rhinovirus-induced changes in airway smooth muscle responsiveness.
Whooping Cough
Mechanism of sodium transport inhibition by epidermal growth factor in cortical collecting ducts.
Whooping Cough
Mechanism of stress-induced attenuation of the testicular response to gonadotropin: possible involvement of testicular opioids, a pertussis toxin-sensitive G-protein, and phosphodiesterase.
Whooping Cough
Mechanism of synaptic inhibition by noradrenaline acting at alpha 2-adrenoceptors.
Whooping Cough
Mechanism of the cardiovascular effects of GABAB receptor activation in the nucleus tractus solitarii of the rat.
Whooping Cough
Mechanism of the effects of acetylcholine on the contractile properties and Ca2+ transients in ferret ventricular muscles.
Whooping Cough
Mechanism of the mitogenic effect of fluoride on osteoblast-like cells: evidences for a G protein-dependent tyrosine phosphorylation process.
Whooping Cough
Mechanism of the prolactin rebound after dopamine withdrawal in rat pituitary cells.
Whooping Cough
Mechanism of thrombin-induced vasodilation in human coronary arterioles.
Whooping Cough
Mechanism of toxic action of fluoride in dental fluorosis: whether trimeric G proteins participate in the disturbance of intracellular transport of secretory ameloblast exposed to fluoride.
Whooping Cough
Mechanism underlying histamine-induced desensitization of amylase secretion in rat parotid glands.
Whooping Cough
Mechanism(s) of activation of secretory phospholipase A(2)s in mouse keratinocytes.
Whooping Cough
Mechanisms and modulation of pituitary adenylate cyclase-activating protein-induced calcium mobilization in human neutrophils.
Whooping Cough
Mechanisms contributing to fluid-flow-induced Ca2+ mobilization in articular chondrocytes.
Whooping Cough
Mechanisms for direct inhibition of canine gastric parietal cells by somatostatin.
Whooping Cough
Mechanisms for inhibition of the catalytic activity of adenylate cyclase by the guanine nucleotide-binding proteins serving as the substrate of islet-activating protein, pertussis toxin.
Whooping Cough
Mechanisms for lipoxin A4-induced neutrophil-dependent cytotoxicity for human endothelial cells.
Whooping Cough
Mechanisms for muscarinic inhibition of somatostatin release from canine fundic D cells.
Whooping Cough
Mechanisms for the coupling of cannabinoid receptors to intracellular calcium mobilization in rat insulinoma beta-cells.
Whooping Cough
Mechanisms for the inhibition of amiloride-sensitive Na+ absorption by extracellular nucleotides in mouse trachea.
Whooping Cough
Mechanisms for the stimulatory and inhibitory effects of carbamoylcholine on canine gastric D-cells.
Whooping Cough
Mechanisms for vagal modulation of ventricular repolarization and of coronary occlusion-induced lethal arrhythmias in cats.
Whooping Cough
Mechanisms in bradykinin stimulated arachidonate release and synthesis of prostaglandin and platelet activating factor.
Whooping Cough
Mechanisms in fluoride-induced interleukin-8 synthesis in human lung epithelial cells.
Whooping Cough
Mechanisms intrinsic to 5-HT2B receptor-induced potentiation of NMDA receptor responses in frog motoneurones.
Whooping Cough
Mechanisms involved in activation of human eosinophil exocytosis by substance P: an in vitro model of sensory neuroimmunomodulation.
Whooping Cough
Mechanisms involved in morphine-induced activation of synaptosomal Na+,K+-ATPase.
Whooping Cough
Mechanisms involved in stimulation of human immunodeficiency virus type 1 replication by aminooxypentane RANTES.
Whooping Cough
Mechanisms involved in the antinociception caused by compound MV8612 isolated from Mandevilla velutina in mice.
Whooping Cough
Mechanisms involved in the interaction of dopamine with angiotensin II on aldosterone secretion in isolated and cultured rat adrenal glomerulosa cells.
Whooping Cough
Mechanisms involved in the metabotropic glutamate receptor-enhancement of NMDA-mediated motoneurone responses in frog spinal cord.
Whooping Cough
Mechanisms leading to adenosine-stimulated proliferation of microvascular endothelial cells.
Whooping Cough
Mechanisms linking adenosine A1 receptors and extracellular signal-regulated kinase 1/2 activation in human trabecular meshwork cells.
Whooping Cough
Mechanisms mediating cholinergic antral circular smooth muscle contraction in rats.
Whooping Cough
Mechanisms of action of angiotensin II on mammalian sperm function.
Whooping Cough
Mechanisms of action of antisecretory drugs. Studies on isolated canine fundic mucosal cells.
Whooping Cough
Mechanisms of action of cyclosporin A on islet alpha- and beta-cells. Effects on cAMP- and calcium-dependent pathways.
Whooping Cough
Mechanisms of action of long-acting analogs of somatostatin.
Whooping Cough
Mechanisms of adenosine 5'-triphosphate-induced dopamine release in the rat nucleus accumbens in vivo.
Whooping Cough
Mechanisms of alpha,beta-methylene atp-induced inhibition in rat ileal smooth muscle: involvement of intracellular Ca2+ stores in purinergic inhibition.
Whooping Cough
Mechanisms of ANG II-induced mitogenic responses: role of 12-lipoxygenase and biphasic MAP kinase.
Whooping Cough
Mechanisms of biomaterial-induced superoxide release by neutrophils.
Whooping Cough
Mechanisms of Bordetella pathogenesis.
Whooping Cough
Mechanisms of bradykinin-induced glucagon release in clonal alpha-cells In-R1-G9: involvement of Ca(2+)-dependent and -independent pathways.
Whooping Cough
Mechanisms of bradykinin-induced insulin secretion in clonal beta cell line RINm5F.
Whooping Cough
Mechanisms of bradykinin-mediated Ca(2+) signalling in canine cultured corneal epithelial cells.
Whooping Cough
Mechanisms of C5a and C3a complement fragment-induced [Ca2+]i signaling in mouse microglia.
Whooping Cough
Mechanisms of calcium mobilization and phosphoinositide hydrolysis in human bronchial smooth muscle cells by endothelin 1.
Whooping Cough
Mechanisms of cell transformation in the embryonic heart.
Whooping Cough
Mechanisms of cocaine-induced sensitization.
Whooping Cough
Mechanisms of coronary microvascular dilation induced by the activation of pertussis toxin-sensitive G proteins are vessel-size dependent. Heterogeneous involvement of nitric oxide pathway and ATP-sensitive K+ channels.
Whooping Cough
Mechanisms of desensitization to parathyroid hormone in human osteoblast-like SaOS-2 cells.
Whooping Cough
Mechanisms of diethylstilbestrol-induced relaxation in rat aorta smooth muscle.
Whooping Cough
Mechanisms of glucagon-induced homologous and heterologous desensitization of adenylate cyclase in membranes and whole Sertoli cells of the rat.
Whooping Cough
Mechanisms of glutamate induced swelling in astroglial cells.
Whooping Cough
Mechanisms of human eosinophil activation by complement protein C5a and platelet-activating factor: similar functional responses are accompanied by different morphologic alterations.
Whooping Cough
Mechanisms of IL-8-induced Ca2+ signaling in human neutrophil granulocytes.
Whooping Cough
Mechanisms of impaired beta-adrenergic receptor signaling in G(alphaq)-mediated cardiac hypertrophy and ventricular dysfunction.
Whooping Cough
Mechanisms of impaired beta-adrenoceptor-induced airway relaxation by interleukin-1beta in vivo in the rat.
Whooping Cough
Mechanisms of inhibition of insulin release.
Whooping Cough
Mechanisms of interaction between human skin fibroblasts and elastin: differences between elastin fibres and derived peptides.
Whooping Cough
Mechanisms of ischemic preconditioning in rat hearts. Involvement of alpha 1B-adrenoceptors, pertussis toxin-sensitive G proteins, and protein kinase C.
Whooping Cough
Mechanisms of kringle fragment of urokinase-induced vascular smooth muscle cell migration.
Whooping Cough
Mechanisms of L-NG nitroarginine/indomethacin-resistant relaxation in bovine and porcine coronary arteries.
Whooping Cough
Mechanisms of leptin secretion from white adipocytes.
Whooping Cough
Mechanisms of lithium-vasopressin interaction in rabbit cortical collecting tubule.
Whooping Cough
Mechanisms of mastoparan-stimulated surfactant secretion from isolated pulmonary alveolar type 2 cells.
Whooping Cough
Mechanisms of mitogen-activated protein kinase activation by nicotine in small-cell lung carcinoma cells.
Whooping Cough
Mechanisms of NE-induced reduction of Ca current in single smooth muscle cells from guinea pig vas deferens.
Whooping Cough
Mechanisms of nonopsonic phagocytosis of Pseudomonas aeruginosa.
Whooping Cough
Mechanisms of norepinephrine mediated corticotropin-releasing factor-41 release from cultured fetal hypothalamic cells.
Whooping Cough
Mechanisms of opioid actions on neurons of the locus coeruleus.
Whooping Cough
Mechanisms of opioid delta (delta) and kappa ( kappa) receptors' cardioprotection in ischaemic preconditioning in a rat model of myocardial infarction.
Whooping Cough
Mechanisms of P2 receptor-evoked DNA synthesis in thyroid FRTL-5 cells.
Whooping Cough
Mechanisms of pertussis toxin inhibition of lymphocyte-HEV interactions. I. Analysis of lymphocyte homing receptor-mediated binding mechanisms.
Whooping Cough
Mechanisms of pertussis toxin-induced myelomonocytic cell adhesion: role of CD14 and urokinase receptor.
Whooping Cough
Mechanisms of pertussis toxin-induced myelomonocytic cell adhesion: role of Mac-1(CD11b/CD18) and urokinase receptor (CD87).
Whooping Cough
Mechanisms of phospholipase C activation by the vasoactive intestinal polypeptide/pituitary adenylate cyclase-activating polypeptide type 2 receptor.
Whooping Cough
Mechanisms of platelet activation: thromboxane A2 as an amplifying signal for other agonists.
Whooping Cough
Mechanisms of platelet-activating factor-induced lipid body formation: requisite roles for 5-lipoxygenase and de novo protein synthesis in the compartmentalization of neutrophil lipids.
Whooping Cough
Mechanisms of PTH-induced rise in cytosolic calcium in adult rat hepatocytes.
Whooping Cough
Mechanisms of rapid desensitization to arginine vasopressin in vascular smooth muscle cells.
Whooping Cough
Mechanisms of recovery from mechanical injury of cultured rat hepatocytes.
Whooping Cough
Mechanisms of serotonin-induced Ca2+ responses in mesangial cells.
Whooping Cough
Mechanisms of signal transduction for adenosine and ATP in pulmonary vascular bed.
Whooping Cough
Mechanisms of somatostatin action in RINm5F cells in culture: preliminary evidence for possible altered G protein function.
Whooping Cough
Mechanisms of the antilipolytic response of human adipocytes to tyramine, a trace amine present in food.
Whooping Cough
Mechanisms of the lysophosphatidic acid-induced increase in [Ca(2+)](i) in skeletal muscle cells.
Whooping Cough
Mechanisms of the palmitoylcarnitine-induced response in vascular endothelial cells.
Whooping Cough
Mechanisms of the thapsigargin-induced Ca(2+) entry in in situ endothelial cells of the porcine aortic valve and the endothelium-dependent relaxation in the porcine coronary artery.
Whooping Cough
Mechanisms of thrombin-induced MAPK activation associated with cell proliferation in human cultured tracheal smooth muscle cells.
Whooping Cough
Mechanisms of vasorelaxation induced by oleoylethanolamide in the rat small mesenteric artery.
Whooping Cough
Mechanisms regulating oxytocin receptor coupling to phospholipase C in rat and human myometrium.
Whooping Cough
Mechanisms underlying attenuated contractile response of aortic rings to noradrenaline in fructose-fed mice.
Whooping Cough
Mechanisms underlying extracellular ATP-evoked interleukin-6 release in mouse microglial cell line, MG-5.
Whooping Cough
Mechanisms underlying intracellular signal transduction of the slow IPSP in submucous neurones of the guinea-pig caecum.
Whooping Cough
Mechanisms underlying presynaptic inhibition through alpha 2-adrenoceptors in guinea-pig submucosal neurones.
Whooping Cough
Mechanisms Underlying the Inhibition of Soman on NMDA-stimulated [(3)H]Norepinephrine Release from Rat Cortical Slices, Role of Phospholipase C and Protein Kinase C.
Whooping Cough
Mechanisms underlying the riluzole inhibition of glutamate release from rat cerebral cortex nerve terminals (synaptosomes).
Whooping Cough
Mechanistic insight into pertussis toxin and lectin signaling using T cells engineered to express a CD8?/CD3? chimeric receptor.
Whooping Cough
Mechanistic insights into ?-opioid-induced cardioprotection: Involvement of caveolin translocation to the mitochondria.
Whooping Cough
Mechanistic investigation of N,N-diethyl-4-(phenyl-piperidin-4-ylidenemethyl)-benzamide-induced insulin depletion in the rat and RINm5F cells.
Whooping Cough
Mediation by G proteins of signals that cause collapse of growth cones.
Whooping Cough
Mediation by protein kinases C and A of Go-linked slow responses of enteric neurons to 5-HT.
Whooping Cough
Mediation of adenylyl cyclase sensitization by PTX-insensitive GalphaoA, Galphai1, Galphai2 or Galphai3.
Whooping Cough
Mediation of growth factor induced DNA synthesis and calcium mobilization by Gq and Gi2.
Whooping Cough
Mediation of serotonin hyperalgesia by the cAMP second messenger system.
Whooping Cough
Meibomian gland dysfunction is suppressed via selective inhibition of immune responses by topical LFA-1/ICAM antagonism with lifitegrast in the allergic eye disease (AED) model.
Whooping Cough
Meiotic resumption in response to luteinizing hormone is independent of a Gi family G protein or calcium in the mouse oocyte.
Whooping Cough
Melanin concentrating hormone depresses synaptic activity of glutamate and GABA neurons from rat lateral hypothalamus.
Whooping Cough
Melanin-concentrating hormone depresses L-, N-, and P/Q-type voltage-dependent calcium channels in rat lateral hypothalamic neurons.
Whooping Cough
Melanin-concentrating hormone reduces somatolactin release from cultured goldfish pituitary cells.
Whooping Cough
Melanocortin receptor-mediated mobilization of intracellular free calcium in HEK293 cells.
Whooping Cough
Melanocortin type 4 receptor-mediated inhibition of A-type K+ current enhances sensory neuronal excitability and mechanical pain sensitivity in rats.
Whooping Cough
Melanocortin-3 receptor activates MAP kinase via PI3 kinase.
Whooping Cough
Melanoma growth stimulatory activity enhances the phosphorylation of the class II interleukin-8 receptor in non-hematopoietic cells.
Whooping Cough
Melanostatin (NPY) inhibited electrical activity in frog melanotrophs through modulation of K+, Na+ and Ca2+ currents.
Whooping Cough
Melatonin action and signal transduction in the rat suprachiasmatic circadian clock: activation of protein kinase C at dusk and dawn.
Whooping Cough
Melatonin agonists induce phosphoinositide hydrolysis in Xenopus laevis melanophores.
Whooping Cough
Melatonin decreases cell proliferation and induces melanogenesis in human melanoma SK-MEL-1 cells.
Whooping Cough
Melatonin directly constricts rat cerebral arteries through modulation of potassium channels.
Whooping Cough
Melatonin enhances alkaline phosphatase activity in differentiating human adult mesenchymal stem cells grown in osteogenic medium via MT2 melatonin receptors and the MEK/ERK (1/2) signaling cascade.
Whooping Cough
Melatonin enhances leptin expression by rat adipocytes in the presence of insulin.
Whooping Cough
Melatonin generates an outward potassium current in rat suprachiasmatic nucleus neurones in vitro independent of their circadian rhythm.
Whooping Cough
Melatonin increases proliferation of cultured neural stem cells obtained from adult mouse subventricular zone.
Whooping Cough
Melatonin inhibition of cancer growth in vivo involves suppression of tumor fatty acid metabolism via melatonin receptor-mediated signal transduction events.
Whooping Cough
Melatonin inhibition of nicotine-stimulated dopamine release in PC12 cells.
Whooping Cough
Melatonin inhibits fatty acid transport in inguinal fat pads of hepatoma 7288CTC-bearing and normal Buffalo rats via receptor-mediated signal transduction.
Whooping Cough
Melatonin inhibits gonadotropin-releasing hormone-induced elevation of intracellular Ca2+ in neonatal rat pituitary cells.
Whooping Cough
Melatonin inhibits insulin secretion in rat insulinoma ?-cells (INS-1) heterologously expressing the human melatonin receptor isoform MT2.
Whooping Cough
Melatonin modulates diacylglycerol and arachidonic acid metabolism in the anterior pituitary of immature rats.
Whooping Cough
Melatonin modulates intercellular communication among cultured chick astrocytes.
Whooping Cough
Melatonin mt1 and MT2 receptors stimulate c-Jun N-terminal kinase via pertussis toxin-sensitive and -insensitive G proteins.
Whooping Cough
Melatonin potentiates glycine currents through a PLC/PKC signalling pathway in rat retinal ganglion cells.
Whooping Cough
Melatonin prevents apoptosis and enhances HSP27 mRNA expression induced by heat shock in HL-60 cells: possible involvement of the MT2 receptor.
Whooping Cough
Melatonin promotes osteoblast differentiation and bone formation.
Whooping Cough
Melatonin receptor agonist ramelteon activates the extracellular signal-regulated kinase 1/2 in mouse cerebellar granule cells.
Whooping Cough
Melatonin Receptor MT1 Signals to Extracellular Signal-Regulated Kinase 1 and 2 via Gi and Gs Dually Coupled Pathways in HEK-293 Cells.
Whooping Cough
Melatonin receptor potentiation of cyclic AMP and the cystic fibrosis transmembrane conductance regulator ion channel.
Whooping Cough
Melatonin receptor signaling in pregnant and nonpregnant rat uterine myocytes as probed by large conductance Ca2+-activated K+ channel activity.
Whooping Cough
Melatonin receptors activate heteromeric G-protein coupled Kir3 channels.
Whooping Cough
Melatonin receptors are present in adult rat Leydig cells and are coupled through a pertussis toxin-sensitive G-protein.
Whooping Cough
Melatonin receptors in benign prostate epithelial cells: evidence for the involvement of cholera and pertussis toxins-sensitive G proteins in their signal transduction pathways.
Whooping Cough
Melatonin receptors in PC3 human prostate tumor cells.
Whooping Cough
Melatonin receptors in the chicken kidney are up-regulated by pinealectomy and linked to adenylate cyclase.
Whooping Cough
Melatonin receptors in the spinal cord.
Whooping Cough
Melatonin signal transduction and mechanism of action in the central nervous system: using the rabbit cortex as a model.
Whooping Cough
Melatonin signal transduction in hamster brain: inhibition of adenylyl cyclase by a pertussis toxin-sensitive G protein.
Whooping Cough
Melatonin Suppresses the Kainate Receptor-Mediated Excitation on Gonadotropin-Releasing Hormone Neurons in Female and Male Prepubertal Mice.
Whooping Cough
Melatonin-induced organelle movement in melanophores is coupled to tyrosine phosphorylation of a high molecular weight protein.
Whooping Cough
Melatonin-induced suppression of PC12 cell growth is mediated by its Gi coupled transmembrane receptors.
Whooping Cough
Melatonin-mediated Bim up-regulation and cyclooxygenase-2 (COX-2) down-regulation enhances tunicamycin-induced apoptosis in MDA-MB-231 cells.
Whooping Cough
Melatonin-mediated inhibition of Purkinje neuron P-type Ca(2+) channels in vitro induces neuronal hyperexcitability through the phosphatidylinositol 3-kinase-dependent protein kinase C delta pathway.
Whooping Cough
Membrane anchored synthetic peptides as a tool for structure-function analysis of pertussis toxin and its target proteins.
Whooping Cough
Membrane androgen receptor characteristics of human ZIP9 (SLC39A) zinc transporter in prostate cancer cells: Androgen-specific activation and involvement of an inhibitory G protein in zinc and MAP kinase signaling.
Whooping Cough
Membrane electrical activity elicits inositol 1,4,5-trisphosphate-dependent slow Ca2+ signals through a Gbetagamma/phosphatidylinositol 3-kinase gamma pathway in skeletal myotubes.
Whooping Cough
Membrane gangliosides modulate interleukin-2-stimulated T-lymphocyte proliferation.
Whooping Cough
Membrane localization of the S1 subunit of pertussis toxin in Bordetella pertussis and implications for pertussis toxin secretion.
Whooping Cough
Membrane signaling and progesterone in female and male osteoblasts. II. Direct involvement of G alpha q/11 coupled to PLC-beta 1 and PLC-beta 3.
Whooping Cough
Membrane type 1-matrix metalloproteinase (MT1-MMP) cooperates with sphingosine 1-phosphate to induce endothelial cell migration and morphogenic differentiation.
Whooping Cough
Membrane-associated 41-kDa GTP-binding protein in collagen-induced platelet activation.
Whooping Cough
Membrane-bound form of ADP-ribosyl cyclase in rat cortical astrocytes in culture.
Whooping Cough
Membrane-delimited G protein-mediated coupling between V1a vasopressin receptor and dihydropyridine binding sites in rat glomerulosa cells.
Whooping Cough
Membrane-impermeable estrogen is involved in regulation of calbindin-D9k expression via non-genomic pathways in a rat pituitary cell line, GH3 cells.
Whooping Cough
MENTHOL INHIBITS 5-HT3 RECEPTOR-MEDIATED CURRENTS.
Whooping Cough
Mepyramine but not cimetidine or clobenpropit blocks pertussis toxin-induced histamine sensitization in rats.
Whooping Cough
Messengers mediating long-term desensitization in cerebellar Purkinje cells.
Whooping Cough
Metabolic activation of A549 human airway epithelial cells by organic dust: a study based on microphysiometry.
Whooping Cough
Metabolic stimulation of mouse spleen lymphocytes by low doses of delta9-tetrahydrocannabinol.
Whooping Cough
Metabolic, humoral, and cellular responses in adult volunteers immunized with the genetically inactivated pertussis toxin mutant PT-9K/129G.
Whooping Cough
Metabolism and biologic effects of 5-oxoeicosanoids on human neutrophils.
Whooping Cough
Metabolite-Induced Protein Expression Guided by Metabolomics and Systems Biology.
Whooping Cough
Metabotropic ?-aminobutyric acid (GABA(B) ) receptors modulate feeding behavior in the calcisponge Leucandra aspera.
Whooping Cough
Metabotropic ?-aminobutyric acid (GABA(B)) receptors modulate feeding behavior in the calcisponge Leucandra aspera.
Whooping Cough
Metabotropic glutamate receptor 6 signaling enhances TRPM1 calcium channel function and increases melanin content in human melanocytes.
Whooping Cough
Metabotropic glutamate receptor activation enhances the activities of two types of Ca2+-activated k+ channels in rat hippocampal astrocytes.
Whooping Cough
Metabotropic glutamate receptor activation modulates kainate and serotonin calcium response in astrocytes.
Whooping Cough
Metabotropic glutamate receptor agonist-induced hyperpolarizations in rat basolateral amygdala neurons: receptor characterization and ion channels.
Whooping Cough
Metabotropic glutamate receptor agonists potentiate cyclic AMP formation induced by forskolin or beta-adrenergic receptor activation in cerebral cortical astrocytes in culture.
Whooping Cough
Metabotropic glutamate receptor analogues inhibit p[NH]ppG-stimulated phospholipase C activity in bovine brain coated vesicles: involvement of a pertussis toxin-sensitive G-protein.
Whooping Cough
Metabotropic glutamate receptor in C6BU-1 glioma cell has NMDA receptor-ion channel complex-like properties and interacts with serotonin2 receptor-stimulated signal transduction.
Whooping Cough
Metabotropic glutamate receptor modulation of glutamate responses in the suprachiasmatic nucleus.
Whooping Cough
Metabotropic glutamate receptor modulation of synaptic transmission in corticostriatal co-cultures: role of calcium influx.
Whooping Cough
Metabotropic glutamate receptor modulation of voltage-gated Ca2+ channels involves multiple receptor subtypes in cortical neurons.
Whooping Cough
Metabotropic glutamate receptor subtype 1A activates adenylate cyclase when expressed in baby hamster kidney cells.
Whooping Cough
Metabotropic glutamate receptor type 4 is involved in autoinhibitory cascade for glucagon secretion by alpha-cells of islet of Langerhans.
Whooping Cough
Metabotropic glutamate receptors activate G-protein-coupled inwardly rectifying potassium channels in Xenopus oocytes.
Whooping Cough
Metabotropic glutamate receptors modulate [(3)H]acetylcholine release from cultured amacrine-like neurons.
Whooping Cough
Metabotropic glutamate receptors negatively regulate melatonin synthesis in rat pinealocytes.
Whooping Cough
Metabotropic glutamate response in acutely dissociated hippocampal CA1 pyramidal neurones of the rat.
Whooping Cough
Metabotropic neurosteroid/sigma-receptor involved in stimulation of nociceptor endings of mice.
Whooping Cough
Metabotropic P2Y1 receptors inhibit P2X3 receptor-channels in rat dorsal root ganglion neurons.
Whooping Cough
Metabotropic signal transduction for bradykinin in submucosal neurons of guinea pig small intestine.
Whooping Cough
Metalloproteinases control brain inflammation induced by pertussis toxin in mice overexpressing the chemokine CCL2 in the central nervous system.
Whooping Cough
Metallothionein mediates leukocyte chemotaxis.
Whooping Cough
Metronidazole Attenuates the Intensity of Inflammation in Experimental Autoimmune Uveitis.
Whooping Cough
Mg(++)-induced endothelial cell migration: substratum selectivity and receptor-involvement.
Whooping Cough
mGluR7 inhibits glutamate release through a PKC-independent decrease in the activity of P/Q-type Ca2+ channels and by diminishing cAMP in hippocampal nerve terminals.
Whooping Cough
mGluR7-like metabotropic glutamate receptors inhibit NMDA-mediated excitotoxicity in cultured mouse cerebellar granule neurons.
Whooping Cough
MHC-restricted recognition of immunogenic T cell epitopes of pertussis toxin reveals determinants in man distinct from the ADP-ribosylase active site.
Whooping Cough
Mice lacking the IFN-gamma receptor or fyn develop severe experimental autoimmune uveoretinitis characterized by different immune responses.
Whooping Cough
Microbial products trigger autoimmune ocular inflammation.
Whooping Cough
Microbiological and serological diagnosis of pertussis.
Whooping Cough
Microbiota metabolite butyrate constrains neutrophil functions and ameliorates mucosal inflammation in inflammatory bowel disease.
Whooping Cough
Microfilament assembly is required for antigen-receptor-mediated activation of human B lymphocytes.
Whooping Cough
Microinjection of the alpha-subunit of the G protein Go2, but not Go1, reduces a voltage-sensitive calcium current.
Whooping Cough
Microsomal and cytosolic fractions of guinea pig hepatocytes contain 100-kilodalton GTP-binding proteins reactive with antisera against alpha subunits of stimulatory and inhibitory heterotrimeric GTP-binding proteins.
Whooping Cough
Microsomal prostaglandin E synthase-1 contributes to ischaemic excitotoxicity through prostaglandin E2 EP3 receptors.
Whooping Cough
Microtubule-dependent regulation of alpha(2B) adrenergic receptors in polarized MDCKII cells requires the third intracellular loop but not G protein coupling.
Whooping Cough
Microtubule-disruption-induced and chemotactic-peptide-induced migration of human neutrophils: implications for differential sets of signalling pathways.
Whooping Cough
Midkine induces histamine release from mast cells and the immediate cutaneous response.
Whooping Cough
Midkine, a retinoic acid-inducible heparin-binding cytokine, is a novel regulator of intracellular calcium in human neutrophils.
Whooping Cough
Migration of antigen-specific T cells away from CXCR4-binding human immunodeficiency virus type 1 gp120.
Whooping Cough
Migration of intestinal intraepithelial lymphocytes into a polarized epithelial monolayer.
Whooping Cough
Mimicking of discontinuous epitopes by phage-displayed peptides, II. Selection of clones recognized by a protective monoclonal antibody against the Bordetella pertussis toxin from phage peptide libraries.
Whooping Cough
Mimicry of a G protein mutation by pertussis toxin expression in transgenic Caenorhabditis elegans.
Whooping Cough
Mini-dystrophin Expression Down-regulates Overactivation of G Protein-mediated IP3 Signaling Pathway in Dystrophin-deficient Muscle Cells.
Whooping Cough
Miniglucagon (glucagon 19-29), a potent and efficient inhibitor of secretagogue-induced insulin release through a Ca2+ pathway.
Whooping Cough
Minimally modified low density lipoprotein-induced inflammatory responses in endothelial cells are mediated by cyclic adenosine monophosphate.
Whooping Cough
Mitigation of beta 1- and/or beta 2-adrenoceptor function in human heart failure.
Whooping Cough
Mitocryptide-2, a neutrophil-activating cryptide, is a specific endogenous agonist for formyl-peptide receptor-like 1.
Whooping Cough
Mitocryptide-2: purification, identification, and characterization of a novel cryptide that activates neutrophils.
Whooping Cough
Mitogen-activated protein kinase activation requires two signal inputs from the human anaphylatoxin C5a receptor.
Whooping Cough
Mitogen-activated protein kinase cascade is involved in endothelin-1-induced rat puerperal uterine contraction.
Whooping Cough
Mitogen-activated protein kinase p38 regulates the Wnt/cyclic GMP/Ca2+ non-canonical pathway.
Whooping Cough
Mitogen-induced activation of Na+/H+ exchange in vascular smooth muscle cells involves janus kinase 2 and Ca2+/calmodulin.
Whooping Cough
Mitogen-induced tyrosine phosphorylation of 41 kDa and 43 kDa proteins. Potential role in integrating multiple mitogenic signalling pathways.
Whooping Cough
Mitogenic action of lysophosphatidic acid in proximal tubular epithelial cells obtained from voided human urine.
Whooping Cough
Mitogenic activity of endothelin on human cultured prostatic smooth muscle cells.
Whooping Cough
Mitogenic effect of oxidized low-density lipoprotein on vascular smooth muscle cells mediated by activation of Ras/Raf/MEK/MAPK pathway.
Whooping Cough
Mitogenic effect of serotonin on vascular endothelial cells.
Whooping Cough
Mitogenic effects of fibroblast growth factors in cultured fibroblasts. Interaction with the G-protein-mediated signaling pathways.
Whooping Cough
Mitogenic effects of pertussis toxin-sensitive G-protein alpha subunits: the mitogenic action of alpha i2 in NIH 3T3 cells is mimicked by alpha i1, but not alpha i3.
Whooping Cough
Mitogenic functions of endocrine gland-derived vascular endothelial growth factor and Bombina variegata 8 on steroidogenic adrenocortical cells.
Whooping Cough
Mitogenic signaling mechanisms of human cementum-derived growth factors.
Whooping Cough
Mitogenic signaling pathways of growth factors can be distinguished by the involvement of pertussis toxin-sensitive guanosine triphosphate-binding protein and of protein kinase C.
Whooping Cough
Mitogenic signalling by delta opioid receptors expressed in rat-1 fibroblasts involves activation of the p70s6k/p85s6k S6 kinase.
Whooping Cough
Mitoxantrone induces nonimmunological histamine release from rat mast cells.
Whooping Cough
Mivazerol prevents the tachycardia caused by emergence from halothane anesthesia partly through activation of spinal alpha 2-adrenoceptors.
Whooping Cough
Mixture model analysis for establishing a diagnostic cut-off point for pertussis antibody levels.
Whooping Cough
MLCK and PKC Involvements via Gi and Rho A Protein in Contraction by the Electrical Field Stimulation in Feline Esophageal Smooth Muscle.
Whooping Cough
Mobilisation of intracellular calcium by P2Y2 receptors in cultured, non-transformed bovine ciliary epithelial cells.
Whooping Cough
Mobilization of intracellular Ca2+ and stimulation of cyclic AMP production by kappa opioid receptors expressed in Xenopus oocytes.
Whooping Cough
Mobilization of intracellular Ca2+ and suppression of inward currents in a neuronal hybrid cell line triggered by bradykinin.
Whooping Cough
Mobilization of intracellular calcium in cultured vascular smooth muscle cells by uridine triphosphate and the calcium ionophore A23187.
Whooping Cough
Mode of inhibition of renin release by angiotensin II.
Whooping Cough
Modeling rates of infection with transient maternal antibodies and waning active immunity: application to Bordetella pertussis in Sweden.
Whooping Cough
Moderate hypothermia attenuates ?(1)-adrenoceptor-mediated contraction in isolated rat aorta: the role of the endothelium.
Whooping Cough
Modification by pertussis toxin of the responses of bovine anterior pituitary cells to acetylcholine and dopamine: effects on hormone secretion and 86Rb efflux.
Whooping Cough
Modification of biological responses to interleukin-1 by agents that perturb signal transduction pathways.
Whooping Cough
Modification of cholinergic-mediated cellular transmembrane signals by the interaction of human chagasic IgG with cardiac muscarinic receptors.
Whooping Cough
Modification of chromaffin cells with pertussis toxin or N-ethylmaleimide lowers cytoskeletal F-actin and enhances Ca(2+)-dependent secretion.
Whooping Cough
Modification of cysteine residues within G(o) and other neuronal proteins by exposure to nitric oxide.
Whooping Cough
Modification of morphine-induced analgesia and toxicity by pertussis toxin.
Whooping Cough
Modification of morphine-induced locomotor activity by pertussis toxin: biochemical and behavioral studies in mice.
Whooping Cough
Modification of opioid agonist binding by pertussis toxin.
Whooping Cough
Modification of plasma membrane protein cysteine residues by ADP-ribose in vivo.
Whooping Cough
Modification of serotonin responses in rat dorsolateral septal nucleus neurons by acute and chronic cocaine.
Whooping Cough
Modification of the amounts of G proteins and of the activity of adenylyl cyclase in human benign thyroid tumours.
Whooping Cough
Modification of the function of pertussis toxin substrate GTP-binding protein by cholera toxin-catalyzed ADP-ribosylation.
Whooping Cough
Modifications of the catalytic and binding subunits of pertussis toxin by formaldehyde: effects on toxicity and immunogenicity.
Whooping Cough
Modified binding assay for improved sensitivity and specificity in the detection of residual pertussis toxin in vaccine preparations.
Whooping Cough
Modulation by 1,25(OH)2-vitamin D3 of the adenylyl cyclase/cyclic AMP pathway in rat and chick myoblasts.
Whooping Cough
Modulation by angiotensin II of isoproterenol-induced cAMP production in preglomerular microvascular smooth muscle cells from normotensive and genetically hypertensive rats.
Whooping Cough
Modulation by mu-opioid agonists of guanosine-5'-O-(3-[35S]thio)triphosphate binding to membranes from human neuroblastoma SH-SY5Y cells.
Whooping Cough
Modulation by neurotransmitters of catecholamine secretion from sympathetic ganglion neurons detected by amperometry.
Whooping Cough
Modulation by pertussis toxin of salbutamol- and arecoline-induced effects in the isolated heart and aorta of the rat.
Whooping Cough
Modulation by protein kinase C of the enhanced responsiveness to tachykinins in ovalbumin-sensitized guinea pig alveolar macrophages.
Whooping Cough
Modulation by sigma ligands of N-methyl-D-aspartate-induced [3H]noradrenaline release in the rat hippocampus: G-protein dependency.
Whooping Cough
Modulation by somatostatin of glutamate sensitivity during development of mouse hypothalamic neurons in vitro.
Whooping Cough
Modulation of 5-HT1A receptor signalling by point-mutation of cysteine351 in the rat Galpha(o) protein.
Whooping Cough
Modulation of ?-opioid receptor signaling by RGS19 in SH-SY5Y cells.
Whooping Cough
Modulation of a delayed-rectifier K+ current by angiotensin II in rat sympathetic neurons.
Whooping Cough
Modulation of adenylate cyclase activity of mouse spinal cord-ganglion explants by opioids, serotonin and pertussis toxin.
Whooping Cough
Modulation of adenylate cyclase in human keratinocytes by protein kinase C.
Whooping Cough
Modulation of adenylyl cyclase by FPP and adenosine involves stimulatory and inhibitory adenosine receptors and g proteins.
Whooping Cough
Modulation of agonist binding to recombinant human alpha2-adrenoceptors by sodium ions.
Whooping Cough
Modulation of ATP-sensitive K+ channels in rabbit ventricular myocytes by adenosine A1 receptor activation.
Whooping Cough
Modulation of basal L-type Ca2+ current by adenosine in ferret isolated right ventricular myocytes.
Whooping Cough
Modulation of big K+ channel activity by ryanodine receptors and L-type Ca2+ channels in neurons.
Whooping Cough
Modulation of bombesin-induced phosphatidylinositol hydrolysis in a small-cell lung-cancer cell line.
Whooping Cough
Modulation of Bordetella pertussis infection with monoclonal antibodies to pertussis toxin.
Whooping Cough
Modulation of bradykinin-induced inositol trisphosphate release in a novel neuroblastoma x dorsal root ganglion sensory neuron cell line (F-11).
Whooping Cough
Modulation of brain Na+ channels by a G-protein-coupled pathway.
Whooping Cough
Modulation of C3a activity: internalization of the human C3a receptor and its inhibition by C5a.
Whooping Cough
Modulation of Ca(2+)-channel currents by protein kinase C in adult rat sympathetic neurons.
Whooping Cough
Modulation of Ca2+ channel currents of acutely dissociated rat periaqueductal grey neurons.
Whooping Cough
Modulation of Ca2+ channels by heterologously expressed wild-type and mutant human micro-opioid receptors (hMORs) containing the A118G single-nucleotide polymorphism.
Whooping Cough
Modulation of Ca2+ channels by intracellular Mg2+ ions and GTP in frog ventricular myocytes.
Whooping Cough
Modulation of Ca2+ channels by opioid receptor-like 1 receptors natively expressed in rat stellate ganglion neurons innervating cardiac muscle.
Whooping Cough
Modulation of Ca2+ channels by PTX-sensitive G-proteins is blocked by N-ethylmaleimide in rat sympathetic neurons.
Whooping Cough
Modulation of Ca2+ currents by various G protein-coupled receptors in sympathetic neurons of male rat pelvic ganglia.
Whooping Cough
Modulation of calcium channels by metabotropic glutamate receptors in cerebellar granule cells.
Whooping Cough
Modulation of calcium currents by a metabotropic glutamate receptor involves fast and slow kinetic components in cultured hippocampal neurons.
Whooping Cough
Modulation of calcium signalling and proliferation in monoblastoid U-937 cells.
Whooping Cough
Modulation of cannabinoid-induced antinociception after intracerebroventricular versus intrathecal administration to mice: possible mechanisms for interaction with morphine.
Whooping Cough
Modulation of cardiac cell Ca2+ currents by PAF.
Whooping Cough
Modulation of cardiac cyclic AMP metabolism by adenosine receptor agonists and antagonists.
Whooping Cough
Modulation of cardiac L-type Ca2+ channels by GTP gamma S in response to isoprenaline, forskolin and photoreleased nucleotides.
Whooping Cough
Modulation of cardiac sodium channels by cAMP receptors on the myocyte surface.
Whooping Cough
Modulation of carrier-induced epitopic suppression by Bordetella pertussis components and muramyl peptide.
Whooping Cough
Modulation of CD4 Th cell differentiation by ganglioside GD1a in vitro.
Whooping Cough
Modulation of Central Control of Hypotensive Effects by Neuropeptide Y is Mediated through RSK Induced Activation of Endothelial Nitric Oxide Synthase.
Whooping Cough
Modulation of cyclic AMP accumulation in glial cells by exogenous phospholipase C.
Whooping Cough
Modulation of dihydropyridine-sensitive calcium channels: a role for G proteins.
Whooping Cough
Modulation of ethanol-induced motor incoordination by mouse striatal A(1) adenosinergic receptor.
Whooping Cough
Modulation of excitatory synaptic transmission by low concentrations of glutamate in cultured rat hippocampal neurons.
Whooping Cough
Modulation of gastric emptying and gastrointestinal transit in rats through intestinal cannabinoid CB(1) receptors.
Whooping Cough
Modulation of GH4 cell cycle via A1 adenosine receptors.
Whooping Cough
Modulation of growth cone calcium current is mediated by a PTX-sensitive G protein.
Whooping Cough
Modulation of high-voltage activated Ca2+ channels in the rat periaqueductal gray neurons by mu-type opioid agonist.
Whooping Cough
Modulation of hippocampal excitability via the hydroxycarboxylic acid receptor 1.
Whooping Cough
Modulation of hypothalamic norepinephrine release by atrial natriuretic peptide: involvement of cyclic GMP.
Whooping Cough
Modulation of IL-1-induced collagenase production in articular chondrocytes by pertussis toxin.
Whooping Cough
Modulation of interleukin 1 production by endotoxin, pertussis toxin, and indomethacin.
Whooping Cough
Modulation of intracellular calcium transients and dopamine release by neuropeptide Y in PC-12 cells.
Whooping Cough
Modulation of ion channels and synaptic transmission by a human sensory neuron-specific G-protein-coupled receptor, SNSR4/mrgX1, heterologously expressed in cultured rat neurons.
Whooping Cough
Modulation of islet G-proteins, alpha-glucosidehydrolase inhibition and insulin release stimulated by various secretagogues.
Whooping Cough
Modulation of keratin intermediate filament distribution in vivo by induced changes in cyclic AMP-dependent phosphorylation.
Whooping Cough
Modulation of L-type Ca current by denopamine, a nonparenteral partial beta 1 stimulant, in rabbit ventricular cells.
Whooping Cough
Modulation of L-type Ca2+ current by extracellular ATP in ferret isolated right ventricular myocytes.
Whooping Cough
Modulation of leukotriene B4 and platelet-activating factor binding to neutrophils.
Whooping Cough
Modulation of leukotriene generation by pertussis toxin.
Whooping Cough
Modulation of ligand responses by coupling of alpha(2A)-adrenoceptors to diverse G(alpha)-proteins.
Whooping Cough
Modulation of meiotic arrest in mouse oocytes by guanyl nucleotides and modifiers of G-proteins.
Whooping Cough
Modulation of melatonin receptors and G-protein function by microtubules.
Whooping Cough
Modulation of muscarinic receptor-mediated adenylate cyclase and phospholipase C responses in rat retina.
Whooping Cough
Modulation of myocardial contractility by lysophosphatidic acid (LPA).
Whooping Cough
Modulation of N-type Ca2+ currents by A1-adenosine receptor activation in male rat pelvic ganglion neurons.
Whooping Cough
Modulation of N-type calcium currents by presynaptic imidazoline receptor activation in rat superior cervical ganglion neurons.
Whooping Cough
Modulation of N-type Ca²? currents by moxonidine via imidazoline I? receptor activation in rat superior cervical ganglion neurons.
Whooping Cough
Modulation of neuronal T-type calcium channel currents by photoactivation of intracellular guanosine 5'-O(3-thio) triphosphate.
Whooping Cough
Modulation of neuropeptide Y expression in rat brain neuronal cultures.
Whooping Cough
Modulation of neurotransmitter release via histamine H3 heteroreceptors.
Whooping Cough
Modulation of neutrophil apoptosis by beta-amyloid proteins.
Whooping Cough
Modulation of neutrophil migration by captopril.
Whooping Cough
Modulation of NO and endothelin by chronic increases in blood flow in canine femoral arteries.
Whooping Cough
Modulation of norepinephrine release by galanin in rat medulla oblongata.
Whooping Cough
Modulation of octopamine-mediated production of cyclic AMP by phorbol-ester-sensitive protein kinase C in an insect cell line.
Whooping Cough
Modulation of Pertussis and Adenylate Cyclase Toxins by Sigma Factor RpoE in Bordetella pertussis.
Whooping Cough
Modulation of phospholipase C pathway and level of Gq alpha/G11 alpha in rat myometrium during gestation.
Whooping Cough
Modulation of pro-inflammatory gene expression by nuclear lysophosphatidic acid receptor type-1.
Whooping Cough
Modulation of prolactin-stimulated Nb2 lymphoma cell mitogenesis by cholera toxin and pertussis toxin.
Whooping Cough
Modulation of prostaglandin E2 synthesis in rat skeletal muscle.
Whooping Cough
Modulation of protein kinase C and cAMP-dependent protein kinase by delta-opioid.
Whooping Cough
Modulation of protein kinase C by adenosine: involvement of adenosine A1 receptor-pertussis toxin sensitive nucleotide binding protein system.
Whooping Cough
Modulation of protein phosphatase 2a by adenosine A1 receptors in cardiomyocytes: role for p38 MAPK.
Whooping Cough
Modulation of respiratory rhythm in vitro: role of Gi/o protein-mediated mechanisms.
Whooping Cough
Modulation of responsiveness of the adenylate cyclase system in avian chondroprogenitor cells by pertussis toxin, PTH, and PGE2.
Whooping Cough
Modulation of responsiveness to cAMP stimulating agonists by phorbol ester in fetal rat osteoblasts.
Whooping Cough
Modulation of sensory neuron potassium conductances by anandamide indicates roles for metabolites.
Whooping Cough
Modulation of silent and constitutively active nociceptin/orphanin FQ receptors by potent receptor antagonists and Na+ ions in rat sympathetic neurons.
Whooping Cough
Modulation of sperm acrosomal exocytosis by guanyl nucleotides and G-protein-modifier agents.
Whooping Cough
Modulation of the accumulation of inositol phosphates and the mobilization of calcium in aortic myocytes.
Whooping Cough
Modulation of the beta-adrenergic receptor-coupled adenylate cyclase by chemical inducers of differentiation: effects on beta receptors and the inhibitory regulatory protein Gi.
Whooping Cough
Modulation of the cardiac pacemaker of Drosophila: cellular mechanisms.
Whooping Cough
Modulation of the delayed rectifier K+ current in neurons by an angiotensin II type 2 receptor fragment.
Whooping Cough
Modulation of the infant immune responses by the first pertussis vaccine administrations.
Whooping Cough
Modulation of the muscarinic K+ channel by P2-purinoceptors in guinea-pig atrial myocytes.
Whooping Cough
Modulation of the neuronal nicotinic acetylcholine receptor-channel by the nootropic drug nefiracetam.
Whooping Cough
Modulation of the pacemaker current If by beta-adrenoceptor subtypes in ventricular myocytes isolated from hypertensive and normotensive rats.
Whooping Cough
Modulation of the priming effects of platelet-activating factor on the release of interleukin-1 from lipopolysaccharide-stimulated rat spleen macrophages.
Whooping Cough
Modulation of the voltage-dependent sodium channel by agents affecting G-proteins: a study in Xenopus oocytes injected with brain RNA.
Whooping Cough
Modulation of thymidine incorporation by kappa-opioid ligands in rat spinal cord-dorsal root ganglion co-cultures.
Whooping Cough
Modulation of total Akt kinase by increased expression of a single isoform: requirement of the sphingosine-1-phosphate receptor, Edg3/S1P3, for the VEGF-dependent expression of Akt3 in primary endothelial cells.
Whooping Cough
Modulation of tryptase secretion from human colon mast cells by histamine.
Whooping Cough
Modulation of tumor necrosis factor-alpha cytotoxicity in L929 cells by bacterial toxins, hydrocortisone and inhibitors of arachidonic acid metabolism.
Whooping Cough
Modulation of vasopressin antidiuretic action by renal alpha 2-adrenoceptors.
Whooping Cough
Modulation of vertebrate neuronal calcium channels by transmitters.
Whooping Cough
Modulation of voltage-activated Ca currents by pain-inducing agents in a dorsal root ganglion neuronal line, F-11.
Whooping Cough
Modulation of voltage-dependent Ca2+ conductance by changing Cl- concentration in rat lactotrophs.
Whooping Cough
Modulation of voltage-dependent calcium currents by serotonin in acutely isolated rat amygdala neurons.
Whooping Cough
Modulation of voltage-gated calcium channels by orphanin FQ in freshly dissociated hippocampal neurons.
Whooping Cough
Modulation of [3H]acetylcholine release from cultured amacrine-like neurons by adenosine A1 receptors.
Whooping Cough
Modulation of [3H]dihydropyridine binding by activation of protein kinase C in vascular smooth muscle.
Whooping Cough
Modulation of [3H]dopamine release by neuropeptide Y in rat striatal slices.
Whooping Cough
Modulatory role of adenosine receptors in insect motor nerve terminals.
Whooping Cough
Moesin regulates neutrophil rolling velocity in vivo.
Whooping Cough
Molecular analysis of CCR-3 events in eosinophilic cells.
Whooping Cough
Molecular and cellular analyses of melatonin receptor-mediated cAMP signaling in rat corpus epididymis.
Whooping Cough
Molecular and pharmacological characterization of zebrafish 'contractile' and 'inhibitory' prostanoid receptors.
Whooping Cough
Molecular aspects of Bordetella pertussis pathogenesis.
Whooping Cough
Molecular basis for cellular effects of naturally occurring polyamines.
Whooping Cough
Molecular basis for somatostatin action: inhibition of c-fos expression and AP-1 binding.
Whooping Cough
Molecular basis for the insulinomimetic effects of C-peptide.
Whooping Cough
Molecular characterization of a G protein alpha-subunit-encoding gene from Mucor circinelloides.
Whooping Cough
Molecular characterization of an operon required for pertussis toxin secretion.
Whooping Cough
Molecular characterization of the in vitro activation of pertussis toxin by ATP.
Whooping Cough
Molecular characterization of two Bordetella bronchiseptica strains isolated from children with coughs.
Whooping Cough
Molecular cloning and analysis of P. 69, a vir-controlled protein from Bordetella pertussis.
Whooping Cough
Molecular cloning and characterization of a novel human G-protein-coupled receptor, EDG7, for lysophosphatidic acid.
Whooping Cough
Molecular cloning and characterization of protective outer membrane protein P.69 from Bordetella pertussis.
Whooping Cough
Molecular cloning and characterization of RGA1 encoding a G protein alpha subunit from rice (Oryza sativa L. IR-36).
Whooping Cough
Molecular cloning and characterization of the type VII isoform of mammalian adenylyl cyclase expressed widely in mouse tissues and in S49 mouse lymphoma cells.
Whooping Cough
Molecular cloning and expression of two melanin-concentrating hormone receptors in goldfish.
Whooping Cough
Molecular cloning and functional characterization of a rat somatostatin sst2(b) receptor splice variant.
Whooping Cough
Molecular cloning of a novel splice variant of the alpha subunit of the mammalian Go protein.
Whooping Cough
Molecular cloning of a novel T cell-directed CC chemokine expressed in thymus by signal sequence trap using Epstein-Barr virus vector.
Whooping Cough
Molecular cloning of heterotrimeric G-protein alpha-subunits in chicken pineal gland.
Whooping Cough
Molecular cloning of pertussis toxin genes.
Whooping Cough
Molecular cloning of prostaglandin EP3 receptors from canine sensory ganglia and their facilitatory action on bradykinin-induced mobilization of intracellular calcium.
Whooping Cough
Molecular cloning, expression, and signaling pathway of four melanin-concentrating hormone receptors from Xenopus tropicalis.
Whooping Cough
Molecular control of cardiac sodium homeostasis in health and disease.
Whooping Cough
Molecular dissection of two distinct actions of melatonin on the suprachiasmatic circadian clock.
Whooping Cough
Molecular effects of proinsulin C-peptide.
Whooping Cough
Molecular epidemiology of Bordetella pertussis and analysis of vaccine antigen genes from clinical isolates from Shenzhen, China.
Whooping Cough
Molecular epidemiology of Bordetella pertussis in Cambodia determined by direct genotyping of clinical specimens.
Whooping Cough
Molecular epidemiology of Bordetella pertussis in the Philippines in 2012-2014.
Whooping Cough
Molecular Epidemiology of Bordetella pertussis.
Whooping Cough
Molecular mechanism for opioid dichotomy: bidirectional effect of ?-opioid receptors on P2X3 receptor currents in rat sensory neurones.
Whooping Cough
Molecular mechanism of nucleotide-induced primary granule release in human neutrophils: role for the P2Y2 receptor.
Whooping Cough
Molecular mechanisms for alpha2-adrenoceptor-mediated regulation of synoviocyte populations.
Whooping Cough
Molecular mechanisms for somatostatin inhibition of c-fos gene expression.
Whooping Cough
Molecular mechanisms for the activation of Ca2+-permeable nonselective cation channels by endothelin-1 in C6 glioma cells.
Whooping Cough
Molecular mechanisms for the effect of mastoparan on G proteins in tissues of vertebrates and invertebrates.
Whooping Cough
Molecular mechanisms for the growth factor action of gastrin.
Whooping Cough
Molecular mechanisms involved in lymphocyte recruitment in inflamed brain microvessels: critical roles for P-selectin glycoprotein ligand-1 and heterotrimeric G(i)-linked receptors.
Whooping Cough
Molecular mechanisms of adenylyl cyclase desensitization in pregnant rat myometrium following in vivo administration of the beta-adrenergic agonist, isoproterenol.
Whooping Cough
Molecular mechanisms of cannabinoid protection from neuronal excitotoxicity.
Whooping Cough
Molecular mechanisms of corticotropin-releasing factor receptor-induced calcium signaling.
Whooping Cough
Molecular mechanisms of homologous desensitization and internalization of muscarinic receptors in primary cultures of neonatal corticostriatal neurons.
Whooping Cough
Molecular mechanisms of lymphocyte extravasation. III. The loss of lymphocyte extravasation potential induced by pertussis toxin is not mediated via the activation of protein kinase C.
Whooping Cough
Molecular mechanisms of lymphocyte homing to peripheral lymph nodes.
Whooping Cough
Molecular mechanisms that control initiation and termination of physiological depolarization-evoked transmitter release.
Whooping Cough
Molecular mechanisms underlying forskolin-mediated up-regulation of human dopamine D2L receptors.
Whooping Cough
Molecular model of the G protein alpha subunit based on the crystal structure of the HRAS protein.
Whooping Cough
Molecular pathways mediating activation by kainate of mitogen-activated protein kinase in oligodendrocyte progenitors.
Whooping Cough
Molecular regulation of phagocyte function. Evidence for involvement of a guanosine triphosphate-binding protein in opsonin-mediated phagocytosis by monocytes.
Whooping Cough
Molecular signalling mediating the protective effect of A1 adenosine and mGlu3 metabotropic glutamate receptor activation against apoptosis by oxygen/glucose deprivation in cultured astrocytes.
Whooping Cough
Molecular typing of Bordetella pertussis isolates recovered from Belgian children and their household members.
Whooping Cough
Mono(ADP-ribosylation) in rat liver mitochondria.
Whooping Cough
Monoclonal anti-CD23 antibodies induce a rise in [Ca2+]i and polyphosphoinositide hydrolysis in human activated B cells. Involvement of a Gp protein.
Whooping Cough
Monoclonal antibodies against pertussis toxin. Biochemical characterization and biological activity.
Whooping Cough
Monoclonal antibodies against the enzymatic subunit of both pertussis and cholera toxins.
Whooping Cough
Monoclonal antibodies and toxins--a perspective on function and isotype.
Whooping Cough
Monoclonal antibodies that define neutralizing epitopes of pertussis toxin: conformational dependence and epitope mapping.
Whooping Cough
Monoclonal antibodies that inhibit ADP-ribosyltransferase but not NAD-glycohydrolase activity of pertussis toxin.
Whooping Cough
Monoclonal antibodies to pertussis toxin: utilization as probes of toxin function.
Whooping Cough
Monoclonal antibody against pertussis toxin: effect on toxin activity and pertussis infections.
Whooping Cough
Monoclonal antibody against pertussis toxin: relationship between toxin neutralization and mouse protection activities.
Whooping Cough
Monoclonal antibody that neutralizes pertussis toxin activities.
Whooping Cough
Monoclonal Lym-1 antibody-targeted lysis of B lymphoma cells by neutrophils. Evidence for two mechanisms of FcgammaRII-dependent cytolysis.
Whooping Cough
Monocyte chemoattractant protein-1 and macrophage inflammatory protein-2 are involved in both excitotoxin-induced neurodegeneration and regeneration.
Whooping Cough
Monocyte chemoattractant protein-1 induces proliferation and interleukin-6 production in human smooth muscle cells by differential activation of nuclear factor-kappaB and activator protein-1.
Whooping Cough
Monocyte chemoattractant protein-1 selectively inhibits the acquisition of CD40 ligand-dependent IL-12-producing capacity of monocyte-derived dendritic cells and modulates Th1 immune response.
Whooping Cough
Monocyte chemoattractant protein-1-induced activation of p42/44 MAPK and c-Jun in murine peritoneal macrophages: a potential pathway for macrophage activation.
Whooping Cough
Monocyte chemotactic protein 1 amplifies serotonin-induced vascular smooth muscle cell proliferation.
Whooping Cough
Monocyte chemotactic protein-1 as a chemoattractant for human hepatic stellate cells.
Whooping Cough
Monocyte chemotactic proteins MCP-1, MCP-2, and MCP-3 are major attractants for human CD4+ and CD8+ T lymphocytes.
Whooping Cough
Monocyte migration: a novel effect and signaling pathways of catestatin.
Whooping Cough
Monocyte Trafficking to Hepatic Sites of Bacterial Infection Is Chemokine Independent and Directed by Focal Intercellular Adhesion Molecule-1 Expression.
Whooping Cough
Monomeric human IgE evokes a transient calcium rise in individual human neutrophils.
Whooping Cough
Morphine negatively regulates interferon-gamma promoter activity in activated murine T cells through two distinct cyclic AMP-dependent pathways.
Whooping Cough
Morphine stimulates phagocytosis of Mycobacterium tuberculosis by human microglial cells: involvement of a G protein-coupled opiate receptor.
Whooping Cough
Morphine- and CaMKII-dependent enhancement of GIRK channel signaling in hippocampal neurons.
Whooping Cough
Morphine-induced chemotaxis and brain-derived neurotrophic factor expression in microglia.
Whooping Cough
Morphine-like opiates selectively antagonize receptor-arrestin interactions.
Whooping Cough
Morphological, biochemical, and electrophysiological characterization of a clonal cell (H9c2) line from rat heart.
Whooping Cough
Morphoregulatory activities of NCAM and N-cadherin can be accounted for by G protein-dependent activation of L- and N-type neuronal Ca2+ channels.
Whooping Cough
Most B cells in non-lymphoid tissues are naïve.
Whooping Cough
Motilin and OHM-11526 activate a calcium current in human and canine jejunal circular smooth muscle.
Whooping Cough
Mouse 5HT1B serotonin receptor: cloning, functional expression, and localization in motor control centers.
Whooping Cough
Mouse and Human Eosinophils Degranulate in Response to Platelet-Activating Factor (PAF) and LysoPAF via a PAF-Receptor-Independent Mechanism: Evidence for a Novel Receptor.
Whooping Cough
Mouse astrocytes respond to the chemokines MCP-1 and KC, but reverse transcriptase-polymerase chain reaction does not detect mRNA for the KC or new MCP-1 receptor.
Whooping Cough
Mouse bone marrow-derived mast cells undergo exocytosis, prostanoid generation, and cytokine expression in response to G protein-activating polybasic compounds after coculture with fibroblasts in the presence of c-kit ligand.
Whooping Cough
Mouse cerebellar adenosinergic modulation of ethanol-induced motor incoordination: possible involvement of cAMP.
Whooping Cough
Mouse cerebellar GABAB participation in the expression of acute ethanol-induced ataxia and in its modulation by the cerebellar adenosinergic A1 system.
Whooping Cough
Mouse lymphoid tissue contains distinct subsets of langerin/CD207 dendritic cells, only one of which represents epidermal-derived Langerhans cells.
Whooping Cough
Mouse prostaglandin E receptor EP3 subtype mediates calcium signals via Gi in cDNA-transfected Chinese hamster ovary cells.
Whooping Cough
Mouse retinal ganglion cell signalling is dynamically modulated through parallel anterograde activation of cannabinoid and vanilloid pathways.
Whooping Cough
MPP(+)-induced cytotoxicity in neuroblastoma cells: Antagonism and reversal by guanosine.
Whooping Cough
Mr 40,000 and Mr 39,000 pertussis toxin substrates are increased in surgically denervated dog ventricular myocardium.
Whooping Cough
MrgprX1 Mediates Neuronal Excitability and Itch Through Tetrodotoxin-Resistant Sodium Channels.
Whooping Cough
MrgX2?mediated internalization of LL?37 and degranulation of human LAD2 mast cells.
Whooping Cough
mt(1) Receptor-mediated antiproliferative effects of melatonin on the rat uterine antimesometrial stromal cells.
Whooping Cough
mu and delta opioid agonists at low concentrations decrease voltage-dependent K+ currents in F11 neuroblastoma x DRG neuron hybrid cells via cholera toxin-sensitive receptors.
Whooping Cough
Mu and delta opioid receptor activation inhibits omega-conotoxin-sensitive calcium channels in a voltage- and time-dependent mode in the human neuroblastoma cell line SH-SY5Y.
Whooping Cough
Mu and delta opioid receptor desensitization in undifferentiated human neuroblastoma SHSY5Y cells.
Whooping Cough
mu and delta opioid receptors differentially couple to G protein subtypes in membranes of human neuroblastoma SH-SY5Y cells.
Whooping Cough
Mu and delta opioid receptors inhibit serotonin release in rat hippocampus.
Whooping Cough
Mu and delta opioids but not kappa opioid inhibit voltage-activated Ba2+ currents in neuronal F-11 cell.
Whooping Cough
Mu type opioid receptors in rat periaqueductal gray-enriched P2 membrane are coupled to G-protein-mediated inhibition of adenylyl cyclase.
Whooping Cough
Mu-opioid agonist enhancement of prostaglandin-induced hyperalgesia in the rat: a G-protein beta gamma subunit-mediated effect?
Whooping Cough
Mu-opioid agonist-induced activation of G-protein-coupled inwardly rectifying potassium current in rat periaqueductal gray neurons.
Whooping Cough
Mu-opioid receptor activation prevents apoptosis following serum withdrawal in differentiated SH-SY5Y cells and cortical neurons via phosphatidylinositol 3-kinase.
Whooping Cough
Mu-opioid receptor down-regulation and tolerance are not equally dependent upon G-protein signaling.
Whooping Cough
mu-Opioid receptor forms a functional heterodimer with cannabinoid CB1 receptor: electrophysiological and FRET assay analysis.
Whooping Cough
mu-Opioid receptor stimulation of inositol (1,4,5)trisphosphate formation via a pertussis toxin-sensitive G protein.
Whooping Cough
mu-Opioid receptor-mediated reduction of neuronal calcium current occurs via a G(o)-type GTP-binding protein.
Whooping Cough
mu-Opioid receptors and not kappa-opioid receptors are coupled to the adenylate cyclase in the cerebellum.
Whooping Cough
mu-Opioid receptors inhibit dopamine-stimulated activity of type V adenylyl cyclase but enhance dopamine-stimulated activity of type VII adenylyl cyclase.
Whooping Cough
Mu-type opioid receptors in rat periaqueductal gray-enriched P2 membrane are coupled to guanine nucleotide binding proteins.
Whooping Cough
Mucosal and systemic immune responses elicited by recombinant Lactococcus lactis expressing a fusion protein composed of pertussis toxin and filamentous hemagglutinin from Bordetella pertussis.
Whooping Cough
Mucosal and systemic immunogenicity of a recombinant, non-ADP-ribosylating pertussis toxin: effects of formaldehyde treatment.
Whooping Cough
Mucosal immunization with a genetically engineered pertussis toxin S1 fragment-cholera toxin subunit B chimeric protein.
Whooping Cough
Mucosal vaccination approach against mosquito-borne Japanese encephalitis virus.
Whooping Cough
Multilocus sequence typing of Bordetella pertussis based on surface protein genes.
Whooping Cough
Multiple actions of anandamide on neonatal rat cultured sensory neurones.
Whooping Cough
Multiple actions of epidermal growth factor and TGF-alpha on rabbit gastric parietal cell function.
Whooping Cough
Multiple affinity binding states of the sigma receptor: effect of GTP-binding protein-modifying agents.
Whooping Cough
Multiple agonist-affinity states of opioid receptors: regulation of binding by guanyl nucleotides in guinea pig cortical, NG108-15, and 7315c cell membranes.
Whooping Cough
Multiple defects occur in the guanine nucleotide regulatory protein system in liver plasma membranes of obese (fa/fa) but not lean (Fa/Fa) Zucker rats: loss of functional Gi and abnormal Gs function.
Whooping Cough
Multiple discontinuity as a remarkable feature of the development of acellular pertussis vaccines.
Whooping Cough
Multiple effector coupling of somatostatin receptor subtype SSTR1.
Whooping Cough
Multiple effects of opiates on intracellular calcium level and on calcium uptake in three neuronal cell lines.
Whooping Cough
Multiple effects of phorbol ester on secretory activity in rabbit gastric glands and parietal cells.
Whooping Cough
Multiple G proteins and phospholipase C isoforms in human myometrial cells: implication for oxytocin action.
Whooping Cough
Multiple G-protein coupling of the dog thyrotropin receptor.
Whooping Cough
Multiple G-protein involvement in parathyroid hormone regulation of acid production by osteoclasts.
Whooping Cough
Multiple G-protein-coupled pathways inhibit N-type Ca channels of neurons.
Whooping Cough
Multiple G-protein-dependent pathways mediate the antisecretory effects of somatostatin and clonidine in the HT29-19A colonic cell line.
Whooping Cough
Multiple Gi protein subtypes regulate a single effector mechanism.
Whooping Cough
Multiple Gi proteins participate in nerve growth factor-induced activation of c-Jun N-terminal kinases in PC12 cells.
Whooping Cough
Multiple GTP-binding proteins from cholinergic synaptic vesicles.
Whooping Cough
Multiple hypothalamic factors regulate pyroglutamyl peptidase II in cultures of adenohypophyseal cells: role of the cAMP pathway.
Whooping Cough
Multiple isoforms of ADP-ribosylated G-like proteins from mammalian thyroid membranes.
Whooping Cough
Multiple mechanisms of arachidonic acid release in Chinese hamster ovary cells transfected with cDNA of substance P receptor.
Whooping Cough
Multiple mechanisms of bradykinin-induced contraction in rat and guinea pig smooth muscles in vitro.
Whooping Cough
Multiple mechanisms of somatostatin inhibition of adrenocorticotropin release from mouse anterior pituitary tumor cells.
Whooping Cough
Multiple mechanisms underlie neurotoxicity by different types of Alzheimer's disease mutations of amyloid precursor protein.
Whooping Cough
Multiple muscarinic pathways mediate the suppression of voltage-gated Ca2+ channels in mouse intestinal smooth muscle cells.
Whooping Cough
Multiple neurological abnormalities in mice deficient in the G protein Go.
Whooping Cough
Multiple pathways for signal transduction in the regulation of arachidonic acid metabolism in rat peritoneal macrophages.
Whooping Cough
Multiple pathways of apolipoprotein E signaling in primary neurons.
Whooping Cough
Multiple pertussis toxin substrates as candidates for regulatory G proteins of adenylate cyclase coupled to the somatostatin receptor in primary rat astrocytes.
Whooping Cough
Multiple pertussis toxin-sensitive G-proteins can couple receptors to GIRK channels in rat sympathetic neurons when expressed heterologously, but only native G(i)-proteins do so in situ.
Whooping Cough
Multiple polyphosphoinositide pathways regulate apoptotic signalling in a dorsal root ganglion derived cell line.
Whooping Cough
Multiple receptor activation elicits synergistic IP formation in nonpigmented ciliary body epithelial cells.
Whooping Cough
Multiple recurrences in melanin-protein-induced uveitis in the rat.
Whooping Cough
Multiple regulation by external ATP of nifedipine-insensitive, high voltage-activated Ca(2+) current in guinea-pig mesenteric terminal arteriole.
Whooping Cough
Multiple roles of Gi/o protein-coupled receptors in control of action potential secretion coupling in pituitary lactotrophs.
Whooping Cough
Multiple Sclerosis Gene Therapy with Recombinant Viral Vectors: Overexpression of IL-4, Leukemia Inhibitory Factor, and IL-10 in Wharton's Jelly Stem Cells Used in EAE Mice Model.
Whooping Cough
Multiple signal transduction pathways lead to extracellular ATP-stimulated mitogenesis in mammalian cells: I. Involvement of protein kinase C-dependent and -independent pathways.
Whooping Cough
Multiple signal transduction pathways lead to extracellular ATP-stimulated mitogenesis in mammalian cells: II. A pathway involving arachidonic acid release, prostaglandin synthesis, and cyclic AMP accumulation.
Whooping Cough
Multiple signal transduction pathways mediated by 5-HT receptors.
Whooping Cough
Multiple signal transduction pathways through two prostaglandin E receptor EP3 subtype isoforms expressed in human uterus.
Whooping Cough
Multiple Signaling Pathways Contribute to the Thrombin-induced Secretory Phenotype in Vascular Smooth Muscle Cells.
Whooping Cough
Multiple signaling pathways control stimulus-secretion coupling in rat peritoneal mast cells.
Whooping Cough
Multiple signaling pathways of histamine H2 receptors. Identification of an H2 receptor-dependent Ca2+ mobilization pathway in human HL-60 promyelocytic leukemia cells.
Whooping Cough
Multiple signalling pathways in the C5a-induced expression of adhesion receptor Mac-1.
Whooping Cough
Multiple species and isoforms of Bordetella pertussis toxin substrates.
Whooping Cough
Multiple T and B cell epitopes in the S1 subunit ("A"-monomer) of the pertussis toxin molecule.
Whooping Cough
Multiple Transduction Pathways Mediate Thyrotropin Receptor Signaling in Preosteoblast-Like Cells.
Whooping Cough
Multiple trimeric G-proteins on the trans-Golgi network exert stimulatory and inhibitory effects on secretory vesicle formation.
Whooping Cough
Multiple weak interactions between BvgA~P and ptx promoter DNA strongly activate transcription of pertussis toxin genes in Bordetella pertussis.
Whooping Cough
Multiplex LightCycler PCR assay for detection and differentiation of Bordetella pertussis and Bordetella parapertussis in nasopharyngeal specimens.
Whooping Cough
Multiplex Point-of-Care Tests for the Determination of Antibodies after Acellular Pertussis Vaccination.
Whooping Cough
Multiplicative interaction between intrathecally and intracerebroventricularly administered morphine for antinociception in the mouse: effects of spinally and supraspinally injected 3-isobutyl-1-methylxanthine, cholera toxin, and pertussis toxin.
Whooping Cough
Multitarget PCR for diagnosis of pertussis and its clinical implications.
Whooping Cough
Murine astrocytes express a functional chemokine receptor.
Whooping Cough
Murine bone marrow-derived mast cells express chemoattractant receptor-homologous molecule expressed on T-helper class 2 cells (CRTh2).
Whooping Cough
Murine Cytomegalovirus Spread Depends on the Infected Myeloid Cell Type.
Whooping Cough
Murine hypothalamic destruction with vascular cell apoptosis subsequent to combined administration of human papilloma virus vaccine and pertussis toxin.
Whooping Cough
Murine model for pertussis vaccine encephalopathy: role of the major histocompatibility complex; antibody to albumin and to Bordetella pertussis and pertussis toxin.
Whooping Cough
Murine responses to immunization with pertussis toxin and bovine serum albumin: I. Mortality observed after bovine albumin challenge is due to an anaphylactic reaction.
Whooping Cough
Muscarine activates a nonselective cation current through a M3 muscarinic receptor subtype in rat dorsolateral septal nucleus neurons.
Whooping Cough
Muscarine and t-LHRH suppress M-current by activating an IAP-insensitive G-protein.
Whooping Cough
Muscarine increases a voltage-independent potassium conductance through an M4 receptor in rat dorsolateral septal nucleus neurons.
Whooping Cough
Muscarine inhibits high-threshold calcium currents with two distinct modes in rat embryonic hippocampal neurons.
Whooping Cough
Muscarine inhibits omega-conotoxin-sensitive calcium channels in a voltage- and time-dependent mode in the human neuroblastoma cell line SH-SY5Y.
Whooping Cough
Muscarine modulates Ca2+ channel currents in rat sensorimotor pyramidal cells via two distinct pathways.
Whooping Cough
Muscarine modulation by a G-protein alpha-subunit of delayed rectifier K+ current in rat ventromedial hypothalamic neurones.
Whooping Cough
Muscarine receptors regulating electrically evoked release of acetylcholine in hippocampus are linked to pertussis toxin-sensitive G proteins but not to adenylate cyclase.
Whooping Cough
Muscarinic (M1) receptor-mediated inhibition of K(+)-evoked [3H]-noradrenaline release from human neuroblastoma (SH-SY5Y) cells via inhibition of L- and N-type Ca2+ channels.
Whooping Cough
Muscarinic (m2/m4) receptors reduce N- and P-type Ca2+ currents in rat neostriatal cholinergic interneurons through a fast, membrane-delimited, G-protein pathway.
Whooping Cough
Muscarinic acetylcholine and histamine-receptor mediated calcium mobilization and cell-growth in human ovarian-cancer cells.
Whooping Cough
Muscarinic acetylcholine receptor knockout mice show distinct synaptic plasticity impairments in the visual cortex.
Whooping Cough
Muscarinic acetylcholine receptor produced in recombinant baculovirus infected Sf9 insect cells couples with endogenous G-proteins to activate ion channels.
Whooping Cough
Muscarinic acetylcholine receptor-mediated phosphoinositide turnover in cultured human retinal pigment epithelium cells.
Whooping Cough
Muscarinic acetylcholine receptor-stimulated binding of guanosine 5'-O-(3-thiotriphosphate) to guanine-nucleotide-binding proteins in cardiac membranes.
Whooping Cough
Muscarinic acetylcholine receptors in the sino-atrial node and right atrium of bovine heart.
Whooping Cough
Muscarinic acetylcholine response in pyramidal neurones of rat cerebral cortex.
Whooping Cough
Muscarinic activation of mitogen-activated protein kinase in PC12 cells.
Whooping Cough
Muscarinic and purinergic Ca2+ mobilizations in the neural retina of early embryonic chick.
Whooping Cough
Muscarinic and quisqualate receptor-induced phosphoinositide hydrolysis in primary cultures of striatal and hippocampal neurons. Evidence for differential mechanisms of activation.
Whooping Cough
Muscarinic Ca2+ responses resistant to muscarinic antagonists at perisynaptic Schwann cells of the frog neuromuscular junction.
Whooping Cough
Muscarinic cation current and suppression of Ca2+ current in guinea pig ileal smooth muscle cells.
Whooping Cough
Muscarinic cholinergic agonists stimulate arachidonic acid release from mouse striatal neurons in primary culture.
Whooping Cough
Muscarinic cholinergic induced secretin subsensitivity in rat isolated pancreatic acini. Effects on amylase release, cyclic adenosine monophosphate and inositol phosphate formation.
Whooping Cough
Muscarinic cholinergic inhibition of cyclic AMP accumulation in airway smooth muscle. Role of a pertussis toxin-sensitive protein.
Whooping Cough
Muscarinic cholinergic receptor-induced enhancement of PGE1-stimulated cAMP accumulation in neuroblastoma X glioma cells: prevention by pertussis toxin.
Whooping Cough
Muscarinic cholinergic receptor-mediated phosphoinositide metabolism in peripheral nerve.
Whooping Cough
Muscarinic cholinergic stimulation of inositol phosphate production in cultured embryonic chick atrial cells. Evidence for a role of two guanine-nucleotide-binding proteins.
Whooping Cough
Muscarinic cholinergic-receptor stimulation of specific GTP hydrolysis related to adenylate cyclase activity in canine cardiac sarcolemma.
Whooping Cough
Muscarinic control of the hyperpolarization-activated current (if) in rabbit sino-atrial node myocytes.
Whooping Cough
Muscarinic depression of synaptic transmission and blockade of norepinephrine-induced long-lasting potentiation in the dentate gyrus.
Whooping Cough
Muscarinic effects on action potential duration and its rate dependence in canine Purkinje fibers.
Whooping Cough
Muscarinic inhibition of calcium current and M current in Galpha q-deficient mice.
Whooping Cough
Muscarinic inhibition of L-type Ca2+ channels in guinea-pig tracheal smooth muscle cells.
Whooping Cough
Muscarinic inhibition of nicotinic transmission in rat sympathetic neurons and adrenal chromaffin cells.
Whooping Cough
Muscarinic inhibition of single KCa channels in smooth muscle cells by a pertussis-sensitive G protein.
Whooping Cough
Muscarinic m1 receptor-stimulated adenylate cyclase activity in Chinese hamster ovary cells is mediated by Gs alpha and is not a consequence of phosphoinositidase C activation.
Whooping Cough
Muscarinic M2 receptors inhibit Ca2+-activated K+ channels in rat bladder smooth muscle.
Whooping Cough
Muscarinic M3 receptor inactivation reveals a pertussis toxin-sensitive contractile response in the guinea pig colon: evidence for M2/M3 receptor interactions.
Whooping Cough
Muscarinic modulation of calcium current in neurones from the interatrial septum of bull-frog heart.
Whooping Cough
Muscarinic modulation of TREK currents in mouse sympathetic superior cervical ganglion neurons.
Whooping Cough
Muscarinic receptor activation modulates Ca2+ channels in rat intracardiac neurons via a PTX- and voltage-sensitive pathway.
Whooping Cough
Muscarinic receptor activation of potassium channels in rat dentate gyrus neurons.
Whooping Cough
Muscarinic receptor heterogeneity in neonatal rat ventricular myocytes in culture.
Whooping Cough
Muscarinic receptor subclassification and G-proteins: significance for lithium action in affective disorders and for the treatment of the extrapyramidal side effects of neuroleptics.
Whooping Cough
Muscarinic receptor subtypes involved in carbachol-induced contraction of mouse uterine smooth muscle.
Whooping Cough
Muscarinic receptor-dependent activation of phospholipase C in human fetal central nervous system organotypic tissue culture.
Whooping Cough
Muscarinic receptor-linked elevation of cAMP in SH-SY5Y neuroblastoma cells is mediated by Ca2+ and protein kinase C.
Whooping Cough
Muscarinic receptor-mediated dual regulation of ADP-ribosyl cyclase in NG108-15 neuronal cell membranes.
Whooping Cough
Muscarinic receptor-mediated hydrolysis of phosphatidylinositols in human neuroblastoma (SH-SY5Y) cells is sensitive to pertussis toxin.
Whooping Cough
Muscarinic receptor-mediated increase in cAMP levels in SK-N-SH human neuroblastoma cells.
Whooping Cough
Muscarinic receptors and gastrointestinal tract smooth muscle function.
Whooping Cough
Muscarinic receptors controlling the carbachol-activated nonselective cationic current in guinea pig gastric smooth muscle cells.
Whooping Cough
Muscarinic receptors in canine colonic circular smooth muscle. II. Signal transduction pathways.
Whooping Cough
Muscarinic receptors in MDCK cells are coupled to multiple messenger systems.
Whooping Cough
Muscarinic receptors mediate carbachol-induced inhibition of maximal electroshock seizures in the nucleus reticularis pontis oralis.
Whooping Cough
Muscarinic receptors mediate stimulation of collagen synthesis in human lung fibroblasts.
Whooping Cough
Muscarinic receptors mediate stimulation of human lung fibroblast proliferation.
Whooping Cough
Muscarinic receptors modulate intracellular calcium level in chick sensory neurons.
Whooping Cough
Muscarinic receptors stimulate Ca2+ influx via phospholipase A2 pathway in ileal smooth muscles.
Whooping Cough
Muscarinic receptors, phosphoinositide metabolism and intracellular calcium in neuronal cells.
Whooping Cough
Muscarinic regulation of basal versus thyrotropin-releasing hormone-induced prolactin secretion in rat anterior pituitary cells. differential roles of nitric oxide and intracellular calcium mobilization.
Whooping Cough
Muscarinic regulation of Ca2+ oscillation frequency in GH3 cells.
Whooping Cough
Muscarinic regulation of cyclic AMP in bovine trachealis cells.
Whooping Cough
Muscarinic regulation of intracellular signaling and neurosecretion in gonadotropin-releasing hormone neurons.
Whooping Cough
Muscarinic regulation of phospholipase A2 and iodide fluxes in FRTL-5 thyroid cells.
Whooping Cough
Muscarinic signaling pathway for calcium release and calcium-activated chloride current in smooth muscle.
Whooping Cough
Muscarinic stimulation of calcium influx and norepinephrine release in PC12 cells.
Whooping Cough
Muscarinic stimulation of gallbladder epithelium. III. Antagonism of cAMP-mediated effects.
Whooping Cough
Muscarinic-agonist and guanine nucleotide activation of polyphosphoinositide phosphodiesterase in isolated islet-cell membranes.
Whooping Cough
Muscarinic-agonist and guanine nucleotide stimulation of myo-inositol trisphosphate formation in membranes isolated from bovine iris sphincter smooth muscle: effects of short-term cholinergic desensitization.
Whooping Cough
Muscarinic-induced mucin secretion and intracellular signaling by hamster tracheal goblet cells.
Whooping Cough
Muscarinic-stimulated norepinephrine release and phosphoinositide hydrolysis in PC12 cells are independent events.
Whooping Cough
Mutagenesis of the amino terminus of the alpha subunit of the G protein Go. In vitro characterization of alpha o beta gamma interactions.
Whooping Cough
Mutagenesis studies toward understanding the intracellular signaling mechanism of antithrombin.
Whooping Cough
Mutants in the ptlA-H genes of Bordetella pertussis are deficient for pertussis toxin secretion.
Whooping Cough
Mutants of pertussis toxin suitable for vaccine development.
Whooping Cough
Mutation analysis of pertussis toxin promoter.
Whooping Cough
Mutation of an aspartate at residue 89 in somatostatin receptor subtype 2 prevents Na+ regulation of agonist binding but does not alter receptor-G protein association.
Whooping Cough
Mutation of Asp100 in the second transmembrane domain of the cholecystokinin B receptor increases antagonist binding and reduces signal transduction.
Whooping Cough
Mutational analysis of G protein alpha subunit G(o) alpha expressed in Escherichia coli.
Whooping Cough
Mutations in the bvgA gene of Bordetella pertussis that differentially affect regulation of virulence determinants.
Whooping Cough
Mutations in the S1 subunit of pertussis toxin that affect secretion.
Whooping Cough
Mutations in the third, but not the first or second, hypervariable regions of DR(beta 1*0101) eliminate DR1-restricted recognition of a pertussis toxin peptide.
Whooping Cough
Mutations of GS alpha designed to alter the reactivity of the protein with bacterial toxins. Substitutions at ARG187 result in loss of GTPase activity.
Whooping Cough
Mycobacterium avium complex promotes recruitment of monocyte hosts for HIV-1 and bacteria.
Whooping Cough
Mycophenolate mofetil and cyclophosphamide treatments suppress inflammation intensity in an experimental model of autoimmune uveitis.
Whooping Cough
Mycoplasma hyopneumoniae increases intracellular calcium release in porcine ciliated tracheal cells.
Whooping Cough
Myelin basic protein binds GTP at a single site in the N-terminus.
Whooping Cough
Myelin oligodendrocyte glycoprotein (MOG35-55) induced experimental autoimmune encephalomyelitis (EAE) in C57BL/6 mice.
Whooping Cough
Myelin oligodendrocyte glycoprotein (MOG35-55)-induced experimental autoimmune encephalomyelitis is ameliorated in interleukin-32 alpha transgenic mice.
Whooping Cough
Myelin Protein Zero180-199 Peptide Induced Experimental Autoimmune Neuritis in C57BL/6 Mice.
Whooping Cough
Myelin/oligodendrocyte glycoprotein-specific T-cells induce severe optic neuritis in the C57BL/6 mouse.
Whooping Cough
Myeloid cell proliferation stimulated by Steel factor is pertussis toxin sensitive and enhanced by cholera toxin.
Whooping Cough
Myeloid cells migrate in response to IL-24.
Whooping Cough
Myenteric ganglionic 5-hydroxytryptamine(1P) signal transmission is mediated via Go protein.
Whooping Cough
Myocardial beta-adrenergic receptor expression and signal transduction after chronic volume-overload hypertrophy and circulatory congestion.
Whooping Cough
Myocardial beta-adrenoceptors and inhibitory G-proteins in myocardial biopsies and in explanted hearts from patients with dilated cardiomyopathy.
Whooping Cough
Myocardial Gi alpha-protein levels in patients with hypertensive cardiac hypertrophy, ischemic heart disease and cardiogenic shock.
Whooping Cough
Myogenic tone is coupled to phospholipase C and G protein activation in small cerebral arteries.
Whooping Cough
Myr+-Gi2 alpha and Go alpha subunits restore the efficacy of opioids, clonidine and neurotensin giving rise to antinociception in G-protein knock-down mice.
Whooping Cough
Mystixin-7 and mystixin-11 increase cytosolic free Ca2+ and inositol trisphosphates in human A-431 cells.
Whooping Cough
N-acetyl beta-endorphin-(1-31) and substance P regulate the supraspinal antinociception mediated by mu opioid and alpha-2 adrenoceptors but not by delta opioid receptors in the mouse.
Whooping Cough
N-acetylaspartylglutamate and beta-NAAG protect against injury induced by NMDA and hypoxia in primary spinal cord cultures.
Whooping Cough
N-acetylaspartylglutamate inhibits forskolin-stimulated cyclic AMP levels via a metabotropic glutamate receptor in cultured cerebellar granule cells.
Whooping Cough
N-acetylated Proline-Glycine-Proline induced G-protein dependent chemotaxis of neutrophils is independent of CXCL8 release.
Whooping Cough
N-acetylation of serotonin is correlated with alpha 2- but not with beta-adrenergic regulation of cyclic AMP levels in cultured chick pineal cells.
Whooping Cough
N-arachidonoyl glycine induces macrophage apoptosis via GPR18.
Whooping Cough
N-arachidonoyl glycine, an endogenous lipid that acts as a vasorelaxant via nitric oxide and large conductance calcium-activated potassium channels.
Whooping Cough
N-ethylmaleimide blocks depolarization-induced suppression of inhibition and enhances GABA release in the rat hippocampal slice in vitro.
Whooping Cough
N-Ethylmaleimide differentiates between the M2- and M4-autoreceptor-mediated inhibition of acetylcholine release in the mouse brain.
Whooping Cough
N-ethylmaleimide diminishes alpha 2-adrenoceptor-mediated effects on norepinephrine release in rat tail arteries.
Whooping Cough
N-ethylmaleimide increases the L-type calcium current in guinea-pig ventricular myocytes.
Whooping Cough
N-Formyl peptide receptor ligation induces rac-dependent actin reorganization through Gbeta gamma subunits and class Ia phosphoinositide 3-kinases.
Whooping Cough
N-formyl-methionyl-leucyl-phenylalanine induces and modulates IL-1 and IL-6 in human PBMC.
Whooping Cough
N-methyl D-aspartate receptor-mediated bidirectional control of extracellular signal-regulated kinase activity in cortical neuronal cultures.
Whooping Cough
N-Methyl-d-aspartate receptor antagonist d-AP5 prevents pertussis toxin-induced alterations in rat spinal cords by inhibiting increase in concentrations of spinal CSF excitatory amino acids and downregulation of glutamate transporters.
Whooping Cough
N-methyl-N'-nitro-N-nitrosoguanidine: the effect on migration and cGMP level of neutrophils.
Whooping Cough
N-palmitoyl glycine, a novel endogenous lipid that acts as a modulator of calcium influx and nitric oxide production in sensory neurons.
Whooping Cough
N-terminal chromogranin-derived peptides as dilators of bovine coronary resistance arteries.
Whooping Cough
N-type Ca(2+) -channels in murine pancreatic beta-cells are inhibited by an exclusive coupling with somatostatin receptor subtype 1.
Whooping Cough
N1E-115 mouse neuroblastoma cells express MT1 melatonin receptors and produce neurites in response to melatonin.
Whooping Cough
N36, a synthetic N-terminal heptad repeat domain of the HIV-1 envelope protein gp41, is an activator of human phagocytes.
Whooping Cough
N6-isopentenyladenosine affects cAMP-dependent microfilament organization in FRTL-5 thyroid cells.
Whooping Cough
Na(+)-dependent metabolic coupling upon 5-HT1B receptor activation by sumatriptan and related agonists.
Whooping Cough
Na(+)-K(+)-ATPase-G protein coupling in myocardial sarcolemma: separation and reconstitution.
Whooping Cough
Na+ regulation of formyl peptide receptor-mediated signal transduction in HL 60 cells. Evidence that the cation prevents activation of the G-protein by unoccupied receptors.
Whooping Cough
Na+/H+ exchange and the regulation of intracellular pH in polymorphonuclear leukocytes.
Whooping Cough
Na+/H+ exchange in hypertension and in diabetes mellitus--facts and hypotheses.
Whooping Cough
NADP efficiently inhibits endogenous but not pertussis toxin-catalyzed covalent modification of membrane proteins incubated with NAD.
Whooping Cough
NADP+ enhances cholera and pertussis toxin-catalyzed ADP-ribosylation of membrane proteins.
Whooping Cough
NADPH-oxidase-dependent reactive oxygen species mediate EGFR transactivation by FPRL1 in WKYMVm-stimulated human lung cancer cells.
Whooping Cough
NaF and guanine nucleotides modulate adenylate cyclase activity in NG108-15 cells by interacting with both Gs and Gi.
Whooping Cough
Naïve T cells re-distribute to the lungs of selectin ligand deficient mice.
Whooping Cough
Naloxone in ultralow concentration restores endomorphin-1-evoked Ca(2+) signaling in lipopolysaccharide pretreated astrocytes.
Whooping Cough
NANC inhibitory neuromuscular transmission in the hamster distal colon.
Whooping Cough
Naphazoline-induced suppression of aqueous humor pressure and flow: involvement of central and peripheral alpha(2)/I(1) receptors.
Whooping Cough
Nasopharyngeal pertussis toxin IgA antibodies in the diagnosis of pertussis in Australian community patients.
Whooping Cough
Native 5-HT1B receptors expressed in OK cells display dual coupling to elevation of intracellular calcium concentrations and inhibition of adenylate cyclase.
Whooping Cough
Native and genetically inactivated pertussis toxins induce human dendritic cell maturation and synergize with lipopolysaccharide in promoting T helper type 1 responses.
Whooping Cough
Native low density lipoprotein-induced calcium transients trigger VCAM-1 and E-selectin expression in cultured human vascular endothelial cells.
Whooping Cough
Native, but not genetically inactivated, pertussis toxin protects mice against experimental allergic encephalomyelitis.
Whooping Cough
Natriuretic peptide receptor-C agonist attenuates the expression of cell cycle proteins and proliferation of vascular smooth muscle cells from spontaneously hypertensive rats: role of Gi proteins and MAPkinase/PI3kinase signaling.
Whooping Cough
NATRIURETIC PEPTIDE RECEPTOR-C UNDERPINS THE DISPARATE REGULATION OF ENDOTHELIAL AND VASCULAR SMOOTH MUSCLE CELL PROLIFERATION BY C-TYPE NATRIURETIC PEPTIDE.
Whooping Cough
Natriuretic peptides inhibit adenylyl cyclase activity in dispersed eel gill cells.
Whooping Cough
Natural competence for DNA transformation in Helicobacter pylori: identification and genetic characterization of the comB locus.
Whooping Cough
Natural course of the impairment of endothelium-dependent relaxations after balloon endothelium removal in porcine coronary arteries. Possible dysfunction of a pertussis toxin-sensitive G protein.
Whooping Cough
Natural polyamines stimulate G-proteins.
Whooping Cough
Naturally occurring opioid receptor agonists stimulate adenylate cyclase activity in rat olfactory bulb.
Whooping Cough
Nature and functioning of the pertussis toxin-sensitive G protein of neutrophils.
Whooping Cough
Nature of DNA binding and RNA polymerase interaction of the Bordetella pertussis BvgA transcriptional activator at the fha promoter.
Whooping Cough
Nature of thrombin-induced sustained increase in cytosolic calcium concentration in cultured endothelial cells.
Whooping Cough
Needle-free and adjuvant-free epicutaneous boosting of pertussis immunity: Preclinical proof of concept.
Whooping Cough
Neferine, a bisbenzylisoquinoline alkaloid of Nelumbo nucifera, inhibits glutamate release in rat cerebrocortical nerve terminals through 5-HT1A receptors.
Whooping Cough
Negative and positive inotropic responses to muscarinic agonists in guinea pig and rat atria in vitro.
Whooping Cough
Negative chronotropic and inotropic effects of endothelin isopeptides in mammalian cardiac muscle.
Whooping Cough
Negative inotropic action of alpha-1a adrenoceptor blocking agents: role of adenosine and ATP-sensitive K+ channels.
Whooping Cough
Neomycin induces high-affinity agonist binding of G-protein-coupled receptors.
Whooping Cough
Neomycin is a potent secretagogue of mast cells that directly activates a GTP-binding protein involved in exocytosis.
Whooping Cough
Neomycin mimics the effects of high extracellular calcium concentrations on parathyroid function in dispersed bovine parathyroid cells.
Whooping Cough
Neonatal immunization with a single dose of recombinant BCG expressing subunit S1 from pertussis toxin induces complete protection against Bordetella pertussis intracerebral challenge.
Whooping Cough
Nerve growth factor changes G protein levels and localization in PC12 cells.
Whooping Cough
Nerve growth factor signaling involves interaction between the Trk A receptor and lysophosphatidate receptor 1 systems: nuclear translocation of the lysophosphatidate receptor 1 and Trk A receptors in pheochromocytoma 12 cells.
Whooping Cough
Nerve growth factor stimulation of p42/p44 mitogen-activated protein kinase in PC12 cells: role of G(i/o), G protein-coupled receptor kinase 2, beta-arrestin I, and endocytic processing.
Whooping Cough
Nerve growth factor-induced stimulation of p38 mitogen-activated protein kinase in PC12 cells is partially mediated via G(i/o) proteins.
Whooping Cough
Nesfatin-1 increases intracellular calcium concentration by protein kinase C activation in cultured rat dorsal root ganglion neurons.
Whooping Cough
Nesfatin-1 Suppresses Cardiac L-type Ca²? Channels Through Melanocortin Type 4 Receptor and the Novel Protein Kinase C Theta Isoform Pathway.
Whooping Cough
Nesfatin-1: distribution and interaction with a g protein-coupled receptor in the rat brain.
Whooping Cough
Neudesin, a novel secreted protein with a unique primary structure and neurotrophic activity.
Whooping Cough
Neural effects of parathyroid hormone: modulation of the calcium channel current and metabolism of monoamines in identified Helisoma snail neurons.
Whooping Cough
Neural FFA3 activation inversely regulates anion secretion evoked by nicotinic ACh receptor activation in rat proximal colon.
Whooping Cough
Neurite outgrowth of spinal neurons on tissue sections of embryonic muscle is largely integrin dependent.
Whooping Cough
Neurite outgrowth-stimulating activities of beta-casomorphins in Neuro-2a mouse neuroblastoma cells.
Whooping Cough
Neuroblastoma differentiation involves the expression of two isoforms of the alpha-subunit of Go.
Whooping Cough
Neurochemical and behavioural evidence that dopamine D-2 receptors in striatum couple to the Ni regulatory protein and inhibition of cyclic AMP accumulation.
Whooping Cough
Neuroinflammation and B-Cell Phenotypes in Cervical and Lumbosacral Regions of the Spinal Cord in Experimental Autoimmune Encephalomyelitis in the Absence of Pertussis Toxin.
Whooping Cough
Neuromedin U inhibits T-type Ca2+ channel currents and decreases membrane excitability in small dorsal root ganglia neurons in mice.
Whooping Cough
Neuromedin U uses G?i2 and G?o to suppress glucose-stimulated Ca2+ signaling and insulin secretion in pancreatic ? cells.
Whooping Cough
Neuromedin-B receptor transfected BALB/3T3 cells: signal transduction and effects of ectopic receptor expression on cell growth.
Whooping Cough
Neuromodulatory effect of the atrial natriuretic factor clearance receptor binding peptide, cANF(4-23)-NH2 in rabbit isolated vasa deferentia.
Whooping Cough
Neuromodulatory effects of atrial natriuretic factor are independent of guanylate cyclase in adrenergic neuronal pheochromocytoma cells.
Whooping Cough
Neuromodulatory effects of atrial natriuretic peptides correlate with an inhibition of adenylate cyclase but not an activation of guanylate cyclase.
Whooping Cough
Neuronal apoptosis by apolipoprotein E4 through low-density lipoprotein receptor-related protein and heterotrimeric GTPases.
Whooping Cough
Neuronal cell apoptosis by a receptor-binding domain peptide of ApoE4, not through low-density lipoprotein receptor-related protein.
Whooping Cough
Neuronal platelet-activating factor receptor signal transduction involves a pertussis toxin-sensitive G-protein.
Whooping Cough
Neuropeptide FF receptors couple to a cholera toxin-sensitive G-protein in rat dorsal raphe neurones.
Whooping Cough
Neuropeptide FF receptors exhibit direct and anti-opioid effects on mice dorsal raphe nucleus neurons.
Whooping Cough
Neuropeptide Y (18-36) modulates chromaffin cell catecholamine secretion by blocking the nicotinic receptor ion channel.
Whooping Cough
Neuropeptide Y and hypertension.
Whooping Cough
Neuropeptide Y and pancreatic polypeptide reduce calcium currents in acutely dissociated neurons from adult rat superior cervical ganglia.
Whooping Cough
Neuropeptide Y and peptide YY inhibit lipolysis in human and dog fat cells through a pertussis toxin-sensitive G protein.
Whooping Cough
Neuropeptide Y and sigma ligand (JO 1784) act through a Gi protein to block the psychological stress and corticotropin-releasing factor-induced colonic motor activation in rats.
Whooping Cough
Neuropeptide Y and truncated neuropeptide Y analogs evoke histamine release from rat peritoneal mast cells. A direct effect on G proteins?
Whooping Cough
Neuropeptide Y depresses GABA-mediated calcium transients in developing suprachiasmatic nucleus neurons: a novel form of calcium long-term depression.
Whooping Cough
Neuropeptide Y Directly Inhibits Neuronal Activity in a Subpopulation of Gonadotropin-Releasing Hormone-1 Neurons via Y1 Receptors.
Whooping Cough
Neuropeptide Y enhances LHRH binding to rat gonadotrophs in primary culture.
Whooping Cough
Neuropeptide Y increases 4-aminopyridine-sensitive transient outward potassium current in rat ventricular myocytes.
Whooping Cough
Neuropeptide Y inhibition of calcium channels in PC-12 pheochromocytoma cells.
Whooping Cough
Neuropeptide Y inhibition of nicotinic receptor-mediated chromaffin cell secretion.
Whooping Cough
Neuropeptide Y inhibits alpha-MSH release from rat hypothalamic slices through a pertussis toxin-sensitive G protein.
Whooping Cough
Neuropeptide Y inhibits axonal transport of particles in neurites of cultured adult mouse dorsal root ganglion cells.
Whooping Cough
Neuropeptide Y inhibits beta-adrenergic agonist- and vasoactive intestinal peptide-induced cyclic AMP accumulation in rat pinealocytes through pertussis toxin-sensitive G protein.
Whooping Cough
Neuropeptide Y inhibits cardiac adenylate cyclase through a pertussis toxin-sensitive G protein.
Whooping Cough
Neuropeptide Y inhibits chromaffin cell nicotinic receptor-stimulated tyrosine hydroxylase activity through a receptor-linked G protein-mediated process.
Whooping Cough
Neuropeptide Y inhibits depolarization-stimulated catecholamine synthesis in rat pheochromocytoma cells.
Whooping Cough
Neuropeptide Y inhibits forskolin-stimulated adenylate cyclase in bovine adrenal chromaffin cells via a pertussis toxin-sensitive process.
Whooping Cough
Neuropeptide Y inhibits nicotinic cholinergic currents but not voltage-dependent calcium currents in bovine chromaffin cells.
Whooping Cough
Neuropeptide Y inhibits pertussis toxin-catalyzed ADP-ribosylation in bovine adrenal chromaffin cell membranes.
Whooping Cough
Neuropeptide Y inhibits renin release by a pertussis toxin-sensitive mechanism.
Whooping Cough
Neuropeptide Y inhibits spontaneous alpha-melanocyte-stimulating hormone (alpha-MSH) release via a Y(5) receptor and suppresses thyrotropin-releasing hormone-induced alpha-MSH secretion via a Y(1) receptor in frog melanotrope cells.
Whooping Cough
Neuropeptide Y inhibits vasoactive intestinal peptide- and dopamine-induced cyclic AMP formation in human Ewing's sarcoma WE-68 cells.
Whooping Cough
Neuropeptide Y inhibits vasoactive intestinal peptide-stimulated adenylyl cyclase in rat ventral prostate.
Whooping Cough
Neuropeptide Y mobilizes Ca2+ and inhibits adenylate cyclase in human erythroleukemia cells.
Whooping Cough
Neuropeptide Y modulates neurotransmitter release and Ca2+ currents in rat sensory neurons.
Whooping Cough
Neuropeptide Y receptor mediates activation of ERK1/2 via transactivation of the IGF receptor.
Whooping Cough
Neuropeptide Y receptor-mediated sensitization of ATP-stimulated inositol phosphate formation.
Whooping Cough
Neuropeptide Y reduces calcium current and inhibits acetylcholine release in nodose neurons via a pertussis toxin-sensitive mechanism.
Whooping Cough
Neuropeptide Y reduces macromolecule permeability of coronary endothelial monolayers.
Whooping Cough
Neuropeptide Y secretion from bovine chromaffin cells inhibits cyclic AMP accumulation.
Whooping Cough
Neuropeptide Y stimulates DNA synthesis in vascular smooth muscle cells.
Whooping Cough
Neuropeptide Y stimulates luteinizing hormone-releasing hormone release from superfused hypothalamic GT1-7 cells.
Whooping Cough
Neuropeptide Y stimulates proliferation of human vascular smooth muscle cells: cooperation with noradrenaline and ATP.
Whooping Cough
Neuropeptide Y stimulation of myosin light chain phosphorylation in cultured aortic smooth muscle cells.
Whooping Cough
Neuropeptide Y Y1 and Y2 receptor-mediated stimulation of mitogen-activated protein kinase activity.
Whooping Cough
Neuropeptide Y Y2 receptor and somatostatin sst2 receptor coupling to mobilization of intracellular calcium in SH-SY5Y human neuroblastoma cells.
Whooping Cough
Neuropeptide Y Y2 receptor signalling mechanisms in the human glioblastoma cell line LN319.
Whooping Cough
Neuropeptide Y Y2 receptor-mediated attenuation of neurogenic plasma extravasation acting through pertussis toxin-sensitive mechanisms.
Whooping Cough
Neuropeptide Y Y5 receptor promotes cell growth through extracellular signal-regulated kinase signaling and cyclic AMP inhibition in a human breast cancer cell line.
Whooping Cough
Neuropeptide Y-induced intracellular Ca2+ increases in vascular smooth muscle cells.
Whooping Cough
Neuropeptide Y2 receptors on nerve endings from the rat neurohypophysis regulate vasopressin and oxytocin release.
Whooping Cough
Neuropeptide-Y stimulation of extracellular signal-regulated kinases in human erythroleukemia cells.
Whooping Cough
Neuroprotective Effects of 6-Shogaol and Its Metabolite, 6-Paradol, in a Mouse Model of Multiple Sclerosis.
Whooping Cough
Neuroprotective effects of riluzole on N-methyl-D-aspartate- or veratridine-induced neurotoxicity in rat hippocampal slices.
Whooping Cough
Neuroprotective potential of CB1 receptor agonists in an in vitro model of Huntington's disease.
Whooping Cough
Neuroprotective signal transduction in model motor neurons exposed to thrombin: G-protein modulation effects on neurite outgrowth, Ca(2+) mobilization, and apoptosis.
Whooping Cough
Neurosteroids enhance spontaneous glutamate release in hippocampal neurons. Possible role of metabotropic sigma1-like receptors.
Whooping Cough
Neurosteroids modulate calcium currents in hippocampal CA1 neurons via a pertussis toxin-sensitive G-protein-coupled mechanism.
Whooping Cough
Neurosteroids stimulate G protein-coupled sigma receptors in mouse brain synaptic membrane.
Whooping Cough
Neurosteroids, via sigma receptors, modulate the [3H]norepinephrine release evoked by N-methyl-D-aspartate in the rat hippocampus.
Whooping Cough
Neurotensin and acetylcholine evoke common responses in frog oocytes injected with rat brain messenger ribonucleic acid.
Whooping Cough
Neurotensin and substance P inhibit low- and high-voltage-activated Ca2+ channels in cultured newborn rat nucleus basalis neurons.
Whooping Cough
Neurotensin decreases the affinity of dopamine D2 agonist binding by a G protein-independent mechanism.
Whooping Cough
Neurotensin excitation of rat ventral tegmental neurones.
Whooping Cough
Neurotensin increases the cationic conductance of rat substantia nigra dopaminergic neurons through the inositol 1,4,5-trisphosphate-calcium pathway.
Whooping Cough
Neurotensin inhibits background K+ channels and facilitates glutamatergic transmission in rat spinal cord dorsal horn.
Whooping Cough
Neurotensin Is Coexpressed, Coreleased, and Acts Together With GLP-1 and PYY in Enteroendocrine Control of Metabolism.
Whooping Cough
Neurotensin modulates the electrical activity of frog pituitary melanotropes via activation of a G-protein-coupled receptor pharmacologically related to both the NTS1 and nts2 receptors of mammals.
Whooping Cough
Neurotensin stimulates inositol trisphosphate-mediated calcium mobilization but not protein kinase C activation in HT29 cells. Involvement of a G-protein.
Whooping Cough
Neurotensin stimulation of mast cell secretion is receptor-mediated, pertussis-toxin sensitive and requires activation of phospholipase C.
Whooping Cough
Neurotensin type 1 receptor-mediated activation of krox24, c-fos and Elk-1: preventing effect of the neurotensin antagonists SR 48692 and SR 142948.
Whooping Cough
Neurotensin, bradykinin and somatostatin inhibit cAMP production in neuroblastoma N1E115 cells via both pertussis toxin sensitive and insensitive mechanisms.
Whooping Cough
Neurotensin-mediated inhibition of cyclic AMP formation in neuroblastoma N1E115 cells: involvement of the inhibitory GTP-binding component of adenylate cyclase.
Whooping Cough
Neurotoxic mechanisms by Alzheimer's disease-linked N141I mutant presenilin 2.
Whooping Cough
Neurotoxic mechanisms triggered by Alzheimer's disease-linked mutant M146L presenilin 1: involvement of NO synthase via a novel pertussis toxin target.
Whooping Cough
Neurotoxicity of Bordetella pertussis.
Whooping Cough
Neurotransmitter modulation of calcium channels in rat sympathetic neurons.
Whooping Cough
Neutralization of pertussis toxin by a single antibody prevents clinical pertussis in neonatal baboons.
Whooping Cough
Neutralizing antibodies and immunoprotection against pertussis and tetanus obtained by use of a recombinant pertussis toxin-tetanus toxin fusion protein.
Whooping Cough
Neutralizing antibodies to pertussis toxin in whooping cough.
Whooping Cough
Neutralizing tumor necrosis factor-alpha activity suppresses activation of infiltrating macrophages in experimental autoimmune uveoretinitis.
Whooping Cough
Neutrophil accumulation on activated, surface-adherent platelets in flow is mediated by interaction of Mac-1 with fibrinogen bound to alphaIIbbeta3 and stimulated by platelet-activating factor.
Whooping Cough
Neutrophil activation by inflammatory microcrystals of monosodium urate monohydrate utilizes pertussis toxin-insensitive and -sensitive pathways.
Whooping Cough
Neutrophil activation by surface bound IgG is via a pertussis toxin insensitive G protein.
Whooping Cough
Neutrophil activation by surface bound IgG: pertussis toxin insensitive activation.
Whooping Cough
Neutrophil activation in response to immune complex-bearing endothelial cells depends on the functional cooperation of Fc gamma RII (CD32) and Fc gamma RIII (CD16).
Whooping Cough
Neutrophil activation induced by the lectin KM+ involves binding to CXCR2.
Whooping Cough
Neutrophil apoptosis mediated by nicotinic acid receptors (GPR109A).
Whooping Cough
Neutrophil chemotaxis by pathogen-associated molecular patterns--formylated peptides are crucial but not the sole neutrophil attractants produced by Staphylococcus aureus.
Whooping Cough
Neutrophil chemotaxis induced by the diacylglycerol kinase inhibitor R59022.
Whooping Cough
Neutrophil CR3 expression and specific granule exocytosis are controlled by different signal transduction pathways.
Whooping Cough
Neutrophil defensins induce histamine secretion from mast cells: mechanisms of action.
Whooping Cough
Neutrophil elastase and proteinase-3 trigger G-protein biased signaling through proteinase activated receptor-1 (PAR1).
Whooping Cough
Neutrophil Priming Mechanisms of Sulfolipid-I and N-Formyl-Methionyl-Leucyl-Phenylalanine.
Whooping Cough
Neutrophil recruitment in Clostridium difficile toxin A enteritis in the rabbit.
Whooping Cough
Neutrophil thrombospondin receptors are linked to GTP-binding proteins.
Whooping Cough
New actions of melatonin on tumor metabolism and growth.
Whooping Cough
New Data on Vaccine Antigen Deficient Bordetella pertussis Isolates.
Whooping Cough
New roles for RGS2, 5 and 8 on the ratio-dependent modulation of recombinant GIRK channels expressed in Xenopus oocytes.
Whooping Cough
New, practical approach to detecting antibody to pertussis toxin for public health and clinical laboratories.
Whooping Cough
Newly synthesized catalytic and regulatory components of adenylate cyclase are expressed in neurites of cultured sympathetic neurons.
Whooping Cough
NF-kappaB activation is required for C5a-induced interleukin-8 gene expression in mononuclear cells.
Whooping Cough
NG2/HMPG modulation of human articular chondrocyte adhesion to type VI collagen is lost in osteoarthritis.
Whooping Cough
Ni-mediated inhibition of human platelet adenylate cyclase by thrombin.
Whooping Cough
Niacin activates the PI3K/Akt cascade via PKC- and EGFR-transactivation-dependent pathways through hydroxyl-carboxylic acid receptor 2.
Whooping Cough
Niacin induces PPARgamma expression and transcriptional activation in macrophages via HM74 and HM74a-mediated induction of prostaglandin synthesis pathways.
Whooping Cough
Niacin receptor GPR109A inhibits insulin secretion and is down-regulated in type 2 diabetic islet beta-cells.
Whooping Cough
Niacin stimulates adiponectin secretion through the GPR109A receptor.
Whooping Cough
Nicotine-induced antinociception in mice: role of G-proteins and adenylate cyclase.
Whooping Cough
Nicotinic acid increases adiponectin secretion from differentiated bovine preadipocytes through G-protein coupled receptor signaling.
Whooping Cough
Nicotinic Acid Inhibits Glucose-Stimulated Insulin Secretion Via the G Protein-Coupled Receptor PUMA-G in Murine Islet ? Cells.
Whooping Cough
Nicotinic and muscarinic acetylcholine responses in differentiated PC12 cells.
Whooping Cough
Nifedipine-sensitive vascular reactivity of femoral arteries in WKY: the effects of pertussis toxin pretreatment and endothelium removal.
Whooping Cough
NIH3T3 cells expressing the deleted in colorectal cancer tumor suppressor gene product stimulate neurite outgrowth in rat PC12 pheochromocytoma cells.
Whooping Cough
Nitric oxide and cyclic nucleotides participate in the relaxation of diclofenac on rat uterine smooth muscle.
Whooping Cough
Nitric oxide and G proteins mediate the response of bovine articular chondrocytes to fluid-induced shear.
Whooping Cough
Nitric oxide attenuates alpha(2)-adrenergic receptors by ADP-ribosylation of G(i)alpha in ciliary epithelium.
Whooping Cough
Nitric oxide induction by pertussis toxin in mouse spleen cells via gamma interferon.
Whooping Cough
Nitric oxide modulates ?-opioid receptor function in vitro.
Whooping Cough
Nitric oxide signaling mediates stimulation of L-type Ca2+ current elicited by withdrawal of acetylcholine in cat atrial myocytes.
Whooping Cough
Nitric oxide-independent, thiol-associated ADP-ribosylation inactivates aldehyde dehydrogenase.
Whooping Cough
Nitroimidazole derivatives inhibit anterior pituitary cell function apparently by a direct effect on the catalytic subunit of the adenylate cyclase holoenzyme.
Whooping Cough
Nitroxide stable radical suppresses autoimmune uveitis in rats.
Whooping Cough
NK Cells Regulate CD8+ T Cell Priming and Dendritic Cell Migration during Influenza A Infection by IFN-? and Perforin-Dependent Mechanisms.
Whooping Cough
NK-LAK induction with IL-2 is regulated by tyrosine phosphorylation of a 105-110 kDa protein.
Whooping Cough
NMR studies on the structure/function correlations of T-cell-epitope analogs from pertussis toxin.
Whooping Cough
No effect of pertussis toxin on peripheral prejunctional alpha 2-adrenoceptor-mediated responses and on endothelium-dependent relaxations in the rat.
Whooping Cough
Noc2 is essential in normal regulation of exocytosis in endocrine and exocrine cells.
Whooping Cough
Nociceptin (ORL-1) and mu-opioid receptors mediate mitogen-activated protein kinase activation in CHO cells through a Gi-coupled signaling pathway: evidence for distinct mechanisms of agonist-mediated desensitization.
Whooping Cough
Nociceptin Inhibits Uterine Contractions in Term-Pregnant Rats by Signaling Through Multiple Pathways.
Whooping Cough
Nociceptin is a potent inhibitor of N-type Ca(2+) channels in rat sympathetic ganglion neurons.
Whooping Cough
Nociceptin/orphanin FQ activates mitogen-activated protein kinase in Chinese hamster ovary cells expressing opioid receptor-like receptor.
Whooping Cough
Nociceptin/orphanin FQ activates protein kinase C, and this effect is mediated through phospholipase C/Ca2+ pathway.
Whooping Cough
Nociceptin/Orphanin FQ peptide receptor (NOP) mediates inhibition of N-type calcium currents in vestibular afferent neurons of the rat.
Whooping Cough
Nociception activates Elk-1 and Sap1a following expression of the ORL1 receptor in Chinese hamster ovary cells.
Whooping Cough
Nocistatin and prepro-nociceptin/orphanin FQ 160-187 cause nociception through activation of Gi/o in capsaicin-sensitive and of Gs in capsaicin-insensitive nociceptors, respectively.
Whooping Cough
Nocistatin inhibits 5-hydroxytryptamine release in the mouse neocortex via presynaptic G(i/o) protein linked pathways.
Whooping Cough
Nod factors activate both heterotrimeric and monomeric G-proteins in Vigna unguiculata (L.) Walp.
Whooping Cough
Noladin ether, a putative endocannabinoid, attenuates sensory neurotransmission in the rat isolated mesenteric arterial bed via a non-CB1/CB2 G(i/o) linked receptor.
Whooping Cough
Non-activated APJ suppresses the angiotensin II type 1 receptor, whereas apelin-activated APJ acts conversely.
Whooping Cough
Non-additive potentiation of glutamate release by phorbol esters and metabotropic mGlu7 receptor in cerebrocortical nerve terminals.
Whooping Cough
Non-anticoagulant heparin increases endothelial nitric oxide synthase activity: role of inhibitory guanine nucleotide proteins.
Whooping Cough
Non-canonical Hedgehog signaling contributes to chemotaxis in cholangiocarcinoma.
Whooping Cough
Non-classical regulation of ?1- and ? 2-adrenoceptor-mediated inotropic responses in rat heart ventricle by the G protein Gi.
Whooping Cough
Non-genomic action of the mineralocorticoid aldosterone on cytosolic sodium in cultured kidney cells.
Whooping Cough
Non-genomic effects of 17beta-estradiol in activation of the ERK1/ERK2 pathway induces cell proliferation through upregulation of cyclin D1 expression in bovine artery endothelial cells.
Whooping Cough
Non-genomic mechanisms of glucocorticoid inhibition of adrenocorticotropin secretion: possible involvement of GTP-binding protein.
Whooping Cough
Non-neuronal release of ATP and inositol 1,4,5-trisphosphate accumulation evoked by P2- and M-receptor stimulation in guinea pig ileal segments.
Whooping Cough
Non-phosphorylated FTY720 Induces Apoptosis of Human Microglia by Activating SREBP2.
Whooping Cough
Non-steady state kinetic analysis of the regulation of adenylate cyclase by GTP-binding proteins.
Whooping Cough
Non-steroidal anti-inflammatory drugs: effects on a GTP binding protein within the neutrophil plasma membrane.
Whooping Cough
Nonbiocompatible hemodialysis membranes induce apoptosis in mononuclear cells: the role of G-proteins.
Whooping Cough
Noncanonical signaling by ionotropic kainate receptors.
Whooping Cough
Noncoordinate regulation of alpha-1 adrenoreceptor coupling and reexpression of alpha skeletal actin in myocardial infarction-induced left ventricular failure in rats.
Whooping Cough
Nongenomic actions of 1,25-dihydroxyvitamin D3 in rat osteosarcoma cells: structure-function studies using ligand analogs.
Whooping Cough
Nongenomic aldosterone effects: the cell membrane as a specific target of mineralocorticoid action.
Whooping Cough
Nongenomic effect of testosterone on chloride secretion in cultured rat efferent duct epithelia.
Whooping Cough
Nongenomic effect of thyroid hormone on free-radical production in human polymorphonuclear leukocytes.
Whooping Cough
Nongenomic effects of androstenedione on human granulosa luteinizing cells.
Whooping Cough
Nongenomic mechanism of glucocorticoid inhibition of bradykinin-induced calcium influx in PC12 cells: possible involvement of protein kinase C.
Whooping Cough
Nongenomic mechanisms of glucocorticoid inhibition of nicotine-induced calcium influx in PC12 cells: involvement of protein kinase C.
Whooping Cough
Nongenomic oestrogen signalling in oestrogen receptor negative breast cancer cells: a role for the angiotensin II receptor AT1.
Whooping Cough
Nonpathogenic, environmental fungi induce activation and degranulation of human eosinophils.
Whooping Cough
Nonpeptidic antagonists of ETA and ETB receptors reverse the ET-1-induced sustained increase of cytosolic and nuclear calcium in human aortic vascular smooth muscle cells.
Whooping Cough
Nonrestricted differential intoxication of cells by pertussis toxin.
Whooping Cough
Nonselective cation channels activated by the stimulation of muscarinic receptors in mammalian gastric smooth muscle.
Whooping Cough
Nonselective cationic currents activated by acetylcholine in swine tracheal smooth muscle cells.
Whooping Cough
Nootropic drug modulation of neuronal nicotinic acetylcholine receptors in rat cortical neurons.
Whooping Cough
NOP receptor pharmacological profile - A dynamic mass redistribution study.
Whooping Cough
Noradrenaline and alpha-adrenergic signaling induce the hsp70 gene promoter in mollusc immune cells.
Whooping Cough
Noradrenaline release enhanced by cholera toxin and pertussis toxin in rat cerebral cortical slices.
Whooping Cough
Noradrenaline release from rat sympathetic neurones triggered by activation of B2 bradykinin receptors.
Whooping Cough
Noradrenaline stimulates 5-hydroxytryptamine release from mouse ileal tissues via alpha(2)-adrenoceptors.
Whooping Cough
Noradrenaline- and Enkephalin-Induced Inhibition of Voltage-Sensitive Calcium Currents in NG108-15 Hybrid Cells.
Whooping Cough
Noradrenaline-induced cation currents in isolated rat paratracheal ganglion neurons.
Whooping Cough
Noradrenaline-mediated contractions of ovine uterine artery: role of inositol 1,4,5-trisphosphate.
Whooping Cough
Noradrenergic inhibition and voltage-dependent facilitation of omega-conotoxin-sensitive Ca channels in insulin-secreting RINm5F cells.
Whooping Cough
Noradrenergic modulation of synaptic transmission between olfactory bulb neurons in culture: implications to olfactory learning.
Whooping Cough
Noradrenergic potentiation of cerebellar Purkinje cell responses to GABA: cyclic AMP as intracellular intermediary.
Whooping Cough
Norepinephrine and neuropeptide Y increase intracellular Ca2+ in cultured porcine aortic smooth muscle cells.
Whooping Cough
Norepinephrine attenuates serotonin inhibition of pial venous tone.
Whooping Cough
Norepinephrine down-regulates the activity of protein S on endothelial cells.
Whooping Cough
Norepinephrine inhibits a Ca2+ current in rat sympathetic neurons via a G-protein.
Whooping Cough
Norepinephrine inhibits calcium currents and EPSPs via a G-protein-coupled mechanism in olfactory bulb neurons.
Whooping Cough
Norepinephrine modulates high voltage-activated calcium channels in freshly dissociated rat nucleus tractus solitarii neurons.
Whooping Cough
Norepinephrine release and neuropeptide Y in medulla oblongata of spontaneously hypertensive rats.
Whooping Cough
Norepinephrine, acting via adenylate cyclase, inhibits melatonin output but does not phase-shift the pacemaker in cultured chick pineal cells.
Whooping Cough
Norepinephrine-induced calcium mobilization in C6 glioma cells.
Whooping Cough
Norepinephrine-stimulated PI hydrolysis in oligodendrocytes is mediated by alpha 1A-adrenoceptors.
Whooping Cough
Normal autophagic activity in macrophages from mice lacking G?i3, AGS3, or RGS19.
Whooping Cough
Normal hematopoiesis and inflammatory responses despite discrete signaling defects in Galpha15 knockout mice.
Whooping Cough
Nosocomial pertussis in healthcare workers from a pediatric emergency unit in France.
Whooping Cough
Novel bacterial ADP-ribosylating toxins: structure and function.
Whooping Cough
Novel biological property of pertussis toxin: chemotactic activity on human monocytes.
Whooping Cough
Novel bradykinin signalling events in PC-12 cells: stimulation of the cAMP pathway leads to cAMP-mediated translocation of protein kinase Cepsilon.
Whooping Cough
Novel CD47-dependent intercellular adhesion modulates cell migration.
Whooping Cough
Novel configurations of high molecular weight species of the pertussis toxin vaccine component.
Whooping Cough
Novel gamete receptors that facilitate sperm adhesion to the egg coat.
Whooping Cough
Novel GTP-binding proteins in plasma membranes of the fungus Metarhizium anisopliae.
Whooping Cough
Novel inhibition of gbetagamma-activated potassium currents induced by M(2) muscarinic receptors via a pertussis toxin-insensitive pathway.
Whooping Cough
Novel isoforms of Mel1c melatonin receptors modulating intracellular cyclic guanosine 3',5'-monophosphate levels.
Whooping Cough
Novel lipid mediator aspirin-triggered lipoxin A4 induces heme oxygenase-1 in endothelial cells.
Whooping Cough
Novel mechanism for non-genomic action of 17 beta-oestradiol on kainate-induced currents in isolated rat CA1 hippocampal neurones.
Whooping Cough
Novel metabotropic glutamate receptor negatively coupled to adenylyl cyclase in cultured rat cerebellar astrocytes.
Whooping Cough
Novel method for following lymphocyte traffic in mice using [3H]glycerol labeling.
Whooping Cough
Novel mitogenic effect of adenosine on coronary artery smooth muscle cells: role for the A1 adenosine receptor.
Whooping Cough
Novel model of integration of signaling pathways in rat pancreatic acinar cells.
Whooping Cough
Novel modulatory effect of L-type calcium channels at newly formed neuromuscular junctions.
Whooping Cough
Novel molecular biology approaches to acellular vaccines.
Whooping Cough
Novel multitarget real-time PCR assay for rapid detection of Bordetella species in clinical specimens.
Whooping Cough
Novel regulatory properties of human type 9 adenylate cyclase.
Whooping Cough
Novel role of Gi?2 in cell migration: Downstream of PI3-kinase-AKT and Rac1 in prostate cancer cells.
Whooping Cough
Novel role of the membrane-bound chemokine fractalkine in platelet activation and adhesion.
Whooping Cough
Novel Targeting to XCR1+ Dendritic Cells Using Allogeneic T Cells for Polytopical Antibody Responses in the Lymph Nodes.
Whooping Cough
NPY-(18-36) and pertussis toxin distinguish between the negative and positive contractile effects of neuropeptide Y (NPY) in ventricular cardiomyocytes.
Whooping Cough
NPY-stimulated Ca2+ mobilization in SK-N-MC cells is enhanced after isoproterenol treatment.
Whooping Cough
Nrg-1 belongs to the endothelial differentiation gene family of G protein-coupled sphingosine-1-phosphate receptors.
Whooping Cough
Nuclear factor-kappaB activation regulates cyclooxygenase-2 induction in human astrocytes in response to CXCL12: role in neuronal toxicity.
Whooping Cough
Nuclear membrane R-type calcium channels mediate cytosolic ET-1-induced increase of nuclear calcium in human vascular smooth muscle cells.
Whooping Cough
Nucleotide exchange and cGMP phosphodiesterase activation by pertussis toxin inactivated transducin.
Whooping Cough
Nucleotide regulatory protein-mediated activation of phospholipase C in human polymorphonuclear leukocytes is disrupted by phorbol esters.
Whooping Cough
Nucleotide responses of human neutrophils.
Whooping Cough
Nucleotide sequence homology to pertussis toxin gene in Bordetella bronchiseptica and Bordetella parapertussis.
Whooping Cough
Nucleotide-, chemotactic peptide- and phorbol ester-induced exocytosis in HL-60 leukemic cells.
Whooping Cough
Nucleotide-independent modulation of Ca(2+)-dependent K+ channel current by a mu-type opioid receptor.
Whooping Cough
Nucleotide-mediated mucin secretion from differentiated human bronchial epithelial cells.
Whooping Cough
Nucleotides induce chemotaxis and actin polymerization in immature but not mature human dendritic cells via activation of pertussis toxin-sensitive P2y receptors.
Whooping Cough
Obestatin-mediated proliferation of human retinal pigment epithelial cells: regulatory mechanisms.
Whooping Cough
Occurrence and biochemical characterization of GTP-binding proteins in Candida albicans.
Whooping Cough
Octreotide inhibition of serotonin-induced ileal chloride secretion.
Whooping Cough
Octreotide, a somatostatin analogue, mediates its antiproliferative action in pituitary tumor cells by altering phosphatidylinositol 3-kinase signaling and inducing Zac1 expression.
Whooping Cough
Oestradiol-induced relaxation of rabbit basilar artery by inhibition of voltage-dependent Ca channels through GTP-binding protein.
Whooping Cough
Oestrogen exerts anti-inflammation via p38 MAPK/NF-?B cascade in adipocytes.
Whooping Cough
Oleamide is a selective endogenous agonist of rat and human CB1 cannabinoid receptors.
Whooping Cough
Oligomerization of mu- and delta-opioid receptors. Generation of novel functional properties.
Whooping Cough
Oligomerization of neuropeptide Y (NPY) Y2 receptors in CHO cells depends on functional pertussis toxin-sensitive G-proteins.
Whooping Cough
Omega-agatoxin IVA blocks spinal morphine/clonidine antinociceptive synergism.
Whooping Cough
On technological and immunological benefits of multivalent single-injection microsphere vaccines.
Whooping Cough
On the adaptation of endosteal stem cell niche function in response to stress.
Whooping Cough
On the mechanism of action of dexamethasone in a rat mast cell line (RBL-2H3 cells). Evidence for altered coupling of receptors and G-proteins.
Whooping Cough
On the mechanism of activation of muscarinic K+ channels by adenosine in isolated atrial cells: involvement of GTP-binding proteins.
Whooping Cough
On the mechanism of cytosolic phospholipase A2 activation in CHO cells carrying somatostatin receptor: wortmannin-sensitive pathway to activate mitogen-activated protein kinase.
Whooping Cough
On the mechanism of G protein beta gamma subunit activation of the muscarinic K+ channel in guinea pig atrial cell membrane. Comparison with the ATP-sensitive K+ channel.
Whooping Cough
On the mechanism of M-current inhibition by muscarinic m1 receptors in DNA-transfected rodent neuroblastoma x glioma cells.
Whooping Cough
On the mechanism of muscarinic inhibition of the cardiac Ca current.
Whooping Cough
On the mechanism of the enhancement of delayed rectifier K+ current by extracellular ATP in guinea-pig ventricular myocytes.
Whooping Cough
On the mechanism of the interaction of ketamine and halothane in vitro.
Whooping Cough
On the mechanisms of the growth-promoting effect of prostaglandins in hepatocytes: the relationship between stimulation of DNA synthesis and signaling mediated by adenylyl cyclase and phosphoinositide-specific phospholipase C.
Whooping Cough
On the potassium conductance increase activated by GABAB and dopamine D2 receptors in rat substantia nigra neurones.
Whooping Cough
On the presynaptic action of baclofen at inhibitory synapses between cultured rat hippocampal neurones.
Whooping Cough
On the selectivity of the G?q inhibitor UBO-QIC: A comparison with the G?i inhibitor pertussis toxin.
Whooping Cough
On the transduction mechanism for muscarine-induced inhibition of M-current in cultured rat sympathetic neurones.
Whooping Cough
Oncogenes and Angiogenesis: down-regulation of thrombospondin-1 in normal fibroblasts exposed to factors from cancer cells harboring mutant ras.
Whooping Cough
One-dimensional peptide mapping of the subunits of pertussis toxin.
Whooping Cough
Ontogenesis of alpha 2-adrenoceptor coupling with GTP-binding proteins in the rat telencephalon.
Whooping Cough
Ontogenetic and pharmacological studies on metabotropic glutamate receptors coupled to phospholipase D activation.
Whooping Cough
Ontogenic aspects of D1 receptor coupling to G proteins and regulation of rat jejunal Na+, K+ ATPase activity and electrolyte transport.
Whooping Cough
Ontogeny of pulmonary neuroendocrine cells which express the alpha-subunit of guanine nucleotide-binding protein Go.
Whooping Cough
Ontogeny of the inhibitory guanine nucleotide-binding regulatory protein in the rat testis: mRNA expression and modulation of LH and FSH action.
Whooping Cough
Oocyte adenylyl cyclase contains Ni, yet the guanine nucleotide-dependent inhibition by progesterone is not sensitive to pertussis toxin.
Whooping Cough
Opening of ATP-sensitive K+ channels responsible for adenosine A2 receptor-mediated vasodepression does not involve a pertussis toxin-sensitive G protein.
Whooping Cough
Operational characteristics of somatostatin receptors mediating inhibitory actions on rat locus coeruleus neurones.
Whooping Cough
Opiate and peptide inhibition of transmitter release in parasympathetic nerve terminals.
Whooping Cough
Opiate-dependent changes in the sensitivity of adenylate cyclase to stimulatory agonists and 5'-guanylylimidodiphosphate are independent of G protein abundance and eukaryotic ADP-ribosyltransferase activity in NG108-15 cells.
Whooping Cough
Opiate-inhibited adenylate cyclase in rat brain membranes depleted of Gs-stimulated adenylate cyclase.
Whooping Cough
Opiate-mediated inhibition of calcium signaling is decreased in dorsal root ganglion neurons from the diabetic BB/W rat.
Whooping Cough
Opioid analgesic-induced apoptosis and caspase-independent cell death in human lung carcinoma A549 cells.
Whooping Cough
Opioid and cannabinoid receptor inhibition of adenylyl cyclase in brain.
Whooping Cough
Opioid dependence prevents the action of pertussis toxin in the guinea-pig myenteric plexus.
Whooping Cough
Opioid effects on contractility, Ca(2+)-transients and intracellular pH in cultured cardiac myocytes.
Whooping Cough
Opioid efficacy in a C6 glioma cell line stably expressing the delta opioid receptor.
Whooping Cough
Opioid efficacy in a C6 glioma cell line stably expressing the human kappa opioid receptor.
Whooping Cough
Opioid inhibition and desensitization of calcium channel currents in rat dorsal root ganglion neurons.
Whooping Cough
Opioid inhibition of adenylyl cyclase in membranes from pertussis toxin-treated NG108-15 cells.
Whooping Cough
Opioid inhibition of Ca2+ channel subtypes in bovine chromaffin cells: selectivity of action and voltage-dependence.
Whooping Cough
Opioid modulation of calcium current in cultured sensory neurons: mu-modulation of baroreceptor input.
Whooping Cough
Opioid modulation of extracellular signal-regulated protein kinase activity is ras-dependent and involves Gbetagamma subunits.
Whooping Cough
Opioid peptide receptor stimulation reverses beta-adrenergic effects in rat heart cells.
Whooping Cough
Opioid peptides promote cholera-toxin-catalysed ADP-ribosylation of the inhibitory guanine-nucleotide-binding protein (Gi) in membranes of neuroblastoma x glioma hybrid cells.
Whooping Cough
Opioid potentiation of N-type Ca2+ channel currents via pertussis-toxin-sensitive G proteins in NG108-15 cells.
Whooping Cough
Opioid receptor agonists activate pertussis toxin-sensitive G proteins and inhibit adenylyl cyclase in canine cardiac sarcolemma.
Whooping Cough
Opioid receptor agonists enhance the phosphorylation state of Fas-associated death domain (FADD) protein in the rat brain: Functional interactions with casein kinase Ialpha, Galpha(i) proteins, and ERK1/2 signaling.
Whooping Cough
Opioid receptor and calcium channel regulation of adenylyl cyclase, modulated by GM1, in NG108-15 cells: competitive interactions.
Whooping Cough
Opioid receptor-mediated effects of interleukin-2 on the [Ca2+]i transient and contraction in isolated ventricular myocytes of the rat.
Whooping Cough
Opioid receptor-mediated inhibition of omega-conotoxin GVIA-sensitive calcium channel currents in rat intracardiac neurons.
Whooping Cough
Opioid receptors are coupled tightly to G proteins but loosely to adenylate cyclase in NG108-15 cell membranes.
Whooping Cough
Opioid receptors in magnesium-digitonin-solubilized rat brain membranes are tightly coupled to a pertussis toxin-sensitive guanine nucleotide-binding protein.
Whooping Cough
Opioid receptors of neuroblastoma cells are in two domains of the plasma membrane that differ in content of G proteins.
Whooping Cough
Opioid signal transduction in intact and fragmented SH-SY5Y neural cells.
Whooping Cough
Opioid-induced adenylyl cyclase supersensitization in human embryonic kidney 293 cells requires pertussis toxin-sensitive G proteins other than G(i1) and G(i3).
Whooping Cough
Opioid-induced Down-Regulation of RGS4: ROLE OF UBIQUITINATION AND IMPLICATIONS FOR RECEPTOR CROSS-TALK.
Whooping Cough
Opioid-induced increase in [Ca2+]i in ND8-47 neuroblastoma x dorsal root ganglion hybrid cells is mediated through G protein-coupled delta-opioid receptors and desensitized by chronic exposure to opioid.
Whooping Cough
Opioid-Mediated Modulation of Acid-Sensing Ion Channel Currents in Adult Rat Sensory Neurons.
Whooping Cough
Opioids as modulators of cell death and survival--unraveling mechanisms and revealing new indications.
Whooping Cough
Opioids binding mu and delta receptors exhibit diverse efficacy in the activation of Gi2 and G(x/z) transducer proteins in mouse periaqueductal gray matter.
Whooping Cough
Opioids excite rather than inhibit sensory neurons after chronic opioid exposure of spinal cord-ganglion cultures.
Whooping Cough
Opioids inhibit endothelin-mediated DNA synthesis, phosphoinositide turnover, and Ca2+ mobilization in rat C6 glioma cells.
Whooping Cough
Opioids inhibit purinergic nociceptors in the sensory neurons and fibres of rat via a G protein-dependent mechanism.
Whooping Cough
Opioids mobilize calcium from inositol 1,4,5-trisphosphate-sensitive stores in NG108-15 cells.
Whooping Cough
Opposing actions of endocannabinoids on cholangiocarcinoma growth: recruitment of Fas and Fas ligand to lipid rafts.
Whooping Cough
Opposing effects of acetylcholine on the two classes of voltage-dependent calcium channels in hippocampal neurons.
Whooping Cough
Opposing effects of beta(1)- and beta(2)-adrenergic receptors on cardiac myocyte apoptosis : role of a pertussis toxin-sensitive G protein.
Whooping Cough
Opposing effects of fibroblast growth factor and pertussis toxin on alkaline phosphatase, osteopontin, osteocalcin, and type I collagen mRNA levels in ROS 17/2.8 cells.
Whooping Cough
Opposing influences of dexamethasone and retinoic acid on adenylate cyclase activity in ROS 17/2.8 cells.
Whooping Cough
Opposite action of beta1- and beta2-adrenergic receptors on Ca(V)1 L-channel current in rat adrenal chromaffin cells.
Whooping Cough
Opposite coupling of prostaglandin E receptor EP3C with Gs and G(o). Stimulation of Gs and inhibition of G(o).
Whooping Cough
Opposite modulation of astroglial proliferation by adenosine 5'-O-(2-thio)-diphosphate tetralithium and 2-methylthioadenosine-5'-diphosphate trisodium: mechanisms involved.
Whooping Cough
Opposite paracrine effects of 5-HT and dopamine on Na(+)-Pi cotransport in opossum kidney cells.
Whooping Cough
Opposite, phase-dependent effects of 3,4,5-trimethoxybenzoic acid 8-(diethylamino) octyl ester or tetracaine on islet function during three phases of glucose-stimulated insulin secretion.
Whooping Cough
Opsonophagocytic activity and other serological indications of Bordetella pertussis infection in military recruits in Norway.
Whooping Cough
Optical neuritis induced by different concentrations of myelin oligodendrocyte glycoprotein presents different profiles of the inflammatory process.
Whooping Cough
Optimal conditions for the toxoiding of pertussis toxin with 1-ethyl-3(3-dimethylaminopropyl) carbodiimide.HCl.
Whooping Cough
Optimization of rPDT fusion protein expression by Escherichia coli in pilot scale fermentation: a statistical experimental design approach.
Whooping Cough
Optimization of sample preparation for culture-independent sequencing of Bordetella pertussis.
Whooping Cough
Oral colonization and immune responses to Streptococcus gordonii expressing a pertussis toxin S1 fragment in mice.
Whooping Cough
Orexin (hypocretin) effects on constitutively active inward rectifier K+ channels in cultured nucleus basalis neurons.
Whooping Cough
Orexin receptor type-1 couples exclusively to pertussis toxin-insensitive G-proteins, while orexin receptor type-2 couples to both pertussis toxin-sensitive and -insensitive G-proteins.
Whooping Cough
Orexin-A differentially modulates AMPA-preferring responses of ganglion cells and amacrine cells in rat retina.
Whooping Cough
Orexin-A protects against oxygen-glucose deprivation/reoxygenation-induced cell damage by inhibiting endoplasmic reticulum stress-mediated apoptosis via the Gi and PI3K signaling pathways.
Whooping Cough
Orexins (hypocretins) directly interact with neuropeptide Y, POMC and glucose-responsive neurons to regulate Ca 2+ signaling in a reciprocal manner to leptin: orexigenic neuronal pathways in the mediobasal hypothalamus.
Whooping Cough
Orexins/Hypocretins Acting at G(i) Protein-Coupled OX (2) Receptors Inhibit Cyclic AMP Synthesis in the Primary Neuronal Cultures.
Whooping Cough
Organophosphate-induced alterations in muscarinic receptor binding and phosphoinositide hydrolysis in the human SK-N-SH cell line.
Whooping Cough
Osteopontin expression in the brain triggers localized inflammation and cell death when immune cells are activated by pertussis toxin.
Whooping Cough
Outbreak of pertussis in a residential facility for handicapped people.
Whooping Cough
Outer membrane vesicles as acellular vaccine against pertussis.
Whooping Cough
Outer membrane vesicles obtained from Bordetella pertussis Tohama expressing the lipid A deacylase PagL as a novel acellular vaccine candidate.
Whooping Cough
Outer Membrane Vesicles of Bordetella pertussis encapsulated into sodium alginate nanoparticles as novel vaccine delivery system.
Whooping Cough
Ovarian cancer G protein-coupled receptor 1, a new metastasis suppressor gene in prostate cancer.
Whooping Cough
Overcoming Codon-Usage Bias in Heterologous Protein Expression in Streptococcus gordonii.
Whooping Cough
Overexpression of beta 1 and beta 2 adrenergic receptors in rat atrial myocytes. Differential coupling to G protein-gated inward rectifier K(+) channels via G(s) and G(i)/o.
Whooping Cough
Overexpression of the cardiac beta(2)-adrenergic receptor and expression of a beta-adrenergic receptor kinase-1 (betaARK1) inhibitor both increase myocardial contractility but have differential effects on susceptibility to ischemic injury.
Whooping Cough
Overexpression of the CXCR5 chemokine receptor, and its ligand, CXCL13 in B-cell chronic lymphocytic leukemia.
Whooping Cough
Overexpression of the RNA polymerase alpha subunit reduces transcription of Bvg-activated virulence genes in Bordetella pertussis.
Whooping Cough
Overview of currently available Japanese acellular pertussis vaccines and future problems.
Whooping Cough
Overview of recent clinical trials of acellular pertussis vaccines.
Whooping Cough
OX1 orexin receptors couple to adenylyl cyclase regulation via multiple mechanisms.
Whooping Cough
Oxidant-mediated activation of cytosolic phospholipase a(2) in pulmonary endothelium: role of protein kinase C alpha and a pertussis toxin-sensitive protein.
Whooping Cough
Oxidized lipids and lysophosphatidylcholine induce the chemotaxis and intracellular calcium influx in natural killer cells.
Whooping Cough
Oxidized low density lipoproteins inhibit relaxations of porcine coronary arteries. Role of scavenger receptor and endothelium-derived nitric oxide.
Whooping Cough
Oxidized low-density lipoprotein downregulates endothelial basic fibroblast growth factor through a pertussis toxin-sensitive G-protein pathway: mediator role of platelet-activating factor-like phospholipids.
Whooping Cough
Oxidized low-density lipoprotein stimulates protein kinase C (PKC) and induces expression of PKC-isotypes via prostaglandin-H-synthase in P388D1 macrophage-like cells.
Whooping Cough
Oxidized phospholipid-induced endothelial cell/monocyte interaction is mediated by a cAMP-dependent R-Ras/PI3-kinase pathway.
Whooping Cough
OxLDL induces mitogen-activated protein kinase activation mediated via PI3-kinase/Akt in vascular smooth muscle cells.
Whooping Cough
OxLDL upregulates CXCR2 expression in monocytes via scavenger receptors and activation of p38 mitogen-activated protein kinase.
Whooping Cough
Oxygen alters caveolin-1 and nitric oxide synthase-3 functions in ovine fetal and neonatal lung microvascular endothelial cells.
Whooping Cough
Oxygen pressure-dependent control of carbonic anhydrase synthesis in chick embryonic erythrocytes.
Whooping Cough
Oxymetazoline inhibits adenylate cyclase by activation of serotonin-1 receptors in the OK cell, an established renal epithelial cell line.
Whooping Cough
Oxytocin activates mitogen-activated protein kinase and up-regulates cyclooxygenase-2 and prostaglandin production in human myometrial cells.
Whooping Cough
Oxytocin and lysophosphatidic acid induce stress fiber formation in human myometrial cells via a pathway involving Rho-kinase.
Whooping Cough
Oxytocin Downregulates the CaV1.2 L-Type Ca2+ Channel via Gi/cAMP/PKA/CREB Signaling Pathway in Cardiomyocytes.
Whooping Cough
Oxytocin induced a biphasic increase in the intracellular Ca2+ concentration of porcine myometrial cells: participation of a pertussis toxin-insensitive G-protein, inositol 1,4,5-trisphosphate-sensitive Ca2+ pool, and Ca2+ channels.
Whooping Cough
Oxytocin induces the migration of prostate cancer cells: involvement of the Gi-coupled signaling pathway.
Whooping Cough
Oxytocin signalling in human myometrium.
Whooping Cough
Oxytocin-stimulated insulin release in a clonal beta-cell line RINm5F: involvement of phospholipase C-dependent and -independent pathways.
Whooping Cough
Oxytocin-stimulated phosphoinositide hydrolysis in human myometrial cells: involvement of pertussis toxin-sensitive and -insensitive G-proteins.
Whooping Cough
P-selectin cross-links PSGL-1 and enhances neutrophil adhesion to fibrinogen and ICAM-1 in a Src kinase-dependent, but GPCR-independent mechanism.
Whooping Cough
P0 protein peptide 180-199 together with pertussis toxin induces experimental autoimmune neuritis in resistant C57BL/6 mice.
Whooping Cough
P0(106-125) is a neuritogenic epitope of the peripheral myelin protein P0 and induces autoimmune neuritis in C57BL/6 mice.
Whooping Cough
P2 purinergic agonists and 12-O-tetradecanoylphorbol-13-acetate, as well as protein kinase A activators, stimulate thyroglobulin secretion in FRTL-5 cells.
Whooping Cough
P2 purinoceptor stimulation attenuates PTH inhibition of phosphate uptake by a G protein-dependent mechanism.
Whooping Cough
P2 purinoceptor-mediated inhibition of cyclic AMP accumulation in NG108-15 cells.
Whooping Cough
P2 purinoceptors contribute to ATP-induced inhibition of L-type Ca2+ current in rabbit atrial myocytes.
Whooping Cough
P2 purinoceptors in cultured bovine middle cerebral artery endothelial cells.
Whooping Cough
P2 receptor-mediated inhibition of adenylyl cyclase in PC12 cells.
Whooping Cough
P2 Receptor-mediated Inhibition of Vasopressin-stimulated Fluid Transport and cAMP Responses in AQP2-transfected MDCK Cells.
Whooping Cough
P2-purigenic receptors regulate phospholipase C and adenylate cyclase activities in immortalized Schwann cells.
Whooping Cough
P2-purinergic receptors are coupled to two signal transduction systems leading to inhibition of cAMP generation and to production of inositol trisphosphate in rat hepatocytes.
Whooping Cough
P2-purinoceptor activation stimulates phosphoinositide hydrolysis and inhibits accumulation of cAMP in cultured ventricular myocytes.
Whooping Cough
P2-purinoceptor induced prostaglandin synthesis in primary rat astrocyte cultures.
Whooping Cough
P2-purinoceptor-mediated formation of inositol phosphates and intracellular Ca2+ transients in human coronary artery smooth muscle cells.
Whooping Cough
P2-purinoceptor-stimulated phosphoinositide turnover in chick myotubes. Calcium mobilization and the role of guanyl nucleotide-binding proteins.
Whooping Cough
P2U-purinergic receptor activation mediates inhibition of cAMP accumulation in cultured renal mesangial cells.
Whooping Cough
P2X receptor activation elicits transporter-mediated noradrenaline release from rat hippocampal slices.
Whooping Cough
P2X7 and P2Y13 purinergic receptors mediate intracellular calcium responses to BzATP in rat cerebellar astrocytes.
Whooping Cough
P2Y purinergic receptor regulation of CFTR chloride channels in mouse cardiac myocytes.
Whooping Cough
P2Y purinoceptor activation mobilizes intracellular Ca2+ and induces a membrane current in rat intracardiac neurones.
Whooping Cough
P2Y purinoceptors are responsible for oscillatory fluid flow-induced intracellular calcium mobilization in osteoblastic cells.
Whooping Cough
P2Y purinoceptors inhibit exocytosis in adrenal chromaffin cells via modulation of voltage-operated calcium channels.
Whooping Cough
P2Y receptor linked to phospholipase C: stimulation of neuro 2A cells by UTP and ATP and possible regulation by protein kinase C subtype epsilon.
Whooping Cough
P2Y receptor subtypes differentially couple to inwardly-rectifying potassium channels.
Whooping Cough
P2Y receptor-mediated Ca2+ signalling in cultured rat aortic smooth muscle cells.
Whooping Cough
P2Y receptor-mediated inhibition of tumor necrosis factor alpha -stimulated stress-activated protein kinase activity in EAhy926 endothelial cells.
Whooping Cough
P2Y receptor-mediated inhibition of voltage-activated Ca(2+) currents in PC12 cells.
Whooping Cough
P2Y receptors activate MAPK/ERK through a pathway involving PI3K/PDK1/PKC-zeta in human vein endothelial cells.
Whooping Cough
P2Y(13) receptor is responsible for ADP-mediated degranulation in RBL-2H3 rat mast cells.
Whooping Cough
P2Y(2) receptor-mediated proliferation of C(6) glioma cells via activation of Ras/Raf/MEK/MAPK pathway.
Whooping Cough
P2Y-receptors mediating an inhibition of the evoked entry of calcium through N-type calcium channels at neuronal processes.
Whooping Cough
P2Y1 and P2Y13 purinergic receptors mediate Ca2+ signaling and proliferative responses in pulmonary artery vasa vasorum endothelial cells.
Whooping Cough
P2Y12 receptor stimulation inhibits beta-adrenergic receptor-induced differentiation by reversing the cyclic AMP-dependent inhibition of protein kinase B.
Whooping Cough
P2Y12 receptors in primary microglia activate nuclear factor of activated T-cell signaling to induce C-C chemokine 3 expression.
Whooping Cough
P2Y2 nucleotide receptors expressed heterologously in sympathetic neurons inhibit both N-type Ca2+ and M-type K+ currents.
Whooping Cough
P2Y5 is a G{alpha}i, G{alpha}12/13 G Protein Coupled Receptor Activated by Lysophosphatidic Acid that Reduces Intestinal Cell Adhesion.
Whooping Cough
p2y5/LPA6 attenuates LPA1-mediated VE-cadherin translocation and cell-cell dissociation through G12/13 protein-Src-Rap1.
Whooping Cough
p38 mitogen-activated protein kinase pathway protects adult rat ventricular myocytes against beta -adrenergic receptor-stimulated apoptosis. Evidence for Gi-dependent activation.
Whooping Cough
p42/mitogen-activated protein kinase as a converging target for different growth factor signaling pathways: use of pertussis toxin as a discrimination factor.
Whooping Cough
p75 neurotrophin receptor mediates neuronal cell death by activating GIRK channels through phosphatidylinositol 4,5-bisphosphate.
Whooping Cough
PACAP and VIP stimulate Ca2+ oscillations in rat gonadotrophs through the PACAP/VIP type 1 receptor (PVR1) linked to a pertussis toxin-insensitive G-protein and the activation of phospholipase C-beta.
Whooping Cough
PACAP inhibits delayed rectifier potassium current via a cAMP/PKA transduction pathway: evidence for the involvement of I k in the anti-apoptotic action of PACAP.
Whooping Cough
PAF effects on transmembrane signaling pathways in rat Kupffer cells.
Whooping Cough
PAF receptors and G-proteins in human blood eosinophils and neutrophils.
Whooping Cough
Paired-pulse depression of the N-methyl-D-aspartate receptor-mediated synaptic potentials in the amygdala.
Whooping Cough
Palmitoylation of human proteinase-activated receptor-2 differentially regulates receptor-triggered ERK1/2 activation, calcium signalling and endocytosis.
Whooping Cough
Pancreastatin activates pertussis toxin-sensitive guanylate cyclase and pertussis toxin-insensitive phospholipase C in rat liver membranes.
Whooping Cough
Pancreastatin activates protein kinase C by stimulating the formation of 1,2-diacylglycerol in rat hepatocytes.
Whooping Cough
Pancreastatin increases free cytosolic Ca2+ in rat hepatocytes, involving both pertussis-toxin-sensitive and -insensitive mechanisms.
Whooping Cough
Pancreastatin inhibits insulin release from Rin m 5F cells: reversion by pertussis toxin.
Whooping Cough
Pancreastatin inhibits insulin secretion in RINm5F cells through obstruction of G-protein mediated, calcium-directed exocytosis.
Whooping Cough
Pancreastatin receptor is coupled to a guanosine triphosphate-binding protein of the G(q/11)alpha family in rat liver membranes.
Whooping Cough
Pancreastatin: a novel peptide inhibitor of parietal cell signal transduction.
Whooping Cough
Pancreatic glucagon-like peptide-1 receptor couples to multiple G proteins and activates mitogen-activated protein kinase pathways in Chinese hamster ovary cells.
Whooping Cough
Pancreatic polypeptide inhibits calcium channels in rat sympathetic neurons via two signaling pathways.
Whooping Cough
Pancreatic polypeptide-fold peptide receptors and angiotensin II-induced renal vasoconstriction.
Whooping Cough
PAR-2 activation regulates IL-8 and GRO-alpha synthesis by NF-kappaB, but not RANTES, IL-6, eotaxin or TARC expression in nasal epithelium.
Whooping Cough
PAR1 and PAR2 couple to overlapping and distinct sets of G proteins and linked signaling pathways to differentially regulate cell physiology.
Whooping Cough
Paradoxes of pertussis toxin.
Whooping Cough
Paradoxical attenuation of {beta}2-AR function in airway smooth muscle by Gi-mediated counterregulation in transgenic mice overexpressing type 5 adenylyl cyclase.
Whooping Cough
Paradoxical effect of pertussis toxin on the delayed hypersensitivity response to autoantigens in mice.
Whooping Cough
Parallel activation of phosphatidylinositol 4-kinase and phospholipase C by the extracellular calcium-sensing receptor.
Whooping Cough
Parallel inactivation of Y2 receptor and G-proteins in CHO cells by pertussis toxin.
Whooping Cough
Parallel signaling pathways of melatonin in the pancreatic beta-cell.
Whooping Cough
Parapertussis and pertussis: differences and similarities in incidence, clinical course, and antibody responses.
Whooping Cough
Parathyroid hormone activates mitogen-activated protein kinase in opossum kidney cells.
Whooping Cough
Parathyroid hormone increases cytosolic calcium concentration in adult rat cardiac myocytes.
Whooping Cough
Parathyroid hormone inhibits Na(+)-K(+)-ATPase through a cytochrome P-450 pathway.
Whooping Cough
Parathyroid hormone raises cytosolic calcium in pancreatic islets: study on mechanisms.
Whooping Cough
Parathyroid hormone-related protein inhibits indothelin-1 production.
Whooping Cough
Parathyroid hormone/adenylate cyclase coupling in vascular smooth muscle cells.
Whooping Cough
Parenteral immunization of mice with a genetically inactivated pertussis toxin DNA vaccine induces cell-mediated immunity and protection.
Whooping Cough
Parenteral medium-chain triglyceride-induced neutrophil activation is not mediated by a Pertussis Toxin sensitive receptor.
Whooping Cough
Parents as source of pertussis transmission in hospitalized young infants.
Whooping Cough
PARPs and PAR as novel pharmacological targets for the treatment of stress granule-associated disorders.
Whooping Cough
Parstatin: a cryptic peptide involved in cardioprotection after ischemia and reperfusion injury.
Whooping Cough
Partial agonistic activity of naloxone on the opioid receptors expressed from complementary deoxyribonucleic acids in Chinese hamster ovary cells.
Whooping Cough
Partial characterization of GTP-binding proteins in Neurospora.
Whooping Cough
Partial ligand-receptor engagement yields functional bias at the human complement receptor, C5aR1.
Whooping Cough
Participation of cAMP in the facilitatory action of beta,gamma-methylene ATP on the noradrenaline release from rabbit ear artery.
Whooping Cough
Participation of G proteins in natriuretic peptide hormone secretion from heart atria.
Whooping Cough
Participation of membrane progesterone receptor ? in the inhibitory effect of progesterone on prolactin secretion.
Whooping Cough
Participation of pertussis toxin-sensitive GTP-binding regulatory proteins in the suppression of baroreceptor reflex by neurotensin in the rat.
Whooping Cough
Participation of presenilin 2 in apoptosis: enhanced basal activity conferred by an Alzheimer mutation.
Whooping Cough
Parturition: activation of stimulatory pathways or loss of uterine quiescence?
Whooping Cough
Pasteurella (Mannheimia) haemolytica leukotoxin-induced cytolysis of bovine leukocytes: role of arachidonic acid and its regulation.
Whooping Cough
Pasteurella haemolytica A1-derived leukotoxin and endotoxin induce intracellular calcium elevation in bovine alveolar macrophages by different signaling pathways.
Whooping Cough
Pasteurella multocida toxin activates the inositol triphosphate signaling pathway in Xenopus oocytes via G(q)alpha-coupled phospholipase C-beta1.
Whooping Cough
Pasteurella multocida toxin as a tool for studying Gq signal transduction.
Whooping Cough
Pathogenesis and histopathology of pertussis: implications for immunization.
Whooping Cough
Pathways involved in PTH-induced rise in cytosolic Ca2+ concentration of rat renal proximal tubule.
Whooping Cough
Pathways of transduction engaged by sphingosine 1-phosphate through G protein-coupled receptors.
Whooping Cough
Pathways through which glucose induces a rise in [Ca2+]i of polymorphonuclear leukocytes of rats.
Whooping Cough
PD-L1 is increased in the spinal cord and infiltrating lymphocytes in experimental allergic encephalomyelitis.
Whooping Cough
PDGF-mediated activation of phosphatidylinositol 3 kinase in human mesangial cells.
Whooping Cough
PECAM-1 modulates thrombin-induced tissue factor expression on endothelial cells.
Whooping Cough
PEI6, a new basic secretagogue in rat peritoneal mast cells: characteristics of polyethylenimine PEI6 resemble those of compound 48/80.
Whooping Cough
Penetration of CD4 T cells by HIV-1. The CD4 receptor does not internalize with HIV, and CD4-related signal transduction events are not required for entry.
Whooping Cough
Peptide inhibitors of ADP-ribosylation by pertussis toxin are substrates with affinities comparable to those of the trimeric GTP-binding proteins.
Whooping Cough
Peptide mapping studies of the pertussis toxin substrate in human neutrophils, platelets and erythrocytes.
Whooping Cough
Peptide YY inhibition of rat gastric enterochromaffin-like cell function.
Whooping Cough
Peptide YY inhibits vasopressin-stimulated chloride secretion in inner medullary collecting duct cells.
Whooping Cough
Peptide YY receptors in the proximal tubule PKSV-PCT cell line derived from transgenic mice. Relation with cell growth.
Whooping Cough
Peptidergic modulation of G-protein coupled cyclic-AMP accumulation in the rat caudate nucleus.
Whooping Cough
Peptides from pertussis toxin interfere with neutrophil adherence in vitro and counteract inflammation in vivo.
Whooping Cough
Per- and Polyfluoroalkyl Substances Differentially Inhibit Placental Trophoblast Migration and Invasion In Vitro.
Whooping Cough
Performance of commercial enzyme-linked immunosorbent assays for the detection of antibodies to Bordetella pertussis.
Whooping Cough
Perinatal PTX-sensitive G-protein expression and regulation of conductive 22Na+ transport in lung apical membrane vesicles.
Whooping Cough
Peripheral and central neuronal ATF3 precedes CD4+ T-cell infiltration in EAE.
Whooping Cough
Peripheral and central vascular smooth muscle cells from rat lung exhibit different cytoskeletal protein profiles but similar growth factor requirements.
Whooping Cough
Peripheral antinociceptive effect of pertussis toxin: activation of the arginine/NO/cGMP/PKG/ ATP-sensitive K channel pathway.
Whooping Cough
Peripheral group II metabotropic glutamate receptors (mGluR2/3) regulate prostaglandin E2-mediated sensitization of capsaicin responses and thermal nociception.
Whooping Cough
Peripheral nociceptive effects of alpha 2-adrenergic receptor agonists in the rat.
Whooping Cough
Peripheral non-opioid analgesic effects of kyotorphin in mice.
Whooping Cough
Peripheral pain is enhanced by insulin-like growth factor 1 through a G protein-mediated stimulation of T-type calcium channels.
Whooping Cough
Peripheral sensory neuron injury contributes to neuropathic pain in experimental autoimmune encephalomyelitis.
Whooping Cough
Permeabilization and calcium-dependent activation of rabbit polymorphonuclear leukocytes by poly-L-arginine.
Whooping Cough
Permeabilization in a cerebral endothelial barrier model by pertussis toxin involves the PKC effector pathway and is abolished by elevated levels of cAMP.
Whooping Cough
Permissive stimulation of Ca(2+)-induced phospholipase A2 by an adenosine receptor agonist in a pertussis toxin-sensitive manner in FRTL-5 thyroid cells: a new 'cross-talk' mechanism in Ca2+ signalling.
Whooping Cough
Persistence of Antibodies against Diphtheria, Tetanus, Pertussis, and Poliovirus Types I, II, and III Following Immunization with DTaP Combined with Inactivated Wild-Type Polio Vaccine (DTaP-wIPV).
Whooping Cough
Persistence of antibody after accelerated immunisation with diphtheria/tetanus/pertussis vaccine.
Whooping Cough
Persistence of T-cell immune response induced by two acellular pertussis vaccines in children five years after primary vaccination.
Whooping Cough
Persistent Inflammation in the CNS during Chronic EAE Despite Local Absence of IL-17 Production.
Whooping Cough
Pertactin-deficient Bordetella pertussis isolates: evidence of increased circulation in Europe, 1998 to 2015.
Whooping Cough
Pertactin-negative Bordetella pertussis strains in Canada: characterization of a dozen isolates based on a survey of 224 samples collected in different parts of the country over the last 20 years.
Whooping Cough
Perturbation of regulated secretion in the pancreatic acinar cell line, AR42J.
Whooping Cough
Pertussis (whooping cough) toxin and Bordetella pertussis whole-cell antibody levels in a healthy New Zealand population.
Whooping Cough
Pertussis adjuvant prolongs intestinal hypersensitivity.
Whooping Cough
Pertussis and cholera toxin ADP-ribosylation in Dictyostelium discoideum membranes.
Whooping Cough
Pertussis and cholera toxins inhibit prostaglandin synthesis in rat astrocyte cultures at distinct metabolic steps.
Whooping Cough
Pertussis and cholera toxins modulate kappa-opioid receptor agonists-induced hypothermia and gut inhibition.
Whooping Cough
Pertussis antibodies in postpartum women and their newborns.
Whooping Cough
Pertussis antibodies, protection, and vaccine efficacy after household exposure.
Whooping Cough
Pertussis Antibody Concentrations in Infants Born Prematurely to Mothers Vaccinated in Pregnancy.
Whooping Cough
Pertussis antibody levels in infants and their mothers receiving combined tetanus-diphtheria toxoid and acellular pertussis vaccine during pregnancy in Turkey.
Whooping Cough
Pertussis Booster Vaccination in HIV-Infected Children Receiving Highly Active Antiretroviral Therapy.
Whooping Cough
Pertussis but not cholera toxin inhibits the stimulated increase in actin association with the cytoskeleton in rabbit neutrophils: role of the "G proteins" in stimulus-response coupling.
Whooping Cough
Pertussis encephalopathy in an adult: case report and review.
Whooping Cough
Pertussis encephalopathy with high cerebrospinal fluid antibody titers to pertussis toxin and filamentous hemagglutinin.
Whooping Cough
Pertussis holotoxoid formed in vitro with a genetically deactivated S1 subunit.
Whooping Cough
Pertussis IgE and atopic disease.
Whooping Cough
Pertussis immunization with acellular vaccines in Ghanaian children.
Whooping Cough
Pertussis in adults: possible use of booster doses for control.
Whooping Cough
Pertussis in infants less than 6 months of age and household contacts, Italy, April 2014.
Whooping Cough
Pertussis in infants, in their mothers and other contacts in Casablanca, Morocco.
Whooping Cough
Pertussis infection among adults during the 1993 outbreak in Chicago.
Whooping Cough
Pertussis infection in adults with persistent cough.
Whooping Cough
Pertussis is under diagnosed in infants hospitalized with lower respiratory tract infection in the pediatric intensive care unit.
Whooping Cough
Pertussis Leukocytosis: Mechanisms, Clinical Relevance and Treatment.
Whooping Cough
Pertussis of adults and infants.
Whooping Cough
Pertussis Prevention: Reasons for Resurgence, and Differences in the Current Acellular Pertussis Vaccines.
Whooping Cough
Pertussis resurgence: waning immunity and pathogen adaptation - two sides of the same coin.
Whooping Cough
Pertussis seroepidemiology in Taipei.
Whooping Cough
Pertussis seroepidemiology in women and their infants in Sarlahi District, Nepal.
Whooping Cough
Pertussis serology: assessment of IgG anti-PT ELISA for replacement of the CHO cell assay.
Whooping Cough
Pertussis Seronegativity in Pregnant Women in the City of Al Ain, United Arab Emirates.
Whooping Cough
Pertussis seroprevalence among adults of reproductive age (20-39 years) in fourteen European countries.
Whooping Cough
Pertussis seroprevalence in different age groups in Greece.
Whooping Cough
Pertussis seroprevalence in emergency department staff.
Whooping Cough
Pertussis serosurveillance study in izmir, Turkey.
Whooping Cough
Pertussis specific cell-mediated immune responses ten years after acellular pertussis booster vaccination in young adults.
Whooping Cough
Pertussis surveillance by small serosurveys of blood donors.
Whooping Cough
Pertussis toxin (IAP) enhances maitotoxin (a putative Ca2+ channel agonist)-induced Ca2+ entry into synaptosomes.
Whooping Cough
Pertussis toxin (PTX) B subunit and the nontoxic PTX mutant PT9K/129G inhibit Tat-induced TGF-beta production by NK cells and TGF-beta-mediated NK cell apoptosis.
Whooping Cough
Pertussis toxin abolishes angiotensin II-induced phosphoinositide hydrolysis and prostaglandin synthesis in rat renal mesangial cells.
Whooping Cough
Pertussis toxin abolishes mu- and delta-opioid agonist-induced place preference.
Whooping Cough
Pertussis toxin abolishes the antinociception mediated by opioid receptors in rat spinal cord.
Whooping Cough
Pertussis toxin abolishes the cardioprotective effect of ischemic preconditioning in intact rat heart.
Whooping Cough
Pertussis toxin abolishes the effect of neuropeptide Y on rat resistance arteriole contraction.
Whooping Cough
Pertussis toxin abolishes the inhibition of Ca2+ currents and of noradrenaline release via alpha 2-adrenoceptors in chick sympathetic neurons.
Whooping Cough
Pertussis toxin abolishes the inhibitory effects of prostaglandins E1, E2, I2 and F2 alpha on hormone-induced cAMP accumulation in cultured hepatocytes.
Whooping Cough
Pertussis toxin actions on the pituitary-derived 235-1 clone: effects of PGE1, cholera toxin, and forskolin on cyclic AMP metabolism and prolactin release.
Whooping Cough
Pertussis toxin activates adult and neonatal naive human CD4+ T lymphocytes.
Whooping Cough
Pertussis toxin activates L-arginine uptake in pulmonary endothelial cells through downregulation of PKC-alpha activity.
Whooping Cough
Pertussis toxin activates platelets through an interaction with platelet glycoprotein Ib.
Whooping Cough
Pertussis toxin activates protein kinase C and a tyrosine protein kinase in the human T cell line Jurkat.
Whooping Cough
Pertussis toxin activates tyrosine kinase signaling cascade in myelomonocytic cells: a mechanism for cell adhesion.
Whooping Cough
Pertussis toxin administered spinally induces a hypoglycemic effect on normal and diabetic mice.
Whooping Cough
Pertussis toxin administration increases the expression of proneurotensin and preproenkephalin A mRNAs in rat striatum.
Whooping Cough
Pertussis toxin alters the concentration and turnover of manganese superoxide dismutase in rat lung.
Whooping Cough
Pertussis toxin alters the growth characteristics of Swiss 3T3 cells.
Whooping Cough
Pertussis toxin alters the innate and the adaptive immune responses in a pertussis-dependent model of autoimmunity.
Whooping Cough
Pertussis Toxin Ameliorates Microglial Activation Associated With Ischemic Stroke.
Whooping Cough
Pertussis toxin analog with reduced enzymatic and biological activities is a protective immunogen.
Whooping Cough
Pertussis toxin and 4-aminopyridine differentially affect the hypnotic-anesthetic action of dexmedetomidine and pentobarbital.
Whooping Cough
Pertussis toxin and adenylate cyclase toxin provide a one-two punch for establishment of Bordetella pertussis infection of the respiratory tract.
Whooping Cough
Pertussis toxin and adenylate cyclase toxin: key virulence factors of Bordetella pertussis and cell biology tools.
Whooping Cough
Pertussis toxin and extracytoplasmic adenylate cyclase as virulence factors of Bordetella pertussis.
Whooping Cough
Pertussis toxin and H-7 distinguish mechanisms involved in eicosanoid release from lipopolysaccharide-primed macrophages. Eicosanoid release from lipopolysaccharide-primed macrophages.
Whooping Cough
Pertussis toxin and its binding unit inhibit HIV-1 infection of human cervical tissue and macrophages involving a CD14 pathway.
Whooping Cough
Pertussis toxin and lipopolysaccharide influence phagocytosis of Bordetella pertussis by human monocytes.
Whooping Cough
Pertussis toxin and N-ethylmaleimide inhibit histamine- but not calcium ionophore-induced endothelium-dependent relaxation.
Whooping Cough
Pertussis toxin and pre-junctional alpha 2-adrenoreceptors in rat heart and vas deferens.
Whooping Cough
Pertussis toxin and target eukaryotic cells: binding, entry, and activation.
Whooping Cough
Pertussis toxin and the adenylate cyclase toxin from Bordetella pertussis activate human monocyte-derived dendritic cells and dominantly inhibit cytokine production through a cAMP-dependent pathway.
Whooping Cough
Pertussis toxin and voltage dependence distinguish multiple pathways modulating calcium channels of rat sympathetic neurons.
Whooping Cough
Pertussis toxin as a probe of neutrophil activation.
Whooping Cough
Pertussis toxin as an adjuvant suppresses the number and function of CD4(+)CD25(+) T regulatory cells.
Whooping Cough
Pertussis toxin attenuates 5-hydroxytryptamine1A receptor-mediated inhibition of forskolin-stimulated adenylate cyclase activity in rat hippocampal membranes.
Whooping Cough
Pertussis toxin attenuates angiotensin II but not beta-adrenoceptor facilitation of noradrenaline release from rat kidney cortex.
Whooping Cough
Pertussis toxin attenuates angiotensin II-induced vasoconstriction and inhibition of renin release.
Whooping Cough
Pertussis toxin attenuates atrial natriuretic factor-mediated inhibition of adenylate cyclase. Involvement of inhibitory guanine nucleotide regulatory protein.
Whooping Cough
Pertussis toxin attenuates clonidine inhibition of catecholamine release in adrenal chromaffin cells.
Whooping Cough
Pertussis toxin attenuates D2 inhibition and enhances D1 stimulation of adenylate cyclase by dopamine in rat striatum.
Whooping Cough
Pertussis toxin attenuates experimental autoimmune encephalomyelitis by upregulating neuronal vascular endothelial growth factor.
Whooping Cough
Pertussis toxin attenuates intracranial morphine self-administration.
Whooping Cough
Pertussis toxin attenuates platelet-activating factor-induced pulmonary hemodynamic alterations in pigs.
Whooping Cough
Pertussis toxin attenuates postsynaptic actions of neuropeptide Y on the guinea-pig uterine artery.
Whooping Cough
Pertussis toxin attenuates presynaptic inhibition of cholinergic but not nonadrenergic noncholinergic contraction in guinea pig airways.
Whooping Cough
Pertussis toxin augments beta-adrenergic relaxation of muscarinic contraction in canine trachealis.
Whooping Cough
Pertussis toxin B-oligomer dissociates T cell activation and HIV replication in CD4 T cells released from infected lymphoid tissue.
Whooping Cough
Pertussis toxin B-oligomer inhibits HIV infection and replication in hu-PBL-SCID mice.
Whooping Cough
Pertussis toxin B-oligomer suppresses human immunodeficiency virus-1 Tat-induced neuronal apoptosis through feedback inhibition of phospholipase C-beta by protein kinase C.
Whooping Cough
Pertussis toxin B-oligomer suppresses IL-6 induced HIV-1 and chemokine expression in chronically infected U1 cells via inhibition of activator protein 1.
Whooping Cough
Pertussis toxin B-pentamer mediates intercellular transfer of membrane proteins and lipids.
Whooping Cough
Pertussis toxin B-subunit-induced Ca2(+)-fluxes in Jurkat human lymphoma cells: the action of long-term pre-treatment with cholera and pertussis holotoxins.
Whooping Cough
Pertussis toxin blocks 5-HT1A and GABAB receptor-mediated inhibition of serotonergic neurons.
Whooping Cough
Pertussis toxin blocks a late inhibitory postsynaptic potential in hippocampal CA3 neurons.
Whooping Cough
Pertussis toxin blocks activin A-induced production of inositol phosphates in rat hepatocytes.
Whooping Cough
Pertussis toxin blocks adenosine A1 receptor mediated protection of the ischemic rat heart.
Whooping Cough
Pertussis toxin blocks an inhibition of hormone-stimulated glycogenolysis by prostaglandin E2 and its analogue in cultured hepatocytes.
Whooping Cough
Pertussis toxin blocks angiotensin II-induced calcium influx but not inositol trisphosphate production in adrenal glomerulosa cell.
Whooping Cough
Pertussis toxin blocks autoreceptor-mediated inhibition of dopaminergic neurons in rat substantia nigra.
Whooping Cough
Pertussis toxin blocks both cyclic AMP-mediated and cyclic AMP-independent actions of somatostatin. Evidence for coupling of Ni to decreases in intracellular free calcium.
Whooping Cough
Pertussis toxin blocks depressant effects of opioid, monoaminergic and muscarinic agonists on dorsal-horn network responses in spinal cord-ganglion cultures.
Whooping Cough
Pertussis toxin blocks M2 muscarinic receptor-mediated effects on contraction and cyclic AMP in the guinea pig ileum, but not M3-mediated contractions and phosphoinositide hydrolysis.
Whooping Cough
Pertussis toxin blocks melatonin-induced inhibition of forskolin-stimulated adenylate cyclase activity in the chick brain.
Whooping Cough
Pertussis toxin blocks melatonin-induced pigment aggregation in Xenopus dermal melanophores.
Whooping Cough
Pertussis toxin blocks presynaptic glutamate receptors--a novel 'glutamateB' receptor in the lobster neuromuscular synapse.
Whooping Cough
Pertussis toxin blocks somatostatin inhibition of calcium mobilization and reduces the affinity of somatostatin receptors for agonists.
Whooping Cough
Pertussis toxin blocks somatostatin's inhibition of stimulated cyclic AMP accumulation in anterior pituitary tumor cells.
Whooping Cough
Pertussis toxin blocks the action of morphine, norepinephrine and clonidine on isolated guinea-pig ileum.
Whooping Cough
Pertussis toxin blocks the dipsogenic actions of carbachol, but does not block the dipsogenic and pressor actions of angiotensin II.
Whooping Cough
Pertussis toxin blocks the effects of alpha 2-agonists and antagonists on locus coeruleus activity in vivo.
Whooping Cough
Pertussis toxin blocks the inhibitory effect of adenosine on rat cerebral cortical neurons.
Whooping Cough
Pertussis toxin blocks the inhibitory effect of muscarinic cholinergic agonists on cyclic AMP accumulation and prolactin secretion in GH3 anterior-pituitary tumour cells.
Whooping Cough
Pertussis toxin blocks the inhibitory effects of calcitonin on cyclic AMP accumulation in stimulated cultured human monocytes.
Whooping Cough
Pertussis toxin blocks the inhibitory effects of somatostatin on cAMP-dependent vasoactive intestinal peptide and cAMP-independent thyrotropin releasing hormone-stimulated prolactin secretion of GH3 cells.
Whooping Cough
Pertussis toxin blocks the outward currents evoked by opiate and alpha 2-agonists in locus coeruleus neurons.
Whooping Cough
Pertussis toxin blocks the somatostatin-induced inhibition of growth hormone release and adenosine 3',5'-monophosphate accumulation.
Whooping Cough
Pertussis toxin by inducing IL-6 promotes the generation of IL-17-producing CD4 cells.
Whooping Cough
Pertussis toxin can activate human platelets. Comparative effects of holotoxin and its ADP-ribosylating S1 subunit.
Whooping Cough
Pertussis toxin can distinguish the augmentary effect elicited by epidermal growth factor from that of phorbol ester on luteal adenylate cyclase activity.
Whooping Cough
Pertussis toxin can replace T cell receptor signals that induce positive selection of CD8 T cells.
Whooping Cough
Pertussis toxin catalyzed ADP-ribosylation of a 41 kDa G-protein impairs insulin-stimulated glucose metabolism in BC3H-1 myocytes.
Whooping Cough
Pertussis toxin catalyzes the ADP-ribosylation of two distinct peptides, 40 and 41 kDa, in rat fat cell membranes.
Whooping Cough
Pertussis toxin converts hyperpolarizations caused by alpha(2)-adrenoceptor agonists containing an imidazoline moiety into depolarizations in MIN 6 cells.
Whooping Cough
Pertussis toxin decreases absence seizures and GABA(B) receptor binding in thalamus of a genetically prone rat (GAERS).
Whooping Cough
Pertussis toxin decreases opiate receptor binding and adenylate inhibition in a neuroblastoma x glioma hybrid cell line.
Whooping Cough
Pertussis toxin differentially reduces the efficacy of opioids to produce supraspinal analgesia in the mouse.
Whooping Cough
Pertussis toxin differentiates between alpha 1- and alpha 2-adrenoceptor-mediated inhibition of noradrenaline release from rat kidney cortex.
Whooping Cough
Pertussis toxin differentiates between two mechanisms of attenuation of cyclic AMP accumulation by muscarinic cholinergic receptors.
Whooping Cough
Pertussis toxin directly activates endothelial cell p42/p44 MAP kinases via a novel signaling pathway.
Whooping Cough
Pertussis toxin distinguishes between muscarinic receptor-mediated inhibition of adenylate cyclase and stimulation of phosphoinositide hydrolysis in Flow 9000 cells.
Whooping Cough
Pertussis toxin does not affect the adenosine-induced inhibition of the efferent function of cardiac capsaicin-sensitive nerves.
Whooping Cough
Pertussis toxin does not affect the time course of exocytosis in mast cells stimulated by intracellular application of GTP-gamma-S.
Whooping Cough
Pertussis toxin does not affect the time course of quantal release in crayfish and mouse muscle, but has other post- and presynaptic effects, especially on adenosine autoreceptors.
Whooping Cough
Pertussis toxin does not attenuate alpha 2-adrenoceptor mediated inhibition of noradrenaline release in mouse atria.
Whooping Cough
Pertussis toxin does not inhibit alpha 1-adrenergic potentiation of beta-adrenergic stimulation of cyclic AMP accumulation in rat pinealocytes.
Whooping Cough
Pertussis toxin does not inhibit muscarinic-receptor-mediated phosphoinositide hydrolysis or calcium mobilization.
Whooping Cough
Pertussis toxin does not inhibit the alpha 1-adrenoceptor-mediated effect on inositol phosphate production in the heart.
Whooping Cough
Pertussis toxin does not prevent alpha adrenergic stimulated breakdown of phosphoinositides or respiration in brown adipocytes.
Whooping Cough
Pertussis toxin effects on adenylate cyclase activity, cyclic AMP accumulation and lipolysis in adipocytes from hypothyroid, euthyroid and hyperthyroid rats.
Whooping Cough
Pertussis toxin effects on chemoattractant-induced response heterogeneity in human PMNs utilizing Fluo-3 and flow cytometry.
Whooping Cough
Pertussis toxin effects on T lymphocytes are mediated through CD3 and not by pertussis toxin catalyzed modification of a G protein.
Whooping Cough
Pertussis toxin effects on transmitter release from perivascular nerve terminals.
Whooping Cough
Pertussis toxin enhanced IgG1 and IgE responses to primary tetanus immunization are mediated by interleukin-4 and persist during secondary responses to tetanus alone.
Whooping Cough
Pertussis toxin enhances colony organization of enzymatic-dissociated single human embryonic stem cells.
Whooping Cough
Pertussis toxin enhances fetal calf serum-induced alkaline phosphatase activity in osteoblast-like cells.
Whooping Cough
Pertussis toxin enhances follicle-stimulating hormone-stimulated cAMP production in rat seminiferous tubules in a stage-dependent manner.
Whooping Cough
Pertussis toxin enhances human immunodeficiency virus type 1 replication.
Whooping Cough
Pertussis toxin enhances proenkephalin synthesis in bovine chromaffin cells.
Whooping Cough
Pertussis toxin enhances Th1 responses by stimulation of dendritic cells.
Whooping Cough
Pertussis toxin enhances the beta-adrenergic and blocks the alpha 2-adrenergic regulation of renin secretion in renal cortical slices.
Whooping Cough
Pertussis toxin exacerbates and prolongs airway inflammatory responses during Bordetella pertussis infection.
Whooping Cough
Pertussis Toxin Exploits Host Cell Signaling Pathways Induced by Meningitis-Causing E. coli K1-RS218 and Enhances Adherence of Monocytic THP-1 Cells to Human Cerebral Endothelial Cells.
Whooping Cough
Pertussis Toxin Exploits Specific Host Cell Signaling Pathways for Promoting Invasion and Translocation of Escherichia coli K1 RS218 in Human Brain-derived Microvascular Endothelial Cells.
Whooping Cough
Pertussis toxin export genes are regulated by the ptx promoter and may be required for efficient translation of ptx mRNA in Bordetella pertussis.
Whooping Cough
Pertussis toxin export requires accessory genes located downstream from the pertussis toxin operon.
Whooping Cough
Pertussis toxin expression in Drosophila alters the visual response and blocks eating behaviour.
Whooping Cough
Pertussis toxin facilitates secretagogue-induced catecholamine release from cultured bovine adrenal chromaffin cells.
Whooping Cough
Pertussis toxin facilitates the progesterone-induced maturation of Xenopus oocyte. Possible role of protein phosphorylation.
Whooping Cough
Pertussis toxin from Bordetella pertussis blocks neutrophil migration and neutrophil-dependent edema in response to inflammation.
Whooping Cough
Pertussis toxin gene: nucleotide sequence and genetic organization.
Whooping Cough
Pertussis toxin has eukaryotic-like carbohydrate recognition domains.
Whooping Cough
Pertussis toxin IgA testing over-diagnoses recent pertussis infection.
Whooping Cough
Pertussis toxin improves immune responses to a combined pneumococcal antigen and leads to enhanced protection against Streptococcus pneumoniae.
Whooping Cough
Pertussis toxin in the A10 region increases dopamine synthesis and metabolism.
Whooping Cough
Pertussis toxin in the analysis of receptor mechanisms.
Whooping Cough
Pertussis toxin inactivates the presynaptic serotonin autoreceptor in the hippocampus.
Whooping Cough
Pertussis toxin increases isoproterenol induced relaxation in field-stimulated ileum.
Whooping Cough
Pertussis toxin increases sensitivity to the lethal effect of morphine in mice.
Whooping Cough
Pertussis toxin induces angiogenesis in brain microvascular endothelial cells.
Whooping Cough
Pertussis toxin induces bronchopulmonary hyperresponsiveness in guinea-pigs while antagonizing the effects of formyl-L-methionyl-L-leucyl-L-phenylalanine.
Whooping Cough
Pertussis toxin induces fatty liver, hyperlipemia and ketosis in hamsters.
Whooping Cough
Pertussis toxin induces lymphocytosis in rhesus macaques.
Whooping Cough
Pertussis toxin induces parallel loss of neuropeptide Y Y1 receptor dimers and Gi alpha subunit function in CHO cells.
Whooping Cough
Pertussis toxin induces structural changes in G alpha proteins independently of ADP-ribosylation.
Whooping Cough
Pertussis toxin inhibition of alpha 1-adrenergic or vasopressin-induced Ca2+ fluxes in rat liver. Selective inhibition of the alpha 1-adrenergic receptor-coupled metabolic activation.
Whooping Cough
Pertussis toxin inhibition of anti-immunoglobulin-stimulated proliferation and inositol phosphate formation.
Whooping Cough
Pertussis toxin inhibition of B cell and macrophage responses to bacterial lipopolysaccharide.
Whooping Cough
Pertussis toxin inhibition of chemotactic factor-induced calcium mobilization and function in human polymorphonuclear leukocytes.
Whooping Cough
Pertussis toxin inhibition of chemotaxis and the ADP-ribosylation of a membrane protein in a human-mouse hybrid cell line.
Whooping Cough
Pertussis toxin inhibition of T-cell hybridoma invasion is reversed by manganese-induced activation of LFA-1.
Whooping Cough
Pertussis toxin inhibits 1-methyladenine-induced maturation in starfish oocytes.
Whooping Cough
Pertussis toxin inhibits activation-induced cell death of human thymocytes, pre-B leukemia cells and monocytes.
Whooping Cough
Pertussis toxin inhibits alpha 2-adrenoceptor-mediated inhibition of adenylate cyclase without affecting muscarinic regulation of [Ca2+]i or inositol phosphate generation in SH-SY5Y human neuroblastoma cells.
Whooping Cough
Pertussis toxin inhibits angiotensin II-mediated phosphatidylinositol breakdown and ADP-ribosylates a 40 Kd protein in cultured smooth muscle cells.
Whooping Cough
Pertussis toxin inhibits antinociception produced by intrathecal injection of morphine, noradrenaline and baclofen.
Whooping Cough
Pertussis toxin inhibits autophosphorylation and activation of the insulin receptor kinase.
Whooping Cough
Pertussis toxin inhibits cAMP surface receptor-stimulated binding of [35S]GTP gamma S to Dictyostelium discoideum membranes.
Whooping Cough
Pertussis toxin inhibits cAMP-induced desensitization of adenylate cyclase in Dictyostelium discoideum.
Whooping Cough
Pertussis toxin inhibits chemotactic factor-induced phospholipase C stimulation and lysosomal enzyme secretion in rabbit neutrophils.
Whooping Cough
Pertussis toxin inhibits chemotactic peptide-stimulated generation of inositol phosphates and lysosomal enzyme secretion in human leukemic (HL-60) cells.
Whooping Cough
Pertussis toxin inhibits cholecystokinin- and epidermal growth factor-induced mitogen-activated protein kinase activation by disinhibition of the cAMP signaling pathway and inhibition of c-Raf-1.
Whooping Cough
Pertussis toxin inhibits contractions but not endothelium-dependent relaxations of rabbit pulmonary artery in response to acetylcholine and other agonists.
Whooping Cough
Pertussis toxin inhibits differentiation induced by retinoic acid in a human promyelocytic leukemia cell line HL-60.
Whooping Cough
Pertussis toxin inhibits early chemokine production to delay neutrophil recruitment in response to Bordetella pertussis respiratory tract infection in mice.
Whooping Cough
Pertussis toxin inhibits EGF-, phorbol ester- and insulin-stimulated DNA synthesis in BALB/c3T3 cells: evidence for post-receptor activation of Gi alpha.
Whooping Cough
Pertussis Toxin Inhibits Encephalitogenic T-Cell Infiltration and Promotes a B-Cell-Driven Disease during Th17-EAE.
Whooping Cough
Pertussis toxin inhibits endothelium-dependent relaxations evoked by fluoride.
Whooping Cough
Pertussis toxin inhibits endothelium-dependent relaxations to certain agonists in porcine coronary arteries.
Whooping Cough
Pertussis toxin inhibits enkephalin stimulation of GTPase of NG108-15 cells.
Whooping Cough
Pertussis toxin inhibits fMet-Leu-Phe- but not phorbol ester-stimulated changes in rabbit neutrophils: role of G proteins in excitation response coupling.
Whooping Cough
Pertussis toxin inhibits hormonal stimulation of bone resorption in fetal rat limb bones.
Whooping Cough
Pertussis toxin inhibits human neutrophil responses mediated by the 42-kilodalton IgG Fc receptor.
Whooping Cough
Pertussis toxin inhibits induction of human immunodeficiency virus type 1 in infected monocytes.
Whooping Cough
Pertussis toxin inhibits induction of tissue-specific autoimmune disease by disrupting G protein-coupled signals.
Whooping Cough
Pertussis toxin inhibits intracellular pH changes in human neutrophils stimulated by N-formyl-methionyl-leucyl-phenylalanine.
Whooping Cough
Pertussis toxin inhibits migration of B and T lymphocytes into splenic white pulp cords.
Whooping Cough
Pertussis toxin inhibits morphine analgesia and prevents opiate dependence.
Whooping Cough
Pertussis toxin inhibits morphine-induced release of adenosine from the spinal cord.
Whooping Cough
Pertussis toxin inhibits negative inotropic and negative chronotropic muscarinic cholinergic effects on the heart.
Whooping Cough
Pertussis toxin inhibits neuropeptide Y-induced feeding in rats.
Whooping Cough
Pertussis toxin inhibits neutrophil recruitment to delay antibody-mediated clearance of Bordetella pertussis.
Whooping Cough
Pertussis toxin inhibits noradrenaline accumulation by bovine adrenal medullary chromaffin cells.
Whooping Cough
Pertussis toxin inhibits norepinephrine-stimulated inositol phosphate formation in primary brain cell cultures.
Whooping Cough
Pertussis toxin inhibits phospholipase C activation and Ca2+ mobilization by sphingosylphosphorylcholine and galactosylsphingosine in HL60 leukemia cells. Implications of GTP-binding protein-coupled receptors for lysosphingolipids.
Whooping Cough
Pertussis toxin inhibits retinoic acid-induced expression of tissue transglutaminase in macrophages.
Whooping Cough
Pertussis toxin inhibits signal transduction at a specific metabolotropic glutamate receptor in primary cultures of cerebellar granule cells.
Whooping Cough
Pertussis toxin inhibits somatostatin-induced K+ conductance in human pituitary tumor cells.
Whooping Cough
Pertussis toxin inhibits stimulated motility independently of the adenylate cyclase pathway in human melanoma cells.
Whooping Cough
Pertussis toxin inhibits the action of insulin-like growth factor-I.
Whooping Cough
Pertussis toxin inhibits the angiotensin II and serotonin-induced rise of free cytoplasmic calcium in cultured smooth muscle cells from rat aorta.
Whooping Cough
Pertussis toxin inhibits the antinociceptive action of morphine in the rat.
Whooping Cough
Pertussis toxin inhibits the behavioural and ECoG effects induced by clonidine and yohimbine after their microinfusion into the locus coeruleus.
Whooping Cough
Pertussis toxin inhibits the FMLP-induced membrane association of protein kinase C in human neutrophils.
Whooping Cough
Pertussis toxin inhibits the rise in the intracellular concentration of free calcium that is induced by chemotactic factors in rabbit neutrophils: possible role of the "G proteins" in calcium mobilization.
Whooping Cough
Pertussis toxin inhibits thrombin-induced activation of phosphoinositide hydrolysis and Na+/H+ exchange in hamster fibroblasts.
Whooping Cough
Pertussis toxin interferes with superantigen-induced deletion of peripheral T cells without affecting T cell activation in vivo. Inhibition of deletion and associated programmed cell death depends on ADP-ribosyltransferase activity.
Whooping Cough
Pertussis Toxin Is a Robust and Selective Inhibitor of High Grade Glioma Cell Migration and Invasion.
Whooping Cough
Pertussis toxin is required for pertussis vaccine encephalopathy.
Whooping Cough
Pertussis toxin is superior to TLR ligands in enhancing pathogenic autoimmunity, targeted at a neo-self antigen, by triggering robust expansion of Th1 cells and their cytokine production.
Whooping Cough
Pertussis toxin lesioning of the nucleus caudate-putamen attenuates adenylate cyclase inhibition and alters neuronal electrophysiological activity.
Whooping Cough
Pertussis toxin lesions of the rat substantia nigra block the inhibitory effects of the gamma-hydroxybutyrate agent, S(-)HA-966 without affecting the basal firing properties of dopamine neurons.
Whooping Cough
Pertussis toxin mediates ADP-ribosylation of pituitary membrane proteins.
Whooping Cough
Pertussis toxin modification of PC12 cells inhibits a protein phosphatase 2A-like phosphatase.
Whooping Cough
Pertussis toxin modification of PC12 cells lowers cytoskeletal F-actin and enhances norepinephrine secretion: involvement of protein kinase C and protein phosphatases.
Whooping Cough
Pertussis toxin modifies the characteristics of both the inhibitory GTP binding proteins and the somatostatin receptor in anterior pituitary tumor cells.
Whooping Cough
Pertussis toxin modifies the effect of central morphine on rat intestinal motility.
Whooping Cough
Pertussis toxin modulates dopamine inhibition of Na,K-ATPase activity in rat proximal convoluted tubule segments.
Whooping Cough
Pertussis toxin modulates microglia and T cell profile to protect experimental autoimmune encephalomyelitis.
Whooping Cough
Pertussis toxin modulates the immune response to neuroantigens injected in incomplete Freund's adjuvant: induction of Th1 cells and experimental autoimmune encephalomyelitis in the presence of high frequencies of Th2 cells.
Whooping Cough
Pertussis toxin non-sensitive G protein mediates cholinergic stimulation for secretion of pancreastatin and somatostatin from QGP-1N cells.
Whooping Cough
Pertussis toxin normalizes enhanced renovascular responses to angiotensin II in spontaneously hypertensive rats.
Whooping Cough
Pertussis Toxin Nullifies the Depolarization of the Membrane Potential and the Stimulation of the Rapid Phase of Ca Entry Through L-type Calcium Channels that are Produced by Follicle Stimulating Hormone in 10- to 12-Day-Old Rat Sertoli Cells.
Whooping Cough
Pertussis toxin or 8-bromo-cAMP block inhibition of the acoustic startle response by the alpha 2-adrenergic agonist ST-91.
Whooping Cough
Pertussis toxin or phorbol 12-myristate 13-acetate can distinguish between epidermal growth factor- and angiotensin-stimulated signals in hepatocytes.
Whooping Cough
Pertussis toxin partially inhibits phagocytosis of immunoglobulin G-opsonized Staphylococcus aureus by human granulocytes but does not affect intracellular killing.
Whooping Cough
Pertussis toxin permeabilization enhances the traversal of Escherichia coli K1, macrophages, and monocytes in a cerebral endothelial barrier model in vitro.
Whooping Cough
Pertussis toxin plays an early role in respiratory tract colonization by Bordetella pertussis.
Whooping Cough
Pertussis toxin potentiates anesthesia-induced renin secretion.
Whooping Cough
Pertussis toxin potentiates seizures induced by pilocarpine, kainic acid and N-methyl-D-aspartate.
Whooping Cough
Pertussis toxin potentiates Th1 and Th2 responses to co-injected antigen: adjuvant action is associated with enhanced regulatory cytokine production and expression of the co-stimulatory molecules B7-1, B7-2 and CD28.
Whooping Cough
Pertussis toxin pretreatment abolishes dihydropyridine inhibition of calcium flux in the 235-1 pituitary cell line.
Whooping Cough
Pertussis toxin pretreatment abolishes the inhibitory effect of riluzole and carbachol on D-[3H]aspartate release from cultured cerebellar granule cells.
Whooping Cough
Pertussis toxin pretreatment affects opiate/nonopiate and stress-induced analgesia differently.
Whooping Cough
Pertussis toxin pretreatment alters agonist binding to beta-adrenoceptors in rabbit ventricular myocardium.
Whooping Cough
Pertussis toxin pretreatment alters the in vivo cell division behaviour and survival of B lymphocytes after intravenous transfer.
Whooping Cough
Pertussis toxin pretreatment antagonizes the actions of mu- and delta-opiate agonists in hippocampal slices.
Whooping Cough
Pertussis toxin pretreatment discriminates between pre- and postsynaptic actions of baclofen in rat dorsal raphe nucleus in vitro.
Whooping Cough
Pertussis toxin pretreatment enhances catecholamine secretion induced by pituitary adenylate cyclase-activating polypeptide in cultured porcine adrenal medullary chromaffin cells: a possible role of the inositol lipid cascade.
Whooping Cough
Pertussis toxin pretreatment reveals differential effects of adenosine analogs on IgE-dependent histamine and peptidoleukotriene release from RBL-2H3 cells.
Whooping Cough
Pertussis toxin prevents adenosine receptor- and m-cholinoceptor-mediated sinus rate slowing and AV conduction block in the guinea-pig heart.
Whooping Cough
Pertussis toxin prevents homologous desensitization of adenylate cyclase in cultured renal epithelial cells.
Whooping Cough
Pertussis toxin prevents induction of hippocampal long-term potentiation in the stratum radiatum and stratum oriens inputs to CA1 neurons.
Whooping Cough
Pertussis toxin prevents neomycin-induced calcium-dependent electrophysiological effects in rat hippocampal slices.
Whooping Cough
Pertussis toxin prevents presynaptic inhibition by kainate receptors of rat hippocampal [(3)H]GABA release.
Whooping Cough
Pertussis toxin prevents the induction of peripheral T cell anergy and enhances the T cell response to an encephalitogenic peptide of myelin basic protein.
Whooping Cough
Pertussis toxin prevents the inhibitory effect of adenosine and unmasks adenosine-induced excitation of mammalian motor nerve endings.
Whooping Cough
Pertussis toxin produces differential inhibitory effects on basal, P2-purinergic, and chemotactic peptide-stimulated inositol phospholipid breakdown in HL-60 cells and HL-60 cell membranes.
Whooping Cough
Pertussis toxin promoter sequences involved in modulation.
Whooping Cough
Pertussis toxin promotes macrophage survival through inhibition of acid sphingomyelinase and activation of the phosphoinositide 3-kinase/protein kinase B pathway.
Whooping Cough
Pertussis toxin promotes pulmonary hypertension in an infant mouse model of Bordetella pertussis infection.
Whooping Cough
Pertussis toxin promotes relapsing-remitting experimental autoimmune encephalomyelitis in Lewis rats.
Whooping Cough
Pertussis toxin provides evidence for two independent signalling pathways leading to the activation of the nerve growth factor gene.
Whooping Cough
Pertussis toxin reduces calcium influx to protect ischemic stroke in a middle cerebral artery occlusion model.
Whooping Cough
Pertussis toxin reduces endothelium-dependent and independent responses to alpha-2- adrenergic stimulation in systemic canine arteries and veins.
Whooping Cough
Pertussis toxin reduces the antiadrenergic effect of 2-chloroadenosine on papillary muscle and the direct negative inotropic effect of 2-chloroadenosine on atrium.
Whooping Cough
Pertussis toxin reduces the day-night rhythm of nociception and mu and kappa opioid peptide-mediated antinociception in the snail, Cepaea nemoralis.
Whooping Cough
Pertussis toxin reduces the number of splenic Foxp3+ regulatory T cells.
Whooping Cough
Pertussis toxin relaxes small arteries with no vascular lesions or vascular smooth muscle cell injury.
Whooping Cough
Pertussis toxin reversal of the antilipolytic action of insulin in rat adipocytes in the presence of forskolin does not involve cyclic AMP.
Whooping Cough
Pertussis toxin reverses adenosine inhibition of neuronal glutamate release.
Whooping Cough
Pertussis toxin reverses adenosine receptor-mediated inhibition of renin secretion in rat renal cortical slices.
Whooping Cough
Pertussis toxin reverses Gpp(NH)p inhibition of basal and forskolin activated adipocyte adenylate cyclase.
Whooping Cough
Pertussis toxin reverses prostaglandin E2- and somatostatin-induced inhibition of rat parietal cell H(+)-production.
Whooping Cough
Pertussis toxin reverses the inhibition of insulin secretion caused by [Arg8]vasopressin in rat pancreatic islets.
Whooping Cough
Pertussis toxin reverses the inhibition of the adenylyl cyclase system by khellin in HeLa cells.
Whooping Cough
Pertussis toxin S1 mutant with reduced enzyme activity and a conserved protective epitope.
Whooping Cough
Pertussis toxin selectively abolishes hormone induced lowering of cytosolic calcium in GH3 cells.
Whooping Cough
Pertussis toxin selectively interferes with the responses of the HL-60 human promyelocytic cell line to dimethylsulfoxide.
Whooping Cough
Pertussis toxin sensitive and insensitive effects of adenosine and carbachol in murine atria overexpressing A(1)-adenosine receptors.
Whooping Cough
Pertussis toxin sensitive effects of dipyridamole on rat atrial rate.
Whooping Cough
Pertussis toxin sensitive endothelin-1 coupling to inositol phosphate formation via a GTP-binding protein: comparison in SHR and WKY cultured aortic smooth muscle cells.
Whooping Cough
Pertussis toxin sensitive G-protein coupling of HDL receptor to phospholipase C in human platelets.
Whooping Cough
Pertussis toxin sensitive G-proteins are not involved in the mitogenic signaling pathway of insulin-like growth factor-I in normal rat kidney epithelial (NRKE) cells.
Whooping Cough
Pertussis toxin sensitive photoaggregation of pigment in isolated Xenopus tail-fin melanophores.
Whooping Cough
Pertussis toxin sensitivity of drug-induced potentials on the rat superior cervical ganglion.
Whooping Cough
Pertussis toxin sensitization alters the pathogenesis of subsequent respiratory syncytial virus infection.
Whooping Cough
Pertussis toxin separates two muscarinic receptor-effector mechanisms in the striatum.
Whooping Cough
Pertussis toxin shows distinct early signalling events in platelet-activating factor-, leukotriene B4-, and C5a-induced eosinophil homotypic aggregation in vitro and recruitment in vivo.
Whooping Cough
Pertussis toxin signals through the TCR to initiate cross-desensitization of the chemokine receptor CXCR4.
Whooping Cough
Pertussis toxin specifically inhibits growth cone guidance by a mechanism independent of direct G protein inactivation.
Whooping Cough
Pertussis toxin stimulates cholecystokinin-induced cyclic AMP formation but is without effect on secretagogue-induced calcium mobilization in exocrine pancreas.
Whooping Cough
Pertussis toxin stimulates delayed-onset, Ca2+-dependent catecholamine release and the ADP-ribosylation of a 40 kDa protein in bovine adrenal chromaffin cells.
Whooping Cough
Pertussis toxin stimulates hypersensitivity and enhances nerve-mediated antigen uptake in rat intestine.
Whooping Cough
Pertussis toxin stimulates IL-17 production in response to Bordetella pertussis infection in mice.
Whooping Cough
Pertussis toxin stimulates the secretion of [Met5]-enkephalin and the expression of proenkephalin A mRNA in bovine adrenal medullary chromaffin cells.
Whooping Cough
Pertussis toxin stimulation of catecholamine release from adrenal medullary chromaffin cells: mechanism may be by direct activation of L-type and G-type calcium channels.
Whooping Cough
Pertussis toxin substrate is a guanosine 5'-[beta-thio]diphosphate-, N-ethylmaleimide-, Mg2+- and temperature-sensitive GTP-binding protein.
Whooping Cough
Pertussis toxin substrate, the putative Ni component of adenylyl cyclases, is an alpha beta heterodimer regulated by guanine nucleotide and magnesium.
Whooping Cough
Pertussis toxin suppresses carbachol-evoked cardiodepression but does not modify cardiostimulation mediated through beta1- and putative beta4-adrenoceptors in mouse left atria: no evidence for beta2- and beta3-adrenoreceptor function.
Whooping Cough
Pertussis toxin suppresses long-term potentiation of hippocampal mossy fiber synapses.
Whooping Cough
Pertussis toxin targets airway macrophages to promote Bordetella pertussis infection of the respiratory tract.
Whooping Cough
Pertussis toxin targets the innate immunity through DAP12, FcR?, and MyD88 adaptor proteins.
Whooping Cough
Pertussis toxin transiently affects barrier integrity, organelle organization and transmigration of monocytes in a human brain microvascular endothelial cell barrier model.
Whooping Cough
Pertussis toxin treatment alters manganese superoxide dismutase activity in lung. Evidence for lung oxygen toxicity in air-breathing rats.
Whooping Cough
Pertussis toxin treatment attenuates some effects of insulin in BC3H-1 murine myocytes.
Whooping Cough
Pertussis toxin treatment blocks hyperpolarization by muscarinic agonists in chick atrium.
Whooping Cough
Pertussis toxin treatment blocks the inhibition of somatostatin and increases the stimulation by forskolin of cyclic AMP accumulation and adrenocorticotropin secretion from mouse anterior pituitary tumor cells.
Whooping Cough
Pertussis toxin treatment counteracts intramembrane interactions between neuropeptide Y receptors and alpha 2-adrenoceptors.
Whooping Cough
Pertussis toxin treatment counteracts the cardiovascular effects of neuropeptide Y and clonidine in the awake unrestrained rat.
Whooping Cough
Pertussis toxin treatment differentially affects cholinergic and dopaminergic receptor stimulation of midbrain dopaminergic neurons.
Whooping Cough
Pertussis toxin treatment does not inhibit the effects of the potassium channel opener BRL 34915 on rat isolated vascular and cardiac tissues.
Whooping Cough
Pertussis toxin treatment in vivo is associated with a decline in G-protein beta-subunits.
Whooping Cough
Pertussis toxin treatment in vivo reduces surface expression of the adhesion integrin leukocyte function antigen-1 (LFA-1).
Whooping Cough
Pertussis toxin treatment increases glutamate release and dihydropyridine binding sites in cultured rat cerebellar granule neurons.
Whooping Cough
Pertussis toxin treatment modifies opiate action in the rat brain striatum.
Whooping Cough
Pertussis toxin treatment of whole blood. A novel approach to assess G protein function in congestive heart failure.
Whooping Cough
Pertussis toxin treatment prevents 5-HT(5a) receptor-mediated inhibition of cyclic AMP accumulation in rat C6 glioma cells.
Whooping Cough
Pertussis toxin treatment results in tolerance to the depressant effects of opioid, monoaminergic, and muscarinic agonists on dorsal-horn network responses in mouse spinal cord-ganglion cultures.
Whooping Cough
Pertussis toxin triggers rapid second messenger production in human T lymphocytes.
Whooping Cough
Pertussis toxin uncouples dopamine agonist inhibition of prolactin release.
Whooping Cough
Pertussis toxin unmasks stimulatory myocardial A2-adenosine receptors on ventricular cardiomyocytes.
Whooping Cough
Pertussis toxin upregulates angiotensin type 1 receptors through Toll-like receptor 4-mediated Rac activation.
Whooping Cough
Pertussis toxin utilizes proximal components of the T-cell receptor complex to initiate signal transduction events in T cells.
Whooping Cough
Pertussis Toxin, an Inhibitor of G(?i) PCR, Inhibits Bile Acid- and Cytokine-Induced Apoptosis in Primary Rat Hepatocytes.
Whooping Cough
Pertussis toxin, but not tyrosine kinase inhibitors, abolishes effects of U-50488H on [Ca2+]i in myocytes.
Whooping Cough
Pertussis toxin- and PMA-insensitive calcium mobilization by sphingosine in CFPAC-1 cells: evidence for a phosphatidic acid-dependent mechanism.
Whooping Cough
Pertussis toxin-catalysed ADP-ribosylation of endometrial proteins in sheep.
Whooping Cough
Pertussis toxin-catalyzed ADP-ribosylation of a G protein in mouse oocytes, eggs, and preimplantation embryos: developmental changes and possible functional roles.
Whooping Cough
Pertussis toxin-catalyzed ADP-ribosylation of adenylate cyclase. Effects of guanyl nucleotides and rhodopsin.
Whooping Cough
Pertussis toxin-catalyzed ADP-ribosylation of G(o) alpha with mutations at the carboxyl terminus.
Whooping Cough
Pertussis toxin-catalyzed ADP-ribosylation of Gi-2 and Gi-3 in CHO cells is modulated by inhibitors of intracellular trafficking.
Whooping Cough
Pertussis toxin-catalyzed ADP-ribosylation of GTP-binding proteins with digoxigenin-conjugated NAD. Identification of the proteins in plasma membranes and nuclei.
Whooping Cough
Pertussis toxin-catalyzed ADP-ribosylation of transducin. Cysteine 347 is the ADP-ribose acceptor site.
Whooping Cough
Pertussis toxin-catalyzed ADP-ribosylation: effects on the coupling of inhibitory receptors to the adenylate cyclase system.
Whooping Cough
Pertussis toxin-dependent and -independent hormonal effects on cultured renal epithelioid cells.
Whooping Cough
Pertussis toxin-induced ADP ribosylation of inhibitor G proteins alters vagal control of heart rate in vivo.
Whooping Cough
Pertussis toxin-induced alterations of murine hepatic drug metabolism following administration of diphtheria and tetanus toxoids and pertussis vaccine adsorbed.
Whooping Cough
Pertussis toxin-induced cytokine differentiation and clonal expansion of T cells is mediated predominantly via costimulation.
Whooping Cough
Pertussis toxin-induced histamine sensitisation: an aspecific phenomenon independent from the nitric oxide system?
Whooping Cough
Pertussis toxin-induced hyperacute autoimmune encephalomyelitis in Lewis rats is correlated with increased expression of inducible nitric oxide synthase and tumor necrosis factor alpha.
Whooping Cough
Pertussis toxin-induced inflammatory response exacerbates intracerebral haemorrhage and ischaemic stroke in mice.
Whooping Cough
Pertussis toxin-induced lung edema. Role of manganese superoxide dismutase and protein kinase C.
Whooping Cough
Pertussis toxin-induced lymphocytosis is associated with alterations in thymocyte subpopulations.
Whooping Cough
Pertussis toxin-induced mitogenesis in human T lymphocytes.
Whooping Cough
Pertussis toxin-induced redistribution of cortical actomyosin and inhibition of phagocytosis in rat Kupffer cells.
Whooping Cough
Pertussis toxin-induced reversible encephalopathy dependent on monocyte chemoattractant protein-1 overexpression in mice.
Whooping Cough
Pertussis toxin-insensitive activation of the heterotrimeric G-proteins Gi/Go by the NG108-15 G-protein activator.
Whooping Cough
Pertussis toxin-insensitive effects of mastoparan, a wasp venom peptide, in PC12 cells.
Whooping Cough
Pertussis toxin-insensitive G protein mediates substance P-induced inhibition of potassium channels in brain neurons.
Whooping Cough
Pertussis toxin-insensitive phosphoinositide hydrolysis, membrane depolarization, and positive inotropic effect of carbachol in chick atria.
Whooping Cough
Pertussis toxin-insensitive regulation of phosphatidylinositol hydrolysis by vanadate in brain microvessels.
Whooping Cough
Pertussis toxin-insensitive signaling of the ORL1 receptor: coupling to Gz and G16 proteins.
Whooping Cough
Pertussis toxin-mediated ADP-ribosylation of rabbit luteal Gi uncouples enkephalin inhibition of adenylyl cyclase.
Whooping Cough
Pertussis toxin-mediated ADP-ribosylation of target proteins in Chinese hamster ovary cells involves a vesicle trafficking mechanism.
Whooping Cough
Pertussis toxin-sensitive activation of p21ras by G protein-coupled receptor agonists in fibroblasts.
Whooping Cough
Pertussis toxin-sensitive activation of phospholipase A2 can be resolved from phosphoinositidase C in primary cultures of mouse osteoblasts using indomethacin.
Whooping Cough
Pertussis toxin-sensitive activation of phospholipase C by the C5a and fMet-Leu-Phe receptors.
Whooping Cough
Pertussis toxin-sensitive airway beta-adrenergic dysfunction by somatostatin.
Whooping Cough
Pertussis toxin-sensitive and -insensitive mechanisms for diacylglycerol-protein kinase C signalling during insulin action in BC3H-1 myocytes.
Whooping Cough
Pertussis toxin-sensitive and -insensitive mechanisms of alpha1-adrenoceptor-mediated inotropic responses in rat heart.
Whooping Cough
Pertussis toxin-sensitive and -insensitive thrombin stimulation of Shc phosphorylation and mitogenesis are mediated through distinct pathways.
Whooping Cough
Pertussis toxin-sensitive and insensitive intracellular signalling pathways in undifferentiated 3T3-L1 cells stimulated by insulin converge with phosphatidylinositol 3-kinase upstream of the Ras mitogen-activated protein kinase cascade.
Whooping Cough
Pertussis toxin-sensitive and pertussis toxin-insensitive inhibition of parietal cell response to GLP-1 and histamine.
Whooping Cough
Pertussis toxin-sensitive cholinergic inhibition of somatostatin release from canine D-cells.
Whooping Cough
Pertussis toxin-sensitive factor differentially regulates lipopolysaccharide-induced tumor necrosis factor-alpha and nitric oxide production in mouse peritoneal macrophages.
Whooping Cough
Pertussis toxin-sensitive G protein alpha-subunits: production of monoclonal antibodies and detection of differential increases on differentiation of PC12 and LA-N-5 cells.
Whooping Cough
Pertussis toxin-sensitive G protein but not NO/cGMP pathway mediates the negative inotropic effect of carbachol in adult rat cardiomyocytes.
Whooping Cough
Pertussis toxin-sensitive G protein mediates coronary microvascular control during autoregulation and ischemia in canine heart.
Whooping Cough
Pertussis toxin-sensitive G protein mediation of PGE2 inhibition of cAMP metabolism and phasic glucose-induced insulin secretion in HIT cells.
Whooping Cough
Pertussis toxin-sensitive G protein modulates the ability of histamine to stimulate cAMP production in the chick pineal gland.
Whooping Cough
Pertussis toxin-sensitive G protein that supports vitellogenin uptake by promoting patency.
Whooping Cough
Pertussis toxin-sensitive G proteins as mediators of stretch-induced decrease in nitric-oxide release of osteoblast-like cells.
Whooping Cough
Pertussis toxin-sensitive G proteins as mediators of the signal transduction pathways activated by cytomegalovirus infection of smooth muscle cells.
Whooping Cough
Pertussis toxin-sensitive G proteins in regenerated endothelial cells of porcine coronary artery.
Whooping Cough
Pertussis toxin-sensitive G proteins influence nitric oxide synthase III activity and protein levels in rat heart.
Whooping Cough
Pertussis toxin-sensitive G proteins mediate carbachol-induced REM sleep and respiratory depression.
Whooping Cough
Pertussis toxin-sensitive G proteins mediate the inhibition of basal phosphoinositide metabolism caused by adenosine A1 receptors in rat hippocampal slices.
Whooping Cough
Pertussis toxin-sensitive G(i)-proteins and intracellular calcium sensitivity of vasoconstriction in the intact rat tail artery.
Whooping Cough
Pertussis toxin-sensitive G-protein activation does not influence the response to Bay K 8644 in embryonic chick myocytes.
Whooping Cough
Pertussis toxin-sensitive G-protein and protein kinase C activity are involved in normal synapse elimination in the neonatal rat muscle.
Whooping Cough
Pertussis toxin-sensitive G-protein mediates galanin's inhibition of scopolamine-evoked acetylcholine release in vivo and carbachol-stimulated phosphoinositide turnover in rat ventral hippocampus.
Whooping Cough
Pertussis toxin-sensitive G-proteins and regulation of blood pressure in the spontaneously hypertensive rat.
Whooping Cough
Pertussis toxin-sensitive G-proteins are not involved in activation of T-lymphocytes.
Whooping Cough
Pertussis toxin-sensitive G-proteins in the sino-atrial node and right atrium of bovine heart.
Whooping Cough
Pertussis toxin-sensitive G-proteins inhibit fibroblast growth factor-induced signaling in pancreatic acini.
Whooping Cough
Pertussis toxin-sensitive G-proteins regulate lymphoid lineage specification in multipotent hematopoietic progenitors.
Whooping Cough
Pertussis toxin-sensitive Galphai protein and ERK-dependent pathways mediate ultrasound promotion of osteogenic transcription in human osteoblasts.
Whooping Cough
Pertussis toxin-sensitive Gi protein involvement in epidermal growth factor-induced activation of phospholipase C-gamma in rat hepatocytes.
Whooping Cough
Pertussis toxin-sensitive Gi/o proteins are involved in nerve growth factor-induced pro-survival Akt signaling cascade in PC12 cells.
Whooping Cough
Pertussis toxin-sensitive GTP-binding proteins characterized in synaptosomal fractions of embryonic avian cerebral cortex.
Whooping Cough
Pertussis toxin-sensitive GTP-binding proteins may regulate phospholipase A2 in response to thrombin in rabbit platelets.
Whooping Cough
Pertussis toxin-sensitive GTP-binding proteins regulate activation-induced apoptotic cell death of human natural killer cells.
Whooping Cough
Pertussis toxin-sensitive heterotrimeric G?i/o proteins mediate WNT/?-catenin and WNT/ERK1/2 signaling in mouse primary microglia stimulated with purified WNT-3A.
Whooping Cough
Pertussis toxin-sensitive inhibition of glucagon-like peptide 1-stimulated acid production by epidermal growth factor and transforming growth factor alpha in rat parietal cells.
Whooping Cough
Pertussis toxin-sensitive melatonin receptors negatively coupled to adenylate cyclase associated with cultured human and rat retinal pigment epithelial cells.
Whooping Cough
Pertussis toxin-sensitive modulation of glutamate transport by endothelin-1 type A receptors in glioma cells.
Whooping Cough
Pertussis toxin-sensitive muscarinic relaxation in the rat iris dilator muscle.
Whooping Cough
Pertussis toxin-sensitive pathway in the stimulation of c-myc expression and DNA synthesis by bombesin.
Whooping Cough
Pertussis toxin-sensitive pathway inhibits glucose-stimulated Ca2+ signals of rat islet beta-cells by affecting L-type Ca2+ channels and voltage-dependent K+ channels.
Whooping Cough
Pertussis toxin-sensitive secretory phospholipase A2 expression and motility in activated primary human keratinocytes.
Whooping Cough
Pertussis toxin-sensitive signal controls the trafficking of thymocytes across the corticomedullary junction in the thymus.
Whooping Cough
Pertussis toxin-treated dog: a whole animal model of impaired inhibitory regulation of adenylate cyclase.
Whooping Cough
Pertussis toxin. Affinity purification of a new ADP-ribosyltransferase.
Whooping Cough
Pertussis toxin. Entry into cells and enzymatic activity.
Whooping Cough
Pertussis Toxin: A Key Component in Pertussis Vaccines?
Whooping Cough
Pertussis toxin: a tool for studying the regulation of adenylate cyclase.
Whooping Cough
Pertussis toxin: lessons from biological and biochemical effects in different cells.
Whooping Cough
Pertussis toxin: the cause of the harmful effects and prolonged immunity of whooping cough. A hypothesis.
Whooping Cough
Pertussis toxin: transition state analysis for ADP-ribosylation of G-protein peptide alphai3C20.
Whooping Cough
Pertussis vaccination during pregnancy in Belgium: Follow-up of infants until 1 month after the fourth infant pertussis vaccination at 15 months of age.
Whooping Cough
Pertussis vaccination during pregnancy in Belgium: Results of a prospective controlled cohort study.
Whooping Cough
Pertussis vaccination during pregnancy in Vietnam: Results of a randomized controlled trial Pertussis vaccination during pregnancy.
Whooping Cough
Pertussis vaccine and pertussis toxin increase lithium levels in rats: possible role of G-proteins.
Whooping Cough
Pertussis vaccine: a critique.
Whooping Cough
Pertussis whole cell vaccine: relation between intracerebral protection in mice and antibody response to pertussis toxin, filamentous hemagglutinin and adenylate cyclase.
Whooping Cough
Pertussis-specific cell-mediated immunity in infants after vaccination with a tricomponent acellular pertussis vaccine.
Whooping Cough
Pertussis-toxin insensitive enkephalin inhibition of adenylyl cyclase in lacrimal acinar cells.
Whooping Cough
Pertussis-toxin-sensitive inhibition by (-) baclofen of Ca signals in bovine chromaffin cells.
Whooping Cough
Pertussis: an important target for maternal immunization.
Whooping Cough
Pertussis: current concepts of pathogenesis and prevention.
Whooping Cough
PGE2 increases the tetrodotoxin-resistant Nav1.9 sodium current in mouse DRG neurons via G-proteins.
Whooping Cough
PGE2 receptors rescue motor neurons in a model of amyotrophic lateral sclerosis.
Whooping Cough
PGE2 regulates cAMP production in cultured rabbit CCD cells: evidence for dual inhibitory mechanisms.
Whooping Cough
PGE2 reverses AVP inhibition of HCO3- absorption in rat MTAL by activation of protein kinase C.
Whooping Cough
PGE2-induced inhibition of AVP-dependent cAMP accumulation in the OMCD of the rat kidney is cumulative with respect to the effects of alpha 2-adrenergic and alpha 1-adenosine agonists, insensitive to pertussis toxin and dependent on extracellular calcium.
Whooping Cough
PGF2alpha-induced signaling events in glomerular mesangial cells.
Whooping Cough
Phagocyte-like NADPH oxidase generates ROS in INS 832/13 cells and rat islets: role of protein prenylation.
Whooping Cough
Pharmacologic control of histamine release from human basophils induced by platelet-activating factor.
Whooping Cough
Pharmacologic evidence for 5-HT1A receptors associated with human retinal pigment epithelial cells in culture.
Whooping Cough
Pharmacologic regulation of histamine release by the human recombinant histamine-releasing factor.
Whooping Cough
Pharmacologic reversal of pertussis toxin-induced thermal allodynia in mice.
Whooping Cough
Pharmacological actions of AH-9700 on micturition reflex in anesthetized rats.
Whooping Cough
Pharmacological Activation Gi/o Protein Increases Glial Cell Line-Derived Neurotrophic Factor Production through Fibroblast Growth Factor Receptor and Extracellular Signal-Regulated Kinase Pathway in Primary Cultured Rat Cortical Astrocytes.
Whooping Cough
Pharmacological analysis of signal transduction pathways required for oxidative burst in chicken heterophils stimulated by a Toll-like receptor 2 agonist.
Whooping Cough
Pharmacological analysis of the contractile role of M2 and M3 muscarinic receptors in smooth muscle.
Whooping Cough
Pharmacological and biochemical characterization of dopamine receptors mediating stimulation of a high affinity GTPase in rat striatum.
Whooping Cough
Pharmacological and functional characterization of bradykinin receptors in rat cultured vascular smooth muscle cells.
Whooping Cough
Pharmacological and functional characterization of D2, D3 and D4 dopamine receptors in fibroblast and dopaminergic cell lines.
Whooping Cough
Pharmacological and functional characterization of muscarinic receptors in the frog pars intermedia.
Whooping Cough
Pharmacological and immunocytochemical characterization of metabotropic glutamate receptors in cultured Purkinje cells.
Whooping Cough
Pharmacological and molecular characterization of the mechanisms involved in prostaglandin E2-induced mouse paw edema.
Whooping Cough
Pharmacological and molecular evidence for dopamine D(1) receptor expression by striatal astrocytes in culture.
Whooping Cough
Pharmacological and signaling properties of endogenous P2Y1 receptors in cystic fibrosis transmembrane conductance regulator-expressing Chinese hamster ovary cells.
Whooping Cough
Pharmacological characterisation of melatonin mt1 receptor-mediated stimulation of [35S]-GTPgammaS binding.
Whooping Cough
Pharmacological characterisation of the goldfish somatostatin sst5 receptor.
Whooping Cough
Pharmacological characterisation of the somatostatin analogue TT-232: effects on neurogenic and non-neurogenic inflammation and neuropathic hyperalgesia.
Whooping Cough
Pharmacological characterization of a UTP-sensitive P2Y nucleotide receptor in organ cultured coronary arteries.
Whooping Cough
Pharmacological characterization of A2-adenosine receptors in guinea-pig ventricular cardiomyocytes.
Whooping Cough
Pharmacological characterization of adenosine receptors in PGT-beta mouse pineal gland tumour cells.
Whooping Cough
Pharmacological characterization of alpha 2-adrenoceptor regulated serotonin release in the rat hippocampus.
Whooping Cough
Pharmacological characterization of alpha 2-adrenoceptors in isolated jejunum of rabbits.
Whooping Cough
Pharmacological characterization of endothelin-stimulated phosphoinositide breakdown and cytosolic free Ca2+ rise in rat C6 glioma cells.
Whooping Cough
Pharmacological characterization of extracellular acidification rate responses in human D2(long), D3 and D4.4 receptors expressed in Chinese hamster ovary cells.
Whooping Cough
Pharmacological characterization of human recombinant melatonin mt(1) and MT(2) receptors.
Whooping Cough
Pharmacological characterization of lysophospholipid receptor signal transduction pathways in rat cerebrocortical astrocytes.
Whooping Cough
Pharmacological characterization of muscarinic receptors mediating inhibition of adenylate cyclase activity in the rat retina.
Whooping Cough
Pharmacological characterization of muscarinic responses in rat hippocampal pyramidal cells.
Whooping Cough
Pharmacological characterization of phosphoinositide-linked glutamate receptor excitation of hippocampal neurons.
Whooping Cough
Pharmacological characterization of rat retinal dopamine receptors.
Whooping Cough
Pharmacological characterization of regulation of phosphoinositide metabolism by recombinant 5-HT2 receptors of the rat.
Whooping Cough
Pharmacological characterization of the "silent" 5-hydroxytryptamine1B-like receptors of rabbit ear artery.
Whooping Cough
Pharmacological characterization of the adenylate cyclase-coupled adenosine receptor in isolated guinea pig atrial myocytes.
Whooping Cough
Pharmacological characterization of the contractile effects of galanin (1-29)-NH2, galantide and galanin (1-14)-(alpha-aminobutyric acid8)scyliorhinin-I in the rat gastric fundus.
Whooping Cough
Pharmacological characterization of the human P2Y4 receptor.
Whooping Cough
Pharmacological characterization of the M1 muscarinic receptors expressed in murine fibroblast B82 cells.
Whooping Cough
Pharmacological characterization of type 1alpha metabotropic glutamate receptor-stimulated [35S]-GTPgammaS binding.
Whooping Cough
Pharmacological comparison of UTP- and thapsigargin-induced arachidonic acid release in mouse RAW 264.7 macrophages.
Whooping Cough
Pharmacological control of human basophil histamine release stimulated by eosinophil granule major basic protein.
Whooping Cough
Pharmacological Cyclophilin Inhibitors Prevent Intoxication of Mammalian Cells with Bordetella pertussis Toxin.
Whooping Cough
Pharmacological differentiation by pertussis toxin of the in vivo acute responses to fMLP and PAF in guinea-pig lungs.
Whooping Cough
Pharmacological differentiation of angiotensin effects in the rabbit isolated vas deferens with dithiothreitol and pertussis toxin.
Whooping Cough
Pharmacological discrimination between muscarinic receptor signal transduction cascades with bethanechol chloride.
Whooping Cough
Pharmacological effects mediated by UDP-glucose that are independent of P2Y14 receptor expression.
Whooping Cough
Pharmacological modulation of the hyperpolarization-activated current (I f) in human atrial myocytes: focus on G protein-coupled receptors.
Whooping Cough
Pharmacological profile of the neuropeptide S receptor: Dynamic mass redistribution studies.
Whooping Cough
Pharmacological profiles of the novel analgesic M58996 in rat models of persistent and neuropathic pain.
Whooping Cough
Pharmacological properties of two cloned somatostatin receptors.
Whooping Cough
Pharmacological study of signal transduction during stimulation of prothoracic glands from Manduca sexta.
Whooping Cough
Pharmacological targeting of host chaperones protects from pertussis toxin in vitro and in vivo.
Whooping Cough
Pharmacologically distinct actions of serotonin on single pyramidal neurones of the rat hippocampus recorded in vitro.
Whooping Cough
Pharmacologically distinct, pertussis toxin-resistant inward currents evoked by metabotropic glutamate receptor (mGluR) agonists in dorsolateral septal nucleus (DLSN) neurons.
Whooping Cough
Pharmacology of 5-hydroxytryptamine-1A receptors which inhibit cAMP production in hippocampal and cortical neurons in primary culture.
Whooping Cough
Pharmacology of Ca2+ channels in smooth muscle.
Whooping Cough
Pharmacology of pertussis toxin B-oligomer.
Whooping Cough
Phase I clinical trial of an acellular pertussis vaccine composed of genetically detoxified pertussis toxin combined with FHA and 69 kDa.
Whooping Cough
Phase II trial of whole-cell pertussis vaccine vs an acellular vaccine containing agglutinogens.
Whooping Cough
Phase variation in Bordetella pertussis by frameshift mutation in a gene for a novel two-component system.
Whooping Cough
Phenotypic and functional evidence for the expression of CXCR4 receptor during megakaryocytopoiesis.
Whooping Cough
Phentolamine inhibits exocytosis of glucagon by Gi2 protein-dependent activation of calcineurin in rat pancreatic alpha -cells.
Whooping Cough
Phenylalanine-stimulated secretion of cholecystokinin is calcium dependent.
Whooping Cough
Phenylephrine acts via IP3-dependent intracellular NO release to stimulate L-type Ca2+ current in cat atrial myocytes.
Whooping Cough
Phorbol 12-myristate 13-acetate and vasopressin potentiate the effect of corticotropin-releasing factor on cyclic AMP production in rat anterior pituitary cells. Mechanisms of action.
Whooping Cough
Phorbol ester and phospholipase C-induced growth hormone secretion from pituitary somatotroph adenoma cells in culture: effects of somatostatin, bromocriptine, and pertussis toxin.
Whooping Cough
Phorbol ester dissociates endothelin-stimulated phosphoinositide hydrolysis and arachidonic acid release in vascular smooth muscle cells.
Whooping Cough
Phorbol ester modulates serotonin-stimulated phosphoinositide breakdown in cultured vascular smooth muscle cells.
Whooping Cough
Phorbol ester modulation of cyclic AMP accumulation in a primary culture of rat aortic smooth muscle cells.
Whooping Cough
Phorbol ester regulates stimulatory and inhibitory pathways of the hormone-sensitive adenylate cyclase system in rat reticulocytes.
Whooping Cough
Phorbol ester-induced augmentation and inhibition of epinephrine-stimulated adenylate cyclase in S49 lymphoma cells.
Whooping Cough
Phorbol ester-induced changes in cytoplasmic Ca2+ in human neutrophils. Involvement of a pertussis toxin-sensitive G protein.
Whooping Cough
Phorbol ester-induced inhibition of the beta-adrenergic system in pulmonary endothelium: role of a pertussis toxin-sensitive protein.
Whooping Cough
Phorbol esters and thyroliberin have distinct actions regarding stimulation of prolactin secretion and activation of adenylate cyclase in rat pituitary tumour cells (GH4C1 cells).
Whooping Cough
Phosphate-dependent stimulation of MGP and OPN expression in osteoblasts via the ERK1/2 pathway is modulated by calcium.
Whooping Cough
Phosphatidic acid and lysophosphatidic acid induce haptotactic migration of human monocytes.
Whooping Cough
Phosphatidic acid and phospholipase D both stimulate phosphoinositide turnover in cultured human keratinocytes.
Whooping Cough
Phosphatidic acid inhibits ceramide 1-phosphate-stimulated macrophage migration.
Whooping Cough
Phosphatidic Acid Stimulates Myoblast Proliferation through Interaction with LPA1 and LPA2 Receptors.
Whooping Cough
Phosphatidylinositol 3-kinase functionally compartmentalizes the concurrent G(s) signaling during beta2-adrenergic stimulation.
Whooping Cough
Phosphatidylinositol 3-kinase is a central mediator of NMDA receptor signalling to MAP kinase (Erk1/2), Akt/PKB and CREB in striatal neurones.
Whooping Cough
Phosphatidylinositol 3-kinase mediates inhibitory effect of angiotensin II on sodium/glucose cotransporter in renal epithelial cells.
Whooping Cough
Phosphatidylinositol 3-kinase offsets cAMP-mediated positive inotropic effect via inhibiting Ca2+ influx in cardiomyocytes.
Whooping Cough
Phosphatidylinositol 3-kinase regulates human immunodeficiency virus type 1 replication following viral entry in primary CD4+ T lymphocytes and macrophages.
Whooping Cough
Phosphatidylinositol transfer protein alpha regulates growth and apoptosis of NIH3T3 cells: involvement of a cannabinoid 1-like receptor.
Whooping Cough
Phosphatidylinositol-3-kinase-atypical protein kinase C signaling is required for Wnt attraction and anterior-posterior axon guidance.
Whooping Cough
Phosphodiesterases inhibition unmask a positive inotropic effect mediated by beta2-adrenoceptors in rat ventricular myocardium.
Whooping Cough
Phosphoinositide 3-kinase-dependent and -independent activation of the small GTPase Rac2 in human neutrophils.
Whooping Cough
Phosphoinositide metabolism in a polyoma-BK-virus-transformed pancreatic islet cell line: evidence for constitutively activated phospholipase C.
Whooping Cough
Phosphoinositides and GTP binding proteins involved in muscarinic generation of hippocampal rhythmic slow activity.
Whooping Cough
Phospholipase A and Somatostatin Release are Activated in Response to N-Methyl-D-Aspartate Receptor Stimulation in Hypothalamic Neurons in Primary Culture.
Whooping Cough
Phospholipase A2 activation in chemotactic peptide-stimulated HL60 granulocytes: synergism between diacylglycerol and Ca2+ in a protein kinase C-independent mechanism.
Whooping Cough
Phospholipase A2 and phospholipase C are activated by distinct GTP-binding proteins in response to alpha 1-adrenergic stimulation in FRTL5 thyroid cells.
Whooping Cough
Phospholipase C activation and Ca2+ mobilization by cloned human somatostatin receptor subtypes 1-5, in transfected COS-7 cells.
Whooping Cough
Phospholipase C activation by neurotensin and neuromedin N in Chinese hamster ovary cells expressing the rat neurotensin receptor.
Whooping Cough
Phospholipase C activation in rat pituitary adenoma (GH) cells.
Whooping Cough
Phospholipase C activity in NCB-20 cells is inhibited by protein kinase A-mediated phosphorylation of low molecular mass GTP-binding proteins.
Whooping Cough
Phospholipase C and phospholipase D are activated independently of each other in chemotactic peptide-stimulated human neutrophils.
Whooping Cough
Phospholipase C inhibitors attenuate arrhythmias induced by kappa-receptor stimulation in the isolated rat heart.
Whooping Cough
Phospholipase C isoforms in vascular smooth muscle and their regulation by G-proteins.
Whooping Cough
Phospholipase C, protein kinase C, Ca(2+)/calmodulin-dependent protein kinase II, and tyrosine phosphorylation are involved in carbachol-induced phospholipase D activation in Chinese hamster ovary cells expressing muscarinic acetylcholine receptor of Caenorhabditis elegans.
Whooping Cough
Phospholipase C-beta 1 is regulated by a pertussis toxin-insensitive G-protein.
Whooping Cough
Phospholipase C-beta3 mediates the thrombin-induced Ca2+ response in glial cells.
Whooping Cough
Phospholipase D activation by sphingosine 1-phosphate regulates interleukin-8 secretion in human bronchial epithelial cells.
Whooping Cough
Phospholipase D activity in PC12 cells. Effects of overexpression of alpha2A-adrenergic receptors.
Whooping Cough
Phospholipase D activity in the Tetrahymena pyriformis GL.
Whooping Cough
Phospholipase D from photoreceptor rod outer segments is a downstream effector of RhoA: evidence of a light-dependent mechanism.
Whooping Cough
Phospholipase D is activated by G protein and not by calcium ions in vascular smooth muscle.
Whooping Cough
Phospholipase D stimulation is required for sphingosine-1-phosphate activation of actin stress fibre assembly in human airway epithelial cells.
Whooping Cough
Phospholipase D1 is threonine-phosphorylated in human-airway epithelial cells stimulated by sphingosine-1-phosphate by a mechanism involving Src tyrosine kinase and protein kinase Cdelta.
Whooping Cough
Phospholipid metabolism induced by Clostridium perfringens alpha-toxin elicits a hot-cold type of hemolysis in rabbit erythrocytes.
Whooping Cough
Phospholipid metabolism is required for M1 muscarinic inhibition of N-type calcium current in sympathetic neurons.
Whooping Cough
Phospholipids regulate growth and function of MDCK cells in hormonally defined serum free medium.
Whooping Cough
Phosphorylated BvgA is sufficient for transcriptional activation of virulence-regulated genes in Bordetella pertussis.
Whooping Cough
Phosphorylated FTY720 stimulates ERK phosphorylation in astrocytes via S1P receptors.
Whooping Cough
Phosphorylation and action of the immunomodulator FTY720 inhibits vascular endothelial cell growth factor-induced vascular permeability.
Whooping Cough
Phosphorylation, dephosphorylation, and recycling of the C5a receptor in differentiated HL60 cells.
Whooping Cough
Phosphorylation, desensitization and internalization of human alpha1B-adrenoceptors induced by insulin-like growth factor-I.
Whooping Cough
Phosphorylation- and voltage-dependent inhibition of neuronal calcium currents by activation of human D2(short) dopamine receptors.
Whooping Cough
Phosphorylation-dependent regulation of phospholipase A2 by G-proteins and Ca2+ in HL60 granulocytes.
Whooping Cough
Photolabeling of Glu-129 of the S-1 subunit of pertussis toxin with NAD.
Whooping Cough
Photolabelling of mutant forms of the S1 subunit of pertussis toxin with NAD+.
Whooping Cough
Photolysis of Caged Sphingosine-1-phosphate Induces Barrier Enhancement and Intracellular Activation of Lung Endothelial Cell Signaling Pathways.
Whooping Cough
Photosensitivity of the isolated pigment epithelium and arachidonic acid metabolism: preliminary results.
Whooping Cough
Photosensory transduction in ciliates. II. Possible role of G-protein and cGMP in Stentor coeruleus.
Whooping Cough
Photosensory transduction in ciliates. IV. Modulation of the photomovement response of Blepharisma japonicum by cGMP.
Whooping Cough
Phototransduction cascade and circadian oscillator in chicken pineal gland.
Whooping Cough
Phylogenetic approach for inferring the origin and functional evolution of bacterial ADP-ribosylation superfamily.
Whooping Cough
Physical and functional association of cytosolic inositolphospholipid-specific phospholipase C of calf thymocytes with a GTP-binding protein.
Whooping Cough
Physical and functional association of follitropin receptors with cholera toxin-sensitive guanine nucleotide-binding protein.
Whooping Cough
Physical and immunological characterization of a guanine nucleotide-binding protein purified from bovine cerebral cortex.
Whooping Cough
Physical evidence of the coupling of solubilized 5-HT1A binding sites with G regulatory proteins.
Whooping Cough
Physico-chemical analysis of Bordetella pertussis antigens.
Whooping Cough
Physicochemical characterisation of the pertussis vaccine.
Whooping Cough
Physiological antagonism between ventricular beta 1-adrenoceptors and alpha 1-adrenoceptors but no evidence for beta 2- and beta 3-adrenoceptor function in murine heart.
Whooping Cough
Physiological effects and therapeutic potential of proinsulin C-peptide.
Whooping Cough
Physiological evidence for ?3-adrenoceptor in frog (Rana esculenta) heart.
Whooping Cough
Physiopathological roles of spontaneously released outer membrane vesicles of Bordetella pertussis.
Whooping Cough
Phytosphingosine-1-phosphate stimulates chemotactic migration of L2071 mouse fibroblasts via pertussis toxin-sensitive G-proteins.
Whooping Cough
PI3 kinase-dependent stimulation of platelet migration by stromal cell-derived factor 1 (SDF-1).
Whooping Cough
PI3Kgamma differentially regulates FcepsilonRI-mediated degranulation and migration of mast cells by and toward antigen.
Whooping Cough
Pien Tze Huang Alleviates Relapsing-Remitting Experimental Autoimmune Encephalomyelitis Mice by Regulating Th1 and Th17 Cells.
Whooping Cough
Pineal muscarinic phosphoinositide response: pertussis toxin resistant signaling with very low receptor number.
Whooping Cough
Pinoresinol-4,4'-di-O-beta-D-glucoside from Valeriana officinalis root stimulates calcium mobilization and chemotactic migration of mouse embryo fibroblasts.
Whooping Cough
Pioglitazone is superior to quetiapine, clozapine and tamoxifen at alleviating experimental autoimmune encephalomyelitis in mice.
Whooping Cough
Pipette GTP is essential for receptor-mediated regulation of Cl- current in dialysed myocytes from guinea-pig ventricle.
Whooping Cough
Pituitary adenylate cyclase activating polypeptide induces degranulation of rat peritoneal mast cells via high-affinity PACAP receptor-independent activation of G proteins.
Whooping Cough
Pituitary adenylate cyclase activating polypeptide induces multiple signaling pathways in rat peritoneal mast cells.
Whooping Cough
Pituitary adenylate cyclase activating polypeptide stimulates rat Leydig cell steroidogenesis through a novel transduction pathway.
Whooping Cough
Pituitary adenylate cyclase polypeptide (PACAP) stimulates cyclic AMP formation in pituitary fibroblasts and 3T3 tumor fibroblasts: lack of enhancement by protein kinase C activation.
Whooping Cough
Pituitary adenylate cyclase-activating polypeptide (PACAP) stimulates adenylyl cyclase and phospholipase C activity in rat cerebellar neuroblasts.
Whooping Cough
Pituitary cell line GH3 expresses two somatostatin receptor subtypes that inhibit adenylyl cyclase: functional expression of rat somatostatin receptor subtypes 1 and 2 in human embryonic kidney 293 cells.
Whooping Cough
Pituitary PRL secretion induced by tetraethylammonium is inhibited by dopamine through D2 receptors.
Whooping Cough
PK 11195 blockade of benzodiazepine-induced inhibition of forskolin-stimulated adenylate cyclase activity in the striatum.
Whooping Cough
PKA-mediated phosphorylation of the beta1-adrenergic receptor promotes Gs/Gi switching.
Whooping Cough
PKC modulation of inhibitory coupling of angiotensin II receptors with adenylate cyclase in lactotroph cells.
Whooping Cough
PKD in intestinal epithelial cells: rapid activation by phorbol esters, LPA, and angiotensin through PKC.
Whooping Cough
PLA2 and secondary metabolites of arachidonic acid control filopodial behavior in neuronal growth cones.
Whooping Cough
Plasma membrane associated phospholipase C from human platelets: synergistic stimulation of phosphatidylinositol 4,5-bisphosphate hydrolysis by thrombin and guanosine 5'-O-(3-thiotriphosphate).
Whooping Cough
Plasma membrane estrogen receptors are coupled to endothelial nitric-oxide synthase through Galpha(i).
Whooping Cough
Plasma Norepinephrine in Hypertensive Rats Reflects ?(2)-Adrenoceptor Release Control Only When Re-Uptake is Inhibited.
Whooping Cough
Plasmacytoid dendritic cells employ multiple cell adhesion molecules sequentially to interact with high endothelial venule cells molecular basis of their trafficking to lymph nodes.
Whooping Cough
Plasmin induces smooth muscle cell proliferation.
Whooping Cough
Plasmin is a potent and specific chemoattractant for human peripheral monocytes acting via a cyclic guanosine monophosphate-dependent pathway.
Whooping Cough
Platelet activating factor activates MAPK and increases in intracellular calcium via independent pathways in B lymphocytes.
Whooping Cough
Platelet activating factor stimulates a receptor-coupled membrane GTPase in guinea pig eosinophils.
Whooping Cough
Platelet adenylate cyclase and phospholipase C are affected differentially by ADP-ribosylation. Effects on thrombin-mediated responses.
Whooping Cough
Platelet cytosolic 44-kDa protein is a substrate of cholera toxin-induced ADP-ribosylation and is not recognized by antisera against the alpha subunit of the stimulatory guanine nucleotide-binding regulatory protein.
Whooping Cough
Platelet endothelial cell adhesion molecule-1 modulates endothelial cell motility through the small G-protein Rho.
Whooping Cough
Platelet factor 4 induces human natural killer cells to synthesize and release interleukin-8.
Whooping Cough
Platelet pertussis toxin-sensitive G proteins in affective disorders.
Whooping Cough
Platelet-activating factor (PAF) induces a contraction of isolated smooth muscle cells from guinea pig ileum: intracellular pathway involved.
Whooping Cough
Platelet-activating factor (PAF) stimulates phosphatidylinositol hydrolysis in human peripheral blood mononuclear leukocytes.
Whooping Cough
Platelet-activating factor activates mitogen-activated protein kinases through the activation of phosphatidylinositol 3-kinase and tyrosine kinase in human eosinophils.
Whooping Cough
Platelet-activating factor activates two distinct effector pathways in human eosinophils.
Whooping Cough
Platelet-activating factor both stimulates and "primes" human polymorphonuclear leukocyte actin filament assembly.
Whooping Cough
Platelet-activating factor exerts mitogenic activity and stimulates expression of interleukin 6 and interleukin 8 in human lung fibroblasts via binding to its functional receptor.
Whooping Cough
Platelet-activating factor increases pH(i) in bovine neutrophils through the PI3K-ERK1/2 pathway.
Whooping Cough
Platelet-activating factor induces NF-kappa B activation through a G protein-coupled pathway.
Whooping Cough
Platelet-activating factor induces tyrosine phosphorylation in human neutrophils.
Whooping Cough
Platelet-activating factor mediated effects on human neutrophil function are inhibited by pertussis toxin.
Whooping Cough
Platelet-activating factor mediated potentiation of stimulation-evoked catecholamine release and the rise in intracellular free Ca2+ concentration in adrenal chromaffin cells.
Whooping Cough
Platelet-activating factor stimulates calcium-dependent activation of protein-tyrosine kinase Syk in a human B cell line.
Whooping Cough
Platelet-activating factor stimulates multiple signaling pathways in cultured rat mesangial cells.
Whooping Cough
Platelet-activating factor stimulates phosphoinositide turnover in neurohybrid NCB-20 cells: involvement of pertussis toxin-sensitive guanine nucleotide-binding proteins and inhibition by protein kinase C.
Whooping Cough
Platelet-activating factor stimulates transcription of the heparin-binding epidermal growth factor-like growth factor in monocytes. Correlation with an increased kappa B binding activity.
Whooping Cough
Platelet-activating factor-induced hydrolysis of phosphatidylinositol 4,5-bisphosphate stimulates the production of reactive oxygen intermediates in macrophages.
Whooping Cough
Platelet-activating factor-induced phosphoinositide metabolism in differentiated U-937 cells in culture.
Whooping Cough
Platelet-activating factor-mediated synthesis of prostaglandins in rat Kupffer cells.
Whooping Cough
Platelet-activating factor: a putative neuromodulator and mediator in the pathophysiology of brain injury.
Whooping Cough
Platelet-activating factor: diminished acetylcholine release from rat brain slices is mediated by a Gi protein.
Whooping Cough
Platelet-conditioned medium increases endothelial electrical resistance independently of cAMP/PKA and cGMP/PKG.
Whooping Cough
Platelet-derived growth factor and angiotensin II cause increases in cytosolic free calcium by different mechanisms in vascular smooth muscle cells.
Whooping Cough
Platelet-derived sphingosine 1-phosphate induces migration of Jurkat T cells.
Whooping Cough
Platelet-derived-growth-factor stimulation of the p42/p44 mitogen-activated protein kinase pathway in airway smooth muscle: role of pertussis-toxin-sensitive G-proteins, c-Src tyrosine kinases and phosphoinositide 3-kinase.
Whooping Cough
Platelets from spontaneously hypertensive rats exhibit decreased expression of inhibitory guanine nucleotide regulatory protein. Relation with adenylyl cyclase activity.
Whooping Cough
Pleiotropic effects of lysophosphatidic acid on striatal astrocytes.
Whooping Cough
Pleurocidin, a novel antimicrobial peptide, induces human mast cell activation through the FPRL1 receptor.
Whooping Cough
Pneumocystis carinii infection alters GTP-binding proteins in the lung.
Whooping Cough
Polarization of chemokine receptors to the leading edge during lymphocyte chemotaxis.
Whooping Cough
Polarized 86Rb+ effluxes in primary cultures of rabbit kidney proximal cells: role of calcium and hypotonicity.
Whooping Cough
Polarized rabbit type 1 angiotensin II receptors manifest differential rates of endocytosis and recycling.
Whooping Cough
Polyarginine, polylysine, and protamine mimic the effects of high extracellular calcium concentrations on dispersed bovine parathyroid cells.
Whooping Cough
Polymerase chain reaction for the detection of Bordetella pertussis in clinical nasopharyngeal aspirates.
Whooping Cough
Polymerase chain reaction identification of Bordetella pertussis infections in vaccinees and family members in a pertussis vaccine efficacy trial in Germany.
Whooping Cough
Polymerization of actin in RBL-2H3 cells can be triggered through either the IgE receptor or the adenosine receptor but different signaling pathways are used.
Whooping Cough
Polymorphism in Bordetella pertussis pertactin and pertussis toxin virulence factors in the United States, 1935-1999.
Whooping Cough
Polymorphism in the Bordetella pertussis virulence factors P.69/pertactin and pertussis toxin in The Netherlands: temporal trends and evidence for vaccine-driven evolution.
Whooping Cough
Polymorphism in the pertussis toxin promoter region affecting the DNA-based diagnosis of Bordetella infection.
Whooping Cough
Polymorphism of Bordetella pertussis isolates circulating for the last 10 years in France, where a single effective whole-cell vaccine has been used for more than 30 years.
Whooping Cough
Polymorphism of IL-10 gene promoter region: association with T cell proliferative responses after acellular pertussis vaccination in adults.
Whooping Cough
Polymorphisms in the pertussis toxin promoter in Bordetella bronchiseptica veterinary isolates from Argentina.
Whooping Cough
Polymorphonuclear leukocyte adherence induces actin polymerization by a transduction pathway which differs from that used by chemoattractants.
Whooping Cough
Polymorphonuclear leukocyte dysregulation during the systemic inflammatory response syndrome.
Whooping Cough
Polymorphonuclear leukocyte opsonic receptor expression after hypoxia/reoxygenation.
Whooping Cough
Polymorphonuclear leukocytes activation: in vitro modulation by 6-methoxy-2-naphthylacetic acid, the major active metabolite of nabumetone.
Whooping Cough
Polyphosphoinositide hydrolysis and protein kinase C activation in guinea pig tracheal smooth muscle cells in culture by leukotriene D4 involve a pertussis toxin sensitive G-protein.
Whooping Cough
Poor immune responses to a birth dose of diphtheria, tetanus, and acellular pertussis vaccine.
Whooping Cough
Population dynamics and antigenic drift of Bordetella pertussis following whole cell vaccine replacement, Barcelona, Spain, 1986-2015.
Whooping Cough
Population dynamics of Bordetella pertussis in Finland and Sweden, neighbouring countries with different vaccination histories.
Whooping Cough
Population-based incidence of pertussis among adolescents and adults, Minnesota, 1995-1996.
Whooping Cough
Porcine pancreatic phospholipase A2 stimulates secretin release from secretin-producing cells.
Whooping Cough
Positive Allosteric Modulation of the Calcium-sensing Receptor by Physiological Concentrations of Glucose.
Whooping Cough
Positive and negative contractile effects of neuropeptide Y on ventricular cardiomyocytes.
Whooping Cough
Positive and negative coupling of the metabotropic glutamate receptors to a G protein-activated K+ channel, GIRK, in Xenopus oocytes.
Whooping Cough
Positive and negative inotropic effects of muscarinic receptor stimulation in mouse left atria.
Whooping Cough
Positive chronotropic responses induced by alpha 1-adrenergic stimulation of normal and "ischemic" Purkinje fibers have different receptor-effector coupling mechanisms.
Whooping Cough
Positive inotropic effect of carbachol and inositol phosphate levels in mammalian atria after pretreatment with pertussis toxin.
Whooping Cough
Positive inotropism induced by androgens in isolated left atrium of rat: evidence for a cAMP-dependent transcriptional mechanism.
Whooping Cough
Positive regulation of human T cell activation by Gi2 proteins and interleukin-8.
Whooping Cough
Positive regulation of pertussis toxin expression.
Whooping Cough
Positive vs. negative inotropic effects of carbachol in avian atrial muscle: role of Ni-like protein.
Whooping Cough
Possible coupling of prostaglandin E2 receptor with pertussis toxin-sensitive guanine nucleotide-binding protein in osteoblast-like cells.
Whooping Cough
Possible direct linkage of insulin-like growth factor-II receptor with guanine nucleotide-binding proteins.
Whooping Cough
Possible existence of two subsets of platelet-activating factor receptor to mediate polyphosphoinositide breakdown and calcium influx in neuroblastoma x glioma hybrid NG 108-15 cells.
Whooping Cough
Possible involvement of a GTP-binding protein in a late event during endogenous ganglioside-modulated cellular proliferation.
Whooping Cough
Possible involvement of a GTP-binding protein, the substrate of islet-activating protein, in receptor-mediated signaling responsible for cell proliferation.
Whooping Cough
Possible involvement of a pertussis toxin-sensitive GTP-binding protein in protein transport into nuclei isolated from rat liver.
Whooping Cough
Possible involvement of C-C chemokines in functional augmentation of adhesion molecules in asthmatic patients.
Whooping Cough
Possible involvement of cell surface receptors in sphingosine 1-phosphate-induced activation of extracellular signal-regulated kinase in C6 glioma cells.
Whooping Cough
Possible involvement of different GTP-binding proteins in noradrenaline- and thrombin-stimulated release of arachidonic acid in rabbit platelets.
Whooping Cough
Possible involvement of G(i3) protein in augmented contraction of bronchial smooth muscle from antigen-induced airway hyperresponsive rats.
Whooping Cough
Possible involvement of GTP-binding proteins in 1 alpha,25-dihydroxyvitamin D3 induction of tissue transglutaminase in mouse peritoneal macrophages.
Whooping Cough
Possible involvement of GTP-binding proteins in growth regulation of human epidermoid carcinoma cell line A431.
Whooping Cough
Possible involvement of M5 muscarinic receptor in the enhancing actions of the novel gastroprokinetic agent Z-338 on nifedipine-sensitive voltage-dependent Ca2+ currents in guinea pig stomach.
Whooping Cough
Possible involvement of pertussis toxin substrates (Gi, Go) in desipramine-induced refractoriness of adenylate cyclase in cerebral cortices of rats.
Whooping Cough
Possible involvement of pertussis toxin-sensitive G protein in hepatocyte growth factor-induced signal transduction in cultured rat hepatocytes: pertussis toxin treatment inhibits activation of phospholipid signaling, calcium oscillation, and mitogen-activated protein kinase.
Whooping Cough
Possible involvement of pertussis toxin-sensitive G proteins and D2 dopamine receptors in the A1 adenosine receptor-adenylate cyclase system in rat cerebral cortex.
Whooping Cough
Possible involvement of pertussis toxin-sensitive GTP-binding protein(s) in c-fos expression during differentiation of 3T3-L1 fibroblasts to adipocytes.
Whooping Cough
Possible involvement of phosphatidylinositol-specific phospholipase C related to pertussis toxin-sensitive GTP-binding proteins during adipocyte differentiation of 3T3-L1 fibroblasts: negative regulation of protein kinase C.
Whooping Cough
Possible involvement of protein kinase C and cyclic AMP-dependent protein kinase in the sodium fluoride-mediated inhibition of cyclic nucleotide accumulation in smooth muscle cells.
Whooping Cough
Possible involvement of protein kinase C and low molecular weight GTP-binding proteins in thrombin-induced histamine secretion in human platelets.
Whooping Cough
Possible Involvement of Sphingosine-1-Phosphate/G(i)/RhoA Pathways in Adherence of Eosinophils to Pulmonary Endothelium.
Whooping Cough
Possible mechanism of CCL2-induced Akt activation in prostate cancer cells.
Whooping Cough
Possible mechanism of chrysotile asbestos-stimulated superoxide anion production in guinea pig alveolar macrophages.
Whooping Cough
Possible participation of an islet B-cell calcium-sensing receptor in insulin release.
Whooping Cough
Possible participation of histamine H3 receptors in the modulation of noradrenaline release from rat spinal cord slices.
Whooping Cough
Possible role for G-proteins in behavioral sensitization to cocaine.
Whooping Cough
Possible role of cGMP in excitatory amino acid induced cytotoxicity in cultured cerebral cortical neurons.
Whooping Cough
Possible role of striatal adenosine in the modulation of acute ethanol-induced motor incoordination in rats.
Whooping Cough
Possible roles of neuropeptide Y Y3-receptor subtype in rat aortic endothelial cell proliferation under hypoxia, and its specific signal transduction.
Whooping Cough
Post- and presynaptic GABA(B) receptor activation in neonatal rat rostral ventrolateral medulla neurons in vitro.
Whooping Cough
Post-receptor defect accounts for phosphorylase hypersensitivity in cultured diabetic cardiomyocytes.
Whooping Cough
Post-receptor signal transduction and regulation of 14(R),15(S)-epoxyeicosatrienoic acid (14,15-EET) binding in U-937 cells.
Whooping Cough
Post-stroke dementia. Nootropic drug modulation of neuronal nicotinic acetylcholine receptors.
Whooping Cough
Postnatal decrease in muscarinic cholinergic influence on Ca2+ currents of rabbit ventricular cells.
Whooping Cough
Postreceptor signal transduction mechanisms involved in octreotide-induced inhibition of angiogenesis.
Whooping Cough
Postsynaptic action mechanism of somatostatin on the membrane excitability in spinal substantia gelatinosa neurons of juvenile rats.
Whooping Cough
Postsynaptic kainate receptor recycling and surface expression are regulated by metabotropic autoreceptor signalling.
Whooping Cough
Postsynaptic mechanisms underlying responsiveness of amygdaloid neurons to nociceptin/orphanin FQ.
Whooping Cough
Potassium conductance increased by noradrenaline, opioids, somatostatin, and G-proteins: whole-cell recording from guinea pig submucous neurons.
Whooping Cough
Potent activation of multiple signalling pathways by C-peptide in opossum kidney proximal tubular cells.
Whooping Cough
Potent agonist action of 2-thioether derivatives of adenine nucleotides at adenylyl cyclase-linked P2Y-purinoceptors.
Whooping Cough
Potent and cooperative feedback inhibition of adenylate cyclase activity by calcium in pituitary-derived GH3 cells.
Whooping Cough
Potent histamine-releasing activity of atrahagin, a novel snake venom metalloproteinase.
Whooping Cough
Potential mechanisms involved in the negative coupling between serotonin 5-HT1A receptors and carbachol-stimulated phosphoinositide turnover in the rat hippocampus.
Whooping Cough
Potential role and mechanism of IFN-gamma inducible protein-10 on receptor activator of nuclear factor kappa-B ligand (RANKL) expression in rheumatoid arthritis.
Whooping Cough
Potential role for a guanine nucleotide regulatory protein in chemoattractant receptor mediated polyphosphoinositide metabolism, Ca++ mobilization and cellular responses by leukocytes.
Whooping Cough
Potentiating effects of pertussis toxin on leukotriene C4 induced formation of inositol phosphate and prostacyclin in human umbilical vein endothelial cells.
Whooping Cough
Potentiation by adenosine of ATP-evoked dopamine release via a pertussis toxin-sensitive mechanism in rat phaeochromocytoma PC12 cells.
Whooping Cough
Potentiation by cholera toxin of bradykinin-induced inositol phosphate production in the osteoblast-like cell line MC3T3-E1.
Whooping Cough
Potentiation by higenamine of the aconitine-induced positive chronotropic effect in isolated right atria of mice: the effects of cholera toxin, forskolin and pertussis toxin.
Whooping Cough
Potentiation by insulin and insulin-like growth factor-1 of glibenclamide-sensitive K+ currents in follicle-enclosed Xenopus oocytes.
Whooping Cough
Potentiation of acetylcholine-induced responses in freshly isolated rabbit aortic endothelial cells.
Whooping Cough
Potentiation of chemotactic peptide-induced superoxide generation by CD38 ligation in human myeloid cell lines.
Whooping Cough
Potentiation of cyclic adenosine monophosphate production by thrombin in the human erythroleukemia cell line, HEL.
Whooping Cough
Potentiation of mitogen-activated protein kinase by ethanol in embryonic liver cells.
Whooping Cough
Potentiation of neuronal NMDA response induced by dehydroepiandrosterone and its suppression by progesterone: effects mediated via sigma receptors.
Whooping Cough
Potentiation of nicotinic currents by bradykinin in the paratracheal ganglia neurons of rats.
Whooping Cough
Potentiation of NMDA receptor-mediated transmission in turtle cerebellar granule cells by activation of metabotropic glutamate receptors.
Whooping Cough
Potentiation of Sulfonylurea Action by an EPAC-selective cAMP Analog in INS-1 cells: comparison of Tolbutamide and Gliclazide and a potential role for EPAC activation of a 2-APB-sensitive Ca2+ influx.
Whooping Cough
Potentiation of the glycine-activated Cl- current by ethanol in cultured mouse spinal neurons.
Whooping Cough
Potentiation of thyrotropin-releasing hormone-stimulated prolactin mRNA levels in GH3 cells by acetylcholine.
Whooping Cough
Potentiation of transmitter release from NMB human neuroblastoma cells by kappa-opioids is mediated by N-type voltage-dependent calcium channels.
Whooping Cough
Poxvirus infection rapidly activates tyrosine kinase signal transduction.
Whooping Cough
Pre- and postsynaptic GABAB receptors in the hippocampus have different pharmacological properties.
Whooping Cough
Pre- and postsynaptic inhibition by nociceptin in guinea pig small intestinal myenteric plexus in vitro.
Whooping Cough
Pre-synaptic histamine H3 receptors regulate glutamate, but not GABA release in rat thalamus.
Whooping Cough
Preactivation permits subsequent stimulation of phospholipase C by G(i)-coupled receptors.
Whooping Cough
Preconditioning against infarction in the rat heart does not involve a pertussis toxin sensitive G protein.
Whooping Cough
Preconditioning modulates susceptibility to ischemia-induced arrhythmias in the rat heart: the role of alpha-adrenergic stimulation and K(ATP) channels.
Whooping Cough
Precoupling of alpha-2B adrenergic receptors and G-proteins in transfected PC-12 cell membranes: influence of pertussis toxin and a lysine-directed cross-linker.
Whooping Cough
Predominance of alpha 2-adrenoceptors in porcine thyroid: biochemical and pharmacological correlations.
Whooping Cough
Predominant expression of type II vasoactive intestinal peptide receptors by human T lymphoblastoma cells: transduction of both Ca2+ and cyclic AMP signals.
Whooping Cough
Preferential involvement of Go and Gz proteins in mediating rat natural killer cell lysis of allogeneic and tumor target cells.
Whooping Cough
Preferential processing of the S1 subunit of pertussis toxin that is bound to eukaryotic cells.
Whooping Cough
Pregnancy enhances G protein activation and nitric oxide release from uterine arteries.
Whooping Cough
Pregnancy switches adrenergic signal transduction in rat and human uterine myocytes as probed by BKCa channel activity.
Whooping Cough
Pregnenolone sulfate acts through a G-protein-coupled sigma1-like receptor to enhance short term facilitation in adult hippocampal neurons.
Whooping Cough
Prejunctional alpha 2-adrenoceptors in mouse atria function through G-proteins which are sensitive to N-ethylmaleimide, but not pertussis toxin.
Whooping Cough
Prejunctional beta-adrenoceptors, angiotensin II and neuropeptide Y receptors on sympathetic nerves in mouse atria are linked to N-ethylmaleimide-susceptible G-proteins.
Whooping Cough
Prejunctional neuropeptide Y receptors in human kidney and atrium.
Whooping Cough
Preliminary data from a clinical trial (phase 2) of an acellular pertussis vaccine, J-NIH-6.
Whooping Cough
Preliminary studies on the development of IgA-loaded chitosan-dextran sulphate nanoparticles as a potential nasal delivery system for protein antigens.
Whooping Cough
Preliminary studies on the use of pertussis toxin for the modulation of intravaginal SIV transmission in rhesus macaques.
Whooping Cough
Preliminary X-ray crystallographic analysis of holotoxin from Bordetella pertussis.
Whooping Cough
Prenatal Stress Impairs Spinal Cord Oligodendrocyte Maturation via BDNF Signaling in the Experimental Autoimmune Encephalomyelitis Model of Multiple Sclerosis.
Whooping Cough
Preparation and characterization of Pertussis toxin subunits.
Whooping Cough
Preparation of filamentous hemagglutinin from Bordetella pertussis and assay for serum antibodies to filamentous hemagglutinin and pertussis toxin for clinical and public health laboratories.
Whooping Cough
Presence of a functional inhibitory GTP-binding regulatory component, Gi, linked to adenylate cyclase in adipocytes of ob/ob mice.
Whooping Cough
Presence of delta opioid receptors on a subset of hypothalamic gonadotropin releasing hormone (GnRH) neurons.
Whooping Cough
Presence of phospholipase C in coated vesicles from bovine brain. Dual regulatory effects of GTP-analogs.
Whooping Cough
Presence of three pertussis toxin substrates and Go alpha immunoreactivity in both plasma and granule membranes of chromaffin cells.
Whooping Cough
Pressor actions of arginine vasopressin in pithed Sprague-Dawley, Wistar-Kyoto and spontaneously hypertensive rats before and after treatment with nifedipine or pertussis toxin.
Whooping Cough
Presynaptic Cav2.1 and Cav2.2 differentially influence release dynamics at hippocampal excitatory synapses.
Whooping Cough
Presynaptic GABA(B) receptor modulation of glutamate exocytosis from rat cerebrocortical nerve terminals: receptor decoupling by protein kinase C.
Whooping Cough
Presynaptic GABAB autoreceptor modulation of P/Q-type calcium channels and GABA release in rat suprachiasmatic nucleus neurons.
Whooping Cough
Presynaptic inhibition and the participation of GABA(B) receptors at neuromuscular junctions of the crab Eriphia spinifrons.
Whooping Cough
Presynaptic inhibition by concanavalin A: are alpha-latrotoxin receptors involved in action potential-dependent transmitter release?
Whooping Cough
Presynaptic inhibition by neuropeptide Y and baclofen in hippocampus: insensitivity to pertussis toxin treatment.
Whooping Cough
Presynaptic inhibition of excitatory synaptic transmission mediated by alpha adrenergic receptors in area CA3 of the rat hippocampus in vitro.
Whooping Cough
Presynaptic inhibition of gamma lobe neurons is required for olfactory learning in Drosophila.
Whooping Cough
Presynaptic inhibition of spontaneous acetylcholine release mediated by P2Y receptors at the mouse neuromuscular junction.
Whooping Cough
Presynaptic inhibition of transmitter release from rat sympathetic neurons by bradykinin.
Whooping Cough
Presynaptic inhibitory effect of baclofen on hippocampal inhibitory synaptic transmission involves a pertussis toxin-sensitive G-protein.
Whooping Cough
Presynaptic kappa-opioid receptors on noradrenergic nerve terminals couple to G proteins and interact with the alpha 2-adrenoceptors.
Whooping Cough
Presynaptic mechanisms underlying cannabinoid inhibition of excitatory synaptic transmission in rat striatal neurons.
Whooping Cough
Presynaptic muscarinic M(2)-receptor-mediated inhibition of N-type Ca(2+) channels in cultured sphenopalatine ganglion: direct evidence for acetylcholine inhibition of cerebral nitrergic neurogenic vasodilation.
Whooping Cough
Presynaptic opioid receptors on dopaminergic nerves in the rabbit caudate nucleus: coupling to pertussis toxin-sensitive G-proteins and interaction with D2 autoreceptors?
Whooping Cough
Pretreatment of cerebellar granule cells with concanavalin A potentiates quisqualate-stimulated phosphoinositide hydrolysis.
Whooping Cough
Pretreatment of mouse striatal neurons in primary culture with 17 beta-estradiol enhances the pertussis toxin-catalyzed ADP-ribosylation of G alpha o,i protein subunits.
Whooping Cough
Pretreatment with cholera or pertussis toxin differentially modulates morphine- and beta-endorphin-induced antinociception in the mouse formalin test.
Whooping Cough
Pretreatment with pertussis toxin blocks morphine- but not beta-endorphin-induced antinociception in the mouse.
Whooping Cough
Pretreatment with pertussis toxin blocks the protective effects of preconditioning: evidence for a G-protein mechanism.
Whooping Cough
Pretreatment with pertussis toxin differentially modulates morphine- and beta-endorphin-induced antinociception in the mouse.
Whooping Cough
Pretreatment with pertussis toxin spinally, but not supraspinally, blocks the cold water swimming-induced antinociception in the mouse.
Whooping Cough
Prevalence and incidence of adult pertussis in an urban population.
Whooping Cough
Prevalence of antibody to Bordetella pertussis antigens in serum specimens obtained from 1793 adolescents and adults.
Whooping Cough
Prevalence of Bordetella pertussis and Bordetella parapertussis infections in Tunisian hospitalized infants: results of a 4-year prospective study.
Whooping Cough
Prevalence of markers of exposure to Bordetella pertussis among Italian young adults.
Whooping Cough
Prevalence of Pertussis Antibodies in Maternal Blood, Cord Serum, and Infants From Mothers With and Those Without Tdap Booster Vaccination During Pregnancy in Argentina.
Whooping Cough
Prevalence of pertussis antibodies in maternal delivery, cord, and infant serum.
Whooping Cough
Prevalence, diagnosis, and disease course of pertussis in adults with acute cough: a prospective, observational study in primary care.
Whooping Cough
Prevention of alpha 2-adrenergic inhibition on ADH action by pertussis toxin in rabbit CCT.
Whooping Cough
Prevention of experimental autoimmune uveoretinitis by intrathymic S-antigen injection.
Whooping Cough
Prevention of pertussis: An unresolved problem.
Whooping Cough
Prevention of the agonist binding to gamma-aminobutyric acid B receptors by guanine nucleotides and islet-activating protein, pertussis toxin, in bovine cerebral cortex. Possible coupling of the toxin-sensitive GTP-binding proteins to receptors.
Whooping Cough
Primary immunization of infants with an acellular pertussis vaccine in a double-blind randomized clinical trial.
Whooping Cough
Primary Macrophage Chemotaxis Induced by Cannabinoid Receptor 2 Agonists Occurs Independently of the CB2 Receptor.
Whooping Cough
Primary role for Gi protein signaling in the regulation of interleukin 12 production and the induction of T helper cell type 1 responses.
Whooping Cough
Priming by grepafloxacin on respiratory burst of human neutrophils: its possible mechanism.
Whooping Cough
Priming effects of granulocyte-macrophage colony-stimulating factor are coupled to cholera toxin-sensitive guanine nucleotide binding protein in human T lymphocytes.
Whooping Cough
Priming of human neutrophils with N-formyl-methionyl-leucyl-phenylalanine by a calcium-independent, pertussis toxin-insensitive pathway.
Whooping Cough
Prior exposure to Bordetella species as an exclusion criterion in the baboon model of pertussis.
Whooping Cough
Pro-adhesive and chemotactic activities of thrombospondin-1 for breast carcinoma cells are mediated by alpha3beta1 integrin and regulated by insulin-like growth factor-1 and CD98.
Whooping Cough
Pro-collagen I COOH-terminal trimer induces directional migration and metalloproteinases in breast cancer cells.
Whooping Cough
Pro-fibrotic processes in human lung fibroblasts are driven by an autocrine/paracrine endothelinergic system.
Whooping Cough
Pro-inflammatory effector Th cells transmigrate through anti-inflammatory environments into the murine fetus.
Whooping Cough
Proadrenomedullin N-terminal 20 peptide (PAMP) inhibits proliferation of human neuroblastoma TGW cells.
Whooping Cough
Proadrenomedullin N-terminal 20 peptide hyperpolarizes the membrane by activating an inwardly rectifying K+ current in differentiated PC12 cells.
Whooping Cough
Proadrenomedullin NH2-terminal 20 peptide inhibits the voltage-gated Ca2+ channel current through a pertussis toxin-sensitive G protein in rat pheochromocytoma-derived PC 12 cells.
Whooping Cough
Probable occurrence of toxin-susceptible G proteins in the nematode Caenorhabditis elegans.
Whooping Cough
Probing cell type-specific functions of Gi in vivo identifies GPCR regulators of insulin secretion.
Whooping Cough
Probing the G-protein regulation of GIRK1 and GIRK4, the two subunits of the KACh channel, using functional homomeric mutants.
Whooping Cough
Probing the genome-scale metabolic landscape of Bordetella pertussis, the causative agent of whooping cough.
Whooping Cough
Probiotics and the immunological response to infant vaccinations; a double-blind randomized controlled trial.
Whooping Cough
Problem solved: a modified enzyme-linked immunosorbent assay for detection of human antibodies to pertussis toxin eliminates false-positive results occurring at analysis of heat-treated sera.
Whooping Cough
Production and purification of Bordetella pertussis toxin.
Whooping Cough
Production and release of tumor necrosis factor alfa, interleukin-1B and interleukin-6 by human mononuclear leukocytes stimulated with pertussis toxin.
Whooping Cough
Production and secretion of pertussis toxin subunits in Bacillus subtilis.
Whooping Cough
Production of a safe, potent and immunogenic partially purified acellular pertussis vaccine using simple indigenous techniques.
Whooping Cough
Production of beta-defensin-2 by human colonic epithelial cells induced by Salmonella enteritidis flagella filament structural protein.
Whooping Cough
Production of cell mass and pertussis toxin by Bordetella pertussis.
Whooping Cough
Production of nontypeable Haemophilus influenzae HtrA by recombinant Bordetella pertussis with the use of filamentous hemagglutinin as a carrier.
Whooping Cough
Production of stromal cell-derived factor-1 (SDF-1)and expression of CXCR4 in human bone marrow endothelial cells.
Whooping Cough
Production of tumor necrosis factors alpha and beta by human mononuclear leukocytes stimulated with mitogens, bacteria, and malarial parasites.
Whooping Cough
Progesterone and the zona pellucida activate different transducing pathways in the sequence of events leading to diacylglycerol generation during mouse sperm acrosomal exocytosis.
Whooping Cough
Progesterone induces relaxation of human umbilical cord vascular smooth muscle cells through mPR? (PAQR7).
Whooping Cough
Progesterone inhibition of Xenopus oocyte adenylate cyclase is not mediated via the Bordetella pertussis toxin substrate.
Whooping Cough
Progesterone inhibits K conductance in plasma membrane of cultured renal epitheloid MDCK cells.
Whooping Cough
Progesterone primes zona pellucida-induced activation of phospholipase A2 during acrosomal exocytosis in guinea pig spermatozoa.
Whooping Cough
PROGESTERONE RECEPTOR A (PRA) and PRB -INDEPENDENT EFFECTS OF PROGESTERONE ON GNRH RELEASE.
Whooping Cough
Progesterone triggers rapid transmembrane calcium influx and/or calcium mobilization from endoplasmic reticulum, via a pertussis-insensitive G-protein in granulosa cells in relation to luteinization process.
Whooping Cough
Progestin signaling through an olfactory G protein and membrane progestin receptor-alpha in Atlantic croaker sperm: potential role in induction of sperm hypermotility.
Whooping Cough
Progress towards the development of new vaccines against whooping cough.
Whooping Cough
Proinflammatory receptor switch from G?s to G?i signaling by ?-arrestin-mediated PDE4 recruitment in mixed RA synovial cells.
Whooping Cough
Proinsulin C-peptide and its analogues induce intracellular Ca2+ increases in human renal tubular cells.
Whooping Cough
Proinsulin C-peptide rapidly stimulates mitogen-activated protein kinases in Swiss 3T3 fibroblasts: requirement of protein kinase C, phosphoinositide 3-kinase and pertussis toxin-sensitive G-protein.
Whooping Cough
Prokaryotic peptides that block leukocyte adherence to selectins.
Whooping Cough
Prokineticin receptors interact unselectively with several G protein subtypes but bind selectively to ?-arrestin 2.
Whooping Cough
Prokineticin-1/endocrine gland-derived vascular endothelial growth factor is a survival factor for human multiple myeloma cells.
Whooping Cough
Prolactin induced production of cytokines in macrophages involves Ca++ and p42/44 MAP kinase signaling pathway.
Whooping Cough
Prolactin stimulates integrin-mediated adhesion of circulating mononuclear cells to endothelial cells.
Whooping Cough
Prolactin-releasing peptide activation of the prolactin promoter is differentially mediated by extracellular signal-regulated protein kinase and c-Jun N-terminal protein kinase.
Whooping Cough
Proliferation of bovine undifferentiated mammary epithelial cells in vitro is modulated by G-proteins.
Whooping Cough
Proliferative effect of PGD2 on osteoblast-like cells; independent activation of pertussis toxin-sensitive GTP-binding protein from PGE2 or PGF2 alpha.
Whooping Cough
Proliferative responses and gamma interferon and tumor necrosis factor production by lymphocytes isolated from tracheobroncheal lymph nodes and spleen of mice aerosol infected with Bordetella pertussis.
Whooping Cough
Proliferative responses to purified and fractionated Bordetella pertussis antigens in mice immunized with whole-cell pertussis vaccine.
Whooping Cough
Proliferin induces endothelial cell chemotaxis through a G protein-coupled, mitogen-activated protein kinase-dependent pathway.
Whooping Cough
Proline-rich tyrosine kinase 2 and Rac activation by chemokine and integrin receptors controls NK cell transendothelial migration.
Whooping Cough
Prolonged activation of extracellular signal-regulated kinase by a protein kinase C-dependent and N17Ras-insensitive mechanism mediates the proliferative response of G(i/o)-coupled somatostatin sst(4) receptors.
Whooping Cough
Prolonged activation of inhibitory somatostatin receptors increases adenylate cyclase activity in wild-type and Gs alpha-deficient (cyc-) S49 mouse lymphoma cells.
Whooping Cough
Prolonged elevation of intracellular cyclic AMP levels in U937 cells increases the number of receptors for and the responses to formylmethionyl-leucylphenylalanine, independently of the differentiation process.
Whooping Cough
Prolonged incubation with neuropeptide Y upregulates beta-adrenoceptors yet does not cause supersensitivity of beta-adrenoceptor signaling.
Whooping Cough
Prolonged pertussis toxin treatment affects morphine's action on tuberoinfundibular dopaminergic neuron activity and on prolactin secretion.
Whooping Cough
Promiscuous G-protein coupled receptor inhibition of transient receptor potential melastatin 3 ion channels by G?? subunits.
Whooping Cough
Promiscuous or heterogeneous muscarinic receptors in rat atria? I. Schild analysis with simple competitive antagonists.
Whooping Cough
Promiscuous or heterogeneous muscarinic receptors in rat atria? II. Antagonism of responses to carbachol by pirenzepine.
Whooping Cough
Promoter of the pertussis toxin operon and production of pertussis toxin.
Whooping Cough
Promotion of lipolysis in rat adipocytes by pertussis toxin: reversal of endogenous inhibition.
Whooping Cough
Pronounced direct inhibitory action mediated by adenosine A1 receptor and pertussis toxin-sensitive G protein on the ferret ventricular contraction.
Whooping Cough
Properties of 1-methyladenine receptors in starfish oocyte membranes: involvement of pertussis toxin-sensitive GTP-binding protein in the receptor-mediated signal transduction.
Whooping Cough
Properties of a novel GTP-binding protein which is associated with soluble phosphoinositides-specific phospholipase C.
Whooping Cough
Properties of AT1a and AT1b angiotensin receptors expressed in adrenocortical Y-1 cells.
Whooping Cough
Properties of Ca2+ currents in acutely dissociated neurons of the chick ciliary ganglion: inhibition by somatostatin-14 and somatostatin-28.
Whooping Cough
Properties of delta opioid receptor in neuroblastoma NS20Y: receptor activation and neuroblastoma proliferation.
Whooping Cough
Properties of diazoxide and cromakalim-induced activation of potassium channels in cultured rat and RINm5F insulin-secreting cells; effects of GTP.
Whooping Cough
Properties of membranous phospholipase C from WRK1 cell: sensitivity to guanylnucleotides and bacterial toxins.
Whooping Cough
Properties of muscarinic-stimulated adenylate cyclase activity in rat olfactory bulb.
Whooping Cough
Properties of pertussis toxin B oligomer assembled in vitro from recombinant polypeptides produced by Escherichia coli.
Whooping Cough
Properties of pertussis toxin mutant PT-9K/129G after formaldehyde treatment.
Whooping Cough
Properties of the B oligomer of pertussis toxin.
Whooping Cough
Property of receptor for vasoactive intestinal contractor (VIC) expressed in Xenopus oocytes injected with mRNA from rat intestine.
Whooping Cough
Propionate induces polymorphonuclear leukocyte activation and inhibits formylmethionyl-leucyl-phenylalanine-stimulated activation.
Whooping Cough
Propionic acid-induced calcium mobilization in human neutrophils.
Whooping Cough
Prosaposin receptor: evidence for a G-protein-associated receptor.
Whooping Cough
Prosaposin treatment induces PC12 entry in the S phase of the cell cycle and prevents apoptosis: activation of ERKs and sphingosine kinase.
Whooping Cough
Prosaposin upregulates AR and PSA expression and activity in prostate cancer cells (LNCaP).
Whooping Cough
Prosaposin: a new player in cell death prevention of U937 monocytic cells.
Whooping Cough
Prosaptide activates the MAPK pathway by a G-protein-dependent mechanism essential for enhanced sulfatide synthesis by Schwann cells.
Whooping Cough
Prosaptide D5 reverses hyperalgesia: inhibition of calcium channels through a pertussis toxin-sensitive G-protein mechanism in the rat.
Whooping Cough
Prospective evaluation of an Australian pertussis toxin IgG and IgA enzyme immunoassay.
Whooping Cough
Prostacyclin receptor induces STAT1 and STAT3 phosphorylations in human erythroleukemia cells: A mechanism requiring PTX-insensitive G proteins, ERK and JNK.
Whooping Cough
Prostacylin receptor activation inhibits proliferation of aortic smooth muscle cells by regulating cAMP response element-binding protein- and pocket protein-dependent cyclin a gene expression.
Whooping Cough
Prostaglandin D(2) Induces IL-8 and GM-CSF by Bronchial Epithelial Cells in a CRTH2-Independent Pathway.
Whooping Cough
Prostaglandin D2 induces the production of human beta-defensin-3 in human keratinocytes.
Whooping Cough
Prostaglandin E receptors in bovine adrenal medulla are coupled to adenylate cyclase via Gi and to phosphoinositide metabolism in a pertussis toxin-insensitive manner.
Whooping Cough
Prostaglandin E receptors in myometrial cells.
Whooping Cough
Prostaglandin E(2) inhibits calcium current in two sub-populations of acutely isolated mouse trigeminal sensory neurons.
Whooping Cough
Prostaglandin E-prostanoid-3 receptor activation of cyclic AMP response element-mediated gene transcription.
Whooping Cough
Prostaglandin E2 activates phospholipase C and elevates intracellular calcium in cultured myometrial cells: involvement of EP1 and EP3 receptor subtypes.
Whooping Cough
Prostaglandin E2 and alpha 2 adrenoceptor agonists inhibit the pentose phosphate shunt in pancreatic islets.
Whooping Cough
Prostaglandin E2 can bimodally inhibit and stimulate the epididymal adipocyte adenylyl cyclase activity.
Whooping Cough
Prostaglandin E2 contracts vascular smooth muscle and inhibits potassium currents in vascular smooth muscle cells of rat tail artery.
Whooping Cough
Prostaglandin E2 inhibits sodium transport in rabbit cortical collecting duct by increasing intracellular calcium.
Whooping Cough
Prostaglandin E2 is an inhibitor of adenylate cyclase in rabbit proximal tubule.
Whooping Cough
Prostaglandin E2 mediates IL-1beta-related fibroblast mitogenic effects in acute lung injury through differential utilization of prostanoid receptors.
Whooping Cough
Prostaglandin E2 production in rat IMCD cells. I. Stimulation by dopamine.
Whooping Cough
Prostaglandin E2 receptors in the heart are coupled to inhibition of adenylyl cyclase via a pertussis toxin sensitive G protein.
Whooping Cough
Prostaglandin E2 regulates angiogenesis via activation of fibroblast growth factor receptor-1.
Whooping Cough
Prostaglandin E2 upregulates EGF-stimulated signaling in mitogenic pathways involving Akt and ERK in hepatocytes.
Whooping Cough
Prostaglandin E2-EP3 signaling induces inflammatory swelling by mast cell activation.
Whooping Cough
Prostaglandin E2-induced arachidonic acid release and catecholamine secretion from cultured bovine adrenal chromaffin cells.
Whooping Cough
Prostaglandin EP3 receptor superactivates adenylyl cyclase via the Gq/PLC/Ca2+ pathway in a lipid raft-dependent manner.
Whooping Cough
Prostaglandin F(2alpha) receptor-dependent regulation of prostaglandin transport.
Whooping Cough
Prostaglandin F2 alpha activates phospholipase D independently from activation of protein kinase C in osteoblast-like cells.
Whooping Cough
Prostaglandin F2 alpha and alpha-adrenergic agonists regulate parathyroid cell function via the inhibitory guanine nucleotide regulatory protein.
Whooping Cough
Prostaglandin F2 alpha-stimulated phospholipase D activation in osteoblast-like MC3T3-E1 cells: involvement in sustained 1,2-diacylglycerol production.
Whooping Cough
Prostaglandin modulation of Ca2+ channels in rat sympathetic neurones is mediated by guanine nucleotide binding proteins.
Whooping Cough
Prostaglandin receptors in NIH 3T3 cells: coupling of one receptor to adenylate cyclase and of a second receptor to phospholipase C.
Whooping Cough
Prostaglandin-concentration-dependent desensitization of adenylate cyclase in human erythroleukaemia (HEL) cells is abolished by pertussis toxin and enhanced by induction by dimethyl sulphoxide.
Whooping Cough
Prostaglandin-sensitive adenylyl cyclase of cultured preadipocytes and mature adipocytes of the rat: probable role of Gi in determination of stimulatory or inhibitory action.
Whooping Cough
Prostaglandins and muscarinic agonists induce cyclic AMP attenuation by two distinct mechanisms in the pregnant-rat myometrium. Interaction between cyclic AMP and Ca2+ signals.
Whooping Cough
Prostaglandins and the urinary concentrating defect in potassium-depleted rabbits.
Whooping Cough
Prostaglandins induce calcium influx in human spermatozoa.
Whooping Cough
Prostaglandins induce proliferation of rat hepatocytes through a prostaglandin E2 receptor EP3 subtype.
Whooping Cough
Prostaglandins inhibit pancreatic beta-cell replication and long-term insulin secretion by pertussis toxin-insensitive mechanisms but do not mediate the actions of interleukin-1 beta.
Whooping Cough
Prostaglandins inhibit proliferation of the murine P815 mastocytoma by decreasing cytoplasmic free calcium levels [( Ca+2]i).
Whooping Cough
Prostaglandins inhibit secretion of histamine and pancreastatin from isolated rat stomach ECL cells.
Whooping Cough
Prostaglandins mediate the defect in AVP-stimulated cAMP generation in immature collecting duct.
Whooping Cough
Prostaglandin E2 promotes liver cancer cell growth by the upregulation of FUSE-binding protein 1 expression.
Whooping Cough
Prostanoid EP3 and TP receptors-mediated inhibition of noradrenaline release from the isolated rat stomach.
Whooping Cough
Prostanoid inhibition of canine parietal cells: mediation by the inhibitory guanosine triphosphate-binding protein of adenylate cyclase.
Whooping Cough
Prostanoid signaling, localization, and expression of IP receptors in rat thick ascending limb cells.
Whooping Cough
Prosurvival activity for airway neutrophils in severe asthma.
Whooping Cough
Protean agonism at alpha2A-adrenoceptors.
Whooping Cough
Protean effects of a natural peptide agonist of the G protein-coupled secretin receptor demonstrated by receptor mutagenesis.
Whooping Cough
Protease treatment of pertussis toxin identifies the preferential cleavage of the S1 subunit.
Whooping Cough
Protease-activated receptor (PAR)-independent growth and pro-inflammatory actions of thrombin on human cultured airway smooth muscle.
Whooping Cough
Protease-activated receptor-1-mediated DNA synthesis in cardiac fibroblast is via epidermal growth factor receptor transactivation: distinct PAR-1 signaling pathways in cardiac fibroblasts and cardiomyocytes.
Whooping Cough
Protection against autoimmune disease by bacterial agents. II. PPD and pertussis toxin as proteins active in protecting mice against experimental autoimmune encephalomyelitis.
Whooping Cough
Protection and humoral immune responses against Bordetella pertussis infection in mice immunized with acellular or cellular pertussis immunogens.
Whooping Cough
Protection of mice inoculated with purified pertussis toxin and filamentous haemagglutinin against intracerebral challenge with live Bordetella pertussis.
Whooping Cough
Protective activities in mice of monoclonal antibodies against pertussis toxin.
Whooping Cough
Protective antigens of Bordetella pertussis mouse-protection test against intracerebral and aerosol challenge of B. pertussis.
Whooping Cough
Protective effect of acellular pertussis vaccines.
Whooping Cough
Protective effects of catalpol and rhein in murine experimental autoimmune encephalomyelitis via regulation of T helper (Th) 1, Th2, Th17, and regulatory T cell responses.
Whooping Cough
Protective effects of human gamma-globulin preparations against experimental aerosol infections of mice with Bordetella pertussis.
Whooping Cough
Protective effects of morphine in peroxynitrite-induced apoptosis of primary rat neonatal astrocytes: potential involvement of G protein and phosphatidylinositol 3-kinase (PI3 kinase).
Whooping Cough
Protective effects of pertussis immunoglobulin (P-IGIV) in the aerosol challenge model.
Whooping Cough
Protective effects of pharmacological therapies in animal models of multiple sclerosis: a review of studies 2014-2019.
Whooping Cough
Protective effects of remote ischemic preconditioning in isolated rat hearts.
Whooping Cough
Protective immunity against Bordetella pertussis by a recombinant DNA vaccine and the effect of coinjection with a granulocyte-macrophage colony stimulating factor gene.
Whooping Cough
Protective immunogenicity of synthetic peptides selected from the amino acid sequence of Bordetella pertussis toxin subunit S1.
Whooping Cough
Protective immunogenicity of two synthetic peptides selected from the amino acid sequence of Bordetella pertussis toxin subunit S1.
Whooping Cough
Protective role of immunoglobulin G antibodies to filamentous hemagglutinin and pertactin of Bordetella pertussis in Bordetella parapertussis infection.
Whooping Cough
Protein acylation in the inhibition of insulin secretion by norepinephrine, somatostatin, galanin, and PGE2.
Whooping Cough
Protein intake affects levels of G-protein subunits G alpha i2, G alpha i3, and G beta in rat glomerular membranes.
Whooping Cough
Protein kinase A phosphorylation and G protein regulation of purified renal Na+ channels in planar bilayer membranes.
Whooping Cough
Protein kinase A phosphorylation and G protein regulation of type II pneumocyte Na+ channels in lipid bilayers.
Whooping Cough
Protein kinase A-mediated phosphorylation of the beta 2-adrenergic receptor regulates its coupling to Gs and Gi. Demonstration in a reconstituted system.
Whooping Cough
Protein kinase and G-protein regulation of Ca2+ currents in Hermissenda photoreceptors by 5-HT and GABA.
Whooping Cough
Protein kinase C activates the non-selective cation channel in the rabbit portal vein.
Whooping Cough
Protein kinase C activation and positive and negative agonist regulation of 3',5'-cyclic adenosine monophosphate levels in cultured rat Sertoli cells.
Whooping Cough
Protein kinase C activation enhances cAMP accumulation in Swiss 3T3 cells: inhibition by pertussis toxin.
Whooping Cough
Protein kinase C activation generates superoxide and contributes to impairment of cerebrovasodilation induced by G protein activation after brain injury.
Whooping Cough
Protein kinase C activation mimics but does not mediate thyrotropin-induced desensitization of adenylyl cyclase in cultured dog thyroid cells.
Whooping Cough
Protein kinase C activation stimulates the phosphorylation and internalization of the sst2A somatostatin receptor.
Whooping Cough
Protein kinase C activator phorbol 12, 13-dibutyrate inhibits platelet activating factor-stimulated Ca2+ mobilization and phosphoinositide turnover in neurohybrid NG108-15 cells.
Whooping Cough
Protein kinase C activators sensitize cyclic AMP accumulation by intact 1321N1 human astrocytoma cells.
Whooping Cough
Protein kinase C and G(i/o) proteins are involved in adenosine- and ischemic preconditioning-mediated renal protection.
Whooping Cough
Protein kinase C and Gi-protein mediated modulation of cAMP production in different stages of the rat seminiferous epithelium.
Whooping Cough
Protein kinase C and protein tyrosine kinase activity contribute to mitogenic signaling by endothelin-1. Cross-talk between G protein-coupled receptors and pp60c-src.
Whooping Cough
Protein kinase C antagonizes pertussis-toxin-sensitive coupling of the calcitonin receptor to adenylyl cyclase.
Whooping Cough
Protein kinase C differentially modulates PTH- and PGE2-sensitive adenylate cyclase in osteoblast-like cells.
Whooping Cough
Protein kinase C enhances growth hormone releasing factor (1-40)-stimulated cyclic AMP levels in anterior pituitary. Actions of somatostatin and pertussis toxin.
Whooping Cough
Protein kinase C inhibitor chelerythrine attenuates the morphine-induced excitatory amino acid release and reduction of the antinociceptive effect of morphine in rats injected intrathecally with pertussis toxin.
Whooping Cough
Protein kinase C inhibits arginine vasopressin-stimulated cAMP accumulation via a Gi-dependent mechanism.
Whooping Cough
Protein kinase C inhibits cyclic adenosine monophosphate generation by histamine and truncated glucagon like peptide 1 in the human gastric cancer cell line HGT-1.
Whooping Cough
Protein kinase C isoforms and A1 adenosine receptors in porcine coronary smooth muscle cells.
Whooping Cough
Protein kinase C mediates neurotensin inhibition of inwardly rectifying potassium currents in rat substantia nigra dopaminergic neurons.
Whooping Cough
Protein kinase C modulates parathyroid hormone- but not prostaglandin E2-mediated stimulation of cyclic AMP production via the inhibitory guanine nucleotide binding protein in UMR-106 osteosarcoma cells.
Whooping Cough
Protein kinase C potentiates isoproterenol-mediated cyclic AMP production without modifying the homologous desensitization process in J774 cells.
Whooping Cough
Protein kinase C regulates functional coupling of beta1-adrenergic receptors to Gi/o-mediated responses in cardiac myocytes.
Whooping Cough
Protein kinase C regulation of the adenylyl cyclase system in rat prostatic epithelium.
Whooping Cough
Protein kinase C stimulates adenylate cyclase activity in prolactin-secreting rat adenoma (GH4C1) pituicytes by inactivating the inhibitory GTP-binding protein Gi.
Whooping Cough
Protein kinase C-dependent coupling of alpha(2A/D)-adrenergic receptors to phospholipase D.
Whooping Cough
Protein kinase C-epsilon regulates sphingosine 1-phosphate-mediated migration of human lung endothelial cells through activation of phospholipase D2, protein kinase C-zeta, and Rac1.
Whooping Cough
Protein kinase C-independent stimulation of activator protein-1 and c-Jun N-terminal kinase activity in human endometrial cancer cells by the LHRH agonist triptorelin.
Whooping Cough
Protein kinase C-mediated enhancement of glycine response in rat sacral dorsal commissural neurones by serotonin.
Whooping Cough
Protein kinase C? as a therapeutic target stabilizing blood-brain barrier disruption in experimental autoimmune encephalomyelitis.
Whooping Cough
Protein kinases A and C positively regulate G protein-dependent activation of phosphatidylinositol-specific phospholipase C by tumor necrosis factor-alpha in MC3T3-E1 osteoblasts.
Whooping Cough
Protein phosphatase 1 and 2A inhibitors prolong the switch in the control of glutamate release by group I metabotropic glutamate receptors: characterization of the inhibitory pathway.
Whooping Cough
Protein tyrosine kinase involvement in the production of superoxide anion by neutrophils exposed to Aroclor 1242, a mixture of polychlorinated biphenyls.
Whooping Cough
Protein tyrosine phosphatase inhibition by angiotensin II in rat pheochromocytoma cells through type 2 receptor, AT2.
Whooping Cough
Protein tyrosine phosphorylation and calcium signaling in thyroid FRTL-5 cells.
Whooping Cough
Protein tyrosine phosphorylation induced by lysophosphatidic acid in Rat-1 fibroblasts. Evidence that phosphorylation of map kinase is mediated by the Gi-p21ras pathway.
Whooping Cough
Protein-chemical analysis of pertussis toxin reveals homology between the subunits S2 and S3, between S1 and the A chains of enterotoxins of Vibrio cholerae and Escherichia coli and identifies S2 as the haptoglobin-binding subunit.
Whooping Cough
Protein-tyrosine phosphatase SHP2 is positively linked to proteinase-activated receptor 2-mediated mitogenic pathway.
Whooping Cough
Protein-tyrosine phosphorylations induced by concanavalin A and N-formyl-methionyl-leucyl-phenylalanine in human neutrophils.
Whooping Cough
Proteinase-activated receptor-1 regulation of macrophage elastase (MMP-12) secretion by serine proteinases.
Whooping Cough
Proteolytic action of duodenase is required to induce DNA synthesis in pulmonary artery fibroblasts.
Whooping Cough
Proteolytic activation of protein kinase Calpha by peroxynitrite in stimulating cytosolic phospholipase A2 in pulmonary endothelium: involvement of a pertussis toxin sensitive protein.
Whooping Cough
Proteolytic cleavage of pertussis toxin S1 subunit is not essential for its activity in mammalian cells.
Whooping Cough
Proteolytic processing of the mosquitocidal toxin from Bacillus sphaericus SSII-1.
Whooping Cough
Prothrombin fragments containing kringle domains induce migration and activation of human neutrophils.
Whooping Cough
Proximal tubular epithelial cells possess a novel 42-kilodalton guanine nucleotide-binding regulatory protein.
Whooping Cough
Pseudopterosin A inhibits phagocytosis and alters intracellular calcium turnover in a pertussis toxin sensitive site in Tetrahymena thermophila.
Whooping Cough
PT pretreatment inhibits 48/80-induced activation of Ca(+)-permeable channels in rat peritoneal mast cells.
Whooping Cough
PTH and DA regulate Na-K ATPase through divergent pathways.
Whooping Cough
PTH elevates inositol polyphosphates and diacylglycerol in a rat osteoblast-like cell line.
Whooping Cough
PTH-dependent adenylyl cyclase activation in SaOS-2 cells: passage dependent effects on G protein interactions.
Whooping Cough
PTX cruiser: driving autoimmunity via TLR4.
Whooping Cough
PTX-sensitive and -insensitive synaptic modulation at the frog neuromuscular junction.
Whooping Cough
PTX-sensitive G proteins and permissive action of prostacyclin in newborn pig cerebral circulation.
Whooping Cough
PTX-sensitive signals in bone marrow homing of fetal and adult hematopoietic progenitor cells.
Whooping Cough
Pulmonary and activation-regulated chemokine stimulates collagen production in lung fibroblasts.
Whooping Cough
Pulmonary endothelial cell barrier enhancement by FTY720 does not require the S1P1 receptor.
Whooping Cough
Pulsatile flow-induced angiogenesis: role of G(i) subunits.
Whooping Cough
Pulsed-field gel electrophoresis analysis of Bordetella pertussis isolates circulating in Europe from 1998 to 2009.
Whooping Cough
Pulsed-field gel electrophoresis, pertactin, pertussis toxin S1 subunit polymorphisms, and surfaceome analysis of vaccine and clinical Bordetella pertussis strains.
Whooping Cough
Purification and characterization of a GTP-binding protein serving as pertussis toxin substrate in starfish oocytes.
Whooping Cough
Purification and characterization of G proteins from human brain: modification of GTPase activity upon phosphorylation.
Whooping Cough
Purification and characterization of Go alpha and three types of Gi alpha after expression in Escherichia coli.
Whooping Cough
Purification and characterization of predominant G-protein from bovine lung membranes. Biochemical and immunochemical comparison with Gi1 and Go purified from brain.
Whooping Cough
Purification and characterization of the 22,000-dalton GTP-binding protein substrate for ADP-ribosylation by botulinum toxin, G22K.
Whooping Cough
Purification and characterization of the heat-labile toxin of Bordetella pertussis.
Whooping Cough
Purification and characterization of transducin from capybara Hydrochoerus hydrochaeris.
Whooping Cough
Purification and G protein subunit regulation of a phospholipase C-beta from Xenopus laevis oocytes.
Whooping Cough
Purification and identification of two pertussis-toxin-sensitive GTP-binding proteins of bovine spleen.
Whooping Cough
Purification and immunochemical characterization of the major pertussis-toxin-sensitive guanine-nucleotide-binding protein of bovine-neutrophil membranes.
Whooping Cough
Purification and immunogenicity of a recombinant Bordetella pertussis S1S3FHA fusion protein expressed by Streptococcus gordonii.
Whooping Cough
Purification and immunological characterization of HPLC-purified pertussis toxin subunits.
Whooping Cough
Purification and properties of the inhibitory guanine nucleotide regulatory unit of brain adenylate cyclase.
Whooping Cough
Purification and some properties of GTP-binding proteins from pig heart plasma membranes.
Whooping Cough
Purification design and practice for pertactin, the third component of acellular pertussis vaccine, from Bordetella pertussis.
Whooping Cough
Purification from bovine liver membranes of a guanine nucleotide-dependent activator of phosphoinositide-specific phospholipase C. Immunologic identification as a novel G-protein alpha subunit.
Whooping Cough
Purification of a histamine H3 receptor negatively coupled to phosphoinositide turnover in the human gastric cell line HGT1.
Whooping Cough
Purification of a novel G-protein alpha 0-subtype from mammalian brain.
Whooping Cough
Purification of GTP-binding proteins from bovine brain membranes. Identification of heterogeneity of the alpha-subunit of Go proteins.
Whooping Cough
Purification of heterotrimeric GTP-binding proteins from brain: identification of a novel form of Go.
Whooping Cough
Purification of pertussis toxin substrates from bovine heart membranes.
Whooping Cough
Purification of pertussis toxin.
Whooping Cough
Purification of the active C5a receptor from human polymorphonuclear leukocytes as a receptor-Gi complex.
Whooping Cough
Purification of unique alpha subunits of GTP-binding regulatory proteins (G proteins) by affinity chromatography with immobilized beta gamma subunits.
Whooping Cough
Purified epithelial Na+ channel complex contains the pertussis toxin-sensitive G alpha i-3 protein.
Whooping Cough
Purified Wnt5a protein activates or inhibits beta-catenin-TCF signaling depending on receptor context.
Whooping Cough
Purine and pyrimidine nucleotides potentiate activation of NADPH oxidase and degranulation by chemotactic peptides and induce aggregation of human neutrophils via G proteins.
Whooping Cough
Purine metabolites suppress proliferation of human NK cells through a lineage-specific purine receptor.
Whooping Cough
Purinergic agonist ATP is a comitogen in thyroid FRTL-5 cells.
Whooping Cough
Purinergic agonists stimulate the secretion of endothelin-1 in rat thyroid FRTL-5 cells.
Whooping Cough
Purinergic P2Y receptors on astrocytes are directly coupled to phospholipase A2.
Whooping Cough
Purinergic P2Y1 receptor signaling mediates wound stimuli-induced cyclooxygenase-2 expression in intestinal subepithelial myofibroblasts.
Whooping Cough
Purinergic P2Y?? receptor modulates stress-induced hematopoietic stem/progenitor cell senescence.
Whooping Cough
Purinergic receptor-mediated morphological changes in microglia are transient and independent from inflammatory cytokine release.
Whooping Cough
Purinergic receptors activating rapid intracellular Ca increases in microglia.
Whooping Cough
Purinergic receptors on insulin-secreting cells.
Whooping Cough
Purines and pyrimidines are not involved in NANC relaxant responses in the rabbit vaginal wall.
Whooping Cough
Purinoceptor-stimulated phosphoinositide hydrolysis in Madin-Darby canine kidney (MDCK) cells.
Whooping Cough
Purkinje cell protein-2 (Pcp2) stimulates differentiation in PC12 cells by Gbetagamma-mediated activation of Ras and p38 MAPK.
Whooping Cough
Pyrimidine nucleotide-evoked inhibition of cyclic AMP accumulation in equine epithelial cells.
Whooping Cough
Pyrimidinoceptor-mediated activation of phospholipase C and phospholipase A2 in RAW 264.7 macrophages.
Whooping Cough
Quantification of cell-associated and free antigens in Bordetella pertussis suspensions by antigen binding ELISA.
Whooping Cough
Quantification of Gi alpha-proteins in the failing and nonfailing human myocardium.
Whooping Cough
Quantification of kappa opioid receptor ligand potency, efficacy and desensitization using a real-time membrane potential assay.
Whooping Cough
Quantification of pertussis toxin, filamentous haemagglutinin, 69 kDa outer membrane protein, agglutinogens 2 and 3 and lipopolysaccharide in the Danish whole-cell pertussis vaccine.
Whooping Cough
Quantification of the alpha and beta subunits of the transducing elements (Gs and Gi) of adenylate cyclase in adipocyte membranes from lean and obese (ob/ob) mice.
Whooping Cough
Quantitation of actin polymerization in two human fibroblast sub-types responding to mechanical stretching.
Whooping Cough
Quantitation of pertussis toxin in an enzyme linked immunosorbent assay with improved specificity.
Whooping Cough
Quantitative determination of bioactive proteins in diphtheria tetanus acellular pertussis (DTaP) vaccine by liquid chromatography tandem mass spectrometry.
Whooping Cough
Quantitative determination of pertussis toxin-sensitive G proteins using [32P]ADP-ribosylation in human platelet membranes: negative correlation with ages.
Whooping Cough
Quantitative priming with inactivated pertussis toxoid vaccine in the aerosol challenge model.
Whooping Cough
Quantity and quality of antibodies after acellular versus whole cell pertussis vaccines in infants born to mothers who received Tdap during pregnancy: a randomised trial.
Whooping Cough
Quartz crystal microbalance investigation of the interaction of bacterial toxins with ganglioside containing solid supported membranes.
Whooping Cough
Quercetin sensitizes RBL-2H3 cells to polybasic mast cell secretagogues through increased expression of Gi GTP-binding proteins linked to a phospholipase C signaling pathway.
Whooping Cough
R(+)-methanandamide induces cyclooxygenase-2 expression in human neuroglioma cells via a non-cannabinoid receptor-mediated mechanism.
Whooping Cough
R-(+)-[2,3-Dihydro-5-methyl-3-(4-morpholinylmethyl)-pyrrolo-[1,2,3-de]-1,4-benzoxazin-6-yl]-1-naphtalenylmethanone (WIN-2) ameliorates experimental autoimmune encephalomyelitis and induces encephalitogenic T cell apoptosis: partial involvement of the CB(2) receptor.
Whooping Cough
rab3-peptide stimulates exocytosis from mast cells via a pertussis toxin-sensitive mechanism.
Whooping Cough
Rac activation by lysophosphatidic acid LPA1 receptors through the guanine nucleotide exchange factor Tiam1.
Whooping Cough
Rac-1-mediated O2- secretion requires Ca2+ influx in neutrophil-like HL-60 cells.
Whooping Cough
RACK1 regulates angiotensin II-induced contractions of SHR preglomerular vascular smooth muscle cells.
Whooping Cough
Radioimmunochemical quantification of Gi alpha in right and left ventricles from patients with ischaemic and dilated cardiomyopathy and predominant left ventricular failure.
Whooping Cough
Raf-1 kinase activation by angiotensin II in adrenal glomerulosa cells: roles of Gi, phosphatidylinositol 3-kinase, and Ca2+ influx.
Whooping Cough
Raf-1 kinase mediates adenylyl cyclase sensitization by TNF-alpha in human airway smooth muscle cells.
Whooping Cough
Rainbow trout somatostatin receptor subtypes SSTR1A, SSTR1B, and SSTR2 differentially activate the extracellular signal-regulated kinase and phosphatidylinositol 3-kinase signaling pathways in transfected cells.
Whooping Cough
Ranakinin, a naturally occurring tachykinin, stimulates phospholipase C activity in the frog adrenal gland.
Whooping Cough
Randomized clinical trial of the safety and immunogenicity of the Tdap vaccine in pregnant Mexican women.
Whooping Cough
Randomized controlled trial of acellular diphtheria, pertussis and tetanus vaccines in southern Ghana.
Whooping Cough
Rantes activates Jak2 and Jak3 to regulate engagement of multiple signaling pathways in T cells.
Whooping Cough
RANTES and platelet-activating factor open Ca2+-activated K+ channels in eosinophils.
Whooping Cough
RANTES and related chemokines activate human basophil granulocytes through different G protein-coupled receptors.
Whooping Cough
RANTES stimulates inflammatory cascades and receptor modulation in murine astrocytes.
Whooping Cough
RANTES, a monocyte and T lymphocyte chemotactic cytokine releases histamine from human basophils.
Whooping Cough
Rap1a activation by CalDAG-GEFI and p38 MAPK is involved in E-selectin-dependent slow leukocyte rolling.
Whooping Cough
Rapid action of oestrogen in luteinising hormone-releasing hormone neurones: the role of GPR30.
Whooping Cough
Rapid activation of endothelial NO synthase by estrogen: evidence for a steroid receptor fast-action complex (SRFC) in caveolae.
Whooping Cough
Rapid activation of phosphatidate phosphohydrolase in mesangial cells by lipid A.
Whooping Cough
Rapid activation of Ras by fluid flow is mediated by Galpha(q) and Gbetagamma subunits of heterotrimeric G proteins in human endothelial cells.
Whooping Cough
Rapid and efficient homing of human CD34(+)CD38(-/low)CXCR4(+) stem and progenitor cells to the bone marrow and spleen of NOD/SCID and NOD/SCID/B2m(null) mice.
Whooping Cough
Rapid and non-genomic reduction of intracellular [Ca(2+)] induced by aldosterone in human bronchial epithelium.
Whooping Cough
Rapid Ca2+ influx and diacylglycerol synthesis in growth hormone-mediated islet beta -cell mitogenesis.
Whooping Cough
Rapid degradation of NAD by retinoic acid-differentiated HL-60 granulocyte membranes prevents ADP ribosylation.
Whooping Cough
Rapid depletion of peripheral antigen-specific T cells in TCR-transgenic mice after oral administration of myelin basic protein.
Whooping Cough
Rapid desensitization of the metabotropic glutamate receptor that facilitates glutamate release in rat cerebrocortical nerve terminals.
Whooping Cough
Rapid detection of the recently emerged Bordetella pertussis strains with the ptxP3 pertussis toxin promoter allele by real-time PCR.
Whooping Cough
Rapid effects of androgens in macrophages.
Whooping Cough
Rapid effects of pesticides on human granulosa-lutein cells.
Whooping Cough
Rapid elevation of calcium concentration in cultured dorsal spinal cord astrocytes by corticosterone.
Whooping Cough
Rapid estrogenic regulation of extracellular signal- regulated kinase 1/2 signaling in cerebellar granule cells involves a G protein- and protein kinase A-dependent mechanism and intracellular activation of protein phosphatase 2A.
Whooping Cough
Rapid fine conformational epitope mapping using comprehensive mutagenesis and deep sequencing.
Whooping Cough
Rapid G protein-regulated activation event involved in lymphocyte binding to high endothelial venules.
Whooping Cough
Rapid high mass resolution mass spectrometry using matrix-assisted ionization.
Whooping Cough
Rapid induction of arachidonic acid release by monocyte chemotactic protein-1 and related chemokines. Role of Ca2+ influx, synergism with platelet-activating factor and significance for chemotaxis.
Whooping Cough
Rapid induction of Thy-1 antigenic markers on keratinocytes and epidermal immune cells in the skin of mice following topical treatment with common preservatives used in topical medications and in foods.
Whooping Cough
Rapid inhibitory effects of corticosterone on calcium influx in rat dorsal root ganglion neurons.
Whooping Cough
Rapid internalization and recycling of the human neuropeptide Y Y(1) receptor.
Whooping Cough
Rapid membrane responses to dihydrotestosterone are sex dependent in growth plate chondrocytes.
Whooping Cough
Rapid nongenomic E2 effects on p42/p44 MAPK, activator protein-1, and cAMP response element binding protein in rat white adipocytes.
Whooping Cough
Rapid purification of Bordetella pertussis toxin by alternating affinity and hydrophobic chromatography.
Whooping Cough
Rapid purification of pertussis toxin (PT) and filamentous hemagglutinin (FHA) by cation-exchange chromatography.
Whooping Cough
Rapid release of bound glucose-6-phosphate dehydrogenase by growth factors. Correlation with increased enzymatic activity.
Whooping Cough
Rapid Remodeling of Invadosomes by Gi-coupled Receptors: DISSECTING THE ROLE OF Rho GTPases.
Whooping Cough
Rapid signaling responses in Sertoli cell membranes induced by follicle stimulating hormone and testosterone: Calcium inflow and electrophysiological changes.
Whooping Cough
Rapid typing of Bordetella pertussis pertussis toxin gene variants by LightCycler real-time PCR and fluorescence resonance energy transfer hybridization probe melting curve analysis.
Whooping Cough
Ras activation in response to lysophosphatidic acid requires a permissive input from the epidermal growth factor receptor.
Whooping Cough
Ras-dependent mitogen-activated protein kinase activation by G protein-coupled receptors. Convergence of Gi- and Gq-mediated pathways on calcium/calmodulin, Pyk2, and Src kinase.
Whooping Cough
Ras-independent activation of Ral by a Ca(2+)-dependent pathway.
Whooping Cough
Ras/MAP kinase-dependent and -independent signaling pathways target distinct ternary complex factors.
Whooping Cough
Ras/Rac-Dependent activation of p38 mitogen-activated protein kinases in smooth muscle cells stimulated by cyclic strain stress
Whooping Cough
Ras/Raf1-dependent signal in sphingosine-1-phosphate-induced tube formation in human coronary artery endothelial cells.
Whooping Cough
Rat adipose tissue adenosine sensitivity and adenosine content after subcutaneous administration of N6-(phenylisopropyl)adenosine.
Whooping Cough
Rat brain cannabinoid receptor modulates N-type Ca2+ channels in a neuronal expression system.
Whooping Cough
Rat fat-cells have three types of adenosine receptors (Ra, Ri and P). Differential effects of pertussis toxin.
Whooping Cough
Rat group I metabotropic glutamate receptors inhibit neuronal Ca2+ channels via multiple signal transduction pathways in HEK 293 cells.
Whooping Cough
Rat heart cell membranes contain three substrates for cholera toxin-catalyzed ADP-ribosylation and a single substrate for pertussis toxin-catalyzed ADP-ribosylation.
Whooping Cough
Rat somatostatin receptor type 1 couples to G proteins and inhibition of cyclic AMP accumulation.
Whooping Cough
Rat somatostatin sst2(a) and sst2(b) receptor isoforms mediate opposite effects on cell proliferation.
Whooping Cough
Rat striatal adenosinergic modulation of ethanol-induced motor impairment: possible role of striatal cyclic AMP.
Whooping Cough
Rat white adipocytes activate p85/p110 PI3K and induce PM GLUT4 in response to adrenoceptor agonists or aluminum fluoride.
Whooping Cough
Ratiometric analysis of fura red by flow cytometry: a technique for monitoring intracellular calcium flux in primary cell subsets.
Whooping Cough
Rational medium design for Bordetella pertussis: basic metabolism.
Whooping Cough
Re-expression of alpha skeletal actin and regulation of alpha 1 adrenoceptor signalling in DOCA-salt hypertension in rats.
Whooping Cough
Reactivating Immunity Primed by Acellular Pertussis Vaccines in the Absence of Circulating Antibodies: Enhanced Bacterial Control by TLR9 Rather Than TLR4 Agonist-Including Formulation.
Whooping Cough
Reactive oxygen species contribute to the presynaptic action of extracellular ATP at the frog neuromuscular junction.
Whooping Cough
Reactive sulfhydryl groups of alpha 39, a guanine nucleotide-binding protein from brain. Location and function.
Whooping Cough
Reactogenicity and immunogenicity at preschool age of a booster dose of two three-component diphtheria-tetanus-acellular pertussis vaccines in children primed in infancy with acellular vaccines.
Whooping Cough
Reactogenicity and immunogenicity of a booster dose of a combined diphtheria, tetanus, and tricomponent acellular pertussis vaccine at fourteen to twenty-eight months of age.
Whooping Cough
Reactogenicity and immunogenicity of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine (Tdap) in pregnant and nonpregnant women.
Whooping Cough
Real-time analysis of agonist-induced activation of protease-activated receptor 1/Galphai1 protein complex measured by bioluminescence resonance energy transfer in living cells.
Whooping Cough
Real-time analysis of very late antigen-4 affinity modulation by shear.
Whooping Cough
Real-time detection of G protein activation using monomolecular G? FRET sensors.
Whooping Cough
Reasons for instability of bacterial vaccines.
Whooping Cough
Rebound stimulation of the cAMP-regulated Cl- current by acetylcholine in guinea-pig ventricular myocytes.
Whooping Cough
Receptor and G protein-mediated responses to thrombin in HEL cells.
Whooping Cough
Receptor and mechanism that mediate endothelin- and big endothelin-1-induced phosphoinositide hydrolysis in the rat spinal cord.
Whooping Cough
Receptor crosstalk: effects of prolonged carbachol exposure on beta 1-adrenoceptors and adenylyl cyclase activity in neonatal rat ventricular myocytes.
Whooping Cough
Receptor mechanisms mediating cyanide generation in PC12 cells and rat brain.
Whooping Cough
Receptor mechanisms of opioid tolerance in SH-SY5Y human neural cells.
Whooping Cough
Receptor number and caveolar co-localization determine receptor coupling efficiency to adenylyl cyclase.
Whooping Cough
Receptor subtype involved and mechanism of norepinephrine-induced stimulation of glutamate uptake into primary cultures of rat brain astrocytes.
Whooping Cough
Receptor up-regulation, internalization, and interconverting receptor states. Critical components of a quantitative description of N-formyl peptide-receptor dynamics in the neutrophil.
Whooping Cough
Receptor-effector coupling pathway for alpha 1-adrenergic modulation of abnormal automaticity in 'ischemic' canine Purkinje fibers.
Whooping Cough
Receptor-evoked Cl- current in Xenopus oocytes is mediated through a beta-type phospholipase C. Cloning of a new form of the enzyme.
Whooping Cough
Receptor-independent activation of atrial muscarinic potassium channels in the absence of nucleotides.
Whooping Cough
Receptor-independent activation of guanine nucleotide-binding regulatory proteins by terminal complement complexes.
Whooping Cough
Receptor-independent effects of natural cannabinoids in rat peritoneal mast cells in vitro.
Whooping Cough
Receptor-independent G protein activation may account for the stimulatory effects of first-generation H1-receptor antagonists in HL-60 cells, basophils, and mast cells.
Whooping Cough
Receptor-linked early events induced by vasoactive intestinal contractor (VIC) on neuroblastoma and vascular smooth-muscle cells.
Whooping Cough
Receptor-mediated action of hepoxilin A3 releases diacylglycerol and arachidonic acid from human neutrophils.
Whooping Cough
Receptor-mediated activation of G proteins is increased in postmortem brains of bipolar affective disorder subjects.
Whooping Cough
Receptor-mediated activation of nitric oxide synthesis by arginine in endothelial cells.
Whooping Cough
Receptor-mediated activation of phospholipase D by sphingosine 1-phosphate in skeletal muscle C2C12 cells. A role for protein kinase C.
Whooping Cough
Receptor-mediated autocrine growth-stimulatory effect of 5-hydroxytryptamine on cultured human pancreatic carcinoid cells.
Whooping Cough
Receptor-mediated increases in cytosolic Ca2+ in the human erythroleukaemia cell line involve pertussis toxin-sensitive and -insensitive pathways.
Whooping Cough
Receptor-mediated inhibition of adenylate cyclase and stimulation of arachidonic acid release in 3T3 fibroblasts. Selective susceptibility to islet-activating protein, pertussis toxin.
Whooping Cough
Receptor-mediated internalization is critical for the inhibition of the expression of growth hormone by somatostatin in the pituitary cell line AtT-20.
Whooping Cough
Receptor-mediated modulation of recombinant neuronal class E calcium channels.
Whooping Cough
Receptor-mediated phagocytosis in human neutrophils is associated with increased formation of inositol phosphates and diacylglycerol. Elevation in cytosolic free calcium and formation of inositol phosphates can be dissociated from accumulation of diacylglycerol.
Whooping Cough
Receptor-mediated regulation of calcium channels and neurotransmitter release.
Whooping Cough
Receptor-mediated regulation of the TRPM7 channel through its endogenous protein kinase domain.
Whooping Cough
Receptor-Mediated Vascular Smooth Muscle Migration Induced by LPA Involves p38 Mitogen-Activated Protein Kinase Pathway Activation.
Whooping Cough
Receptor-operated calcium influx in rat hepatocytes. Identification and characterization using manganese.
Whooping Cough
Receptor-regulated interaction of activator of G-protein signaling-4 and Galphai.
Whooping Cough
Receptor-stimulated dissociation of GTP[S] from Gi-proteins in membranes of HL-60 cells.
Whooping Cough
Receptor-type protein tyrosine phosphatase zeta as a component of the signaling receptor complex for midkine-dependent survival of embryonic neurons.
Whooping Cough
Receptors and transduction pathways for monocyte chemotactic protein-2 and monocyte chemotactic protein-3. Similarities and differences with MCP-1.
Whooping Cough
Receptors couple to L-type calcium channels via distinct Go proteins in rat neuroendocrine cell lines.
Whooping Cough
Receptors for bitter, sweet and umami taste couple to inhibitory G protein signaling pathways.
Whooping Cough
Receptors for pancreastatin in rat liver membranes: molecular identification and characterization by covalent cross-linking.
Whooping Cough
Reciprocal inhibition of voltage-gated potassium currents (I K(V)) by activation of cannabinoid CB1 and dopamine D1 receptors in ON bipolar cells of goldfish retina.
Whooping Cough
Reciprocal modulation of function between the D1 and D2 dopamine receptors and the Na+,K+-ATPase.
Whooping Cough
Reciprocal modulation of thyrotropin actions by P1-purinergic agonists in FRTL-5 thyroid cells. Inhibition of cAMP pathway and stimulation of phospholipase C-Ca2+ pathway.
Whooping Cough
Reciprocal protective immunity against Bordetella pertussis and Bordetella parapertussis in a murine model of respiratory infection.
Whooping Cough
Recognition of a bacterial adhesion by an integrin: macrophage CR3 (alpha M beta 2, CD11b/CD18) binds filamentous hemagglutinin of Bordetella pertussis.
Whooping Cough
Recognition of pertussis toxin by antibodies to synthetic peptides.
Whooping Cough
Recombinant acellular pertussis vaccine--from the laboratory to the clinic: improving the quality of the immune response.
Whooping Cough
Recombinant alpha i-3 subunit of G protein activates Gk-gated K+ channels.
Whooping Cough
Recombinant human CXC-chemokine receptor-4 in melanophores are linked to Gi protein: seven transmembrane coreceptors for human immunodeficiency virus entry into cells.
Whooping Cough
Recombinant human eotaxin induces oxygen radical production, Ca(2+)-mobilization, actin reorganization, and CD11b upregulation in human eosinophils via a pertussis toxin-sensitive heterotrimeric guanine nucleotide-binding protein.
Whooping Cough
Recombinant human G protein-coupled lysophosphatidic acid receptors mediate intracellular calcium mobilization.
Whooping Cough
Recombinant human G-CSF and GM-CSF prime human neutrophils for superoxide production through different signal transduction mechanisms.
Whooping Cough
Recombinant human serotonin 5A receptors stably expressed in C6 glioma cells couple to multiple signal transduction pathways.
Whooping Cough
Recombinant interleukin-8 induces changes in cytosolic Ca2+ in human neutrophils.
Whooping Cough
Recombinant Mycobacterium bovis BCG expressing pertussis toxin subunit S1 induces protection against an intracerebral challenge with live Bordetella pertussis in mice.
Whooping Cough
Recombinant Production of a Novel Fusion Protein: Listeriolysin O Fragment Fused to S1 Subunit of Pertussis Toxin.
Whooping Cough
Reconstitution of chemokine-induced actin polymerization in undifferentiated human leukemia cells (HL-60) by heterologous expression of interleukin-8 receptors.
Whooping Cough
Reconstitution of muscarinic cholinergic inhibition of adenylate cyclase activity in homogenates of embryonic chick hearts by membranes of adult chick hearts.
Whooping Cough
Reconstitution of somatostatin and muscarinic receptor mediated stimulation of K+ channels by isolated GK protein in clonal rat anterior pituitary cell membranes.
Whooping Cough
Reconstitution of the purified porcine atrial muscarinic acetylcholine receptor with purified porcine atrial inhibitory guanine nucleotide binding protein.
Whooping Cough
Reconstitution of the solubilized mu-opioid receptor coupled to a GTP-binding protein.
Whooping Cough
Recovery of deficient cholinergic calcium signaling by adenosine in cultured rat cortical astrocytes.
Whooping Cough
Recovery of endothelium-dependent relaxations four weeks after ischemia and progressive reperfusion in canine coronary arteries.
Whooping Cough
Recruitment and proliferation of T lymphocytes is supported by IFNgamma- and TNFalpha-activated human osteoblasts: Involvement of CD54 (ICAM-1) and CD106 (VCAM-1) adhesion molecules and CXCR3 chemokine receptor.
Whooping Cough
Recruitment of actin to the cytoskeletons of human monocyte-like cells activated by complement fragment C5a. Is protein kinase C involved?
Whooping Cough
Recruitment of individually (all-or-none) responding cells, rather than amplitude enhancement, is the single-cell mechanism subserving the dose-responsive activation of intracellular calcium second messenger signaling by the human luteinizing-hormone receptor.
Whooping Cough
Recruitment of pleckstrin and phosphoinositide 3-kinase gamma into the cell membranes, and their association with G beta gamma after activation of NK cells with chemokines.
Whooping Cough
Reduced adenylyl cyclase inhibition by carbachol and GTP during acute myocardial ischaemia.
Whooping Cough
Reduced concentrations of the alpha-subunit of GTP-binding protein Go in schizophrenic brain.
Whooping Cough
Reduced G(i) and G(o) protein function in the rat nucleus accumbens attenuates sensorimotor gating deficits.
Whooping Cough
Reduced glutathione is required for pertussis toxin secretion by Bordetella pertussis.
Whooping Cough
Reduced hormone-stimulated adenylate cyclase activity in NIH-3T3 cells expressing the EJ human bladder ras oncogene.
Whooping Cough
Reduced-antigen, combined diphtheria, tetanus and acellular pertussis vaccine, adsorbed (boostrix®): a review of its properties and use as a single-dose booster immunization.
Whooping Cough
Reduced-antigen, combined diphtheria, tetanus, and acellular pertussis vaccine, adsorbed (boostrix(®)): a guide to its use as a single-dose booster immunization against pertussis.
Whooping Cough
Reducing agents and light break an S-S bond activating rhodopsin in vivo in Chlamydomonas.
Whooping Cough
Reduction of in vivo striatal 5-hydroxytryptamine release by 8-OH-DPAT after inactivation of Gi/G(o) proteins in dorsal raphe nucleus.
Whooping Cough
Reduction of Pertussis Inflammatory Pathology by Therapeutic Treatment With Sphingosine-1-Phosphate Receptor Ligands by a Pertussis Toxin-Insensitive Mechanism.
Whooping Cough
Reduction of Potassium Conductances Mediated by Metabotropic Glutamate Receptors in Rat CA3 Pyramidal Cells Does Not Require Protein Kinase C or Protein Kinase A.
Whooping Cough
Reduction of the same calcium current component by A and C kinases: differential pertussis toxin sensitivity.
Whooping Cough
Regeneration of entorhinal fibers in mouse slice cultures is age dependent and can be stimulated by NT-4, GDNF, and modulators of G-proteins and protein kinase C.
Whooping Cough
Regional characterization of G-protein subunits in glomeruli, cortices and medullas of the rat kidney.
Whooping Cough
Regional differences of the inhibition of GABAB ligand binding by the GTP analogue Gpp(NH)p.
Whooping Cough
Regional effects of pertussis toxin in vivo and in vitro on GABAB receptor binding in rat brain.
Whooping Cough
Regulation and functional characterization of a rat recombinant dopamine D3 receptor.
Whooping Cough
Regulation by bradykinin of phosphoinositide metabolism in the endothelial cells of the pulmonary artery.
Whooping Cough
Regulation by complement C3a and C5a anaphylatoxins of cytokine production in human umbilical vein endothelial cells.
Whooping Cough
Regulation by GTP and its stable thiol derivatives of calcium current components in rat nodose ganglion neurons.
Whooping Cough
Regulation by GTP of a Ca(2+)-activated K+ channel in the apical membrane of rabbit cortical collecting duct cells.
Whooping Cough
Regulation of 1,2-diacylglycerol production by angiotensin-II in bovine adrenal glomerulosa cells.
Whooping Cough
Regulation of 5-hydroxytryptamine release from rat midbrain raphe nuclei by 5-hydroxytryptamine1D receptors: effect of tetrodotoxin, G protein inactivation and long-term antidepressant administration.
Whooping Cough
Regulation of a G protein-gated inwardly rectifying K+ channel by a Ca(2+)-independent protein kinase C.
Whooping Cough
Regulation of acetyl-CoA carboxylase by ADP-ribosylation.
Whooping Cough
Regulation of acetylated low density lipoprotein uptake in macrophages by pertussis toxin-sensitive G proteins.
Whooping Cough
Regulation of acetylcholine release by muscarinic receptors at the mouse neuromuscular junction depends on the activity of acetylcholinesterase.
Whooping Cough
Regulation of adenylyl cyclase type V/VI in smooth muscle: interplay of inhibitory G protein and Ca2+ influx.
Whooping Cough
Regulation of adenylyl cyclase, ERK1/2, and CREB by Gz following acute and chronic activation of the delta-opioid receptor.
Whooping Cough
Regulation of adipogenesis by ceramide 1-phosphate.
Whooping Cough
Regulation of adrenocortical function by vasopressin.
Whooping Cough
Regulation of alkaline phosphatase activity by p38 MAP kinase in response to activation of Gi protein-coupled receptors by epinephrine in osteoblast-like cells.
Whooping Cough
Regulation of alphaIIb beta3 function in human B lymphocytes.
Whooping Cough
Regulation of angiotensin II-induced G protein signaling by phosducin-like protein.
Whooping Cough
Regulation of arachidonic acid release and prostaglandin E2 production in thymic epithelial cells by ATPgammaS and transforming growth factor-alpha.
Whooping Cough
Regulation of arachidonic acid release in vascular endothelium. Ca(2+)-dependent and -independent pathways.
Whooping Cough
Regulation of ATP-dependent surfactant secretion and activation of second-messenger systems in alveolar type II cells.
Whooping Cough
Regulation of ATP-sensitive K+ channels in insulinoma cells: activation by somatostatin and protein kinase C and the role of cAMP.
Whooping Cough
Regulation of atrial natriuretic peptide-stimulated cGMP production in the inner medulla.
Whooping Cough
Regulation of Basal and stimulated prolactin release in prolactin-secreting rat pituitary tumors*.
Whooping Cough
Regulation of bradykinin receptor level by cholera toxin, pertussis toxin and forskolin in cultured human fibroblasts.
Whooping Cough
Regulation of bradykinin- and ATP-activated Ca(2+)-permeable channels in rat pheochromocytoma (PC12) cells.
Whooping Cough
Regulation of bradykinin-induced Ins(1,4,5)P3 formation by protein kinase C in human fibroblasts.
Whooping Cough
Regulation of bradykinin-induced phosphoinositide turnover in cultured cerebellar astrocytes: possible role of protein kinase C.
Whooping Cough
Regulation of Ca2+-sensitive adenylyl cyclase in gonadotropin-releasing hormone neurons.
Whooping Cough
Regulation of calcitonin secretion in vitro.
Whooping Cough
Regulation of calcium currents by chemokines and their receptors.
Whooping Cough
Regulation of calcium homeostasis in sensory neurons by bradykinin.
Whooping Cough
Regulation of cAMP metabolism by PGE2 in cortical and medullary thick ascending limb of Henle's loop.
Whooping Cough
Regulation of carbachol- and histamine-induced inositol phospholipid hydrolysis in a human oligodendroglioma.
Whooping Cough
Regulation of cardiac ?3-adrenergic receptors in hyperglycemia.
Whooping Cough
Regulation of chemokine-induced transendothelial migration of T lymphocytes by endothelial activation: differential effects on naive and memory T cells.
Whooping Cough
Regulation of cholecystokinin secretion by peptones and peptidomimetic antibiotics in STC-1 cells.
Whooping Cough
Regulation of cyclic adenosine 3',5'- monophosphate signaling and pulsatile neurosecretion by Gi-coupled plasma membrane estrogen receptors in immortalized gonadotrophin-releasing hormone neurons.
Whooping Cough
Regulation of cyclic adenosine 3',5'-monophosphate signaling and pulsatile neurosecretion by Gi-coupled plasma membrane estrogen receptors in immortalized gonadotropin-releasing hormone neurons.
Whooping Cough
Regulation of cyclic AMP accumulation in lymphoid cells.
Whooping Cough
Regulation of cyclic AMP formation in cultures of human foetal astrocytes by beta 2-adrenergic and adenosine receptors.
Whooping Cough
Regulation of cyclic AMP levels by phorbol esters in bovine adrenal medullary cells.
Whooping Cough
Regulation of cyclic AMP metabolism in rabbit cortical collecting tubule cells by prostaglandins.
Whooping Cough
Regulation of cytosolic calcium by angiotensins in vascular smooth muscle.
Whooping Cough
Regulation of cytosolic calcium by cAMP and cGMP in freshly isolated smooth muscle cells from bovine trachea.
Whooping Cough
Regulation of cytosolic pH in bovine parathyroid cells: effect of fluoride.
Whooping Cough
Regulation of delta opioid receptors by delta9-tetrahydrocannabinol in NG108-15 hybrid cells.
Whooping Cough
Regulation of DTH and IgE responses by IL-4 and IFN-gamma in immunized mice given pertussis toxin.
Whooping Cough
Regulation of endothelial cell branching morphogenesis by endogenous chemokine stromal-derived factor-1.
Whooping Cough
Regulation of endothelin-1- and lysophosphatidic acid-stimulated tyrosine phosphorylation of focal adhesion kinase (pp125fak) in Rat-1 fibroblasts.
Whooping Cough
Regulation of eNOS expression in brain endothelial cells by perinuclear EP(3) receptors.
Whooping Cough
Regulation of eosinophil function by phosphatidylinositol-specific PLC and cytosolic PLA(2).
Whooping Cough
Regulation of experimental autoimmune encephalomyelitis by CD4+, CD25+ and CD8+ T cells: analysis using depleting antibodies.
Whooping Cough
Regulation of expression of early growth response transcription factors in rat primary cortical neurons by extracellular ATP.
Whooping Cough
Regulation of extracellular-signal regulated kinase and c-Jun N-terminal kinase by G-protein-linked muscarinic acetylcholine receptors.
Whooping Cough
Regulation of F-actin and endoplasmic reticulum organization by the trimeric G-protein Gi2 in rat hepatocytes. Implication for the activation of store-operated Ca2+ inflow.
Whooping Cough
Regulation of fibroblast procollagen production. Transforming growth factor-beta 1 induces prostaglandin E2 but not procollagen synthesis via a pertussis toxin-sensitive G-protein.
Whooping Cough
Regulation of follicle-stimulating hormone binding to receptors on bovine calf testis membranes by cholera toxin-sensitive guanine nucleotide binding protein.
Whooping Cough
Regulation of formyl peptide receptor binding to rabbit neutrophil plasma membranes. Use of monovalent cations, guanine nucleotides, and bacterial toxins to discriminate among different states of the receptor.
Whooping Cough
Regulation of G protein activation and effector modulation by fusion proteins between the human 5-hydroxytryptamine(1A) receptor and the alpha subunit of G(i1): differences in receptor-constitutive activity imparted by single amino acid substitutions in G(i1)alpha.
Whooping Cough
Regulation of G protein-coupled receptor-adenylyl cyclase responsiveness in human airway smooth muscle by exogenous and autocrine adenosine.
Whooping Cough
Regulation of G proteins by adenosine receptor agonist in coronary artery.
Whooping Cough
Regulation of G proteins by chronic opiate and clonidine treatment in the guinea pig myenteric plexus.
Whooping Cough
Regulation of G(q/11)alpha by the gonadotropin-releasing hormone receptor.
Whooping Cough
Regulation of gadd153 mRNA expression by hypoxia in pulmonary artery smooth muscle cells.
Whooping Cough
Regulation of gap-junction protein connexin 43 by beta-adrenergic receptor stimulation in rat cardiomyocytes.
Whooping Cough
Regulation of GH3 pituitary tumour-cell adenylate cyclase activity by activators of protein kinase C.
Whooping Cough
Regulation of GH3-cell function via adenosine A1 receptors. Inhibition of prolactin release, cyclic AMP production and inositol phosphate generation.
Whooping Cough
Regulation of glucose carrier activity by AlCl3 and phospholipase C in fat-cells.
Whooping Cough
Regulation of glucose transport by insulin, bombesin, and bradykinin in Swiss 3T3 fibroblasts: involvement of protein kinase C-dependent and -independent mechanisms.
Whooping Cough
Regulation of glutamate release from primary afferents and interneurons in the spinal cord by muscarinic receptor subtypes.
Whooping Cough
Regulation of GTPase and adenylate cyclase activity by amyloid beta-peptide and its fragments in rat brain tissue.
Whooping Cough
Regulation of guanine nucleotide binding regulatory proteins in cultured adrenal cells by adrenocorticotropin and angiotensin-II.
Whooping Cough
Regulation of guanine nucleotide turnover on Gi/Go by agonist-stimulated and spontaneously active muscarinic receptors in cardiac membranes.
Whooping Cough
Regulation of heat-shock protein (hsp70) gene expression by hGH and IL2 in rat Nb2 lymphoma cells.
Whooping Cough
Regulation of high-conductance anion channels by G proteins and 5-HT1A receptors in CHO cells.
Whooping Cough
Regulation of homocysteine-induced MMP-9 by ERK1/2 pathway.
Whooping Cough
Regulation of HSP70 by PTH: a model of gene regulation not mediated by changes in cAMP levels.
Whooping Cough
Regulation of human interleukin-8 receptor A: identification of a phosphorylation site involved in modulating receptor functions.
Whooping Cough
Regulation of I(Cl,swell) in neuroblastoma cells by G protein signaling pathways.
Whooping Cough
Regulation of IL-6 synthesis in human peripheral blood mononuclear cells by C3a and C3a(desArg).
Whooping Cough
Regulation of inositol phospholipid and inositol phosphate metabolism in chemoattractant-activated human polymorphonuclear leukocytes.
Whooping Cough
Regulation of integrin function by CD47 ligands. Differential effects on alpha vbeta 3 and alpha 4beta1 integrin-mediated adhesion.
Whooping Cough
Regulation of intestinal proglucagon-derived peptide secretion by intestinal regulatory peptides.
Whooping Cough
Regulation of intracellular calcium by extracellular nucleotides in pig tracheal submucosal gland cells.
Whooping Cough
Regulation of intracellular free calcium in human myometrial cells by prostaglandin F2 alpha: comparison with oxytocin.
Whooping Cough
Regulation of intracellular [Ca2+] and GABA release by presynaptic GABAB receptors in rat cerebrocortical synaptosomes.
Whooping Cough
Regulation of ion content in primary cultures from reabsorptive ducts of human sweat glands studied by X-ray microanalysis.
Whooping Cough
Regulation of K+ and Ca++ channels by a family of neuropeptide Y receptors.
Whooping Cough
Regulation of kindling epileptogenesis by hippocampal galanin type 1 and type 2 receptors: The effects of subtype-selective agonists and the role of G-protein-mediated signaling.
Whooping Cough
Regulation of kinesin expression and type IV collagenase secretion in invasive human prostate PC-3 tumor sublines.
Whooping Cough
Regulation of lens cyclic nucleotide metabolism by Ca2+ plus calmodulin.
Whooping Cough
Regulation of leptin release by insulin, glucocorticoids, G(i)-coupled receptor agonists, and pertussis toxin in adipocytes and adipose tissue explants from obese humans in primary culture.
Whooping Cough
Regulation of leukotriene-dependent induction of cyclooxygenase-2 and Bcl-2.
Whooping Cough
Regulation of ligand-receptor dynamics by guanine nucleotides. Real-time analysis of interconverting states for the neutrophil formyl peptide receptor.
Whooping Cough
Regulation of limbic status epilepticus by hippocampal galanin type 1 and type 2 receptors.
Whooping Cough
Regulation of lipolysis by somatotropin: functional alteration of adrenergic and adenosine signaling in bovine adipose tissue.
Whooping Cough
Regulation of luminol-dependent chemiluminescence and degranulation by bovine neutrophils stimulated with opsonized zymosan.
Whooping Cough
Regulation of lysophosphatidic acid receptor-stimulated response by G-protein-coupled receptor kinase-2 and beta-arrestin1 in FRTL-5 rat thyroid cells.
Whooping Cough
Regulation of lysophosphatidic acid-induced COX-2 expression by ERK1/2 activation in cultured feline esophageal epithelial cells.
Whooping Cough
Regulation of lysophosphatidic acid-stimulated tyrosine phosphorylation of mitogen-activated protein kinase by protein kinase C- and pertussis toxin-dependent pathways in the endothelial cell line EAhy 926.
Whooping Cough
Regulation of MAP kinase by calcium-sensing receptor in bovine parathyroid and CaR-transfected HEK293 cells.
Whooping Cough
Regulation of melanoma cell adhesion stabilization to fibronectin.
Whooping Cough
Regulation of melanoma-cell motility by the lipoxygenase metabolite 12-(S)-HETE.
Whooping Cough
Regulation of membrane associated protein kinase C activity by guanine nucleotide in rabbit peritoneal neutrophils.
Whooping Cough
Regulation of mGlu4 metabotropic glutamate receptor signaling by type-2 G-protein coupled receptor kinase (GRK2).
Whooping Cough
Regulation of mitogen-activated protein kinase cascades by low density lipoprotein and lysophosphatidic acid.
Whooping Cough
Regulation of mitogen-activated protein kinase phosphatase-1 expression by extracellular signal-related kinase-dependent and Ca2+-dependent signal pathways in Rat-1 cells.
Whooping Cough
Regulation of mouse placental lactogen secretion by G proteins before midpregnancy.
Whooping Cough
Regulation of mTOR and p70 S6 kinase by the muscarinic M4 receptor in PC12 cells.
Whooping Cough
Regulation of multiple effectors by the cloned delta-opioid receptor: stimulation of phospholipase C and type II adenylyl cyclase.
Whooping Cough
Regulation of myogenesis by fibroblast growth factors requires beta-gamma subunits of pertussis toxin-sensitive G proteins.
Whooping Cough
Regulation of Na(+)-pump activity by dopamine in rat tail arteries.
Whooping Cough
Regulation of Na+,K(+)-ATPase activity by dopamine in cultured rat aortic smooth muscle cells.
Whooping Cough
Regulation of Na+-K+-ATPase activity in kidney proximal tubules: involvement of GTP binding proteins.
Whooping Cough
Regulation of neutrophil NADPH oxidase activation in a cell-free system by guanine nucleotides and fluoride. Evidence for participation of a pertussis and cholera toxin-insensitive G protein.
Whooping Cough
Regulation of neutrophil O2- production by neutrophil-endothelial cell interaction via CD11b: its modulation by tumor necrosis factor-alpha (TNF-alpha) and lipopolysaccharide (LPS).
Whooping Cough
Regulation of NHE3 activity by G protein subunits in renal brush-border membranes.
Whooping Cough
Regulation of NPY/NPY Y1 receptor/G protein system in rat brain cortex.
Whooping Cough
Regulation of oxytocin receptor expression in cultured human myometrial cells by fetal bovine serum and lysophospholipids.
Whooping Cough
Regulation of p42 and p44 MAP kinase isoforms in Rat-1 fibroblasts stably transfected with alpha 2C10 adrenoreceptors.
Whooping Cough
Regulation of p42/p44 MAPK and p38 MAPK by the adenosine A(1) receptor in DDT(1)MF-2 cells.
Whooping Cough
Regulation of p42/p44 mitogen-activated protein kinase by the human adenosine A3 receptor in transfected CHO cells.
Whooping Cough
Regulation of parathyroid hormone messenger RNA levels by protein kinase A and C in bovine parathyroid cells.
Whooping Cough
Regulation of phosphate transport by second messengers in capillaries of the blood-brain barrier.
Whooping Cough
Regulation of phosphoinositide and phosphatidylcholine phospholipases by G proteins.
Whooping Cough
Regulation of phospholipase D (PLD) in growth plate chondrocytes by 24R,25-(OH)2D3 is dependent on cell maturation state (resting zone cells) and is specific to the PLD2 isoform.
Whooping Cough
Regulation of phospholipase D and primary granule secretion by P2-purinergic- and chemotactic peptide-receptor agonists is induced during granulocytic differentiation of HL-60 cells.
Whooping Cough
Regulation of phospholipase D in human placental trophoblasts by the P(2) purinergic receptor.
Whooping Cough
Regulation of phosphorylation of Gi2 alpha protein controls the secretory response to isoproterenol in rat parotid tissues.
Whooping Cough
Regulation of PI hydrolysis and cAMP formation by muscarinic M3 receptor in guinea pig gallbladder.
Whooping Cough
Regulation of PI3K/Akt signaling by N-desmethylclozapine through activation of ?-opioid receptor.
Whooping Cough
Regulation of pinocytosis in murine macrophages by colony-stimulating factors and other agents.
Whooping Cough
Regulation of plasminogen activator inhibitor activity by plasmin in endothelial cells.
Whooping Cough
Regulation of porcine adipocyte metabolism by insulin and adenosine.
Whooping Cough
Regulation of prostatic smooth muscle contractility by intracellular second messengers: implications for the conservative treatment of benign prostatic hyperplasia.
Whooping Cough
Regulation of Rac and Cdc42 pathways by G(i) during lysophosphatidic acid-induced cell spreading.
Whooping Cough
Regulation of Ras.GTP loading and Ras-Raf association in neonatal rat ventricular myocytes by G protein-coupled receptor agonists and phorbol ester. Activation of the extracellular signal-regulated kinase cascade by phorbol ester is mediated by Ras.
Whooping Cough
Regulation of rat hepatocyte function by P2Y receptors: focus on control of glycogen phosphorylase and cyclic AMP by 2-methylthioadenosine 5'-diphosphate.
Whooping Cough
Regulation of renal cortical Na-HCO3 cotransporter. II. Role of G proteins.
Whooping Cough
Regulation of renal epithelial sodium channels.
Whooping Cough
Regulation of responsiveness at D2 dopamine receptors by receptor desensitization and adenylyl cyclase sensitization.
Whooping Cough
Regulation of spontaneous activity of the delta-opioid receptor: studies of inverse agonism in intact cells.
Whooping Cough
Regulation of spontaneous Ca(2+) spikes by metabotropic glutamate receptors in primary cultures of rat cortical neurons.
Whooping Cough
Regulation of spontaneous opening of muscarinic K+ channels in rabbit atrium.
Whooping Cough
Regulation of stably transfected platelet activating factor receptor in RBL-2H3 cells. Role of multiple G proteins and receptor phosphorylation.
Whooping Cough
Regulation of STAT3 by mu-opioid receptors in human neuroblastoma SH-SY5Y cells.
Whooping Cough
Regulation of striatal cyclic-3',5'-adenosine monophosphate accumulation and GABA release by glutamate metabotropic and dopamine D1 receptors.
Whooping Cough
Regulation of superoxide anion generation in bovine alveolar macrophages by bacterial lipopolysaccharide, serum proteins, and modulators of signal transduction.
Whooping Cough
Regulation of synaptic efficacy in hypocretin/orexin-containing neurons by melanin concentrating hormone in the lateral hypothalamus.
Whooping Cough
Regulation of the action of the novel cholecystokinin-releasing peptide diazepam binding inhibitor by inhibitory hormones and taurocholate.
Whooping Cough
Regulation of the affinity state of the N-formylated peptide receptor of neutrophils: role of guanine nucleotide-binding proteins and the cytoskeleton.
Whooping Cough
Regulation of the AGS3·G{alpha}i signaling complex by a seven-transmembrane span receptor.
Whooping Cough
Regulation of the amiloride-blockable sodium channel from epithelial tissue.
Whooping Cough
Regulation of the CHAPS-solubilized muscarinic receptors by an inhibitory GTP binding protein (Gi) in the brain of neonatal and adult rats.
Whooping Cough
Regulation of the coupling to different G proteins of rat corticotropin-releasing factor receptor type 1 in human embryonic kidney 293 cells.
Whooping Cough
Regulation of the extracellular signal-regulated kinase pathway in adult myocardium: differential roles of G(q/11), Gi and G(12/13) proteins in signalling by alpha1-adrenergic, endothelin-1 and thrombin-sensitive protease-activated receptors.
Whooping Cough
Regulation of the G protein Galphai2 by growth and development in fetal airway epithelium.
Whooping Cough
Regulation of the G-protein regulatory-G?i signaling complex by nonreceptor guanine nucleotide exchange factors.
Whooping Cough
Regulation of the mannose 6-phosphate/IGF II receptor expression at the cell surface by mannose 6-phosphate, insulin like growth factors and epidermal growth factor.
Whooping Cough
Regulation of the phosphoinositide hydrolysis pathway in thrombin-stimulated platelets by a pertussis toxin-sensitive guanine nucleotide-binding protein. Evaluation of its contribution to platelet activation and comparisons with the adenylate cyclase inhibitory protein, Gi.
Whooping Cough
Regulation of the phosphoinositide pathway in cultured Sertoli cells from immature rats: effects of follicle-stimulating hormone and fluoride.
Whooping Cough
Regulation of the potassium current and cytosolic Ca2+ release induced by 2-methylthio ATP in hippocampal neurons.
Whooping Cough
Regulation of the PRL promoter by Akt through cAMP response element binding protein.
Whooping Cough
Regulation of the renal Na-HCO3 cotransporter: IV. Mechanisms of the stimulatory effect of angiotensin II.
Whooping Cough
Regulation of the serum-activated Ca(2+)-dependent chloride channel in Xenopus oocytes.
Whooping Cough
Regulation of thrombin-induced endothelial cell activation by bacterial toxins.
Whooping Cough
Regulation of thyrotropin-releasing hormone receptor binding and phospholipase C activation by a single GTP-binding protein.
Whooping Cough
Regulation of transforming growth factor beta 1 action by multiple transducing pathways: evidence for both G protein-dependent and -independent signaling.
Whooping Cough
Regulation of transmembrane signal transduction of insulin-like growth factor II by competence type growth factors or viral ras p21.
Whooping Cough
Regulation of transmembrane signaling by ganglioside GM1: interaction of anti-GM1 with Neuro2a cells.
Whooping Cough
Regulation of tumour necrosis factor production by mouse peritoneal macrophages: the role of cellular cyclic AMP.
Whooping Cough
Regulation of type V adenylate cyclase by Ric8a, a guanine nucleotide exchange factor.
Whooping Cough
Regulation of vascular angiotensin II receptors by EGF.
Whooping Cough
Regulation of vascular proteoglycan synthesis by angiotensin II type 1 and type 2 receptors.
Whooping Cough
Regulation of volume-sensitive osmolyte efflux from human SH-SY5Y neuroblastoma cells following activation of lysophospholipid receptors.
Whooping Cough
Regulation of Xenopus oocyte meiosis arrest by G protein betagamma subunits.
Whooping Cough
Regulator of G protein signaling 2 deficiency causes endothelial dysfunction and impaired endothelium-derived hyperpolarizing factor-mediated relaxation by dysregulating Gi/o signaling.
Whooping Cough
Regulator of G Protein Signaling Protein 12 (Rgs12) Controls Mouse Osteoblast Differentiation via Calcium Channel/Oscillation and G?i-ERK Signaling.
Whooping Cough
Regulator of G protein signaling protein suppression of Galphao protein-mediated alpha2A adrenergic receptor inhibition of mouse hippocampal CA3 epileptiform activity.
Whooping Cough
Regulator of G-protein signalling 3 redirects prototypical Gi-coupled receptors from Rac1 to RhoA activation.
Whooping Cough
Regulators involved in the electrically stimulated response of feline esophageal smooth muscle.
Whooping Cough
Regulators of G protein signaling (RGS) proteins constitutively activate Gbeta gamma-gated potassium channels.
Whooping Cough
Regulatory effects of platelet-derived growth factor-AA homodimer on migration of vascular smooth muscle cells.
Whooping Cough
Regulatory factors that determine growth and phenotype of normal human melanocytes.
Whooping Cough
Regulatory mechanisms underlying the modulation of GIRK1/GIRK4 heteromeric channels by P2Y receptors.
Whooping Cough
Regulatory role of the GTP-binding protein, G(o), in the mechanism of exocytosis in adrenal chromaffin cells.
Whooping Cough
Relation of the [3H] gamma-hydroxybutyric acid (GHB) binding site to the gamma-aminobutyric acidB (GABAB) receptor in rat brain.
Whooping Cough
Relationship between increased cyclic AMP-phosphodiesterase activity and abnormal adenylyl cyclase regulation in leukocytes from patients with atopic dermatitis.
Whooping Cough
Relationship between membrane depolarization and extracellular calcium influx during neutrophil activation.
Whooping Cough
Relationship between NaF- and thapsigargin-induced endothelium-dependent hyperpolarization in rat mesenteric artery.
Whooping Cough
Relationship between pH, sodium, and shape changes in chemotactic-factor-stimulated human neutrophils.
Whooping Cough
Relationship between phospholipase C activation and prostaglandin E2 and cyclic adenosine monophosphate production in rabbit tubular epithelial cells. Effects of angiotensin, bradykinin, and arginine vasopressin.
Whooping Cough
Relationship between proliferation and cell cycle-dependent Ca2+ influx induced by a combination of thyrotropin and insulin-like growth factor-I in rat thyroid cells.
Whooping Cough
Relationship between structure and biological and protective activities of pertussis toxin.
Whooping Cough
Relationship between the inhibition of adenylate cyclase by pentobarbital and the functional coupling of Ns and the catalytic unit.
Whooping Cough
Relationship between the self-incompatibility and cAMP level in Lilium longiflorum.
Whooping Cough
Relationship of GTP-binding proteins, phospholipase C, and PGE2 synthesis in rat glomerular mesangial cells.
Whooping Cough
Relationship of immunogenicity to protective potency in acellular pertussis vaccines.
Whooping Cough
Relationship of molecular structure to the mechanism of lysophospholipid-induced smooth muscle cell proliferation.
Whooping Cough
Relationships between dopamine-induced changes in cytosolic free calcium concentration ([Ca2+]i) and rate of prolactin secretion. Elevated [Ca2+]i does not indicate prolactin release.
Whooping Cough
Relationships between functional assays and enzyme immunoassays as measurements of responses to acellular and whole-cell pertussis vaccines.
Whooping Cough
Relative potencies of the somatostatin analogs octreotide, BIM-23014, and RC-160 on the inhibition of hormone release by cultured human endocrine tumor cells and normal rat anterior pituitary cells.
Whooping Cough
Relaxation of bovine mesenteric arteries by glyceryl trinitrate and other nitro-compounds: evidence for partly different mechanisms of action.
Whooping Cough
Relaxation of bovine mesenteric artery induced by glyceryl trinitrate is attenuated by pertussis toxin.
Whooping Cough
Relaxation of evoked contractile activity of isolated guinea-pig ileum by (+/-)-kavain.
Whooping Cough
Relaxin family peptide receptor 1 activation stimulates peroxisome proliferator-activated receptor gamma.
Whooping Cough
Relaxin induces rapid dilation of rodent small renal and human subcutaneous arteries via PI3 kinase and nitric oxide.
Whooping Cough
Release of C-type natriuretic peptide accounts for the biological activity of endothelium-derived hyperpolarizing factor.
Whooping Cough
Release of calcium from inositol 1,4,5-trisphosphate receptor-regulated stores by HIV-1 Tat regulates TNF-alpha production in human macrophages.
Whooping Cough
Release of glutamate and CGRP from trigeminal ganglion neurons: Role of calcium channels and 5-HT1 receptor signaling.
Whooping Cough
Release of guanosine triphosphate binding protein alpha subunits from mouse myocardial membranes: basic properties and their alterations in acute murine Chagas disease.
Whooping Cough
Release of interleukin-6 by human thyroid epithelial cells immortalized by simian virus 40 DNA transfection.
Whooping Cough
Release of pertussis toxin and its interaction with outer-membrane antigens.
Whooping Cough
Release of serotonin from RBL-2H3 cells by the Escherichia coli peptide toxin STb.
Whooping Cough
Relief from glucose-induced over-stimulation sensitizes the adenylate cyclase-cAMP system of rat pancreatic islets.
Whooping Cough
Removal of endotoxin from culture supernatant of Bordetella pertussis with aminated poly(gamma-methyl L-glutamate) spherical beads.
Whooping Cough
Removal of partial agonism from parathyroid hormone (PTH)-related protein-(7-34)NH2 by substitution of PTH amino acids at positions 10 and 11.
Whooping Cough
Reorientation of macrophage mediator production in endotoxin tolerance.
Whooping Cough
Reovirus transport--studies using lymphocytosis promoting factor.
Whooping Cough
Reoxygenation after severe hypoxia induces cardiomyocyte hypertrophy in vitro: activation of CREB downstream of GSK3beta.
Whooping Cough
Repeated administration of whole-cell and acellular pertussis vaccines affects haemodynamics and autonomic responsiveness.
Whooping Cough
Repetitive pertussis toxin promotes development of regulatory T cells and prevents central nervous system autoimmune disease.
Whooping Cough
Report on the international workshop on alternatives to the murine histamine sensitization test (HIST) for acellular pertussis vaccines: State of the science and the path forward.
Whooping Cough
Reporter cell lines for detection of pertussis toxin in acellular pertussis vaccines as a functional animal-free alternative to the in vivo histamine sensitization test.
Whooping Cough
Requirement for both choleragen and pertussis toxin to obtain maximal activation of adenylate cyclase in cultured cells.
Whooping Cough
Requirement for G proteins in insulin-like growth factor-I-induced growth of prostate cells.
Whooping Cough
Requirement for Rho-mediated myosin light chain phosphorylation in thrombin-stimulated cell rounding and its dissociation from mitogenesis.
Whooping Cough
Requirement of ADP-ribosylation for the pertussis toxin-induced alteration in electrophoretic mobility of G-proteins.
Whooping Cough
Requirement of Galphai in thymic homing and early T cell development.
Whooping Cough
Requirement of Gbetagamma and c-Src in D2 dopamine receptor-mediated nuclear factor-kappaB activation.
Whooping Cough
Requirement of phosphatidylinositol 3-kinase activation and calcium influx for leukotriene B4-induced enzyme release.
Whooping Cough
Requirements for assembly of PtlH with the pertussis toxin transporter apparatus of Bordetella pertussis.
Whooping Cough
Requirements for C5a receptor-mediated IL-4 and IL-13 production and leukotriene C4 generation in human basophils.
Whooping Cough
Requirements for Langerhans' cell depletion following in vitro exposure of murine skin to ultraviolet-B.
Whooping Cough
Requirements for T lymphocyte migration in explanted lymph nodes.
Whooping Cough
Rescheduling Behavioral Subunits of a Fixed Action Pattern by Genetic Manipulation of Peptidergic Signaling.
Whooping Cough
Rescue of functional F508del cystic fibrosis transmembrane conductance regulator by vasoactive intestinal peptide in the human nasal epithelial cell line JME/CF15.
Whooping Cough
Resistance of the insulinotropic action of alpha-D-glucose and beta-L-glucose pentaacetates to cholera and pertussis toxins.
Whooping Cough
Resolution of a low molecular weight G protein in neutrophil cytosol required for NADPH oxidase activation and reconstitution by recombinant Krev-1 protein.
Whooping Cough
Resolvin D1 binds human phagocytes with evidence for proresolving receptors.
Whooping Cough
Resolving TRPV1- and TNF-?-mediated spinal cord synaptic plasticity and inflammatory pain with neuroprotectin D1.
Whooping Cough
Response and decline of serum IgG antibodies to pertussis toxin, filamentous hemagglutinin and pertactin in children with pertussis.
Whooping Cough
Response of human thalamic neurons to high-frequency stimulation.
Whooping Cough
Response to lysophosphatidic acid in Xenopus oocytes and its rapid desensitization: the role of Gq and Go G-protein families.
Whooping Cough
Response to prejunctional adenosine receptors is dependent on stimulus frequency.
Whooping Cough
Responses of pertussis toxin-treated microvascular endothelial cells to transforming growth factor beta 1. No evidence for pertussis-sensitive G-protein involvement in TGF-beta signal transduction.
Whooping Cough
Responses to an acellular pertussis booster vaccination in children, adolescents, and young and older adults: A collaborative study in Finland, the Netherlands, and the United Kingdom.
Whooping Cough
Responses to Bordetella pertussis mutant strains and to vaccination in the coughing rat model of pertussis.
Whooping Cough
Responses to primary and a booster dose of acellular, component, and whole-cell pertussis vaccines initiated at 2 months of age.
Whooping Cough
Restoration of the transient outward potassium current by noradrenaline in chagasic canine epicardium.
Whooping Cough
Resumption of meiosis induced by meiosis-activating sterol has a different signal transduction pathway than spontaneous resumption of meiosis in denuded mouse oocytes cultured in vitro.
Whooping Cough
Resveratrol stimulates nitric oxide production by increasing estrogen receptor alpha-Src-caveolin-1 interaction and phosphorylation in human umbilical vein endothelial cells.
Whooping Cough
Retention of CXCR4 in the endoplasmic reticulum blocks dissemination of a T cell hybridoma.
Whooping Cough
Reticulocyte cytosol activator protein: effects on the stimulatory and inhibitory regulatory proteins of adenylate cyclase.
Whooping Cough
Retinal ganglion cell damage induced by spontaneous autoimmune optic neuritis in MOG-specific TCR transgenic mice.
Whooping Cough
Retinoic acid-induced gene expression of tissue transglutaminase via protein kinase C-dependent pathway in mouse peritoneal macrophages.
Whooping Cough
Retraction: Murine hypothalamic destruction with vascular cell apoptosis subsequent to combined administration of human papilloma virus vaccine and pertussis toxin.
Whooping Cough
Retrograde transport of pertussis toxin in the mammalian cell.
Whooping Cough
Reversal by pertussis toxin and N-ethylmaleimide of the facilitation of baroreceptor reflex response by somatostatin in the rat.
Whooping Cough
Reversal of ongoing thermal hyperalgesia in mice by a recombinant herpesvirus that encodes human preproenkephalin.
Whooping Cough
Reversal of pertussis toxin-induced thermal allodynia by muscarinic cholinergic agonists in mice.
Whooping Cough
Reversal of somatostatin inhibition of AVP-induced cAMP by pertussis toxin.
Whooping Cough
Reversal of the CD4(+)/CD8(+) T-cell ratio in lymph node cells upon in vitro mitogenic stimulation by highly purified, water-soluble S3-S4 dimer of pertussis toxin.
Whooping Cough
Reversible modulation of opioid receptor binding in intact neural cells by endogenous guanosine triphosphate.
Whooping Cough
Review of the laboratory approaches to the detection of antibody and cell-mediated immunity to pertussis disease and vaccine.
Whooping Cough
Review of the neutrophil response to Bordetella pertussis infection.
Whooping Cough
RGS2 blocks slow muscarinic inhibition of N-type Ca(2+) channels reconstituted in a human cell line.
Whooping Cough
RGS2 overexpression or G(i) inhibition rescues the impaired PKA signaling and slow AP firing of cultured adult rabbit pacemaker cells.
Whooping Cough
RGS4 inhibits Gq-mediated activation of mitogen-activated protein kinase and phosphoinositide synthesis.
Whooping Cough
Rhes and AGS1/Dexras1 affect signaling by dopamine D1 receptors through adenylyl cyclase.
Whooping Cough
Rhizobium nod factor signaling. Evidence for a g protein-mediated transduction mechanism
Whooping Cough
Rho family small GTPases control migration of hematopoietic progenitor cells into multicellular spheroids of bone marrow stroma cells.
Whooping Cough
Rho GTPases mediated integrin alpha v beta 3 activation in sphingosine-1-phosphate stimulated chemotaxis of endothelial cells.
Whooping Cough
Rho-mediated cytoskeletal rearrangement in response to LPA is functionally antagonized by Rac1 and PIP2.
Whooping Cough
Rho-mediated phosphorylation of focal adhesion kinase and myosin light chain in human endothelial cells stimulated with sphingosine 1-phosphate, a bioactive lysophospholipid released from activated platelets.
Whooping Cough
RhoA- and RhoD-dependent regulatory switch of Galpha subunit signaling by PAR-1 receptors in cellular invasion.
Whooping Cough
Rhodopsin expressed in Chinese hamster ovary cells regulates adenylyl cyclase activity.
Whooping Cough
Rhythmic expression of adenylyl cyclase VI contributes to the differential regulation of serotonin N-acetyltransferase by bradykinin in rat pineal glands.
Whooping Cough
Rhythmical bursting activity and GABAergic mechanisms in the medial septum of normal and pertussis toxin-pretreated rats.
Whooping Cough
Riboflavin: Inhibitory Effects on Receptors, G-Proteins, and Adenylate Cyclase.
Whooping Cough
Ric-8A and Gi alpha recruit LGN, NuMA, and dynein to the cell cortex to help orient the mitotic spindle.
Whooping Cough
Ric-8A-mediated stabilization of the trimeric G protein subunit G?i is inhibited by pertussis toxin-catalyzed ADP-ribosylation.
Whooping Cough
Riluzole increases high-affinity glutamate uptake in rat spinal cord synaptosomes.
Whooping Cough
Rimonabant, a CB1 Inverse Agonist, Inhibits Hepatocyte Lipogenesis by Activating LKB1 and AMPK Axis Downstream of G{alpha}i/o Inhibition.
Whooping Cough
Ring-deleted analogs of atrial natriuretic factor inhibit adenylate cyclase/cAMP system. Possible coupling of clearance atrial natriuretic factor receptors to adenylate cyclase/cAMP signal transduction system.
Whooping Cough
Rise in intracellular calcium via a nongenomic effect of allopregnanolone in fetal rat hypothalamic neurons.
Whooping Cough
Rod-type transducin alpha-subunit mediates a phototransduction pathway in the chicken pineal gland.
Whooping Cough
Role for cyclic AMP in the postreceptor control of cytokine-stimulated stromal cell growth factor production.
Whooping Cough
Role in host cell invasion of Trypanosoma cruzi-induced cytosolic-free Ca2+ transients.
Whooping Cough
Role of a guanine nucleotide regulatory protein in the activation of phospholipase C by different chemoattractants.
Whooping Cough
Role of a guanine nucleotide-binding protein in alpha 1-adrenergic receptor-mediated Ca2+ mobilization in DDT1 MF-2 cells.
Whooping Cough
Role of a pertussis toxin sensitive G-protein in mediating the effects of phorbol esters on receptor activated cyclic AMP accumulation in Jurkat cells.
Whooping Cough
Role of a pertussis toxin substrate in the control of lectin-induced cap formation in human neutrophils.
Whooping Cough
Role of a pertussis toxin-sensitive protein in the modulation of canine Purkinje fiber automaticity.
Whooping Cough
Role of a protein regulating guanine nucleotide binding in phosphoinositide breakdown and calcium mobilization by bradykinin in neuroblastoma X glioma hybrid NG108-15 cells: effects of pertussis toxin and cholera toxin on receptor-mediated signal transduction.
Whooping Cough
Role of adenosine A(1) receptors in modulating extracellular adenosine levels.
Whooping Cough
Role of adenosine on glucagon-induced cAMP in a human cortical collecting duct cell line.
Whooping Cough
Role of adhesins and toxins in invasion of human tracheal epithelial cells by Bordetella pertussis.
Whooping Cough
Role of ADP-ribosyltransferase activity of pertussis toxin in toxin-adhesin redundancy with filamentous hemagglutinin during Bordetella pertussis infection.
Whooping Cough
Role of alpha2-adrenergic receptors and cyclic adenosine monophosphate-dependent protein kinase in the regulation of norepinephrine release in the central nervous system of spontaneously hypertensive rats.
Whooping Cough
Role of altered G-protein expression in the regulation of myocardial adenylate cyclase activity and force of contraction in spontaneous hypertensive cardiomyopathy in rats.
Whooping Cough
Role of amino- and carboxyl-terminal regions of G(alphaZ) in the recognition of Gi-coupled receptors.
Whooping Cough
Role of an aprotinin-sensitive protease in protein kinase Calpha-mediated activation of cytosolic phospholipase A2 by calcium ionophore (A23187) in pulmonary endothelium.
Whooping Cough
Role of antibodies against Bordetella pertussis virulence factors in adherence of Bordetella pertussis and Bordetella parapertussis to human bronchial epithelial cells.
Whooping Cough
Role of APP Interactions with Heterotrimeric G Proteins: Physiological Functions and Pathological Consequences.
Whooping Cough
Role of beta 1- and beta 2-adrenoceptors in hypertrophic and apoptotic effects of noradrenaline and adrenaline in adult rat ventricular cardiomyocytes.
Whooping Cough
Role of beta1- and beta2-adrenergic receptors in regulation of Cl- and Ca2+ channels in guinea pig ventricular myocytes.
Whooping Cough
Role of Bordetella pertussis virulence factors in adherence to epithelial cell lines derived from the human respiratory tract.
Whooping Cough
Role of calcium channels in parathyroid hormone secretion.
Whooping Cough
Role of calcium-sensitive tyrosine kinase Pyk2/CAKbeta/RAFTK in angiotensin II induced Ras/ERK signaling.
Whooping Cough
Role of cAMP in the functional interaction of carbachol with different cAMP elevating agents in rabbit atrium.
Whooping Cough
Role of cAMP in the promotion of colorectal cancer cell growth by prostaglandin E2.
Whooping Cough
Role of cannabinoid CB1 receptors and Gi/o protein activation in the modulation of synaptosomal Na+,K+-ATPase activity by WIN55,212-2 and triangle up9-THC.
Whooping Cough
Role of cannabinoid receptors in Delta-9-tetrahydrocannabinol suppression of IL-12p40 in mouse bone marrow-derived dendritic cells infected with Legionella pneumophila.
Whooping Cough
Role of carbohydrate recognition domains of pertussis toxin in adherence of Bordetella pertussis to human macrophages.
Whooping Cough
Role of cdk5 and tau phosphorylation in heterotrimeric G protein-mediated retinal growth cone collapse.
Whooping Cough
Role of ceramide in Ca2+-sensing receptor-induced apoptosis.
Whooping Cough
Role of chemokine signaling pathways in pancreatic islet rejection during allo- and xenotransplantation.
Whooping Cough
Role of cholinergic neurons in the motor effects of glucagon-like peptide-2 in mouse colon.
Whooping Cough
Role of cysteine 41 of the A subunit of pertussis toxin.
Whooping Cough
Role of D-alanylation of Streptococcus gordonii lipoteichoic acid in innate and adaptive immunity.
Whooping Cough
Role of dopamine and indolamine derivatives in the regulation of the sea urchin adenylate cyclase.
Whooping Cough
Role of endocannabinoids in the pathogenesis of cirrhotic cardiomyopathy in bile duct-ligated rats.
Whooping Cough
Role of endothelin-1 in regulating proliferation of cultured human uterine smooth muscle cells.
Whooping Cough
Role of endothelin-1 in regulating proliferation of cultured rabbit airway smooth muscle cells.
Whooping Cough
Role of Evolutionary Selection Acting on Vaccine Antigens in the Re-Emergence of Bordetella Pertussis.
Whooping Cough
Role of G alpha q or G alpha o proteins in alpha 1-adrenoceptor subtype-mediated responses in Fischer 344 rat aorta.
Whooping Cough
Role of G proteins and KCa channels in the muscarinic and beta-adrenergic regulation of airway smooth muscle.
Whooping Cough
Role of G proteins in agonist-induced Ca2+ sensitization of tracheal smooth muscle.
Whooping Cough
Role of G proteins in mouse egg activation: stimulatory effects of acetylcholine on the ZP2 to ZP2f conversion and pronuclear formation in eggs expressing a functional m1 muscarinic receptor.
Whooping Cough
Role of G proteins in shear stress-mediated nitric oxide production by endothelial cells.
Whooping Cough
Role of G proteins in the acetylcholine-induced potassium current of canine atrial cells.
Whooping Cough
Role of G proteins in the vasodilator response to endothelin isopeptides in vivo.
Whooping Cough
Role of G(i)-proteins in norepinephrine-mediated vasoconstriction in rat tail artery smooth muscle.
Whooping Cough
Role of G-protein beta gamma subunits in the augmentation of P2Y2 (P2U)receptor-stimulated responses by neuropeptide Y Y1 Gi/o-coupled receptors.
Whooping Cough
Role of G-proteins and adenylate cyclase in antinociception produced by intrathecal purines.
Whooping Cough
Role of G-proteins in ciliary process adenylyl cyclase responses of the albino rabbit eye.
Whooping Cough
Role of G-proteins in the regulation of organic osmolyte efflux from isolated rat renal inner medullary collecting duct cells.
Whooping Cough
Role of GABAB receptors in intracellular Ca2+ homeostasis and possible interaction between GABAA and GABAB receptors in regulation of transmitter release in cerebellar granule neurons.
Whooping Cough
Role of gelsolin in actin depolymerization of adherent human neutrophils.
Whooping Cough
Role of Gi proteins in the antidepressant-like effect of amitriptyline and clomipramine.
Whooping Cough
Role of Go/i subgroup of G proteins in olfactory signaling of Drosophila melanogaster.
Whooping Cough
Role of Gq alpha in insulin-stimulated glucose uptake by C6 glioma cells.
Whooping Cough
Role of GTP-binding proteins in the polyunsaturated fatty acid stimulated proliferation of mouse mammary epithelial cells.
Whooping Cough
Role of GTP-binding proteins in the regulation of mammalian cardiac chloride conductance.
Whooping Cough
Role of guanine nucleotide binding protein, cytosolic calcium and cAMP in fluoride-induced suppression of PTH secretion.
Whooping Cough
Role of guanine nucleotide regulatory protein in polyphosphoinositide degradation and activation of phagocytic leukocytes by chemoattractants.
Whooping Cough
Role of guanine nucleotide regulatory proteins and inositol phosphates in the hormone induced mobilization of hepatocyte calcium.
Whooping Cough
Role of guanine nucleotide regulatory proteins in insulin stimulation of glucose transport in rat adipocytes. Influence of bacterial toxins.
Whooping Cough
Role of guanine nucleotide-binding protein and tyrosine kinase in platelet-activating factor activation of phospholipase C in A431 cells: proposal for dual mechanisms.
Whooping Cough
Role of guanine nucleotide-binding protein in the regulation by adenosine of cardiac potassium conductance and force of contraction. Evaluation with pertussis toxin.
Whooping Cough
Role of guanine nucleotide-binding proteins--ras-family or trimeric proteins or both--in Ca2+ sensitization of smooth muscle.
Whooping Cough
Role of heterotrimeric G protein and calcium in cardiomyocyte hypertrophy induced by IGF-1.
Whooping Cough
Role of histidine 35 of the S1 subunit of pertussis toxin in the ADP-ribosylation of transducin.
Whooping Cough
Role of intracellular Ca(2+)-stores in the 5-hydroxytryptamine-induced Ca(2+)-current inhibition in NG108-15 hybrid cells.
Whooping Cough
Role of intracellular Mg2+ in the activation of muscarinic K+ channel in cardiac atrial cell membrane.
Whooping Cough
Role of intracellular signalling pathways in hydrogen peroxide-induced injury to rat glomerular mesangial cells.
Whooping Cough
Role of kinases and G-proteins on arachidonate release induced by zymosan in mouse peritoneal macrophages.
Whooping Cough
Role of L-type Ca(2+) channels in pertussis toxin induced antagonism of U50,488H analgesia and hypothermia.
Whooping Cough
Role of lipoprotein-associated lysophospholipids in migratory activity of coronary artery smooth muscle cells.
Whooping Cough
Role of lysophosphatidic acid and rho in glioma cell motility.
Whooping Cough
Role of M2 muscarinic receptors in airway smooth muscle contraction.
Whooping Cough
Role of macrophage inflammatory protein-3alpha and its ligand CCR6 in rheumatoid arthritis.
Whooping Cough
Role of Major Toxin Virulence Factors in Pertussis Infection and Disease Pathogenesis.
Whooping Cough
Role of mitogen-activated protein kinase in prostaglandin f(2alpha) action in human granulosa-luteal cells.
Whooping Cough
Role of mitogen-activated protein kinase pathway in prostaglandin F2alpha-induced rat puerperal uterine contraction.
Whooping Cough
Role of mitogen-activated protein kinase/extracellular signal-regulated kinase cascade in gonadotropin-releasing hormone-induced growth inhibition of a human ovarian cancer cell line.
Whooping Cough
Role of MMP-2 in PKCdelta-mediated inhibition of Na+ dependent Ca2+ uptake in microsomes of pulmonary smooth muscle: involvement of a pertussis toxin sensitive protein.
Whooping Cough
Role of mPR? (PAQR7) in progesterone-induced Ca2+ decrease in human vascular smooth muscle cells.
Whooping Cough
Role of neutrophils in response to Bordetella pertussis infection in mice.
Whooping Cough
Role of Ni in coupling angiotensin receptors to inhibition of adenylate cyclase in hepatocytes.
Whooping Cough
Role of nifedipine-sensitive sympathetic vasoconstriction in maintenance of high blood pressure in spontaneously hypertensive rats: effect of Gi-protein inactivation by pertussis toxin.
Whooping Cough
Role of NPR-C natriuretic receptor in nitric oxide system activation induced by atrial natriuretic peptide.
Whooping Cough
Role of nuclear factor-kappa B in the regulation of intercellular adhesion molecule 1 after infection of human bronchial epithelial cells by Bordetella pertussis.
Whooping Cough
Role of Osteoblast Gi Signaling in Age-Related Bone Loss in Female Mice.
Whooping Cough
Role of p38 mitogen-activated kinase and c-Jun terminal kinase in migration response to lysophosphatidic acid and sphingosine-1-phosphate in glioma cells.
Whooping Cough
Role of PCR in the diagnosis of pertussis infection in infants: 5 years' experience of provision of a same-day real-time PCR service in England and Wales from 2002 to 2007.
Whooping Cough
Role of pertussis toxin A subunit in neutrophil migration and vascular permeability.
Whooping Cough
Role of pertussis toxin in causing symptoms of Bordetella parapertussis infection.
Whooping Cough
Role of pertussis toxin sensitive G proteins in the alpha 1 adrenergic receptor but not in the thyrotropin receptor mediated activation of membrane phospholipases and iodide fluxes in FRTL-5 thyroid cells.
Whooping Cough
Role of pertussis toxin-sensitive G protein in metabolic vasodilation of coronary microcirculation.
Whooping Cough
Role of pertussis toxin-sensitive G proteins in stimulus-dependent human eosinophil degranulation.
Whooping Cough
Role of pertussis toxin-sensitive G-protein, K(+) channels, and voltage-gated Ca (2+) channels in the antinociceptive effect of inosine.
Whooping Cough
Role of pertussis toxin-sensitive G-proteins in intracellular Ca2+ release and apoptosis induced by inhibiting cystic fibrosis transmembrane conductance regulator (CFTR) Cl- channels in HepG2 human hepatoblastoma cells.
Whooping Cough
Role of pertussis toxin-sensitive G-proteins in synaptic transmission and plasticity at corticostriatal synapses.
Whooping Cough
Role of pertussis toxin-sensitive G-proteins in the analgesic and anesthetic actions of alpha 2-adrenergic agonists in the rat.
Whooping Cough
Role of pertussis toxin-sensitive guanosine triphosphate-binding proteins in the response of erythroblasts to erythropoietin.
Whooping Cough
Role of phosphatidylinositol 3-kinase in the development of hepatocyte preconditioning.
Whooping Cough
Role of phospholipase A2 and G-proteins in the IgE-dependent activation of mast cells and macrophages.
Whooping Cough
Role of PKC-? in NADPH oxidase-PKC?-Gi? axis dependent inhibition of ?-adrenergic response by U46619 in pulmonary artery smooth muscle cells.
Whooping Cough
Role of PKC?-NADPH oxidase signaling axis in PKC?-mediated Gi?2 phosphorylation for inhibition of adenylate cyclase activity by angiotensin II in pulmonary artery smooth muscle cells.
Whooping Cough
Role of PKC?-p38 MAPK-Gi? axis in peroxynitrite-mediated inhibition of ?-adrenergic response in pulmonary artery smooth muscle cells.
Whooping Cough
Role of positive charges of neuropeptide Y fragments in mast cell activation.
Whooping Cough
Role of potassium channels in stretch-promoted atrial natriuretic factor secretion.
Whooping Cough
Role of potassium channels in the antinociception induced by agonists of alpha2-adrenoceptors.
Whooping Cough
Role of presynaptic 5-HT1A and 5-HT3 receptors in modulation of synaptic GABA transmission in dissociated rat basolateral amygdala neurons.
Whooping Cough
Role of prostaglandin E2 in regulation of low and high water osmotic permeability in frog urinary bladder.
Whooping Cough
Role of prostanoid IP and EP receptors in mediating vasorelaxant responses to PGI2 analogues in rat tail artery: Evidence for Gi/o modulation via EP3 receptors.
Whooping Cough
Role of protein kinase C and transcription factor AP-1 in the acid-induced increase in Na/H antiporter activity.
Whooping Cough
Role of protein kinase C in ethanol-induced activation of adenylyl cyclase.
Whooping Cough
Role of protein kinase C in mediating alpha-1-adrenoceptor-induced negative inotropic response in rat ventricles.
Whooping Cough
Role of protein kinase C in transforming growth factor-beta 1 induction of carcinoembryonic antigen in human colon carcinoma cells.
Whooping Cough
Role of protein kinase Calpha in signaling from the histamine H(1) receptor to the nucleus.
Whooping Cough
Role of receptor binding and gene transcription for both the stimulatory and inhibitory effects of interleukin-1 in pancreatic beta-cells.
Whooping Cough
Role of renal sympathetic nerves in regulating renovascular responses to angiotensin II in spontaneously hypertensive rats.
Whooping Cough
Role of Rho and Rho kinase in the activation of volume-regulated anion channels in bovine endothelial cells.
Whooping Cough
Role of scavenger receptor class B type I and sphingosine 1-phosphate receptors in high density lipoprotein-induced inhibition of adhesion molecule expression in endothelial cells.
Whooping Cough
Role of secretory and cytosolic phospholipase A(2) enzymes in lysophosphatidylcholine-stimulated monocyte arachidonic acid release.
Whooping Cough
Role of sodium-hydrogen exchange in the proliferation of immortalised lymphoblasts from patients with essential hypertension and normotensive subjects.
Whooping Cough
Role of sphingosine 1-phosphate in the pathogenesis of Sjögren's syndrome.
Whooping Cough
Role of sphingosine-1 phosphate in the enhancement of endothelial barrier integrity by platelet-released products.
Whooping Cough
Role of sphingosine-1-phosphate phosphatase 1 in epidermal growth factor-induced chemotaxis.
Whooping Cough
Role of the A subunit of pertussis toxin in alteration of Chinese hamster ovary cell morphology.
Whooping Cough
Role of the adrenal medulla in stress-induced hyperinsulinaemia in normal mice and in mice infected with Bordetella pertussis or treated with pertussis toxin.
Whooping Cough
Role of the cell wall microenvironment in expression of a heterologous SpaP-S1 fusion protein by Streptococcus gordonii.
Whooping Cough
Role of the D2 dopamine receptor in molecular adaptation to chronic hypoxia in PC12 cells.
Whooping Cough
Role of the G-protein-coupled receptor GPR12 as high-affinity receptor for sphingosylphosphorylcholine and its expression and function in brain development.
Whooping Cough
Role of the GTP-binding protein G(o) in the suppressant effect of ethanol on voltage-activated calcium channels of murine sensory neurons.
Whooping Cough
Role of the protein kinase C signaling pathway in high-density lipoprotein receptor-mediated efflux of intracellular cholesterol.
Whooping Cough
Role of the sphingosine 1-phosphate receptor EDG-1 in vascular smooth muscle cell proliferation and migration.
Whooping Cough
Role of the third intracellular loop and of the cytoplasmic tail in the mitogenic signaling of the protease-activated receptor 1.
Whooping Cough
Role of tryptophan 26 in the NAD glycohydrolase reaction of the S-1 subunit of pertussis toxin.
Whooping Cough
Role of two different guanine nucleotide-binding proteins in the antagonistic modulation of the S-type K+ channel by cAMP and arachidonic acid metabolites in Aplysia sensory neurons.
Whooping Cough
Role of tyrosine kinase in insulin release in an insulin secreting cell line (INS-1).
Whooping Cough
Roles of atypical protein kinase C in lysophosphatidic acid-induced type II adenylyl cyclase activation in RAW 264.7 macrophages.
Whooping Cough
Roles of cyclic GMP and inositol trisphosphate in phototransduction of the molluscan extraocular photoreceptor.
Whooping Cough
Roles of dopamine 2 receptor isoforms and g proteins in ethanol regulated prolactin synthesis and lactotropic cell proliferation.
Whooping Cough
Roles of Gi and Gq/11 in mediating desensitization of the luteinizing hormone/choriogonadotropin receptor in porcine ovarian follicular membranes.
Whooping Cough
Roles of GPR41 and GPR43 in leptin secretory responses of murine adipocytes to short chain fatty acids.
Whooping Cough
Roles of heterotrimeric and monomeric G proteins in sperm-induced activation of mouse eggs.
Whooping Cough
Roles of M2 and M3 muscarinic receptors in cholinergic nerve-induced contractions in mouse ileum studied with receptor knockout mice.
Whooping Cough
Roles of progesterone receptor membrane component 1 and membrane progestin receptor alpha in regulation of zebrafish oocyte maturation.
Whooping Cough
Roles of protein kinase C and G proteins in activation of murine resting B lymphocytes by endotoxin-associated protein.
Whooping Cough
Roles of the disulfide bond and the carboxy-terminal region of the S1 subunit in the assembly and biosynthesis of pertussis toxin.
Whooping Cough
RXFP1 Receptor Activation by Relaxin-2 Induces Vascular Relaxation in Mice via a G?i2-Protein/PI3Kß/?/Nitric Oxide-Coupled Pathway.
Whooping Cough
S100 protein CP-10 stimulates myeloid cell chemotaxis without activation.
Whooping Cough
S100A8 Triggers Oxidation-sensitive Repulsion of Neutrophils.
Whooping Cough
S18616, a highly potent, spiroimidazoline agonist at alpha(2)-adrenoceptors: I. Receptor profile, antinociceptive and hypothermic actions in comparison with dexmedetomidine and clonidine.
Whooping Cough
S1P induced changes in epithelial ovarian cancer proteolysis, invasion, and attachment are mediated by Gi and Rac.
Whooping Cough
S1P stimulates chemotactic migration and invasion in OVCAR3 ovarian cancer cells.
Whooping Cough
S1P1 and VEGFR-2 form a signaling complex with extracellularly regulated kinase 1/2 and protein kinase C-alpha regulating ML-1 thyroid carcinoma cell migration.
Whooping Cough
S1P1 receptor signaling overrides retention mediated by G alpha i-coupled receptors to promote T cell egress.
Whooping Cough
S1P3 receptors mediate the potent constriction of cerebral arteries by sphingosine-1-phosphate.
Whooping Cough
Saccharomyces boulardii inhibits secretagogue-mediated adenosine 3',5'-cyclic monophosphate induction in intestinal cells.
Whooping Cough
Safety and efficacy of DTaP-IPV vaccine use in healthcare workers for prevention of pertussis.
Whooping Cough
Safety and immunogenicity of a combined pentavalent diphtheria, tetanus, acellular pertussis, inactivated poliovirus and Haemophilus influenzae type b-tetanus conjugate vaccine in infants, compared with a whole cell pertussis pentavalent vaccine.
Whooping Cough
Safety and immunogenicity of a combined Tetanus, Diphtheria, recombinant acellular Pertussis vaccine (TdaP) in healthy Thai adults.
Whooping Cough
Safety and immunogenicity of a measles, mumps, rubella and varicella vaccine given with combined Haemophilus influenzae type b conjugate/hepatitis B vaccines and combined diphtheria-tetanus-acellular pertussis vaccines.
Whooping Cough
Safety and immunogenicity of an acellular pertussis vaccine booster in 15- to 20-month-old children previously immunized with acellular or whole-cell pertussis vaccine as infants.
Whooping Cough
Safety and immunogenicity of Biken acellular pertussis vaccine in combination with diphtheria and tetanus toxoid as a fifth dose at four to six years of age. Munich Vaccine Study Group.
Whooping Cough
Safety and immunogenicity of heptavalent pneumococcal CRM197 conjugate vaccine in infants and toddlers.
Whooping Cough
Safety and immunogenicity of hydrogen peroxide-inactivated pertussis toxoid in 18-month-old children.
Whooping Cough
Safety and immunogenicity of six acellular pertussis vaccines and one whole-cell pertussis vaccine given as a fifth dose in four- to six-year-old children.
Whooping Cough
Safety and immunogenicity of the epicutaneous reactivation of pertussis toxin immunity in healthy adults: a phase I, randomized, double-blind, placebo-controlled trial.
Whooping Cough
Safety testing of acellular pertussis vaccines: use of animals and 3Rs alternatives.
Whooping Cough
Safety, immunogenicity and an open, retrospective study of efficacy of a monocomponent pertussis toxoid vaccine in infants.
Whooping Cough
Salmonella enterica serotype Typhimurium DT104 ArtA-dependent modification of pertussis toxin-sensitive G proteins in the presence of [32P]NAD.
Whooping Cough
Salt intake and intestinal dopaminergic activity in adult and old Fischer 344 rats.
Whooping Cough
Salvinorin A exerts opposite presynaptic controls on neurotransmitter exocytosis from mouse brain nerve terminals.
Whooping Cough
Sar1 translocation onto the ER-membrane for vesicle budding has different pathways for promotion and suppression of ER-to-Golgi transport mediated through H89-sensitive kinase and ER-resident G protein.
Whooping Cough
Sarafotoxin-induced calcium mobilization in cultured dog tracheal smooth muscle cells.
Whooping Cough
Scavenger receptor A mediates H2O2 production and suppression of IL-12 release in murine macrophages.
Whooping Cough
SCFAs induce mouse neutrophil chemotaxis through the GPR43 receptor.
Whooping Cough
SCH-202676: An allosteric modulator of both agonist and antagonist binding to G protein-coupled receptors.
Whooping Cough
Schizophrenia Plasma Autoantibodies Promote 'Biased Agonism' at the 5-Hydroxytryptamine 2A Receptor: Neurotoxicity is Positively Modulated by Metabotropic Glutamate 2/3 Receptor Agonism.
Whooping Cough
Screening of several H-2 congenic mouse strains identified H-2(q) mice as highly susceptible to MOG-induced EAE with minimal adjuvant requirement.
Whooping Cough
SDF-1 alpha induces chemotaxis and enhances Sonic hedgehog-induced proliferation of cerebellar granule cells.
Whooping Cough
SDF-1 suppresses cytokine-induced adhesion of human haemopoietic progenitor cells to immobilized fibronectin.
Whooping Cough
SDF-1-induced activation of ERK enhances HIV-1 expression.
Whooping Cough
SDF-1/CXCL12 regulates cAMP production and ion transport in intestinal epithelial cells via CXCR4.
Whooping Cough
SDF1alpha/CXCR4 signaling stimulates beta-catenin transcriptional activity in rat neural progenitors.
Whooping Cough
Second messenger pathways involved in up-regulation of an L-type calcium channel.
Whooping Cough
Second messenger regulation of lipoprotein uptake by an arterial wall model.
Whooping Cough
Second messengers associated with the action of AII and dopamine D2 receptors in anterior pituitary. Relationship with prolactin secretion.
Whooping Cough
Second messengers involved in genetic regulation of the number of calcium channels in bovine adrenal chromaffin cells in culture.
Whooping Cough
Second messengers involved in the control of renin secretion in cultured human nephroblastoma cells.
Whooping Cough
Second-generation antipsychotic drugs, olanzapine, quetiapine, and clozapine enhance neurite outgrowth in PC12 cells via PI3K/AKT, ERK, and pertussis toxin-sensitive pathways.
Whooping Cough
Second-messenger generation in PC12 cells. Interactions between cyclic AMP and Ca2+ signals.
Whooping Cough
Second-messenger regulation of receptor association with clathrin-coated pits: a novel and selective mechanism in the control of CD4 endocytosis.
Whooping Cough
Secondary lymphoid-tissue chemokine (SLC) stimulates integrin alpha 4 beta 7-mediated adhesion of lymphocytes to mucosal addressin cell adhesion molecule-1 (MAdCAM-1) under flow.
Whooping Cough
Secretin inhibits cholangiocarcinoma growth via dysregulation of the cAMP-dependent signaling mechanisms of secretin receptor.
Whooping Cough
Secretion of heterologous proteins in Bacillus subtilis can be improved by engineering cell components affecting post-translocational protein folding and degradation.
Whooping Cough
Secretion of Matrix Metalloproteinase-9 from Astrocytes by Inhibition of Tonic P2Y(14)-Receptor-Mediated Signal(s).
Whooping Cough
Secretion of Pertussis Toxin from Bordetella pertussis.
Whooping Cough
Secretion-stimulating and secretion-inhibiting hormones stimulate high-affinity pertussis-toxin-sensitive GTPases in membranes of a pituitary cell line.
Whooping Cough
Secretoneurin and chemoattractant receptor interactions.
Whooping Cough
Secretoneurin promotes pertussis toxin-sensitive neurite outgrowth in cerebellar granule cells.
Whooping Cough
Secretoneurin-induced in vitro chemotaxis of human monocytes is inhibited by pertussis toxin and an inhibitor of protein kinase C.
Whooping Cough
Secretory IgA against pertussis toxin and surface structures of Bordetella pertussis in saliva of children with culture proven pertussis.
Whooping Cough
Secretory IgA-mediated basophil activation. II. Roles of GTP-binding regulatory proteins and phosphatidylinositol 3-kinase.
Whooping Cough
Secretory phospholipase A2 activates the cascade of mitogen-activated protein kinases and cytosolic phospholipase A2 in the human astrocytoma cell line 1321N1.
Whooping Cough
Secretory phospholipase A2 induces phospholipase Cgamma-1 activation and Ca2+ mobilization in the human astrocytoma cell line 1321N1 by a mechanism independent of its catalytic activity.
Whooping Cough
Segment-dependent activation of muscarinic acetylcholine receptor-mediated [35S]Guanosine-5'-O-(gamma-thiotriphosphate) binding in airway tissue membranes.
Whooping Cough
Selection and emergence of pertussis toxin promoter ptxP3 allele in the evolution of Bordetella pertussis.
Whooping Cough
Selective ?1B- and ?1D-adrenoceptor antagonists suppress noradrenaline-induced activation, proliferation and ECM secretion of rat hepatic stellate cells in vitro.
Whooping Cough
Selective A2-adenosine receptor agonists do not alter action potential duration, twitch shortening, or cAMP accumulation in guinea pig, rat, or rabbit isolated ventricular myocytes.
Whooping Cough
Selective activation by atrial natriuretic factor of phosphatidylcholine-specific phospholipase activities in purified heart muscle plasma membranes.
Whooping Cough
Selective activation of a chimeric Gi1/Gs G protein alpha subunit by the human IP prostanoid receptor: analysis using agonist stimulation of high affinity GTPase activity and [35S]guanosine-5'-O-(3-thio)triphosphate binding.
Whooping Cough
Selective activation of Galphao by D2L dopamine receptors in NS20Y neuroblastoma cells.
Whooping Cough
Selective activation of Gi1 and Gi2 in mouse sperm by the zona pellucida, the egg's extracellular matrix.
Whooping Cough
Selective activation of heterologously expressed G protein-gated K+ channels by M2 muscarinic receptors in rat sympathetic neurones.
Whooping Cough
Selective activation of nuclear phospholipase D-1 by g protein-coupled receptor agonists in vascular smooth muscle cells.
Whooping Cough
Selective antagonism of the AT1 receptor inhibits the effect of angiotensin II on DNA and protein synthesis of rat proximal tubular cells.
Whooping Cough
Selective attraction of naive and memory B cells by dendritic cells.
Whooping Cough
Selective blockade of dopamine D-1 receptor by SCH 23390 affects dopamine agonist binding to 3H-spiperone labeled D-2 receptors in rat striatum.
Whooping Cough
Selective blockade of P/Q-type calcium channels by the metabotropic glutamate receptor type 7 involves a phospholipase C pathway in neurons.
Whooping Cough
Selective blockage by islet-activating protein, pertussis toxin, of negative signal transduction from receptors to adenylate cyclase.
Whooping Cough
Selective changes in mu opioid receptor properties induced by chronic morphine exposure.
Whooping Cough
Selective coupling of alpha 2-adrenergic receptor subtypes to cyclic AMP-dependent reporter gene expression in transiently transfected JEG-3 cells.
Whooping Cough
Selective coupling of different muscarinic acetylcholine receptors to neuronal calcium currents in DNA-transfected cells.
Whooping Cough
Selective coupling of mouse brain metabotropic sigma receptor with recombinant Gi1.
Whooping Cough
Selective coupling of purified alpha-subunits of pertussis toxin-substrate GTP-binding proteins to endogenous receptors in rat brain membranes treated with N-ethylmaleimide.
Whooping Cough
Selective coupling of the S1P3 receptor subtype to S1P-mediated RhoA activation and cardioprotection.
Whooping Cough
Selective decrease in the affinity of D2 dopamine receptor for agonist induced by islet-activating protein, pertussis toxin, associated with ADP-ribosylation of the specific membrane protein of bovine striatum.
Whooping Cough
Selective enhancement of antagonist ligand binding at muscarinic M2 receptors by heparin due to receptor uncoupling.
Whooping Cough
Selective enhancement of beta-adrenergic receptor signaling by overexpression of adenylyl cyclase type 6: colocalization of receptor and adenylyl cyclase in caveolae of cardiac myocytes.
Whooping Cough
Selective expression and cellular localization of pro-inflammatory chemokine ligand/receptor pairs in the sciatic nerves of a severe murine experimental autoimmune neuritis model of Guillain-Barré syndrome.
Whooping Cough
Selective G-protein regulation of neuronal calcium channels.
Whooping Cough
Selective inhibition of adenylyl cyclase by octopamine via a human cloned alpha 2A-adrenoceptor.
Whooping Cough
Selective inhibition of adenylyl cyclase type V by the dopamine D3 receptor.
Whooping Cough
Selective inhibition of beta(2)-adrenergic receptor-mediated cAMP generation by activation of the P2Y(2) receptor in mouse pineal gland tumor cells.
Whooping Cough
Selective inhibition of high voltage-activated L-type and Q-type Ca2+ currents by serotonin in rat melanotrophs.
Whooping Cough
Selective ligands and cellular effectors of a G protein-coupled endothelial cannabinoid receptor.
Whooping Cough
Selective loss of pertussis toxin-sensitive G-proteins from the plasma membrane after antibody-induced internalization of T-cell surface molecules.
Whooping Cough
Selective modulation by guanine nucleotides of the high affinity subset of plasma membrane receptors for leukotriene B4 on human polymorphonuclear leukocytes.
Whooping Cough
Selective mu and kappa Opioid Agonists Inhibit Voltage-Gated Ca2+ Entry in Isolated Neonatal Rat Carotid Body Type I Cells.
Whooping Cough
Selective parasympathectomy increases the quantity of inhibitory guanine nucleotide-binding proteins in canine cardiac ventricle.
Whooping Cough
Selective pharmacological inhibitors reveal the role of Syk tyrosine kinase, phospholipase C, phosphatidylinositol-3'-kinase, and p38 mitogen-activated protein kinase in Fc receptor-mediated signaling of chicken heterophil degranulation.
Whooping Cough
Selective protection of murine cerebral Gi/o-proteins from inactivation by parenterally injected pertussis toxin.
Whooping Cough
Selective regulation by pertussis toxin of insulin-induced activation of particulate cAMP phosphodiesterase activity in 3T3-L1 adipocytes.
Whooping Cough
Selective regulation of somatostatin receptor subtype signaling: evidence for constitutive receptor activation.
Whooping Cough
Selective suppression of antigen-specific Th2 cells by continuous micro-dose oral tolerance.
Whooping Cough
Selectively enhanced cellular signaling by Gi proteins in essential hypertension. G alpha i2, G alpha i3, G beta 1, and G beta 2 are not mutated.
Whooping Cough
Selectivity and evolutionary divergence of metabotropic glutamate receptors for endogenous ligands and G proteins coupled to phospholipase C or TRP channels.
Whooping Cough
Selenazoles (selenium compounds) facilitate survival of cultured rat pheochromocytoma PC12 cells after serum-deprivation and stimulate their neuronal differentiation via activation of Akt and mitogen-activated protein kinase, respectively.
Whooping Cough
Seminal fluid factor increases the resistance of the tight junctional complex of cultured human cervical epithelium CaSki cells.
Whooping Cough
Semiquantitative polymerase chain reaction enzyme immunoassay for the diagnosis of pertussis.
Whooping Cough
Sensitivity of adipocyte lipolysis to stimulatory and inhibitory agonists in hypothyroidism and starvation.
Whooping Cough
Sensitivity of G-protein involved in endothelin-1-induced Ca2+ influx to pertussis toxin in porcine endothelial cells in situ.
Whooping Cough
Sensitivity of histamine H3 receptor agonist-stimulated [35S]GTP gamma[S] binding to pertussis toxin.
Whooping Cough
Sensitivity of norepinephrine-evoked vasoconstriction to pertussis toxin in the old rat.
Whooping Cough
Sensitization of adenylate cyclase by halothane in human myocardium and S49 lymphoma wild-type and cyc- cells: evidence for inactivation of the inhibitory G protein Gi alpha.
Whooping Cough
Sensitization of adenylate cyclase by short-term activation of 5-HT1A receptors.
Whooping Cough
Sensitization of adenylate cyclase induced by a dopamine D2 receptor mutant: inverse agonism by D2 receptor antagonists.
Whooping Cough
Sensitization of adrenocortical cell adenylate cyclase activity to ACTH by angiotensin II and activators of protein kinase C.
Whooping Cough
Sensitization of endogenous and recombinant adenylate cyclase by activation of D2 dopamine receptors.
Whooping Cough
Sensitization of human alpha 1- and alpha 2-adrenergic venous responses by guanadrel sulfate.
Whooping Cough
Sensitization of neuronal A2A adenosine receptors after persistent D2 dopamine receptor activation.
Whooping Cough
Sensitization of the adenylyl cyclase system in cloned kappa-opioid receptor-transfected cells following sustained agonist treatment: A chimeric study using G protein alpha(i)2/alpha(q) subunits.
Whooping Cough
Sensitization of the cardiac Na channel to alpha1-adrenergic stimulation by inhalation anesthetics: evidence for distinct modulatory pathways.
Whooping Cough
Sensitization of the histamine H1 receptor by increased ligand affinity.
Whooping Cough
Sensitization to cocaine produced by injection of pertussis toxin into the A10 dopamine region.
Whooping Cough
Sensitization to psychostimulants and stress after injection of pertussis toxin into the A10 dopamine region.
Whooping Cough
Sensitized heat shock protein 27 induces retinal ganglion cells apoptosis in rat glaucoma model.
Whooping Cough
Sepsis causes presynaptic histamine H3 and alpha2-adrenergic dysfunction in canine myocardium.
Whooping Cough
Sequence analysis of bovine retinal S-antigen. Relationships with alpha-transducin and G-proteins.
Whooping Cough
Sequence analysis of cDNA and genomic DNA for a putative pertussis toxin-insensitive guanine nucleotide-binding regulatory protein alpha subunit.
Whooping Cough
Sequence and structural links between distant ADP-ribosyltransferase families.
Whooping Cough
Sequence of the alpha subunit of photoreceptor G protein: homologies between transducin, ras, and elongation factors.
Whooping Cough
Sequence variation and conservation in virulence-related genes of Bordetella pertussis isolates from the UK.
Whooping Cough
Sequence variation in pertussis S1 subunit toxin and pertussis genes in Bordetella pertussis strains used for the whole-cell pertussis vaccine produced in Poland since 1960: efficiency of the DTwP vaccine-induced immunity against currently circulating B. pertussis isolates.
Whooping Cough
Sequential activation and environmental regulation of virulence genes in Bordetella pertussis.
Whooping Cough
Sequential activation of MAP kinase cascade by angiotensin II in opossum kidney cells.
Whooping Cough
Sequential morphologic events during apoptosis of human neutrophils. Modulation by lipoxygenase-derived eicosanoids.
Whooping Cough
Sequential recruitment of neutrophils into lung and bronchoalveolar lavage fluid in LPS-induced acute lung injury.
Whooping Cough
Serine 232 of the alpha(2A)-adrenergic receptor is a protein kinase C-sensitive effector coupling switch.
Whooping Cough
Sero epidemiology of Bordetella pertussis immune responses in a healthy population in northern Greece.
Whooping Cough
Sero-epidemiology of Bordetella pertussis in England and Wales.
Whooping Cough
Seroepidemiologic study on pertussis, diphtheria, and tetanus in the Fukuoka area of southern Japan: seroprevalence among persons 0-80 years old and vaccination program.
Whooping Cough
Seroepidemiology of Bordetella pertussis infections in the Spanish population: a cross-sectional study.
Whooping Cough
Seroepidemiology of diphtheria and pertussis in Beijing, China: A cross-sectional study.
Whooping Cough
Seroepidemiology of diphtheria and pertussis in Chongqing, China: serology-based evidence of Bordetella pertussis infection.
Whooping Cough
Seroepidemiology of pertussis in a cross-sectional study of an adult general population in Denmark.
Whooping Cough
Seroepidemiology of pertussis in China: A population-based, cross-sectional study.
Whooping Cough
Seroepidemiology of pertussis in Italy.
Whooping Cough
Seroepidemiology of pertussis infection in an urban childhood population in Cameroon.
Whooping Cough
Seroepidemiology of whooping cough in the Czech Republic: estimates of incidence of infection in adults.
Whooping Cough
Serologic diagnosis of pertussis: evaluation of pertussis toxin and other antigens in enzyme-linked immunosorbent assay.
Whooping Cough
Serologic evidence of subclinical pertussis in immunized children.
Whooping Cough
Serologic response and antibody-titer decay in adults with pertussis.
Whooping Cough
Serological correlates in whooping cough.
Whooping Cough
Serological diagnosis of pertussis: evaluation of IgA against whole cell and specific Bordetella pertussis antigens as markers of recent infection.
Whooping Cough
Serological responses to infection with B. pertussis.
Whooping Cough
Seroprevalence and placental transportation of maternal antibodies specific for Neisseria meningitidis serogroup C, Haemophilus influenzae type B, diphtheria, tetanus, and pertussis.
Whooping Cough
Seroprevalence of an antibody against diphtheria, tetanus, and pertussis among the elderly in Khon Kaen, Thailand.
Whooping Cough
Seroprevalence of antibodies against diphtheria, tetanus, and pertussis among healthy Thai adolescents.
Whooping Cough
Seroprevalence of antibodies for pertussis and diphtheria among people leaving or entering China: a cross-sectional study.
Whooping Cough
Seroprevalence of antibodies to diphtheria, tetanus and pertussis among healthy adolescents and adults in Iran.
Whooping Cough
Seroprevalence of antibodies to pertussis and diphtheria among healthy adults in China.
Whooping Cough
Seroprevalence of Antibodies to Pertussis Toxin among Different Age Groups in Thailand after 37 Years of Universal Whole-Cell Pertussis Vaccination.
Whooping Cough
Seroprevalence of Bordetella pertussis among vaccinated and unvaccinated pregnant women and newborn infants in a university hospital of Buenos Aires.
Whooping Cough
Seroprevalence of Bordetella pertussis antibodies in Flanders (Belgium).
Whooping Cough
Seroprevalence of Bordetella pertussis antibodies to pertussis toxin among healthy children.
Whooping Cough
Seroprevalence of Bordetella pertussis Antibody in Children and Adolescents in China.
Whooping Cough
Seroprevalence of Bordetella pertussis infection during pregnancy measured by IgG antibodies against pertussis toxin.
Whooping Cough
Seroprevalence of Bordetella pertussis specific Immunoglobulin G antibody levels among asymptomatic individuals aged 4 to 24 years: a descriptive cross sectional study from Sri Lanka.
Whooping Cough
Seroprevalence of Bordetella pertussis toxin antibodies in children and adolescents in Tunis, Tunisia.
Whooping Cough
Seroprevalence of IgG antibodies against Bordetella pertussis in healthy individuals aged 4-24 years in Turkey.
Whooping Cough
Seroprevalence of IgG antibodies to pertussis toxin in children and adolescents in Estonia.
Whooping Cough
Seroprevalence of IgG antibodies to pertussis toxin in the Slovene population.
Whooping Cough
Seroprevalence of Immunoglobulin G antibodies against pertussis toxin among asymptomatic medical students in the west of Iran: a cross sectional study.
Whooping Cough
Seroprevalence of pertussis among healthcare workers: A cross-sectional study from Tunisia.
Whooping Cough
Seroprevalence of pertussis antibodies among adolescents in Israel.
Whooping Cough
Seroprevalence of pertussis antitoxin (anti-PT) in Sweden before and 10 years after the introduction of a universal childhood pertussis vaccination program.
Whooping Cough
Seroprevalence of pertussis in China: Need to improve vaccination strategies.
Whooping Cough
Seroprevalence of pertussis in The Netherlands: evidence for increased circulation of Bordetella pertussis.
Whooping Cough
Seroprevalence study of B. pertussis infection in health care workers in Catalonia, Spain.
Whooping Cough
Serotonergic signalling between thyroid cells: protein kinase C and 5-HT2 receptors in the secretion and action of serotonin.
Whooping Cough
Serotonergic, 5-HT2, receptor-mediated phosphoinositide turnover and mobilization of calcium in cultured rat retinal pigment epithelium cells.
Whooping Cough
Serotonin 5-HT2C receptor stimulates cyclic GMP formation in choroid plexus.
Whooping Cough
Serotonin and melatonin, neurohormones for homeostasis, as novel inhibitors of infections by the intracellular parasite chlamydia.
Whooping Cough
Serotonin as a major serum factor inducing the phospholipase C-mediated hydrolysis of phosphoinositides in normal rat kidney cells.
Whooping Cough
Serotonin decreases population spike amplitude in hippocampal cells through a pertussis toxin substrate.
Whooping Cough
Serotonin depresses excitatory synaptic transmission and depolarization-evoked Ca2+ influx in rat basolateral amygdala via 5-HT1A receptors.
Whooping Cough
Serotonin modulates high-voltage-activated Ca2+ channels in rat ventromedial hypothalamic neurons.
Whooping Cough
Serotonin potentiates angiotensin II--induced vascular smooth muscle cell proliferation.
Whooping Cough
Serotonin receptor activation leads to neurite outgrowth and neuronal survival.
Whooping Cough
Serotonin receptor heterogeneity and the role of potassium channels in neuronal excitability.
Whooping Cough
Serotonin receptor-mediated activation of adenylate cyclase in the neuroblastoma NCB.20: a novel 5-hydroxytryptamine receptor.
Whooping Cough
Serotonin stimulates a Ca2+ permeant nonspecific cation channel in hepatic endothelial cells.
Whooping Cough
Serotonin stimulates DNA synthesis in fibroblasts acting through 5-HT1B receptors coupled to a Gi-protein.
Whooping Cough
Serotonin stimulates rapid increase of inositol 1,4,5-trisphosphate in ovine uterine artery: correlation with contractile state.
Whooping Cough
Serotonin type-1D receptor stimulation of A-type K(+) channel decreases membrane excitability through the protein kinase A- and B-Raf-dependent p38 MAPK pathways in mouse trigeminal ganglion neurons.
Whooping Cough
Serotonin-2 receptors coupled to phosphoinositide hydrolysis in a clonal cell line.
Whooping Cough
Serotonin-induced deoxyribonucleic acid synthesis in vascular smooth muscle cells involves a novel, pertussis toxin-sensitive pathway.
Whooping Cough
Serotonin-induced hypercontraction through 5-hydroxytryptamine 1B receptors in atherosclerotic rabbit coronary arteries.
Whooping Cough
Serotonin-operated potassium current in CA1 neurons dissociated from rat hippocampus.
Whooping Cough
Serum amyloid A induces calcium mobilization and chemotaxis of human monocytes by activating a pertussis toxin-sensitive signaling pathway.
Whooping Cough
Serum amyloid A induces chemotaxis of human mast cells by activating a pertussis toxin-sensitive signal transduction pathway.
Whooping Cough
Serum amyloid A induces IL-8 secretion through a G protein-coupled receptor, FPRL1/LXA4R.
Whooping Cough
Serum amyloid A induces WISH cell apoptosis.
Whooping Cough
Serum amyloid A mediates human neutrophil production of reactive oxygen species through a receptor independent of formyl peptide receptor like-1.
Whooping Cough
Serum Amyloid A3 Secreted by Preosteoclasts Inhibits Parathyroid Hormone-stimulated cAMP Signaling in Murine Osteoblasts.
Whooping Cough
Serum antibodies against a 69-kilodalton outer-membrane protein, pertactin, from Bordetella pertussis in nonvaccinated children with and without a history of clinical pertussis.
Whooping Cough
Serum antibodies to diphtheria-tetanus-pertussis vaccine components in Argentine children.
Whooping Cough
Serum antibodies to the components of diphtheria-tetanus-pertussis vaccine in Polish children related to vaccination status.
Whooping Cough
Serum antibody response to B. pertussis Tn5 mutants, purified PT and FHA in two different mouse strains and passive protection in the murine intranasal infection model.
Whooping Cough
Serum antibody response to filamentous hemagglutinin in patients with clinical pertussis measured by an enzyme-linked immunosorbent assay.
Whooping Cough
Serum contains a potent factor that decreases beta-adrenergic receptor-stimulated L-type Ca2+ current in cardiac myocytes.
Whooping Cough
Serum factors involved in human microvascular endothelial cell morphogenesis.
Whooping Cough
Serum from diabetic BB/W rats enhances calcium currents in primary sensory neurons.
Whooping Cough
Serum IgG antibody response to pertussis toxin in persons for whom pertussis vaccination failed depends upon the number of antigens in the vaccine.
Whooping Cough
Serum IgG antibody responses to pertussis toxin and filamentous hemagglutinin in nonvaccinated and vaccinated children and adults with pertussis.
Whooping Cough
Serum IgG, IgA, and IgM responses to pertussis toxin, filamentous hemagglutinin, and agglutinogens 2 and 3 after infection with Bordetella pertussis and immunization with whole-cell pertussis vaccine.
Whooping Cough
Serum resistance in bvg-regulated mutants of Bordetella pertussis.
Whooping Cough
Serum uncouples elevation of cyclic adenosine monophosphate concentration from cyclic adenosine monophosphate dependent morphological changes exhibited by cultured pituicytes.
Whooping Cough
Serum-borne lipids amplify TLR-activated inflammatory responses.
Whooping Cough
Serum-induced sensitization of cyclic AMP accumulation in 1321N1 human astrocytoma cells.
Whooping Cough
Serum-induced sensitization of cyclic AMP accumulation in C62B rat glioma cells.
Whooping Cough
Seven transmembrane G protein-coupled receptor repertoire of gastric ghrelin cells.
Whooping Cough
Severe reactions associated with diphtheria-tetanus-pertussis vaccine: detailed study of children with seizures, hypotonic-hyporesponsive episodes, high fevers, and persistent crying.
Whooping Cough
Sex differences in EAE reveal common and distinct cellular and molecular components.
Whooping Cough
Sf9 cells: A versatile model system to investigate the pharmacological properties of G protein-coupled receptors.
Whooping Cough
Shape changes, exocytosis, and cytosolic free calcium changes in stimulated human eosinophils.
Whooping Cough
Shc adaptor proteins are key transducers of mitogenic signaling mediated by the G protein-coupled thrombin receptor.
Whooping Cough
Shear stress elevates endothelial cGMP. Role of a potassium channel and G protein coupling.
Whooping Cough
Shear-dependent eosinophil transmigration on interleukin 4-stimulated endothelial cells: a role for endothelium-associated eotaxin-3.
Whooping Cough
Shock wave application enhances pertussis toxin protein-sensitive bone formation of segmental femoral defect in rats.
Whooping Cough
Short Chain Fatty Acids Enhance Expression and Activity of the Umami Taste Receptor in Enteroendocrine Cells via a G?i/o Pathway.
Whooping Cough
Short- and long-term heterologous sensitization of adenylate cyclase by D4 dopamine receptors.
Whooping Cough
Short- and long-term regulation of adenylyl cyclase activity by delta-opioid receptor are mediated by Galphai2 in neuroblastoma N2A cells.
Whooping Cough
Short-chain fatty acid signaling pathways in bovine mammary epithelial cells.
Whooping Cough
Short-chain fatty acids act as antiinflammatory mediators by regulating prostaglandin E(2) and cytokines.
Whooping Cough
Short-chain fatty acids induce acute phosphorylation of the p38 mitogen-activated protein kinase/heat shock protein 27 pathway via GPR43 in the MCF-7 human breast cancer cell line.
Whooping Cough
Short-term inhibitory effect of somatostatin on gastric histamine synthesis.
Whooping Cough
Short-term inverse-agonist treatment induces reciprocal changes in delta-opioid agonist and inverse-agonist binding capacity.
Whooping Cough
Short-term regulation of Na+,K(+)-ATPase activity by dopamine.
Whooping Cough
Sigma ligands stimulate the electrical activity of frog pituitary melanotrope cells through a G-protein-dependent inhibition of potassium conductances.
Whooping Cough
Signal pathway involved in the development of hypoxic preconditioning in rat hepatocytes.
Whooping Cough
Signal pathway of mitogen-induced Ca2+-activated K+ currents in young and aged T-cell clones of C57BL/6 mice.
Whooping Cough
Signal pathway regulation of interleukin-8-induced actin polymerization in neutrophils.
Whooping Cough
Signal pathways that transduce growth factor-stimulated mitogenesis in bone cells.
Whooping Cough
Signal transducing properties of the N-formyl peptide receptor expressed in undifferentiated HL60 cells.
Whooping Cough
Signal transduction alterations in GH(1)2C1 rat pituitary tumour cells following treatment with 5-azacytidine.
Whooping Cough
Signal transduction and glial cell modulation of cultured brain microvessel endothelial cell tight junctions.
Whooping Cough
Signal transduction and ligand specificity of the human monocyte chemoattractant protein-1 receptor in transfected embryonic kidney cells.
Whooping Cough
Signal transduction and pharmacological characteristics of a metabotropic glutamate receptor, mGluR1, in transfected CHO cells.
Whooping Cough
Signal transduction by neutrophil immunoglobulin G Fc receptors. Dissociation of intracytoplasmic calcium concentration rise from inositol 1,4,5-trisphosphate.
Whooping Cough
Signal transduction by tumor necrosis factor alpha is mediated through a guanine nucleotide-binding protein in osteoblast-like cell line, MC3T3-E1.
Whooping Cough
Signal transduction during antibody-dependent cellular cytotoxicity mediated by U937 cells.
Whooping Cough
Signal transduction events in Chinese hamster ovary cells expressing human CD14; effect of endotoxin desensitization.
Whooping Cough
Signal transduction for chemotaxis and haptotaxis by matrix molecules in tumor cells.
Whooping Cough
Signal transduction for interleukin-3-dependent leukotriene synthesis in normal human basophils: opposing role of tyrosine kinase and protein kinase.
Whooping Cough
Signal transduction for melatonin in human lymphocytes: involvement of a pertussis toxin-sensitive G protein.
Whooping Cough
Signal transduction in activation of human eosinophils: G protein-dependent and -independent pathways.
Whooping Cough
Signal transduction in cells following binding of chemoattractants to membrane receptors.
Whooping Cough
Signal transduction in Coprinus congregatus: evidence for the involvement of G proteins in blue light photomorphogenesis.
Whooping Cough
Signal transduction in hamster fibroblasts overexpressing the human EGF receptor.
Whooping Cough
Signal transduction in human alveolar macrophages: diminished chemotactic response to FMLP correlates with a diminished density of Gi proteins and FMLP receptors.
Whooping Cough
Signal transduction in human myometrial cells.
Whooping Cough
Signal transduction in insulin secretion: comparison between fuel stimuli and receptor agonists.
Whooping Cough
Signal transduction in monocytes and granulocytes measured by multiparameter flow cytometry.
Whooping Cough
Signal transduction in N-formyl-methionyl-leucyl-phenylalanine and concanavalin A stimulated human neutrophils: superoxide production without a rise in intracellular free calcium.
Whooping Cough
Signal transduction involved in MCP-1-mediated monocytic transendothelial migration.
Whooping Cough
Signal transduction mechanism involved in Clostridium perfringens alpha-toxin-induced superoxide anion generation in rabbit neutrophils.
Whooping Cough
Signal transduction mechanism via adenosine A1 receptor in the cat esophageal smooth muscle cells.
Whooping Cough
Signal transduction mechanism(s) involved in prostacyclin production elicited by acetylcholine in coronary endothelial cells of rabbit heart.
Whooping Cough
Signal transduction mechanisms for leukotriene B4 induced hyperadhesiveness of endothelial cells for neutrophils.
Whooping Cough
Signal transduction mechanisms of C1q-mediated superoxide production. Evidence for the involvement of temporally distinct staurosporine-insensitive and sensitive pathways.
Whooping Cough
Signal transduction modulation by lithium: cell culture, cerebral microdialysis and human studies.
Whooping Cough
Signal transduction of a tissue interaction during embryonic heart development.
Whooping Cough
Signal transduction of arginine vasopressin-induced arachidonic acid release in H9c2 cardiac myoblasts: role of Ca2+ and the protein kinase C-dependent activation of p42 mitogen-activated protein kinase.
Whooping Cough
Signal transduction of cannabinoid CB1 receptors in a smooth muscle cell line.
Whooping Cough
Signal transduction of somatostatin in human B lymphoblasts.
Whooping Cough
Signal transduction pathway for IL-1. Involvement of a pertussis toxin-sensitive GTP-binding protein in the activation of adenylate cyclase.
Whooping Cough
Signal transduction pathway of the muscarinic receptors mediating gallbladder contraction.
Whooping Cough
Signal transduction pathways activated by engaging immunoglobulin Fc receptors on chicken heterophils.
Whooping Cough
Signal transduction pathways activated by insulin-like peptide 5 at the relaxin family peptide RXFP4 receptor.
Whooping Cough
Signal transduction pathways for activation of extracellular signal-regulated kinase by arachidonic acid in rat neutrophils.
Whooping Cough
Signal transduction pathways mediating CCK-induced gallbladder muscle contraction.
Whooping Cough
Signal transduction pathways of muscarinic receptors in circular smooth muscle from the rabbit caecum.
Whooping Cough
Signal transduction via the B cell antigen receptor: involvement of a G protein and regulation of signaling.
Whooping Cough
Signal-dependent translocation of transducin, RGS9-1-Gbeta5L complex, and arrestin to detergent-resistant membrane rafts in photoreceptors.
Whooping Cough
Signal-transducing GTP-binding proteins of mammalian heart and lungs.
Whooping Cough
Signal-transduction pathways causing slow synaptic excitation in guinea pig myenteric AH neurons.
Whooping Cough
Signaling and growth responses of LLC-PK1/Cl4 cells transfected with the rabbit AT1 ANG II receptor.
Whooping Cough
Signaling characteristics and functional regulation of delta opioid-kappa opioid receptor (DOP-KOP) heteromers in peripheral sensory neurons.
Whooping Cough
Signaling cross-talk between cannabinoid and muscarinic systems actives Rho-kinase and increases the contractile responses of the bovine ciliary muscle.
Whooping Cough
Signaling cross-talk from Gbeta4 subunit to Elk-1 in the rapid action of androgens.
Whooping Cough
Signaling events during induction of plasminogen activator inhibitor-1 expression by sphingosylphosphorylcholine in cultured human dermal fibroblasts.
Whooping Cough
Signaling events in amyloid beta-peptide-induced neuronal death and insulin-like growth factor I protection.
Whooping Cough
Signaling events initiated by transforming growth factor-beta 1 that require Gi alpha 1.
Whooping Cough
Signaling mechanisms of angiotensin II-induced attenuation of GABAergic input to hypothalamic presympathetic neurons.
Whooping Cough
Signaling mechanisms of pertussis toxin-induced myelomonocytic cell adhesion: role of tyrosine phosphorylation.
Whooping Cough
Signaling mechanisms that mediate nitric oxide production induced by acetylcholine exposure and withdrawal in cat atrial myocytes.
Whooping Cough
Signaling mechanisms underlying muscarinic receptor-mediated increase in contraction rate in cultured heart cells.
Whooping Cough
Signaling networks from Gbeta1 subunit to transcription factors and actin remodeling via a membrane-located ERbeta-related protein in the rapid action of daidzein in osteoblasts.
Whooping Cough
Signaling of rat Frizzled-2 through phosphodiesterase and cyclic GMP.
Whooping Cough
Signaling pathway associated with stimulation of CB2 peripheral cannabinoid receptor. Involvement of both mitogen-activated protein kinase and induction of Krox-24 expression.
Whooping Cough
Signaling pathway from the human adenosine A(3) receptor expressed in Chinese hamster ovary cells to the extracellular signal-regulated kinase 1/2.
Whooping Cough
Signaling pathway of lysophosphatidic Acid-induced contraction in feline esophageal smooth muscle cells.
Whooping Cough
Signaling pathways downstream of P2 receptors in human neutrophils.
Whooping Cough
Signaling pathways for tissue factor expression in lipopolysaccharide-stimulated bovine alveolar macrophages.
Whooping Cough
Signaling pathways in the biphasic effect of angiotensin II on apical Na/H antiport activity in proximal tubule.
Whooping Cough
Signaling pathways involved in DNA synthesis and migration in response to lysophosphatidic acid and low-density lipoprotein in coronary artery smooth muscle cells.
Whooping Cough
Signaling pathways leading to phosphorylation of Akt and GSK-3{beta} by activation of cloned human and cerebral rat D2 and D3 receptors.
Whooping Cough
Signaling pathways mediating induction of the early response genes prostaglandin G/H synthase-2 and egr-1 by serotonin via 5-HT2A receptors.
Whooping Cough
Signaling responses to alkyllysophosphatidic acid: the activation of phospholipases A2 and C and protein tyrosine phosphorylation in human platelets.
Whooping Cough
Signaling through delta opioid receptors on murine splenic T cells and stably transfected Jurkat cells.
Whooping Cough
Signaling via histamine receptors in cat duodenal smooth muscle cells.
Whooping Cough
Signalling by CXC-chemokine receptors 1 and 2 expressed in CHO cells: a comparison of calcium mobilization, inhibition of adenylyl cyclase and stimulation of GTPgammaS binding induced by IL-8 and GROalpha.
Whooping Cough
Signalling components involved in the coupling of alpha 1-adrenoceptors to phospholipase D in neonatal rat cardiac myocytes.
Whooping Cough
Signalling events mediating the activation of protein kinase C by interleukin-2 in cytotoxic T cells.
Whooping Cough
Signalling for increased cytoskeletal actin in neutrophils.
Whooping Cough
Signalling functions and biochemical properties of pertussis toxin-resistant G-proteins.
Whooping Cough
Signalling mechanism coupled to 5-hydroxytryptamine4 receptor-mediated facilitation of fast synaptic transmission in the guinea-pig ileum myenteric plexus.
Whooping Cough
Signalling mechanism for somatostatin receptor 5-mediated suppression of AMPA responses in rat retinal ganglion cells.
Whooping Cough
Signalling mechanisms in sphingosine 1-phosphate-promoted mesangial cell proliferation.
Whooping Cough
Signalling mechanisms of endothelin-induced mitogenesis and melanogenesis in human melanocytes.
Whooping Cough
Signalling pathway of goldfish melanin-concentrating hormone receptors 1 and 2.
Whooping Cough
Signalling pathways activated by 5-HT(1B)/5-HT(1D) receptors in native smooth muscle and primary cultures of rabbit renal artery smooth muscle cells.
Whooping Cough
Signalling pathways for transactivation by dexmedetomidine of epidermal growth factor receptors in astrocytes and its paracrine effect on neurons.
Whooping Cough
Signalling pathways involved in the chemotactic activity of CXCL12 in cultured rat cerebellar neurons and CHP100 neuroepithelioma cells.
Whooping Cough
Signalling pathways involved in the mitogenic action of lysophosphatidylinositol.
Whooping Cough
Signalling pathways regulating human neutrophil migration induced by secretory phospholipases A2.
Whooping Cough
Signalling properties of lysophosphatidic acid in primary human skin fibroblasts: role of pertussis toxin-sensitive GTP-binding proteins.
Whooping Cough
Significant cholinergic role in secretin-stimulated exocrine secretion in isolated rat pancreas.
Whooping Cough
Significant Contribution of Mouse Mast Cell Protease 4 in Early Phases of Experimental Autoimmune Encephalomyelitis.
Whooping Cough
Simple Algorithm for Identification of Bordetella pertussis Pertactin Gene Variants.
Whooping Cough
Simple, efficient purification of filamentous hemagglutinin and pertussis toxin from Bordetella pertussis by hydrophobic and affinity interaction.
Whooping Cough
Simple, speedy, sensitive, and specific serodiagnosis of pertussis by using a particle agglutination test.
Whooping Cough
Simulated Microgravity Disrupts Cytoskeleton Organization and Increases Apoptosis of Rat Neural Crest Stem Cells Via Upregulating CXCR4 Expression and RhoA-ROCK1-p38 MAPK-p53 Signaling.
Whooping Cough
Simulation of generation-collection experiments with homogeneous kinetics: application to electrochemical investigation of superoxide radical anion generation by osteoclasts on bone.
Whooping Cough
Simultaneous amplification of Bordetella repeated insertion sequences and toxin promoter region gene by polymerase chain reaction.
Whooping Cough
Simultaneous coupling of alpha 2-adrenergic receptors to two G-proteins with opposing effects. Subtype-selective coupling of alpha 2C10, alpha 2C4, and alpha 2C2 adrenergic receptors to Gi and Gs.
Whooping Cough
Simultaneous Determination of Antibodies to Pertussis Toxin and Adenylate Cyclase Toxin Improves Serological Diagnosis of Pertussis.
Whooping Cough
Simultaneous determination of Bordetella pertussis toxin and filamentous haemagglutinin concentrations by hydroxyapatite high-performance liquid chromatography.
Whooping Cough
Simultaneous inhibitions of inositol phospholipid breakdown, arachidonic acid release, and histamine secretion in mast cells by islet-activating protein, pertussis toxin. A possible involvement of the toxin-specific substrate in the Ca2+-mobilizing receptor-mediated biosignaling system.
Whooping Cough
Simvastatin modulates cytokine-mediated endothelial cell adhesion molecule induction: involvement of an inhibitory G protein.
Whooping Cough
Simvastatin potenciates PGI(2) release induced by HDL in human VSMC: effect on Cox-2 up-regulation and MAPK signalling pathways activated by HDL.
Whooping Cough
Single Amino Acid Polymorphisms of Pertussis Toxin Subunit S2 (PtxB) Affect Protein Function.
Whooping Cough
Single transmembrane domain insulin-like growth factor-II/mannose-6-phosphate receptor regulates central cholinergic function by activating a G-protein-sensitive, protein kinase C-dependent pathway.
Whooping Cough
Single-cell analysis of macrophage chemotactic protein-1-regulated cytosolic Ca2+ increase in human adherent monocytes.
Whooping Cough
Single-molecule imaging reveals dimerization/oligomerization of CXCR4 on plasma membrane closely related to its function.
Whooping Cough
Single-Peptide TR-FRET Detection Platform for Cysteine-Specific Post-Translational Modifications.
Whooping Cough
Single-step purification of pertussis toxin and its subunits by heat-treated fetuin-sepharose affinity chromatography.
Whooping Cough
Site of pertussis toxin-induced ADP-ribosylation on Gi is critical for receptor modulation of GDP interaction with Gi.
Whooping Cough
Site-directed mutations in the third intracellular loop of the serotonin 5-HT(1A) receptor alter G protein coupling from G(i) to G(s) in a ligand-dependent manner.
Whooping Cough
Site-selective homing of antigen-primed lymphocyte populations can play a crucial role in the efferent limb of cell-mediated immune responses in vivo.
Whooping Cough
Site-specific alterations in the B oligomer that affect receptor-binding activities and mitogenicity of pertussis toxin.
Whooping Cough
Site-specific antibodies directed against G protein beta and gamma subunits: effects on alpha and beta gamma subunit interaction.
Whooping Cough
Site-specific mutagenesis of the catalytic subunit of cholera toxin: substituting lysine for arginine 7 causes loss of activity.
Whooping Cough
Sixteen-month follow-up of antibodies to pertussis toxin after primary immunization with acellular or whole cell vaccine.
Whooping Cough
Slight hyperinsulinaemia but no hypoglycaemia in pertussis patients.
Whooping Cough
Slow oscillations of free intracellular calcium ion concentration in human fibroblasts responding to mechanical stretch.
Whooping Cough
Slug is an essential target of TGFbeta2 signaling in the developing chicken heart.
Whooping Cough
Small mutations in Bordetella pertussis are associated with selective sweeps.
Whooping Cough
Small-conductance Cl- channels in rabbit parietal cells activated by prostaglandin E2 and inhibited by GTP gamma S.
Whooping Cough
Smooth muscle adenosine A1 receptors couple to disparate effectors by distinct G proteins in pregnant myometrium.
Whooping Cough
Smooth muscle cells in human atherosclerotic plaques express the fractalkine receptor CX3CR1 and undergo chemotaxis to the CX3C chemokine fractalkine (CX3CL1).
Whooping Cough
Smoothened activates Galphai-mediated signaling in frog melanophores.
Whooping Cough
SNP-based typing: a useful tool to study Bordetella pertussis populations.
Whooping Cough
Sodium and potassium regulation of guanine nucleotide-stimulated adenylate cyclase in brain.
Whooping Cough
Sodium fluoride mimics the effect of prostaglandin E2 on catecholamine release from bovine adrenal chromaffin cells.
Whooping Cough
Sodium ions attenuate the inhibitory effects of neuropeptide Y on norepinephrine release in rat hypothalamus.
Whooping Cough
Sodium modulates opioid receptors through a membrane component different from G-proteins. Demonstration by target size analysis.
Whooping Cough
Sodium regulation of opioid agonist binding is potentiated by pertussis toxin.
Whooping Cough
Sodium saccharin inhibits adenylyl cyclase activity in non-taste cells.
Whooping Cough
Sodium, hydrogen antiporter activation by extracellular adenosine triphosphate in biliary epithelial cells.
Whooping Cough
Sodium-dependent calcium efflux from adrenal chromaffin cells following exocytosis. Possible role of secretory vesicle membranes.
Whooping Cough
Solid phase enzyme immunoassays of pertussis toxin using peroxidase or biotin labelled antibodies.
Whooping Cough
Solubilization and partial purification from mouse sperm membranes of the specific binding activity for 3-quinuclidinyl benzilate, a potent inhibitor of the zona pellucida-induced acrosome reaction.
Whooping Cough
Solubilization and reprecipitation from intestinal brush border membranes of a complex containing guanylate cyclase activatable by the heat-stable enterotoxin.
Whooping Cough
Solubilization from rat pancreatic plasma membranes of a cholecystokinin (CCK) agonist-receptor complex interacting with guanine nucleotide regulatory proteins coexisting in the same macromolecular system.
Whooping Cough
Solubilization of the vasopressin receptor from rat liver plasma membranes. Evidence for a receptor X GTP-binding protein complex.
Whooping Cough
Soluble and insoluble immune complexes activate human neutrophil NADPH oxidase by distinct Fc gamma receptor-specific mechanisms.
Whooping Cough
Soluble CD30 and lymphocyte activation gene-3 (CD223), as potential serological markers of T helper-type cytokine response induced by acellular pertussis vaccine.
Whooping Cough
Soluble vascular cell adhesion molecule 1 mediation of monocyte chemotaxis in rheumatoid arthritis.
Whooping Cough
Somatocrinin stimulates adenylate cyclase-Ns regulatory subunit in a GH3 cell-line: comparison with VIP.
Whooping Cough
Somatostatin activates an inwardly rectifying K+ channel in neonatal rat atrial cells.
Whooping Cough
Somatostatin activates glibenclamide-sensitive and ATP-regulated K+ channels in insulinoma cells via a G-protein.
Whooping Cough
Somatostatin activates Ras and ERK1/2 via a G protein ??-subunit-initiated pathway in thyroid cells.
Whooping Cough
Somatostatin activation of mitogen-activated protein kinase via somatostatin receptor 1 (SSTR1).
Whooping Cough
Somatostatin acts by inhibiting the cyclic 3',5'-adenosine monophosphate (cAMP)/protein kinase A pathway, cAMP response element-binding protein (CREB) phosphorylation, and CREB transcription potency.
Whooping Cough
Somatostatin acts through G-proteins on dopaminergic adenylate cyclase in the caudate-putamen of the rat.
Whooping Cough
Somatostatin acts via a pertussis toxin-sensitive mechanism on calcitonin secretion in C-cells.
Whooping Cough
Somatostatin and alpha 2-adrenergic agonists selectively inhibit vasopressin-induced cyclic AMP accumulation in MDCK cells.
Whooping Cough
Somatostatin and epinephrine decrease insulin messenger ribonucleic acid in HIT cells through a pertussis toxin-sensitive mechanism.
Whooping Cough
Somatostatin and muscarinic inhibition of canine enteric endocrine cells: cellular mechanisms.
Whooping Cough
Somatostatin antagonizes angiotensin II effects on mesangial cell contraction and glomerular filtration.
Whooping Cough
Somatostatin blocks Ca2+ action potential activity in prolactin-secreting pituitary tumor cells through coordinate actions on K+ and Ca2+ conductances.
Whooping Cough
Somatostatin coordinately regulates glucagon gene expression and exocytosis in HIT-T15 cells.
Whooping Cough
Somatostatin enhances nerve growth factor-induced neurite outgrowth in PC12 cells.
Whooping Cough
Somatostatin enhances neurite outgrowth in PC12 cells.
Whooping Cough
Somatostatin induced hyperpolarization of septal neurons is not blocked by pertussis toxin.
Whooping Cough
Somatostatin induces an inward rectification in rat locus coeruleus neurones through a pertussis toxin-sensitive mechanism.
Whooping Cough
Somatostatin induces hyperpolarization in pancreatic islet alpha cells by activating a G protein-gated K+ channel.
Whooping Cough
Somatostatin induces release of the alpha subunits of pertussis toxin-sensitive G proteins in native membranes and in intact GH4C1 rat pituitary cells.
Whooping Cough
Somatostatin inhibition of adenylate cyclase activity in different brain areas.
Whooping Cough
Somatostatin inhibition of anterior pituitary adenylate cyclase activity: different sensitivity between male and female rats.
Whooping Cough
Somatostatin inhibition of gastrin gene expression: involvement of pertussis toxin-sensitive and -insensitive pathways.
Whooping Cough
Somatostatin inhibition of phosphoinositides turnover in isolated rat acinar pancreatic cells: interaction with bombesin.
Whooping Cough
Somatostatin inhibits AP-1 function via multiple protein phosphatases.
Whooping Cough
Somatostatin inhibits bombesin-stimulated Gi-protein via its own receptor in rabbit colonic smooth muscle cells.
Whooping Cough
Somatostatin inhibits cAMP-dependent and cAMP-independent calcium influx in the clonal pituitary tumor cell line AtT-20 through the same receptor population.
Whooping Cough
Somatostatin inhibits cAMP-mediated cholinergic transmission in the myenteric plexus.
Whooping Cough
Somatostatin inhibits CCK release by inhibiting secretion and action of CCK-releasing peptide.
Whooping Cough
Somatostatin inhibits excitatory transmission at rat hippocampal synapses via presynaptic receptors.
Whooping Cough
Somatostatin inhibits exocytosis in rat pancreatic alpha-cells by G(i2)-dependent activation of calcineurin and depriming of secretory granules.
Whooping Cough
Somatostatin inhibits follicle-stimulating hormone-induced adenylyl cyclase activity and proliferation in immature porcine Sertoli cell via sst2 receptor.
Whooping Cough
Somatostatin inhibits insulin secretion by a G-protein-mediated decrease in Ca2+ entry through voltage-dependent Ca2+ channels in the beta cell.
Whooping Cough
Somatostatin inhibits interleukin 6 release from rat cortical type I astrocytes via the inhibition of adenylyl cyclase.
Whooping Cough
Somatostatin inhibits PDGF-stimulated Ras activation in human neuroblastoma cells.
Whooping Cough
Somatostatin inhibits stem cell factor messenger RNA expression by Sertoli cells and stem cell factor-induced DNA synthesis in isolated seminiferous tubules.
Whooping Cough
Somatostatin inhibits the norepinephrine-activated calcium channels in rMTC 6-23 cells: possible involvement of a pertussis toxin-sensitive G-protein.
Whooping Cough
Somatostatin inhibits vasopressin-stimulated phosphoinositide hydrolysis and influx of extracellular calcium in clonal hamster beta (HIT) cells.
Whooping Cough
Somatostatin modulates high-voltage-activated Ca2+ channels in freshly dissociated rat hippocampal neurons.
Whooping Cough
Somatostatin modulates voltage-dependent Ca2+ channels in GH3 cells via a specific G(o) splice variant.
Whooping Cough
Somatostatin modulates voltage-gated K(+) and Ca(2+) currents in rod and cone photoreceptors of the salamander retina.
Whooping Cough
Somatostatin modulation of adenosine receptor coupled G-protein subunits in the caudate nucleus of the rat.
Whooping Cough
Somatostatin peptides inhibit basolateral potassium channels in human colonic crypts.
Whooping Cough
Somatostatin peptides produce multiple effects on gating properties of native cone photoreceptor cGMP-gated channels that depend on circadian phase and previous illumination.
Whooping Cough
Somatostatin potentiates NMDA receptor function via activation of InsP(3) receptors and PKC leading to removal of the Mg(2+) block without depolarization.
Whooping Cough
Somatostatin potentiates the alpha 1-adrenergic activation of phospholipase C in striatal astrocytes through a mechanism involving arachidonic acid and glutamate.
Whooping Cough
Somatostatin prevents the desensitizing action of growth hormone-releasing factor on growth hormone release.
Whooping Cough
Somatostatin receptor subtype 4 modulates L-type calcium channels via G?? and PKC signaling in rat retinal ganglion cells.
Whooping Cough
Somatostatin receptor subtypes sst1 and sst2 elicit opposite effects on the response to glutamate of mouse hypothalamic neurones: an electrophysiological and single cell RT-PCR study.
Whooping Cough
Somatostatin receptor subtypes SSTR2 and SSTR5 couple negatively to an L-type Ca2+ current in the pituitary cell line AtT-20.
Whooping Cough
Somatostatin receptor-mediated arachidonic acid mobilization: evidence for partial agonism of synthetic peptides.
Whooping Cough
Somatostatin receptors (sst2) are coupled to Go and modulate GTPase activity in the rabbit retina.
Whooping Cough
Somatostatin receptors are expressed by immature cerebellar granule cells: evidence for a direct inhibitory effect of somatostatin on neuroblast activity.
Whooping Cough
Somatostatin receptors in Neuro2A neuroblastoma cells: ligand internalization.
Whooping Cough
Somatostatin receptors in Neuro2A neuroblastoma cells: operational characteristics.
Whooping Cough
Somatostatin receptors on canine fundic D-cells: evidence for autocrine regulation of gastric somatostatin.
Whooping Cough
Somatostatin receptors on pituitary somatotrophs, thyrotrophs, and lactotrophs: pharmacological evidence for loose coupling to adenylate cyclase.
Whooping Cough
Somatostatin sst5 inhibition of receptor mediated regeneration of rat aortic vascular smooth muscle cells.
Whooping Cough
Somatostatin stimulates BKCa channels in rat pituitary tumor cells through lipoxygenase metabolites of arachidonic acid.
Whooping Cough
Somatostatin, misoprostol and galanin inhibit gastrin- and PACAP-stimulated secretion of histamine and pancreastatin from ECL cells by blocking specific Ca2+ channels.
Whooping Cough
Somatostatin-14 and somatostatin-28 induce opposite effects on potassium currents in rat neocortical neurons.
Whooping Cough
Somatostatin-14 blocks the hepatotrophic effects of insulin in the rat.
Whooping Cough
Somatostatin-induced control of cytosolic free calcium in pituitary tumour cells.
Whooping Cough
Somatostatin-induced inhibition of neurotransmission in the mouse isolated vas deferens is resistant to pertussis toxin.
Whooping Cough
Somatostatin-induced paradoxical increase in intracellular Ca2+ concentration and insulin release in the presence of arginine vasopressin in clonal HIT-T15 beta-cells.
Whooping Cough
Somatostatin5 receptor-mediated [35S]guanosine-5'-O-(3-thio)triphosphate binding: agonist potencies and the influence of sodium chloride on intrinsic activity.
Whooping Cough
Some changes of receptor and postreceptor signal transduction regulated by somatostatin in pituitary hGH-secreting adenomas.
Whooping Cough
Some new insights into the effects of opioids in phasic and tonic nociceptive tests.
Whooping Cough
Some sweet and bitter tastants stimulate inhibitory pathway of adenylyl cyclase via melatonin and alpha 2-adrenergic receptors in Xenopus laevis melanophores.
Whooping Cough
Sonic hedgehog enhances calcium oscillations in hippocampal astrocytes.
Whooping Cough
Sonic hedgehog induces capillary morphogenesis by endothelial cells through phosphoinositide 3-kinase.
Whooping Cough
SOS1, ARHGEF1, and DOCK2 rho-GEFs Mediate JAK-Dependent LFA-1 Activation by Chemokines.
Whooping Cough
Special AT-rich sequence binding protein 1 is required for maintenance of T cell receptor responsiveness and development of experimental autoimmune encephalomyelitis.
Whooping Cough
Species differences in actions of islet-activating protein, pertussis toxin.
Whooping Cough
Specific alpha 1-adrenergic receptor subtypes modulate catecholamine-induced increases and decreases in ventricular automaticity.
Whooping Cough
Specific beta(2)AR blocker ICI 118,551 actively decreases contraction through a G(i)-coupled form of the beta(2)AR in myocytes from failing human heart.
Whooping Cough
Specific binding of proinsulin C-peptide to human cell membranes.
Whooping Cough
Specific Gq protein involvement in muscarinic M3 receptor-induced phosphatidylinositol hydrolysis and Ca2+ release in mouse duodenal myocytes.
Whooping Cough
Specific identification of Bordetella pertussis by the polymerase chain reaction.
Whooping Cough
Specific immunoglobulin A to Bordetella pertussis antigens in mucosal secretion for rapid diagnosis of whooping cough.
Whooping Cough
Specific inhibition of FSH-stimulated cAMP accumulation by delta 9-tetrahydrocannabinol in cultures of rat Sertoli cells.
Whooping Cough
Specific involvement of G(alphai2) with epidermal growth factor receptor signaling in rat hepatocytes, and the inhibitory effect of chronic ethanol.
Whooping Cough
Specific leukotriene receptors couple to distinct G proteins to effect stimulation of alveolar macrophage host defense functions.
Whooping Cough
Specific lung mucosal and systemic immune responses after oral immunization of mice with Salmonella typhimurium aroA, Salmonella typhi Ty21a, and invasive Escherichia coli expressing recombinant pertussis toxin S1 subunit.
Whooping Cough
Specific receptor-guanine nucleotide binding protein interaction mediates the release of endothelium-derived relaxing factor.
Whooping Cough
Specific roles of Gi protein family members revealed by dissecting somatostatin receptor 5 (SST5) coupling in human pituitary cells.
Whooping Cough
Specific T cell deletion by transfected human monocytes expressing fas ligand and antigen.
Whooping Cough
Specific uncoupling by islet-activating protein, pertussis toxin, of negative signal transduction via alpha-adrenergic, cholinergic, and opiate receptors in neuroblastoma x glioma hybrid cells.
Whooping Cough
Specificity and detection limit of a dermal temperature histamine sensitization test for absence of residual pertussis toxin in vaccines.
Whooping Cough
Specificity and regulation of extracellularly regulated kinase1/2 phosphorylation through corticotropin-releasing factor (CRF) receptors 1 and 2beta by the CRF/urocortin family of peptides.
Whooping Cough
Specificity and sensitivity of high levels of immunoglobulin G antibodies against pertussis toxin in a single serum sample for diagnosis of infection with Bordetella pertussis.
Whooping Cough
Specificity of coupling of muscarinic receptor isoforms to a novel chick inward-rectifying acetylcholine-sensitive K+ channel.
Whooping Cough
Specificity of metabotropic glutamate receptor 2 coupling to G proteins.
Whooping Cough
Specificity of receptor-G protein interactions. Discrimination of Gi subtypes by the D2 dopamine receptor in a reconstituted system.
Whooping Cough
Spermatozoa contain a guanine nucleotide-binding protein ADP-ribosylated by pertussis toxin.
Whooping Cough
Spheroid formation and invasion capacity are differentially influenced by co-cultures of fibroblast and macrophage cells in breast cancer.
Whooping Cough
Sphingolipid receptor signaling and function in human bladder carcinoma cells: inhibition of LPA- but enhancement of thrombin-stimulated cell motility.
Whooping Cough
Sphingosine 1 phosphate induces the chemotaxis of human natural killer cells. Role for heterotrimeric G proteins and phosphoinositide 3 kinases.
Whooping Cough
Sphingosine 1-phosphate activates Erk-1/-2 by transactivating epidermal growth factor receptor in rat-2 cells.
Whooping Cough
Sphingosine 1-phosphate affects cytokine-induced apoptosis in rat pancreatic islet beta-cells.
Whooping Cough
Sphingosine 1-phosphate and activation of endothelial nitric-oxide synthase. differential regulation of Akt and MAP kinase pathways by EDG and bradykinin receptors in vascular endothelial cells.
Whooping Cough
Sphingosine 1-phosphate and control of vascular tone.
Whooping Cough
Sphingosine 1-phosphate and dioleoylphosphatidic acid are low affinity agonists for the orphan receptor GPR63.
Whooping Cough
Sphingosine 1-phosphate antagonizes human neutrophil apoptosis via p38 mitogen-activated protein kinase.
Whooping Cough
Sphingosine 1-phosphate causes airway hyper-reactivity by rho-mediated myosin phosphatase inactivation.
Whooping Cough
Sphingosine 1-phosphate cross-activates the Smad signaling cascade and mimics transforming growth factor-beta-induced cell responses.
Whooping Cough
Sphingosine 1-phosphate evokes calcium signals in C2C12 myoblasts via Edg3 and Edg5 receptors.
Whooping Cough
Sphingosine 1-phosphate induces alpha-smooth muscle actin expression in lung fibroblasts via Rho-kinase.
Whooping Cough
Sphingosine 1-phosphate induces angiogenesis: its angiogenic action and signaling mechanism in human umbilical vein endothelial cells.
Whooping Cough
Sphingosine 1-phosphate induces cyclooxygenase-2 via Ca2+-dependent, but MAPK-independent mechanism in rat vascular smooth muscle cells.
Whooping Cough
Sphingosine 1-phosphate induces expression of early growth response-1 and fibroblast growth factor-2 through mechanism involving extracellular signal-regulated kinase in astroglial cells.
Whooping Cough
Sphingosine 1-phosphate induces Mcl-1 upregulation and protects multiple myeloma cells against apoptosis.
Whooping Cough
Sphingosine 1-phosphate induces membrane ruffling and increases motility of human umbilical vein endothelial cells via vascular endothelial growth factor receptor and CrkII.
Whooping Cough
Sphingosine 1-phosphate inhibits nitric oxide production induced by interleukin-1beta in rat vascular smooth muscle cells.
Whooping Cough
Sphingosine 1-phosphate is a ligand of the human gpr3, gpr6 and gpr12 family of constitutively active G protein-coupled receptors.
Whooping Cough
Sphingosine 1-phosphate is a novel inhibitor of T-cell proliferation.
Whooping Cough
Sphingosine 1-phosphate may be a major component of plasma lipoproteins responsible for the cytoprotective actions in human umbilical vein endothelial cells.
Whooping Cough
Sphingosine 1-phosphate mobilizes sequestered calcium, activates calcium entry, and stimulates deoxyribonucleic acid synthesis in thyroid FRTL-5 cells.
Whooping Cough
Sphingosine 1-phosphate prevents platelet-activating factor-induced increase in hydraulic conductivity in rat mesenteric venules: pertussis toxin sensitive.
Whooping Cough
Sphingosine 1-phosphate protects human umbilical vein endothelial cells from serum-deprived apoptosis by nitric oxide production.
Whooping Cough
Sphingosine 1-phosphate rapidly activates the mitogen-activated protein kinase pathway by a G protein-dependent mechanism.
Whooping Cough
Sphingosine 1-phosphate receptor 2 antagonist JTE-013 increases the excitability of sensory neurons independently of the receptor.
Whooping Cough
Sphingosine 1-phosphate receptor expression profile in human gastric cancer cells: differential regulation on the migration and proliferation.
Whooping Cough
Sphingosine 1-phosphate receptors mediate stimulatory and inhibitory signalings for expression of adhesion molecules in endothelial cells.
Whooping Cough
Sphingosine 1-phosphate receptors mediate the lipid-induced cAMP accumulation through cyclooxygenase-2/prostaglandin I2 pathway in human coronary artery smooth muscle cells.
Whooping Cough
Sphingosine 1-phosphate regulates melanoma cell motility through a receptor-coupled extracellular action and in a pertussis toxin-insensitive manner.
Whooping Cough
Sphingosine 1-phosphate regulates myogenic differentiation: a major role for S1P2 receptor.
Whooping Cough
SPHINGOSINE 1-PHOSPHATE REGULATION OF EXTRACELLULAR SIGNAL REGULATED KINASE-1/2 IN EMBYRONIC STEM CELLS.
Whooping Cough
Sphingosine 1-phosphate released from platelets during clotting accounts for the potent endothelial cell chemotactic activity of blood serum and provides a novel link between hemostasis and angiogenesis.
Whooping Cough
Sphingosine 1-phosphate stimulates cell migration through a G(i)-coupled cell surface receptor. Potential involvement in angiogenesis.
Whooping Cough
Sphingosine 1-phosphate stimulates G(i)- and Rho-mediated vascular endothelial cell spreading and migration.
Whooping Cough
Sphingosine 1-phosphate stimulates hydrogen peroxide generation through activation of phospholipase C-Ca2+ system in FRTL-5 thyroid cells: possible involvement of guanosine triphosphate-binding proteins in the lipid signaling.
Whooping Cough
Sphingosine 1-phosphate stimulates insulin secretion in HIT-T 15 cells and mouse islets.
Whooping Cough
Sphingosine 1-phosphate stimulates Na+/H+ exchange in thyroid FRTL-5 cells.
Whooping Cough
Sphingosine 1-phosphate stimulates proliferation and migration of human endothelial cells possibly through the lipid receptors, Edg-1 and Edg-3.
Whooping Cough
Sphingosine 1-phosphate stimulates tyrosine phosphorylation of focal adhesion kinase and chemotactic motility of endothelial cells via the G(i) protein-linked phospholipase C pathway.
Whooping Cough
Sphingosine 1-phosphate stimulation of the p42/p44 mitogen-activated protein kinase pathway in airway smooth muscle. Role of endothelial differentiation gene 1, c-Src tyrosine kinase and phosphoinositide 3-kinase.
Whooping Cough
Sphingosine 1-phosphate triggers apoptotic signal for B16 melanoma cells via ERK and caspase activation.
Whooping Cough
Sphingosine 1-phosphate triggers both apoptotic and survival signals for human hepatic myofibroblasts.
Whooping Cough
Sphingosine 1-phosphate-induced cell proliferation, survival, and related signaling events mediated by G protein-coupled receptors Edg3 and Edg5.
Whooping Cough
Sphingosine 1-phosphate-induced signal transduction in cat esophagus smooth muscle cells.
Whooping Cough
Sphingosine 1-phosphate/sphingosine 1-phosphate receptor 1 signaling in rheumatoid synovium: Regulation of synovial proliferation and inflammatory gene expression.
Whooping Cough
Sphingosine 1-phosphate: a novel stimulator of aldosterone secretion.
Whooping Cough
Sphingosine kinase 1 expression is downregulated during differentiation of Friend cells due to decreased c-MYB.
Whooping Cough
Sphingosine Kinase 1/S1P Pathway Involvement in the GDNF-Induced GAP43 Transcription.
Whooping Cough
Sphingosine kinase activation regulates hepatocyte growth factor induced migration of endothelial cells.
Whooping Cough
Sphingosine kinase expression increases intracellular sphingosine-1-phosphate and promotes cell growth and survival.
Whooping Cough
Sphingosine kinase expression regulates apoptosis and caspase activation in PC12 cells.
Whooping Cough
Sphingosine kinase-dependent directional migration of leukocytes in response to phorbol ester.
Whooping Cough
Sphingosine mobilizes intracellular calcium in human neutrophils.
Whooping Cough
Sphingosine-1-phosphate activates BKCa channels independently of G protein-coupled receptor in human endothelial cells.
Whooping Cough
Sphingosine-1-phosphate activates phospholipase D in human airway epithelial cells via a G protein-coupled receptor.
Whooping Cough
Sphingosine-1-phosphate activates the AKT pathway to inhibit chemotherapy induced human granulosa cell apoptosis.
Whooping Cough
Sphingosine-1-phosphate activates the AKT pathway to protect small intestines from radiation-induced endothelial apoptosis.
Whooping Cough
Sphingosine-1-phosphate and endothelin-1 induce the expression of rgs16 protein in cardiac myocytes by transcriptional activation of the rgs16 gene.
Whooping Cough
Sphingosine-1-phosphate and its potentially paradoxical effects on critical parameters of cutaneous wound healing.
Whooping Cough
Sphingosine-1-phosphate and lysophosphatidic acid stimulate endothelial cell migration.
Whooping Cough
Sphingosine-1-phosphate and sphingosylphosphorylcholine constrict renal and mesenteric microvessels in vitro.
Whooping Cough
Sphingosine-1-phosphate attenuates proteoglycan aggrecan expression via production of prostaglandin E2 from human articular chondrocytes.
Whooping Cough
Sphingosine-1-phosphate effects on PKC isoform expression in human osteoblastic cells.
Whooping Cough
Sphingosine-1-phosphate in the plasma compartment regulates basal and inflammation-induced vascular leak in mice.
Whooping Cough
Sphingosine-1-phosphate increases human alveolar epithelial IL-8 secretion, proliferation and neutrophil chemotaxis.
Whooping Cough
Sphingosine-1-phosphate induces early response gene expression in C6 glioma cells.
Whooping Cough
Sphingosine-1-phosphate induces proliferation of astrocytes: regulation by intracellular signalling cascades.
Whooping Cough
Sphingosine-1-phosphate inhibition of apoptosis requires mitogen-activated protein kinase phosphatase-1 in mouse fibroblast C3H10T 1/2 cells.
Whooping Cough
Sphingosine-1-phosphate inhibition of placental trophoblast differentiation through a G(i)-coupled receptor response.
Whooping Cough
Sphingosine-1-phosphate inhibits human keratinocyte proliferation via Akt/protein kinase B inactivation.
Whooping Cough
Sphingosine-1-phosphate is a high-affinity ligand for the G protein-coupled receptor GPR6 from mouse and induces intracellular Ca2+ release by activating the sphingosine-kinase pathway.
Whooping Cough
Sphingosine-1-phosphate is released by cerebellar astrocytes in response to bFGF and induces astrocyte proliferation through G(i)-protein-coupled receptors.
Whooping Cough
Sphingosine-1-phosphate modulates both lipolysis and leptin production in differentiated rat white adipocytes.
Whooping Cough
Sphingosine-1-phosphate promotes lymphangiogenesis by stimulating S1P1/Gi/PLC/Ca2+ signaling pathways.
Whooping Cough
Sphingosine-1-phosphate receptor type 1 regulates glioma cell proliferation and correlates with patient survival.
Whooping Cough
Sphingosine-1-phosphate reduces rat renal and mesenteric blood flow in vivo in a pertussis toxin-sensitive manner.
Whooping Cough
Sphingosine-1-phosphate regulates RGS2 and RGS16 mRNA expression in vascular smooth muscle cells.
Whooping Cough
Sphingosine-1-phosphate stimulates aldosterone secretion through a mechanism involving the PI3K/PKB and MEK/ERK 1/2 pathways.
Whooping Cough
Sphingosine-1-phosphate stimulates cortisol secretion.
Whooping Cough
Sphingosine-1-phosphate stimulates human glioma cell proliferation through Gi-coupled receptors: role of ERK MAP kinase and phosphatidylinositol 3-kinase beta.
Whooping Cough
Sphingosine-1-phosphate stimulates rat primary chondrocyte proliferation.
Whooping Cough
Sphingosine-1-phosphate stimulates smooth muscle cell migration through galpha(i)- and pi3-kinase-dependent p38(MAPK) activation.
Whooping Cough
Sphingosine-1-phosphate-induced oxygen free radical generation in smooth muscle cell migration requires Galpha12/13 protein-mediated phospholipase C activation.
Whooping Cough
Sphingosine-mediated phosphatidylinositol metabolism and calcium mobilization.
Whooping Cough
Sphingosylphosphorylcholine activates Gq, Gi-2, and Gi-3 in thyroid FRTL-5 cells: implications for the activation of calcium fluxes and Na+-H+ exchange.
Whooping Cough
Sphingosylphosphorylcholine activation of mitogen-activated protein kinase in Swiss 3T3 cells requires protein kinase C and a pertussis toxin-sensitive G protein.
Whooping Cough
Sphingosylphosphorylcholine and sphingosine-1-phosphate mobilize cytosolic calcium through different mechanisms in human airway epithelial cells.
Whooping Cough
Sphingosylphosphorylcholine blocks ovariectomy-induced bone loss by suppressing Ca2+ /calmodulin-mediated osteoclast differentiation.
Whooping Cough
Sphingosylphosphorylcholine enhances calcium entry in thyroid FRO cells by a mechanism dependent on protein kinase C.
Whooping Cough
Sphingosylphosphorylcholine induces a hypertrophic growth response through the mitogen-activated protein kinase signaling cascade in rat neonatal cardiac myocytes.
Whooping Cough
Sphingosylphosphorylcholine induces differentiation of human mesenchymal stem cells into smooth-muscle-like cells through a TGF-beta-dependent mechanism.
Whooping Cough
Sphingosylphosphorylcholine induces proliferation of human adipose tissue-derived mesenchymal stem cells via activation of JNK.
Whooping Cough
Sphingosylphosphorylcholine inhibits melanin synthesis via pertussis toxin-sensitive MITF degradation.
Whooping Cough
Sphingosylphosphorylcholine stimulates contraction of fibroblast-embedded collagen gel.
Whooping Cough
Sphingosylphosphorylcholine stimulates mitogen-activated protein kinase via a Ca2+-dependent pathway.
Whooping Cough
Sphingosylphosphorylcholine-induced vasoconstriction of pulmonary artery: activation of non-store-operated Ca2+ entry.
Whooping Cough
Spider toxin and pertussis toxin differentiate post- and presynaptic glutamate receptors.
Whooping Cough
Spinal ?-adrenergic receptors' activation increases the blood glucose level in mice.
Whooping Cough
Spinal and supraspinal antinociceptive action of dipyrone in formalin, capsaicin and glutamate tests. Study of the mechanism of action.
Whooping Cough
Spinal and supraspinal effects of pertussis toxin on opioid analgesia.
Whooping Cough
Spinal morphine/clonidine antinociceptive synergism: involvement of G proteins and N-type voltage-dependent calcium channels.
Whooping Cough
Spinorphin as an endogenous inhibitor of enkephalin-degrading enzymes: roles in pain and inflammation.
Whooping Cough
Spleen tyrosine kinase Syk is necessary for E-selectin-induced alpha(L)beta(2) integrin-mediated rolling on intercellular adhesion molecule-1.
Whooping Cough
Spontaneous activity in transgenic mouse heart: comparison of primary atrial tumor with cultured AT-1 atrial myocytes.
Whooping Cough
Spontaneous and drug-stimulated locomotor activity after the administration of pertussis toxin into the ventral tegmental area.
Whooping Cough
Spontaneous association between opioid receptors and GTP-binding regulatory proteins in native membranes: specific regulation by antagonists and sodium ions.
Whooping Cough
Spontaneous cytosolic calcium pulsing detected in Xenopus melanotrophs: modulation by secreto-inhibitory and stimulant ligands.
Whooping Cough
Spontaneous induction of immunoregulation by an endogenous retinal antigen.
Whooping Cough
Spontaneous phase variation in Bordetella pertussis is a multistep non-random process.
Whooping Cough
Spotlight on Tdap? vaccine (Covaxis®) as a single-booster immunization for the prevention of tetanus, diphtheria, and pertussis: in children (aged ?4 years), adolescents, and adults.
Whooping Cough
Spp24 derivatives stimulate a gi -protein coupled receptor-erk1/2 signaling pathway and modulate gene expressions in w-20-17 cells.
Whooping Cough
SR 144528, an antagonist for the peripheral cannabinoid receptor that behaves as an inverse agonist.
Whooping Cough
SR144528 as inverse agonist of CB2 cannabinoid receptor.
Whooping Cough
Src kinase mediates angiotensin II-dependent increase in pulmonary endothelial nitric oxide synthase.
Whooping Cough
Src-dependence and pertussis-toxin sensitivity of urokinase receptor-dependent chemotaxis and cytoskeleton reorganization in rat smooth muscle cells.
Whooping Cough
Src-regulated extracellular signal-related kinase and Syk-regulated c-Jun N-terminal kinase pathways act in conjunction to induce IL-1 synthesis in response to microtubule disruption in HL60 cells.
Whooping Cough
Stability of antibodies to Bordetella antigens in German adults.
Whooping Cough
Stabilization of the pertussis toxin secretion apparatus by the C terminus of PtlD.
Whooping Cough
Stable expression of pertussis toxin in Bordetella bronchiseptica under the control of a tightly regulated promoter.
Whooping Cough
Stable guanosine 5'-triphosphate-analogues inhibit specific (+)-[3H]isradipine binding in rat hearts by a Ca(2+)-lowering, G protein-independent mechanism.
Whooping Cough
Stable inhibition of adenylate cyclase by muscarinic agonist in rat parotid gland: effects of neomycin and pertussis toxin.
Whooping Cough
Stable transfection of the rat follicle-stimulating hormone receptor complementary DNA into an immortalized murine Sertoli cell line.
Whooping Cough
Standardization of acellular pertussis vaccine by assay of serum neutralizing antibodies to pertussis toxin (antitoxin): analogy with diphtheria toxoid.
Whooping Cough
Staphylococcus albus-induced protein kinase C translocation in human neutrophils: the effect of opsonization, cytochalasin B, pertussis toxin, intra- and extracellular calcium, and R59022.
Whooping Cough
STAT5A interacts with and is phosphorylated upon activation of the mu-opioid receptor.
Whooping Cough
Status epilepticus may be caused by loss of adenosine anticonvulsant mechanisms.
Whooping Cough
Staurosporine clamps cytosolic free Ca2+ concentrations of human neutrophils.
Whooping Cough
Steady and transient fluid shear stress stimulate NO release in osteoblasts through distinct biochemical pathways.
Whooping Cough
Stearate inhibition of breast cancer cell proliferation. A mechanism involving epidermal growth factor receptor and G-proteins.
Whooping Cough
Stem cell factor influences neuro-immune interactions: the response of mast cells to pituitary adenylate cyclase activating polypeptide is altered by stem cell factor.
Whooping Cough
Stem cell factor potentiates histamine secretion by multiple mechanisms, but does not affect tumour necrosis factor-alpha release from rat mast cells.
Whooping Cough
Stepwise activation of the gonadotropic signal transduction pathway, and the ability of prostaglandin F2alpha to inhibit this activated pathway.
Whooping Cough
Stereochemistry of an agonist determines coupling preference of beta2-adrenoceptor to different G proteins in cardiomyocytes.
Whooping Cough
Steroid treatments in mice do not alter the number and function of regulatory T cells, but amplify cyclophosphamide-induced autoimmune disease.
Whooping Cough
Steroid-sensitivity of agonist binding to pituitary cell line histamine H3 receptors.
Whooping Cough
Stimulating properties of 5-oxo-eicosanoids for human monocytes: synergism with monocyte chemotactic protein-1 and -3.
Whooping Cough
Stimulation and inhibition of adenylyl cyclases mediated by distinct regulatory proteins.
Whooping Cough
Stimulation and inhibition of cAMP accumulation by glucagon in canine hepatocytes.
Whooping Cough
Stimulation and inhibition of rat basophilic leukemia cell adenylate cyclase by forskolin.
Whooping Cough
Stimulation by endothelin-1 of mitogen-activated protein kinases and DNA synthesis in bovine tracheal smooth muscle cells.
Whooping Cough
Stimulation by extracellular ATP and UTP of the stress-activated protein kinase cascade in rat renal mesangial cells.
Whooping Cough
Stimulation by leukotriene D4 of increases in the cytosolic concentration of calcium in dimethylsulfoxide-differentiated HL-60 cells.
Whooping Cough
Stimulation by the nucleotides, ATP and UTP of mitogen-activated protein kinase in EAhy 926 endothelial cells.
Whooping Cough
Stimulation by tumor necrosis factor of HL-60 thymidine salvage pathway metabolism dissociated from proliferation.
Whooping Cough
Stimulation of a Gs-like G protein in the osteoclast inhibits bone resorption but enhances tartrate-resistant acid phosphatase secretion.
Whooping Cough
Stimulation of a histone H4 protein kinase in Triton X-100 lysates of rabbit peritoneal neutrophils pretreated with chemotactic factors: lack of requirements of calcium mobilization and protein kinase C activation.
Whooping Cough
Stimulation of adenosine A1 receptors and bradykinin receptors, which act via different G proteins, synergistically raises inositol 1,4,5-trisphosphate and intracellular free calcium in DDT1 MF-2 smooth muscle cells.
Whooping Cough
Stimulation of adenosine receptor enhances alpha 1-adrenergic receptor-mediated activation of phospholipase C and Ca2+ mobilization in a pertussis toxin-sensitive manner in FRTL-5 thyroid cells.
Whooping Cough
Stimulation of alpha 2 adrenoceptors dilates the rat middle cerebral artery.
Whooping Cough
Stimulation of arachidonic acid release by guanine nucleotide in saponin-permeabilized neutrophils: evidence for involvement of GTP-binding protein in phospholipase A2 activation.
Whooping Cough
Stimulation of beta(3)-adrenoceptors causes phosphorylation of p38 mitogen-activated protein kinase via a stimulatory G protein-dependent pathway in 3T3-L1 adipocytes.
Whooping Cough
Stimulation of cAMP accumulation by the cloned Xenopus melatonin receptor through Gi and Gz proteins.
Whooping Cough
Stimulation of cannabinoid receptor agonist 2-arachidonylglycerol by chronic ethanol and its modulation by specific neuromodulators in cerebellar granule neurons.
Whooping Cough
Stimulation of cannabinoid receptor CB1 induces krox-24 expression in human astrocytoma cells.
Whooping Cough
Stimulation of cardiac alpha receptors increases Na/K pump current and decreases gK via a pertussis toxin-sensitive pathway.
Whooping Cough
Stimulation of cell proliferation by calcium and a calcimimetic compound.
Whooping Cough
Stimulation of cortisol production through angiotensin AT2 receptors in bovine fasciculata cells.
Whooping Cough
Stimulation of cyclic adenosine 3',5'-monophosphate production enhances hypothalamic luteinizing hormone-releasing hormone release without increasing prostaglandin E2 synthesis: studies in prepubertal female rats.
Whooping Cough
Stimulation of cyclic AMP production by the Caenorhabditis elegans muscarinic acetylcholine receptor GAR-3 in Chinese hamster ovary cells.
Whooping Cough
Stimulation of DNA synthesis in Jurkat cells by synergistic action between adenine and guanine nucleotides.
Whooping Cough
Stimulation of early gene induction and cell proliferation by lysophosphatidic acid in human amnion-derived WISH cells: role of phospholipase D-mediated pathway.
Whooping Cough
Stimulation of extracellular signal-regulated kinases and proliferation in the human gastric cancer cells KATO-III by obestatin.
Whooping Cough
Stimulation of generation of inositol phosphates by carbamoylcholine and its inhibition by phorbol esters and iodide in dog thyroid cells.
Whooping Cough
Stimulation of glucose incorporation into glycogen by E-series prostaglandins in cultured rat hepatocytes.
Whooping Cough
Stimulation of glycogen degradation by prostaglandin E2 in primary cultured rat hepatocytes.
Whooping Cough
Stimulation of glycogenolysis by three locust adipokinetic hormones involves Gs and cAMP.
Whooping Cough
Stimulation of Gs and inhibition of Gi protein functions by minimally oxidized LDL.
Whooping Cough
Stimulation of guanosine 5'-O-(3-[35S] thiotriphosphate) binding by cholinergic muscarinic receptors in membranes of rat olfactory bulb.
Whooping Cough
Stimulation of high-affinity GTPase activity and cholera toxin-catalysed [32P]ADP-ribosylation of Gi by lysophosphatidic acid (LPA) in wild-type and alpha 2C10 adrenoceptor-transfected Rat 1 fibroblasts.
Whooping Cough
Stimulation of histamine H2- (and H1)-receptors activates Ca2+ influx in all-trans-retinoic acid-differentiated HL-60 cells independently of phospholipase C or adenylyl cyclase.
Whooping Cough
Stimulation of HIV gp120-specific cytolytic T lymphocyte responses in vitro and in vivo using a detoxified pertussis toxin vector.
Whooping Cough
Stimulation of human neutrophils by chemotactic factors is associated with the activation of phosphatidylinositol 3-kinase gamma.
Whooping Cough
Stimulation of human thyroid growth via the inhibitory guanine nucleotide binding (G) protein Gi: constitutive expression of the G-protein alpha subunit Gi alpha-1 in autonomous adenoma.
Whooping Cough
Stimulation of hypothalamic opioid peptide release by lithium is mediated by opioid autoreceptors: evidence from a combined in vitro, ex vivo study.
Whooping Cough
Stimulation of inositol phosphate formation in FRTL-5 rat thyroid cells by catecholamines and its relationship to changes in 45Ca2+ efflux and cyclic AMP accumulation.
Whooping Cough
Stimulation of inositol phosphate production by neurotensin in neuroblastoma N1E115 cells: implication of GTP-binding proteins and relationship with the cyclic GMP response.
Whooping Cough
Stimulation of intracellular calcium concentration by adenosine triphosphate and uridine 5'-triphosphate in human term placental cells: evidence for purinergic receptors.
Whooping Cough
Stimulation of intracellular sphingosine-1-phosphate production by G-protein-coupled sphingosine-1-phosphate receptors.
Whooping Cough
Stimulation of intracellular topoisomerase I activity by vasopressin and thrombin. Differential regulation by pertussis toxin.
Whooping Cough
Stimulation of luteinizing hormone (LH) release and phospholipid breakdown by guanosine triphosphate in permeabilized pituitary gonadotropes: antagonist action suggests association of a G protein and gonadotropin-releasing hormone receptor.
Whooping Cough
Stimulation of luteinizing hormone release by sodium fluoride is independent of protein kinase-C activity and unaffected by desensitization to gonadotropin-releasing hormone.
Whooping Cough
Stimulation of macrophage colony-stimulating factor synthesis by interleukin-1.
Whooping Cough
Stimulation of mitogen activated protein kinase by LDL and oxLDL in human U-937 macrophage-like cells.
Whooping Cough
Stimulation of mitogen-activated protein kinase by gonadotropin-releasing hormone in human granulosa-luteal cells.
Whooping Cough
Stimulation of mitogen-activated protein kinase by thyrotropin in astrocytes.
Whooping Cough
Stimulation of mitogen-activated protein kinase by thyrotropin in primary cultured human thyroid follicles.
Whooping Cough
Stimulation of mono-ADP ribosylation in rat liver plasma membranes after long-term alcohol intake.
Whooping Cough
Stimulation of mu- and delta-opioid receptors enhances phosphoinositide metabolism in mouse spinal cord: evidence for subtypes of delta-receptors.
Whooping Cough
Stimulation of mucosal and systemic antibody responses against Bordetella pertussis filamentous haemagglutinin and recombinant pertussis toxin after nasal administration with chitosan in mice.
Whooping Cough
Stimulation of muscarinic M2 receptors inhibits atrial natriuretic peptide-mediated relaxation in bovine tracheal smooth muscle.
Whooping Cough
Stimulation of naïve T-cell adhesion and immunological synapse formation by chemokine-dependent and -independent mechanisms.
Whooping Cough
Stimulation of neutrophil leukocyte chemotaxis by a cloned cytolytic enterotoxin of Aeromonas hydrophila.
Whooping Cough
Stimulation of neutrophils with a chemoattractant activates several novel protein kinases that can catalyze the phosphorylation of peptides derived from the 47-kDa protein component of the phagocyte oxidase and myristoylated alanine-rich C kinase substrate.
Whooping Cough
Stimulation of P2 purinergic receptors induces the release of eosinophil cationic protein and interleukin-8 from human eosinophils.
Whooping Cough
Stimulation of peripheral cannabinoid receptor CB2 induces MCP-1 and IL-8 gene expression in human promyelocytic cell line HL60.
Whooping Cough
Stimulation of peripheral nociceptor endings by low dose morphine and its signaling mechanism.
Whooping Cough
Stimulation of Phospholipase A(2) by Toxic Main Group Heavy Metals: Partly Dependent on G-proteins?
Whooping Cough
Stimulation of phospholipase A2 activity in bovine rod outer segments by the beta gamma subunits of transducin and its inhibition by the alpha subunit.
Whooping Cough
Stimulation of phospholipase C-mediated hydrolysis of phosphoinositides by adenosine 5'-triphosphate via P2-purinoceptors in cultured rat aortic vascular smooth muscle cells.
Whooping Cough
Stimulation of phospholipase D activity by oxidized LDL in mouse peritoneal macrophages.
Whooping Cough
Stimulation of protein kinase B and p70 S6 kinase by the histamine H1 receptor in DDT1MF-2 smooth muscle cells.
Whooping Cough
Stimulation of rat pancreatic tumoral AR4-2J cell proliferation by pituitary adenylate cyclase-activating peptide.
Whooping Cough
Stimulation of reactive oxidant production in neutrophils by soluble and insoluble immune complexes occurs via different receptors/signal transduction systems.
Whooping Cough
Stimulation of respiratory burst by cyclocommunin in rat neutrophils is associated with the increase in cellular Ca2+ and protein kinase C activity.
Whooping Cough
Stimulation of sodium-dependent inorganic phosphate transport by activation of Gi/o-protein-coupled receptors by epinephrine in MC3T3-E1 osteoblast-like cells.
Whooping Cough
Stimulation of sphingosine-1-phosphate formation by the P2Y(2) receptor in HL-60 cells: Ca(2+) requirement and implication in receptor-mediated Ca(2+) mobilization, but not MAP kinase activation.
Whooping Cough
Stimulation of T cells through the CD3/T-cell receptor complex: role of cytoplasmic calcium, protein kinase C translocation, and phosphorylation of pp60c-src in the activation pathway.
Whooping Cough
Stimulation of T-Cell activation by CXCL12/stromal cell derived factor-1 involves a G-protein mediated signaling pathway.
Whooping Cough
Stimulation of the extracellular signal-regulated kinase 1/2 pathway by human beta-3 adrenergic receptor: new pharmacological profile and mechanism of activation.
Whooping Cough
Stimulation of the mitogen-activated protein kinase via the A2A-adenosine receptor in primary human endothelial cells.
Whooping Cough
Stimulation of the T-cell receptors CD3 and CD2 with OKT3 and OKT11 antibodies activates a common pertussis toxin-insensitive G-protein.
Whooping Cough
Stimulation of the thiol-dependent ADP-ribosyltransferase and NAD glycohydrolase activities of Bordetella pertussis toxin by adenine nucleotides, phospholipids, and detergents.
Whooping Cough
Stimulation of type II adenylyl cyclase by chemoattractant formyl peptide and C5a receptors.
Whooping Cough
Stimulations of arachidonate release and inositol-1,4,5-triphosphate formation are mediated by distinct G-proteins in human platelets.
Whooping Cough
Stimulatory and inhibitory actions of carbachol on chloride secretory responses in human colonic cell line T84.
Whooping Cough
Stimulatory and inhibitory actions of lysophosphatidylcholine, depending on its fatty acid residue, on the phospholipase C/Ca2+ system in HL-60 leukaemia cells.
Whooping Cough
Stimulatory and inhibitory guanine-nucleotide-binding regulatory protein involvement in stimulation of arachidonic-acid release by N-formyl-methionyl-leucyl-phenylalanine and platelet-activating factor from guinea-pig alveolar macrophages. Differential receptor/G-protein interaction assessed by pertussis and cholera toxins.
Whooping Cough
Stimulatory effect of guanine nucleotides on prostaglandin E1 binding to murine renal outer medulla.
Whooping Cough
Stimulatory effect of insulin and insulin-like growth factor I on Gi proteins and angiotensin-II-induced phosphoinositide breakdown in cultured bovine adrenal cells.
Whooping Cough
Stimulatory effect of pertussis toxin on tissue cyclic AMP levels in canine thyroid slices.
Whooping Cough
Stimulatory effects of histamine on migration of nasal fibroblasts.
Whooping Cough
Stimulatory effects of lipoprotein(a) and low-density lipoprotein on human umbilical vein endothelial cell migration and proliferation are partially mediated by fibroblast growth factor-2.
Whooping Cough
Stimulatory effects of quinpirole hydrochloride, D2-dopamine receptor agonist, at low concentrations on prolactin release in female rats in vitro.
Whooping Cough
Stimulatory pathways of the Calcium-sensing receptor on acid secretion in freshly isolated human gastric glands.
Whooping Cough
Stimulatory role of lysophosphatidic acid in cyclooxygenase-2 induction by synovial fluid of patients with rheumatoid arthritis in fibroblast-like synovial cells.
Whooping Cough
Stimulus-dependent transduction mechanisms for nitric oxide release in human polymorphonuclear neutrophil leukocytes.
Whooping Cough
Stimulus-induced dissociation of alpha subunits of heterotrimeric GTP-binding proteins from the cytoskeleton of human neutrophils.
Whooping Cough
Stimulus-response coupling in a cell-free platelet membrane system. GTP-dependent release of Ca2+ by thrombin, and inhibition by pertussis toxin and a monoclonal antibody that blocks calcium release by IP3.
Whooping Cough
Stimulus-response coupling in FMLP-stimulated U937 monocytes: effect of differentiation on Gi2 expression.
Whooping Cough
Stimulus-response coupling in monocytes infected with Leishmania. Attenuation of calcium transients is related to defective agonist-induced accumulation of inositol phosphates.
Whooping Cough
Stomatal Opening Is Induced in Epidermal Peels of Commelina communis L. by GTP Analogs or Pertussis Toxin.
Whooping Cough
Storage at -3 degrees C for 24 h alters the immunogenicity of pertussis vaccines.
Whooping Cough
Store-activated Ca2+ inflow in Xenopus laevis oocytes: inhibition by primaquine and evaluation of the role of membrane fusion.
Whooping Cough
Store-operated Ca(2+) inflow in Reuber hepatoma cells is inhibited by voltage-operated Ca(2+) channel antagonists and, in contrast to freshly isolated hepatocytes, does not require a pertussis toxin-sensitive trimeric GTP-binding protein.
Whooping Cough
Strain variation among Bordetella pertussis isolates in finland, where the whole-cell pertussis vaccine has been used for 50 years.
Whooping Cough
Strategies to alleviate original antigenic sin responses to influenza viruses.
Whooping Cough
Streptococcal glycoprotein-induced tumour cell growth inhibition involves the modulation of a pertussis toxin-sensitive G protein.
Whooping Cough
Stress and glucocorticoids impair memory retrieval via ?2-adrenergic, Gi/o-coupled suppression of cAMP signaling.
Whooping Cough
Stretch-induced inositol trisphosphate and tetrakisphosphate production in rat cardiomyocytes.
Whooping Cough
Stretching increases calcium influx and efflux in cultured pulmonary arterial smooth muscle cells.
Whooping Cough
Stromal Cell-Derived Factor 1 Increases Tetrodotoxin-Resistant Sodium Currents Nav1.8 and Nav1.9 in Rat Dorsal Root Ganglion Neurons via Different Mechanisms.
Whooping Cough
Stromal cell-derived factor 1-mediated CXCR4 signaling in rat and human cortical neural progenitor cells.
Whooping Cough
Stromal cell-derived factor 1alpha activates LIM kinase 1 and induces cofilin phosphorylation for T-cell chemotaxis.
Whooping Cough
Stromal cell-derived factor-1 alpha and stem cell factor/kit ligand share signaling pathways in hemopoietic progenitors: a potential mechanism for cooperative induction of chemotaxis.
Whooping Cough
Stromal cell-derived factor-1/CXCL12 stimulates chemorepulsion of NOD/LtJ T-cell adhesion to islet microvascular endothelium.
Whooping Cough
Stromal cell-derived factor-1alpha directly modulates voltage-dependent currents of the action potential in mammalian neuronal cells.
Whooping Cough
Stromal cell-derived factor-1alpha induces astrocyte proliferation through the activation of extracellular signal-regulated kinases 1/2 pathway.
Whooping Cough
Stromal cell-derived factor-1alpha induces tube-like structure formation of endothelial cells through phosphoinositide 3-kinase.
Whooping Cough
Strong and persistent activation of inositol lipid breakdown induces early mitogenic events but not Go to S phase progression in hamster fibroblasts. Comparison of thrombin and carbachol action in cells expressing M1 muscarinic acetylcholine receptors.
Whooping Cough
Strontium and barium induce exocytosis in electropermeabilized neutrophils.
Whooping Cough
Structural and functional analysis of the S1 subunit of pertussis toxin using synthetic peptides.
Whooping Cough
Structural and functional attributes of zona pellucida glycoproteins.
Whooping Cough
Structural and functional relationships of guanosine triphosphate binding proteins.
Whooping Cough
Structural and functional studies of cross-linked Go protein subunits.
Whooping Cough
Structural and functional studies on the G(o) protein.
Whooping Cough
Structural basis of G protein specificity of human endothelin receptors. A study with endothelinA/B chimeras.
Whooping Cough
Structural characterization of pertussis toxin A subunit.
Whooping Cough
Structural evidence for the evolution of pyrogenic toxin superantigens.
Whooping Cough
Structural relationship between the S1 and S4 subunits of pertussis toxin.
Whooping Cough
Structural requirements for G(o) activation by receptor-derived peptides: activation and modulation domains of the alpha 2-adrenergic receptor i3c region.
Whooping Cough
Structural requirements for neuropeptide Y in mast cell and G protein activation.
Whooping Cough
Structural requirements of platelet chemokines for neutrophil activation.
Whooping Cough
Structurally different lysophosphatidylethanolamine species stimulate neurite outgrowth in cultured cortical neurons via distinct G-protein-coupled receptors and signaling cascades.
Whooping Cough
Structure and compositional analysis of aluminum oxyhydroxide adsorbed pertussis vaccine.
Whooping Cough
Structure and stability of pertussis toxin studied by in situ atomic force microscopy.
Whooping Cough
Structure of a pertussis toxin-sugar complex as a model for receptor binding.
Whooping Cough
Structure-activity analysis of the activation of pertussis toxin.
Whooping Cough
Structure-activity relationship and signal transduction of gamma-MSH peptides in GH3 cells: further evidence for a new melanocortin receptor.
Whooping Cough
Structure-activity relationship of adrenomedullin, a novel vasodilatory peptide, in cultured rat vascular smooth muscle cells.
Whooping Cough
Structure-function analyses of a pertussis-like toxin from pathogenic Escherichia coli reveal a distinct mechanism of inhibition of trimeric G-proteins.
Whooping Cough
Structure-function analysis of Frizzleds.
Whooping Cough
Structure-function relationship of islet-activating protein, pertussis toxin: biological activities of hybrid toxins reconstituted from native and methylated subunits.
Whooping Cough
Structure-function relationships among human cathelicidin peptides: dissociation of antimicrobial properties from host immunostimulatory activities.
Whooping Cough
Structure/function relationships of calcitonin analogues as agonists, antagonists, or inverse agonists in a constitutively activated receptor cell system.
Whooping Cough
Studies of melatonin effects on epithelia using the human embryonic kidney-293 (HEK-293) cell line.
Whooping Cough
Studies of signal transduction in the respiratory burst-associated stimulation of fMet-Leu-Phe-induced tubulin tyrosinolation and phorbol 12-myristate 13-acetate-induced posttranslational incorporation of tyrosine into multiple proteins in activated neutrophils and HL-60 cells.
Whooping Cough
Studies of the antigenic structure of two cross-reacting proteins, pertussis and cholera toxins, using synthetic peptides.
Whooping Cough
Studies of the cellular mechanisms underlying the vasorelaxant effects of rutaecarpine, a bioactive component extracted from an herbal drug.
Whooping Cough
Studies of the renal action of melatonin: evidence that the effects are mediated by 37 kDa receptors of the Mel1a subtype localized primarily to the basolateral membrane of the proximal tubule.
Whooping Cough
Studies on molecular regulation of phagocytosis in neutrophils. Con A-mediated ingestion and associated respiratory burst independent of phosphoinositide turnover, rise in [Ca2+]i, and arachidonic acid release.
Whooping Cough
Studies on nucleotide and receptor regulation of Gi proteins: effects of pertussis toxin.
Whooping Cough
Studies on opsonized zymozan, FMLP, carbachol, PMA and A23187 stimulated respiratory burst of human PMNLs.
Whooping Cough
STUDIES ON PERTUSSIS TOXIN.
Whooping Cough
Studies on phase variation in Bordetella pertussis.
Whooping Cough
Studies on primed precursors of effector T cells involved in delayed-type hypersensitivity to sheep red blood cells in mice.
Whooping Cough
Studies on prn variation in the mouse model and comparison with epidemiological data.
Whooping Cough
Studies on pyrazinoylguanidine. 3. Downregulation of lipolysis in isolated adipocytes.
Whooping Cough
Studies on the activation of human neutrophil 5-lipoxygenase induced by natural agonists and Ca2+ ionophore A23187.
Whooping Cough
Studies on the cell-cycle dependency of the actions of insulin-like growth factor-I in Balb/c 3T3 cells.
Whooping Cough
Studies on the characterization of the subtype(s) of muscarinic receptor involved in prostacyclin synthesis in rabbit cardiomyocytes.
Whooping Cough
Studies on the lymphocytosis induced by pertussis toxin.
Whooping Cough
Studies on the mechanism of desensitization of the cyclic AMP response to TSH stimulation in a cloned rat thyroid cell line.
Whooping Cough
Studies on the mechanism of uptake of low density lipoprotein-proteoglycan complex in macrophages.
Whooping Cough
Studies on the mechanisms of signalling and inhibition by pertussis toxin of fibroblast growth factor-stimulated mitogenesis in Balb/c 3T3 cells.
Whooping Cough
Study of the activation mechanism of adriamycin on rat mast cells.
Whooping Cough
Study of the activation mechanism of human GRF(1-29)NH2 on rat mast cell histamine release.
Whooping Cough
Study of the functional organization of a novel adenylate cyclase signaling mechanism of insulin action.
Whooping Cough
Study of the phorbol ester effect on Alzheimer amyloid precursor processing: sequence requirements and involvement of a cholera toxin sensitive protein.
Whooping Cough
Study protocol of the PIMPI-project, a cohort study on acceptance, tolerability and immunogenicity of second trimester maternal pertussis immunization in relation to term and preterm infants.
Whooping Cough
Subcellular distribution and characterization of GTP-binding proteins in human neutrophils.
Whooping Cough
Subcellular distribution and membrane association of human neutrophil substrates for ADP-ribosylation by pertussis toxin and cholera toxin.
Whooping Cough
Subcellular localization and kinetic characterization of guanine nucleotide binding proteins in normal rat and human pancreatic islets and transformed beta cells.
Whooping Cough
Subcellular localization and quantitation of the major neutrophil pertussis toxin substrate, Gn.
Whooping Cough
Subcellular localization of Gi alpha in human neutrophils.
Whooping Cough
Subcellular mechanisms of angiotensin II and arginine vasopressin activation of area postrema neurons.
Whooping Cough
Subcellular patterns of calcium release determined by G protein-specific residues of muscarinic receptors.
Whooping Cough
Subclass compositions of immunoglobulin G to pertussis toxin in patients with whooping cough, in healthy individuals, and in recipients of a pertussis toxoid vaccine.
Whooping Cough
Subclinical pertussis in incompletely vaccinated and unvaccinated infants.
Whooping Cough
Subcutaneous administration of a fusion protein composed of pertussis toxin and filamentous hemagglutinin from Bordetella pertussis induces mucosal and systemic immune responses.
Whooping Cough
Subcutaneous Immunization with Recombinant Lactococcus lactis Expressing F1S1 Fusion Protein Induces Systemic and Mucosal Immune Responses in BALB/C Mice.
Whooping Cough
Submandibular enzymatic vasoconstrictor increases DNA and phosphoinositol synthesis by mesenchymal cells.
Whooping Cough
Substance P activates the release of histamine from human skin mast cells through a pertussis toxin-sensitive and protein kinase C-dependent mechanism.
Whooping Cough
Substance P and somatostatin inhibit calcium channels in rat sympathetic neurons via different G protein pathways.
Whooping Cough
Substance P modulates sensory action potentials in the lamprey via a protein kinase C-mediated reduction of a 4-aminopyridine-sensitive potassium conductance.
Whooping Cough
Substance P stimulation of polyphosphoinositide hydrolysis in rat anterior pituitary membranes involves a GTP-dependent mechanism.
Whooping Cough
Substance P suppresses GABAA receptor function via protein kinase C in primary sensory neurones of bullfrogs.
Whooping Cough
Substance P-induced activation of p42/44 mitogen-activated protein kinase associated with cell proliferation in human tracheal smooth muscle cells.
Whooping Cough
Substance P-related inhibitors of mast cell exocytosis act on G-proteins or on the cell surface.
Whooping Cough
Substantial gaps in knowledge of Bordetella pertussis antibody and T cell epitopes relevant for natural immunity and vaccine efficacy.
Whooping Cough
Subtype specific roles of beta-adrenergic receptors in apoptosis of adult rat ventricular myocytes.
Whooping Cough
Subtype-specific coupling with ADP-ribosyl cyclase of metabotropic glutamate receptors in retina, cervical superior ganglion and NG108-15 cells.
Whooping Cough
Subtype-specific increase in G-protein alpha-subunit mRNA by interleukin 1 beta.
Whooping Cough
Subtype-specific signaling mechanisms of somatostatin receptors SSTR1 and SSTR2.
Whooping Cough
Subtypes of adrenergic receptors and intracellular mechanisms involved in modulatory effects of noradrenaline on glutamate.
Whooping Cough
Subtypes of Guanine-Nucleotide-Binding Regulatory Proteins at the Locus coeruleus Involved in Fentanyl-Induced Muscular Rigidity in the Rat.
Whooping Cough
Subunit interactions of native and ADP-ribosylated alpha 39 and alpha 41, two guanine nucleotide-binding proteins from bovine cerebral cortex.
Whooping Cough
Subunit S1 of pertussis toxin: mapping of the regions essential for ADP-ribosyltransferase activity.
Whooping Cough
Subunit structure and enzymic activity of pertussis toxin.
Whooping Cough
Subunit structure of islet-activating protein, pertussis toxin, in conformity with the A-B model.
Whooping Cough
Subunits beta gamma of heterotrimeric G protein activate beta 2 isoform of phospholipase C.
Whooping Cough
Succinate receptor GPR91, a G?(i) coupled receptor that increases intracellular calcium concentrations through PLC?.
Whooping Cough
Sulfatides trigger increase of cytosolic free calcium and enhanced expression of tumor necrosis factor-alpha and interleukin-8 mRNA in human neutrophils. Evidence for a role of L-selectin as a signaling molecule.
Whooping Cough
Sulfhydryl G proteins and phospholipase A(2)-associated G proteins are involved in adrenergic signal transduction in the rat pineal gland.
Whooping Cough
Sulfhydryl-alkylating reagents inactivate the NAD glycohydrolase activity of pertussis toxin.
Whooping Cough
Sulfite induces adherence of polymorphonuclear neutrophils to immobilized fibrinogen through activation of Mac-1 beta2-integrin (CD11b/CD18).
Whooping Cough
Superoxide production from human polymorphonuclear leukocytes by human mannan-binding protein (MBP).
Whooping Cough
Superoxide responses of endothelial cells to C5a and TNF-alpha: divergent signal transduction pathways.
Whooping Cough
Supersensitivity of isolated atria from diabetic rats to adenosine and methacholine: modulation by pertussis toxin.
Whooping Cough
Supersensitivity to mu-opioid receptor-mediated inhibition of the adenylyl cyclase pathway involves pertussis toxin-resistant Galpha protein subunits.
Whooping Cough
Supersensitization of the adenylyl cyclase system in Chinese hamster ovary cells co-expressing cloned opioid receptors and Gz, a PTX-insensitive G protein.
Whooping Cough
Suppressing effect of pertussis toxin on clonidine-induced inhibition of noradrenaline release from cerebral cortical slices of rats.
Whooping Cough
Suppression of a nonselective cation conductance by substance P in cochlear outer hair cells.
Whooping Cough
Suppression of cAMP by phosphoinositol/Ca2+ pathway in the cardiac kappa-opioid receptor.
Whooping Cough
Suppression of cyclic GMP-dependent protein kinase is essential to the Wnt/cGMP/Ca2+ pathway.
Whooping Cough
Suppression of cytoskeletal rearrangement in activated human neutrophils by botulinum C2 toxin. Impact on cellular signal transduction.
Whooping Cough
Suppression of insulin release by galanin and somatostatin is mediated by a G-protein. An effect involving repolarization and reduction in cytoplasmic free Ca2+ concentration.
Whooping Cough
Suppression of kindled seizure following intraamygdaloid injection of pertussis toxin in rats.
Whooping Cough
Suppression of lymphocyte adenosine 3':5'-cyclic monophosphate (cAMP) by delta-9-tetrahydrocannabinol.
Whooping Cough
Suppression of passive cutaneous anaphylaxis by pertussis toxin, an islet-activating protein, as a result of inhibition of histamine release from mast cells.
Whooping Cough
Suppression of serum antibody responses by pertussis toxin after respiratory tract colonization by Bordetella pertussis and identification of an immunodominant lipoprotein.
Whooping Cough
Suppression of the carbachol-activated nonselective cationic current by antibody against alpha subunit of Go protein in guinea-pig gastric myocytes.
Whooping Cough
Suppression of the cytotoxic T-lymphocyte response in mice by pertussis toxin.
Whooping Cough
Suppression of the humoral immune response by cannabinoids is partially mediated through inhibition of adenylate cyclase by a pertussis toxin-sensitive G-protein coupled mechanism.
Whooping Cough
Suppression of the Peripheral Immune System Limits the Central Immune Response Following Cuprizone-Feeding: Relevance to Modelling Multiple Sclerosis.
Whooping Cough
Suppression of the voltage-gated K+ current of human megakaryocytes by thrombin and prostacyclin.
Whooping Cough
Suramin has adjuvant properties and promotes expansion of antigen-specific Th1 and Th2 cells in vivo.
Whooping Cough
Surface expression of a protective recombinant pertussis toxin S1 subunit fragment in Streptococcus gordonii.
Whooping Cough
Surface proteins of Bordetella pertussis.
Whooping Cough
Surface proteins of Bordetella pertussis: comparison of virulent and avirulent strains and effects of phenotypic modulation.
Whooping Cough
Survey of pertussis in patients with prolonged cough.
Whooping Cough
Sustained activation of phospholipase D via adenosine A3 receptors is associated with enhancement of antigen- and Ca(2+)-ionophore-induced secretion in a rat mast cell line.
Whooping Cough
Sustained efficacy during the first 6 years of life of 3-component acellular pertussis vaccines administered in infancy: the Italian experience.
Whooping Cough
Sustained MAP kinase activation is required for the expression of cyclin D1, p21Cip1 and a subset of AP-1 proteins in CCL39 cells.
Whooping Cough
Swimming behavior regulation by GABAB receptors in Paramecium.
Whooping Cough
Sympathetic denervation-induced changes in G protein expression in enteric neurons of the guinea pig colon.
Whooping Cough
Sympathetic neural and alpha-adrenergic modulation of arrhythmias.
Whooping Cough
Sympathetic--parasympathetic interaction and sudden death.
Whooping Cough
Synergic effect of genotype changes in pertussis toxin and pertactin on adaptation to an acellular pertussis vaccine in the murine intranasal challenge model.
Whooping Cough
Synergism among lysophosphatidic acid, beta1A integrins, and epidermal growth factor or platelet-derived growth factor in mediation of cell migration.
Whooping Cough
Synergism in cytosolic Ca2+ mobilization between bradykinin and agonists for pertussis toxin-sensitive G-protein-coupled receptors in NG 108-15 cells.
Whooping Cough
Synergistic binding of RNA polymerase and BvgA phosphate to the pertussis toxin promoter of Bordetella pertussis.
Whooping Cough
Synergistic BM-DC activation and immune induction by the oral vaccine vector Streptococcus gordonii and exogenous tumor necrosis factor.
Whooping Cough
Synergistic effects of ATP on oxytocin-induced intracellular Ca2+ response in mouse mammary myoepithelial cells.
Whooping Cough
Synergistic increase in Ca2+ produced by A1 adenosine and muscarinic receptor activation via a pertussis-toxin-sensitive pathway in epithelial cells of the rabbit ciliary body.
Whooping Cough
Synergistic interaction of morphine and halothane in the guinea pig ileum: effects of pertussis toxin.
Whooping Cough
Synergistic interaction of muscarinic and opioid receptors with GS-linked neurotransmitter receptors to stimulate adenylyl cyclase activity of rat olfactory bulb.
Whooping Cough
Synergistic interaction of Y1-neuropeptide Y and alpha 1b-adrenergic receptors in the regulation of phospholipase C, protein kinase C, and arachidonic acid production.
Whooping Cough
Synergistic neutralization of pertussis toxin by a bispecific antibody in vitro and in vivo.
Whooping Cough
Synergistic regulation of cytosolic Ca2+ concentration in mouse astrocytes by NK1 tachykinin and adenosine agonists.
Whooping Cough
Synergistic rise in Ca2+ produced by somatostatin and acetylcholine in ciliary body epithelial cells.
Whooping Cough
Synergistic stimulation of airway smooth muscle cell mitogenesis.
Whooping Cough
Synergistic teratogenic effect produced in mice by whole cell pertussis vaccine.
Whooping Cough
Synergy between phorbol esters, 1-oleyl-2-acetylglycerol, urushiol, and calcium ionophore in eliciting aggregation of marine sponge cells.
Whooping Cough
Synergy between the inositol phosphate responses to transfected human adenosine A1-receptors and constitutive P2-purinoceptors in CHO-K1 cells.
Whooping Cough
Synthesis and characterization of a Pertussis toxin-biotin conjugate.
Whooping Cough
Synthesis and characterization of fluorescently labeled bovine brain G protein subunits.
Whooping Cough
Synthesis of a conjugate vaccine composed of pneumococcus type 14 capsular polysaccharide bound to pertussis toxin.
Whooping Cough
Synthesis of phosphatidylinositol 3,4,5-trisphosphate in permeabilized neutrophils regulated by receptors and G-proteins.
Whooping Cough
Synthetic Lethal Screens Identify Vulnerabilities in GPCR Signaling and Cytoskeletal Organization in E-Cadherin-Deficient Cells.
Whooping Cough
Systemic allergic reactions to gelatin included in vaccines as a stabilizer.
Whooping Cough
Systemic exposure to a single dose of ferucarbotran aggravates neuroinflammation in a murine model of experimental autoimmune encephalomyelitis.
Whooping Cough
Systemic Mesenchymal Stem Cell Treatment Mitigates Structural and Functional Retinal Ganglion Cell Degeneration in a Mouse Model of Multiple Sclerosis.
Whooping Cough
Systemic ocular antigen immunization leads only to a minor secondary immune response.
Whooping Cough
T cell activation via the T cell receptor: a comparison between WT31 (defining alpha/beta TcR)-induced and anti-CD3-induced activation of human T lymphocytes.
Whooping Cough
T cell and chemokine receptors differentially control CD8 T cell motility behavior in the infected airways immediately before and after virus clearance in a primary infection.
Whooping Cough
T cell homeostasis requires G protein-coupled receptor-mediated access to trophic signals that promote growth and inhibit chemotaxis.
Whooping Cough
T cell lines specific for an immunodominant epitope of human basic protein define an encephalitogenic determinant for experimental autoimmune encephalomyelitis-resistant LOU/M rats.
Whooping Cough
T cell mechanisms in experimental autoimmune uveoretinitis: susceptibility is a function of the cytokine response profile.
Whooping Cough
T cell-derived suppressive activity: evidence of autocrine noncytolytic control of HIV type 1 transcription and replication.
Whooping Cough
T-cell immune response assessment as a complement to serology and intranasal protection assays in determining the protective immunity induced by acellular pertussis vaccines in mice.
Whooping Cough
Tachykinins cause inward current through NK1 receptors in bullfrog sensory neurons.
Whooping Cough
TAN-67, a delta 1-opioid receptor agonist, reduces infarct size via activation of Gi/o proteins and KATP channels.
Whooping Cough
Tannin stimulates arachidonic acid release from bovine tracheal epithelial cells.
Whooping Cough
Targeted inactivation of alphai2 or alphai3 disrupts activation of the cardiac muscarinic K+ channel, IK+Ach, in intact cells.
Whooping Cough
Targeting CLA/E-selectin interactions prevents CCR4-mediated recruitment of human Th2 memory cells to human skin in vivo.
Whooping Cough
Targeting Gi/o protein-coupled receptor signaling blocks HER2-induced breast cancer development and enhances HER2-targeted therapy.
Whooping Cough
Targeting V1A-vasopressin receptors with [Arg6, D-Trp7,9, NmePhe8]-substance P (6-11) identifies a strategy to develop novel anti-cancer therapies.
Whooping Cough
Targets for TNF-alpha-induced lipolysis in human adipocytes.
Whooping Cough
Tauopathy-like abnormalities and neurologic deficits in mice immunized with neuronal tau protein.
Whooping Cough
Tax-inducible production of CC chemokine ligand 22 by human T cell leukemia virus type 1 (HTLV-1)-infected T cells promotes preferential transmission of HTLV-1 to CCR4-expressing CD4+ T cells.
Whooping Cough
Tdap booster to adolescents with juvenile idiopathic arthritis on and off anti-TNF agents is safe and immunogenic.
Whooping Cough
Tdap(5) vaccine (covaxis®): a review of its use as a single-booster immunization for the prevention of tetanus, diphtheria, and pertussis in children (aged ?4 years), adolescents, and adults.
Whooping Cough
Temperature-dependent stimulation and inhibition of adenylate cyclase by Aplysia bag cell peptides.
Whooping Cough
Temporal expression of pertussis toxin and Ptl secretion proteins by Bordetella pertussis.
Whooping Cough
Temporal nucleotide changes in pertactin and pertussis toxin genes in Bordetella pertussis strains isolated from clinical cases in Poland.
Whooping Cough
Temporal trends in circulating Bordetella pertussis strains in Australia.
Whooping Cough
Temporally Coarse-Grained All-Atom Molecular Dynamics Achieved via Stochastic Padé Approximants.
Whooping Cough
Terminal serotonin autoreceptor function in the rat hippocampus is not modified by pertussis and cholera toxins.
Whooping Cough
Testicular expression of Adora3i2 in Adora3 knockout mice reveals a role of mouse A3Ri2 and human A3Ri3 adenosine receptors in sperm.
Whooping Cough
Testing implications of varying targets for Bordetella pertussis: comparison of the FilmArray Respiratory Panel and the Focus B. pertussis PCR assay.
Whooping Cough
Testosterone induces an intracellular calcium increase by a nongenomic mechanism in cultured rat cardiac myocytes.
Whooping Cough
Testosterone modulates K(+)ATP channels in sertoli cell membrane via the PLC-PIP2 pathway.
Whooping Cough
Testosterone rapidly increases Ca(2+)-activated K(+) currents causing hyperpolarization in human coronary artery endothelial cells.
Whooping Cough
Testosterone signaling through internalizable surface receptors in androgen receptor-free macrophages.
Whooping Cough
Testosterone stimulates intracellular calcium release and mitogen-activated protein kinases via a G protein-coupled receptor in skeletal muscle cells.
Whooping Cough
Tethering of the platelet-derived growth factor beta receptor to G-protein-coupled receptors. A novel platform for integrative signaling by these receptor classes in mammalian cells.
Whooping Cough
Tetrahydrocannabinol-induced apoptosis of cultured cortical neurones is associated with cytochrome c release and caspase-3 activation.
Whooping Cough
Tetrahydrocannabinol-induced neurotoxicity depends on CB1 receptor-mediated c-Jun N-terminal kinase activation in cultured cortical neurons.
Whooping Cough
TG1019/OXE, a Galpha(i/o)-protein-coupled receptor, mediates 5-oxo-eicosatetraenoic acid-induced chemotaxis.
Whooping Cough
TGF-beta-induced G2/M delay in proliferating rabbit articular chondrocytes is associated with an enhancement of replication rate and a cAMP decrease: possible involvement of pertussis toxin-sensitive pathway.
Whooping Cough
Thapsigargin activates univalent- and bivalent-cation entry in human neutrophils by a SK&F I3 96365- and Gd3+-sensitive pathway and is a partial secretagogue: involvement of pertussis-toxin-sensitive G-proteins and protein phosphatases 1/2A and 2B in the signal-transduction pathway.
Whooping Cough
Thapsigargin and receptor-mediated activation of Drosophila TRPL channels stably expressed in a Drosophila S2 cell line.
Whooping Cough
The 112-Year Odyssey of Pertussis and Pertussis Vaccines-Mistakes Made and Implications for the Future.
Whooping Cough
The 20 kDa C-terminally truncated form of pertussis toxin subunit S1 secreted from Bacillus subtilis.
Whooping Cough
The 5-HT1D receptor antagonist GR-127,935 prevents inhibitory effects of sumatriptan but not CP-122,288 and 5-CT on neurogenic plasma extravasation within guinea pig dura mater.
Whooping Cough
The 5-HT4 receptor antagonist ML10375 inhibits the constitutive activity of human 5-HT4(c) receptor.
Whooping Cough
The 70-kilodalton pertussis toxin-binding protein in Jurkat cells.
Whooping Cough
The A protomer of islet-activating protein, pertussis toxin, as an active peptide catalyzing ADP-ribosylation of a membrane protein.
Whooping Cough
The action is at the terminal.
Whooping Cough
The action mode of lysophosphatidylcholine in human monocytes.
Whooping Cough
The action of 5-HT on calcium-dependent potassium channels and on the spinal locomotor network in lamprey is mediated by 5-HT1A-like receptors.
Whooping Cough
The action of islet activating protein (pertussis toxin) on insulin's ability to inhibit adenylate cyclase and activate cyclic AMP phosphodiesterases in hepatocytes.
Whooping Cough
The action of pertussis toxin on heart adenylate cyclase and lipolysis in the parametrial adipose tissue of the rat.
Whooping Cough
The actions of Pasteurella multocida toxin on neuronal cells.
Whooping Cough
The activation of ?2-adrenergic receptor in the spinal cord lowers sepsis-induced mortality.
Whooping Cough
The activation of human platelets mediated by anti-human platelet p24/CD9 monoclonal antibodies.
Whooping Cough
The activity of purified Bordetella pertussis components in murine encephalopathy.
Whooping Cough
The acute and chronic stimulatory effects of endothelin-1 on glucose transport are mediated by distinct pathways in 3T3-L1 adipocytes.
Whooping Cough
The adenosine/neutrophil paradox resolved: human neutrophils possess both A1 and A2 receptors that promote chemotaxis and inhibit O2 generation, respectively.
Whooping Cough
The adenylyl cyclase-cyclic AMP system modulates morphological and functional development of hypothalamic beta-endorphin neurons in culture.
Whooping Cough
The adipocyte Go alpha-immunoreactive polypeptide is different from the alpha subunit of the brain Go protein.
Whooping Cough
The agonist effect of Bay K 8644 on neuronal calcium channel currents is promoted by G-protein activation.
Whooping Cough
The allosteric enhancer PD81,723 increases chimaeric A1/A2A adenosine receptor coupling with Gs.
Whooping Cough
The amino terminus of G protein alpha subunits is required for interaction with beta gamma.
Whooping Cough
The anaphylatoxin C3a primes model colonic epithelial cells for expression of inflammatory mediators through G?i.
Whooping Cough
The angiotensin II type 2 receptor primarily inhibits cell growth via pertussis toxin-sensitive G proteins.
Whooping Cough
The anti-adrenergic effect of adenosine and its blockade by pertussis toxin: a comparative study in myocytes isolated from guinea-pig, rat and failing human hearts.
Whooping Cough
The anti-apoptotic activity associated with phosphatidylinositol transfer protein alpha activates the MAPK and Akt/PKB pathway.
Whooping Cough
The anti-apoptotic activity of albumin for endothelium is mediated by a partially cryptic protein domain and reduced by inhibitors of G-coupled protein and PI-3 kinase, but is independent of radical scavenging or bound lipid.
Whooping Cough
The anti-infective peptide, innate defense-regulator peptide, stimulates neutrophil chemotaxis via a formyl peptide receptor.
Whooping Cough
The antiadrenergic effect of neuropeptide Y on the ventricular cardiomyocyte.
Whooping Cough
The antiapoptotic effect of guanosine is mediated by the activation of the PI 3-kinase/AKT/PKB pathway in cultured rat astrocytes.
Whooping Cough
The antiarrhythmic action of ischaemic preconditioning in rat hearts does not involve functional Gi proteins.
Whooping Cough
The antiarrhythmic effect of ischaemic preconditioning in isolated rat heart involves a pertussis toxin sensitive mechanism.
Whooping Cough
The antibodies against Bordetella pertussis in sera of patients with Parkinson's disease and other non-neurological diseases.
Whooping Cough
The antineoplastic drug vinorelbine activates non-immunological histamine release from rat mast cells.
Whooping Cough
The association between angiotensin II-induced free radical generation and membrane fluidity in neutrophils of patients with metabolic syndrome.
Whooping Cough
The association of heterotrimeric GTP-binding protein (Go) with microtubules.
Whooping Cough
The atherogenic actions of LPC on vascular smooth muscle cells and its LPA receptor mediated mechanism.
Whooping Cough
The autotaxin-LPA2 GPCR axis is modulated by ?-irradiation and facilitates DNA damage repair.
Whooping Cough
The B subunit of an AB5 toxin produced by Salmonella enterica serovar Typhi up-regulates chemokines, cytokines, and adhesion molecules in human macrophage, colonic epithelial, and brain microvascular endothelial cell lines.
Whooping Cough
The B-oligomer of pertussis toxin deactivates CC chemokine receptor 5 and blocks entry of M-tropic HIV-1 strains.
Whooping Cough
The B-oligomer of pertussis toxin inhibits human immunodeficiency virus type 1 replication at multiple stages.
Whooping Cough
The beneficial effects of 18?-glycyrrhetinic acid on the experimental autoimmune encephalomyelitis (EAE) in C57BL/6 mouse model.
Whooping Cough
The beta(2)-adrenergic receptor delivers an antiapoptotic signal to cardiac myocytes through G(i)-dependent coupling to phosphatidylinositol 3'-kinase.
Whooping Cough
The beta-amyloid precursor protein controls a store-operated Ca2+ entry in cortical neurons.
Whooping Cough
The Beta-Arrestin-Biased Dopamine D2 Receptor Ligand, UNC9994, Is a Partial Agonist at G-Protein-Mediated Potassium Channel Activation.
Whooping Cough
The beta1-adrenergic receptor mediates extracellular signal-regulated kinase activation via Galphas.
Whooping Cough
The beta2-adrenergic receptor specifically sequesters Gs but signals through both Gs and Gi/o in rat sympathetic neurons.
Whooping Cough
The beta3-adrenergic receptor activates mitogen-activated protein kinase in adipocytes through a Gi-dependent mechanism.
Whooping Cough
The beta3-adrenoceptor agonist 4-[[(Hexylamino)carbonyl]amino]-N-[4-[2-[[(2S)-2-hydroxy-3-(4-hydroxyphenoxy)propyl]amino]ethyl]-phenyl]-benzenesulfonamide (L755507) and antagonist (S)-N-[4-[2-[[3-[3-(acetamidomethyl)phenoxy]-2-hydroxypropyl]amino]-ethyl]phenyl]benzenesulfonamide (L748337) activate different signaling pathways in Chinese hamster ovary-K1 cells stably expressing the human beta3-adrenoceptor.
Whooping Cough
The beta6/alpha5 regions of Galphai2 and GalphaoA increase the promiscuity of Galpha16 but are insufficient for pertussis toxin-catalyzed ADP-ribosylation.
Whooping Cough
The binding subunit of pertussis toxin inhibits HIV replication in human macrophages and virus expression in chronically infected promonocytic U1 cells.
Whooping Cough
The binding subunit of pertussis toxin inhibits IL-1 induction of IL-2 and prostaglandin production.
Whooping Cough
The biochemical effect of the naturally occurring Trp64-->Arg mutation on human beta3-adrenoceptor activity.
Whooping Cough
The biological activity of the corticotropin-releasing hormone receptor-adenylate cyclase complex in human myometrium is reduced at the end of pregnancy.
Whooping Cough
The bombesin receptor is coupled to a guanine nucleotide-binding protein which is insensitive to pertussis and cholera toxins.
Whooping Cough
The bradykinin B2 receptor couples less efficiently than the angiotensin AT1 receptor to the G protein Gq in transiently transfected COS-7 cells.
Whooping Cough
The bradykinin receptor--a putative receptor-operated channel in PC12 cells: studies of neurotransmitter release and inositol phosphate accumulation.
Whooping Cough
The brain specific Ras exchange factor CDC25 Mm: modulation of its activity through Gi-protein-mediated signals.
Whooping Cough
The Burden of Pertussis in Patients with and without Recurrent Ischaemic Vascular Events.
Whooping Cough
The Bvg accessory factor (Baf) enhances pertussis toxin expression in Escherichia coli and is essential for Bordetella pertussis viability.
Whooping Cough
The bvgA gene of Bordetella pertussis encodes a transcriptional activator required for coordinate regulation of several virulence genes.
Whooping Cough
The C terminus of the human C5a receptor (CD88) is required for normal ligand-dependent receptor internalization.
Whooping Cough
The C-class chemokine, lymphotactin, impairs the induction of Th1-type lymphokines in human CD4(+) T cells.
Whooping Cough
The C-terminal domain of the Gs-coupled EP4 receptor confers agonist-dependent coupling control to Gi but no coupling to Gs in a receptor hybrid with the Gi-coupled EP3 receptor.
Whooping Cough
The C-Type Natriuretic Peptide Induces Thermal Hyperalgesia through a Noncanonical G??-dependent Modulation of TRPV1 Channel.
Whooping Cough
The Ca(2+)-dependent activation by fluoride of human red cell membrane sodium permeability: evidence for a chemically activated tetrodotoxin-sensitive Na+ channel.
Whooping Cough
The Ca2+ influx induced by beta-amyloid peptide 25-35 in cultured hippocampal neurons results from network excitation.
Whooping Cough
The Ca2+-sensing receptor activates cytosolic phospholipase A2 via a Gqalpha -dependent ERK-independent pathway.
Whooping Cough
The Ca2+-sensing receptor couples to Galpha12/13 to activate phospholipase D in Madin-Darby canine kidney cells.
Whooping Cough
The calcitonin receptor stimulates Shc tyrosine phosphorylation and Erk1/2 activation. Involvement of Gi, protein kinase C, and calcium.
Whooping Cough
The calcium-sensing receptor regulates calcium absorption in MDCK cells by inhibition of PMCA.
Whooping Cough
The calcium-sensing receptor stimulates JNK in MDCK cells.
Whooping Cough
The cAMP assay: a functional in vitro alternative to the in vivo Histamine Sensitization test.
Whooping Cough
The canine mast cell activation via CRP.
Whooping Cough
The cannabinoid agonist DALN positively modulates L-type voltage-dependent calcium-channels in N18TG2 neuroblastoma cells.
Whooping Cough
The cannabinoid agonist WIN55,212-2 increases intracellular calcium via CB1 receptor coupling to Gq/11 G proteins.
Whooping Cough
The cannabinoid receptor: biochemical and cellular properties in neuroblastoma cells.
Whooping Cough
The cannabinoid WIN 55,212-2 inhibits transient receptor potential vanilloid 1 (TRPV1) and evokes peripheral antihyperalgesia via calcineurin.
Whooping Cough
The carboxyl terminus of the S1 subunit of pertussis toxin confers high affinity binding to transducin.
Whooping Cough
The CART receptors: background and recent advances.
Whooping Cough
The CB(1) cannabinoid receptor is coupled to the activation of c-Jun N-terminal kinase.
Whooping Cough
The CB(1) cannabinoid receptor of astrocytes is coupled to sphingomyelin hydrolysis through the adaptor protein fan.
Whooping Cough
The CB1 cannabinoid receptor is coupled to the activation of protein kinase B/Akt.
Whooping Cough
The CB1 endocannabinoid system modulates adipocyte insulin sensitivity.
Whooping Cough
The CC chemokine monocyte chemotactic peptide-1 activates both the class I p85/p110 phosphatidylinositol 3-kinase and the class II PI3K-C2alpha.
Whooping Cough
The cell mediated and humoral immune response to vaccination with acellular and whole cell pertussis vaccine in adult humans.
Whooping Cough
The cellular and molecular basis of bitter tastant-induced bronchodilation.
Whooping Cough
The central analgesia induced by antimigraine drugs is independent from Gi proteins: superiority of a fixed combination of indomethacin, prochlorperazine and caffeine, compared to sumatriptan, in an in vivo model.
Whooping Cough
The central cannabinoid receptor (CB1) mediates inhibition of nitric oxide production by rat microglial cells.
Whooping Cough
The CGRP receptor can couple via pertussis toxin sensitive and insensitive G proteins.
Whooping Cough
The chemokine CCL2 increases Nav1.8 sodium channel activity in primary sensory neurons through a G??-dependent mechanism.
Whooping Cough
The chemokine CX3CL1 reduces migration and increases adhesion of neurons with mechanisms dependent on the beta1 integrin subunit.
Whooping Cough
The chemokine CXCL13 is a key regulator of B cell recruitment to the cerebrospinal fluid in acute Lyme neuroborreliosis.
Whooping Cough
The chemokine CXCL14 (BRAK) stimulates activated NK cell migration: implications for the downregulation of CXCL14 in malignancy.
Whooping Cough
The chemokine KC, but not monocyte chemoattractant protein-1, triggers monocyte arrest on early atherosclerotic endothelium.
Whooping Cough
The chemokine RANTES is more than a chemoattractant: characterization of its effect on human eosinophil oxidative metabolism and morphology in comparison with IL-5 and GM-CSF.
Whooping Cough
The chemokine receptor CCR8 mediates human endothelial cell chemotaxis induced by I-309 and Kaposi sarcoma herpesvirus-encoded vMIP-I and by lipoprotein(a)-stimulated endothelial cell conditioned medium.
Whooping Cough
The chemokine receptor CXCR4 enhances integrin-mediated in vitro adhesion and facilitates engraftment of leukemic precursor-B cells in the bone marrow.
Whooping Cough
The chemokine receptor CXCR4 is expressed within the mast cell lineage and its ligand stromal cell-derived factor-1alpha acts as a mast cell chemotaxin.
Whooping Cough
The chemokine receptor CXCR4 is required for outgrowth of colon carcinoma micrometastases.
Whooping Cough
The chemokine receptor CXCR6 and its ligand CXCL16 are expressed in carcinomas and inhibit proliferation.
Whooping Cough
The chemokine SDF-1 is a chemoattractant for human CD34+ hematopoietic progenitor cells and provides a new mechanism to explain the mobilization of CD34+ progenitors to peripheral blood.
Whooping Cough
The chemokine stromal cell-derived factor-1 alpha modulates alpha 4 beta 7 integrin-mediated lymphocyte adhesion to mucosal addressin cell adhesion molecule-1 and fibronectin.
Whooping Cough
The chemokines CXCL9, CXCL10, and CXCL11 differentially stimulate G alpha i-independent signaling and actin responses in human intestinal myofibroblasts.
Whooping Cough
The chemotactic cytokine eotaxin acts as a granulocyte-macrophage colony-stimulating factor during lung inflammation.
Whooping Cough
The chromogranin A peptide vasostatin-I inhibits gap formation and signal transduction mediated by inflammatory agents in cultured bovine pulmonary and coronary arterial endothelial cells.
Whooping Cough
The chromogranin A-derived peptides vasostatin-I and catestatin as regulatory peptides for cardiovascular functions.
Whooping Cough
The chromosomal nature of LT-II enterotoxins solved: a lambdoid prophage encodes both LT-II and one of two novel pertussis-toxin-like toxin family members in type II enterotoxigenic Escherichia coli.
Whooping Cough
The class III antiarrhythmic drug amiodarone directly activates pertussis toxin-sensitive G proteins.
Whooping Cough
The cloned human 5-HT1E receptor couples to inhibition and activation of adenylyl cyclase via two distinct pathways in transfected BS-C-1 cells.
Whooping Cough
The cloned kappa opioid receptor couples to an N-type calcium current in undifferentiated PC-12 cells.
Whooping Cough
The cloned platelet thrombin receptor couples to at least two distinct effectors to stimulate phosphoinositide hydrolysis and inhibit adenylyl cyclase.
Whooping Cough
The cloned thrombin receptor is necessary and sufficient for activation of mitogen-activated protein kinase and mitogenesis in mouse lung fibroblasts. Loss of responses in fibroblasts from receptor knockout mice.
Whooping Cough
The combined 5-HT2 receptor and calcium channel inhibitor LU49938 restores endothelium dependent responses in the regenerated endothelium of the porcine coronary artery.
Whooping Cough
The comparative analysis of proenkephalin mRNA expression induced by cholera toxin and pertussis toxin in primary cultured rat cortical astrocytes.
Whooping Cough
The complement component C5a induces the expression of plasminogen activator inhibitor-1 in human macrophages via NF-kappaB activation.
Whooping Cough
The complex interaction of ATP and UTP with isolated hepatocytes. How many receptors?
Whooping Cough
The concept of pertussis as a toxin-mediated disease.
Whooping Cough
The construction of a cloning vector designed for gene replacement in Bordetella pertussis.
Whooping Cough
The contractile action of platelet-activating factor on gallbladder smooth muscle.
Whooping Cough
The contribution of Gi/o protein to opioid antinociception in an oxaliplatin-induced neuropathy rat model.
Whooping Cough
The coupling of 5-oxo-eicosanoid receptors to heterotrimeric G proteins.
Whooping Cough
The critical points in induction of experimental autoimmune uveitis.
Whooping Cough
The crystal structure of pertussis toxin.
Whooping Cough
The CXC chemokine receptor 2, CXCR2, is the putative receptor for ELR+ CXC chemokine-induced angiogenic activity.
Whooping Cough
The CXC chemokine stromal cell-derived factor activates a Gi-coupled phosphoinositide 3-kinase in T lymphocytes.
Whooping Cough
The CXCR4 agonist ligand stromal derived factor-1 maintains high affinity for receptors in both Galpha(i)-coupled and uncoupled states.
Whooping Cough
The CXCR4 antagonist plerixafor (AMD3100) promotes proliferation of Ewing sarcoma cell lines in vitro and activates receptor tyrosine kinase signaling.
Whooping Cough
The cytoplasmic domain of Alzheimer's amyloid-beta protein precursor causes sustained apoptosis signal-regulating kinase 1/c-Jun NH2-terminal kinase-mediated neurotoxic signal via dimerization.
Whooping Cough
The D(3) dopamine receptor inhibits dopamine release in PC-12/hD3 cells by autoreceptor signaling via PP-2B, CK1, and Cdk-5.
Whooping Cough
The D1 dopamine receptor agonist SKF-38393 stimulates the release of glutamate in the hippocampus.
Whooping Cough
The D2 dopamine receptor isoforms signal through distinct Gi alpha proteins to inhibit adenylyl cyclase. A study with site-directed mutant Gi alpha proteins.
Whooping Cough
The D2 dopamine receptor mediates inhibition of growth in GH4ZR7 cells: involvement of protein kinase-C epsilon.
Whooping Cough
The D2 receptor: blocked transcription in GH3 cells and cellular pathways employed by D2A to regulate prolactin promoter activity.
Whooping Cough
The D2-dopamine receptor of anterior pituitary is functionally associated with a pertussis toxin-sensitive guanine nucleotide binding protein.
Whooping Cough
The D2S and D2L dopamine receptor isoforms are differentially regulated in Chinese hamster ovary cells.
Whooping Cough
The D2s dopamine receptor stimulates phospholipase D activity: a novel signaling pathway for dopamine.
Whooping Cough
The Decline of Pertussis-Specific Antibodies After Tetanus, Diphtheria, and Acellular Pertussis Immunization in Late Pregnancy.
Whooping Cough
The delta2-opioid receptor subtype stimulates phosphoinositide metabolism in mouse periaqueductal gray matter.
Whooping Cough
The development of hemopoietic cells in response to stromal cells or growth factors is modified by agents that influence ADP-ribosylation.
Whooping Cough
The development of physiologic responsiveness to muscarinic stimulation in embryonic chick heart. Relationship to increased levels of pertussis toxin substrates.
Whooping Cough
The differential effects of a selective kappa-opioid receptor agonist, U50488, in guinea pig heart tissues.
Whooping Cough
The differential regulation of cyclic AMP by sphingomyelin-derived lipids and the modulation of sphingolipid-stimulated extracellular signal regulated kinase-2 in airway smooth muscle.
Whooping Cough
The diphtheria and pertussis components of diphtheria-tetanus toxoids-pertussis vaccine should be genetically inactivated mutant toxins.
Whooping Cough
The Drosophila neuropeptides PDF and sNPF have opposing electrophysiological and molecular effects on central neurons.
Whooping Cough
The effect of 24R,25-(OH)(2)D(3) on protein kinase C activity in chondrocytes is mediated by phospholipase D whereas the effect of 1alpha,25-(OH)(2)D(3) is mediated by phospholipase C.
Whooping Cough
The effect of adrenomedullin on the L-type calcium current in myocytes from septic shock rats: signaling pathway.
Whooping Cough
The effect of amphiphilic polymers on growth of Bordetella pertussis and production of B. pertussis haemagglutinins.
Whooping Cough
The effect of C-terminal truncation of the recombinant delta-opioid receptor on Ca2+i signaling.
Whooping Cough
The effect of cholecystokinin on intracellular Ca2+, membrane-associated protein kinase-C activity, and progesterone production in chicken granulosa cells.
Whooping Cough
The effect of cholera toxin on the inhibition of vasopressin-stimulated inositol phospholipid hydrolysis is a cyclic AMP-mediated event at the level of receptor binding.
Whooping Cough
The effect of CNTF on glutamate-induced increases in intracellular free Ca2+ in hippocampal neurons.
Whooping Cough
The effect of cyclic AMP elevating agents on bradykinin- and carbachol-induced signal transduction in canine cultured tracheal smooth muscle cells.
Whooping Cough
The effect of cyclodextrin on lipopolysaccharide production in cultures of Bordetella pertussis.
Whooping Cough
The effect of formaldehyde, hydrogen peroxide and genetic detoxification of pertussis toxin on epitope recognition by murine monoclonal antibodies.
Whooping Cough
The effect of Gi-protein inactivation on basal, and beta(1)- and beta(2)AR-stimulated contraction of myocytes from transgenic mice overexpressing the beta(2)-adrenoceptor.
Whooping Cough
The effect of glycosyl inositol-phosphate on cAMP production in isolated rat fat-cells is transduced by a pertussis toxin sensitive G-protein.
Whooping Cough
The effect of investigator compliance (observer bias) on calculated efficacy in a pertussis vaccine trial.
Whooping Cough
The effect of islet-activating protein (IAP) of pertussis toxin on the spontaneous diabetic syndrome in the rat.
Whooping Cough
The effect of maternal antibody on the serologic response and the incidence of adverse reactions after primary immunization with acellular and whole-cell pertussis vaccines combined with diphtheria and tetanus toxoids.
Whooping Cough
The Effect of Maternal Pertussis Immunization on Infant Vaccine Responses to a Booster Pertussis-Containing Vaccine in Vietnam.
Whooping Cough
The effect of nociceptin on Ca2+ channel current and intracellular Ca2+ in the SH-SY5Y human neuroblastoma cell line.
Whooping Cough
The effect of oxiferriscorbone on striatal adenylate cyclase of the rat.
Whooping Cough
The effect of pertussis toxin and whole-cell pertussis vaccine on haemodynamics and autonomic responsiveness in the rat depends on route of administration and age.
Whooping Cough
The effect of pertussis toxin on alpha 1-adrenoceptor-mediated vasoconstriction by the full agonist, cirazoline, and the partial agonist, (-)-dobutamine, in pithed rats.
Whooping Cough
The effect of pertussis toxin on alpha-2-adrenoceptor-mediated pigment migration in fish melanophores.
Whooping Cough
The effect of pertussis toxin on beta-adrenoceptor responses in isolated cardiac myocytes from noradrenaline-treated guinea-pigs and patients with cardiac failure.
Whooping Cough
The effect of pertussis toxin on mediator release from human basophils.
Whooping Cough
The effect of pertussis toxin on the growth of vascular smooth muscle cells stimulated by serum or platelet-derived growth factor.
Whooping Cough
The effect of pertussis toxin on zebrafish development: a possible role for inhibitory G-proteins in hedgehog signaling.
Whooping Cough
The effect of pertussis toxin treatment on alpha-1-adrenoceptor-mediated pressor responses in the pithed rat: dependence on agonist efficacy but not chemical class.
Whooping Cough
The effect of PGF2 alpha on parathyroid hormone-stimulated cyclic AMP production in mouse osteoblastic cell, MC3T3E1.
Whooping Cough
The effect of pH on the production of pertussis toxin by Bordetella pertussis.
Whooping Cough
The effect of site-directed mutagenesis of two transmembrane serine residues on agonist-specific coupling of a cloned human alpha2A-adrenoceptor to adenylyl cyclase.
Whooping Cough
The Effect of Tetanus-Diphtheria-Acellular-Pertussis Immunization During Pregnancy on Infant Antibody Responses: Individual-Participant Data Meta-Analysis.
Whooping Cough
The effect of timing of maternal tetanus, diphtheria, and acellular pertussis (Tdap) immunization during pregnancy on newborn pertussis antibody levels - a prospective study.
Whooping Cough
The effect of vasoactive intestinal polypeptide (VIP) on forskolin stimulated adenylate cyclase in the caudate-putamen of the rat.
Whooping Cough
The effect of vasoactive intestinal polypeptide on gastric acid secretion is predominantly mediated by somatostatin.
Whooping Cough
The effects of ageing on prejunctional 5-hydroxytryptamine receptors in the rat vas deferens.
Whooping Cough
The effects of amylin on insulin secretion from Rin m5F cells and glycogen synthesis and lipogenesis in rat primary cultured hepatocytes.
Whooping Cough
The effects of baclofen and pertussis toxin on epileptiform activity induced in the hippocampal slice by magnesium depletion.
Whooping Cough
The effects of cholera toxin, pertussis toxin, sodium fluoride and alpha-interferon on prostaglandin production by the guinea-pig endometrium.
Whooping Cough
The effects of Delta9-tetrahydrocannabinol in rat mesenteric vasculature, and its interactions with the endocannabinoid anandamide.
Whooping Cough
The effects of endothelin on vascular tonus.
Whooping Cough
The effects of endothelin-1 on the PKA-dependent Cl- current in the heart.
Whooping Cough
The effects of endothelins on the secretion of prolactin, luteinizing hormone, and follicle-stimulating hormone are mediated by different guanine nucleotide-binding proteins.
Whooping Cough
The effects of extracellular calcium and epinephrine on cytosolic-free calcium in single rat adipocytes.
Whooping Cough
The effects of female sexual hormones on the expression and function of ?1A- and ?1D-adrenoceptor subtypes in the late-pregnant rat myometrium.
Whooping Cough
The effects of GH-releasing hormone/somatostatin on the 5'-promoter activity of the GH gene in vitro.
Whooping Cough
The effects of hydrostatic pressure on pertussis toxin-catalyzed ribosylation of G proteins from deep-living macrourid fishes.
Whooping Cough
The effects of in vitro and in vivo exposure to insulin upon prostaglandin E1 stimulation of platelet adenylate cyclase activity in healthy subjects.
Whooping Cough
The effects of interfering with GTP-binding proteins on the activation mechanism of calcium release-activated calcium current.
Whooping Cough
The effects of manufacture processes on post-translational modifications of bioactive proteins in pertussis vaccine.
Whooping Cough
The effects of pertussis toxin and cholera toxin on mitogen-induced interleukin-2 production: evidence for G protein involvement in signal transduction.
Whooping Cough
The effects of pertussis toxin on autoreceptor-mediated inhibition of dopamine synthesis in the rat striatum.
Whooping Cough
The effects of pertussis toxin on dopamine D2 and serotonin 5-HT1A autoreceptor-mediated inhibition of neurotransmitter synthesis: relationship to receptor reserve.
Whooping Cough
The effects of pertussis toxin on human T lymphocytes.
Whooping Cough
The effects of pertussis toxin on the induction and transfer of experimental autoimmune uveoretinitis.
Whooping Cough
The effects of pertussis toxin on vasoconstrictor and vasodilator agents in the pithed rat may not be an indicator of G-protein receptor coupling.
Whooping Cough
The effects of pertussis toxin-treatment on integrated vasoactive response of vascular system in spontaneously hypertensive rats.
Whooping Cough
The effects of phorbol 12-myristate 13-acetate, cholera toxin, prostaglandin E2 and norepinephrine on inducible nitric oxide synthase activation induced by lipopolysaccharide in C6 cells.
Whooping Cough
The effects of phorbol myristate acetate and chemotactic peptide on transmembrane potentials and cytosolic free calcium in mature granulocytes evolve sequentially as the cells differentiate.
Whooping Cough
The effects of purified pertussis components and lipopolysaccharide on the results of the mouse weight gain test.
Whooping Cough
The effects of recombinant rat mu-opioid receptor activation in CHO cells on phospholipase C, [Ca2+]i and adenylyl cyclase.
Whooping Cough
The effects of sigma ligands and of neuropeptide Y on N-methyl-D-aspartate-induced neuronal activation of CA3 dorsal hippocampus neurones are differentially affected by pertussin toxin.
Whooping Cough
The efficacy of a whole cell pertussis vaccine and fimbriae against Bordetella pertussis and Bordetella parapertussis infections in a respiratory mouse model.
Whooping Cough
The efficiency of R5 HIV-1 infection is determined by CD4 T-cell surface CCR5 density through G alpha i-protein signalling.
Whooping Cough
The endocannabinoid noladin ether acts as a full agonist at human CB2 cannabinoid receptors.
Whooping Cough
The endocrine-disrupting compound, nonylphenol, inhibits neurotrophin-dependent neurite outgrowth.
Whooping Cough
The endogenous benzodiazepine receptor ligand ODN increases cytosolic calcium in cultured rat astrocytes.
Whooping Cough
The endogenous cannabinoid anandamide inhibits alpha7 nicotinic acetylcholine receptor-mediated responses in Xenopus oocytes.
Whooping Cough
The endogenous cannabinoid anandamide inhibits cromakalim-activated k+ currents in follicle-enclosed Xenopus oocytes.
Whooping Cough
The endogenous cannabinoid anandamide is a lipid messenger activating cell growth via a cannabinoid receptor-independent pathway in hematopoietic cell lines.
Whooping Cough
The endogenous cannabinoid, anandamide, inhibits dopamine transporter function by a receptor-independent mechanism.
Whooping Cough
The endozepine ODN stimulates polyphosphoinositide metabolism in rat astrocytes.
Whooping Cough
The enhanced antigen-specific production of cytokines induced by pertussis toxin is due to clonal expansion of T cells and not to altered effector functions of long-term memory cells.
Whooping Cough
The enhancement of dopamine D1 receptor desensitization by adenosine A1 receptor activation.
Whooping Cough
The epidermal growth factor receptor is coupled to a pertussis toxin-sensitive guanine nucleotide regulatory protein in rat hepatocytes.
Whooping Cough
The epidermal growth factor receptor is coupled to a phospholipase A2-specific pertussis toxin-inhibitable guanine nucleotide-binding regulatory protein in cultured rat inner medullary collecting tubule cells.
Whooping Cough
The epithelial phenotype of human neuroblastoma cells express bradykinin, endothelin, and angiotensin II receptors that stimulate phosphoinositide hydrolysis.
Whooping Cough
The Epstein-Barr virus BILF1 gene encodes a G protein-coupled receptor that inhibits phosphorylation of RNA-dependent protein kinase.
Whooping Cough
The Essential Role of Gi?2 in Prostate Cancer Cell Migration.
Whooping Cough
The evolving nature of Bordetella pertussis in Ontario, Canada, 2009-2017: strains with shifting genotypes and pertactin deficiency.
Whooping Cough
The excitatory effect of cholecystokinin on rat neostriatal neurons: ionic and molecular mechanisms.
Whooping Cough
The experimental power of FR900359 to study Gq-regulated biological processes.
Whooping Cough
The expression and function of G-proteins in experimental intimal hyperplasia.
Whooping Cough
The extracellular nucleotide UTP is a potent inducer of hematopoietic stem cell migration.
Whooping Cough
The failure of whooping-cough and adult sera to neutralise pertussis toxin.
Whooping Cough
The formation of skeletal muscle myotubes requires functional membrane receptors activated by extracellular ATP.
Whooping Cough
The formyl peptide chemoattractant receptor is encoded by a 2 kilobase messenger RNA. Expression in Xenopus oocytes.
Whooping Cough
The formylpeptide chemoattractant receptor copurifies with a GTP-binding protein containing a distinct 40-kDa pertussis toxin substrate.
Whooping Cough
The function but not the expression of rat liver inhibitory guanine nucleotide binding protein is altered in streptozotocin-induced diabetes.
Whooping Cough
The functional activity of inhibitory G protein (G(i)) is not increased in failing heart ventricle.
Whooping Cough
The G protein beta3 subunit splice variant Gbeta3-s causes enhanced chemotaxis of human neutrophils in response to interleukin-8.
Whooping Cough
The G protein G13 mediates inhibition of voltage-dependent calcium current by bradykinin.
Whooping Cough
The G protein-activating peptide, mastoparan, and the synthetic NH2-terminal ARF peptide, ARFp13, inhibit in vitro Golgi transport by irreversibly damaging membranes.
Whooping Cough
The G Protein-coupled Receptor CysLT1 Mediates Chemokine-like Effects and Prolongs Survival in Chronic Lymphocytic Leukemia.
Whooping Cough
The G proteins of the G alpha i and G alpha q family couple the bradykinin receptor to the release of endothelium-derived relaxing factor.
Whooping Cough
The G-protein G(i) regulates mitosis but not DNA synthesis in growth factor-activated fibroblasts: a role for the nuclear translocation of G(i).
Whooping Cough
The G-protein G(o) in mammalian cardiac muscle: localization and coupling to A1 adenosine receptors.
Whooping Cough
The G-protein inhibitor, pertussis toxin, inhibits the secretion of brain-derived neurotrophic factor.
Whooping Cough
The G12 coupled thrombin receptor stimulates mitogenesis through the Shc SH2 domain.
Whooping Cough
The G12/13-RhoA signaling pathway contributes to efficient lysophosphatidic acid-stimulated cell migration.
Whooping Cough
The Galpha13-Rho signaling axis is required for SDF-1-induced migration through CXCR4.
Whooping Cough
The gene encoding the 17-kDa antigen of Bartonella henselae is located within a cluster of genes homologous to the virB virulence operon.
Whooping Cough
The glucocorticoid hormone dexamethasone reverses the growth hormone-releasing properties of the cholinomimetic carbachol.
Whooping Cough
The glutamate-receptor linked cGMP cascade of retinal on-bipolar cells is pertussis and cholera toxin-sensitive.
Whooping Cough
The glycosylphosphatidylinositol-linked Fc gamma receptor III represents the dominant receptor structure for immune complex activation of neutrophils.
Whooping Cough
The GTP-binding protein G(ialpha) translocates to kinetochores and regulates the M-G(1) cell cycle transition of Swiss 3T3 cells.
Whooping Cough
The GTP-binding protein Gi alpha 2 is directly linked to and substrate of a serine kinase in Balb/c3T3 cells.
Whooping Cough
The GTP-binding protein RhoA mediates Na,K-ATPase exocytosis in alveolar epithelial cells.
Whooping Cough
The GTP-binding regulatory proteins of neuroblastoma x glioma, NG108-15, and glioma, C6, cells. Immunochemical evidence of a pertussis toxin substrate that is neither Ni nor No.
Whooping Cough
The GTP-binding regulatory proteins, Gs and G(i), are altered in erythrocyte membranes of patients with ischemic heart disease resulting from coronary atherosclerosis.
Whooping Cough
The guanine-nucleotide-binding protein subunit G alpha i2 is involved in calcium activation of phospholipase A2. Effects of the dominant negative G alpha i2 mutant, [G203T]G alpha i2, on activation of phospholipase A2 in Chinese hamster ovary cells.
Whooping Cough
The H-L subgroup of guinea-pig cardiac M2 receptors (M2 beta) regulates inositol phosphate formation.
Whooping Cough
The H1 receptor agonist 2-(3-chlorophenyl)histamine activates Gi proteins in HL-60 cells through a mechanism that is independent of known histamine receptor subtypes.
Whooping Cough
The HeLa cell glucagon-like peptide-2 receptor is coupled to regulation of apoptosis and ERK1/2 activation through divergent signaling pathways.
Whooping Cough
The heterotrimeric G protein G alpha i2 mediates lysophosphatidic acid-stimulated induction of the c-fos gene in mouse fibroblasts.
Whooping Cough
The heterotrimeric G protein Go2 regulates catecholamine uptake by secretory vesicles.
Whooping Cough
The heterotrimeric G-protein Gi is localized to the insulin secretory granules of beta-cells and is involved in insulin exocytosis.
Whooping Cough
The heterotrimeric GTP-binding protein, GS, modulates the Cl- conductance of rat parotid acinar secretory granules.
Whooping Cough
The high mobility group (HMG) boxes of the nuclear protein HMG1 induce chemotaxis and cytoskeleton reorganization in rat smooth muscle cells.
Whooping Cough
The homophilic binding site of the neural cell adhesion molecule NCAM is directly involved in promoting neurite outgrowth from cultured neural retinal cells.
Whooping Cough
The human 5-HT1A receptor expressed in HeLa cells stimulates sodium-dependent phosphate uptake via protein kinase C.
Whooping Cough
The human 5-ht5A receptor couples to Gi/Go proteins and inhibits adenylate cyclase in HEK 293 cells.
Whooping Cough
The human and dog 5-HT1D receptors can both activate and inhibit adenylate cyclase in transfected cells.
Whooping Cough
The human antimicrobial peptide dermcidin activates normal human keratinocytes.
Whooping Cough
The human chemoattractant complement C5a receptor inhibits cyclic AMP accumulation through Gi and Gz proteins.
Whooping Cough
The human D2 dopamine receptor synergizes with the A2A adenosine receptor to stimulate adenylyl cyclase in PC12 cells.
Whooping Cough
The human delta opioid receptor activates G(i1)alpha more efficiently than G(o1)alpha.
Whooping Cough
The human formyl peptide receptor as model system for constitutively active G-protein-coupled receptors.
Whooping Cough
The human galanin receptor: ligand-binding and functional characteristics in the Bowes melanoma cell line.
Whooping Cough
The human genome encodes at least three non-allellic G proteins with alpha i-type subunits.
Whooping Cough
The human S100 protein MRP-14 is a novel activator of the beta 2 integrin Mac-1 on neutrophils.
Whooping Cough
The human thyrotropin receptor: a heptahelical receptor capable of stimulating members of all four G protein families.
Whooping Cough
The human V3 pituitary vasopressin receptor: ligand binding profile and density-dependent signaling pathways.
Whooping Cough
The Identification and Localization of the Guanine Nucleotide Binding Protein G0 in the Auditory System.
Whooping Cough
The imidazoline NNC77-0020 affects glucose-dependent insulin, glucagon and somatostatin secretion in mouse pancreatic islets.
Whooping Cough
The immunomodulator FTY720 and its phosphorylated derivative activate the Smad signalling cascade and upregulate connective tissue growth factor and collagen type IV expression in renal mesangial cells.
Whooping Cough
The immunomodulator vasoactive intestinal peptide (VIP) does not affect experimental autoimmune uveitis (EAU) in B10.RIII mice.
Whooping Cough
The immunomodulatory effects of measles-mumps-rubella (MMR) vaccination on persistence of heterologous vaccine responses.
Whooping Cough
The impact of prenatal exposure to parasitic infections and to anthelminthic treatment on antibody responses to routine immunisations given in infancy: Secondary analysis of a randomised controlled trial.
Whooping Cough
The impact of RGS and other G-protein regulatory proteins on G?i-mediated signaling in immunity.
Whooping Cough
The implication of the chemokine receptor CXCR4 in HIV-1 envelope protein-induced apoptosis is independent of the G protein-mediated signalling.
Whooping Cough
The importance of Bordetella pertussis strains which do not produce virulence factors in the epidemiology of pertussis.
Whooping Cough
The in vitro invasive behavior of human myelomonocytic cell lines is modulated by HuIFN-gamma and pertussis toxin.
Whooping Cough
The incidence of Bordetella pertussis infections estimated in the population from a combination of serological surveys.
Whooping Cough
The inducible G protein-coupled receptor edg-1 signals via the G(i)/mitogen-activated protein kinase pathway.
Whooping Cough
The induction of breast milk pertussis specific antibodies following gestational tetanus-diphtheria-acellular pertussis vaccination.
Whooping Cough
The inflammasome pyrin contributes to pertussis toxin-induced IL-1? synthesis, neutrophil intravascular crawling and autoimmune encephalomyelitis.
Whooping Cough
The inflammatory effects of UDP-glucose in N9 microglia are not mediated by P2Y14 receptor activation.
Whooping Cough
The inflammatory mediator leukotriene D4 triggers a rapid reorganisation of the actin cytoskeleton in human intestinal epithelial cells.
Whooping Cough
The influence of detergents on the availability of pertussis toxin substrates.
Whooping Cough
The influence of hypotonicity on large-conductance calcium-activated potassium channels in human retinal pigment epithelial cells.
Whooping Cough
The influence of K(+)-induced membrane depolarization on insulin secretion in islets of lean and obese (ob/ob) mice.
Whooping Cough
The influences of g proteins, ca, and k channels on electrical field stimulation in cat esophageal smooth muscle.
Whooping Cough
The inhibition by pertussis and tetanus toxins of evoked catecholamine release from intact and permeabilized bovine adrenal chromaffin cells.
Whooping Cough
The inhibition of alpha 1-adrenoceptor-mediated contractions of rabbit pulmonary artery by Ca2+-withdrawal, pertussis toxin and N-ethylmaleimide is dependent on agonist intrinsic efficacy.
Whooping Cough
The inhibition of glutamate release by metabotropic glutamate receptor 7 affects both [Ca2+]c and cAMP: evidence for a strong reduction of Ca2+ entry in single nerve terminals.
Whooping Cough
The inhibition of high-voltage-activated calcium current by activation of MrgC11 involves phospholipase C-dependent mechanisms.
Whooping Cough
The inhibition of motility that results from contact between two oligodendrocytes in vitro can be blocked by pertussis toxin.
Whooping Cough
The inhibition of neutrophil granule enzyme secretion and chemotaxis by pertussis toxin.
Whooping Cough
The inhibition of stimulus-secretion coupling in pancreatic islets by volatile anaesthetics does not involve pertussis toxin sensitive G-proteins.
Whooping Cough
The inhibitory G protein G(i) identified as pertussis toxin-catalyzed ADP-ribosylation.
Whooping Cough
The inhibitory GTP-binding protein (Gi) occurs in rat Leydig cells and is differentially modified by lutropin and 12-O-tetradecanoylphorbol 13-acetate.
Whooping Cough
The inhibitory guanine nucleotide regulatory protein modulates agonist-stimulated cAMP production in rat osteosarcoma cells.
Whooping Cough
The inhibitory guanine nucleotide-binding protein (Ni) purified from bovine brain is a high affinity GTPase.
Whooping Cough
The inhibitory guanine nucleotide-binding regulatory subunit of adenylate cyclase has an adenylate cyclase-independent modulatory effect on ACTH secretion from mouse pituitary tumor cells.
Whooping Cough
The injury-induced myokine insulin-like 6 is protective in experimental autoimmune myositis.
Whooping Cough
The inositol phosphate response to thrombin in rat right atria differs from the response to noradrenaline.
Whooping Cough
The ins and outs of pertussis toxin.
Whooping Cough
The insulin-like growth factor type 1 and insulin-like growth factor type 2/mannose-6-phosphate receptors independently regulate ERK1/2 activity in HEK293 cells.
Whooping Cough
The insulin-secreting cell line, RINm5F, expresses an alpha-2D adrenoceptor and nonadrenergic idazoxan-binding sites.
Whooping Cough
The interaction between pertussis toxin and 10 monoclonal antibodies.
Whooping Cough
The interaction of a kainate receptor from goldfish brain with a pertussis toxin-sensitive GTP-binding protein.
Whooping Cough
The interaction of adenosine analogues with cAMP-generating and cAMP-independent positive inotropic agents in rabbit left atrium.
Whooping Cough
The interaction of nucleotides with pertussis toxin. Direct evidence for a nucleotide binding site on the toxin regulating the rate of ADP-ribosylation of Ni, the inhibitory regulatory component of adenylyl cyclase.
Whooping Cough
The interactions between the activatory guanine nucleotide binding protein and the catalytic subunit of adenylate cyclase in rat liver plasma membranes.
Whooping Cough
The interleukin-8 receptor B and CXC chemokines can mediate transendothelial migration of human skin homing T cells.
Whooping Cough
The involvement of GABAB receptors and coupled G-proteins in spinal GABAergic presynaptic inhibition.
Whooping Cough
The involvement of inositol phosphoglycan mediators in the modulation of steroidogenesis by insulin and insulin-like growth factor-I.
Whooping Cough
The involvement of K+ channels and Gi/o protein in the antinociceptive action of the gallic acid ethyl ester.
Whooping Cough
The involvement of pertussis toxin-sensitive G proteins in the post receptor mechanism of central I1-imidazoline receptors.
Whooping Cough
The involvement of products of the phospholipase pathway in the acute release of tissue-type plasminogen activator from perfused rat hindlegs.
Whooping Cough
The involvement of VEGF receptors and MAPK in the cannabinoid potentiation of Ca2+ flux into N18TG2 neuroblastoma cells.
Whooping Cough
The isoflavone Equol mediates rapid vascular relaxation: Ca2+-independent activation of endothelial nitric-oxide synthase/Hsp90 involving ERK1/2 and Akt phosphorylation in human endothelial cells.
Whooping Cough
The kappa opioid receptor expressed on the mouse R1.1 thymoma cell line is coupled to adenylyl cyclase through a pertussis toxin-sensitive guanine nucleotide-binding regulatory protein.
Whooping Cough
The kyotorphin (tyrosine-arginine) receptor and a selective reconstitution with purified Gi, measured with GTPase and phospholipase C assays.
Whooping Cough
The location of filamentous hemagglutinin and pertussis toxin antigens of Bordetella pertussis by immunoelectron microscopy.
Whooping Cough
The longevity of the immune response to filamentous hemagglutinin and pertussis toxin in patients with pertussis in a semiclosed community.
Whooping Cough
The luteinizing hormone-releasing hormone receptor in human prostate cancer cells: messenger ribonucleic acid expression, molecular size, and signal transduction pathway.
Whooping Cough
The lymphocytosis promoting action of pertussis toxin can be mimicked in vitro. Holotoxin but not the B subunit inhibits invasion of human T lymphoma cells through fibroblast monolayers.
Whooping Cough
The lymphocytosis-promoting agent pertussis toxin affects virus burden and lymphocyte distribution in the SIV-infected rhesus macaque.
Whooping Cough
The lymphoma transmembrane glycoprotein GP85 (CD44) is a novel guanine nucleotide-binding protein which regulates GP85 (CD44)-ankyrin interaction.
Whooping Cough
The m2 muscarinic acetylcholine receptors are coupled to multiple signaling pathways via pertussis toxin-sensitive guanine nucleotide regulatory proteins.
Whooping Cough
The M2 muscarinic G-protein-coupled receptor is voltage-sensitive.
Whooping Cough
The M2 muscarinic receptor antagonist methoctramine activates mast cells via pertussis toxin-sensitive G proteins.
Whooping Cough
The M3 receptor-mediated K(+) current (IKM3), a G(q) protein-coupled K(+) channel.
Whooping Cough
The M3-muscarinic acetylcholine receptor stimulates glucose uptake in L6 skeletal muscle cells by a CaMKK-AMPK-dependent mechanism.
Whooping Cough
The macrophage-derived lectin, MNCF, activates neutrophil migration through a pertussis toxin-sensitive pathway.
Whooping Cough
The macrophage-derived neutrophil chemotactic factor, MNCF: A lectin with TNF-alpha-like activities on neutrophils.
Whooping Cough
The Major Leukocyte Chemotactic and Activating Factors in the Mouse Gut Lumen Are Not N-Formylpeptide Receptor 1 Agonists.
Whooping Cough
The mechanism for the rapid desensitization in bradykinin-stimulated inositol monophosphate production in NG108-15 cells involves interaction of a single receptor with multiple signaling pathways.
Whooping Cough
The mechanism of action of alpha 2-adrenoceptors in human isolated subcutaneous resistance arteries.
Whooping Cough
The mechanism of calcium channel facilitation in bovine chromaffin cells.
Whooping Cough
The mechanism of CD47-dependent killing of T cells: heterotrimeric Gi-dependent inhibition of protein kinase A.
Whooping Cough
The mechanism of contraction by 2-chloroadenosine in cat detrusor muscle cells.
Whooping Cough
The mechanism of MAP kinase activation under acidic condition in feline esophageal smooth muscle cells.
Whooping Cough
The mechanism of positive inotropy induced by adenosine triphosphate in rat heart.
Whooping Cough
The mechanisms of alpha(2)-adrenoceptor agonist-induced contraction in longitudinal muscle of the porcine uterus.
Whooping Cough
The Mel1a melatonin receptor is coupled to parallel signal transduction pathways.
Whooping Cough
The melanophore aggregating response of isolated fish scales: a very rapid and sensitive diagnosis of whooping cough.
Whooping Cough
The membrane-bound spermatozoal adenylyl cyclase system does not share coupling characteristics with somatic cell adenylyl cyclases.
Whooping Cough
The metabolism of sphingo(glyco)lipids is correlated with the differentiation-dependent autophagic pathway in HT-29 cells.
Whooping Cough
The metabotropic glutamate receptor MGLU7, activates PLC, translocates MUNC-13-1 protein and potentiates glutamate release at cerebrocortical nerve terminals.
Whooping Cough
The metabotropic glutamate receptor types 2/3 inhibit L-type calcium channels via a pertussis toxin-sensitive G-protein in cultured cerebellar granule cells.
Whooping Cough
The mineralocorticoid aldosterone activates a proton conductance in cultured kidney cells.
Whooping Cough
The modulation of placental lactogen release by opioids: a role for extracellular calcium.
Whooping Cough
The modulation of rat hippocampal synaptic conductances by baclofen and gamma-aminobutyric acid.
Whooping Cough
The molecular engineering of pertussis toxoid.
Whooping Cough
The monocyte chemotactic protein-4 induces oxygen radical production, actin reorganization, and CD11b up-regulation via a pertussis toxin-sensitive G-protein in human eosinophils.
Whooping Cough
The monomeric G proteins AGS1 and Rhes selectively influence Galphai-dependent signaling to modulate N-type (CaV2.2) calcium channels.
Whooping Cough
The morphologic change of endothelial cells by ancrod-generated fibrin is triggered by alpha v beta 3 integrin binding and the subsequent activation of a G-protein coupled phospholipase C.
Whooping Cough
The mouse as a model of experimental autoimmune uveoretinitis (EAU).
Whooping Cough
The mouse GalR2 galanin receptor: genomic organization, cDNA cloning, and functional characterization.
Whooping Cough
The mouse putative pheromone receptor was specifically activated by stimulation with male mouse urine.
Whooping Cough
The mu opioid agonist DAMGO stimulates cAMP production in SK-N-SH cells through a PLC-PKC-Ca++ pathway.
Whooping Cough
The mu-opioid receptor down-regulates differently from the delta-opioid receptor: requirement of a high affinity receptor/G protein complex formation.
Whooping Cough
The myocardial depressant effect of volatile anesthetics does not involve arachidonic acid metabolites or pertussis toxin-sensitive G proteins.
Whooping Cough
The NAD-glycohydrolase activity of the pertussis toxin S1 subunit. Involvement of the catalytic HIS-35 residue.
Whooping Cough
The nature and origin of spontaneous noise in G protein-gated ion channels.
Whooping Cough
The negative inotropic effect of neuropeptide Y on the ventricular cardiomyocyte.
Whooping Cough
The neuropeptide FMRFa both inhibits and enhances the Ca2+ current in dissociated Helix neurons via independent mechanisms.
Whooping Cough
The neuropeptide pituitary adenylate cyclase activating polypeptide modulates Ca2+ and pro-inflammatory functions in human monocytes through the G protein-coupled receptors VPAC-1 and formyl peptide receptor-like 1.
Whooping Cough
The neuropeptide pituitary adenylate cyclase activating protein stimulates human monocytes by transactivation of the Trk/NGF pathway.
Whooping Cough
The neuropeptide Y/peptide YY Y1 receptor is coupled to MAP kinase via PKC and Ras in CHO cells.
Whooping Cough
The neuropeptides vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase activating polypeptide (PACAP) modulate several biochemical pathways in human leukemic myeloid cells.
Whooping Cough
The neurotoxic prion peptide fragment PrP(106-126) is a chemotactic agonist for the G protein-coupled receptor formyl peptide receptor-like 1.
Whooping Cough
THE NEUTRALIZATION OF B. PERTUSSIS TOXIN IN A TISSUE CULTURE.
Whooping Cough
The neutrophil-activating protein (HP-NAP) of Helicobacter pylori is a potent stimulant of mast cells.
Whooping Cough
The neutrophil-activating protein (HP-NAP) of Helicobacter pylori is a protective antigen and a major virulence factor.
Whooping Cough
The neutrophil-activating protein of Helicobacter pylori (HP-NAP) activates the MAPK pathway in human neutrophils.
Whooping Cough
The new cardiotonic agent sulmazole is an A1 adenosine receptor antagonist and functionally blocks the inhibitory regulator, Gi.
Whooping Cough
The new positive inotrope sulmazole inhibits the function of guanine nucleotide regulatory proteins by affecting GTP turnover.
Whooping Cough
The new strategy for allele identification of the genes coding for pertussis toxin subunit S1 (ptx S1) and pertactin (prn) in Bordetella pertussis.
Whooping Cough
The non-genomic rapid acidification in peripheral T cells by progesterone depends on intracellular calcium increase and not on Na+/H+-exchange inhibition.
Whooping Cough
The nonpsychoactive cannabinoid cannabidiol inhibits 5-hydroxytryptamine3A receptor-mediated currents in Xenopus laevis oocytes.
Whooping Cough
The novel sphingosine 1-phosphate receptor AGR16 is coupled via pertussis toxin-sensitive and -insensitive G-proteins to multiple signalling pathways.
Whooping Cough
The occupancy of endothelial protein C receptor by its ligand modulates the par-1 dependent signaling specificity of coagulation proteases.
Whooping Cough
The opioid peptide dynorphin modulates AMPA and kainate responses in acutely isolated neurons from the dorsal horn.
Whooping Cough
The opposing effects of calmodulin, adenosine 5'-triphosphate, and pertussis toxin on phorbol ester induced inhibition of atrial natriuretic factor stimulated guanylate cyclase in SK-NEP-1 cells.
Whooping Cough
The optimal gestation for pertussis vaccination during pregnancy: a prospective cohort study.
Whooping Cough
The orphan G protein-coupled receptor GPR40 is activated by medium and long chain fatty acids.
Whooping Cough
The oxime HGG-12 as a muscarinic acetylcholine receptor antagonist without intrinsic activity in cardiac membranes.
Whooping Cough
The P2U purinoceptor obligatorily engages the heterotrimeric G protein G16 to mobilize intracellular Ca2+ in human erythroleukemia cells.
Whooping Cough
The P2Y purinoceptor in rat brain microvascular endothelial cells couple to inhibition of adenylate cyclase.
Whooping Cough
The P2Y purinoceptor-operated potassium channel is possibly regulated by the beta gamma subunits of a pertussis toxin-insensitive G-protein in cultured rat inferior colliculus neurons.
Whooping Cough
The P2Y(1) and P2Y(12) receptors mediate autoinhibition of transmitter release in sympathetic innervated tissues.
Whooping Cough
The P2Y14 receptor of airway epithelial cells: coupling to intracellular Ca2+ and IL-8 secretion.
Whooping Cough
The P2Y2 nucleotide receptor interacts with alphav integrins to activate Go and induce cell migration.
Whooping Cough
The palmitoylation status of the G-protein G(o)1 alpha regulates its activity of interaction with the plasma membrane.
Whooping Cough
The PDZ binding motif of the beta 1 adrenergic receptor modulates receptor trafficking and signaling in cardiac myocytes.
Whooping Cough
The peripheral cannabinoid receptor: adenylate cyclase inhibition and G protein coupling.
Whooping Cough
The pertussis hypothesis: Bordetella pertussis colonization in the etiology of asthma and diseases of allergic sensitization.
Whooping Cough
The pertussis toxin liberation genes of Bordetella pertussis are transcriptionally linked to the pertussis toxin operon.
Whooping Cough
The pertussis toxin S1 subunit is a thermally unstable protein susceptible to degradation by the 20S proteasome.
Whooping Cough
The phorbol ester TPA potentiates cholera toxin- and isoproterenol-stimulated cyclic AMP-synthesis in primary astrocyte cultures.
Whooping Cough
The phospholipase C activating P2U purinoceptor also inhibits cyclicAMP formation in DDT1 MF-2 smooth muscle cells.
Whooping Cough
The phospholipids sphingosine-1-phosphate and lysophosphatidic acid prevent apoptosis in osteoblastic cells via a signaling pathway involving G(i) proteins and phosphatidylinositol-3 kinase.
Whooping Cough
The phosphotyrosine phosphatase eta mediates somatostatin inhibition of glioma proliferation via the dephosphorylation of ERK1/2.
Whooping Cough
The photoactivatable NAD+ analogue [32P]2-azido-NAD+ defines intra- and inter-molecular interactions of the C-terminal domain of the G-protein G alpha t.
Whooping Cough
The pituitary adenylate cyclase activating polypeptide (PACAP I) and VIP (PACAP II VIP1) receptors stimulate inositol phosphate synthesis in transfected CHO cells through interaction with different G proteins.
Whooping Cough
The plant cannabinoid Delta9-tetrahydrocannabivarin can decrease signs of inflammation and inflammatory pain in mice.
Whooping Cough
The PLPp-specific T-cell population promoted by pertussis toxin is characterized by high frequencies of IL-17-producing cells.
Whooping Cough
The possible mechanisms by which phanoside stimulates insulin secretion from rat islets.
Whooping Cough
The potential of adjuvants to improve immune responses against TdaP vaccines: A preclinical evaluation of MF59 and monophosphoryl lipid A.
Whooping Cough
The potential role of subclinical Bordetella Pertussis colonization in the etiology of multiple sclerosis.
Whooping Cough
The potentiating effects of phorbol ester on ACTH-, cholera toxin-, and forskolin-induced cAMP production by cultured bovine adrenal cells is not mediated by the inactivation of alpha subunit of Gi protein.
Whooping Cough
The preimplantation mouse embryo is a target for cannabinoid ligand-receptor signaling.
Whooping Cough
The presence of a heterotrimeric G protein and its role in signal transduction of extracellular calmodulin in pollen germination and tube growth
Whooping Cough
The presence of atrial-natriuretic-factor receptors of ANF-R2 subtype in rat platelets. Coupling to adenylate cyclase/cyclic AMP signal-transduction system.
Whooping Cough
The presumed atypical chemokine receptor CXCR7 signals through G(i/o) proteins in primary rodent astrocytes and human glioma cells.
Whooping Cough
The prevention of severe pertussis and pertussis deaths in young infants.
Whooping Cough
The primary and secondary cellular immune responses to whole cell Bordetella pertussis vaccine and its components.
Whooping Cough
The primary structure of the alpha subunit of a starfish guanosine-nucleotide-binding regulatory protein involved in 1-methyladenine-induced oocyte maturation.
Whooping Cough
The priming effect of 12(S)-hydroxyeicosatetraenoic acid on lymphocyte phospholipase D involves specific binding sites.
Whooping Cough
The product of a novel growth factor-activated gene, fic, is a biologically active "C-C"-type cytokine.
Whooping Cough
The proliferative effect of vascular endothelial growth factor requires protein kinase C-alpha and protein kinase C-zeta.
Whooping Cough
The proline residue at position 319 of BvgS is essential for BvgAS activation in Bordetella pertussis.
Whooping Cough
The prostacyclin analogues, cicaprost and iloprost, increase cytosolic Ca2+ concentration in the human erythroleukemia cell line, HEL, via pertussis toxin-insensitive G-proteins.
Whooping Cough
The prostaglandin E series modulates high-voltage-activated calcium channels probably through the EP3 receptor in rat paratracheal ganglia.
Whooping Cough
The protective effect of atrial natriuretic peptide (ANP) on cells damaged by oxygen radicals is mediated through elevated CGMP-levels, reduction of calcium-inflow and probably G-proteins.
Whooping Cough
The protective effect of immunisation against diphtheria, pertussis and tetanus (DPT) in relation to sudden infant death syndrome.
Whooping Cough
The protein kinase C activator 1-oleoyl-2-acetylglycerol inhibits voltage-dependent Ca2+ current in the pituitary cell line AtT-20.
Whooping Cough
The proteinase-activated receptor-2 mediates phagocytosis in a Rho-dependent manner in human keratinocytes.
Whooping Cough
The proximal portion of the COOH terminus of the oxytocin receptor is required for coupling to g(q), but not g(i). Independent mechanisms for elevating intracellular calcium concentrations from intracellular stores.
Whooping Cough
The PtlE protein of Bordetella pertussis has peptidoglycanase activity required for Ptl-mediated pertussis toxin secretion.
Whooping Cough
The purification and characterization of an acellular pertussis vaccine.
Whooping Cough
The purification and protective capacity of Bordetella pertussis outer membrane proteins.
Whooping Cough
The purification of a cysteine-dependent NAD+ glycohydrolase activity from bovine erythrocytes and evidence that it exhibits a novel ADP-ribosyltransferase activity.
Whooping Cough
The purification of a guanine nucleotide regulatory protein from rat brain membrane and the measurement of its GTPase.
Whooping Cough
The purinergic P2Y(13) receptor activates the Nrf2/HO-1 axis and protects against oxidative stress-induced neuronal death.
Whooping Cough
The putative <> 5-HT(1A) receptor antagonist, WAY 100635, has inverse agonist properties at cloned human 5-HT(1A) receptors.
Whooping Cough
The putative melatonin receptor antagonist GR128107 is a partial agonist on Xenopus laevis melanophores.
Whooping Cough
The quantitative analysis of the mechanism involved in pertussis toxin-mediated cell clustering and its implications in the in vitro quality control of diphtheria tetanus and whole cell pertussis vaccines.
Whooping Cough
The rabbit neutrophil N-formyl peptide receptor. cDNA cloning, expression, and structure/function implications.
Whooping Cough
The rat cytomegalovirus R33-encoded G protein-coupled receptor signals in a constitutive fashion.
Whooping Cough
The Rate of CD4 T Cell Entry into the Lungs during Mycobacterium tuberculosis Infection Is Determined by Partial and Opposing Effects of Multiple Chemokine Receptors.
Whooping Cough
The reaction of bacterial toxins with formaldehyde and its use for antigen stabilization.
Whooping Cough
The receptor attributable to C-type natriuretic peptide-induced differentiation of osteoblasts is switched from type B- to type C-natriuretic peptide receptor with aging.
Whooping Cough
The receptor mechanism mediating the contractile response to adenosine on lung parenchymal strips from actively sensitised, allergen-challenged Brown Norway rats.
Whooping Cough
The receptors for ATP and fMetLeuPhe are independently coupled to phospholipases C and A2 via G-protein(s). Relationship between phospholipase C and A2 activation and exocytosis in HL60 cells and human neutrophils.
Whooping Cough
The reduction of neuronal calcium currents by ATP-gamma-S is mediated by a G protein and occurs independently of cyclic AMP-dependent protein kinase.
Whooping Cough
The reemergence of pertussis in immunized populations: a case study.
Whooping Cough
The regulation of adenylate cyclase by guanine nucleotides in Dictyostelium discoideum membranes.
Whooping Cough
The regulation of adenylate cyclase in liver membranes of lean and obese mice.
Whooping Cough
The regulation of neutrophil phospholipase A2 by granulocyte-macrophage colony-stimulating factor and its role in priming superoxide production.
Whooping Cough
The regulator of G protein signaling RGS4 selectively enhances alpha 2A-adreoreceptor stimulation of the GTPase activity of Go1alpha and Gi2alpha.
Whooping Cough
The regulator of G-protein signaling RGS16 promotes insulin secretion and ?-cell proliferation in rodent and human islets.
Whooping Cough
The regulatory effect of liuwei dihuang pills on cytokines in mice with experimental autoimmune encephalomyelitis.
Whooping Cough
The relationship between 3',5'-cyclic adenosine monophosphate and calcium in mediating follicle-stimulating hormone signal transduction in Sertoli cells.
Whooping Cough
The relationship between Bordetella pertussis genotype and clinical severity in Australian children with pertussis.
Whooping Cough
The relationship between motility factor receptor internalization and the lung colonization capacity of murine melanoma cells.
Whooping Cough
The relationship between pertussis-toxin-induced ADP-ribosylation of a plasma-membrane protein and reversal of muscarinic inhibition of prolactin secretion in GH3 cells.
Whooping Cough
The relationship between the metabolism of sphingomyelin species and the hemolysis of sheep erythrocytes induced by Clostridium perfringens {alpha}-toxin.
Whooping Cough
The release of endothelium-derived relaxing factor via alpha 2-adrenergic receptor activation is specifically mediated by Gi alpha 2.
Whooping Cough
The requirement for pertussis to induce EAU is strain-dependent: B10.RIII, but not B10.A mice, develop EAU and Th1 responses to IRBP without pertussis treatment.
Whooping Cough
The resistance of macrophage-like tumour cell lines to growth inhibition by lipopolysaccharide and pertussis toxin.
Whooping Cough
The Rho/Rho-kinase and the phosphatidylinositol 3-kinase pathways are essential for spontaneous locomotion of Walker 256 carcinosarcoma cells.
Whooping Cough
The rise in pertussis cases urges replacement of chemically-inactivated with genetically-inactivated toxoid for DTP.
Whooping Cough
The RNA Chaperone Hfq is Required for Virulence of Bordetella pertussis.
Whooping Cough
The role of A3 adenosine receptors in central regulation of arterial blood pressure.
Whooping Cough
The role of autotaxin and other motility stimulating factors in the regulation of tumor cell motility.
Whooping Cough
The role of beta-adrenergic receptor signaling in cardioprotection.
Whooping Cough
The role of beta-arrestins in the formyl peptide receptor-like 1 internalization and signaling.
Whooping Cough
The role of calcium in modulating the reactivity of the smooth muscle cells during ischemia/reperfusion. Part 1.
Whooping Cough
The role of cyclic nucleotides in atrial natriuretic peptide-mediated inhibition of aldosterone secretion.
Whooping Cough
The role of cysteine 41 in the enzymatic activities of the pertussis toxin S1 subunit as investigated by site-directed mutagenesis.
Whooping Cough
The role of cytosolic free calcium in the generation of inositol 1,4,5-trisphosphate and inositol 1,3,4-trisphosphate in HL-60 cells. Differential effects of chemotactic peptide receptor stimulation at distinct Ca2+ levels.
Whooping Cough
The role of G protein in muscarinic depolarization near resting potential in cultured hippocampal neurons.
Whooping Cough
The role of G protein methylation in the function of a geranylgeranylated beta gamma isoform.
Whooping Cough
The role of G proteins in the activity and mercury modulation of GABA-induced currents in rat neurons.
Whooping Cough
The role of G proteins in thromospondin-1-induced vascular smooth muscle cell migration.
Whooping Cough
The role of G-protein in matrix-mediated motility of highly and poorly invasive melanoma cells.
Whooping Cough
The role of G-protein signaling in hematopoietic stem/progenitor cell mobilization.
Whooping Cough
The role of G-proteins in the activation of human leukocytes by particulate stimuli to produce reactive oxygen metabolites.
Whooping Cough
The role of G-proteins in the dimerisation of human somatostatin receptor types 2 and 5.
Whooping Cough
The role of G-proteins in the mitogenesis of rat lactogen-dependent and lactogen-independent Nb2 lymphoma cells.
Whooping Cough
The role of Gi and the membrane-fluidizing agent benzyl alcohol in modulating the hysteretic activation of human platelet adenylate cyclase by guanylyl 5'-imidodiphosphate.
Whooping Cough
The role of Gi proteins in reduced vasorelaxation response to beta-adrenoceptor agonists in rat aorta during maturation.
Whooping Cough
The role of Gi-proteins and beta-adrenoceptors in the age-related decline of contraction in guinea-pig ventricular myocytes.
Whooping Cough
The role of glial cells in influencing neurite extension by dorsal root ganglion cells.
Whooping Cough
The role of GTP binding proteins in ischemic brain damage: autoradiographic and histopathological study.
Whooping Cough
The role of guanyl nucleotide binding proteins in the formation of inositol phosphates in adrenal glomerulosa cells.
Whooping Cough
The role of intracellular acidification in calcium mobilization in human neutrophils.
Whooping Cough
The role of lysophosphatidic acid receptors in phenotypic modulation of vascular smooth muscle cells.
Whooping Cough
The Role of M. leprae Hsp65 Protein and Peptides in the Pathogenesis of Uveitis.
Whooping Cough
The role of members of the pertussis toxin-sensitive family of G proteins in coupling receptors to the activation of the G protein-gated inwardly rectifying potassium channel.
Whooping Cough
The role of mitogen-activated protein kinases in eotaxin-induced cytokine production from bronchial epithelial cells.
Whooping Cough
The role of N-, Q- and R-type Ca2+ channels in feedback inhibition of ACh release from rat basal forebrain neurones.
Whooping Cough
The role of neutrophils in tissue localized cell-mediated immunologic responses: I. The intensity of contact-type and delayed-type hypersensitivity responses may be influenced by the extent of extracellular matrix degradation by neutrophil proteases.
Whooping Cough
The role of P2Y(14) and other P2Y receptors in degranulation of human LAD2 mast cells.
Whooping Cough
The role of pertussis toxin and betamethasone on lymphocyte accumulation in the lungs of mice.
Whooping Cough
The role of potassium channels in antihistamine analgesia.
Whooping Cough
The role of protein kinase C in alpha-adrenergic regulation of NaCl(K) cotransport in human airway epithelial cells.
Whooping Cough
The role of protein kinases A and C pathways in the regulation of mitogen-activated protein kinase activation in response to gonadotropin-releasing hormone receptor activation.
Whooping Cough
The role of spinally located dopamine D2 receptors in the regulation of the blood glucose level in mice.
Whooping Cough
The role of the bone marrow in neutrophil clearance under homeostatic conditions in the mouse.
Whooping Cough
The role of the cytosolic free Ca2+ transient for fMet-Leu-Phe induced actin polymerization in human neutrophils.
Whooping Cough
The role of the GPR91 ligand succinate in hematopoiesis.
Whooping Cough
The role of the nucleus accumbens in sensitization to drugs of abuse.
Whooping Cough
The role of the S-1 and B-oligomer components of pertussis toxin in its adjuvant properties for Th1 and Th2 cells.
Whooping Cough
The role of thymus-expressed chemokine and its receptor CCR9 on lymphocytes in the regional specialization of the mucosal immune system.
Whooping Cough
The role of Toll-like receptor-4 in pertussis vaccine-induced immunity.
Whooping Cough
The roles of alpha2-adrenoceptor subtypes in the control of cervical resistance in the late-pregnant rat.
Whooping Cough
The seroepidemiology of B. pertussis infection in Catalonia, Spain.
Whooping Cough
The seroepidemiology of Bordetella pertussis in Israel--Estimate of incidence of infection.
Whooping Cough
The seroepidemiology of Bordetella pertussis infection in Western Europe.
Whooping Cough
The seroepidemiology of Bordetella pertussis infections: a study of persons ages 1-65 years.
Whooping Cough
The seroepidemiology of Immunoglobulin G antibodies against pertussis toxin in China: a cross sectional study.
Whooping Cough
The seroepidemiology of pertussis in Australia during an epidemic period.
Whooping Cough
The seroepidemiology of pertussis in NSW: fluctuating immunity profiles related to changes in vaccination schedules.
Whooping Cough
The short-chain free fatty acid receptor FFAR3 is expressed and potentiates contraction in human airway smooth muscle.
Whooping Cough
The signal transduction of endothelin-1-induced circular smooth muscle cell contraction in cat esophagus.
Whooping Cough
The signal transduction pathway causing the synergistic hypertrophic effects of neuropeptide Y and norepinephrine on primary cardiomyocyte.
Whooping Cough
The signal transduction pathway involved in the migration induced by a monocyte chemotactic cytokine.
Whooping Cough
The signaling mechanism of the sphingosylphosphorylcholine-induced contraction in cat esophageal smooth muscle cells.
Whooping Cough
The signaling pathway in photoresponses that may be mediated by visual pigments in erythrophores of Nile tilapia.
Whooping Cough
The signaling pathways linking to lysophosphatidic acid-promoted meiotic maturation in mice.
Whooping Cough
The signaling signature of the neurotensin type 1 receptor with endogenous ligands.
Whooping Cough
The somatostatin receptor family.
Whooping Cough
The somatostatin receptor SSTR1 is coupled to phosphotyrosine phosphatase activity in CHO-K1 cells.
Whooping Cough
The somatostatin receptors SSTR1 and SSTR2 are coupled to inhibition of adenylyl cyclase in Chinese hamster ovary cells via pertussis toxin-sensitive pathways.
Whooping Cough
The specific activation of TRPC4 by Gi protein subtype.
Whooping Cough
The specific GTP requirement for inositol 1,4,5-trisphosphate-induced Ca2+ release from skinned vascular smooth muscle.
Whooping Cough
The sphingomyelin/ceramide pathway is involved in ERK1/2 phosphorylation, cell proliferation, and uPAR overexpression induced by tissue-type plasminogen activator.
Whooping Cough
The sphingosine kinase 1 and S1P1 axis specifically counteracts LPS-induced IL-12p70 production in immune cells of the spleen.
Whooping Cough
The spleen is a major site of megakaryopoiesis following transplantation of murine hematopoietic stem cells.
Whooping Cough
The standardization of an assay for pertussis toxin and antitoxin in microplate culture of Chinese hamster ovary cells.
Whooping Cough
The steroidal Na+/K+ ATPase inhibitor 3-[(R)-3-pyrrolidinyl]oxime derivative (3-R-POD) induces potent pro-apoptotic responses in colonic tumor cells.
Whooping Cough
The stimulation of beta(3)-adrenoceptor causes phosphorylation of extracellular signal-regulated kinases 1 and 2 through a G(s)- but not G(i)-dependent pathway in 3T3-L1 adipocytes.
Whooping Cough
The stimulation of human neutrophil migration by angiotensin IL: its dependence on Ca2+ and the involvement of cyclic GMP.
Whooping Cough
The stimulation of ketogenesis by cannabinoids in cultured astrocytes defines carnitine palmitoyltransferase I as a new ceramide-activated enzyme.
Whooping Cough
The stimulation of lymphocyte motility by cultured high endothelial cells and its inhibition by pertussis toxin.
Whooping Cough
The stimulatory and inhibitory effects of dopamine on prolactin secretion involve different G-proteins.
Whooping Cough
The stimulatory and inhibitory effects of quinpirole hydrochloride, D2-dopamine receptor agonist, on secretion of prolactin as assessed by the reverse hemolytic plaque assay.
Whooping Cough
The stimulatory and inhibitory guanine nucleotide-binding proteins of adenylate cyclase in erythrocytes from patients with pseudohypoparathyroidism type I.
Whooping Cough
The stimulatory effect of cannabinoids on calcium uptake is mediated by Gs GTP-binding proteins and cAMP formation.
Whooping Cough
The stimulatory effect of insulin on diacylglycerol generation in adipocyte membranes from ob/ob mice is impaired by growth hormone.
Whooping Cough
The stimulatory effect of opioids on mitogen-activated protein kinase in Chinese hamster ovary cells transfected to express mu-opioid receptors.
Whooping Cough
The stimuli releasing histamine from murine bone marrow-derived mast cells. 2. Mechanisms involved in histamine release induced by extracellular ATP and its metabolites.
Whooping Cough
The stromal cell-derived factor-1 chemokine is a potent platelet agonist highly expressed in atherosclerotic plaques.
Whooping Cough
The subcellular localization of the G-protein Gi alpha in the basal ganglia reveals its potential role in both signal transduction and vesicle trafficking.
Whooping Cough
The subunit S1 is important for pertussis toxin secretion.
Whooping Cough
The synthetic cannabinoid R(+)WIN 55,212-2 inhibits the interleukin-1 signaling pathway in human astrocytes in a cannabinoid receptor-independent manner.
Whooping Cough
The synthetic peptide Trp-Lys-Tyr-Met-Val-D-Met is a potent chemotactic agonist for mouse formyl peptide receptor.
Whooping Cough
The synthetic peptide, His-Phe-Tyr-Leu-Pro-Met, is a chemoattractant for Jukat T cells.
Whooping Cough
The tachykinin NK1 receptor. Part I: ligands and mechanisms of cellular activation.
Whooping Cough
The terminal complement complex C5b-9 stimulates interleukin-6 production in human smooth muscle cells through activation of transcription factors NF-kappa B and AP-1.
Whooping Cough
The third intracellular loop and the carboxyl terminus of beta2-adrenergic receptor confer spontaneous activity of the receptor.
Whooping Cough
The third signal in T cell-mediated autoimmune disease?
Whooping Cough
The thrombin receptor in adrenal medullary microvascular endothelial cells is negatively coupled to adenylyl cyclase through a Gi protein.
Whooping Cough
The thrombin receptor, PAR-1, causes transformation by activation of Rho-mediated signaling pathways.
Whooping Cough
The thrombospondin receptor integrin-associated protein (CD47) functionally couples to heterotrimeric Gi.
Whooping Cough
The thromboxane A2 receptor activates mitogen-activated protein kinase via protein kinase C-dependent Gi coupling and Src-dependent phosphorylation of the epidermal growth factor receptor.
Whooping Cough
The thyrotropin receptor is not involved in the activation of p42/p44 mitogen-activated protein kinases by thyrotropin preparations in Chinese hamster ovary cells expressing the human thyrotropin receptor.
Whooping Cough
The transcriptional responses of respiratory epithelial cells to Bordetella pertussis reveal host defensive and pathogen counter-defensive strategies.
Whooping Cough
The transduction signalling protein Go during embryonic development of Drosophila melanogaster.
Whooping Cough
The type I insulin-like growth factor receptor is a motility receptor in human melanoma cells.
Whooping Cough
The tyrosine phosphatase SHP-1 associates with the sst2 somatostatin receptor and is an essential component of sst2-mediated inhibitory growth signaling.
Whooping Cough
The use of Haemophilus influenzae type b-tetanus toxoid conjugate vaccine mixed with diphtheria-tetanus-pertussis vaccine in Gambian infants.
Whooping Cough
The use of microcalorimetry to characterize tetanus neurotoxin, pertussis toxin and filamentous haemagglutinin.
Whooping Cough
The use of the potential-sensitive fluorescent probe bisoxonol in mast cells.
Whooping Cough
The uterotonic action of the aqueous extract of Bridelia atroviridis in the rat.
Whooping Cough
The utility of seroepidemiology for tracking trends in pertussis infection.
Whooping Cough
The vaccine containing recombinant pertussis toxin induces early and long-lasting protection.
Whooping Cough
The Virulence Factors of Bordetella pertussis: Talented Modulators of Host Immune Response.
Whooping Cough
Theileria parva sporozoite entry into bovine lymphocytes involves both parasite and host cell signal transduction processes.
Whooping Cough
Therapeutic approach by Aloe vera in experimental model of multiple sclerosis.
Whooping Cough
Therapeutic effect of EDTA in experimental model of multiple sclerosis.
Whooping Cough
Thermal injury induces macrophage hyperactivity through pertussis toxin-sensitive and -insensitive pathways.
Whooping Cough
Thermal Unfolding of the Pertussis Toxin S1 Subunit Facilitates Toxin Translocation to the Cytosol by the Mechanism of Endoplasmic Reticulum-Associated Degradation.
Whooping Cough
Thimerosal-induced Ca2+ mobilization in isolated guinea pig cochlear outer hair cells.
Whooping Cough
Thioaryl naphthylmethanone oxime ether analogs as novel anticancer agents.
Whooping Cough
Thiol reagents are substrates for the ADP-ribosyltransferase activity of pertussis toxin.
Whooping Cough
Thioredoxin, a redox enzyme released in infection and inflammation, is a unique chemoattractant for neutrophils, monocytes, and T cells.
Whooping Cough
Third prize: Prostaglandin E(2)-3 receptor is involved in ureteral contractility in obstruction.
Whooping Cough
Third-Trimester Maternal Vaccination Against Pertussis and Pertussis Antibody Concentrations.
Whooping Cough
Three distinct G protein pathways mediate inhibition of neuronal calcium current by bradykinin.
Whooping Cough
Three states for the formyl peptide receptor on intact cells.
Whooping Cough
Threshold and graded response behavior in human neutrophils: effect of varying G-protein or ligand concentrations.
Whooping Cough
Threshold-dependent DNA synthesis by pure pressure in human aortic smooth muscle cells: Gialpha-dependent and -independent pathways.
Whooping Cough
Thrombin activates mitogen-activated protein kinase in primary astrocyte cultures.
Whooping Cough
Thrombin activation of the Na+/H+ exchanger in vascular smooth muscle cells. Evidence for a kinase C-independent pathway which is Ca2+-dependent and pertussis toxin-sensitive.
Whooping Cough
Thrombin and phorbol esters cause the selective phosphorylation of a G protein other than Gi in human platelets.
Whooping Cough
Thrombin and trypsin induce granulocyte-macrophage colony-stimulating factor and interleukin-6 gene expression in cultured normal human keratinocytes.
Whooping Cough
Thrombin Ca(2+)-dependently stimulates protein tyrosine phosphorylation in BC3H1 muscle cells.
Whooping Cough
Thrombin induces c-fos expression in cultured human endothelial cells by a Ca2(+)-dependent mechanism.
Whooping Cough
Thrombin induces mast cell adhesion to fibronectin: evidence for involvement of protease-activated receptor-1.
Whooping Cough
Thrombin induces neoangiogenesis in the chick chorioallantoic membrane.
Whooping Cough
Thrombin induces proliferation of osteoblast-like cells through phosphatidylcholine hydrolysis.
Whooping Cough
Thrombin induces proteinase-activated receptor-1 gene expression in endothelial cells via activation of Gi-linked Ras/mitogen-activated protein kinase pathway.
Whooping Cough
Thrombin inhibits Bim (Bcl-2-interacting mediator of cell death) expression and prevents serum-withdrawal-induced apoptosis via protease-activated receptor 1.
Whooping Cough
Thrombin is a novel regulator of hexokinase activity in mesangial cells.
Whooping Cough
Thrombin modulates phosphoinositide metabolism, cytosolic calcium, and impulse initiation in the heart.
Whooping Cough
Thrombin modulates the expression of a set of genes including thrombospondin-1 in human microvascular endothelial cells.
Whooping Cough
Thrombin receptor activating peptide (TRAP) stimulates mitogenesis, c-fos and PDGF-A gene expression in human vascular smooth muscle cells.
Whooping Cough
Thrombin receptor activation by thrombin and receptor-derived peptides in platelet and CHRF-288 cell membranes: receptor-stimulated GTPase and evaluation of agonists and partial agonists.
Whooping Cough
Thrombin receptor agonist peptide induction of mitogenesis in CCL39 cells.
Whooping Cough
Thrombin receptor on rat primary hippocampal neurons: coupled calcium and cAMP responses.
Whooping Cough
Thrombin receptors activate G(o) proteins in endothelial cells to regulate intracellular calcium and cell shape changes.
Whooping Cough
Thrombin signal transduction of the fibrinolytic system in human adult venous endothelium in vitro.
Whooping Cough
Thrombin signalling in U937 human monocytic cells is coupled to inositol phosphate formation but not to thromboxane B2 synthesis nor to inhibition of adenylate cyclase: distinct differences in thrombin signalling between U937 cells and platelets.
Whooping Cough
Thrombin stimulates inositol phosphate formation, intracellular calcium fluxes and DNA synthesis in cultured fetal human non-pigmented ciliary epithelial cells.
Whooping Cough
Thrombin stimulates inositol phosphate production and intracellular free calcium by a pertussis toxin-insensitive mechanism in osteosarcoma cells.
Whooping Cough
Thrombin stimulates pertussis toxin-sensitive and -insensitive GTPase activities and ADP-ribosylation of G(i) in human neuroblastoma SH-EP.
Whooping Cough
Thrombin, unlike vasopressin, appears to stimulate two distinct guanine nucleotide regulatory proteins in human platelets.
Whooping Cough
Thrombin-induced activation of cultured rodent microglia.
Whooping Cough
Thrombin-induced Ca2+ mobilization in vascular smooth muscle utilizes a slowly ribosylating pertussis toxin-sensitive G protein. Evidence for the involvement of a G protein in inositol trisphosphate-dependent Ca2+ release.
Whooping Cough
Thrombin-induced proliferation and expression of platelet-derived growth factor-A chain gene in human vascular smooth muscle cells.
Whooping Cough
Thrombin-induced prostacyclin biosynthesis in human endothelium: role of guanine nucleotide regulatory proteins in stimulus/coupling responses.
Whooping Cough
Thrombin-mediated phosphoinositide hydrolysis in Chinese hamster ovary cells overexpressing phospholipase C-delta 1.
Whooping Cough
Thrombin-promoted release of UDP-glucose from human astrocytoma cells.
Whooping Cough
Thrombin-stimulated cell proliferation mediated through activation of Ras/Raf/MEK/MAPK pathway in canine cultured tracheal smooth muscle cells.
Whooping Cough
Thrombin-stimulated proliferation of cultured human synovial fibroblasts through proteolytic activation of proteinase-activated receptor-1.
Whooping Cough
Thrombospondin modulates alpha v beta 3 function through integrin-associated protein.
Whooping Cough
Thrombospondin promotes chemotaxis and haptotaxis of human peripheral blood monocytes.
Whooping Cough
Thrombospondin stimulates focal adhesion disassembly through Gi- and phosphoinositide 3-kinase-dependent ERK activation.
Whooping Cough
Thrombospondin-1 differentially induces chemotaxis and DNA synthesis of human venous smooth muscle cells at the receptor-binding level.
Whooping Cough
Thromboxane A(2) receptor mediated activation of the mitogen activated protein kinase cascades in human uterine smooth muscle cells.
Whooping Cough
Thromboxane A2 activates phospholipase C in astrocytoma cells via pertussis toxin-insensitive G-protein.
Whooping Cough
Thromboxane A2 agonist modulation of excitatory synaptic transmission in the rat hippocampal slice.
Whooping Cough
Thromboxane A2 analogue U 46619 enhances tumour cell proliferation in HeLa cells via specific receptors which are apparently distinct from TXA2 receptors on human platelets.
Whooping Cough
Thromboxane A2 and vascular smooth muscle cell proliferation.
Whooping Cough
Thromboxane A2 mediates the stimulation of inositol 1,4,5-trisphosphate production and intracellular calcium mobilization by bradykinin in neonatal rat ventricular cardiomyocytes.
Whooping Cough
Thromboxane A2 receptor activates a rock/LKB1/Pten pathway to attenuate endothelium insulin signaling.
Whooping Cough
Thromboxane A2 receptor-mediated signal transduction in rabbit aortic smooth muscle cells.
Whooping Cough
Thromboxane prostanoid receptor in human airway smooth muscle cells: a relevant role in proliferation.
Whooping Cough
Thromboxane prostanoid receptor signals through Gi protein to rapidly activate extracellular signal-regulated kinase in human airways.
Whooping Cough
Thromboxane receptor signalling in human myometrial cells.
Whooping Cough
Thrombspondin acts via integrin-associated protein to activate the platelet integrin alphaIIbbeta3.
Whooping Cough
Thy-1 antibody-triggered neurite outgrowth requires an influx of calcium into neurons via N- and L-type calcium channels.
Whooping Cough
Thymic emigrants isolated by a new method possess unique phenotypic and functional properties.
Whooping Cough
Thymoquinone from nutraceutical black cumin oil activates Neu4 sialidase in live macrophage, dendritic, and normal and type I sialidosis human fibroblast cells via GPCR Galphai proteins and matrix metalloproteinase-9.
Whooping Cough
Thymoquinone-induced Neu4 sialidase activates NF?B in macrophage cells and pro-inflammatory cytokines in vivo.
Whooping Cough
Thymoquinone-induced platelet apoptosis.
Whooping Cough
Thyroliberin action in pituitary cells is not inhibited by pertussis toxin.
Whooping Cough
Thyrotropin Causes Dose-dependent Biphasic Regulation of cAMP Production Mediated by Gs and Gi/o Proteins.
Whooping Cough
Thyrotropin effect on the availability of Ni regulatory protein in FRTL-5 rat thyroid cells to ADP-ribosylation by pertussis toxin.
Whooping Cough
Thyrotropin stimulates invasion and growth of follicular thyroid cancer cells via PKC- rather than PKA-activation.
Whooping Cough
Thyrotropin-releasing hormone activates a Ca2+-dependent polyphosphoinositide phosphodiesterase in permeable GH3 cells. GTP gamma S potentiation by a cholera and pertussis toxin-insensitive mechanism.
Whooping Cough
Thyrotropin-releasing hormone and gonadotropin-releasing hormone receptors activate phospholipase C by coupling to the guanosine triphosphate-binding proteins Gq and G11.
Whooping Cough
Thyrotropin-releasing hormone and gonadotropin-releasing hormone-associated peptide modulation of [Ca2+]i in human lactotrophs.
Whooping Cough
Thyrotropin-releasing hormone induces opposite effects on Ca2+ channel currents in pituitary cells by two pathways.
Whooping Cough
Thyrotropin-releasing hormone stimulation of polyphosphoinositide hydrolysis in GH3 cell membranes is GTP dependent but insensitive to cholera or pertussis toxin.
Whooping Cough
Tight association of the human Mel(1a)-melatonin receptor and G(i): precoupling and constitutive activity.
Whooping Cough
Time course of action of pertussis toxin to block the inhibition of stimulated insulin release by norepinephrine.
Whooping Cough
Time-course of infection and responses in a coughing rat model of pertussis.
Whooping Cough
Time-dependent effects of in vivo pertussis toxin on morphine analgesia and G-proteins in mice.
Whooping Cough
Time-dependent reversal of long-term potentiation by low-frequency stimulation at the hippocampal mossy fiber-CA3 synapses.
Whooping Cough
Time-dependent vascular actions of cannabidiol in the rat aorta.
Whooping Cough
TIMP-1 inhibits apoptosis in breast carcinoma cells via a pathway involving pertussis toxin-sensitive G protein and c-Src.
Whooping Cough
Tiopronin (2-mercaptopropionylglycine) has chemokinetic and chemotactic properties for polymorphonuclear leukocytes.
Whooping Cough
Tissue factor is induced by monocyte chemoattractant protein-1 in human aortic smooth muscle and THP-1 cells.
Whooping Cough
Tissue plasminogen activator increases canine endothelial cell proliferation rate through a plasmin-independent, receptor-mediated mechanism.
Whooping Cough
Tissue- and subunit-specific regulation of G-protein expression by hypo- and hyperthyroidism.
Whooping Cough
Titration of myelin oligodendrocyte glycoprotein (MOG) - Induced experimental autoimmune encephalomyelitis (EAE) model.
Whooping Cough
TLR2 transmodulates monocyte adhesion and transmigration via Rac1- and PI3K-mediated inside-out signaling in response to Porphyromonas gingivalis fimbriae.
Whooping Cough
TLR4 contributes to disease-inducing mechanisms resulting in central nervous system autoimmune disease.
Whooping Cough
Tn5-induced mutations affecting virulence factors of Bordetella pertussis.
Whooping Cough
TNF alpha-induced activation of eosinophil oxidative metabolism and morphology--comparison with IL-5.
Whooping Cough
TNF-alpha rapidly antagonizes the beta-adrenergic responses of the chloride current in guinea-pig ventricular myocytes.
Whooping Cough
TNF-alpha stimulates increased plasma membrane guanine nucleotide binding protein activity in polymorphonuclear leukocytes.
Whooping Cough
TNF-alpha stimulates monocyte adhesion to glomerular mesangial cells. The role of intercellular adhesion molecule-1 gene expression and protein kinases.
Whooping Cough
TNF-[alpha] modulates murine tracheal rings responsiveness to G-protein-coupled receptor agonists and KCl.
Whooping Cough
TNF-{alpha} potentiates lysophosphatidic acid-induced COX-2 expression via PKD in human colonic myofibroblasts.
Whooping Cough
Tofacitinib inhibits the development of experimental autoimmune uveitis and reduces the proportions of Th1 but not of Th17 cells.
Whooping Cough
Tolerance induction by acylated peptides: suppression of EAE in the mouse with palmitoylated PLP peptides.
Whooping Cough
Toll-like receptor 4 coupled GI protein signaling pathways regulate extracellular signal-regulated kinase phosphorylation and AP-1 activation independent of NFkappaB activation.
Whooping Cough
Tonic inhibition and rebound facilitation of a neuronal calcium channel by a GTP-binding protein.
Whooping Cough
Tonic inhibition of adenylate cyclase in cultured hamster Sertoli cells.
Whooping Cough
Tonic inhibition of renal response to vasopressin by a pertussis toxin substrate.
Whooping Cough
Toosendanin induces outgrowth of neuronal processes and apoptosis in PC12 cells.
Whooping Cough
Topographic analysis of antigenic determinants recognized by monoclonal antibodies to the photoreceptor guanyl nucleotide-binding protein, transducin.
Whooping Cough
Topological mimicry and epitope duplication in the guanylyl cyclase C receptor.
Whooping Cough
Total body irradiation causes profound changes in endothelial traffic molecules for hematopoietic progenitor cell recruitment to bone marrow.
Whooping Cough
Toward a mechanism-based in vitro safety test for pertussis toxin.
Whooping Cough
Toward an Alum Free Mono-Component Monovalent Pertussis Vaccine: A Cytokine Response Assay.
Whooping Cough
Towards better pertussis vaccines.
Whooping Cough
Towards replacement of the acellular pertussis vaccine safety test: Comparison of in vitro cytotoxic activity and in vivo activity in mice.
Whooping Cough
Towards third-generation whooping cough vaccines.
Whooping Cough
Toxicity of the specific antimuscarinic agent methoctramine and other non-specific anticholinergic drugs in human neuroblastoma cell lines in vitro.
Whooping Cough
Toxin-neutralizing antibodies in patients with pertussis, as determined by an assay using Chinese hamster ovary cells.
Whooping Cough
Toxins which activate adenylate cyclase.
Whooping Cough
Toxins-useful biochemical tools for leukocyte research.
Whooping Cough
Toxoplasma gondii triggers Gi-dependent PI 3-kinase signaling required for inhibition of host cell apoptosis.
Whooping Cough
TPA induction of EL4 resistance to macrophage-released TNF: role of ADP-ribosylation in tumoricidal activities of TNF and other factors.
Whooping Cough
Trafficking of neutrophils across airway epithelium is dependent upon both thioredoxin- and pertussis toxin-sensitive signaling mechanisms.
Whooping Cough
Trans-ACPD inhibits cAMP formation via a pertussis toxin-sensitive G-protein.
Whooping Cough
Trans-ACPD, a metabotropic receptor agonist, produces calcium mobilization and an inward current in cultured cerebellar Purkinje neurons.
Whooping Cough
Trans-cinnamic acid increases adiponectin and the phosphorylation of AMP-activated protein kinase through G-protein-coupled receptor signaling in 3T3-L1 adipocytes.
Whooping Cough
Transactivation of CXCR4 by the insulin-like growth factor-1 receptor (IGF-1R) in human MDA-MB-231 breast cancer epithelial cells.
Whooping Cough
Transcription mediated by a cAMP-responsive promoter element is reduced upon activation of dopamine D2 receptors.
Whooping Cough
Transcription of the muscle regulatory gene Myf4 is regulated by serum components, peptide growth factors and signaling pathways involving G proteins.
Whooping Cough
Transcriptional activation of gonadotropin-releasing hormone (GnRH) receptor gene by GnRH and cyclic adenosine monophosphate.
Whooping Cough
Transcriptional regulation of Na/K-ATPase by corticosteroids, glycyrrhetinic acid and second messenger pathways in rat kidney epithelial cells.
Whooping Cough
Transducin and the cyclic GMP phosphodiesterase: amplifier proteins in vision.
Whooping Cough
Transduction mechanism involving the presynaptic adenosine receptor at mouse motor nerve terminals.
Whooping Cough
Transduction mechanisms involved in thrombin receptor-induced nerve growth factor secretion and cell division in primary cultures of astrocytes.
Whooping Cough
Transduction of intracellular calcium signals through G protein-mediated activation of phospholipase C by recombinant sphingosine 1-phosphate receptors.
Whooping Cough
Transduction of the chemotactic signal to the actin cytoskeleton of Dictyostelium discoideum.
Whooping Cough
Transduction of the modulatory effect of catecholamines at the mammalian motor neuron terminal.
Whooping Cough
Transendothelial migration of megakaryocytes in response to stromal cell-derived factor 1 (SDF-1) enhances platelet formation.
Whooping Cough
Transfected adenosine A1 receptor-mediated modulation of thrombin-stimulated phospholipase C and phospholipase A2 activity in CHO cells.
Whooping Cough
Transfected D2 dopamine receptors mediate the potentiation of arachidonic acid release in Chinese hamster ovary cells.
Whooping Cough
Transfected D2 short dopamine receptors inhibit voltage-dependent potassium current in neuroblastoma x glioma hybrid (NG108-15) cells.
Whooping Cough
Transfected human somatostatin receptor type 2, SSTR2, not only inhibits adenylate cyclase but also stimulates phospholipase C and Ca2+ mobilization.
Whooping Cough
Transfected m2 muscarinic acetylcholine receptors couple to G alpha i2 and G alpha i3 in Chinese hamster ovary cells. Activation and desensitization of the phospholipase C signaling pathway.
Whooping Cough
Transfected platelet-activating factor receptor activates mitogen-activated protein (MAP) kinase and MAP kinase kinase in Chinese hamster ovary cells.
Whooping Cough
Transfection of NG108-15 cells with antisense opioid-binding cell adhesion molecule cDNA alters opioid receptor-G-protein interaction.
Whooping Cough
Transfer of a pertussis toxin expression locus to isogenic bvg-positive and bvg-negative strains of Bordetella bronchiseptica using an in vivo technique.
Whooping Cough
Transfer of thyroiditis, with syngeneic spleen cells sensitized with the human thyrotropin receptor, to naive BALB/c and NOD mice.
Whooping Cough
Transferability of dermal temperature histamine sensitisation test for estimation of pertussis toxin activity in vaccines.
Whooping Cough
Transferability study of CHO cell clustering assays for monitoring of pertussis toxin activity in acellular pertussis vaccines.
Whooping Cough
Transformation by a nucleotide-activated P2Y receptor is mediated by activation of Galphai, Galphaq and Rho-dependent signaling pathways.
Whooping Cough
Transforming growth factor ?2 (TGF-?2)-induced connective tissue growth factor (CTGF) expression requires sphingosine 1-phosphate receptor 5 (S1P5) in human mesangial cells.
Whooping Cough
Transforming growth factor beta 1 treatment of AKR-2B cells is coupled through a pertussis-toxin-sensitive G-protein(s).
Whooping Cough
Transforming growth factor beta enhances parathyroid hormone stimulation of adenylate cyclase in clonal osteoblast-like cells.
Whooping Cough
Transforming growth factor-beta 1 has both promoting and inhibiting effects on induction of DNA synthesis in human fibroblasts.
Whooping Cough
Transforming growth factor-beta 1 regulation of signal transduction in two renal epithelial cell lines.
Whooping Cough
Transforming growth factor-beta up-regulates low density lipoprotein receptor-mediated cholesterol metabolism in vascular smooth muscle cells.
Whooping Cough
Transforming growth factor-beta-mediated proliferation of renal tubular epithelial cells involves pertussis toxin-sensitive G protein-and protein kinase C-dependent pathways.
Whooping Cough
Transforming growth factor-beta1 regulation of growth zone chondrocytes is mediated by multiple interacting pathways.
Whooping Cough
Transgenic expression of stromal cell-derived factor-1/CXC chemokine ligand 12 enhances myeloid progenitor cell survival/antiapoptosis in vitro in response to growth factor withdrawal and enhances myelopoiesis in vivo.
Whooping Cough
Transgenic mice that express a myelin basic protein-specific T cell receptor develop spontaneous autoimmunity.
Whooping Cough
Transgenic mice with cardiac overexpression of alpha1B-adrenergic receptors. In vivo alpha1-adrenergic receptor-mediated regulation of beta-adrenergic signaling.
Whooping Cough
Transient Ca2+ changes in endothelial cells induced by low doses of reactive oxygen species: role of hydrogen peroxide.
Whooping Cough
Transient increase in phosphatidylinositol 3,4-bisphosphate and phosphatidylinositol trisphosphate during activation of human neutrophils.
Whooping Cough
Transient inhibition of capacitative calcium entry in human neutrophils by a monoclonal antibody directed against a 19-kDa antigen.
Whooping Cough
Transition-state structure for the ADP-ribosylation of recombinant Gialpha1 subunits by pertussis toxin.
Whooping Cough
Translocation of activated heterotrimeric G protein Galpha(o) to ganglioside-enriched detergent-resistant membrane rafts in developing cerebellum.
Whooping Cough
Translocation of Activator of G-protein Signaling 3 to the Golgi Apparatus in Response to Receptor Activation and Its Effect on the trans-Golgi Network.
Whooping Cough
Transmembrane mechanochemical coupling in cardiac myocytes: novel activation of Gi by hyposmotic swelling.
Whooping Cough
Transmembrane signaling pathways involved in phagocytosis and associated activation of NADPH oxidase mediated by Fc gamma Rs in human neutrophils.
Whooping Cough
Transmembrane signalling by the N-formyl peptide receptor in stably transfected fibroblasts.
Whooping Cough
Transmembrane signalling of atrial natriuretic peptide in rat renal juxtaglomerular cells.
Whooping Cough
Transmembrane signalling pathways initiating cell growth in fibroblasts.
Whooping Cough
Treatment in hypertensive cardiac hypertrophy, II. Postreceptor events.
Whooping Cough
Treatment of bone-derived ROS 17/2.8 cells with dexamethasone and pertussis toxin enables detection of partial agonist activity for parathyroid hormone antagonists.
Whooping Cough
Treatment of human platelets with trypsin, thrombin, or collagen inhibits the pertussis toxin-induced ADP-ribosylation of a 41-kDa protein.
Whooping Cough
Treatment of intact hepatocytes with either the phorbol ester TPA or glucagon elicits the phosphorylation and functional inactivation of the inhibitory guanine nucleotide regulatory protein Gi.
Whooping Cough
Treatment of intact striatal neurones with cholera toxin or 8-bromoadenosine 3',5'-(cyclic)phosphate decreases the ability of pertussis toxin to ADP-ribosylate the alpha-subunits of inhibitory and other guanine-nucleotide-binding regulatory proteins, Gi and Go. Evidence for two distinct mechanisms.
Whooping Cough
Treatment of rabbit neutrophils with phorbol esters results in increased ADP-ribosylation catalyzed by pertussis toxin and inhibition of the GTPase stimulated by fMet-Leu-Phe.
Whooping Cough
Treatment of severe pertussis: a study of the safety and pharmacology of intravenous pertussis immunoglobulin.
Whooping Cough
Treatment with pertussis toxin does not prevent central effects of eel calcitonin.
Whooping Cough
Treatment with Vitamin D/MOG Association Suppresses Experimental Autoimmune Encephalomyelitis.
Whooping Cough
Trends in Hospital Admissions for Pertussis Infection: A Nationwide Retrospective Observational Study in Italy, 2002-2016.
Whooping Cough
TRH raises cytosolic Ca2+ in human adenomatous lactotrophs.
Whooping Cough
Trial of a new acellular pertussis vaccine in healthy adult volunteers.
Whooping Cough
Trichinella spiralis: histamine secretion induced by TSL-1 antigens from unsensitized mast cells.
Whooping Cough
Tricyclic Antidepressant Amitriptyline-induced Glial Cell Line-derived Neurotrophic Factor Production Involves Pertussis Toxin-sensitive G?i/o Activation in Astroglial Cells.
Whooping Cough
Tricyclic antidepressants inhibit Ca(2+)-activated K(+)-efflux in cultured spinal cord neurons.
Whooping Cough
Triggering by ATP of product release by mucous granules of the land slug Ariolimax columbianus.
Whooping Cough
Triggering of degranulation in mast cells by exogenous type II phospholipase A2.
Whooping Cough
Triggers of autoimmune disease in a murine TCR-transgenic model for multiple sclerosis.
Whooping Cough
Triglyceride modulation by acifran analogs: activity towards the niacin high and low affinity G protein-coupled receptors HM74A and HM74.
Whooping Cough
Trimer carboxyl propeptide of collagen I produced by mature osteoblasts is chemotactic for endothelial cells.
Whooping Cough
Trimeric G proteins regulate the cytosol-induced redistribution of Golgi enzymes into the endoplasmic reticulum.
Whooping Cough
Triplex real-time PCR assay for detection and differentiation of Bordetella pertussis and Bordetella parapertussis.
Whooping Cough
Trophic effect of angiotensin II in neonatal rat cardiomyocytes: role of endothelin-1 and non-myocyte cells.
Whooping Cough
Trp-Lys-Tyr-Met-Val-D-Met is a chemoattractant for human phagocytic cells.
Whooping Cough
Trp-Lys-Tyr-Met-Val-Met activates mitogen-activated protein kinase via a PI-3 kinase-mediated pathway independent of PKC.
Whooping Cough
Truncation of the carboxyl-terminal region of the rat parathyroid hormone (PTH)/PTH-related peptide receptor enhances PTH stimulation of adenylyl cyclase but not phospholipase C.
Whooping Cough
Trypanosoma brucei: characterisation of a life cycle stage-specific G-protein.
Whooping Cough
Trypanosoma cruzi: infection of cultured human endothelial cells alters inositol phosphate synthesis.
Whooping Cough
Trypsin stimulates integrin alpha(5)beta(1)-dependent adhesion to fibronectin and proliferation of human gastric carcinoma cells through activation of proteinase-activated receptor-2.
Whooping Cough
Trypsin stimulates the phosphorylation of p42,44 mitogen-activated protein kinases via the proteinase-activated receptor-2 and protein kinase C epsilon in human cultured prostate stromal cells.
Whooping Cough
Tryptamine induces phosphoinositide turnover and modulates adrenergic and muscarinic cholinergic receptor function in cultured cerebellar granule cells.
Whooping Cough
Tryptase and agonists of PAR-2 induce the proliferation of human airway smooth muscle cells.
Whooping Cough
Tryptase enhances release of vascular endothelial growth factor from human osteoarthritic chondrocytes.
Whooping Cough
Tryptase inhibits motility of human spermatozoa mainly by activation of the mitogen-activated protein kinase pathway.
Whooping Cough
TSH Activates Macrophage Inflammation by G13- and G15-dependent Pathways.
Whooping Cough
TSH Receptor Homodimerization in Regulation of cAMP Production in Human Thyrocytes in vitro.
Whooping Cough
TSH/IGF-1 Receptor Cross-talk Rapidly Activates Extracellular Signal-regulated Kinases in Multiple Cell Types.
Whooping Cough
Tumor cell autocrine motility factor receptor.
Whooping Cough
Tumor cell motility.
Whooping Cough
Tumor necrosis factor alpha 'primes' the platelet-activating factor-induced superoxide production by human neutrophils: possible involvement of G proteins.
Whooping Cough
Tumor necrosis factor alpha inhibits collagen alpha 1(I) gene expression in rat hepatic stellate cells through a G protein.
Whooping Cough
Tumor necrosis factor alpha modulates parathyroid hormone action in UMR-106-01 osteoblastic cells.
Whooping Cough
Tumor necrosis factor and interleukin 1 inhibit parathyroid hormone-responsive adenylate cyclase in clonal osteoblast-like cells by down-regulating parathyroid hormone receptors.
Whooping Cough
Tumor necrosis factor induced release of endothelial cell lipoprotein lipase.
Whooping Cough
Tumor necrosis factor inhibits K+ current expression in cultured oligodendrocytes.
Whooping Cough
Tumor necrosis factor reduces cAMP production in rat microglia.
Whooping Cough
Tumor necrosis factor-alpha inhibits the cardiac delayed rectifier K current via the asphingomyelin pathway.
Whooping Cough
Tumor necrosis factor-alpha-stimulated cell proliferation is mediated through sphingosine kinase-dependent Akt activation and cyclin D expression.
Whooping Cough
Tumor necrosis factor-alpha/cachectin activates the O2(-)-generating system of human neutrophils independently of the hydrolysis of phosphoinositides and the release of arachidonic acid.
Whooping Cough
Tumor necrosis factor-mediated biological activities involve a G-protein-dependent mechanism.
Whooping Cough
Tumor necrosis factor/cachectin increases permeability of endothelial cell monolayers by a mechanism involving regulatory G proteins.
Whooping Cough
Tumour necrosis factor (cachectin) induces phospholipase A2 activity and synthesis of a phospholipase A2-activating protein in endothelial cells.
Whooping Cough
Tumour necrosis factor-alpha stimulates invasiveness of T-cell hybridomas and cytotoxic T-cell clones by a pertussis toxin-insensitive mechanism.
Whooping Cough
Tumour necrosis factor-alpha- and interleukin-1beta-stimulated cell proliferation through activation of mitogen-activated protein kinase in canine tracheal smooth muscle cells.
Whooping Cough
Tungstate-targeting of BK??1 channels tunes ERK phosphorylation and cell proliferation in human vascular smooth muscle.
Whooping Cough
Two basic amino acids in the second inner loop of the interleukin-8 receptor are essential for Galpha16 coupling.
Whooping Cough
Two C-terminal peptides of human CKLF1 interact with the chemokine receptor CCR4.
Whooping Cough
Two different G-proteins mediate neuropeptide Y and bradykinin-stimulated phospholipid breakdown in cultured rat sensory neurons.
Whooping Cough
Two different ionotropic receptors are activated by ATP in rat microglia.
Whooping Cough
Two different P2Y receptors linked to steroidogenesis in bovine adrenocortical cells.
Whooping Cough
Two different signal transductions of neuropeptide Y1 receptor in SK-N-MC cells.
Whooping Cough
Two different signaling mechanisms involved in the excitation of rat sympathetic neurons by uridine nucleotides.
Whooping Cough
Two distinct Gi-proteins mediate formyl peptide receptor signal transduction in human leukemia (HL-60) cells.
Whooping Cough
Two distinct light regulated G-proteins in octopus photoreceptors.
Whooping Cough
Two distinct P2 purinergic receptors, P2Y and P2U, are coupled to phospholipase C in mouse pineal gland tumor cells.
Whooping Cough
Two distinct pathways in the down-regulation of type-1 angiotension II receptor gene in rat glomerular mesangial cells.
Whooping Cough
Two distinct pathways of platelet-activating factor-induced hydrolysis of phosphoinositides in primary cultures of rat Kupffer cells.
Whooping Cough
Two growth factor signalling pathways in fibroblasts distinguished by pertussis toxin.
Whooping Cough
Two guanine nucleotide-binding proteins in rat brain serving as the specific substrate of islet-activating protein, pertussis toxin. Interaction of the alpha-subunits with beta gamma-subunits in development of their biological activities.
Whooping Cough
Two human alpha 2-adrenoceptor subtypes alpha 2A-C10 and alpha 2B-C2 expressed in Sf9 cells couple to transduction pathway resulting in opposite effects on cAMP production.
Whooping Cough
Two intracellular signaling pathways for activation of protein kinase C are involved in oxidized low-density lipoprotein-induced macrophage growth.
Whooping Cough
Two isoforms of prostaglandin EP3 receptor exhibiting constitutive activity and agonist-dependent activity in Rho-mediated stress fiber formation.
Whooping Cough
Two isoforms of the EP3 receptor with different carboxyl-terminal domains. Identical ligand binding properties and different coupling properties with Gi proteins.
Whooping Cough
Two mechanisms of photoendocrine transduction in cultured chick pineal cells: pertussis toxin blocks the acute but not the phase-shifting effects of light on the melatonin rhythm.
Whooping Cough
Two opposite signal transducing mechanisms regulate a G-protein-coupled guanylyl cyclase.
Whooping Cough
Two phases of pseudopod protrusion in tumor cells revealed by a micropipette.
Whooping Cough
Two subtypes of G protein-coupled nucleotide receptors, P2Y(1) and P2Y(2) are involved in calcium signalling in glioma C6 cells.
Whooping Cough
Two types of G proteins involved in regulation of phosphoinositide turnover in pulmonary endothelial cells.
Whooping Cough
Two types of voltage-dependent calcium current in rat somatotrophs are reduced by somatostatin.
Whooping Cough
Two-Component Cluster Analysis of a Large Serodiagnostic Database for Specificity of Increases of IgG Antibodies against Pertussis Toxin in Paired Serum Samples and of Absolute Values in Single Serum Samples.
Whooping Cough
Two-pore potassium ion channels are inhibited by both G(q/11)- and G(i)-coupled P2Y receptors.
Whooping Cough
Two-step activation of T cells, clonal expansion and subsequent Th1 cytokine production, is essential for the development of clinical autoimmune encephalomyelitis.
Whooping Cough
TXA2 agonists inhibit high-voltage-activated calcium channels in rat hippocampal CA1 neurons.
Whooping Cough
Type 1 angiotensin receptor (AT1-R)-mediated decrease in type 2 angiotensin receptor mRNA level is dependent on Gq and extracellular signal-regulated kinase 1//2 in AT1-R-transfected PC12 cells.
Whooping Cough
Type 2 lysophosphatidic acid receptor in gastric surface mucous cells: Possible implication of prostaglandin E2 production.
Whooping Cough
Type A allatostatins from Drosophila melanogaster and Diplotera puncata activate two Drosophila allatostatin receptors, DAR-1 and DAR-2, expressed in CHO cells.
Whooping Cough
Type II phospholipase A2 recombinant overexpression enhances stimulated arachidonic acid release.
Whooping Cough
Type IV collagen stimulates an increase in intracellular calcium. Potential role in tumor cell motility.
Whooping Cough
Tyramine receptor (SER-2) isoforms are involved in the regulation of pharyngeal pumping and foraging behavior in Caenorhabditis elegans.
Whooping Cough
Tyrosine 308 is necessary for ligand-directed Gs protein-biased signaling of ?2-adrenoceptor.
Whooping Cough
Tyrosine kinase activation by Newcastle disease virus is required for TNF-alpha gene induction in astrocytes.
Whooping Cough
Tyrosine kinase-activating growth factors potentiate thrombin- and AIF4- -induced phosphoinositide breakdown in hamster fibroblasts. Evidence for positive cross-talk between the two mitogenic signaling pathways.
Whooping Cough
Tyrosine phosphorylation and activation of Janus kinase 1 and STAT3 by sublytic C5b-9 complement complex in aortic endothelial cells.
Whooping Cough
Tyrosine phosphorylation and oxygen consumption induced by G proteins in neutrophils.
Whooping Cough
Tyrosine phosphorylation in activated human neutrophils. Comparison of the effects of different classes of agonists and identification of the signaling pathways involved.
Whooping Cough
Tyrosine phosphorylation in human neutrophil.
Whooping Cough
Tyrosine phosphorylation induced by cross-linking of Fc gamma-receptor type II in human neutrophils.
Whooping Cough
Tyrosine phosphorylation is an obligatory event in IL-2 secretion.
Whooping Cough
Tyrosine phosphorylation is involved in reorganization of the actin cytoskeleton in response to serum or LPA stimulation.
Whooping Cough
Tyrosine phosphorylation is required for eosinophil degranulation induced by immobilized immunoglobulins.
Whooping Cough
Tyrosine phosphorylation of a 34-kDa protein induced by cross-linking a novel glycosylphosphatidylinositol-anchored glycoprotein (GPI-80) on human neutrophils that may regulate their adherence and migration.
Whooping Cough
Tyrosine phosphorylation of a 58 kDa protein induced by morphine in SK-N-SH cells.
Whooping Cough
Tyrosine phosphorylation of a low molecular weight protein induced by RANTES in T-lymphocytes.
Whooping Cough
Tyrosine phosphorylation of an SH2-containing protein tyrosine phosphatase is coupled to platelet thrombin receptor via a pertussis toxin-sensitive heterotrimeric G-protein.
Whooping Cough
U-73122, a phospholipase C antagonist, inhibits effects of endothelin-1 and parathyroid hormone on signal transduction in UMR-106 osteoblastic cells.
Whooping Cough
U50,488H inhibits effects of norepinephrine in rat cardiomyocytes-cross-talk between kappa-opioid and beta-adrenergic receptors.
Whooping Cough
U50,488H-induced internalization of the human kappa opioid receptor involves a beta-arrestin- and dynamin-dependent mechanism. Kappa receptor internalization is not required for mitogen-activated protein kinase activation.
Whooping Cough
UDP-glucose acting at P2Y14 receptors is a mediator of mast cell degranulation.
Whooping Cough
Ultra-low dose naloxone restores the antinocicepitve effect of morphine in PTX-treated rats: Association of IL-10 upregulation in the spinal cord.
Whooping Cough
Ultra-low dose naloxone restores the antinociceptive effect of morphine in pertussis toxin-treated rats and prevents glutamate transporter downregulation by suppressing the p38 mitogen-activated protein kinase signaling pathway.
Whooping Cough
Ultra-low dose naloxone restores the antinociceptive effect of morphine in pertussis toxin-treated rats by reversing the coupling of mu-opioid receptors from Gs-protein to coupling to Gi-protein.
Whooping Cough
Ultra-low-dose naloxone enhances the antinociceptive effect of morphine in PTX-treated rats: regulation on global histone methylation.
Whooping Cough
Ultra-low-dose naloxone restores the antinociceptive effect of morphine and suppresses spinal neuroinflammation in PTX-treated rats.
Whooping Cough
Unbinding forces of single pertussis toxin-antibody complexes measured by atomic force spectroscopy correlate with their dissociation rates determined by surface plasmon resonance.
Whooping Cough
Unchanged efficacy of a pertussis toxoid vaccine throughout the two years after the third vaccination of infants.
Whooping Cough
Uncoupling of gamma-aminobutyric acid B receptors from GTP-binding proteins by N-ethylmaleimide: effect of N-ethylmaleimide on purified GTP-binding proteins.
Whooping Cough
Undifferentiated U937 cells transfected with chemoattractant receptors: a model system to investigate chemotactic mechanisms and receptor structure/function relationships.
Whooping Cough
Unidirectional, heterologous desensitization of the pertussis toxin receptor by the CD3/TCR complex.
Whooping Cough
Unique inhibitory profile of platelet activating factor induced calcium mobilization, polyphosphoinositide turnover and granule enzyme secretion in rabbit neutrophils towards pertussis toxin and phorbol ester.
Whooping Cough
Unique monoclonal antibody recognizing the third extracellular loop of CXCR4 induces lymphocyte agglutination and enhances human immunodeficiency virus type 1-mediated syncytium formation and productive infection.
Whooping Cough
Unique SDF-1-induced activation of human precursor-B ALL cells as a result of altered CXCR4 expression and signaling.
Whooping Cough
Unmasking of LPA(1) receptor-mediated migration response to lysophosphatidic acid by interleukin-1?-induced attenuation of Rho signaling pathways in rat astrocytes.
Whooping Cough
Unopposed matrix metalloproteinase-9 expression in human tuberculous granuloma and the role of TNF-alpha-dependent monocyte networks.
Whooping Cough
Unrecognized pertussis infection in adolescents.
Whooping Cough
Unsaturated fatty acids mobilize intracellular calcium independent of IP3 generation and VIA insertion at the plasma membrane.
Whooping Cough
Untangling the genetic link between type 1 and type 2 diabetes using functional genomics.
Whooping Cough
Up-regulation in late pregnancy of both Go1 alpha and Go2 alpha isoforms in human myometrium.
Whooping Cough
Up-regulation of endothelial nitric-oxide synthase promoter by the phosphatidylinositol 3-kinase gamma /Janus kinase 2/MEK-1-dependent pathway.
Whooping Cough
Up-regulation of human neutrophil receptors for Neisseria gonorrhoeae expressing PII outer membrane proteins.
Whooping Cough
Up-regulation of interleukin-6 in human ovarian cancer cell via a Gi/PI3K-Akt/NF-kappaB pathway by lysophosphatidic acid, an ovarian cancer-activating factor.
Whooping Cough
Up-regulation of RGS4 mRNA by opioid receptor agonists in PC12 cells expressing cloned mu- or kappa-opioid receptors.
Whooping Cough
Up-regulation of the alpha2-macroglobulin signaling receptor on rheumatoid synovial fibroblasts.
Whooping Cough
Upregulation of Na(+)-dependent alanine transport in vascular endothelial cells by serum: role of intracellular Ca2+.
Whooping Cough
Upregulation of TNF-alpha-induced ICAM-1 surface expression by adenylate cyclase-dependent pathway in human endothelial cells.
Whooping Cough
Uptake and intracellular survival of Bordetella pertussis in human macrophages.
Whooping Cough
Urinary pheromones promote ERK/Akt phosphorylation, regeneration and survival of vomeronasal (V2R) neurons.
Whooping Cough
Urocortin 3 elevates cytosolic calcium in nucleus ambiguus neurons.
Whooping Cough
Urokinase potentiates PDGF-induced chemotaxis of human airway smooth muscle cells.
Whooping Cough
Urokinase-induced smooth muscle cell responses require distinct signaling pathways: a role for the epidermal growth factor receptor.
Whooping Cough
Urokinase/urokinase receptor and vitronectin/alpha(v)beta(3) integrin induce chemotaxis and cytoskeleton reorganization through different signaling pathways.
Whooping Cough
Urotensin-II receptor stimulation of cardiac L-type Ca2+ channels requires the ?? subunits of Gi/o-protein and phosphatidylinositol 3-kinase-dependent protein kinase C beta 1 isoform.
Whooping Cough
Use of a cAMP BRET sensor to characterize a novel regulation of cAMP by the sphingosine 1-phosphate/G13 pathway.
Whooping Cough
Use of a Chinese hamster ovary cell cytotoxicity assay for the rapid diagnosis of pertussis.
Whooping Cough
Use of biotinylated NAD to label and purify ADP-ribosylated proteins.
Whooping Cough
Use of chemokine receptors by poxviruses.
Whooping Cough
Use of constitutive G protein-coupled receptor activity for drug discovery.
Whooping Cough
Use of cyclodextrin as an agent to induce excretion of Bordetella pertussis antigens.
Whooping Cough
Use of erythromycin to prevent pertussis in newborns of mothers with pertussis.
Whooping Cough
Use of fluoride ion as a probe for the guanine nucleotide-binding protein involved in the phosphoinositide-dependent neutrophil transduction pathway.
Whooping Cough
Use of G-protein coupled and uncoupled CCR5 receptors by CCR5 inhibitor-resistant and -sensitive human immunodeficiency virus type 1 variants.
Whooping Cough
Use of glycosyltransferases to restore pertussis toxin receptor activity to asialoagalactofetuin.
Whooping Cough
Use of implantable intraperitoneal diffusion chambers to study Bordetella pertussis pathogenesis: growth and toxin production in vivo.
Whooping Cough
Use of pertussis toxin encoded by ptx genes from Bordetella bronchiseptica to model the effects of antigenic drift of pertussis toxin on antibody neutralization.
Whooping Cough
Use of pertussis toxin to investigate the mechanism of action of prostaglandin F2 alpha on the corpus luteum in sheep.
Whooping Cough
Use of replication-deficient adenoviruses to study signal transduction pathways. Muscarinic responses in HSG and HT29 epithelial cell lines are mediated by G protein betagamma-subunits.
Whooping Cough
Use of RGS-insensitive Galpha subunits to study endogenous RGS protein action on G-protein modulation of N-type calcium channels in sympathetic neurons.
Whooping Cough
Use of synthetic peptides to map antigenic sites of Bordetella pertussis toxin subunit S1.
Whooping Cough
Use of the Membrane Invasion Culture System (MICS) as a screen for anti-invasive agents.
Whooping Cough
Use of the promoter fusion transposon Tn5 lac to identify mutations in Bordetella pertussis vir-regulated genes.
Whooping Cough
Use of type I and type IV hypersensitivity responses to define the immunopharmacological profile of drugs.
Whooping Cough
Usefulness of laboratory methods in diagnosis of pertussis in adult with paroxysmal cough.
Whooping Cough
Utilization of sialic acid-binding synthetic peptide sequences derived from pertussis toxin as novel anti-inflammatory agents.
Whooping Cough
V642I APP-inducible neuronal cells: a model system for investigating Alzheimer's disorders.
Whooping Cough
Vaccination against the gastrointestinal nematode, Haemonchus contortus, using a purified larval surface antigen.
Whooping Cough
Vaccination of infants with a four-dose and a three-dose vaccination schedule.
Whooping Cough
Vaccination with amyloid-beta peptide induces autoimmune encephalomyelitis in C57/BL6 mice.
Whooping Cough
Vaccination with pertussis toxin alters the antibody response to simultaneous respiratory syncytial virus challenge.
Whooping Cough
Vaccine acquired pertussis immunity was weakened at 4 years of age and asymptomatic pertussis infection was suspected based on serological surveillance.
Whooping Cough
Vaccine- and antigen-dependent type 1 and type 2 cytokine induction after primary vaccination of infants with whole-cell or acellular pertussis vaccines.
Whooping Cough
Vaccines, emerging viruses, and how to avoid disaster.
Whooping Cough
Vacuolation Activity and Intracellular Trafficking of ArtB, the Binding Subunit of an AB5 Toxin Produced by Salmonella enterica Serovar Typhi.
Whooping Cough
Validation of nested Bordetella PCR in pertussis vaccine trial.
Whooping Cough
Validation of the toxin-binding inhibition (ToBI) test for the estimation of the potency of the tetanus toxoïd component in vaccines.
Whooping Cough
Valproic Acid Attenuates Disease Symptoms and Increases Endogenous Myelin Repair by Recruiting Neural Stem Cells and Oligodendrocyte Progenitors in Experimental Autoimmune Encephalomyelitis.
Whooping Cough
Vanadate causes synthesis of endothelium-derived NO via pertussis toxin-sensitive G protein in pigs.
Whooping Cough
Vanadate changes Ca2+ influx pathway properties in human red blood cells.
Whooping Cough
Vanadate-induced oscillatory inward Cl- currents in Xenopus laevis oocytes.
Whooping Cough
Variation in the Bordetella pertussis virulence factors pertussis toxin and pertactin in vaccine strains and clinical isolates in Finland.
Whooping Cough
Variations in guanine-binding proteins (Gs, Gi) in cultured bovine adrenal cells. Consequences on the effects of phorbol ester and angiotensin II on adrenocorticotropin-induced and cholera-toxin-induced cAMP production.
Whooping Cough
Varying expression of opioid receptors and GTP-binding proteins in human pheochromocytomas.
Whooping Cough
Vascular and immunopathological role of Asymmetric Dimethylarginine (ADMA) in Experimental Autoimmune Encephalomyelitis.
Whooping Cough
Vascular beta-adrenoceptor blocking activity of endotoxin and pertussis toxin from Bordetella pertussis in rats.
Whooping Cough
Vascular effects of delta 9-tetrahydrocannabinol (THC), anandamide and N-arachidonoyldopamine (NADA) in the rat isolated aorta.
Whooping Cough
Vascular endothelial growth factor production in human prostate cancer cells is stimulated by overexpression of platelet 12-lipoxygenase.
Whooping Cough
Vascular function and sphingosine-1-phosphate regulate development of the dorsal pancreatic mesenchyme.
Whooping Cough
Vascular insulin/insulin-like growth factor-1 resistance in female obese Zucker rats.
Whooping Cough
Vascular smooth muscle migration and proliferation in response to lysophosphatidic acid (LPA) is mediated by LPA receptors coupling to Gq.
Whooping Cough
Vascular smooth muscle overexpression of G protein-coupled receptor kinase 5 elevates blood pressure, which segregates with sex and is dependent on Gi-mediated signaling.
Whooping Cough
Vascular smooth muscle proliferation: synergistic interaction between serotonin and low density lipoproteins.
Whooping Cough
Vascular smooth muscle: availability of calcium through alpha-adrenoceptor stimulation.
Whooping Cough
Vascular vasopressin receptors mediate phosphatidylinositol turnover and calcium efflux in an established smooth muscle cell line.
Whooping Cough
Vasoactive intestinal peptide and epidermal growth factor: co-mitogens or inhibitors of keratinocyte proliferation in vitro?
Whooping Cough
Vasoactive intestinal peptide is a secretagogue in bovine chromaffin cells pretreated with pertussis toxin.
Whooping Cough
Vasoactive intestinal peptide/pituitary adenylate cyclase-activating peptide-dependent activation of membrane-bound NO synthase in smooth muscle mediated by pertussis toxin-sensitive Gi1-2.
Whooping Cough
Vasoactive intestinal polypeptide modulates GABAA receptor function through activation of cyclic AMP.
Whooping Cough
Vasoactive intestinal polypeptide modulation of nicotinic ACh receptor channels in rat intracardiac neurones.
Whooping Cough
Vasodilator signals from the ischemic myocardium are transduced to the coronary vascular wall by pertussis toxin-sensitive G proteins: a new experimental method for the analysis of the interaction between the myocardium and coronary vessels.
Whooping Cough
Vasopressin activates phospholipase D through pertussis toxin-insensitive GTP-binding protein in aortic smooth muscle cells: function of Ca2+/calmodulin.
Whooping Cough
Vasopressin and amastatin induce V(1)-receptor-mediated suppression of excitatory transmission in the rat parabrachial nucleus.
Whooping Cough
Vasopressin and protein kinase A activate G protein-sensitive epithelial Na+ channels.
Whooping Cough
Vasopressin induces arachidonic acid release through pertussis toxin-sensitive GTP-binding protein in aortic smooth muscle cells: independence from phosphoinositide hydrolysis.
Whooping Cough
Vasopressin induces breakdown of phosphoinositides in adrenal tumor Y-1 cells without a steroidogenic effect.
Whooping Cough
Vasopressin induces V1 receptors to activate phosphatidylinositol- and phosphatidylcholine-specific phospholipase C and stimulates the release of arachidonic acid by at least two pathways in the smooth muscle cell line, A-10.
Whooping Cough
Vasopressin rapidly stimulates protein kinase C in digitonin-permeabilized Swiss 3T3 cells: involvement of a pertussis toxin-insensitive guanine nucleotide binding protein.
Whooping Cough
Vasopressin regulates adrenal functions by acting through different vasopressin receptor subtypes.
Whooping Cough
Vasopressin resistance in chronic renal failure. Evidence for the role of decreased V2 receptor mRNA.
Whooping Cough
Vasopressin V1 receptors on the principal cells of the rabbit cortical collecting tubule. Stimulation of cytosolic free calcium and inositol phosphate production via coupling to a pertussis toxin substrate.
Whooping Cough
Vasopressin-induced currents in rat neonatal spinal lateral horn neurons are G-protein mediated and involve two conductances.
Whooping Cough
Vasorelaxant effects of oleamide in rat small mesenteric artery indicate action at a novel cannabinoid receptor.
Whooping Cough
Vectors to achieve selective expression of vaccine antigens within eukaryotic cells using Salmonella spp. as carrier strains.
Whooping Cough
Ventricular zone gene-1 (vzg-1) encodes a lysophosphatidic acid receptor expressed in neurogenic regions of the developing cerebral cortex.
Whooping Cough
Verapamil has antiarrhythmic effects that are mediated in brain through endogenous opioids.
Whooping Cough
Violet Light Down-Regulates the Expression of Specific Differentiation Markers through Rhodopsin in Normal Human Epidermal Keratinocytes.
Whooping Cough
VIP activates G(s) and G(i3) in rat alveolar macrophages and G(s) in HEK293 cells transfected with the human VPAC(1) receptor.
Whooping Cough
VIP and PACAP potentiation of nicotinic ACh-evoked currents in rat parasympathetic neurons is mediated by G-protein activation.
Whooping Cough
VIP inhibits N-type Ca2+ channels of sympathetic neurons via a pertussis toxin-insensitive but cholera toxin-sensitive pathway.
Whooping Cough
Virodhamine and CP55,940 modulate cAMP production and IL-8 release in human bronchial epithelial cells.
Whooping Cough
Virulence factor secretion and translocation by Bordetella species.
Whooping Cough
Virulence factors of Bordetella pertussis.
Whooping Cough
Virulence of Bordetella bronchiseptica: role of adenylate cyclase-hemolysin.
Whooping Cough
Virus stimulation of human mast cells results in the recruitment of CD56+ T cells by a mechanism dependent on CCR5 ligands.
Whooping Cough
Visible light exposure induces VEGF gene expression through activation of retinoic acid receptor-alpha in retinoblastoma Y79 cells.
Whooping Cough
Visualization of IL-12/23p40 in vivo reveals immunostimulatory dendritic cell migrants that promote Th1 differentiation.
Whooping Cough
Visualization of muscarinic cholinergic receptors on chick cardiomyocytes and their involvement in phosphatidylcholine hydrolysis.
Whooping Cough
Vitamin D receptor-dependent 1 alpha,25(OH)2 vitamin D3-induced anti-apoptotic PI3K/AKT signaling in osteoblasts.
Whooping Cough
Voltage- and ligand-activated inwardly rectifying currents in dorsal raphe neurons in vitro.
Whooping Cough
Voltage- and time-dependent inhibition of neuronal calcium channels by a GTP-binding protein in a mammalian cell line.
Whooping Cough
Voltage-dependent calcium channels and Gi regulatory protein mediate the human sperm acrosomal exocytosis induced by N-acetylglucosaminyl/mannosyl neoglycoproteins.
Whooping Cough
Voltage-Dependent Dopamine Potency at D1-Like Dopamine Receptors.
Whooping Cough
Voltage-dependent inhibition of Ca2+ channels in GH3 cells by cloned mu- and delta-opioid receptors.
Whooping Cough
Voltage-dependent noradrenergic modulation of omega-conotoxin-sensitive Ca2+ channels in human neuroblastoma IMR32 cells.
Whooping Cough
Voltage-dependent, pertussis toxin insensitive inhibition of calcium currents by histamine in bovine adrenal chromaffin cells.
Whooping Cough
Voltage-Gated R-Type Calcium Channel Inhibition via Human ?-, ?-, and ?-opioid Receptors Is Voltage-Independently Mediated by G?? Protein Subunits.
Whooping Cough
Voltage-independent autocrine modulation of L-type channels mediated by ATP, opioids and catecholamines in rat chromaffin cells.
Whooping Cough
Volume-activated taurine transport is differentially activated in human cervical cancer HT-3 cells but not in human papillomavirus-immortalized Z183A and normal cervical epithelial cells.
Whooping Cough
Voluntary exercise-induced changes in beta2-adrenoceptor signalling in rat ventricular myocytes.
Whooping Cough
Waning vaccine immunity and vaccination responses in children treated for acute lymphoblastic leukemia: A Canadian Immunization Research Network Study.
Whooping Cough
WAY208466 inhibits glutamate release at hippocampal nerve terminals.
Whooping Cough
Western blot analysis of antibody responses of young infants to pertussis infection.
Whooping Cough
What to do and what not to do in serological diagnosis of pertussis: recommendations from EU reference laboratories.
Whooping Cough
Whole-cell but not acellular pertussis vaccines induce convulsive activity in mice: evidence of a role for toxin-induced interleukin-1beta in a new murine model for analysis of neuronal side effects of vaccination.
Whooping Cough
Whole-cell calcium current in guinea-pig ventricular myocytes dialysed with guanine nucleotides.
Whooping Cough
Whole-cell Cl- currents in a human peripheral airway epithelial cell line.
Whooping Cough
Whole-cell recordings of inwardly rectifying K+ currents activated by 5-HT1A receptors on dorsal raphe neurones of the adult rat.
Whooping Cough
Whooping cough and Parkinson's disease. The Europarkinson Preparatory Activity Research Group.
Whooping Cough
Whooping Cough in Adults: A Series of Severe Cases.
Whooping Cough
Why are several inhibitory transmitters present in the innervation of pituitary melanotrophs? Actions and interactions of dopamine, GABA and neuropeptide Y on secretion from neurointermediate lobes of Xenopus laevis.
Whooping Cough
Widespread distribution of Gq alpha/G11 alpha detected immunologically by an antipeptide antiserum directed against the predicted C-terminal decapeptide.
Whooping Cough
Widespread silent transmission of pertussis in families: antibody correlates of infection and symptomatology.
Whooping Cough
Win 55212-2, a cannabinoid receptor agonist, attenuates leukocyte/endothelial interactions in an experimental autoimmune encephalomyelitis model.
Whooping Cough
Withdrawal of somatostatin augments L-type Ca2+ current in primary cultured rat somatotrophs.
Whooping Cough
WNT-3A-induced ?-catenin signaling does not require signaling through heterotrimeric G proteins.
Whooping Cough
Wnt-5a and G-protein signaling are required for collagen-induced DDR1 receptor activation and normal mammary cell adhesion.
Whooping Cough
WNT-5A stimulates the GDP/GTP exchange at pertussis toxin-sensitive heterotrimeric G proteins.
Whooping Cough
Wnt3a stimulation elicits G-protein-coupled receptor properties of mammalian Frizzled proteins.
Whooping Cough
Workshop on Animal free Detection of Pertussis Toxin in Vaccines--Alternatives to the Histamine Sensitisation Test.
Whooping Cough
Wortmannin-sensitive activation of p70s6k by endogenous and heterologously expressed Gi-coupled receptors.
Whooping Cough
Xaliproden (SR57746A) induces 5-HT1A receptor-mediated MAP kinase activation in PC12 cells.
Whooping Cough
Xamoterol impairs hippocampus-dependent emotional memory retrieval via Gi/o-coupled ?2-adrenergic signaling.
Whooping Cough
Y2 receptors for neuropeptide Y are coupled to three intracellular signal transduction pathways in a human neuroblastoma cell line.
Whooping Cough
YtxR, a conserved LysR-like regulator that induces expression of genes encoding a putative ADP-ribosyltransferase toxin homologue in Yersinia enterocolitica.
Whooping Cough
Zebrafish Mir antagonizes Frizzled 7-induced gastrulation defects.
Whooping Cough
Zinc hydroxide induced respiratory burst in rat neutrophils.
Whooping Cough
Zinc hydroxide stimulates superoxide production by rat alveolar macrophages.
Whooping Cough
Zona pellucida induces activation of phospholipase A2 during acrosomal exocytosis in guinea pig spermatozoa.
Whooping Cough
[3H]-BIBP3226 and [3H]-NPY binding to intact SK-N-MC cells and CHO cells expressing the human Y1 receptor.
Whooping Cough
[3H]GDP release from rat and hamster adipocyte membranes independently linked to receptors involved in activation or inhibition of adenylate cyclase. Differential susceptibility to two bacterial toxins.
Whooping Cough
[A field survey carried out on the confirmation of a pertussis case in a village of Kirikkale Province, Turkey]
Whooping Cough
[A molecular mechanism for supersensitization of adenylyl cyclase system in cloned opioid receptor-transfected cells following sustained opioid treatment]
Whooping Cough
[A polyvalent complex of Bordetella pertussis antigens as the basis for an acellular pertussis vaccine]
Whooping Cough
[A study of the ability of Bordetella pertussis toxin to induce the formation of B-suppressors]
Whooping Cough
[Abnormalities in the beta-adrenergic receptor-adenylate cyclase system in the ventricular myocardium of spontaneously hypertensive rats]
Whooping Cough
[Acellular pertussis vaccines--safe alternative]
Whooping Cough
[Activation mechanisms by thrombin and vasopressin of fibroblasts in spontaneously hypertensive rats]
Whooping Cough
[Activation of p38 and c-Jun NH2-terminal kinase mitogen-activated protein kinases in human prostate carcinoma cell lines with different metastatic potentials]
Whooping Cough
[Analysis of the nature of responses of neurons of rat spinal ganglia evoked by the activation of GABA-B receptors]
Whooping Cough
[Antigenic composition and serologic characteristics of domestic acellular pertussis vaccine]
Whooping Cough
[Antigenic variability of Bordetella pertussis strains isolated in 1967-2010 in the Czech Republic--possible explanation for the rise in cases of pertussis?].
Whooping Cough
[Biological behavior of SDF-1/CXCR4 in patients with myelodysplastic syndrome].
Whooping Cough
[Bordetella pertussis lipooligosaccharide-derived neoglycoconjugates - new components of pertussis vaccine].
Whooping Cough
[Ca2+]i oscillations induced by high [K+]o in acetylcholine-stimulated rat submandibular acinar cells: regulation by depolarization, cAMP and pertussis toxin.
Whooping Cough
[Ca2+]i rises via G protein during regulatory volume decrease in rabbit proximal tubule cells.
Whooping Cough
[Ca2+]i-transients and actin polymerization in human neutrophils under stimulation with GRO alpha and complement fragment C5a.
Whooping Cough
[Calcium-independent inhibition of the spontaneous release of GABA by baclofen in the rat hippocampus]
Whooping Cough
[Can the determination of IgG antibodies to the pertussis toxin help the diagnosis of the disease?]
Whooping Cough
[Cellular and acellular anti-pertussis vaccines]
Whooping Cough
[Characterization of adrenal medullary opioid receptors. II. Coupling of adrenal medullary opioid receptors to GTP binding proteins]
Whooping Cough
[Chemoattractive effects of chemokine-like factor 1 on human arterial smooth muscle cells.]
Whooping Cough
[Chemotactic and mitogenic effect of rat chemokine-like factor 1 on aortic smooth muscle cells.]
Whooping Cough
[Cloning and expression of subunit genes of pertussis toxin and its immunological evaluation]
Whooping Cough
[Cloning and gene expression of the leukocytosis (lymphocytosis) stimulating factor of Bordatella pertussis in Escherichia coli by bringing the PT genes close to the lactose promoter of plasmid pUC19]
Whooping Cough
[Comparison of routine serological investigations performed in three different laboratories in Poland for the diagnosis of pertussis]
Whooping Cough
[Construction of the genetically attenuated bacteria Aordetella pertussis devoid of dermonecrotic toxin activity and producing modified nontoxic pertussis toxin form]
Whooping Cough
[Contents of antibodies to Bordetella pertussis antigens in patients with rheumatic diseases]
Whooping Cough
[Coupling of GTP-binding protein to inositol phospholipid metabolism in chemoattractant-stimulated guinea pig peritoneal exudate macrophages]
Whooping Cough
[Coupling of guanine nucleotide inhibitory protein to somatostatin receptors on rat pancreatic acinar membranes]
Whooping Cough
[Cytomorphological and enzymocytochemical studies of tissue cultures treated with pertussis toxin]
Whooping Cough
[Demonstration of the immunostimulating component(s) in Bordetella pertussis (Phase I, strain Tohama), other than cell wall peptidoglycan, endotoxic lipopolysaccharide and pertussis toxin]
Whooping Cough
[Detection of the gene sequences of the leukocytosis (lymphocytosis)-stimulating factor of Bordetella pertussis in Bordetella parapertussis and Bordetella bronchiseptica by using molecular hybridization]
Whooping Cough
[Determination of tracheal cytotoxin in pertussis and diphtheria tetanus acellular pertussis vaccines using liquid chromatography-tandem mass spectrometry].
Whooping Cough
[Development and optimization of an in-house PCR method for molecular diagnosis of pertussis].
Whooping Cough
[Development of a method for the quantitative determination of Bordetella pertussis toxin and the prospects of its use for diagnosis]
Whooping Cough
[Development of a time-resolved fluoroimmunoassay for detecting S1 subunit of pertussis toxin and its application].
Whooping Cough
[Diagnosis of whooping cough by serology and real-time PCR].
Whooping Cough
[Diagnostic value of IgG, IgA, and IgM to Bordetella pertussis antigens in patients with pertussis]
Whooping Cough
[Domestic acellular pertussis vaccine]
Whooping Cough
[Effect of bacterial toxins on the GTPase activity of transducin from bovine rod outer segments]
Whooping Cough
[Effect of bacterial toxins on the mitogen-induced increase of the Ca2+ concentration in the cytoplasm of rat thymocytes. The role of N proteins]
Whooping Cough
[Effect of ET-1 on intracellular free calcium in cultured neonatal myocardial cells]
Whooping Cough
[Effect of interleukin-2 on intracellular calcium transients in rat ventricular myocytes]
Whooping Cough
[Effect of interleukin-2 on the activity of Ca(2+)ATPase and Na(+)/K(+)ATPase of sarcoplasmic reticulum and sarcolemma]
Whooping Cough
[Effect of pertussis toxin on cells cultivated in vitro.]
Whooping Cough
[Effect of solution environment on the purification of pertussis toxin]
Whooping Cough
[Effects of G-Protein Regulators and Stylar S-RNase on the Growth and Ca(2+) Concentration of Pyrus pyrifolia Pollen Tube.]
Whooping Cough
[Effects of lithium and antidepressants on monoaminergic receptors and receptor-coupled adenylate cyclase system in rat brain]
Whooping Cough
[Effects of matrix metalloproteinase-9 inhibitor in Lewis rats with experimental autoimmune myocarditis.]
Whooping Cough
[Effects of praeruptorin C on cell hypertrophy, intracellular [Ca2+]i, nitric oxide and signal transduction in isolated hypertrophied rat smooth muscle cells induced by angiotensin II]
Whooping Cough
[Effects of sphingosine-1-phosphate, a lipid mediator, in cardiovascular tissues]
Whooping Cough
[Endothelial dysfunction and atherosclerosis]
Whooping Cough
[Engineering of attenuated Bordetella pertussis bacteria producing immunogenic non-toxic form of pertussis toxin]
Whooping Cough
[Eosinophil and neutrophil degranulation in allergic inflammation: immunohistochemical localization of granule proteins in fatal asthma and stimulus-dependent degranulation in vitro]
Whooping Cough
[Evaluation of Bordetella pertussis strains toxicity in vitro using CHO cell lines].
Whooping Cough
[Evaluation of G(i/o) protein signal transduction pathway in cardioprotection of hypoxic preconditioning]
Whooping Cough
[Evaluation of the usefulness of Bordetella pertussis toxins for serodiagnosis of whooping cough]
Whooping Cough
[Evaluation of whole-cell and acellular pertussis vaccines effectiveness in clearance of experimental B. pertussis infection in mice]
Whooping Cough
[Facilitatory actions of the cognitive enhancer nefiracetam on neuronal Ca2+ channels and nicotinic ACh receptors: their intracellular signal transduction pathways]
Whooping Cough
[Features of Bordetella pertussis, Bordetella spp. infection and whopping cough in Córdoba province, Argentina].
Whooping Cough
[Features of expression of the pertussis toxin operon under the control of its own and heterologous promotors in Bordetella bronchiseptica cells]
Whooping Cough
[Functional characteristics of nucleotide-receptors in human neutrophils]
Whooping Cough
[Functional guanine nucleotide-binding proteins in receptor-mediated modulation of voltage-dependent ion channels]
Whooping Cough
[G(i) proteins in regulation of water permeability of the rat kidney collecting tube epithelium cell membrane]
Whooping Cough
[Genetic variability of Bordetella pertussis strains. Part I. Current knowledge]
Whooping Cough
[Genetic variability of Bordetella pertussis strains. Part II. Perspectives]
Whooping Cough
[Goniodomin A induces modulation of actomyosin ATPase activity mediated through conformational change of actin]
Whooping Cough
[Growth and invasion of differentiated thyroid gland carcinoma: importance of signal transduction]
Whooping Cough
[Health Council of the Netherlands advisory report 'Vaccination against pertussis'--time for a new vaccine]
Whooping Cough
[Hormone-like action of blood plasma lipoproteins on human platelets and smooth vascular muscle cells]
Whooping Cough
[Humoral imunity to pertussis in children with diabetes of type 1]
Whooping Cough
[Humoral reaction to Bordetella pertussis antigens: pertussis toxin, filamentous hemagglutinin and lipopolysaccharide in children with clinical symptoms of whooping cough. I. Antibody level for B pertussis antigens in children without respiratory tract infection symptoms]
Whooping Cough
[Humoral reaction to Bordetella pertussis antigens: pertussis toxin, filamentous hemagglutinin and lipopolysaccharide in children with clinical symptoms of whooping cough. II. Occurence and level of B. pertussis antigens in children with suspected whooping cough]
Whooping Cough
[Humoral response to the injection of acellular Pertussis vaccine]
Whooping Cough
[Hybridomas synthesizing monoclonal antibodies to Bordetella pertussis toxins]
Whooping Cough
[Identification and isolation of GTP-binding regulator protein from plasma membranes of oocytes from the starfish Asterias amurensis]
Whooping Cough
[Identification and purification of GTP-binding regulatory proteins from plasma membranes of swine heart]
Whooping Cough
[Immunobiologic activity of Bordetella pertussis strains defective in various virulence factors]
Whooping Cough
[Immunogenicity and safety of Di-Te-Ki-Pol vaccine "SSI" in Danish infants]
Whooping Cough
[Immunogenicity and safety of vaccine preparations based on circulating Bordetella pertussis strains].
Whooping Cough
[Immunological effect of systemically administered allopurinol in experimental autoimmune uveitis]
Whooping Cough
[Impairment of atypical beta-adrenergic-mediated relaxation in spontaneously hypertensive rats before and during the development of arterial hypertension]
Whooping Cough
[In vitro study of endothelium-dependent relaxation and contraction of human atherosclerotic femoral artery]
Whooping Cough
[Inactivation and toxoiding of biologically-active components of Bordetella pertussis by tea catechins]
Whooping Cough
[Increase of intradermal vascular permeability by pertussis toxin]
Whooping Cough
[Induction of protective immunity for Bordetella pertussis by nasal inoculation of pertussis vaccine in mice]
Whooping Cough
[Influence of pertussis toxin on GPER-mediated activation of phosphatidylinositol 3-kinase/protein kinase B signaling induced by 17?-estradiol in endometrial carcinoma cells].
Whooping Cough
[Inhibiting effect of ADP-ribosylation by pertussis toxin on passive transport of Ca2+ into the cell membrane of porcine myometrium]
Whooping Cough
[Inhibitory effect of pertussis toxin on the metabolism of guanine nucleotides in transducin from bovine outer rod segments]
Whooping Cough
[Intracellular messengers in the regulation of renin secretion]
Whooping Cough
[Intracellular signal transmission of low density lipoprotein receptors in human monocytes]
Whooping Cough
[Involvement of G proteins between receptors and KCa channels in the regulation of airway tone by the autonomic nervous system]
Whooping Cough
[Isolation of hemolytic cultures of Bordetella pertussis intended for the production of acellular pertussis preparations and the characterization of their biological properties]
Whooping Cough
[Isoproterenol, denopamine, and atenolol-induced alterations in beta-adrenergic receptor-adenylate cyclase system of rat myocardium]
Whooping Cough
[Kainate receptors. Their function in the regulation of GABAergic synaptic transmission in the hippocampus]
Whooping Cough
[Laboratory diagnosis of pertussis. Role of serology]
Whooping Cough
[Localization of segments in the Gs protein interacting with adenylate cyclase using a Gs/G0-chimera]
Whooping Cough
[Macrophage depletion inhibits leukocyte recruitment in experimental melanin-induced uveitis (EMIU)]
Whooping Cough
[Mechanism of carbachol and adenosine action on spontaneous quantal mediator release at frog neuromuscular junction]
Whooping Cough
[Mechanism of the activation of extracellular signal-regulated kinase (ERK) in prostate cancer cell lines with different metastatic potential]
Whooping Cough
[Mechanisms of opioid receptor-induced elevation in intracellular calcium by confocal laser scanning microscopy]
Whooping Cough
[Membrane receptors and coupling proteins in adenohypophyseal cells]
Whooping Cough
[Metabolic and ionic dependence of neuronal responses evoked by serotonin in the rat sensory ganglia]
Whooping Cough
[Modern strains of Bordetella pertussis: immunobiological properties and vaccine improvement]
Whooping Cough
[Modulation of the action of interferon-gamma by protein G]
Whooping Cough
[Molecular genetic characteristics of the B. pertussis strains isolated in different periods of the pertussis epidemic process]
Whooping Cough
[Multispecific monoclonal antibodies]
Whooping Cough
[Noradrenaline-induced alterations in beta-adrenergic receptor-adenylate cyclase system of rat myocardium]
Whooping Cough
[Novel approaches to control the rise in pertussis cases].
Whooping Cough
[Pathogenetic significance of Bordetella pertussis toxin]
Whooping Cough
[Pathways of signal transduction of intracellular Ca2+ increase mediated by three subtypes of alpha 1-adrenoceptor in HEK293 cells]
Whooping Cough
[Pertussis outbreak in a poorly immunized community]
Whooping Cough
[Pertussis seroprevalence and vaccination status in three selected province of Turkey]
Whooping Cough
[Pertussis toxin and cross-reactive antigens in dynamics of Bordetella pertussis cultivation]
Whooping Cough
[Pertussis toxin stimulates brain adenyl cyclase and induces ADP ribosylation of a 40,000 dalton membrane protein]
Whooping Cough
[Pharmacological characterization of alpha 2-adrenoceptor regulated 5-HT release in the rat hippocampus]
Whooping Cough
[Physicochemical and biological characteristics of preparations of an antigenic complex isolated from the cultivation medium of Bordetella pertussis]
Whooping Cough
[Physiopathological role of low affinity IgE receptor (CD23) in hematopoietic cells]
Whooping Cough
[Production of pertussis toxin by Bordetella pertussis strains isolated from patients with whooping cough].
Whooping Cough
[Prophylaxis of pertussis: development and use of acellular pertussis vaccine]
Whooping Cough
[Prostaglandin E2 receptor and GTP binding protein in the normal and nephrotic rat kidney]
Whooping Cough
[Protection and its mechanism of catechin morphon on hypoxia-reoxynation induced injury in myocardial cells]
Whooping Cough
[Protective activity of tea and catechins against Bordetella pertussis]
Whooping Cough
[Purification and properties of Bordetella pertussis toxin]
Whooping Cough
[Receptor-mediated signal transduction]
Whooping Cough
[Regulation by cations of adenylate cyclase activity in chicken tissues]
Whooping Cough
[Regulation mechanisms of receptors mediated activation of phospholipase c and inositol-1,4,5-triphosphate sensitive Ca2+ release and Ca2+ uptake in exocrine glandular cells]
Whooping Cough
[Regulation of adenylyl cyclase signaling system by insulin, biogenic amines, and glucagon at their separate and combined action in the muscle membranes of the mollusc Anodonta cygnea].
Whooping Cough
[Regulation of inositol-1,4,5-triphosphate receptor by G(i)-protein]
Whooping Cough
[Reorganization of microtubule system in pulmonary endothelial cells in response to thrombin treatment]
Whooping Cough
[Role of a guanine nucleotide regulatory protein in exocrine pancreatic secretion--effects of cholera toxin and pertussis toxin on cholecystokinin action]
Whooping Cough
[Role of sphingosine 1-phosphate receptor signaling in hematopoietic stem/progenitor cell transmigration.]
Whooping Cough
[ROLE PHOSPHOINOSITID SIGNALING PATHWAY IN OPIOIDS CONTROL OF P2X3 RECEPTORS IN THE PRIMARY SENSORY NEURONS].
Whooping Cough
[Seroepidemiological Studies on Pertussis, Diphtheria and Tetanus among Nursing Students Enrolled between 1994 and 2011 in the Kitakyushu District].
Whooping Cough
[Seroepidemiology of pertussis in 10-15 years old healthy children in Isparta province, Turkey].
Whooping Cough
[Seroprevalence of pertussis toxin antibody in Manisa province of Turkey, after six years implementation of acellular pertussis vaccine].
Whooping Cough
[Serum immunoglobulin IgG subclass distribution of antibody responses to pertussis toxin and filamentous hemagglutinin of Bordetella pertussis in patients with whooping cough].
Whooping Cough
[Signal transduction of prostaglandin E2 and thromboxane A2]
Whooping Cough
[Structural organization of a segment of chromosome, containing the vir gene of Bordetella pertussis]
Whooping Cough
[Studies of the reaction of the living body to pertussis vaccine, with special reference to electromyographic experiments with the intercostal muscles. II. Electromyogram of the intercostal muscles by inoculation with Hemophilus pertussis type I and Hemophilus pertussis toxin after Hemophilus pertussis vaccination.]
Whooping Cough
[Studies on the toxins of Bordetella pertussis. 7. Investigation by sedimentation analysis of some methods of detoxication of pertussis toxin.]
Whooping Cough
[Studies on the toxins of Bordetella pertussis. 8. Pathohistologic studies on all organs of mice inoculated with pertussis toxin.]
Whooping Cough
[Study on pertussis using nerve tissue culture. 2. Study on the influence of pertussis toxin on cultured nerve elements]
Whooping Cough
[Suppression of platelet activating factor effects (PAF) on the retina by G-proteins inhibitors]
Whooping Cough
[Synthesis of monoclonal antibodies to tissue-specific antigens of human skin and thymus epithelium in polyclonal activation by pertussis toxin]
Whooping Cough
[The Clinical Signs of Experimental Autoimmune Uveitis].
Whooping Cough
[The development of a new generation of pertussis vaccine]
Whooping Cough
[The development of a process for culturing Bordetella pertussis immobilized on a polyurethane carrier]
Whooping Cough
[The discovery of neuromedin U and its pivotal role in the central regulation of energy homeostasis].
Whooping Cough
[The effect of cortisol and pertussis toxin on the cyclic AMP level in human lymphocytes]
Whooping Cough
[The effect of G protein regulator on pollen germination and [Ca2+]i variation in Pyrus serotina Rehd. pollen.]
Whooping Cough
[The effect of methylated cyclodextrin on pertussis toxin accumulation in a Bordetella pertussis culture in a bioreactor]
Whooping Cough
[The elastin-laminin receptor]
Whooping Cough
[The frequency of detection of IgA, IgG and IgM antibodies to pertussis toxin in patients with respiratory tract infections in Poland]
Whooping Cough
[The involvement of muscarinic M1 receptor in the regulation of action potentials in mouse isolated right atria]
Whooping Cough
[The phenotypic properties of freshly isolated strains of Bordetella]
Whooping Cough
[The risk of pertussis and diphtheria infections among pediatric healthcare workers in Japan]
Whooping Cough
[The role of a GTP-binding protein in coupling of a muscarinic cholinergic receptor and Na,K-ATPase in myocardial sarcolemma]
Whooping Cough
[The role of different subtypes of G protein in the secretory function of macrophages stimulated by activated complement following severe burn injury]
Whooping Cough
[The role of G protein, protein kinase C and Na(+)-H+ exchanger in endothelin-1-induced cardiomyocyte hypertrophic responses]
Whooping Cough
[The standardization of the in-vitro tetanus toxin neutralization test on Chinese hamster ovary cells]
Whooping Cough
[Thiol reagent thimerosal-induced Ca2+ mobilization in isolated guinea pig cochlear outer hair cells]
Whooping Cough
[Trial of pertussis toxin activity in vitro on CHO cells]
Whooping Cough
[Use of an immunoblotting method for identifying the individual proteins in the antigenic complexes of Bordetella pertussis]
Whooping Cough
{beta}-adrenergic activation of electrogenic K+ and Cl- secretion in guinea pig distal colonic epithelium proceeds via separate cAMP signaling pathways.
Whooping Cough
{delta} Opioid Receptors Stimulate Akt-Dependent Phosphorylation of c-jun in T Cells.
Wound Infection
Production of extracellular virulence factors by Pseudomonas aeruginosa isolates obtained from tracheal, urinary tract, and wound infections.
Wound Infection
Pseudomonas aeruginosa strains obtained from patients with tracheal, urinary tract and wound infection: variations in virulence factors and virulence genes.
Xeroderma Pigmentosum
Hypermutation of immunoglobulin genes in memory B cells of DNA repair-deficient mice.
Xeroderma Pigmentosum
Kinetics and thermodynamics of zinc(II) and arsenic(III) binding to XPA and PARP-1 zinc finger peptides.
Xeroderma Pigmentosum
PARP10 deficiency manifests by severe developmental delay and DNA repair defect.
Xeroderma Pigmentosum
Poly(ADP-ribose) contributes to an association between poly(ADP-ribose) polymerase-1 and xeroderma pigmentosum complementation group A in nucleotide excision repair.
Xeroderma Pigmentosum
Role of poly(ADP-ribose) polymerase-1 in the removal of UV-induced DNA lesions by nucleotide excision repair.
Xeroderma Pigmentosum
Xeroderma Pigmentosum Group A Promotes Autophagy to Facilitate Cisplatin Resistance in Melanoma Cells through the Activation of PARP1.
Zika Virus Infection
ADP-ribosyltransferase PARP11 suppresses Zika virus in synergy with PARP12.
Zika Virus Infection
PARP-1 mediated cell death is directly activated by ZIKV infection.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.